<SEC-DOCUMENT>0001213900-24-037520.txt : 20240430
<SEC-HEADER>0001213900-24-037520.hdr.sgml : 20240430
<ACCEPTANCE-DATETIME>20240430093034
ACCESSION NUMBER:		0001213900-24-037520
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240430
DATE AS OF CHANGE:		20240430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aptorum Group Ltd
		CENTRAL INDEX KEY:			0001734005
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38764
		FILM NUMBER:		24894311

	BUSINESS ADDRESS:	
		STREET 1:		17 HANOVER SQUARE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1S 1BN
		BUSINESS PHONE:		852 3953 7700

	MAIL ADDRESS:	
		STREET 1:		17 HANOVER SQUARE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1S 1BN
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0203681-20f_aptorum.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 09:10:55 UTC 2024 -->
<html xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:apm="http://aptorumgroup.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>WASHINGTON, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-26340">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement" id="ixv-32"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
<b>REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-44"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric>
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-26341"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-26342">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-26343">2023</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-61"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-73"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
<b>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of event requiring this shell company report</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the transition period from __________ to
__________</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-26344">001-38764</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-94"><b>APTORUM GROUP LIMITED</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Exact Name of Registrant as Specified in its
Charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>N/A</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Translation of Registrant&#8217;s Name into
English)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-111"><b>Cayman Islands</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Jurisdiction of Incorporation or Organization)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-26345">Ian Huen</ix:nonNumeric>, Chief Executive Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Aptorum Group Limited</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-26346"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-26347">17 Hanover Square</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-26348"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-26349">London</ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-26350"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-26351">W1S 1BN</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-26352"><ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-26353">United Kingdom</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Tel: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-26354">+44</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-26355">20 8092 9299</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Fax: +44 20 3928 8277</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Address of principal executive offices and
Name, Telephone, E-mail and/or Facsimile number and<br/>
Address of Company Contact Person)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Securities registered or to be registered pursuant
to Section 12(b) of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of Each Class</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name of Each Exchange on Which Registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-160"><span style="font-size: 10pt"><b>Class A Ordinary shares, par value $0.00001</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-165"><span style="font-size: 10pt"><b>APM</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName" id="ixv-26356">NASDAQ</ix:nonNumeric> Capital Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered or to be registered pursuant
to Section 12(g) of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Title of Class)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Title of Class)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of each
of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Class A Ordinary Shares: <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-26357">2,937,921</ix:nonFraction></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Class B Ordinary Shares: <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-26358">2,243,776</ix:nonFraction></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-26359">No</ix:nonNumeric>
<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-26360">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-26361">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-26362">Yes</ix:nonNumeric>
<span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large
accelerated filer,&#8221; accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="white-space: nowrap; width: 20%"><span style="font-size: 10pt">Large accelerated filer </span></td> <td style="white-space: nowrap; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="white-space: nowrap; width: 20%"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="white-space: nowrap; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="white-space: nowrap; width: 30%"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-264"><span style="font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="white-space: nowrap; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap"><span style="font-size: 10pt">Emerging growth company </span></td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-276"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards<sup>+ </sup>provided pursuant to Section 13(a) of the Exchange
Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt"><sup>+</sup></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-298"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-304"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 20%; text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-26363">U.S. GAAP</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;</span></td> <td style="width: 60%; text-align: center"><span style="font-size: 10pt">International Financial Reporting Standards as issued by the International Accounting Standards Board <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td> <td style="width: 20%; text-align: center"><span style="font-size: 10pt">Other <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 &#9744; Item 18 &#9744;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by check
mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes
<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-343"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#a_001"><span style="font-size: 10pt">INTRODUCTION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">ii</span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 9%">&#160;</td>
    <td style="vertical-align: top; width: 81%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_002"><span style="font-size: 10pt">PART I</span></a></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 1.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_003"><span style="font-size: 10pt">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 2.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_004"><span style="font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 3.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_005"><span style="font-size: 10pt">KEY INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 4.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_006"><span style="font-size: 10pt">INFORMATION ON THE COMPANY</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 4A.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_007"><span style="font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">97</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 5.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_008"><span style="font-size: 10pt">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">97</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 6.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_009"><span style="font-size: 10pt">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">112</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 7.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_010"><span style="font-size: 10pt">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">125</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 8.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_011"><span style="font-size: 10pt">FINANCIAL INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">128</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 9.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_012"><span style="font-size: 10pt">THE OFFER AND LISTING</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">129</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 10.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_013"><span style="font-size: 10pt">ADDITIONAL INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">129</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 11.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_014"><span style="font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">136</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 12.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_015"><span style="font-size: 10pt">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">136</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_016"><span style="font-size: 10pt">PART II</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">137</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 13.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_017"><span style="font-size: 10pt">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">137</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 14.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_018"><span style="font-size: 10pt">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">137</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 15.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_019"><span style="font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">137</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_020"><span style="font-size: 10pt">[RESERVED]</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">138</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16A.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_021"><span style="font-size: 10pt">AUDIT COMMITTEE FINANCIAL EXPERT</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">138</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16B.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_022"><span style="font-size: 10pt">CODE OF ETHICS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">138</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16C.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_023"><span style="font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">138</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16D.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_024"><span style="font-size: 10pt">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">139</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16E.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_025"><span style="font-size: 10pt">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">139</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16F.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_026"><span style="font-size: 10pt">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">139</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16G.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_027"><span style="font-size: 10pt">CORPORATE GOVERNANCE</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">139</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16H.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_028"><span style="font-size: 10pt">MINE SAFETY DISCLOSURE</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">139</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16I.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_029"><span style="font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">139</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16J.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_030"><span style="font-size: 10pt">INSIDER TRADING POLICIES</span></a></td>
    <td style="vertical-align: bottom; text-align: center">139</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16K.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_031"><span style="font-size: 10pt">CYBERSECURITY</span></a></td>
    <td style="vertical-align: bottom; text-align: center">139</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_035"><span style="font-size: 10pt">PART III</span></a></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">140</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 17.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_032"><span style="font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">140</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 18.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_033"><span style="font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">140</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 19.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_034"><span style="font-size: 10pt">EXHIBITS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">140</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>INTRODUCTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Unless the context otherwise
requires, in this annual report on Form 20-F references to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;505(b)(2) Application&#8221; refers to an application for which one or more of the investigations relied upon by the applicant for approval &#8220;were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted&#8221; (21 U.S.C. 355(b)(2)).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;A*STAR&#8221; refers to Agency for Science, Technology and Research.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Acticule&#8221; refers to Acticule Life Sciences Limited, an 80% owned subsidiary of Aptorum Group.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Aeneas Group&#8221; refers to Aeneas Limited and its subsidiaries. Aeneas Limited is 76.8% owned by Jurchen Investment Corporation. Because Mr. Huen, a director, holds 100% equity interest in Jurchen Investment Corporation, we refer Aeneas Group as a fellow subsidiary of Aptorum Group.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;AML&#8221; refers to Aptorum Medical Limited, a 90% owned subsidiary of Aptorum Group, as of the date of this report.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;AML Clinic&#8221; refers to an outpatient medical clinic operated by AML under the name of Talem Medical.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Aptorum Group,&#8221; and &#8220;Group&#8221; refer to Aptorum Group Limited, a Cayman Islands exempted company with limited liability whose principal place of business is in Hong Kong, all of its subsidiaries and the consolidated VIEs to which we are regarded as the primary beneficiary for accounting purposes.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Aptorum Non-Therapeutics Group&#8221; refers to the Company&#8217;s non-therapeutics segment that encompasses diagnostics projects including the novel molecular-based rapid pathogen identification and detection diagnostics (&#8220;Paths<sup>Dx</sup> Test&#8221;, formerly known as &#8220;RPIDD&#8221;) technology.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Aptorum Therapeutics Group&#8221; refers to the Company&#8217;s therapeutics segment that is operated through its wholly-owned subsidiary, Aptorum Therapeutics Limited, a Cayman Islands exempted company with limited liability, whose principal place of business is in Hong Kong and its indirect subsidiary companies, whose principal places of business are in the United Kingdom, Singapore and Hong Kong.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;At The Market Offering&#8221; or &#8220;ATM Offering&#8221; refers to the offering and sale of the Company&#8217;s Class A Ordinary Shares, offered pursuant to the prospectus supplement and the accompanying prospectus to the registration statement on Form F-3 (File No. 333-268873), in which H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;), acted as the Company&#8217;s sales agent in accordance with certain at the market offering agreement (the &#8220;Sales Agreement&#8221;), dated as of March 26, 2021, by and between the Company and Wainwright.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;cGCP&#8221; refers to Current Good Clinical Practice as adopted by the applicable regulatory authority.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;cGLP&#8221; refers to Current Good Laboratory Practice as adopted by the applicable regulatory authority.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;cGMP&#8221; refers to Current Good Manufacturing Practice as adopted by the applicable regulatory authority.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Class A Ordinary Shares&#8221; refers to the Company&#8217;s Class A Ordinary Shares, par value $0.00001 per share.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Class B Ordinary Shares&#8221; refers to the Company&#8217;s Class B Ordinary Shares, par value $0.00001 per share.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Company,&#8221; &#8220;we&#8221; and &#8220;us&#8221; refer to Aptorum Group Limited, a Cayman Islands exempted company with limited liability whose principal place of business is in Hong Kong.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;CMC&#8221; refers to chemical, manufacturing and control.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Covar&#8221; refers to Covar Pharmaceuticals Incorporated, a contract research organization engaged by the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;CROs&#8221; refers to contract research organizations.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;CTA&#8221; refers to Clinical Trial Application.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;EEA&#8221; refers to the European Economic Area.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;EMA&#8221; refers to the European Medicines Agency.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;EMEA&#8221; refers to Europe, the Middle East and Africa.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;EPO&#8221; refers to the European Patent Organization or the European Patent Office operated by it.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;European Patent&#8221; refers to patents issuable by the EPO.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;EU&#8221; refers to the European Union. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Exchange Act&#8221; refers to the U.S. Securities Exchange Act of 1934, as amended.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;FDA&#8221; refers to U.S. Food and Drug Administration.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;FDCA&#8221; refers to the U.S. Federal Food, Drug and Cosmetic Act.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Fiscal year&#8221; refers to the period from January 31 of each calendar year to December 31 of the following calendar year.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;HKD&#8221; refers to Hong Kong Dollars.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Hong Kong&#8221; or &#8220;H.K.&#8221; refers to Hong Kong Special Administrative Region of the People&#8217;s Republic of China.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Hong Kong Doctors&#8221; refers to the doctors in Hong Kong under the employment of AML Clinic.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;IND&#8221; refers to Investigational New Drugs.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;IP&#8221; refers to intellectual property.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;IPO&#8221; or &#8220;Offering&#8221; means the initial public offering by the Company of 76,142 Class A Ordinary Shares consummated on December 17, 2018.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Jurchen&#8221; refers to Jurchen Investment Corporation, a company wholly-owned by one of our directors and former CEO, Ian Huen, and a holding company of Aptorum Group.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Lead Projects&#8221; refers to ALS-4, SACT-1 and Paths<sup>Dx</sup> Test.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Libra&#8221; refers to Libra Sciences Limited, a VIE in which we hold 97.27% economic interest and 31.51% voting power. Libra is incorporated under the laws of the Cayman Islands. We are not deemed as the primary beneficiary of Libra for accounting purposes.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">&#8220;Major Patent Jurisdictions&#8221;
refers to the United States, member states of the European Patent Organization and the People&#8217;s Republic of China.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Mios&#8221; refers to Mios Pharmaceuticals Limited, a consolidated VIE in which we indirectly hold 97.93% economic interest and 36.17% voting power. Aptorum is regarded as the primary beneficiary of Mios for accounting purposes.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Nativus&#8221; refers to Nativus Life Sciences Limited, a wholly-owned subsidiary of Aptorum Group.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;NMPA&#8221; refers to China&#8217;s National Medical Products Administration and its predecessor, the China Food and Drug Administration.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;NDA&#8221; refers to a New Drug Application issued by the FDA.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Ordinary Shares&#8221; refers to the Class A Ordinary Shares and Class B Ordinary Shares collectively.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;PRC&#8221; and &#8220;China&#8221; refer to the People&#8217;s Republic of China.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Registered Direct Offering&#8221; means the registered direct offering by the Company of 135,135 Class A Ordinary Shares and warrants to purchase up to 135,135 Class A Ordinary Share consummated on February 28, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Restructure&#8221; refers to the Company&#8217;s change from an investment fund with management shares and non-voting participating redeemable preference shares to a holding company with operating subsidiaries, effective as of March 1, 2017.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Registration Statement&#8221; refers to the Company&#8217;s Registration Statement on Form F-1 (File No. 333-227198) for the sale of up to 349,397 Class A Ordinary Shares (including Class A Ordinary Shares underlying certain warrants and a bond, as fully described therein) which initially filed on September 5, 2018 and became effective on December 3, 2018.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;R&amp;D&#8221; refers to research and development.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;R&amp;D Center&#8221; refers to an in-house pharmaceutical development center located in Hong Kong Science and Technology Park.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Securities Exchange Commission,&#8221; &#8220;SEC,&#8221; &#8220;Commission&#8221; or similar terms refer to the Securities Exchange Commission.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Sarbanes-Oxley Act&#8221; refers to the Sarbanes-Oxley Act of 2002.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Scipio&#8221; refers to Scipio Life Sciences Limited, a consolidated VIE in which we indirectly hold 97.93% economic interest and 35.06% voting power. Aptorum is regarded as the primary beneficiary of Scipio for accounting purposes.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Securities Act&#8221; refers to the Securities Act of 1933.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;UK&#8221; refers to the United Kingdom.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;United States,&#8221; &#8220;U.S.&#8221; and &#8220;US&#8221; refer to the United States of America.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Videns&#8221; refers to Videns Incorporation Limited, a wholly-owned subsidiary of Aptorum Group.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;VIE&#8221; refers to a variable interest entity.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;US$,&#8221; &#8220;U.S. dollars,&#8221; or &#8220;dollars&#8221; are to the legal currency of the United States.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify; text-indent: 0.5in">Discrepancies in any table
between the amounts identified as total amounts and the sum of the amounts listed therein are due to rounding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report on Form
20-F includes our audited consolidated balance sheets as of December 31, 2023 and 2022, and the related consolidated statements of operations
and comprehensive loss, equity and cash flows for the years ended December 31, 2023, 2022 and 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify; text-indent: 0.5in">Our operations and equity are
funded in U.S. dollars and we currently incur the majority of our expenses in U.S. dollars or in H.K. dollars. H.K. dollar is currently
pegged to the U.S. dollar; however, we cannot guarantee that such peg will continue to be in place in the future. Our exposure to foreign
exchange risk primarily relates to the limited cash denominated in currencies other than the functional currencies of each entity and
limited revenue contracts dominated in H.K. dollars in certain PRC operating entities. We do not believe that we currently have any significant
direct foreign exchange risk and have not hedged exposures denominated in foreign currencies or any other derivative financial instruments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Part I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT
AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3. KEY INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. [Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. <span style="text-decoration:underline">Capitalization and Indebtedness</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. <span style="text-decoration:underline">Reasons for the Offer and Use of Proceeds</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">D. <span style="text-decoration:underline">Risk Factors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Our business faces significant
risks. You should carefully consider all of the information set forth in this annual report on Form 20-F and in our other filings with
the United States Securities and Exchange Commission, or the SEC, including the following risk factors which we face and which are faced
by our industry. Our business, financial condition, results of operations and growth prospects could be materially adversely affected
by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially
differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below
and elsewhere in this annual report and our other SEC filings. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; below.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Summary Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes some,
but not all, of the risks provided below. Please carefully consider all of the information discussed in this Item 3.D. &#8220;Risk Factors&#8221;
in this annual report for a more thorough description of these and other risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify"><b>Risks Related to Doing Business in
Hong Kong</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to legal and regulatory risks associated with our operations in Hong Kong.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If we become directly subject to the recent scrutiny, criticism and negative publicity involving U.S.-listed Chinese companies, we may have to expend significant resources to investigate and resolve the matter which could harm our business operations, stock price and reputation and could result in a loss of your investment in our stock, especially if such matter cannot be addressed and resolved favorably.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the U.S. Senate and the U.S. House of Representatives, all call for additional and more stringent criteria to be applied to emerging market companies. These developments could add uncertainties to our offering, business operations, share price and reputation.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our business, financial condition and results of operations, and/or the value of our Class A Ordinary Shares or our ability to offer or continue to offer securities to investors may be materially and adversely affected to the extent the laws and regulations of the PRC become applicable to a company such as us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our Class A Ordinary Shares may be delisted under the HFCA Act if the PCAOB is unable to inspect our auditors. The delisting of our Class A Ordinary Shares, or the threat of their being delisted, may materially and adversely affect the value of your investment. Furthermore, on December 29, 2022, a legislation entitled &#8220;Consolidated Appropriations Act, 2023&#8221; (the &#8220;Consolidated Appropriations Act&#8221;), was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things, an identical provision to the Accelerating Holding Foreign Companies Accountable Act (the &#8220;AHFCAA&#8221;), which reduces the number of consecutive non-inspection years required for triggering the prohibitions under the HFCA Act from three years to two.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even though our auditor is based in New York, New York and under full inspection by the PCAOB and that it is not currently subject to the determinations announced by the PCAOB on December 16, 2021, if&#160;any PRC law relating to the access of the PCAOB to auditor files were to apply to a company such as us or its auditor, the PCAOB may be unable to fully inspect our auditor, which may result in our securities being delisted or prohibited from being traded &#8220;over-the-counter&#8221; pursuant to the HFCA Act and materially and adversely affect the value and/or liquidity of your investment.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The uncertainties with respect to the Chinese legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in laws and regulations in China with little advance notice could adversely affect us and limit the legal protections available to you and us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to the Preclinical and Clinical
Development of Our Drug Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to not generate sufficient revenue </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to uncertainty in preclinical development process</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to fail to identify additional drug candidates</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to conduct clinical trials in or outside the U.S.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Obtaining Regulatory Approval
for Our Drug Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to fail or delay to obtain regulatory approval </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to undesirable adverse event</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to fail to complete the 505(b)(2) pathway for the pediatric formulation</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to our third-party suppliers fail to comply with the FDA&#8217;s good manufacturing practice regulations or fail to respond to an FDA Form 483 or subsequent Warning Letter</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to the Proposed Merger and Separation Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Proposed Transactions are subject to the satisfaction of certain conditions, which may not be satisfied on a timely basis, if at all</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aptorum and YOOV equity holders may not realize a benefit from the Proposed Transactions commensurate with the ownership dilution they will experience in connection with the Proposed Transactions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of Aptorum Class A ordinary shares following the Proposed Transactions may decline as a result of the merger.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aptorum shareholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing as compared to their current ownership and voting interest in the respective companies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combined company may need to raise additional capital by issuing securities or debt or through licensing or other strategic arrangements, which may cause dilution to the combined company&#8217;s shareholders or restrict the combined company&#8217;s operations or impact its proprietary rights.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the pendency of the Proposed Transactions, Aptorum and YOOV may not be able to enter into a business combination with another party because of restrictions in the Merger Agreement, which could adversely affect their respective businesses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Commercialization of Our Drug
Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to fail to achieve market acceptance</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our IP</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to being unaware of others&#8217; pending patent applications </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to unable to protect and enforce our IP rights throughout the world</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to lawsuits for protecting our IP or against infringing IP rights of other parties</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to non-compliance with patent protection requirements or obligations in the license agreements</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to the terms and scope of our patents not sufficient to protect our candidates</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to unable to obtain or maintain rights of the developing technology through acquisitions or licenses</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Reliance on Unrelated
Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to manufacturers fail to provide sufficient quantities of clinical supply on our candidate at acceptable quality levels or prices</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Industry, Business and
Operation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to not complying with laws </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to difficulties in managing our growth</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to unable to collaborations, strategic alliances or acquisitions or enter into royalty-seeking or sublicensing arrangements</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to our disclosure controls and procedures and internal financial reporting controls</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to do business internationally</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to product liability lawsuits arise from clinical trials</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to inadequate insurance coverage</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to failure in safeguarding our computer network system</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to outbreak of the novel coronavirus disease, COVID-19, or other pandemic, epidemic or outbreak of an infectious disease</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Corporate Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to our Class B shareholders have higher voting rights</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to certain existing shareholders have substantial influence over our Company and their interests may not be aligned with the interests of our other shareholders</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to conduct substantially all of our operations outside the United States </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Risks relating to adopt certain home country practices or take advantage of certain reduced reporting requirements </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have ceased to qualify as an &#8220;emerging growth company&#8221; and will incur increased costs as a result.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to the Preclinical and Clinical
Development of Our Drug Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently do not generate revenue from
product sales and may never become profitable; unless we can raise more capital through additional financings, of which there can be no
guarantee.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to generate revenue
and become profitable depends upon our ability to successfully complete the development of, and obtain the necessary regulatory approvals
for, the drug candidates in our Lead Projects and any future drug candidates we may develop, as we do not currently have any drugs that
are available for commercial sale. We expect to continue to incur losses before commercialization of our drug candidates and any future
drug candidates. None of our drug candidates has been approved for marketing in the U.S., Europe, the PRC or any other jurisdictions and
may never receive such approval. Our ability to generate revenue and achieve profitability is dependent on our ability to complete the
development of our drug candidates and any future drug candidates we develop in our portfolio, obtain necessary regulatory approvals,
and have our drugs products under development manufactured and successfully marketed, of which there can be no guarantee. We may not be
able to generate a profit until our drug candidates become profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive regulatory
approval and marketing authorization for one or more of our drug candidates or one or more of any future drug candidates for commercial
sale, a potential product may not generate revenue at all unless we are successful in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">developing a sustainable and scalable manufacturing process for our drug candidates and any approved products, including establishing and maintaining commercially viable supply relationships with third parties;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">launching and commercializing drug candidates following regulatory approvals and marketing authorizations, either directly or with a collaborator or distributor;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtaining market acceptance of our drug candidates as viable treatment options;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">addressing any competing technological and market developments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">negotiating and maintaining favorable terms in any collaboration, licensing or other arrangement into which we may enter to commercialize drug candidates for which we have obtained required approvals and marketing authorizations; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">maintaining, protecting and expanding our portfolio of IP rights, including patents, trade secrets and know-how.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our ability to
achieve and maintain profitability depends on timing and the amount of expenses we will incur. Our expenses could increase materially
if we are required by the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities to perform studies in addition to those
that we currently have anticipated. Even if our drug candidates are approved for commercial sale, we anticipate incurring significant
costs associated with the commercial launch of these products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to become and remain
profitable depends on our ability to generate revenue. Even if we are able to generate revenues from the sale or sublicense of any products
we may develop or license, we may not become profitable on a sustainable basis or at all. Our failure to become and remain profitable
would decrease the value of our Company and adversely affect the market price of our Class A Ordinary Shares, which could impair our ability
to raise capital, expand our business or continue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preclinical development is a long, expensive
and uncertain process, and we may terminate one or more of our current preclinical development programs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Traditionally, drug discovery
and development is a time-consuming, costly and high-risk business. On average, the cost of launching a new drug is estimated to approach
US$2.6 billion and can take around 12 years to make it to the market (4 key benefits of drug repositioning. (n.d.). Retrieved from http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/).
Despite the huge expenditures, only approximately 1 in 1,000 potential drugs is graduated to human clinical trials after pre-clinical
testing in the United States, (Norman, G. A. Drugs, Devices, and the FDA: Part 1. JACC: Basic to Translational Science, 1(3), 170-179,
2016) and nearly 86.2% of drug candidates entering phase 1 trials fails to achieve drug approval. (Wong C. H., Siah K. W. &amp; Lo A.
W. (2019, April), &#8220;Estimation of clinical trial success rates and related parameters,&#8221; retrieved from https://academic.oup.com/biostatistics/article/20/2/273/4817524).
Even after a drug is commercialized, there are just too many factors affecting the sales of pharmaceutical products, including unmet need/burden
of disease (68.2%), clinical efficacy (47.3%), comparator choice (36.4%), safety profile (36.4%), and price (35.5%) (Sendyona, S., Odeyemi,
I., &amp; Maman, K. &#8220;Perceptions and factors affecting pharmaceutical market access: Results from a literature review and survey
of stakeholders in different settings&#8221; Journal of Market Access &amp; Health Policy, 4(1), 31660, 2016). In the end, on average,
only 20% of approved new drugs generate revenues that exceed the average R&amp;D investment. (Rosenblatt, M. (2014, December 19) &#8220;The
Real Cost of &#8220;High-Priced&#8221; Drugs,&#8221; retrieved from https://hbr.org/2014/11/the-real-cost-of-high-priced-drugs). We may
determine that certain preclinical product candidates or programs do not have sufficient potential to warrant the allocation of resources
toward them. Accordingly, we may elect to terminate our programs for and, in certain cases, our licenses to, such product candidates or
programs. If we terminate a preclinical program in which we have invested significant resources, we will have expended resources on a
program that will not provide a full return on our investment and missed the opportunity to have allocated those resources to potentially
more productive uses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management has discretion to terminate the
development of any of our projects at any time.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the costs, both
in time and expense, as well as the preclinical results and general business considerations, management may decide not to continue developing
a particular preclinical program without announcement. Management will always base its decision on what it believes to be the most efficient
use of the Company&#8217;s resources to provide the most value to its shareholders. As a result, investors may not always be aware of
the termination of a previously announced study or trial. The Company will continue to provide update on its active preclinical projects
in its SEC filings and/or press releases, as appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in our efforts
to identify or discover additional drug candidates. Due to our limited resources and access to capital, we must continue to prioritize
development of certain drug candidates; such decisions may prove to be wrong and may adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we intend to explore
other therapeutic opportunities in addition to the drug candidates that we are currently developing, we may fail to identify other drug
candidates for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential drug candidates
or those we identify may be shown to have harmful side effects or other undesirable characteristics that make them unmarketable or unlikely
to receive regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research programs to pursue
the development of our drug candidates for additional indications and to identify new drug candidates and disease targets require substantial
technical, financial and human resources whether or not we ultimately are successful. Our research programs may initially show promise
in identifying potential indications and/or drug candidates, yet fail to yield results for clinical development for a number of reasons,
including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the research methodology used may not be successful in identifying potential indications and/or drug candidates;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential drug candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">it may take greater human and financial resources to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs than we will possess, thereby limiting our ability to diversify and expand our drug portfolio.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we have limited financial
and managerial resources, we have chosen to focus at present on our three Lead Projects, which may ultimately prove to be unsuccessful.
As a result of this focus, we may forego or delay pursuit of opportunities with other drug candidates, or for other indications that later
prove to have greater commercial potential or a greater likelihood of success. Even if we determine to pursue alternative therapeutic
or diagnostic drug candidates, these other drug candidates or other potential programs may ultimately prove to be unsuccessful. In short,
our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, there can be no
assurance that we will ever be able to develop suitable potential drug candidates through internal research programs. This could materially
adversely affect our future growth and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we obtained CTA/FDA
approval to initiate clinical trials for our Lead Projects, there can be no assurance, timely completion of clinical trials in accordance
with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who meet the trial criteria
and remain in the trial until its conclusion. We may experience difficulties enrolling and retaining appropriate patients in our clinical
trials for a variety of reasons, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the size and nature of the patient population;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">patient eligibility criteria defined in the clinical protocol;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the size of study population required for statistical analysis of the trial&#8217;s primary endpoints;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the proximity of patients to trial sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the design of the trial and changes to the design of the trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competing clinical trials for similar therapies or other new therapeutics exist and will reduce the number and types of patients available to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and maintain patient consents;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">patients enrolled in clinical trials may not complete a clinical trial; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the availability of approved therapies that are similar to our drug candidates.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we are able to enroll
a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the
timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to
advance the development of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical drug development involves a lengthy
and expensive process and could fail at any stage of the process. We have limited experience in conducting clinical trials and results
of earlier studies and trials may not be reproduced in future clinical trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our drug candidates, clinical
testing is expensive and can take many years to complete, while failure can occur at any time during the clinical trial process. The results
of studies in animals and early clinical trials of our drug candidates may not predict the results of later-stage clinical trials. Drug
candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through
studies in animals and initial clinical trials. In some instances, there can be significant variability in safety and/or efficacy results
between different trials of the same drug candidate due to numerous factors, including changes in trial procedures set forth in protocols,
differences in the size and type of the patient populations (including genetic differences), patient adherence to the dosing regimen and
the patient dropout rate. Results in later trials may also differ from earlier trials due to a larger number of clinical trial sites and
additional countries and languages involved in such trials. In addition, the design of a clinical trial can determine whether its results
will support approval of a drug candidate, and flaws in the design of a clinical trial may not become apparent until the clinical trial
is well advanced and significant expense has been incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of demonstrated
efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Clinical trials of potential products often
reveal that it is not practical or feasible to continue development efforts. Furthermore, if the trials we conduct fail to meet their
primary statistical and clinical endpoints, they will not support the approval from the FDA, NMPA, EMA, Health Canada or other comparable
regulatory authorities for our drug candidates. If this occurs, we would need to replace the failed study with new trials, which would
require significant additional expense, cause substantial delays in commercialization and materially adversely affect our business, financial
condition, cash flows and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If clinical trials of our drug candidates
fail to demonstrate safety and efficacy to the satisfaction of the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities,
or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable
to complete, the development and commercialization of our drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before applying for and obtaining
regulatory approval for the sale of any of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety and
efficacy of our drug candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete
and may fail. A failure of one or more of our clinical trials can occur at any stage of testing and successful interim results of a clinical
trial do not necessarily predict successful final results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our CROs are required
to comply with current Good Clinical Practices (&#8220;cGCP&#8221;) requirements, which are regulations and guidelines enforced by the
FDA, NMPA, EMA, Health Canada and other comparable regulatory authorities for all drugs in clinical development. Regulatory authorities
enforce these cGCP through periodic inspections of trial sponsors, principal investigators and trial sites. Compliance with cGCP can be
costly and if we or any of our CROs fail to comply with applicable cGCP, the clinical data generated in our clinical trials may be deemed
unreliable and the FDA, NMPA, EMA, Health Canada or comparable regulatory authorities may require us to perform additional clinical trials
before approving our marketing applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may experience numerous
unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or
commercialize our drug candidates, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulators, institutional review boards (&#8220;IRBs&#8221;) or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment may be insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our contractors and investigators may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a lack of clinical response or a determination that participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulators, IRBs or ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including non-compliance with regulatory requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of clinical trials of our drug candidates may be greater than we anticipate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our drug candidates may cause adverse events, have undesirable side effects or other unexpected characteristics, causing us, our investigators, or regulators to suspend or terminate the trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are required to conduct
additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully
complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only
modestly positive or if they raise safety concerns, we may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">be delayed in obtaining regulatory approval for our drug candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">not obtain regulatory approval at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtain approval for indications that are not as broad as intended;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">have a drug removed from the market after obtaining regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">be subject to additional post-marketing testing requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">be subject to restrictions on how a drug is distributed or used; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">be unable to obtain reimbursement for use of a drug.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delays in testing or approvals
may result in increases in our drug development costs. We do not know whether any clinical trials will begin as planned, will need to
be restructured, or will be completed on schedule, or at all. Clinical trials may produce negative or inconclusive results. Moreover,
these trials may be delayed or proceed less quickly than intended. Delays in completing our clinical trials will increase our costs, slow
down our drug candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues and
we may not have sufficient funding to complete the testing and approval process. Any of these events may significantly harm our business,
financial condition and prospects, lead to the denial of regulatory approval of our drug candidates or allow our competitors to bring
drugs to market before we do, impairing our ability to commercialize our drugs if and when approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant clinical trial
delays also could shorten any periods during which we have the exclusive right to commercialize our drug candidates or allow our competitors
to bring products to market before we do, impair our ability to commercialize our drug candidates and may harm our business and results
of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may in the future conduct clinical trials
for our drug candidates in sites outside the U.S. and the FDA may not accept data from trials conducted in such locations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may in the future conduct
certain of our clinical trials outside the U.S. Although the FDA may accept data from clinical trials conducted outside the U.S. for our
New Drug Application (&#8220;NDA&#8221;), acceptance of this data is subject to certain conditions imposed by the FDA. There can be no
assurance the FDA will accept data from any of the clinical trials we conduct outside the U.S. If the FDA does not accept the data from
any of our clinical trials conducted outside the U.S., it would likely result in the need for additional clinical trials in the U.S.,
which would be costly and time-consuming and could delay or prevent the commercialization of any of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Obtaining Regulatory Approval
for Our Drug Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory approval processes of the
FDA, NMPA, EMA, Health Canada and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable, and
if we are ultimately unable to obtain regulatory approval for our current drug candidates or any future drug candidates we may develop,
our business will be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot commercialize drug
candidates without first obtaining regulatory approval to market each drug from the FDA, NMPA, EMA, Health Canada or comparable regulatory
authorities. Before obtaining regulatory approvals for the commercial sale of any drug candidate for a target indication, we must demonstrate
in studies in animals and well-controlled clinical trials, and, with respect to approval in the United States and other regulatory agencies,
to the satisfaction of the FDA, NMPA, EMA, Health Canada or comparable regulatory authorities, that the drug candidate is safe and effective
for use for that target indication and that the manufacturing facilities, processes and controls are adequate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The time required to obtain
approval from the FDA, NMPA, EMA, Health Canada and other comparable regulatory authorities is unpredictable but typically takes many
years following the commencement of studies in animals and clinical trials and depends upon numerous factors, including the substantial
discretion of the regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, approval policies,
regulations or the type and amount of clinical data necessary to gain approval can differ among regulatory authorities and may change
during the course of the development of a drug candidate. We have not obtained regulatory approval for any drug candidate. It is possible
that neither our existing drug candidates nor any drug candidates we may discover or acquire for development in the future will ever obtain
regulatory approval. Even if we obtain regulatory approval in one jurisdiction, we may not obtain it in other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidates could fail
to receive regulatory approval from any of the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities for many reasons,
including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disagreement with regulators regarding the design or implementation of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to demonstrate that a drug candidate is safe and effective or safe, pure and potent for its proposed indication;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure of clinical trial results to meet the level of statistical significance required for approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to demonstrate that a drug candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disagreement with regulators regarding our interpretation of data from studies in animals or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">insufficiency of data collected from clinical trials of our drug candidates to support the submission and filing of a New Drug Application (&#8220;NDA&#8221;), or other submission or to obtain marketing approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA, NMPA, EMA, Health Canada or a comparable regulatory authority&#8217;s finding of deficiencies related to the manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in approval policies or regulations that render our preclinical studies and clinical data insufficient for approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the FDA, NMPA, EMA,
Health Canada or other comparable regulatory authorities may require more information, including additional preclinical studies or clinical
data, to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development
program. If we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited indications
than we request. Regulatory authorities also may grant approval contingent on the performance of costly post-marketing clinical trials,
or may approve a drug candidate with a label that is not desirable for the successful commercialization of that drug candidate. In addition,
if our drug candidate produces undesirable side effects or involves other safety issues, the FDA may require the establishment of a Risk
Evaluation Mitigation Strategy (&#8220;REMS&#8221;), or NMPA, EMA, Health Canada or other comparable regulatory authorities may require
the establishment of a similar strategy. Such a strategy may, for instance, restrict distribution of our drug candidates, require patient
or physician education, or impose other burdensome implementation requirements on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulatory approval may be substantially
delayed or may not be obtained for one or all of our drug candidates if regulatory authorities require additional time or studies to assess
the safety or efficacy of our drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have any
drug candidates that have gained approval for sale by the FDA, NMPA or EMA, Health Canada or other regulatory authorities in any other
country, and we cannot guarantee that we will ever have marketable drugs. Despite SACT-1 having been granted orphan drug status, this
is not an approval for sale by the FDA. Our business is substantially dependent on our ability to complete the development of, obtain
marketing approval for and successfully commercialize drug candidates in a timely manner. We cannot commercialize drug candidates without
first obtaining marketing approval from the FDA, NMPA, EMA, Health Canada and comparable regulatory authorities. In the U.S., we hope
to file INDs for the drug candidates from our Lead Projects and, subject to the approval of IND, Phase 1 clinical trials in humans. Even
if we are permitted to commence such clinical trials, they may not be successful and regulators may not agree with our conclusions regarding
the data generated by our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable to complete
development of our drug candidates or initiate or complete development of any future drug candidates we may develop on our projected schedule.
While we believe that our existing cash will likely enable us to complete the preclinical development of at least one of our current Lead
Projects, the full clinical development, manufacturing and launch of that drug candidate, will take significant additional time and likely
require funding beyond the existing cash. In addition, if regulatory authorities require additional time or studies to assess the safety
or efficacy of our drug candidates, we may not have or be able to obtain adequate funding to complete the necessary steps for approval
for our drug candidates or any future drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical studies in animals
and clinical trials in humans to demonstrate the safety and efficacy of our drug candidates are time-consuming, expensive and take several
years or more to complete. Delays in preclinical or clinical trials, regulatory approvals or rejections of applications for regulatory
approval in the U.S., Europe, the PRC or other markets may result from many factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our inability to obtain sufficient funds required to conduct or continue a trial, including lack of funding due to unforeseen costs or other business decisions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory reports for additional analysts, reports, data, preclinical studies and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to reach agreement with, or inability to comply with conditions imposed by the FDA, NMPA, EMA, Health Canada or other regulators regarding the scope or design of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory questions regarding interpretations of data and results and the emergence of new information regarding our drug candidates or other products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delay or failure in obtaining authorization to commence a clinical trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care or the ineligibility of a site to participate in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unfavorable or inconclusive results of clinical trials and supportive non-clinical studies, including unfavorable results regarding effectiveness of drug candidates during clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulty in maintaining contact with patients during or after treatment, resulting in incomplete data;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our inability to obtain approval from IRBs or ethics committees to conduct clinical trials at their respective sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our inability to enroll and retain a sufficient number of patients who meet the inclusion and exclusion criteria in a clinical trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our inability to conduct a clinical trial in accordance with regulatory requirements or our clinical protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, withdrawing from or dropping out of a trial, or becoming ineligible to participate in a trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure of our clinical trial managers to satisfy their contractual duties or meet expected deadlines;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">manufacturing issues, including problems with manufacturing or timely obtaining from third parties sufficient quantities of a drug candidate for use in a clinical trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">ambiguous or negative interim results, or results that are inconsistent with earlier results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">feedback from the FDA, NMPA, EMA, Health Canada, an IRB, data safety monitoring boards, or comparable entities, or results from earlier stage or concurrent studies in animals and clinical trials, regarding our drug candidates, including which might require modification of a trial protocol;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unacceptable risk-benefit profile or unforeseen safety issues or adverse side effects; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a decision by the FDA, NMPA, EMA, Health Canada, an IRB, comparable entities, or the Company, or recommendation by a data safety monitoring board or comparable regulatory entity, to suspend or terminate clinical trials at any time for safety issues or for any other reason.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in regulatory requirements
and guidance may also occur, and we may need to amend clinical trial protocols submitted to applicable regulatory authorities to reflect
these changes. Amendments may require us to resubmit clinical trial protocols to IRBs or ethics committees for re-examination, which may
increase the costs or time required to complete a clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we experience delays in
the completion of, or the termination of, a clinical trial, of any of our drug candidates, the commercial prospects of our drug candidates
will be harmed, and our ability to generate product sales revenues from any of those drug candidates will be delayed. In addition, any
delay in completing our clinical trials will increase our costs, slow down our drug candidate development and approval process, and jeopardize
our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects
significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may
also ultimately lead to the denial of regulatory approval of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are required to conduct
additional clinical trials or other studies with respect to any of our drug candidates beyond those that we initially contemplated, if
we are unable to successfully complete our clinical trials or other studies or if the results of these studies are not positive or are
only modestly positive, we may be delayed in obtaining regulatory approval for that drug candidate, we may not be able to obtain regulatory
approval at all or we may obtain approval for indications that are not as broad as intended. Our product development costs will also increase
if we experience delays in testing or approvals, and we may not have sufficient funding to complete the testing and approval process.
Significant clinical trial delays could allow our competitors to bring their products to market before we do and impair our ability to
commercialize our drugs, if and when approved. If any of this occurs, our business will be materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our drug candidates may cause undesirable
adverse events or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved
label, or result in significant negative consequences following any regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable adverse events
caused by our drug candidates or any future drug candidates we may develop could cause us or regulatory authorities to interrupt, delay
or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, NMPA, EMA,
Health Canada or other comparable regulatory authorities. Results of our potential clinical trials could reveal a high and unacceptable
severity or prevalence of adverse effects. In such event, our trials could be suspended or terminated and the FDA, NMPA, EMA, Health Canada
or other comparable regulatory authorities could order us to cease further development of, or deny approval of, our drug candidates for
any or all target indications. Drug-related adverse events could also affect patient recruitment or the ability of enrolled subjects to
complete the trial, could result in potential product liability claims and may harm our reputation, business, financial condition and
business prospects significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if any of our
current or future drug candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such
drugs, a number of potentially significant negative consequences could result, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">suspending the marketing of the drug;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">having regulatory authorities withdraw approvals of the drug;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">adding warnings on the label;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">developing a REMS for the drug or, if a REMS is already in place, incorporating additional requirements under the REMS, or to develop a similar strategy as required by a comparable regulatory authority;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">conducting post-market studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">being sued and held liable for harm caused to subjects or patients; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">damage to our reputation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could prevent
us from achieving or maintaining market acceptance of the particular drug candidate, if approved, and could significantly harm our business,
results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval for
our drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant
additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems
with our drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our drug candidates or any
future drug candidates we develop are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,
storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and
other post-market information, including both federal and state requirements in the United States and requirements of comparable regulatory
authorities outside of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturers and manufacturers&#8217;
facilities are required to comply with extensive requirements from the FDA, NMPA, EMA, Health Canada and comparable regulatory authorities,
including, in the United States, ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, our
contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments
made in any NDA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with whom
we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and
quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we receive for our drug candidates may be subject to limitations on the approved indicated uses for which the drug may be marketed or
to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials
and surveillance to monitor the safety and efficacy of the drug candidate. The regulatory authorities may also require risk management
plans or programs as a condition of approval of our drug candidates (such as REMS of the FDA and risk-management plan of the EMA), which
could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to
ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA,
NMPA, EMA, Health Canada or a comparable regulatory authority approves our drug candidates, we will have to comply with requirements including,
for example, submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with
cGCP and cGMP, for any clinical trials that we conduct post-approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may impose consent
decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
drug reaches the market. Later discovery of previously unknown problems with our drug candidates, including adverse events of unanticipated
severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements,
may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies
to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences
include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">restrictions on the marketing or manufacturing of our drug candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">fines, untitled or warning letters, or holds on clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our drug candidates; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Companies may promote drugs only for the approved
indications and in accordance with the provisions of the approved label and may not promote drugs for any off-label use, such as uses
that are not described in the product&#8217;s labeling and that differ from those approved by the regulatory authorities. However, physicians
may prescribe drug products for off-label uses and such off-label uses are common across some medical specialties. Thus, they may, unbeknownst
to us, use our product for an &#8220;off label&#8221; indication for a specific treatment recipient. The FDA, NMPA, EMA, Health Canada
and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and if we are
found to be out of compliance with the requirements and restrictions imposed on us under those laws and restrictions, we may be subject
to significant liability, including civil and administrative remedies as well as criminal sanctions, and the off-label use of our products
may increase the risk of product liability claims. In addition, management&#8217;s attention could be diverted from our business operations
and our reputation could be damaged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The policies of the FDA, NMPA,
EMA, Health Canada and other regulatory authorities may change and we cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt
to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance,
we may lose any regulatory approval that we may have obtained and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Despite FDA&#8217;s consent for us to pursue
the 505(b)(2) development pathway for SACT-1, we may be unable to successfully complete the 505(b)(2) pathway for the pediatric formulation
of SACT-1 to treat neuroblastoma as planned, which would materially impact our likelihood of obtaining FDA approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even though the FDA is allowing
us to pursue the 505(b)(2) regulatory pathway for our product candidates, we will need to conduct additional clinical trials, provide
additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources
required to obtain FDA approval for our product candidates would likely substantially increase. We cannot assure you that we will receive
the requisite or timely approvals for commercialization of such product candidate. Any failure to obtain regulatory approval of our product
candidates would significantly limit our ability to generate revenues, and any failure to obtain such approval for all of the indications
and labeling claims we deem desirable could reduce our potential revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we or our third-party suppliers fail
to comply with the FDA&#8217;s good manufacturing practice regulations or fail to adequately, timely, or sufficiently respond to an FDA
Form 483 or subsequent Warning Letter, this could impair our ability to market our products in a cost-effective and timely manner and
could result in FDA enforcement action.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our third-party suppliers
are required to comply with the FDA&#8217;s Current Good Manufacturing Practices (cGMP) which covers the methods and documentation of
the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our products.
The FDA audits compliance with the cGMP and related regulations through periodic announced and unannounced inspections of manufacturing
and other facilities. The FDA may conduct these inspections or audits at any time. If, during the inspection, FDA identifies issues which,
in FDA&#8217;s judgment, may constitute violations of the Federal Food, Drug, and Cosmetic Act or FDA&#8217;s regulations, the FDA inspector
may issue an FDA Form 483 listing these observations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Note that if an entity does
not address observations found in an FDA Form 483 to FDA&#8217;s satisfaction, the FDA could take enforcement action, including any of
the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">untitled letters, warning letters,
fines, injunctions, consent decrees and civil penalties;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">customer notifications or recall,
detention or seizure of our product;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">operating restrictions or partial
suspension or total shutdown of production;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">refusing or delaying our requests
for pre-market approval of new products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">withdrawing pre-market approvals
that have already been granted;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">refusal to grant export approval
for our product; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">criminal prosecution.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the foregoing actions
could have a material adverse effect on our reputation, business, financial condition and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Commercialization of Our Drug
Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if any of our drug candidates receive
regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in
the medical community necessary for commercial success.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After we complete clinical
trials and receive regulatory approval for any of our drug candidates, which may not happen for some time, we recognize that such candidate(s)
may ultimately fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community.
We may not be able to achieve or maintain market acceptance of our products over time if new products or technology are introduced that
are more favorably received than our products, are more cost effective or render our drug obsolete. We will face competition with respect
to our drug candidates from other pharmaceutical companies developing products in the same disease/therapeutic area and specialty pharmaceutical
and biotechnology companies worldwide. Many of the companies against which we may be competing have significantly greater financial resources
and expertise in research and development, manufacturing, animal testing, conducting clinical trials, obtaining regulatory approvals and
marketing approval for drugs than we do. Physicians, patients and third-party payors may prefer other novel products to ours, which means
that we may not generate significant sales revenues for that product and that product may not become profitable. The degree of market
acceptance of our drug candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical indications for which our drug candidates are approved;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">physicians, hospitals, and patients considering our drug candidates as a safe and effective treatment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the potential and perceived advantages of our drug candidates over alternative treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the prevalence and severity of any side effects;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product labeling or product insert requirements of the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">limitations or warnings contained in the labeling approved by the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the timing of market introduction of our drug candidates as well as competitive drugs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of treatment in relation to alternative treatments and their relative benefits;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">lack of experience and financial and other limitations on our ability to create and sustain effective sales and marketing efforts or ineffectiveness of our sales and marketing partners; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in legislative and regulatory requirements that could prevent or delay regulatory approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any drug candidates for which we obtain regulatory approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend substantially on the success of
the drug candidates being researched as our current Lead Projects. If we are unable to license or sublicense, sell or otherwise commercialize
our drug candidates, or experience significant delays in doing so, our business will be materially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and the ability
to generate revenue related to product sales, if ever achieved, will depend on the successful development, regulatory approval and licensing
or sublicensing or other commercialization of our drug candidates or any other drug candidates we may develop. We have invested a significant
amount of financial resources in the development of our drug candidates and we may invest in other drug candidates. The success of our
drug candidates and any other potential drug candidates will depend on many factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">successful enrollment in, and completion of, studies in animals and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">other parties&#8217; ability in conducting our clinical trials safely, efficiently and according to the agreed protocol;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">receipt of regulatory approvals from the FDA, NMPA, EMA, Health Canada and other comparable regulatory authorities for our drug candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to establish commercial manufacturing capabilities by making arrangements with third-party manufacturers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reliance on other parties to conduct our clinical trials swiftly and effectively;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">launch of commercial sales of our drug candidates, if and when approved;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtaining and maintaining patents, trade secrets and other IP protection and regulatory exclusivity, as well as protecting our rights in our own IP;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">ensuring that we do not infringe, misappropriate or otherwise violate patents, trade secrets or other IP rights of other parties;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtaining acceptance of our drug candidates by doctors and patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtaining reimbursement from third-party payors for our drug candidates, if and when approved;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to compete with other drug candidates and drugs; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">maintenance of an acceptable safety profile for our drug candidates following regulatory approval, if and when received.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not achieve regulatory
approval and commercialization in a timely manner or at all. Significant delays in obtaining approval for and/or to successfully commercialize
our drug candidates would materially harm our business and we may not be able to generate sufficient revenues and cash flows to continue
our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our IP</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A significant portion of our IP portfolio
currently includes pending patent applications that have not yet been issued as granted patents and if the pending patent applications
covering our product candidates fail to be issued, our business will be adversely affected. If we or our licensors are unable to obtain
and maintain patent protection for our technology and drugs, our competitors could develop and commercialize technology and drugs similar
or identical to ours, and our ability to successfully commercialize our technology and drugs may be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends largely
on our ability to obtain and maintain patent protection&#160;and other forms of IP rights for the composition of matter, method of use
and/or method of manufacture for each of our drug candidates. Failure to obtain, maintain protection, enforce or extend adequate patent
and other IP rights could materially adversely affect our ability to develop and market one or more of our drug candidates. We also rely
on trade secrets and know-how to develop and maintain our proprietary and IP position for each of our drug candidates. Any failure to
protect our trade secrets and know-how with respect to any specific drug and diagnostics technology candidate could adversely affect the
market potential of that potential product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
the Company has, through its licenses, obtained rights to patents and patent applications covering some or all its drug and diagnostics
technology candidates that have been filed in major jurisdictions such as the United States, member states of the European Patent Organization
(the &#8220;EPO&#8221;) and the PRC (collectively, &#8220;Major Patent Jurisdictions&#8221;), as well as in other countries. We have also
filed a number of provisional applications to establish earlier filing dates for certain of our other ongoing researches, the specifics
of which are currently proprietary and confidential. To the extent we do not seek or obtain patent protection in a particular jurisdiction,
we may not have commercial incentive to seek marketing authorization in such jurisdiction. Nonetheless, other parties might enter those
markets with generic versions or copies of our products and received regulatory approval without having significantly invested in their
own research and development costs compared to the Company&#8217;s investment. For more information about our IP portfolio, please refer
to the Intellectual Property section below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to issued patents
in certain jurisdictions, for example in the U.S. and under the EPO, we may be entitled to obtain a patent term extension to extend the
patent expiration date provided we meet the applicable requirements for obtaining such patent term extensions. We have sought to support
our proprietary position by working with our licensors in filing patent applications in the names of the licensors in the United States
and through the PCT, related to the Lead Projects and certain other drug candidates. In the future, we intend to file patent applications
on supplemental or improvement IP derived from the licensed technologies, where those IP would be solely or jointly owned by the Company
pursuant to the terms of respective license agreements. Filing patents covering multiple technologies in multiple countries is time-consuming
and expensive, and we may not have the resources file and prosecute all necessary or desirable patent applications in a timely manner.
It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain
patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain that patents
will be issued or granted with respect to patent applications that are currently pending, or that issued or granted patents will not later
be found to be invalid or unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent position of biotechnology
and pharmaceutical companies is generally uncertain because it involves complex legal and factual considerations. The standards applied
by the EPO, the U.S. Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied uniformly
or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable
in biotechnology and pharmaceutical patents. Consequently, patents may not issue from our pending patent applications and even if they
do issue, such patents may not issue in a form that effectively prevents others from commercializing competing products. As such, we do
not know the degree of future protection that we will have on our proprietary products and technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the issuance
of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts
or patent offices in the United States and abroad. Even if patents do successfully issue and even if such patents cover our drug candidates,
other parties may initiate, for patents filed before March 16, 2013 (i.e., the enactment of the America Invents Act), interference or
re-examination proceedings, for patents filed on or after March 16, 2013, post-grant review,&#160;<i>inter partes</i>&#160;review, nullification
or derivation proceedings, in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope
of such patents, which may result in the patent claims being narrowed or invalidated. Successful defense of its patents can constitute
a material factor in a company&#8217;s expenses. According to an article published by BlueIron (https://finance.yahoo.com/news/current-patent-litigation-costs-between-120200165.html),
depending on the value at stake, the American Intellectual Property Law Association&#8217;s &#8220;2019 Report of the Economic Survey&#8221;
reported the average costs of a patent litigation are between $2.3 million to $4.0 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the fact that
the Company has exclusive rights to prevent others from using a patented invention does not&#160;necessarily&#160;mean that the Company
itself will have the unrestricted right to use that invention.&#160;Other parties may obtain ownership or licenses to patents or other
IP rights that cover the manufacture, use or sale of our current or future products (or elements thereof).&#160;This may enable such other
parties to enforce their patents or IP rights against us, and may, as a result, affect the commercialization of our products or exploitation
of our own technology.&#160;We endeavor to identify early patents and patent applications which may block development of a product or
technology and minimize this risk by conducting prior art searches before and during the projects. However, relevant documents may be
overlooked, yet-to-be published or missed, which may in turn impact on the freedom to commercialize the relevant asset.&#160;In such cases,
we may not be in a position to develop or commercialize products or drug candidates unless we successfully pursue litigation to nullify
or invalidate the other IP rights concerned, or enter into a license agreement with the IP right holder, if available on commercially
reasonable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
the appropriate scope for our patents, our competitors could develop and commercialize technology and drugs similar or identical to ours,
and our ability to successfully commercialize our technology and drugs may be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not obtain sufficient
claim scope in those patents to prevent another party from competing successfully with our drug and diagnostics technology candidates.
Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent
competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our
patents by developing similar or alternative technology or drug and diagnostics technology candidates in a non-infringing manner. The
issuance of a patent is not conclusive as to its scope, validity or enforceability, and our patents may be challenged in the courts or
patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable,
which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology
and drug and diagnostics technology candidates, or limit the duration of the patent protection of our technology and drug and diagnostics
technology candidates. Given the amount of time required for the development, testing and regulatory review of new drug and diagnostics
technology candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As
a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug and diagnostics technology
candidates similar or identical to ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the issuance, scope,
validity, enforceability and commercial value of our and our current or future licensors&#8217; or collaboration partners&#8217; patent
rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued
which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies
and products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect and enforce
our IP rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success will
depend, in part, on our ability to maintain IP protection for our drug candidates in which we seek to develop and commercialize. While
we rely primarily upon a combination of patents, trademarks, trade secrets and other contractual obligations to protect the IP related
to our brands, products and other proprietary technologies, these legal means may afford only limited protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing and prosecuting patents
on drug candidates and defending the validity of the same (if challenged) in all countries throughout the world could be prohibitively
expensive for us, and our IP rights in countries outside the Major Patent Jurisdictions can be less extensive than those in the Major
Patent Jurisdictions. In addition, the laws of some countries in the rest of the world such as India do not protect IP rights to the same
extent as laws in the Major Patent Jurisdictions. Consequently, we may not be able to prevent other parties from practicing our inventions
in the rest of the world, despite our continued efforts in enforcing our IP rights through legal means. Competitors may use our technology
in jurisdictions where we have not or not yet obtained patent protection to develop their own drugs and further, may export otherwise
infringing drugs to non-U.S. jurisdictions where we have patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our, our licensors&#8217; or
collaboration partners&#8217; patent applications cannot be enforced against other parties practicing the technology claimed in such applications
unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. In addition,
patents and other IP rights also will not protect our technology, drug candidates if another party, including our competitors, design
around our protected technology, drug candidates without infringing, misappropriating or otherwise violating our patents or other IP rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, currently and as
our R&amp;D continues to progress, some of our patents and patent applications are or may be co-owned with another party. Some of our
licenses already provide that future-developed technologies (and any resulting patents) will be co-owned with the licensors and other
patents for technologies we may acquire or develop with other parties may also be jointly owned. If we are unable to obtain an exclusive
license to any such co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights
to other persons, including our competitors, and our competitors could market competing products and technology, and we will be unable
to transfer or grant exclusive rights to potential purchasers or development partners of such co-owned technologies. In addition, we may
need the cooperation of any such co-owners of our patents in order to enforce such patents against other parties, and such cooperation
may not be provided to us. Any of the foregoing could limit the revenue we might generate from our patents or patent applications and
thus have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because patent applications
are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors or
collaborators were or will be the first to file any patent application related to a drug and diagnostics technology candidate. Furthermore,
in the United States, if patent applications of other parties have an effective filing date before March&#160;16, 2013, an interference
proceeding can be initiated by such other party to determine who was the first to invent any of the subject matter covered by the patent
claims of our applications. If patent applications of other parties have an effective filing date on or after March&#160;16, 2013, in
the United States a derivation proceeding can be initiated by such other parties to determine whether our invention was derived from theirs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even where we have a valid
and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used
the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, we may be subject
to other challenges regarding our exclusive ownership of our IP. If another party were successful in challenging our exclusive ownership
of any of our IP, we may lose our right to use such IP, such other party may be able to license such IP to other parties, including our
competitors, and our competitors could market competing products and technology. Any of the foregoing could have a material adverse effect
on our competitive position, business, financial conditions, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending IP rights in jurisdictions outside Major Patent Jurisdictions. The legal systems of some
countries do not favor the enforcement of patents, trade secrets and other IP, which could make it difficult in those jurisdictions for
us to stop the infringement or misappropriation of our patents or other IP rights, or the marketing of competing drugs in violation of
our proprietary rights generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not sought
to enforce any issued patents in any jurisdictions. Proceedings to enforce our patent and other IP rights in any jurisdictions could result
in substantial costs and divert our efforts and attention from other aspects of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, such proceedings
could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at
risk of not issuing, and could provoke other parties to assert claims of infringement or misappropriation against us. We may not prevail
in any lawsuits that we initiate in jurisdictions where opposition proceedings are available and the damages or other remedies awarded,
if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing
countries. Certain countries in Europe, the PRC, and developing countries including India, have compulsory licensing laws under which
a patent owner may be compelled to grant licenses to other parties. In those countries, we and our licensors may have limited remedies
if patents are infringed or if we or our licensors are compelled to grant a license to another party, which could materially diminish
the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our IP rights around
the world may be inadequate to obtain a significant commercial advantage from the IP that we develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become involved in lawsuits to protect
or enforce our IP, which could be expensive, time-consuming and unsuccessful. Our patent rights relating to our drug and diagnostics technology
candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable non-U.S. authority.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
patent rights or misappropriate or otherwise violate our IP rights. To counter infringement or unauthorized use, litigation may be necessary
in the future to enforce or defend our IP rights, to protect our trade secrets or determine the validity and scope of our own IP rights
or the proprietary rights of others. This can be expensive and time-consuming. Any claim that we assert against perceived infringers could
also provoke these parties to assert counterclaims against us alleging that we infringe their IP rights. Many of our current and potential
competitors have the ability to dedicate substantially greater resources to enforce and/or defend their IP rights than we can. Accordingly,
despite our efforts, we may not be able to prevent other parties from infringing upon or misappropriating our IP. Litigation could result
in substantial costs and diversion of management resources, which could harm our business and financial results. In addition, in an infringement
proceeding, a court may decide that patent rights or other IP rights owned by us are invalid or unenforceable, or may refuse to stop the
other party from using the technology at issue on the grounds that our patent rights or other IP rights do not cover the technology in
question. An adverse result in any litigation proceeding could put our patent, as well as any patents that may issue in the future from
our pending patent applications, at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the
substantial amount of discovery required in connection with IP litigation, there is risk that some of our confidential information could
be compromised by disclosure during this type of litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we initiate legal proceedings
against another party to enforce our patent, or any patents that may be issued in the future from our patent applications, that relates
to one of our drug and diagnostics technology candidates, the defendant could counterclaim that such patent rights are invalid or unenforceable.
In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there
are numerous grounds upon which another party can assert invalidity or unenforceability of a patent. Parties may also raise similar claims
before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include ex parte
re-examination,&#160;<i>inter partes</i>&#160;review, post-grant review, derivation and equivalent proceedings in non-U.S. jurisdictions,
such as opposition proceedings. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer
cover and protect our drug and diagnostics technology candidates. With respect to the validity of our patents, for example, there may
be invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were
to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection
on our drug and diagnostics technology candidates. Such a loss of patent protection could have a material adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to prevent
misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights
as fully as in the United States. Furthermore, because of the substantial amount of discovery required in connection with IP litigation,
there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our patents and other IP.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we are not currently
experiencing any claims challenging the inventorship of our patents or ownership of our IP, we may in the future be subject to claims
that former employees, collaborators or other parties have an interest in our patents or other IP as inventors or co-inventors. For example,
we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our drug
and diagnostics technology candidates and who have not clearly contracted to transfer or assign any rights they may have to the Company.
In addition, for our licensed patents, although a majority of our licensors have procured assignment forms and records from inventors
to affirm their ownership in the licensed IP, another party or former employee or collaborator of our licensors not named in the patents
may challenge the inventorship of claim an ownership interest in one or more of our or our licensors&#8217; patents.&#160;Litigation may
be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to
paying monetary damages, we may lose rights such as exclusive ownership of, or right to use, our patent rights or other IP. Such an outcome
could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result
in substantial costs and be a distraction to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are sued for infringing IP rights
of other parties, such litigation could be costly and time-consuming and could prevent or delay us from developing or commercializing
our drug candidates, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and other IP rights of other parties. There is a substantial amount of litigation
involving patent and other IP rights in the biotechnology and pharmaceutical industries. Numerous issued patents, provisional patents
and pending patent applications, which are owned by other parties, exist in the fields in which we are developing drug candidates. As
the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our drug candidates may give
rise to claims of infringement of the patent rights of others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other parties may assert that
we are employing their proprietary technology without authorization. There may be other patents of which we are currently unaware with
claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our drug candidates.
Because patent applications can take many years to issue, there may be currently pending patent applications or provisional patents which
may later result in issued patents that our drug candidates may infringe. In addition, other parties may obtain patents in the future
and claim that use of our technology infringes upon these patents. If any other patents were held by a court of competent jurisdiction
to cover the manufacturing process of any of our drug candidates, any molecules formed during the manufacturing process or any final drug
itself, the holders of any such patents may be able to prevent us from commercializing such drug candidate unless we obtain a license
under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly,
if any other patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or
methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability
to develop and commercialize the applicable drug candidate unless we obtain a license, limit our uses, or until such patent expires, or
is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable
terms or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other parties who bring successful
claims against us for infringement of their IP rights may obtain injunctive or other equitable relief, which could prevent us from developing
and commercializing one or more of our drug candidates. Defense of these claims, regardless of their merits, would involve substantial
litigation expense and be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
or misappropriation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees in the case
of willful infringement, obtain one or more licenses from other parties, pay royalties or redesign our infringing drug candidates, which
may be impossible or require substantial time and monetary expenditure. In the event of an adverse result in any such litigation, or even
in the absence of litigation, we may need to obtain licenses from other parties to advance our research or allow commercialization of
our drug candidates. Any required license may not be available at all, or may not be available on commercially reasonable terms. In the
event that we are unable to obtain such a license, we would be unable to further develop and commercialize one or more of our drug candidates,
which could harm our business significantly. We may also elect to enter into license agreements in order to settle patent infringement
claims or resolve disputes prior to litigation, and any such license agreements may require us to pay royalties and other fees that could
significantly reduce our profitability for any product related to that patent and thus harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if resolved in our favor,
litigation or other legal proceedings relating to IP claims may cause us to incur significant expenses, and could distract our technical
personnel, management personnel, or both from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be
negative, it could have a substantial adverse effect on the market price of our Class A Ordinary Shares. Such litigation or proceedings
could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing
or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their
greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could
have a material adverse effect on our ability to compete in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There may be patent applications pending
of which we are not aware, but which cover similar products to the ones we are attempting to license or develop, which may result in lost
time and money, as well as litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that we have
failed to identify relevant outstanding patents or applications. For example, U.S. applications filed before November&#160;29, 2000 and
certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents are
issued. Patent applications filed in the United States after November 29, 2000 and generally filed elsewhere are published approximately
18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority
date. Therefore, patent applications covering our products could have been filed by others without our knowledge. Additionally, pending
patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our products
or the use of our products. Holders of any such unanticipated patents or patent applications may actively bring infringement claims against
us, with the same potential litigation consequences as alluded to elsewhere in this annual report. Any of these events could require us
to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance fees on
any issued patent are due to be paid to the USPTO and other patent agencies in several stages over the lifetime of the patent. The USPTO
and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other
similar provisions during the patent application process. Although an inadvertent lapse can in many cases be cured by payment of a late
fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance
events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within
prescribed time limits, non-payment of fees, and failure to properly submit documents requesting an extension of time. In any such event,
our competitors might be able to enter the market, which would have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The terms of our patents may not be sufficient
to effectively protect our drug and diagnostics technology candidates and business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In most countries in which
we file, including the United States, the term of an issued patent is generally 20 years from the earliest claimed filing date of a non-provisional
patent application in the applicable country. Although various extensions may be available, the life of a patent and the protection it
affords is limited. For example, depending upon the timing, duration and specifics of the FDA regulatory approval for our drug candidates,
one or more of our U.S. patents, if issued, might be eligible for limited patent term restoration under the Drug Price Competition and
Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension
of up to five years as compensation for patent term lost during drug development and the FDA regulatory review process. Patent term extensions,
however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval by the FDA, and only one
patent can be extended for a particular drug. The application for patent term extension is subject to approval by the USPTO, in conjunction
with the FDA. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply
prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period
or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension for a given
patent or the term of any such extension is less than we request, the period during which we will have the right to exclusively market
our drug will be that of the originally issued patents themselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if patents covering one
of our drug candidates are obtained, thereby giving us a period of exclusivity for manufacturing and marketing that drug, we will not
be able to assert such patent rights upon the expiration of the issued patents against potential competitors who may begin marketing generic
copies of our medications, and our business and results of operations may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in patent law in the United States
could diminish the value of patents in general, thereby impairing our ability to protect our drug and diagnostics technology candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The United States has recently
enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope
of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to
increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the value of patents once obtained, if any. Depending on decisions by the U.S. Congress, the federal courts and the USPTO,
the laws and regulations governing patents in the United States could change in unpredictable ways that would weaken our ability to obtain
new patents, or to enforce our existing patents and patents that we might obtain in the future. For example, in a recent case,&#160;<i>Assoc.
for Molecular Pathology v. Myriad Genetics, Inc.</i>, the U.S. Supreme Court held that certain claims to naturally-occurring substances
are not patentable. Although we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision,
future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patent rights. There could be similar changes
in the laws of foreign jurisdictions that may impact the value of our patent rights or our other IP rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, recent patent
reform legislation in the U.S., including the Leahy-Smith America Invents Act, or the America Invents Act, could increase those uncertainties
and costs. The America Invents Act was signed into law on September&#160;16, 2011, and many of the substantive changes became effective
on March&#160;16, 2013. The America Invents Act reforms U.S. patent law in part by changing the U.S. patent system from a &#8220;first
to invent&#8221; system to a &#8220;first inventor to file&#8221; system, expanding the definition of prior art, and developing a post-grant
review system, thus changing the U.S. patent law in a way that may weaken our ability to obtain patent protection in the U.S. for those
applications filed after March&#160;16, 2013. Further, the America Invents Act created new procedures to challenge the validity of issued
patents in the U.S., including post-grant review and<i>&#160;inter&#160;</i>partes&#160;review proceedings, which some other parties have
been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent with an effective filing
date of March&#160;16, 2013 or later, a petition for post-grant review can be filed by another party in a nine-month window from issuance
of the patent. A petition for<i>&#160;inter partes</i>&#160;review can be filed immediately following the issuance of a patent if the
patent has an effective filing date prior to March&#160;16, 2013. A petition for<i>&#160;inter partes</i>&#160;review can be filed after
the nine-month-period for filing a post-grant review petition has expired for a patent with an effective filing date of March&#160;16,
2013 or later. Post-grant review proceedings can be brought on any ground of invalidity, whereas<i>&#160;inter partes</i>&#160;review
proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the USPTO review
patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts, and use a lower burden
of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or other party
to have a U.S. patent invalidated in a USPTO post-grant review or&#160;<i>inter partes</i>&#160;review proceeding than invalidated in
a litigation in a U.S. federal court. If any of our patents are challenged by another party in such a USPTO proceeding, there is no guarantee
that we or our licensors or collaborators will be successful in defending the patent, which would result in our loss of the challenged
patent right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our issued patents,
provisional patent, and pending patent applications, we expect to rely on trade secrets, including unpatented know-how, technology and
other proprietary information, to maintain our competitive position and protect our drug and diagnostics technology candidates. We seek
to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties that have access
to them, such as our employees, corporate collaborators, outside scientific collaborators, sponsored researchers, contract manufacturers,
consultants, advisors and other parties. We also enter into confidentiality and invention or patent assignment agreements with our employees
and consultants. However, any of these parties may breach such agreements and disclose our proprietary information, and we may not be
able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret
can be difficult, expensive and time-consuming, and the outcome is unpredictable. If trade secrets which are material to our business
were to be obtained by a competitor, our competitive position would be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our employees
have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we try to ensure that
our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or
these employees have used or disclosed IP, including trade secrets or other proprietary information, of any such employee&#8217;s former
employer. In addition, while we typically require our employees, consultants and contractors who may be involved in the development of
IP to execute agreements assigning such IP to us, we may be unsuccessful in executing such an agreement with each party who in fact develops
IP that we regard as our own, which may result in claims by or against us related to the ownership of such IP. We are not aware of any
threatened or pending claims that any of our projects involve misappropriated IP or other proprietary information, but in the future litigation
may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may
lose valuable IP rights. Even if we are successful in defending against such claims, litigation could result in substantial costs and
be a distraction to management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to execute on the optimal
development plan for one or more of our existing product candidates if we are unable to obtain or maintain necessary rights for some aspect
of the developing technology through acquisitions or licenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our existing programs currently
use or may in the future use additional technologies subject to proprietary rights held by others, such as particular compositions or
methods of manufacture, treatment or use. The licensing and acquisition of IP rights is a competitive area, and more established companies
may pursue strategies to license or acquire such IP rights that we may consider necessary or useful. These established companies may have
a competitive advantage over us due to their size, cash resources and greater capabilities in clinical development and commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, companies that
perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire IP rights
on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain or maintain licenses
or other rights from other parties to use IP of those parties, our business, financial condition and prospects for growth could suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with our obligations
in the agreements under which we license IP rights from other parties or otherwise experience disruptions to our business relationships
with our licensors, we could be required to pay monetary damages or could lose license rights that are important to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our projects (including
our Lead Projects) are based on IP which we have licensed from other parties. (See &#8220;Item 4. Information on the Company &#8211; B.
Business Overview &#8211; Intellectual Property&#8221;) Certain of these license agreements impose diligence, development or commercialization
obligations on us, such as obligations to pay royalties on net product sales of our drug candidates once commercialized by us, to pay
a percentage of sublicensing revenues if the licensed product is sublicensed, to make other specified milestone and/or annual payments
relating to our drug candidates or to pay license maintenance and other fees, as well as obligations to pursue commercialization with
due diligence. Specifically, a number of our license agreements also require us to meet development timelines in order to maintain the
related license(s). In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such
license agreements and might therefore seek to terminate the license agreements. If one of our licensors, despite our efforts, were to
be successful in terminating its agreement with us, we would not be able to continue to develop, manufacture or market any drug candidate
under that license agreements, and we could face claims for monetary damages or other penalties under that agreement. Such an occurrence
would diminish or eliminate the value of that project to our Company, even if we are able to negotiate new or reinstated agreements, which
may have less favorable terms. Depending on the importance of the IP and the related project, any such development could have a material
adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, disputes may arise
regarding intellectual property subject to a licensing agreement, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the priority of invention of patented technology.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the agreements
under which we currently license intellectual property or technology from other parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow
what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our
financial or other obligations under the relevant agreement, either of which (depending on the importance of the IP and the related project)
could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes
over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangement for a project
on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug and diagnostics technology
candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not have complete control of the
preparation, filing and prosecution of patent applications, or to maintain patents, licensed by us from other parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has in-licensed,
and may in the future in-license patents owned or controlled by others for our use as part of our development plans. We also may out-license
or sublicense patents which we own or control in collaborations with others for development and commercialization of our products. In
either case, the continuing right to control the preparation, filing and prosecution of patent applications, or to maintain the patents,
covering technology under development is a matter for negotiation and we may not always be the party that obtains such control, in which
case we will be reliant on our licensors, collaboration partners or sublicensees for determining strategies with respect to those patents.
For our existing licenses, while we have an understanding with most of the licensors who maintain control over patent prosecution and
we have jointly appointed and engaged patent agents nominated by us under one or more of our licenses, we cannot guarantee that such licensors
or collaborators will always accept prosecution strategies proposed by us and/or our patent agents. Therefore, these patents and applications
may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our current or future licensors
or collaboration partners fail to establish, maintain or protect such patents and other IP rights, such rights may be reduced or eliminated.
If our licensors or joint development partners are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement
of any patent rights, such patent rights could be compromised.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Reliance on Unrelated
Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on unrelated parties to conduct
discovery and further improvement of our innovations and licensed technologies, as well as our preclinical studies and clinical trials.
If these unrelated parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain
regulatory approval for or commercialize our drug candidates, and our business could be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relied upon and plan
to continue to rely upon CROs and collaborating institutions to monitor and manage data for our ongoing preclinical studies and programs.
We rely on these parties for execution of preclinical studies and clinical trials, and control only certain aspects of their activities.
Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal,
and regulatory requirements and scientific standards, and our reliance on the CROs and collaborating institutions does not relieve us
of our regulatory responsibilities. If CROs, collaborating institutions or clinical investigators do not successfully carry out their
contractual duties or obligations or meet expected deadlines, development of our product candidates could be delayed and our business
could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our CROs and collaborating
institutions, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures
and the handling, use, storage, treatment and disposal of hazardous materials and waste. In the event of contamination or injury resulting
from our use of hazardous materials, we might be held liable for any resulting damages, and any liability could exceed our resources.
We could also be subject to civil or criminal fines and penalties, and significant associated costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If an IND for one of our drug candidates
requires significantly larger quantities of the candidate to be tested, we expect to rely on unrelated parties to manufacture supplies
of that candidate. If those unrelated parties fail to provide us with sufficient quantities of clinical supply on that candidate or fail
to do so at acceptable quality levels or prices, or fail to maintain required cGMP licenses, we may not be able to manufacture that candidate
in sufficient quantities to conduct the necessary human trials. Should the failure by the CRO occur in anticipation of or after marketing
approval of that candidate, we may be unable to generate as much revenue as rapidly (and such revenue may not be as profitable) as we
had anticipated.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture of many drug
products, particularly in commercial quantities, can be complex and may require significant expertise and capital investment, particularly
if the development of advanced manufacturing techniques and process controls are required. We intend to contract with outside contractors
to manufacture clinical supplies and process our drug candidates. We have not yet had our drug candidates to be manufactured or processed
on a commercial scale and may not be able to do so for any of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we expect to engage contract
manufacturers, the Company will be exposed to the following risks:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we might be unable to identify manufacturers on acceptable terms or at all because the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities must approve any manufacturers we determine to use and any potential manufacturer may be unable to satisfy federal, state or international regulatory standards;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">although we would be choosing manufacturers with the type of experience most suitable for our drug candidates, it is possible that our contract manufacturers may not be able to execute unique manufacturing procedures and other logistical support requirements we have developed and they might require a significant amount of support from us to implement and maintain the infrastructure and processes required to manufacture our particular drug candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our contract manufacturers might be unable to reproduce the quantity and quality of the drugs we need to meet our clinical and commercial needs within the time frames when we require those drugs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our contract manufacturers may breach their contracts with us, including by not performing as agreed or not devoting sufficient resources to our drug candidates, or they may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">even if initially accepted by regulatory authorities, a manufacturer remains subject to ongoing periodic unannounced inspection by regulatory authorities to ensure strict compliance with cGMP and other government regulations, and our contract manufacturers may fail to comply with these regulations and requirements, resulting in rescission of cGMP licenses and our inability to continue using their services, requiring us to find a replacement manufacturer;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">depending on the terms of our agreement with a manufacturer, we may not own, or may have to share, the IP rights to any improvements made by the manufacturer in the manufacturing process for our drug candidates; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of these risks could delay
or prevent the completion of our clinical trials or the approval of any of our drug candidates by the FDA, NMPA, EMA, Health Canada or
other comparable regulatory authorities, result in higher costs or adversely impact commercialization of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also responsible for
quality control by our manufacturers. We intend to rely on those unrelated-party manufactures to perform certain quality assurance tests
on our drug candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients
could be put at risk of serious harm and the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities could place significant
restrictions on our Company until deficiencies are remedied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturers of drug products
often encounter difficulties in production, particularly in scaling up or out, validating the production process, and assuring high reliability
of the manufacturing process (including the absence of contamination). These problems include logistics and shipping, difficulties with
production costs and yields, quality control, including stability of the product, product testing, operator error, availability of qualified
personnel, as well as compliance with strictly enforced federal, state and non-U.S. regulations. Furthermore, if contaminants are discovered
in our supply of our drug candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended
period of time to investigate and remedy the contamination. It is possible that stability failures or other issues relating to the manufacture
of our drug candidates may occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource
constraints, or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these
difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our drug candidate to patients in
clinical trials would be jeopardized. Any delay or interruption in the manufacturing of clinical trial supplies could delay the completion
of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require
us to begin new clinical trials with additional costs or terminate clinical trials completely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Review of changes in the manufacturing process
of our drug candidates could cause delays resulting from the need for additional regulatory approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in a process or procedure
for manufacturing one of our drug candidates, including a change in the location where the drug candidate is manufactured or a change
of a contract manufacturer, could require prior review by the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities
and approval of the manufacturing process and procedures in accordance with the FDA, NMPA, EMA, or Health Canada&#8217;s regulations,
or comparable requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The new facility
will also be subject to pre-approval inspection. In addition, we would have to demonstrate that the product made at the new facility is
equivalent to the product made at the former facility by physical and chemical methods, which are costly and time-consuming. It is also
possible that the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities may require clinical testing as a way to prove
equivalency, which would result in additional costs and delay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Diagnostics Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products could in the future be subject
to additional regulation by the U.S. Food and Drug Administration or other domestic and international regulatory agencies, which could
increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has statutory authority
to assure that medical devices and&#160;in&#160;vitro&#160;diagnostics, including those where the Paths<sup>Dx</sup> Test technology may
be utilized, are safe and effective for their intended uses. Should the Paths<sup>Dx</sup> Test technology be utilized in U.S. as a Laboratory
Developed Test (LDT), the FDA has historically exercised its enforcement discretion and may not enforce applicable provisions of the FDC
Act and regulations with respect to LDTs. We believe the Paths<sup>Dx</sup> Test may not be subject to the FDA&#8217;s enforcement of
its medical device regulations and the applicable FDC Act provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, if and when we utilize
the Paths<sup>Dx</sup> Test technology in the U.S., the FDA may disagree with our assessment that the Paths<sup>Dx</sup> Test falls within
the definition of an LDT and seek to regulate the Paths<sup>Dx</sup> Test as medical devices. If the FDA determines that our products
are subject to such requirements, we could be subject to enforcement action, including administrative and judicial sanctions, and additional
regulatory controls and submissions for the Paths<sup>Dx</sup> Test, all of which could be burdensome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, certain of our
products or related applications could be subject to additional FDA regulation. Even where a product is not subject to FDA clearance or
approval requirements, the FDA may impose restrictions as to the types of customers to which we can market and sell our products. Such
regulation and restrictions may materially and adversely affect our business, financial condition and results of operations. Other regulatory
regimes that do not currently present material challenges but that could in the future subject to regulations include biosecurity should
our Paths<sup>Dx</sup> Test technology be utilized in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, many countries
have laws and regulations that could affect our products and which could limit our ability to sell our products in those countries. The
number and scope of these requirements are increasing. We may not be able to obtain regulatory approvals in such countries or may incur
significant costs in obtaining or maintaining foreign regulatory approvals. For example, the European Union, or EU, is transitioning from
the existing European Directive 98/79/EC on in vitro diagnostic medical devices, or In Vitro Diagnostic Directive (IVDD), to the In Vitro
Diagnostic Device Regulation (EU) 2017/746 (IVDR), which imposes stricter requirements for the marketing and sale of medical devices,
including in the area of clinical evaluation requirements, quality systems and post-market surveillance. The IVDR is expected to become
effective in May 2022. It is likely that we will be impacted by this new regulation, either directly as a manufacturer of IVDs, or indirectly
as a supplier to customers who are placing IVDs in the EU market for clinical or diagnostic use. Complying with the requirements of the
IVDR may require us to incur significant expenditures. Failure to meet these requirements could adversely impact our business in the EU
and other regions that tie their product registrations or chemical regulations to the EU requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Industry, Business and
Operation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not comply with laws regulating
the protection of the environment and health and human safety, our business could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
operations involve the use of hazardous materials, chemicals and various radioactive compounds/radiation. Our R&amp;D Center may maintain
quantities of various flammable and toxic chemicals in our facilities that are required for our research, development and manufacturing
activities. We are subject to local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous
materials and of medical waste at the jurisdictions where we operate our research facilities, which are currently limited to Hong Kong.
We believe our procedures for storing, handling and disposing of these materials comply with the relevant guidelines and laws of the jurisdictions
in which our facilities are located. Although we believe that our safety procedures for handling and disposing of these materials comply
with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated.
If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental,
health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and
the handling of biohazardous materials and medical waste.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we maintain workers&#8217;
compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these
materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental
liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or
radioactive materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future.
We may incur substantial costs to comply with, and substantial fines or penalties, if we violate any of these laws or regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future success depends on our ability
to retain our Chief Executive Officer, our scientific and clinical advisors, and other key executives and to attract, retain and motivate
qualified personnel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent on
Ian Huen, our Chief Executive Officer, as well as, other principal members of our management teams, scientific teams as well as scientific
and clinical advisors. Although we have formal employment agreements, which we refer to as appointment letters, with all of our executive
officers, these agreements do not prevent our executives from terminating their employment with us at any time, subject to applicable
notice periods. Nevertheless, the loss of the services of any of these persons could impede the achievement of our research, development
and commercialization objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To induce valuable employees
to remain at our Company, in addition to salary and cash incentives, we provide share incentive grants that vest over time. The value
to employees of these equity grants that vest over time may be significantly affected by movements in the price of our Class A Ordinary
Shares that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Although
we have appointment letters with our key employees, any of our employees could resign at any time, with 1-month to 3-months prior written
notice or with payment in lieu of notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recruiting and retaining qualified
officers, scientific, clinical, sales and marketing personnel or consultants will also be critical to our success. In addition, we rely
on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery and preclinical studies
development and commercialization strategy. The loss of the services of our executive officers or other key employees and consultants
could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully
implement our business strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, replacing executive
officers and key employees or consultants may be difficult and may take an extended period of time, because of the limited number of individuals
in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize
drug and diagnostics technology candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train,
retain or motivate these key personnel or consultants on acceptable terms given the competition among numerous pharmaceutical and biotechnology
companies for similar personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also experience competition
for the hiring of scientific and clinical personnel from universities and research institutions. Our consultants and advisors may be employed
by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability
to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to increase the size and capabilities
of our organization, and we may experience difficulties in managing our growth.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual
report, we have 3 full-time employees. Of these, 3 full-time are engaged in general and administrative functions. As of the date of this
annual report, 3 of our employees are located in Asia. In addition, we have engaged and may continue to engage 10 independent contracted
consultants and advisors to assist us with our operations. As our development and commercialization plans and strategies develop, and
as we have transitioned into operating as a public company, we will need to establish and maintain effective disclosure and financial
controls and make changes in our corporate governance practices. We will need to add a significant number of additional managerial, operational,
sales, marketing, financial and other personnel with the appropriate public company experience and technical knowledge and we may not
successfully recruit and maintain such personnel. Future growth will impose significant added responsibilities on members of management,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">managing our internal development efforts effectively, including clinical, the FDA or other comparable regulatory authority review process for our drug and diagnostics technology candidates, while complying with our contractual obligations to contractors and others; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">improving our operational, financial and management controls, reporting systems and procedures.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we refine our operational
strategy to streamline operations, we have adjusted our employment model. The company has shifted from a direct employment approach to
outsourcing key functions, including research and development and back-office operations. While this allows for greater focus and flexibility,
it also introduces dependencies on third-party vendors, which may present new risks related to quality control, data security, and operational
continuity that we are actively managing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future financial performance
and our ability to commercialize our drug candidates will depend, in part, on our ability to effectively manage our future growth, and
our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a
substantial amount of time to managing these growth activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely, and for
the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants for significant
input in selecting and evaluating new products to pursue. These independent organizations, advisors and consultants may not continue to
be available to us on a timely basis when needed, and in such case, we may not have the ability to find qualified replacements. In addition,
if we are unable to effectively manage our outsourced activities, or if the quality or accuracy of the services provided by consultants
is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory
approval of our drug candidates or otherwise advance our business. Furthermore, we may not be able to manage our existing consultants
or find other competent outside contractors and consultants on economically reasonable terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are not able to effectively
expand our organization by hiring new employees, outsourcing works or expanding our groups of consultants and contractors, we may not
be able to successfully implement the tasks necessary to further develop and commercialize our drug and diagnostics technology candidates
and, accordingly, may not achieve our research, development and commercialization goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We intend to seek additional collaborations,
strategic alliances or acquisitions or enter into royalty-seeking or sublicensing arrangements in the future, but we may not realize the
benefits of these arrangements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to form or seek strategic
alliances, create joint ventures or collaborations, acquire complimentary products, IP rights, technology or businesses or enter into
additional licensing arrangements with unrelated parties that we determine may complement or augment our development and commercialization
efforts with respect to our drug and diagnostics technology candidates. Any of these relationships may require us to incur non-recurring
and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our
management and business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will face significant competition
in seeking appropriate strategic partners and the negotiation process is likely to be time-consuming, costly and complex. Moreover, we
may not be successful in our efforts to establish a strategic partnership or another alternative arrangement for any of our drug and diagnostics
technology candidates because their state of development may be deemed to be too early for collaborative effort and others may not view
our drug candidates as having the requisite potential to demonstrate safety and efficacy. If and when we enter into an agreement with
a collaboration partner or sublicensee for development and commercialization of a drug or diagnostics technology candidate, we can expect
to relinquish some or all of the control over the future success of that drug candidate to the unrelated-party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, even if we enter into
a collaboration involving any of our drug and diagnostics technology candidates, the arrangement will be subject to numerous risks, which
may include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaborators will likely have significant discretion in determining the efforts and resources that they will apply to a collaboration;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaborator may ultimately choose not pursue development and commercialization of our drug or diagnostics technology candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaborator may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a drug or diagnostics technology candidate, repeat or conduct new clinical trials, or require a new formulation of a drug or diagnostics technology candidate for clinical testing;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaborator could independently develop, or develop with unrelated parties, drugs that compete directly or indirectly with our drugs or drug candidates;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to their marketing and distribution;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaborator may not properly maintain or defend our IP rights or may use our IP or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our IP or proprietary information or expose us to potential liability;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disputes may arise between us and the collaborator that cause the delay or termination of the research, development or commercialization of our drug and diagnostics technology candidates, or that result in costly litigation or arbitration that diverts management attention and resources;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaboration may be terminated and, if terminated, may result the Company needing additional capital to pursue further development or commercialization of the applicable drug and diagnostics technology candidates;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaborator may own or co-own IP covering our drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such IP;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaboration may result in increased operating expenses or the assumption of indebtedness or contingent liabilities; and&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the collaboration arrangement may result in the loss of key personnel and uncertainties in our ability to maintain key business relationships.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, if we enter into
collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the benefit of such transactions,
which could delay our timelines or otherwise adversely affect our business. Following a strategic transaction or license, we may not achieve
the revenue or specific net income that justifies such transaction. If we are unable to reach agreements with a suitable collaborator
on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug or diagnostics technology candidate,
reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce
the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities
at our own expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to enter into collaborations,
we may seek to fund and undertake development or commercialization activities on our own, but we may not have sufficient funds or expertise
to undertake the necessary development and commercialization activities. In such a case, we may not be able to further develop our drug
and diagnostics technology candidates or bring them to market and generate product sales revenue, which would harm our business prospects,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our employees, independent contractors,
consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory
standards and requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the risk
of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors.
Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA and
other similar non-U.S. regulatory authorities; provide true, complete and accurate information to the FDA and other similar non-U.S. regulatory
authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States
and similar non-U.S. fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities
to us. If we obtain the FDA approval for any of our drug and diagnostics technology candidates and begin commercializing those drugs in
the United States, our potential exposure under U.S. laws will increase significantly and our costs associated with compliance with such
laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators of our
sponsored researches and research patients and our use of information obtained in the course of patient recruitment for clinical trials,
as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare
items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent
fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing,
discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements
generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is not always possible to
identify and deter misconduct by employees and other parties, and the precautions we take to detect and prevent this activity may not
be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are
not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including
the imposition of significant fines or other sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our disclosure controls and procedures may
not prevent or detect all errors or acts of fraud.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our disclosure controls and
procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange
Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that any disclosure
controls and procedures, or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These inherent limitations
include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.
Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized
override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud
may occur and not be detected, which&#160;would likely cause investors to lose confidence in our reported financial information. This
could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of our Class
A Ordinary Shares. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse
of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil
or criminal sanctions. We may also be required to restate our financial statements from prior periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to establish and maintain proper
internal financial reporting controls, our ability to produce accurate financial statements or comply with applicable regulations could
be impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Section 404 of
the Sarbanes-Oxley Act, we are required to file a report by our management on our internal control over financial reporting, including
an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However,
while we remain a non-accelerated filer, we will not be required to include an attestation report on internal control over financial reporting
issued by our independent registered public accounting firm. The presence of material weaknesses in internal control over financial reporting
could result in financial statement errors which, in turn, could lead to errors in our financial reports and/or delays in our financial
reporting, which could require us to restate our operating results. In connection with the audit of our financial statements for the year
ended December 31, 2023, we and our independent registered public accounting firm identified one material weakness in our internal control
over financial reporting, as defined in the standards established by the Public Company Accounting Oversight Board of the United States.
The material weakness identified was the lack of dedicated resources to take responsibility for the finance and accounting functions and
the preparation of financial statements in compliance with generally accepted accounting principles in the United States, or U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have took actions to remediate
the abovementioned material weakness:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide trainings to staff regarding to the preparation of financial statements in compliance with generally accepted accounting principles in the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">change to a new and well-established accounting system to enhance effectiveness and financial and system control;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">establish clear roles and responsibilities for accounting and financial reporting staff to address finance and accounting issues; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">continue to monitor the improvement on internal control over financial reporting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, since we are still
in the process of replenishing and building up a qualified finance and accounting team with sufficient dedicated resources, our management
assessed that the deficiency related to the lack of dedicated resources to take responsibility for the finance and accounting functions
and the preparation of financial statements in compliance with generally accepted accounting principles in the United States, or U.S.
GAAP, still existed as of December 31, 2023. We cannot assure you that we will not identify additional material weaknesses or significant
deficiencies in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management concluded that
our internal controls over financial reporting were not effective as of December 31, 2023. Investors may lose confidence in our operating
results, the price of the Class A Ordinary Shares could decline and we may be subject to litigation or regulatory enforcement actions.
In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, the Class A Ordinary Shares may not be
able to remain listed on the NASDAQ Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may market our products, if approved,
globally; if we do, we will be subject to the risk of doing business internationally.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate and expect to operate
in various countries, and we may not be able to market our products in, or develop new products successfully for, these markets. We may
also encounter other risks of doing business internationally including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unexpected changes in, or impositions of, legislative or regulatory requirements;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">efforts to develop an international sales, marketing and distribution organization may increase our expenses, divert our management&#8217;s attention from the acquisition or development of drug candidates or cause us to forgo profitable licensing opportunities in these geographies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the occurrence of economic weakness, including inflation or political instability;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the effects of applicable non-U.S. tax structures and potentially adverse tax consequences;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">differences in protection of our IP rights including patent rights of other parties;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the burden of complying with a variety of foreign laws including difficulties in effective enforcement of contractual provisions;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays resulting from difficulty in obtaining export licenses, tariffs and other barriers and restrictions, potentially longer payment cycles, greater difficulty in accounts receivable collection and potentially adverse tax treatment; and&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are subject
to general geopolitical risks in foreign countries where we operate, such as political and economic instability and changes in diplomatic
and trade relationships, which could affect, among other things, customers&#8217; inventory levels and consumer purchasing, which could
cause our results to fluctuate and our net sales to decline. The occurrence of any one or more of these risks of doing business internationally,
individually or in the aggregate, could materially and adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we engage in future acquisitions or strategic
partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities,
and subject us to other risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may evaluate various acquisitions
and strategic partnerships, including licensing or acquiring complementary products, IP rights, technology or businesses. Any potential
acquisition or strategic partnership may entail numerous risks, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">increase in operating expenses
and cash requirements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the assumption of additional
indebtedness or contingent liabilities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the issuance of our equity securities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">assimilation of operations,
IP and products of an acquired company, including difficulties associated with integrating new personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the diversion of our management&#8217;s
attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">retention of key employees,
the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">risks and uncertainties associated
with the other party to such a transaction, including the prospects of that party and their existing drugs or drug and diagnostics technology
candidates and regulatory approvals; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our inability to generate revenue
from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated
acquisition and maintenance costs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if we undertake
acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible
assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities
and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development
of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with the U.S. Foreign
Corrupt Practices Act (&#8220;FCPA&#8221;),&#160;or other anti-bribery laws, including the Bribery Act 2010 of the United Kingdom (UK
Bribery Act&#8221;), our reputation may be harmed and we could be subject to penalties and significant expenses that have a material adverse
effect on our business, financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the FCPA.
The FCPA and UK Bribery Act generally prohibits us from making improper payments to non-U.S. officials for the purpose of obtaining or
retaining business or other benefits. We are also subject to the anti-bribery laws of other jurisdictions, particularly the PRC. As our
business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. Our procedures and controls
to monitor anti-bribery compliance may fail to protect us from reckless or criminal acts committed by our employees or agents. If we,
due to either our own deliberate or inadvertent acts or those of others, fail to comply with applicable anti-bribery laws, our reputation
could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material
adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business and results of operations may
be negatively impacted by the UK&#8217;s withdrawal from the EU.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 23, 2016, the UK held
a referendum in which a majority of voters approved an exit from the EU, or Brexit, and the UK formally left the EU on January 31, 2020.
There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. However,
the EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and
has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual
recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale
mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing,
promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol,
the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently aligns
in the most part with EU regulations, however it is possible that these regimes will diverge in the future now that Great Britain&#8217;s
regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation.
For example, the new Clinical Trials Regulation which became effective in the EU on January 31, 2022 and provides for a streamlined clinical
trial application and assessment procedure covering multiple EU Member States has not been implemented into UK law, and a separate application
will need to be submitted for clinical trial authorization in the UK. In addition, as we are headquartered in the UK, it is possible that
Brexit may impact some or all of our current operations. For example, Brexit will impact our ability to freely move employees from our
headquarters in the UK to other locations in the EU. Furthermore, if other EU Member States pursue withdrawal, barrier-free access among
the EEA overall could be diminished or eliminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The long-term effects of Brexit
will depend in part on how the terms of the TCA continue to take effect in practice and the terms of any further agreements the UK makes
with the EU. Such a withdrawal from the EU is unprecedented, and it is unclear how the restrictions on the UK&#8217;s access to the European
single market for goods, capital, services and labor, or single market, and the wider commercial, legal and regulatory environment, will
impact our future operations (including business activities conducted by third parties and contract manufacturers on our behalf) and clinical
activities in the UK in the long term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we commence clinical trials of one of
our drug or diagnostics technology candidates, and product liability lawsuits are brought against us, we may incur substantial liabilities
and the commercialization of such drug or diagnostics technology candidates may be affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our drug or diagnostics
technology candidates enter clinical trials, we will face an inherent risk of product liability suits and will face an even greater risk
if we obtain approval to commercialize any drugs. For example, we may be sued if our drug candidates cause or are perceived to cause injury
or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may
include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the drug, negligence, strict
liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend
ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our drug
candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual
outcome, liability claims may result in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">decreased demand for our drugs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">injury to our reputation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">withdrawal of clinical trial participants and inability to continue clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">initiation of investigations by regulators;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">costs to defend the related litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a diversion of management&#8217;s time and our resources;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">substantial monetary awards to trial participants or patients;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">loss of revenue;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">exhaustion of any available insurance and our capital resources;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the inability to commercialize any drug candidate; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a decline in the price of our Class A Ordinary Shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We shall seek to obtain the
appropriate insurance once our candidates are ready for clinical trial. However, our inability to obtain sufficient product liability
insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of
drugs we develop, alone or with collaborators. We currently do not have in place product liability insurance and although we plan to have
in place such insurance as and when the products are ready for commercialization, as well as insurance covering clinical trials, the amount
of such insurance coverage may not be adequate, we may be unable to maintain such insurance, or we may not be able to obtain additional
or replacement insurance at a reasonable cost, if at all. Our insurance policies may also have various exclusions, and we may be subject
to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement
that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital
to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such
indemnification may not be available or adequate should any claim arise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we may be sued
if the products that we commercialize, market or sell cause or are perceived to cause injury or are found to be otherwise unsuitable,
and may result in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">decreased demand for those products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">damage to our reputation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">costs incurred related to product recalls;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">limiting our opportunities to enter into future commercial partnership; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a decline in the price of our Class A Ordinary Shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our insurance coverage may be inadequate
to protect us against losses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently maintain property
insurance for our office premises. We hold employer&#8217;s liability insurance generally covering death or work-related injury of employees;
we maintain company insurance for those persons working in our offices and medical insurance for our certain employee. We hold public
liability insurance covering certain incidents involving unrelated parties that occur on or in the premises of the Company. We have directors
and officers liability insurance. We do not have key-man life insurance on any of our senior management or key personnel, or business
interruption insurance. Our insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets
or employee injuries. If any claims for damage are brought against us, or if we experience any business disruption, litigation or natural
disaster, we might incur substantial costs and diversion of resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fluctuations in exchange rates could result
in foreign currency exchange losses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations and equity are
funded in U.S. dollars and we currently incur the majority of our expenses in U.S. dollars or in H.K. dollars. H.K. dollar is currently
pegged to the U.S. dollar; however, we cannot guarantee that such peg will continue to be in place in the future. Our exposure to foreign
exchange risk primarily relates to the limited cash denominated in currencies other than the functional currencies of each entity and
limited revenue contracts dominated in H.K. dollars in certain Hong Kong operating entities. We do not believe that we currently have
any significant direct foreign exchange risk and have not hedged exposures denominated in foreign currencies or any other derivative financial
instruments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are exposed to foreign
currency exchange risk as our results of operations, cash flows maybe subject to fluctuations in foreign currency exchange rates. For
example, if a significant portion of our clinical trial activities may be conducted outside of the United States, and associated costs
may be incurred in the local currency of the country in which the trial is being conducted, which costs could be subject to fluctuations
in currency exchange rates. We currently do not engage in hedging transactions to protect against uncertainty in future exchange rates
between particular foreign currencies and the U.S. dollar. A decline in the value of the U.S. dollar against currencies in countries in
which we conduct clinical trials could have a negative impact on our research and development costs. Foreign currency fluctuations are
unpredictable and may adversely affect our financial condition, results of operations and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our investments are subject to risks that
could result in losses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had unrestricted cash and
cash equivalents of $2.01 million, $1.88 million, and 8.13 million as of December 31, 2023, 2022, and 2021, respectively. We may invest
our cash in a variety of financial instruments. All of these investments are subject to credit, liquidity, market and interest rate risk.
Such risks, including the failure or severe financial distress of the financial institutions that hold our cash, cash equivalents and
investments, may result in a loss of liquidity, impairment to our investments, realization of substantial future losses, or a complete
loss of the investments in the long-term, which may have a material adverse effect on our business, results of operations, liquidity and
financial condition. While we believe our cash position does not expose us to excessive risk, future investments may be subject to adverse
changes in market value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are exposed to risks associated with
our computer hardware, network security and data storage.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to all other computer
network users, our computer network system is vulnerable to attack of computer virus, worms, trojan horses, hackers or other similar computer
network disruptive problems. Any failure in safeguarding our computer network system from these disruptive problems may cause breakdown
of our computer network system and leakage of confidential information of the Company. Any failure in the protection of our computer network
system from external threat may disrupt our operation and may damage our reputation for any breach of confidentiality to our customers,
which in turn may adversely affect our business operation and performance. In the event that our confidential information is stolen and
misused, we may become exposed to potential risks of losses from litigation and possible liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are highly
dependent on our IT infrastructure to store research data and information and manage our business operations. We do not backup all data
on a real-time basis and the effectiveness of our business operations may be materially affected by any failure in our IT infrastructure.
If our communications and IT systems do not function properly, or if there is any partial or complete failure of our systems, we could
suffer financial losses, business disruption or damage to our reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Business disruptions could seriously harm
our future revenue and financial condition and increase our costs and expenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations, and those of
our research institution collaborators, CROs, suppliers and other contractors and consultants, could be subject to supply chain disruptions,
earthquakes, power shortages, telecommunications failures, damage from computer viruses, material computer system failures, water shortages,
floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business
interruptions. In addition, we partially rely on our research institution collaborators for conducting research and development of our
drug candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions
could seriously harm our operations and financial condition and increase our costs and expenses. We rely on contract manufacturers to
produce and process our drug candidates. Our ability to obtain clinical supplies of our drug candidates could be disrupted if the operations
of these suppliers are affected by a man-made or natural disaster or other business interruption. A large portion of our contract manufacturer&#8217;s
operations is located in a single facility. Damage or extended periods of interruption to our corporate or our contract manufacturer&#8217;s
development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events
could cause us to cease or delay development of some or all of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be exposed to various risks related
to the regulatory environment of the pharmaceutical industry in the PRC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are the exclusive licensee
to certain PRC patents directed to our drug candidates; and we also intend to file application for certain products in the PRC. The pharmaceutical
industry in the PRC is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing,
packaging, licensing and marketing of new drugs. (See &#8220;Item 4. Information on the Company &#8211; B. Business Overview &#8211; Regulations&#8221;).
In recent years, the regulatory framework in the PRC regarding the pharmaceutical industry has undergone significant changes, and we expect
that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business
or cause delays in or prevent the successful development or commercialization of our drug candidates in the PRC and reduce the current
benefits that we believe are available to us from developing and manufacturing drugs in the PRC. Chinese authorities have become increasingly
vigilant in enforcing laws in the pharmaceutical industry and any failure by us or our partners to maintain compliance with applicable
laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business
activities in the PRC. We believe our strategy and approach is aligned with the PRC government&#8217;s policies, but we cannot ensure
that our strategy and approach will continue to be aligned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in the political and
economic policies of the PRC government may materially and adversely affect our business, financial condition and results of operations
and may result in our inability to sustain our growth and expansion strategies. Our financial condition and results of operation in the
PRC could be materially and adversely affected by government control over capital investments or changes in tax regulations that are applicable
to us, and consequently have a material adverse effect on our businesses, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the U.S. Public Company Accounting Oversight
Board, or the PCAOB, is unable to inspect our auditors as required under the Holding Foreign Companies Accountable Act, the SEC will prohibit
the trading of our Class A Ordinary Shares. A trading prohibition for our Class A Ordinary Shares, or the threat of a trading prohibition,
may materially and adversely affect the value of your investment. Additionally, the inability of the PCAOB to conduct inspections of our
auditors would deprive our investors of the benefits of such inspections.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 24, 2021, the SEC
adopted interim final rules relating to the implementation of certain disclosure and documentation requirements of the HFCAA. An identified
issuer will be required to comply with these rules if the SEC identifies it as having a &#8220;non-inspection&#8221; year under a process
to be subsequently established by the SEC. On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable
Act, and on December 29, 2022, legislation entitled &#8220;Consolidated Appropriations Act, 2023&#8221; (the &#8220;Consolidated Appropriations
Act&#8221;) was signed into law by President Biden, which contained, among other things, an identical provision to the Accelerating Holding
Foreign Companies Accountable Act and amended the HFCAA by requiring the SEC to prohibit an issuer&#8217;s securities from trading on
any U.S stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three, thus reducing the
time period for triggering the prohibition on trading. If our auditor cannot be inspected by the Public Company Accounting Oversight Board,
or the PCAOB, for two consecutive years, the trading of our securities on any U.S. national securities exchanges, as well as any over-the-counter
trading in the U.S., will be prohibited. On September 22, 2021, the PCAOB adopted a final rule implementing the HFCAA, which provides
a framework for the PCAOB to use when determining, as contemplated under the HFCAA, whether the PCAOB is unable to inspect or investigate
completely registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities
in that jurisdiction. On December 2, 2021, the SEC issued amendments to finalize rules implementing the submission and disclosure requirements
in the HFCAA. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a
registered public accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely
because of a position taken by an authority in foreign jurisdictions. On December 16, 2021, the PCAOB issued a report on its determinations
that it is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in mainland China and in
Hong Kong, because of positions taken by PRC authorities in those jurisdictions, which determinations were vacated on December 15, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 26, 2022, the PCAOB
announced that it had signed a Statement of Protocol (the &#8220;SOP&#8221;) with the China Securities Regulatory Commission and the Ministry
of Finance of China. The SOP, together with two protocol agreements governing inspections and investigations (together, the &#8220;SOP
Agreement&#8221;), establishes a specific, accountable framework to make possible complete inspections and investigations by the PCAOB
of audit firms based in mainland China and Hong Kong, as required under U.S. law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 15, 2022, the PCAOB announced that it was able to secure
complete access to inspect and investigate PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong completely
in 2022. The PCAOB Board vacated its previous 2021 determinations that the PCAOB was unable to inspect or investigate completely registered
public accounting firms headquartered in mainland China and Hong Kong. However, whether the PCAOB will continue to be able to satisfactorily
conduct inspections of PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong is subject to uncertainties
and depends on a number of factors out of our and our auditor&#8217;s control. The PCAOB continues to demand complete access in mainland
China and Hong Kong moving forward and is making plans to resume regular inspections in early 2023 and beyond, as well as to continue
pursuing ongoing investigations and initiate new investigations as needed. The PCAOB has also indicated that it will act immediately to
consider the need to issue new determinations with the HFCAA if needed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current independent accounting
firm, Marcum Asia CPAs LLP, whose audit report is included in this annual report on Form 20-F, is headquartered in Manhattan, New York,
and was not included in the list of PCAOB Identified Firms in the PCAOB December 2021 Release. It has been inspected by the PCAOB on a
regular basis with the last inspection in 2023. Our ability to retain an auditor subject to PCAOB inspection and investigation, including
but not limited to inspection of the audit working papers related to us, may depend on the relevant positions of U.S. and Chinese regulators.
With respect to audits of companies with operations in China or Hong Kong, such as the Company, there are uncertainties about the ability
of our auditor to fully cooperate with a request by the PCAOB for audit working papers in China or Hong Kong without the approval of Chinese
authorities. If in the future Marcum Asia CPAs LLP is included in the list of PCAOB Identified Firms and we are unable to retain a PCAOB-registered
auditor subject to PCAOB inspection and investigation, a trading prohibition for our Class A Ordinary Shares could be issued shortly after
our filing of the second consecutive annual report on Form 20-F for which we have retained a PCAOB Identified Firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our Class A Ordinary Shares
are subject to a trading prohibition under the HFCA Act, the price of our Class A Ordinary Shares may be adversely affected, and the threat
of such a trading prohibition would also adversely affect their price.&#160;If we are unable to be listed on another securities exchange
that provides sufficient liquidity, such a trading prohibition may substantially impair your ability to sell or purchase our Class A Ordinary
Shares when you wish to do so.&#160;Furthermore, if we are able to maintain a listing of our Class A Ordinary Shares on a non-U.S. exchange,
investors owning our Class A Ordinary Shares may have to take additional steps to engage in transactions on that exchange, including establishing
non-U.S. brokerage accounts.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HFCA Act also imposes additional
certification and disclosure requirements for Commission Identified Issuers, and these requirements apply to issuers in the year following
their listing as Commission Identified Issuers. The additional requirements include a certification that the issuer is not owned or controlled
by a governmental entity in the Relevant Jurisdiction, and the additional requirements for annual reports include disclosure that the
issuer&#8217;s financials were audited by a firm not subject to PCAOB inspection, disclosure on governmental entities in the Relevant
Jurisdiction&#8217;s ownership in and controlling financial interest in the issuer, the names of Chinese Communist Party, or CCP, members
on the board of the issuer or its operating entities, and whether the issuer&#8217;s article&#8217;s include a charter of the CCP, including
the text of such charter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The SEC could take the position that we
are an &#8220;investment company&#8221; subject to the extensive requirements of the Investment Company Act of 1940. Such a characterization
and the associated compliance requirements could have a material adverse effect on our business, financial condition, and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our business had historically
included passive healthcare related investments in early stage companies primarily in the United States. Although we are in the process
of liquidating those securities that remain in our portfolio, we still hold some such investments and these are included as assets of
our Company on a consolidated basis. As part of the Restructure, we resolved to exit such portfolio investments over an appropriate timeframe
and focus our resources on our current business. Since the date of the Restructure, we have not held ourselves out as an investment company
and we do not believe we are an &#8220;investment company&#8221; under the&#160;Investment Company Act of 1940. If the SEC or a court,
however, were to disagree with us, we could be required to register as an investment company. This would subject us to disclosure and
accounting rules geared toward investment companies, rather than operating companies, which may limit our ability to borrow money, issue
options, issue multiple classes of stock and debt, and engage in transactions with affiliates, and may require us to undertake significant
costs and expenses to meet the disclosure and regulatory requirements to which we would be subject as a registered investment company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are classified as a passive foreign
investment company for U.S. federal income tax purposes, United States holders of our Class A Ordinary Shares may be subject to adverse
United States federal income tax consequences.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">A non-U.S. corporation will
be a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes, for such year, if either</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">At least 75% of its gross income for such year is passive income; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The average percentage of our assets (determined at the end of each quarter) during such year which produce passive income or which are held for the production of passive income is at least 50%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Passive income generally includes
dividends, interests, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains
from the disposition of passive assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A separate determination must
be made after the close of each taxable year as to whether a non-U.S. corporation is a PFIC for that year. For purposes of the PFIC analysis,
in general, a non-U.S. corporation is deemed to own its pro rata share of the gross income and assets of any entity in which it is considered
to own at least 25% of the equity by value. Based on the current and anticipated value of our assets, we believe we were a PFIC for U.S.
federal income tax purposes for our taxable year ended December 31, 2023, and we may be a PFIC for U.S. federal income tax purposes for
our current taxable year ending December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In determining whether we
are a PFIC, cash and cash equivalents and investments are considered by the U.S. Internal Revenue Service (&#8220;IRS&#8221;) to be a
passive asset. During our taxable year ended December 31, 2023, we believe that the amount of cash we had on hand and investments were
greater than 50% of our total assets. The composition of our assets during the current taxable year may cause us to continue to be classified
as a PFIC. The determination of whether we will be a PFIC for our current taxable year or a future year may depend in part upon how quickly
we spend our liquid assets, and on the value of our goodwill and other unbooked intangibles not reflected on our balance sheet, which
may depend upon the market value of our Class A Ordinary Shares from time to time. Further, while we will endeavor to use a classification
methodology and valuation approach that is reasonable, the IRS may challenge our classification or valuation of our goodwill and other
unbooked intangibles for purposes of determining whether we are a PFIC in the current or one or more future taxable years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC for any taxable
year during which a U.S. Holder owns our Class A Ordinary Shares or warrants, certain adverse U.S. federal income tax consequences could
apply to such U.S. Holder. As discussed under &#8220;Taxation &#8211; Material U.S. Federal Income Tax Considerations for U.S. Holders
&#8211; Passive Foreign Investment Company Rules&#8221;, a U.S. Holder may be able to make certain tax elections that would lessen the
adverse impact of PFIC status; however, in order to make such elections the U.S. holder will usually have to have been provided information
about the company by us, and there is no assurance that the company will provide such information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more detailed discussion
of the application of the PFIC rules to us and the consequences to U.S. holders if we were determined to be a PFIC. (See &#8220;Item 10.
Additional Information &#8211; E. Taxation&#160;&#8211;&#160;Material U.S. Federal Income Tax Considerations for U.S. Holders&#160;&#8211;&#160;Passive
Foreign Investment Company Rules&#8221;)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our results of operation may be negatively
affected should the 2019-nCov virus (Coronavirus) continue to spread on a wider scale.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could be adversely
affected by the effects of a widespread outbreak of contagious disease, including the outbreak of respiratory illness caused by a novel
coronavirus. Any outbreak of contagious diseases, and other adverse public health developments, particularly in China, could have a material
and adverse effect on our business operations. These could include disruptions or restrictions on our ability to travel or to distribute
our products, as well as temporary closures of our facilities or the facilities of our suppliers or customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic continues
to rapidly evolve. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future
developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease,
the duration of the pandemic, travel restrictions and social distancing in various countries, business closures or business disruptions
and the effectiveness of actions taken to contain and treat the disease. If we or any of the third parties with whom we engage were to
experience shutdowns, undergo the compulsory universal testing by the HKSAR Government or other business disruptions, our ability to conduct
our business in the manner and on the timelines presently planned could be materially and negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the trading prices
for our Class A Ordinary Shares and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic.
As a result, we may face difficulties raising capital through sales of our securities or such sales may be on unfavorable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The outbreak of the novel coronavirus disease,
COVID-19, or other pandemic, epidemic or outbreak of an infectious disease may materially and adversely impact our preclinical studies
and clinical trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the COVID-19
outbreak, or similar pandemics, we have and may in the future experience disruptions that could materially and adversely impact our manufacturing,
preclinical development activities, preclinical studies and planned clinical trial. Potential disruptions include but are not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">delays or difficulties in enrolling
patients in our clinical trials, should the relevant clinical trials be approved;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">delays or difficulties in initiating
or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators
and clinical site staff;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">increased rates of patients
withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced
to quarantine;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">diversion of healthcare resources
away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff
supporting the conduct of our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">interruption of key clinical
trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by governments, employers
and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and
clinical study endpoints;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">interruption or delays in the
operations of the FDA or other regulatory authorities, which may impact review and approval timelines for regulatory submission and trial
initiation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">interruption or delays in our
CROs and collaborators meeting expected deadlines or complying with regulatory requirements related to preclinical development activities,
preclinical studies and planned clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">delays or disruptions in preclinical
experiments and investigational new drug application-enabling or clinical trial application-enabling studies due to restrictions of on-site
staff and unforeseen circumstances at contract research organizations and vendors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">interruption of, or delays in
receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns
or stoppages and disruptions in delivery systems;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">limitations on our ability to
recruit and hire key personnel due to our inability to meet with candidates because of travel restrictions and &#8220;shelter in place&#8221;
orders;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">limitations on employee resources
that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees
or their families or the desire of employees to avoid contact with large groups of people; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">interruption or delays to our sourced discovery and clinical activities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Corporate Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>One of our directors controls a majority
of our voting shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of our Executive Directors
and CEO, Mr. Ian Huen, and his affiliates, over which he is deemed to have control and/or have substantial influence, has voting rights
with respect to an aggregate of 2,168,168 Ordinary Shares, on an as converted basis (562,021 Class A Ordinary Shares and 1,606,147 Class
B Ordinary Shares), representing approximately 88% of the voting power of our outstanding ordinary shares as of the date hereof. As a
result, Mr.&#160;Huen has the ability to control the outcome of matters submitted to our shareholders for approval, including the election
of directors and any merger, consolidation, or sale of all or substantially all of our assets. Additionally, in the event that Mr. Huen
controls our company at the time of his death, control may be transferred to a person or entity that he designates as his successor.
As a board member, Mr.&#160;Huen owes a fiduciary duty to our shareholders and must act in good faith in a manner he reasonably believes
to be in the best interests of our shareholders. As a shareholder, even a controlling shareholder, Mr.&#160;Huen is entitled to vote
his shares, and shares over which he has voting control as a result of voting agreements, in his own interests, which may not always
be in the interests of our shareholders generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a &#8220;controlled company&#8221; under
the rules of the NASDAQ Capital Market, we may choose to exempt our company from certain corporate governance requirements that could
have an adverse effect on our public shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors and officers
beneficially own a majority of the voting power of our outstanding Ordinary Shares. Under the Rule 4350(c) of the NASDAQ Capital Market,
a company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221;
and may elect&#160;not&#160;to comply with certain corporate governance requirements, including the requirement that a majority of our
directors be independent, as defined in the NASDAQ Capital Market Rules, and the requirement that our compensation and nominating and
corporate governance committees consist entirely of independent directors. Although we do not intend to rely on the &#8220;controlled
company&#8221; exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the future. If we elect to rely on
the &#8220;controlled company&#8221; exemption, a majority of the members of our board of directors might not be independent directors
and our nominating and corporate governance and compensation committees might not consist entirely of independent directors. Accordingly,
during any time while we remain a&#160;controlled company&#160;relying on the exemption and during any transition period following a time
when we are no longer a&#160;controlled company, you would not have the same protections afforded to shareholders of companies that are
subject to all of the NASDAQ Capital Market corporate governance requirements. Our status as a controlled company could cause our Class&#160;A
Ordinary Share to look less attractive to certain investors or otherwise harm our trading price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to consolidate the financial
results of some of our affiliated companies or such consolidation could materially adversely affect our operating results and financial
condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has three VIEs
which are incorporated under the laws of Cayman Islands and conduct operations in Hong Kong. The Company currently consolidates two of
those VIEs since the Group has a variable interest in them and is determined to be the primary beneficiary of those two VIEs under U.S.
GAAP. This determination is based on whether the Group has a variable interest (or combination of variable interests) that provides the
Company with (a) the power to direct the activities that most significantly impact the VIEs&#8217; economic performance and (b) the obligation
to absorb losses or right to receive benefits that could be potentially significant to the VIE. The Group continually reassesses whether
it is the primary beneficiary of a VIE throughout the entire period the Group is involved with the VIE. According to those standards,
we determined that we have the power to manage and make decisions that affect Mios and Scipio&#8217;s research and development activities,
which activities most significantly impact Mios and Scipio&#8217;s economic performance. However, we do not have such power over Libra&#8217;s
research and development activities, which activities most significantly impact Libra&#8217;s economic performance. Accordingly, we determined
that we are the primary beneficiary of Mios and Scipio, but not the primary beneficiary of Libra. As a result, Mios and Scipio&#8217;s
financial results are consolidated in our consolidated financial statements. In the event that in the future the VIEs no longer meet the
definition of a VIE, or we are deemed not to be the primary beneficiary of the VIE for accounting purpose, we would not be able to consolidate
line by line that VIE&#8217;s financial results in our consolidated financial statements. Also, if in the future an affiliate company
becomes a VIE and we become the primary beneficiary of it for accounting purposes, we would be required to consolidate that entity&#8217;s
financial results in our consolidated financial statements. If such entity&#8217;s financial results were negative, this could have a
corresponding negative impact on our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The economic substance legislation of the
Cayman Islands may adversely impact us or our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to
Cayman Islands economic substance legislation (&#8220;ESA&#8221;) requiring that where the Company carries on a relevant activity (as
defined in the ESA) it must maintain economic substance within the Cayman Islands, including adequate premises and employees within the
Cayman Islands. As an entity subject to the ESA, the Company is required to assess its operations to determine the required compliance
(if any) with the ESA, to file an annual notification with the Cayman Islands Registrar of Companies disclosing whether the Company is
carrying out any relevant activities within the meaning of the ESA and an annual return with the Department of International Tax Co-Operation.
Where applicable, the Company must establish that its operations satisfy the economic substance requirements of the ESA. The Company is
required to monitor its operations to ensure it remains in compliance with all requirements under the ESA. Failure to satisfy these requirements
may subject the Company to penalties under the ESA.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with the continued
listing requirements of NASDAQ, we would face possible delisting, which would result in a limited public market for our shares and make
obtaining future debt or equity financing more difficult for us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 8, 2023, the Company
received a deficiency letter from the Nasdaq Listing Qualifications Department (the &#8220;<b>Staff</b>&#8221;) of the Nasdaq Stock Market
LLC (&#8220;<b>Nasdaq</b>&#8221;) notifying the Company that the Company does not meet the minimum Market Value of Publicly Held Shares
(&#8220;<b>MVPHS</b>&#8221;) of $5,000,000 for the previous 30 consecutive business days. The Nasdaq deficiency letter has no immediate
effect on the listing of the Company&#8217;s Class A Ordinary Shares, and its Class A Ordinary Shares will continue to trade on The Nasdaq
Global Market under the symbol &#8220;APM&#8221; at this time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Nasdaq
Listing Rule 5810(c)(3)(D), the Company has been given 180 calendar days, or until August 7, 2023, to regain compliance with Rule 5450(b)(1)(C).
If at any time before August 7, 2023, the MVPHS closes at $5,000,000 or more for a&#160;<i>minimum&#160;</i>of ten consecutive business
days, the Staff will provide written confirmation that the Company has achieved compliance and the matter will be closed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company does not regain
compliance with Rule 5450(b)(1)(C) by August 7, 2023, the Company will receive written notification that its securities are subject to
delisting and the Company may appeal the delisting determination to a Hearing&#8217;s Panel. Alternatively, the Company may consider applying
to transfer the Class A Ordinary Shares to The Nasdaq Capital Market. The Company intends to remain on the Nasdaq Global Market and will
actively monitor its MVPHS and will consider available options to resolve the deficiency and regain compliance with Rule 5450(b)(1)(C).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company fails to regain
compliance with any other listing rules when required in the future, we could be subject to suspension and delisting proceedings. If our
securities lose their status on the Nasdaq Capital Market, our securities would likely trade in the over-the-counter market. If our securities
were to trade on the over-the-counter market, selling our securities could be more difficult because smaller quantities of securities
would likely be bought and sold, transactions could be delayed, and security analysts&#8217; coverage of us may be reduced. In addition,
in the event our securities are delisted, broker-dealers have certain regulatory burdens imposed upon them, which may discourage broker-dealers
from effecting transactions in our securities, further limiting the liquidity of our securities. These factors could result in lower prices
and larger spreads in the bid and ask prices for our securities. Such delisting from the NASDAQ Capital Market and continued or further
declines in our share price could also greatly impair our ability to raise additional necessary capital through equity or debt financing,
and could significantly increase the ownership dilution to shareholders caused by our issuing equity in financing or other transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 31, 2023, the Company
requested to transfer its Class A Ordinary Shares from the Nasdaq Global Market to the Nasdaq Capital Market. On August 8, 2023, the Company
received an approval letter (the &#8220;Nasdaq Approval Letter&#8221;) from the Nasdaq Listing Qualifications Department indicating that
the staff has approved the Company&#8217;s application to transfer its Class A Ordinary Shares to the Nasdaq Capital Market. The Company&#8217;s
securities have been transferred to the Nasdaq Capital Market at the opening of business on August 10, 2023 and the trading activities
of its Class A Ordinary Shares have not been affected. The transfer became effective on August 10, 2023, thereby closing the prior deficiencies
on the Nasdaq Global Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Class A Ordinary Shares eligible for future
sale may adversely affect the market price of our Class A Ordinary Shares if the shares are successfully listed on NASDAQ or other stock
markets, as the future sale of a substantial amount of outstanding Class A Ordinary Shares in the public marketplace could reduce the
price of our Class A Ordinary Shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our Class A Ordinary Shares could decline as a
result of sales of substantial amounts of our Class A Ordinary Shares in the public market, or the perception that these sales could occur.
In addition, these factors could make it more difficult for us to raise funds through future offerings of our Class A Ordinary Shares.
An aggregate of 3,674,164 Class A Ordinary Shares are outstanding as of the issuance date of this annual report. 1,277,019 of the Class
A Ordinary Shares are freely transferable without restriction or further registration under the Securities Act. The remaining Class A
Ordinary Shares will be &#8220;restricted securities&#8221; as defined in Rule 144. These Class A Ordinary Shares may be sold without
registration under the Securities Act to the extent permitted by Rule 144 or other exemptions under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A sale or perceived sale of a substantial
number of our Ordinary Shares may cause the price of our Class A Ordinary Shares to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our shareholders sell substantial
amounts of our Class A Ordinary Shares in the public market, the market price of our Class A Ordinary Shares could fall. Moreover, the
perceived risk of this potential dilution could cause shareholders to attempt to sell their shares and investors to short our Class A
Ordinary Shares. These sales also may make it more difficult for us to sell equity or equity-related securities in the future at a time
and price that we deem reasonable or appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Issuances by us of additional securities,
could affect ownership and voting rights over us. In addition, the issuance of preferred shares, or options or warrants to purchase those
preferred shares, could negatively impact the value of the Ordinary Shares as the result of preferential dividend rights, conversion rights,
redemption rights and liquidation provisions granted to the stockholders of such preferred shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
issue in public or private sales additional securities to third party investors. Such securities may provide holders with ownership and
voting rights that could provide the holders thereof with substantial influence over our business. Any preferred shares that may be issued
shall have such rights, preferences, privileges and restrictions as may be designated from time-to-time by our board, including preferential
dividend rights, voting rights, conversion rights, redemption rights and liquidation provisions. There cannot be any assurance that we
will not issue preferred securities with rights and preferences that are more beneficial than those provided to our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not paid dividends in the past and
do not expect to pay dividends in the future, and any return on investment may be limited to the value of our shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid any cash
dividends on our Class A Ordinary Shares and do not anticipate paying any cash dividends on our Class A Ordinary Shares in the foreseeable
future, and any return on investment may be limited to the value of our Class A Ordinary Shares. We plan to retain any future earnings
to finance growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our dividend policy is subject
to the discretion of our Board of Directors and will depend on, among other things, our earnings, financial condition, capital requirements
and other factors. There is no assurance that our Board of Directors will declare dividends even if we are profitable. Under Cayman Islands
law, dividends may be declared and paid only out of funds legally available therefor, namely out of either profit or our share premium
account, and provided further that a dividend may not be paid if this would result in our Company being unable to pay its debts as they
fall due in the ordinary course of business and the realizable value of assets of our Company will not be less than the sum of our total
liabilities, other than deferred taxes as shown on our books of account, and our capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Class B Ordinary Shares have greater
voting power than our Class A Ordinary Shares and certain existing shareholders have substantial influence over our Company and their
interests may not be aligned with the interests of our other shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a dual-class voting
structure consisting of Class A Ordinary Shares and Class B Ordinary Shares. Under this structure, holders of Class A Ordinary Shares
are entitled to one vote per share, and holders of Class B Ordinary Shares are entitled to one hundred votes per share, which can cause
the holders of Class B Ordinary Shares to have an unbalanced, higher concentration of voting power. Our management team as a group beneficially
owns over 1.6 million Class B Ordinary Shares representing approximately 88% voting power. As a result, until such time as their collective
voting power is below 50%, our management team as a group of controlling shareholders have substantial influence over our business, including
decisions regarding mergers, consolidations and the sale of all or substantially all of our assets, election of directors and other significant
corporate actions. They may take actions that are not in the best interests of us or our other shareholders. These corporate actions may
be taken even if they are opposed by our other shareholders.&#160;Further,&#160;concentration&#160;of ownership of our Class B Ordinary
Shares may discourage, prevent or delay the consummation of change of control transactions that shareholders may consider favorable, including
transactions in which shareholders might otherwise receive a premium for their shares. Future issuances of Class B Ordinary Shares may
also be dilutive to the holders of Class A Ordinary Shares. As a result, the market price of our Class A Ordinary Shares could be adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders who hold
shares of Class&#160;B Ordinary Shares, including our executive officers and their affiliates, hold approximately 99% of the voting
power of our outstanding ordinary shares. Because of the one hundred-to-one voting ratio between our Class&#160;B Ordinary Shares
and Class&#160;A Ordinary Shares, the holders of our Class&#160;B Ordinary Shares will collectively continue to control a majority
of the combined voting power of our Ordinary Shares and therefore be able to control all matters submitted to our shareholders for
approval, so long as the Class&#160;B Ordinary Shares represent at least 1.0% of all outstanding shares of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital may cause dilution
to our shareholders, restrict our operations or require us to relinquish rights to our technology or drug and diagnostics technology candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional funding
through a combination of equity offerings, debt financings, collaborations, licensing arrangements, strategic alliances and marketing
or distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a holder of our Class A Ordinary Shares. The incurrence of additional indebtedness or the issuance of certain equity securities could
result in increased fixed payment obligations, and could also result in certain additional restrictive covenants, such as limitations
on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license IP rights and other
operating restrictions that could adversely impact our ability to conduct our business. In addition, issuance of additional equity securities,
or the possibility of such issuance, may cause the market price of our Class A Ordinary Shares to decline. In the event that we enter
into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms, including relinquishing
or licensing to another party on unfavorable terms our rights to technology or drug and diagnostics technology candidates that we otherwise
would seek to develop or commercialize ourselves or potentially reserve for future potential arrangements when we might be able to achieve
more favorable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Since we are a Cayman Islands exempted company,
the rights of our shareholders may be more limited than those of shareholders of a company organized in the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate affairs are
governed by our Third Amended and Restated Memorandum and Articles of Association (as may be amended from time to time) (&#8220;Memorandum
and Articles&#8221;), the Companies Act (As Revised) of the Cayman Islands (the &#8220;Companies Law&#8221;) and the common law of the
Cayman Islands.&#160;The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary
responsibilities of our directors are to a large extent governed by the common law of the Cayman Islands. This common law is derived in
part from comparatively limited judicial precedent in the Cayman Islands as well as from English common law, which has persuasive, but
not binding, authority on a court in the Cayman Islands.&#160;Under the laws of some jurisdictions in the United States, majority and
controlling shareholders generally have certain fiduciary responsibilities to the minority shareholders. Shareholder action must be taken
in good faith, and actions by controlling shareholders which are obviously unreasonable may be declared null and void. Cayman Islands
law protecting the interests of minority shareholders may not be as protective in all circumstances as the law protecting minority shareholders
in some U.S. jurisdictions. In addition, the circumstances in which a shareholder of a Cayman Islands company may sue the company derivatively,
and the procedures and defenses that may be available to the company, may result in the rights of shareholders of a Cayman Islands company
being more limited than those of shareholders of a company organized in the United States. Accordingly, shareholders may have fewer alternatives
available to them if they believe that corporate wrongdoing has occurred. The Cayman Islands courts are also unlikely to recognize or
enforce judgments from U.S. courts based on certain liability provisions of U.S. securities laws that are penal in nature. There is no
statutory recognition in the Cayman Islands of judgments obtained in the United States, although the courts of the Cayman Islands will
generally recognize and enforce non-penal judgment of a foreign court of competent jurisdiction for a liquidated sum without retrial on
its merits which is not obtained in a manner contrary to public policy in the Cayman Islands and in respect of which there are no concurrent
proceedings in the Cayman Islands. This means, even if shareholders were to sue us successfully, they may not be able to recover anything
to make up for the losses suffered.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, our directors
have the power to take certain actions without shareholder approval which would require shareholder approval under the laws of most U.S.
jurisdictions. For example, the directors of a Cayman Islands company, without shareholder approval, may implement a sale of any assets,
property, part of the business, or securities of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While Cayman Islands law allows
a dissenting shareholder to express the shareholder&#8217;s view that a court sanctioned reorganization of a Cayman Islands company would
not provide fair value for the shareholder&#8217;s shares, Cayman Islands statutory law does not specifically provide for shareholder
appraisal rights on a merger or consolidation of a company. This may make it more difficult for you to assess the value of any consideration
you may receive in a merger or consolidation or to require that the acquirer gives you additional consideration if you believe the consideration
offered is insufficient. However, Cayman Islands&#8217; statutory law does provide a mechanism for a dissenting shareholder in a merger
or consolidation to apply to the Grand Court for a determination of the fair value of the dissenter&#8217;s shares, if it is not possible
for the Company and the dissenter to agree a fair price within the time limits prescribed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders of Cayman Islands
exempted companies, such as our Company, have no general rights under Cayman Islands&#8217; law to inspect corporate records and accounts
or to obtain copies of lists of shareholders. Our directors have discretion under our Memorandum and Articles to determine whether or
not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available
to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder
motion or to solicit proxies from other shareholders in connection with a proxy contest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lastly, under the law of the
Cayman Islands, there is little statutory law for the protection of minority shareholders. The principal protection under statutory law
is that shareholders may bring an action to enforce the constituent documents of the corporation, our Memorandum and Articles. Shareholders
are entitled to have the affairs of the company conducted in accordance with the general law and the memorandum and articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are common law rights
for the protection of shareholders that may be invoked, largely dependent on English company law, since the common law of the Cayman Islands
for business companies is limited. Under the general rule pursuant to English company law known as the rule in Foss v. Harbottle, a court
will generally refuse to interfere with the management of a company at the insistence of a minority of its shareholders who express dissatisfaction
with the conduct of the company&#8217;s affairs by the majority or the board of directors. However, every shareholder is entitled to have
the affairs of the company conducted properly according to law and the constituent documents of the company. As such, if those who control
the company have persistently disregarded the requirements of company law or the provisions of the company&#8217;s memorandum and articles
of association, then the courts will grant relief. Generally, the areas in which the courts will intervene are the following: (1) an act
complained of which is outside the scope of the authorized business or is illegal or not capable of ratification by the majority; (2)
acts that constitute fraud on the minority where the wrongdoers control the company; (3) acts that infringe on the personal rights of
the shareholders, such as the right to vote; and (4) where the company has not complied with provisions requiring approval of a special
or extraordinary majority of shareholders, which are more limited than the rights afforded minority shareholders under the laws of many
states in the United States subject to limited exceptions, under Cayman Islands Law a minority shareholder may not bring a derivative
action against directors. Our Cayman Islands&#8217; counsel has advised us that they are aware of one recent as yet unreported derivative
action having been brought in a Cayman Islands&#8217; court. Class actions are not recognized in the Cayman Islands, but groups of shareholders
with identical interests may bring representative proceedings, which are similar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, you may be limited
in your ability to protect your interests if you are harmed in a manner that would otherwise enable you to sue in a United States federal
court. In addition, shareholders of Cayman Islands companies may not have standing to initiate a shareholder derivative action in U.S.
federal courts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of all of the
above, shareholders of our Company may have more difficulty in protecting their interests in the face of actions taken by management,
members of the board of directors or controlling shareholders than they would have as shareholders of a public U.S. company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may face difficulties in protecting
your interests, and your ability to protect your rights through the U.S. federal courts may be limited because we are incorporated under
Cayman Islands law, we currently conduct substantially all of our operations outside the United States and some of our directors and executive
officers reside outside the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated in the
Cayman Islands and currently conduct substantially all of our operations outside the United States through our subsidiaries. Some of our
directors and executive officers reside outside the United States and a substantial portion of their assets are located outside of the
United States. As a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the
Cayman Islands, the United Kingdom or in Hong Kong, in the event that you believe that your rights have been infringed under the securities
laws of the United States or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands,
the United Kingdom and Hong Kong may render you unable to enforce a judgment against our assets or the assets of our directors and officers.
There is no statutory recognition in the Cayman Islands of judgments obtained in the United States, the United Kingdom or Hong Kong, although
the courts of the Cayman Islands will generally recognize and enforce a non-penal judgment of a foreign court of competent jurisdiction
without retrial on the merits if such judgment is final, for a liquidated sum, not in the nature of taxes, a fine or penalty, is not inconsistent
with a Cayman Islands&#8217; judgment in respect of the same matters, and was not obtained in a manner which is contrary to public policy.
In addition, a Cayman Islands court may stay proceedings if concurrent proceedings are being brought elsewhere.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a foreign private issuer, we are permitted
to adopt certain home country practices in relation to corporate governance matters that differ significantly from the NASDAQ Capital
Market corporate governance listing standards. These practices may afford less protection to shareholders than they would enjoy if we
complied fully with corporate governance listing standards.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are permitted to take advantage of certain provisions in the NASDAQ Capital Market listing rules that allow us to follow Cayman Islands
law for certain governance matters. Certain corporate governance practices in the Cayman Islands may differ significantly from corporate
governance listing standards as, except for general fiduciary duties and duties of care, Cayman Islands law has no corporate governance
regime which prescribes specific corporate governance standards. We may follow Cayman Islands corporate governance practices in lieu of
the corporate governance requirements of the NASDAQ Capital Market in respect of the following. For instance, Cayman law does not require
that we obtain shareholder approval to issue 20% or more of our outstanding Ordinary Shares in a private offering nor we make our interim
results available to shareholders, although as a NASDAQ listed company we are required to publicly file interim results for the first
six months of our fiscal year. Therefore, our shareholders may be afforded less protection than they otherwise would have under corporate
governance listing standards applicable to U.S. domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Doing Business in Hong Kong
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Our company currently does
not have operations in mainland China. Accordingly, the laws and regulations of the PRC do not currently have any material impact on our
business, financial condition and results of operations. However, if certain PRC laws and regulations were to become applicable to a company
such as us in the future, the application of such laws and regulations may have a material adverse impact on our business, financial condition
and results of operations and our ability to offer or continue to offer securities to investors, any of which may cause the value of our
Class A Ordinary Shares, to significantly decline or become worthless. See the following risk factors of &#8220;Our business, financial
condition and results of operations, and/or the value of our Class A Ordinary Shares or our ability to offer or continue to offer securities
to investors may be materially and adversely affected to the extent the laws and regulations of the PRC become applicable to a company
such as us&#8221; and &#8220;The PRC government exerts substantial influence and discretion over the manner in which companies incorporated
under the laws of PRC must conduct their business activities. If we were to become subject to such direct influence or discretion, it
may result in a material change in our operations and/or the value of your Class A Ordinary Shares, which would materially affect the
interests of investors.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Political risks associated with conducting business in Hong Kong.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most of our operations are
based in Hong Kong. Accordingly, our business operations and financial conditions will be affected by the political and legal developments
in Hong Kong. During the period covered by the financial information incorporated by reference into and included in this Report, we maintain
substantially most of our operations in Hong Kong. Any adverse economic, social and/or political conditions, material social unrest, strike,
riot, civil disturbance or disobedience, as well as significant natural disasters, may affect the market may adversely affect the business
operations of our operations. Hong Kong is a special administrative region of the PRC and the basic policies of the PRC regarding Hong
Kong are reflected in the Basic Law (the &#8220;Hong Kong Basic Law&#8221; or the &#8220;Basic Law&#8221;), namely, Hong Kong&#8217;s
constitutional document, which provides Hong Kong with a high degree of autonomy and executive, legislative and independent judicial powers,
including that of final adjudication under the principle of &#8220;one country, two systems&#8221;. However, there is no assurance that
there will not be any changes in the economic, political and legal environment in Hong Kong in the future. Since our operation is based
in Hong Kong, any change of such political arrangements may pose immediate threat to the stability of the economy in Hong Kong, thereby
directly and adversely affecting our results of operations and financial positions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Basic Law of the
Hong Kong Special Administrative Region of the People&#8217;s Republic of China, Hong Kong is exclusively in charge of its internal affairs
and external relations, while the government of the PRC is responsible for its foreign affairs and defense. As a separate customs territory,
Hong Kong maintains and develops relations with foreign states and regions. Based on certain recent development including the Law of the
People&#8217;s Republic of China on Safeguarding National Security in the Hong Kong Special Administrative Region issued by the Standing
Committee of the PRC National People&#8217;s Congress in June 2020, the U.S. State Department has indicated that the United States no
longer considers Hong Kong to have significant autonomy from China and Former President Trump signed an executive order and Hong Kong
Autonomy Act (&#8220;HKAA&#8221;) to remove Hong Kong&#8217;s preferential trade status and to authorize the U.S. administration to impose
blocking sanctions against individuals and entities who are determined to have materially contributed to the erosion of Hong Kong&#8217;s
autonomy. The United States may impose the same tariffs and other trade restrictions on exports from Hong Kong that it places on goods
from mainland China. These and other recent actions may represent an escalation in political and trade tensions involving the U.S., China
and Hong Kong, which could potentially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the relatively small
geographical size of Hong Kong, any of such incidents may have a widespread effect on our business operations, which could in turn adversely
and materially affect our business, results of operations and financial condition. It is difficult to predict the full impact of the HKAA
on Hong Kong and companies with operations in Hong Kong like us. Furthermore, legislative or administrative actions in respect of China-U.S.
relations could cause investor uncertainty for affected issuers, including us, and the market price of our Ordinary Shares could be adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we become directly subject to the recent
scrutiny, criticism and negative publicity involving U.S.-listed Chinese companies, we may have to expend significant resources to investigate
and resolve the matter which could harm our business operations, stock price and reputation and could result in a loss of your investment
in our stock, especially if such matter cannot be addressed and resolved favorably.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, U.S. public companies
that have substantially all of their operations in China, including Hong Kong, have been the subject of intense scrutiny, criticism and
negative publicity by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and
negative publicity has centered around financial and accounting irregularities and mistakes, a lack of effective internal controls over
financial accounting, inadequate corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud.
As a result of the scrutiny, criticism and negative publicity, the publicly traded stock of many U.S. listed Chinese companies has sharply
decreased in value and, in some cases, has become virtually worthless. Many of these companies are now subject to shareholder lawsuits
and SEC enforcement actions and are conducting internal and external investigations into the allegations. It is not clear what effect
this sector-wide scrutiny, criticism and negative publicity will have on our company, our business and our stock price. If we become the
subject of any unfavorable allegations, whether such allegations are proven to be true or untrue, we will have to expend significant resources
to investigate such allegations and/or defend our company. This situation will be costly and time consuming and distract our management
from growing our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The recent joint statement by the SEC, proposed
rule changes submitted by Nasdaq, and an act passed by the U.S. Senate and the U.S. House of Representatives, all call for additional
and more stringent criteria to be applied to emerging market companies. These developments could add uncertainties to our offering, business
operations, share price and reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. public companies that
have substantially all of their operations in China and Hong Kong have been the subject of intense scrutiny, criticism and negative publicity
by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and negative publicity
has centered on financial and accounting irregularities and mistakes, a lack of effective internal controls over financial accounting,
inadequate corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 21, 2020, SEC Chairman
Jay Clayton and PCAOB Chairman William D. Duhnke III, along with other senior SEC staff, released a joint statement highlighting the risks
associated with investing in companies based in or have substantial operations in emerging markets including China, including Hong Kong,
reiterating past SEC and PCAOB statements on matters including the difficulty associated with inspecting accounting firms and audit work
papers in China and Hong Kong and higher risks of fraud in emerging markets and the difficulty of bringing and enforcing SEC, Department
of Justice and other U.S. regulatory actions, including in instances of fraud, in emerging markets generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 20, 2020, the U.S.
Senate passed the HFCA Act requiring a foreign company to certify it is not owned or controlled by a foreign government if the PCAOB is
unable to audit specified reports because the company uses a foreign auditor not subject to PCAOB inspection. If the PCAOB is unable to
inspect the company&#8217;s auditors for three consecutive years, the issuer&#8217;s securities are prohibited to trade on a national
exchange. On December 2, 2020, the U.S. House of Representatives approved the HFCA Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 21, 2021, Nasdaq filed
three proposals with the SEC to (i) apply minimum offering size requirement for companies primarily operating in a &#8220;Restrictive
Market&#8221;, (ii) prohibit Restrictive Market companies from directly listing on Nasdaq Capital Market, and only permit them to list
on Nasdaq Global Select or Nasdaq Global Market in connection with a direct listing and (iii) apply additional and more stringent criteria
to an applicant or listed company based on the qualifications of the company&#8217;s auditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 24, 2021, the SEC
announced the adoption of interim final amendments to implement the submission and disclosure requirements of the HFCA Act. In the announcement,
the SEC clarifies that before any issuer will have to comply with the interim final amendments, the SEC must implement a process for identifying
covered issuers. The announcement also states that the SEC staff is actively assessing how best to implement the other requirements of
the HFCA Act, including the identification process and the trading prohibition requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 22, 2021, the U.S.
Senate passed the AHFCAA, which, if signed into law, would amend the HFCA Act and require the SEC to prohibit an issuer&#8217;s securities
from trading on any U.S. stock exchanges if its auditor is not subject to the PCAOB inspections for two consecutive years instead of three
consecutive years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 22, 2021, the
PCAOB adopted a final rule implementing the HFCA Act, which provides a framework for the PCAOB to use when determining, as contemplated
under the HFCA Act, whether the board of directors of a company is unable to inspect or investigate completely registered public accounting
firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 2, 2021, the SEC
adopted amendments to finalize rules implementing the submission and disclosure requirements in the HFCA Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 16, 2021, the
PCAOB issued a report on its determinations that it is unable to inspect or investigate completely PCAOB-registered public accounting
firms headquartered in mainland China and in Hong Kong because of positions taken by PRC and Hong Kong authorities in those jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 29, 2022, the
Consolidated Appropriations Act was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things,
an identical provision to AHFCAA, which reduce the number of consecutive non-inspection years required for triggering the prohibitions
under the HFCA Act from three years to two.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lack of access to the
PCAOB inspection in China prevents the PCAOB from fully evaluating audits and quality control procedures of the auditors based in China.
As a result, investors may be deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of
auditors in China makes it more difficult to evaluate the effectiveness of these accounting firm&#8217;s audit procedures or quality control
procedures as compared to auditors outside of China that are subject to the PCAOB inspections, which could cause investors and potential
investors in our Class A Ordinary Shares to lose confidence in our audit procedures and reported financial information and the quality
of our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our auditor, Marcum Asia CPAs
LLP, as the auditor of companies that are traded publicly in the U.S. and registered with the PCAOB, are subject to laws in the U.S.,
pursuant to which the PCAOB conducts regular inspections to assess their compliance with the applicable professional standards. Marcum
Asia CPAs LLP is headquartered in Manhattan, New York, and have been inspected by the PCAOB on a regular basis, and Marcum Asia CPAs LLP
is not subject to the determinations announced by the PCAOB on December 16, 2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, the recent developments
would add uncertainties to our ability to offer or continue to offer securities and we cannot assure you whether the national securities
exchange we apply to for listing or regulatory authorities would apply additional and more stringent criteria to us after considering
the effectiveness of our auditor&#8217;s audit procedures and quality control procedures, adequacy of personnel and training, or sufficiency
of resources, geographic reach, or experience as it relates to our audit. In addition, the HFCA Act, as amended, which requires that the
PCAOB be permitted to inspect an issuer&#8217;s public accounting firm within two years, may result in the delisting of our Company or
prohibition of trading in our Class A Ordinary Shares in the future if the PCAOB is unable to inspect our accounting firm at such future
time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 26, 2022, the China
Securities Regulatory Commission, the MOF, and the PCAOB signed the Protocol governing inspections and investigations of audit firms based
in mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate registered public
accounting firms headquartered in mainland China and Hong Kong. Pursuant to the fact sheet with respect to the Protocol disclosed by the
SEC, the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability
to transfer information to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete access
to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous
determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB&#8217;s access in the
future, the PCAOB Board will consider the need to issue a new determination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of this scrutiny,
criticism and negative publicity, the publicly traded stock of many U.S. listed Chinese and Hong Kong companies sharply decreased in value
and, in some cases, has become virtually worthless. Many of these companies are now subject to shareholder lawsuits and SEC enforcement
actions and are conducting internal and external investigations into the allegations. It is not clear what effect this sector-wide scrutiny,
criticism and negative publicity will have on us, our ability to offer or continue to offer securities, business and our share price.
If we become the subject of any unfavorable allegations, whether such allegations are proven to be true or untrue, we will have to expend
significant resources to investigate such allegations and/or defend our company. This situation will be costly and time consuming and
distract our management from developing our growth. If such allegations are not proven to be groundless, we and our business operations
will be severely affected and you could sustain a significant decline in the value of our share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq may apply additional and more stringent
criteria for our continued listing because our insiders hold a large portion of our listed securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nasdaq Listing Rule 5101 provides
Nasdaq with broad discretionary authority over the initial and continued listing of securities in Nasdaq and Nasdaq may use such discretion
to deny initial listing, apply additional or more stringent criteria for the initial or continued listing of particular securities, or
suspend or delist particular securities based on any event, condition, or circumstance that exists or occurs that makes initial or continued
listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though the securities meet all enumerated
criteria for initial or continued listing on Nasdaq. In addition, Nasdaq has used its discretion to deny initial or continued listing
or to apply additional and more stringent criteria in the instances, including but not limited to: (i) where the company engaged an auditor
that has not been subject to an inspection by PCAOB, an auditor that PCAOB cannot inspect, or an auditor that has not demonstrated sufficient
resources, geographic reach, or experience to adequately perform the company&#8217;s audit; (ii) where the company planned a small public
offering, which would result in insiders holding a large portion of the company&#8217;s listed securities; and (iii) where the company
did not demonstrate sufficient nexus to the U.S. capital market, including having no U.S. shareholders, operations, or members of the
board of directors or management. The insiders of our Company hold a large portion of the company&#8217;s listed securities. Therefore,
we may be subject to the additional and more stringent criteria of Nasdaq for our continued listing, which might result in deficiency
letters or inquiries that will take management&#8217;s time away from focusing on our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business, financial condition and results
of operations, and/or the value of our Class A Ordinary Shares or our ability to offer or continue to offer securities to investors may
be materially and adversely affected to the extent the laws and regulations of the PRC become applicable to a company such as us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have or
intend to have any subsidiary or any contractual arrangement to establish a variable interest entity structure with any entity in mainland
China. All of our operating entities are in jurisdictions outside of mainland China, including all three of our VIEs which are incorporated
under the laws of Cayman Islands and conduct operations in Hong Kong. However, as our principal place of business is in Hong Kong, a special
administrative region of China, there is no guarantee that if certain existing or future laws of the PRC become applicable to a company
such as us, it will not have a material adverse impact on our business, financial condition and results of operations and/or our ability
to offer or continue to offer securities to investors, any of which may cause the value of such securities to significantly decline or
be worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for the Basic Law,
the national laws of the PRC do not apply in Hong Kong unless they are listed in Annex III of the Basic Law and applied locally by promulgation
or local legislation. National laws that may be listed in Annex III are currently limited under the Basic Law to those which fall within
the scope of defense and foreign affairs as well as other matters outside the limits of the autonomy of Hong Kong. National laws and regulations
relating to data protection, cybersecurity and anti-monopoly have not been listed in Annex III and so do not apply directly to Hong Kong.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The laws and regulations in
the PRC are evolving, and their enactment timetable, interpretation and implementation involve significant uncertainties. To the extent
any PRC laws and regulations become applicable to us, we may be subject to the risks and uncertainties associated with the legal system
in the PRC, including with respect to the enforcement of laws and the possibility of changes of rules and regulations with little or no
advance notice. We currently do not have plan to expand our operation or acquire any operation in the mainland China. However, we may
also become subject to the laws and regulations of the PRC to the extent we commence business and customer facing operations in mainland
China as a result of any future acquisition, expansion or organic growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The PRC government exerts substantial influence
and discretion over the manner in which companies incorporated under the laws of PRC must conduct their business activities. If we were
to become subject to such direct influence or discretion, it may result in a material change in our operations and/or the value of our
Class A Ordinary Shares, which would materially affect the interest of the investors. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC legal system is evolving
rapidly and the PRC laws, regulations, and rules may change quickly with little advance notice. In particular, because these laws, rules
and regulations are relatively new, and because of the limited number of published decisions and the non-precedential nature of these
decisions, the interpretation of these laws, rules and regulations may contain inconsistences, the enforcement of which involves uncertainties.
The PRC government has exercised and continues to exercise substantial control over many sectors of the PRC economy through regulation
and/or state ownership. Government actions have had, and may continue to have, a significant effect on economic conditions in the PRC
and businesses which are subject to such government actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have business operations
in Hong Kong, but not in mainland China, and we directly, or indirectly via our subsidiaries, own equity interests in our operating entities,
none of which are located in mainland China, although all three of our VIEs are incorporated under the laws of Cayman Islands and conduct
operations in Hong Kong. Our principal executive offices are located in Europe, but our principal place of business is in Hong Kong, a
special administrative region of China. The PRC government currently does not exert direct influence and discretion over the manner in
which we conduct our business activities outside of mainland China, however, there is no guarantee that we will not be subject to such
direct influence or discretion in the future due to changes in laws or other unforeseeable reasons or as a result of our future expansion
or acquisition of operations in mainland China. See &#8220;- Our business, financial condition and results of operations, and/or the value
of our Class A Ordinary Shares or our ability to offer or continue to offer securities to investors may be materially and adversely affected
to the extent the laws and regulations of the PRC become applicable to a company such as us.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have plans
to expand our operation or acquire any operation in the mainland China. However, if we were to become subject to the direct intervention
or influence of the PRC government at any time due to changes in laws or other unforeseeable reasons or as a result of our future development,
expansion or acquisition of operations in the PRC, it may require a material change in our operations and/or result in increased costs
necessary to comply with existing and newly adopted laws and regulations or penalties for any failure to comply. In addition, the market
prices of our Class A Ordinary Shares could be adversely affected as a result of anticipated negative impacts of any such government actions,
as well as negative investor sentiment towards Hong Kong-based companies subject to direct PRC government oversight and regulation, regardless
of our actual operating performance. There can be no assurance that the Chinese government would not intervene in or influence our operations
at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were not required to obtain
permission from the PRC government to list on a U.S. securities exchange, however there is no guarantee that this will continue to be
the case in the future in relation to the continued listing of our securities on a securities exchange outside of the PRC, or even when
such permission is obtained, it will not be subsequently denied or rescinded. Any actions by the PRC government to exert more oversight
and control over offerings (including of businesses whose primary operations are in Hong Kong) that are conducted overseas and/or foreign
investments in Hong Kong-based issuers could significantly limit or completely hinder our ability to offer or continue to offer securities
to investors and cause the value of our securities, including our Class A Ordinary Shares, to significantly decline or be worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The enactment of Law of the PRC on Safeguarding
National Security in the Hong Kong Special Administrative Region (the &#8220;Hong Kong National Security Law&#8221;) could impact our
Hong Kong holding subsidiary. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2020, the Standing
Committee of the PRC National People&#8217;s Congress adopted the Hong Kong National Security Law. This law defines the duties and government
bodies of the Hong Kong National Security Law for safeguarding national security and four categories of offences - secession, subversion,
terrorist activities, and collusion with a foreign country or external elements to endanger national security - and their corresponding
penalties. On July 14, 2020, the former U.S. President Donald Trump signed the Hong Kong Autonomy Act, or HKAA, into law, authorizing
the U.S. administration to impose blocking sanctions against individuals and entities who are determined to have materially contributed
to the erosion of Hong Kong&#8217;s autonomy. On August 7, 2020 the U.S. government imposed HKAA-authorized sanctions on eleven individuals,
including former HKSAR chief executive Carrie Lam. On October 14, 2020, the U.S. State Department submitted to relevant committees of
Congress the report required under HKAA, identifying persons materially contributing to &#8220;the failure of the Government of China
to meet its obligations under the Joint Declaration or the Basic Law.&#8221; The HKAA further authorizes secondary sanctions, including
the imposition of blocking sanctions, against foreign financial institutions that knowingly conduct a significant transaction with foreign
persons sanctioned under this authority. The imposition of sanctions may directly affect the foreign financial institutions as well as
any third parties or customers dealing with any foreign financial institution that is targeted. It is difficult to predict the full impact
of the Hong Kong National Security Law and HKAA on Hong Kong and companies located in Hong Kong. If our Hong Kong subsidiaries are determined
to be in violation of the Hong Kong National Security Law or the HKAA by competent authorities, our business operations, financial position
and results of operations could be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Hong Kong legal system embodies uncertainties
which could limit the availability of legal protections. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As one of the conditions for
the handover of the sovereignty of Hong Kong to China, China accepted conditions such as Hong Kong&#8217;s Basic Law. The Basic Law ensured
Hong Kong will retain its own currency (Hong Kong Dollar), legal system, parliamentary system and people&#8217;s rights and freedom for
fifty years from 1997. This agreement has given Hong Kong the freedom to function with a high degree of autonomy. The Special Administrative
Region of Hong Kong is responsible for its own domestic affairs including, but not limited to, the judiciary and courts of last resort,
immigration and customs, public finance, currencies and extradition. Hong Kong continues using the English common law system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, if the PRC attempts
to alter its agreement to allow Hong Kong to function autonomously, this could potentially impact Hong Kong&#8217;s common law legal system
and may in turn bring about uncertainty in, for example, the enforcement of our contractual rights. This could, in turn, materially and
adversely affect our business and operations. Additionally, intellectual property rights and confidentiality protections in Hong Kong
may not be as effective as in the United States or other countries. Accordingly, we cannot predict the effect of future developments in
the Hong Kong legal system, including the promulgation of new laws, changes to existing laws or the interpretation or enforcement thereof,
or the preemption of local regulations by national laws. These uncertainties could limit the legal protections available to us, including
our ability to enforce our agreements with our customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There remain some uncertainties as to whether
we will be required to obtain approvals from Chinese authorities to list on the U.S. exchanges and offer or continue to offer securities
in the future, and if required, we cannot assure you that we will be able to obtain such approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Regulations on Mergers
and Acquisitions of Domestic Companies by Foreign Investors (the &#8220;M&amp;A Rules&#8221;), adopted by six PRC regulatory agencies
in 2006 and amended in 2009, requires an overseas special purpose vehicle formed for listing purposes through acquisitions of PRC domestic
companies and controlled by PRC companies or individuals to obtain the approval of the China Securities Regulatory Commission (&#8220;CSRC&#8221;)
prior to the listing and trading of such special purpose vehicle&#8217;s securities on an overseas stock exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also aware that recently,
the PRC government initiated a series of regulatory actions and statements to regulate business operations in certain areas in mainland
China with little advance notice, including cracking down on illegal activities in the securities market, enhancing supervision over mainland-China-based
companies listed overseas using variable interest entity structure, adopting new measures to extend the scope of cybersecurity reviews,
and expanding the efforts in anti-monopoly enforcement. For example, on July 6, 2021, the General Office of the Communist Party of China
Central Committee and the General Office of the State Council jointly issued a document to crack down on illegal activities in the securities
market and promote the high-quality development of the capital market, which, among other things, requires the relevant governmental authorities
to strengthen cross-border oversight of law-enforcement and judicial cooperation, to enhance supervision over mainland-China-based companies
listed overseas, and to establish and improve the system of extraterritorial application of the PRC securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 28, 2021, the
Cyberspace Administration of China (&#8220;CAC&#8221;), and other PRC authorities promulgated the Cybersecurity Review Measures, which
took effect on February 15, 2022. In addition, the Cybersecurity Law, which was adopted by the Standing Committee of the National People&#8217;s
Congress on November 7, 2016 and came into force on June 1, 2017, and the Cybersecurity Review Measures, or the &#8220;Review Measures&#8221;,
provide that personal information and important data collected and generated by a critical information infrastructure operator in the
course of its operations in mainland China must be stored in mainland China, and if a critical information infrastructure operator purchases
internet products and services that affect or may affect national security, it should be subject to national security review by the CAC
together with competent departments of the State Council. In addition, for critical information infrastructure operators, or the &#8220;CIIOs&#8221;,
that purchase network-related products and services, the CIIOs shall declare any network-related product or service that affects or may
affect national security to the Office of Cybersecurity Review of the CAC for cybersecurity review. Due to the lack of further interpretations,
the exact scope of what constitutes a &#8220;CIIO&#8221; remains unclear. Further, the PRC government authorities may have wide discretion
in the interpretation and enforcement of these laws. In addition, the Review Measures stipulates that any online platform operators holding
more than one million users/users&#8217; individual information shall be subject to cybersecurity review before listing abroad. As of
the date of the annual report, neither we nor our subsidiaries have received any notice from any authorities identifying us or our subsidiaries
as a CIIO or requiring us or our subsidiaries to undertake a cybersecurity review by the CAC. Further, as of the date of the annual report,
neither we nor our subsidiaries have been subject to any penalties, fines, suspensions, or investigations from any competent authorities
for violation of the regulations or policies that the CAC has issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 10, 2021, the Standing
Committee of the National People&#8217;s Congress promulgated the Data Security Law, which took effect on September 1, 2021. The Data
Security Law requires that data shall not be collected by theft or other illegal means, and it also provides for a data classification
and hierarchical protection system. The data classification and hierarchical protection system protects data according to its importance
in economic and social development, and the damages it may cause to national security, public interests, or the legitimate rights and
interests of individuals and organizations if the data is falsified, damaged, disclosed, illegally obtained or illegally used, which protection
system is expected to be built by the state for data security in the near future. On November 14, 2021, CAC published the Regulations
on the Data Security Administration Draft, or the &#8220;Data Security Regulations Draft&#8221;, to solicit public opinion and comments.
Under the Data Security Regulations Draft, an overseas initial public offering to be conducted by a data processor processing the personal
information of more than one million individuals shall apply for a cybersecurity review. Data processor means an individual or organization
that independently makes decisions on the purpose and manner of processing in data processing activities, and data processing activities
refers to activities such as the collection, retention, use, processing, transmission, provision, disclosure, or deletion of data. Currently
we do not expect the Review Measures to have an impact on the business and operations of our Hong Kong subsidiaries, because (i) our Hong
Kong subsidiaries are incorporated and operating in Hong Kong without any subsidiary or variety interest entity (&#8220;VIE&#8221;) structure
in mainland China, and it is unclear whether the Review Measures shall be applied to a Hong Kong company; (ii) as of the date of the annual
report, our Hong Kong subsidiaries have not collected or stored personal information of any individual clients of mainland China; and
(iii) as of the date of this annual report, our Hong Kong subsidiaries have not been informed by any PRC governmental authority of any
requirement that it file for a cybersecurity review for the offering. Based on laws and regulations currently in effect in the PRC as
of the date of this annual report, we believe our Hong Kong subsidiaries are not required to pass the cybersecurity review of the CAC
in order to list our Class A Ordinary Shares in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on February 17,
2023, the CSRC promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, or the
Trial Measures, and five supporting guidelines, which came into effect on March 31, 2023. Pursuant to the Trial Measures, domestic companies
that seek to offer or list securities overseas, both directly and indirectly, shall complete filing procedures with the CSRC pursuant
to the requirements of the Trial Measures within three working days following its submission of initial public offerings or listing application.
If a PRC company fails to complete required filing procedures or conceals any material fact or falsifies any major content in its filing
documents, such PRC company may be subject to administrative penalties, such as order to rectify, warnings, fines, and its controlling
shareholders, actual controllers, the person directly in charge and other directly liable persons may also be subject to administrative
penalties, such as warnings and fines. In addition, on February 24, 2023, the CSRC, together with Ministry of Finance of the PRC, National
Administration of State Secrets Protection and National Archives Administration of China, revised the Provisions on Strengthening Confidentiality
and Archives Administration for Overseas Securities Offering and Listing which was issued by the CSRC, National Administration of State
Secrets Protection and National Archives Administration of China in 2009, or the Provisions. The revised Provisions is issued under the
title the Provisions on Strengthening Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic
Companies, and came into effect on March 31, 2023 together with the Trial Measures. One of the major revisions to the revised Provisions
is expanding its application to cover indirect overseas offering and listing, as is consistent with the Trial Measures. The revised Provisions
require that, including but not limited to (a) a domestic company that plans to, either directly or indirectly through its overseas listed
entity, publicly disclose or provide to relevant individuals or entities including securities companies, securities service providers
and overseas regulators, any documents and materials that contain state secrets or working secrets of government agencies, shall first
obtain approval from competent authorities according to law, and file with the secrecy administrative department at the same level; and
(b) domestic company that plans to, either directly or indirectly through its overseas listed entity, publicly disclose or provide to
relevant individuals and entities including securities companies, securities service providers and overseas regulators, any other documents
and materials that, if leaked, will be detrimental to national security or public interest, shall strictly fulfill relevant procedures
stipulated by applicable national regulations. As of the date of this annual report, we have not received any formal inquiry, notice,
warning, sanction, or objection from the CSRC with respect to the listing of our Class A Ordinary Shares. However, there remains significant
uncertainty as to the enactment, interpretation and implementation of regulatory requirements related to overseas securities offerings
and other capital markets activities. If it is determined that we are subject to the Trial Measures for the listing of the Ordinary Shares
on the Nasdaq, we may fail to obtain required approval, complete required filing or meet such requirements in a timely manner or at all,
or completion could be rescinded. Any failure or perceived failure of us to fully comply with such new regulatory requirements could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors, cause significant disruption to our business
operations, and severely damage our reputation, which could materially and adversely affect our financial condition and results of operations
and could cause the value of our securities to significantly decline or be worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are determined to be
subject to the Draft Rules Regarding Overseas Listings, we cannot assure you that we will be able to receive clearance of such filing
requirements in a timely manner, or at all, even though we believe that none of the situations that would clearly prohibit overseas listing
and offering applies to us. Based on laws and regulations currently in effect in the PRC as of the date of this annual report, we believe
our Hong Kong subsidiaries are not required to obtain regulatory approval from the CSRC in order to list our Class A Ordinary Shares in
the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since these proposed rules,
statements and regulatory actions are new, it is highly uncertain how soon the legislative or administrative regulation making bodies
will respond and what existing or new laws or regulations or detailed implementations and interpretations will be modified or promulgated,
if any. Any failure of us to fully comply with new regulatory requirements may significantly limit or completely hinder our ability to
offer or continue to offer the Class A Ordinary Shares, cause significant disruption to our business operations, severely damage our reputation,
materially and adversely affect our financial condition and results of operations, and cause the Class A Ordinary Shares to significantly
decline in value or become worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual
report, we believe are not required to obtain approvals from the PRC authorities to operate our business or list on the U.S. exchanges
and offer or continue to offer securities; specifically, we are currently not required to obtain any permission or approval from the CSRC,
the CAC or any other PRC governmental authority to operate our business or to list our securities on a U.S. securities exchange or issue
securities to foreign investors. However, if we and our Hong Kong subsidiaries (i) do not receive or maintain such approval, should the
approval be required in the future by the PRC government, (ii) inadvertently conclude that such approval is not required, or (iii) applicable
laws, regulations, or interpretations change and we are required to obtain such approval in the future, our operations and financial condition
could be materially adversely affected, and our ability to offer or continue to offer securities to investors could be significantly limited
or completely hindered and the securities currently being offered may substantially decline in value and become worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevertheless, since these
statements and regulatory actions are new, it is highly uncertain how soon the legislative or administrative regulation making bodies
will respond and what existing or new laws or regulations or detailed implementations and interpretations will be modified or promulgated,
if any. It is also highly uncertain what potential impact such modified or new laws and regulations will have on Aptorum Group&#8217;s
daily business operations, our ability to accept foreign investments and the listing of our Class A Ordinary Shares on a U.S. or other
foreign exchanges. If there is significant change to current political arrangements between mainland China and Hong Kong, the PRC government
intervenes or influences operations of companies operated in Hong Kong like us, or exerts more control through change of laws and regulations
over offerings conducted overseas and/or foreign investment in issuers like us, it may result in a material change in our operations and/or
the value of the securities we are registering for sale or could significantly limit or completely hinder our ability to offer or continue
to offer securities to investors and cause the value of our Class A Ordinary Shares to significantly decline or become worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult for overseas shareholders
and/or regulators to conduct investigations or collect evidence within China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholder claims or regulatory
investigations that are common in the United States generally are difficult to pursue as a matter of law or practicality in China. For
example, in China, there are significant legal and other obstacles to providing information needed for regulatory investigations or litigation
initiated outside China. Although the authorities in China may establish a regulatory cooperation mechanism with the securities regulatory
authorities of another country or region to implement cross-border supervision and administration, such cooperation with the securities
regulatory authorities in the Unities States may not be efficient in the absence of mutual and practical cooperation mechanisms. Furthermore,
according to Article 177 of the PRC Securities Law, or Article 177, which became effective in March 2020, no overseas securities regulator
is allowed to directly conduct investigation or evidence collection activities within the territory of the PRC. While detailed interpretation
of or implementation rules under Article 177 have yet to be promulgated, the inability for an overseas securities regulator to directly
conduct investigation or evidence collection activities within China may further increase difficulties faced by you in protecting your
interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our auditor&#8217;s audit
working papers are located in PRC. In the event that the U.S. regulators carry out investigation on us and there is a need to conduct
investigation or collect evidence within the territory of the PRC, the U.S. regulators may not be able to carry out such investigation
or evidence collection directly in the PRC under the PRC laws. The U.S. regulators may consider cross-border cooperation with securities
regulatory authority of the PRC by way of judicial assistance, diplomatic channels or regulatory cooperation mechanism established with
the securities regulatory authority of the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have ceased to qualify as an &#8220;emerging
growth company&#8221; and will incur increased costs as a result</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We ceased to be an &#8220;emerging
growth company&#8221; on December 31, 2023. Accordingly, we are no longer eligible for reduced disclosure requirements and exemptions
available to EGCs and, among other things, will formally become subject to new accounting pronouncement effective dates for non-EGCs.
While we have determined that we are neither an accelerated filer nor a large accelerated filer (as such terms are defined under U.S.
federal securities laws) and therefore not required to obtain an attestation report from our independent registered public accounting
firm on the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act, we nevertheless
expect to incur additional legal, accounting, financial and other costs associated with being a public company that is not an EGC, including
mandatory adoption of new accounting pronouncements. We may also incur costs associated with compliance with the requirements of additional
disclosure requirements, including Section 404(b) of the Sarbanes-Oxley Act in the event that we determine that we have become an accelerated
filer or large accelerated filer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, investors may find
our securities less attractive because of our reliance on the foregoing exemption from Section 404(b) of the Sarbanes-Oxley Act, as well
as any other exemptions available to us under U.S. federal securities laws. This could contribute to a less active trading market for
our securities and prices of the securities may be more volatile or decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to the Proposed Merger and Separation
Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 1, 2024, we entered
into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among Company, and YOOV Group Holding Limited, a BVI
business company organized under the laws of British Virgin Islands (&#8220;YOOV&#8221;). The Merger Agreement was unanimously approved
by Company&#8217;s and YOOV&#8217;s boards of directors (each board of directors, the &#8220;Board&#8221;), respectively. Upon consummation
of the transactions contemplated by the Merger Agreement, a wholly-owned subsidiary of the Company organized under the laws of the British
Virgin Islands (&#8220;Merger Sub&#8221;) will merge with and into YOOV, with YOOV surviving the merger as a wholly-owned subsidiary of
Company (collectively, the &#8220;Merger&#8221;). In connection with the Merger, on March 1, 2024, Aptorum entered into a Split-Off Agreement
(the &#8220;Split-Off Agreement&#8221;, the transaction contemplated by the Split-Off Agreement, the &#8220;Separation&#8221;) by and
among Aptorum, Aptorum Therapeutics Limited (&#8220;ATL&#8221;), and Jurchen Investment Corporation (&#8220;Jurchen&#8221;), pursuant
to which, Aptorum will assign and transfer the assets and liabilities of its legacy business to ATL, and Jurchen will acquire 100% issued
and outstanding shares of ATL from Aptorum and surrender certain ordinary shares of Aptorum held by Jurchen to Aptorum. Aptorum owns all
issued and outstanding capital shares of ATL, which holds the business assets and liabilities listed on Exhibit A of the Split-Off Agreement.
The Separation and the Merger are referred hereto as the &#8220;Proposed Transactions.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are a number of significant
risks related to the Proposed Transactions, including the risk factors enumerated below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Proposed Transactions are subject to
the satisfaction of certain conditions, which may not be satisfied on a timely basis, if at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transactions contemplated
by the Merger Agreement and the Split-Off Agreement are subject to approval by Aptorum shareholders and YOOV shareholders, approval by
Nasdaq of the listing of shares of Aptorum Class A ordinary shares to be issued in connection with the Proposed Transactions, and approval
by Nasdaq of the initial listing of the combined company on Nasdaq, as well as other conditions set forth in the Merger Agreement and
the Split-Off Agreement, which must be satisfied or waived to complete the Proposed Transactions. These conditions are set forth in the
Merger Agreement and described in the section entitled &#8220;Conditions to Closing&#8221; in this report. Aptorum and YOOV cannot assure
you that all of the conditions will be satisfied or waived. If the conditions are not satisfied or waived, the Proposed Transactions will
not occur or will be delayed, and Aptorum and YOOV each may lose some or all of the intended benefits of the Proposed Transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to complete the Proposed
Transactions may result in either YOOV or Aptorum paying a termination fee to the other party, as described in the section entitled &#8220;Termination
of Merger Agreement&#8221; in this report. Payment by Aptorum of a termination fee could materially and adversely affect its financial
condition and termination of the transaction could have a material adverse effect on the market price of Aptorum Class A ordinary shares
and negatively affect its future business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Aptorum and YOOV equity holders may not
realize a benefit from the Proposed Transactions commensurate with the ownership dilution they will experience in connection with the
Proposed Transactions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aptorum may not be able to
achieve the full strategic and financial benefits expected to result from the Proposed Transaction. Further, such benefits, if ultimately
achieved, may be delayed. If the combined company is unable to realize the full strategic and financial benefits currently anticipated
from the Proposed Transactions, Aptorum shareholders and YOOV shareholders will have experienced substantial dilution of their ownership
interests in their respective companies, without receiving any commensurate benefit, or only receiving part of the commensurate benefit
to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the
Proposed Transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of Aptorum
Class A ordinary shares may also decline as a result of the Proposed Transactions for a number of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">if investors react negatively to the prospects of the combined
company&#8217;s product candidates and services, business and financial condition post-Closing;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify">the effect of the Proposed Transactions on the combined company&#8217;s
business and prospects is not consistent with the expectations of financial or industry analysts; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify">the combined company does not achieve the perceived benefits
of the Proposed Transactions as rapidly or to the extent anticipated by financial or industry analysts.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Aptorum shareholders will have a reduced
ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing
as compared to their current ownership and voting interest in the respective companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Proposed Transactions
are completed, the current shareholders of Aptorum will own a smaller percentage of the combined company than their ownership in their
respective companies prior to the Proposed Transactions. Accordingly, the issuance of shares of Aptorum Class A and Class B ordinary shares
to YOOV&#8217;s shareholders in the Proposed Transactions will reduce significantly the relative voting power of each share of Aptorum
Class A and Class B ordinary shares held by its current shareholders. Consequently, Aptorum shareholders as a group will have less influence
over the management and policies of the combined company after the Proposed Transactions than prior to the Proposed Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The combined company may need to raise additional
capital by issuing securities or debt or through licensing or other strategic arrangements, which may cause dilution to the combined company&#8217;s
shareholders or restrict the combined company&#8217;s operations or impact its proprietary rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The combined company may be
required to raise additional funds sooner than currently planned. If either or both of Aptorum or YOOV hold less cash at the time of the
Closing than the parties currently expect, the combined company may need to raise additional capital sooner than expected. Additional
financing may not be available to the combined company when it needs it or may not be available on favorable terms. To the extent that
the combined company raises additional capital by issuing equity securities, such an issuance may cause significant dilution to the combined
company&#8217;s shareholders&#8217; ownership and the terms of any new equity securities may have preferences over the combined company&#8217;s
Class A and Class B ordinary shares. Any debt financing the combined company enters into may involve covenants that restrict its operations.
These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined company&#8217;s
assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the
combined company raises additional funds through licensing, partnering or other strategic arrangements, it may be necessary to relinquish
rights to some of the combined company&#8217;s technologies and proprietary rights, or grant licenses on terms that are not favorable
to the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These restrictive covenants
could deter or prevent the combined company from raising additional capital as and when needed. The combined company&#8217;s failure to
raise capital as and when needed would have a negative effect on its financial condition and its ability to pursue the combined company&#8217;s
business strategy and the combined company may be unable to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>During the pendency of the Proposed Transactions,
Aptorum and YOOV may not be able to enter into a business combination with another party because of restrictions in the Merger Agreement,
which could adversely affect their respective businesses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Covenants in the Merger Agreement
impede the ability of Aptorum and YOOV to make acquisitions, subject to certain exceptions relating to fiduciary duties, or to complete
other transactions that are not in the ordinary course of business pending completion of the Proposed Transaction. As a result, if the
Proposed Transactions are not completed, the parties may be at a disadvantage to their competitors during such period. In addition, while
the Merger Agreement is in effect, each party is generally prohibited from soliciting, initiating, encouraging or entering into certain
extraordinary transactions, such as a merger, sale of assets, or other business combination outside the ordinary course of business with
any third party, subject to certain exceptions relating to fiduciary duties. Any such transactions could be favorable to such party&#8217;s
shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4. INFORMATION ON THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. <span style="text-decoration:underline">History and Development of the Company</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aptorum was incorporated under the laws of the Cayman Islands on September
13, 2010. As of the issuance date of this annual report, our authorized share capital is $100,000,000.00 divided into 9,999,996,000,000
Class A Ordinary Shares with a nominal or par value of $0.00001 each and 4,000,000 Class B Ordinary Shares with a nominal or par value
of $0.00001 each.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aptorum is not a Chinese operating
company. Aptorum is a Cayman Islands holding company with operations conducted through our subsidiaries and the variable interest entities
(VIEs). We have determined that we have three VIEs, namely, Libra, Mios and Scipio, according to the U.S. GAAP. In accordance with ASC
810, we concluded that we are the primary beneficiary of two VIEs, Mios and Scipio, therefore, are able to consolidate their financial
statements into ours. Mios and Scipio are incorporated under the laws of the Cayman Islands and conduct operations in Hong Kong. Our corporate
structure is based on the equity ownership and control we have over our subsidiaries and the consolidated VIEs. Our corporate structure
was not set up to be used to provide investors with exposure to foreign investment in China-based companies where Chinese law prohibits
direct foreign investment in the operating companies. Foreign investment can be made directly into the VIEs, however, your investments
into Aptorum are made into the Cayman Islands holding company, not any of our VIEs, and you may never own any equity into the VIEs or
any other subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aptorum Therapeutics Limited,
a Cayman Islands company with limited liability, entered into two concerted action agreements (&#8220;Concerted Action Agreements&#8221;),
with Peace Range Limited, a shareholder of the two consolidated VIEs, on December 30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the two Concerted
Action Agreements, Peace Range Limited and Aptorum Therapeutics Limited agreed to act in concert and give the same expression of intentions
in regard with (1) exercising voting rights at shareholders&#8217; meetings; (2) making proposals to shareholder&#8217;s meetings; (3)
nominating candidates of directors and supervisors; (4) making material decisions for the consolidated VIEs (save for the administrative
and managerial duty of work being managed by the board of directors and executives of the consolidated VIEs); (5) exercising the rights
as shareholders of the consolidated VIEs in accordance with their articles of association and other relevant agreements or documents between
the consolidated VIEs and other related parties; (6) performing the obligations as shareholders of the consolidated VIEs in accordance
with the articles of association and other relevant agreements or documents between the consolidated VIEs and other related parties; and
(7) exercising other rights granted to shareholders of the consolidated VIEs under laws, administrative regulations, other normative documents,
and the articles of association of the consolidated VIEs. The Concerted Action Agreements are governed by and interpreted in accordance
with the laws of Hong Kong. The copies of the Concerted Action Agreements were filed as exhibits 4.47 and 4.48 to the Form 20-F filed
on April 29, 2022. The Concerted Action Agreements are governed by the laws of Hong Kong. The &#8220;acting in concert&#8221; agreements
like the Concerted Actions Agreements with substantially the same nature have been tested in the courts in Hong Kong. The Hong Kong courts
will enforce unless the agreements are unenforceable for other reason(s) such as the agreements are, among others, illegal or made to
mislead others, or for the purpose of avoidance of legal requirements and lack a bona fide business purpose. We do not believe that the
Concerted Actions Agreements fall within the exceptions that will make them unenforceable in Hong Kong courts.&#8221; (Please see the
risk factor section, &#8220;Risks Related to our Corporate Structure&#8221; and &#8220;Risks Related to Doing Business in Hong Kong&#8221;
for more information about the VIEs).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current business consists
of &#8220;therapeutics&#8221; and &#8220;non-therapeutics&#8221; segments, all of which we operate through our subsidiaries (See the ownership
chart on page 61).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We refer to our therapeutics
segment as Aptorum Therapeutics Group, which is operated through Aptorum&#8217;s wholly-owned subsidiary, Aptorum Therapeutics Limited,
a Cayman Islands exempted company with limited liability, whose principal place of business is in Hong Kong and whose subsidiaries (who
we sometimes refer to herein as project companies) are based in the United Kingdom, Singapore and Hong Kong.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We refer to our non-therapeutics
segment as Aptorum Non-Therapeutics Group, which operates diagnostics projects including PathsDx Test, a novel molecular-based rapid pathogen
identification and detection diagnostics technology. PathsDx Test technology is currently under co-development with A*STAR.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 25, 2020, Aptorum,
via its subsidiaries, enters into a series of transactions with Accelerate Technologies Pte. Ltd.&#8217;s (&#8220;Accelerate Technologies&#8221;),
the commercialization arm of the Singapore Agency for Science, Technology and Research (&#8220;A*STAR&#8221;), in relation to the research
and development of Paths<sup>Dx</sup> Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology,
through its subsidiaries. Specifically, Paths Diagnostics Pte. Limited (formerly known as Aptorum Innovations Holding Pte. Limited), one
of the Company&#8217;s subsidiaries, entered into an Exclusive Licence Agreement with Accelerate Technologies to co-develop the Paths<sup>Dx</sup>
Test technology. The term of the Exclusive Licence Agreement is described in Exhibit 4.62 on Form 20-F filed with the SEC on April 19,
2021. Furthermore, Accelerate Technologies, the inventors of the Paths<sup>Dx</sup> Test technologies in A*STAR (&#8220;Founding Scientists&#8221;),
Paths Diagnostics Pte. Limited, and Paths Innovations Limited (formerly known as Aptorum Innovations Holding Limited), a wholly owned
subsidiary of the Company, entered into a Share Subscription &amp; Shareholders Agreement on the same day to subscribe ordinary shares
of Paths Diagnostics Pte. Limited. The shares are subscribed and issued in two tranches, the first tranche has taken place at closing
of the Share Subscription &amp; Shareholders Agreement, while the second tranche will take place after the certain first milestone is
met. The total number of shares subscribed by the shareholders under the Share Subscription &amp; Shareholders Agreement is around 2.7
million. After the two tranches of subscription, Aptorum, Accelerate Technologies and the Founding Scientists are expected to control
71.23%, 14.25% and 9.53% of the share of Paths Diagnostics Pte. Limited respectively, with 4.99% of the shares reserved for its employee
share plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">APTUS CAPITAL LIMITED, which
has since been renamed to AENEAS CAPITAL LIMITED, was always under the direct ownership of Jurchen and not under the ownership chain of
Aptorum Group. However, Aptus Asia Financial Holdings Limited (&#8220;AAFH&#8221;), which has since been renamed to Aeneas Group Limited,
was transferred out of the Aptorum Group on November 10, 2017 to be held directly by Jurchen Investment Corporation and that subsequently,
APTUS CAPITAL LIMITED was then transferred to be under AAFH.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 4, 2017, Mr. Huen transferred
all of the ordinary shares in the Company he owned (in the amount of 2,230,760) to Jurchen, a company incorporated in the British Virgin
Islands and wholly-owned by Mr. Huen. On October 13, 2017, as part of the Conversions (as defined below) the ordinary shares held by Jurchen
were redesignated as 223,076 Class A Ordinary Shares and 2,007,684 Class B Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 21 and March 1,
2017, the Company&#8217;s board of directors and shareholders resolved to restructure the Company from an investment fund with management
shares and non-voting participating redeemable preference shares to a holding company with operating subsidiaries, respectively (the &#8220;Restructuring
Plan&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Restructuring
Plan, the 256,571.12 then issued participating shares with par value of $0.01 (&#8220;Participating Shares&#8221;) were redeemed and 4,743,418.88
unissued Participating Shares were cancelled;  following such redemption and cancellation, we no longer have any Participating
Shares authorized or issued. Additionally, the Company authorized a class of securities consisting of 10,000,000 ordinary shares, par
value $10.00 per share and issued 2,565,711 ordinary shares to our original investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the period March 1,
2017 through October 13, 2017, an aggregate of 220,703 ordinary shares were issued at a price of approximately $39 per share in a private
placement we described as a &#8220;Series A&#8221; offering. Each investor of the Series A offering, in addition to a subscription agreement,
signed a shareholder agreement, which set forth the basic governance terms of the Company, as well as our capital structure. The shareholders
agreement was terminated in October 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 13, 2017, ordinary
resolutions were passed at an extraordinary general meeting of the Company approving (the &#8220;Conversions&#8221;): (i) converting 7,213,587
of authorized but unissued ordinary shares into 5,457,362 authorized but unissued Class A Ordinary Shares, par value of $10.00 per share
and 1,756,225 authorized but unissued Class B Ordinary Shares, par value of $10.00 per share, respectively; (ii) converting 2,493,085
ordinary shares held by three shareholders into an aggregate of 249,309 Class A Ordinary Shares and 2,243,776 Class B Ordinary Shares;
and (iii) converting 293,330 ordinary shares held by 24 shareholders into an aggregate 293,330 Class A Ordinary Shares. Following these
issuances, we had 27 shareholders of record.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 19, 2017, we changed
our name from APTUS Holdings Limited to our current name, Aptorum Group Limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 23, 2018, Jurchen
transferred 44,615 Class A Ordinary Shares and 401,537 Class B Ordinary Shares to CGY Investments Limited, a company incorporated in Hong
Kong and which we deem Mr. Darren Lui jointly controls and/or of which he has substantial influence on the disposition rights and voting
rights of such shares.&#160;Following this transfer, Jurchen owns approximately 33% and 72% of our Class A Ordinary Shares and Class B
Ordinary Shares, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 17, 2018, the
Company consummated its IPO of 76,142 Class A Ordinary Shares. The Registration Statement was declared effective by the U.S. Securities
and Exchange Commission on December 3, 2018 (the &#8220;Effective Date&#8221;). The shares were sold at a price of $158 per share, generating
gross proceeds to the Company of approximately $12,030,420.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 26, 2021, the Company
entered into a private placement shares purchase agreement with Jurchen, issuing 138,793 Class A Ordinary Shares, par value $10 per share,
at $28.82 per share, representing a 10% premium to the last closing price of the Company&#8217;s Class A Ordinary Shares on the NASDAQ
stock exchange on that date. The Company received aggregate gross proceeds of $4,000,000 from the purchase of these shares. Following
the purchase, Mr. Huen&#8217;s total shareholding represented 55.52% of the total issued share capital of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 23, 2023, the Company
effectuated a ten-for-one share consolidation of its authorized share capital, such that every 10 Class A Ordinary Shares, par value of
US$1.00 per share, in the authorized share capital of the Company (including issued and unissued share capital) were consolidated into
1 Class A Ordinary Share, par value of US$10.00 per share, and that every 10 Class B Ordinary Shares, par value of US$1.00 per share in
the authorized share capital of the Company (including issued and unissued share capital) were consolidated into 1 Class B Ordinary Share,
par value of US$10.00 per share (the &#8220;Share Consolidation&#8221; or &#8220;Reverse Split&#8221;).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 21, 2023, the
shareholders of the Company approved a merger of the Company with Aptorum Group Cayman Limited, a wholly owned subsidiary of the Company,
whereby the Company was the surviving company, on the terms of the plan of merger that includes the change in par value in the authorized
shares of the Company from $10 to $0.00001. In addition, among other things, the shareholders approved to increase the voting rights of
the Class B Ordinary Shares from 10 votes per share to 100 votes per share, and to increase the number of Class A Ordinary Shares authorized
to 9,999,996,000,000 shares, par value $0.00001 each. These corporate actions were effective as of February 21, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023, we entered into
securities purchase agreements to sell $3,000,000 unsecured convertible notes to 4 investors (the &#8220;June 23 Notes&#8221;). All the
June 23 Notes were subsequently converted into an aggregate of 1,000,000 Class A Ordinary Shares, par value $0.00001 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
September 2023, we entered into a securities purchase agreement to sell a $3,000,000 unsecured convertible note (&#8220;Sep 23 Note&#8221;)
to Jurchen Investment Corporation, our largest shareholder. The Sep 23 Note is convertible into our Class A Ordinary Shares, and have
a maturity date that is 24 months from the issuance date, although upon such date the investor has the right to extend the term of the
Note for twelve (12) months or more or such term subject to mutual consent. The Sep 23 Note has an interest rate of 6% per annum and a
conversion price of $2.42 per share. The Sep 23 Note is secured by a first priority lien and security interest on certain shares that
we own (&#8220;Collateral&#8221;). Upon our disposal of all or a portion of the Collateral, the investor has the right, to request that
we prepay the then-remaining outstanding balance of the Sep 23 Note, in part or in full and we can make that payment in cash or in shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">On
March 1, 2024, we entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among Company, and YOOV Group
Holding Limited, a BVI business company organized under the laws of British Virgin Islands (&#8220;YOOV&#8221;). The Merger Agreement
was unanimously approved by Company&#8217;s and YOOV&#8217;s boards of directors (each board of directors, the &#8220;Board&#8221;),
respectively. Upon consummation of the transactions contemplated by the Merger Agreement, a wholly-owned subsidiary of the Company organized
under the laws of the British Virgin Islands (&#8220;Merger Sub&#8221;) will merge with and into YOOV, with YOOV surviving the merger
as a wholly-owned subsidiary of Company (collectively, the &#8220;Merger&#8221;). The Company, upon the closing of the Merger, is referred
to herein as the &#8220;combined company.&#8221; Upon consummation of the transaction, YOOV will become a wholly-owned subsidiary of
Company, and the existing YOOV shareholders and existing Company shareholders will own approximately 90% and 10%, respectively, of the
outstanding shares of the combined company. The consummation of this Merger remains uncertain as it is contingent upon the fulfillment
of specific closing conditions.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
obligations of the parties (or, in some cases, some of the parties) to consummate the Merger are subject to the satisfaction or waiver
of certain conditions to closing, including, among other things: (i) obtaining the approval by the shareholders of Aptorum and YOOV of
the matters required under the Merger Agreement, (ii) approval of the Initial Listing Application by Nasdaq, (iii) consummation of the
Separation of ATL, (iv) delivery of legal opinions from British Virgin Islands counsel and Hong Kong counsel of YOOV to Aptorum and Merger
Sub, (v) delivery of legal opinions from Cayman Islands counsel of Aptorum and British Virgin Islands counsel of Merger Sub to YOOV, (vi)
delivery of an opinion by Colliers International (Hong Kong) Limited to the Board of Aptorum to the effect that (subject to various qualifications
and assumptions) the merger consideration (the total Class A ordinary shares and Class B ordinary shares to be issued to YOOV&#8217;s
shareholders) is fair, from a financial point of view (based on the conclusion that the equity value of YOOV is no less than $250 million),
to the shareholders of Aptorum. (vii) availability of audited financial statements for YOOV and its Subsidiaries as of March 31, 2023
and 2022 the related audited consolidated statements of operations, of changes in shareholders&#8217; equity and of cash flows for the
year ended March 31, 2023 and 2022 in conformity with International Financial Reporting Standards, which shall not be materially different
from the unaudited financial statements of YOOV for the same period as presented to Aptorum, as determined by Aptorum in its sole discretion,
(viii) delivery of fully executed lock-up agreement and support agreement by the major shareholder of Aptorum and the delivery of fully
executed lock-up agreement by the directors and officers of YOOV and by the shareholders of YOOV who will beneficially own 5% or more
outstanding shares of the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">In
connection with the Merger, on March 1, 2024, the Company entered into a Split-Off Agreement (the &#8220;Split-Off Agreement&#8221;,
the transaction contemplated by the Split-Off Agreement, the &#8220;Separation&#8221;) by and among the Company, one of its wholly-owned
subsidiaries - Aptorum Therapeutics Limited (&#8220;ATL&#8221;), and Jurchen Investment Corporation (&#8220;Jurchen&#8221;), pursuant
to which, the Company will assign and transfer the assets and liabilities of its legacy business to ATL, and Jurchen will acquire 100%
issued and outstanding shares of ATL from the Company and surrender certain ordinary shares of the Company held by Jurchen to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
closing of the Separation must occur simultaneously with the closing of the Merger, or on a later date, as mutually agreed by the Parties.
The Split-Off Agreement contains conditions precedent to closing of the parties thereto, with respect to, among other things, the following
as applicable to each party:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify"><b>Representations, Warranties and Performance.</b> All representations
and warranties made by the parties in the Split-Off Agreement must have been accurate and truthful, to the best of their knowledge, when
initially made and must remain accurate and truthful, to the best of their knowledge, at the time of the Closing. The parties are obligated
to fulfill all commitments, agreements, and conditions outlined in the Split-Off Agreement to the satisfaction of the parties involved,
with significant emphasis on adherence to these obligations before or at the Closing.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify"><b>Additional Documents.</b> Jurchen shall deliver or cause
to be delivered such additional documents as may be necessary in connection with the consummation of the transactions contemplated by
the Split-Off Agreement and the performance of their obligations hereunder.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify"><b>Release by Buyer and Split-Off Subsidiary.</b> At the Closing,
Jurchen and ATL are required to execute and provide Aptorum with a comprehensive release. This release will absolve Aptorum from all
liabilities and obligations owed to Jurchen or ATL in any capacity, as well as from any claims that Jurchen or ATL may assert against
Aptorum or its related managers, members, officers, directors, shareholders, employees, and agents. However, this release does not cover
liabilities arising from the Split-Off Agreement or any document related to it.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(iv)</td><td style="text-align: justify"><b>Shareholder Approval.</b> Aptorum shall have obtained the
affirmative vote of its shareholders representing at least two-thirds of the voting power of the issued and outstanding ordinary shares
of the Seller entitled to vote at a general meeting of the shareholders voting in person or by proxy, to approve the Split-Off Agreement
and the transaction contemplated herein.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
April 8, 2024, CGY Investments Limited and DSF Investment Holdings Limited voluntarily converted 401,537 Class B Ordinary Shares and 45,305
Class B Ordinary Shares, respectively into Class A Ordinary Shares on a one-for-one basis. Upon conversion, 1,796,934 Class B Ordinary
Shares were issued and outstanding, CGY Investments Limited owned 533,575 Class A Ordinary Shares and did not own any Class B Ordinary
Share; and DSF Investment Holdings Limited owned 45,305 Class A Ordinary Shares and did not own any Class B Ordinary Share.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the past three years,
we have invested approximately $0.3 million towards our principal capital expenditures, which include laboratory equipment, leasehold
improvements, and other equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following diagram illustrates
our corporate structure as of the date of this annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg" style="height: 297px; width: 750px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Note 1: Both Mios Pharmaceuticals
Limited (&#8220;Mios&#8221;) and Scipio Life Sciences Limited (&#8220;Scipio&#8221;) issued Class A and Class B ordinary shares to various
parties; for each such entity, each Class A ordinary share is entitled to 1 vote and 1 share of economic interest of the respective company,
while each Class B ordinary share is entitled to 10 votes and 0.001 share of economic interest of the respective company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual
report, we indirectly hold 97.93% economic interest and 36.17% voting power in Mios, and 97.93% economic interest and 35.06% voting power
in Scipio. An independent third party shareholder, Peace Range Limited, holds 0.15% economic interest and 63.61% voting power in Mios,
and 0.15% economic interest and 64.72% voting power in Scipio. The remaining shareholders hold 1.92% economic interest and 0.22% voting
power in Mios, and 1.92% economic interest and 0.22% voting power in Scipio respectively. Our ownership interest in these entities is
through direct equity ownership and not through any contractual arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Note 2: Dr. Clark Cheng, a
former Executive Director of Aptorum Group, holds the remaining 10% shareholding of Aptorum Medical Limited.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Note 3: Angen Funds Limited,
a company designated by an investor of ALS series projects, holds the remaining 20% shareholding of Acticule Life Sciences Limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Note 4: Accelerate Technologies
Pte. Ltd., the commercialization arm of the Singapore Agency for Science, Technology and Research (&#8220;A*STAR&#8221;), hold 15% shareholding
of Paths Diagnostics Pte. Limited. The inventors of Paths<sup>Dx</sup> Test technologies in A*STAR hold the remaining 10% of shareholding
of Paths Diagnostics Pte. Limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Note 5: An investor of project
VLS-2 holds the remaining 10% shareholding of mTor (Hong Kong) Limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, we conduct the
majority of our operations through the following subsidiaries: Aptorum Therapeutics Limited, Acticule Life Sciences Limited and Paths
Diagnostics Pte. Limited. All investments into our company are into the parent company, Aptorum Group Limited, a Cayman Islands exempted
company with limited liability whose principal place of business is in Hong Kong; you may never hold direct equity interests in our subsidiaries
or the VIEs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the provisions
of Accounting Standards Codification (&#8220;ASC&#8221;) 810, Consolidation, we consolidate any VIE of which we are regarded as the primary
beneficiary for accounting purposes. The typical condition for a controlling financial interest ownership is holding a majority of the
voting interests of an entity; however, a controlling financial interest may also exist in entities, such as VIEs, through arrangements
that do not involve controlling voting interests. On December 30, 2021, Libra (formerly known as Aptorum Pharmaceutical Development Limited),
Mios and Scipio, issued Class A and Class B ordinary shares to various parties; for each such entity, each Class A ordinary share is entitled
to 1 vote and 1 share of economic benefit of the respective company, while each Class B ordinary share is entitled to 10 votes and 0.001
share of economic benefit of the respective company. Following such share issuances, the Group lost its majority voting rights in each
of these three companies and only holds 48.33%, 48.39% and 48.36% economic interest in Libra, Mios and Scipio, respectively. However,
the Group still holds a majority of each of these three company&#8217;s outstanding Class A ordinary shares and therefore will absorb/receive
portions of these entities&#8217; expected losses or residual returns. In addition, none of these three companies have sufficient equity
to sustain its own activities, and they have two classes of ordinary shares which have different rights, benefits and obligations. We
determined that all these three companies are VIEs. On December 31, 2021, Libra, Mios and Scipio further issued Class A ordinary shares
to the Group in exchange of certain projects licenses. Upon these share issuances, the Group was holding 97.27% economic interest and
31.51% voting power in Libra, 97.93% economic interest and 36.17% voting power in Mios, and 97.93% economic interest and 35.06% voting
power in Scipio, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have considered each of
these entity&#8217;s memorandum and article of association and their respective board of directors (the sole director of each of Mios
and Scipio is an executive director of the Group), and determined that we have the power to manage and make decisions that affect Mios
and Scipio&#8217;s research and development activities, which activities most significantly impact Mios and Scipio&#8217;s economic performance.
However, we do not have such power over Libra&#8217;s research and development activities, which activities most significantly impact
Libra&#8217;s economic performance. Accordingly, we determined that we are regarded as the primary beneficiary of Mios and Scipio for
accounting purposes, but not the primary beneficiary of Libra.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Private Issuer Status</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
within the meaning of the rules under the Exchange. As such, we are exempt from certain provisions applicable to United States domestic
public companies. For example:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we are not required to provide
as many Exchange Act reports, or as frequently, as a domestic public company;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">for interim reporting, we are
permitted to comply solely with our home country requirements, which are less rigorous than the rules that apply to domestic public companies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we are not required to provide
the same level of disclosure on certain issues, such as executive compensation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we are exempt from provisions
of Regulation FD aimed at preventing issuers from making selective disclosures of material information;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we are not required to comply
with the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
under the Exchange Act; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we are not required to comply
with Section 16 of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and establishing
insider liability for profits realized from any &#8220;short-swing&#8221; trading transaction.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. <span style="text-decoration:underline">Business Overview</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview of our Company</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aptorum is not a Chinese operating
company. Aptorum is a Cayman Islands holding company with operations conducted through our subsidiaries and the variable interest entities
(VIEs). We have determined that we have three VIEs, namely, Libra, Mios and Scipio, according to the U.S. GAAP. All three of the VIEs
are incorporated in Cayman Islands and operate in Hong Kong. In accordance with ASC 810, we concluded that we are the primary beneficiary
of two VIEs, Mios and Scipio, therefore, are able to consolidate their financial statements into ours. Our corporate structure is based
on the equity ownership and control we have over our subsidiaries and the consolidated VIEs. Our corporate structure was not set up to
be used to provide investors with exposure to foreign investment in China-based companies where Chinese law prohibits direct foreign investment
in the operating companies. Foreign investment can be made directly into Mios and Scipio; however, your investments into Aptorum are made
into the Cayman Islands holding company, not any of the consolidated VIEs, and you may never own any equity into the VIEs or any other
subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the consolidated VIEs
operate in Hong Kong, they face various legal and operational risks and uncertainties associated with doing business in Hong Kong. Our
current corporate structure does not contain any variable interest entity in mainland China and we do not have intention establishing
any VIEs in mainland China in the future. However, if in the future there is any significant change to the current political arrangements
between mainland China and Hong Kong and mainland China&#8217;s expanded authority in Hong Kong result in the PRC regulatory authorities
disallowing our current corporate structure, or if in the future our structure were to contain a VIE and the mainland PRC regulatory authorities
expand to Hong Kong and disallow our corporate structure, it would likely result in a material adverse change in the VIE&#8217;s operations,
and the value of our securities may decline significantly in value or become worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although currently we do not
have any business operations or VIE in mainland China and we believe that the laws and regulations of the PRC applicable in China do not
currently have any material impact on our business, financial condition or results of operations, we face risks and uncertainties associated
with the complex and evolving PRC laws and regulations and as to whether and how the recent PRC government statements and regulatory developments,
such as those relating to VIE, data and cyberspace security, and anti-monopoly concerns, would be applicable to a company such as Mios
and Scipio given their substantial operations in Hong Kong and the Chinese government&#8217;s significant oversight authority over the
conduct of business in Hong Kong.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of China&#8217;s
recent expansion of authority in Hong Kong, we are subject to the risks of uncertainty about any future actions of the PRC government
or authorities in Hong Kong. The Chinese government may intervene or influence our current and future operations in Hong Kong at any time,
or may exert more control over offerings conducted overseas and/or foreign investment in issuers likes ourselves. We believe that, on
the basis that we currently do not have any business operations in mainland China, we currently are not required to obtain approvals from
Chinese authorities to operate our business or list on the U.S. exchanges and offer securities; specifically, none of Mios or Scipio is
currently required to obtain any permission or approval from the China Securities Regulatory Commission (&#8220;CSRC&#8221;), Cyberspace
Administration of China (&#8220;CAC&#8221;) or any other PRC governmental authority to operate its business or for us to continue to list
our securities on a U.S. securities exchange or issue securities to foreign investors. However, there is no assurance that there will
not be any changes in the economic, political and legal environment in Hong Kong in the future. Should the PRC government choose to affect
operations of any company with any level of operations in Hong Kong, or should certain PRC laws and regulations or these statements or
regulatory actions become applicable to the VIEs in the future. Such governmental actions: (i) could significantly limit or completely
hinder our ability to continue our operations; (ii) could significantly limit or hinder our ability to offer or continue to offer our
Class A Ordinary Shares to investors; and (iii) may cause the value of our Class A Ordinary Shares to significantly decline or be worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also aware that recently,
the PRC government initiated a series of regulatory actions and statements to regulate business operations in certain areas in mainland
China with little advance notice, including cracking down on illegal activities in the securities market, enhancing supervision over mainland
Chinese companies listed overseas using variable interest entity structure, adopting new measures to extend the scope of cybersecurity
reviews, and expanding the efforts in anti-monopoly enforcement. Nevertheless, since these statements and regulatory actions are new,
it is highly uncertain how soon the legislative or administrative regulation making bodies will respond and what existing or new laws
or regulations or detailed implementations and interpretations will be modified or promulgated, if any. It is also highly uncertain what
the potential impact such modified or new laws and regulations will have on the VIEs&#8217; daily business operation, and the continued
listing of our Class A Ordinary Shares on a U.S. or other foreign exchanges. If any or all of the foregoing were to occur, it may significantly
limit or completely hinder our ability to complete this offering or cause the value of our Class A Ordinary Shares to significantly decline
or become worthless. See &#8220;Risk Factors - Risks Related to Our Corporate Structure&#8221; and &#8220;Risk Factors - Risks Relating
to Doing Business in Hong Kong&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our Class A Ordinary
Shares may be prohibited from trading on a national exchange or over-the-counter under the Holding Foreign Companies Accountable Act,
as amended (the &#8220;HFCA Act&#8221;) if the Public Company Accounting Oversight Board (United States) (the &#8220;PCAOB&#8221;) is
unable to inspect our auditors for two consecutive years beginning in 2021. Our auditor, Marcum Asia CPAs LLP, have been inspected by
the PCAOB on a regular basis, and Marcum Asia CPAs LLP is not subject to the determinations announced by the PCAOB on December 16, 2021.
If trading in our Class A Ordinary Shares is prohibited under the HFCA Act in the future because the PCAOB determines that it cannot inspect
or fully investigate our auditor at such future time, Nasdaq may determine to delist our Class A Ordinary Shares and trading in our Class
A Ordinary Shares could be prohibited. While our auditor is based in the U.S. and is registered with the PCAOB and subject to PCAOB inspection,
in the event it is later determined that the PCAOB is unable to inspect or investigate completely our auditor because of a position taken
by an authority in a foreign jurisdiction, then such lack of inspection could cause trading in our Ordinary Shares to be prohibited under
the HFCA Act, and ultimately result in a determination by a securities exchange to delist our Ordinary Shares. On August 26, 2022, the
PCAOB signed a Statement of Protocol (the &#8220;SOP&#8221;) Agreement with the CSRC and China&#8217;s Ministry of Finance. The SOP Agreement,
together with two protocol agreements (collectively, &#8220;SOP Agreements&#8221;), governing inspections and investigations of audit
firms based in mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate registered
public accounting firms headquartered in mainland China and Hong Kong. Pursuant to the fact sheet with respect to the Protocol disclosed
by the SEC, the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered
ability to transfer information to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete
access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate
its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB&#8217;s
access in the future, the PCAOB Board will consider the need to issue a new determination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash Transfers and Dividend Distribution</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is directly
supervising cash management. Our finance department is responsible for establishing the cash management policies and procedures among
our departments and the operating entities. Majority of the cash are managed by a few of the subsidiaries of Aptorum Group. Each department
or operating entity initiates a cash request by putting forward a payment requisition form, which explains the specific amount and timing
of cash requested, and submitting it to designated management members of our Company, based on the amount and the nature of payment. The
designated management member examines and approves the cash transfer based on the sources of cash and the priorities of the needs, and
submit it to the cashier specialists of our finance department for a second review. Other than the above, we currently do not have other
cash management policies or procedures that dictate how funds are transferred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are permitted under the
laws of Cayman Islands to provide funding to our subsidiaries and the consolidated VIEs through loans or capital contributions without
restrictions on the amount of the funds. Under the Cayman Islands law, the VIEs are permitted to pay a dividend on its shares out of either
profit or share premium amount, provided that in no circumstances may a dividend be paid if this would result in the consolidated VIEs
being unable to pay its debts due in the ordinary course of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual
report, none of our subsidiaries or the consolidated VIEs have made any dividends or distributions to our Company and our Company has
not made any dividends or distributions to our shareholders. We intend to keep any future earnings to finance the expansion of our business,
and we do not anticipate that any cash dividends will be paid in the foreseeable future. Subject to the passive foreign investment company
(&#8220;PFIC&#8221;) rules, the gross amount of distributions we make to investors with respect to our Class A Ordinary Shares (including
the amount of any taxes withheld therefrom) will be taxable as a dividend, to the extent that the distribution is paid out of our current
or accumulated earnings and profits, as determined under U.S. federal income tax principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2021, Mios
and Scipio has issued Class A ordinary shares to Aptorum Therapeutics Limited, in exchange of Aptorum Therapeutics Limited&#8217;s granting
of license of certain patents to each of them. Other than this, there has been no transfer of cash or other assets occurred between us,
our subsidiaries, and the consolidated VIEs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Business Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage biopharmaceutical
company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs,
particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through
the co-development of Paths<sup>Dx</sup> Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology,
with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore&#8217;s Agency for Science, Technology and Research.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to develop a broad
range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components
of our strategy for achieving this goal include: (for details of our strategy, See &#8220;Business Overview &#8211; Our Strategy&#8221;)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Developing therapeutic and diagnostic
innovations across a wide range of disease/therapeutic areas;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Selectively expanding our portfolio
with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Collaborating with leading academic
institutions and CROs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Expanding our in-house pharmaceutical
development center;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Leveraging our management&#8217;s
expertise, experience and commercial networks;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Obtaining and leveraging government
grants to fund project development.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have devoted a substantial
portion of the proceeds from our offerings, to our Lead Projects. Our Lead Projects are ALS-4, SACT-1 and Paths<sup>Dx</sup> Test. In
March 2023, we announced that we completed the Pre-IND discussions with the US FDA on ALS-4. With the positive feedback on the overall
development strategy from the US FDA, we are proceeding towards the IND submission of ALS-4. In March 2023, we also announced the completion
of the End of Phase 1 (EOP1) meeting of SACT-1 with the US FDA. The FDA generally agreed with the chemistry-manufacturing-control (CMC)
strategy and our proposed clinical development plan for SACT-1 Phase 1/2 trials. We commenced clinical validation of our molecular based
Paths<sup>Dx</sup> Test and will continue to undergo validations in parallel with its pre-commercialization process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current business consists
of &#8220;therapeutics&#8221; and &#8220;non-therapeutics&#8221; segments. However, our focus is on the therapeutics segments. Because
of the risks, costs and extended development time required for successful drug development, we have determined to pursue projects within
our non-therapeutics segments, such as diagnostics technology, that may be brought to market and generate revenue more quickly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Therapeutics Segment</span></i>.
In our therapeutics segment (&#8220;Aptorum Therapeutics Group&#8221;), we are currently seeking to develop various drug molecules (including
projects seeking to use extracts or derivatives from natural substances to treat diseases) and certain technologies for the treatment
of human disease conditions to tackle unmet needs, in particular, two of our Lead Projects targeting infectious disease and cancer (including
orphan oncology indications). Aptorum Therapeutics Group is operated through Aptorum&#8217;s wholly-owned subsidiary, Aptorum Therapeutics
Limited, a Cayman Islands exempted company with limited liability, whose principal place of business is in Hong Kong and whose subsidiaries
(who we sometimes refer to herein as project companies) are based in the United Kingdom, Singapore and Hong Kong.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Non-Therapeutics Segment</span></i>.
The non-therapeutics segment (&#8220;Aptorum Non-Therapeutics Group&#8221;) refers to diagnostics projects including Paths<sup>Dx</sup>
Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology. Paths<sup>Dx</sup> Test technology is
currently under co-development with A*STAR. The core objectives of Paths<sup>Dx</sup> Test are to rapidly and accurately identify and
detect existing or emerging unknown pathogens (including DNA/RNA-based viruses such as coronavirus, antibiotic-resistant bacteria, fungi,
etc.), in a cost-effective, unbiased and broad-spectrum manner, through liquid biopsy (patients&#8217; blood samples and is potentially
adaptable for other sample types), genome sequencing and artificial intelligence driven software analytics. A key objective is also to
develop Paths<sup>Dx</sup> Test to leverage existing and emerging Next-Generation Sequencing platforms for pathogenic genome sequencing
analysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the second quarter of 2023, the Company made a decision to streamline
its operations by terminating clinic services and suspending non-lead R&amp;D projects. This measure is aimed at optimizing the allocation
of our resources and focusing our efforts on advancing our lead projects, which hold the most promise for commercial success and beneficial
impact. This decision aligns with our commitment to enhance shareholder value and effectively drive our core objectives forward in the
competitive landscape.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to March 2017, the Company
had pursued passive healthcare related investments in early stage companies primarily in the United States. However, we have since ceased
pursuing further passive investment operations and intend to exit all such portfolio investments over an appropriate timeframe to focus
resources on our current business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 25, 2020, Aptorum,
via its subsidiaries, enters into a series of transactions with Accelerate Technologies Pte. Ltd.&#8217;s (&#8220;Accelerate Technologies&#8221;),
the commercialization arm of the Singapore Agency for Science, Technology and Research (&#8220;A*STAR&#8221;), in relation to the research
and development of Paths<sup>Dx</sup> Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology,
through its subsidiaries. Specifically, Paths Diagnostics Pte. Limited, one of the Company&#8217;s subsidiaries, entered into an Exclusive
Licence Agreement with Accelerate Technologies to co-develop the Paths<sup>Dx</sup> Test technology. The term of the Exclusive Licence
Agreement is described in Exhibit 4.62 on Form 20-F filed with the SEC on April 19, 2021. Furthermore, Accelerate Technologies, the inventors
of the Paths<sup>Dx</sup> Test technologies in A*STAR (&#8220;Founding Scientists&#8221;), Paths Diagnostics Pte. Limited, and Paths Innovations
Limited, a wholly owned subsidiary of the Company, entered into a Share Subscription &amp; Shareholders Agreement on the same day to subscribe
ordinary shares of Paths Diagnostics Pte. Limited. The shares are subscribed and issued in two tranches, the first tranche has taken place
at closing of the Share Subscription &amp; Shareholders Agreement, while the second tranche will take place after the certain first milestone
is met. The total number of shares subscribed by the shareholders under the Share Subscription &amp; Shareholders Agreement is around
2.7 million. After the two tranches of subscription, Aptorum, Accelerate Technologies and the Founding Scientists are expected to control
71.23%, 14.25% and 9.53% of the share of Paths Diagnostics Pte. Limited respectively, with 4.99% of the shares reserved for its employee
share plan.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020, Paths
Innovations Limited, one of the Company&#8217;s wholly-owned subsidiaries, entered into an Evaluation Agreement with Illumina Inc (&#8220;Illumina&#8221;).
Pursuant to the agreement, Paths Innovations Limited will evaluate the data and performance of Illumina&#8217;s sequencing technology
based on the workflow of Paths<sup>Dx</sup> Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology,
at Paths Innovations Limited&#8217;s Singapore based evaluation site.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
May 2023, our subsidiary, Aptorum Therapeutics Limited (&#8220;ATL&#8221;), a company incorporated under the laws of Grand Cayman Islands
entered into a non-binding Letter of Intent and Term Sheet (&#8220;Term Sheet&#8221;) to merge (&#8220;Transaction&#8221;) its 100% subsidiary,
Paths Innovation Limited and its underlying business (collectively &#8220;PathsDx Group&#8221;) with Universal Sequencing Technology Corporation
(&#8220;UST&#8221;), a San Diego and Boston based US company dedicated to the development and commercialization of advanced proprietary
DNA sequencing technologies. Paths Innovation Limited currently holds, through its majority owned subsidiary Paths Diagnostics Pte. Limited,
the PathsDx technology &#8211; a liquid biopsy NGS based technology for the diagnostics of infectious diseases. As consideration of the
transaction upon closing, ATL will become a shareholder of the combined company. The transaction and other ancillary distributions, where
relevant, remain subject to, among other matters, the execution of a mutually agreeable definitive agreement, completion of due diligence
and subject to several conditions including, but not limited to, director and shareholder approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
March 1, 2024, we entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among Company, and YOOV Group
Holding Limited, a BVI business company organized under the laws of British Virgin Islands (&#8220;YOOV&#8221;). The Merger Agreement
was unanimously approved by Company&#8217;s and YOOV&#8217;s boards of directors (each board of directors, the &#8220;Board&#8221;), respectively.
Upon consummation of the transactions contemplated by the Merger Agreement, a wholly-owned subsidiary of the Company organized under the
laws of the British Virgin Islands (&#8220;Merger Sub&#8221;) will merge with and into YOOV, with YOOV surviving the merger as a wholly-owned
subsidiary of Company (collectively, the &#8220;Merger&#8221;). The Company, upon the closing of the Merger, is referred to herein as
the &#8220;combined company.&#8221; Upon consummation of the transaction, YOOV will become a wholly-owned subsidiary of Company, and the
existing YOOV shareholders and existing Company shareholders will own approximately 90% and 10%, respectively, of the outstanding shares
of the combined company. The consummation of the Merger remains uncertain as it is contingent upon the fulfillment of specific closing
conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
obligations of the parties (or, in some cases, some of the parties) to consummate the Merger are subject to the satisfaction or waiver
of certain conditions to closing, including, among other things: (i) obtaining the approval by the shareholders of Aptorum and YOOV of
the matters required under the Merger Agreement, (ii) approval of the Initial Listing Application by Nasdaq, (iii) consummation of the
Separation of ATL, (iv) delivery of legal opinions from British Virgin Islands counsel and Hong Kong counsel of YOOV to Aptorum and Merger
Sub, (v) delivery of legal opinions from Cayman Islands counsel of Aptorum and British Virgin Islands counsel of Merger Sub to YOOV, (vi)
delivery of an opinion by Colliers International (Hong Kong) Limited to the Board of Aptorum to the effect that (subject to various qualifications
and assumptions) the merger consideration (the total Class A ordinary shares and Class B ordinary shares to be issued to YOOV&#8217;s
shareholders) is fair, from a financial point of view (based on the conclusion that the equity value of YOOV is no less than $250 million),
to the shareholders of Aptorum. (vii) availability of audited financial statements for YOOV and its Subsidiaries as of March 31, 2023
and 2022 the related audited consolidated statements of operations, of changes in shareholders&#8217; equity and of cash flows for the
year ended March 31, 2023 and 2022 in conformity with International Financial Reporting Standards, which shall not be materially different
from the unaudited financial statements of YOOV for the same period as presented to Aptorum, as determined by Aptorum in its sole discretion,
(viii) delivery of fully executed lock-up agreement and support agreement by the major shareholder of Aptorum and the delivery of fully
executed lock-up agreement by the directors and officers of YOOV and by the shareholders of YOOV who will beneficially own 5% or more
outstanding shares of the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
connection with the Merger, on March 1, 2024, the Company entered into a Split-Off Agreement (the &#8220;Split-Off Agreement&#8221;, the
transaction contemplated by the Split-Off Agreement, the &#8220;Separation&#8221;) by and among the Company, Aptorum Therapeutics Limited
(&#8220;ATL&#8221;), and Jurchen Investment Corporation (&#8220;Jurchen&#8221;), pursuant to which, the Company will assign and transfer
the assets and liabilities of its legacy business to ATL, and Jurchen will acquire 100% issued and outstanding shares of ATL from the
Company and surrender certain ordinary shares of the Company held by Jurchen to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
closing of the Separation must occur simultaneously with the closing of the Merger, or on a later date, as mutually agreed by the Parties.
The Split-Off Agreement contains conditions precedent to closing of the parties thereto, with respect to, among other things, the following
as applicable to each party:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify"><b>Representations, Warranties and Performance.</b> All representations
and warranties made by the parties in the Split-Off Agreement must have been accurate and truthful, to the best of their knowledge, when
initially made and must remain accurate and truthful, to the best of their knowledge, at the time of the Closing. The parties are obligated
to fulfill all commitments, agreements, and conditions outlined in the Split-Off Agreement to the satisfaction of the parties involved,
with significant emphasis on adherence to these obligations before or at the Closing.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify"><b>Additional Documents.</b> Jurchen shall deliver or cause
to be delivered such additional documents as may be necessary in connection with the consummation of the transactions contemplated by
the Split-Off Agreement and the performance of their obligations hereunder.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify"><b>Release by Buyer and Split-Off Subsidiary.</b> At the Closing,
Jurchen and ATL are required to execute and provide Aptorum with a comprehensive release. This release will absolve Aptorum from all
liabilities and obligations owed to Jurchen or ATL in any capacity, as well as from any claims that Jurchen or ATL may assert against
Aptorum or its related managers, members, officers, directors, shareholders, employees, and agents. However, this release does not cover
liabilities arising from the Split-Off Agreement or any document related to it.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(iv)</td><td style="text-align: justify"><b>Shareholder Approval.</b> Aptorum shall have obtained the
affirmative vote of its shareholders representing at least two-thirds of the voting power of the issued and outstanding ordinary shares
of the Seller entitled to vote at a general meeting of the shareholders voting in person or by proxy, to approve the Split-Off Agreement
and the transaction contemplated herein.</td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Strategy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As disclosed above, we have
entered into a Merger Agreement and a Split-off Agreement to sell our legacy business caried by ATL and to acquire 100% equity interests
of YOOV. Upon closing of the Proposed Transactions, YOOV&#8217;s business will become our business. We will file a registration statement
on a Form F-4 with the SEC and will mail notices of shareholders meeting and other relevant documents to our shareholders about the Proposed
Transactions. Investors and security holders of Aptorum are advised to read, when available, the Form F-4, and amendments thereto, the
notice to shareholders, and amendments thereto, in connection with Aptorum&#8217;s solicitation of proxies for its shareholder&#8217;
meeting to be held to approve the transactions described herein because the notice to shareholders will contain important information
about the Proposed Transactions and parties to the Proposed Transactions. If any closing conditions to the Merger Agreement or Split-Off
Agreement do not meet, or parties decide not to proceed with the Proposed Transactions, we will continue to focus the development of our
Lead Projects over the next 24-36 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that execution
of this strategy will position the Company to catalyze the development and improvement of a broad range of novel and repurposed therapeutics
and diagnostics across a wide range of disease/therapeutic areas. Failure to achieve positive results in at least one of the programs
for a Lead Project could have a material adverse effect on the Company&#8217;s prospects and business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To achieve this goal, we are
implementing the following strategies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Selectively expanding our
portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs.&#160;</b>We
have selected innovations for development which we believe are of superior scientific quality, whilst taking into account the potential
market size and demand for same, for example, taking into consideration whether the relevant product can satisfy significant unmet medical
needs. In particular, Aptorum Group Limited has established a Scientific Advisory Board, which helped us to select our current projects
and which we expect will provide input from a scientific perspective towards any future opportunities for acquiring or licensing life
science innovations. We intend to continue expanding our line of projects under development, and subject to our financial and other resource
limitations, exploring acquisitions or licenses of additional products which may be able to attain orphan drug designations (e.g., rare
types of cancer) or satisfy significant unmet medical needs and that show strong preclinical and/or early clinical data to provide promising
opportunities for clinical and commercial success.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Collaborating with leading
academic institutions and CROs.&#160;</b>In building and developing our product portfolio, we believe that accessing external innovation,
expertise and technology through collaboration with leading academic institutions and CROs is a vital and cost-efficient strategy. We
have established strong relationships with leading academic institutions around the world and expect to continue to strengthen our collaborations
by, for example, seeking to provide their affiliated Principal Investigators resources through sponsorship to conduct further research
in specialty fields of interest and association with personnel connected to our current project companies, in exchange for obtaining
for the Company the first right to negotiate for an exclusive license to any resulting innovations. In addition, we have entered and
will continue to actively source arrangements with pharmaceutical companies, in most cases in roles as contract research organizations,
to streamline the development of our projects. This may include outsourcing part of the preclinical, clinical studies and clinical supplies
manufacturing to externally accredited cGLP, cGMP and cGCP standard contract research organizations or laboratories in order to attain
the required studies for submission to the regulatory authorities as part of the clinical development plan. (See &#8220;Item 4. Information
on the Company &#8211; B. Business Overview &#8211; Arrangements with Other Parties&#8221;)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Obtaining and leveraging government grants to fund project development.&#160;</b>Governments across the world pays close attention to the development of the biotechnology sector and provides support and funding. We intend to aggressively seek government support from the governments in the United States, the United Kingdom, Hong Kong, Singapore and elsewhere for our product development and to facilitate the development of some of our projects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Arrangements with Other Parties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As mentioned above, part of
our business model includes collaborating with research entities such as academic institutions and CROs, as well as highly regarded experts
in their respective fields. We engage these entities and researchers either for purposes of exploring new innovations or advancing preclinical
studies of our existing licensed drug candidates. Although the financial cost of these arrangements does not represent a material expense
to the Company, the relationships we can access through, specifically, sponsored research arrangements (&#8220;SRAs&#8221;) with academic
institutions and organizations can provide significant value for our business; for example, we may decide whether to continue development
of certain early-staged projects and/or out-license a project based on the data and results from research governed by SRAs. However, as
of the date of this annual report, we do not consider the particulars of any of our SRAs to be material to the success of our current
business plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug discovery programs
are based upon licenses from universities and are mainly conducted in universities via SRAs. As for the development of our drug candidates,
our R&amp;D Center conducts part of the CMC work. However, since our current facilities are not cGMP, cGLP or cGCP qualified, we will
have to rely on CROs to conduct that type of work, if and when our drug candidates reach the level of development that requires such qualification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Lead Projects</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are actively operating
and managing the development of our drug candidates through various subsidiaries. Each candidate is being researched in a subsidiary with
a medical/scientific area of focus related to the drug candidate in development. We refer to these as our &#8220;Project Companies&#8221;
and their products or areas of focus as our Lead Projects (i.e., ALS-4, SACT-1 and Paths<sup>Dx</sup> Test). The selection of a drug candidate
is based on our estimate of the market potential for that candidate, the scientific expertise required to develop it, and our overall
corporate strategy, including our ability to commit personnel and future investment to that candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To pursue a number of our
current projects, our Project Companies have entered into standard license agreements with various universities and licensing entities
customized to the nature of each project. These license agreements largely contain the same terms, as is typically seen in license agreements
for an early-stage life science invention; such terms include a worldwide license with licensed field comprising indications in the intended
treatment areas, having upfront payments, certain royalty rates, sublicensing royalties, as well as provisions for payments upon occurrence
of development and/or regulatory milestones. Under the license agreements, the Project Company must also adhere to certain diligence obligations
(which may include specific diligence) and the types of activities or achievements that will satisfy those diligence obligations. Additionally,
our Project Company may or may not be required to obtain prior consent from the licensor to sublicense the invention. The license terms
of our Lead Projects are discussed in detail below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally speaking, pharmaceutical
development consists of preclinical and clinical phases. The preclinical phase can further sub-divided into the following stages:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Target Identification &amp;
Selection</span>: The target is the naturally existing cellular or modular structure that appears to have an important role in a particular
disease pathway and will be targeted by the drug that will subsequently be developed. Target validation techniques for different disease
areas can be very different but typically include from in vitro and in silico methods through to the use of whole animal models.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Lead Discovery</span>: Following
&#8220;Target Identification &amp; Selection,&#8221; compound screening assays are developed as part of the Lead Discovery. &#8216;Lead&#8217;
molecules can mean slightly different things to different researches or companies, but in this annual report, we refer to Lead Discovery
as the process of identifying one or more small molecules with the desired activity against the identified targets. Leads can be identified
through one or more approaches, which can depend on the target and what, if any, previous knowledge exists.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Lead Optimization</span>: In
this stage of the drug discovery process, the aim is to produce a preclinical drug candidate by maintaining the desired and favorable
properties in the lead compounds, while repairing or reducing deficiencies in their structures. For example, to optimize the chemical
structures to improve, among others, efficacy, reduce toxicity, improve metabolism, absorption and pharmacokinetic properties.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">CTA-Enabling Studies</span>:
Includes all the essential studies such as GLP toxicology studies, pharmacology and efficacy, pharmacokinetics, in vitro metabolism,
CMC studies, and the data of which are used for CTA submission.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">IND-Enabling Studies</span>:
Includes all the essential studies such as GLP toxicology studies, pharmacology and efficacy, pharmacokinetics, in vitro metabolism,
CMC studies, and the data of which are used for IND submission.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">In vitro validation</span>:
At this stage, the efficacy and safety of a drug candidate are assessed at cellular levels.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">In vivo validation</span>: At
this stage, the efficacy, safety and pharmacokinetic of a drug candidate are assessed in animal models.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">IND Preparation and Submission</span>:
Preparation of a package of documents for different sections such as CMC, clinical, nonclinical, etc. and getting them reviewed, approved
and final checked and followed by submission to regulatory agencies.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials are
typically conducted in three sequential phases that may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Phase 1.</b>&#160;Phase 1
includes the initial introduction of an investigational new drug into humans. These studies are closely monitored and may be conducted
in patients, but are usually conducted in healthy volunteer subjects. These studies are designed to determine the metabolic and pharmacologic
actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.
During Phase 1, sufficient information about the drug&#8217;s pharmacokinetics and pharmacological effects should be obtained to permit
the design of well-controlled, scientifically valid, Phase 2 studies. Phase 1 studies also evaluate drug metabolism, structure-activity
relationships, and the mechanism of action in humans. These studies also determine which investigational drugs are used as research tools
to explore biological phenomena or disease processes. The total number of subjects included in Phase 1 studies varies with the drug,
but is generally in the range of twenty to eighty.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Phase 2.</b>&#160;Phase 2
includes the early controlled clinical studies conducted to obtain some preliminary data on the effectiveness of the drug for a particular
indication or indications in patients with the disease or condition. This phase of testing also helps determine the common short-term
side effects and risks associated with the drug. Phase 2 studies are typically well-controlled, closely monitored, and conducted in a
relatively small number of patients, usually involving several hundred people.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Phase 3.&#160;</b>Phase 3
studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the
drug has been obtained in Phase 2, and are intended to gather the additional information about effectiveness and safety that is needed
to evaluate the overall benefit-risk relationship of the drug. Phase 3 studies are designed to provide an adequate basis for extrapolating
the results to the general population and transmitting that information in the physician labeling. Phase 3 studies usually include several
hundred to several thousand people.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our non-therapeutics projects
can be sub-divided into the following stages:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Development and Experimentation</span>: Early development work for proof-of-concept.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Product Optimization</span>: The practice of making changes or adjustments to a product to make it more desirable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Clinical Validation</span>: Confirming the performance of a technology using clinical/patient samples.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Pre-commercialization preparation</span>: The logistics that need to be accomplished before commercialization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Formulation</span>: Preparation of a marketed dosage form from active ingredients and excipients/additives.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Commercialization</span>: The process of introducing a new product or production method into commerce&#8212;making it available on the market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><img alt="" src="image_002.jpg" style="height: 187px; width: 620px"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ALS-4: Small molecule for the treatment of
bacterial infections caused by Staphylococcus aureus including but not limited to Methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Just as certain strains of
viruses, such as human immunodeficiency virus (&#8220;HIV&#8221;) and influenza have developed resistance to drugs developed to treat
them, certain bacteria such as&#160;<i>Staphylococcus aureus</i>,&#160;<i>Mycobacterium tuberculosis</i>&#160;and&#160;<i>Pseudomonas
aeruginosa&#160;</i>have become &#8220;superbugs&#8221;, having developed resistance to many, if not all, of the existing drugs available
to treat them, rendering those treatments ineffective in many instances. MRSA is one such bacterium, a gram-positive bacterium that is
genetically different from other strains of Staphylococcus aureus. Staphylococcus aureus and MRSA can cause a variety of problems ranging
from skin infections and sepsis to pneumonia and bloodstream infections. It is estimated that about one out of every three people (33%)
carry Staphylococcus aureus in their nose, usually without any illness; about two in a hundred (2%) carry MRSA (source: https://www.cdc.gov/mrsa/tracking/index.html).
Both adults and children may carry MRSA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most MRSA infections occur
in people who have been in hospital or other health care settings, such as nursing homes and dialysis centers (source: https://www.mayoclinic.org/diseases-conditions/mrsa/symptoms-causes/syc-20375336),
which is known as Healthcare-Associated MRSA (&#8220;HA-MRSA&#8221;). HA-MRSA infections are typically associated with invasive procedures
or devices, such as surgeries, intravenous tubing or artificial joints. Another type of MRSA infection, known as Community-Associated
MRSA (&#8220;CA-MRSA&#8221;), has occurred in wider community among healthy people. It often begins as a painful skin boil and spreads
by skin-to-skin contact. About 85% of serious, invasive MRSA infections are healthcare associated infections (https://www.cdc.gov/media/pressrel/2007/r071016.htm).
The incidence of CA-MRSA varies according to population and geographic location. In the U.S., more than 94,000 people develop serious
MRSA infection and about 19,000 patients die as a result each year (https://www.cdc.gov/media/pressrel/2007/r071016.htm). According to
the US Centers for Disease Control and Prevention (&#8220;CDC&#8221;), Staphylococcus aureus, including MRSA, caused about 11% of healthcare-associated
infections in 2011 (source: http://www.healthcommunities.com/mrsa-infection/incidence.shtml). Each year in the U.S., around one out of
every twenty-five hospitalized patients contracts at least one infection in the hospital (N Engl J Med. 2014, 27;370(13):1198-208). In
the U.S., there were over 80,000 invasive MRSA infections and 11,285 related deaths in 2011 (source: https://edition.cnn.com/2013/06/28/us/mrsa-fast-facts/index.html).
Indeed, severe MRSA infections most commonly occur during or soon after inpatient medical care. More than 290,000 hospitalized patients
are infected with Staphylococcus aureus and of these staphylococcal infections, approximately 126,000 are related to MRSA (source: http://www.healthcommunities.com/mrsa-infection/incidence.shtml).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-4 is a small drug molecule
which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium
in the body or that cause damage to the body&#8217;s systems. These products of bacterial genes are referred to as &#8220;virulence expression.&#8221;
Targeting bacterial virulence is an alternative approach to antimicrobial therapy that offers promising opportunities to overcome the
emergence and increasing prevalence of antibiotic-resistant bacteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Professor Richard Kao from
The University of Hong Kong (who is also the Founder and Principal Investigator of Acticule and Inventor of ALS-1, ALS-2, ALS-3 and ALS-4)
initiated a high throughput approach for screening compounds which are active against virulence expression, which resulted in the discovery
of ALS-1, ALS-2, ALS-3 and ALS-4.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-4 targets an enzyme essential
for Staphylococcus aureus (including MRSA) survival in vivo. This enzyme is involved in the production of Staphyloxanthin, a carotenoid
pigment produced by Staphylococcus aureus including MRSA, and is responsible for the characteristic golden color. This pigment has proven
to be an important factor in promoting bacterial invasion as well as rendering the bacteria resistant to attack from reactive oxygen species
(ROS) and neutrophils. In other words, pigmented bacteria have increased resistance to the host&#8217;s immune defenses. ALS-4 may have
particular value if it can be shown to be an effective therapy in situations where a Staphylococcus aureus infection is resistant to available
antibiotics (i.e., where the pathogen is MRSA).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a study by the inventor,
Prof. Richard Kao, ALS-4 demonstrates potent activity against Staphylococcus aureus pigment formation in vitro, as indicated in Figure
1, with an IC<sub>50</sub>&#160;(IC<sub>50</sub>&#160;is defined as the concentration of a drug which inhibits half of the maximal response
of a biochemical process. In this case, inhibition of the formation of the golden pigment is the response) equal to 20 nM.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 1</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;<img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 1: In vitro pigment
inhibition by compound ALS-4: Inhibition of staphyloxathin (the golden pigment in <i>S. Aureus</i>) in the presence of increasing concentrations
of ALS-4</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Efficacy of ALS-4 in a MRSA Wound Infection
Mouse Model</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A study conducted by a third-party
contract research organization, assessed ALS-4&#8217;s effect in the healing of open wounds infected with MRSA in a mouse model. Compared
with topical dosing of 2% Mupirocin and oral dosing of Linezolid at 100mg/kg twice a day, oral dosing of ALS-4 at 30mg/kg twice a day
showed statistically significant improvement in wound healing. Specifically, at the end of the study on Day 7, ALS-4 exhibited 63.8% of
wound closure compared with 48.4% for oral Linezolid and 43.2% for topical Mupirocin 2%. The results are further illustrated in the graph
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 2</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_004.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Unpaired student&#8217;s t-test,
p&lt;0.05</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 2: Result of study
on ALS-4&#8217;s effect in the healing of open wounds infected with MRSA in a mouse model&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Efficacy of ALS-4 in a Bacteraemia Mouse Model</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a further round of&#160;<i>in
vivo</i>&#160;studies, conducted by a third-party contract research organization, in a non-lethal MRSA bacteraemia mouse model, the mice
were orally administered with different doses of ALS-4 from 0.3 to 30mg/kg twice a day for 7 days, compared to those who received vancomycin
only group (3mg/kg of vancomycin administered intravenously) and a no treatment control group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the conclusion of the study
on Day 7, ALS-4 brought a statistically significant reduction in bacterial counts in major organs such as the kidneys, lungs, liver and
spleen compared with the no drug control and vancomycin only groups (unpaired student&#8217;s t-test, p&lt;0.05). This is in addition
to the previous&#160;<i>in vivo</i>&#160;results announced in February 2020, whereby ALS-4 demonstrated on a statistically significant
basis better survival rates (56% vs 0% control group) in the lethal MRSA bacteraemia rat model (Figure 3a) and higher reduction of bacterial
load (by 99.5% against the control group) in the non-lethal MRSA bacteraemia rat model (Figure 3b).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 3a</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 3a: Oral Formulation of ALS-4 in an MRSA
Survival Study</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 3b</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_006.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 3b: Oral Formulation
of ALS-4 in a Non-Lethal Bacteremia Model&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">CFU = Colony Forming Unit, a unit used
to estimate the number of viable bacteria in a sample</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Clinical Trial Application
(&#8220;CTA&#8221;) was submitted with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of ALS-4,
an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant
Staphylococcus aureus (MRSA) in Q4 2020. ALS-4 received clearance from Health Canada regarding the CTA to initiate a Phase 1 clinical
study in January 2021. In March 2021, we announced dosing the first human subject in its Phase 1 clinical trial evaluating ALS-4. In January
2022, we further announced the completion of our Phase I clinical trial for ALS-4. The first-in-human Phase 1 trial was a randomized,
double-blinded, placebo-controlled, single and multiple ascending dose study designed to evaluate safety, tolerability, and pharmacokinetics
of orally administered ALS-4 in healthy male and female adult volunteers. The single-ascending dose studies (SAD) and multiple-ascending
dose studies (MAD) have been completed for a total of 72 healthy subjects and no subjects were dropped from the studies. There were no
serious adverse events observed and no relevant clinical changes in respect of vital signs. In March 2023, we announced the completion
of the Pre-IND discussions with the US FDA. The Pre-IND discussions focused on overall development plan in preparation for the IND application
of ALS-4 targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI) initially.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the positive feedback
on the overall development strategy from the US FDA, we may proceed towards the IND submission of ALS-4 seeking to initiate a Phase 2
clinical study to assess the efficacy of ALS-4 in patients in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Patent License</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 18, 2017, the Company&#8217;s
subsidiary, Acticule, entered into an exclusive license agreement with Versitech Limited, the licensing entity of HKU, for ALS-4. Subsequently
on June 7, 2018, the parties entered into a first amendment to the exclusive license agreement,&#160;and on July 10, 2019, the parties
entered into a second amendment to the license agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 11, 2019, Acticule
and Versitech Limited entered into a second license agreement for ALS-4, where Acticule exclusively licensed the intellectual property
rights on certain HKU-owned improvements to the original licensed invention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the exclusive license
agreements, we were granted an exclusive, royalty-bearing, sublicensable licenses to develop, make, have made, use, sell, offer for sale
and import products that are covered by the licensed patents (as described below). The territory of the licenses is worldwide and the
field of the licenses is for treatment or prevention of bacterial infections caused by Staphylococcus aureus including MRSA and bacterial
virulence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We paid an upfront fee upon
entering into the license agreements. We are required to pay less than 10% of the net sales of the licensed products sold by us or our
affiliates as royalties, as well as a low teens percentage of sublicense royalties that we receive from our sublicensees, if any. In addition,
we agreed to pay to the licensor aggregate regulatory milestones of up to US$1 million subject to the following achievements: submission
of investigational new drug application; completion of phase 1, 2 and 3 clinical trials; and submission of new drug application; grant
of regulatory approval. We also agreed to pay to the licensor aggregate sales milestones of up to US$7.8 million subject to the following
achievement: first commercial sale; and annual net sales exceeding US$100 million in one jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the license agreements,
Acticule became the exclusive licensee of 2 pending U.S. non-provisional patent applications and 2 PCT applications (now expired). Prior
to the expiration of the PCT applications, we filed national phase applications in member states of the PCT including Europe, PRC and
12 other jurisdictions. The claimed inventions are described as: &#8220;Compounds Affecting Pigment Production and Methods for Treatment
of Bacterial Diseases.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Four (4) US patents, two (2)
PRC patents, two (2) Japanese patents, and two (2) Israeli patents have been granted by various patent offices respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Acticule has the right to
grant sublicenses to third parties under the license agreements without prior approval from Versitech Limited and to assign the agreements
to any successor to the business related to the licenses. In the event that Acticule makes an improvement to the licensed technologies,
so long as the improvement does not incorporate any licensed patents, Acticule will be the owner to such improvement, subject to a non-exclusive
royalty-free license being granted back to Versitech Limited for academic and research purposes only.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exclusive license agreements
shall be in effect until the expiration of all licensed patents (please refer to the patent expiration dates under &#8220;Item 4. Information
on the Company &#8211; B. Business Overview &#8211; Intellectual Property&#8221;). Acticule may terminate the licenses at any time with
6-month written notice in advance. Either party may terminate the agreements upon a material breach by other party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SACT-1: A Repurposed Drug for the Treatment
of Neuroblastoma</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug repurposing is a strategy
for identifying new indications for approved or investigational drugs that are outside the scope of the original medical uses. It is often
viewed as a lower-cost method for drug commercialization, as it is based on already-approved drugs (which has been proven to be safe for
human use by the respective governing regulatory agency) and explores new target indications. (Ashburn, T. T. &amp; Thor, K. B. Drug repositioning:
identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673&#8211;683, 2004).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the advantages of drug
repurposing is a lower development risk due to safety and toxicity, as well as other properties related to water solubility, absorption,
distribution and metabolism, as the safety and CMC profiles of marketed drugs are usually well-established. Due to the same reason, the
development time is also shortened because there is no need to repeat the whole spectrum of the safety assessment. As a result, the drug
repurposing approach appears to be attractive due to its superior risk management, smaller capital investment and quicker financial return.
(Sudeep Pushpakom, et. al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41-58, 2019)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of bringing a repurposed
drug is estimated to be around US$300 million, which is only one-tenth of the development cost for a new drug. (Nosengo, N. Can you teach
old drugs new tricks? Nature. 534, 314-316, 2016).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In summary, drug repurposing
offers the following advantages:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Well-established safety profiles:
The development risk for new indications can be substantially reduced by applying existing drugs that are approved or have been shown
to be safe in large scale late-stage trials. Since safety accounts for approximately 30% of drug failures in clinical trials, this is
a key advantage that repositioned drugs can harness to great effect. (The benefits of drug repositioning. (n.d.). Retrieved from https://www.ddw-online.com/the-benefits-of-drug-repositioning-1779-201104/)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Time-saving: As repositioned
drugs can rely on existing data, including efficacy and toxicity studies, the process is usually faster than de novo development. Developing
a new chemical entity (NCE) can take 10 to 17 years, depending on indications. (Roin, B. N. Solving the Problem of New Uses, 2013). For
a drug repositioning company, the development process from compound identification to launch can be around 3 to 8 years. (Walker, N.
(2017, December 07). Accelerating Drug Development Through Repurposing, Repositioning and Rescue. Retrieved from https://www.pharmoutsourcing.com/Featured-Articles/345076-Accelerating-Drug-Development-Through-Repurposing-Repositioning-and-Rescue/)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Cost-saving: Along with time-saving,
money-saving is also a key benefit. The cost to relaunch a repositioned drug averages $8.4 million, whereas to relaunch a new formulation
of an existing drug in its original indication costs an average $41.3 million. Given that the average cost of launching a new chemical
entity (NCE) is more than $1.3 billion, successfully bringing a repositioned drug to market seems to cost approximately 160 times less
than the current standard of NCE development. Even if this differential is off by a hundred times or more, from the purely financial
perspective, repositioning is in a completely different league of investment needed to create a new drug product in the market. (https://www.ddw-online.com/the-benefits-of-drug-repositioning-1779-201104/)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Potential for out-licensing:
Pharmaceutical companies are said to be exploring new models to out-license some of their clinical drug candidates that may have been
shelved for pure business reasons unrelated to safety or efficacy, even though they have met their endpoints and have proven themselves
to be safe. If such drugs were to be repositioned, the pharmaceutical company increases the attractiveness of these drugs and gives itself
more options to find interested buyers. (https://www.ddw-online.com/the-benefits-of-drug-repositioning-1779-201104/)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Lower failure rate: According
to BCC Research, approval rates for repurposed drugs are close to 30%, which is greater than the approval rate for new drug applications.
(Front Oncol. 2017; 7: 273)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the major limitations
of the current drug repurposing and repositioning practice is that there is a lack of a systematic way to identify and reinvestigate drugs
that are approved and/or have failed approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SACT-1 is the first repurposed
drug candidate to be developed under the Smart-ACT<sup>&#174;</sup> drug discovery platform. SCAT-1 is one of the Company&#8217;s proprietary
technologies. Our first targeted indication is neuroblastoma. Neuroblastoma is a rare form of cancer, and classified as an orphan disease,
that forms in certain types of nerve tissue and most frequently in the adrenal glands as well as spine, chest, abdomen or neck, predominantly
in children, especially for those aged 5 years and below. For the high-risk group, which is close to 20% (Annu Rev Med. 2015; 66: 49&#8211;63.)
of total new patient population per year, the 5-year survival rate of this condition is around 40-50% as observed by the American Cancer
Society (https://www.cancer.org/cancer/neuroblastoma/detection-diagnosis-staging/survival-rates.html). The current high drug treatment
cost for high risk patients can average USD200,000 per regimen (all 6 cycles) (https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnEGR_NOREDACT-ABBREV_Post_26Mar2019_final.pdf).
In addition, most pediatric patients often do not tolerate or survive the relevant chemotherapy stage which, subject to further clinical
studies, may be positively addressed by the SACT-1 candidate due to the potential synergistic effects when applied with standard chemotherapy.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our studies, SACT-1 has
been shown to be effective against numerous neuroblastoma cell lines, of which 2 are MYCN-amplified cells, which represent the high-risk
neuroblastoma patient group. In addition, by using a bliss score as a quantitative measure of the extent of drug interaction, Aptorum
Group has seen a high and robust synergism between SACT-1 and traditional chemotherapy in vitro (Figure 4), indicating a potential efficacy
enhancement/dose reduction of the chemotherapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 4</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_007.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 4: synergism between
SACT-1 and traditional chemotherapy in vitro</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in our study,
the maximum tolerable dose of SACT-1 in a rodent model was determined to be higher than 400mg/kg. Compared with the MTD of standard chemotherapy
such as paclitaxel (20-30mg/kg) (Clin Cancer Res. 5(11):3632-8) and cisplatin (6mg/kg) (BMC Cancer 17: 684 (2017)), the safety profile
of SACT-1 appears to be very impressive. Based on our internal observations of pre-existing information from approved products, (subject
to FDA&#8217;s approval and on a case-by-case basis, a 505(b)(2) Application can rely in part on existing information from approved products
(such as the FDA&#8217;s previous findings on safety and efficacy) or products in literature (such as data available). However, typically
speaking, the applicant is nonetheless required to carry out a Phase 1 bridging study to compare the Reference Listed Drug and reference
the established safety and efficacy information), SACT-1 also exhibits a well-established safety profile: at 150mg/day, the death rate
was 0% in prior clinical studies with no dosage related adverse events (Table 1). In addition, the pharmacokinetic profile of SACT-1 has
also been reported (Table 2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Table 1: Safety Profiles of SACT-1 in Human Clinical
Trials</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_008.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Table 2: The pharmacokinetic Profile of SACT-1
in Humans</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_009.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have developed a pediatric
formulation of SACT-1 to better address the needs of neuroblastoma patients who are exclusively children younger than 5. Positive data
from our latest&#160;internal <i>in vivo</i>&#160;studies show significant activity against neuroblastoma tumor reduction when treated
with the compound SACT-1 in combination with standard of care (SOC) chemotherapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Separately, we also screened
SACT-1 for its&#160;<i>in vitro</i>&#160;activity against over 300 cancer cell lines and showed positive results in a number of cancer
types including in particular colorectal cancer, leukemia and lymphoma, etc. Similar to our previous findings against neuroblastoma cell
lines, SACT-1 exhibits similar anti-tumor efficacy across one or more other major cancer types, including but not limited to colorectal
cancer, leukemia and lymphoma cell lines. As a result, in addition to treating neuroblastoma, SACT-1 may have potential applications in
the treatment of other cancers. Based on this discovery, we plan to carry out further&#160;<i>in vivo</i>&#160;studies to study the efficacy
of SACT-1 over other types of cancers to maximize the potential of SACT-1. Based on the initial 22 day data of a recent study we conducted
in a xenograft mouse model of neuroblastoma, SACT-1 was orally administered daily at 60mg/kg in combination of SOC chemotherapy brought
a statistically significant tumor shrinkage (unpaired student&#8217;s t-test, p&lt;0.01) from Day 15 to Day 22, compared to the control
group which received SOC only. The combination reduced the tumor size by up to 54.2% in the first 22 days compared with the control (SOC
only). SACT-1 appears to be effective in accelerating the effect of the SOC in early time points (from Day 1 - 7 vs control). This further
supports our earlier&#160;<i>in vitro</i>&#160;observation that SACT-1 promotes tumor DNA damage and tumor cell death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 5</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_010.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Figure 5: 22 days data of <i>in vivo</i>&#160;studies
in a xenograft mouse model of neuroblastoma</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-size: 10pt">Unpaired student&#8217;s t-test,
p&lt;0.01, n=8 (based on initial 22 days period)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2021, we announced
that we received clearance from the US FDA regarding the IND application to initiate clinical trials of SACT-1. In January 2022, we further
announced that the completion of our Phase I clinical trial for assessing relative bioavailability and food effect of SACT-1, and no serious
adverse events were observed. SACT-1&#8217;s Phase 1 clinical trial is an Open-label Randomized, Single Cross Over Bioavailability and
Food Effect Study of SACT-1 in healthy adult volunteers. In additions, the US FDA has granted Orphan Drug Designation to SACT-1 in January
2022. In March 2023, we further announced the completion of the End of Phase 1 (EOP1) meeting with the US FDA on SACT-1. The EOP1 meeting
was focused on gaining alignment with the US FDA regarding the clinical and regulatory pathway for SACT-1 for the treatment of neuroblastoma
in pediatric patients aged 2-18. The FDA generally agreed with the chemistry-manufacturing-control (CMC) strategy and our proposed clinical
development plan for Phase 1/2 trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may submit an IND application
to the US FDA seeking to initiate our planned Phase 1b/2a trial for SACT-1 in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Patent License</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2022, the US Patent
and Trademark Office has granted the first patent regarding Aptorum&#8217;s SACT-1 (through Aptorum&#8217;s subsidiary) repurposed drug
for the treatment of various cancers including but not limited to neuroblastoma (US Patent 11,166,952). Another US patent (US Patent 11,571,422)
&#160;was granted in February 2023, and altogether the SACT-1 patent portfolio has four (4) active national phase patent applications
all over the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Paths<sup>Dx </sup>Test: A novel molecular-based
rapid pathogen identification and detection diagnostics technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Infectious disease diagnostic
standard of care (SOC) often involves techniques that are slow (e.g., bacterial culturing takes several days) or expensive (e.g., current
pathogen diagnostic sequencing solutions are not comprehensive, are expensive, and often inaccessible to physicians). Although infectious
disease diagnosis capabilities have been improving in recent years, there are still issues with the public health capacity to control
infectious disease threats.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Infectious disease diagnostic
standard of care (SOC) does not necessarily provide the physician a comprehensive diagnosis or report. Most point of care diagnostic solutions,
while rapid, screen only for a single pathogen and only focus on common and widespread pathogens (e.g., HIV). Thus, for infectious disease
patients in developed nations that present with an uncommon, novel or emerging pathogen threat, diagnosis is often slow (2-5 days) and
inconclusive leaving time for pathogen spread and increased patient suffering and/or death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Paths<sup>Dx </sup>Test is
a rapid infectious disease diagnostic test that we believe will be potentially able to identify all pathogens in a patient&#8217;s sample,
both known and unknown, by employing Next Generation Sequencing (NGS). The goal of Paths<sup>Dx</sup> Test is to cost-effectively return
a 99% accurate result within 24-48 hours. Our internal results show that, in principle, Paths<sup>Dx</sup> Test can identify pathogens
such as viruses (e.g. COVID-19/SARS-CoV-2) or any other known or emerging infectious disease event in one test (e.g., DNA or RNA-based
pathogens). With these properties, Paths<sup>Dx</sup> Test is expected to track the infectome landscape (e.g., tracking mutations), rapidly
identify antibiotic resistant microbials in the process, and be more affordable than current NGS-based diagnostic platforms, which will
make it a superior product to those currently on the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preliminary data from our
internal studies, which have not been verified or confirmed by third parties, presented below demonstrate additional points of innovation
and proof of concept feasibility data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Case Study #1</span>:</i> We examined a bio
banked blood sample from a patient with a diagnosed Hepatitis B infection (Figure 6). Our technology successfully detected the presence
of Hepatitis B, as well as additional pathogens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 6</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_011.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 6: Aptorum&#8217;s
technology successfully confirmed a known Hepatitis B diagnosis in a bio banked sample.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Case Study #2</span>:</i> A patient was undergoing
chemotherapy and developed a severe lung infection that was refractory to first-line antibiotics but eventually responded to the traditional
trial and error approach. Using our technology, we found that 10% of all reads came from Leuconostoc, a Gram+ bacteria (Figure 7). Importantly,
Leuconostoc was not identified by physicians, demonstrating that our technology can identify pathogens that allude a traditional diagnosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 7</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_012.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 7: Aptorum&#8217;s
technology identified pathogen(s) that allude the traditional diagnostic approach.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Paths<sup>Dx </sup>Test has
the revolutionary potential to cover simultaneously over 1300 pathogens due to the unbiased approach in analyzing pathogen genome information
and caters to patients who are infected with multi-strains of pathogen. The technology can be updated through our software analytics on
an ongoing basis as further pathogenic genome sequences are updated through public databases, ensuring g that it is up-to-date on new
and emerging pandemic threats.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Paths<sup>Dx </sup>Test is
currently undergoing Clinical Validation to confirm the performance of Paths<sup>Dx</sup> Test using clinical/patient samples. Paths<sup>Dx</sup>
Test will continue to undergo validations during 2023, in parallel with its pre-commercialization process in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Patent License and Application</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 25, 2020, the
Company&#8217;s subsidiary, Paths Diagnostics Pte. Limited, entered into an exclusive licence agreement with Accelerate Technologies Pte
Ltd, the commercialization arm of the Singapore&#8217;s Agency for Science, Technology and Research (&#8220;A*STAR&#8221;), to co-develop
Paths<sup>Dx</sup> Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology. No upfront fee or
royalty on net sales is payable under the license agreements, although we are required to pay a mid-teens to mid-twenties percentage of
sublicense revenue that we receive from our sublicensees, if any. In addition, we agreed to pay to the licensor aggregate development
milestones of up to US$250,000. When specific development milestone is reached, we are also required to satisfy certain diligence obligations,
including recruitment of staff, establishment of relationship with potential customers and exercise commercially reasonable efforts in
selling the Licensed Products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Two (2) US provisional patent
applications and one (1) Singapore patent application was filed in 2021, but subsequently abandoned. In addition, one (1) US non-provisional
patent application was filed on October 8, 2021 and we filed two (2) Paris Convention (PCT) applications on February 24, 2022 and January
7, 2023 respectively. Prior to the expiration of the first PCT applications, we filed national phase applications in 12 member states
including Europe, PRC, Japan, Korea and eight (8) other jurisdictions. The claimed inventions are described as: &#8220;Unbiased And Simultaneous
Amplification Method For Preparing A Double-Stranded DNA Library From A Sample Of More Than One Type Of Nucleic Acid&#8221; and &#8220;Method
of Degrading Nucleic Acids and Associated Compositions.&#8221; Altogether, the Paths<sup>Dx</sup> patent portfolio has five (5) US patents,
one (1) European patent and one (1) Great Britain patent granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Statistical Significance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term statistical significance
is to define the probability that a measured difference between two groups (e.g. two treatment groups, treatment versus control groups)
is the result of a real difference in the tested variations and not the result of chance. It means that the result of a test does not
appear randomly or by chance, but because of a specific change that is tested, so it can be attributed to a specific cause.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The confidence level indicates
to what percentage the test results will not commit a type 1 error, the false positive. A false positive occurs when a change in the result
is due to randomness (or other noise) and not the change in variations. At a 95% confidence level (p = 0.05), there is a 5% chance that
the test results are due to a type 1 error. 95% has become the standard and usually be the minimum confidence level for the tests. To
make the test more stringent, a 99% confidence level (p = 0.01) is also commonly employed, which means that there is a 1% chance that
the test results are due to a type 1 error.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In other words, a p value
represents the confidence level. For example, if the p-value for a test is &lt; 0.05, it means that there is less than 5% chance the difference
between two groups is due to random error or by chance. If the p-value is &lt; 0.01, it means that there is less than 1% chance the difference
between two groups is due to random error or by chance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employed statistical testing
to compare different treatment groups in animal studies simply for proof of concept and to aid internal decision making for further development.
We do not intend to use this standard for any regulatory submission. The US FDA or other regulatory agencies may not necessarily employ
the same statistical standard to assess the efficacy in clinical trials, the results of which would be submitted for regulatory approval.&#160;Although
a p-value of 0.05 has become the standard,&#160;the US FDA or other regulatory agencies may also individualize their efficacy standard
for different clinical programs based on the indications, the purpose of a clinical trial, among others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA Application Status</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this the
annual report, we received CTA and IND approvals for ALS-4 and SACT-1 from Health Canada and the US FDA to initiate human clinical trial.
We have not submitted other applications for IND to the FDA or other regulatory agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our industry is highly competitive
and subject to rapid and significant change. While we believe that our development and commercialization experience, scientific knowledge
and industry relationships provide us with competitive advantages, we face competition from pharmaceutical and biotechnology companies,
including specialty pharmaceutical companies, and generic drug companies, academic institutions, government agencies and research institutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are a number of large
pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drugs for the diagnosis
and treatment of diseases for which we are developing products or technology. Moreover, a number of additional drugs are currently in
clinical trials and may become competitors if and when they receive regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors have
longer operating histories, better name recognition, stronger management capabilities, better supplier relationships, a larger technical
staff and sales force and greater financial, technical or marketing resources than we do. Mergers and acquisitions in the pharmaceutical
and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial
opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective,
safer or less costly than our current drug candidates, or any future drug candidates we may develop, or obtain regulatory approval for
their products more rapidly than we may obtain approval for our current drug candidates or any such future drug candidates. Our success
will be based in part on our ability to identify, develop and manage a portfolio of drug candidates that are safer and more effective
than competing products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Inflation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation affects us by generally
increasing our cost of labor and research and development costs, the way it does to all labor and research costs. However, we do not
anticipate that inflation will materially affect our business in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Seasonality</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our operation and
sales do not experience seasonality.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual
report, we have 3 full-time employees. Of these, 3 full-time are engaged in general and administrative functions. As of the date of this
annual report, 3 of our employees are located in Asia. In addition, we have engaged and may continue to engage 10 independent contracted
consultants and advisors to assist us with our operations. None of our employees are represented by a labor union or covered by a collective
bargaining agreement. We have never experienced any employment related work stoppages, and we consider our relations with our employees
to be good.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The technologies underlying
our various research and development projects are the subject of various patents and patent applications claiming, in certain instances,
composition of matter and, in other instances, methods of use. Prosecution, maintenance and enforcement of these patents, as well as those
on any future protectable technologies we may acquire, are and will continue to be an important part of our strategy to develop and commercialize
novel medicines, as described in more detail below. Through entering into license agreements with their owners, we have obtained exclusive
rights to these patents, applications and related know-how in the U.S. and certain other countries to develop, manufacture and commercialize
the products using or incorporating the protected inventions that are described in this annual report and that are expected to contribute
significant value to our business. The technologies protected by these patents may also for the basis for the development of other products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to licensed intellectual
property, our in-house science team has been actively developing our own proprietary intellectual property. No non-provisional&#160;patent
application has yet been filed in the Company&#8217;s own name for the Lead Projects. We have, however, filed a number of provisional
applications to establish earlier filing dates for certain of our other ongoing researches, the specifics of which are currently proprietary
and confidential.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. patent system permits
the filing of provisional and non-provisional patent applications (i.e., a regular patent application). A non-provisional patent application
is examined by the USPTO, and can mature into a patent once the USPTO determines that the claimed invention meets the standards for patentability.
On the other hand, a provisional patent application is not examined for patentability, and automatically expires 12 months after its filing
date. As a result, a provisional patent application cannot mature into a patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisional applications are
often used, among other things, to establish an earlier filing date for a subsequent non-provisional patent application. The term of individual
patents depends upon the legal term of the patents in the countries in which they are obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The effective filing date
of a non-provisional patent application is used by the USPTO to determine what information is prior art when it considers the patentability
of a claimed invention. If certain requirements are satisfied, a non-provisional patent application can claim the benefit of the filing
date of an earlier filed provisional patent application. As a result, the filing date accorded by the provisional patent application may
supersede information that otherwise could preclude the patentability of an invention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A provisional patent application
is not eligible to become an issued patent unless, among other things, we file a non-provisional patent application within 12 months of
the filing date of the provisional patent application. If we do not timely file&#160;a non-provisional patent application claiming priority
to said provisional application, we may lose our priority date with respect to our provisional patent applications. Further, if any (self
or by others) publication of the invention is made after such priority date, and if we do not file a non-provisional application claiming
priority to said provisional application, our invention may become unpatentable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we cannot predict
whether such future patent applications will result in the issuance of patents that effectively protect any of our product candidates
or will effectively prevent others from commercializing competitive products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect to incur
material expenses in the prosecution of the provisional applications or other licensed patent applications. We expect to fund the patent
costs from our cash and cash equivalents.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The value of our drug products
will depend significantly on our ability to obtain and maintain patent and other proprietary protection for those products, preserve the
confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of other
parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, we
are the patentee of a number of provisional and non-provisional patent applications, both on our proprietarily developed projects and
improvement to our in-licensed projects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
a list of our patent rights under the exclusive licenses as of the date of this annual report related to our Lead Projects, ALS-4 and
Paths<sup>Dx</sup> Test; on the other hand, our other Lead Project, SACT-1 is a proprietary technology not subject to any license agreement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 8%"><span style="font-size: 10pt"><b>Project<br/>
 Company<br/>
 / Project<br/>
 name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; border-bottom: black 1.5pt solid; width: 18%"><span style="font-size: 10pt"><b>License Agreement</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%"><span style="font-size: 10pt"><b>Licensor(s)</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 10%"><span style="font-size: 10pt"><b>Licensee</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; border-bottom: black 1.5pt solid; width: 28%"><span style="font-size: 10pt"><b>Licensed / IP Rights</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 20%"><span style="font-size: 10pt"><b>Patent Expiration <br/>
Dates</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Acticule / ALS-4</span></td>
    <td>&#160;</td>
    <td style="text-align: left">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Exclusive Patent License Agreement, dated October
    18, 2017</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">First Amendment to Exclusive License Agreement,
    dated June 7, 2018</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Second Amendment to Exclusive License Agreement
    dated July 10, 2019</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Exclusive Patent License Agreement dated January
    11, 2019</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Versitech Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Acticule Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Exclusive licensee: 4 US patents (US10471045,&#160;US11446280,
    US11052078, US11040949),&#160;&#160;2 PRC patents&#160;(ZL201880048665.6, ZL201880048674.5),&#160;2&#160;Japanese patents (JP7232238, JP
    7348893), 2 Israeli patents (271863, 271864), and 9 pending applications in other foreign jurisdictions including Canada, Europe,
    PRC, Korea, and US.</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The licensed IP rights include granted patents
    in the US, PRC, Japan, Israel, and pending patent applications in 3 other foreign jurisdictions.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. patents will expire in 2038-2040. Any
    other patents derived from the pending applications, if granted, will have a 20-year patent term from 2018.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Paths<sup>Dx</sup> Test</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Exclusive Patent License Agreement, dated September 25, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Accelerate Technologies Pte Ltd</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Paths Diagnostics Pte. Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Exclusive licensee: 4 U.S. patents (US7635566, US8241850, US9920355, US10472667, US11,280,028), 1 European patent (EP3224374), 1 Great Britain patent (GB2532749) and 12 pending applications in other jurisdictions including Europe, PRC, Japan, Korea, etc.</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The U.S. patents will expire in 2027, 2028, 2034, 2037 and 2041 respectively. The UK patent will expire in 2034. The European patent will expire in 2035. Any other patents derived from the pending applications, if granted, will have a 20-year patent term from 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the extensive time
required for clinical development and regulatory review of a drug we may develop, it is possible that, before any of our drug candidates
can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing
any advantage of any such patent. If appropriate, the Company may seek to extend the period during which it has exclusive rights to a
product by pursuing patent term extensions and marketing exclusivity periods that are available from the regulatory authorities of certain
countries (including the United States) and the EPO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even though the Company has
certain patent rights, the ability to obtain and maintain protection of biotechnology and pharmaceutical products and processes such as
those we intend to develop and commercialize involves complex legal and factual questions. No consistent policy regarding the breadth
of claims allowed in such patents has emerged to date in the U.S. The scope of patent protection outside the United States is even more
uncertain. Changes in the patent laws or in interpretations of patent laws in the United States and other countries have diminished (and
may further diminish) our ability to protect our inventions and enforce our IP rights and, more generally, could affect the value of IP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we have already secured
rights to a number of issued patents directed to our drug candidates, we cannot predict the breadth of claims that may issue from the
pending patent applications and provisional patents that we have licensed or that we have filed. Substantial scientific and commercial
research has been conducted for many years in the areas in which we have focused our development efforts, which has resulted in other
parties having a number of issued patents, provisional patents and pending patent applications relating to such areas. The patent examiner
in any particular jurisdiction may take the view that prior issued patents and prior publications render our patent claims &#8220;obvious&#8221;
and therefore unpatentable or require us to reduce the scope of the claims for which we are seeking patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, patent applications
in the United States and elsewhere generally are not available to the public until at least 18 months from the priority date, and the
publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying
discoveries were made. Therefore, patent applications relating to drugs similar to our drug candidates may have already been filed, which
(if they result in issued patents) could restrict or prohibit our ability to commercialize our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and pharmaceutical
industries are characterized by extensive litigation regarding patents and other IP rights. Our ability to prevent competition for our
drug candidates and technologies will depend on our success in obtaining patents containing substantial and enforceable claims for those
candidates and enforcing those claims once granted. With respect to any applications which have not yet resulted in issued patents, there
can be no assurance that meaningful claims will be obtained. Even issued patents may be challenged or invalidated. If others have prepared
and filed patent applications in the United States that also claim technology to which we have filed patent applications or otherwise
wish to challenge our patents, we may have to participate in interferences, post-grant reviews, inter parties reviews, derivation or other
proceedings in the USPTO and other patent offices to determine issues such as priority of claimed invention or validity of such patent
applications as well as our own patent applications and issued patents. Patents may also be circumvented, and our competitors may be able
to independently develop and commercialize similar drugs or mimic our technology, business model or strategy without infringing our patents.
The rights granted under any issued patents may not provide us with proprietary protection or competitive advantages against competitors
with similar technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may rely, in some limited
circumstances, on unpatented trade secrets and know-how to protect aspects of our technology. However, it is challenging to monitor and
prevent the disclosure of trade secrets. We seek to protect our proprietary trade secrets and know-how, in part, by entering into confidentiality
agreements with consultants, scientific advisors and contractors and invention assignment agreements with our employees. We also seek
to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical
and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems,
agreements or security measures may be breached, giving our competitors knowledge of our trade secrets and know-how, and we may not have
adequate remedies for any such breach, in which case our business could be adversely affected. Our trade secrets will not prevent our
competitors from independently discovering or developing the same know-how. Although our agreements with our consultants, contractors
or collaborators require them to provide us only original work product and prohibit them from incorporating or using IP owned by others
in their work for us, if they breach these obligations, disputes may arise as to the rights in any know-how or inventions that arise from
their work.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success will
also depend in part on not infringing the proprietary rights of other parties. Although we seek to review the patent landscape relevant
to our technologies on an ongoing basis, we may become aware of a new patent which has been issued to others with claims covering or related
to aspects of one of our drug candidate. The issuance of such a patent could require us to alter our development plans for that candidate,
redesign the candidate, obtain a license from the patent holder or cease development. Our inability to obtain a license to proprietary
rights that we may require to develop or commercialize any of our drug candidates would have a material adverse impact on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Trademarks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual
report, we own trademark registrations covering the trade names and logos of Aptorum and our subsidiaries, including but not limited to
&#8220;APTORUM&#8221;, &#8220;<span style="text-transform: uppercase">APTORUM THERAPEUTICS</span>,&#8221; &#8220;<span style="text-transform: uppercase">VIDENS
LIFE SCIENCES,</span>&#8221; &#8220;ACTICULE LIFE SCIENCES,&#8221; &#8220;NATIVUS LIFE SCIENCES,&#8221; and &#8220;NATIVUSWELL&#8221;
in jurisdictions such as Australia, EU, Hong Kong, the United Kingdom, US and PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own certain unregistered
trademark rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All other trade names, trademarks
and service marks of other companies appearing in this annual report are the property of their respective holders. Solely for convenience,
the trademarks and trade names in annual report are referred to without the <sup>&#174;</sup> and <sup>&#8482; </sup>symbols, but such
references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable
law, their rights thereto. We do not intend our use or display of other companies&#8217; trademarks and trade names to imply a relationship
with, or endorsement or sponsorship of us by, any other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities in
the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research
and clinical development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising,
distribution, post-approval monitoring and reporting, marketing, pricing, export and import of drug products (&#8220;Regulated Products&#8221;),
such as those we are developing. Generally, before a new Regulated Product can be marketed, considerable data demonstrating its quality,
safety and efficacy must be obtained, organized to address the requirements of and in the format specific to each regulatory authority,
submitted for review and approved by the regulatory authority. This process is very lengthy and expensive, and success is uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulated Products are also
subject to other federal, state and local statutes and regulations in the United States and other countries, as applicable. The process
of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
require the expenditure of substantial time and financial resources. Failure to comply with the applicable regulatory requirements at
any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial
sanctions. These sanctions could include, among other actions, the regulatory authority&#8217;s refusal to approve pending applications,
withdrawal of an approval, clinical holds, untitled or warning letters, voluntary product recalls or withdrawals from the market, product
seizures, total or partial suspension of production or distribution, injunctions, disbarment, fines, refusals of government contracts,
restitution, disgorgement, or civil or criminal penalties. Any such administrative or judicial enforcement action could have a material
adverse effect on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the Company&#8217;s
principal place of business is in Hong Kong, the Company is subject to various Hong Kong laws and regulation covering its business activities
there, described in further detail below. Also, the Company anticipates that, if it obtains marketing approval for any of its drug candidates,
it intends to focus its marketing and sales efforts primarily in three regions: the United States, Canada, Europe and PRC. The regulatory
framework for each of these regions is described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. Drug Development Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of obtaining regulatory
approvals and maintaining compliance with appropriate federal, state and local statutes and regulations requires the expenditure of substantial
time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process,
approval process, or after approval, may subject an applicant to administrative or judicial sanctions or lead to voluntary product recalls.
Administrative or judicial sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval,
a clinical hold, untitled or warning letters, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. The process required by the FDA before
a drug may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">completion of non-clinical laboratory
tests, preclinical studies according to cGLP and manufacturing of clinical supplies according to cGMP;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">submission to the FDA of an
IND, which must become effective before human clinical trials may begin;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">approval by an independent IRB,
at each clinical site before each trial may be initiated;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">performance of adequate and
well-controlled human clinical trials according to cGCP, to establish the safety and efficacy of the proposed product for its intended
use;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">preparation and submission to
the FDA of an NDA, for a drug;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">satisfactory completion of an
FDA advisory committee review, if applicable;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">satisfactory completion of an
FDA inspection of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance
with cGMP; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">payment of user fees and the
FDA review and approval of the NDA.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The testing and approval process
requires substantial time, effort and financial resources and we cannot be certain that any approvals for our drug candidates, or any
future drug candidates we may develop, will be granted on a timely basis, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once a drug candidate is identified
for development, it enters the non-clinical testing stage. Non-clinical tests include laboratory evaluations of product chemistry, toxicity,
formulation and stability, as well as preclinical studies. An IND sponsor must submit the results of the non-clinical tests, together
with manufacturing information, analytical data and any available clinical data or literature, to the FDA as part of the IND prior to
commencing any testing in humans. An IND sponsor must also include a protocol detailing, among other things, the objectives of the clinical
trial, dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated if the initial clinical trial lends itself to an efficacy evaluation. Some non-clinical testing may continue
even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns
or questions related to a proposed clinical trial and places the trial on a clinical hold within that 30-day time period. In such a case,
the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed
by the FDA at any time before or during clinical trials due to safety concerns or non-compliance, and may be imposed on all products within
a certain class of products. The FDA also can impose partial clinical holds, for example, prohibiting the initiation of clinical trials
for certain duration or for certain doses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All clinical trials must be
conducted under the supervision of one or more qualified investigators in accordance with cGCP regulations. These regulations include
the requirement that all research subjects provide informed consent in writing before their participation in any clinical trial. Further,
an IRB representing each institution participating in a clinical trial must review and approve the plan for any clinical trial before
it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. An IRB is responsible
for protecting the rights of clinical trial subjects and considers, among other things, whether the risks to individuals participating
in the clinical trial are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the information regarding
the clinical trial and the consent form that must be provided to each clinical trial subject or his or her legal representative and must
monitor the clinical trial until completed. Each new clinical protocol and any amendments to the protocol must be submitted to the FDA
for review, and to the IRBs for approval. Protocol detail, among other things, includes the objectives of the clinical trial, testing
procedures, sublease selection and exclusion criteria, and the parameters to be used to monitor subject safety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials are
typically conducted in three sequential phases that may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Phase 1.</b>&#160;Phase 1
includes the initial introduction of an investigational new drug into humans. These studies are closely monitored and may be conducted
in patients, but are usually conducted in healthy volunteer subjects. These studies are designed to determine the metabolic and pharmacologic
actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.
During Phase 1, sufficient information about the drug&#8217;s pharmacokinetics and pharmacological effects should be obtained to permit
the design of well-controlled, scientifically valid, Phase 2 studies. Phase 1 studies also evaluate drug metabolism, structure-activity
relationships, and the mechanism of action in humans. These studies also determine which investigational drugs are used as research tools
to explore biological phenomena or disease processes. The total number of subjects included in Phase 1 studies varies with the drug,
but is generally in the range of twenty to eighty.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Phase 2.</b>&#160;Phase 2
includes the early controlled clinical studies conducted to obtain some preliminary data on the effectiveness of the drug for a particular
indication or indications in patients with the disease or condition. This phase of testing also helps determine the common short-term
side effects and risks associated with the drug. Phase 2 studies are typically well-controlled, closely monitored, and conducted in a
relatively small number of patients, usually involving several hundred people.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Phase 3.&#160;</b>Phase 3
studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the
drug has been obtained in Phase 2, and are intended to gather the additional information about effectiveness and safety that is needed
to evaluate the overall benefit-risk relationship of the drug. Phase 3 studies are designed to provide an adequate basis for extrapolating
the results to the general population and transmitting that information in the physician labeling. Phase 3 studies usually include several
hundred to several thousand people.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Progress reports detailing
the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and
clinical investigators within 15 calendar days for serious and unexpected suspected adverse events, any clinically important increase
in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator&#8217;s brochure, or any findings
from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the drug candidate. Additionally,
a sponsor must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction no later than 7 calendar days after
the sponsor&#8217;s receipt of the information. There is no assurance that Phase 1, Phase 2 and Phase 3 testing can be completed successfully
within any specified period, or at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend
or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s
requirements or if the product has been associated with unexpected serious harm to subjects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrent with clinical trials,
companies usually complete additional preclinical studies and must also develop additional information about the chemistry and physical
characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product drug and, among other things, the manufacturer
must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging
must be selected and tested and stability studies must be conducted to demonstrate that the product drug does not undergo unacceptable
deterioration over its shelf life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of product development,
non-clinical studies and clinical trials, together with other detailed information regarding the manufacturing process, analytical tests
conducted on the product, proposed labeling and other relevant information, are submitted to the FDA as part of an NDA requesting approval
to market the new drug. The FDA reviews all NDAs submitted within 60 days of submission to ensure that they are sufficiently complete
for substantive review before it accepts them for filing. If the submission is accepted for filing, the FDA begins an in-depth substantive
review.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval process is lengthy
and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional
clinical data or other data and information. Even if such data and information are submitted, the FDA may ultimately decide that the NDA
does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data
differently than we interpret the same data. The FDA will issue a complete response letter if the agency decides not to approve the NDA
in its present form. The complete response letter usually describes all of the specific deficiencies that the FDA identified in the NDA
that must be satisfactorily addressed before it can be approved. The deficiencies identified may be minor, for example, requiring labeling
changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended
actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the
applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application or request
an opportunity for a hearing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If after such review a product
receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may
otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications,
warnings or precautions be included in the product labeling. Any products for which we receive the FDA approval would be subject to continuing
regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product,
providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain
electronic records and signature requirements and complying with the FDA promotion and advertising requirements. In addition, the FDA
may require post-approval studies, including Phase 4 clinical trials, to further assess a product&#8217;s safety and effectiveness after
NDA approval and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.
The FDA also may conclude that an NDA may only be approved with a Risk Evaluation and Mitigation Strategy designed to mitigate risks through,
for example, a medication guide, physician communication plan, or other elements to assure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Post-Approval Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any products for which we receive
the FDA approval are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting
of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution
requirements, complying with certain electronic records and signature requirements and complying with the FDA promotion and advertising
requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on
the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Further,
manufacturers must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing
investment to ensure compliance. In addition, changes to the manufacturing process generally require prior the FDA approval before being
implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also
subject to further the FDA review and approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may withdraw a product
approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later
discovery of previously unknown problems with a product may result in restrictions on the product&#8217;s marketing or even complete withdrawal
of the product from the market. Further, the failure to maintain compliance with regulatory requirements may result in administrative
or judicial actions, such as fines, untitled or warning letters, holds on clinical trials, product seizures, product detention or refusal
to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing,
injunctions or consent decrees, or civil or criminal penalties, or may lead to voluntary product recalls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent Term Restoration and Marketing Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because drug approval can take
an extended period of time, there may be limited remaining life for the patents covering the approved drug, meaning that the company has
limited time to use the patents to protect the sponsor&#8217;s exclusive rights to make, use and sell that drug. In such a case, U.S.
patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly
referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent
term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining
term of a patent beyond a total of 14 years from the product&#8217;s approval date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDCA provides
a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for
a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active
moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not
accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or a 505(b)(2) Application submitted by another company for
another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, if appropriate,
we intend to apply for restorations of patent term and/or marketing exclusivity for some of our products; however, there can be no assurance
that any such extension or exclusivity will be granted to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disclosure of Clinical Trial Information</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sponsors of clinical trials
of the FDA-regulated products, including drugs are required to register and disclose certain clinical trial information, which is publicly
available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators,
and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results
of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication
being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development
programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pharmaceutical Coverage, Pricing and Reimbursement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Much of the revenue generated
by new Regulated Products depends on the willingness of third-party payors to reimburse the price of the product. Significant uncertainty
exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States,
sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage
and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers
and other organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process
for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products
on an approved list, or formulary, which is not required to include all of the FDA-approved products for a particular indication. Moreover,
a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate
third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our
investment in product development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third-party payors are increasingly
challenging the price and examining the medical necessity and cost- effectiveness of medical products and services, in addition to their
safety and efficacy. To obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of any products, in addition to the costs
required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party
payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval
as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a
profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. government and state
legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care
costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription
drugs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and
measures, could limit payments for pharmaceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if favorable coverage
and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies
and reimbursement rates may be implemented in the future. Unfavorable coverage or reimbursement policies regarding any of the Company&#8217;s
products would have a material adverse impact on the value of that product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Healthcare Laws and Compliance Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain regulatory approval
of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws
may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy
regulation by both the federal government and the states in which we conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patient Protection and the Affordable Care
Act</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Affordable Care Act, enacted
in March 2010, includes measures that have or will significantly change the way health care is financed in the United States by both governmental
and private insurers. Among the provisions of the Affordable Care Act of greatest importance to the pharmaceutical industry are the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. The Affordable Care Act increased pharmaceutical manufacturers&#8217; rebate liability on most branded prescription drugs from 15.1% of the average manufacturer price to 23.1% of the average manufacturer price, added a new rebate calculation for line extensions of solid oral dosage forms of branded products, and modified the statutory definition of average manufacturer price. The Affordable Care Act also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and expanding the population potentially eligible for Medicaid drug benefits.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The Affordable Care Act expanded the types of entities eligible to receive discounted 340B pricing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Affordable Care Act imposed a requirement on manufacturers of branded drugs to provide a 50% discount off the negotiated price of branded drugs dispensed to Medicare Part D patients in the coverage gap (i.e., the &#8220;donut hole&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Affordable Care Act imposed an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, although this fee does not apply to sales of certain products approved exclusively for orphan indications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to these provisions,
the Affordable Care Act established a number of bodies whose work may have a future impact on the market for certain pharmaceutical products.
These include the Patient-Centered Outcomes Research Institute, established to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, the Independent Payment Advisory Board, which has authority to recommend certain changes to the Medicare
program to reduce expenditures by the program, and the Center for Medicare and Medicaid Innovation within the Centers for Medicare and
Medicaid Services, to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other laws may result
in additional reductions in healthcare funding, which could have a material adverse effect on customers for our product candidates, if
we gain approval for any of them. Although we cannot predict the full effect on our business of the implementation of existing legislation
or the enactment of additional legislation pursuant to healthcare and other legislative reform, we believe that legislation or regulations
that would reduce reimbursement for, or restrict coverage of, our products could adversely affect how much or under what circumstances
healthcare providers will use our product candidates if we gain approval for any of them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Canadian Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Canada, our pharmaceutical
product candidates and our research and development activities are primarily regulated by the&#160;<i>Food and Drugs Act&#160;</i>and
the rules and regulations thereunder, which are enforced by Health Canada. Health Canada regulates, among other things, the research,
development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, post-approval monitoring,
marketing and import and export of pharmaceutical products. Drug approval laws require licensing of manufacturing facilities, carefully
controlled research and testing of products, government review and approval of experimental results prior to giving approval to sell drug
products. Regulators also typically require that rigorous and specific standards such as Good Manufacturing Practices (GMP), Good Laboratory
Practices, or GLP, and Good Clinical Practices, or GCP, are followed in the manufacture, testing and clinical development, respectively,
of any drug product. The processes for obtaining regulatory approvals in Canada, along with subsequent compliance with applicable statutes
and regulations, require the expenditure of substantial time and financial resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The principal steps required for drug
approval in Canada is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preclinical Toxicology Studies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-clinical&#160;studies are
conducted&#160;<i>in vitro&#160;</i>and in animals to evaluate pharmacokinetics, metabolism and possible toxic effects to provide evidence
of the safety of the drug candidate prior to its administration to humans in clinical studies and throughout development. Such studies
are conducted in accordance with applicable laws and GLP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Initiation of Human Testing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Canada, the process of conducting
clinical trials with a new drug cannot begin until we have received a NOL (No objection Letter) from Health Canada, typically within 30
days (during Covid the 30 days extended to 45 days) of a CTA submission. Similar regulations apply in Canada to a CTA as to an IND in
the United States. Once approved, two key factors influencing the rate of progression of clinical trials are the rate at which patients
can be enrolled to participate in the research program and whether effective treatments are currently available for the disease that the
drug is intended to treat. Patient enrollment is largely dependent upon the incidence and severity of the disease, the treatments available
and the potential side effects of the drug to be tested and any restrictions for enrollment that may be imposed by regulatory agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Trials</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar regulations apply in
Canada regarding clinical trials as in the United States. In Canada, Research Ethics Boards, or REBs, instead of IRBs, are used to review
and approve clinical trial plans. Clinical trials involve the administration of an investigational new drug to human subjects under the
supervision of qualified investigators in accordance with current Good Clinical Practices, or cGCP, requirements, which include review
and approval by REBs. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial
procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan.
Human clinical trials are typically conducted in three sequential phases, as discussed above in similar context to government regulation
in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture of investigational
drugs for the conduct of human clinical trials is subject to current Good Manufacturing Practice, or cGMP, requirements. Investigational
drugs and active pharmaceutical ingredients imported into Canada are also subject to regulation by Health Canada relating to their labeling
and distribution. Post authorization requirements include reporting of serious adverse events and clinical trial site inspection program.
Phase 1, Phase 2 and Phase 3 clinical trials are subject to a clinical trial application (CTA) for each phase of study. Furthermore, in
Canada, Health Canada or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that
the research subjects are being exposed to an unacceptable health risk. Similarly, an REB can suspend or terminate approval of a clinical
trial at its institution if the clinical trial is not being conducted in accordance with the REB&#8217;s requirements or if the drug has
been associated with unexpected serious harm to subjects. Additionally, some clinical trials are overseen by an independent group of qualified
experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group regularly reviews accumulated
data and advises the study sponsor regarding the continuing safety of trial subjects, potential trial subjects and the continuing validity
and scientific merit of the clinical trial. We may also suspend or terminate a clinical trial based on evolving business objectives or
competitive climate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New Drug Submission (NDS)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon successful completion
of Phase 3 clinical trials, in Canada the company sponsoring a new drug then assembles all the preclinical and clinical data and other
testing relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls, and submits it to Health Canada as part of
a New Drug Submission, or NDS. The NDS is then reviewed by Health Canada for approval to market the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the approval process,
an additional application for a Drug Establishment License (DEL) 90 days prior the NDS submission to Health Canada to initiate review
and inspection of the facility or the facilities at which the drug is manufactured are compliant with GMP requirements. Health Canada
will not approve the product unless compliance with cGMP&#8212;a quality system regulating manufacturing&#8212;is satisfactory and the
NDS contains data that provide substantial evidence that the drug is safe and effective in the indication studied. In addition, before
approving an NDS, Health Canada will typically inspect one or more clinical sites to assure compliance with GCP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The testing and approval process
for an NDS requires substantial time, effort and financial resources, and may take several years to complete. Data obtained from preclinical
and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent
regulatory approval. Health Canada may not grant approval of an NDS on a timely basis, or at all. In Canada, NDSs are subject to user
fees and these fees are typically increased annually to reflect inflation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if Health Canada approves
a product candidate, the relevant authority may limit the approved indications for use of the product candidate, require that contraindications,
warnings or precautions be included in the product labeling, including a black box warning, require that post-approval studies, including
Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs
to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management
mechanisms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Health Canada may prevent or
limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types
of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject
to further testing requirements, notification, and regulatory authority review and approval. Further, should new safety information arise,
additional testing, product labeling or regulatory notification may be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>European Union Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulation in the European Union</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process governing approval
of medicinal products in the EU generally follows the same lines as in the United States. It entails satisfactory completion of pharmaceutical
development, non-clinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the medicinal
product for each proposed indication. It also requires the submission to relevant competent authorities for clinical trials authorization
and to the European Medicines Authority, or EMA, for a marketing authorization application, or MAA, and granting of a marketing authorization
by these authorities before the product can be marketed and sold in the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Trial Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the currently applicable
Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on cGCP, a system for the approval of clinical trials in the EU (the
equivalent of the IND process in the United States) has been implemented through national legislation of the EU member states. Under this
system, an applicant must obtain approval from the competent national authority of an EU member state in which the clinical trial is to
be conducted or in multiple EU member states if the clinical trial is to be conducted in a number of EU member states. Furthermore, the
applicant may only start a clinical trial at a specific study site after the independent ethics committee has issued a favorable opinion.
The clinical trial application, or CTA, must be accompanied by an investigational medicinal product dossier with supporting information
prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding national laws of the EU member states and further detailed
in applicable guidance documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2014, the EU adopted
a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. It is expected
that the new Clinical Trials Regulation will apply in 2019. It will overhaul the current system of approvals for clinical trials in the
EU. Specifically, the new regulation, which will be directly applicable in all EU member states, aims at simplifying and streamlining
the approval of clinical trials in the EU. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure
using a single entry point and strictly defined deadlines for the assessment of clinical trial applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Marketing Authorization</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain a marketing authorization
for a product under the EU regulatory system (the equivalent of the NDA process in the United States), an applicant must submit an MAA,
either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in EU member
states (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to
an applicant established in the EU. Regulation (EC) No. 1901/2006 provides that prior to obtaining a marketing authorization in the EU,
an applicant must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering
all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver, or a deferral for one or
more of the measures included in the PIP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The centralized procedure provides
for the grant of a single marketing authorization by the European Commission that is valid for all EU member states. Pursuant to Regulation
(EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological
processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated
for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated
for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients,
the centralized procedure may be optional.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized procedure,
the Committee for Medicinal Products for Human Use, or the CHMP, established by the EMA is responsible for conducting the assessment of
a product to define its risk/benefit profile. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210
days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response
to questions of the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major
interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the CHMP accepts such a
request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit
for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Periods of Authorization and Renewals</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A marketing authorization is
valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk benefit balance
by the EMA or by the competent authority of the authorizing Member State. To that end, the marketing authorization holder must provide
the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations
introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once
renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides,
on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is
not followed by the placement of the drug on the EU market (in the case of the centralized procedure) or on the market of the authorizing
Member State within three years after authorization ceases to be valid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulatory Requirements after Marketing
Authorization</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following approval, the holder
of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion
and sale of the medicinal product. These include compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules,
pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized
products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s
cGMP requirements and comparable requirements of other regulatory bodies in the EU, which mandate the methods, facilities and controls
used in manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized
products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the
general public, are strictly regulated in the EU under Directive 2001/83EC, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orphan Drug Designation and Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulation (EC) No. 141/2000
and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor
can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating
condition affecting not more than five in ten thousand persons in the EU when the application is made, or (2) a life-threatening, seriously
debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the
EU would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate
that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized
in the EU or, if such method exists, the drug has to be of significant benefit compared to products available for the condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An orphan drug designation
provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized EU marketing
authorization. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity
period, neither the EMA nor the European Commission or the EU member states can accept an application or grant a marketing authorization
for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing
a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic
indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end
of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the
product is sufficiently profitable not to justify market exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>PRC Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to protect our potential
market in the PRC, we have obtained an exclusive license of certain PRC patents directed to certain of the drug candidates that we are
developing and are currently seeking approval of additional patent and other IP filings in the PRC. Seeking IP approval in the PRC subjects
us to some of the rules and practices of the PRC government. Since the Company intends eventually to market its products in the PRC, at
least some of our drug candidates may become subject to regulatory approval and marketing authorization in the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Permission Required from the PRC Authorities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual
report, we are not required to obtain approvals from the PRC authorities to operate our business or list on the U.S. exchanges and offer
or continue to offer securities; specifically, we are currently not required to obtain any permission or approval from the CSRC, the CAC
or any other PRC governmental authority to operate our business or to list our securities on a U.S. securities exchange or issue securities
to foreign investors. The laws and regulations of mainland China do not currently have any material impact on our business, financial
condition or results of operations and we are currently not subject to the PRC government&#8217;s direct influence or discretion over
the manner in which we conduct our business activities outside of the mainland China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevertheless, we are aware
that recently, the PRC government initiated a series of regulatory actions and statements to regulate business operations in certain areas
in mainland China with little advance notice, including cracking down on illegal activities in the securities market, enhancing supervision
over mainland Chinese companies listed overseas using a VIE structure, adopting new measures to extend the scope of cybersecurity reviews,
and expanding the efforts in anti-monopoly enforcement. Since these statements and regulatory actions are new, it is highly uncertain
how soon the legislative or administrative regulation making bodies will respond and what existing or new laws or regulations or detailed
implementations and interpretations will be modified or promulgated, if any. It is also highly uncertain what potential impact such modified
or new laws and regulations will have on Aptorum Group&#8217;s daily business operations, its ability to accept foreign investments and
the listing of our Class A Ordinary Shares on a U.S. or other foreign exchange. If there is significant change to current political arrangements
between mainland China and Hong Kong, the PRC government intervenes or influences operations of companies operated in Hong Kong like us,
or exerts more control through change of laws and regulations over offerings conducted overseas and/or foreign investment in issuers like
us, it may result in a material change in our operations and/or the value of the securities we are registering for sale or could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of our Class A Ordinary
Shares to significantly decline or become worthless. (Please see the risk factor section, &#8220;Risks Related to our Corporate Structure&#8221;
and &#8220;Risks Related to Doing Business in Hong Kong&#8221; for more information).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Hong Kong Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operations of laboratory
in Hong Kong are subject to certain general laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Waste Disposal Ordinance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Waste Disposal Ordinance
(Chapter 354 of the Laws of Hong Kong) (&#8220;WDO&#8221;) and the Waste Disposal (Clinical Waste) (General) Regulation (Chapter 354O
of the Laws of Hong Kong) (the &#8220;WDR&#8221;) provide for, among others, the control and regulation of the production, storage, collection
and disposal of clinical waste.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the WDO, clinical waste
means waste consisting of any substance, matter or thing generated in connection with:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a dental, medical, nursing or veterinary practice;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any other practice, or establishment (howsoever described), that provides medical care and services for the sick, injured, infirm or those who require medical treatment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">dental, medical, nursing, veterinary, pathological or pharmaceutical research; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a dental, medical, veterinary or pathological laboratory practice,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">and which consists wholly or
partly of any of the materials specified in one or more of the groups listed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">used or contaminated sharps;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">laboratory waste;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">human and animal tissues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">infectious materials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">dressings; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">such other wastes as specified by the Director of the Environmental Protection Department (&#8220;EPD&#8221;) of Hong Kong.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the research works in
our R&amp;D Center may produce used or contaminated sharps such as syringes and needles as well as dressings, we are subject to WDO, WDR
and the Code of Practice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Rest of the World Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For other countries in the
world, the requirements governing the conduct of clinical trials, medical product licensing, pricing and reimbursement vary from country
to country. In all cases if clinical trials are required, they must be conducted in accordance with cGCP requirements and the applicable
regulatory requirements and the ethical principles having their origin in the Declaration of Helsinki.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to comply with applicable
foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product
recalls, seizure of products, operating restrictions and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. <span style="text-decoration:underline">Our Structure</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 4. Information
on the Company &#8211; A. History and Development of the Company.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">D. <span style="text-decoration:underline">Property, plants and equipment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an operating lease
for laboratory in Hong Kong, with 2,021 square feet lab space under a lease that commenced in March 2020, renewed in March 2023 and expires
in March 2026. The monthly rent ranges from $6,348 to $9,068. Payments under operating leases are expensed on a straight-line basis over
the periods of the respective leases, and the terms of the leases do not contain contingent rent and renewal or purchase options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our current facilities
are sufficient to meet our needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5. OPERATING AND FINANCIAL REVIEW AND
PROSPECTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion of
our financial condition and results of operations is based upon and should be read in conjunction with our consolidated financial statements
and their related notes included in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of Item 5, reference
to the &#8220;We&#8221;, &#8220;Our&#8221;, &#8220;Ours&#8221; or &#8220;Group&#8221; means Aptorum Group Limited and all of its subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report includes
consolidated financial statements for the years ended December 31, 2023, 2022, and 2021. However, as permitted by Instruction 6 to Item
5 of Form 20-F, a discussion of the changes in our results of operations for the years ended December 31, 2021 and 2020 has been omitted
from this annual report, but may be found in &#8220;Item 5.&#160;Operating And Financial Review And Prospects&#8221;&#160;in our annual
report on Form 20-F&#160;for the year ended December 31, 2021, filed with the SEC on April 29, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report contains
forward-looking statements that are based on our management&#8217;s beliefs and assumptions and on information currently available to
us. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance
or achievements to be materially different from those expressed or implied by the forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You can identify these forward-looking
statements by words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221;
&#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221;
&#8220;is/are likely to&#8221; or other similar expressions. We have based these forward-looking statements largely on our current expectations
and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business
strategy and financial needs. These forward-looking statements include, among other things, statements relating to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our goals and strategies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our future business development, financial conditions and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our expectations regarding demand for and market acceptance of our products once available;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our expectations regarding our development and commercialization of our therapeutics;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competition in our industry; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">relevant government policies and regulations relating to our industry.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should thoroughly read
this annual report and the documents that we refer to in this annual report with the understanding that our actual results in the future
may be materially different from or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements.
Other sections of this annual report include additional factors which could adversely affect our business and financial performance. Moreover,
we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for our management
to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any
factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Important risks and factors that could cause our actual results to be materially different from our expectations are generally set forth
in &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; and elsewhere in this annual report. We caution you that our businesses
and financial performance are subject to substantial risks and uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking statements
made in this annual report relate only to events or information as of the date on which these statements are made in this annual report.
We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or
otherwise, after the date of this annual report. You should not rely upon forward-looking statements as predictions of future events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. <span style="text-decoration:underline">Operating Results</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage biopharmaceutical
company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs,
particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through
the co-development of Paths<sup>Dx</sup> Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology,
with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore&#8217;s Agency for Science, Technology and Research.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our evaluation of
preliminary data and our consideration of a number of factors including substantial unmet needs, benefits over existing therapies, potential
market size, competition in market, the Company decides how to prioritize its resources among projects. Overall, our rationale for selecting
Lead Projects is not based on any mechanical formula or rigid selection criteria, but instead focused on a combination of the factors
and individual attributes of the Lead Projects themselves. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212; Risks Related
to the Preclinical and Clinical Development of Our Drug Candidates&#8212; &#8220;Preclinical development is a long, expensive and uncertain
process, and we may terminate one or more of our current preclinical development programs.&#8221; and &#8220;Management has discretion
to terminate the development of any of our projects at any time.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current business consists
of &#8220;therapeutics&#8221; and &#8220;non-therapeutics&#8221; segments. However, our focus is on the therapeutics segments. Because
of the risks, costs and extended development time required for successful drug development, we have determined to pursue projects within
our non-therapeutics segments, such as diagnostics technology that may be brought to market and generate revenue more quickly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Therapeutics Segment</span></i>.
In our therapeutics segment (&#8220;Aptorum Therapeutics Group&#8221;), we are currently seeking to develop various drug molecules (including
projects seeking to use extracts or derivatives from natural substances to treat diseases) and certain technologies for the treatment
of human disease conditions to tackle unmet needs, in particular, two of our Lead Projects targeting infectious disease and cancer (including
orphan oncology indications). Aptorum Therapeutics Group is operated through Aptorum&#8217;s wholly-owned subsidiary, Aptorum Therapeutics
Limited, a Cayman Islands exempted company with limited liability, whose principal place of business is in Hong Kong and whose subsidiaries
(who we sometimes refer to herein as project companies) are based in the United Kingdom, Singapore and Hong Kong.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Non-Therapeutics Segment</span></i>.
The non-therapeutics segment (&#8220;Aptorum Non-Therapeutics Group&#8221;) refers to diagnostics projects including Paths<sup>Dx</sup>
Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology. Paths<sup>Dx</sup> Test technology is
currently under co-development with A*STAR. The core objectives of Paths<sup>Dx</sup> Test are to rapidly and accurately identify and
detect existing or emerging unknown pathogens (including DNA/RNA-based viruses such as coronavirus, antibiotic-resistant bacteria, fungi,
etc.), in a cost-effective, unbiased and broad-spectrum manner, through liquid biopsy (patients&#8217; blood samples and is potentially
adaptable for other sample types), genome sequencing and artificial intelligence driven software analytics. A key objective is also to
develop Paths<sup>Dx</sup> Test to leverage existing and emerging Next-Generation Sequencing platforms for pathogenic genome sequencing
analysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to develop a broad
range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components
of our strategy for achieving this goal include: (for details of our strategy, See &#8220;Item 4. Information on the Company &#8211; B.
Business Overview &#8211; Our Strategy&#8221;)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Selectively expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Collaborating with leading academic institutions and CROs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Expanding our in-house pharmaceutical development center;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leveraging our management&#8217;s expertise, experience and commercial networks;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Obtaining and leveraging government grants to fund project development.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have devoted a substantial
portion of the proceeds from our offerings to our Lead Projects. Our Lead Projects are ALS-4, SACT-1 and Paths<sup>Dx </sup>Test. In March
2023, we announced that we completed the Pre-IND discussions with the US FDA on ALS-4. With the positive feedback on the overall development
strategy from the US FDA, we are proceeding towards the IND submission of ALS-4. In March 2023, we also announced the completion of the
End of Phase 1 (EOP1) meeting of SACT-1 with the US FDA. The FDA generally agreed with the chemistry-manufacturing-control (CMC) strategy
and our proposed clinical development plan for SACT-1 Phase 1/2 trials. We commenced clinical validation of our molecular based Paths<sup>Dx</sup>
Test and will continue to undergo validations in parallel with its pre-commercialization process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the second quarter of 2023, the Company made a decision to streamline
its operations by terminating clinic services and suspending non-lead R&amp;D projects. This measure is aimed at optimizing the allocation
of our resources and focusing our efforts on advancing our lead projects, which hold the most promise for commercial success and beneficial
impact. This decision aligns with our commitment to enhance shareholder value and effectively drive our core objectives forward in the
competitive landscape.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Potential Take-Over</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
March 1, 2024, we entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among Company, and YOOV Group
Holding Limited, a BVI business company organized under the laws of British Virgin Islands (&#8220;YOOV&#8221;). The Merger Agreement
was unanimously approved by Company&#8217;s and YOOV&#8217;s boards of directors (each board of directors, the &#8220;Board&#8221;), respectively.
Upon consummation of the transactions contemplated by the Merger Agreement, a wholly-owned subsidiary of the Company organized under the
laws of the British Virgin Islands (&#8220;Merger Sub&#8221;) will merge with and into YOOV, with YOOV surviving the merger as a wholly-owned
subsidiary of Company (collectively, the &#8220;Merger&#8221;). The Company, upon the closing of the Merger, is referred to herein as
the &#8220;combined company.&#8221; Upon consummation of the transaction, YOOV will become a wholly-owned subsidiary of Company, and the
existing YOOV shareholders and existing Company shareholders will own approximately 90% and 10%, respectively, of the outstanding shares
of the combined company. The consummation of this Merger remains uncertain as it is contingent upon the fulfillment of specific closing
conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
obligations of the parties (or, in some cases, some of the parties) to consummate the Merger are subject to the satisfaction or waiver
of certain conditions to closing, including, among other things: (i) obtaining the approval by the shareholders of Aptorum and YOOV of
the matters required under the Merger Agreement, (ii) approval of the Initial Listing Application by Nasdaq, (iii) consummation of the
Separation of ATL, (iv) delivery of legal opinions from British Virgin Islands counsel and Hong Kong counsel of YOOV to Aptorum and Merger
Sub, (v) delivery of legal opinions from Cayman Islands counsel of Aptorum and British Virgin Islands counsel of Merger Sub to YOOV, (vi)
delivery of an opinion by Colliers International (Hong Kong) Limited to the Board of Aptorum to the effect that (subject to various qualifications
and assumptions) the merger consideration (the total Class A ordinary shares and Class B ordinary shares to be issued to YOOV&#8217;s
shareholders) is fair, from a financial point of view (based on the conclusion that the equity value of YOOV is no less than $250 million),
to the shareholders of Aptorum. (vii) availability of audited financial statements for YOOV and its Subsidiaries as of March 31, 2023
and 2022 the related audited consolidated statements of operations, of changes in shareholders&#8217; equity and of cash flows for the
year ended March 31, 2023 and 2022 in conformity with International Financial Reporting Standards, which shall not be materially different
from the unaudited financial statements of YOOV for the same period as presented to Aptorum, as determined by Aptorum in its sole discretion,
(viii) delivery of fully executed lock-up agreement and support agreement by the major shareholder of Aptorum and the delivery of fully
executed lock-up agreement by the directors and officers of YOOV and by the shareholders of YOOV who will beneficially own 5% or more
outstanding shares of the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">In connection with the Merger, on March 1, 2024, the Company entered
into a Split-Off Agreement (the &#8220;Split-Off Agreement&#8221;, the transaction contemplated by the Split-Off Agreement, the &#8220;Separation&#8221;)
by and among the Company, Aptorum Therapeutics Limited (&#8220;ATL&#8221;), and Jurchen Investment Corporation (&#8220;Jurchen&#8221;),
pursuant to which, the Company will assign and transfer the assets and liabilities of its legacy business to ATL, and Jurchen will acquire
100% issued and outstanding shares of ATL from the Company and surrender certain ordinary shares of the Company held by Jurchen to the
Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
closing of the Separation must occur simultaneously with the closing of the Merger, or on a later date, as mutually agreed by the Parties.
The Split-Off Agreement contains conditions precedent to closing of the parties thereto, with respect to, among other things, the following
as applicable to each party:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify"><b>Representations, Warranties and Performance.</b> All representations
and warranties made by the parties in the Split-Off Agreement must have been accurate and truthful, to the best of their knowledge, when
initially made and must remain accurate and truthful, to the best of their knowledge, at the time of the Closing. The parties are obligated
to fulfill all commitments, agreements, and conditions outlined in the Split-Off Agreement to the satisfaction of the parties involved,
with significant emphasis on adherence to these obligations before or at the Closing.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify"><b>Additional Documents.</b> Jurchen shall deliver or cause
to be delivered such additional documents as may be necessary in connection with the consummation of the transactions contemplated by
the Split-Off Agreement and the performance of their obligations hereunder.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify"><b>Release by Buyer and Split-Off Subsidiary.</b> At the Closing,
Jurchen and ATL are required to execute and provide Aptorum with a comprehensive release. This release will absolve Aptorum from all
liabilities and obligations owed to Jurchen or ATL in any capacity, as well as from any claims that Jurchen or ATL may assert against
Aptorum or its related managers, members, officers, directors, shareholders, employees, and agents. However, this release does not cover
liabilities arising from the Split-Off Agreement or any document related to it.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(iv)</td><td style="text-align: justify"><b>Shareholder Approval.</b> Aptorum shall have obtained the
affirmative vote of its shareholders representing at least two-thirds of the voting power of the issued and outstanding ordinary shares
of the Seller entitled to vote at a general meeting of the shareholders voting in person or by proxy, to approve the Split-Off Agreement
and the transaction contemplated herein.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; "></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>At the Market Offering</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 26, 2021, the Company
entered into an at the market offering agreement (the &#8220;Sales Agreement&#8221;), with H.C. Wainwright&#160;&amp; Co., LLC, acting
as our sales agent (the &#8220;Sales Agent&#8221;), relating to the sale of our Class A Ordinary Shares, offered pursuant to the prospectus
supplement and the accompanying prospectus to the registration statement on Form F-3 (File No. 333-268873) (such offering, the &#8220;ATM
Offering&#8221;, or &#8220;At The Market Offering&#8221;). In accordance with the terms of the Sales Agreement, we may offer and sell
shares of our Class A Ordinary Shares having an aggregate offering price of up to $15,000,000 from time to time through the Sales Agent
under such prospectus supplement and the accompanying prospectus. As of the date of this annual report, we have issued 215,959 Class A
Ordinary Shares pursuant to the ATM Offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Private Placement Offering</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Sales of Class A Ordinary
Shares</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 26, 2021, the Company
entered into a private placement shares purchase agreement with Jurchen, issuing 138,793 Class A Ordinary Shares, par value $10 each,
at $28.82 per share, representing a 10% premium to the last closing price of the Company&#8217;s Class A Ordinary Shares on the NASDAQ
stock exchange on that date. The Company received aggregate gross proceeds of $4,000,000 from the purchase of these shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Sales of convertible notes</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 9, 2022, the Company
entered into a securities purchase agreement with Aenco Technologies Limited (&#8220;Aenco&#8221;). Pursuant to the securities purchase
agreement, Aenco is purchasing a convertible note in the original principal amount of $3,000,000 (the &#8220;Dec 2022 Note&#8221;). The
Dec 2022 Note is unsecured, convertible into the Company&#8217;s restricted Class A Ordinary Shares at Aencco&#8217;s option. The Dec
2022 Notes have a maturity date of 12 months subject to the Aenco&#8217;s extension, a bullet interest rate of 7% per annum, and a conversion
price of $12.00 per Class A Ordinary share. The Company shall have an obligation to repay the principal amount and interest of the Dec
2022 Note on the maturity date in cash or in unregistered Class A Ordinary Shares or a combination of such at the Company&#8217;s discretion.
In April 2023, Aenco transferred the whole Dec 2022 Note to two external investors, and the two external investors fully converted the
Dec 2022 Note into 250,000 Class A Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2023, the Company
entered into a securities purchase agreement with 4 investors. Pursuant to the securities purchase agreement, the investors are purchasing
a convertible note in the original principal amount of $3,000,000 (the &#8220;June 2023 Note&#8221;). The whole proceeds from the June
2023 Note was used to settle a related party loan. The June 2023 Note is unsecured, convertible into the Company&#8217;s restricted Class
A Ordinary Shares at the Note holder option. The June 2023 Notes have a maturity date of 12 months subject to the investors extension,
a bullet interest rate of 7% per annum, and a conversion price of $3.00 per Class A Ordinary share. The Company shall have an obligation
to repay the principal amount and interest of the June 2023 Note on the maturity date in cash or in unregistered Class A Ordinary Shares
or a combination of such at the Company&#8217;s discretion. Immediately following the issuance of June 2023 Note, the June 2023 Note was
fully converted into 1,000,000 Class A Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 11, 2023, the
Company entered into a Securities Purchase Agreement with Jurchen Investment Corporation, the largest shareholder of the Company, pursuant
to which the Company sold a secured convertible note in the aggregate principal amount of $3,000,000 (the &#8220;Sep 2023 Notes&#8221;).
The Sep 2023 Notes are convertible into the Company&#8217;s Class A Ordinary Shares and have a maturity date that is 24 months from the
issuance date, although upon such date the investor has the right to extend the term of the Sep 2023 Note for twelve (12) months or more
or such term subject to mutual consent. The Sep 2023 Notes have an interest rate of 6% per annum and a conversion price of $2.42 per share.
The Company has the right to repay the principal amount of the Sep 2023 Notes, but in the case of such prepayment it must be paid in cash,
unless otherwise agreed by both parties. The Sep 2023 Note is secured by a first priority lien and security interest on certain shares
that the Company owns (&#8220;Collateral&#8221;). Upon the Company&#8217;s disposal of all or a portion of the Collateral, the investor
has the right, to request that the Company prepay the then-remaining outstanding balance of the Sep 2023 Note, in part or in full and
the Company can make that payment in cash or in shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Factors Affecting our Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our ability to successfully
develop innovative drug candidates will be the primary factor affecting our long-term competitiveness, as well as our future growth and
development. Creating high quality global first-in-class or best-in-class drug candidates requires significant investment of resources
over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. As a result
of this commitment, our pipeline of drug candidates has been steadily advancing. For more information on the nature of the efforts and
steps necessary to develop our drug candidates, see Item 4.B. &#8220;Business Overview&#8212; Lead Projects, Natural Supplements and Other
Projects under Development.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidates are still
in development, and we have incurred and will continue to incur significant research and development costs for pre-clinical studies and
clinical trials. We expect that our research and development expenses will significantly increase in future periods in line with the advancement
and expansion of the development of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">employee and consultant compensation related expenses, including salaries, benefits and share based compensation expenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expenses incurred for payments to CROs, investigators and clinical trial sites that conduct our clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of acquiring IP rights which did not meet the criteria of capitalization under the U.S. GAAP;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">cost associated with sponsored research programs with various universities and research institutions</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">facilities, depreciation, and other expenses, which include office leases and other overhead expenses; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">costs associated with patent applications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
incurred totaled $5.2 million, $9.2 million and $10.9 million for the years ended December 31, 2023, 2022 and 2021, respectively, representing
approximately 46.6%, 49.0%, and 52.4% of our total operating expenses for the respective period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been able to fund the
research and development expenses for our drug candidates through a range of sources, including the proceeds raised from our public offering
and follow-on offerings on Nasdaq, private placement to other investors and line of credit facilities from shareholders, related parties
and banks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This diversified approach to
funding allows us to not depend on any one method of funding for our research and development activities, thereby reducing the risk that
sufficient financing will be unavailable as we continue to accelerate the development of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Results of Operations for the Years ended
December 31, 2023 and 2022</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the second quarter of 2023, the Company made a decision to streamline
its operations by terminating clinic services and suspending non-lead R&amp;D projects. This measure is aimed at optimizing the allocation
of our resources and focusing our efforts on advancing our lead projects, which hold the most promise for commercial success and beneficial
impact. This decision aligns with our commitment to enhance shareholder value and effectively drive our core objectives forward in the
competitive landscape.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial statements and information
are presented for the years ended December 31, 2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations for the years ended December 31, 2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Healthcare services income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">431,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,295,889</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost of healthcare services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420,812</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,215,824</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,198,329</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,219,595</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,930,637</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,220,405</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,538,161</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,888,140</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,067,690</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(261,038</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,155,629</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,805,002</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on investments in marketable securities, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,266</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(134,134</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized gain from fair value change of the long-term investments,
net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,353,888</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,588,051</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest (expense) income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(121,145</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">146,588</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Sundry income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,799</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">383,506</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,383,276</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,984,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(4,340,975</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(11,525,102</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Impact of COVID-19 Outbreak</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">On
January 30, 2020, the World Health Organization declared the coronavirus outbreak a &#8220;Public Health Emergency of International Concern&#8221;
and on March 10, 2020, declared it to be a pandemic.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">The
coronavirus pandemic continues to have global impacts on workforces, economies, and financial markets. It is not possible for the Company
to predict the duration or magnitude of any adverse effects that the pandemic may have on the Company&#8217;s business or ability to raise funds.
As of the date of this annual report, COVID-19 has had minimal impact on the Company&#8217;s ability to conduct its operations but may impact
the Company&#8217;s ability to raise funding should restrictions related to COVID-19 be expanded in scope.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenue</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare services income was $431,378 and $1,295,889 for the years
ended December 31, 2023 and 2022, which related to the service income derived from clinic. The decline in healthcare services income was
attributed primarily to the decision to terminate clinic services in the second quarter of 2023. This was done to reallocate resources
towards the development of the Company&#8217;s leading projects.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cost of healthcare services</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cost of healthcare services
was $420,812 and $1,215,824 for the years ended December 31, 2023 and 2022, which related to the cost incurred by clinic. The decline
in cost of healthcare services was aligned with the decline in revenue when compared to last period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and development expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth a summary of our research and development
expenses for the years ended December 31, 2023 and 2022. As a consequence of exclusive emphasis on its lead projects and suspension of
non-lead projects, there was a notable decrease in the utilization of external consultants and full impairment of patents related to these
non-lead projects. Moreover, the payroll expenses for research and development staff decreased as a result of the reversal of deferred
cash bonus payables to employees and consultants, and reduction of employees during current period. The reversal was due to the Group&#8217;s
agreements with employees and consultants to discharge the Group&#8217;s obligation to settle their outstanding deferred cash bonus payables
from previous years in exchange of fully vested ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Research and Development Expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Payroll expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">363,139</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,305,363</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Contracted research organizations services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,387,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,709,927</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Sponsored research</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,149</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,061</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Amortization and depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,071,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,064,012</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Consultation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,207,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,423,963</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Loss on disposal and impairments of an intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">519,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205,189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other R&amp;D expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">632,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">494,080</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total Research and Development Expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,198,329</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,219,595</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>R&amp;D expenses by projects</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">ALS-4</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,384,329</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,055,717</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">SACT-1</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">269,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,660,840</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Paths<sup>Dx</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,305,773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296,047</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other projects</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,238,450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,206,991</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,198,329</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,219,595</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General and administrative fees</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
a summary of our general and administrative expenses for the years ended December 31, 2023 and 2022. The decrease in general and administrative
fees was primary due to the reversal of deferred cash bonus payables to employees and reduction of employees during current period. The
reversal was due to the Group&#8217;s agreements with employees to discharge the Group&#8217;s obligation to settle their outstanding
deferred cash bonus payables from previous years in exchange of fully vested ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and Administrative Fees:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 18pt">Payroll expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">893,437</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,793,367</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Rent and rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">213,701</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">265,558</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Travelling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,874</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,357</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Amortization and depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143,498</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 18pt">Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">474,746</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546,675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Advertising and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,082</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">186,098</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">214,868</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total General and Administrative Fees</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,930,637</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,220,405</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Legal and professional fees</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2023 and 2022, the legal and professional fees were $2,538,161 and $2,888,140, respectively. The decrease in legal and professional
fees was mainly due to less consulting services engaged during 2023 as a consequence of exclusive emphasis on its lead projects and suspension
of non-lead projects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other operating expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December 31, 2023 and 2022, the other operating
expenses was $1,067,690 and $261,038, respectively. The increase in other operating expenses was primarily due to impairment losses of
long-lived assets during current period, such as right-of-use assets, which resulted from the decision to terminate clinic services in
the second quarter of 2023, and allowance of credit losses for amount due from related parties, which results from the decision to suspend
non-lead projects owned by the related party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other income, net</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2023 and 2022, the other income, net was $6,383,276 and $5,984,011, respectively.&#160;The increase in other income, net was mainly
due to the increase in unrealized gain from fair value change of the long-term investments, net.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Net loss attributable to Aptorum Group Limited</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2023 and 2022, net loss attributable to Aptorum Group Limited (excluding net loss attributable to non-controlling interests) was $2,824,647
and $9,799,560, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Results of Operations for the Years ended
December 31, 2022 and 2021</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial statements and information
are presented for the years ended December 31, 2022 and 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations for the years ended December 31, 2022 and 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Healthcare services income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,295,889</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,541,778</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost of healthcare services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,215,824</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,459,924</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,219,595</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,869,642</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,220,405</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,409,302</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,888,140</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,617,834</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(261,038</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(392,511</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,805,002</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,749,213</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expenses), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on investments in marketable securities, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(134,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,031,595</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized gain from fair value change of the long-term investments,
net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,588,051</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on investments in derivatives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,289</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on use of digital currencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,918</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gain on derecognition of non-financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">146,588</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,601</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on disposal of subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,638</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Sundry income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">383,506</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">146,347</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,984,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,906,858</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,525,102</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,114,293</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenue</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare services income
was $1,295,889 and $1,541,778 for the years ended December 31, 2022 and 2021, which related to the service income derived from the AML
clinic. The decrease in revenue was mainly due to the number of patients decreased when compared to last year due to one of the general
practitioner did not provide service in our clinic in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cost of healthcare services</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cost of healthcare services
was $1,215,824 and $1,459,924 for the years ended December 31, 2022 and 2021, which related to the cost incurred by the AML clinic. The
decrease in cost of healthcare services was in line with the decrease in revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and development expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
a summary of our research and development expenses for the years ended December 31, 2022 and 2021. The decrease in research and development
expenses was mainly due to the decrease in contracted research organizations services as we are in a planning process for Phase 2 of our
lead projects which does not require many services from contracted research organizations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended<br/>
December&#160;31,<br/>
2022</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended <br/>
December&#160;31, <br/>
2021</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Research and Development Expenses:</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%; padding-left: 9pt"><span style="font-size: 10pt">Payroll expenses</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,305,363</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,320,020</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Contracted research organizations services</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,709,927</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,569,538</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Sponsored research</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">17,061</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">248,865</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Amortization and depreciation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,064,012</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">961,447</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Consultation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,423,963</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,214,824</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Loss on disposal of an intangible asset</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">205,189</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">Other R&amp;D expenses</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">494,080</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">554,948</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total Research and Development Expenses</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">9,219,595</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">10,869,642</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended<br/>
December&#160;31,<br/>
2022</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended <br/>
December&#160;31, <br/>
2021</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">R&amp;D expenses by projects</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">ALS-4</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,055,717</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">5,430,177</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">SACT-1</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,660,840</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,702,955</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">NLS-2</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,028,656</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">934,869</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Other projects</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,474,382</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">801,641</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">9,219,595</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">10,869,642</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General and administrative fees</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
a summary of our general and administrative expenses for the years ended December 31, 2022 and 2021. The decrease in general and administration
fees was mainly due to decrease in payroll expenses due to decrease in number of staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>General and Administrative Fees:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 18pt">Payroll expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,793,367</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,951,421</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Rent and rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">265,558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288,806</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Travelling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,857</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Amortization and depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">231,131</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 18pt">Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,159</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Advertising and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,953</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">214,868</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264,975</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total General and Administrative Fees</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,220,405</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,409,302</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Legal and professional fees</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2022 and 2021, the legal and professional fees were $2,888,140 and $2,617,834, respectively. The increase in legal and professional
fees was mainly due to more consulting services engaged during 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other operating expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2022 and 2021, the other operating expenses was $261,038 and $392,511, respectively. The decrease in other operating expenses was
mainly due to an impairment loss on other receivables in 2021 while there were no such expenses in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other income (expenses), net</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2022 and 2021, the other income (expenses), net was $5,984,011 and $(7,906,858), respectively.&#160;The other income, net in 2022
was mainly consists of unrealized gain from fair value change of the long-term investments, net and government subsidies; while the other
expenses, net in 2021 was mainly consists of loss on investment in marketable securities, net.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Net loss attributable to Aptorum Group Limited</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2022 and 2021, net loss attributable to Aptorum Group Limited (excluding net loss attributable to non-controlling interests) was $9,799,560
and $25,048,389, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">B. <span style="text-decoration:underline">Liquidity and Capital Resources</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group reported a net loss
of $4,340,975 and net operating cash outflow of $7,724,364 for the year ended December 31, 2023. In addition, the Group had an accumulated
deficit of $68,161,722 as of December 31, 2023. The Group&#8217;s operating results for future periods are subject to numerous uncertainties
and it is uncertain if the Group will be able to reduce or eliminate its net losses for the foreseeable future. If management is not able
to generate significant revenues from its product candidates currently in development, the Group may not be able to achieve profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s principal
sources of liquidity have been cash, line of credit facility from related parties, bank loan, public offerings and convertible bonds.
As of the date of issuance of the consolidated financial statements, the Group has approximately $1.0 million of unrestricted cash or
cash equivalents, and approximately $12 million of undrawn line of credit facility from a related party. In addition, the Group will need
to maintain its operating costs at a level through strict cost control and budget, such as staff reductions, to ensure operating costs
are minimized and will not exceed such aforementioned sources of funds to continue as a going concern for a period within 12 months after
the issuance of its consolidated financial statements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group believes that available
cash, together with the efforts from aforementioned management plan and actions, should enable the Group to meet current anticipated cash
needs for at least the next 12 months after the date that the consolidated financial statements are issued and the Group has prepared
the consolidated financial statements on a going concern basis. The Group may, however, need additional capital in the future to fund
its continued operations. If the Group determine that its cash requirements exceed the amount of cash and cash equivalents the Group has
at the time, the Group may seek to issue equity or debt securities or obtain credit facilities. The issuance and sale of additional equity
or convertible debts would result in further dilution to its shareholders. The incurrence of indebtedness would result in increased fixed
obligations and could result in operating covenants that might restrict its operations. The Group cannot assure that the financing will
be available in amounts or on terms acceptable to the Group, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Condensed Summary of Cash Flows for the
Years Ended December 31, 2023 and 2022</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,724,364</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(12,318,965</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">624,767</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,444,896</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,092,068</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,625,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net decrease in cash and cash equivalents
    and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3,007,529</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3,248.607</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Operating activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities amounted to $7.7 million and $12.3 million for the years ended December 31, 2023 and 2022. The net cash used in operating activities
declined due to the implementation of stringent budgetary control measures, as a result of the Company&#8217;s exclusive emphasis on its lead
projects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investing activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities amounted to $0.6 million and $2.4 million for the years ended December 31, 2023 and 2022. The decrease in net cash provided
by investing activities was due to the decrease in net cash repayment from loan to related parties by $2.1 million, which was partially
mitigated by a $0.2 million decrease in capital expenditures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Financing activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities amounted to $4.1 million and $6.6 million for the year ended December 31, 2023 and 2022. The decrease in net cash inflow from
financing activities was primarily a result of the repayment of a bank loan in the amount of $3.0 million and decrease in loan from bank
of $3.0 million, partially mitigated by a $2.0 million increase in loan from a related party, and a $1.6 million increase in proceeds
from issuance of Class A Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Condensed Summary of Cash Flows for the
Years Ended December 31, 2022 and 2021</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(12,318,965</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14,651,633</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,444,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,507,039</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,625,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,780,725</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net (decrease) increase in cash and cash equivalents and restricted
cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3,248.607</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,636,131</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Operating activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities amounted to $12.3 million and $14.7 million for the years ended December 31, 2022 and 2021. The decrease in net cash used in
operating activities is mainly due to our net loss excluding non-cash items decreased by $2.0 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investing activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities amounted to $2.4 million and $16.5 million for the year ended December 31, 2022 and 2021. The decrease in net cash provided
by investing activities was due to there was a proceeds from disposal of investment in marketable securities of $20.1 million in 2021,
partly offset by a loan provided to a related party of $3.4 million in 2021 and a repayment of loan from a related party of $3.0 million
in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Financing activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities amounted to $6.6 million and $2.8 million for the year ended December 31, 2022 and 2021. The increase in net cash provided
by financing activities was due to there was a loan repayment due to related parties of $5.5 million in 2021, partly offset.by decrease
in total proceeds from issuance of shares, warrants and debts by $1.6 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CAPITAL EXPENDITURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capital expenditures were
$3,000, $0.2 million and $0.1 million for the years ended December 31, 2023, 2022 and 2021, respectively. These capital expenditures were
incurred primarily for investments in facilities, leasehold improvements, equipment and technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>COMMITMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
our contractual obligations as of December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payment Due by Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">less than<br/> one year</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">One to<br/> three years</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three to<br/> five years</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating lease commitments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">242,938</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120,824</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">122,114</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Debt obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,360,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,360,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,602,938</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">120,824</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,482,114</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Operating lease commitments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have two operating leases
for laboratories and clinic as of December 31, 2023. Operating lease commitments reflect our obligation to make payments under these operating
leases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Debt obligations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Debt obligations reflects outstanding
principal and accrued interest payable to Jurchen Investment Corporation, the largest shareholder of the Company, pursuant to a convertible
note arrangement. This instrument features a conversion option at a price of $2.42 per share into the Company&#8217;s Class A Ordinary
Shares. It carries a two-year maturity from the date of issuance and bears an annual interest rate of 6%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group can access up to
a total $12 million under a line of credit offered by Aeneas Group Limited. The line of credit was originally mature on August 12, 2022.
The Group and Aeneas Group Limited has mutually agreed to extend the line of credit arrangement further 3 years to August 12, 2025. The
interest on the outstanding principal indebtedness is at the rate of 8% per annum. The Group may early repay, in whole or in part, the
principal indebtedness and all interest accrued at any time prior to the maturity date without the prior written consent of the lender
and without payment of any premium or penalty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>CONTINGENT PAYMENT OBLIGATIONS</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, the
Group does not have any non-cancellable purchase commitments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has contingency payment
obligations under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain
condition or milestone is met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Milestone payments are due
upon achievements of specific conditions, such as Investigational New Drugs (&#8220;IND&#8221;) filing or U.S. Food and Drug Administration
(&#8220;FDA&#8221;) approval, first commercial sale of the licensed products, or other achievements. The aggregate amounts of the contingent
milestone payments that the Group is required to pay up to different achievements of conditions and milestones under all license agreements
in effect as of December 31, 2023 are below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Drug molecules: up to the conditions and milestones of</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">Preclinical to IND filing</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">132,564</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">From entering phase 1 to before first commercial sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,376,410</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">First commercial sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,882,051</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net sales amount more than certain threshold in a year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,769,231</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,160,256</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Diagnostics technology: up to the conditions and milestones of</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Before FDA approval</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208,656</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">74,368,912</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended
December 31, 2023, 2022 and 2021, the Group incurred $50,000, $nil and $nil milestone payments under license agreements, respectively. For the years ended
December 31, 2023, 2022 and 2021, the Group did not incur any royalties or research and development funding, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">C. <span style="text-decoration:underline">Research and Development, Patents and Licenses, etc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual
report, the Company has 2 exclusively licensed technologies in the area of neurology, infectious diseases, oncology, and diagnostics.
In addition, the Company is actively developing 1 proprietary technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2023, 2022, and 2021, the Group incurred $5,198,329, $9,219,595, and $10,869,642, respectively, on research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. <span style="text-decoration:underline">Trend Information</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as disclosed elsewhere
in this annual report, we are not aware of any material recent trends in production, sales and inventory, the state of the order book
and costs and selling prices since our last fiscal year. We are also unaware of any known trends, uncertainties, demands, commitments
or events for the year ended December 31, 2023 that are reasonably likely to have a material adverse effect on our revenues, net income,
profitability, liquidity or capital resources, or that would cause reported financial information not necessarily to be indicative of
future operating results or financial conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E. <span style="text-decoration:underline">Critical Accounting Estimates</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial statements have been prepared in accordance
with U.S. GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
revenues and expenses, and related disclosures of contingent liabilities in the consolidated financial statements and accompanying notes.
We base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities. Changes in the economic environment,
financial markets, and any other parameters used in determining such estimates could cause actual results to differ. The critical accounting
estimates should be read in conjunction with our risk factors as disclosed in &#8220;Item 3. Key Information&#8212;D. Risk Factors.&#8221;
See note 3 to our consolidated financial statements for the year ended December 31, 2023 for more information. Out of our significant
accounting policies, which are described in Note 3&#8212;Summary of Significant Accounting Policies of our consolidated financial statements
included elsewhere in this Form 20-F, certain accounting policies and practices are deemed &#8220;critical,&#8221; as they require management&#8217;s
highest degree of judgment, estimates and assumptions, including (i) impairment of long-lived assets; (ii) share based compensation, and
(iii) allowance of credit losses (iv) fair value of long-term investment and (v) provision of income tax and valuation allowance for deferred
tax asset. We believe that the following estimates are critical accounting estimates that involve the most significant judgments used
in the preparation of our financial statements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Impairment of long-lived assets</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Long-lived assets or asset
group, including intangible assets with finite lives, are evaluated for impairment whenever events or changes in circumstances (such as
a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an
asset may not be fully recoverable or that the useful life is shorter than we had originally estimated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We primarily consider the
following factors when evaluating impairment:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">significant underperformance relative to projected operating
results;</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">significant changes in the overall business strategy;</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">significant adverse changes in legal or business environment;
and</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">significant competition, unfavorable industry trends, or economic
outlook.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When these events occur, we
evaluate the impairment for the long-lived assets by comparing the carrying value of the assets to an estimate of future undiscounted
cash flows expected to be generated from the use of the assets and their eventual disposition. If the sum of the expected future undiscounted
cash flows is less than the carrying value of the assets, we recognize an impairment loss based on the excess of the carrying value of
the assets over the fair value of the assets. The sum of the expected undiscounted cash flow is sensitive to key assumption such as projected
revenue and research and development expenses, which are required management&#8217;s judgement. For the year ended December 31, 2023,
we recorded total $519,496 and $230,885 impairments of long-lived assets, such as licensed patents, medical equipment and right-of-use
assets, in research and development expenses and other operating expenses, respectively, due to our decision to streamline its operations
by terminating clinic services and suspending non-lead R&amp;D projects. For the years ended December 31, 2022 and 2021, no impairment
loss was recorded.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Allowance for credit losses</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The allowance for credit losses
is management&#8217;s estimate of expected losses over the life of our receivable portfolio calculated using loss forecast models that
take into consideration historical credit loss experience, current economic conditions and forecasts and scenarios that capture industry-specific
economic factors. In addition, we consider qualitative factors not able to be fully captured in our loss forecast models, including borrower-specific
and company-specific factors. These qualitative factors are subjective and require a degree of management judgment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We measure the allowance for
credit losses on a collective (pool) basis when similar risk characteristics exist and on an individual basis when we determine that similar
risk characteristics do not exist. We identify receivables for individual evaluation based on past due status and information available
about the debtors, such as financial statements, as well as general information regarding the economic environment. The allowance for
credit losses attributable to receivables that are individually evaluated is based on the present value of expected future cash flows
discounted at the receivables&#8217; effective interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While management believes it has exercised prudent judgment and applied
reasonable assumptions, there can be no assurance that in the future, changes in economic conditions or other factors would not cause
changes in the financial health of our debtors. If the financial health of our debtors deteriorates, the timing and level of payments
received could be impacted and therefore, could result in a change to our estimated losses. As of December 31, 2023 and 2022, $521,007
and $71 allowance for credit losses were made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Share based compensation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use the fair value method
of accounting for our share options granted to directors, employees, external consultants and advisors to measure the cost services received
in exchange for the share based awards. Determining the appropriate valuation model and estimating the fair values of share option grants
requires the input of subjective assumptions, including expected share price volatility, risk-free interest rate, expected term from grant
date, dividend rate, and dilution factor. The expected volatility assumption is based partially upon the historical volatility of our
Class A ordinary shares, which may or may not be a true indicator of future volatility. The assumptions used in calculating the fair values
of share option grants represent management&#8217;s best estimates, but these estimates involve inherent uncertainties and the application
of judgment. As a result, if factors change and different assumptions are used, share-based compensation expense could be significantly
different from what we recorded in the current period. Share-based compensation expense is recognized on a graded vesting basis, net of
actual forfeitures in the period. In connection with the grant of share options to employees and non-employees, we recorded share-based
compensation charges of $697,446 and $391,479, respectively, for the year ended December 31, 2023, $1,123,122 and $523,877, respectively,
for the year ended December 31, 2022, $1,203,000 and $479,460, respectively, for the year ended December 31, 2021. We accounted for exchange
share awards or share options as a modification to share based compensation which required the remeasurement of existing share options
value at the time of the modification. The total incremental cost as a result of the modification was $0.7 million, $nil and $nil for
the years ended December 31, 2023, 2022 and 2021, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Provision of income tax
and valuation allowance for deferred tax asset</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant judgment is required
in determining income tax expense based on tax laws in the various jurisdictions in which we operate. In calculating our effective income
tax rate, estimates are required regarding the timing and amount of taxable and deductible items which will adjust the pre-tax income
or loss reported in various tax jurisdictions. Through our interpretation of local tax regulations, adjustments to pre-tax income or loss
for income or loss reported in various tax jurisdictions are reflected within various tax filings. Although we believe that our estimates
and judgments discussed herein are reasonable, actual results may be materially different than the estimated amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We record a valuation allowance
to reduce our deferred tax assets to the amount that is more likely than not to be realized. Significant judgment is required in determining
the valuation allowance. In assessing the need for a valuation allowance, we consider all sources of taxable income, including projected
future taxable income, reversing taxable temporary differences and ongoing tax planning strategies. If it is determined that we are able
to realize deferred tax assets in excess of the net carrying value or to the extent we are unable to realize a deferred tax asset, we
would adjust the valuation allowance in the period in which such a determination is made, with a corresponding increase or decrease to
earnings. As of December 31, 2023 and 2022, we have made full valuation allowance to deferred tax assets with amount of $17.4 million
and $15.7 million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. <span style="text-decoration:underline">Directors and Senior Management</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below is a list of our directors,
senior management and any employees upon whose work we are dependent as of the date of this annual report, and a brief account of the
business experience of each of them. The business address for the directors and officers of Aptorum Group Limited is 17 Hanover Square,
London, W1S 1BN, United Kingdom.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023, Dr. Thomas Lee
resigned from his position as Head of Research and Development of Aptorum Group due to personal reason.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, Mr. Darren
Lui and Dr. Clark Cheng resigned from their positions as executive directors and key officers. Concurrently, Mr. Ian Huen, a current director
of the Company, took on the role of Chief Executive Officer. Mr. Huen previously served as the Company&#8217;s Chief Executive Officer
from October 2017 until his prior resignation in June 2022. With his extensive experience and contributions to the Company during significant
events, the Board is confident that Mr. Huen will play a crucial role in realizing the Company&#8217;s full potential.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 63%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><i>Executive Officers</i></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Ian Huen</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">44</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Founder, Chief Executive Officer and Executive Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Martin Siu</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">45</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Head of Finance</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><i>Non-Management Directors</i></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Charles Bathurst</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">68</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Independent Non-Executive Director and Chair of Audit Committee</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Mirko Scherer</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">55</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Independent Non-Executive Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Justin Wu</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">54</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Independent Non-Executive Director and Chair of Compensation Committee</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Douglas Arner</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">54</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Independent Non-Executive Director and Chair of Nominating and Corporate Governance Committee</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Executive Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>MR. IAN HUEN, Founder, Chief Executive Officer
and Executive Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Ian Huen is the Founder,
Chief Executive Officer and an Executive Director of Aptorum Group Limited. Mr. Huen previous served as Non-Executive Director of Aptorum
Group from June 2022 to November 2023, and as Chief Executive Officer and Executive Director of Aptorum Group Limited from October 2017
to May 2022. He has extensive experience in global asset management and previously covered the U.S. healthcare sector as an equity research
analyst at Janus Henderson Group plc (formerly known as Janus Capital). Mr. Huen was the financial advisor in the sale of Seng Heng Bank
Limited (Macau) to Industrial and Commercial Bank of China in 2007 and was appointed as the vice president of the Board of General Meeting
in Industrial and Commercial Bank of China (Macau) Capital Limited in March 2007 for a term of 12 years until March 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a trustee board member of
the Dr. Stanley Ho Medical Development Foundation, Mr. Huen facilitates advisory, development funding, access to research resources across
Asia and continues to establish relationships with leading academic institutions to propel innovations in healthcare.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Huen graduated from Princeton
University with an A.B. degree in Economics in June 2001, earned a MA in Comparative and Public History from CUHK in June 2016. Mr. Huen
is also a Chartered Financial Analyst (&#8220;CFA&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>MR. MARTIN SIU, Head of Finance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Martin Siu is the Head
of Finance of Aptorum Group Limited since July 2022. Prior to that, Mr. Siu supported over 8 listed companies and licensed corporations
in Asia as consultant, advisor and financial manager. Extensively experienced in audit and financial strategy, he worked in the field
of audit for over 18 years, also led a professional team to provide strategic consultancy services to sizable corporate clients specialized
in audit, compliance, risk management, financial reporting and fund raising. Mr. Siu is a certified public accountant and graduated with
a BBA (Hons) in Accounting at City University of Hong Kong in 2001.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Executive Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>MR. CHARLES BATHURST</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Bathurst is an Independent
Non-Executive Director of Aptorum Group Limited, chairs the Audit Committee and is a member of both the Compensation Committee and the
Nominating and Corporate Governance Committee. He has over 48 years&#8217; experience of management and senior executive roles across
the financial services, technology and healthcare industries. In 2011, he set up his own independent consultancy service, Summerhill Advisors
Limited, advising on management structure, business development, financial reporting, internal audit controls and compliance to both emerging
and multinational companies. Today he holds Non-Executive and Advisory board positions on fast-growing companies in healthcare, technology
and financial services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to establishing Summerhill,
he served as a Director for J.O. Hambro Investment Management from September 2008 to August 2011, where he oversaw the restructuring and
commercialization of a range of in-house investment funds. He was appointed to the management board and supervised reporting teams including
Business development, accounting, regulatory reporting and internal controls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From April 2004 to March 2008,
Mr. Bathurst served in multiple roles at Old Mutual Asset Managers (UK), including being a member of the senior management team and head
of international sales. Duties included business development, launching new investment funds, recruitment, establishing and supervision
of regulatory and financial reporting teams, as well as ensuring compliance with funds&#8217; regulatory requirements and corporate governance
standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this, Mr. Bathurst
was an advisor to Lion Capital Advisors Limited from April 2003 to March 2004, and from June 2002 to March 2003 business development consultant
reporting to the board of management of LCF Rothschild Asset Management Limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From April 1995 to March 2002,
Mr. Bathurst joined a newly formed alternative investment management team at Credit Agricole Asset Management, establishing the London
Branch as the Managing Director in 1998. He was responsible for the recruitment and development strategy for marketing, sales, investment,
financial reporting, compliance and regulatory controls and investor relations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between the period of September
1989 and December 1994, Mr. Bathurst worked for GNI, the largest futures and options execution and clearing broker on the London International
Financial Futures Exchange, where he focused on marketing to European and Middle East financial institutions. In 1991, he joined a new
management team to launch a series of specialist investment funds while serving as the Head of Sales and Product Development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Bathurst graduated from
the Royal Military Academy Sandhurst in November 1974 and commissioned into the British Army serving in the UK and Germany.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>DR. MIRKO SCHERER</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Mirko Scherer is an Independent
Non-Executive Director of Aptorum Group Limited. Dr. Scherer has been serving as the Chief Executive Officer at CoFeS China (formerly
known as &#8220;TVM Capital China&#8221;) in Hong Kong since March 2015. CoFeS China focuses on cross-border activities in the life science
industry between China and the West. CoFeS China acts as a bridge between China and the West, assisting Chinese investors and pharmaceutical
companies accessing western innovations, while collaborating with innovative life science companies from the West to enter the fast-growing
China market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Scherer has served on the
Board of the Frankfurt Stock Exchange from 2005 to 2007 and has been a board member of the Stichting Preferente Aandelen QIAGEN since
2004. From August 2016 through July 2018, Dr. Scherer served as a Non-Executive board member of Quantapore Inc. and from April 2015 through
September 2017, he was a director of China BioPharma Capital I, (GP).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Scherer is an experienced
biotechnology executive and has led numerous financing M&amp;A and licensing transactions, in both public and private markets, in Europe
and the U.S. for over 20 years. He consulted MPM Capital for the period between July 2012 and December 2014. Dr. Scherer was also a co-founder
and partner of KI Kapital from November 2008 to February 2014, a company which was specialized in providing consultation in life science
industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to working in the venture
capital industry, Dr. Scherer co-founded GPC Biotech (Munich and Princeton, NJ) and served as the Chief Financial Officer from October
1997 to December 2007. GPC Biotech engaged in numerous pharmaceutical alliances with companies such as Sanofi Aventis, Boehringer Ingelheim,
Altana (now part of Takeda), Yakult, and Pharmion (now part of Celgene). Over the past 20 years, Dr. Scherer has established an extensive
network in the U.S., European, and China&#8217;s biotechnology and venture capital industry. Prior to his time at GPC Biotech, Dr. Scherer
worked as a consultant from May 1993 to June 1994 at the Boston Consulting Group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Scherer earned a Doctorate
in Finance from the European Business School in Oestrich-Winkel/Germany in 1998, a MBA from Harvard Business School in June 1996, and
a degree in Business Administration from the University of Mannheim/Germany in February 1993.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>PROFESSOR JUSTIN WU</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Professor Justin Wu is an Independent
Non-Executive Director of Aptorum Group Limited. He also has been serving as the Chief Operating Officer of CUHK Medical Centre since
August 2018. He served as the Associate Dean (Development) of the Faculty of Medicine at CUHK from July 2014 to June 2018 and the Associate
Dean (Clinical) of the Faculty of Medicine at CUHK from December 2012 to July 2014, and has been serving a Professor in the Department
of Medicine and Therapeutics since 2009, also the Director of the S. H. Ho Center for Digestive Health, a research center specializing
in functional gastrointestinal diseases, reflux and motility disorders, and digestive endoscopy. Active in research publications and assessments,
Professor Wu served as the International Associate Editor of American Journal of Gastroenterology (&#8220;AJG&#8221;), and Managing Editor
of Journal of Gastroenterology and Hepatology (&#8220;JGH&#8221;). He is also the Secretary General of the Asian Neurogastroenterology
and Motility Association (&#8220;ANMA&#8221;), and Secretary General of the Asia Pacific Association of Gastroenterology (&#8220;APAGE&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Professor Wu has won a number
of awards including the Emerging Leader in Gastroenterology Award by the JGH Foundation, and the Vice Chancellor&#8217;s Exemplary Teaching
Award at CUHK. Aside from his expertise in gastroenterology, Professor Wu has an extensive interest in the development of Integrative
Medicine in Hong Kong. He is the Founding Director of the Hong Kong Institute of Integrative Medicine, working closely with the School
of Chinese Medicine to develop an integrative model at an international level. The institute aims at maximizing the strength of Western
and Chinese medicine to provide a safe and effective integrative treatment to patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Professor Wu served as a consultant
and an advisory board member for Takeda Pharmaceutical, AstraZeneca, Menarini, Reckitt Benckiser and Abbott Laboratory. He earned his
Bachelor of Medicine and Bachelor of Surgery Degree (1993), and his Doctor of Medicine Degree (2000) from CUHK. Additionally, he attained
Fellowships of the Royal College of Physicians of Edinburgh and London in 2007 and 2012 respectively, Fellowship of the Hong Kong College
of Physicians in 2002, Fellowship of the Hong Kong Academy of Medicine in 2002, and has been an American Gastroenterological Association
Fellow since 2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>PROFESSOR DOUGLAS ARNER</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Professor Douglas W. Arner
is an Independent Non-Executive Director of Aptorum Group Limited. Douglas is the Kerry Holdings Professor in Law and Director and co-founder
of the Asian Institute of International Financial Law at the University of Hong Kong, as well as Faculty Director and co-founder of the
LLM in Compliance and Regulation, LLM in Corporate and Financial Law, and Law, Innovation, Technology and Entrepreneurship (LITE) Programmes.
He served as Head of the HKU Department of Law from 2011 to 2014 and as Co-Director of the Duke University-HKU Asia-America Institute
in Transnational Law from 2005 to 2016. Douglas has published eighteen books and more than 200 articles, chapters and reports on international
financial law and regulation, most recently Reconceptualising Global Finance and its Regulation (Cambridge 2016) (with Ross Buckley and
Emilios Avgouleas) and The RegTech Book (Wiley 2019 (Janos Barberis and Ross Buckley). His recent papers are available on SSRN at https://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfm?per_id=524849,
where he is among the top 75 authors in the world by total downloads. Professor Arner led the development of Introduction to FinTech &#8211;
launched with edX in May 2018 and now with over 80,000 learners spanning the world &#8211; and the foundation of the edx-HKU Online Professional
Certificate in FinTech. He is a Senior Visiting Fellow of Melbourne Law School, University of Melbourne, a non-executive director of NASDAQ
and Euronext listed Aptorum Group and an Advisory Board Member of the Centre for Finance, Technology and Entrepreneurship (CFTE). Professor
Arner was an inaugural member of the Hong Kong Financial Services Development Council (2013-2019) and has served as a consultant with,
among others, the World Bank, Asian Development Bank, APEC, Alliance for Financial Inclusion, and European Bank for Reconstruction and
Development. He has lectured, co-organised conferences and seminars and been involved with financial sector reform projects around the
world. Professor Arner has been a visiting professor or fellow at Duke, Harvard, the Hong Kong Institute for Monetary Research, IDC Herzliya,
McGill, Melbourne, National University of Singapore, University of New South Wales, Shanghai University of Finance and Economics, and
Zurich, among others. Professor Arner is the Senior Regulatory&#160;&amp; Strategic Advisor of Aeneas Group, a multi-disciplinary financial
services institution with technology-driven growth initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">He holds a BA from Drury College
(where he studied literature, economics and political science) in 1992, a JD (cum laude) from Southern Methodist University in 1995, an
LLM (with distinction) in banking and finance law from the University of London (Queen Mary College) in 1996, and a PhD from the University
of London in 2005.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. <span style="text-decoration:underline">Compensation of Executive Directors and
Executive Officers</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
all cash compensation paid by us, as well as certain other compensation paid or accrued, in fiscal 2023 to each of the following named
executive officers. The total amount was $1.0 million in 2023. A total 403,820 options were awarded to executive directors and executive
officers in 2023. This amount does not include business travel, relocation, professional and business association dues, and expenses reimbursed
to such persons, and other benefits commonly reimbursed or paid by companies in our industry. (See &#8220;Item 6. Directors, Senior Management
and Employees &#8211; E. Share Ownership&#8221;)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with mutual agreements reached with the board of directors,
Mr. Clark Cheng and Mr. Ian Huen has agreed to forgo their monthly remuneration effective July 1, 2023 until further notice. Additionally,
Mr. Darren Lui and CGY Investments Limited have consented to suspend their monthly remuneration from August 1, 2023 until further notice.
Before the suspension of remuneration, Mr. Clark Cheng, Mr. Ian Huen, and Mr. Darren Lui had a monthly remuneration of $6,410, $27,333
and $6,667, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, Mr. Darren
Lui and Dr. Clark Cheng resigned from their positions as executive directors and key officers. Concurrently, Mr. Ian Huen, a current director
of the Company, took on the role of Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The base salary of Mr. Martin
Siu was set forth in an Operations Services &amp; Secondment Agreement between Aptus Management Limited and MG Consultancy Limited (&#8220;MG&#8221;),
through which Mr. Siu provides his services. MG charges an initial monthly fee of approximately USD7,600, which may be increased to approximately
USD12,700 during the term of the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The base salary of all directors
and senior officer remains unchanged in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fiscal <br/> Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Salary<br/> ($) <sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<br/> Awards<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Non-Equity<br/> Incentive<br/> Plan<br/> Compensation<br/> ($)<sup>(8)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change in <br/> Pension<br/> Value&#160;and<br/> Nonqualified <br/> Deferred <br/> Compensation <br/> Earnings<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other<br/> Compensation<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt"><b>Ian Huen <sup>(2)<br/> </sup>(CEO)</b></span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt"><b>Martin Siu <sup>(3)<br/> </sup>(Head of Finance)</b></span></td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: center">2023</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">92,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">92,308</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt"><b>Darren Lui <sup>(4)<br/> </sup>(former CEO and CAO)</b></span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">359,347</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt"><b>Clark Cheng <sup>(5) (6)<br/> </sup>(former CMO)</b></span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">185,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,257</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,725</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt"><b>Thomas Lee <sup>(7) <br/> </sup>(former Head of R&amp;D)</b></span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249,250</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Appointment Letters provide salaries in HKD; for purposes of this table, we used a conversion ratio of HKD7.80 to USD1.00 to determine the salary in USD.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mr. Huen is the founder of Aptorum Group, and was re-appointed as Chief Executive Officer and Executive Officer in November 2023. He was previously appointed as non-executive director from June 2022 to November 2023, and appointed as the Chief Executive Officer and Executive Director from October 2017 to May 2022. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mr. Siu was appointed as Head of Finance of Aptorum Group from July 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mr. Lui served as the Chief Executive Officer and Chief Accounting Officer from June 2022 to November 2023. Before that, Mr. Lui served as Chief Business Officer and President of Aptorum Group from October 2017 to May 2022, and Chief Business Officer from October 2017 to October 2019.&#160;&#160;CGY is 50% held by Seng Fun Yee, 25% held by Mandy Lui and 25% held by Adrian Lui (all of whom are related to our former CEO, Mr. Darren Lui). Mr. Lui controls and/or has substantial influence on the disposition and voting rights of the shares held by his spouse, but no such control over the shares held by his sister or brother. Hence, for the purposes of this filing and disclosure, 50% of the consulting service fee and share options are deemed as Mr. Lui&#8217;s compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dr. Cheng served as the Chief Medical Officer of Aptorum Group from January 2018 to November 2023. Dr. Cheng is the sole director and shareholder of ACC Medical Limited. Hence, for the purposes of this filing and disclosure, the consulting service fee and share options granted to ACC Medical Limited are deemed as Dr. Cheng&#8217;s compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pursuant to Dr. Cheng&#8217;s appointment letter, Dr. Cheng received a share bonus of 526 ordinary shares of AML, representing 5% of AML&#8217;s issued and outstanding ordinary shares (the &#8220;Share Bonus&#8221;) in 2018. Based on the Company&#8217;s financial position and Dr. Cheng&#8217;s performance, on each anniversary of Dr. Cheng&#8217;s employment commencement date, the Share Bonus is eligible to increase by 1% of AML&#8217;s then issued and outstanding ordinary share count per year up to a maximum additional amount of 5% of AML&#8217;s then issued and outstanding ordinary share count by the 5<sup>th</sup> anniversary from his employment commencement date. As of the date of this annual report, Dr. Cheng received a total of 1,111 ordinary shares of AML, representing 10% of AML&#8217;s issued and outstanding ordinary shares; during fiscal 2023, Dr. Cheng received 122 ordinary shares with cash value of which is USD122.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dr. Lee served as the Head of Research &amp; Development of Aptorum Group from April 2019 to June 2023. Before that, he was the Chief Executive Officer and Chief Scientific Officer of Aptorum Therapeutics Limited, a wholly owned therapeutics subsidiary of Aptorum Group Limited from January 2018 to March 2019. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents deferred bonuses provided to directors and executive officers, which will be vested after 9.5 months &#8211; 21.5 months vesting period.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation of Non-executive Directors</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information for the fiscal year ended December 31, 2023, regarding the compensation of our non-executive directors who at December 31,
2023, were not also named executive officers. A total 89,556&#160;Class A Ordinary Shares were awarded to non-executive directors in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with mutual
agreements reached with the board of directors, Mr. Ian Huen has agreed to forgo their monthly remuneration effective July 1, 2023 until
further notice. Additionally, Mr. Charles Bathurst, Dr. Mirko Scherer, Professor Justin Wu and Professor Douglas Arner have consented
to suspend their monthly remuneration from September 1, 2023 until further notice. Before the suspension of remuneration, Mr. Ian Huen
had a monthly remuneration of $27,333.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees&#160;Earned<br/> or&#160;Paid<br/> in&#160;Cash<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<br/> Awards<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<br/> Awards<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity<br/> Incentive Plan<br/> Compensation<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-qualified<br/> Deferred<br/> Compensation<br/> Earnings<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other<br/> Compensation<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 16%; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Ian Huen <sup>(6)</sup></b></span></td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">164,000</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">-</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">233,367</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">397,367</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Charles Bathurst&#160;<sup>(1)</sup></b></span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">31,673</td><td style="font-weight: bold; text-align: left"><sup>(2)</sup></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">18,441</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">50,114</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Mirko Scherer&#160;<sup>(3)</sup></b></span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">21,115</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">18,441</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">39,556</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Justin Wu&#160;<sup>(4)</sup></b></span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">21,115</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">18,441</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">39,556</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Douglas Arner&#160;<sup>(5)</sup></b></span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">21,115</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">18,441</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">39,556</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mr. Bathurst was appointed as one of our directors as of October 2017 and is entitled to receive $50,676 annually for his combined services as a director and a committee member effective from January 1, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mr. Bathurst&#8217;s appointment Letter provides his salary in GBP. For purposes of this table, we used a conversion ratio of GBP0.8 to USD1.00 to determine his salary in USD; however, the ultimate amount paid is based on the actual rate as of the relevant pay day at the end of each month.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dr. Scherer was appointed as one of our directors as of October 2017 and is entitled to receive $31,673 annually for his services as a director effective from January 1, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Professor Wu was appointed as one of our directors as of October 2017 and is entitled to receive $31,673 annually for his combined services as a director and a committee member effective from January 1, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Professor Arner&#8217;s appointment as one of our directors became effective as of April 1, 2018, and is entitled to receive $31,673 annually for his combined services as a director and a committee member effective from January 1, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">From November 2023, Mr. Huen was re-appointed as Chief Executive Officer and Executive Officer of Aptorum Group whereas all other previous employment terms and conditions remain unchanged. Before that, Mr. Huen served as a non-executive director from June 2022 to November 2023. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2017 Share Option Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 13, 2017, we adopted
the 2017 Share Option Plan (the &#8220;Option Plan&#8221;) and on November 5, 2021, we amended the Option Plan. Under the Option Plan,
up to an aggregate of 550,000 Class A Ordinary Shares (subject to subsequent adjustments described more fully below) may be issued pursuant
to awards under the Option Plan. Subsequent adjustments include that on each January 1, starting with January 1, 2020, an additional number
of shares equal to the lesser of (A) 2% of the outstanding number of Class A Ordinary Shares (on a fully diluted basis) on the immediate
preceding December 31, and (B) such lower number of Class A Ordinary Shares as may be determined by the board of directors, subject in
all cases to adjustments as provided in Section 10 of the Option Plan. Awards will be made pursuant to agreements and may be subject to
vesting and other restrictions as determined by the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We adopted the Option Plan
to provide additional incentives to selected directors, officers, employees and consultants, and enable our Company to obtain and retain
the services of these individuals. The Option Plan will enable us to grant options, restricted shares or other awards to our directors,
employees and consultants. Awards will be made pursuant to agreements and may be subject to vesting and other restrictions as determined
by the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21,853 options were granted
on March 15, 2019 to directors, employees, external consultants and advisors of the Group. One-half of each option grant vests on January
1, 2020 and expires on December 31, 2030, and the other half vests on January 1, 2021 and expires on December 31, 2031. The exercise price
is $129.1 per share, which was based on the closing price of the shares traded on the NASDAQ stock exchange on the trading day preceding
the grant date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">53,694 options were granted
on March 16, 2020 to directors, employees, external consultants and advisors of the Group. One-half of each option grant vests on January
1, 2021 and expires on December 31, 2031 and the other half vests on January 1, 2022 and expires on December 31, 2032. The exercise price
is $29.9 per share, which was based on the average closing price of the shares traded on the NASDAQ stock exchange for the five trading
days immediately preceding the grant date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14,896 options were granted
on June 1, 2020 to directors and employees of the Group. Nearly one-half of each option grant vests on December 1, 2020 and expires on
November 30, 2030 and the remaining vests on January 1, 2021 and expires on December 31, 2031. The exercise price is US$31.1 per share,
which was based on the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding
the grant date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2,748 options were granted
on August 10, 2020 to Dr. Weiss, which will be vested on August 10, 2021 and expires on August 9, 2032. The exercise price is $36.4 per
share, which was based on the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately
preceding the grant date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">75,235 options were granted
on March 11, 2021 to directors, employees, external consultants and advisors of the Group with an exercise price of $27.6 per share, which
was based on the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding
the grant date.<i>&#160;</i>36,796 options vest on January 1, 2022 and expire on December 31, 2032; 36,808 options vest on January 1,
2023 and expire on December 31, 2033; 906 options vest on June 8, 2021 and expire on June 7, 2032; and 725 options vest on July 14, 2021
and expire on July 13, 2032.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">153,146 options were granted
on March 8, 2022 to directors, employees, external consultants and advisors of the Group with an exercise price of $13.4 per share, which
was based on the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding
the grant date.<i>&#160;</i>74,881 options vest on January 1, 2023 and expire on December 31, 2033; 74,906 options vest on January 1,
2024 and expire on December 31, 2034; 1,866 options vest on June 8, 2022 and expire on June 7, 2033; and 1,493 options vest on July 14,
2022 and expire on July 13, 2033.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2023, we entered
into exchange agreements and cancelled 177,667 existing vested and unvested share options held by related parties option holders and cancelled
our obligations for deferred cash bonus payables of $3.1 million by granting of 403,820 share options (&#8220;New Options&#8221;) with
6 months vesting period. The New Options&#8217; exercise price was $2.68 per share, which was based on the last closing price of the shares
traded on the NASDAQ stock exchange on the grant date. All options fully vested on October 1, 2023 and expires on September 30, 2033.
On March 31, 2023, we entered into supplemental agreements with the same related parties option holders to provide additional cash compensation
to cover the exercise price of the New Options. On March 31, 2023, we entered into exchange agreements and cancelled 70,428 existing vested
and unvested share options held by non-related parties option holders and cancelled our obligations for deferred cash bonus payables of
$1.6 million by issuance of 70,430 fully vested Class A Ordinary Shares. We accounted for this exchange for both related parties and non-related
parties share option holders as a modification to share based compensation which required the remeasurement of existing share options
value at the time of the modification. The total incremental cost as a result of the modification was $0.7 million.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In line with Nasdaq requirements, we have established
a clawback policy which, subject to limited exceptions, requires that any incentive compensation (including both cash and equity compensation)
paid to any current or former executive officer on or after October 2, 2023 is subject to recoupment if (i) the incentive compensation
was calculated based on financial statements that were required to be restated due to material noncompliance with financial reporting
requirements, without regard to any fault or misconduct; and (ii) that noncompliance resulted in overpayment of the incentive compensation
within the three fiscal years preceding the date the restatement. A copy of our clawback policy has been filed as Exhibit 97.1 to this
annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. <span style="text-decoration:underline">Board Practices</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors currently
consists of seven members, all of whom were elected pursuant to our current Memorandum and Articles. Our nominating and governance committee
and board of directors will consider a broad range of factors relating to the qualifications and background of nominees, which may include
diversity and is not limited to race, gender or national origin. We have no formal policy regarding board diversity. Our nominating and
governance committee&#8217;s and board of directors&#8217; priority in selecting board members is identification of persons who will further
the interests of our shareholders through his or her established record of professional accomplishment, the ability to contribute positively
to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape and professional
and personal experiences and expertise relevant to our growth strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which operates pursuant
to a separate charter adopted by our Board of Directors. The composition and functioning of all of our committees will comply with all
applicable requirements of the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the NASDAQ Capital Market
and SEC rules and regulations. Our Board of Directors may establish other committees from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Audit Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Charles Bathurst, Douglas Arner
and Justin Wu currently serve on the audit committee, which is chaired by Charles Bathurst. Our Board of Directors has determined that
each member of the audit committee is &#8220;independent&#8221; for audit committee purposes as that term is defined in the rules of the
SEC and the applicable rules of the NASDAQ Capital Market. The audit committee&#8217;s responsibilities include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">selecting and appointing our independent registered public accounting firm, and approving the audit and permitted non-audit services to be provided by our independent registered public accounting firm;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">evaluating the performance and independence of our independent registered public accounting firm;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements or accounting matters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">establishing procedures for the receipt, retention and treatment of accounting-related complaints and concerns;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing and discussing with the independent registered public accounting firm the results of our year-end audit, and recommending to our Board of Directors, based upon such review and discussions, whether our financial statements shall be included in our annual report on Form 20-F;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing all related party transactions for potential conflict of interest situations and approving all such transactions; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing the type and presentation of information to be included in our earnings press releases, as well as financial information and earnings guidance provided by us to analysts and rating agencies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Audit Committee Financial Expert</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have one financial expert
as of the date of this report. Our Board of Directors has determined that Mr. Charles Bathurst, Chair of our audit committee, qualifies
as an &#8220;audit committee financial expert&#8221; as defined in the SEC rules and satisfies the financial sophistication requirements
of The NASDAQ Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Charles Bathurst, Douglas Arner
and Justin Wu currently serve on the compensation committee, which is chaired by Justin Wu. Our Board of Directors has determined that
each member of the compensation committee is &#8220;independent&#8221; as that term is defined in the applicable rules of the NASDAQ Capital
Market. The compensation committee&#8217;s responsibilities include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing the goals and objectives of our executive compensation plans, as well as our executive compensation plans in light of such goals and objectives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">evaluating the performance of our executive officers in light of the goals and objectives of our executive compensation plans and recommending to our Board of Directors with respect to the compensation of our executive officers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing the goals and objectives of our general compensation plans and other employee benefit plans as well as our general compensation plans and other employee benefit plans in light of such goals and objectives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">retaining and approving the compensation of any compensation advisors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing all equity-compensation plans to be submitted for shareholder approval under the NASDAQ listing rules, and reviewing and approving all equity-compensation plans that are exempt from such shareholder approval requirement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">evaluating the appropriate level of compensation for board and board committee service by non-employee directors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing and approving description of executive compensation included in our annual report on Form 20-F.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nominating and Corporate Governance Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Charles Bathurst, Douglas Arner
and Justin Wu currently serve on the nominating and corporate governance committee, which is chaired by Professor Arner. Our Board of
Directors has determined that each member of the nominating and corporate governance committee is &#8220;independent&#8221; as that term
is defined in the applicable rules of the NASDAQ Capital Market. The nominating and corporate governance committee&#8217;s responsibilities
include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">assisting our Board of Directors in identifying prospective director nominees and recommending nominees for election by the shareholders or appointment by our Board of Directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">advising the board of directors periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to our Board of Directors on all matters of corporate governance and on any corrective action to be taken;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">overseeing the evaluation of our Board of Directors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending members for each board committee of our Board of Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Scientific Advisory Board</i>s</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We restructured the Scientific
Assessment Committee into a newly formed Scientific Advisory Board. The Scientific Advisory Board shall help the Company sharpen its focus
on innovation and technological advancements and address critical scientific challenges in our research and development; it will provide
overall advise on the scientific development of the company. As of the date of this annual report, we have 29 members on this board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the Company&#8217;s
focus on developing treatment for infectious diseases, we have established a second scientific advisory board, i.e., the Infectious Diseases
Scientific Advisory Board in April 2020. As of the date hereof, the Infectious Diseases Scientific Advisory Board has 4 members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no family relationship
among any of our directors or executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Duties of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Cayman Islands law, our
directors have a duty to act honestly, in good faith and bona fide with a view to our best interests. Our directors also have a duty to
exercise the care, diligence and skills that a reasonably diligent person would exercise in comparable circumstances. In fulfilling their
duty of care to us, our directors must ensure compliance with our Memorandum and Articles. We have the right to seek damages if a duty
owed by our directors is breached.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The functions and powers of
our Board of Directors include, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">appointing officers and determining the term of office of the officers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">authorizing the payment of donations to religious, charitable, public or other bodies, clubs, funds or associations as deemed advisable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">exercising the borrowing powers of the company and mortgaging the property of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">executing checks, promissory notes and other negotiable instruments on behalf of the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">maintaining or registering a register of mortgages, charges or other encumbrances of the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Terms of Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no Cayman Islands
law requirement that a director must hold office for a certain term and stand for re-election unless the resolutions appointing the director
impose a term on the appointment. The Memorandum and Articles provide that we have a&#160;staggered board of directors consisting of three
classes of directors, with directors serving staggered three-year terms. Our Board of Directors is divided into three classes of directors.
At each annual general meeting of shareholders, one class of directors will be elected for a three-year term to succeed the class whose
terms are then expiring, to serve from the time of election and qualification until the third annual meeting following their election
or until their earlier death, resignation or removal, starting with the Annual General Meeting of Shareholders held in December 2023.
The Company&#8217;s Board has initially designated the three classes to contain the directors set forth below. Shareholders will only
elect the Class II directors at the Company&#8217;s next Annual General Meeting; the Class III and I directors shall not be required to
stand for re-election until the years specified below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 40%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name &amp; Class</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Positions</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Expiration&#160;of&#160;Director Term/Re-Election Year</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b><i>Class III</i></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Not Applicable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b><i>Class II</i></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Ian Huen</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Executive Officer &amp; Executive Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2024</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b><i>Class I</i></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Charles Bathurst</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Independent Non-Executive Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2026</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Mirko Scherer</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Independent Non-Executive Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2026</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Justin Wu</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Independent Non-Executive Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2026</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Douglas Arner</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Independent Non-Executive Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2026</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any age limit
requirements relating to our director&#8217;s term of office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Memorandum and Articles
also provide that our directors may be removed by the directors or ordinary resolution of the shareholders, and that any vacancy on our
Board of Directors, including a vacancy resulting from an enlargement of our Board of Directors (which shall not exceed any maximum number
stated therein), may be filled by ordinary resolution or by vote of a majority of our directors then in office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into agreements
with our executive officers. Each of our executive officers is employed for a specified time period, which will be renewed upon both parties&#8217;
agreement. We may terminate the employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer,
including but not limited to the commitments of any serious or persistent breach or non-observance of the terms and conditions of the
employment, conviction of a criminal offense, willful disobedience of a lawful and reasonable order, fraud or dishonesty, receipt of bribery,
or severe neglect of his or her duties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each executive officer has
agreed to hold, both during and after the employment agreement expires, in strict confidence and not to use or disclose to any person,
corporation or other entity without written consent, any confidential information. Each executive officer has also agreed to assign to
our group all his or her all inventions, improvements, designs, original works of authorship, formulas, processes, compositions of matter,
computer software programs, databases, mask works, concepts and trade secrets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board Diversity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below provides certain
information regarding the diversity of our board of directors as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="4" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Diversity Matrix</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="4" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Country of Principal Executive Offices:</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The United Kingdom</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign Private Issuer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Prohibited under Home Country Law</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Number of Directors</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Female</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Male</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non- <br/>
Binary</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Did Not<br/>
Disclose Gender</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part I: Gender Identity</b></span></td>
    <td>&#160;</td>
    <td colspan="14" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part II: Demographic Background</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#8239;&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underrepresented Individual in Home Country Jurisdiction</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">1</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did Not Disclose Demographic Background</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">4</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently only have five
Board members who are all male, 1 of whom are diverse. While we value diversity, we have not made any changes to increase the diversity
amongst our board members due to board members deciding to stand for re-election. We plan to explore ways to have board diversity including
possibly increasing the size of our board and/or as part of our board rotation process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">D. <span style="text-decoration:underline">Employees</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual
report, we have 3 full-time employees. Of these, 3 full-time are engaged in general and administrative functions. As of the date of this
annual report, 3 of our employees are located in Asia. In addition, we have engaged and may continue to engage 10 independent contracted
consultants and advisors to assist us with our operations. None of our employees are represented by a labor union or covered by a collective
bargaining agreement. We have never experienced any employment related work stoppages, and we consider our relations with our employees
to be good.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">E. <span style="text-decoration:underline">Share Ownership</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information with respect to the beneficial ownership, within the meaning of Rule 13d-3 under the Exchange Act, of our Ordinary Shares
as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each of our directors and executive officers who beneficially own our Ordinary Shares; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each person known to us to own beneficially more than 5.0% of our Ordinary Shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership includes
voting or investment power with respect to the securities. Except as indicated below, and subject to applicable community property laws,
the persons named in the table have sole voting and investment power with respect to all Ordinary Shares shown as beneficially owned by
them. Percentage of beneficial ownership of each listed person is based on 3,674,164 Class A Ordinary Shares and 1,796,934 Class B Ordinary
Shares outstanding as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information with respect to
beneficial ownership has been furnished by each director, officer or beneficial owner of 5% or more of our Ordinary Shares. Beneficial
ownership is determined in accordance with the rules of the SEC and generally requires that such person have voting or investment power
with respect to securities. In computing the number of Ordinary Shares beneficially owned by a person listed below and the percentage
ownership of such person, Ordinary Shares underlying options, warrants or convertible securities held by each such person that are exercisable
or convertible within 60 days of the date of this annual report are deemed outstanding, but are not deemed outstanding for computing the
percentage ownership of any other person. Except as otherwise indicated in the footnotes to this table, or as required by applicable community
property laws, all persons listed have sole voting and investment power for all Ordinary Shares shown as beneficially owned by them. As
of the date of the annual report, we have 2 shareholders of record holding beneficial ownership of 5% or more, none of which are located
in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
the business address of each of the&#160; individuals is 17 Hanover Square, London, W1S 1BN, United Kingdom.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Address of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Class A <br/> Ordinary<br/> Shares <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Class B <br/> Ordinary<br/> Shares <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Percentage<br/> of Total <br/> Class A and<br/> Class B <br/> Ordinary <br/> Shares<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Percentage <br/> of Total <br/> Voting <br/> Power<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Ian Huen<sup>(3)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">562,021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,606,147</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">39.24</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">87.81</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Martin Siu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Charles Bathurst</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Mirko Scherer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Justin Wu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Douglas Arner</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">All directors and executive officers as a group (5 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">625,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,606,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39.40</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87.84</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">5% Beneficial Owner</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Jurchen Investment&#160;Corporation<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,606,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.75</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87.80</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">CGY Investments Limited<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533,575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.75</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.29</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Less than 1% of total outstanding Ordinary Shares on an as converted basis.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For each person and group included in this column, percentage ownership is calculated by dividing the number of Class A Ordinary Shares and Class B Ordinary Shares beneficially owned by such person or group, including shares that such person or group has the right to acquire within 60 days after the date of this annual report, by the sum of Class&#160;A Ordinary Shares and Class&#160;B Ordinary Shares, and the number of Class&#160;A Ordinary Shares that such person or group has the right to acquire beneficial ownership within 60 days after the date of this annual report. Following the IPO, each Class B Ordinary Share can be converted at any time on a one-for-one basis into Class A Ordinary Shares at the discretion of the holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For each person and group included in this column, percentage of total voting power represents voting power based on both Class&#160;A Ordinary Shares and Class&#160;B Ordinary Shares beneficially owned by such person or group with respect to all of our outstanding Class&#160;A Ordinary Shares and Class&#160;B Ordinary Shares as one single class. Holders of Class&#160;A Ordinary Shares are entitled to one vote per share and holders of Class&#160;B Ordinary Shares are entitled to one hundred votes per share on all matters subject to a shareholders&#8217; vote.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 370,308 Class A Ordinary Shares owned by Jurchen, warrants held by Jurchen to purchase 54,054 Class A Ordinary Shares, options granted to Mr. Huen to purchase 137,659 Class A Ordinary Shares, and 1,606,147 Class B Ordinary Shares owned by Jurchen. Jurchen Investment Corporation, is a company wholly-owned by Mr. Huen. Mr. Huen maintains sole voting control over the shares held by Jurchen, the principal office address of which is at 17<sup>th</sup> Floor, Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">CGY Investments Limited is 50% held by Seng Fun Yee, 25% held by Mandy Lui and 25% held by Adrian Lui (all of whom are related to our former CEO, Mr. Darren Lui). Mr. Lui controls and/or has substantial influence on the disposition and voting rights of the shares held by his spouse, but no such control over the shares held by his sister or brother. Includes 533,575 Class A Ordinary Shares held by CGY Investments Limited. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">F. <span style="text-decoration:underline">Disclosure of a registrant&#8217;s action
to recover erroneously awarded compensation. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7. MAJOR SHAREHOLDERS AND RELATED PARTY
TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. <span style="text-decoration:underline">Major Shareholders</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please refer to &#8220;Item
6. Directors, Senior Management and Employees&#8212;E. Share Ownership.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. <span style="text-decoration:underline">Related Party Transactions</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Lines of Credit</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 13, 2019 (the &#8220;Effective
Date&#8221;), Aptorum Therapeutics Limited (&#8220;ATL&#8221;), one of our wholly-owned subsidiaries, entered into two separate Promissory
Notes and Line of Credit Agreements (the &#8220;Agreements&#8221;) with Aeneas Group Limited and Jurchen Investment Corporation (&#8220;Jurchen&#8221;).
The Aeneas Group Limited Agreement and Jurchen Agreement provide ATL with a line of credit up to twelve million dollars ($12,000,000)
and three million dollars ($3,000,000), respectively (collectively, the &#8220;Line of Credit&#8221;), representing the maximum aggregate
amount of the advances of funds from the Line of Credit that may be outstanding at any time under the Line of Credit (the &#8220;Principal
Indebtedness&#8221;). ATL may draw down from the Line of Credit at any time through the day immediately preceding the third anniversary
of the Effective Date (the &#8220;Maturity Date&#8221;). As of the date of this annual report, the Jurchen Agreement is matured, and the
maturity of Aeneas Group Limited Agreement is extended for additional three years and will be matured on August 12, 2025. Interest is
payable on the outstanding Principal Indebtedness at the rate of eight percent (8%) per annum, payable semi-annually in arrears on February
12 and August 12 in each year. ATL may pre-pay in whole or in part, the Principal Indebtedness of the Line of Credit, and all interest
accrued at any time prior to the Maturity Date, without penalty. Under the Agreements, in addition to certain standard covenants, we are
also not permitted, without the prior written consent of Aeneas Group and Jurchen to (i) liquidate, dissolve or wind-up our business and
affairs; (ii) effect any merger or consolidation transaction; (iii) sell, lease, transfer, license or otherwise dispose, in a single transaction
or series of related transactions, all or substantially all of our assets; or (iv) consent to any of the foregoing. The Agreements are
subject to standard events of default, which if not cured within the agreed upon cure period, permits Aeneas Group Limited or Jurchen,
as applicable, to declare the outstanding Principal Indebtedness immediately due and payable, to exercise any other remedy provided for
in the Agreements or any other right available to Aeneas Group Limited or Jurchen as provided at law or in equity. Jurchen and Aeanas
Group Limited also maintain the right to set-off during the term of the Agreements. As of the date of this annual report, the Company
has not drawn down from the Line of Credit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2021,
Aptorum Therapeutics Limited (the &#8220;Lender&#8221;) entered into a loan agreement with Talem Medical Group Limited
(&#8220;Talem&#8221; or the &#8220;Borrower&#8221;). According to the loan agreement, the Lender will grant a loan of up to AUD 4.7
million for the Borrower for general working capital purposes of the Borrower and its subsidiaries. The loan is interest-bearing at
a rate of 10% per annum and secured by the entire issued shares of Talem Medical Group (Australia) Pty Limited held by the Borrower.
The loan is initially matured 6 months from the date of the first drawdown date. The maturity date may be extended for 6 months to
the first extended maturity date, and further extended for another 6 months to the second extended maturity date, if certain
conditions stated in loan agreement are satisfied. We consider this loan to be a related party transaction as certain insiders,
including Ian Huen, our Chief Executive Officer, Executive Director and Director of the Lender; Dr. Clark Cheng, our Chief Medical
Officer, Executive Director and Director of the Lender; Darren Lui, our former President, Executive Director and Director of the
Lender; Professor Justin Wu, our Independent Non-Executive Director; and Dr. Thomas Lee, our Head of Research and Development and
Director of the Lender have direct and indirect minority interests in the Borrower. As of the date of this annual report, there is
no outstanding balance from the Borrower.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 13, 2022, the Group
entered a line of credit facility with Libra to provide up to a total $1 million in line of credit debt financing for its daily operation
The line of credit is originally matured on January 12, 2023, and is extended for additional 3 years. The interest on the outstanding
principal indebtedness is at the rate of 10% per annum. As of the date of this annual report, $0.5 million is outstanding from Libra Sciences
Limited.&#160;For the year ended December 31, 2023, the Group has assessed that the amounts due from Libra Science Limited and its subsidiary
are potentially unrecoverable. Accordingly, an allowance for credit loss amounting to $0.5 million
has been recognized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales and Purchases of Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Private Placement Offering</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Sale of Class A Ordinary
Shares</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 26, 2021, the Company
entered into a private placement shares purchase agreement with Jurchen, issuing 138,793 Class A Ordinary Shares, par value $10 each,
at $28.82 per share, representing a 10% premium to the last closing price of the Company&#8217;s Class A Ordinary Shares on the NASDAQ
stock exchange on that date. The Company received aggregate gross proceeds of $4,000,000 from the purchase of these shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Sales of convertible notes</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 9, 2022, the Group
entered into a securities purchase agreement with Aenco Technologies Limited (&#8220;Aenco&#8221;). Pursuant to the securities purchase
agreement, Aenco is purchasing a convertible note in the original principal amount of $3,000,000 (the &#8220;Dec 2022 Note&#8221;). The
Dec 2022 Note is unsecured, convertible into the Company&#8217;s restricted Class A Ordinary Shares at Aencco&#8217;s option. The Dec
2022 Notes have a maturity date of 12 months subject to the Aenco&#8217;s extension, a bullet interest rate of 7% per annum, and a conversion
price of $12.00 per Class A Ordinary share. The Company shall have an obligation to repay the principal amount and interest of the Dec
2022 Note on the maturity date in cash or in unregistered Class A Ordinary Shares or a combination of such at the Company&#8217;s discretion.
In April 2023, Aenco transferred the whole Dec 2022 Note to two external investors, and the two external investors fully converted the
Dec 2022 Note into 250,000 Class A Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2023, the Group
entered into a securities purchase agreement with 4 investors. Pursuant to the securities purchase agreement, the investors are purchasing
a convertible note in the original principal amount of $3,000,000 (the &#8220;June 2023 Note&#8221;). The whole proceeds from the June
2023 Note was used to settle a related party loan. The June 2023 Note is unsecured, convertible into the Company&#8217;s restricted Class
A Ordinary Shares at the Note holder option. The June 2023 Notes have a maturity date of 12 months subject to the investors extension,
a bullet interest rate of 7% per annum, and a conversion price of $3.00 per Class A Ordinary share. The Company shall have an obligation
to repay the principal amount and interest of the June 2023 Note on the maturity date in cash or in unregistered Class A Ordinary Shares
or a combination of such at the Company&#8217;s discretion. Immediately following the issuance of June 2023 Note, the June 2023 Note was
fully converted into 1,000,000 Class A Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 11, 2023, the
Group entered into a securities purchase agreement with Jurchen Investment Corporation, the largest shareholder of the Company, pursuant
to which the Group sold a secured convertible note in the aggregate principal amount of $3,000,000 (the &#8220;Sep 2023 Notes&#8221;).
The Sep 2023 Notes are convertible into the Company&#8217;s Class A Ordinary Shares and have a maturity date that is 24 months from the
issuance date, although upon such date the investor has the right to extend the term of the Sep 2023 Note for twelve (12) months or more
or such term subject to mutual consent. The Sep 2023 Notes have an interest rate of 6% per annum and a conversion price of $2.42 per share.
The Company has the right to repay the principal amount of the Sep 2023 Notes, but in the case of such prepayment it must be paid in cash,
unless otherwise agreed by both parties. The Sep 2023 Note is secured by a first priority lien and security interest on certain shares
that the Group owns (&#8220;Collateral&#8221;). Upon the Group&#8217;s disposal of all or a portion of the Collateral, the investor has
the right, to request that the Group prepay the then-remaining outstanding balance of the Sep 2023 Note, in part or in full and the Group
can make that payment in cash or in shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disposal of a subsidiary</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 27, 2021, Aptorum Therapeutics
Limited, which is a wholly owned subsidiary of Aptorum Group Limited, entered a Share Sale Agreement to sell all of the shares of SMPTH
Limited, a previously wholly owned subsidiary of Aptorum Therapeutics Limited, to Aeneas Group Limited at the consideration $1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Consulting Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">CGY Investment Limited</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a consulting
agreement with CGY Investment Limited (&#8220;CGY&#8221;) effective on January 10, 2020. Pursuant to this agreement, CGY shall provide
certain consultancy, advisory, and management services to the Group on potential investment projects related to health care or R&amp;D
platform; CGY Investment Limited is initially entitled to receive HK $104,000 (approximately $13,333) per calendar month plus reimbursement;
such monthly service fee is adjusted to HK$171,200 (approximately US$21,949) with effect from March 1, 2022. In August 2023, CGY Investment
Limited has agreed to suspended its monthly services fee from August 1, 2023. In November 2023, CGY Investment Limited and the Group reached
a mutual agreement to terminate their contractual relationship.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CGY is 50% held by Seng Fun
Yee, 25% held by Mandy Lui and 25% held by Adrian Lui (all of who are related to Mr. Lui). Mr. Lui, the former Chief Executive Officer
and Executive Director of the Group, controls and/or has substantial influence on the disposition and voting rights of the shares held
by his spouse, but no such control over the shares held by his sister or brother. Hence, 50% of the consulting service fee will be deemed
as Mr. Lui&#8217;s compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">ACC Medical Limited</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a consulting
agreement with ACC Medical Limited (&#8220;ACC&#8221;) effective on December 1, 2020. Pursuant to this agreement, ACC shall provide certain
consultancy, advisory, and management services to the Group on clinic operations and other related projects for clinics&#8217; business
development; ACC Medical Limited is initially entitled to receive HK $101,542 (approximately $13,018) per calendar month plus reimbursement;
such monthly service fee is adjusted to HK$143,200 (approximately US$18,359 per month) effective from March 1, 2022. During the year ended
December 31, 2023 and 2022, ACC Medical Limited also received $28,615 and $23,275 one-off compensation respectively. The agreement was
terminated on June 30, 2023. ACC is wholly owned by Dr. Clark Cheng, who is also the sole director of ACC, the Group&#8217;s former Chief
Medical Officer and Executive Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Administrative Management Services </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Libra Sciences Limited</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 1, 2022, the Group
entered into an administrative management services agreement with Libra Sciences Limited. According to the agreement, the Group will provide
documentation and administrative services, include but are not limited to human resources and payroll administration, general secretarial
and administrative support, and accounting and financial reporting services. The Group is entitled to receive a fixed amount of services
fees of HKD 25,000 (approximately $3,205) per calendar month with the expiry date on December 31, 2023. The Group and Libra Sciences Limited
mutually agreed to terminate the administrative management service agreement effect as of March 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into Appointment
Letters with each of our executive officers. The terms of the Appointment Letters for each of our executive officers are consistent with
each other, except with regard to the individual&#8217;s compensation, term of employment and duties and responsibilities, the latter
of which coincides with the standard functions normally associated with the given position. In addition to setting forth the individual
compensation and such, the appointment letters contain the following material terms:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may terminate employment
for cause, at any time, without advance notice or remuneration, for certain acts of the executive officer, such as conviction or plea
of guilty to a felony or any crime involving moral turpitude, negligent or dishonest acts to our detriment, or misconduct or a failure
to perform agreed duties. We may also terminate an executive officer&#8217;s employment without cause upon three-month advance written
notice. In such case of termination by us, we will provide severance payments to the executive officer as expressly required by applicable
law of the jurisdiction where the executive officer is based. The executive officer may resign at any time with three-month advance written
notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each executive officer has
agreed to hold, both during and after the termination or expiration of his or her Appointment Letter, in strict confidence and not to
use, except as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of
our confidential information or trade secrets, any confidential information or trade secrets of our clients or prospective clients, or
the confidential or proprietary information of any third-party received by us and for which we have confidential obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, each executive
officer has agreed to be bound by non-solicitation and non-compete restrictions during the term of his or her employment and typically
for one year following the last date of employment. Specifically, each executive officer has agreed not to (i) solicit or entice away
from the Company, any person, firm, company or organization that is or shall have been at any time within 12 months prior to termination
of employee a customer, client, identified prospective customer or client of the Company or in the habit of dealing with the Company;
(ii) employ, solicit or entice away from the Company any person who is or shall have been on the date of or within 12 months prior to
termination of employment an employee of the Company; or (iii) assume employment with or provide services to, or otherwise engage in income
generating activities with any of our competitors, or engage, whether as principal, partner, licensor or otherwise, any of our competitors,
without our express consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our Appointment Letters
also provide for the executive officer to participate in our mandatory provident fund, which is similar to a pension fund.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on November 27, 2023, we re-appointed Mr. Huen as Chief Executive
Officer and Executive Director whereas all other previous employment terms and conditions remain unchanged. Under the previous appointment
letter, we paid Mr. Huen approximately USD27,308 per month. The appointment letter can be earlier terminated by either party with two-months&#8217;
written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2022, we appointed
Mr. Siu as our Head of Finance, effective on July 11, 2022, pursuant to an Operations Services &amp; Secondment Agreement between Aptus
Management Limited and MG Consultancy Limited (&#8220;MG&#8221;), through which Mr. Siu provides his services. MG charges an initial monthly
fee of approximately USD7,600, which may be increased to approximately USD12,700 during the term of the agreement. The agreement has a
three-year term, which will automatically renew for additional one-year terms, unless earlier terminated by either party with one-month
written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6. Directors,
Senior Management and Employees &#8212; C. Board Practices &#8212; Employment Agreements&#8221;. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. <span style="text-decoration:underline">Interests of Experts and Counsel</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8. FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. <span style="text-decoration:underline">Consolidated Statements and Other Financial
Information</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have appended consolidated
financial statements filed as part of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we are subject
to legal proceedings, investigations and claims incidental to the conduct of our business. We are not currently a party to any legal proceeding
or investigation which, in the opinion of our management, is likely to have a material adverse effect on our business, financial condition
or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or paid
cash dividends to our shareholders, and we do not intend to pay cash dividends in the foreseeable future. We intend to reinvest any earnings
in developing and expanding our business. Any future determination relating to our dividend policy will be at the discretion of our Board
of Directors and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual
restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable law and other
factors that our Board of Directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Cayman Islands law, dividends
may be declared and paid only out of funds legally available therefor, namely out of either profit or our share premium account, and provided
further that a dividend may not be paid if this would result in our Company being unable to pay its debts as they fall due in the ordinary
course of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. <span style="text-decoration:underline">Significant Changes</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as disclosed elsewhere
in this annual report, we have not experienced any significant changes since the date of our audited consolidated financial statements
included in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9. THE OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. <span style="text-decoration:underline">Offering and Listing Details.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Class A Ordinary Shares
are currently listed on NASDAQ Capital Market under the symbol &#8220;APM.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. <span style="text-decoration:underline">Plan of Distribution</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. <span style="text-decoration:underline">Markets</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Class A Ordinary Shares
are currently listed on NASDAQ Capital Market under the symbol &#8220;APM.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following a comprehensive review
of the trading volume, costs and administrative requirements related to its listing on Euronext Paris, Company voluntary delisted its
Class A Ordinary Shares (ISIN KYG6096M1226) from Euronext Paris as of July 5, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">D. <span style="text-decoration:underline">Selling Shareholders</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">E. <span style="text-decoration:underline">Dilution</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">F. <span style="text-decoration:underline">Expenses of the Issue</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 10. ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. <span style="text-decoration:underline">Share Capital</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. <span style="text-decoration:underline">Amended and Restated Memorandum and Articles
of Association</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">We
are a Cayman Islands exempted company with limited liability and our affairs are governed by our Third Amended and Restated Memorandum
and Articles of Association (the &#8220;Memorandum and Articles&#8221;), the Companies Law, the common law of the Cayman Islands, our
corporate governance documents and rules and regulations of the stock exchange on which are shares are traded. The Memorandum and Articles
of the Company is filed herein as Exhibit 1.2 to this annual report and is hereby incorporated by reference into this annual report. You
may refer to Exhibit 2.3 for a detailed disclosure of description of our securities registered under Section 12 of the Exchange Act of
1934, as amended, of the Memorandum and Articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">As
of the date hereof, the authorized share capital of the Company is $100,000,000.00, divided into 9,999,996,000,000 Class A Ordinary Shares
with a nominal or par value of $0.00001 each and 4,000,000 Class B Ordinary Shares with a nominal or par value of $0.00001 each. As of
the date hereof, 3,674,164 Class A Ordinary Shares and 1,796,934 Class B Ordinary Shares are issued and outstanding. All of our issued
and outstanding Class A Ordinary Shares and Class B Ordinary Shares are fully paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; "></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">At
the February 21, 2023 special extraordinary meeting of shareholders, the shareholders approved by a special resolution an amendment and
restatement of the Company&#8217;s Second Amended and Restated Memorandum and Articles of Association (the &#8220;M&amp;A&#8221;) in the
form of the Third Amended and Restated Memorandum and Articles of Association,&#160;&#160;to reflect (i) the merger between the Company
and Aptorum Group Cayman Limited, a newly established wholly owned subsidiary of the Company, whereby the Company would be the surviving
company (the &#8220;Merger&#8221;) pursuant to a plan of merger, which also forces a change in par value to Ordinary Shares of the Company
from USD10 to USD0.00001 (the &#8220;Plan of Merger&#8221;); (ii) the voting rights of the Class B Ordinary Shares be increased from 10
votes per share to 100 votes per share; (iii) a staggered board of directors consisting of three (3) classes, such that only one (1) class
is subject to re-election each year; (iv) to increase the number of Class A Ordinary Shares authorized; (v) reducing the vote required
for class consent from two-thirds (2/3) to a simple majority; and (vi) to decrease the number of days for effective service by post to
shareholders from 14 days to 3 days (collectively, the &#8220;Amendments of M&amp;A&#8221;) and that the Third Amended and Restated Memorandum
and Articles of Association be adopted as the Memorandum and Articles of Association of the Company, to the exclusion of the existing
M&amp;A with effect from February 21, 2023, which is the date of the registration of the Merger with the Registrar of Companies of the
Cayman Islands.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. <span style="text-decoration:underline">Material Contracts</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not entered into any
material contracts other than in the ordinary course of business and other than those described in &#8220;Item 4. Information on the Company&#8221;
or elsewhere in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">D. <span style="text-decoration:underline">Exchange Controls</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no governmental laws,
decrees, regulations or other legislation in the Cayman Islands, the United Kingdom or Hong Kong that may affect the import or export
of capital, including the availability of cash and cash equivalents for use by us, or that may affect the remittance of dividends, interest,
or other payments by us to non-resident holders of our ordinary shares, other than withholding tax requirements. There is no limitation
imposed by Cayman Islands law, the United Kingdom law, Hong Kong law or our articles of association on the right of non-residents to hold
or vote shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">E. <span style="text-decoration:underline">Taxation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cayman Islands Tax Considerations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Cayman Islands currently
levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature
of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the government of the Cayman Islands
except for stamp duties which may be applicable on instruments executed in, or brought within, the jurisdiction of the Cayman Islands.
The Cayman Islands is not party to any double tax treaties which are applicable to any payments made by or to our Company. There are no
exchange control regulations or currency restrictions in the Cayman Islands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payments of dividends and capital
in respect of our Class A Ordinary Shares will not be subject to taxation in the Cayman Islands and no withholding will be required on
the payment of a dividend or capital to any holder of our Class A Ordinary Shares, nor will gains derived from the disposal of our Class
A Ordinary Shares be subject to Cayman Islands income or corporation tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No stamp duty is payable in
respect of the issue of our Class A Ordinary Shares or on an instrument of transfer in respect of our Class A Ordinary Shares except on
instruments executed in, or brought within, the jurisdiction of the Cayman Islands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material U.S. Federal Income Tax Considerations
for U.S. Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of the material U.S. federal income tax consequences to U.S. Holders (as defined below) of purchasing, owning and disposing of Class A
Ordinary Shares. It is not a comprehensive description of all U.S. federal income tax considerations that may be relevant to a particular
person&#8217;s decision to acquire Class A Ordinary Shares. This discussion applies only to a U.S. Holder that holds a Class A Ordinary
Share as a capital asset for U.S. federal income tax purposes (generally, property held for investment). In addition, it does not describe
all of the tax consequences that may be relevant in light of a U.S. Holder&#8217;s particular circumstances, including state and local
tax consequences, non-U.S. tax consequences, federal estate or gift tax consequences, alternative minimum tax consequences, the potential
application of the provisions of the Code known as the Medicare Contribution Tax, and tax consequences applicable to U.S. Holders subject
to special rules, such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">banks and other financial institutions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">insurance companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">dealers or traders in securities who use a mark-to-market method of tax accounting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons holding Class A Ordinary Shares as part of a hedging transaction, &#8220;straddle,&#8221; wash sale, conversion transaction or integrated transaction or persons entering into a constructive sale with respect to the Class A Ordinary Shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons whose &#8220;functional currency&#8221; for U.S. federal income tax purposes is not the U.S. dollar;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">tax exempt entities, including &#8220;individual retirement accounts&#8221; and &#8220;Roth IRAs&#8221;;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">former citizens or long-term residents of the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">entities or arrangements classified as partnerships for U.S. federal income tax purposes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulated investment companies or real estate investment trusts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who acquired our Class A Ordinary Shares pursuant to the exercise of an employee share option or otherwise as compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons that own or are deemed to own ten percent or more of our shares; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons holding Class A Ordinary Shares in connection with a trade or business conducted outside the United States.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an entity or arrangement
that is classified as a partnership for U.S. federal income tax purposes holds Class A Ordinary Shares, the U.S. federal income tax treatment
of such partnership and each partner thereof will generally depend on the status of the partner and the activities of the partnership.
Partnerships holding Class A Ordinary Shares and partners in such partnerships are encouraged to consult their tax advisors as to the
particular U.S. federal income tax consequences of purchasing, holding and disposing of Class A Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussion is based on
the Code, the Treasury Regulations issued thereunder, and administrative and judicial interpretations thereof, all as in effect on the
date hereof and all of which are subject to change, possibly with retroactive effect, or to different interpretation. Such change could
materially and adversely affect the tax consequences described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this discussion,
a &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of Class A Ordinary Shares and
that is:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an individual citizen or resident of the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a trust, (i) if a court within the United States is able to exercise primary supervision over its administration and one or more &#8220;U.S. persons&#8221; (within the meaning of the Code) have the authority to control all of its substantial decisions, or (ii) if a valid election is in effect for the trust to be treated as a U.S. person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders are encouraged
to consult their tax advisors concerning the U.S. federal, state, local and foreign tax consequences of purchasing, owning and disposing
of Class A Ordinary Shares in their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><b><i>Taxation of Distributions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion below
under &#8220;Passive Foreign Investment Company Rules,&#8221; a U.S. Holder will be required to include in gross income as dividend income
the gross amount of any distributions paid on Class A Ordinary Shares (including any amount of taxes withheld), other than certain&#160;<i>pro
rata&#160;</i>distributions of Class A Ordinary Shares, to the extent paid out of our current or accumulated earnings and profits (as
determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits would
be treated as a non-taxable return of capital to the extent of the U.S. Holder&#8217;s adjusted tax basis in the Class A Ordinary Shares
and thereafter as a gain from the sale of the Class A Ordinary Shares. However, because we do not calculate our earnings and profits under
U.S. federal income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In case of a U.S. Holder that
is a corporation, dividends paid on the Class A Ordinary Shares will be subject to regular corporate rates and will not be eligible for
the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders with respect to dividends received from U.S.
corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends received by an individual,
trust or estate will be subject to taxation at standard tax rates. A reduced income tax rate applies to dividends paid by a &#8220;qualified
foreign corporations&#8221; (if certain holding period requirements and other conditions are met). A non-U.S. corporation generally will
be considered to be a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United
States which includes an exchange of information program or (ii) with respect to any dividend it pays on stock which is readily tradable
on an established securities market in the United States. US. Treasury Department guidance indicates that our Class A Ordinary Shares,
which is listed on the NASDAQ Capital Market is readily tradable on an established securities market in the United States. There can be
no assurance, however, that our Class A Ordinary Shares will be considered readily tradable on an established securities market in later
years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-corporate U.S. Holders
will not be eligible for reduced rates of taxation on any dividends received from us if we are a PFIC in the taxable year in which such
dividends are paid or in the preceding taxable year (See &#8220;Item 10. Additional Information &#8211; E. Taxation &#8211; Material U.S.
Federal Income Tax Considerations for U.S. Holders&#160;&#8211;&#160;Passive Foreign Investment Company Rules&#8221; below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may be eligible,
subject to a number of complex limitations, to claim a foreign tax credit in respect of any foreign withholding taxes imposed on dividends
received on the Class A Ordinary Shares. A U.S. Holder who does not elect to claim a foreign tax credit for foreign income tax withheld
may instead claim a deduction for U.S. federal income tax purposes in respect of such withholding, but only for a year in which such investor
elects to do so for all creditable foreign income taxes. For purposes of calculating the foreign tax credit limitation, dividends paid
by us will, depending on the circumstances of the U.S. Holder, be either general or passive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we do not expect to pay
dividends in the near future, in the event any dividends are paid and if a dividend is paid in non-U.S. currency, it must be included
in a U.S. Holder&#8217;s income as a U.S. dollar amount based on the exchange rate in effect on the date such dividend is actually or
constructively received, regardless of whether the dividend is in fact converted into U.S. dollars. If the dividend is converted to U.S.
dollars on the date of receipt, a U.S. Holder generally will not recognize a foreign currency gain or loss. If the non-U.S. currency is
converted into U.S. dollars on a later date, however, the U.S. Holder must include in income any gain or loss resulting from any exchange
rate fluctuations. Such gain or loss will generally be ordinary income or loss and will be from sources within the United States for foreign
tax credit limitation purposes. U.S. Holders should consult their own tax advisors regarding the tax consequences to them if we pay dividends
in non-U.S. currency.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><b><i>Sale or Other Taxable Disposition of Ordinary
Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion below
under &#8220;Passive Foreign Investment Company Rules,&#8221; gain or loss realized on the sale or other taxable disposition of Class
A Ordinary Shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the Class A Ordinary
Shares for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#8217;s tax basis in the
Class A Ordinary Shares disposed of and the amount realized on the disposition. Long-term capital gain of a non-corporate U.S. Holder
is generally taxed at preferential rates. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes.
The deductibility of capital losses is subject to limitations. U.S. Holders are urged to consult their tax advisors regarding the tax
consequences if a foreign tax is imposed on the disposition of Class A Ordinary Shares, including the availability of the foreign tax
credit under an investor&#8217;s own particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder that receives
non-U.S. currency on the disposition of the Class A Ordinary Shares will realize an amount equal to the U.S. dollar value of the foreign
currency received on the date of disposition (or in the case of cash basis and electing accrual basis taxpayers, the settlement date)
whether or not converted into U.S. dollars at that time. Very generally, the U.S. Holder will recognize currency gain or loss if the U.S.
dollar value of the currency received on the settlement date differs from the amount realized with respect to the Class A Ordinary Shares.
Any currency gain or loss on the settlement date or on any subsequent disposition of the foreign currency generally will be U.S.-source
ordinary income or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><b><i>Passive Foreign Investment
Company Rules</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special U.S. federal income
tax rules apply to a U.S. Holder that holds stock in a foreign corporation classified as a PFIC for U.S. federal income tax purposes.
In general, a non-U.S. corporation will be classified as a PFIC for any taxable year in which, after applying certain look-through rules,
either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">at least 75% of its gross income for such taxable year is passive income (e.g., dividends, interest, capital gains and rents derived other than in the active conduct of a rental business); or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">at least 50% of its gross assets (determined on the basis of a quarterly average) is attributable to assets that produce passive income or are held for the production of passive income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be treated as owning
our proportionate share of the assets and earning our proportionate share of the income of any other corporation in which we own, directly
or indirectly, 25% or more (by value) of the equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A separate determination must
be made after the close of each taxable year as to whether we are a PFIC for that year. As a result, our PFIC status may change. In particular,
the total value of our assets generally will be calculated using the market price of our Class A Ordinary Shares, which may fluctuate
considerably. Fluctuations in the market price of our Class A Ordinary Shares may result in our being a PFIC for any taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the amount of
cash and cash equivalents and investments that we had on hand during our year ending December 31, 2023, we believe that we were
classified as a PFIC for that tax year. Depending on the future composition and value of our assets, we may be classified as a PFIC
for future years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we were to be classified
as a PFIC, a U.S. Holder would be subject to different taxation rules depending on whether the U.S. Holder (i) takes no action, (ii) makes
an election to treat us as a &#8220;Qualified Electing Fund&#8221; (a &#8220;QEF election&#8221;) or (iii) if permitted, makes a &#8220;mark-to-market&#8221;
election with respect to our Class A Ordinary Shares. A U.S. Holder of our Class A Ordinary Shares will also be required under applicable
Treasury Regulations to file an annual information return (Form 8621) containing information regarding our company. Additional explanations
of the PFIC rules are set forth below: this material is complex and may affect different U.S. Holders differently. Accordingly, U.S. Holders
should consult their own tax advisors about the consequences of our company being classified as a PFIC and about what steps, if any, they
might take to lessen the tax impact of our PFIC status on them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder who does not
make a timely QEF or mark-to-market election (a &#8220;Non-Electing Holder&#8221;), as discussed below, will be subject to special tax
rules with respect to any &#8220;excess distribution&#8221; that you receive and any gain you realize from a sale or other disposition
(including a pledge) of Class A Ordinary Shares. Distributions you receive in a taxable year that are greater than 125% of the average
annual distributions you received during the shorter of the three preceding taxable years or your holding period for the Class A Ordinary
Shares will be treated as an excess distribution. Under these special tax rules:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the excess distribution or gain will be allocated ratably over your holding period for the Class A Ordinary Shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we became a PFIC, will be treated as ordinary income; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It should be noted that, until
such time as we make a distribution, there are no tax consequences to Non-Electing Holders. However, if we ever did make a distribution
it would in all likelihood be an excess distribution (because we would not have previously made any distributions to holders of Class
A Ordinary Shares). At that point, and for all subsequent distributions, the rules described above would apply to Non-Electing Holders.
The tax liability for amounts allocated to years prior to the year of disposition or &#8220;excess distribution&#8221; cannot be offset
by any net operating losses for such years, and gains (but not losses) realized on the sale of the Class A Ordinary Shares cannot be treated
as capital, even if you hold the Ordinary Shares as capital assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain elections may be available
that would result in alternative treatments. The adverse consequences of owning stock in a PFIC could be mitigated if a U.S. Holder makes
a valid QEF election (a U.S. Holder which we refer to as an &#8220;Electing Holder&#8221;) which, among other things, would require the
Electing Holder to include currently in income its pro rata share of the PFIC&#8217;s net capital gain and ordinary earnings, if any,
for our taxable year that ends with or within the taxable year of the Electing Holder, regardless of whether or not the Electing Holder
actually received distributions from us. When an Electing Holder makes a QEF election, its adjusted tax basis in our Class A Ordinary
Shares is increased to reflect taxed but undistributed earnings and profits. Distributions of earnings and profits that had been previously
taxed will result in a corresponding reduction in the adjusted tax basis in our Class A Ordinary Shares and will not be taxed again once
distributed. An Electing Holder would generally recognize capital gain or loss on the sale, exchange or other disposition of our Class
A Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder can make a QEF
election with respect to any year that we are a PFIC by filing IRS Form 8621 with its U.S. federal income tax return. This election must
be made by the deadline (including extensions) for filing the U.S. Holder&#8217;s federal tax return for the year in question. U.S. Holders
should discuss their election alternatives with their own tax advisors. Once an election is made, the Electing Holder is subject to the
QEF rules for as long as we are a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It should be noted that in
order to make a QEF election a U.S. Holder needs information from us concerning our PFIC status and our financial results for the year.
We cannot assure our U.S. Holders that we will provide such information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an alternative to making
a QEF election, a U.S. Holder may make a &#8220;mark-to-market&#8221; election with respect to our Class A Ordinary Shares provided our
Class A Ordinary Shares are treated as &#8220;marketable stock.&#8221; The Class A Ordinary Shares generally will be treated as marketable
stock if they are regularly traded on a &#8220;qualified exchange or other market&#8221; (within the meaning of applicable Treasury Regulations)
on at least 15 days during each calendar quarter (other than in de minimis amounts).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a U.S. Holder makes an effective
mark-to-market election, for each taxable year that we are a PFIC, the U.S. Holder will include as ordinary income the excess of the fair
market value of its Class A Ordinary Shares at the end of the year over its adjusted tax basis in the Class A Ordinary Shares. You will
be entitled to deduct as an ordinary loss in each such year the excess of your adjusted tax basis in the Class A Ordinary Shares over
their fair market value at the end of the year, but only to the extent of the net amount previously included in income as a result of
the mark-to-market election. A U.S. Holder&#8217;s adjusted tax basis in the Class A Ordinary Shares will be increased by the amount of
any income inclusion and decreased by the amount of any deductions under the mark-to-market rules. In addition, upon the sale or other
disposition of your Class A Ordinary Shares in a year that we are PFIC, any gain will be treated as ordinary income and any loss will
be treated as ordinary loss, but only to the extent of the net amount of previously included income as a result of the mark-to-market
election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a U.S. Holder makes a mark-to-market
election, it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the Class A
Ordinary Shares are no longer regularly traded on a qualified exchange or other market, or the IRS consents to the revocation of the election.
You are urged to consult your tax advisor about the availability of the mark-to-market election, and whether making the election would
be advisable in your particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><b><i>Information Reporting
and Backup Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payments of dividends and sales
proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information
reporting, and may be subject to backup withholding, unless (i)&#160;the U.S. Holder is a corporation or other exempt recipient or (ii)&#160;in
the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject
to backup withholding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not an
additional tax. The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the holder&#8217;s
U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><b><i>Information with Respect
to Foreign Financial Assets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. Holders may be
required to report information relating to the Class A Ordinary Shares, subject to certain exceptions (including an exception for Class
A Ordinary Shares held in accounts maintained by certain U.S. financial institutions). U.S. Holders should consult their tax advisors
regarding their reporting obligations with respect to their purchase, ownership and disposition of the Class A Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">F. <span style="text-decoration:underline">Dividends and Paying Agents</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">G. <span style="text-decoration:underline">Statement by Experts</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">H. <span style="text-decoration:underline">Documents on Display</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have previously filed the
Registration Statement with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the periodic
reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we are required to file reports and other
information with the SEC. Specifically, we are required to file annually a Form 20-F within four months after the end of each fiscal year.
Copies of reports and other information, when so filed, may be inspected without charge and may be obtained at prescribed rates at the
public reference facilities maintained by the SEC at Judiciary Plaza, 100 F Street, N.E., Washington, D.C. 20549. The public may obtain
information regarding the Washington, D.C. Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a web site
at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic
filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing,
among other things, the furnishing and content of proxy statements to shareholders, and our executive officers, directors and principal
shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also maintain a corporate
website at www.aptorumgroup.com. Information contained on, or that can be accessed through, our website does not constitute a part of
this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I. <span style="text-decoration:underline">Subsidiary Information</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a listing of our subsidiaries,
see &#8220;Item 4. Information on the Company &#8212; A. History and Development of the Company.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">J. <span style="text-decoration:underline">Annual Report to Security Holders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>For purposes of Item 11,
reference to the &#8220;Group&#8221; means Aptorum Group Limited and all of its subsidiaries.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Exchange Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currency risk is the risk that
the value of financial assets or liabilities will fluctuate due to changes in foreign exchange rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Currency risk sensitivity analysis</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, 2023 and 2022,
the Group has no significant foreign currency risk because most of the transactions are denominated in Hong Kong dollar or the United
States dollar. Since the Hong Kong dollar is pegged to the United States dollar, the Group&#8217;s exposure to foreign currency risk in
respect of the balances denominated in Hong Kong dollars is considered to be minimal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Credit Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial assets which potentially
subject the Group to concentrations of credit risk consist principally of bank deposits and balances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group takes on exposure
to credit risk on cash balances majority held with HSBC for the purposes of payments of Group expenses. The risk of default is considered
minimal as the Group considers HSBC is well established with high credit rating.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Liquidity risk is the risk
that the Group will encounter difficulty in raising funds to meet commitments associated with financial assets and liabilities. Liquidity
risk may result from an inability to sell a financial asset quickly at an amount close to its fair value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group invested in private
equities which are generally unquoted and not readily marketable before its restructuring to an operating company. After the restructuring
in 2017, the Group generally does not acquire new investments in unlisted securities that cannot be readily disposed of to minimize the
liquidity risk. Investment of the Group&#8217;s assets in unquoted securities may restrict the ability of the Group to dispose of its
investment at a price and time it wishes to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interest Rate Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest rate risk arises from
the possibility that changes in interest rates will affect future cash flows or the fair values of financial instruments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Interest rate risk sensitivity analysis</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s cash and
time deposits held with banks are exposed to interest rate risk. However, Management considers the risk on cash and time deposits to be
minimal as they are short-term with terms less than three months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inflation Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In recent years, inflation
has not had a material impact on our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 12. DESCRIPTION OF SECURITIES OTHER THAN
EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Items 12.D.3 and 12.D.4 of
this Item 12 is not applicable, as the Company does not have any American Depositary Shares; all other applicable information required
by this Item 12 is included in Exhibit 2.3.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Part II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 13. DEFAULTS, DIVIDEND ARREARAGES AND
DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 10. Additional
Information&#8221; for a description of the rights of securities holders, which remain unchanged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 15. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision and with
the participation of our management, including our chief executive officer and our chief financial accounting officer, we carried out
an evaluation of the effectiveness of our disclosure controls and procedures, which is defined in Rules 13a-15(e) of the Exchange Act,
as of December 31, 2023. Based on that evaluation, our chief executive officer and chief financial accounting officer concluded that our
disclosure controls and procedures, as of December 31, 2023, were not effective at the reasonable assurance level due to the material
weakness described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under
the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance
with Generally Accepted Accounting Principles (GAAP) in the United States of America and includes those policies and procedures that (1)
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
assets of our company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated
financial statements in accordance with GAAP, and that receipts and expenditures of our company are being made only in accordance with
authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of the unauthorized
acquisition, use or disposition of our company&#8217;s assets that could have a material effect on the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by Section 404
of the Sarbanes-Oxley Act of 2002 and related rules as promulgated by the Securities and Exchange Commission, our management including
our Chief Executive Officer and Chief Financial Accounting Officer assessed the effectiveness of internal control over financial reporting
as of December 31, 2023 using the criteria set forth in the report &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; published
by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that our internal
control over financial reporting was effective as of December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the previous
audit of our financial statements for the year ended December 31, 2023, we and our independent registered public accounting firm identified
one material weakness in our internal control over financial reporting, as defined in the standards established by the Public Company
Accounting Oversight Board of the United States. The material weakness identified was the lack of dedicated resources to take responsibility
for the finance and accounting functions and the preparation of financial statements in compliance with generally accepted accounting
principles in the United States, or U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since 2019, we took actions
to remediate the abovementioned material weakness, and we believe we have remediated the material weakness by implementing the following
measures:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide trainings to staff regarding to the preparation of financial statements in compliance with generally accepted accounting principles in the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">change to a new and well-established accounting system to enhance effectiveness and financial and system control; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">establish clear roles and responsibilities for accounting and financial reporting staff to address finance and accounting issues; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">continue to monitor the improvement on internal control over financial reporting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, since we are still
in the process of replenishing and building up a qualified finance and accounting team with sufficient dedicated resources, our management
assessed that the deficiency related to the lack of dedicated resources to take responsibility for the finance and accounting functions
and the preparation of financial statements in compliance with generally accepted accounting principles in the United States, or U.S.
GAAP, still existed as of December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that we
will not identify additional material weaknesses or significant deficiencies in the future. See &#8220;Item 3. Key Information&#8212;D.
Risk Factors&#8212; Risks Related to Our Industry, Business and Operation &#8212; If we fail to establish and maintain proper internal
financial reporting controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding there is a
material weakness identified as described above, we believe that our consolidated financial statements contained in this annual report
on Form 20-F fairly present our financial position, results of operations and cash flows for the years covered thereby in all material
respects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Attestation Report of the Company&#8217;s
Registered Public Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not include an attestation
report of the company&#8217;s registered public accounting firm due to rules of the SEC where domestic and foreign registrants that are
non-accelerated filers, which we are, are not required to provide the auditor attestation report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our
internal controls over financial reporting that occurred during the period covered by this annual report on Form 20-F that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16. [RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have one financial expert
as of the date of this report. Our Board of Directors has determined that Mr. Charles Bathurst, Chair of our audit committee, qualifies
as an &#8220;audit committee financial expert&#8221; as defined in the SEC rules and satisfies the financial sophistication requirements
of The NASDAQ Capital Market. Mr. Bathurst is &#8220;independent&#8221; as that term is defined in the rules of the SEC and the applicable
rules of the NASDAQ Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Code of
Ethics became effective on the effective date of the Registration Statement. The Code of Ethics is incorporated by reference to exhibit
14.1 of the Registration Statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the aggregate fees by categories specified below in connection with certain professional services rendered by our principal external auditors,
for the periods indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended<br/> December&#160;31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(In thousand)</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Audit fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">363</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Audit-related fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Tax fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">363</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">300</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Audit fees&#8221; represents
the aggregate fees billed or to be billed for each of the fiscal years listed for professional services rendered by our principal auditor
for the audit of our annual financial statements or services that in connection with statutory and regulatory filings or engagements for
those fiscal years.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Audit-related fees&#8221;
are the aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit and are not
reported under audit fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Tax fees&#8221; include
fees for professional services rendered by our principal auditor for tax compliance and tax advice on actual or contemplated transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Other fees&#8221; include
fees for services rendered by our independent registered public accounting firm with respect to other matters not reported under &#8220;Audit
fees&#8221;, &#8220;Audit-related fees&#8221; and &#8220;Tax fees&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The policy of our audit committee
is to pre-approve all audit and non-audit services provided by our principal auditor including audit services, audit-related services,
tax services and other services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16G. CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6. Directors,
Senior Management and Employees&#8221; for more information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16J. INSIDER TRADING POLICIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16K. CYBERSECURITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business activity to date has been focusing
on the healthcare field, and have not yet adopted formal cybersecurity risk management programs or formal processes for assessing cybersecurity
risks. We understand the importance of managing material risks from cybersecurity threats and are committed, as part of our continuing
growth, to implementing and maintaining an adequate information security program to manage such risks and safeguard our systems and data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently manage our cybersecurity risk through
a variety of practices that are applicable to all users of our information technology and information assets, including our employees
and contractors. We use a combination of technology, policies, training, and monitoring to promote security awareness and prevent security
incidents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the early stage of development of our projects,
we believe have limited exposure to cyber threats other than emails and project data storage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not, as of the date of this annual report,
experienced a cybersecurity threat or incident in the last three years, that materially affected or is reasonably likely to affect our
business, results of operations, or financial condition. However, there can be no guarantee that we will not experience such an incident
in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors oversees cybersecurity
risk as part of its role of overseeing enterprise-wide risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Part III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 17. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to provide
financial statements pursuant to Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 18. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements of Aptorum
Group Limited, and its subsidiaries are included at the end of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_034"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 19. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%"><span style="font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; text-align: justify; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">1.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022ex1-2_aptorumgroup.htm"><span style="font-size: 10pt">Third Amended and Restated Articles of Association, as amended <sup>(21)</sup></span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022ex2-1_aptorumgroup.htm"><span style="font-size: 10pt">Registrant&#8217;s Specimen Certificate for Ordinary Shares <sup>(21)</sup></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018015857/ff12018a2ex4-3_aptorum.htm">Form of Underwriter&#8217;s Warrant+++</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022ex2-3_aptorumgroup.htm"><span style="font-size: 10pt">Description of Securities registered under Section 12 of the Exchange Act of 1934, as amended <sup>(21)</sup></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020004797/ea119035ex99-3_aptorumgroup.htm">Form of Warrant+</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018015857/ff12018a2ex1-1_aptorum.htm">Form of Underwriting Agreement+++</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018012108/ff12018ex10-1_aptorum.htm">Appointment Letter between the Company and Ian Huen (Founder, Chief Executive Officer &amp; Executive Director), dated September 25, 2017*</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">4.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022ex4-51_aptorumgroup.htm"><span style="font-size: 10pt">Appointment
letter between the Company and Ian Huen (Non-Executive Director), dated May 27, 2022 <sup>(21)</sup></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea020368101ex4-4_aptorum.htm">Appointment letter between the Company and Ian Huen (Executive Director), dated <span style="font-size: 10pt">November 20</span>, 2023 <span style="font-size: 10pt">**</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">4.5</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018012108/ff12018ex10-10_aptorum.htm">Appointment Letter between the Company and Charles Bathurst (Independent Non-Executive Director), dated September 24, 2017*</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.6</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018012108/ff12018ex10-11_aptorum.htm">Appointment Letter between the Company and Mirko Scherer (Independent Non-Executive Director), dated September 24, 2017*</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">4.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018012108/ff12018ex10-12_aptorum.htm">Employment Agreement between the Company and Justin Wu (Independent Non-Executive Director), dated September 18, 2017*</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.8</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018012108/ff12018ex10-13_aptorum.htm">Employment Agreement between the Company and Douglas Arner (Independent Non-Executive Director), dated February 13, 2018*</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">4.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390021060309/ea150652ex99-1_aptorum.htm"><span style="font-size: 10pt">2017 Share Option Plan, as amended <sup>(15)</sup></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.10</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018012108/ff12018ex10-35_aptorum.htm">Service Agreement Between Covar Pharmaceuticals Incorporated and Videns Incorporation Limited*</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">4.11</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018012108/ff12018ex10-32_aptorum.htm"><span style="font-size: 10pt">Exclusive Patent License Agreement for ALS-4 dated October 18, 2017<sup>(3)</sup></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.12</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018012108/ff12018ex10-33_aptorum.htm">First Amendment to Exclusive License Agreement for ALS-4 dated June 7, 2018*</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">4.13</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020010347/f20f2019ex4-35_aptorum.htm"><span style="font-size: 10pt">Second Amendment to Exclusive License Agreement for ALS-4 dated July 10, 2019<sup>(6)</sup></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.14</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1734005/000121390019006328/f20f2018ex4-39_aptorumgroup.htm" style="-sec-extract: exhibit">Exclusive
    License Agreement for ALS-4 dated January 11, 2019<sup>(4)</sup></a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="vertical-align: top; text-align: justify; width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390019007008/f6k042419ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master Collaboration Agreement by and between the Company, A*ccelerate Technologies Pte. Ltd, and AENEAS CAPITAL LIMITED dated April 24, 2019<sup>(1)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390019007008/f6k042419ex10-2_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bond Repurchase Agreement dated April 24, 2019<sup>(1)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390019015761/f6k081419ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Line of Credit Agreement<sup>(2)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390019015761/f6k081419ex10-2_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Promissory Note<sup>(2)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020004797/ea119035ex99-2_aptorumgroup.htm">Form of Securities Purchase Agreement+</a></span></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390021003841/ea133776ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation Agreement with Illumina Inc. (portions of the exhibit have been omitted because they (i) are not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.)<sup>(7)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020004797/ea119035ex99-1_aptorumgroup.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agency Agreement, dated February 25, 2020 between the Company and Alliance Global Partners<sup>(8)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020004797/ea119035ex99-2_aptorumgroup.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement<sup>(8)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020004797/ea119035ex99-3_aptorumgroup.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant<sup>(8)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020029907/ea127736ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement dates as of September 29, 2020, by and among the Company and the purchasers named therein<sup>(9)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020029907/ea127736ex4-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant<sup>(9)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.26</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020029907/ea127736ex4-2_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant<sup>(9)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.27</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390020029907/ea127736ex4-3_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant<sup>(9)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.28</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390021021984/f20f2020ex4-62_aptorumgroup.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive License Agreement with Accelerate Technologies Pte Ltd.&#8217;s dated September 25, 2020<sup>(11, 12)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.29</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390021018040/ea138489ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement, dated March 26, 2021 between the Company and H.C. Wainwright<sup>(10)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.30</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390021021984/f20f2020ex4-64_aptorumgroup.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Subscription and Shareholders Agreement dated as of September 25, 2020<sup>(11,12)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.31</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390021029202/ea141720ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private Placement Shares Purchase Agreement with Jurchen Investment Corporation<sup>(14)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.32</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390022022702/f20f2021ex4-47_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concerted Action Agreement between Aptorum Therapeutics Limited and Peace Range Limited dated December 30, 2021 regarding to Mios Pharmaceuticals Limited&#160;<sup>(17)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.33</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390022022702/f20f2021ex4-48_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concerted Action Agreement between Aptorum Therapeutics Limited and Peace Range Limited dated December 30, 2021 regarding to Scipio Life Sciences Limited&#160;<sup>(17)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.34</span></td>
    <td style="vertical-align: top; text-align: justify"/>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390022038559/ea162582ex10-0_aptorumgroup.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations Services &amp; Secondment Agreement between Aptus Management Limited and MG Consultancy Limited&#160; <sup>(16)</sup></span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.35</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390022078577/ea169770ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement <sup>(18)</sup></span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.36</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390023022946/ea175787ex99-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-binding Letter of Intent<sup>(20)</sup></span></a></td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.37</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390024020286/ea0201196ex2-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger
    Agreement by and between Aptorum and YOOV, dated March 1, 2024 (Certain schedules have been omitted pursuant to Item 601(a)(5) of
    Regulation S-K. A copy of any omitted schedule will be furnished to the SEC upon request.) <sup>(22)</sup></span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.38</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390024020286/ea0201196ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Split-Off Agreement by and between Aptorum, ATL and Jurchen, dated March 1, 2024 <sup>(22)</sup></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.39</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390023075760/ea184688ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement and Form of convertible note dated September 11, 2023 <sup>(23)</sup></span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.40</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390023053553/ea180980ex10-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement dated June 28, 2023 <sup>(24)</sup></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">4.41</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390024020286/ea0201196ex10-2_aptorum.htm">Support Agreement by and between Aptorum and its major shareholder, dated March 1, 2024 (Certain
    schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished to the
    SEC upon request.) <sup>(22)</sup></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">4.42</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1734005/000121390024020286/ea0201196ex10-3_aptorum.htm">Form of Lock-up Agreement <sup>(22)</sup></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022ex8-1_aptorumgroup.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries (21)</span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea020368101ex12-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a)**</span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea020368101ex12-2_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a)** </span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea020368101ex13-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**</span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea020368101ex15-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Marcum Asia CPAs LLP**</span></a></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea020368101ex97-1_aptorum.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Policy for the Recovery of Erroneously Awarded Compensation**</span></a></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1734005/000121390018012108/ff12018ex14-1_aptorum.htm">Code of Business Ethics*</a></span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document**</span></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document**</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document**</span></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document**</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document**</span></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document**</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)**</span></td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.3in; text-align: justify"><span style="font-size: 10pt">***</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Furnished with this annual report on Form 20-F </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed with this annual report on Form 20-F</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Registration Statement Filed on Form F-1 on September 5, 2018</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.3in; text-align: justify"><span style="font-size: 10pt">+++</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Registration Statement Filed on Form F-1 on November 15, 2018</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">++</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on April 1, 2019</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">+</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on February 26, 2020</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.3in; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td>Incorporated by reference to our Current Report on Form 6-K filed on April 24, 2019 &#160;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.3in"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on August 14, 2019</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.3in; text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Registration Statement Filed on Form F-1 on September 5, 2018; portions of the exhibit were previously omitted in reliance on the confidential treatment provisions available pursuant to revised paragraph 4(a) of Instructions as to Exhibits of Form 20-F.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our annual report on Form 20-F filed on April 15, 2019; portions of the exhibit were previously omitted in reliance on the confidential treatment provisions available pursuant to revised paragraph 4(a) of Instructions as to Exhibits of Form 20-F.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our annual report on Form 20-F filed on April 15, 2019</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our annual report on Form 20-F filed on April 29, 2020. Certain information from this exhibit has been excluded from this exhibit because it both (i) is not material and (ii) would likely cause&#160;competitive harm to the Registrant if publicly disclosed.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on January 25, 2021; portions of the exhibit were omitted because they (i) are not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on February 26, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on October 2, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on March 26, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certain information from this exhibit has been excluded from this exhibit because it both (i) is not material and (ii) is the type that the registrant treats as private or confidential.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our annual report on Form 20-F filed on April 19, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on November 17, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(14)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on May 26, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(15)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on November 17, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(16)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on July 11, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(17)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our annual report on Form 20-F filed on April 29, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(18)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on December 9, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 29px"><span style="font-size: 10pt">(19)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Annual Report on Form 20-F/A filed on January 17, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.3in"><span style="font-size: 10pt">(20)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on March 27, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(21)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our annual report on Form 20-F filed on April 28, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(22) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on March 6, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(23) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on September 11, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(24)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated by reference to our Current Report on Form 6-K filed on June 30, 2023</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
annual report on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt">Aptorum Group Limited</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; width: 62%"><span style="font-size: 10pt">Date: April 30, 2024</span></td>
    <td style="vertical-align: top; width: 3%"><span style="font-size: 10pt">By:</span></td>
    <td style="vertical-align: bottom; width: 35%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Ian Huen</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Ian Huen</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Date: April 30, 2024</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">By:&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">/s/ Martin Siu</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Martin Siu</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Head of Finance</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Financial Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 93%"><span style="font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm (PCAOB&#160;ID: <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-26364">5395</ix:nonNumeric>)</a></span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; vertical-align: bottom; width: 6%; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#f_002"><span style="font-size: 10pt">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></td> <td>&#160;</td> <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-3</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#f_003">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021</a></span></td> <td>&#160;</td> <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#f_004">Consolidated Statements of Equity for the years ended December 31, 2023, 2022 and 2021</a></span></td> <td>&#160;</td> <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-5</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#f_005">Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021</a></span></td> <td>&#160;</td> <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#f_006">Notes to Consolidated Financial Statements</a></span></td> <td>&#160;</td> <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-7</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 150; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_013.jpg" style="width: 216px; height: 34px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders and Board of Directors of
Aptorum Group Limited</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Aptorum Group Limited (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements
of operations and comprehensive loss, equity and cash flows for each of the three years in the period ended December 31, 2023, and the
related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and
its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted
in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Critical audit matters are matters arising from the current period
audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to
accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex
judgments. We determined that there are no critical audit matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-15933">Marcum Asia CPAs <span style="font-variant: small-caps">llp</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum Asia CPAs <span style="font-variant: small-caps">llp</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-15945"><b>New York, NY</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>April 30, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NEW YORK OFFICE &#9679; 7 Penn Plaza &#9679; Suite
830 &#9679; New York, New York &#9679; 10001</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Phone 646.442.4845 &#9679; Fax 646.349.5200 &#9679; www.marcumasia.com</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2023 and 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-26365">2,005,351</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-26366">1,882,545</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-26367">3,130,335</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-26368">47,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-26369">174,426</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-26370">27,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Marketable securities, at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" unitRef="usd" id="ixv-26371">102,481</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Amounts due from related parties, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-26372">961</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-26373">129,677</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Due from brokers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:DueFromBrokers" scale="0" unitRef="usd" id="ixv-26374">652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loan receivable from related parties, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-26375">875,956</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other receivables and prepayments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-26376">422,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-26377">744,008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-26378">2,476,092</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-26379">7,067,802</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-26380">1,663,926</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-26381">2,825,059</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-26382">182,057</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-26383">347,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Long-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-26384">16,098,846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-26385">9,744,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-26386">147,347</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-26387">752,705</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Long-term deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-26388">71,823</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-26389">129,847</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-26390">20,640,091</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-26391">20,867,371</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">LIABILITIES AND EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Amounts due to related parties</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26392">79,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26393">12,693</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26394">1,894,341</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26395">6,166,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-26396">125,232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-26397">310,548</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Bank loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd" id="ixv-26398">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Convertible notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-26399">3,013,234</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26400">2,098,753</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26401">12,503,282</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating lease liabilities, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-26402">99,485</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-26403">30,784</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Convertible notes to a related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="0" unitRef="usd" id="ixv-26404">3,058,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Loan payables to related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-26405">500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-26406">5,256,738</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-26407">13,034,066</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">Class A Ordinary Shares ($<ix:nonFraction contextRef="c2" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-26408">0.00001</ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-26409">9,999,996,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-26410"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-26411">2,937,921</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023; $<ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-26412">10.00</ix:nonFraction> par value; <ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-26413">6,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-26414"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-26415">1,326,953</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of and 2022<sup>(1)</sup>)</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">13,269,528</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">Class B Ordinary Shares ($<ix:nonFraction contextRef="c3" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-26418">0.00001</ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-26419">4,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-26420"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-26421">2,243,776</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2023; $<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-26422">10.00</ix:nonFraction> par value; <ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-26423">4,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-26424"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-26425">2,243,776</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022<sup>(1)</sup>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">22,437,754</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-26428">93,018,528</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-26429">45,308,080</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accumulated other comprehensive (loss) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-26430">10,623</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-26431">33,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-26432">68,161,722</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-26433">65,337,075</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total equity attributable to the shareholders of Aptorum Group Limited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-26434">24,846,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-26435">15,712,094</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-26436">9,462,883</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-26437">7,878,789</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26438">15,383,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26439">7,833,305</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Liabilities and Equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-26440">20,640,091</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-26441">20,867,371</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For Years Ended December 31, 2023, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Healthcare services income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-26442">431,378</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-26443">1,295,889</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-26444">1,541,778</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Cost of healthcare services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-26445">420,812</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-26446">1,215,824</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-26447">1,459,924</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-26448">5,198,329</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-26449">9,219,595</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-26450">10,869,642</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">General and administrative fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-26451">1,930,637</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-26452">5,220,405</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-26453">5,409,302</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-26454">2,538,161</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-26455">2,888,140</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-26456">2,617,834</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="0" unitRef="usd" id="ixv-26457">1,067,690</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="0" unitRef="usd" id="ixv-26458">261,038</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="0" unitRef="usd" id="ixv-26459">392,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd" id="ixv-26460">11,155,629</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd" id="ixv-26461">18,805,002</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd" id="ixv-26462">20,749,213</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Other income (expenses), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss on investments in marketable securities, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-26463">9,266</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-26464">134,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-26465">8,031,595</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Unrealized gain from fair value change of the long-term investments,
net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfInvestments" scale="0" unitRef="usd" id="ixv-26466">6,353,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfInvestments" scale="0" unitRef="usd" id="ixv-26467">5,588,051</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss on investments in derivatives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" sign="-" unitRef="usd" id="ixv-26468">4,289</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Gain on use of digital currencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:GainOnUseOfDigitalCurrencies" scale="0" sign="-" unitRef="usd" id="ixv-26469">4,918</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Gain on derecognition of non-financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:GainOnDerecognitionOfNonfinancialAssets" scale="0" unitRef="usd" id="ixv-26470">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest (expense) income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" sign="-" unitRef="usd" id="ixv-26471">121,145</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" unitRef="usd" id="ixv-26472">146,588</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" sign="-" unitRef="usd" id="ixv-26473">93,601</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss on disposal of subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" scale="0" sign="-" unitRef="usd" id="ixv-26474">3,638</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Sundry income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:SundryIncome" scale="0" unitRef="usd" id="ixv-26475">159,799</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:SundryIncome" scale="0" unitRef="usd" id="ixv-26476">383,506</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:SundryIncome" scale="0" unitRef="usd" id="ixv-26477">146,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total other income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-26478">6,383,276</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-26479">5,984,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-26480">7,906,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26481">4,340,975</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26482">11,525,102</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26483">27,114,293</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss attributable to non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26484">1,516,328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26485">1,725,542</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26486">2,065,904</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss attributable to Aptorum Group Limited</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-26487">2,824,647</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-26488">9,799,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-26489">25,048,389</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss per share attributable to Aptorum Group Limited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">- Basic<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.62</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">2.75</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">7.15</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><span style="font-size: 10pt">- Diluted<sup>(1)</sup></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.62</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">2.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">7.15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">- Basic<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">4,521,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">3,569,484</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">3,503,396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><span style="font-size: 10pt">- Diluted<sup>(1)</sup></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">4,521,133</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">3,569,484</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">3,503,396</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26502">4,340,975</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26503">11,525,102</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26504">27,114,293</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Other comprehensive (loss) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-26505">44,430</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-26506">35,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-26507">55,315</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other comprehensive (loss) income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="0" sign="-" unitRef="usd" id="ixv-26508">44,430</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="0" unitRef="usd" id="ixv-26509">35,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="0" sign="-" unitRef="usd" id="ixv-26510">55,315</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26511">4,385,405</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26512">11,489,276</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26513">27,169,608</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Comprehensive loss attributable to non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26514">1,516,328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26515">1,725,542</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26516">2,065,904</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Comprehensive loss attributable to the shareholders of Aptorum Group Limited</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-26517">2,869,077</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-26518">9,763,734</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-26519">25,103,704</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For Years Ended December 31, 2023, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Class
    A <br/>
    Ordinary Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Class
    B <br/>
    Ordinary Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-size: 8pt">Additional<br/>
    Paid-in<br/>
    Capital</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-size: 8pt">Accumulated<br/>
    deficit</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-size: 8pt">Accumulated<br/>
    other<br/>
    comprehensive<br/>
    (loss) income</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-size: 8pt">Non-<br/>
    controlling<br/>
    interests</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-size: 8pt">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares<sup>(1)</sup></b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares<sup>(1)</sup></b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Amount</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; width: 37%; font-weight: bold; padding-left: 0.125in"><span style="font-size: 8pt">Balance, January
    1, 2021</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,158,432</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26521">11,584,324</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">2,243,776</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26523">22,437,754</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26524">38,247,903</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26525">30,489,126</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26526">53,296</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26527">3,681,858</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26528">38,152,293</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Issuance of Class A Ordinary
    Shares</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" id="ix_18_fact" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">138,793</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-26530">1,387,925</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-26531">2,612,075</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-26532">4,000,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Issuance of shares to non-controlling
    interest</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26533">66,783</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26534">61,423</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26535">5,360</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Disposal of subsidiaries
    under common control transaction</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" scale="0" unitRef="usd" id="ixv-26536">303,419</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" scale="0" sign="-" unitRef="usd" id="ixv-26537">5,386</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" scale="0" sign="-" unitRef="usd" id="ixv-26538">300,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" scale="0" sign="-" unitRef="usd" id="ixv-26539">1,967</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Disposal of subsidiaries</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries" scale="0" unitRef="usd" id="ixv-26540">7,962</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries" scale="0" unitRef="usd" id="ixv-26541">7,962</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" unitRef="usd" id="ixv-26542">1,682,460</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" unitRef="usd" id="ixv-26543">1,682,460</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Exercise of warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="apm:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" unitRef="shares">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" unitRef="usd" id="ixv-26545">40,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" unitRef="usd" id="ixv-26546">90,012</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" unitRef="usd" id="ixv-26547">130,012</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Exercise of options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" id="ix_20_fact" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">19,016</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26549">190,159</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26550">504,065</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26551">694,224</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Exchange difference on translation
    of foreign operation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" scale="0" sign="-" unitRef="usd" id="ixv-26552">49,929</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" scale="0" sign="-" unitRef="usd" id="ixv-26553">49,929</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-size: 8pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26554">25,048,389</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26555">2,065,904</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26556">27,114,293</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; font-weight: bold; padding-left: 0.125in"><span style="font-size: 8pt">Balance, December 31, 2021</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" id="ix_21_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,320,241</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26558">13,202,408</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" id="ix_22_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">2,243,776</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26560">22,437,754</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26561">43,506,717</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26562">55,537,515</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26563">2,019</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26564">6,101,223</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26565">17,506,122</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Issuance of shares to non-controlling
    interest</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26566">52,024</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26567">52,024</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-size: 8pt">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" unitRef="usd" id="ixv-26568">1,646,999</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" unitRef="usd" id="ixv-26569">1,646,999</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Exercise of options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" id="ix_23_fact" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">6,712</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26571">67,120</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26572">102,340</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26573">169,460</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Exchange difference on translation
    of foreign operation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" scale="0" unitRef="usd" id="ixv-26574">35,826</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" scale="0" unitRef="usd" id="ixv-26575">35,826</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-size: 8pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26576">9,799,560</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26577">1,725,542</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26578">11,525,102</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; padding-left: 0.125in"><span style="font-size: 8pt">Balance, December 31, 2022</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" id="ix_24_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,326,953</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26580">13,269,528</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" id="ix_25_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">2,243,776</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26582">22,437,754</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26583">45,308,080</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26584">65,337,075</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26585">33,807</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26586">7,878,789</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26587">7,833,305</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Adjustment for change of par value</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" scale="0" unitRef="usd" id="ixv-26588">13,269,514</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" scale="0" unitRef="usd" id="ixv-26589">22,437,732</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" scale="0" sign="-" unitRef="usd" id="ixv-26590">35,707,246</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-size: 8pt">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Issuance of shares to non-controlling
    interest</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26591">67,766</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26592">67,766</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-size: 8pt">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Issuance of shares in exchange
    of share options and settlement of liabilities</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" id="ix_26_fact" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">70,430</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-26594">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-26595">3,078,195</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-26596">3,078,196</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Issuance of shares for share-based
    compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" id="ix_27_fact" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares">65,770</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd" id="ixv-26598">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd" id="ixv-26599">176,263</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd" id="ixv-26600">176,264</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Issuance of shares</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" id="ix_28_fact" name="apm:StockIssuedDuringPeridSharesIssuanceOfShares" scale="0" unitRef="shares">215,959</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodValueIssuanceOfShares" scale="0" unitRef="usd" id="ixv-26602">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodValueIssuanceOfShares" scale="0" unitRef="usd" id="ixv-26603">1,575,560</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:StockIssuedDuringPeriodValueIssuanceOfShares" scale="0" unitRef="usd" id="ixv-26604">1,575,562</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" unitRef="usd" id="ixv-26605">1,088,925</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" unitRef="usd" id="ixv-26606">1,088,925</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Conversion of convertible
    notes</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" id="ix_29_fact" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">1,250,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-26608">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-26609">5,999,987</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-26610">6,000,000</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Exercise of share options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" id="ix_30_fact" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">791</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26612">16,506</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26613">16,506</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Rounding up for reverse stock
    split</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" id="ix_31_fact" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares">8,018</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-size: 8pt">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-size: 8pt">Exchange difference on translation
    of foreign operation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" scale="0" sign="-" unitRef="usd" id="ixv-26615">44,430</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" scale="0" sign="-" unitRef="usd" id="ixv-26616">44,430</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-size: 8pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26617">2,824,647</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26618">1,516,328</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26619">4,340,975</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt; padding-left: 0.125in"><span style="font-size: 8pt">Balance,
    December 31, 2023</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" id="ix_32_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">2,937,921</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26621">31</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" id="ix_33_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">2,243,776</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26623">22</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26624">93,018,528</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26625">68,161,722</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26626">10,623</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-26627">9,462,883</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">)</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-26628">15,383,353</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For Years Ended December 31, 2023, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Cash flows from operating activities</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 70%; font-weight: bold; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26629">4,340,975</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26630">11,525,102</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26631">27,114,293</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Amortization and depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-26632">1,125,254</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-26633">1,207,510</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-26634">1,192,578</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-26635">1,265,189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-26636">1,646,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-26637">1,682,460</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss on investments in marketable securities, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:LossGainOnInvestmentsInMarketableSecuritiesNet" scale="0" sign="-" unitRef="usd" id="ixv-26638">9,266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:LossGainOnInvestmentsInMarketableSecuritiesNet" scale="0" sign="-" unitRef="usd" id="ixv-26639">134,134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:LossGainOnInvestmentsInMarketableSecuritiesNet" scale="0" sign="-" unitRef="usd" id="ixv-26640">8,031,595</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Unrealized gain from fair value change of the long-term investments,
net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" unitRef="usd" id="ixv-26641">6,353,888</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" unitRef="usd" id="ixv-26642">5,588,051</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss on investments in derivatives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" sign="-" unitRef="usd" id="ixv-26643">4,289</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Gain on derecognition of non-financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" unitRef="usd" id="ixv-26644">75,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss on disposal of long-lived assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:LossOnDisposalOfLonglivedAssets" scale="0" sign="-" unitRef="usd" id="ixv-26645">110,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:LossOnDisposalOfLonglivedAssets" scale="0" sign="-" unitRef="usd" id="ixv-26646">205,189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:LossOnDisposalOfLonglivedAssets" scale="0" sign="-" unitRef="usd" id="ixv-26647">392</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Impairment loss on long-lived assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" unitRef="usd" id="ixv-26648">750,381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Allowance for credit loss of due from a related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:AllowanceForCreditLossOfDueFromARelatedParty" scale="0" unitRef="usd" id="ixv-26649">521,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Write-off of prepayment and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:WritteoffOfPrepaymentAndOtherReceivables" scale="0" unitRef="usd" id="ixv-26650">62,369</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Write-down of inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd" id="ixv-26651">13,206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss on disposal of subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" scale="0" sign="-" unitRef="usd" id="ixv-26652">3,638</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Gain on use of digital currencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:GainOnUseOfDigitalsCurrencies" scale="0" unitRef="usd" id="ixv-26653">4,918</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Settlement of service fee by tokens and digital currencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:SettlementOfServiceFeeByDigitalCurrenciesAndTokens" scale="0" sign="-" unitRef="usd" id="ixv-26654">90,457</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-26655">252,345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-26656">349,031</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-26657">425,280</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-26658">235,560</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-26659">41,246</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest expense and accretion of convertible debts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:InterestExpenseAndAccretionOfConvertibleDebts" scale="0" unitRef="usd" id="ixv-26660">45,266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:InterestExpenseAndAccretionOfConvertibleDebts" scale="0" unitRef="usd" id="ixv-26661">87,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:InterestExpenseAndAccretionOfConvertibleDebts" scale="0" unitRef="usd" id="ixv-26662">130,397</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accretion of finance lease obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:AccretionOfFinanceLeaseObligation" scale="0" unitRef="usd" id="ixv-26663">1,435</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:AccretionOfFinanceLeaseObligation" scale="0" unitRef="usd" id="ixv-26664">4,450</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reversal of deferred cash bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:ReversalDeferredCashBonus" scale="0" sign="-" unitRef="usd" id="ixv-26665">1,646,228</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Changes in operating assets and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd" id="ixv-26666">126,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-26667">95,704</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-26668">16,501</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-26669">14,516</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-26670">8,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-26671">3,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other receivables and prepayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-26672">226,805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" unitRef="usd" id="ixv-26673">105,584</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-26674">695,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Long-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="0" sign="-" unitRef="usd" id="ixv-26675">29,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="0" sign="-" unitRef="usd" id="ixv-26676">19,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Due from brokers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:IncreaseDecreaseDueFromBrokers" scale="0" sign="-" unitRef="usd" id="ixv-26677">652</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:IncreaseDecreaseDueFromBrokers" scale="0" sign="-" unitRef="usd" id="ixv-26678">75,728</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:IncreaseDecreaseDueFromBrokers" scale="0" sign="-" unitRef="usd" id="ixv-26679">83,957</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Amounts due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-26680">63,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" unitRef="usd" id="ixv-26681">46,349</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-26682">112,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Amounts due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-26683">8,524</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-26684">6,805</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-26685">264,934</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-26686">398,635</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-26687">1,918,751</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-26688">855,272</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-26689">389,365</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-26690">369,505</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-26691">450,807</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-26692">7,724,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-26693">12,318,965</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-26694">14,651,633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Purchases of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd" id="ixv-26695">6,026</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-26696">3,015</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-26697">186,916</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-26698">131,750</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from disposal of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-26699">15,385</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Disposal of subsidiaries, net of cash disposed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:DisposalOfSubsidiariesNetOfCashDisposed" scale="0" unitRef="usd" id="ixv-26700">113,830</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from sales of investment securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" unitRef="usd" id="ixv-26701">93,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" unitRef="usd" id="ixv-26702">20,116,734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loan to a related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="0" unitRef="usd" id="ixv-26703">92,459</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="0" unitRef="usd" id="ixv-26704">330,341</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="0" unitRef="usd" id="ixv-26705">3,358,089</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Repayment of loan and interest from a related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:RepaymentOfLoanFromRelatedParty" scale="0" sign="-" unitRef="usd" id="ixv-26706">611,641</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:RepaymentOfLoanFromRelatedParty" scale="0" sign="-" unitRef="usd" id="ixv-26707">2,962,153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd" id="ixv-26708">624,767</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd" id="ixv-26709">2,444,896</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd" id="ixv-26710">16,507,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loan from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-26711">2,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-26712">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-26713">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Repayment of loan due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-26714">5,489,665</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from issuance of subsidiaries shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="0" unitRef="usd" id="ixv-26715">5,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from issuance of Class A Ordinary Shares and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-26716">1,575,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-26717">4,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Payments of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercise of share options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26718">16,506</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26719">169,460</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd" id="ixv-26720">694,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd" id="ixv-26721">130,012</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loan from a bank</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromBankDebt" scale="0" unitRef="usd" id="ixv-26722">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Repayment of bank loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-26723">3,000,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from issuance of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-26724">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-26725">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Payment of finance lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd" id="ixv-26726">49,358</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd" id="ixv-26727">53,846</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-26728">4,092,068</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-26729">6,625,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-26730">2,780,725</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net (decrease) increase in cash and cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-26731">3,007,529</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-26732">3,248,607</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-26733">4,636,131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents and restricted cash &#8211; Beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-26734">5,012,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-26735">8,261,487</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-26736">3,625,356</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Cash and cash equivalents and restricted cash &#8211; End of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-26737">2,005,351</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-26738">5,012,880</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-26739">8,261,487</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Supplemental disclosures of cash flow information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-26740">94,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-26741">64,744</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-26742">273,155</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Income taxes paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds in broker accounts</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:ProceedsInBrokerAccounts" scale="0" unitRef="usd" id="ixv-26743">20,116,734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Non-cash operating, investing and financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-26744">338,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-26745">549,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Settlement of service fee by tokens and digital currencies</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" scale="0" unitRef="usd" id="ixv-26746">90,457</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Convertible notes converted to Class A Ordinary Shares</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:ConvertibleNotesConvertedToClassAOrdinaryShares" scale="0" unitRef="usd" id="ixv-26747">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Settlement of deferred cash bonus by issuance of share options</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:SettlementOfDeferredCashBonusByIssuanceOfShareOptions" scale="0" unitRef="usd" id="ixv-26748">3,078,196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Reconciliation of cash and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-26749">2,005,351</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-26750">1,882,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-26751">8,131,217</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-26752">3,130,335</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" unitRef="usd" id="ixv-26753">130,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-26754">2,005,351</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-26755">5,012,880</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-26756">8,261,487</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated financial
statements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-20968"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. ORGANIZATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the financial statements of Aptorum Group Limited (the &#8220;Company&#8221;) and its subsidiaries. The Company and its subsidiaries are
hereinafter collectively referred to as the &#8220;Group&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, formerly known as APTUS Holdings
Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, is a company incorporated on September 13, 2010 under the laws of the Cayman
Islands with limited liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company researches and develops life science
and biopharmaceutical products within its wholly-owned subsidiary, Aptorum Therapeutics Limited, formerly known as APTUS Therapeutics
Limited (&#8220;Aptorum Therapeutics&#8221;) and its indirect subsidiary companies (collectively, &#8220;Aptorum Therapeutics Group&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" id="ixv-26757">Below summarizes the list of the major subsidiaries consolidated as
of December 31, 2023:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 22%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Incorporation<br/>
date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Ownership</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Place of<br/>
incorporation</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Principle activities</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Aptorum Therapeutics Limited (&#8220;ATL&#8221;)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c56" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21009"><span style="font-size: 10pt">June 30, 2016</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26758">100</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c56" name="apm:EntityIncorporationsStateCountryName" id="ixv-21016"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c56" name="apm:PrincipleActivities" id="ixv-21020"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">APTUS MANAGEMENT LIMITED</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c58" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21027"><span style="font-size: 10pt">May 16, 2017</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c59" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26759">100</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c58" name="apm:EntityIncorporationsStateCountryName" id="ixv-21034"><span style="font-size: 10pt">Hong Kong</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c58" name="apm:PrincipleActivities" id="ixv-21038"><span style="font-size: 10pt">Provision of management services to its holding company and fellow subsidiaries</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Aptorum Medical Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c60" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21045"><span style="font-size: 10pt">August 28, 2017</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c61" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26760">90</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c60" name="apm:EntityIncorporationsStateCountryName" id="ixv-21052"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c60" name="apm:PrincipleActivities" id="ixv-21056"><span style="font-size: 10pt">Provision of medical clinic services</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Paths Innovations Limited </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c62" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21063"><span style="font-size: 10pt">April 15, 2019</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26761">100</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c62" name="apm:EntityIncorporationsStateCountryName" id="ixv-21070"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c62" name="apm:PrincipleActivities" id="ixv-21074"><span style="font-size: 10pt">Investment holding company</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Paths Diagnostics Pte. Limited </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c64" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21081"><span style="font-size: 10pt">June 5, 2019</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26762">75</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c64" name="apm:EntityIncorporationsStateCountryName" id="ixv-21088"><span style="font-size: 10pt">Singapore</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c64" name="apm:PrincipleActivities" id="ixv-21092"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Acticule Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c66" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21099"><span style="font-size: 10pt">June 30, 2017</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26763">80</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c66" name="apm:EntityIncorporationsStateCountryName" id="ixv-21106"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c66" name="apm:PrincipleActivities" id="ixv-21110"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Claves Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c68" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21117"><span style="font-size: 10pt">August 2, 2017</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26764">100</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c68" name="apm:EntityIncorporationsStateCountryName" id="ixv-21124"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c68" name="apm:PrincipleActivities" id="ixv-21128"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Nativus Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c70" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21135"><span style="font-size: 10pt">July 7, 2017</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26765">100</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c70" name="apm:EntityIncorporationsStateCountryName" id="ixv-21142"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c70" name="apm:PrincipleActivities" id="ixv-21146"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Videns Incorporation Limited </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c72" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21153"><span style="font-size: 10pt">March 2, 2017</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26766">100</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c72" name="apm:EntityIncorporationsStateCountryName" id="ixv-21160"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c72" name="apm:PrincipleActivities" id="ixv-21164"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Mios Pharmaceuticals Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c74" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21171"><span style="font-size: 10pt">March 6, 2018</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c75" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26767">97.93</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c74" name="apm:EntityIncorporationsStateCountryName" id="ixv-21178"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c74" name="apm:PrincipleActivities" id="ixv-21182"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">mTOR (Hong Kong) Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c76" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21189"><span style="font-size: 10pt">November 4, 2016</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26768">90</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c76" name="apm:EntityIncorporationsStateCountryName" id="ixv-21196"><span style="font-size: 10pt">Hong Kong</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c76" name="apm:PrincipleActivities" id="ixv-21200"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Scipio Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c78" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21207"><span style="font-size: 10pt">July 19, 2017</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c79" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26769">97.93</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c78" name="apm:EntityIncorporationsStateCountryName" id="ixv-21214"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c78" name="apm:PrincipleActivities" id="ixv-21218"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Signate Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c80" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-21225"><span style="font-size: 10pt">August 28, 2017</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-26770">100</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c80" name="apm:EntityIncorporationsStateCountryName" id="ixv-21232"><span style="font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c80" name="apm:PrincipleActivities" id="ixv-21236"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></ix:nonNumeric></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="apm:LiquidityDisclosureTextBlock" id="ixv-21264"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. LIQUIDITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group reported a net loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26771">4,340,975</ix:nonFraction> and
net operating cash outflow of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-26772">7,724,364</ix:nonFraction> for the year ended December 31, 2023. In addition, the Group had an accumulated deficit of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-26773">68,161,722</ix:nonFraction>
as of December 31, 2023. The Group&#8217;s operating results for future periods are subject to numerous uncertainties and it is uncertain
if the Group will be able to reduce or eliminate its net losses for the foreseeable future. If management is not able to generate significant
revenues from its product candidates currently in development, the Group may not be able to achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s principal sources of liquidity
have been cash, line of credit facility from related parties, bank loan, public offerings and convertible bonds. As of the date of issuance
of the consolidated financial statements, the Group has approximately $<ix:nonFraction contextRef="c82" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashEquivalents" scale="6" unitRef="usd" id="ixv-26774">1.0</ix:nonFraction> million of unrestricted cash or cash equivalents, and approximately
$<ix:nonFraction contextRef="c4" decimals="-6" format="ixt:num-dot-decimal" name="apm:UnrestrictedCashEquivalents" scale="6" unitRef="usd" id="ixv-26775">12</ix:nonFraction> million of undrawn line of credit facility from a related party. In addition, the Group will need to maintain its operating costs
at a level through strict cost control and budget, such as staff reductions, to ensure operating costs are minimized and will not exceed
such aforementioned sources of funds to continue as a going concern for a period within 12 months after the issuance of its consolidated
financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group believes that available cash, together
with the efforts from aforementioned management plan and actions, should enable the Group to meet current anticipated cash needs for at
least the next 12 months after the date that the consolidated financial statements are issued and the Group has prepared the consolidated
financial statements on a going concern basis. The Group may, however, need additional capital in the future to fund its continued operations.
If the Group determine that its cash requirements exceed the amount of cash and cash equivalents the Group has at the time, the Group
may seek to issue equity or debt securities or obtain credit facilities. The issuance and sale of additional equity or convertible debts
would result in further dilution to its shareholders. The incurrence of indebtedness would result in increased fixed obligations and could
result in operating covenants that might restrict its operations. The Group cannot assure that the financing will be available in amounts
or on terms acceptable to the Group, if at all.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-21277"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-21281"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Principles of presentation and consolidation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of the Group
are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;),
and include the accounts of the Company, its direct and indirect wholly and majority owned subsidiaries. In accordance with the provisions
of Accounting Standards Codification (&#8220;ASC&#8221;) 810, Consolidation, we consolidate any variable interest entity (&#8220;VIE&#8221;)
of which we are the primary beneficiary. The typical condition for a controlling financial interest ownership is holding a majority of
the voting interests of an entity; however, a controlling financial interest may also exist in entities, such as VIEs, through arrangements
that do not involve controlling voting interests. ASC 810 requires a variable interest holder to consolidate a VIE if that party has the
power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and the obligation to absorb
losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially
be significant to the VIE. We do not consolidate a VIE in which we have a majority ownership interest when we are not considered the primary
beneficiary. We have determined that we are not one of the primary beneficiary of the VIE (see Note 13, Variable Interest Entity). We
evaluate our relationships with the VIE on an ongoing basis to determine whether we become the primary beneficiary. All material intercompany
balances and transactions have been eliminated in preparation of the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="apm_NoncontrollingInterestsPolicyTextBlock-c0_cont_1" escape="true" name="apm:NoncontrollingInterestsPolicyTextBlock" id="ixv-21314"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Non-controlling interests</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="apm_NoncontrollingInterestsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-controlling interests are recognized to reflect
the portion of the equity of majority-owned subsidiaries which are not attributable, directly or indirectly, to the controlling shareholder.
Non-controlling interests are classified as a separate line item in the equity section of the Group&#8217;s consolidated balance sheets
and have been separately disclosed in the Group&#8217;s consolidated statements of operations and comprehensive loss and consolidated
statements of equity to distinguish the interests from that of the Group.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-21321"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of estimates</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as income
and expenses during the reporting period. Significant accounting estimates reflected in the Group&#8217;s consolidated financial statements
include fair value of long-term investments, fair value measurement for share options, impairment of long-lived assets, allowance for
credit losses and valuation allowance for deferred tax assets. Actual results could differ from those estimates.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-21328"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency translation and transaction</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">USD is the reporting currency. The functional
currency of subsidiaries in the Cayman Islands, Seychelles, Samoa and the United States are USD, the functional currency of subsidiaries
in Hong Kong is Hong Kong Dollars (&#8220;HKD&#8221;), the functional currency of a subsidiary in Singapore is Singapore Dollars (&#8220;SGD&#8221;),
the functional currency of a subsidiary in the United Kingdom is Great British Pound (&#8220;GBP&#8221;), and the functional currency
of subsidiaries in Canada is Canadian Dollars (&#8220;CAD&#8221;). An entity&#8217;s functional currency is the currency of the primary
economic environment in which it operates, normally that is the currency of the environment in which it primarily generates and expends
cash. The management considered various indicators, such as cash flows, market expenses, financing and inter-company transactions and
arrangements in determining the Group&#8217;s functional currency.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the consolidated financial statements, the
financial information of the Company and its subsidiaries, which use HKD, SGD, GBP and CAD as their functional currency, has been translated
into USD. Assets and liabilities are translated from each subsidiary&#8217;s functional currency at the exchange rates on the balance
sheet dates, equity amounts are translated at historical exchange rates, and revenues, expenses, gains, and losses are translated using
the average exchange rates for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a
separate component of other comprehensive income or loss in the consolidated statements of operations and comprehensive income or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-21338"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cash and cash equivalents</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consists of cash on
hand, bank deposits and time deposits with an original maturity of three months or less at the date of purchase.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-21345"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Restricted cash</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash represented time deposits pledged
for banking facilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ixv-21378"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable and amounts due from related
parties</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group adopted ASC 326 from January 1, 2023.
Accounts receivable and amounts due from related parties are stated at the original amount less an allowance for credit losses, if any,
based on a review of all outstanding amounts at period end. An allowance is estimated in accordance with ASC Topic 326, <i>Credit Losses</i>
and records the allowance for credit losses as an offset to accounts receivable or amounts due from related parties, and the expected
credit losses charged to the allowance is included in other operating expenses in the consolidated statements of operations and comprehensive
loss. In determining expected credit losses, the Group considers the historical level of credit losses, current economic trends, and reasonable
and supportable forecasts that affect the collectability of the future cash flows. As of December 31, 2023 and 2022, $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:AllowanceForCreditLossOfDueFromARelatedParty" scale="0" unitRef="usd" id="ixv-26776">521,007</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-192">$71</span>
allowance for credit losses were made.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-21387"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inventories</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_2" id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at lower of cost and net
realizable value. Cost is determined using the weighted average method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where there is evidence that the utility of inventories,
in their disposal in the ordinary course of business, will be less than cost, whether due to physical deterioration, obsolescence, changes
in price levels, or other causes, the inventories are written down to net realizable value. During the years ended December 31, 2023,
2022 and 2021, the write-down of inventories were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd" id="ixv-26777">13,206</ix:nonFraction>, $<span style="-sec-ix-hidden: hidden-fact-193">nil</span> and $<span style="-sec-ix-hidden: hidden-fact-194">nil</span> respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_MarketableSecuritiesPolicy-c0_cont_1" escape="true" name="us-gaap:MarketableSecuritiesPolicy" id="ixv-21399"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Marketable securities</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_MarketableSecuritiesPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable securities are publicly traded stocks
measured at fair value and classified within Level 1 and 2 in the fair value hierarchy because the Group either uses quoted prices for
identical assets in active markets, inputs that are based upon quoted prices for similar instruments in active markets, or quoted prices
for identical assets in markets with insufficient volume or infrequent transaction (less active markets).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="apm:LongtermInvestmentsPolicyPolicyTextBlock" id="ixv-21406"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Long-term investments</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_2" id="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s long-term investments consist
of equity method investment in common stocks and non-marketable investments in non-redeemable preferred shares of privately-held companies
that are not required to be consolidated under the variable interest or voting models. Long-term investments are classified as non-current
assets on the consolidated balance sheets as those investments do not have stated contractual maturity dates.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_3" id="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Non-marketable investments</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_4" id="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The non-marketable equity securities not accounted
for under the equity method are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in
orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach
as of the transaction date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_5" id="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Equity method investment &#8211; Fair value option</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="apm_LongtermInvestmentsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group elects the fair value option for an
investment that would otherwise be accounted for using the equity method of accounting. Such election is irrevocable and is applied on
an investment by investment basis at initial recognition. The fair value of such investments is based on quoted prices in an active market,
if any, or recent orderly transactions for identical or similar investment of the same issuer. Changes in the fair value of these equity
method investments are recognized in other income (expenses), net in the consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-21453"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair value measurement</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the price that would
be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the
Group considers the principal or most advantageous market in which it would transact its business, and it considers assumptions that market
participants would use when pricing the asset or liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a basis for considering such assumptions, a
three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The hierarchy requires the Group to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s categorization
within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Group has
estimated the fair value amounts of its financial instruments using the available market information and valuation methodologies considered
to be appropriate and has determined that the carrying value of the Group&#8217;s cash, restricted cash, accounts receivable, due from
brokers, other receivables and prepayments, loan receivables from related parties, amounts due from/to related parties, accounts payable
and accrued expenses, bank loan, and loan payables to a related party as of December 31, 2023 and 2022 approximate fair value due to the
short-term nature of these assets and liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-21495"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and equipment, net</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment, net, is stated at cost
less accumulated depreciation and impairment losses. Cost represents the purchase price of the asset and other costs incurred to bring
the asset into its existing use. Maintenance, repairs and betterments, including replacement of minor items, are charged to expense; major
additions to physical properties are capitalized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets under construction are stated at cost less
impairment losses. Cost comprises of cost of laboratory equipment delivered but not ready to be used, together with interest expense capitalized
during the period of construction or installation and testing. Capitalization of these costs ceases and the asset concerned is transferred
to the appropriate fixed assets category when substantially all the activities necessary to prepare the asset for its intended use are
completed.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock-c0_cont_1" escape="true" name="apm:PropertyPlantAndEquipmentUsefullLifeTableTextBlock" id="ixv-26778">Depreciation of property, plant and equipment
is provided using the straight-line method over their estimated useful lives:</ix:nonNumeric>&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_5" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 51%"><span style="font-size: 10pt">Computer equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 48%; text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c85" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-26779">3</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Furniture, fixture, and office and medical equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c86" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-26780">5</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c87" name="apm:LeaseholdImprovementsEstimatedUsefulLives" id="ixv-21528"><span style="font-size: 10pt">Shorter of the remaining lease terms or 5 years</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c88" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-26781">5</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Motor vehicle</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c89" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-26782">5</ix:nonNumeric> years</span></td></tr>
  </table></ix:continuation></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon sale or disposal, the applicable amounts
of asset cost and accumulated depreciation are removed from the accounts and the net amount less proceeds from disposal is charged or
credited to income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="ixv-21572"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Intangible assets, net</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_2" id="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finite-lived intangible assets are carried at
cost less accumulated amortization and impairment if any. The finite intangible assets are amortized over their estimated useful life,
which is the period over which the assets are expected to contribute directly or indirectly to the future cash flows of the Group.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s intangible assets mainly consist
of computer software and is amortized over its useful life. The estimated useful life is generally <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-26783">5</ix:nonNumeric> years. The Group will reassess the
remaining useful life on annual basis.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-21582"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of long-lived assets</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group reviews its long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When these events
occur, the Group compares the carrying value of the long-lived assets to the estimated undiscounted future cash flows expected to result
from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flow is less than the carrying
amount of the assets, the Group would recognize an impairment loss, which is the excess of carrying amount over the fair value of the
assets, using the expected future discounted cash flows.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DebtPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock" id="ixv-21589"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Convertible notes</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DebtPolicyTextBlock-c0_cont_2" id="_DebtPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group evaluates and accounts for conversion
options embedded in convertible notes in accordance with ASC 815 &#8220;Derivatives and Hedging Activities&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DebtPolicyTextBlock-c0_cont_3" id="_DebtPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applicable GAAP requires companies to bifurcate
conversion options from their host instruments and account for them as derivative financial instruments according to certain criteria.
The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly
and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded
derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings
as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DebtPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for the convertible notes as
a single unit of account, unless the conversion feature requires bifurcation and recognition as derivatives. Additionally, the Group uses
the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential
share settlement for instruments that may be settled in cash or shares.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="apm_OperatingLeasesPolicyTextBlock-c0_cont_1" escape="true" name="apm:OperatingLeasesPolicyTextBlock" id="ixv-21628"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Operating leases</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="apm_OperatingLeasesPolicyTextBlock-c0_cont_2" id="apm_OperatingLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of a contract, the Group determines
if the arrangement is, or contains, a lease. Operating lease liabilities are recognized at lease commencement based on the present value
of lease payments over the lease term. Operating lease right-of-use assets are initially measured at cost, which comprises the initial
amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs
incurred and less any lease incentives received. As the rate implicit in the lease cannot be readily determined, the Group uses incremental
borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental
borrowing rate is determined based on the rate of interest that the Group would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term in a similar economic environment. The lease term for all of the Group&#8217;s leases includes
the non-cancellable period of the lease plus any additional periods covered by either a Group&#8217;s option to extend (or not to terminate)
the lease that the Group is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.
For operating leases, the Group recognizes a single lease cost on a straight-line basis over the remaining lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="apm_OperatingLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has elected not to recognize right-of-use
assets or lease liabilities for leases with an initial term of 12 months or less and the Group recognizes lease expense for these leases
on a straight-line basis over the lease terms.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="apm_WarrantLiabilitiesPolicyTextBlock-c0_cont_1" escape="true" name="apm:WarrantLiabilitiesPolicyTextBlock" id="ixv-21638"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Warrants </span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="apm_WarrantLiabilitiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection of the issuance of Class A Ordinary
Shares, the Company may issue warrants to purchase Class A Ordinary Shares. Warrants classified as equity are initially recorded at fair
value and subsequent changes in fair value are not recognized.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-21645"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues are derived from healthcare services
rendered to patients for healthcare consultation and medical treatment. Revenue is reported at the amount that reflects the consideration
to which the Group expects to be entitled in exchange for providing healthcare services.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group recognizes revenue as its performance
obligations are completed. Healthcare services are treated as a single performance obligation satisfied at a point in time because the
performance obligations are generally satisfied over a period of less than one day.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock" id="ixv-21655"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cost of healthcare services</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of healthcare services rendered represents
cost in relation to the medical services provided including the compensation of the physicians, cost of pharmaceutical supplies and medicine
and write-down of inventories.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-21662"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Research and development expenses</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed as
incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including
amortization of the patent license, depreciation of laboratory equipment, costs of engaging external consultants, advisors and contracted
research organization to conduct preclinical development activities and trials, payroll expenses to research and development staff, sponsored
research expenses to universities and research institutions, and impairment of patent license and laboratory equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-21695"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share-based compensation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group uses the fair value method of accounting
for the share options granted to directors, employees, external consultants and advisors to measure the cost services received in exchange
for the share based awards. The fair value of share option awards with only service condition is estimated on the grant or offering date
using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires inputs such as the risk-free interest rate,
expected term and expected volatility. These inputs are subjective and generally require significant judgment. The resulting cost is recognized
over the period during which a director, employee, external consultant or advisor is required to provide service in exchange for the awards,
usually the vesting period, which is generally from <ix:nonNumeric contextRef="c83" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-26784">9.5</ix:nonNumeric> months to <ix:nonNumeric contextRef="c84" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-26785">21.5</ix:nonNumeric> months. Share-based compensation expense is recognized on a graded
vesting basis, net of actual forfeitures in the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based compensation expense is recorded in
cost of healthcare services, research and development expenses, general and administrative fees and legal and professional fees in the
consolidated statements of operations and comprehensive loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 718, modifications to stock-based
awards are accounted for as exchanges of the original awards for new awards. The incremental fair value, which is the difference between
the fair value of the modified award and the original award immediately before modification, is measured at the modification date. This
incremental fair value is recognized immediately as compensation cost for vested awards. For unvested awards, the incremental compensation
cost, along with any remaining unrecognized compensation cost of the original award, is recognized over the remaining requisite vesting
period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-21708"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income taxes</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for income taxes under the
asset and liability method. Under this method, deferred income taxes are determined based on differences between the financial carrying
amounts of existing assets and liabilities and their tax bases. Income taxes are provided for in accordance with the laws of the relevant
taxing authorities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is provided for deferred
tax assets if it is more likely than not that these items will either expire before the Group is able to realize their benefits, or that
future deductibility is uncertain. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxUncertaintiesPolicy-c0_cont_1" escape="true" name="us-gaap:IncomeTaxUncertaintiesPolicy" id="ixv-21718"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Uncertain tax positions</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_IncomeTaxUncertaintiesPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for uncertainty in income taxes
using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition
by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit,
including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest
amount that is more than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-26786">50</ix:nonFraction>% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized
and recorded as necessary in the provision for income taxes. The Group recognizes interest on non-payment of income taxes and penalties
associated with tax positions when a tax position does not meet more likely than not thresholds be sustained under examination. The tax
returns of the Group&#8217;s Hong Kong subsidiaries are subject to examination by the relevant tax authorities. According to the Hong
Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed or has
been assessed at less than the proper amount, the statute of limitation is extended to ten years if the underpayment of taxes is due to
fraud or willful evasion. According to United Kingdom, Singapore, the United States, Canada and Ireland tax rule, trading losses are available
to be carried forward indefinitely. The Group did not have any material interest or penalties associated with tax positions for the years
ended December 31, 2023, 2022 and 2021, and did not have any significant unrecognized uncertain tax positions as of December 31, 2023
and 2022. The Group does not believe that its assessment regarding unrecognized tax benefits will materially change over the next twelve
months.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ixv-21725"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Comprehensive income or loss</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain changes in assets and liabilities are
reported as separate components of the equity section of the consolidated balance sheets, such items, along with net income or loss, are
components of comprehensive income or loss. The components of other comprehensive income or loss consist of exchange differences on translation
of foreign operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-21732"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Net income or loss per share</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net income or loss per share is computed
by dividing net income or loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during
the period. Diluted net income or loss per share reflects the potential dilution that could occur if securities or other contracts to
issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation
of diluted loss per share in loss periods as their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-21765"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of credit risk</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial assets which potentially subject the
Group to concentrations of credit risk consist principally of bank deposits and balances.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group takes on exposure to credit risk on
cash balances majority held with HSBC for the purposes of payments of Group expenses. The risk of default is considered minimal as the
Group considers HSBC is well established with high credit rating.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-21775"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recently adopted accounting pronouncements</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)
No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13
is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held
by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets
held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires
enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used
in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#8217;s portfolio. These disclosures
include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements.
In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13
are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December
15, 2022 for the Group. The Group has adopted ASU 2016-13 on January 1, 2023 and the impact of this adoption for the years ended December
31, 2023 and 2022 were assessed to be not material.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="ixv-21782"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recently issued accounting standards which have not yet been adopted</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_2" id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements,
primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. The amendments
in this ASU are effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years
beginning after December 15, 2024, with early adoption permitted. The Group is still evaluating the effect of the adoption of this guidance.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_3" id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued Accounting Standards
Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness
of income tax disclosures. The amendments address more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. The ASU also includes certain other amendments to improve
the effectiveness of income tax disclosures. The amendments in this ASU are effective for public business entities for annual periods
beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Group is still evaluating the effect of the
adoption of this guidance.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_4" id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2024, the SEC approved a rule that
will require registrants to provide certain climate-related information in their registration statements and annual reports. The rule
requires information about a registrant&#8217;s climate-related risks that are reasonably likely to have a material impact on its business,
results of operations, or financial condition. The required information about climate-related risks also includes disclosure of a registrant&#8217;s
greenhouse gas emissions. In addition, the rules will require registrants to present certain climate-related financial metrics in their
audited financial statements. The Group is evaluating the potential impact of this rule on the consolidated financial statements and related
disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group does not believe other recently issued
but not yet effective accounting standards, if currently adopted, would have a material impact on the consolidated financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-21800"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. REVENUE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023, 2022 and
2021, all revenue came from provision of healthcare services in Hong Kong.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2023, the Group made
a decision to streamline its operations by terminating clinic services and suspending non-lead R&amp;D projects.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-21837"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. INVESTMENT AND FAIR VALUE MEASUREMENT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Assets Measured at Fair Value on a Recurring Basis</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="ixv-26787">The following table provides the assets and liabilities
carried at fair value measured on a recurring basis as of December 31, 2023 and 2022:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2" id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Non-current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in">Long-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Common stocks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total assets at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in">Marketable securities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.25in">Common stocks</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd" id="ixv-26788">10,202</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd" id="ixv-26789">92,279</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd" id="ixv-26790">102,481</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Long-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Common stocks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd" id="ixv-26791">77,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd" id="ixv-26792">77,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total assets at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd" id="ixv-26793">10,202</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd" id="ixv-26794">92,279</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd" id="ixv-26795">77,200</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd" id="ixv-26796">179,681</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="ixv-26797">The following is a reconciliation of Level 3 assets
measured and recorded at fair value on a recurring basis during the years ended December 31, 2023 and 2022:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<ix:continuation id="_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" scale="0" unitRef="usd" id="ixv-26798">77,200</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd" id="ixv-26799">77,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net change in unrealized appreciation relating to investments still held at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Balance at January 1, 2022</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" scale="0" unitRef="usd" id="ixv-26800">77,200</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in unrealized appreciation, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" scale="0" unitRef="usd" id="ixv-26801">77,200</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in unrealized appreciation relating to investments still held at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, an impairment
loss relating to an equity method investment amounted to $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-26802">77,200</ix:nonFraction>, was recorded in other expenses, net, as the Group considered that the
carrying amount of the equity method investment may not be recoverable, and this condition is determined to be other-than-temporary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="ixv-26803">The following table presents the quantitative
information about the Group&#8217;s Level 3 fair value measurements of investment as of December 31, 2023 and 2022, which utilized significant
unobservable internally-developed inputs:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_2" id="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>December 31, 2023</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation technique</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Unobservable input</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Range<br/>
(weighted average)</b></p></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Common stocks</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c117" name="apm:FairValueMeasurementValuationTechniques" id="ixv-22183"><span style="font-size: 10pt">Recent transactions</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c117" name="apm:FairValueMeasurementsUnobservableInput" id="ixv-22187"><span style="font-size: 10pt">Recent transaction price</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c117" name="apm:FairValueMeasurementsWeightedAverageRange" id="ixv-22191"><span style="font-size: 10pt">$0.0001 - $0.01</span></ix:nonNumeric></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>December 31, 2022</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation technique</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Unobservable input</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Range<br/>
(weighted average)</b></p></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Common stocks</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c118" name="apm:FairValueMeasurementValuationTechniques" id="ixv-22226"><span style="font-size: 10pt">Recent transactions</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c118" name="apm:FairValueMeasurementsUnobservableInput" id="ixv-22230"><span style="font-size: 10pt">Recent transaction price</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c118" name="apm:FairValueMeasurementsWeightedAverageRange" id="ixv-22234"><span style="font-size: 10pt">$0.0001 - $0.01</span></ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-marketable investments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s non-marketable investments are
investments in privately held companies without readily determinable fair values. The carrying value of the non-marketable investments
are adjusted based on price changes from observable transactions of identical or similar securities of the same issuer (referred to as
the measurement alternative) or for impairment if the carrying amount of the non-marketable investments may not be fully recoverable.
Any changes in carrying value are recorded within other income (expenses), net in the consolidated statements of operations and comprehensive
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock-c0_cont_1" escape="true" name="apm:ScheduleOfUnrealizedLossOnInvestmentTableTextBlock" id="ixv-26804">The following is a summary of annual upward or
downwards adjustments and impairment recorded in other income (expenses), net, and included as adjustments to the carrying value of non-marketable
investments held as of&#160;December 31, 2023, 2022 and 2021 based on the observable price in an orderly transaction for the same or similar
security of the same issuers:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Upward adjustments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:UpwardAdjustments" scale="0" unitRef="usd" id="ixv-26805">6,431,088</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:UpwardAdjustments" scale="0" unitRef="usd" id="ixv-26806">6,108,872</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Downward adjustments and impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:DownwardAdjustmentsAndImpairment" scale="0" sign="-" unitRef="usd" id="ixv-26807">520,821</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total unrealized gain from fair value change of non-marketable investments,
net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:TotalUnrealizedGainForNonmarketableInvestments" scale="0" unitRef="usd" id="ixv-26808">6,431,088</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:TotalUnrealizedGainForNonmarketableInvestments" scale="0" unitRef="usd" id="ixv-26809">5,588,051</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group did not sell any non-marketable investments
or recorded any realized gains or losses for the non-marketable investments measured at fair value on a non-recurring basis during the
years ended December 31, 2023, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock-c0_cont_1" escape="true" name="apm:ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock" id="ixv-26810">The following table summarizes the total carrying
value of the non-marketable investments held as of&#160;December 31, 2023 and 2022&#160;including cumulative unrealized upward and downward
adjustments and impairment made to the initial cost basis of the investments:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Initial cost basis</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:InitialCostBasis" scale="0" unitRef="usd" id="ixv-26811">4,079,707</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:InitialCostBasis" scale="0" unitRef="usd" id="ixv-26812">4,079,707</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Upward adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:UpwardAdjustment" scale="0" unitRef="usd" id="ixv-26813">12,539,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:UpwardAdjustment" scale="0" unitRef="usd" id="ixv-26814">6,108,872</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Downward adjustments and impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:DownwardAdjustmentAndImpairment" scale="0" sign="-" unitRef="usd" id="ixv-26815">520,821</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:DownwardAdjustmentAndImpairment" scale="0" sign="-" unitRef="usd" id="ixv-26816">520,821</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total carrying value at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:TotalCarryingValueAtTheEndOfThePeriod" scale="0" unitRef="usd" id="ixv-26817">16,098,846</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:TotalCarryingValueAtTheEndOfThePeriod" scale="0" unitRef="usd" id="ixv-26818">9,667,758</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group did not transfer any non-marketable
investments into marketable securities for the years ended December 31, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, one of the
non-marketable investments with initial cost of $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherInvestments" scale="6" unitRef="usd" id="ixv-26819">2.6</ix:nonFraction> million and had a carrying value of $<ix:nonFraction contextRef="c90" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherInvestments" scale="6" unitRef="usd" id="ixv-26820">15.1</ix:nonFraction> million was pledged for a convertible note
issued to a related party (Note 15).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity method investment, fair value option</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2021, one of the Group&#8217;s subsidiaries,
Libra Sciences Limited (&#8220;Libra&#8221;, formerly known as Aptorum Pharmaceutical Development Limited), issued Class A and Class B
ordinary shares to various parties in exchange of licenses or cash. <ix:nonNumeric contextRef="c0" name="us-gaap:KeyProvisionsOfOperatingOrPartnershipAgreementDescription" id="ixv-26821">Each Class A share of Libra is entitled to 1 vote while each Class
B share of Libra is entitled to 10 votes.</ix:nonNumeric> Upon the share issuance, the Group was holding <ix:nonFraction contextRef="c91" decimals="4" format="ixt:num-dot-decimal" name="apm:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-26822">97.27</ix:nonFraction>% economic interest and <ix:nonFraction contextRef="c92" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-26823">31.51</ix:nonFraction>% voting power
in Libra. The Group lost the controlling interest in Libra because it was transferred to a third party, and therefore deconsolidated Libra.
However, the Group still owns <ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="apm:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-26824">97.27</ix:nonFraction>% economic interest and <ix:nonFraction contextRef="c93" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-26825">31.51</ix:nonFraction>% voting power, which is deemed as having significant influence over Libra.
As a result, the Group&#8217;s investment in Libra is subject to the equity method of accounting. The Group assessed that the fair value
option can better reflect the true value of Libra. Pursuant to ASC 825 &#8211; Financial Instruments (&#8220;ASC 825&#8221;), the Group
elected to apply the fair value option for its investments in Libra and will remeasure its investments in Libra at fair value every reporting
period. For the year ended December 31, 2023, the Group has determined that the carrying value of the investment is not recoverable and
this condition is determined to be other-than-temporary. Consequently, an impairment for the investment of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="0" unitRef="usd" id="ixv-26826">77,200</ix:nonFraction> has been recognized
for the year end December 31, 2023.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-22426"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6.&#160;OTHER RECEIVABLES AND PREPAYMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="ixv-26827">Other receivables and prepayments as of December 31, 2023 and 2022
consisted of:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:PrepaidResearchAndDevelopmentExpenses" scale="0" unitRef="usd" id="ixv-26828">185,633</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:PrepaidResearchAndDevelopmentExpenses" scale="0" unitRef="usd" id="ixv-26829">305,178</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" unitRef="usd" id="ixv-26830">33,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" unitRef="usd" id="ixv-26831">47,833</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid service fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:PrepaidServiceFee" scale="0" unitRef="usd" id="ixv-26832">46,303</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:PrepaidServiceFee" scale="0" unitRef="usd" id="ixv-26833">148,346</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Rental deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="0" unitRef="usd" id="ixv-26834">102,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="0" unitRef="usd" id="ixv-26835">16,296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid rental expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidRent" scale="0" unitRef="usd" id="ixv-26836">15,683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-26837">22,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-26838">204,752</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-26839">16,253</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-26840">21,603</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-26841">422,071</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-26842">744,008</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, the Group
considered certain other receivables and prepayments were not recoverable. Hence, the write-off of other receivables and prepayments of
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:WritteoffOfPrepaymentAndOtherReceivables" scale="0" unitRef="usd" id="ixv-26843">62,369</ix:nonFraction> was recorded in other operating expenses.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-22540"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. PROPERTY AND EQUIPMENT, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-26844">Property and equipment as of December 31, 2023 and 2022 consisted of:</ix:nonNumeric>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26845">81,138</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26846">84,636</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture, fixture, and office and medical equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26847">150,292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26848">298,738</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26849">543,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26850">543,975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26851">4,336,764</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26852">6,229,072</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Motor vehicle</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26853">239,093</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26854">239,093</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26855">5,351,262</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-26856">7,395,514</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-26857">3,687,336</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-26858">4,570,455</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-26859">1,663,926</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-26860">2,825,059</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses for property, plant and
equipment amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-26861">1,041,234</ix:nonFraction>, $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-26862">1,092,957</ix:nonFraction> and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-26863">1,086,564</ix:nonFraction> for the years ended December 31, 2023, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, an impairment loss relating to
the office and medical equipment, and computer equipment related to the Hong Kong healthcare services amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses" scale="0" unitRef="usd" id="ixv-26864">28,128</ix:nonFraction>, was recorded
in other operating expenses, as the Group considered that, with the termination of the healthcare services, the carrying amount of these
property and equipment are not recoverable and are fully impaired. For the years ended December 31, 2022 and 2021, no impairment loss
was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, the Group
recorded $<ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" unitRef="usd" id="ixv-26865">79,822</ix:nonFraction> of loss on disposal of laboratory equipment, and furniture, fixture, and office and medical equipment in other operating
expense. For the year ended December 31, 2021, the Group recorded $<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" unitRef="usd" id="ixv-26866">392</ix:nonFraction> of loss on disposal of office equipment in other operating expenses.
For the year ended December 31, 2022, no gain or loss on disposal was recorded.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-22678"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. INTANGIBLE ASSETS, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ixv-22683"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Gross carrying amount</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid patented licenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-26867">728,205</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-26868">1,038,205</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Computer software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-26869">223,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-26870">223,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-26871">952,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-26872">1,262,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: accumulated amortization and impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid patented licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-26873">728,205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-26874">474,131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Computer software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-26875">76,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-26876">35,227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-26877">804,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-26878">509,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid patented licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-26879">564,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Computer software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-26880">147,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-26881">188,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-26882">147,347</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-26883">752,705</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Group has capitalized
eight of the exclusive licenses, which includes seven patented technologies in relation to the Group&#8217;s therapeutics segment respectively.
Pursuant to the license agreements, the Group paid upfront payments and became the exclusive licensee to prosecute certain patents developed
or licensed under the applicable agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, the Group terminated two of the
licenses. The Group is also in the process of terminating the other six licenses, and hence the Group considered that the carrying amount
of these intangible assets are not recoverable and are fully impaired. As a result, the Group recorded $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-26884">519,496</ix:nonFraction> impairment loss on intangible
assets in research and development expenses. Besides, an impairment loss related to the computer software for Hong Kong healthcare services
amounted to $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-26885">1,841</ix:nonFraction>&#160;was recorded in other operating expenses, as the Group considered that the carrying amount of these intangible
assets are not recoverable and are fully impaired. For the year ended December 31, 2022, a loss on disposal of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="0" sign="-" unitRef="usd" id="ixv-26886">205,189</ix:nonFraction> related to a patented
license was recognized in research and development expenses. For the year ended December 31, 2021, no impairment loss and gain or loss
on disposal was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid patented licenses and computer software
are finite-lived intangible assets which are amortized over their estimated useful life. Amortization expenses for finite-lived intangible
assets amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-26887">84,020</ix:nonFraction>, $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-26888">114,553</ix:nonFraction> and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-26889">106,014</ix:nonFraction> for the years ended December 31, 2023, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group wrote off the cost and the related amortization
of $<span style="-sec-ix-hidden: hidden-fact-215">nil</span>, $<span style="-sec-ix-hidden: hidden-fact-216">nil</span> and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:WroteOffOfCostRelatedAmortization" scale="0" unitRef="usd" id="ixv-26890">1,344</ix:nonFraction> after the expiration of the computer software for the years ended December 31, 2023, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock-c0_cont_1" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="ixv-26891">The Group expects amortization expense related
to its finite-lived intangible assets for the next five years and thereafter to be as follows as of December 31, 2023:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">For the years ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd" id="ixv-26892">38,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd" id="ixv-26893">38,439</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd" id="ixv-26894">38,439</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" unitRef="usd" id="ixv-26895">32,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-26896">147,347</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LongTermDebtTextBlock" id="ixv-22913"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. LONG-TERM DEPOSITS</b></p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="apm_ScheduleOfLongTermDepositsTableTextBlock-c0_cont_1" escape="true" name="apm:ScheduleOfLongTermDepositsTableTextBlock" id="ixv-26897">Long-term deposits as of December 31, 2023 and 2022 consisted of:</ix:nonNumeric>&#160;</p>

<p style="margin: 0">&#160;</p>

<ix:continuation id="apm_ScheduleOfLongTermDepositsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Rental deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:RentalDeposits" scale="0" unitRef="usd" id="ixv-26898">71,823</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:RentalDeposits" scale="0" unitRef="usd" id="ixv-26899">127,303</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepayments for equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:PrepaymentsForEquipment" scale="0" unitRef="usd" id="ixv-26900">2,544</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-26901">71,823</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-26902">129,847</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>



</div><p style="margin: 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-22973"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-26903">Accounts payable and accrued expenses as of December 31, 2023 and 2022
consisted of:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:continuation id="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Deferred bonus and salaries payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26904">451,660</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26905">5,084,969</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development expenses payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:ResearchAndDevelopmentExpensesPayable" scale="0" unitRef="usd" id="ixv-26906">1,162,155</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:ResearchAndDevelopmentExpensesPayable" scale="0" unitRef="usd" id="ixv-26907">563,913</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-26908">175,324</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-26909">226,407</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost of healthcare services payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:CostOfHealthcareServicesPayable" scale="0" unitRef="usd" id="ixv-26910">61,826</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:CostOfHealthcareServicesPayable" scale="0" unitRef="usd" id="ixv-26911">138,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Insurance expenses payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:InsuranceExpensePayable" scale="0" unitRef="usd" id="ixv-26912">27,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:InsuranceExpensePayable" scale="0" unitRef="usd" id="ixv-26913">33,367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-26914">15,913</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-26915">119,835</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26916">1,894,341</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-26917">6,166,807</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group entered into exchange
agreements and cancelled <ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="apm:VestedAndUnvestedShareOptions" scale="0" unitRef="shares" id="ixv-26918">177,667</ix:nonFraction> existing vested and unvested share options held by related parties option holders and cancelled its obligations
for deferred cash bonus payables of $<ix:nonFraction contextRef="c133" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" unitRef="usd" id="ixv-26919">3.1</ix:nonFraction> million by granting <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26920">403,820</ix:nonFraction> share options with 6 months vesting period (see Note 17). The settlement
of obligations of $<ix:nonFraction contextRef="c135" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" scale="6" unitRef="usd" id="ixv-26921">3.1</ix:nonFraction> million deferred cash bonus payables was deemed as capital contribution from related parties and was credited to
additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group entered into exchange
agreements and cancelled <ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="apm:VestedAndUnvestedShareOptions" scale="0" unitRef="shares" id="ixv-26922">70,428</ix:nonFraction> existing vested and unvested share options held by non-related parties option holders and cancelled its
obligations for deferred cash bonus payables of $<ix:nonFraction contextRef="c136" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" unitRef="usd" id="ixv-26923">1.6</ix:nonFraction> million by issuance of <ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-26924">70,430</ix:nonFraction> fully vested Class A Ordinary Shares (see Note 16).
The reversal of deferred cash bonus payables for $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost" scale="6" unitRef="usd" id="ixv-26925">1.0</ix:nonFraction> million and $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="6" unitRef="usd" id="ixv-26926">0.6</ix:nonFraction> million was credited to research and development expenses and general
and administrative fees, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-23079"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The&#160;Company and&#160;its subsidiaries file tax returns separately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cayman Islands: under the current laws of the
Cayman Islands, the Company and its subsidiaries in the Cayman Islands are not subject to taxes on their income and capital gains.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hong Kong: in accordance with the relevant tax
laws and regulations of Hong Kong, a company registered in Hong Kong is subject to income taxes within Hong Kong at the applicable tax
rate on taxable income. In March 2018, the Hong Kong Government introduced a two-tiered profit tax rate regime by enacting the Inland
Revenue (Amendment) (No.3) Ordinance 2018 (the &#8220;Ordinance&#8221;). <ix:nonNumeric contextRef="c139" name="apm:IncomeTaxDescription" id="ixv-26927">Under the two-tiered profits tax rate regime, the first $2 million
of assessable profits of qualifying corporations is taxed at 8.25% and the remaining assessable profits at 16.5%. The Ordinance is effective
from the year of assessment 2018-2019. According to the policy, if no election has been made, the whole of the taxpaying entity&#8217;s
assessable profits will be chargeable to Profits Tax at the rate of 16.5% or 15%, as applicable. Because the preferential tax treatment
is not elected by the Group, all the subsidiaries registered in Hong Kong are subject to income tax at a rate of 16.5%.</ix:nonNumeric> The subsidiaries
registered in Hong Kong did not have assessable profits that were derived Hong Kong during the years ended December 31, 2023, 2022 and
2021. Therefore, no Hong Kong profit tax has been provided for in the periods presented. Our returns for 2017 and subsequent tax years
remain subject to examination by Hong Kong Inland Revenue Department.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">United Kingdom: in accordance with the relevant
tax laws and regulations of United Kingdom, a company registered in the United Kingdom is subject to income taxes within United Kingdom
at the applicable tax rate on taxable income. All the United Kingdom subsidiaries that are not entitled to any tax holiday were subject
to income tax at a rate of <ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-26928">19</ix:nonFraction>%. The subsidiary in United Kingdom did not have assessable profits that were derived from United Kingdom
during the years ended December 31, 2023, 2022 and 2021. Therefore, no United Kingdom profit tax has been provided for in the periods
presented. Our returns for 2019 and subsequent tax years remain subject to examination by the UK tax authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Singapore: in accordance with the relevant tax
laws and regulations of Singapore, a company registered in the Singapore is subject to income taxes within Singapore at the applicable
tax rate on taxable income. All the Singapore subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate
of <ix:nonFraction contextRef="c141" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-26929">17</ix:nonFraction>%. The subsidiary in Singapore did not have assessable profits that were derived from Singapore during the years ended December 31,
2023, 2022 and 2021. Therefore, no Singapore profit tax has been provided for in the periods presented. Our returns for 2019 and subsequent
tax years remain subject to examination by the Singapore tax authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">United States (Nevada): in accordance with the
relevant tax laws and regulations of the United States, a company registered in the United States is subject to income taxes within the
United States at the applicable tax rate on taxable income. All the United States subsidiaries in Nevada that are not entitled to any
tax holiday were subject to income tax at a rate of <ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-26930">21</ix:nonFraction>%. The subsidiary in the United States did not have assessable profits that were
derived from the United States during the years ended December 31, 2023, 2022 and 2021. Therefore, no United States profit tax has been
provided for in the periods presented. Our returns for 2020 and subsequent tax years remain subject to examination by Internal Revenue
Service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Canada: in accordance with the relevant tax laws
and regulations of Canada, a company registered in Canada is subject to income taxes within Canada at the applicable tax rate on taxable
income. All the Canada subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of <ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-26931">15</ix:nonFraction>%. The subsidiary
in Canada did not have assessable profits that were derived from Canada during the years ended December 31, 2023, 2022 and 2021. Therefore,
no Canada profit tax has been provided for in the periods presented. Our returns for 2019 and subsequent tax years remain subject to examination
by the Canada tax authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-26932">The components of the provision for income taxes expenses are:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/> December&#160;31,<br/> 2023</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/> December&#160;31,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/> December&#160;31,<br/> 2021</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total income taxes expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-26933">The reconciliation of income taxes expenses computed
at the Hong Kong statutory tax rate applicable to income tax expense is as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 203</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26934">4,340,975</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26935">11,525,102</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-26936">27,114,293</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for income taxes at Hong Kong statutory income tax rate (<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-26937">16.5</ix:nonFraction>%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-26938">716,261</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-26939">1,901,642</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-26940">4,473,859</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact of different tax rates in other jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" sign="-" unitRef="usd" id="ixv-26941">16,272</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" sign="-" unitRef="usd" id="ixv-26942">263,787</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" sign="-" unitRef="usd" id="ixv-26943">214,135</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" scale="0" unitRef="usd" id="ixv-26944">1,071,774</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" scale="0" unitRef="usd" id="ixv-26945">907,495</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" scale="0" unitRef="usd" id="ixv-26946">716,628</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" unitRef="usd" id="ixv-26947">98,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" unitRef="usd" id="ixv-26948">1,992,463</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26949">1,705,603</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26950">3,072,924</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26951">3,412,159</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Effective income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Deferred tax asset, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-26952">Deferred tax assets and deferred tax liabilities
reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purpose
and the tax bases used for income tax purpose. The following represents the tax effect of each major type of temporary difference.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax asset:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Tax loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-26953">16,956,748</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-26954">14,865,121</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd" id="ixv-26955">229,126</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd" id="ixv-26956">948,893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:DeferredTaxAssetsDepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-26957">128,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Impairment of long-lived assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" scale="0" unitRef="usd" id="ixv-26958">92,416</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-26959">17,407,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-26960">15,814,014</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax liability:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-26961">108,926</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:NetDeferredTaxAssetsBeforeValuationAllowance" scale="0" unitRef="usd" id="ixv-26962">17,407,156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:NetDeferredTaxAssetsBeforeValuationAllowance" scale="0" unitRef="usd" id="ixv-26963">15,705,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26964">17,407,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26965">15,705,088</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023 and 2022, the Group had
net operating loss carry-forwards of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-26966">102,367,435</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-26967">90,060,983</ix:nonFraction>, respectively, including its Hong Kong, Singapore, the United States,
the United Kingdom and Canada operations, which are available to reduce future taxable income and have an unlimited carryover period.
For the year ended December 31, 2023, there was no tax loss carried forward expired, while tax loss brought forward of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:LossCarryforwardCancelled" scale="0" unitRef="usd" id="ixv-26968">28,281</ix:nonFraction> was cancelled
due to the disposal of various subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Valuation allowance was provided against deferred
tax assets in entities where it was determined, it was more likely than not that the benefits of the deferred tax assets will not be realized.
The Group had deferred tax assets which consisted of tax loss carry forward, which can be carried forward to offset future taxable income.
The Group maintains a full valuation allowance on its net deferred tax assets. The management determines it is more likely than not that
all of its deferred tax assets will not be utilized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_SummaryOfValuationAllowanceTextBlock-c0_cont_1" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="ixv-26969">Changes in valuation allowance are as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:continuation id="_SummaryOfValuationAllowanceTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance as of January 1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26970">15,705,088</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26971">12,632,164</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26972">9,561,560</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:ValuationAllowanceDeferredTaxAssetIncrease" scale="0" unitRef="usd" id="ixv-26973">1,705,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:ValuationAllowanceDeferredTaxAssetIncrease" scale="0" unitRef="usd" id="ixv-26974">3,072,924</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:ValuationAllowanceDeferredTaxAssetIncrease" scale="0" unitRef="usd" id="ixv-26975">3,412,159</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Disposal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:ValuationAllowanceDeferredTaxAssetDecreaseAmount" scale="0" sign="-" unitRef="usd" id="ixv-26976">3,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:ValuationAllowanceDeferredTaxAssetDecreaseAmount" scale="0" sign="-" unitRef="usd" id="ixv-26977">341,555</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance as of December 31</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26978">17,407,156</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26979">15,705,088</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-26980">12,632,164</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-23610"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. RELATED PARTY BALANCES AND TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a list of a director and related parties to which
the Group has transactions with:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Ian Huen, the Chief Executive Officer and Executive Director of the Group since November 2023. He was a Non-executive Director from June 2022 to November 2023. Before June 2022, he was the Chief Executive Officer and Executive Director;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Jurchen Investment Corporation, the holding company and an entity controlled by Ian Huen;</span></td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">CGY Investment Limited, an entity owns more than <ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-26981">10</ix:nonFraction>% voting interest of the Group before April 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Aeneas Group Limited, an entity controlled by Ian Huen;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">(e)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Aenco Technologies Ltd, an entity being <ix:nonFraction contextRef="c145" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedPercentOfNetAssets" scale="-2" unitRef="pure" id="ixv-26982">34.56</ix:nonFraction>% effectively owned by Ian Huen;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">(f)</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt">Aeneas Management Limited, an entity controlled by Ian Huen;</span></td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(g)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Talem Medical Group Limited, an entity which Clark Cheng was a director;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(h)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Libra Sciences Limited, an entity which was originally a wholly owned subsidiary of ATL. Since December 30, 2021, Libra has been turned into a related party to the Group due to the voting power owned by ATL is decreased to below <ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="apm:DecreasedOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-26983">50</ix:nonFraction>% but more than <ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="apm:DecreasedOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-26984">20</ix:nonFraction>%. (Note 13) </span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Libra Therapeutics Limited, a wholly owned subsidiary of Libra Sciences Limited; </span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(j)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Clark Cheng, a former Executive Director of the Group before November 30, 2023. After his resignation on November 30, 2023, he was no longer a related party of the Group.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(k)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">ACC Medical Limited, an entity controlled by Clark Cheng.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>(l)</td> <td style="text-align: justify">Darren Lui, a former Executive Director of the Group before November
27, 2023. After his resignation on November 27, 2023, he was no longer a related party of the Group.</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Amounts due from related parties, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock-c0_cont_1" escape="true" name="apm:ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock" id="ixv-26985">Amounts due from related parties consisted of the following as of December
31, 2023 and 2022:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Aeneas Management Limited</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueFromRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26986">961</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Libra Sciences Limited (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueFromRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26987">521,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueFromRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26988">378,036</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Libra Therapeutics Limited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueFromRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26989">17,459</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Talem Medical Group Limited (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueFromRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26990">610,138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetInvestmentInLease" scale="0" unitRef="usd" id="ixv-26991">521,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueFromRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26992">961</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueFromRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26993">1,005,633</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Amounts due to related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="apm_ScheduleOfDueToRelatedPartiesTableTextBlock-c0_cont_1" escape="true" name="apm:ScheduleOfDueToRelatedPartiesTableTextBlock" id="ixv-26994">Amounts due to related parties consisted of the following as of December
31, 2023 and 2022:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="apm_ScheduleOfDueToRelatedPartiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Aeneas Group Limited (Note a)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26995">79,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26996">8,110</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Aenco Technologies Ltd</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26997">3,013,234</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Clark Cheng</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26998">4,583</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-26999">79,180</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesCurrent" scale="0" unitRef="usd" id="ixv-27000">3,025,927</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jurchen Investment Corporation (Note 15)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesNoncurrent" scale="0" unitRef="usd" id="ixv-27001">3,058,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Aeneas Group Limited (Note a)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesNoncurrent" scale="0" unitRef="usd" id="ixv-27002">500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesNoncurrent" scale="0" unitRef="usd" id="ixv-27003">3,058,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="apm:AmountsDueToRelatedPartiesNoncurrent" scale="0" unitRef="usd" id="ixv-27004">500,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Related party transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-27005">Related party transactions consisted of the following
for the years ended December 31, 2023, 2022 and 2021:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Loan from related parties (Note a)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-27006">2,500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-27007">500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-27008">1,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-27009">2,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan repayment and interest paid to related parties (Note a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="apm:LoanRepaymentAndInterestPaidToRelatedParties" scale="0" unitRef="usd" id="ixv-27010">2,673,389</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="apm:LoanRepaymentAndInterestPaidToRelatedParties" scale="0" unitRef="usd" id="ixv-27011">3,085,097</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of Convertible Note to related parties (Note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="apm:LoanRepaymentAndInterestPaidToRelatedParties" scale="0" unitRef="usd" id="ixv-27012">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aenco Technologies Ltd</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-27013">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Settlement of loan from a related party through issuance of Convertible Note (Note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="apm:ConsultantSecondmentManagementAndAdministrativeServicesFees" scale="0" unitRef="usd" id="ixv-27014">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expenses (Note a and Note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-27015">71,123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-27016">8,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-27017">64,753</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-27018">58,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-27019">65,644</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aenco Technologies Ltd</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" sign="-" unitRef="usd" id="ixv-27020">13,234</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-27021">13,234</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan to related parties (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Talem Medical Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="0" unitRef="usd" id="ixv-27022">3,358,089</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Libra Sciences Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="0" unitRef="usd" id="ixv-27023">92,459</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="0" unitRef="usd" id="ixv-27024">330,341</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan repayment and interest received from a related party (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Talem Medical Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="apm:RepaymentOfLoanFromRelatedParty" scale="0" unitRef="usd" id="ixv-27025">611,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="apm:RepaymentOfLoanFromRelatedParty" scale="0" unitRef="usd" id="ixv-27026">2,962,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest income (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Talem Medical Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-27027">4,637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-27028">164,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-27029">39,561</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Libra Sciences Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-27030">8,963</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-27031">14,232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consultant, secondment, management and administrative services fees (Note c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- CGY Investments Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="apm:ConsultantSecondmentManagementAndAdministrativeServicesFees" scale="0" unitRef="usd" id="ixv-27032">153,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="apm:ConsultantSecondmentManagementAndAdministrativeServicesFees" scale="0" unitRef="usd" id="ixv-27033">268,102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="apm:ConsultantSecondmentManagementAndAdministrativeServicesFees" scale="0" unitRef="usd" id="ixv-27034">173,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- ACC Medical Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="apm:ConsultantSecondmentManagementAndAdministrativeServicesFees" scale="0" unitRef="usd" id="ixv-27035">138,768</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="apm:ConsultantSecondmentManagementAndAdministrativeServicesFees" scale="0" unitRef="usd" id="ixv-27036">209,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="apm:ConsultantSecondmentManagementAndAdministrativeServicesFees" scale="0" unitRef="usd" id="ixv-27037">157,511</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Administrative management services (Note d)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Libra Sciences Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="apm:AdministrativeManagementServices" scale="0" unitRef="usd" id="ixv-27038">9,615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="apm:AdministrativeManagementServices" scale="0" unitRef="usd" id="ixv-27039">38,462</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Healthcare services income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Management Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-27040">961</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-27041">1,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-27042">7,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note a: On August 13, 2019, Aptorum Therapeutics
Limited (&#8220;ATL&#8221;), a wholly owned subsidiary of the Company, entered into financing arrangements with Aeneas Group Limited,
a related party, and Jurchen Investment Corporation, the ultimate parent of the Group, allowing ATL to access up to a total $<ix:nonFraction contextRef="c146" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermLineOfCredit" scale="6" unitRef="usd" id="ixv-27043">15</ix:nonFraction> million
in line of credit debt financing. Both line of credits have originally matured on August 12, 2022. ATL and Aeneas Group Limited has mutually
agreed to extend the line of credit arrangement further <ix:nonNumeric contextRef="c147" format="ixt-sec:duryear" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="ixv-27044">3</ix:nonNumeric> years to August 12, 2025. The interest on the outstanding principal indebtedness
is at the rate of <ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-27045">8</ix:nonFraction>% per annum. ATL may early repay, in whole or in part, the principal indebtedness and all interest accrued at any time
prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty. As of the issuance
date of this consolidated financial statements, the undrawn line of credit facility is $<ix:nonFraction contextRef="c146" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" unitRef="usd" id="ixv-27046">12</ix:nonFraction> million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note b: On November 17, 2021, ATL entered into
a loan agreement with Talem Medical Group Limited (the &#8220;Borrower&#8221;). According to the loan agreement, ATL granted a loan of
up to <span style="-sec-ix-hidden: hidden-fact-253">AUD4,700,000</span> for the Borrower for general working capital purposes of the Borrower and its subsidiaries. The loan is interest-bearing
at a rate of <ix:nonFraction contextRef="c150" decimals="2" format="ixt:num-dot-decimal" name="apm:LoansInterestbearingRate" scale="-2" unitRef="pure" id="ixv-27047">10</ix:nonFraction>% per annum and secured by the entire issued shares of Talem Medical Group (Australia) Pty Limited held by the Borrower.
The loan is initially matured 6 months from the date of the first drawdown. The maturity date was extended for 6 months to the first extended
maturity date, and further extended for another 6 months to the second extended maturity date. As of the date of the issuance of this
consolidated financial statements, there is no outstanding balance from the Borrower following a repayment in February 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 13, 2022, ATL entered a line of credit
facility with Libra Sciences Limited to provide up to a total $<ix:nonFraction contextRef="c151" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-27048">1</ix:nonFraction> million line of credit for its daily operation. The line of credit is
originally matured on <ix:nonNumeric contextRef="c151" format="ixt:date-monthname-day-year-en" name="us-gaap:LongTermDebtMaturityDate" id="ixv-27049">January 12, 2023</ix:nonNumeric>, and is extended for additional <ix:nonNumeric contextRef="c152" format="ixt-sec:duryear" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="ixv-27050">3</ix:nonNumeric> years. The interest on the outstanding principal indebtedness
is at the rate of <ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-27051">10</ix:nonFraction>% per annum. ATL and Libra Science Limited mutually agreed to terminate the line of credit agreement effect as of
March 31, 2023. All existing liabilities arising from the line of credit agreement shall remain enforceable and repayable on demand by
ATL. As of the issuance date of this consolidated financial statements, $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" scale="6" unitRef="usd" id="ixv-27052">0.5</ix:nonFraction> million is outstanding from Libra Sciences Limited. For the
year ended December 31, 2023, the Group has assessed that the amounts due from Libra Science Limited and its subsidiary are potentially
unrecoverable. Accordingly, an allowance for credit loss amounting to $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" unitRef="usd" id="ixv-27053">0.5</ix:nonFraction> million has been recognized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note c: CGY Investment Limited provided certain
consultancy, advisory and management services to the Group on potential investment projects related to healthcare or R&amp;D platforms.
CGY Investment Limited is initially entitled to receive HK $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFees" scale="0" unitRef="hkd" id="ixv-27054">104,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFees" scale="0" unitRef="usd" id="ixv-27055">13,333</ix:nonFraction>) per calendar month plus reimbursement; such
monthly service fee is adjusted to HK$<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFeesAdjusted" scale="0" unitRef="hkd" id="ixv-27056">171,200</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFeesAdjusted" scale="0" unitRef="usd" id="ixv-27057">21,949</ix:nonFraction>) with effect from March 1, 2022. In August 2023, CGY Investment
Limited has agreed to suspended its monthly services fee from August 1, 2023. In November 2023, CGY Investment Limited and the Group reached
a mutual agreement to terminate their contractual relationship.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ACC Medical Limited provided certain consultancy,
advisory, and management services to the Group on clinic operations and other related projects for clinics&#8217; business development.
ACC Medical Limited is initially entitled to receive HK $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFees" scale="0" unitRef="hkd" id="ixv-27058">101,542</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFees" scale="0" unitRef="usd" id="ixv-27059">13,018</ix:nonFraction>) per calendar month plus reimbursement; such monthly
service fee is adjusted to HK$<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFeesAdjusted" scale="0" unitRef="hkd" id="ixv-27060">143,200</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFeesAdjusted" scale="0" unitRef="usd" id="ixv-27061">18,359</ix:nonFraction> per month) effective from March 1, 2022. During the year ended December
31, 2023 and 2022, ACC Medical Limited also received $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CompensationAndBenefitsTrust" scale="0" unitRef="usd" id="ixv-27062">28,615</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CompensationAndBenefitsTrust" scale="0" unitRef="usd" id="ixv-27063">23,275</ix:nonFraction> one-off compensation respectively. The agreement was terminated
on June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note d:&#160;On January 1, 2022, Aptus
Management Limited (&#8220;AML&#8221;), a wholly owned subsidiary of the Company, entered into an administrative management services
agreement with Libra Sciences Limited. According to the agreement, AML will provide documentation and administrative services,
include but are not limited to human resources and payroll administration, general secretarial and administrative support, and
accounting and financial reporting services. AML is entitled to receive a fixed amount of services fees of HKD <ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFees" scale="0" unitRef="hkd" id="ixv-27064">25,000</ix:nonFraction> (approximately
$<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="apm:ServicesFees" scale="0" unitRef="usd" id="ixv-27065">3,205</ix:nonFraction>) per calendar month with the original expiry date on December 31, 2023. AML and Libra Sciences Limited mutually agreed to
terminate the administrative management service agreement effect as of March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note e: In accordance with mutual agreements reached with the board
of directors, Mr. Clark Cheng and Mr. Ian Huen agreed to forgo their monthly remuneration effective July 1, 2023 until further notice.
Moreover, Mr. Darren Lui, a former executive director before his resignation on November 27, 2023, consented to suspend their monthly
remuneration from August 1, 2023. Additionally, all independent non-executive directors have consented to suspend their monthly remuneration
from September 1, 2023 until further notice. Before the suspension of remuneration, Mr. Clark Cheng, Mr. Ian Huen, and Mr. Darren Lui
had a monthly remuneration of $<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="apm:RemunerationAmount" scale="0" unitRef="usd" id="ixv-27066">6,410</ix:nonFraction>, $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="apm:RemunerationAmount" scale="0" unitRef="usd" id="ixv-27067">27,333</ix:nonFraction> and $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="apm:RemunerationAmount" scale="0" unitRef="usd" id="ixv-27068">6,667</ix:nonFraction>, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_VariableInterestEntityDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="ixv-24632"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13. VARIABLE INTEREST ENTITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company consolidates VIEs in which the Group
has a variable interest and is determined to be the primary beneficiary. This determination is based on whether the Group has a variable
interest (or combination of variable interests) that provides the Company with (a) the power to direct the activities that most significantly
impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses or right to receive benefits that could be potentially
significant to the VIE. The Group continually reassesses whether it is the primary beneficiary of a VIE throughout the entire period the
Group is involved with the VIE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2021, three of the Group&#8217;s
subsidiaries, Libra Sciences Limited (&#8220;Libra&#8221;, formerly known as Aptorum Pharmaceutical Development Limited),
Mios Pharmaceuticals Limited (&#8220;Mios&#8221;) and Scipio Life Sciences Limited (&#8220;Scipio&#8221;), issued Class A and Class B
ordinary shares to various parties; for each such entity, <ix:nonNumeric contextRef="c0" name="us-gaap:CommonStockVotingRights" id="ixv-27069">each Class A ordinary share is entitled to 1 vote and 1 share of economic benefit
of the respective company, while each Class B ordinary share is entitled to 10 votes</ix:nonNumeric> and <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="apm:ShareOfEconomic" scale="0" unitRef="usdPershares" id="ixv-27070">0.001</ix:nonFraction> share of economic benefit of the respective
company. Following such share issuances, the Group lost its majority voting rights in each of these three companies and only holds <ix:nonFraction contextRef="c196" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-27071">48.33</ix:nonFraction>%,
<ix:nonFraction contextRef="c197" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-27072">48.39</ix:nonFraction>% and <ix:nonFraction contextRef="c198" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-27073">48.36</ix:nonFraction>% economic interest in Libra, Mios and Scipio, respectively. However, the Group still holds a majority of each of these
three company&#8217;s outstanding Class A ordinary shares and therefore will absorb/receive portions of these subsidiaries&#8217; expected
losses or residual returns. In addition, none of these three companies have sufficient equity to sustain its own activities, and they
have two classes of ordinary shares which have different rights, benefits and obligations. We determined that all these three companies
are variable interest entities (&#8220;VIE&#8221;). On December 31, 2021, Libra, Mios and Scipio further issued Class A ordinary shares
to the Group in exchange of certain projects licenses. Upon these share issuances, the Group was holding <ix:nonFraction contextRef="c199" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-27074">97.27</ix:nonFraction>% economic interest and
<ix:nonFraction contextRef="c200" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-27075">31.51</ix:nonFraction>% voting power in Libra, <ix:nonFraction contextRef="c75" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-27076">97.93</ix:nonFraction>% economic interest and <ix:nonFraction contextRef="c201" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-27077">36.17</ix:nonFraction>% voting power in Mios, and <ix:nonFraction contextRef="c79" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-27078">97.93</ix:nonFraction>% economic interest and <ix:nonFraction contextRef="c202" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-27079">35.06</ix:nonFraction>% voting
power in Scipio, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have considered each of these entity&#8217;s
Memorandum and Article of Association and their respective board of directors (the sole director of each of Mios and Scipio is an executive
director of the Group), and determined that we have the power to manage and make decisions that affect Mios and Scipio&#8217;s research
and development activities, which activities most significantly impact Mios and Scipio&#8217;s economic performance. However, we do not
have such power over Libra&#8217;s research and development activities, which activities most significantly impact Libra&#8217;s economic
performance. Accordingly, we determined that we are the primary beneficiary of Mios and Scipio, but not the primary beneficiary of Libra.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfVariableInterestEntitiesTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="ixv-27080">The following tables summarize the aggregate carrying
value of VIEs&#8217; assets and liabilities in the consolidated balance sheets that are consolidated</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfVariableInterestEntitiesTextBlock-c0_cont_2" id="_ScheduleOfVariableInterestEntitiesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Assets/<br/>
 (Liabilities)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">Total</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssets" scale="0" unitRef="usd" id="ixv-27081">24,352</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="0" unitRef="usd" id="ixv-27082">3,558</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNet" scale="0" unitRef="usd" id="ixv-27083">20,794</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssets" scale="0" unitRef="usd" id="ixv-27084">61,630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="0" unitRef="usd" id="ixv-27085">86,306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNet" scale="0" sign="-" unitRef="usd" id="ixv-27086">24,676</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables summarize the aggregate carrying
value of assets and liabilities in the Group&#8217;s consolidated balance sheets that relate to the VIE in which the Group holds a variable
interest but is not the primary beneficiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfVariableInterestEntitiesTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum<br/> Exposure to<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>December 31, 2023</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">     -</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Total</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssets" scale="0" unitRef="usd" id="ixv-27087">472,695</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNet" scale="0" unitRef="usd" id="ixv-27088">472,695</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" scale="0" unitRef="usd" id="ixv-27089">472,695</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_VariableInterestEntityDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s maximum exposure to loss from
its involvement with unconsolidated VIE represents the estimated loss that would be incurred if the VIE is liquidated, so that the fair
value of the equity investment in VIE is <ix:nonFraction contextRef="c203" decimals="0" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-27090">zero</ix:nonFraction> and the amounts due from the VIE have to be fully impaired.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-24840"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. LEASE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Group has two long-term
operating leases for laboratories and clinic with remaining terms expiring from 2024 through 2026 and a weighted average remaining lease
term of <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-27091">1.9</ix:nonNumeric> years. <ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-27092">Weighted average discount rates used in the calculation of the operating lease liability is <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="apm:OperatingLeaseWeightedAverageDiscountRate" scale="-2" unitRef="pure" id="ixv-27093">8</ix:nonFraction>%.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;year<br/> ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;year<br/> ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Lease cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance lease cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Depreciation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:FinanceLeaseDepreciation" scale="0" unitRef="usd" id="ixv-27094">47,818</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Interest on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="0" unitRef="usd" id="ixv-27095">1,435</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-27096">252,345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-27097">349,031</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Short-term lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" unitRef="usd" id="ixv-27098">65,221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" unitRef="usd" id="ixv-27099">85,598</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Sublease income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-27100">317,566</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-27101">483,882</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-27102">389,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-27103">369,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Financing cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd" id="ixv-27104">49,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-27105">338,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-27106">549,596</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Weighted-average remaining lease term &#8211; finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average remaining lease term &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-27107">1.9</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-27108">1.1</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Weighted-average discount rate &#8211; finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-27109">2.5</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-27110">8.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-27111">8.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, an impairment
loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" unitRef="usd" id="ixv-27112">200,916</ix:nonFraction> on right-of-use assets was recognized in other operating expenses as the Group considered that the carrying amount of
a right-of-use asset related to a lease of clinic may not be recoverable. Additionally, the Group early terminated a lease agreement for
a right-of-use asset relating to an office, which resulted in a recognized loss on early termination of the right-of-use asset totaling
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-27113">31,030</ix:nonFraction> in other operating expenses. For the years ended December 31, 2022 and 2021, the Group did not recognize any impairment losses
and loss on disposal of right-of-use assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-27114">The maturity analysis of operating leases liabilities
as of December 31, 2023 is as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Remaining periods ending December 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-27115">120,824</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-27116">97,541</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd" id="ixv-27117">24,573</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total future undiscounted cash flow</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-27118">242,938</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Discount on operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-27119">18,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Present value of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-27120">224,717</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-27121">125,232</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Non-current portion of operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-27122">99,485</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-25150"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. CONVERTIBLE NOTE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2022, the Group entered into a
securities purchase agreement with Aenco Technologies Limited (&#8220;Aenco&#8221;). Pursuant to the securities purchase agreement, Aenco
is purchasing a convertible note in the original principal amount of $<ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-27123">3,000,000</ix:nonFraction> (the &#8220;Dec 2022 Note&#8221;). The Dec 2022 Note is
unsecured, convertible into the Company&#8217;s restricted Class A Ordinary Shares at Aencco&#8217;s option. The Dec 2022 Notes have a
maturity date of 12 months subject to the Aenco&#8217;s extension, a bullet interest rate of <ix:nonFraction contextRef="c208" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-27124">7</ix:nonFraction>% per annum, and a conversion price of $<ix:nonFraction contextRef="c208" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-27125">12.00</ix:nonFraction>
per Class A Ordinary share. The Company shall have an obligation to repay the principal amount and interest of the Dec 2022 Note on the
maturity date in cash or in unregistered Class A Ordinary Shares or a combination of such at the Company&#8217;s discretion. In April
2023, Aenco transferred the whole Dec 2022 Note to two external investors, and the two external investors fully converted the Dec 2022
Note into <ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-27126">250,000</ix:nonFraction> Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2023, the Group entered into a securities
purchase agreement with 4 investors. Pursuant to the securities purchase agreement, the investors are purchasing a convertible note in
the original principal amount of $<ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd" id="ixv-27127">3,000,000</ix:nonFraction> (the &#8220;June 2023 Note&#8221;). The whole proceeds from the June 2023 Note was used to
settle a related party loan. The June 2023 Note is unsecured, convertible into the Company&#8217;s restricted Class A Ordinary Shares
at the Note holders&#8217; option. The June 2023 Notes have a maturity date of 12 months subject to the investors extension, a bullet
interest rate of <ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-27128">7</ix:nonFraction>% per annum, and a conversion price of $<ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-27129">3.00</ix:nonFraction> per Class A Ordinary share. The Company shall have an obligation to repay
the principal amount and interest of the June 2023 Note on the maturity date in cash or in unregistered Class A Ordinary Shares or a combination
of such at the Company&#8217;s discretion. Immediately following the issuance of June 2023 Note, the June 2023 Note was fully converted
into <ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-27130">1,000,000</ix:nonFraction> Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 11, 2023, the Group entered into
a securities purchase agreement with Jurchen Investment Corporation, the largest shareholder of the Company, pursuant to which the Group
sold a secured convertible note in the aggregate principal amount of $<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd" id="ixv-27131">3,000,000</ix:nonFraction> (the &#8220;Sep 2023 Notes&#8221;). The Sep 2023 Notes
are convertible into the Company&#8217;s Class A Ordinary Shares and have a maturity date that is 24 months from the issuance date, although
upon such date the investor has the right to extend the term of the Sep 2023 Note for twelve (12) months or more or such term subject
to mutual consent. The Sep 2023 Notes have an interest rate of <ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-27132">6</ix:nonFraction>% per annum and a conversion price of $<ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-27133">2.42</ix:nonFraction> per share. The Company has
the right to repay the principal amount of the Sep 2023 Notes, but in the case of such prepayment it must be paid in cash, unless otherwise
agreed by both parties. The Sep 2023 Note is secured by a first priority lien and security interest on certain preferred shares that the
Group owns (&#8220;Collateral&#8221;) (Note 5). Upon the Group&#8217;s disposal of all or a portion of the Collateral, the investor has
the right, to request that the Group prepay the then-remaining outstanding balance of the Sep 2023 Note, in part or in full and the Group
can make that payment in cash or in shares.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-25164"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>16. ORDINARY SHARES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 26, 2021, the Company entered into an
at-the-market offering agreement (the &#8220;Sales Agreement&#8221;), with H.C. Wainwright&#160;&amp; Co., LLC, acting as its sales agent
(the &#8220;Sales Agent&#8221;), relating to the sale of its Class A Ordinary Shares (such offering, the &#8220;ATM Offering&#8221;, or
&#8220;At The Market Offering&#8221;). In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of its
Class A Ordinary Shares having an aggregate offering price of up to $<ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherValueOutstanding" scale="0" unitRef="usd" id="ixv-27134">15,000,000</ix:nonFraction> from time to time through the Sales Agent under such prospectus
supplement and the accompanying prospectus. As of the date of issuance of the consolidated financial statements, the Company has issued
<ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-27135">215,959</ix:nonFraction> Class A Ordinary Shares at average issuance price of $<ix:nonNumeric contextRef="c217" format="ixt-sec:duryear" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="ixv-27136">7.53</ix:nonNumeric> per share pursuant to the ATM Offering with gross proceeds of $<ix:nonFraction contextRef="c217" decimals="-5" format="ixt:num-dot-decimal" name="apm:GrossProceed" scale="6" unitRef="usd" id="ixv-27137">1.6</ix:nonFraction>
million, less transaction costs of $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleLeasebackTransactionTransactionCostsInvestingActivities" scale="0" unitRef="usd" id="ixv-27138">50,183</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2021, the Company entered into a private
placement shares purchase agreement with Jurchen Investment Corporation, issuing <ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-27139">138,793</ix:nonFraction> Class A Ordinary Shares at $<ix:nonFraction contextRef="c218" decimals="2" format="ixt:num-dot-decimal" name="apm:SharesPrice" scale="0" unitRef="usdPershares" id="ixv-27140">28.82</ix:nonFraction> per share,
representing a <ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="apm:OrdinarySharesClosingPricePercentage" scale="-2" unitRef="pure" id="ixv-27141">10</ix:nonFraction>% premium to the last closing price of the Company&#8217;s Class A Ordinary Shares on the NASDAQ stock exchange on that
date. The Company received aggregate gross proceeds of $<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="apm:GrossProceed" scale="0" unitRef="usd" id="ixv-27142">4,000,000</ix:nonFraction> from the purchase of these shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 23, 2023, the Company effectuate a
<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-27143">10</ix:nonFraction> for <ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-27144">1</ix:nonFraction> share consolidation of its authorized share capital, such that every <ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-27145">10</ix:nonFraction> Class A Ordinary Shares, par value of US$<ix:nonFraction contextRef="c222" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-27146">1.00</ix:nonFraction> per share,
in the authorized share capital of the Company (including issued and unissued share capital) were consolidated into <ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnitsAuthorized" scale="0" unitRef="shares" id="ixv-27147">1</ix:nonFraction> Class A Ordinary
Share, par value of US$<ix:nonFraction contextRef="c222" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-27148">10.00</ix:nonFraction> per share, and that every <ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-27149">10</ix:nonFraction> Class B Ordinary Shares, par value of US$<ix:nonFraction contextRef="c224" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-27150">1.00</ix:nonFraction> per share in the authorized share
capital of the Company (including issued and unissued share capital) were consolidated into <ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnitsAuthorized" scale="0" unitRef="shares" id="ixv-27151">1</ix:nonFraction> Class B Ordinary Share, par value of US$<ix:nonFraction contextRef="c223" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-27152">10.00</ix:nonFraction>
per share. As a consequence of the reverse stock split, fractional shares were rounded up to the next whole share, resulting in the creation
of an additional <ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" unitRef="shares" id="ixv-27153">8,018</ix:nonFraction> Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2023, the Company was merged with
Aptorum Group Cayman Limited, a newly established wholly owned subsidiary of the Company, whereby the Company is the surviving company
on the terms of the plan of merger. According to the plan of merger, the par value of its Class A and Class B Ordinary Shares are changed
from <span style="-sec-ix-hidden: hidden-fact-265">USD10</span> to <span style="-sec-ix-hidden: hidden-fact-264">USD0.00001</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group issued <ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-27154">70,430</ix:nonFraction> Class
A Ordinary Shares to a majority of the share option holders. This issuance served as an exchange for their share options and facilitated
the reversal of deferred cash bonus payables owed to these holders (See Note 10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group also issued <ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-27155">65,770</ix:nonFraction>
fully vested Class A Ordinary Shares to certain employees and external consultants. The grant date fair value of each of the shares was
$<ix:nonFraction contextRef="c228" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-27156">2.68</ix:nonFraction> based on grant date quoted market price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, the Group
issued <ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-27157">791</ix:nonFraction> Class A Ordinary Shares to share option holders as a result of exercise of options. For the year ended December 31, 2022, the
Group issued <ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-27158">6,712</ix:nonFraction> Class A Ordinary Shares to share option holders as a result of exercise of share options. For the year ended December
31, 2021, the Group issued <ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-27159">4,000</ix:nonFraction> and <ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-27160">19,016</ix:nonFraction> Class A Ordinary Shares to warrant holders and share option holders respectively as a result
of exercise of warrants or options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, the Group
issued <ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="apm:ShareIssuedToConvertibleNoteHolders" scale="0" unitRef="shares" id="ixv-27161">1,250,000</ix:nonFraction> Class A Ordinary Shares to convertible note holders upon conversion (See Note 15).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Class A Ordinary Shares and Class B
Ordinary Shares have the same rights except for the following: (i) each Class A Ordinary Share is entitled to one vote while each Class
B Ordinary Share is entitled to ten votes; and (ii) each Class B Ordinary Share is convertible into one Class A Ordinary Share at any
time while Class A Ordinary Shares are not convertible under any circumstances.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-25215"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>17. SHARE BASED COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share option plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2017, the Group adopted the 2017
Share Option Plan (the &#8220;Option Plan&#8221;) and on November 5, 2021, the Group amended the Option Plan. A total of <ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitIssued" scale="0" unitRef="shares" id="ixv-27162">550,000</ix:nonFraction> Class
A Ordinary Shares (subject to subsequent adjustments described more fully below) may be issued pursuant to awards under the Option Plan.
Subsequent adjustments include that on each January 1, starting with January 1, 2020, an additional number of shares equal to the lesser
of (i) <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-27163">2</ix:nonFraction>% of the outstanding number of Class A Ordinary Shares (on a fully diluted basis) on the immediate preceding December 31, and
(ii) such lower number of Class A Ordinary Shares as may be determined by the board of directors, subject in all cases to adjustments
as provided in Section 10 of the Option Plan. Awards will be made pursuant to agreements and may be subject to vesting and other restrictions
as determined by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-27164">75,235</ix:nonFraction> options were granted on March 11, 2021
to directors, employees, external consultants and advisors of the Group with an exercise price of $<ix:nonFraction contextRef="c236" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-27165">27.6</ix:nonFraction> per share, which was based on
the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding the grant
date.&#160;<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-27166">36,796</ix:nonFraction> options vest on January 1, 2022 and expire on <ix:nonNumeric contextRef="c155" format="ixt:date-monthname-day-year-en" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-27167">December 31, 2032</ix:nonNumeric>; <ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-27168">36,808</ix:nonFraction> options vest on January 1, 2023 and expire on
<ix:nonNumeric contextRef="c237" format="ixt:date-monthname-day-year-en" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-27169">December 31, 2033</ix:nonNumeric>; <ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-27170">906</ix:nonFraction> options vest on June 8, 2021 and expire on <ix:nonNumeric contextRef="c238" format="ixt:date-monthname-day-year-en" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-27171">June 7, 2032</ix:nonNumeric>; and <ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-27172">725</ix:nonFraction> options vest on July 14, 2021 and expire on <ix:nonNumeric contextRef="c240" format="ixt:date-monthname-day-year-en" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-27173">July
13, 2032</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-27174">153,146</ix:nonFraction> options were granted on March 8, 2022
to directors, employees, external consultants and advisors of the Group with an exercise price of $<ix:nonFraction contextRef="c242" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-27175">13.4</ix:nonFraction> per share, which was based on
the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding the grant
date.<i>&#160;</i><ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-27176">74,881</ix:nonFraction> options vest on January 1, 2023 and expire on <ix:nonNumeric contextRef="c243" format="ixt:date-monthname-day-year-en" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-27177">December 31, 2033</ix:nonNumeric>; <ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-27178">74,906</ix:nonFraction> options vest on January 1, 2024 and expire
on <ix:nonNumeric contextRef="c244" format="ixt:date-monthname-day-year-en" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-27179">December 31, 2034</ix:nonNumeric>; <ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-27180">1,866</ix:nonFraction> options vest on June 8, 2022 and expire on <ix:nonNumeric contextRef="c245" format="ixt:date-monthname-day-year-en" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-27181">June 7, 2033</ix:nonNumeric>; and <ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-27182">1,493</ix:nonFraction> options vest on July 14, 2022 and expire
on <ix:nonNumeric contextRef="c246" format="ixt:date-monthname-day-year-en" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-27183">July 13, 2033</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group entered into exchange
agreements and cancelled <ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" unitRef="shares" id="ixv-27184">177,667</ix:nonFraction> existing vested and unvested share options held by related parties option holders and cancelled the Group&#8217;s
obligations for deferred cash bonus payables of $<ix:nonFraction contextRef="c247" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="6" unitRef="usd" id="ixv-27185">3.1</ix:nonFraction> million by granting of <ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-27186">403,820</ix:nonFraction> share options (&#8220;New Options&#8221;) with <ix:nonNumeric contextRef="c247" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-27187">6</ix:nonNumeric> months
vesting period. The New Options&#8217; exercise price was $<ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-27188">2.68</ix:nonFraction> per share, which was based on the last closing price of the shares traded
on the NASDAQ stock exchange on the grant date. All options fully vested on October 1, 2023 and expires on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-27189">September 30, 2033</ix:nonNumeric>. On March
31, 2023, the Group entered into supplemental agreements with the same related parties option holders to provide additional cash compensation
to cover the exercise price of the New Options. On March 31, 2023, the Group entered into exchange agreements and cancelled <ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" unitRef="shares" id="ixv-27190">70,428</ix:nonFraction> existing
vested and unvested share options held by non-related parties option holders and cancelled the Group&#8217;s obligations for deferred
cash bonus payables of $<ix:nonFraction contextRef="c249" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="6" unitRef="usd" id="ixv-27191">1.6</ix:nonFraction> million by issuance of <ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-27192">70,430</ix:nonFraction> fully vested Class A Ordinary Shares. The Group accounted for this exchange
for both related parties and non-related parties share option holders as a modification to share based compensation which required the
remeasurement of existing share options value at the time of the modification. The total incremental cost as a result of the modification
was $<ix:nonFraction contextRef="c248" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" unitRef="usd" id="ixv-27193">0.7</ix:nonFraction> million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-27194">A summary of the option activity for the years
ended December 31, 2023, 2022 and 2021 and changes during the period is presented below:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_2" id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number of<br/> share&#160;options<sup>(1)</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise <br/> price<br/> $</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> contractual<br/> term in<br/> years</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c262" decimals="INF" format="ixt:num-dot-decimal" id="ix_34_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">272,126</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c262" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27196">21.54</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c263" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-27197">10.83</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">     &#8239;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c263" decimals="INF" format="ixt:num-dot-decimal" id="ix_35_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">403,820</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c263" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27199">2.68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c263" decimals="INF" format="ixt:num-dot-decimal" id="ix_36_fact" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">791</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c263" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27201">20.90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Modified</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c263" decimals="INF" format="ixt:num-dot-decimal" id="ix_37_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">248,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c263" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27203">21.74</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c264" decimals="INF" format="ixt:num-dot-decimal" id="ix_38_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">427,060</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c264" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27205">3.59</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c263" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-27206">9.28</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c264" decimals="INF" format="ixt:num-dot-decimal" id="ix_39_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">420,157</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c264" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27208">3.43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c263" format="ixt-sec:duryear" name="apm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" id="ixv-27209">9.42</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_3" id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number of<br/> share&#160;options<sup>(1)</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise <br/> price<br/> $</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> contractual<br/> term in<br/> years</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c265" decimals="INF" format="ixt:num-dot-decimal" id="ix_40_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">127,404</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c265" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27211">31.91</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c266" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-27212">11.01</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">       </td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="INF" format="ixt:num-dot-decimal" id="ix_41_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">153,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27214">13.40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c266" format="ixt-sec:duryear" name="apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="ixv-27215">12.30</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c266" decimals="INF" format="ixt:num-dot-decimal" id="ix_42_fact" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">6,721</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27217">25.25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c266" decimals="INF" format="ixt:num-dot-decimal" id="ix_43_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">1,268</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27219">28.11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c266" decimals="INF" format="ixt:num-dot-decimal" id="ix_44_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" unitRef="shares">435</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c266" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27221">116.71</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c262" decimals="INF" format="ixt:num-dot-decimal" id="ix_45_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">272,126</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c262" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27223">21.54</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c266" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-27224">10.83</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c262" decimals="INF" format="ixt:num-dot-decimal" id="ix_46_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">89,300</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c262" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27226">32.71</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c266" format="ixt-sec:duryear" name="apm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" id="ixv-27227">9.64</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_4" id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number of<br/> share&#160;options<sup>(1)</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise <br/> price<br/> $</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> contractual<br/> term in<br/> years</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c267" decimals="INF" format="ixt:num-dot-decimal" id="ix_47_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">71,756</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c267" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27229">37.63</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c268" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-27230">11.22</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">      </td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="INF" format="ixt:num-dot-decimal" id="ix_48_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">75,235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27232">27.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c268" format="ixt-sec:duryear" name="apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="ixv-27233">12.29</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c268" decimals="INF" format="ixt:num-dot-decimal" id="ix_49_fact" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">19,037</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27235">36.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c268" decimals="INF" format="ixt:num-dot-decimal" id="ix_50_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">550</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c268" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27237">29.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding, December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c265" decimals="INF" format="ixt:num-dot-decimal" id="ix_51_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">127,404</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c265" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27239">31.91</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c268" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-27240">11.01</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable, December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c265" decimals="INF" format="ixt:num-dot-decimal" id="ix_52_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">31,456</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c265" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27242">42.62</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c268" format="ixt-sec:duryear" name="apm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" id="ixv-27243">9.63</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s <ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-27244">1</ix:nonFraction> for <ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-27245">10</ix:nonFraction> reverse stock split, which was effective on January 23, 2023.</span></ix:footnote></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted-average grant date fair value of
share option grants during the years ended December 31, 2023, 2022 and 2021 was $<ix:nonFraction contextRef="c253" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27246">2.68</ix:nonFraction>, $<ix:nonFraction contextRef="c254" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27247">10.02</ix:nonFraction> and $<ix:nonFraction contextRef="c255" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-27248">25.72</ix:nonFraction>, respectively. The maximum contractual
term for share option was <ix:nonNumeric contextRef="c253" format="ixt-sec:duryear" name="apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" id="ixv-27249">12.8</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-27250">The fair value of each stock option award is estimated
on the date of grant using the Black-Scholes option pricing model under the following assumptions.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted in<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted in <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted in<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right"><ix:nonFraction contextRef="c83" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-27251">170.10</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-27252">89.55</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-27253">97.70</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction contextRef="c83" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-27254">3.48</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction contextRef="c10" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-27255">1.86</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction contextRef="c11" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-27256">1.64</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term from grant date (in years)</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonNumeric contextRef="c83" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-27257">5.25</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c269" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-27258">5.63</ix:nonNumeric>-<ix:nonNumeric contextRef="c270" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-27259">6.41</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c271" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-27260">5.62</ix:nonNumeric>-<ix:nonNumeric contextRef="c272" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-27261">6.41</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Dividend rate</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277; -sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279; -sec-ix-hidden: hidden-fact-278">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dilution factor</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" scale="0" unitRef="pure" id="ixv-27262">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" scale="0" unitRef="pure" id="ixv-27263">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" scale="0" unitRef="pure" id="ixv-27264">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Fair value</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-27265">2.68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c269" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-27266">9.74</ix:nonFraction>
- $<ix:nonFraction contextRef="c270" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-27267">10.16</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c271" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-27268">25.11</ix:nonFraction> - $<ix:nonFraction contextRef="c272" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-27269">26.01</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the grant of share options
to employees and non-employees, the Group recorded share-based compensation charges of $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-27270">697,446</ix:nonFraction> and $<ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-27271">391,479</ix:nonFraction>, respectively, for the year
ended December 31, 2023, $<ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-27272">1,123,122</ix:nonFraction> and $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-27273">523,877</ix:nonFraction>, respectively, for the year ended December 31, 2022, and $<ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-27274">1,203,000</ix:nonFraction> and $<ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-27275">479,460</ix:nonFraction>, respectively,
for the year ended December 31, 2021.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:MinorityInterestDisclosureTextBlock" id="ixv-25947"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>18. NON-CONTROLLING INTEREST</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2021, two of the Group&#8217;s
subsidiaries, Mios Pharmaceuticals Limited (&#8220;Mios&#8221;) and Scipio Life Sciences Limited (&#8220;Scipio&#8221;), issued Class
A and Class B ordinary shares to various parties; for each such entity, each Class A ordinary share is entitled to 1 vote and 1 share
of economic interest of the respective company, while each Class B ordinary share is entitled to 10 votes and <ix:nonFraction contextRef="c273" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OtherOwnershipInterestsUnitsIssued" scale="0" unitRef="shares" id="ixv-27276">0.001</ix:nonFraction> share of economic
interest of the respective company. On December 31, 2021, Mios and Scipio further issued Class A ordinary shares to the Group in exchange
of certain projects licenses. Upon these share issuances, the Group was holding <ix:nonFraction contextRef="c75" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-27277">97.93</ix:nonFraction>% economic interest and <ix:nonFraction contextRef="c201" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-27278">36.17</ix:nonFraction>% voting power in Mios,
and <ix:nonFraction contextRef="c79" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-27279">97.93</ix:nonFraction>% economic interest and <ix:nonFraction contextRef="c202" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-27280">35.06</ix:nonFraction>% voting power in Scipio, respectively. Since the sole director of Mios and Scipio is
an executive director of the Group, the Group can effectively participate in all significant financial and operating decisions in these
two companies through the power granted to the sole director in Mios and Scipio&#8217;s Articles of Association. The Group is deemed to
have control over Mios and Scipio and hence these two companies are still within the Group. As a result, a total deficit of $<ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="apm:AdjustmentIncreaseDecreaseRetainedEarningsDeficit" scale="0" unitRef="usd" id="ixv-27281">27,293</ix:nonFraction> was
reclassified from additional paid-in capital to non-controlling interests within the Group&#8217;s consolidated financial statements for
the year end December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 2, 2021, Aptorum Medical Limited issued
<ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOwnershipInterestsUnitsIssued" scale="0" unitRef="shares" id="ixv-27282">117</ix:nonFraction> shares to Clark Cheng in according to the appointment agreement, decreasing the equity interest of the Company from <ix:nonFraction contextRef="c276" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27283">93</ix:nonFraction>% to <ix:nonFraction contextRef="c277" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27284">92</ix:nonFraction>%. On
February 25, 2022, Aptorum Medical Limited further issued <ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOwnershipInterestsUnitsIssued" scale="0" unitRef="shares" id="ixv-27285">119</ix:nonFraction> shares to Clark Cheng in according to the appointment agreement, decreasing
the equity interest of the Company from <ix:nonFraction contextRef="c279" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27286">92</ix:nonFraction>% to <ix:nonFraction contextRef="c280" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27287">91</ix:nonFraction>%. On February 1, 2023, Aptorum Medical Limited further issued <ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOwnershipInterestsUnitsIssued" scale="0" unitRef="shares" id="ixv-27288">122</ix:nonFraction> shares to Clark Cheng
in according to the appointment agreement, decreasing the equity interest of the Company from <ix:nonFraction contextRef="c282" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27289">91</ix:nonFraction>% to <ix:nonFraction contextRef="c283" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27290">90</ix:nonFraction>%. As a result, a total deficit
of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PartnersCapitalAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-27291">67,766</ix:nonFraction>, $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PartnersCapitalAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-27292">52,024</ix:nonFraction>, and $<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PartnersCapitalAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-27293">34,130</ix:nonFraction> were reclassified from additional paid-in capital to non-controlling interests within the Group&#8217;s
consolidated financial statements for the years ended December 31, 2023, 2022 and 2021, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-25958"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>19. NET LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 30pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-27294">The following table sets forth the computation of basic and diluted
loss per share:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_2" id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Net loss attributable to Aptorum Group Limited</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-27295">2,824,647</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-27296">9,799,560</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-27297">25,048,389</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Weighted average shares outstanding<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#8211; Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_53_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">4,521,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" id="ix_54_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">3,569,484</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" id="ix_55_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">3,503,396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#8211; Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_56_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">4,521,133</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" id="ix_57_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">3,569,484</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" id="ix_58_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">3,503,396</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Net loss per share attributable to Aptorum Group Limited<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#8211; Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_59_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.62</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" id="ix_60_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">2.75</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" id="ix_61_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">7.15</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#8211; Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_62_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.62</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" id="ix_63_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">2.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" id="ix_64_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">7.15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s <ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-27310">1</ix:nonFraction> for <ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-27311">10</ix:nonFraction> reverse stock split, which was effective on January 23, 2023.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023, 2022 and
2021, the total number of share options, warrants and convertible notes excluded from the calculation of diluted earnings per share due
to their anti-dilutive nature, are <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" unitRef="shares" id="ixv-27312">1,293,723</ix:nonFraction>, <ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" unitRef="shares" id="ixv-27313">54,054</ix:nonFraction> and <ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" unitRef="shares" id="ixv-27314">54,054</ix:nonFraction>, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-26161"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>20. COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Contingent Payment Obligations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Group does not have
any non-cancellable purchase commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has contingency payment obligations
under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain condition or
milestone is met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Milestone payments are due upon achievements of
specific conditions, such as Investigational New Drugs (&#8220;IND&#8221;) filing or U.S. Food and Drug Administration (&#8220;FDA&#8221;)
approval, first commercial sale of the licensed products, or other achievements. <ix:nonNumeric contextRef="c0" continuedAt="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock-c0_cont_1" escape="true" name="apm:ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" id="ixv-27315">The aggregate amounts of the contingent milestone payments
that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as
of December 31, 2023 are below:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Drug molecules: up to the conditions and milestones of</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Preclinical to IND filing</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:PreclinicalToIndFiling" scale="0" unitRef="usd" id="ixv-27316">132,564</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">From entering phase 1 to before first commercial sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:FromEnteringPhase1ToBeforeFirstCommercialSale" scale="0" unitRef="usd" id="ixv-27317">17,376,410</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">First commercial sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:FirstCommercialSale" scale="0" unitRef="usd" id="ixv-27318">11,882,051</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net sales amount more than certain threshold in a year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:NetSalesAmountMoreThanCertainThresholdInYear" scale="0" unitRef="usd" id="ixv-27319">44,769,231</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" scale="0" unitRef="usd" id="ixv-27320">74,160,256</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Diagnostics technology: up to the conditions and milestones of</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Before FDA approval</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:FdaApprovalObtaine" scale="0" unitRef="usd" id="ixv-27321">208,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="apm:MilestonePaymentsTotal" scale="0" unitRef="usd" id="ixv-27322">74,368,912</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023, 2022 and
2021, the Group incurred $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="apm:MilestonePayments" scale="0" unitRef="usd" id="ixv-27323">50,000</ix:nonFraction>, $<span style="-sec-ix-hidden: hidden-fact-280">nil</span> and $<span style="-sec-ix-hidden: hidden-fact-281">nil</span> milestone payments under license agreements, respectively. For the years ended December
31, 2023, 2022 and 2021, the Group did not incur any royalties or research and development funding, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-26247"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>21. SEGMENT REPORTING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s chief operating decision maker, the Chief Executive
Officer, reviews the consolidated results when making decisions about allocating resources and accessing performance of the Group as a
whole and hence, the Group has only <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-27324">one</ix:nonFraction> reportable segment. The Group does not distinguish between markets or segments for the purpose
of internal reporting. The Group&#8217;s long-lived assets are substantially located in Hong Kong and majority of the Group&#8217;s revenue
and expense is derived from within Hong Kong. Therefore, no geographical segments are presented.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-26256"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>22. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has evaluated subsequent events through
the date of issuance of the consolidated financial statements. Except for the events disclosed elsewhere in the consolidate financial
statements and the following events with material financial impact on the Group&#8217;s consolidated financial statements, no other subsequent
event is identified that would have required adjustment or disclosure in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2024, the Group entered into an Agreement
and Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among Company, and YOOV Group Holding Limited, a company organized under
the laws of British Virgin Islands (&#8220;YOOV&#8221;). The Merger Agreement was unanimously approved by Company&#8217;s and YOOV&#8217;s
boards of directors (each board of directors, the &#8220;Board&#8221;), respectively. If the Merger Agreement is approved by Company&#8217;s
and YOOV&#8217;s shareholders (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and
upon consummation of the transactions contemplated by the Merger Agreement, the Group will incorporate a wholly-owned subsidiary under
the laws of the British Virgin Islands (&#8220;Merger Sub&#8221;) that will merge with and into YOOV, with YOOV surviving the merger as
a wholly-owned subsidiary of the Group (collectively, the &#8220;Merger&#8221;). The Group upon the closing is referred to herein as the
&#8220;combined company.&#8221; Upon consummation of the transaction, YOOV will become a wholly-owned subsidiary of the Group, and the
existing YOOV shareholders and existing the Group&#8217;s shareholders will own approximately <ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="apm:sharesOutstandingPerentage" scale="-2" unitRef="pure" id="ixv-27325">90</ix:nonFraction>% and <ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="apm:sharesOutstandingPerentage" scale="-2" unitRef="pure" id="ixv-27326">10</ix:nonFraction>%, respectively, of the outstanding
shares of the combined company. The consummation of this merger remains uncertain as it is contingent upon the fulfillment of specific
closing conditions.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APTORUM GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in U.S. Dollars)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The obligations of the parties (or, in some cases,
some of the parties) to consummate the Merger are subject to the satisfaction or waiver of certain conditions to closing, including, among
other things: (i) obtaining the approval by the shareholders of Aptorum and YOOV of the matters required under the Merger Agreement, (ii)
approval of the Initial Listing Application by Nasdaq, (iii) consummation of the Separation of ATL, (iv) delivery of legal opinions from
British Virgin Islands counsel and Hong Kong counsel of YOOV to Aptorum and Merger Sub, (v) delivery of legal opinions from Cayman Islands
counsel of Aptorum and British Virgin Islands counsel of Merger Sub to YOOV, (vi) delivery of an opinion by Colliers International (Hong
Kong) Limited to the Board of Aptorum to the effect that (subject to various qualifications and assumptions) the merger consideration
(the total Class A ordinary shares and Class B ordinary shares to be issued to YOOV&#8217;s shareholders) is fair, from a financial point
of view (based on the conclusion that the equity value of YOOV is no less than $<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueAdjustment" scale="6" unitRef="usd" id="ixv-27327">250</ix:nonFraction> million), to the shareholders of Aptorum. (vii) availability
of audited financial statements for YOOV and its Subsidiaries as of March 31, 2023 and 2022 the related audited consolidated statements
of operations, of changes in shareholders&#8217; equity and of cash flows for the year ended March 31, 2023 and 2022 in conformity with
International Financial Reporting Standards, which shall not be materially different from the unaudited financial statements of YOOV for
the same period as presented to Aptorum, as determined by Aptorum in its sole discretion, (viii) delivery of fully executed lock-up agreement
and support agreement by the major shareholder of Aptorum and the delivery of fully executed lock-up agreement by the directors and officers
of YOOV and by the shareholders of YOOV who will beneficially own <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="apm:OutstandingSharesPercentage" scale="-2" unitRef="pure" id="ixv-27328">5</ix:nonFraction>% or more outstanding shares of the combined company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Merger, on March 1, 2024,
the Company entered into a Split-Off Agreement (the &#8220;Split-Off Agreement&#8221;, the transaction contemplated by the Split-Off Agreement,
the &#8220;Separation&#8221;) by and among the Company, Aptorum Therapeutics Limited (&#8220;ATL&#8221;), and Jurchen Investment Corporation
(&#8220;Jurchen&#8221;), pursuant to which, the Company will assign and transfer the assets and liabilities of its legacy business to
ATL, and Jurchen will acquire 100% issued and outstanding shares of ATL from the Company and surrender certain ordinary shares of the
Company held by Jurchen to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
closing of the Separation must occur simultaneously with the closing of the Merger, or on a later date, as mutually agreed by the Parties.
The Split-Off Agreement contains conditions precedent to closing of the parties thereto, with respect to, among other things, the following
as applicable to each party:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify"><b>Representations, Warranties and Performance.</b> All representations
and warranties made by the parties in the Split-Off Agreement must have been accurate and truthful, to the best of their knowledge, when
initially made and must remain accurate and truthful, to the best of their knowledge, at the time of the Closing. The parties are obligated
to fulfill all commitments, agreements, and conditions outlined in the Split-Off Agreement to the satisfaction of the parties involved,
with significant emphasis on adherence to these obligations before or at the Closing.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify"><b>Additional Documents.</b> Jurchen shall deliver or cause
to be delivered such additional documents as may be necessary in connection with the consummation of the transactions contemplated by
the Split-Off Agreement and the performance of their obligations hereunder.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify"><b>Release by Buyer and Split-Off Subsidiary.</b> At the
Closing, Jurchen and ATL are required to execute and provide Aptorum with a comprehensive release. This release will absolve Aptorum
from all liabilities and obligations owed to Jurchen or ATL in any capacity, as well as from any claims that Jurchen or ATL may assert
against Aptorum or its related managers, members, officers, directors, shareholders, employees, and agents. However, this release does
not cover liabilities arising from the Split-Off Agreement or any document related to it.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">(iv)</td><td style="text-align: justify"><b>Shareholder Approval.</b> Aptorum shall have obtained
the affirmative vote of its shareholders representing at least two-thirds of the voting power of the issued and outstanding ordinary
shares of the Seller entitled to vote at a general meeting of the shareholders voting in person or by proxy, to approve the Split-Off
Agreement and the transaction contemplated herein.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2024, CGY Investments Limited and
DSF Investment Holdings Limited voluntarily converted <ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOtherShares" scale="0" unitRef="shares" id="ixv-27329">401,537</ix:nonFraction> Class B Ordinary Shares and <ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOtherShares" scale="0" unitRef="shares" id="ixv-27330">45,305</ix:nonFraction> Class B Ordinary Shares, respectively
into Class A Ordinary Shares on a one-for-one basis. Upon conversion, <ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-27331"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-27332">1,796,934</ix:nonFraction></ix:nonFraction> Class B Ordinary Shares were issued and outstanding, CGY
Investments Limited owned <ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOtherShares" scale="0" unitRef="shares" id="ixv-27333">533,575</ix:nonFraction> Class A Ordinary Shares and did not own any Class B Ordinary Share; and DSF Investment Holdings Limited
owned <ix:nonFraction contextRef="c288" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOtherShares" scale="0" unitRef="shares" id="ixv-27334">45,305</ix:nonFraction> Class A Ordinary Shares and did not own any Class B Ordinary Share.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-33</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:RestrictedCashCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="apm:DueFromBrokers" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-4" name="us-gaap:NotesAndLoansReceivableNetCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:ShortTermBankLoansAndNotesPayable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:ConvertibleNotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-7" name="us-gaap:ConvertibleDebtNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-8" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-9" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-10" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-11" name="us-gaap:GainLossOnSaleOfInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-12" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-13" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-14" name="apm:GainOnUseOfDigitalCurrencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-15" name="apm:GainOnUseOfDigitalCurrencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-16" name="apm:GainOnDerecognitionOfNonfinancialAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-17" name="apm:GainOnDerecognitionOfNonfinancialAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-18" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-19" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-25" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-26" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-27" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-28" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-29" name="apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-30" name="apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-31" name="apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-32" name="apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-33" name="apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-34" name="apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-35" name="apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-36" name="apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-37" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-38" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-39" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-40" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-41" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-42" name="apm:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-43" name="apm:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-44" name="apm:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-45" name="apm:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-46" name="apm:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-50" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-51" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-52" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-53" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-54" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-55" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-56" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-57" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-58" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-59" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-60" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-61" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-62" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-63" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-64" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-65" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-66" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-67" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-68" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-69" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-70" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-71" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-72" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-73" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-74" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-75" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-76" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-77" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-78" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-79" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-80" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-81" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-82" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-83" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-84" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-85" name="apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-86" name="apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-87" name="apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-88" name="apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-89" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-90" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-91" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-92" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-93" name="apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-94" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-95" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-96" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-97" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-98" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-99" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-100" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-101" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-102" name="apm:StockIssuedDuringPeriodValueIssuanceOfShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-103" name="apm:StockIssuedDuringPeriodValueIssuanceOfShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-104" name="apm:StockIssuedDuringPeriodValueIssuanceOfShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-105" name="apm:StockIssuedDuringPeriodValueIssuanceOfShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-106" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-107" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-108" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-109" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-110" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-111" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-112" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-113" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-114" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-115" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-116" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-117" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-118" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-119" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-120" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-121" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c46" id="hidden-fact-122" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-123" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-124" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-125" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-126" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-127" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-128" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c46" id="hidden-fact-129" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-130" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-131" name="apm:ExchangeDifferenceOnTranslationOfForeignOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-132" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c46" id="hidden-fact-133" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-134" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-135" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-136" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-137" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-138" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-139" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-140" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-141" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-142" name="apm:AllowanceForCreditLossOfDueFromARelatedParty" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-143" name="apm:AllowanceForCreditLossOfDueFromARelatedParty" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-144" name="apm:WritteoffOfPrepaymentAndOtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-145" name="apm:WritteoffOfPrepaymentAndOtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-146" name="us-gaap:InventoryWriteDown" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-147" name="us-gaap:InventoryWriteDown" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-148" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-149" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-150" name="apm:GainOnUseOfDigitalsCurrencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-151" name="apm:GainOnUseOfDigitalsCurrencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-152" name="apm:SettlementOfServiceFeeByDigitalCurrenciesAndTokens" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-153" name="apm:SettlementOfServiceFeeByDigitalCurrenciesAndTokens" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-154" name="us-gaap:InterestIncomeOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-155" name="apm:AccretionOfFinanceLeaseObligation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-156" name="apm:ReversalDeferredCashBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-157" name="apm:ReversalDeferredCashBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-158" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-159" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-160" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-161" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-162" name="apm:DisposalOfSubsidiariesNetOfCashDisposed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-163" name="apm:DisposalOfSubsidiariesNetOfCashDisposed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-164" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-165" name="apm:RepaymentOfLoanFromRelatedParty" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-166" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-167" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-168" name="us-gaap:ProceedsFromOtherEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-169" name="us-gaap:ProceedsFromOtherEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-170" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-171" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-172" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-173" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-174" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-175" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-176" name="us-gaap:ProceedsFromBankDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-177" name="us-gaap:RepaymentsOfBankDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-178" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-179" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-180" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-181" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-182" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-183" name="apm:ProceedsInBrokerAccounts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-184" name="apm:ProceedsInBrokerAccounts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-185" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-186" name="apm:SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-187" name="apm:SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-188" name="apm:ConvertibleNotesConvertedToClassAOrdinaryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-189" name="apm:ConvertibleNotesConvertedToClassAOrdinaryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-190" name="apm:SettlementOfDeferredCashBonusByIssuanceOfShareOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-191" name="apm:SettlementOfDeferredCashBonusByIssuanceOfShareOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-192" name="apm:AllowanceForCreditLossOfDueFromARelatedParty" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-193" name="us-gaap:InventoryWriteDown" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-194" name="us-gaap:InventoryWriteDown" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c94" id="hidden-fact-195" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c95" id="hidden-fact-196" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c96" id="hidden-fact-197" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-198" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c97" id="hidden-fact-199" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c98" id="hidden-fact-200" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c99" id="hidden-fact-201" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c100" id="hidden-fact-202" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c103" id="hidden-fact-203" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c105" id="hidden-fact-204" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c106" id="hidden-fact-205" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c114" id="hidden-fact-206" name="apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c113" id="hidden-fact-207" name="apm:NetChangeInUnrealizedDepreciationRelatingToInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c116" id="hidden-fact-208" name="apm:FairValueOfChangeInUnrealizedAppreciationDepreciation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c116" id="hidden-fact-209" name="apm:NetChangeInUnrealizedDepreciationRelatingToInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-210" name="apm:UpwardAdjustments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-211" name="apm:DownwardAdjustmentsAndImpairment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-212" name="apm:TotalUnrealizedGainForNonmarketableInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-213" name="us-gaap:PrepaidRent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c129" id="hidden-fact-214" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-215" name="apm:WroteOffOfCostRelatedAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-216" name="apm:WroteOffOfCostRelatedAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-217" name="apm:PrepaymentsForEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-218" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-219" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-220" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-221" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-222" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-223" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-224" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-225" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-226" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-227" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-228" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-229" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-230" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-231" name="apm:DeferredTaxAssetsDepreciationAndAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-232" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-233" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-234" name="us-gaap:DeferredTaxLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-235" name="us-gaap:DeferredTaxLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c160" id="hidden-fact-236" name="apm:AmountsDueFromRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c163" id="hidden-fact-237" name="apm:AmountsDueFromRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c165" id="hidden-fact-238" name="apm:AmountsDueFromRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-239" name="us-gaap:NetInvestmentInLease" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c170" id="hidden-fact-240" name="apm:AmountsDueToRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c173" id="hidden-fact-241" name="apm:AmountsDueToRelatedPartiesNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c177" id="hidden-fact-242" name="us-gaap:ProceedsFromRelatedPartyDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c174" id="hidden-fact-243" name="apm:LoanRepaymentAndInterestPaidToRelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c177" id="hidden-fact-244" name="apm:LoanRepaymentAndInterestPaidToRelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c181" id="hidden-fact-245" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c175" id="hidden-fact-246" name="apm:ConsultantSecondmentManagementAndAdministrativeServicesFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c181" id="hidden-fact-247" name="us-gaap:InterestExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c183" id="hidden-fact-248" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c187" id="hidden-fact-249" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c184" id="hidden-fact-250" name="apm:RepaymentOfLoanFromRelatedParty" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c187" id="hidden-fact-251" name="us-gaap:InterestIncomeOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c187" id="hidden-fact-252" name="apm:AdministrativeManagementServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c149" decimals="0" id="hidden-fact-253" name="us-gaap:LoansAndLeasesReceivableRelatedParties" unitRef="usd">4700000</ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-254" name="us-gaap:OtherAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c206" id="hidden-fact-255" name="us-gaap:OtherLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c206" id="hidden-fact-256" name="us-gaap:AssetsNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c206" id="hidden-fact-257" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c207" id="hidden-fact-258" name="us-gaap:OtherLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-259" name="us-gaap:VariableLeaseCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-260" name="us-gaap:VariableLeaseCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-261" name="us-gaap:SubleaseIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-262" name="us-gaap:SubleaseIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c4" id="hidden-fact-263" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" xsi:nil="true"/>
<ix:nonFraction contextRef="c227" decimals="5" id="hidden-fact-264" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares">0.00001</ix:nonFraction>
<ix:nonFraction contextRef="c226" decimals="0" id="hidden-fact-265" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares">10</ix:nonFraction>
<ix:nonFraction contextRef="c263" id="hidden-fact-266" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c264" id="hidden-fact-267" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c264" id="hidden-fact-268" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c266" id="hidden-fact-269" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c262" id="hidden-fact-270" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c262" id="hidden-fact-271" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c268" id="hidden-fact-272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c265" id="hidden-fact-273" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c265" id="hidden-fact-274" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c83" id="hidden-fact-275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c269" id="hidden-fact-276" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-277" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c271" id="hidden-fact-278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-279" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-280" name="apm:MilestonePayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-281" name="apm:MilestonePayments" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-27619">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-27620">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-27621">0001734005</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="apm-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><ix:relationship fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact" toRefs="ix_0_footnote"/>
<ix:relationship fromRefs="ix_4_fact ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact ix_10_fact ix_11_fact ix_12_fact ix_13_fact ix_14_fact ix_15_fact" toRefs="ix_1_footnote"/>
<ix:relationship fromRefs="ix_16_fact ix_17_fact ix_18_fact hidden-fact-20 ix_19_fact hidden-fact-42 ix_20_fact hidden-fact-47 ix_21_fact ix_22_fact ix_23_fact hidden-fact-71 ix_24_fact ix_25_fact ix_26_fact ix_27_fact ix_28_fact ix_29_fact ix_30_fact ix_31_fact ix_32_fact ix_33_fact" toRefs="ix_2_footnote"/>
<ix:relationship fromRefs="ix_34_fact ix_35_fact ix_36_fact ix_37_fact ix_38_fact ix_39_fact ix_40_fact ix_41_fact ix_42_fact ix_43_fact ix_44_fact ix_45_fact ix_46_fact ix_47_fact ix_48_fact ix_49_fact ix_50_fact ix_51_fact ix_52_fact" toRefs="ix_3_footnote"/>
<ix:relationship fromRefs="ix_53_fact ix_54_fact ix_55_fact ix_56_fact ix_57_fact ix_58_fact ix_59_fact ix_60_fact ix_61_fact ix_62_fact ix_63_fact ix_64_fact" toRefs="ix_4_footnote"/>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:AptorumTherapeuticsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:AptorumTherapeuticsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:APTUSMANAGEMENTLIMITEDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:APTUSMANAGEMENTLIMITEDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:AptorumMedicalLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:AptorumMedicalLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:PathsInnovationsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:PathsInnovationsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:PathsDiagnosticsPteLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:PathsDiagnosticsPteLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ActiculeLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ActiculeLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ClavesLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ClavesLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:NativusLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:NativusLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:VidensIncorporationLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:VidensIncorporationLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:MiosPharmaceuticalsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:MiosPharmaceuticalsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:mTORHongKongLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:mTORHongKongLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ScipioLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ScipioLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:SignateLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:SignateLifeSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apm:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:LibraMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apm:LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apm:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZk9BQMOWQfrm8jHnK3iPqh/RGOZRChD6nBq3dVwAwj4+/8SLuZTW/liOfKmyEBpRrTV6V//wh8natqXLVrpArUZiEOpCUQ4sWmUCqPSbJB1eeE0YXZR+qpcGF8VKslPcXkQ+inlG1l8YPuGFp3JEZ5VoAJF844sVddHhNq3xJYgqGGsxym9XDdIcU6KpUuCPd+5wjzHvI76g==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apm:HongKongHealthcareServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">apm:PrepaidPatentedLicensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">apm:PrepaidPatentedLicensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-31</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">apm:IanHuenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-08-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-13</xbrli:startDate>
    <xbrli:endDate>2019-08-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-13</xbrli:startDate>
    <xbrli:endDate>2019-08-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-17</xbrli:startDate>
    <xbrli:endDate>2021-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-01-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:ACCMedicalLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:MrClarkChengMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:MrIanHuenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:MrDarrenLuiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraTherapeuticsLimitedOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraTherapeuticsLimitedOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AencoTechnologiesLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:SabrinaKhanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:SabrinaKhanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentsCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentsCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentCorporationOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AencoTechnologiesLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AencoTechnologiesLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AencoTechnologiesLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:ACCMedicalLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:ACCMedicalLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:MiosMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:ScipioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">apm:GroupsSubsidiariesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:MiosPharmaceuticalsLimitedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">apm:GroupsSubsidiariesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ScipioLifeSciencesLimitedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">apm:GroupsSubsidiariesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">apm:VaribaleInterestEntityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apm:ConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apm:ConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-23</xbrli:startDate>
    <xbrli:endDate>2023-01-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesAndExternalConsultantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:SharesWarrantHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:SharesWarrantHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:SharesWarrantHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:ShareOptionHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apm:TwoThousandSeventeenShareOptionPlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-08</xbrli:startDate>
    <xbrli:endDate>2021-06-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-14</xbrli:startDate>
    <xbrli:endDate>2021-07-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-08</xbrli:startDate>
    <xbrli:endDate>2022-06-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-14</xbrli:startDate>
    <xbrli:endDate>2022-07-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-31</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-23</xbrli:startDate>
    <xbrli:endDate>2023-01-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-23</xbrli:startDate>
    <xbrli:endDate>2023-01-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apm:TwoThousandSeventeenShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apm:TwoThousandSeventeenShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apm:TwoThousandSeventeenShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:NonemployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:NonemployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:NonemployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:MiosPharmaceuticalsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:AptorumMedicalLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:AptorumMedicalLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:ClarkChengMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:ClarkChengMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:ClarkChengMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:ClarkChengMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-08</xbrli:startDate>
    <xbrli:endDate>2024-04-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:DSFInvestmentHoldingsLimitedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-08</xbrli:startDate>
    <xbrli:endDate>2024-04-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-08</xbrli:startDate>
    <xbrli:endDate>2024-04-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001734005</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:DSFInvestmentHoldingsLimitedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-08</xbrli:startDate>
    <xbrli:endDate>2024-04-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="hkd">
  <xbrli:measure>iso4217:HKD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>ea020368101ex4-4_aptorum.htm
<DESCRIPTION>APPOINTMENT LETTER BETWEEN THE COMPANY AND IAN HUEN (EXECUTIVE DIRECTOR), DATED NOVEMBER 20, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex4-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">20 November 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. HUEN Chung Yuen Ian</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Present</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Ian,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Re: Appointment as Chief Executive Officer</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We refer to the employment contract entered into
between the Company, and you dated 1 June 2022 and hereby inform you in writing, effective 24 November 2023, you will be appointed as
<B><U>Chief Executive Officer</U></B> of Aptorum Group Limited (&ldquo;the Group&rdquo;) whereas all other current employment terms and
conditions remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Starting from 24 November 2023, your job title
of Non-Executive Director will be released, and you will be redesignated as <B><U>CEO and Executive Director</U></B> of the Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kindly signify your understanding and acceptance
of the new appointment by signing and returning the duplicate of this letter to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours truly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For and on behalf of </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>APTUS MANAGEMENT LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(A member of Aptorum Group)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Marianna Wong</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Marianna Wong</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>General Manager</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I understand and accept the aforesaid new appointment
and hereby acknowledge receipt of the copy of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Ian Huen</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>HUEN Chung Yuen Ian</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD></TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Unit 110, Building 15W, Hong Kong Science Park,
N.T., Hong Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">T: (852) 34697942</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>ea020368101ex12-1_aptorum.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification by the Principal Executive Officer
pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Ian Huen, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 20-F of Aptorum Group Limited;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 30, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/  <FONT STYLE="font-size: 10pt">Ian
    Huen</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian Huen</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer <BR>
    <I>(Principal Executive Officer)</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>ea020368101ex12-2_aptorum.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification by the Principal Financial Officer
pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Martin Siu, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 20-F of Aptorum Group Limited;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 35%; font-size: 10pt"><FONT STYLE="font-size: 10pt">April 30,
    2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/ Martin Siu</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Martin Siu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Head of Finance<BR>
(<I>Principal Financial Officer</I>)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>ea020368101ex13-1_aptorum.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Certifications Pursuant
to 18 U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to U.S.C. Section
1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned
officers of Aptorum Group Limited (the &ldquo;Company&rdquo;), do hereby certify, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Annual Report on
Form 20-F for the year ended December 31, 2023 of the Company fully complies, in all material respects, with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 20-F fairly presents, in all material respects,
the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: April 30,
    2024</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ <FONT STYLE="font-size: 10pt">Ian
    Huen</FONT></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian Huen</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Martin
    Siu</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Martin Siu</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head of Finance</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>6
<FILENAME>ea020368101ex15-1_aptorum.htm
<DESCRIPTION>CONSENT OF MARCUM ASIA CPAS LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex15-1_001.jpg" ALT="" STYLE="height: 34px; width: 220px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference in the
Registration Statement of Aptorum Group Limited on Form F-3 (FILE NO. 333-268873) and Form S-8 (FILE NO. 333-232591) of our report dated
April 30, 2024, with respect to our audits of the consolidated financial statements of Aptorum Group Limited as of December 31, 2023 and
2022, and for each of the three years in the period ended December 31, 2023, which report is included in this Annual Report on Form 20-F
of Aptorum Group Limited for the year ended December 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Marcum Asia CPAs <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Marcum Asia CPAs <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">April 30, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NEW YORK OFFICE &#9679; 7 Penn Plaza &#9679; Suite
830 &#9679; New York, New York &#9679; 10001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Phone 646.442.4845 &#9679; Fax 646.349.5200 &#9679;
www.marcumasia.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>7
<FILENAME>ea020368101ex97-1_aptorum.htm
<DESCRIPTION>POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 97.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APTORUM GROUP LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Policy for the Recovery of Erroneously Awarded
Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Effective: December 1, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Introduction</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors (the
&ldquo;<B>Board</B>&rdquo;) of APTORUM GROUP LIMITED (the &ldquo;<B>Company</B>&rdquo;) has adopted this policy, which provides for the
recovery of certain executive compensation in the event of certain accounting restatements (the &ldquo;<B>Policy</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy is designed to
comply with Section 10D, as implemented by Rule 10D-1, of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;)
and is made in accordance with the applicable listing rules (the &ldquo;<B>Nasdaq Rules</B>&rdquo;) of the Nasdaq Stock Market (&ldquo;<B>Nasdaq</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Covered Executives</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy applies to the
Company&rsquo;s current and former executive officers, as determined by the Committee (as defined below) in accordance with Section 10D
of the Exchange Act and the Nasdaq Rules, who, for the avoidance of doubt, will include, at a minimum, executive officers identified pursuant
to 17 C.F.R. 229.401(b), as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting
officer, the controller), and such other senior executives/employees who may from time to time be deemed subject to the Policy by the
Committee (&ldquo;<B>Covered Executives</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy shall be binding
and enforceable against all Covered Executives, as described herein, and, to the extent required by applicable law or guidance from the
United States Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) or Nasdaq, Covered Executives&rsquo; beneficiaries, heirs,
executors, administrators or other legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Recovery of Erroneously Awarded Compensation</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event the Company is
required to prepare an Accounting Restatement of its financial statements, the Remuneration Committee (if composed entirely of independent
directors, or in the absence of such a committee, a majority of independent directors serving on the Board) (the &ldquo;<B>Committee</B>&rdquo;)
will determine the amount of Erroneously Awarded Incentive Compensation (defined below) and the Company will promptly notify each Covered
Executive who received Erroneously Awarded Incentive Compensation of the amount of Erroneously Awarded Incentive Compensation received
by such Covered Executive and will require reimbursement or forfeiture of not less than the full amount of any Erroneously Awarded Incentive
Compensation received or deemed received by any Covered Executive, except to the extent determined impracticable in Section 7 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any such recovery shall apply
to Incentive Compensation Eligible for Recovery paid during the three (3) completed fiscal years immediately preceding the Restatement
Date and, if the Company changes its fiscal year, any transition period of less than nine months within or immediately following those
three completed fiscal years (the &ldquo;<B>Recovery Period</B>&rdquo;).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Incentive Compensation shall
be deemed received in the Company&rsquo;s fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation
award is attained, even if the payment or grant of the Incentive Compensation to the Covered Executive occurs after the end of that period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any recovery under this Policy
shall be made reasonably promptly and in accordance with the Exchange Act and Nasdaq Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Incentive Compensation and Financial Reporting Measures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Policy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Accounting Restatement</B>&rdquo;
means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities
laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to
the previously issued financial statements (a &ldquo;Big R&rdquo; restatement), or that would result in a material misstatement if the
error were corrected in the current period or left uncorrected in the current period (a &ldquo;little r&rdquo; restatement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Financial Reporting
Measures</B>&rdquo; are measures that are determined and presented in accordance with the accounting principles used in preparing the
Company&rsquo;s financial statements, and all other measures that are derived wholly or in part from such measures. Share price and total
shareholder return (and any measures that are derived wholly or in part from share price or total shareholder return) shall, for purposes
of this Policy, be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented
in the Company&rsquo;s financial statements or included in a filing with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Incentive Compensation</B>&rdquo;
means any compensation that is granted, earned, or vested based wholly or in part on the attainment of a Financial Reporting Measure,
including, but not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Annual bonuses and other
short- and long-term cash incentives;<SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Stock options;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Restricted stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Restricted stock units;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) Performance shares.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">To the extent that a Covered Executive receives a salary increase
earned wholly or in part based on the attainment of a Financial Reporting Measure performance goal, such a salary increase is subject
to recovery as a non-equity incentive plan award for purposes of Rule 10D-1.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Incentive Compensation
Eligible for Recovery</B>&rdquo; means Incentive Compensation received by a Covered Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) after beginning service
as a Covered Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) who served as a Covered
Executive at any time during the performance period for the applicable Incentive Compensation (regardless of whether such individual is
serving as a Covered Executive at the time the Erroneously Awarded Incentive Compensation is required to be repaid);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) while the Company had
a class of securities listed on a national securities exchange or a national securities association;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) during the applicable
Recovery Period; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) on or after the effective
date of the applicable Nasdaq Rules (i.e., October 2, 2023&nbsp;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Restatement Date</B>&rdquo;
means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such
action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting
Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Erroneously Awarded Incentive Compensation &ndash; Amount Subject to Recovery</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount to be recovered
will be the excess of the Incentive Compensation Eligible for Recovery paid to the Covered Executive based on the erroneous data over
the Incentive Compensation Eligible for Recovery that would have been paid to the Covered Executive had it been based on the restated
results (calculated without regard to any taxes paid), as determined by the Committee (the &ldquo;<B>Erroneously Awarded Incentive Compensation</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Committee cannot determine
the amount of Erroneously Awarded Incentive Compensation received by the Covered Executive directly from the information in the Accounting
Restatement (i.e., the Erroneously Awarded Incentive Compensation is not subject to mathematical recalculation directly from the information
in the applicable Accounting Restatement), then it will make its determination based on a reasonable estimate of the effect of the Accounting
Restatement. The Company shall maintain documentation of the determination of such reasonable estimate and provide the relevant documentation
to Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall promptly
notify each Covered Executive with a written notice containing the amount of any Erroneously Awarded Incentive Compensation and a demand
for repayment or return of such compensation, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>6.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Method of Recovery</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee will determine,
in its sole discretion, the method for recouping Erroneously Awarded Incentive Compensation hereunder which may include, without limitation,
any of the following or combination thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) requiring reimbursement
of cash Incentive Compensation Eligible for Recovery previously paid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) seeking recovery of any
gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) offsetting the recouped
amount from any compensation otherwise owed by the Company to the Covered Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) cancelling outstanding
vested or unvested equity awards; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) taking any other remedial
and recovery action permitted by law, as determined by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in Section
7 below, in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Incentive Compensation in satisfaction
of a Covered Executive&rsquo;s obligations hereunder. To the extent that a Covered Executive fails to repay all Erroneously Awarded Incentive
Compensation to the Company when due, the Company shall take all actions reasonable and appropriate to recover such Erroneously Awarded
Incentive Compensation from the applicable Covered Executive. The applicable Covered Executive shall be required to reimburse the Company
for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously Awarded Incentive Compensation
in accordance with the immediately preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that the Covered
Executive has already reimbursed the Company for any Erroneously Awarded Incentive Compensation received under any duplicative recovery
obligations established by the Company or applicable law, it shall be appropriate for any such reimbursed amount to be credited to the
amount of Erroneously Awarded Incentive Compensation that is subject to recovery under this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>7.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Impracticality</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall recover
any Erroneously Awarded Incentive Compensation in accordance with this Policy, unless such recovery would be duplicative of compensation
recovered by the Company from the Covered Executive pursuant to Section 304 of the Sarbanes-Oxley Act or would be impracticable, as determined
by the Committee in accordance with Rule 10D-1 of the Exchange Act and the Nasdaq Rules, <U>and</U> any of the following conditions are
satisfied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The Committee has determined
that the direct expenses paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before making
this determination, the Company must make a reasonable attempt to recover the Erroneously Awarded Incentive Compensation, documented such
attempt(s) and provide such documentation to Nasdaq; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Recovery would violate
home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable
to recover any amount of Erroneously Awarded Incentive Compensation based on violation of home country law, the Company has obtained an
opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation and a copy of the opinion is provided
to Nasdaq; or</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Recovery would likely
cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet
the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>8.</B></FONT> <FONT STYLE="font-size: 10pt"><B>No Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall not insure
or indemnify any Covered Executive against the loss of any Erroneously Awarded Incentive Compensation that is repaid, returned or recovered
in accordance with the terms of this Policy, or for any claims relating to the Company&rsquo;s enforcement of any of its rights under
this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall not enter
into any agreement or arrangement that exempts any Incentive Compensation that is granted, paid or awarded to any Covered Executive from
the application of this Policy or that waives the Company&rsquo;s right to recover any Incentive Compensation Eligible for Recovery, and
this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date of this Policy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>9.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Other Recovery Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee intends that
this Policy will be applied to the fullest extent required by applicable law. Any employment agreement, equity award agreement, compensatory
plan or any other agreement or arrangement with a Covered Executive shall be deemed to include, as a condition to the grant of any benefit
thereunder, an agreement by the Covered Executive to abide by the terms of this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may require
that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition
to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any right of recovery under
this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company under
applicable law, regulation or rule or pursuant to the terms of any similar policy in any employment agreement, equity award agreement,
or similar agreement and any other legal remedies available to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Disclosure Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall file all
disclosures with respect to this Policy required by applicable SEC filings and rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>11.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Interpretation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee is authorized
to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this
Policy, and for the Company&rsquo;s compliance with Nasdaq Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation, rule
or interpretation of the SEC or Nasdaq promulgated or issued in connection therewith. It is intended that this Policy be interpreted in
a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by
the SEC or Nasdaq.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>12.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Amendment and Termination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may amend or
terminate this Policy from time to time in its discretion; provided, that, no amendment or termination of this Policy shall be effective
if such amendment or termination would cause the Company to violate any applicable federal securities laws, SEC rule or Nasdaq Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>13.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Effective Date</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy shall be effective
as of December 1, 2023 (the &ldquo;<B>Effective Date</B>&rdquo;) and shall apply to Incentive Compensation that is approved, awarded or
granted to Covered Executives on or after October 2, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>14.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Policy Administration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy shall be administered
by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>ANNEX A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APTORUM GROUP LIMITED </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Policy for the Recovery of Erroneously Awarded
Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Acknowledgement Form</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By signing below, the undersigned acknowledges
and confirms they have received and reviewed a copy of the APTORUM GROUP LIMITED Policy for the Recovery of Erroneously Award Compensation
(the &ldquo;<B>Policy</B>&rdquo;). Capitalized terms used but not otherwise defined in this Acknowledgement Form shall have the meanings
given to such terms in the Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By signing this Acknowledgement Form, the undersigned
acknowledges and agrees that they are and will continue to be subject to the Policy and that the Policy will apply both during and after
the undersigned&rsquo;s employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy,
including, without limitation, by returning any Erroneously Awarded Incentive Compensation (as defined in the Policy) to the Company to
the extent required by, and in a manner permitted by, the Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the avoidance of doubt, any recovery affected
under the Policy shall not constitute grounds to terminate the undersigned&rsquo;s employment for &ldquo;Good Reason&rdquo; (or any term
of similar meaning) under any employment, change in control or severance, equity award or compensation arrangements, agreements, plans
or programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Signed</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Name (Printed)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Y [@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFU7PQI6HW 03W5G%-)L&%W,@)P/3)H RO^%C^#_^A@L_^^C_ (4?\+'\'_\
M0P6?_?1_PKJ** .7_P"%C^#_ /H8+/\ [Z/^%'_"Q_!__0P6?_?1_P *ZBB@
M#E_^%C^#_P#H8+/_ +Z/^%7-,\9>'=:OELM.U>VN;IE+")&^8@=36Y7+:U_R
M4+PK_P!<;W_T&.@#J:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@ HHHH *Y;6O^2A>%?^N-[_ .@QUU-<MK7_ "4+PK_UQO?_ $&.@#J:***
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M'5W_ /'*/^$"TG_G\UW_ ,'5W_\ '*7_ (3_ $#UU/\ \%%W_P#&Z/\ A/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUOHIMKA+]KB&58V.P[@@8\OD'E %Z9SBO5_#7_(JZ/\ ]>4/_H IL#4HHHI
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M .O&'_T 5H7$$5U;2V\Z!X94*.AZ,I&"/RKF5^&WA%5"KHZA0, ">4 ?^/4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%S+$"#YBI;-*H#=N0.16=_PLJ],:QKX<S?-)@0&^4+L^S^>&W[>NWC&.O<T
MM3;_ .%@^'?^>U__ ."NZ_\ C='_  L'P[_SVO\ _P %=U_\;K&_X6<9IT6S
MT5YXY B)FZ596F:W\]5\O!.W:0-_KVQS5>^^+MG;65O?6^G_ &BTGF$:,)R&
M90L9=@H0CY6DV\D#(/-%M; =#_PL'P[_ ,]K_P#\%=U_\;H_X6#X=_Y[7_\
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M9KG;Y(VNQ_@.<;.Y!^8<4!8WO^%@^'?^>U__ ."NZ_\ C='_  L'P[_SVO\
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MGE,<8B0(-X!'(Z@=R:.M@\SK/^%@^'?^>U__ ."NZ_\ C='_  L'P[_SVO\
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M_P">_AO_ +\S_P#Q5=310!RVSQ[_ ,]_#?\ WYG_ /BJ-GCW_GOX;_[\S_\
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MS:0L*-]J3RHY%E8LNS(&XHP*D< DY(I#/29]/T+3=/C>>ST^VL[(,8RT2(D
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M'J$8=XWB.T*2V%VR$!QW &,@5U_AS2I)?#-AHVNZ,@6PM+>-6E9)%D?R=KX
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M$ZB\7@N"W2QU!CYMR!-;QJ0,SR<C)Z_44 :7_"6W$FG6T\6FH9WLY;R:%KC
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M5']MO_T"-3_[]+_\50!JT5E?VV__ $"-3_[]+_\ %4?VV_\ T"-3_P"_2_\
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M3KVR9/"?B*2WM?.=0WV48=]H 51-A4 #<#N:8CT>BN8_X2S4?^A+\0?^2O\
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M_$'_ )*__'J .GHKF/\ A+-1_P"A+\0?^2O_ ,>H_P"$LU'_ *$OQ!_Y*_\
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M?V9XT_Z&?2O_  3M_P#'Z .GHKF/[,\:?]#/I7_@G;_X_1_9GC3_ *&?2O\
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M=O\ X_1_9GC3_H9]*_\ !.W_ ,?H Z>BN8_LSQI_T,^E?^"=O_C]']F>-/\
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MS%<!2PSM/^T!R1[CUKB_"WA'1=<TF?4-1@N)[J34+U6?[9,N0MS(JC < 8
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M6JM_X)N[VYUI1K*1V.JRQSO!]DRZ.@C (??R/W?3'>M?1M1N[O4KN&Z3R_\
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M_KC_ , ;C_XBC_A8OAC_ )_KC_P!N/\ XBNIHH Y;_A8OAC_ )_KC_P!N/\
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M8.W:NGHH **** "BBB@ HHHH R]+_P"0IK?_ %]I_P"B(JU*R]+_ .0IK?\
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M H^QVO\ S[0_]\"IJ* (?L=K_P ^T/\ WP*/L=K_ ,^T/_? J:B@"'[':_\
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MPL"#%X1\5LP/!DA#8 C,8'^LZ!#BD!T%SXOM5NK5+99)+=I,3W'E,45?):7
M/7=MVG&._K5JUU];V\TX0QD6M]%(R,P^8,FTCD$@@@G\JY:.[L8IHY(_"?BU
M/+P518P%#"/RPV/,^]LXS[9ZTMEJ,5A?07$/A?Q/MB\UMK6B$M)(5W.3YGHN
M,8[FF(]"HKEO^$TD_P"A3\2_^ B?_%T?\)I)_P!"GXE_\!$_^+H&=317+?\
M":2?]"GXE_\  1/_ (NC_A-)/^A3\2_^ B?_ != '4US&F?\E(\1?]@^P_\
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M_P (AX9_Z%W2?_ */_XFC_A$/#/_ $+ND_\ @%'_ /$UG_\ ":2?]"GXE_\
M 1/_ (NC_A-)/^A3\2_^ B?_ != &A_PB'AG_H7=)_\  */_ .)H_P"$0\,_
M]"[I/_@%'_\ $UG_ /":2?\ 0I^)?_ 1/_BZ/^$TD_Z%/Q+_ . B?_%T :'_
M  B'AG_H7=)_\ H__B:/^$0\,_\ 0NZ3_P" 4?\ \36?_P )I)_T*?B7_P !
M$_\ BZ/^$TD_Z%/Q+_X")_\ %T :'_"(>&?^A=TG_P  H_\ XFC_ (1#PS_T
M+ND_^ 4?_P 36?\ \)I)_P!"GXE_\!$_^+H_X323_H4_$O\ X")_\70!H?\
M"(>&?^A=TG_P"C_^)H_X1#PS_P!"[I/_ (!1_P#Q-9__  FDG_0I^)?_  $3
M_P"+H_X323_H4_$O_@(G_P 70!H?\(AX9_Z%W2?_  "C_P#B:/\ A$/#/_0N
MZ3_X!1__ !-9_P#PFDG_ $*?B7_P$3_XNC_A-)/^A3\2_P#@(G_Q= &A_P (
MAX9_Z%W2?_ */_XFC_A$/#/_ $+ND_\ @%'_ /$UG_\ ":2?]"GXE_\  1/_
M (NC_A-)/^A3\2_^ B?_ != &A_PB'AG_H7=)_\  */_ .)JQ9:!HVFS^?8Z
M186LV,>9!;(C8],@9K'_ .$TD_Z%/Q+_ . B?_%U-I_C&&]UFWTN;2-7L)[E
M'>(WD"HKA "V"&//(H Z.BBB@ HHHH ***YJ]\90VNL7>F0:-K%_-:;/.:SM
MU=%+*& R6'8T =+17+?\)I)_T*?B7_P$3_XNC_A-)/\ H4_$O_@(G_Q= '4T
M5RW_  FDG_0I^)?_  $3_P"+H_X323_H4_$O_@(G_P 70!U-%<M_PFDG_0I^
M)?\ P$3_ .+H_P"$TD_Z%/Q+_P" B?\ Q= '4T5RW_":2?\ 0I^)?_ 1/_BZ
M/^$TD_Z%/Q+_ . B?_%T =317+?\)I)_T*?B7_P$3_XNC_A-)/\ H4_$O_@(
MG_Q= '4T5RW_  FDG_0I^)?_  $3_P"+H_X323_H4_$O_@(G_P 70!U-%<M_
MPFDG_0I^)?\ P$3_ .+H_P"$TD_Z%/Q+_P" B?\ Q= '4T5RW_":2?\ 0I^)
M?_ 1/_BZ/^$TD_Z%/Q+_ . B?_%T =317+?\)I)_T*?B7_P$3_XNC_A-)/\
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M;>2"9 \4JE'1NC*1@@US0^''@X  >'[, = %/^- '4T5R_\ PKCP?_T +/\
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M  KCP?\ ] "S_(_XT =16/XB1V@L'"LT<5_ \@ S\N[&?P)!_"L__A7'@_\
MZ %G^1_QH_X5SX/_ .@!:?D?\: ,R+PWKMMI]J8+F07,2WA6-FC"0L^[85(7
M/.1U)QFIFT;6K@RA&O[>T/FM# ]\3(C>4H7<P<Y'F D#<0/QQ5W_ (5QX/\
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M_"N/!_\ T +/\C_C0!U%%<O_ ,*X\'_] "S_ "/^-'_"N/!__0 L_P C_C0
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M 4L7 0%-NX!MP&/4@@U)9?$30YI--MKJY6*]O@-D<:NZ*2[(N6*C&XJ0,@4
M2_\ "Q_!_P#T'K7_ ,>_PH_X6/X/_P"@]:_^/?X4V#XC>'+FUEGBN+I@GE[4
M^QR[YMY*KY:[<ODJP^7/0T]OB'X:2_ELGOF2:*%IGW0. H5/,9<X^\%Y*]:
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M  H_X6/X/_Z#UK_X]_A74T4 <M_PL?P?_P!!ZU_\>_PH_P"%C^#_ /H/6O\
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MM.[ P3DKUXS5>U^(VC+:6PU*22WO'L([V55MW*!2BLVUL8( ;)] #Z4 6/\
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M>%_%(\37>KB*!XK:TFCCA,L3Q2,&B5R65@".6XXZ8H A_P"%C^#_ /H/6O\
MX]_A1_PL?P?_ -!ZU_\ 'O\ "NIHH HZ3K.G:[9F[TN\CNK<.8S)&> PZCZ\
MT5B>"?O>(_\ L-W'\DHH ZFBBB@ HHHH *RM1_Y#>C?]=9?_ $6U:M96H_\
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M'LK+0DNY+Q4>^F6UB60^5'@!6ST5F."1SP<5@/X@\2ZCJ6O:OI%_.=&M(I)
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M\D8P![5T]-Z <M_;?B[_ *$Z+_P;)_\ $59T'Q!?:GJNH:9J.D?V==6<4,I
MN5F#K(7 Y &/]6?SKH*YC3/^2D>(O^P?8?\ H5Q2 Z>BBB@ HHHH **** .>
MM[R[M]9UE8-,FNE-RA+I+&H!\B+C#,#3;I)[R_MKV;0=0,UL<Q;;Y%4>N5$F
M#D<<BK^E_P#(4UO_ *^T_P#1$5:E '(II,,<91/#%Z!\NPB]7=&%)*A#YF4
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MZ* .8_LGQC_T->G_ /@G_P#MU9Q\&:XT\D[:YI322$ERVC$@DD%CCSL#.!G
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M\'5S_P#%T?\ ""Z?_P!!3Q#_ .#JY_\ BZZ>B@#F/^$%T_\ Z"GB'_P=7/\
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M6]*O1>V;QV;6KL7@9I@88RA1)"W"'.<$'FO1Z8CF/^$%T_\ Z"GB'_P=7/\
M\71_P@NG_P#04\0_^#JY_P#BZZ>BD!S'_""Z?_T%/$/_ (.KG_XNC_A!=/\
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MXPEUEKJTDB(N@"EN5GD\Z19/WCY^;;@J.!QBD@-'_A!=/_Z"GB'_ ,'5S_\
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MG T\[Y)6*E6"R['0@'*L0K$9[8-4UL?$:0F(>$M!*,C(V=8E)8,0S9)@R<D
MDGGBLN'PUXLBEN&.CZ2T<[%GC&J,N\&42$.1;_/R,9/0$^M"W ]-HKE_[0\;
M_P#0O:+_ .#>3_XQ1_:'C?\ Z%[1?_!O)_\ &* .HHKE_P"T/&__ $+VB_\
M@WD_^,4?VAXW_P"A>T7_ ,&\G_QB@#J**Y?^T/&__0O:+_X-Y/\ XQ1_:'C?
M_H7M%_\ !O)_\8H ZBBN7_M#QO\ ]"]HO_@WD_\ C%']H>-_^A>T7_P;R?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=% 'F-UI.HS:;<V47@G48TN/*5RVIP/MCC?>$4&3Y>K#CU[UK_:=7^T_:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $1 XD# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFT;3YVF=[9?,FF6=Y%)5O,50H8,#D$* ,C''% ]#&N?'-A:JK/;7#[PC(BE
MVUDWDG<RCY1P0"23P :GE\42"_@M[;0]0N8);HVPND:%8R0K%R T@;Y2A!!
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M:/[:U7_H)WG_ '_;_&J-%%D%V7O[:U7_ *"=Y_W_ &_QH_MK5?\ H)WG_?\
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M]O\ &C^VM5_Z"=Y_W_;_ !JC119!=E[^VM5_Z"=Y_P!_V_QH_MK5?^@G>?\
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M1HHL@NR]_;6J_P#03O/^_P"W^-']M:K_ -!.\_[_ +?XU1HHL@NR]_;6J_\
M03O/^_[?XT?VUJO_ $$[S_O^W^-4:*+(+L]<^!6H7MWXWO8[F\N)D&G.0LDK
M, ?,CYP37T'7SI\ _P#D>K[_ +!DG_HV*OHNO+Q7\0[J'P!7RQ\6/^1ZNO\
M@?\ Z->OJ>OECXL?\CU=?\#_ /1KU6$^,G$?"</116_X>UF'2+'4BTDZSR&$
MQ+#(8V;:^3\P!P*])NR.-&!176)=^'+W%Q=0VT=[+ TLI?SQ%Y[7#$J0AR (
ML8V\>O-;-Q;>%+"UMUU.VN2[P>99PWD\T>(&N)\'Y58JQ3RR/EVG)/?F'.VZ
M*Y;[,\ZHKM],O/"MJ+M9(K%HI]/6-/-6X,@ES$6#-@A>D@#(/TKGO$9T@ZS(
MVAC;8E$*H"Y"MM&X9?YCSGD@?04U*[M83CI>YDU._P#QX0_]=7_DE05._P#Q
MX0_]=7_DE4Q$%%%%,04444 %%%% !16UX9O[>PO;MYY_L[RV<L4%QM)\J1AP
M> 2.XR!D9S6M9MX;FT^^;6]06]U)HYC%<[[C=N$:^4.5P06R/FQC'I@U#E9[
M%*-^IQ]%=]97?@JU\0)=P;(4@NB\!(G*!%N$*L1RV[R]V.V1R,U<EUOPL^IV
ME^MX7N(AR\YN&" O<%@@Z _-$<8V\GOFI=1]AJ&NYYK17H-C<^![/2#@PO?R
M6DL3NZ3,"S0K@X(PK;]XRI/7.<'C'U[_ (1235;./1T\FQ\_$TWFRNWE97!9
M6088#=]TL#_-J?O6L+ETO<Y:BO0_"'B70O*\00>))VBM]7NXI)42-F)53(YQ
M@''S%!^-)J>J^$=<U6?4M1;=)/\ -.5$HDSY4041X&S 8.#N[#CM1SN]K!RJ
MU[GGM%>F/?>!KE-/M+N>W>TM&D58XQ=*JH]QNR&P6+;.<'CGJ#571]<\.0B!
M;^99%CMHX@DB2M&"(KD9*@8)#/%@XR-QQWI>T=MF5R>9Y[174>-=-TW2KNPA
ML+9[>2>T2ZGBD9BT32 'R\$]!C(SSAN:Y>KB^97(:L%%%%4(**** "I[?_4W
M7_7(?^AK4%3V_P#J;K_KD/\ T-:3&B"BBBF(**** "BBB@ HHHH **["POO#
M<UEHT.K;9?L\,<,JL)1Y:FZE:3&S&3Y; ]^OKQ6K#J_A2T\+FPM+IXFDVRNH
M\X2&3[),C;F'&/-=1A3@J>1C-9RFUT-(P3:5SSJBNUM!X+_MU6NC;'2PB80?
M:1(WS1[MYQ]X#?C:,'GIP:N7VH>#Y[>VMXY5$"+ C1HLR!BGVC+2  !N6BY'
MS89L8YI.I:VC!0OU//J*[@'P-_94RN$^W&.7#Q_:-JN+=2FS/8R[A\WOGC%<
M/5J5V]"&K*X44450@HHHH **** "M(S-%H%KM"'-U/\ >16_AB]16;5^7_D
M6?\ U]3_ /H,53+H-=2O]KD_NP_]^$_PH^UR?W8?^_"?X5!13L@N=#=Z+J5N
M+$6XMKY[RW^TQQVEJ781[BN2#&.X-55T[6WV[-(G;=G;BPSG#;3CY>S<'WXJ
MW9>,K^QFMI4MK1VMK,6<9=7R$$GF9R&!#9.,@CCC%:%IXT2]UB:YUR(+!)&P
M*VL)?+&Y^T=#(I^\6&=W QP>:S]Y="_=[F/::3KE]<00PZ6^Z>7R49K154OD
MC&XK@8(.?H:S6NIE8JT<(8'!!@3(/Y5T$GCO4VNK>9$C'V:82Q O)@@2F0*R
MA@K#)ZXSP.:YAB&8D*%!.<#H*J*?5$NW0F^UR?W8?^_"?X5,MPYM)'*0[A(@
M!\E.A#9[>PJE4Z?\>$W_ %U3^3TVD*X?:Y/[L/\ WX3_  H^UR?W8?\ OPG^
M%044[(+D_P!KD_NP_P#?A/\ "C[7)_=A_P"_"?X5!119!<G^UR?W8?\ OPG^
M%'VN3^[#_P!^$_PJ"BBR"Y/]KD_NP_\ ?A/\*FMKAY)6#)"0(W/^I3J%)';U
M%4JGM/\ 7-_URD_] -)I6!,/M<G]V'_OPG^%'VN3^[#_ -^$_P *@HIV07)_
MM<G]V'_OPG^%'VN3^[#_ -^$_P *N:#90ZAJ3P3AB@M+F48./F2%W7]5%:>C
M^#I=8T%M0BNP)FD=(8 F[=LV;MQ!RO\ K%Q\I'J1D93:6X[,P/M<G]V'_OPG
M^%'VN3^[#_WX3_"NZ@^'EK#XBL[:YU&::SE>)3LML2,S3M$5(WG:N8W^<$]N
M.>.!E4)*ZCH&(%3&49;#E&4=R3[7)_=A_P"_"?X5-:W#R7<*.D)5I%!'DIR"
M?I5*I[+_ (_[;_KJO\Q5-*Q*8?:Y/[L/_?A/\*W?#F@:GXHF\JQ:P1O.6']]
M&JC<8Y)!T4\8B;\2/?'-UL:+XCO-"CF2UC@<2OO;S5)P?+ECXP1VF;\0/?))
M:.VX)]S;7P3K1%H'FTR.6[>*.&)X\,9)%+*A_=X!^4CDXSWK'M]+U2ZTZ6\A
M@A<)<BV$*6ZM([E68[0%.0 IS]16M/\ $C6+F>WN)[:Q>>WDBFCE*/D21J55
M_O8)Y).1C/:J&G>)A8Z#/9M#YMRURTJEQE'22)HY5;!!!P5((]^E96J=C3W#
M-FBU*VB,L]B8HUD,1>2T"@. "5R5ZX(./>NJNOA]X@M8+B9Y-+:. W"R,J#@
MPIO/\'< X]P<XKF=4UZZU:"&&>.%(X9"Z",$8S''&%Y)X"Q)COUR36[-\2M;
MF:\)ALE6[AN(955&QB;;N(^;J-HP?<YSFJDI_9%'EOJ9FKZ3?:.DCR2V,Z17
M4EG(T$(PDJ8R#N0>O!'H:R/M<G]V'_OPG^%:&K^(;G6$D22"W@26ZDO)%A#8
M:5\9)W,?3@>YK(JHIV]XF370NW5P\=W,B)"%61@!Y*< 'Z5I0:5=SW6GVGVG
M3TNKYHA%"\/S 2'"DD1D <@]<X/X5CWO_'_<_P#75OYFM&#Q#-!<Z?=?9+5[
MJQ:(Q3/OW$1G*A@& (X Z9P/QHMIH%Q3INK,,V]BURHC$CM#8DA =QY.ST1C
MD<8!YX-+<Z7J]O(RK8M.BA"9([!@H+*I ^9 <_.HZ<Y&,@@FS9^--2LO+\N"
MU/EA -R-_"DJ#^+TG?\ (>^77'C6\O+NUNKFPT^:2U=)(=Z.54JL:]-^""(E
MR#GJ>G&)M*^Q3Y=;%.;3M4MK"XN[JU2V$$D4;1S6H1SY@<J0"O3]VWZ5-/H]
M_'9V%Q;M:7AOE=X8;:U+2;4)#$@QCIM/\Z=K?C'4-=LA:7,-ND86)<IO+8C,
MI7EF/_/9L_0?C5B\17<-M9P+' 5M+>XMHR5.2LP8,3SU&\X_#K32E;5 ^6^@
M26&JHC2)8M+"D:2/*EB=J!D#\DH,8##GIW!(P3%J<=UI6J76GS_96FMI6B<I
M"I4E3@XRHXK7@\>ZE;Z?+9I:V6R6V-LS[7#%/)6'G#@$[4!&0<$G'7%8&IZA
M+JNJ76H3JBS7,K2N$!"@L<G&2>*$I7U6@GRV\Q]S</'*H5(0#&A_U*=2H)[>
MIJ'[7)_=A_[\)_A1=_ZY?^N4?_H J"J25B6R?[7)_=A_[\)_A1]KD_NP_P#?
MA/\ "H**=D%R?[7)_=A_[\)_A1]KD_NP_P#?A/\ "H**+(+D_P!KD_NP_P#?
MA/\ "C[7)_=A_P"_"?X5!119!<NM<.+2-PD.XR."?)3H N.WN:A^UR?W8?\
MOPG^%#_\>$/_ %U?^25!2207)_M<G]V'_OPG^%'VN3^[#_WX3_"H**=D%R?[
M7)_=A_[\)_A1]KD_NP_]^$_PJ"BBR"Y/]KD_NP_]^$_PH^UR?W8?^_"?X5!1
M19!<]C^ 9$WB'5I72/S$M%565 I +@D<#_9'Y5[Y7@7[/O\ R'-9_P"O9/\
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M*EOX]0B*"-Y8D:,@NJP+.<_W3M;&.>1Z<UQU:PM=V9D[V1/=_P"N7_KE'_Z
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MT%%'UFIW#V$#G_\ A'I?^>Z?D:/^$>E_Y[I^1KH**/K-3N'L('/_ /"/2_\
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MX/\ X5#HG_/]J'_?2?\ Q-'_  J'1/\ G^U#_OI/_B:]!HH \^_X5#HG_/\
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M.&)))SF9O!MJ;YKQ6A6=I1(9!;C?D7!F^]G.<$IG\?:FQ&)_PJ'1/^?[4/\
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M^?V+_OPG^%'_  LOQ1_S^Q?]^$_PK#ZU ];_ %?Q7>/W_P# .U_X5#HG_/\
M:A_WTG_Q-'_"H=$_Y_M0_P"^D_\ B:XK_A9?BC_G]B_[\)_A1_PLOQ1_S^Q?
M]^$_PH^M0#_5_%=X_?\ \ [7_A4.B?\ /]J'_?2?_$T?\*AT3_G^U#_OI/\
MXFN*_P"%E^*/^?V+_OPG^%'_  LOQ1_S^Q?]^$_PH^M0#_5_%=X_?_P#M?\
MA4.B?\_VH?\ ?2?_ !--/PCT3>%^W:AR"?O)[?[-<9_PLOQ1_P _L7_?A/\
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M^^D_^)KBO^%E^*/^?V+_ +\)_A1_PLOQ1_S^Q?\ ?A/\*/K4 _U?Q7>/W_\
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MG_Q-'_"H=$_Y_M0_[Z3_ .)KT&B@D\^_X5#HG_/]J'_?2?\ Q-'_  J'1/\
MG^U#_OI/_B:]!HH \^_X5#HG_/\ :A_WTG_Q-'_"H=$_Y_M0_P"^D_\ B:]!
MHH Y/PYX(T_POJ[75I<74KRP/&1,RD ;D/8#TKK*B;_C\C_ZYO\ S6I: "HH
M/^6O_70U+4(BE4MLD0!B3AD)_K0!-2.I9&4,5)&-PZBH]MQ_SUB_[]G_ .*H
MVW'_ #UB_P"_9_\ BJ .-E^%F@&S>VMYK^T66T%I,89AF4!U<.VY2-X92<C
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M?\]8O^_9_P#BJ-MQ_P ]8O\ OV?_ (JCZO3[!_;>-_F_!'E7_"G[S_H+P?\
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M+P?]^3_C1_PI^\_Z"\'_ 'Y/^->J[;C_ )ZQ?]^S_P#%4;;C_GK%_P!^S_\
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MNH/+N-Q;S8LD8_U9_P#BJ=MN/^>L7_?L_P#Q5=)X;;;N]R6BHMMQ_P ]8O\
MOV?_ (JC;<?\]8O^_9_^*H$2T5%MN/\ GK%_W[/_ ,51MN/^>L7_ '[/_P 5
M0!+146VX_P">L7_?L_\ Q5&VX_YZQ?\ ?L__ !5  W_'Y'_US?\ FM2U$L<G
MG"21U;"E0%3'7'N?2I: "LVZ\0Z)8S&&[UC3[>4=4FN41NN.A/L:TJ^7_C#_
M ,CU)_UR/_HV2M:5/VDN4SJ3Y(W/HC_A+?#?_0PZ3_X&Q_XT?\);X;_Z&'2?
M_ V/_&OCBBNOZFNYA]8?8^Q_^$M\-_\ 0PZ3_P"!L?\ C1_PEOAO_H8=)_\
M V/_ !KXXHH^IKN'UA]C['_X2WPW_P!##I/_ (&Q_P"-'_"6^&_^AATG_P #
M8_\ &OCBBCZFNX?6'V/L?_A+?#?_ $,.D_\ @;'_ (T?\);X;_Z&#2O_  -C
M_P :^.*>?]0G^\W\A1]37</K#['V)_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
M0PZ3_P"!L?\ C7QQ11]37</K#['V/_PEOAO_ *&'2?\ P-C_ ,:/^$M\-_\
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ME:M$SM-*LNFW%Q*)E_X]I5@$@1MC#YQG=SQ@KD'D5G+#QB[.14:TI;(^AO\
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M-_\  N/_ !KXUHH^IKN'UA]C[*_X2;0/^@YIO_@7'_C1_P )-H'_ $'--_\
M N/_ !KXUHH^IKN'UA]C[3L]6TW4'9++4+2Y=1EEAF5R!ZG!JY7@7[/O_(<U
MG_KV3_T*O?:XZL.23B=$)<T;A7R_\8?^1ZD_ZY'_ -&R5]05\O\ QA_Y'J3_
M *Y'_P!&R5KA?XAG7^ X"MC0]!?6A<,KRJ(3&"(H3*QWMM!P".!WK'JU!?RV
M]A=V:*ACNMF\D'(VG(Q7J.]M#B1<E\-ZG'<-&L*R*"Y$JNNQE60QELD\*6&
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MA865TV+#& %>,1, -O V #CZ]>:PZM<UW<AVMH%%%%4(**** "BBB@ J=_\
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MBLI0F\[;=B @C^TO*5X[,KA" .B]QP.>U[5(-4EMS"DF8D96EE #OEV89QV
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M5 %50J@!0 ,  =.U$5-?$.3AT/6?V??^0YK/_7LG_H5>^UX%^S[_ ,AS6?\
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M/DR_\\G_ .^31Y,O_/)_^^37;44?7'V#ZNNYQ/DR_P#/)_\ ODT>3+_SR?\
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M_P">3_\ ?)H\F7_GD_\ WR:[:BG]<?8/JZ[G$^3+_P \G_[Y-'DR_P#/)_\
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MZ/ZT >!_\*\\5?\ 0);_ +_1_P#Q5'_"O/%7_0);_O\ 1_\ Q5>_T4 > ?\
M"O/%7_0);_O]'_\ %4?\*\\5?] EO^_T?_Q5>_T4 > ?\*\\5?\ 0);_ +_1
M_P#Q5'_"O/%7_0);_O\ 1_\ Q5>_T4 > ?\ "O/%7_0);_O]'_\ %4?\*\\5
M?] EO^_T?_Q5>_T4 > ?\*\\5?\ 0);_ +_1_P#Q5'_"O/%7_0);_O\ 1_\
MQ5>_T4 > ?\ "O/%7_0);_O]'_\ %4?\*\\5?] EO^_T?_Q5>_T4 > ?\*\\
M5?\ 0);_ +_1_P#Q5'_"O/%7_0);_O\ 1_\ Q5>_T4 > ?\ "O/%7_0);_O]
M'_\ %4?\*\\5?] EO^_T?_Q5>_T4 > ?\*\\5?\ 0);_ +_1_P#Q5'_"O/%7
M_0);_O\ 1_\ Q5>_T4 > ?\ "O/%7_0);_O]'_\ %4?\*\\5?] EO^_T?_Q5
M>_T4 > ?\*\\5?\ 0);_ +_1_P#Q5'_"O/%7_0);_O\ 1_\ Q5>_T4 > ?\
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M[_1__%5[_10!Y=\./"^LZ'XCGGU*R,$3VCHK&16R=Z''!/I7J-1-_P ?D?\
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M\?W3Z]*(_$EI;Z'IU]J3F*2ZM1<$10NX&$#.<*"0!GO4]KX=TNR;=!;NN"A
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MQ9RYW 'YAN9C@Y R:8,OT444 %%%% !1110 4444 %,?[T?^]_0T^F/]Z/\
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M.I2G.^BZ-;WZ+N>D>&-8FUW2(KZ>TDMI'4 JXP&Z_,O^R>U;5,4!9"%  "J
M!VZT^O32:6I\#4E&4VXJR[=@HHHID!1110 4444 1-_Q^1_]<W_FM2U$W_'Y
M'_US?^:U+0 5!$=AD#!N7)'RFIZ* &>8OHW_ 'P:/,7T;_O@T^B@!GF+Z-_W
MP:/,7T;_ +X-/HH 9YB^C?\ ?!H\Q?1O^^#3Z* &>8OHW_?!IH<>:QP^,#^
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MB@!GF+Z-_P!\&FR.#$X ?)!_@-2T4 ,\Q?1O^^#1YB^C?]\&GT4 ,\Q?1O\
MO@T>8OHW_?!I]% #/,7T;_O@T>8OHW_?!I]% #/,7T;_ +X-'F+Z-_WP:?10
M!%&X$2 A\@#^ T[S%]&_[X-/HH 9YB^C?]\&CS%]&_[X-/HH 9YB^C?]\&CS
M%]&_[X-/HH 9YB^C?]\&CS%]&_[X-/HH B1P%.0_4_P'UIWF+Z-_WP:?10 S
MS%]&_P"^#1YB^C?]\&GT4 ,\Q?1O^^#1YB^C?]\&GT4 ,\Q?1O\ O@T"10,
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M^YWG_"Y_&W_01A_\!8_\*/\ A<_C;_H(P_\ @+'_ (5P%%'L*?8/:S[G?_\
M"Y_&W_01A_\  6/_  H_X7/XV_Z",/\ X"Q_X5P%%'L*?8/:S[G?_P#"Y_&W
M_01A_P# 6/\ PH_X7/XV_P"@C#_X"Q_X5P%%'L*?8/:S[G?_ /"Y_&W_ $$8
M?_ 6/_"G+\9?&S*Y.I0_*,C_ $6/U ]*\^I\?W)?]W^HH=&GV!59]SO/^%S^
M-O\ H(P_^ L?^%'_  N?QM_T$8?_  %C_P *X"BCV%/L'M9]SO\ _A<_C;_H
M(P_^ L?^%'_"Y_&W_01A_P# 6/\ PK@**/84^P>UGW.__P"%S^-O^@C#_P"
ML?\ A1_PN?QM_P!!&'_P%C_PK@**/84^P>UGW.__ .%S^-O^@C#_ . L?^%'
M_"Y_&W_01A_\!8_\*X"BCV%/L'M9]SO_ /A<_C;_ *",/_@+'_A1_P +G\;?
M]!&'_P !8_\ "N"9'559E8!QE21U&<9'X@TY+>:5"\<,CH#@LJD@'!/\@3^%
M'L:?8/:3[G=_\+G\;?\ 01A_\!8_\*/^%S^-O^@C#_X"Q_X5P%.".49PK%%(
M!;' )Z?R/Y4>PI]@]K/N=[_PN?QM_P!!&'_P%C_PH_X7/XV_Z",/_@+'_A7
M44>PI]@]K/N=_P#\+G\;?]!&'_P%C_PH_P"%S^-O^@C#_P" L?\ A7 44>PI
M]@]K/N=__P +G\;?]!&'_P !8_\ "C_A<_C;_H(P_P#@+'_A7 44>PI]@]K/
MN=__ ,+G\;?]!&'_ ,!8_P#"C_A<_C;_ *",/_@+'_A7 44>PI]@]K/N=_\
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MUGPE::5X134X[F>XGEEMV4^4%58Y(BV&&3@Y&,Y[>]+]TTFEOY#_ 'G<L?\
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M6_F^3;PO''YJX8J)5Q]>._?KQ7N-<%9+G]W8ZJ=^74*^7_C#_P CU)_UR/\
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MX6[J_P#T#['\G_QK'^T/[S/1_P!7L5_(OO0__AG_ $7_ *#.H?\ ?*?X4?\
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M^@?8_D_^-']H?WF'^KV*_D7WH?\ \*"T:4>8=8OP7^8X5._X4?\ #/\ HO\
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M"?N5BSTSNPI'7'/3/-:5IHUO9WC7,;REB) J,P*H'?>P QW;GG/ITJWMN/\
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M8O\ OV?_ (J@"6F/]Z/_ 'OZ&F[;C_GK%_W[/_Q5-,=P2#YL7!S_ *L__%4
M,OK"#4(X4G#$13).NTX^9&#+^HK-OO"6DZCK(U6Z@\RZ$;1!B%R%*,A ;&X#
M#M\H(&3G&>:U]MQ_SUB_[]G_ .*HVW'_ #UB_P"_9_\ BJ'JK,-G<Q)?!VE3
MHJS>?(5?S-QDP2WD&#/ '\!/X\U5U+PI<3ZC;W=K>MYBDM))*PRSDQG<RA=K
M "-!MPOW0<YKI=MQ_P ]8O\ OV?_ (JC;<?\]8O^_9_^*H Q;7P=HMEJ4M_;
M6D<4\LWGLZ11JQ<L6.7"[V&23AF(_*KDF@V,NF6VGLK^1;(4C&[G!C:,Y/\
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MJ904U9F^'Q%3#S]I2=F>8?\ "GKC_H,Q?^ Y_P#BJ/\ A3UQ_P!!F+_P'/\
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M_P#%4?5Z?8/[:QO\_P""/+_^%/7'_09B_P# <_\ Q5'_  IZX_Z#,7_@.?\
MXJO4MMQ_SUB_[]G_ .*HVW'_ #UB_P"_9_\ BJ/J]/L']M8W^?\ !'EO_"GK
MC_H,Q?\ @.?_ (JC_A3UQ_T&8O\ P'/_ ,57J6VX_P">L7_?L_\ Q5&VX_YZ
MQ?\ ?L__ !5'U>GV#^VL;_/^"/+?^%/7'_09B_\  <__ !5'_"GKC_H,Q?\
M@.?_ (JO4MMQ_P ]8O\ OV?_ (JC;<?\]8O^_9_^*H^KT^P?VUC?Y_P1Y;_P
MIZX_Z#,7_@.?_BJ/^%/7'_09B_\  <__ !5>I;;C_GK%_P!^S_\ %4;;C_GK
M%_W[/_Q5'U>GV#^VL;_/^"/+?^%/7'_09B_\!S_\51_PIZX_Z#,7_@.?_BJ]
M2VW'_/6+_OV?_BJ-MQ_SUB_[]G_XJCZO3[!_;6-_G_!'EO\ PIZX_P"@S%_X
M#G_XJC_A3UQ_T&8O_ <__%5ZEMN/^>L7_?L__%4;;C_GK%_W[/\ \51]7I]@
M_MK&_P _X(\M_P"%/7'_ $&8O_ <_P#Q5'_"GKC_ *#,7_@.?_BJ]2VW'_/6
M+_OV?_BJ-MQ_SUB_[]G_ .*H^KT^P?VUC?Y_P1Y;_P *>N/^@S%_X#G_ .*H
M_P"%/7'_ $&8O_ <_P#Q5>I;;C_GK%_W[/\ \51MN/\ GK%_W[/_ ,51]7I]
M@_MK&_S_ ((\K7X/W#(K?VS%R,_Z@_\ Q5._X4]<?]!F+_P'/_Q5>H+'<*H4
M2Q8 Q_JS_P#%4[;<?\]8O^_9_P#BJ/J]/L']M8W^?\$>6_\ "GKC_H,Q?^ Y
M_P#BJ/\ A3UQ_P!!F+_P'/\ \57J6VX_YZQ?]^S_ /%4;;C_ )ZQ?]^S_P#%
M4?5Z?8/[:QO\_P""/+?^%/7'_09B_P# <_\ Q5'_  IZX_Z#,7_@.?\ XJO4
MMMQ_SUB_[]G_ .*HVW'_ #UB_P"_9_\ BJ/J]/L']M8W^?\ !'EO_"GKC_H,
MQ?\ @.?_ (JC_A3UQ_T&8O\ P'/_ ,57J6VX_P">L7_?L_\ Q5&VX_YZQ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +' G # 2(  A$! Q$!_\0
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MP>D.G2M%?W\HAC9#AE'?'\OQKSCQIX-E\'?#VRUJ/7=2.L712.<&X.V3>,D
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MX5\&WNC:N8A+<3.V87W85E _.LKP'X&\6>"-:N+"&>PG\/7$QDDD<GS2,8
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M76/%Q96&;O@D8S\S5['!:06P(MX(X0W+;% R?>E@M+>V9S!!'$7.6**!GZT
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MVO\ 8O"NG65J%MK>_OXX;D1*%WIZ'%=['H&DCPVNE_8H!8&WV%/+&-NWK]:
M&ZY>6^H>"M1N[69)K>6SD9'0Y##::R/A,,?#+1L?\\C_ #-<I\/IY#\*O$5E
MO9[6RDN8+5FYS&,XYKJ_A-_R3+1O^N1_F: .VHHHH **** "BBB@ HHHH **
M** "BBB@ JAJ^HP:3I-WJ-S*L<-M$TCLW08%7\UY)\=-6D@\.6.C0"5Y-1N
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MVVGIIMK86CV]VDTC"!1O0=5X%=W10!5MK.WLX!#:P101CHD2!5'X"K(Z4M%
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MI+_SPE_*D_M-?^>$E9,E[*?NM@5#Y\C')D:L)8F"=KEJFS=_M-?^>,GY4O\
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MZ*** "BC-4AJ5F;XV0NX3=#DP[QO ^E %VBD/2J-UJ=E931PW-[!#+)]Q9'
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MJ'&)0/>JZB9TZ_='TI:0?='TI:T$%%%% !1110 4444 %%%% !1110 4444
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MUT.HQYA?UZUR\;@2$&OG,PNZB._#K0V[>,*@.ZK2M$%QG)K'%PQ(0GCM5A)
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M4@ R( 3D_E6]\,9$D^&^A%#P+8#\J\_MHY+GQ!\5+BW<&+R3'\O=@IS_ "-
M%C0M#U;XKVLGB'5=>O\ 3K.25DM+.S;8$0="3W-;WPZU35+77]<\&ZK=M>OI
M15K>YD^^\;=,_3BI_@O*C_#'30IR5W*<=CN-9^A(9_C[XBFC(V0642R8]2*
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M%88/6J$;F-B0<CTJY%,DG3@^]0RAHM><@THML9R>:G]*?TJ>1#N1"$8/-/P
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MI6P.III;/ ID@6W'Z4QNM/X! %-?KVH 0' ZT]) 1CO3#]W.147(/!Q2 LL
M:;MSVXID<V[Y6P"/>I>IX(-"U ;L3&=M'"G@8IQ%-QFG9 )N)ZTX?TIIPJY-
M ?=T(I@*1NP"*9_& .Q%3JF 3G%0 _O!W^8?SIH3.O'W1]*6D'W1]*6MR0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH Y;6B?[4< ?PBLQAN.<=:T=<S_
M &F_^Z*SZXY?$RUL-!QQBC'.<<TX+W[4NPD9[5+*$5W'1C2^=+_?:E '3CBG
MI'NZ$4AC#-+C[YIA!;DDDU8:U8C((J-D88!!S3L(C6G[O:D]>* ,GK3 <2S'
MCH*::=3:E@ H(5ATYI<<B@]>* !6=<88T_SY/6D"9&<T\0@X^8"@8GG2D=::
M69B<DU86U9NC(?QICPO&.1UXXJ@(0OY4Y6YZ\4OMB@+@]*!#P03Q0Q.,9I 1
MUH;GZT ,QS32 >II^,4W [U+ %RHX)IWFOV;B@(Q^E/2(9.#18!OF2>M&]B/
MO&I1;;NA'YTC6[IT(/TJ@(<'/6G FD*[3R#0#S31(_<:0G@TF>:7% #>M&.:
M4#I2D&@!H3!R,YIVY@.&-."MP,T_RNG(I@1[Y/[U&]SWJUY(.#FD-KP<,!0!
M6R<X(I<&G-&4.3S2<CJ*: <#Q2$TE'%4 E!P:7'O1CMUI !0&@!N@IRJ3Q4J
M1=F/%%@(#N!QDD>M WYSDU:-NK#@TIA51S18"KCCDDFE&0:D-OGD-UZ"F%2G
M!% A"<\U&QXI^:8P]:8$=.VXH YI1UQ2 0KG^$4@RH^4U($+''/Y5.MGD<MB
MBPRMO8]Z0,PSAJNK8)@Y;FD-CM&?,'XT["*63WYIT8&,G[V>*L/:MQMP3Z"H
M,%201CZT 2-+GIQ3%QN&/44W&:<H.Y?J*:!G8#H/I2TT=!3JW)"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#D]</_$T<?[(JE& 3R,BKFO?\A9_]Q:H!
M@J;NU<DGJRUL3L53YB.>PJ(EI&YSCTIFXEBW:JT]ZJ\*2#7%B,0J2OU-H4W)
MEY=HJ1)$+84BL7[4Y;:&)-6DCN"-RI^M>4\QJ7T1T_5T:Y8=*@,KQOD'@]C5
M6.>2,[) P^M65VN-PY^M>AA\8JNCW,*E'EV+,317!VL K_SJ*>$*I91@@U"<
MJ<@8(Z&K3N)[7/1_XO>O0,2CD^M+D]Z3-*H^85(%B-5/+]JC9@7_ ':\>]1.
MQ9L"D>98$RS\G@"LZE2,%=E1BVR=$_O-4JA.!G(K':\<,?F^6GQ232M^[5S7
MCRS*5[11U+#Z:FVI '!ICE^HJEON8B-RLH/MFK$5PKY'\5=5#'*;M)6,IT7%
M71-'*DAQ,@![$4Z:W15+ >_%5G7G*_I4UO/UB?GC@UZ:::,"OP&I0=S#ZTAP
M&.#301O'UI 60H;C%12,D0PO+TDDI3Y5/7]*C 4 LWZU,IJ*NQI7=AP5GY9O
MRJ9=@[\UG37HX"<>],CGD<D+DGT%>54S'E=HHZHX>^YLX'4&HI ^/E)X[U6"
MW07)1OI4L<Y^ZP(/O5T<?S.TD3*C;8EBN,861 1ZXYJZMK#.A=.!C.16=*!C
M<O6G6MR8) ,G:W!%>K&2:NCF:LQA^\1Z&@=<4Z8?O"?4U%U/6J)+2*A4>].8
MQ1#!Y)[5%N*)VSVIJ#G<W)]: )0K2<DA?I4L<07WJ#S0#R:>)F]\UDZJ3L7R
MEM4Q4<L9/0XI\4<[KG;QZDT\HZ@[U-4JA-BHKO$V."/0U<B^S70(P$<#IZU
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MZ+B$:96D*0+NQU-3QQRL/G)S20HL8R.*G$P'4U$JD8[EI7'(C*.I_.H9 V>
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M.*>0,YH"\YH K20;FSFHS:_-P>*N''UII % %<6^.0>32B KWS4XZ_C2D<T
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M1ZM!JAUG28]/E@G:.U7G$JCH3[=*YN;QSX[LG>QG\"R7%X#M6>WDS WH<^E
M%OX;^)M9O+[5O#/B-EEU72G ,ZCB5#T)KT*7_CWDS_=/\JX?X?>$]2TBYU77
M-?:(ZOJLOF2I$<K$O90>]=Q("8G ZE2 /PH \(^%'@W3/$4>N76KJ]Y;QZA(
MD=F[$1 YY8@=3TKI/ UFOAWXI^(O#EA)(NDK;QW$5LS$K$Q/.WTJY\'M'U+1
MM-UN/4K*:U>747DC$JXW*>XJSI.E:A#\9M<U.2SE6QFL8DCG(^1F'4 T <=X
M>TJ/7/B/\2-+F172YB*!6&0&SP?P.*TO GCI],^%^I7&K,\MSH+-;,#]YNR
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M<%Q!C@.1GL:EC\EVP9=N>FZHA9E -IQD\TCVTBYP-U- RT8 #Q(&]QTI?*P
M,U365X,X) ]ZGCF$A(##/IZ4Q W&1FF FAMVXYIN>.:3 5I% Y)S3?.4#DU!
M-)R5'2J-S=[1M0Y8>O:@#5\R//WL?6E$T.Y1N+'/(%8D1EG/0_6M*VM7+#MZ
MT@- R6N2-DA^AI?W!'WF7CC/-,6SD!^5@1Z4KVLJX(Z50$PMU;&V56R,X%.%
MJ).K@8JD4:+[P*GVJ:*[1OED;#G@''\Z $=3&^W<#BG!BW4TZ?:2*A)YI /:
M1(^II!-&>C53F^60\\=34)F11R?H*8&F'1NC U+B-6VN^2?[M8JSEVVJ"N.U
M:5O;2-AB<8[4!8MJL"Y/ENQ[Y.*";<CB.1#[&I(K=NN2WM2R6W&1U]JL".-(
MY&^^!CL>*L-9C&=_&.U4GC*CYASZT17)B(^8E#U!_I0 Z:+R9-I;/%,W5-<%
M)4$J'ZU6R:!CC*H S3?.4&JMR<,IQ40E.,$5(6-%)4/&:L10!U+O(%Q_#WK-
MCD/ CSN/&:U[6U^1BQ.X^]- /BAM\Y*LP]^*D,%N&8["1VYJ:.#Y/4CI2M;$
M+SU[^U:6$RKY,)).\J/>K"Z>K)\DH.>OK4$L>P^M0>8T9W*: "YA-N^TMN!Z
M&H4/[Q?J/YU8N+@3Q+D88=:J+_K%_P!X?SJ5N!Z4OW1]*=35^XOT%.KL,@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \X\7<>(I?^N:_RKG9F" NQ^45
MT/B\9\1R_P#7-?Y5RU\_S! ,XZUP5/B9M'8JMOFDZYSTJQ;VF.7/%/MXQ&NX
MX^M*9\DJG/O7!7KJFC:G3<V7(X@<8^4"K<2*YX/-9*O(".OT%7H+J6 @^2#Z
MY%>8\;4OH=7L(]342 J>5Z>E7$6,QXD0'WJI9ZI!(=DJF$YX(Y%6[G:L+%6Z
M\BO1PV*4U:1S5*7+JBA=@*V4*@]ZH,Z-+E3\W<5#>RM&X Y![UG1S[)@V>]=
M][F!K$^U(20.!1G=R.XJ*Y<QV['.#4CL9MU.TLGEJ<J.WK4UI;\992"*9;09
MDW.,U<>4*.#SVK&K54(W*A3YF6%4<< >]6HE1CPXW"LQ)&8@YSFK49FC.Y4!
M.,9->1+'3;T.Q4(I:FS# <#YAGL:F"%!AE'UK,CU>X@"AX@0/6M"*^AGC!Y#
MGDJ>U=-#&MNTC&='L4;T[6SC%4EF"\YSSR*N:@H=F&<=ZPW8[BN:]124E='/
M:QJ-UX[TW'6FP'? C9YQ3B" 3GMFJ$9UU<<E%.">#3+:V\QA(3@>E1!/.G.>
MYS6EN6&(<CBL*E3D5RXQ;>A:1$1>*DC==P&?PK,$S2Y"]*L0"; *+G'<UX]3
M&S;T.Q4$MS=5 4'.?4>E/:(JN< BLM+J]A&0>^35R#5!)\DT>&[,*NCCI)VD
M1.@NA1O>1D+\W?-9PF990RG&/2MB\12I>/)!ZY]:Q9(RDG8>M>S"HIKF1R./
M+HS063S8PP.0>OUI<U!:-\C+CH:FX#<]*L1G7TQC) /S#I5."!IW!(//)J6]
M"R71 ;.#Q6C;H(H\GDU$I<HTKDEM"L2@ #-7877N<5EM=$MM51UJ:%6+#J37
MD5L9*]HG9"@DM39C(<84]*F:,NI"G''4UG W83"?*/:GQ:I<P-LF4.#ZBLX8
MRI%Z@Z,7L.N8F\KG)*]*RFRK8ZFMIYTN%W)P#U'I65=#H0 *]:C755'+*GRC
MXYFD&UCRM/\ >JD)VR#T-6V&.,"N@@I7K;<,#R:H#,L@'KZ^E7+[EE'M1:VQ
MP)'')Z#VJ6[!8M6UNJ8;:"16G'*H[X]JR9)_* VG!I;=YG89Y'7->7B,9)/E
MB==.AI=F_%*".O'>IL!L8[UFQ/.JX1 ?>C[3>P/NW$@]NU80Q51:ME.G$L7$
M#$$YR/2LR0;6Q6FM_P">F)$"OZBJMV@8 @#->G0Q*J:,YYT^4K1N<A0<*>U/
M*D'D\5&AVMSBIRN5/.*ZS(S[_P"5E;M55'+)GVJQ?LK)&I;&3@4R* J0I(I,
M"]I\>1N8<]JUEF5=H+<]ZRFE\A !@MVJ!97D;Y?6O,Q.,Y?=@=5.BGJSITNE
M(RHXJPC;UR <'O6-;!XUW?>)['M2R27I8X? ] :YEB:G5E.E$TY4^7 Y-9DZ
ME<<@4Z*]D3 ?) ]:+HAT#"O0P^*YO=9A4I<I73D].M*H_>#V8?SI8_E%.+*9
M%QZC^=>@G=HQ/1%^X/I3J:OW%^E!8 X-=ID.HI :,T +1129]C0 M%)N% .1
MWH 6BD)Q2T %%%!H **3=]:-PH 6BD!STI10!YSXNS_PD<N/^>:5R$^3<N#Z
MUUWB[_D8Y?\ KFG\JY&8'[2YSWKSJK]YF\=A;B4K"N._%);(<!CUJ"[<[5!I
M89BJJ>HKP,4KS/2I.T;FJLRQC&!N]:<EZ2><$>XK*\WYC\U.$F:Y.4J]S7)2
M5=RCFI$N9"FQB<#UK-MI@&SNR/2IVD#$TH<T9: U=$5\"RG#' [5F#K^-:5R
M<QGG'O68.2,GO7TE)WBCS9*S.@CSY:GVJO>J?*7W-6$SL7Z57O<^6I[9K4D@
M3*J,&J[R"6=5R:G4@+@<U1CEVS9/0&O*QK>R.S#HU(RL9![BI3=G/4UFR7*D
M<&G))G!->9R'2S5CN0_#J33Q\IW#(YK,64;AR:NI.'7K^%0XM,2+4TA*9_B(
MQFL2?(D(SS6B'!W8-9DYS,:][!2;IV9P5E:1J6!8V@SZU),2('/^S4.GG-J/
MK4THS$X_V:[C$S+=09/H*?=2;6V#TJ.UQO8DXXJ&]?$P.3TKS\9\%CJH;E^#
M]W&#@<U/]I( 56P/2LW[4HB7DG'!I5E5NAKQ.0ZW>YII=MG#$D5/PY!%9*M[
M5:AGYP3^%3*-F!=+':5W<53G!"\]:F:3\*JW9;;\IKV<O;<3EKQ)[(AO,XZ>
ME6\9/2J&G[AYG-703FO5.4QG7.H/@#[U79Y#';YS[56=-MZY(Q\U%VQ\G@YQ
M7+B/A-*7Q"VA5Y"QSQ6@L_EGCK6-:3%2<G&:LF=2WWLUX48=3T)&E]JEW YX
M]JD$XF4AAFLQ)P.#S4T<ZEL9 JIP31*+H)0X!XHD*LOT&>:B,HQZ^]&\,I/;
M%;X*ZG8RK)6*\;9E0^]:+MS66A'FJ >]:1RHXKWCB,^^XD3 P,<U+!)B(')R
M/7TJ*]!\Y<D4"0^5R,5C5^%E0W(6?S)@#W-:J.D2*><5S8N-LX.> W6M9[E2
M%]Q7S_+[VIZ3V+[7Q!^1B%IZ71. V2*R?/5C@5,DXR 3S6CC=&=C2)!^8=Z?
M)GR\GFJR2!D'%/W\8/(JZ&DT3-71 Y^;('%65RR"JLF-_'2K*$;!7OHX&4[V
M,%H^ 3GBG1@"7V%-O6P$X[U'')@DTI; MQ+F7=*=O4=:L62[8@W(K'NWVS$@
MXSUQ5ZUN@+?'<5\W4C^\9ZJ7NFH]RRC"DY%(+MQSFL]+@%L%J>9EY[5IRF=C
M3699>V34@?(96%9\%P$Z<FK*MGD]ZTH^[-$26FH[=P:(SEU^H_G43'!XJ2(_
M,OU'\Z]ZGL<+6YZ6OW5^E4-6U*WT?2[K4;LX@MHFE?'H!T%7U^ZOTKAOB^)#
M\,-9$08GRUSM]-PS7H&)SWAW1O$OCF ^(-6\27VG6%YE[&SLI-A5,G!8^N.U
M>@>'='N=#TTV=UJUUJ;!R5FN<;\>A(KR_P *?#G4=;\':?>MXRU-/,ME:VC@
M^6.'VQWKI/A)K.J:AI6J:?J]RUW<Z5?-:BY8Y\P#WH [Z]%P;&<6C*MR4/E%
MN@;'&:\PN_ GB]]&NM0N_'.H#5D1I52V;9;C SMQ7J^[.<<UYUX^\6NS/X/\
M/Q-=ZY?QF)_+.4M4/!9SVXSQ0!/\(_$6H>)?!8NM4D\Z[@N'@:3NV,<_K7*>
M&=#U3QGJGB2>X\7:W9"SU22VBCMY\*%'(X/UKT3P-X6B\'>%[;1TD$KQY:60
M# =SUKG[WX/:'=7-[=0ZAJUK<W<C3,T-R54.>^WO0!U'AKP_)X>L9+:75[[4
MV=]PEO7W,/8>U;A8*"3T R:\N^&&HZK;:]K_ (2U2_?43ID@:&Z8Y^4\;3_A
M7I\O^ID_W3_*@#CI/BEX2ATR6_DU0+#'.UN5*'>7'4!>I'O6YX>\2Z3XITU;
M_2+H7$!;:3C!4^A!Y%>6_!CP_I5]'KNHW=E%<7*ZC)&K2KN"+GL#TK9\*VL&
ME?&KQ)8V,:V]H]G#*88QA=YZG'K0!Y_X@\1^+;?Q]X@OK+5+LZ?HMVC3VHD.
MT1%@/NU]$65U'>V4%U$P:.:-9%*]"",UX]X2LH]2^*?Q#L)%!2YC,1!YZ\57
M\*^,KGP9\.M>TW4MW]IZ),8;>&1OF;><)CU ZT 8WQ'\9^(+[Q'?R:/J=S::
M5I,\5JPA<J))&/)..O3I7T%IS,^G6SL<LT2DD]SBO"?%VA-HGP3TM;A1]NN[
M^*ZNW(^9Y'))S^8KW;3O^079_P#7%/Y"@#@_%_\ R,<O_7-/Y5R=U\MP3ZUU
MGB_/_"12_P#7-?Y5S%RF\Y"\UY]1>\S:.Q0NUW0AAU%4#,RCKQZ5ID$@JPS[
M5G3VQY^7Y<UY.(I/FN=U&>EB..Z!^4MBK7V@ #!K*:)U8X'%21J_0YQ7*XHZ
M#7AG.>.]7%D+=*S8%8XP.*T(D"<D\4H4G*6A,YJ*"<L8B#QFJ:ABP&.<U-/)
MYC\?=J6R@\R7>V-J]*]N$>56/-D[NYJ D(H]!45RID@QW'-3?UJ.3)0CK5B,
M]&XZ5G7 :*7.?<5H,A1SCI44T2R+_M=JY:]+GC<Z*,^5V,A[HJXYR>]6X[M2
MN<U6N;0CH.:B2&1>"#@UYTH)'8W<T5N03D&KT4WRBLN"!L^@K3M8>A;-9^S<
MG9 Y**NR[#]PM5&0YE;ZU:DF"C8G!JM'$TDH'7G)->O0I\D;'G5)\TKFI8*4
MM5SWJPX&TY[C%("-H"C '%(_S*1BNDBYEK\I(Z"JUZK,NX#@5=DC(R0.G6H2
M%="".*YJ]/GB:4I\K,<S[..OM4B7?.1P14DUD0.%ZU3^RRAC@?G7DRA9ZGH*
M29=-SN^Z^3[5=MW9@#67#;2#^'FM&WAD.!GFHE3OL-N)H1.S'GD5'<'+@'/%
M2 K"E0G,A)[UZN%I.G'4\^K/F98T\<R'M5T#)J*"'R4QW/6I?3%=QB9MT,73
M''6HI07A9:N7"ABV>OK55>.":QJ0YE9E0=G<QI-\9ZGBDCN2#\W%:5W;AUR.
MM94ELV<H#GO7D3IN#L>@JBDB\MXN,YI]O<$G('6L]+>0$9%7;:!]V*B16B-6
M)SMP?O>@JP[;(P#WJ"*/8,D\TLAWD9/ KLPM!I\S.:M43T0D2YF3'K6B3Q56
MVA)^9A@#I5K'8"O4.4I7*%F![U&,E<>U3W(.X<]JJ*PW8-3)75AIV9FW49CD
M/'%1"[92 V:UYH5F7!QQTK*EL7#'Y< ]\UY%6BXRN=U.HI*PZ*ZPY!_.I_M1
M9@,UF_9I0V.H[5:M[:7=C%9&NAKP3?(,DY%6T<GYJJ00.#EZLL>@%=&'H.4K
MLYJLUT',Q)R.:M+C:..:JQH?,R>E6SUR!Q7KV.-E*^(P@)Z57C;<G(JS?+CH
M:I1OL;&#BDU<$5+\%9LD<&J?VB2-N#P:W98%F0 CG'!K)DLGC<C;E:\BO0<9
M71Z%*JFK,1;L'GO3VO0QPOZU5:T?>2G ]#3H[24,-V"36!KH:5I([$EFQ6M;
MR%N">!ZUFVEK+W(V^E:BA54!1BNBA1<Y7.>K46R'$[F]JGB WH >X_G4"Y[5
M*A/F)_O#^=>Q%6T.)GIJ_<7Z55U&QM]3T^XL+J/S()XS'(OJ#Q5I?N+]*=7>
M8GD$'A#XC>'XGT30-:L6T4$K!+<#][;H>P]<5V?A'P@GA'PY-I]M<M->3EI9
M;EQ]^5A][\ZZS%&* .-\/:=XNM?"=Y;:QJ,5SK#^9]GG&-JY'RYXKSCP]X&^
M*7AB2[ET^;1FN+Q]\\\SEY'/U(Z5[SBDVB@#C/"5OXT%O?)XLN;(NXQ;-:\E
M.#DFN?ETSXLVSM9VFM:5<VI.%NYX]LH4]R/6O4\"C H Y'P/X)B\(VMR\MV]
M]J5[)YMW=N,%V]AV%=7("R,OJ"*DHQ0!P?PU\)ZCX1L-5AU PE[J]>>/RVS\
MIZ9J?3?#-_:_%'5?$4AA-C=VD<,8#?/N7KD5VF*,#TH \_\ "W@_4M%^(GB/
M7;EX&L]2(,.QB6'/<=JH^*/AH=?^)6FZ\1&=.10;N/=@NZ_=X[UZ=@>E+B@#
MAOB;X6U#Q;X9@T_3#"LT=U',?-;:-JYKL+.,PV<,+?>C14./4"K&!2T ><>+
MN/$4O_7-?Y5@2\CI6]XO/_%1RC_IFO\ *L(\G->?/XF:K8HLA4DX[U$P4].:
MTRH.<CK4+VR-VP?6LW%/<M.QF^2F<[12^5'G[M7/L//WZ<+(8QO-9>PAV*]I
M(K#:F,+S3&<MWJ\+)<\N<4];2)#ZGWJHTXQV0G)RW,^.%F(RIQ6I"B(H &.*
M7RQ3L#TK4D>>U-8 ]:44N.* *LJ @C!/I5(JR=5./6M<*>H%(R*W!4%:5@,@
M$$8(I=J=<"M V<+$Y4CZ4"R@_P!JLW3B^A7/(I*(QS3C)@8! JX+.+K\U*MI
M"O1<_6A4XK9 Y-F>B,[\ GWK1@B6(  9/<U(% 7 P*<H-:$#\CM2&E H(R<#
MK3 K29SP*J%"HR0<^@K2(.::1VP*07,MF]1@^AI%"9^8<UIO!')]Y1GUIGV2
M+^[6<J47NBE)KJ4P%'.*DWA1P *L_98_[IIQM8N/E_6DJ45T&Y/N4N6/J:N6
M\ CPQ&2?6I4B0=%P:DP16UB6.)]*3B@49Q3)*LZ$@D#(JF\;AN%)K5/(Q3=H
M Y%*PS+P5 W#'UI55<<C-:#1*_W@#]:%MX\?=J94XLI-HHF)",X%2J% XQFK
M)AC/\-(;>// /YU'L8=A^TD5R68]*L10@#+?E4B1A>U28YK5)+8EZNX[/R@
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M5'R+]*=34^XOTIU=AB%%%% !1110 4444 %%%% !1110 4444 %%%% 'FOC
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MN23UI1S.O'\0_G6R>I)Z>GW5^E.IJ?<7Z4ZNLR"BBB@ HHHH **** "BBB@
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M^$)ML_\ 'Y-^0HHHY(BNP_X0FW_Y_)OR%!\$VQ_Y?)OR%%%+D0^9A_PA%O\
M\_LW_?(I1X)MA_R^3?D***.1#YF \%VX&/MDW_?(I?\ A"K;_G\F_(444<J%
M=A_PA=M_S]S?D*/^$+MO^?N;\A111RH=V(?!5L?^7R;_ +Y%'_"$VQ_Y?)OR
M%%%'*A78A\$VQ_Y?)OR%'_"$VV/^/R;\A111R(+L7_A";;_G\F_(4?\ "$VW
M_/Y-^0HHI\J"[#_A"K;_ )_)O^^12_\ "%6W_/Y-^0HHI<J"[#_A"K;_ )_)
MOR%+_P (9;?\_<WY"BBCE0[L/^$,MO\ G[F_(4A\%6Q_Y>YOR%%%'*@NP_X0
MJV_Y_)OR%'_"%6W_ #^3?D***?*A78?\(5;?\_DWY"D_X0JVQ_Q^3?\ ?(HH
MHY4%V*/!5L/^7R;\A2_\(7;?\_DWY"BBCE0<S$_X0NV_Y_)OR%'_  A5MG_C
M\F_(444<J#F8O_"%VW_/Y-^0II\%VQ_Y?)O^^1111RH+L!X+M@,?;)O^^10?
M!5L?^7R;_OD444<J%=B_\(5;?\_DWY"C_A"[;_G\F_[Y%%%'*AW8?\(7;?\
M/Y-_WR*0^"K8_P#+Y-^0HHIV078'P3;$?\?D_P"0H3P7;(P;[7,<'.,"BBG9
J#NSJ%&% ]*6BBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '8 G # 2(  A$! Q$!_\0
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M/Y?_ %J/(^-G_/SH/Y?_ %J]8HH \G\CXV?\_.@_E_\ 6H\CXV?\_.@_E_\
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MF!)+6-EBCV;4!'097H*]%NK:"ZMWAN84EA<?.CC*GZBI(8EAA2-$1$4 !4&
M/I0!R7_"%ZK_ -#MKGYI_P#$T?\ "%ZK_P!#MKGYI_\ $UV=% '&?\(7JO\
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M.1_]^V_PH_X7'X#_ .@Y'_W[;_"@"U_PA>J?]#KKGYI_\37)_$CPOJ%A\/\
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M (#)_A1_PAGAG_H :;_X#)_A6Y10!A_\(9X9_P"@!IO_ (#)_A1_PAGAG_H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3- "T4W)[CFE!S0 M%%% !1110 4444 %%%% !1110 4444 <_XP_P"0 _\
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M&\7^(-I U)@<<?** /9,TM8GA:ZGOO#UK<W,IDF<'<Q'7FMN@ HHHH ****
M"BBB@ HHHH **** "D/TI:0]* ,[6M1.DZ'>ZB$\W[-"TNSINP.E>'C]I*3
MSX?7\):][G@CN87AF0/%(I5E/0BL-? WA?  T2SQ_N4 >0_\-)2?]"^/^_U'
M_#2,A./^$?')_P">M<@-+L#\=XM-^S)]B^W;#%CY<>E?1I\">%SQ_8EI]=E
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MY+9X"_[:?SKU@5Y/X]_Y+9X"_P"VM>L=J %JAJNH)I6EW6H2JSQVT32N%ZD
M9XJ]FJM[90ZA9S6EPNZ&9"D@]0>HH \C'[1WAS'.DZD/^^/\:7_AH[PY_P!
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M **** "BBB@ HHHH *Y7X@_\BN__ %U3^==57*_$'_D5W_ZZI_.@#RJBBB@
MHHHH *0TM(: /7_!7_(IV7^Z?YFNAKGO!7_(IV7^Z?YFNAH **** "BBB@ H
MHHH **** "BBB@ KY[\9?\CGJW_7;^E?0E?/?C+_ )'/5O\ KM_04 8E%%%
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MJ<<4 6!THH%% !1110!Y-X]_Y+9X"_[:UZS7DWCW_DMG@+_MK7K- 'F&N_\
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M]=1\//\ D>;'_<?^1H ]WHHHH **** "BBB@ HHHH **** "BBB@#G_&'_(
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M 6SU'(XH C\=Y_X73X"[#]Y7JXZU\VZ?X3U_PM\6O",.NZK]ODGD9HCYC/L
MSD?-7TBHPQ]#VH \SUW_ )#][_UT_I6?WK0UW_D/WO\ UT_I6?WJ@"BBB@ H
MHHH V/"W_(Q6_P#NM_*O1Z\X\+?\C%;_ .ZW\J]'I, HHHI %%%% !1110 4
M444 %%%% !7*_$'_ )%=_P#KJG\ZZJN5^(/_ "*[_P#75/YT >54444 %%%%
M !2&EI#0!Z_X*_Y%.R_W3_,UT-<]X*_Y%.R_W3_,UT- !1110 4444 %%%%
M!1110 4444 %?/?C+_D<]6_Z[?TKZ$KY[\9?\CGJW_7;^@H Q**** "BBB@
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MC%;_ .ZW\J]'KSCPM_R,5O\ [K?RKT>DP"BBBD 4444 %%%% !1110 4444
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MSH&*GL<5YMX0^%/@RW:TUVQ^T7T;J)8#<2;E7WQZUZ<1Q0 X=*6@44 %%%%
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M/[TT 4444P"BBB@#8\+?\C%;_P"ZW\J]'KSCPM_R,5O_ +K?RKT>DP"BBBD
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ML8!O.1D5]8DG.*\\U'X:O??%&V\8C4P@A*'[/Y>2=JXZT >2Y^+G_0#G_P#
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M _X2SXW_ /0%;_P$7_&C_A+/C?\ ] 5O_ 1?\:^@J* /GW_A+/C?_P! 5O\
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M;7?$>G^'(H9=0D<&9]D4<2%V8^P%<=&?$FN'Q!<1^(IK)-/NY4MXXHU.0HR
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M>5>"=5N[8^$-,AEVV5Q8R,T..X)P:FUWQ/KEM<>+(K2Z"M9-"MK\HPA;&<T
M>GYJC8:G;:EYYM7+B&0Q/D8PPZBN&O+K6_":Z1JEYK$M]'=S)%=P.HVKN[IC
MT)JG>:[KAT:465ZD%R^O&U68( /*]#[^] 'J0.:7L:\XGEUN3Q)!X3@URX&R
M$W5Q?%%\PJ>BKVJM>^(]:\.3:CH<MX+RY(A-G=3##*)&V_-CN.M 'I4TRP02
M3/PB*68^P%0Z9J-MJMA'>6CEH9/NEA@URATGQ'H_F7+Z^U]:_9I#<1W*#*L%
M)!3';/:N>L=<U[4_^$9L(-16T74+>1YY(HAN!!ZJ.@- 'K%+7$^%;K5;?Q1K
M&A:AJ#W\5HD4D,\B@/ANH.*[:@ HHHH *,444 %%%% $<CK'&SN<*H)/TJCI
M6KV6M67VVPF\V#<4STY!P:M7G_'E<?\ 7-OY5QOPHV_\(0FWI]JFS[?.: .I
M_M>T&LC2RY^V&/S-N.,?6KXZ\?E7%:AJUW;_ !!DM(V3R%TQYL%!N##ISUKG
M/[0\30^![;Q7)KTDDNX.UJL:^4REL8/?- 'K//:C->4:AXPGU#Q+=V,NJWND
MVUI"A!M+<RF5V&23P< 9K0T75M3U[PW>/>ZM=Z6-.F(:^\D(;B/&0V&'% 'H
M^:0\Y%>3V.M^(K#0-5\3/J-Q=V&T1Z=;W<81F)('F-CMZ5=U5_$?A&PL]<N-
M=DOT:6-;RVE0! K==F.>* .OE\6:1 MYON&!LY5AGVH?E8]!6S&P>-63.&4$
M?2O(;K4;C3I?%E[9E4DDU& !G0,-K8[5TBRZUXF\1W]E:ZM-IMKIB(@,*@F:
M0C.6]O:@#K=*UBRU=9FLY2XA<QOQT8=:TJ\^^%27$>D:FETZO<"^D#L!C<<]
M?QKT&@ HHHH **** #%%%% !1110!"[A0S,0%49)(Z>]9VAZ_IGB"&:33;D3
MK$^Q\#&#6)\1]=71/"DX5RMQ=L+:' ).6ZG ]LUR/AG5M)T'QK866G7#FSU&
MU6&3="4 F4<'GUH ]+T_7=.U/4+VQM9_,N+)@LZ8^Z34M_J5II5G)>7TZ0P)
MU9C^GN:X;P(/^+A>-,@ FY7C\*WO&NA_\)!I=M;QW<-O=0SK- LW*.ZG@$=Q
M0 FG>/-"U.ZCMDFGMY9/]5]JA,0<^Q/6NG7/;\<]<UYK?:M?JEO%XW\-1+:1
MW"".^M7RB/GY3CJ!G%=4WB_1TU4Z6UQ*+I<@CR&V],]<8Q0!IZMK.GZ%9?:]
M1N%@A+!-S'JQZ"M!&#H&'0C(KQ3Q?K.G^*=*U/4KF]A%K:LL>GVK/R[!AF1A
M_*O8=-FBN=-MIH9%DC:-2&4Y!XH N44"B@ HHHH **** "BBB@ HHHH ****
M .>'AM5\9MXB%R^YK;R##@8'OFL[5O -GJ/B^P\1PS&VN;=@9451MFQTS78]
MZ/YT <,_@O4[)KVVT36S9:;>R-(\/EAC$6^]L/O5S3/ ]EI&L6%]:S.%L[4V
MXC(^\2<EB?4FNL XZ?6E^G6@#$TW04L=:U74#,9#J#*QB9>%VC%+K.@1:O)I
MI\SR1972W("#AB.U:B312.525&<=0&!(H,T*N(S*@<]%+#)_"@#%TOPXFF0Z
MK&+AG.HSR3$D?<W#H*IV/@V.R'A__2V8:.)%&5_UF[^5=2\B1J2S*OJ6.*HZ
MIJMKI6D3ZG.^;>!=[%"#D>U '-R>#]2L;J\?0-9^Q6]Z^^2%X@X1CU93ZTMQ
MX+86^GS66J3KJNGYV7DPWF0-U5L]C^E=1!>VT]K%=+*@CD0.K%AT/(J5YX8P
M/,FC4-]W<P&?I0!Q\W@BZU#2=3BU+699;^_"@RJH"P[3D!5Z5:A\&+)J4]]J
M5ZUW)<62V<R[0H8#J:U-7UV'2;K3+>2,NU_<"!<= 2,YK8Y'>@#@V\"ZE<6L
M.CWFMO)H<1!\D1@/(H.0A;TK>TGPU#I6NZAJ44S-]L"CRR.$"C Q6_\ 7FC%
M &+X=T)/#^GS6JSM*)+B2;+#&-QSBMH>E'M0* %HHHH *0TM(?:@# U+PVFI
M>)]+UHW+(;!741 <.&]:RM*\ 6VEWNNSI=NZZIN"(5XMP>H6NS('YUR%UXUD
M^UWD6G:-=WL-BQ6XE08&1U"^I% %0^ 9[*QT<Z7JS6^HZ9&T23O&&$BL>016
M-XF\(7.E>%/$-W)J,]_>ZAY7F$1X((8?= KJ)_&<,VGZ7-I-J]W/J>XV\3?+
M@*/FW'MB@>+[2;PY%J\,$DDDLOD):G[WFAL$?@>_I0!GZ=X3U"]&CRZUJS75
MG8A)H(#$%+-C@O\ 2KA\#Q&!8C>.2-5_M$DKW_N_2NG4L8E,N%; + '(4_U%
M<AXB\<:EX?DNW?PU=SVEN 3<J1M84 :.N^&9;W5+?6=-O/L>J0(4W[=RR*?X
M2#6>O@-+NWU!]6OY;K4+X+FYV[?*VG*A![&KOA[Q/J6M7:QW/AZYL;=H]ZSR
MD8/I721SQR,425&9>JA@2* .1A\*:M<S;]8UV2X2&)HK=$0*#N7&YL=34NG>
M!X].N]%G6^=O[+B>(#:/W@8YYKJGGA0@--&I/8L!FI">@XYH QK/0UM/$VH:
MT)V9KR-(_+QPH7O6W30?_K4Z@ HHHH ***3(]: #/)I-W!/7%<TOC+2IO&$?
MARW<S73Q-([I]U-O;/K1K/BDZ?JJZ58V$U]?&+S72/I&O8DT =#(HGA>/.-R
ME3[9KA-,\$>(-#LVLM,\4F&U\YY$5K56(W'/6M6+QMIC^&[C66691 _E36^/
MWBRYQLQ]:-+\8"XU6#3-3T^;3KFY4O;B0?+(/3/][VH <OA9I=9AU:YOWDN5
ML6M)/D #$CEL4V3P;'+X'C\,F[=410HF ^8X.:ZG*JIW$ >IJ,3PLS 2H2HR
MP##Y?K0!REQX0O+34SJ.AZG]EN)85BN4>,.LI48#<]#5#4_A]?ZEI-O9R>)+
MMW6X^T3NZ@B5O3'3;[5WJ2I*NZ-U=?53D4Q;B%V*K-&Q'4!@<4 <L/"VIWEK
M<6.LZNMW831;/)2 )M/8@CTJL/!6IW[6EMK6MF\TZSD5XX1$ 9=O3>:UO$7B
MA="N(X5MC.QB:9\'[J+U-:.DZI%JNE6>H)^[2Y0.J,>>: .=O? <5XNJ#[?)
M'_:%RDY"J"(]IX J2[\)7D&K2:CHFJ&RFN$"72L@99,# ;V-=2T\*.$:6-6/
M12P!-/!!Y4@@]P: .?\ "/AG_A%M.FMC>27DD\S3/,XP2371!L^]<+>>/KL:
M_J.E:;X?NK]K%U262/  )&:T=!\:VFK27=K=VTVF7UG'YL]O<C!6/^\/:@#J
M=U*#D9KA/^$ZU"_#76B>';J^TU"09R=ID [H.]='H'B"S\1:?]LM"RA6*2Q2
M##Q..JD4 ;-%%% "$T@<'I^%5-1OX-+T^XOKMBL$"[V*C)Q]*YBU\=![NS2]
MTF[M;:_?R[:=UX8GIGTSVH [+=QSUI<UR6I^,OL^JSZ?I^FW&HR6B[KIHAQ'
M_L_[U;.BZS:Z]I4.H6C'RI0>&'*D=0?<4 5-3\-QZGXBTW5;B=C'8!C';XRI
M<_Q?6CQ)X8MO$-C##O\ LTT$Z3Q31J,JRFMIY8HP2\B(!QDL!2&>%653*@+#
M*@L.?I0!PZ^!M7LM>U/5-*\1&U;4'#RQFW5P"!ZFK][X0N-8T6*VU?5I)[VW
ME\ZWO(XPAC/T'!KJGFBB"F21$!Z%F S4<US'!!+<R,HBB4LS!N@ S0!QQ\(:
MWJ12'7/$+75A'(KK#'"J^:0<C<?K7:^3$/\ EFG3'3M7/:-XK35+^ULFM&BE
MGMFN5] N[ _,<UT(DCVL=ZX4_,<]/K0!SVN>"=&UK29K);.V@:7'[V.$9'.:
MW;2UBLK6*WA14BC4*JJ,  >U2)-#( 4E1P>FU@:Q?%OB1?"NB?VBUL]SF58E
MC0\DL<"@#>S@<=*-U<$?B%=6:+<ZMX:O[*R+ -<$ A,]"?:M;7?&%MI4EI:6
MEO-J&H7B;X+>W&25_O-Z+0!TX.0"*4'-<78>-I8M2@T_Q!I4NE3W+[+=V.Z.
M1O3/K79KTH =1110 4444 %%%% !1110 4444 %<G\0M0NM,\'7=Q:2F*4LL
M?F+U16."?RKK*JW=I;W]I+:W42R02J5=&Y!!H X<^'-)T&UT_5K&\%M?K$3N
M,A/VQMN<,,\\^E9&C:%I_B#P1=Z]J5T_]INTDQNC(0;5ER0J^@'2NOTSP-I>
MEW\=R#/<B$_Z/'.^Y;?_ '145W\/M&N[J23]_%;3/OFM(W(BE;/4B@#CM,SX
MK\1Z!#J[S.DNEF26(.0LI!QN-03V$(\-^-]&):33["4FVC=R?+/'&?2O44T"
MPBUB'4XX=L\,/D1XX"IZ"JK>%M+=-6C>)G&J9-USC- '"'0+.^\4>'M'8R)I
MC:0)'MXW(#MZDU>T;1;+Q3K6N1ZRDDBV$BVMM;LY40H%X88[^]=;IOA33M-N
M;.YA\QI;2#[/$SMDA/2H=8\&Z?JMZUZ);BTN)%VS/;/M,@]#0!P6GWUS/)HE
MI+*\T%EKS6\$TAR74 ]^^*]B'>L"#PKI-O:Z?;0V^R.PE\Z$9Y#]R?K6^* %
MHHHH **** "BBB@ HHHH 0UQ&MZW+)=W/A[PI'"VH29:ZN,@1VN[JS>K>U=N
M1D$5P[_"[P^]W<W*-=1RW+EY3'*1N/O0!9C\$P0Z1I=M9WDL5WIP8PW0.26;
M[Y/KGFN9$T>C2H]E";FUT^?[/:H3CSKIS\\A/H,UZ!9Z-#I^AC2[:698E1HU
MD+[G&>^:J2>%--E\/PZ,-ZPQ$.D@/SAP<[L^N: &^'M>N=4EU"SO;58;VPE6
M.4(VY6!&014?Q!/_ !0&L'./W']15_1=$MM&CF$3R2W$[;YIY3\TI]35K4].
M@U;3)]/N06@F7:WTH Y+QGJ=WIOPYAEM)#$\J0Q-*!DQJP +5DZWH=CX6M-%
MU?1YY([X3Q1MB0DWBN1NSZ^M>B3:?:W.FG3YH4EM3'Y;1OT*XQBL#3? >DZ=
M?PW9DN+DVQ)M4GDW+ /1: .7T/0=,UH^);G4I6FFAN76/=(1]FP,C'/!KIOA
M[J%UJ'@^UEO9&>8.\:NYY=5. ??BL/2?A_Y]_K<^JF>W%W>%\12X6:/'>NDO
M/#,4UUHDEF?LL.ER;A&I(5EQC&._XT =&A&>,8I],7KVQGM3Z "BBB@!#490
M$$>O7WJ6B@#@KFPLM.^(_A^&SMHX5:"X=@HY)QUS3/#Z30_%CQ)YS$"2WB:(
M-_=SV]JZZYTFVN-8M-3=3]HM59$/LW6L_7/"5CKMQ%=2236UY&NT3P-M8K_=
M/J* /,M;5I?[8N+0_P"BIX@@,C ?*1P#^M=MXM>*3Q5X2C4*TWVPR KR0NWG
M\*W(O#&E0Z"^BK:+]A;.Y">6)YW$^N:K:)X.T[1;H7:23W-R%*1RW#[C&OHO
MH* (OB',\7@;4FBD:-M@ 93R,FN.UKPS9:;K?AF.TFNH#?L4O&68YN!M'#5Z
M9JFF6VKZ=-872;H9<!A4%[H-E?75A<3H3)8',!!Z<8H \RNWE\*WOBZTT9GB
MMD@C9(P21"6.&89]N:3Q-X?TW2-#T'4-,N)4NI[F'S9(YCFZW8)W<UZ%J.@1
MHVJ:C96T<]_>6_E-%-RD@'8UY\/"=SJKZ?;V^B7&GFWG66>:XF+1P!>2L:]Z
M -W6#_:%QXKU D-%9V8M8#VY7+_K6#X$FGO-0TZ'Q$#%/!9B72+='/ER(!RQ
M]6]J]+M_#MC%I-UIP5S!=.\DNX\L6ZU%+X5TR6VTZ'RV0Z<P:VE4X9,>_I[4
M <'I>DV?B7P[KNMZG*_]I^;,%E$A5K;;T YXKKOAN[OX!THR2M*_ED&1CDM\
MQY-<GK.B74]_JD<GAJ9[J[)$;VT^R&?/1W'8CO7=>%-(ET'PS8:9,ZM+!'AB
MHX!)S@4 <%IX\2GQ_P"+O^$?DLUC^T1F3SQG)VU9UKPGJ<.C>(M=U.>.[U>X
MM!"%ME*JD0ZCW.*[^PT2QT[4K^_MH]L]^X>=L]2!@5H$*X(8!@>"* ,+PE=6
M,_A/37L'06P@4* P^7'7-<]X)/G^-?%=[:C_ (EKSJBNI^5Y1]XBM&X^'>CR
MW#R6\EU:12,3+!!*51\]>.U=#IFE6>CV$=E86Z001_=5?YGU- %X9S_6G4F*
M6@"G?7%M:V<EQ>O&EL@S(9!QCWKS[QK%=6VI:3XBEU&.ZTF&[C$-B@P"6X#9
M[XKT2\M(+^SEM;F)98)5VNC=&%<U8^ ='LKZ&<F>>*V;=;6\SEHX3Z@?XT 4
MO!3^7KWBH7$B"4WOF$-P=A48/TI/A>A_L"[?:RPO>RF,$_[1SCVK5U?P7IVL
M:@+YWFM[EEV2O VWS4_NL*W-/T^VTRPBL[.(1P1#"J* //6TFW\1?$K6[/47
MDEM(H8V6WWD*&Q][BN>BT*WN?A]J>JSSW<U[87+QVTQE(,2HX  ]J]:M]%LK
M76KK5(E/VJZ4+(<]0.E51X8TT:1>:7L86UW(TD@![DY.* .-T^TA\5>+KN+7
M"SI96L/V>!G*KDCE\=S5#2G-AX2U[3;>Z>Z6XU<V43LVXA7P#CZ#-;7B?27&
MMK*^@S7-ND"QPW-E*4D./X&]14O@[P7]BM4N-0MA;2)=O=0VJOD)N&!N]30!
M@^,I-9T;Q/9P:##YLL.D^7+(/O1QAN64>N*=-'82Z?X:TZQNICI.ISEKN=Y#
MOF?!.QCVYKTK^RK5M;_M9HR;KR/(+9XVYS7*:]X7ALM)\G3M(^WVLEUY\UN9
M-K19ZM'Z'- %*PTBRT+XIVUKIDKK:OI[L]J'++&<C! ]ZM?%P2GP8OD,JS?;
MH=A?IG=57PIX=G3Q>=:CTV:RM8K8P*US(7EG)/4^@%=IK.BVFNV26E\I>,2+
M(,?WE/% ''RZ#XS\2:<=.U?4+"WTZ4+Y@@BR[KP<>U1:+"FE?%B_M;DF/?81
MI9;VX>->"%]\UZ.BA$"#HHQ63KWAO3?$,4:W\.9(CNAF1BKQGU!% '-?$^2W
M?0[2T(\R^EO8_LJJ?F# \GVXKNXL^4N>N!FN;TCP3I>EWHOF,UY> 82:Y;<4
M'MZ5TX&* %HHHH **** "BBB@ HHHH **** "DVTM% #0H'84;3ZTZB@!-H/
M6DVTZB@! #G)I"N1UIU% #=O7WIPHHH **** "BBB@ HHHH *0G':EI#U% &
M7=>(-*L;M;6YOH(IV_@9QD?7TJ'5?$%EI>C-J3L9X#Q&(1N\P]@,5P^B6^A'
M2O$S:^+<7YN)_/\ M!^<1\[-N><8]*WOATD3_#C2PHW1K$WE[N<#G% $_ACQ
M;+K7A&?7KFS,(B,A^SQC+$+V^M8\WBWQ18:5#X@O])LDTR1UWP L+B.-C@$Y
MXS[5-\-[J&R\%WES<R!(8;F9I&;H #S6?#JUKX_NX[J\O[>T\.Q2YAMFF DO
M&!X+\\+GH* -Q/'%K#XGO]/OYK>VL[>%)4ED;#-N&<5U=M=V][;K/:S1RPL,
MJZ-D&O/['2].U3XJZW]LM8;A8[:((LB!E QU%6_ <]GINE:YODCAL[?4I0#G
M"H,]/:@#NLC!(ZBO/]-\2^,-?FU%]+LM*6"UN6@7SV;<V/I7?@AXPZL&7&0?
M48KQ7PQHNF:C/KK7/B2XTYCJ+@PI<B//OUH ZF3X@74?@34]7>RC74--D\F:
M G,9?/8^F*EOO%VOSZ]I&D:196)GO=/%Z[W#'"^H&*XVXFV_"_Q=I\,ZW=C9
MSK';WFW#39()SZD'O6W:7EM9_$#PN]W<Q0I_8'WW?:">.* -^W\4ZWI.O6>F
M>)+"VCBOVV6]W:L=@?\ NMGO7<;AG%><>,M2L_$.L:#H>ES1W5T+U+F22([A
M#&N<G(Z5Z+CD#/(H ?1110 4444 -*Y.<TAXQ3ZR]?\ M(\/ZB;0,;C[-)Y8
M7KNV\8H A/B;11=26K:G:B5#A@9!@'TSZU2\5^++;PUIK3"&2ZNI(R\$$2D[
M\>I'05YWJ-OX<'P=B?%M]N7869L>;YQ;YL]\YS7I$Z(/!3N0 ZZ></W VT 5
MU\43CP';Z^;%I[F:W606T/S99NU9O_"3>(M&NM,;7[&Q6TU"40C[*QWQ,WW0
MP/7\*L:!K-GH/POT[5+QPMO!9JQQU;T ]ZR='E3Q;K-GKFN7UI%'$V[3],64
M$J3T=^?O>U ';>(+Z72M!OM0AC622WB,BHW1B/6J>D>*=,U2WLT:^M?ML\"R
M-"D@."1DBCQGQX*U@,22;5P2.W%<#K^D:=IO@GPU=VEK##<>;;'SHU =B0,Y
M- 'K@ )Z\BN4\9>(]3T.?2K72[:WFGOY_)7SV("G\*Z&*_M9;N2S29&N8U!>
M,'E01QFO/_BM##<W?AF">Z:UC>_ ,ZMM*>^: - ^)?$FB:Q86WB&QL3:7TGD
MQRV9)*OVR#VJU+XLNHO$FNZ;]GB,>FV/VJ-R3N<^A]JX_5+*RT'6=(OM,\0R
M:MJ#7BPK;32^:-C'YB .A'K5^Y(_X3OQF ?^80,@GV- %W2=?\>:QH,.K6^G
MZ0T<J;UBWMN(]/K73^%O$4/B71_MJQ-#-'(89X&ZQR+P17/^!/$.CV'@#36N
M=2M8_+@RRF09 ^E+\-()&MM7U?8R6^HWSRP*1@E,\-CWH [X#%+0** "BBB@
M!,4=*6FM0!2O]4LM,@,U[<I"@. 7.,GV]:;:ZQI]ZI-K>0S;4WD(X)"^IKC?
M$"V[?$W1AJP7^S_LS_9_- \OS>^<\9Q5?PK'IR?%3Q FF^6(?LJ;EC^YNR.G
M:@#6T[QRFK^-1HMI:2"S$#2?:I%*[V!QA?:I-0UOQ!<^()],T.PM_*M8PTUU
M>!@C,W14QUJ.\"Q_%+2T4*%_LZ0!%&/XNM0>)O&+)K/_  C.DSP0W[)NGNYW
M 2V0]_=O:@"/_A.;J/0!>3V<,%Y%J2V%VA?Y%.>6!KK;'6M*U.:2.ROH)Y$.
M&5'!->>Z]I.DV7@;3["VNEOH9-5A-Q,'!,LA/S$X]:T[[2]/TKXC>'?L%M';
M&6&97$0VAP!QF@#O^,8':N-\3>(M;LO$^FZ)HUK9RR7<+2M)<L1MP>V*ZBRU
M"TOQ)]DN$E\I]DFPYVMW!KS;X@6=M?\ Q&\/P7.HOIZ_99/WZ2;#U[&@#HM+
M\0Z[!XGBT+7K.UC>XA:6">T8E3MZ@@]*S[WQY?VMAXGN!9P,VDW(@A7)Q)[M
M6':+!H'Q"TB'2M7DUAKQ6CG61_-,*?W@W;FLW6"IT3Q^-RD+J"DG/'44 =E+
MK7C>TTP:I/INE3VRQB5XX';S-F,\9[XKK-&U>VUW2+;4K1B8;A=RYZCU%8TO
MBO1-/\+K+-?6TA6T'[E7#,QV_=P*/AY9W%AX,LTN83%)(6E\L_P!CD#\C0!U
MF.:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *:V2,#J:** ,;4O#>D:G+)<W.G6\MT8R@ED3)Z4SPIH
M\^A^&+33;EE:2%2I*G@\T44 7ETK3X[.6S6TA6VER7B ^5L]<BLX>"_#"E67
M0[(8Z8CQBBB@#4BL;2"X:XBMXTF*A#(J_,0.@JAJ.@6-[I5W8)#%"EVVZ4JO
M#-G.3[T44 :L,2Q1)$/NHH0#V Q61<>#O#EQ<//-HMF\CG+.8^2:** +O]CZ
M8-._LX6,'V,\>2$ 7\JKWWAO1-2\HWNF6T_DKLC,B?=7T'M110!+I^A:5I+.
M^GZ?;VS/]YHD )%:E%% !1110 4444 %,89Z'![444 <AXH\#Z=J^DW:V%C:
M1:C.01.5QSN!)KH[6T\O2X;6<*^V(1R ]&XP1110!%-HNFW6G+IT]E#)9+C;
M 5^1<>U58O"'AVWN$N(-&M%E1MRNJ8(/K110!K3P17-N\$Z+)%(NUD;HP]*@
METRQG@B@EM8I(82#'&5R$(Z8]*** *T&C00:]<ZN2//F18^!C  [^M3ZCI&F
MZQ$L>HV4-TB<J)5W8HHH @L?#&AZ9<?:;'2K6";^^B &K)TNR-Q/.+6(RW">
M7*Y',B^AHHH S8_!?AA7#1Z)9 J<\1]#6XD:1(L<:!47@*!@ 444 2BBBB@
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:<+/!HMDDBG*L(QP:W,8XZ444 /HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %G @8# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[E;=7BNS(03U.,5WU<+\0O\ D,>#_P#L*C^548'='K12GJ:2@84444 %%%%
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MZUH_V_HO_07T_P#\"4_QKG=&^&7AK3--CMKK3X-0G!)>XN8P68^WH/:M'_A
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MR!0\L:NP7H"1VJYWJT[ZF+3BW%]!:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*X^Z/K4M17'W1]:3
MV''<JT445F;A1110 4444 %%%% !3XO]:OUIE/B_UJ_6@3V+E%%%:F 4444
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M*** "BBB@ HHHH *BN/NCZU+45Q]T?6D]AQW*M%%%9FX4444 %%%% !1110
M4^+_ %J_6F4^+_6K]:!/8N4445J8!1110 5P?B#_ )*]X4_Z]Y_Y&N\K@_$'
M_)7O"G_7O/\ R- CO****!A1110 4444 %%%% !1110 5PGQ=_Y$I/\ K]@_
MF:[NN"^+S*/!: L 3>PD GKS0([N+_4Q_P"Z/Y4ZHX6#01,I!4H,$'(/%24
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M'<UZ%9RM/8V\SXWR1*[8]2 37(?%O_DG5_\ [\?_ *$*ZW3/^059_P#7"/\
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MBD@<'Z5V=-55C0(BA548"J, "G4@"BBB@84444 %%%% !1110 4444 %%%%
M!45Q]T?6I:BN/NCZTGL..Y5HHHK,W"BBB@ HHJIJC7B:1>MIRJU\MO(;=6&0
M9-IVC\\4 <7XS-D->'VCQ+X;TQO)7]SJ>G13RD9/S;F8':>P]C4OPXO_ +9_
M;=NMQIUW%;7**EWIMFMO!,"F>"/O$=#Z>IS63%XDO/%=GI.DZ7;$ZX\2_P!K
M:E>:: ++ ^< .N"Y;(4#(KHO!=YJ/VW7M&OKE;V+2[E(H+U;=8?-#)N92J@+
ME3P2*OH9+>YL:[*;6UAO1;Z?-]FDWG[;*(MO!&4=@0K\]_<9%<IJ/BC4]2UR
MWATV?4[>![;='!9K;&9YMQSDRG:\>,8,9(ZYQ6SXXT][S3[&>.TNKB2SN?.7
M[-#'.4^1EW&%R!(.>@Y'4=*P='U7P?I^FS:;?F]O&N+AKB:";1)H\2$ ?)$L
M>$Z#ISGG.30@D>@Z+;72Z=;W.IV]M'J\L""\>%1AG Z9[@$FM2L+P]J+7]J5
MBTS4;*RA54@DU#Y9)AZ[6)< <<M@G-;M49H****!A7!^(/\ DKWA3_KWG_D:
M[RN#\0?\E>\*?]>\_P#(T".\HHHH&%%%% !1110 4444 %%%% !1110 4444
M <'\7)8T^']Y$TB+)(\>Q"P!;##.!WKK](ECFT:RDBD21# F&1@0?E'<5XE\
M3?#GB&7Q?<7YM+F\LY0OV>2%"X1<?=P/NG.?K6M\.?#'C2TTZYDM[_\ L:VE
M8%(KJV\TN>[!21M_K0(]DHKD?[&\;_\ 0W6G_@L7_&LOQ"/&N@:!>ZJ?$]I,
M+6/?Y8TU5W<XZY]Z /0J*S/#]W-J'AS3;RY8-//;1R2,!@%B 3Q6G0,****
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MX4_Z]Y_Y&N\K@_$'_)7O"G_7O/\ R- CO****!A1110 4444 %%%% !1110
M4444 %%%% !1110 5RWB7P#HGBNY2YOHY8KE%V^? ^UBO8'((-=310!SGACP
M7H_A2.0:?$YFEP))Y6W.P';T ]A71X'H/RHHH Y[QT!_P@FN<#_CT?M[4_P3
M_P B/HG_ %Z)_*JGQ!O+:U\$ZLEQ<11/-;.D2NX!=O0#N:=X!O+:Z\%Z4MO<
M12M#;(DJHX)1L=".QH$=/1110,**** "BF.Z1(SR,J(HRS,< #U)J"SU*PU$
M,;&]MKH(<-Y$JOM^N#0!:HJI!J-C<W,EM;WMM+/']^*.569?J <BIEFB>5XE
MD1I(\%T# E<],CMF@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "HKC[H^M2U%<?='UI/8<=RK11169N%%%% !1110 4444 %/B_UJ_6F
M4^+_ %J_6@3V+E%%%:F 4444 %<'X@_Y*]X4_P"O>?\ D:[RN#\0?\E>\*?]
M>\_\C0([RBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!X]\5?".O:OK<&IZ?;R7MJ(1%Y49RT1!.?E]#ZBJ/@'P)XIANI[Q[NZT%'C
MV;@BM)*<]"AZ >IKV^B@1Q__  B?B/\ Z'K4/_ 6*JNH>'O$=EIEW=KXXU!S
M!"\H4VL0SM!..GM7=5GZ]_R+FJ?]>DO_ * : ,GP#J%UJW@C3;Z_G:>YE1B\
MC 9/S$=JZ:N1^%__ "3C1_\ KFW_ *&:ZZ@9Q'Q,8MI>DV\I(L9]3@CO#G ,
M>>C>Q-5M7L+:T^)OA^+3(8[9[BTN([I;<!,P@<$@>AZ'UKN+VRM=2LY+2]MX
M[BWE&'CD7*L*HZ7X=TG19))=/L8X99%"M)DLQ4=!N8DX]J8K'(-H=UH%SHEM
M%<6D]U8I*MDL<)1G!7#2SMGA%!R<?>;'<UH>&];MK>.QC^Q7/E:Q([17\K*6
MN9,$EG4'*Y .!T  '%=7'9VT=Y-=K"HN)E5)).I*CH/8<GBJ=GX=TFQNQ=6U
MA'%*N[8021'N^]M!.%S[ 4!8UJ***0PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "HKC[H^M2U%<?='UI/8<=RK11169N%%%% !1110 4444 %/
MB_UJ_6F4^+_6K]:!/8N4445J8 .37"+XRU(NFHM;V@TA]4_LT1X;SQ\VWS-V
M<=?X<=.]=W7.KX-TQ=2%T'NO*%S]K%GYO[@3?W]N.O?&<9[4+<3V-'6=7M]"
ML3>7,5S+&'";;:$R-D^PYQ7F6L>,=/NOB)H&IK:ZDL-M#,KH]FXD8D'&U>I_
M"O7LU@:AX<-]XNTG7?M13^SXY(_)V9W[AUSGB@#._P"%DZ/_ ,^&M_\ @ND_
MPH_X63H__/AK?_@ND_PKL<GU-&3ZF@#CO^%DZ/\ \^&M_P#@ND_PH_X63H__
M #X:W_X+I/\ "NQR?4T9/J: .._X63H__/AK?_@ND_PH_P"%DZ/_ ,^&M_\
M@ND_PKL<GU-&3ZF@#CO^%DZ/_P ^&M_^"Z3_  H_X63H_P#SX:W_ ."Z3_"N
MQR?4T9/J: .._P"%DZ/_ ,^&M_\ @ND_PH_X63H__/AK?_@ND_PKL<GU-&3Z
MF@#CO^%DZ/\ \^&M_P#@ND_PJ*;XH:';1^9/;:O"F<;I+!U&?3)KMLGU-<_X
MO\.'Q5H@TW[7]FQ.DOF;-WW3G&,B@#-_X63H_P#SX:W_ ."Z2E_X63H__/AK
M?_@ND_PKKURJ*N2< "G9/J: .._X63H__/AK?_@ND_PH_P"%DZ/_ ,^&M_\
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M4YS@J/O#D\]J]#_X63H__/AK?_@ND_PJ7PAX%TSPC;!HE6?464K+>,I#.,]
M,G:.G2NLR?4T <=_PLG1_P#GPUO_ ,%TG^%'_"R='_Y\-;_\%TG^%=CD^IHR
M?4T <=_PLG1_^?#6_P#P72?X4?\ "R='_P"?#6__  72?X5V.3ZFC)]30!QW
M_"R='_Y\-;_\%TG^%'_"R='_ .?#6_\ P72?X5V.3ZFC)]30!QW_  LG1_\
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M9K2XL_-CB;^_C< 6]ST[4 =/#,)X(Y5#!9%# ,,$ C/(J6HXPZQJ)&#. -S
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MC:6MMM"DR/*RB0N 6.3@D#^0H:70$WU*=_XHALK+4[Q+2:>"PD6%F1@/-D)
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M=&W(P#*1W!Z4-6!-,6BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%%
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L4 %*!FBB@"5;:0]<8]JL1V/]]ORHHJTD<\YLM1Q+&.!3Z**W,&+1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $7 G # 2(  A$! Q$!_\0
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MK&U_PMH.KPS7>I:3:7=S%;,B33)N8*H) S]<FJ/PO_Y)CX?_ .O8_P#H;4=
MN[V.MHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH @OO^0;=_]<)/_037,_"__DF/A_\ Z]C_
M .AM737W_(-N_P#KA)_Z":YGX7_\DQ\/_P#7L?\ T-J?0G[1UM%%%(H****
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MKI[WP[IE_>F\FAD6X90CO#.\1D4= VTC</K5NWT^UM5N5BB 6ZE:696.X,S
M ]>Q Z4KARLQ'U*>.[\,%[IE@N+:66Y)/#A85;<?H3FJ-KXEU%;>XE6R:[D^
MSMJ<BR3B,00,3Y4:\')*ID].IYK1?P;I2VDT%JLL!EC\C>96D\N(D%HT#$A
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MX$_Z#O\ Y*R__$T?\+@\"?\ 0=_\E9?_ (FNT\B#_GA%_P!\"CR(/^>$7_?
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M8K>+6C'<);LS1 3,FTG&>A'H*K^'?#7@SPI=RW>C)%;SRQ^4[&=GRN0<<GU
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M%7FDUFW2PF^V)@1(Q\N%5_AW'YBQ[TTKBD['NE^,:==C_IA)_P"@FN9^%_\
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M (FC^U[/^^__ 'Y?_P")HNBK/L7:*I?VO9_WW_[\O_\ $T?VO9_WW_[\O_\
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MIH(0"_SIM#H#U*GMUP36_13N'*<>]G?:]XBN[N/^U-,@?3EA5I(U3S6WO\K
M@\<^QYJO9-="'P]%>:;=64>AQM)>S3J!& D)3"'/S9SGCM7<4A 8$, 0>H(R
M#1<.4XZ6ROW\+PW/D7+RW]\EYJ$-L2)3"Q^XN"#PH0$#G -7/![976E5;A(D
MU!DBCN'+,BA$^7DG&/3/%;]Y96VH6QM[N%9H202C9ZCH>*+.RM=/MEMK."."
M!<D)&,#)ZGZT7!+4GHHHI%!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!!??\@V[_ .N$G_H)KF?A?_R3'P__
M ->Q_P#0VKIK[_D&W?\ UPD_]!-<S\+_ /DF/A__ *]C_P"AM3Z$_:.MHHHI
M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !10.37BNMZ]KKP>)_%UOKE[;C0]66SM]/0@0/&K*K!UQR3G
MK_D"5R6['L=]_P @V[_ZX2?^@FN9^%__ "3'P_\ ]>Q_]#:K/B'QCX>T:*6S
MU34X+2ZFM3(D,F[)#*0.@]<BN2^'_C[PEI7@'1K&^UVU@NH8-LD3ALJ=S'!P
M/>JMH3=<QZC17)?\+0\$?]#)9_D_^%'_  M#P1_T,EG^3_X5-F7S(ZVBN2_X
M6AX(_P"ADL_R?_"C_A:'@C_H9+/\G_PHLPYD=;17)?\ "T/!'_0R6?Y/_A2_
M\+0\$?\ 0R6?Y/\ X468<R.LHKD_^%H>"/\ H9+/\G_PH_X6AX(_Z&2S_)_\
M*+,.9'645R7_  M#P1_T,EG^3_X4?\+0\$?]#)9_D_\ A19AS(ZVBN3_ .%H
M>"/^ADL_R?\ PH_X6AX(_P"ADL_R?_"BS#F1UE%<E_PM#P1_T,EG^3_X4?\
M"T/!'_0R6?Y/_A19AS(ZVBN2_P"%H>"/^ADL_P G_P */^%H>"/^ADL_R?\
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M1^?_ &/J4-[Y&WS?+S\F[.,Y ZX/Y5KT %%%% PHHHH **** "BBB@ HHHH
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M_P (QX?_ .@#I?\ X!Q_X5JT4!9&5_PC'A__ * .E_\ @''_ (4?\(QX?_Z
M.E_^ <?^%:M% 61E?\(QX?\ ^@#I?_@''_A1_P (QX?_ .@#I?\ X!Q_X5JT
M4!9&5_PC'A__ * .E_\ @''_ (4?\(QX?_Z .E_^ <?^%:M% 61E?\(QX?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %; G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBF_C0 ZBD!I: "BBH7E1&56=5+'"@G&3[4 345%YJ>:(MZ[R-P7/./6GT
M.HI :6@ HHHH **3-0&XAW[/.0-NVXW<Y]* +%%1"6,N5#J64X(SR*D% "T4
M4W()ZT .HI <\YI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?^U^1J:B@"+[0G^U^5)]HBSC<<_0U-47_+Q_P&@ ^TQ_[7Y4GVB/U/Y&IJ*
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M*ND9HQ1<0R&99HPZ$%34E4I89(G,UL.?XD/1O_KU-!<).FY>HZJ>H- Q\_\
MJ6J0=*BF_P!2U2#I0 M%%% !1110!&O^N?Z"I*C7_7/]!4E "&DQ3J2@!:9+
M_JV^E/IDO^K;Z4 .7[H^E+2+]T?2EH **** $)I.^>]*>O2O,]$\5ZO<?$S4
M(+HL=#N!)#8J<8\R$?/CZ\T >F"EKRR;XNQ7NC:G+IFDWD=U#9M<6IG3"S!3
MAB/8&M+_ (6)-9:7H]YJ.@W\<-VD?VBXP D#,0!GUS[4 >@T5PC?$JR7Q(VF
M-I]T+,&5?[0./*)C7+X[\53B^+6F?8+VZNM,OK4VZ)-%%(OS7$+MM#I[9[4
M>BGD4H  XKS<^.[+5CIEY)_:.F&WOI(I[5EY.U"V''ICFK4GQ*BAT2UU.30]
M0Q>SF*SA0!FGXR&&/7% '?T5POACXE6'B;5X=/BTZ^M3/"TD,MPFU9"IPZCW
M!KNJ "BBB@",_P"N'TJ2F'_6CZ4^@ HHHH *#THH- #(_P#5K3Z9'_JUI] !
M6;K6HC2]'NKXIO$*Y(QGOBM*J&J8&G3LUL;H*N[R1U;':@#F?!,6G+<ZA+I]
MS=3&=A+*+B(J58]EST7VKK+RUCO;.6UESLE4J<=JR="\0MK$LD4NG363K&LB
MK(P)93]*W0/>@#F)?"DLFD/8C5KH/(0TDQ49<CIG\A3_ !0C0^#YXW<R,BHI
M<C&[D<UTM<YXU<Q^$[UA&TA !"(.6YZ"LYM*+N#5T81Y;&?2N<2%[[Q-K<$U
MK=16MS;)$)\8#8ZX-:!U6\)S_P (]JO3_GF/\:/[6O3Q_P (_JN/3RQ_C7B?
M6:*?QK[U_F<WLY]C-T3P^VE>)+V=;F\EM_LZ1QF9]RM[?A6KK?\ R")/]]/Y
MU'_:MY_T+VJ_]^Q_C5'6=4NVTN13H.II\Z<M&,=?K1]9I-_&OO0.G/L=">N/
M85@VTLR>+=6D-C<>4UN@CE*_+(RCD U;_M6\./\ BGM5Z#_EF/\ &E_M:]Q_
MR+VJ_P#?L?XT+%4?YU]Z_P P5*?8JZ:\NJZU_;#V,]FL=N;<).,.Y)R?P%6?
M$'_(#G_WD_\ 0A2_VM>DY/A[5<^\8_QK-U[5+HZ+.'T'4XQE"6:,8'S#WK2C
MB:3J)*2^]"E3GV.B/;Z"L3Q7YS:$T=O;37,C2H0D0R< Y)H/B)^/^)%JG0?\
MLA0/$<@_Y@6J_A$/\:^PBTT<UG<V0XD57 (W '!ZBJ.M_P#('G_X#_,54_X2
M)_\ H!:K_P!^A_C5'6?$+'2+@OHNIQJ "6:,8'-5=6L*QU!Z#Z"L3Q:)G\//
M%;VLUS*\J$)$,D ')-4/^$_TX_\ ,/U'M_RRI1\0-.'2PU$?]LZ;3:V)NCJ
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M%,E_U;?2@"-;>,J/O=/[QI?LT?\ M?\ ?1J5?NCZ4M $/V:/_:_[Z-'V:/\
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M^OU6%:'*DV>+[*=[V*-BMTEC$+Z19+O&963[I.>WM5+Q-_R+&H?]<_ZUM_\
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M #7^XWTI(O\ 5+]*5_N-]*2'_5+]* 'T444 %%%% ##_ *T?2GU&?]</I4E
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M0]:F_?\ ^Q2 FIDO^J;Z4P>?_L4V3S_+;.R@"=?NCZ4M0+Y^T?<Z4[]__LT
M2T5%^_\ ]FC]_P#[- $M1_\ +Q_P&D_?_P"S4?[[SOX,[: +-%1?O_\ 8_6C
M]_\ [- $M%1?O_\ 9H_?_P"S0 ]_N-]*2+_5+]*C?S]C9V=*2/S_ "UQLZ4
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M C/^N7Z5)49_UP^E24 %%%% !2&EH/2@!D?^K6GTR/\ U:T^@ HHHH ****
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M>98EW'L>IXK$G\9:B='LM;LM-@GTI\-<R>=AE!;'RCOCK0!W5%1HX=%=?NL
M14E !1110 4G>EHH X^W^_<?]?#5M:'_ *FX_P"NI_D*Q;?[]Q_U\-6UH?\
MJKC_ *['^0JFK*Y$=S6HHHJ2PHHHH *Q_$D4,^CR17$R11NR@L_0\]*V*YKQ
M4NEW5M#9:K&S0/NE+*^W;L&?Q]* (O"5BNG2ZC;A[4A9%PEOT"XX+>YKHA*J
M2R YSD=!7-^"GLC97$=KI+Z:P8,T;ON+J1\K$^XKIXS^\D^M !]H3T;\J/M"
M>C?E4M% $7VA/1ORH^T)Z-^52T4 5IIT,3##?E3Q<)Z-^5.F_P!4U/'2@"/[
M0GHWY4?:$]&_*I:* (OM">C?E1]H3T;\JEHH K"9?.8X;IZ5)]H3T;\J5?\
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M2!3N0K]TFN"/4](JZ=+<KXYOH+^TCA)M%^P/$<J8 <$'WS5[Q-_R+EU]4_\
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M^A5G*G%P;-(U)*:5SZ1AQY*8_NC^52U'#_J4_P!T?RJ2OGSW0HHHH ***3-
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MK#S(EN]M$[R0$N<L7^]D=L4K(+&/*GA2*TDN/^$=E813>5*@B.Z,]B1GH:Z
M>#?#LB _V1;X(!P0:H66@WVV99DCABGOA<21K*7(4>Y]3V[5U]%D%C"_X0SP
M[_T"8/U_QK/MM#\*W=_>V<6E1>;9[?-W(0.1D8]:ZP_I7/PPZK%X@U&Y^S0?
M9Y1&L3&3DA>N1VZT<J"QD)9^#I([20:2N+N<V\68V^\.N?05LGP9X<(P=(MR
M/0@UGG3]=>VM ;&V5X]0,SCSN/+]>G7VKK^]%D*Q@_\ "&>'?^@3;_D?\:SD
MT/PP^K3:<VB*DL:;PS(=KCOM.:["N9>PU+_A*)M3AAB6,0^4H:4GS>>N/X<>
MW6JNPLC&,/A-89)'T!U\JX\B4&(YC]&//3FM_P#X0WPXR\Z1;$'M@D&L27P_
MJTEM=QB&)!<WHG"^>3Y6#][/\6?[M=RH(4 G)]:+L+(P/^$(\,_] 6T_[XJC
MJ7AWPGI<44EQHMOB658EV19^8GC\*Z[%8WB&WOKC3DCL((II?.1B)'V@*#R<
M^M'-+N3RKL8=EHO@^_U*XL8M$@$D'\3185\'!VGO@UJIX+\-QR*Z:-:AE((.
MSH:BTC2+RTU:6:Y\L01AE@*,27#'<<CMCI72T<S[ARKL(O Q3J,44BQ*IC3;
M-5N56W3%T29QC_69&#G\*NT4 9L>C:;%&L:6<2HL@E "\!P, _6JL_A30[J.
M:.;3(&2:;SY 1]Z3^]6YBC% 'G^I^!)[G6O-M7M([%C&58H1-;!#G;&1V/\
M6NIC\.:1%?W-^EA"MU<J4FD"\N#U_.M?%&* ,TZ-IS@!K2(@(L8!'15.5'X5
M7'AC1 +X?V9"1??\?.03YGU_^M6UBB@#%G\,:+<Z<UA-I\+VS,K&,CN!@'ZX
MK3@@CMH$AA0)%&H55'0 =JGHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH I:CIMKJEHUK>1>9$QR5R1_*HHM&T^".1(K6-5DB$+@=T]/
MUK2HH QQX>TH7MO>"S3S[=0L;@G( Z?7%7;2SMK"%HK>,1QLS.0.Y/)-6Z*
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M?NLN0<'\JGAT;3;>,1Q6,"H"" $& 1TK1HH S[338K.ZGFC9L2XPG\* >E:
FZ444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Y G # 2(  A$! Q$!_\0
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MI.E37IC\SRAG;GK6E7/^,_\ D5;X_P"Q54HJ4U%]63-M1;1S/_"TE_Z!K?\
M?5'_  M%>?\ B7'_ +ZKE?#&D6NK2W"7#DM''E(5;:TA],U/I^@P7>N/!<07
M%M:PAGE#]0/3->S+#X6+:DMCSO:U6KIG1_\ "T5_Z!I_[ZI/^%I+_P! T_\
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MT\M#OSE:Q:*OV4>92ZH7.[6#O2&EI#6I(M%%% !1110 4444 %%%% !1110
M4444 (>M H/6@4 +1110 4444 %%%% !1110 4444 %(:6D- !_'2TG\=+0
M4444 %%%% !0>E%!Z4 :/A__ )#MK_O'^1JC+_KY?]\_SJ]X?_Y#MK_O'^1J
MC+_KY?\ ?/\ .LE\93^$W?\ A(+0Z#'I9L'5%Y9DDQO/J:6S\21:;:-#96!C
M,I5I"[YR!V'I7/5MZ-I,%WIE]>7)8"':B '^(FL9TZ4(MSV*4I2=B2^\3->0
M7T7V4*+J59<[NF*Z+2O%MG+:NL[);2@HA##(*@=1[U7F\"VZ:G;0I/(UM)&=
M[#JK#G%<Y/H%R)IQ"8C&CD#=( >/:N=1H5%RK0VO5CN:6K:AI\6CW-MILS,U
MU<;I"W4*.E+'XQ0)O?3E:Y, @,F[@J/:K \'VXM"#)+]I6W%P9 ,H?856.@Z
M>-'CU$_:(U$JHRR#_6 ]2*5Z%K,?[R]Q]WXS^TV+VT5F(&<J2RM\J[>X%1>+
M]<BU>>UB@<-'%&"Q QE\<UE^(--72M8FM$),8PR$^AK-KHIT*>DXF,JD]8LU
MM"ZW_P#U[-62.@K6T+K?_P#7LU9(Z5NOB9#V1J'6<:"FE1P!%\S?(X/,GI5V
MU\2QZ=:&"RL3&9&5I2SY#8[#TKGJVM(TJWNM)O;VY+8C*QQA3_$36-2%.$;R
M6A492;LBQ/XI,PN1]D&)[A)OO=-O:NDM_%>GW=@6N)5@9W9I$'WAD8&#5"X\
M#P17UND<SM;R1$R'NK@9KG%T&[<JP:#8S8W&49 SZ5S<M"HKQTL:WJ1>I?U3
M5+6VL=/L],DWQPN9W+=V)XJ>3QC&RW!33%$ER5,K%^I%6IO!MHBN$EE5H'C6
M5W'RN&[K5&^T2QT_4XH9(+G[.6*^:6RK^F#1%T&E'L#]HM26Z\9&YL6MH[3R
M69T;>&X4CT%0^,-=BU>>VBMV5HH8QD@=6/6LO7-.72M8FM8\^6N&0GT-9PX%
M=-/#T[J<?4SE4EJF:WA__C\N?^O9_P"59 X XXK7\/\ _'Y<_P#7L_\ *LD=
M*WCI-_(A[(W;?7+2#0)-+:Q=Q(VYG\SJ:EMO%"Z;:&#3;,P%W#R,SYSCL*YV
MK.GVOV[4;>UY'G.%)'I6<J$+-OU&IRV1OCQ='#)++::>(9;AP\S%\AL'M4,O
MBHRB8?9 /-NA<8W=,=JT;'PMINHZGJ%M'+)"+3Y5)/5JSKWPQ+;V=J8V N9&
M<.LC  8[BN2/U=RM8VE[2USHX?%&FWFFDS3B$R,YE0?>&1QM-<[JNJVT%KIM
MIIDA:.W;S6/J^>,T:;X8$D=S-?L2D(&$MV#,2?Z5<C\(V?\ ;%S92W3ADA\Z
M)0.2,9YI<M"$]QWJ-7&-XRC/G,NF*'FD624EN&(J0^,OM=W8J(/LR13^8[EL
MC!ZC%8\FEP'PRFI0[Q,DQBE!/:L?'7WK>%"C-.W0S=2<3:\4:JFKZS+/#S;H
M-L6/059\"_\ (UVWT-<Y72^!?^1LMOH?Y55:"AAW%=@@W*HFSVBEI*6OED>P
M)7/^,_\ D5;W_<K?%5=0MH+NQDANDWPL/F7UJJ<K34NQ,U>+1\^#I2UZZ/"_
MAO\ Y\#^=+_PB_AO/_'@?SKW_P"T(=F>;]5EW/(:/QKU[_A%_#?_ #X'\Z3_
M (1CPUC_ (\3^=']H0[,/JL^YY%17KW_  B_AOO8'\Z3_A&/#?\ SX'\Z/[0
MAV8?59=SR*D->O\ _"+^&_\ GP/YT?\ "+^&O^?$_G1_:$.S#ZK/N>0YHKU[
M_A&/#?\ SXG\Z/\ A%_#?_/@?SH_M"'9A]5GW/(:*]>_X1CPW_SX'\Z3_A&/
M#?\ SX'\Z/[0AV8?59]SR*BO7O\ A&/#?_/@?SH_X1?PW_SX'\Z/[0AV8?59
M=SR&BO7?^$8\-?\ /B>/>C_A&/#7_/B?SH_M"'9C^JS[GD5%>O?\(QX;_P"?
M _G1_P (OX;_ .? _G1_:$.S%]5EW/(:*]>_X1?PW_SX'\Z3_A&/#?\ SX'\
MZ/[0AV8?59=SR$]:!7KW_"+^&?\ GQ/YFC_A&/#7:Q/YT?VA#LP^K2[GD5%>
MO?\ "+^&_P#GP/YTG_",>&_^? _G1_:$.S#ZK+N>1<45Z[_PC/AK./L)_.@>
M&/#9/_'@?SH_M"'9A]5EW/(J*]>_X1?PW_SX'\Z3_A&/#?\ SX'\Z/[0AV8?
M5I=SR*BO7O\ A&/#?_/B?SH_X1CPW_SX'\Z/[0AV8?5I=SR&BO7?^$8\-_\
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MPB_AO_GP/YU+KT?Y6'L:G<\V\37\>H:Y--"<Q@!$;U %97'K7KW_  C'AO\
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M1:_$D\LY&T&5\A1[4 :H[D9HH X_KCK1_GI3$%%&?\XHS_G% PHHS_G%&?\
M.* "BC/^<4?YZ4 %%'^>E&?\XH **,_YQ1G_ #B@ HHS_G%&?\XH **/\]*,
M_P"<4");;_CX3ZU&?O-]34EM_P ?*?7TJ-OOMZ9/:DMP$HH_/\J,_P"<52 I
MZG%<2V3K;W!@<<[@,US<%Q>WVFZ-8M=RQM=LXDF7ASMKI-3T]=3L_L[SSP*3
MDM"VTUF0^$K&'3%L5N+PI&Y>*4R_.A/7!J>HS*FNM1/AZ1EOI ]K=B(R=Y5S
MW-=FF2B9')49K#O/"ME>Z;%8^?=11(VX^7)@R'U8UL6T*VUM'"KNX0;0SG)-
M-: 2T49^OY4GY_E0(GM_X_\ <J&IK?\ Y:9_N>E0_C^E"W **,_YQ1G_ #BC
MJ!E^(OM2Z)<R6MP;=XUW;E'.*R+B2[U*:VLQ>S6ZI9?:&>,\LV._M6YJ^E1:
MS8FTFFGBC;[WDMM)]LU2?PK9O;6\!N;O-NNT2"3#E?[I/<5(VCGX+_4=5L+J
M]-]-"^GQ JB8 D/JU=K9RM/803-]]XU8_B*S)_"VG3R1,/.B5%",D;X5P.FX
M=ZV54*BHJ@*HP !T%4A"]Z*/\]*/\]*8R:V&9&_W#4-36N0[?[A[5!GG_P"M
M4]1"T49_SBDS_G%,89 YS7.37%]9>(KS=<&6);,S)&1\JFNC!P>,\5C'PS:M
MK+:FUU>-*P*F,R?)M/;'I2 YVXO]1TFWM+U;Z:=]0C)9).1&?516SI N;'7#
MI\MY+=1RVPN TIR5;/0>U6+?PMIT#2Y\Z59%*A9&)$8/]WTJQIFAVNE.[Q/-
M-(XVEYGR0/3Z4!8T_6BDS_G%+G_.*8@JU8_\?:_2JO;_ .M5K3_^/L?3TJ9;
M#1L4M)2US%A39/N&G4Q_N-0@*I Z;5_ 4O&?NKZ]*Y[QEJ:6&B>4TKQ-=N(@
M\8RR@]2*YW1O&#)HUS:PR>;<6TJ0Q23J1D'C<<UJ2>A;D.>$S["E)4$_*O/7
MBN LM7U+2M;U&6_E@FA$Z).\?W54C((I+SQCKN^&*QLA))(IF7"Y!CS@#GO0
M!Z!E<_=7\J,KC[J_E7(#6]?N;R\6VAMT2U@21H7^\6(^[FJ%QXQU6/3;..V1
M+G4)Y&1RL> F!G!![T#.^RO]U?RHR.N%Q]*YY]>O+7P8VKW5F5NT0DP^ISC\
M*Q;3Q-XF?39+B:P4;'4AB -R'D\#T]: .[R!_"OY497^ZOY5PFH^--0;!TRW
M62.>01V[@9Y RQ]ZE7Q!XBN5M(4@M[6X>"2682C.-OI]: .VX/\ "N/3%'&1
MA5/X5PFGZOKFH:Z+J*>$6[6'FBU8?>?/8UN^&M6NM1M+DWLD9N86.Z-$P8^.
M![T ;H*%B,(2.N,4N .R@#Z8KSZ?5DC\(9FN)(Y=1NVC9TR60 GICTQ5&[U&
M36/#>E6L#/<2Q79@E5I#$9 .F30!Z=E<@;4!/3IS2DKGA5Q]*Y"^MVT?3=/E
M2-H94NXU*"4OD'@C-=?3$&5]%_*C*_W5_*BBD 97.=J_E1E?[J_E110 97^Z
MOY4GRC@JOY4O2BF 97^ZOY4F5'\*_E2T4 &5_NK^5&5_NK^5%%( X/\  OY4
M<=T7\J** #*_W5_*C*_W5_*BB@ RO]U?RHRO]U?RHHH ,KZ+^5)D>B_E2T4P
M#@=E_*C*_P!U?RHHH ,K_=7\J,K_ '5_*BBIU ,K_=7\J,K_ '5_*BBC4 R/
M[H_*C*_W5_*BBF Z/&\?*OY4T[03POY4Z/[XIIZFEU ,KZ+^5&5_NK^5%%4
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M:12RY?K@'C-;-4 ?B:,GU-%% !D^IHR?4T44 &3ZFC)]3110 9/J:,GU-%%
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7*.9@,\E/2E$:J<@4ZBCF8"T444P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #T G # 2(  A$! Q$!_\0
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MW.VHKB?^%EZ7_P \9ORH_P"%F:7_ ,\9ORH^J5OY6'MH=SMZ*XG_ (67I?\
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M )XS?E1_PLS2_P#GC+^5'U2M_*Q^VAW.WHS7$?\ "R]+_P">,WY4?\++TO\
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M1III=0E-R2\@HHHK4@**** "BBB@ K6\+_\ (T:?_P!=:R:UO"__ "-&G_\
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MQ_SPE_[Y-/GCW#E9%14OV6X_YX2_]\FC[+<?\^\O_?)HYX]PY6145+]EN/\
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MX%9U%'*N[%J:/VFR_P">"_\ ? H^TV7_ #P7_O@5G44<J[L-31^T67_/!?\
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M^]1;Z'I]K<6\\,.)+>/RXSGHM,&:/<\?CZT4>M'XB@044<>HH_*BX!11^5%
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M#_GDM']H#_GDM4J*.1!<N_V@/^>2T?V@/^>2U2HHY$%R[_: _P">2T?V@/\
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M%>*E@OO,F5?* SWK.J:T'^E1TG!)#N;@ZTM(*6N8H3M6+?\ %VW?O6U6+?\
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &[ G # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %4[ZS-[$(O.:-#PX4?>'I5RB@#%;P];EE(E
MD41MOA /^K;N16A:6B6ENL*9(&22>Y/4U:HH J68"RW( P-_2K=5;3_77/\
MOU:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"K:?ZZY_WZM55M/\ 77/^_5J@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** *MI_KKG_?JU56T_UUS_OU:H **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5
M;3_77/\ OU:JK:?ZZY_WZM4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 9&O?=T__ *_8_P"M:]9&O?=T_P#Z_8_ZUKT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %6T_P!=<_[]6JJVG^NN?]^K5 !1110 4444 %%%% !1
M110 4444 5;Z.26SE2*9H7*_+(HR5K.\-&[DTB.:\O'N9)"3N90,8..U:\W^
MHD_W3_*LWPW_ ,@"V_X%_P"A&@#6HHHH **** "BBB@#(U[[NG_]?L?]:UZR
M->^[I_\ U^Q_UK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBD) &2< 4 +16<-<THS^0-0MO-SC
M;Y@ZT^_NY;2V\^.(2*O+Y;&![>M %ZBL.77RDT:+;Y$[F* EOO..H/I6A8W8
MO+43;=C9*LN>A'6@!UI_KKG_ 'ZM54M#F:Y(Y&^K= !1110 4444 %%%% !1
M110 4444 1S?ZB3_ '3_ "K-\-_\@"U^C?\ H1K1F_U$G^Z?Y5G>&_\ D 6O
MT;_T(T :U%%% !1110 444E &3KWW=/_ .OV/^M:]8^O$8T[D?\ '['_ %K7
MH 6BBB@ HHHH **** "BBB@"CJ4EU%8RR68C,RC<!(<+@=:CT6ZNKW2+>YO$
MC2:5=Q6,Y !Z5:O?^/*X_P"N;?RJKH/_ " ;'_KBM &E1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %5-0C>73[B.-0SM&0%/?BK=)0!R&FZ
M-9QQ/I^JPZ8\AQY:HJJ_T]<^];M]ISW$5M%!,(HX6#%"NX-CH#7,6QB_X32Z
M!&FAOM _U^3/T_AKNJ ,*;03+.LOVDCRI#-"-OW'/7ZBM*SLUM+40;B_4LQ[
MD]:MT4 4[)0DEPJC #\"KE5;3_77/^_5J@ HHHH **** "BBB@ HHHH ***J
M7M_:Z? 9KJ=(D'=CUHM<!US(D5M(\CJB!3EF. *S?#$\<NA6_ENK[=P.#T^8
MUBZM<ZCXDTRXMM.LC':,O,T_REP/[H_"J'A/PM)-IC37=U<PI(WRQPR;<XXR
M:U]G%0<F]>QBYRYDDM#OVFC3[SJOU.*KR:I8Q F2[@4#UD%98\'Z2?\ 6I-,
M?629C5B+PSHT/W-/A_$9_G4>[W+]X;)XHT6,X.H1$^BY/\J@D\7Z8K;8Q<S'
M_IG"QK5CTVQB_P!79P+](P*L+&BC"JH'L*+Q70+2,'_A)WE4FWT?4)/3,>W-
M(-9UR4XBT%T'K+*!718I<4<RZ(.5]6>8>+QX@N9K-IH/*3=MB6!]WS^_O746
M/B-;6&&VUB&:TN @!>1<HQ]<UH:[PNG_ /7Y'_6M*:"*>,I+&KH>JL,BKE54
MHJ+6Q*IN+NF$4\4\8>*170]"IR*ES7/2>&8X9#-I5U+8R]=J'*'ZJ:C_ +3U
MC3!C4['[3"/^7BUYX]UJ.5/X65S-;HZ7-+698:U8ZDO^C7*,W=#PP_ UITFF
MMRDT]@HHHI#"BBB@"O>_\>5Q_P!<V_E570?^0#8_]<5JU>_\>5Q_US;^55=!
M_P"0#8_]<5H TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI#2U#-(8H7D5&D*J2$7JWL* ./6[\[QE)&]P5,<P54BM RD8[R=C7;5P2:O8
MQZP]W#-K*S2/N>P6#Y2WH>/ZUW$3F2)'*%"P!*GJ/:@"6BBB@"K:?ZZY_P!^
MK55;3_77/^_5J@ HI,TM !1110 44F:BGN(K:(RSR+&@ZLQP* )">*@NKRWL
MH3-<S)%&.K,<5A/K]WJ3F+1+3S5!P;J88C'T]:EM?#:/,+K59VO[D<C?PB?1
M:KE2^(CFO\)"VLZAJS&/1;79#T-W<#"_\!'>K-GX<@CF%U?2/?7?7S)N0O\
MNCH*V@H4    = !TH=T099E4>I.*ESLK+1#4>XV4 0.!_=/\JS_#?_( MO\
M@7_H1J#5-<MX+:46[B67& %&0/J:K^%;]9+,VC8!B/RC/)!YK#V\>?EN.ZV.
MEHI!2UN,**** "BBB@#(U[[NG_\ 7['_ %K7K(U[[NG_ /7['_6M>@ HHHH
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MM/)L!:1P 6S]*0[EVBBB@84444 %%%% !124M !1110 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444
M03VL%RFV:)7'N*S3IEQ:$MI]RR+_ ,\I/F7\*V:*B4$P,9=7DMR$U"V:$_\
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M* "D-+10!CWFB+=ZI!?F\N(VA^[&C?+[\5L444 %%%% !1110 4444 %%%%
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MILTM0PW$5P@>*174]U.:FK=-/5#"BBBJ **** "BBB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110 4444 %%%% !1110!5M/]=<_[]6JJVG^NN?]^K5
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M=.NU@52NU4!"LHS_  ^G3M6A;6L%I"L5O$D:#LHQ6+JEC:2>)-*F>W1I3O\
MF/7@#%=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110: ,X
MZM%FX/ER;(&V%L?>;T%3VEVEY )4!7DJRL,%2.H-95UI=S/>//&(XL'< K'$
MK Y&[TK0L+62"WD$^WS)I&D<+T!/84 26G^NN?\ ?JW5.Q01R7"+]T/Q5R@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[-']G6_]QO\ OLU<HH I_P!G6_\ <;_OLT?V=;_W&_[[-7** *?]G6_]QO\
MOLT?V=;_ -QO^^S5RB@"G_9UO_<;_OLT?V=;_P!QO^^S5RB@"F=-M\<*V?\
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MF94=N^5!P?QKIMJYS@9Z=*"H/4 ]Z .5U":1M;#3/,3#."D*+D%-O7ZYJO\
MVI?)"TD+S^4]QY$8;D@N.#GV-=GM&<X&?6JTUG#<&(R+_JGWJ!P,^M &%K"D
M7$RR?-MM4YQDD;^356ZN_LD=Y):+,L,K@P>6,+N"\_A74O:Q/<I<,N9%4J#[
M'M4NQ< ;1@=L4 <I)=7<PU&UGD9EMK<R$D<.6Y4?A73VI8VD);[VP9_*HGTZ
MVD,Y=,^>09.>N.E6P,  =J %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &# R # 2(  A$! Q$!_\0
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M"_\ S.U^U-% 'XK?\/,/VPO^D2'[3_\ X7?@7_YG:/\ AYA^V%_TB0_:?_\
M"[\"_P#S.U^U-% 'XK?\/,/VPO\ I$A^T_\ ^%WX%_\ F=H_X>8?MA?](D/V
MG_\ PN_ O_S.U^U-% 'XK?\ #S#]L+_I$A^T_P#^%WX%_P#F=H_X>8?MA?\
M2)#]I_\ \+OP+_\ ,[7[4T4 ?BM_P\P_;"_Z1(?M/_\ A=^!?_F=H_X>8?MA
M?](D/VG_ /PN_ O_ ,SM?M310!^*W_#S#]L+_I$A^T__ .%WX%_^9VC_ (>8
M?MA?](D/VG__  N_ O\ \SM?M310!^*W_#S#]L+_ *1(?M/_ /A=^!?_ )G:
M/^'F'[87_2)#]I__ ,+OP+_\SM?M310!^*W_  \P_;"_Z1(?M/\ _A=^!?\
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MQDCZ$@_I4$JD 8,IR<91R".F<Y/3&3[8)XYH _%C_AYA^V$?^<2'[4'X^//
M8_EX;&:/^'F7[8*9!_X)(?M0<]AX\\"G&/\ =\.9[]S].]?JC\2?BGIGPTA@
MDO= \7>(!.Q!B\,Z1<:S<1-B,JTODNOV=7$G[MBP$A1QQLQ7E,7[7'PH35K?
M1=>N/%7@^ZG6'+^*/#UYHMN#,?W$=UJ,@9%P00[(X$:MF0@,#1R.M^[_ $;\
M_3\C&=90DXWVM^*OW2/@=/\ @IG^V$^?^-2/[4'&,@^// QZY]?#N>W;\>U/
M_P"'F'[87_2)#]I__P +OP+_ /,[7[$Z?JB7Q26"59K=X8)8)X6\RTN(9P[1
MR073?\?(**#+P&CS&1C?D[!D)/=0!P.G7/)]_E/T'/>E[)4/W6BY>BLK<WO;
M+U[&D)<\5*][WU]';N^Q^+W_  \P_;"_Z1(?M/\ _A=^!?\ YG:/^'F'[87_
M $B0_:?_ /"[\"__ #.U^TL9)+<DC"]\^O\ 3'Z5)3*/Q6_X>8?MA?\ 2)#]
MI_\ \+OP+_\ ,[1_P\P_;"_Z1(?M/_\ A=^!?_F=K]J:* /Q6_X>8?MA?](D
M/VG_ /PN_ O_ ,SM'_#S#]L+_I$A^T__ .%WX%_^9VOVIHH _%;_ (>8?MA?
M](D/VG__  N_ O\ \SM'_#S#]L+_ *1(?M/_ /A=^!?_ )G:_:FB@#\5O^'F
M'[87_2)#]I__ ,+OP+_\SM'_  \P_;"_Z1(?M/\ _A=^!?\ YG:_:FB@#\5O
M^'F'[87_ $B0_:?_ /"[\"__ #.T?\/,/VPO^D2'[3__ (7?@7_YG:_:FB@#
M\5O^'F'[87_2)#]I_P#\+OP+_P#,[1_P\P_;"_Z1(?M/_P#A=^!?_F=K]J:*
M /Q6_P"'F'[87_2)#]I__P +OP+_ /,[1_P\P_;"_P"D2'[3_P#X7?@7_P"9
MVOVIHH _%67_ (*7_MBO"X/_  26_:=@4# 8?$3P'&Y XZ'PX^TCN-G&/PK=
M^ ?_  4_\9_%+]J#P9^RK\6_V-_C5^S1XS\:^!_&7CCPGJ_CW6-,\0:;K5MX
M#TJVU&Y7_BFK>VEE@N([@MY8MXC/\JM#$2%7]B)8S(,!B/H2#^'ID$@]"1WK
M\7/CDI'_  6R_86MB#&O_#-?[2\@D7/+/HULK$$G@[@S#_=89/)H Q?VOO\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110!@7UG(\@\N)Y 2=VUM@
MP,%@, YR<>A&?:OEG]KS2?*_9Z^)]XL%FL]EX4UFY7S;)+MPOV&;[0%D?B [
M$RQ7_6 #=D1 U]B-T/T-?,?[8?\ R;;\83T_XH7Q2<>O_$@U/@_7I_G%=.'K
M.,N5;1:_%W^[77K\CCQM_9/?1/\ K]3U;P5"R>'-#^S6Q>.;2M)F)E8?NVDT
MFQWA$./+!8,&0?*&4\ BN\(?RB7.20?E ^Z=K@C\R!]?K7.^#O\ D :%_P!@
MBT_,Q*3_ #KJF^X_T?\ K7#7ES8RK+^:<=]7\%-7_"Y6"TPM+TD^V]2;_"]A
MD'W!^'_H"U-34^XO^ZO\A3JU.H**** "BBB@ HHHH **** "BBB@ HHHH **
M** "OQ9_: _Y3:?L)?\ 9M?[2'_IBU2OVFK\6?C_ /\ *;3]A'_LVO\ :0_]
M,6J4 8?[7_\ RFA_X)=?]D-_; _]2/X%5^W$'WF_X%_*.OQ'_:__ .4T/_!+
MK_LAO[8'_J1_ JOVX@^\W_ OY1T 6J*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BD) ZD#ZF@$'H0?H: %HH
MHH ***3('4@?C0 $@8R0,G R0,GT&>II"RCJRCG') Y].O7VZU6NW"1;UPSH
M=R+D?,V#\H!/S-WVC+8[8/./_:<P5_-\N"0+OF$JX@LXADB:YD;"P!P&SYK*
M/W?7FC3NOO U+APY*["ZK@JRR *S#JH'=AD9 .<9X&*YN[\1Z7IKSK?W5M&\
M2(4LXYM^H9*Y&]"V%1QS'D#Y3GGDUQE]XLUG5KJ72O"EF#)(PAD\12+YNGD#
M*R+;%5,.Y.?WHD(.1@\5T/A_P%I.FO+J-]%_:NLW"H;J\N-TK&0 ?+%YA\H(
M@^5  -J@ DY!K@FO?V>B[/R\K 82>)/%6OSS?\(]H4=K:Y CU#5G*;]I"2%4
M4>6P5@0NPDD $G<30?"/BO5<MK?C"[MXV.#9Z7"D-N-H"%5E $Y#@;F+ #>7
MVD+MKU5+950)EB!G *A<#.0"L:A..@(&3W)-/^SYY!QGU+9XXYZ4X0YVXVM9
M7U79I=O,#Q?7/@?X.\3::FD^)#>ZO:,7DDM[^[FGMIG#EUD <E(74%5Z@EU+
M $DUY^O[+?PIA\Z)=(U!;$S64T]E'>,\5_<V\[".:[Y)G6"-(XUW9V11JF0%
M45]5-#F(1YZ9]<'))_ YQS]>QJ%;51\O (!ZY/!).,C'0$ \#/-54P<:BBFU
M[LN9?)->7<#\6/VG/^"9M_\ %V;XY:UX,\767P]\8^/;KPD/!_BQ='GEM+/0
M]&FL(]4T'75M[Z%[ZQOK>TE@$+1JJR7"SA2JACXXO_!-3X_:IJ'@[Q!?>(/A
MQ87?PETK0K'PSH>C6.I6FC?%9]'(,NH>.(H]4$,LC/)));QW(++&(HP/DQ7[
M\7F@V=W()IO.C93G,$C#S&Z!G0[DX '5>V2>PEBT:)8U#/,S $%I& <X) W!
M/ESMQ]WBNN"Y(1IIZ+7\+ ?SC_%'_@EG^TG\3OBHWBV\\>> ]/T&^UF6?4--
MT.#5]).F:)*ZO%I=C#;ZJJ316N6C19QG !(YXM^-?^"5'QW\71:1X#M/$GPP
M\.^%? C>+KKPOX]DTW4;WQQXC3Q3JC:E8MJ!&J,R7.A1;+&W"?*(RPC^3K_1
M6-#M1(9%9P,GS!D_,>-W4<^N>0:MQ6%M'M81!L LDC#+Q8)("@C*@ 8XP1PO
MK3 _G/\ A1_P32_::^&?Q<C^+^I^)_AUXE2RU'3X5\!>((-6F\/:I)+I+Z3<
MZXVDG53'!J>C!VFLK@(-KH!$V-IKGO%?_!(7X^SZA\46\.?%337N]?U#5[S0
MM;U!M;GMKZ#Q:%@U;11:MJI:UMM,CC%M9SNJH;>.-E.TBOZ1I-(LY)3<.)1.
MS,RR-ND.2<EL88C@\*0, X[$"0:+:M\S23EF&6(<H&9N6(4 ;03DA<?*..U
M'\_O[+'_  2B^+?P5^,O@#Q_XT^(MEX@TOPE?6.O20V-WJ;7%I>Z8LJPZ; D
M]VV89/M#QN4++A3\S  G^@:$!(YUP$ AC55!R!M3&U222P'0'))ZY-*--AC
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113'D2, R.J
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M:;FW4[3/$#Z&1<_SHL^S^YASP_GA_P"!P_\ DB>BH?M-N,YGA&THK9D08:0
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M(HPB0Z/;M. HX14 51@(",9.,8XXR >;0I\8=3;S4LO#?AG[5F6:6XG?5+N
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M4OA_I^D0Z'JFOW7B@Z]8G5H]!@D3^Q8K32#=*MQ%):_;[5BT9F1J_<"P4+O
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M?^F+5* ,/]K_ /Y30_\ !+K_ +(;^V!_ZD?P*K]N(/O-_P "_E'7XC_M?_\
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M:A#JUU/,UP)A*D[ LV"><)5G)6>BNGK=+KU:7Y@? WC/_@HK\+;2&XU3P?\
M!ZRT_5-2\,VVH?#?7-;\.6"VGBGP]<W,%KJ.FW4,D:M:P:39/J=M)&RJ#%9N
M8]X;;7FT7_!5KX!^'?A%X3\0^/O@/8S_ !#TC?KMQX1T?3=*EAL/#^J:SJ-I
M_P )%HK)(T3)Y5E)++:O*MQ%&B'[.-XS^LOB3]GO]GC5(=+MM<^'6C:I_9M@
MVGZ/8)8E;;3[6Y,KO96\D"&:*W1IY8PC(K AV*X<$^.2_P#!/;]DZZTR+3;_
M .#^E6>D2ZC+>6EO9M//>1W-R4-W%<W=P$E73I/+C,-J!Y4+&4J,R'.7M''6
M'O-Z6CJ[/=V5]-->@'QU\0/V[-"T?X>VOQ1^$O[..B7_ (5\5OI,MAXGGB\/
M6SWUAKD\*ZS%?:2UPMX)HHY9%CDFMUWE6P3MI_A;_@I!\!?$.K/X;\'_ +.N
MJWOCK0]?_P"$7\)K'X;TXP0S+8+JESJ5I<2^4P@M;MIF:565(FC^5\#G[^TS
M]BS]F[PW:W^F6'PTT=$U"T@T^"*XO+C4K:"WMBCV8@M+C%I8R1()&$N8LX;#
M,1@=5X4_9?\ @7X0OWU;0/AYIMM=-?/,FIO$KWB2&T:RN/L<CJHCLKU"6NR[
M)R?W'F+@FU14_?>C>Z>CU\G;\@/RXU;_ (+)>%5U;6?AUHO@K4[3Q7IZ1F/7
MKP*WA[4[NVOO)U>!'@:64W-O&LJ.J(1O0J":ZBX_X+6?"?3/#E[KP^%7Q%EN
M_#GB*TT#Q%<W-FD&FV_A\_86U/Q:LCLGFZ39&^MV3R1+=^1)$/L^_P Q5^W+
M+]@[]EH>+!XEM?A!H::U9W$E^BI+(=(:>X)ENA#E"&>[E=YY2XVB61@>F*W-
M<_8>_9Q\3:'?>%=:^&FG7.EWFIR:Z\0F,*QR73VS7&E!X5^>(O9I)M?<FQU&
MX%2HN%)0=TT]&M[[V_R ^I/#/B>P\6Z/I>NZ8COIVN:-9Z]IYD!1G@N[=)(&
MVL%8 I@KN4$J1D G V!8"1EERWE@">)8^,2D@NK \'YB2 >3@YQWJZ5HEMI=
MGIUCIUE_9UCI^EK9VMFK^8MK$IS%:*^1D0H=B@950-@8JH)Z& $11AEVL% *
MGJ"..V>O7\>W2M *SV:R@[@!G!('N 3^N?Q)-5FTN-UV-\Z+P%("C!SW R<'
MZ8S@<5KT4 88TE%91$\L2J,   @'ZGE@"<Y/IC)SPLVEO./+:8B(@A^,2,<G
M+;@>"W/3IFMNB@#!_L:'[,L&Q2$?"EX]SLBG:K.<\MM );(R<D\GBQ'IH5X)
M-V#;126\8QP(G 7 ]  ,#VXK6HH QXM+CA9MKN (U4;% Z#;P>Y[^OOP*<-.
MSSN?GGEL'\1Z^OO6M10!B_V=)EL3L#)Q.?+7:4QP(AT##Y1D8Y!/?-7[:#[-
M$1\SGKCJ>.@Z]3WQQ5NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 0]/Q7^8KYB_;&_P"3;?C%_P!B#XK_
M /4>U*OIT]/Q7^8KYB_;&_Y-M^,7_8@^*_\ U'M2JJ/\27^)?E YL1M\OT9[
M7X(_Y%70_P#L'6W_ *+KH_XO^VG_ +4KG/!'_(JZ'_V#K;_T7719&[&>?,Z?
M]M*X:[7URKK]J#^7) O#_P "GH_M]'_S\J>1?3[B_P"ZO\A3J8K *N3_  KZ
M^E/Z5UQ^%>B-@HI 0>AI:8!1110 4444 %%%% !1110 4444 %%%% !7XL_'
M_P#Y3:?L(_\ 9M?[2'_IBU2OVFK\6?C_ /\ *;3]A'_LVO\ :0_],6J4 8?[
M7_\ RFA_X)=?]D-_; _]2/X%5^W$'WF_X%_*.OQ'_:__ .4T/_!+K_LAO[8'
M_J1_ JOVX@^\W_ OY1T 6J*** "BBB@ HHHH **** "BBB@ HHHH *89$"JQ
M8!6(523@$L< <XY)XQ1(VU20"2<*, GEC@'@' &>IP!W('-<IXLU^R\+Z3-J
MVIW9L--L+:>XO;G:C"&*--[_ #2'RU8KE4R2Y) C#N0";Z+5O9+J!TUP$D38
MR%\LN%WF($D$C#G /T!)]N*X+Q+XX\&^$+5;CQ+XI\/^'8HYMP&JZO:PLS!)
M(_+,5W<0?-\Y<*S!W",$5^17S7/X]^*/QJLDM_A+(? _@J\F\I_'&O1&#6+N
M")R)GT:RU(VDDT<XW!;F""1%"AHVZYW?#?[,?PYTVZ_M?7X-0\?>))PJZEK?
MB[4)[G_25^;?:6*7]G!'!*X8@^>S(JJIA+/@/W(SC&LU"+:4N9J.G7XK)?/0
M5UW7WGX8_M;_ +8?[-W@7XZ?%"XD_:;U_P ,3-IFEZ?HGAGPOXSL]3TC69(U
MDDO==>TO9KW^R8K1RADL8+6-IB5,18HJOR7[+'_!3KX/>%O'GB_XI>.OV@O$
M?B_P)H'P4T^Z\=Z7K6J:6^H+XUL!J=OIT/AN.QMK=S]NTMD655?9+-<6X<F>
M,+'^PO[3$W[.WP?ELK_QO^S]X>\5B\T;4]7EOGTZ!I([;1T\Z\\FRGA^VF:*
MPCNYE*3.\HB>*WCN'D05\U6UQ^P+^U%^S#XN\9^(_A]H?PD^#6B?$#1F^(J2
MV-GI\_B&W\-HVHZ9H=YJ!LKM#I6LVEVSS6$<EK<272VELT\-RC6[>DUE-&GS
MU,#.N^7W)PASW>BO%Q3ON]4K[V[#_,W/"O\ P6M_8[\9>&?!GB_P_)\1]9U7
MQF->N+;P7X8\'ZOK&L:-%X<MM/@O)/$<%GI,MU8I'+=65N+^Z2'3FEOK:**Y
MEDEAC;@E_P""Q7@#QW;O+X5^&/Q/\,:3<V]]-$VI>#]?N]=OFT_4K>S?4X='
M^P17NGV%G<212W.JWEO#911*XDG$;[AYW\"OV</^"?\ =?%6Z^)G[/OQKU3X
M%MX@U^XM?&'P5BN])L]"EFU^>5KOPR--UB 7=@)7\-Z9J$5_9:A/;7*VXCM1
M<>:98_HCX<?L^?LL>&/B+XNT:S^/>I7?CZ\M/&?AB#PEJ%_I[ZAHOAS6KT6N
MMSP6<T8U"32XE6:(S&,6LC.CV\\KO!NY95L&[RIX:I1@M7&<)1TNDOB2TU6^
MO?<;3[/[CA/$7[>'P<\/6GB/QKK%]XQ\>3:#;:&TE_I>BWLEIJFI^*4BB33-
M%O+&*\L]8O;!+@7$NGZ/=-=$Q.K-O5HZ]*L/VZ/V6[6R\&Q^(_B!KN@Q>.+T
M:6FA:GX:NO"MIHNM)8"^ET_Q9HUQ!%J4%Q>6>7MKF\D_TB<A"B.Z;L2#_@F?
M\)K#P5>_#[P;\>_&&@_#<^(-#U7PKH^CW6A0S>&/B-H=Q;I#K>BZO?%C=V<C
M)=O<V+L2R?/$K*T9?POX[?\ !-7]G:]U/0O&'QX_:D\47?BN]\;Z?)XLO[ZX
MT:6T\7:[';I:Z4LMI%$AT:XM;:&&21Y!"K&W<3E!)%NAXC"O:,8RZ2;M;SOI
MT_,1]=V/_!1_]E3PM<6.EZ=H_P 0]#TG4)YX?[<UCX;^)+#P_P#V3;12W4GB
M*/5[ZQABO](G> 0:<UM+.6EG#>7B1"T^E_\ !4_]E_7](L;_ ,-ZUK?B*?5+
MJV\.WMB^BW<,FFLVMVWAR#4-0E,$D$<5_/+93:0KR1LPNIIY0(E>2/FK_P#X
M)U^&?$G@^#P9X_\ CY\0O&/A^UT.>Q\*6'V+24LK+X?06\5QI-C;M;$BZM+)
MA;7DVJ1M+:R16QB$[2RK&?&_"/[)G['?@_P+XF^%4?Q9U7Q?J>L16MSKGB'X
M>:5H][<V4?AC7?.TJYENK 7)LIM(^P)8R6UPT%]>/;?;;:VFBN;9YL*]:*I2
M=.2G-6Y8Q?-)ZQO9*[=HN^BV5_,J"3DDVDG>[>BV?FOS/T<^ 7[5OPF_:*\3
M^._"O@.Y\07VH?#FYM3K":_87%A/+#>6:W%J+>2:WAMY;.15+*WG.<2*/O)*
M$^Q8'!C3<A&8XGP!O">;NQ$"@88CVX+9(Y!R 1G\G_V7?V2[[]F*_P#%'C7X
M?ZOJ'BK4/'FC6NG2WOC6>&$78L6N1H+[8IPD[OIE^LMX\9>.UD5+2\>&Z1X%
M^SE\%_&S6V)U;XBVF@VYQOL_#]M),L0:-"L<<D@Q^[(8#RBRY.6(&PMY[Q%>
M6DJ55)]Z<DO+6QJZ4.E2'_@2_#4^BK@*\LJ$.%6W+?ZN3RPP888E4(8@%N%)
M.,Y[&OSH_:1_:T\5_!SXX_#?X8Z9X=\+7FD^,F2WO1JFII8W^JVTVH6EA/#I
MULTBSW$L*W8E)2,L@7:N2:^F(O@U=WL9&K?$;XAW\P.V1Q?VFF1[3R?*271=
M5,@8J,E6@" #<KLP*_,_[37P_P#@7\+/#^D>/OB1K?Q#%X_B"QTKPY>:9J%G
MJ'B$:Y-&1;-HWE>&56&Y1!YK&YGM;=A&45_-9%*]O5@N:%.<I*WNJ$FVGHW9
M1Z+?:P_9PVYX_P#@26W_ &]U\KKT,;P1^U/\4?$^L_"_0]8^'.A:98>-O&_Q
M'\ :OJ6DZQ;W>LZ'%X*EC.GRHHNG16N+642;B<[WZ@[E'8^!/^"A7[/7C#6K
M70WU/Q/HVF7GB35?#-AXL\5:3J&B^&;O5='DN(YO^)YJ-C9:;%"$M'8S75Y#
M$KHZL6<JIXSX=>!/A9K7Q2?PKHGC/Q^OC?2O#FD^.9]-NM*@\-:C:V'B61X!
MK-SJ+Q!3<:C);1_VJ88C+*N\,$;:A^-I_P#@D]XJ\/?!JVT#X<>(?!.F_%"_
M\=>*/%VL:[<PZI=>%+Z?6)S>6UI#9/XSB@OM1^Q32P7>HC3H"9XI%6,1")WU
MITZE=WE>E)W=YIQMY:VM=?,F<(1BW&46[K123_"[_(_7W3?VD/@?XFTS5-1\
M-_%WX=>(M-T>2U76-4T'Q?X?O+:RN+XRQV%I<?9KYW-_>+;.MK9HC7=R8]L$
M4C<'S'QO^V3^S_X4U3P9H>I_%GP+IL'Q%UR\\(^'O$,OB71KC2I/%.B+J%U>
MZ1%?PW$MJVH)#97 :W>52S6S1INEPA_)OX=?\$GOC)IU_H*ZU\0O"_A'PEX@
MN]5B^+7ACPQ'JK'Q-<C3;F3X>:EI7V;Q%')I?B7P]J,G]KVMJ%*VUGJBR7LD
M0,HBQYO^"6G[06GW?PW\6G2_@;KMS\/]8ETR3X?:L-;N?A_K-EIWPS\:^ +'
MXD"YOO%L*:9XM\07&I6OC#5;JUF-Z/$4TYN(8O+7&_U24=95837\O,F[O9[]
M/U,3]QK;XQ_!:VU?4+.3XI^ W\0:9HD/BSQ!:WWBC3+6ZTO0+BTAGM]6O; S
MB:RT^>VV2P3SQQF21IK=5,]M-#'R^@_M:_LS>,M8\7Z5X;^-GPXUR\\(Z#IN
MO^)+K2O&FD76FZ5I&K7%U;Z=+>3FY2.V>>XMID4%BY(& <,1^'FL?\$H?VH-
M0\3_  ]O?^%E>"];C\-Z<=8NH?%-_K5W8^/9FM[/7/\ A![>VL?$\6KM8Z4;
MJ;2U\1A]7MC:0)'<65M:6L5S=^H_$;_@F)\4OB@OC:]T>T^%/PVN/&4O@'7;
MS0?AM>3MJ'V[P;>O->^%+GQ',)6LM,NHXPPO0U[',SSQO9P.N9ZC24'=:NS6
MFN_S?Y ?KS%^T]\$(M;T;PY_PLSPUK-UK"?;3#H^K:5J&EV&DI:SRQWVM:G;
MS3);VS113/&9)54^6=BL33++]K;]G^ZU?5-%M/B;X4BM](LK&ZO-8&NZ;=^&
MY;:[4&V6VU(2O;ET#!+B!)!<0%2LT,6":_&KPQ_P29^(O@GX17=EX9U_X;:)
M\2]=\5^)-=O-1\7G_A(UU'PWJMFMM::,VJ7&IV'EQ:6Z-&DZ1JZM=%S91*K8
M\_A_X))_M!ZAX9TZW\2^-?"MMK6B7=K-8>$K3Q; ^AZY9R1B&6.\N1!;0+9E
M2;BSM)IB8T CBEG?#-K9]GHKO1Z);OT _HA\$?&;X4>/=:NO#/A#XD^#?&/B
M33K9;V^TSPAXATK6'L[&7Y[66[M]-NKE[0O"T9Q.(GEW>9$K1LK-Z]%*68@0
M#Y&96*O&X!!((.';D'ANI# @X(K\-?V%/^"?OQ3_ &7?CCJOB^ZUS1K'X8IX
M8N;#6O#MGK-OXFN=>\1WMTUW%?V=MY5M/I=K9F8HN[4+HNB!A"@/DC]M+;SX
M@TL2N8Y5!?S)WD:-<':[M.(I,NH5_+"'8&$:DJ@R)-QYDFXWMS)75^UUI<#H
MMZDL,D%<9R"!R,\,0%;KSM)P>#@@BA71QE65ASRI!''!Y%<XD[S*L4;3&(/\
MD[*?)N&>54<(F/-(2>80,S($!#$XC!<*LGSN"DF<+_J4E\M6*1LBGY<1,XD7
M:DNUG<L KD$)*E%W2DG97=FG9+=OLA-I;M*^BOU9T8(/0@_0YH!!&1[]B.AP
M>#@]:R[,F,L,EL$AT'SM&W78Y3>(SCYQO8,P9<Y'(OQSQN/O*#SD @X.3QE2
M03ZX/)SP.0)E4IP2E.<(Q;LI2DDF[7LFW9NVMET';J345&94 8_.0N"=L4KY
MSC&T(C%NO\.<<YZ'#&D )&V0Y/\ "LA]!R%4X_'%95*T4HN$HRNVO=:?2ZZ,
M"3S$&06&02#]13P00".A&1]#50RKN;B0?=;/E2[#YA&W:^S8Q)(R%8E<_,!4
MOG1(HW-L&40%@RJ7=BBHK$;6;<I!522."0 RDW3G.3?-&45;1M-)N^MM%K;7
MY@344T.I#$'(7[W!XXS@C&<CN.H/!&>*3>I"M\V&Z?(X/XKMRO\ P("M0'TW
M<,9SQ]#Q[D8R![G QSFF;!_?EZ9ZGI_WSU]NOM7$^)M6L=$M;_6KRZFL=.L[
M0W6HWDQ9+0VJ':7$JY"M'NP8U'G$;<1GH6DWLF[;V38TF]DWZ*YW D1@I5@0
MY*J1R"5W9P1Q@;3STXX/(RJNK$J#\P )4@JP!S@D$ X..N*_'FZ_X*X?L\PQ
M"X33?%[Z"GB;Q/X>36=.5VM--L/!T?F1ZJZF(S2F_?>!;1)/>%5"M 1DU[M\
M+/V]O@1X_P# ,WQ(\1>.=(^#>A2:GID2V?Q&UF/3=6>#7-,.L:+Y<EP%$DNK
MZ>'N=,MD:2XNPLL,49GB>,9NI33LYP3[<T;_ '7N5[.I_P ^YZ[>Y+_(_1$,
M#GMMZY!&/?D#(]QQ[T@=3NP3\APWRMP?;CD>XR!SSP:\>\.?$OP%XT-POA;Q
MGI/BR0Q13_9_#NL6NIWL<$_D>5<R:?9RS7T5LPN8#]IDMDMU$@W2+LDV[>M:
MQ9:/I,NJ:AK'V+2],A$TVI7,ZK \8<)EL$R22%\1_9DC>Z:3,8MP^%-Q][6/
MO+O'7?;;N)QDMXR7JFOS1Z*TBJ-Q)*^JJSCZG8&P.Y)P .2<4NY3C!!W#((.
M01USD<8]^E<#:-<76W41->S:?>6JW,*VC;#-;3KNB=K>4K<QI.@Q'YD"EB2%
M&XA39AWJ64S/!RZQV4C;94A1Q%/*K$JKK;9+2LCMY8'F/A1DMIK=->JL*S[/
M[CMLC!.1@=3G@8ZY-&1ZCGISUKD(G@(B,%U//;W#*D=VLT;6LGF2^3MBG+^5
M/)YAV""!Y)W.5CC+'!Q[KQ1IBZC=Z*=8LDU#3+2'4+FT6\A-W;V\LL\-O)<Q
MB3-I)/<6TT,4=SLE,L; Q\ E"V/11(A&[=P&V\@@[LXV[2 VXG@+C)R, Y%+
MN''7G..">G7MQ^-<H+B2-O*D<@>2)U,ZEFF=E$B"RGP;:ZDP5.;:280DCS3&
M.*F:]EDCD4+=LT4<<DR2$0^7'(&*-,S[#'&P4LSD@1HI=RH&: .F# X^]R"1
ME6'0XYR!@^@."1R,B@$,,C..G((_F!^?2N$M;RZG8LLD<T&X-9/#=NQ:$>69
MID\PJLT4)EC664%H8BS"5D,<BKLV^HV6H-'>6.H1SLY>U%NES;E'E@<I+LS(
M!+M=6#-$7R1D9 P0#HZ*KQ.P51)P6P%Y!!.,'!4L N ,=.2?H+% !1110 44
M44 %%%% !1110 4444 %%%% "'I^*_S%?,7[8W_)MOQB_P"Q!\5_^H]J5?3I
MZ?BO\Q7S%^V-_P FV_&+_L0?%?\ ZCVI55'^)+_$OR@<V(V^7Z,]J\$G'A31
M3Z:;;'/_ &S_ ,:Z0<GC)^<D8[X;=[=B#]#QG!KF_!6/^$2T?/!.F6P'7_GF
M2>GL._X5TR9QR,%B2#GH-JD8Z]1UZ'Z=L:E%2Q-2;T3<7?O:,5O]_P!W<VP=
M_J\?\4TO3VDO^"2^8H948@#:,9//8=O\:GW*21GMZ]<_Y_GZ5R-Q'<BX&V9N
MA!8L%0,22JEW*H"1T#$9]2:C*2R_=E:4H""8F#J,$@C*DC<#C(!SCE1C)JH*
M<IXF*C+EH).$E&7+/W(R?([6>K:T;=T_D4Y3J5,5!1;]A\.C]Z\(RTLM=9-:
M:W_#KHY%.[!_BQW/4#^70D\>]2%U4X) .,\^G^17+6:2PW8@F:1%8Y^=6._Y
M0Q90NX,@4X,BYB##RV8-N4;<<T6,K(9 68;]KD#:!D,VW"XY/S$#)(!."2J+
MJ5*49RA-.2;:<7=6E.*O=+?E_0='VM2E"I*G.+DFVG&2:]Z25[I;J-_\R\'4
M]&'I_G-&Y1U91^(_QJ@989#\LV>%.(V9AABP#'8C@ E6&21]UNRDU$_D-(RM
MYS2)A2-L@.#AE*AD0NF7P)4#1[MR;]R.JZ23BKR3BN\E9?C8N2<5>2<5WDFO
MSL:?F(/XA_,?F./P_P :<&#<@Y&<?C_DU0A,2*53=C))SDX..22,CMDY.?TI
M6FPP5&4ENP+<L?=2%' &,D5$9QG=QE&7+\7*T[6WO:]K>8DU)-QU2U;6J2\V
MM$7Z3(]1^8K/\Z3D] O!)+\?^/9/X U"[%VSYC9(^Z@=B0N02!NW'D$8 R3P
M >II:JZU3U36UN]R>>'+S<T>7FY>:ZMS?RWVYO+?R->BH;?B% 22>3\P(;YF
M+#(/()!!P>1GFI00PR#D'_\ 5WHWU6Q0M%%% !1110 5^+/Q_P#^4VG["/\
MV;7^TA_Z8M4K]IJ_%GX__P#*;3]A'_LVO]I#_P!,6J4 8?[7_P#RFA_X)=?]
MD-_; _\ 4C^!5?MQ!]YO^!?RCK\1_P!K_P#Y30_\$NO^R&_M@?\ J1_ JOVX
M@^\W_ OY1T 6J*** "BBB@ HHHH **** "BBBANRN]$M6 4UF"@DD  C)/09
M('/(P.>N<#J>*1WVJ2 2<@ 8(ZD#J< 8SGDUG?VC%*OW3M:Z:S4LI"M/&"^5
MR1YD0VY#KE),;$9F(!E3@VDI)MNR2>K;Z(3:2;;LDKMO9);MF;JNM)H\-S?W
M\PCTZQ@DN[N9B+=4LX(S-<W2.^T31VD(>><1&1EC0Y&< ?'']JZW^T_J@),V
MG?!#1-7'G&-)5C\>F"3-N/.*K+'IZW*J;AYDBAEB#!6.[)WOB?XDOOB]XP?X
M-^!VBETZS:(?$?Q')*_]G6=E;[+NXT>R9'REQ>_9WTZ\A4DM%<LDBB/<Y]DM
M[>ULK/3O"'A-&L=*T6RCTDRVR0QVD-I&@0V]G96Z[(S)ADFN+E%(4EPVX$TJ
MDW14I;3BG*,=I.2V26[>II2A*JUR)RC?644VDNK;1>M[S0]/EM-"T*TAOSI<
M<=I8V<2B+1])LX0$BM[1F\N*1X0JJ[B1MV#@GMHRZ;XBU">1=0UQ-,M)QY1B
MTF...<!E+"(74J26ZC +-^]$I"_(0"V>4O/&?A+P2R:)IXNM8U(D>99::L,M
MVLKXR9+C_5(@;'FJ7R 1P<G.DNL>.]0@2YTG0+'2(I0 6U>>3S8RX(660P"1
M=H&0QP5!()QP#S<_MXMU;0;5WS:>?EK?_@G1[!1:NU'_ !/EUUWN]/N['Y8_
M%#XH_L(^,/C9XHU3XE>'_&7CKQQ\*H;KP1J7B&"&:;2+FWUR'[+<VKVJ:D%N
M5M8HG$LT5DT*L%S*"5CET/&/A#X4_$#X;_$[]E']EWP]I_@KQM\*-5\ ?%O4
MXO'>E6FF>!=6DN[K5(K>RO=3A-R+U[Z'3KZ&TD@BOK:&:V2ZG,2F$R^+?%O_
M ()]_&2?XO\ B[Q;X'^+'P\\*6WQ%U0WMQX7UJZGC82I*DNIZA"TL*F\BC1I
M)0(=ZLY5%R[*M<1^TO\ LI_ML^(O@M\4_$-EX_\  ?C'Q+\35^&OAF>U\)6V
MH6Z77A/P--XI9)IKA8XA);F75HFU?R5O+B)=D$EDS7 9.>&/Q$JBP[IS]G!V
MC+EE9VO:SLTU9?E=[%RC246U4@VE=)33?3L]>O\ PQ]._&7]E7XI_M@^+[GQ
MSX]LOAAH.@Z9IMS?_#71]'NTN?$]I?VUTT;:UXD\1Z=9:7/J%[9M(L>APF)[
M6+3[^ZBFE6]"(?F2^_X)*?&2\\1-XPO]5\%WOCK6/!/C'0M>\:NEU<:C<V>J
M>)H;VRTN^COH+BTE$NDQ%C$LEK/'<)&);E'#PR>??%;X)?MW_LQ:SJ&J?#+4
M[W2X)OA;I=E>P?!71[/4?!$_BRV;1+<&UT[6+?1;B(1*9)M1DATHM=7'DR)<
M,I<-4UC5?^"DFL^$M#T_QSK/Q)T;2[31?#WC#QUXS\,:#IJ^*=:MO$UC%?ZA
MI.AZ%->I8O?Z7K>M)$;:],$+V-E<3VY=DB4]4I5))Q<)ZZ?"_+R\NYS2:L[-
M;;?<>L>,?^">]EX#75=%T'6?AS-X+ET+PV?#O@_4M8O],U/PSXTLO#NF6NJ^
M.[31=/L;MK;5_MMO=RV4%U<@7;W"M) ;20S5\Y_"S_@GW\5/BYX?TS3?$_P4
MTBUBTSXQZOXD\;_$GQWJDR0_&/06M#%IZZ[9Q:7<QV8AG:.*P71DCA^822/D
M-L3PYI?[>/@'XN:KX]T'P-X^US7=?\(6=AHUOX@T+2_$'A?7O#^G:M:P6WB#
MQ#)J%V)-&\8KH=K#J,&DV*FQCOF,4TI*M&?4/AW^T'^W1-K6M^&_'.H_&S1;
M;^WG?PCX@;P5HM]XCUA[N.2T_LC6-+M=5L]$LM"@DE<K-#ON$@B0Q(LXW&8T
MY.23C))O5M-+9]78R.&\<?\ !);]J*[\3V?B$^-/"5GX?\!Z1KR>$/!O@=)D
MOD\(:FINKCPE>ZEJCP7-S:K9PB"V<0ML>:2-"),1B#X4_P#!/+XQ^/8?BYJG
MA_X/> OV:O"WC_0?AQX'TSP'XKU1Y=<OH?#&B>'(O$OQ LHX]-%[IO\ PD%Y
MH^H7<\J,WVY[@%"P">9M6_BO_@J)\.[6]\,?#R?X@^)+J;QUXZN[+4?%\8EM
M+?\ M,2ZCI=O80W>H7F-#M[7>T.G7#Q3K*IAC!P@'7^(M _X* ?#SQC=^.]<
MN/'OQ+\1^)/A#X;DN/$.D^']+CE\/>)=9:P?4=,TNPEU%E:TT[3A*8(IH(FM
MI R9WW2K70J*BU+2Z\[^7=@?J_\ L3^ /$W[-W[.7@CX.^)9M1\4^)_#%UKB
MW-SI4-G?V#VNH>*M?U/3ICJUQ!;S7"#2KVR@B$DLTL"6HA B99(J^T+>\UAX
M-R: J,SO(DEU,(W82$-ED7 R, $!B!QQCAOAO_@G7XF^-/CK]GW[?^T)IVN:
M+XXT+QUXJT"U;Q#I4&BZYJ?AVUO1+HM[J$5C))#(9+2:-H1\KVY>5)@&8J/T
M.CMQM"J\H"A<$3EPP(X/).WH3T&<\DXS6T9*+3:YDNEF[W5MEKIN!P\LWCQV
MS!#HL:#@+<-*6 .,;2&'''S8)&<=.*\"_:)^"7C/X^_#^7P1J'B71?"UN]]!
M=7%Y#8QZD9[4?NKF"**XS):W3Q.RQ7MO)'+$"0AW8-?7!M<]68_[Y#?EQQ[_
M (4Q[+<5 \LKR'#+G(QP!QT) S^&,8S5RJPDN54^5NVJBUMKNW^GD!\(_ ;]
MB'X2_LU>.=>^('@"37D\2ZUX,L_">OW%W?-?#7=/L6>]:X#7NJ7]W]HAEE:2
M#S!:[%58(HW8#/Y3W/[2O[2_@3]G=? 7@32_CCI/Q>T_XG^*I]9URZ\(R^)C
MJ.@)=7CZ/IEE&NL6#P:9=+&MN+JPBN9(^9&F6(+M_H[EL[B>,B2W@#F$QLR;
M1(<2'RU1R<*%7$A/1ON]<BJ\6DWD8<M<CSY7C>6[@2"VDPB31K&-L$A*HK1@
MD\L=QQR<Y ?S=ZQ\6/\ @H'\:?AT->DUWXJ?"[QEIGAOPGX@O/"FF?#86-O:
M1:%KVF1W5W9^,++QI-J+ZCKMG/<PZG8-:R;K6.,F<RRR1)R_Q_\ BK_P4-U_
MQ.]M!8_$?P]X.\,>/=-\3^(/$O@+X71_\)'\+EM9;:STZ3P_:/\ $1K'QO8>
M+]*,LFOF^B>73R9U:T@NWS)_3(-(O62VBG*S(3:VUX6N&F>:S6"07(D>6.-@
M6G2W*QQ@KPS#EF"S#2+B4(MW,7&Y9[E5*A=1?:8Q:7^(R);:%55@,G)9@!M&
M"FTE=M);7?F!_,YJ_P"US_P4H\*^,-$A\/\ @CX@>(=,TIM0TC2-$;X.Q6WA
M7Q?HFH-++I'BK4]8N_'<&H:#J5L)III;2T*32S0?9;F$6J6X/0?$?4/VW?B;
M!X4-Y;?$+Q89O"\-UJ7B"P\'Q>!-1L/$D$^I2G0UM+/Q!=K/8V+/!#;W\]P8
MKD.[3%=A9OZ0KC3;J-P\>IW-LK2PO]GC"26T,2AT=+="@:- F,(,+G.P#.1
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MS/:AO*"L)2C*5KCIO^"LW['T'C%?!4'Q'AO[NX\/7'B"UU6RMK)=.FAMKO\
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M4JAF'^U__P IH?\ @EU_V0W]L#_U(_@57[<0?>;_ (%_*.OQ'_:__P"4T/\
MP2Z_[(;^V!_ZD?P*K]N(/O-_P+^4= %JBBB@ HHH/ )]* VU[:A130X.>O S
M_GFD=PB%O;COSV/THLUN2I1:NFFDKMKMO?[A]0K/$RE@XPK%2?\ :'5?J,5
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M^//B#)&]E\#?$$TNKQ7-WI^NZQJ.GV.AV%I!(Z2O)I=OJ5R\ES;"%VCBD4
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MJ\/_  QTRR\<ZOX5MM>G\(Z.-+DM=:LKB[GNCHVH-+H<KQ7A:6[2P>2$6O\
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MA&T.6#<#]DM#=KG1-+N80+>.\TNRN9+2 "VLVNY[=))IEMHOW<*L[96) RH
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M"9!$)H@-RO%]Y\AP=B.V/E /P-<8:_NGW+]J:^N9E4!]FRT),GS8X+# 10K
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M5J-@;:ZOY)+IAI/E6]N9+B-$(^Z#N:O$?!W[,_Q=\ Z]H7BFR_9M^+/B[0_
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M[EW!T1@3@ GBFR:E;+)Y),V_S7B.VVGE'R*&<AHHW4 !AAF. >& K^>?1?\
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MU2_U'6%GFU*/9;J-+C^R.6$CV\DX:&*7RTD\4_9Q_P""H'Q%^+WC/P+=^)_
M/PLL/A!XY^*GBSX/:?J7A[Q;;-XOL_$.@V6MZGK&IWN@G49[NQ\/++X5U!8;
MV^CM3)/)IT<R123Q)0!^[*7<"$+).=Y+#;(IC^[DC:) I8L =N,ELCCCAO\
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M$>G@'Q6?_*#J3?R/YU5'^(_\6O\ X# Y\3K3:ZZZ?+3\CVCP*NSPIH08C/\
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MNX8Q&'G0K0J2EP]A).$O:5H6DWCKW3C:ZYE963Z+^?'4_#OPSL?'GQPOM/\
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M';@US7@GGPKH@]=-MO\ T773("6D.,G.0H_O D GV&#_ #P*X:_^^5?\4/\
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M.;2/V?/A%97EA/:ZG#X%T.*33K@L9HI4L8=WG!L%)".9(6(\MLIR!SXG=?\
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M-WR!) (0N1T(/S$CMP.>:_#[X=G_ (NS\-??Q38#\K"3_"OW"QB.,'O;VO\
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M /S&/S'Z 8 QG  -=>_Q<^&]N4M8?$UG=F-=J"W5WB48# /%&H#[6!&000%
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M ,%<+WQQ/+H.J_![6KSQ%XJ>"X^'FA: 8(;W5--\N6;4M5U:-HYELDT:)/\
M2HV>3[3R4EBK7^'O_!6&74K/QUJ7Q"^#>I^$O#%IXM\4>$_ 'BYKB&TTCQ=K
MGA>#4[ZYT@3/&5BU.:STF^D";Y%:2!@ 2PK!YWQ+434\2JJMM2G&#CWDW*2N
MGM97U5[+<7U2EY=-[K\TEI]Y^H=G\%_AK:S,!92W+QLT<S?:$FF6X0E9$DA
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MCZ#/K4YN(5QEQ\PR,<\>^,XJ.>]M;>/S9955"ZH,98[FZ# Y&?4X [F@" V
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MW7A_Q;I-K9V.A^&-1U36KR[O(8@)M>UB]N/#^AH)97.Z.W6VG7!:$3J(Q<3
M'Z\61D-NC2!03M*!00/*W?(3R1N8?,0.0" W(KYN_;&_Y-M^,7_8@^*__4>U
M*OHO3?,-NLD@(,R02CD,@RB+A&&#R4WE2B;-P7YNM?.G[8W_ ";;\8O^Q!\5
M_P#J/:E54?XDO\2_*)S8C;Y?HSVOP1_R*NA_]@ZV_P#1==(#AFX^\X'TQ(?\
M?TKF_!'_ "*NA_\ 8.MO_1=='_%_VT_]J5PU_P#?*O\ BA_Z13+P_P# I_\
M;_\ Z<J%R,$?,2/F"D>W4\_G4E-3[B_[J_R%.KKCLO1?D;#2BL<D GIS2>6G
M]T4^BF SRT_NBCRT_NBGT4 ,\M/[HIP4*, 8'6EHH *80^3AE [ C)I]% "#
M.!D@GN1P*6BB@ HHHH **** "OQ9^/\ _P IM/V$?^S:_P!I#_TQ:I7[35^+
M/Q__ .4VG["/_9M?[2'_ *8M4H P_P!K_P#Y30_\$NO^R&_M@?\ J1_ JOVW
MA_C^C?RCK\2/VO\ _E-#_P $NO\ LAO[8'_J1_ JOVWA_C^C?RCH H3\!O\
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M2:_XPTZ?Q-974]_;:W=+=ZM'8-(KW4.I0!=EMKMFT=PQ.[[*NT9X+XL_L_\
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M00< QI;@[-F])D<-#<0FYV1NWRLTJO=,KB12RD!47:Y. !BOSE^%_P#P4^^
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M**8!1110 4444 %%%% !1110 4444 %%%% !7XL_'_\ Y3:?L(_]FU_M(?\
MIBU2OVFK\6?C_P#\IM/V$?\ LVO]I#_TQ:I0!A_M?_\ *:'_ ()=?]D-_; _
M]2/X%5^V\/5_HW\HZ_$C]K__ )30_P#!+K_LAO[8'_J1_ JOVWAZO]&_E'0M
MQK=>J_-%&<97!Z$PC_QROY.O^"D>S_AK#Q]N? _LFR=B "=J*$X!.#D9//\
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M<>R^?Y^?DU]HD>NZGX;\.7UQ.MEKFOQ:1<P))&L,]K+,J3QRI+'(FV>+S(Y
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MK6QC;RU*X"K*^0><8(R<@'VKRK4/C#\5-6D=;OQOKERC+\WD7'E18&XOL5"
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MCY&R4! R""/,)*DX)^0#!X&3ZFORL_;V_P"2@>&N%#)I37!9$6,N93$C1DJ
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M71#KE]$J237$]U$;'SD8%_+@+OD-T8EL8(P.M>QV]W\)O"TI_L[_ (172VC
M!$&EQRSD#[JAD5N>@!!W<<XY%<)HWQ>_9UU5;F#3O'W@F^:UN_L4D=UXBMH8
MI+HQ-*8[9I)PLJ*%VY#$DX'M73^'_&_P&UFV6^TOQ/\ #B2(+,I:X\1:'&MM
M>6TI2XBD6>]CF^4@MG:..0Q7FOHJ>%RV--24ETM:'7INT^F]DM.IK9KJOO\
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M/%#?$CQMH$WAG1+OP]\-IIK^PTS3_ 5O?W6HWAAM+G:L=\+FYFO40WWFD0/
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M>/KGX&S+X8N9OAO!XMTRVO\ 5H=.ANH[C2;:ZBU$2Q^5//!.2"#)% Q?+ 4
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M2.?EZY/J!["IFN854^0H+XPK'KU&>F!RN>,8P>]9OEJ1P #N.#CH 3@?F*>
M%4#&2!^/OC_/],>75IREK%)I6>Z3TY>GR?W'P>)A)XJM)6TYWNKW6NW]>19^
MW7:J5CF:)7R"D9V@D\9R,$8/IQGV-4)8O-:.61G+Q='+EG;(QR2?QX(Z<@U)
MGG(#<$G[OJ /4?7\:/KD#IR,#H>>O)SS]>XK'DDM7&Z6K6CNENK=?Q(7LHPE
M4JTY3<(N:I^S<E/E5^1]+/T?IL,R<J0S;NF2>HPV5(Y7!X'(Z9Y%3RL9,VYV
MA)!A@ !C:%DW XX.1M.?X6-1A 2!D\YYZ#.TX.>W!/KG^3YAY;JP)9LL,$
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M7\V3S)')^SK$OFNX6)Y ,,59:3_"KXA6R1'_ (07Q )X1;QZ?!-IDD\3S1K
MM_<W#!=\LES#:V4VQI!%'<P>=#$AD8-]BYX]JSPLXK2[47_EU_0Z7)I>ZG?T
MMZ[GX]ZM^QK\==8U'PWXUOM7\/:9XH\/Z-I.DOX%MM2U'[/J]_HS"RU*Q>[6
MZ-P\5S+:"24FX!*2'+!N1XU'_P $XOCI+JWBZ^U7Q_I^CV_C+Q5_PD-A8:#K
M>KVT/@4W$D;ZAX:B7[8Z/$ZQ@>9<B:=S.<S$*,?NK+X)\964I5_"WB7[/;_:
M5LQ<Z3<R7!6ZGGN9[IYXA&WVA[NXN@&5EPB1@K\ISE'PUXBMT\L>%=:*R?\
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M]IC3O#,DTEWKFDV]['96\L4-S]O$FH"R22+-U$;^41NL8B8QQY5OF)9\2?\
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M9XXU2\O-'MKS1_%UT)W_ +/U!M9NX[@7HB1_-ETV\A265FV02XPH!^8^@?\
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M9FRU/1]*EL'NM(U:]_L\R1_:K:YW7DUO!G_"7_@G%^T<?#?CKP1\<OASXO\
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MOPLCMO#_ ,/;Z]O](TVRGM+.WU/[?<R75WI_BAXM.6;Q%I<TLH*V=^[);B"
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M'_J1_ JOVWAZO]&_E'7XD?M?_P#*:'_@EU_V0W]L#_U(_@57[;P\%_HW\HZ
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M_P!!B;_P$E_^*I/^&DOAN>?[8EYY_P"/)^__  *CZCB?^?;_ !_R&LDS-_\
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MKF5M+G]#=1;#ZC]?\*\!;]I#X;@976)O8M9-@_DWX_3--_X:0^&O_06E_P#
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M=?\ 9#?VP/\ U(_@57[<0<EAZ[OY1T 4KY%>V>(LX&0/W;%2,[3G(Y')S_\
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M'FF^"O#-C?> 6T:ROO$6H7VEI<K?7'^DJ=,M-0NX)5M[V=6+QK;NL@B@FD3
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MHYH?SP_\"_X!3=-)OVM)V5[*3O\ ^DHDHIN3_?M_^^F_^+HR?[]O_P!]-_\
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MY@9LZ1PN'BG>%;5]%'_Y,G^PLI_Y_P!;[X__ "9^97@?_@F7X9\+6D%KK/Q
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M?XG:-XD/A'Q?;Z=!:W5XEN)+2ZEC79O\EY!#*X7  VJ6[.&.\?ME=ND%O*[
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M3TL#_*I5_P""?7P:.=NH^)P<=5U.&3TZC[-!@>^YNGW>X^\6:3'"3'GO(/\
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M^?\ _P .\_A;_P!#%XC_ ._D/_Q='_#O/X6_]#%XC_[^0_\ Q=??A#\$+M#
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M9/\ #7_0=US_ ,"8_P#XW1_PR?X:_P"@[KG_ ($Q_P#QNOK+R1_SP;_OZO\
MC1Y(_P">#?\ ?U?\:?\ ;^=_\_J?_@4__D _UGSS_H)7_@3_ /D#Y-_X9/\
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MC.[.D N%D8(, DEL5]1[%]/U/^- ;[GQ9_PQ!\/O^BE?'7_PZOB?_P"2:/\
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M;&<<LS,2.I)/:KBIP-W+<Y.2>_'/?C% 'Q;_ ,,0?#[_ **5\=?_  ZOB?\
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M7QU_\.KXG_\ DFOM/8OI^I_QHV+Z?J?\: /BS_AB#X??]%*^.O\ X=7Q/_\
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MRV7;EF)]3G&3C/UJW7XK#_@LK".G_!.;_@HZ/I\,/@@/_>\TO_#Y6+_I'/\
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MU^+H_P""RL0&!_P3F_X*/ >@^&'P0 _]7S1_P^5B_P"D<_\ P4>_\-A\$/\
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1D>65W#JP9Y)&8$NQ)10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &# FP# 2(  A$! Q$!_\0
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M'\949_.DEB)21H=B3,N!(5SCT^M*.':W>EP==/9:_P##'-:8\NH7EG;2@_Z
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M>_<UZ***] XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME+DV9T'6E%8.H7-Q-JD%C!<- #$9'=0"3Z#FJ:ZC=7&G6WFRR(%G:*>6(<X
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M S^%4+0>&=1^S3Q,BLP\U$9RI."3DCZYJRL&A'1[TPW"K;7 ,<TV\D\\8R:
M&/XLABM5GEM)HSO"R(S % <8/OU%*_BF*...9[218GE,88N.@.,X^M9C'PJK
MPV$S\(I99&D)W ;>I_+BM)[;P[=LD1DB)MV"A1(1@DY /KS0 ^;Q.D-E)>&S
ME^SJ3L<L ' SDC\NE.;Q3:H9V>&18H8?-WDCYAQT'XU3NH/"QW1SSQ#>2P7S
M3QG(('IGGBM*VT;2)HQ<01B2*6+8IWDKM/IZ4 )I.NQZI<"..)H_W6]E;J#N
MQU[UMU0L]+M+!E:"/#!-FXDDD9S_ #J_0 4444 %%%% !1110 4444 %%%%
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MDG^M:NFV*Z=816J.76,8#'O5RB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHK'U:]OK2:'[*(60AF=7!S@#/:@
M#8HK&T;4I+^SDFN#%E&Y:,G:1C/Z5:&K6!M4N3=1K"^=K,V,XZT 7Z*RXM>T
MR9%>.[C8,0%P?O'VI9]3BC1V>>*!$(#EFR5STR.U%@+\DJQ#YC]!W-0XFFZY
MCC]!]XU'%):*Z?Z0CRR#*DN"6'M3?[8T[[1Y O(3)M+X#C@#K3 NQQI$N$
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MCU-+L4<L<GU-*X 9%[9/TI/,/9&-+O0=Q1YJ^M(#"N]*%RFHE[;Y[E0J8 &
M/7\>:@UW4-4MK.VAT^SD:X8@L 1PB]?SJSJ&G7-W<7<D,TBK+;A% ?&'!S2:
M[J\^DFQCC6,O-N#,X)QM7/:JN!@ZAX@U2Z@66"YBME$Z@PA"7V>I/H:GM-?U
M&)=YMXS&RLJC:=V0H.2?3FKD?B:R"6YN;8*9H=Y90#R!G&/PJM>>,ELKF2*?
M3&C C5DR1EF8XQ^5*4E%78[-[#9?$=]&\$IFAV@,"H4XGP1]WWYJJWC2ZDN[
MFWB6-4!&V9T.$!.#FE/B2WN&REF\FTJ$X Y(S@>F!5>;Q' (+A[>S$T@R0N
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MU0"_(/[M&Y?44!$'\(K+UZ[EL=/,UL\:2 \;ESN]J &:A-J8U.Q6SC#6>_\
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M:/1O#?\ R ;7_=K6K,T*&2WT:VCE7:X7D'M6G7I45:G%/L>?/XF02VL4OWD
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MB@ HHHH ***3<#W% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.T@#?=R2%ZT ='17/'Q;I?FQ(&DV2*S%RA 7 !Y^N:G7Q'IC*K+,QW(7X0\
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M$EW'+*-IY&#^9ZT[_A'M.&X+?.CAU"R;E&T8.%'YUGMX1N"MQ&K6X<G*JLC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<Z?%
M-FLMQ$MO<N\$ACP$^_CJ5R>0,4 =%14,,R31I(C JZAU^AJ0,&&001[4 .HH
MHH **** "BBB@ II13U IU% #/+3<&VC(Z''2L77M#;6'M'1X0;=F.V9"RMD
M8[$5H7.H16MU#!(DI:8X4JF1GZU;R <$C)[4@.1/A&?S[=A?(T4$>Q4:/K\I
M&.O(YJ6/PK*MLJ/>!G52%^3Y0<@@=>1Q75 @\@YI:8'(Q>$9XU>3[9"9V??C
MR?W><G/RY]ZM+X4B &958@YRT8)^YMKI*2@+G)6_A>5-S>:JO$Z&'S%WJ=HP
M21Z&G2>%))'=C=1]2Z8B_B)!.?4<<"NJR,$Y''6G4 <_H^@W&FZG=7D]VLQF
M7: $VXYSZUT%)D'O5>\NTLK=IY%=E7KL7)H LT5!#.DUNDXRJ,NX;ACCWIRS
M1L,K(A'LU $M%("#R#D49&<9&: %HI 01D'(HR,XSS0 M%%% !1110 454O+
MZ*PA$LP<J3CY%+5%:ZK:WMP\,3-O50WS*1D>HH T**C#HS%0REAU /(I^0:
M%HI"0.IQ2T %%("",@Y%+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M2W-VLEQ+/&LN#($P-N,\?3I^==[1185S@VM/$*VDBB2Z6Z$($>T#RPN.0?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H!<L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5G;O((EDE. 7() _('\JP?\ A:G@;_H9K'_OH_X4 =A17'_\+4\#?]#-8_\
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MH#3M4:*Q\41)IUT?E%W'DP.?]H=4_4>XKV>*6.:))8G62-P&5T.0P/0@]Z^
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M/YO7T10!\P?M'_\ )0=/_P"P5'_Z-EKQ^O8/VC_^2@Z?_P!@J/\ ]&RUX_0
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MK<)BX8F%X[]4/HHHK(["GJW_ "!K[_KWD_\ 037@)ZU[]JW_ "!K[_KWD_\
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M,^KRW2P@[;:TFNI6[*J(3S]3@?C0!GT444 ?5_P!_P"27P?]?<W\Q7J%>7_
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M/_DGGAK_ +!5K_Z*6OB"OM_P'_R3SPU_V"K7_P!%+0!T%%%% !1110 4444
M%%%% !7C'[2/_(F:5_V$!_Z+>O9Z\8_:1_Y$S2O^P@/_ $6] 'S/1110![O^
MS1_R$O$/_7&#^;U]$5\[_LT?\A+Q#_UQ@_F]?1% 'S!^T?\ \E!T_P#[!4?_
M *-EKQ^O8/VC_P#DH.G_ /8*C_\ 1LM>/T %%26\$MU<Q6\"%Y97"(HZEB<
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M8LI OMZ_4_X5Z1XYU$Z=X7GV-B2X(@7\>OZ UXS7=A8?;9\YG.(=U17J_P!
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MCY) ]@VX?A7,Z S)XCTME)#+=Q$$=CO%?0W[1'AO[=X7LM?A3,NGR>7,0/\
MED^ "?HV/^^C0!\T5U'P[\2'PKX[TO5&?;;B7RKCGCRG^5L_3.?J!7+T4 ??
MX((!'0T5P_PD\2_\)-\.].GD??=6J_9+@DY.Y  "?<KM/XUW% !1110 4444
M %%%% !7S[^T?XDW2Z7X:A?A0;RX /<Y5!^6\_B*^@)'2*-I)&"HH+,Q.  .
MIKXA\;>(7\4^,M4UAB=EQ,?*!_AC'RH/^^0* ,"I+>"6ZN8K>!"\TKA$0=68
MG 'YU'7IGP,\-_V[\0X+N5-UMI:&Z?/0OT0?7)W?\!H U/C9H47AG0_!>C0X
MQ:VDJ,P_B?*%F_%B3^->/U[G^TK(QUK08_X5MY&'U+#_  %>&4 6+'_D(6W_
M %U7^8K[V7[H^E?!-C_R$+;_ *ZK_,5][+]T?2@!:*** "BBB@ KRSXDZI]H
MU>'3T;*6R;G_ -]N?Y8_,UZ;=7,=G:37,IQ'$A=C[ 9KP.^NY+^_GNY3\\TA
M<_B:Z\+"\N;L>)G%?EI*FNOY+_@E>BBKVC:>VJZQ:V*Y_>R ,1V7J3^0->@W
M979\Q&+E)16[/4O!>C);^$A'.G-\I>0>JL, ?]\_SKRC4;-]/U&XLY/O0R%#
M[X/6O?T18XU1%"JH  '0"O+?B3IOV?68;]!\ETF&_P!Y>/Y8KAP]2]1WZGT6
M9850PT''[.G]?,XFK^BZ@VE:S:WH)Q%("V.Z]"/R)JA17<U=69\[&3C)26Z/
MHA'61%=2"K#(([BG5S7@74_[1\,P*S9EMOW+?0=/TQ72UXTH\LFC[VC456FI
MKJ@HHHJ34**** //?BC.1%IL /!:1R/I@#^9KS>O0OBD#YNF-C@K(,_]\UY[
M7JX?^&CXS,VWBI?+\@KTKX71*+749<?,71?P /\ C7FM>A?"^\42W]DQ^9@L
MJCUQP?YBC$?PV&6-+%1OY_D>D4445Y1]F%%%% !1110 4444 %><?$_3P)++
M45'W@87/TY7^OY5Z/7+_ ! MQ-X2G<C_ %,B2#\]O_LU;496J(X<PIJIAIKL
MK_<>.T45,EI<R?<MY6_W4)KUCXI)O8]1^&U^;C0)+1C\UM*0/]UN1^NZNSKS
M7X<07UGJUU'/:7$4,L(.YXF W \#)'H37I5>37251V/M,NFY8:/-NM/N*>K?
M\@:^_P"O>3_T$UX">M>_:M_R!K[_ *]Y/_037@)ZUTX39GDYW\</1_F%;/A3
M_D:M._Z["L:MGPI_R-6G?]=A77/X6>-0_BQ]5^9[C1117BGWP4444 %%%% $
M5U<QV=I-<RG$<2%V/L!FO K^[DO[^XNY3\\TA<_B:]0^(VJ?9-#2R1L27;X.
M/[B\G]<?K7D]>AA86BY=SY?.:_-45)=/S?\ P J_HFG'5=9M;(9Q+( V.RCD
M_H#5"O0/AEIF^XNM3=>$'DQGW/)_I^==%6?)!L\W"4?;5HP_JQM?$'2A<^&U
MGB0;K-@1@?P'@C^7Y5Y+7T+=6\=W:S6THS'*A1A[$8KP&]M9+&^GM91AXG*'
M\#7/A9WBXGI9S1Y:D:BZZ?=_P""O0?AEJ>V:[TQVX<>=&/<<-_3\J\^K0T/4
M3I6MVEZ"=L<@WX_NG@_H3715ASP:/-P=;V-:,^GZ'O5%(K!U#*001D$4M>.?
M=!1110 4444 %%%% !1110 4444 %>?_ !M_Y)#KO_;O_P"E$=>@5Y_\;?\
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M;_U]1?\ H8K[?UW2(-?\/WVDW(_=7<#1$X^[D<$>X.#^%?#-C_R$+;_KJO\
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ME$GQ#LU QY>FQJ??]Y(?ZUY%0!8L?^0A;?\ 75?YBOO9?NCZ5\$V/_(0MO\
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M4ODXSSY3?,A_]"7_ (#0,]5HHHH \@_:._Y)Y8?]A6/_ -%2U\OU]0?M'?\
M)/+#_L*Q_P#HJ6OE^@ HHHH **** "BBB@ HHHH **** "BM32_#6N:V0-+T
M>^O ?XH(&91]2!@5Z)X?_9_\6:HZOJK6^D0'KYCB63'LJG'YL* /*%4NP502
MQ.  .2:]Y^%'P5F>>'7O%EKLB3#VVG2CYG/9I1V'HIZ]^.#Z7X,^$WACP8R7
M-O;F\U%?^7RZPS*?]@=%^HY]Z[J@  P,"BBB@#X [T59U"#[-J5U!MV^5,Z8
M!Z8)%5J "OL_X5<_"[P]_P!>H_F:^,*^PO@O.L_PFT,C *+*A&<X(E<?_7_&
M@#O:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^./C#_P E
M7U[_ *ZI_P"BUKAZ[CXP_P#)5]>_ZZI_Z+6N'H *^W_ ?_)//#7_ &"K7_T4
MM?$%?;_@/_DGGAK_ +!5K_Z*6@#H**** "BBB@ HHHH **** "O&/VD?^1,T
MK_L(#_T6]>SUXQ^TC_R)FE?]A ?^BWH ^9Z*** /=_V:/^0EXA_ZXP?S>OHB
MOG?]FC_D)>(?^N,'\WKZ(H ^8/VC_P#DH.G_ /8*C_\ 1LM>/U[!^T?_ ,E!
MT_\ [!4?_HV6O'Z "OON"59K>.500KJ&&>N"*^!*^]M._P"09:_]<4_D* +-
M?/'[1WAKRKS3/$L,>%F'V2X('\0RR$^Y&X?\!%?0]<Q\0_#@\5>!=4TM4W7#
M1&2W]?-3YE'XD8^A- 'Q/3X9I+>>.>%RDL;!T8=5(.0:8002#U%% 'W+X1UZ
M/Q/X3TS68\?Z5 K.!T5QPX_!@1^%;5>$?LX^)/.L-3\-S/\ - WVJW!/\#<.
M![ [3_P(U[O0 4444 %?'?Q?\2?\)+\1=0EC?=:V9^R08/&U"<D?5BQ_&OIW
MXA>(QX5\#:IJJOMG2(QV_//FM\J_D3GZ U\4$EF+$Y).230 E==\,O#7_"5>
M/],L'3?;))]HN<CCRTY(/L3A?^!5R-?1W[.7AO[-HVH^(YDQ)=O]G@)'_+-.
M6(]BW'_ * /<:*** /EG]H?_ )*1%_V#XO\ T)Z\FKU'X_?\E/E_Z](?Y&O+
MJ +%C_R$+;_KJO\ ,5][+]T?2O@FQ_Y"%M_UU7^8K[V7[H^E "T444 (S*B,
M[$!5&23V%>#:YJ3:MK5W>G.)'.P'LHX4?D!7JOCK5/[-\-3(C8ENCY*_0_>/
MY9'XUXU7?A8:.1\UG->\HTETU?Z!3HXWFE2.,;G=@J@=R:;74> =,_M#Q+'*
MZYBM5\T_[W1?UY_"NN<N6+9XM&DZM2,%U9ZKI-@FEZ3:V28Q#&%)'<]S^)R:
MNT45XS=W=GWL8J*45L@HHHI% 1D8->$^(M-_LG7[RS (17S'_NGD?H:]VKSG
MXG:;\UGJ:#@_N)#^J_\ LU=6&G:=NYY&;T>>ASK>/Y'G=.C=HI%D1BKJ0RD=
MB*;17I'R1[YH^H+JFD6MZO\ RUC!(]&[C\\U>K@?AEJ?F6=UIKM\T3>;&/\
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M 'V/EJ?ZUYO0!8L?^0A;?]=5_F*^]E^Z/I7P38_\A"V_ZZK_ #%?>R_='TH
M6BBJVH7L>G:=<7DOW(8RY'KCM^-"5]!-I*[/+OB+JGVW7Q9HV8K1=O\ P,\G
M^@_"N/J6XGDNKF6XE;=)*Y=CZDG)J*O9A'EBHGP6(JNM5E4?4*U=(\0ZCH:R
MK82I'YI!<F,,3CIU^IK*HJFDU9D0G*#YHNS.G_X6!XB_Y^X_^_*_X4?\+ \1
M?\_<?_?E?\*YBBH]E#L;_7,1_._O.G_X6!XB_P"?N/\ [\K_ (4?\+ \1?\
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M=LG979\_3@YS4%NRY'X#\02Q)(MHFU@",RJ#_.G_ /"O_$7_ #Z1_P#?Y?\
M&O8^E%>=]:F?4?V-A^[_ *^1XY_PK_Q%_P ^D?\ W^7_ !H_X5_XB_Y](_\
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M/M4Q9%/54'"+^"@#\*]@^.GQ,BN4D\(Z-.'0-_Q,)T/!(/$0/L>6^@'K7@E
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M* ,?Q3JG]D>';JY5L2E?+B]=S<#\N3^%>'5WOQ,U3S;VVTR-OEA7S9 /[QZ
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MUO1-.\1Z//I.K6_VBQGV^9%O9-VU@PY4@CD \&@#X0HKZ_\ ^%)?#S_H7O\
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ML[$DDS-R?SK>C.,)7D>?F&'JUZ:IT[>9XU17L?\ PK_P[_SZ2?\ ?YO\:/\
MA7_AW_GTD_[_ #?XUU_6H'A_V-B.Z^__ (!3^'&F?9-#DO77$EV^1_N+P/US
M79U%:VT5G:Q6T";(HE"(OH!4M<$Y<TG(^EP]%4:4::Z!1114&X4444 %%%%
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M*@]]#PZF3UX_ T_P/*J*[VX^%]ZN?L^HP2?]=$*?RS5"3X<:ZAPOV5_=9?\
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MT)QL:X'+Z^'K*;:MU_JQKT445Q'OA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex4-4_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-4_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M .\# 2(  A$! Q$!_\0
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MX@6NFW>_[/<WWER;#@X+=C7J?C7X)Z3I_AR\U/1+FZ2>TB:9HIG#K(JC) .
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MWTSQ/;(?^/B2VN\=OF^1OYC\J]$\/_%06/P?N4DF']LV(%G;@GYF##Y'_P"
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E>1_\*$TO_H8-4_\ '?\ "C_A0FE_]#!JG_CO^%>N446079__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H!<L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5G;O((EDE. 7() _('\JP?\ A:G@;_H9K'_OH_X4 =A17'_\+4\#?]#-8_\
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MH#3M4:*Q\41)IUT?E%W'DP.?]H=4_4>XKV>*6.:))8G62-P&5T.0P/0@]Z^
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M/YO7T10!\P?M'_\ )0=/_P"P5'_Z-EKQ^O8/VC_^2@Z?_P!@J/\ ]&RUX_0
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MK<)BX8F%X[]4/HHHK(["GJW_ "!K[_KWD_\ 037@)ZU[]JW_ "!K[_KWD_\
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M,^KRW2P@[;:TFNI6[*J(3S]3@?C0!GT444 ?5_P!_P"27P?]?<W\Q7J%>7_
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M/_DGGAK_ +!5K_Z*6OB"OM_P'_R3SPU_V"K7_P!%+0!T%%%% !1110 4444
M%%%% !7C'[2/_(F:5_V$!_Z+>O9Z\8_:1_Y$S2O^P@/_ $6] 'S/1110![O^
MS1_R$O$/_7&#^;U]$5\[_LT?\A+Q#_UQ@_F]?1% 'S!^T?\ \E!T_P#[!4?_
M *-EKQ^O8/VC_P#DH.G_ /8*C_\ 1LM>/T %%26\$MU<Q6\"%Y97"(HZEB<
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M8LI OMZ_4_X5Z1XYU$Z=X7GV-B2X(@7\>OZ UXS7=A8?;9\YG.(=U17J_P!
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MCY) ]@VX?A7,Z S)XCTME)#+=Q$$=CO%?0W[1'AO[=X7LM?A3,NGR>7,0/\
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M=!1110 4444 %%%% !1110 4444 %>?_ !M_Y)#KO_;O_P"E$=>@5Y_\;?\
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M;_U]1?\ H8K[?UW2(-?\/WVDW(_=7<#1$X^[D<$>X.#^%?#-C_R$+;_KJO\
M,5][#[H^E 'P3J%C/IFHW-A=)LN+:5H9%/9E."/S%5Z]8^/WAK^Q_'2ZK$FV
MVU6+S,@<>:N%<?\ H+?5C7D] 'M'[.WB7[#XGO- F?$6H1>9""?^6J9) ^JY
M_P"^17TO7PAH.KSZ!K]AJUL?WMI.LH&?O8/(/L1D?C7W/87L&I:=;7UL^^"Y
MB66-O56&1^AH L4444 %%%% !1110!YY\:O$G_"/?#J\2)]MUJ)^QQ8Z@-]\
M_P#?((_$5\AUZY^T%XD_M7QM%I$3Y@TN+:P'3S7PS?IL'X&O(Z "OJSX"^&O
M[%\!#494VW.JR>>2>OECA!_-O^!5\S>'-%F\1>(]/TB#/F7<ZQ9'\()Y;\!D
M_A7W+9VD-A8P6=N@2""-8HT'1548 _(4 ?.O[2<BGQ)HL>?F6T9B/8N<?R->
M(U[3^TE_R.&D_P#7A_[4:O%J +%C_P A"V_ZZK_,5][+]T?2O@FQ_P"0A;?]
M=5_F*^]E^Z/I0 M%%% !1110!QGQ'U3[)H:6*-B2[?G']Q>3^N/UKRBNC\;Z
MI_:?B6?:V8;?]RGX=3^>?TKG*]:A#E@CXK,*_ML1)K9:+Y!7?_#+3/,NKK4W
M7B,>3&?]H\G],?G7 5[EX6TS^R?#MI;,N)2N^3_>;D_ET_"HQ,^6%NYOE-'V
ME?F>T=?\C8KF_'.F_P!H^&+@JN9;?]\OX?>_3/Y5TE-=%D1D<!E88(/<5YT9
M<LDSZFM356FX/JCYWHJ]K.GMI>L7=DV?W4A"D]U['\L51KV4[JZ/@I1<9.+W
M1V?PXU/[+KDED[8CNDXY_C7D?IG]*]7KY\L[J2QO8+J(_O(7#K^!KWVTN8[R
MSAN8CF.5 ZGV(S7GXJ%I*7<^FR:MS4W3?3\G_P $FHHHKD/<"BBB@#B?B99F
M;1+:Z49,$V#[!A_B!7E=>_ZI81ZIIEQ8R_<F0KGT/8_@<&O![VSFL+V:TN$*
MRQ,585Z.%G>/+V/ELXHN-55>C_-$%7=)U.?1]3AOK?[\9Y4]&'<&J5%=35U9
MGC1DXM2CNCWG1=:M-<L%NK1_9XS]Y#Z&M&OG_3]2O-+NA<64[PRCNO0CT(Z$
M5WVE?$U"H35;0JW_ #UM^0?JI_QKSZF&DG>.J/J,+FU.:4:VC_#_ (!Z%165
M8>)-'U/ M=0A9ST1FVM^1P:U:Y6FMSUX3C-7B[A1112+"BBB@ ILD:2H4D17
M0]589!IU% #4C2/.Q%7/7 Q3J** "BBB@"GJW_(&OO\ KWD_]!-> GK7OVK?
M\@:^_P"O>3_T$UX">M=^$V9\UG?QP]'^85L^%/\ D:M._P"NPK&K9\*?\C5I
MW_785US^%GC4/XL?5?F>XT445XI]\%%%% !116;K^I#2-#N[S.'1,)_O'@?J
M::5W9$SDH1<GLCRKQQJG]I^)9PK9BM_W*?AU/YYKG*5F+,6)R2<DFDKV8QY4
MDCX&K4=6HYOJ%>Y^&-,_LGP]:6Q7$FS?)_O'D_X?A7E'A'3/[5\26L)7,<;>
M;)_NKS^IP/QKVZN/%SVB>_DM'XJK]%^H5Y/\1]-^RZZEX@PETF3_ +R\'],?
MG7K%<QX]TW^T/#4LB+F6U(E7UQT;].?PKGH3Y9H]',:/M</)+=:_<>.4445Z
MQ\6>S^!]3_M+PS!N;,MO^Y?\.GZ8KHZ\J^&^I_9M:EL7;"7297_?7G^6?RKU
M6O)KPY9L^UR^M[7#Q;W6GW!1116)WA1110 4444 %%%% !1110 5Y_\ &W_D
MD.N_]N__ *41UZ!7G_QM_P"20Z[_ -N__I1'0!\@4444 ?4_[//_ "363_L(
M2_\ H*5ZI/!'<V\D$R!XI5*.IZ,I&"*\F_9SD9_AU>*>B:I(H^GEQ'^IKUV@
M#X9\6:#)X9\5ZGHTN<VD[(A/5DZHWXJ0?QK&KW7]H[PWY&I:9XDA3"7"_9+@
MC^^N2A^I7</^ 5X50!Z9\#/$G]A?$."TE?;;:HGV5P3QOZQGZ[AM_P"!5]9U
M\"03RVMQ%<0.8YHG#HZ]58'((_&ON/PKKL7B;PKINLQ8 NX%=E'17Z,OX,"/
MPH V**** "BBB@ KY8^/_B3^U_'2Z5$^ZWTJ+R\ \>:^&<_EL'U4U]+Z[J\&
M@:#?ZM<_ZFS@:9AG&[ R /<G _&OAB_O9]3U&YO[I]]Q<RM-*WJS$DG\S0!7
MK6\,:'-XE\3Z=HT&0UW.L98?PKU9OP4$_A637N/[.7AK[3K.H^(YH\QVB?9H
M"1_RT?EB/<+@?\#H ^B;:VAL[6&UMT$<,*+'&B]%4#  _ 5PGQM_Y)#KO_;O
M_P"E$=>@5YS\=&9?A/J8!(#2P ^X\U3_ $H ^1J*** /J_X _P#)+X/^ON;^
M8KU"O+_@#_R2^#_K[F_F*]0H **** . ^,GB7_A&_AS?&-]MU?\ ^APX//S@
M[C^"!N?7%?']>O\ [0GB7^U/&4&BPOFWTN+YP#P9GPS?DNP>QS7D% !7JGP#
M\-_VSX^_M*5-UMI41F)/3S&RJ#_T)O\ @->5U]9? KPW_8?P\AO)4VW.J.;I
MLCD)TC'TP-W_  *@#TVBBB@ KY4^/GAW^Q_'YU&)-MOJL0F!'3S%^5Q_Z"W_
M  *OJNO+OCSX=_MGX?/?Q1[KG2Y1< CKY9^5Q],$-_P&@#Y1HHHH ^PO@[XC
M_P"$C^'&GO(^ZYLA]CFR<G*8VG\5*G\Z[VOF7]G?Q']@\5WFA3/B+48M\0)_
MY:QY/'U4M^0KZ:H **** /(/VCO^2>6'_85C_P#14M?+]?4'[1W_ "3RP_["
ML?\ Z*EKY?H *^A_V:/^0?XB_P"NL'\GKYXKV;X'>.O#?@^SUJ/7M1^R-<R1
M-$/(DDW!0V?N*<=1UH ^F:*\_P#^%V_#S_H8?_)*X_\ C='_  NWX>?]##_Y
M)7'_ ,;H ] HKS__ (7;\//^AA_\DKC_ .-T?\+M^'G_ $,/_DE<?_&Z /0*
M*\__ .%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;H ] HKSF?XY^ (1
ME-7FGXSB.SE'X?,HKG-5_:/\/VZ,-+TB_O)!T,Q6%#^.6/Z4 >TUX3\:/BQ;
M1V-QX6\/W(EN)@8[ZZC.5C3H8U/=CT)[#(ZGCSKQ;\9_%?BJ*2U6=--L'X:"
MSRI<>C.>3^& ?2O.Z "BBB@#H/ _AU_%7C/2](528YI@9B!]V)>7/_?(/XXK
M[>50JA5   P .U>/_ CP#)H&C2>(M2A*:AJ"!8488,4'7GW8@'Z >]>PT ?$
MGQ!O3J'Q$\0W!.0;^9%/^RK%1^@%<W5K4YOM&JWD^5/F3N^5Z'+$\55H *^K
M_@#9"U^%\,V,?:[N:;IUP0G_ +)7RA7V/\'H?(^%&@)MVYB=\?[TCMG]: .X
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XX^,/_)5]>_Z
MZI_Z+6N'KN/C#_R5?7O^NJ?^BUKAZ "OM_P'_P D\\-?]@JU_P#12U\05]O^
M _\ DGGAK_L%6O\ Z*6@#H**** "BBB@ HHHH **** "O&/VD?\ D3-*_P"P
M@/\ T6]>SUXQ^TC_ ,B9I7_80'_HMZ /F>BBB@#W?]FC_D)>(?\ KC!_-Z^B
M*^=_V:/^0EXA_P"N,'\WKZ(H ^8/VC_^2@Z?_P!@J/\ ]&RUX_7L'[1__)0=
M/_[!4?\ Z-EKQ^@":T=8[V!W.%6123Z#-?? ^Z/I7P#7W\OW1]* /./C?X:_
MM_X=W-Q$FZZTQOM<9 YV@8<?3:2?^ BODBOOR:&.X@DAF0/%(I1T89# C!!K
MX>\7Z!)X7\6ZGHTF<6TY6,MU9#RA_%2#0!B5]4? +Q)_;'@0Z7*^ZYTJ7RL$
M\F)LLA_]"7_@-?*]>D_ _P 2?V!\1+:WE?;:ZFIM7R>-YY0_7<,?\"- 'UM1
M110 4444 %4-:U6#0]$OM5NC^YM(6F89QG S@>YZ?C5^O&_VA_$G]G^%+30H
M7Q-J4N^4 _\ +),'GZMM_P"^30!\W:GJ$^JZI=ZC=-NN+J9YI&]68DG^=5:*
M* /;?V=/#7VO7K_Q%,F8K*/R("1_RT?[Q'T7C_@=?25<;\+/#7_"+?#[3+*2
M/9<S)]IN 1@^8_.#[@87_@-=E0!\Q?M'LQ\?:<F3M&EH0/<RR_X"O':]=_:+
ME$GQ#LU QY>FQJ??]Y(?ZUY%0!8L?^0A;?\ 75?YBOO9?NCZ5\$V/_(0MO\
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M4ODXSSY3?,A_]"7_ (#0,]5HHHH \@_:._Y)Y8?]A6/_ -%2U\OU]0?M'?\
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MB*;17I'R1[YH^H+JFD6MZO\ RUC!(]&[C\\U>K@?AEJ?F6=UIKM\T3>;&/\
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M 'V/EJ?ZUYO0!8L?^0A;?]=5_F*^]E^Z/I7P38_\A"V_ZZK_ #%?>R_='TH
M6BBJVH7L>G:=<7DOW(8RY'KCM^-"5]!-I*[/+OB+JGVW7Q9HV8K1=O\ P,\G
M^@_"N/J6XGDNKF6XE;=)*Y=CZDG)J*O9A'EBHGP6(JNM5E4?4*U=(\0ZCH:R
MK82I'YI!<F,,3CIU^IK*HJFDU9D0G*#YHNS.G_X6!XB_Y^X_^_*_X4?\+ \1
M?\_<?_?E?\*YBBH]E#L;_7,1_._O.G_X6!XB_P"?N/\ [\K_ (4?\+ \1?\
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M=LG979\_3@YS4%NRY'X#\02Q)(MHFU@",RJ#_.G_ /"O_$7_ #Z1_P#?Y?\
M&O8^E%>=]:F?4?V-A^[_ *^1XY_PK_Q%_P ^D?\ W^7_ !H_X5_XB_Y](_\
MO\O^->QT4?6IC_L;#]W]_P#P#QS_ (5_XB_Y](_^_P O^-'_  K_ ,1?\^D?
M_?Y?\:]CHH^M3#^QL/W?W_\  /'/^%?^(O\ GTC_ ._R_P"-'_"O_$7_ #Z1
M_P#?Y?\ &O8Z*/K4P_L;#]W]_P#P#P'4],N](O&M+V/RY@ < @C!]Q5.O2?B
M;IFZ"TU-%Y0^3(?8\K_7\Z\VKNI3YXIGSN,H>PK.GTZ>@5[GX9U/^UO#]I=%
MLR;-DG^\.#_C7AE>@_#+4]LUWICMPX\Z,>XX;^GY5EB8<T+]CLRFM[.ORO:6
MGSZ'I-%%%>8?7!1110 4444 %%%% !7G_P ;?^20Z[_V[_\ I1'7H%>?_&W_
M ))#KO\ V[_^E$= 'R!1110!]"_LSR*;7Q+%@[E>V8^F")/\#7O5?/\ ^S+_
M ,S3_P!NG_M:OH"@ HHHH 9-#'<P203('BD4HZ-T92,$&OASQ;H,GACQ9J>C
M29_T6=D1CU9.J-^*D'\:^YJ^=OVCO#7DW^F>)84PLZ_9+@@<;URR'ZD;A_P$
M4 >$UZ9\#/$G]A?$."TE?;;:HGV5P3QOZQGZ[AM_X%7F=203RVMQ%<0.8YHG
M#HZ]58'((_&@#U'X^>)/[9\>_P!FQ/NMM*B\D8Z>:V&<_P#H*_\  :\JJ>]O
M)]0O[B]N7WW%Q*TLKG^)F.2?S-04 ;'A309?$_BO3-%BR#=SJC,.JIU=OP4$
M_A7W'!!%:V\5O @CAB0(B+T50, #\*^>?V<?#?GZEJ?B29,I;K]DMR?[[8+G
MZA=H_P"!U]%4 %%%% !7B7[2<C#PSHL8/RM>,Q'N$./YFO;:\-_:5D4:'H,9
M^\US*P^@49_F* /G*BBB@#ZO^ /_ "2^#_K[F_F*E^.?B7^P?AY/:1/MN=4;
M[*H'781F0_3:-O\ P(5%\ ?^27P?]?<W\Q7D7QZ\2_VWX^;3XGS;:5'Y P>#
M(>7/_H*_\!H \MHHHH ]'^"/AO\ M_XC6DTJ;K;35-Y)D<;E.$'UW$'_ (":
M^N*\E_9^\-_V3X'DU:5,7&JR[P2.?*3*J/SWG\17K5 !1110 5S/A_PG#HFM
M:E?#:1,^+<#^!#R1^?'T'O73452DTFEU,IT83E&<EK'8****DU"CJ,&BB@#X
MH^(GAW_A%_'FK:6J[8%F,D&.GE/\RC\ <?4&N7KZ"_:0\.YCTKQ)$G*DV=P0
M.W+(?_0Q^(KY]H .AR*^V/A[XB_X2KP)I6JL^Z=X1'<?]=4^5OS(S]"*^)Z]
M[_9O\1[)]5\-3/PX%Y;@^HPKC\MA_ T =+^T=_R3RP_["L?_ **EKY?KZ@_:
M._Y)Y8?]A6/_ -%2U\OT %?0_P"S1_R#_$7_ %U@_D]?/%?0_P"S1_R#_$7_
M %U@_D] 'O%%%% !1110 4444 %>=?&#P$/&?A9IK.('5]/!EML#F1?XH_QQ
MD>X'J:]%HH ^ 2""01@CJ#25Z_\ ';P#_8.N_P#"1:?#C3M1<^<JCB*?J?H&
MY/UW>U>04 36EW/8WD-W:RM%<0.)(Y%."K Y!'XU]F?#KQI;^.?"<&HJ56\C
MQ%>0C^"4#D@?W3U'UQV-?%M=M\+_ !U+X&\5Q7$CL=,NB(KV,<_)GAP/5>OT
MR.] 'V313(9H[B&.:&19(I%#HZ'(8'D$'N*?0 5\K?'?P<V@>,3K-O'BPU8F
M3@<),/OC\>&_$^E?5-<]XV\*6OC/PK=Z-<X5I!O@E(_U4H^ZW]#[$CO0!\0T
M5<U;2[S1-5NM,OX3#=VTACD0]B/3U!Z@]Q5.@#J/ 'C*Y\#^*K?5(@SVY_=7
M4(/^LB)Y'U'4>XK[,TS4K/6-,M]1L)UGM+A!)%(O0@_YZ5\%UZ5\*OBG<>![
MT6%^7GT*=\R(.6MV/\:>WJ._;GJ ?6M%5=.U&SU?3X;_ $^YCN;6==T<L9R&
M'^>W:K5 !1110 4444 %%%% !117!?$CXH:9X$L6A0I=:U*F8+0'[OH\F.B^
MW4]NY !A?&[XAIX;T)M!TZ8?VMJ$95RIY@A/!/L6Y _$^E?+57-5U6]UO5+C
M4M1N'GN[AR\DC'J?Z = .PJG0 5O>#/"]UXQ\4V>C6H8"5MTT@'^JC'WF/X=
M/4D#O6$B-(ZHBEG8X50,DGTKZV^#_P /!X*\/&ZOHQ_;-^H:?//DIU6,?S/O
M]!0!W^GV%MI>G6UA9Q"*VMHUBB0?PJ!@"K-%% 'SE^TGI+1ZYHVL*OR3V[6S
M$#H4;<,_4.?RKPVOL3XN^%6\5_#^\@MX]][:$75N .2R@[E'U4L,>N*^.Z "
MO<OV<O$J6VJZCX;GDP+M1<VP)ZNHPX'N5P?HAKPVK>EZG=Z-JMKJ5C*8KJVD
M$L3CL1_,>U 'WI17,^!?&EAXY\.1:E:,J3J EU;[LM#)W'T/4'N/QKIJ "BB
MB@ HHHH **** (;N[@L+.>[N9%CMX(VDD=NBJHR3^0KXA\7>()?%/BS4M:ER
M/M4Q9%/54'"+^"@#\*]@^.GQ,BN4D\(Z-.'0-_Q,)T/!(/$0/L>6^@'K7@E
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M* ,?Q3JG]D>';JY5L2E?+B]=S<#\N3^%>'5WOQ,U3S;VVTR-OEA7S9 /[QZ
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MUO1-.\1Z//I.K6_VBQGV^9%O9-VU@PY4@CD \&@#X0HKZ_\ ^%)?#S_H7O\
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ML[$DDS-R?SK>C.,)7D>?F&'JUZ:IT[>9XU17L?\ PK_P[_SZ2?\ ?YO\:/\
MA7_AW_GTD_[_ #?XUU_6H'A_V-B.Z^__ (!3^'&F?9-#DO77$EV^1_N+P/US
M79U%:VT5G:Q6T";(HE"(OH!4M<$Y<TG(^EP]%4:4::Z!1114&X4444 %%%%
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M*@]]#PZF3UX_ T_P/*J*[VX^%]ZN?L^HP2?]=$*?RS5"3X<:ZAPOV5_=9?\
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MT)QL:X'+Z^'K*;:MU_JQKT445Q'OA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>apm-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 09:10:53 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://aptorumgroup.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:apm="http://aptorumgroup.com/20231231" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="apm-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="apm-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="apm-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="apm-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://aptorumgroup.com/role/ConsolidatedBalanceSheet" id="apm_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals" id="apm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome" id="apm_r_ConsolidatedComprehensiveIncome">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ConsolidatedComprehensiveIncomeAlt0" id="apm_r_ConsolidatedComprehensiveIncomeAlt0">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ShareholdersEquityType2or3" id="apm_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ConsolidatedCashFlow" id="apm_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/Organization" id="apm_r_Organization">
        <link:definition>006 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/Liquidity" id="apm_r_Liquidity">
        <link:definition>007 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies" id="apm_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/Revenue" id="apm_r_Revenue">
        <link:definition>009 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/InvestmentandFairValueMeasurement" id="apm_r_InvestmentandFairValueMeasurement">
        <link:definition>010 - Disclosure - Investment and Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/OtherReceivablesandPrepayments" id="apm_r_OtherReceivablesandPrepayments">
        <link:definition>011 - Disclosure - Other Receivables and Prepayments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/PropertyandEquipmentNet" id="apm_r_PropertyandEquipmentNet">
        <link:definition>012 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/IntangibleAssetsNet" id="apm_r_IntangibleAssetsNet">
        <link:definition>013 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/LongTermDeposits" id="apm_r_LongTermDeposits">
        <link:definition>014 - Disclosure - Long-Term Deposits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/AccountsPayableandAccruedExpenses" id="apm_r_AccountsPayableandAccruedExpenses">
        <link:definition>015 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/IncomeTaxes" id="apm_r_IncomeTaxes">
        <link:definition>016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactions" id="apm_r_RelatedPartyBalancesandTransactions">
        <link:definition>017 - Disclosure - Related Party Balances and Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/VariableInterestEntity" id="apm_r_VariableInterestEntity">
        <link:definition>018 - Disclosure - Variable Interest Entity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/Lease" id="apm_r_Lease">
        <link:definition>019 - Disclosure - Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ConvertibleNote" id="apm_r_ConvertibleNote">
        <link:definition>020 - Disclosure - Convertible Note</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/OrdinaryShares" id="apm_r_OrdinaryShares">
        <link:definition>021 - Disclosure - Ordinary Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ShareBasedCompensation" id="apm_r_ShareBasedCompensation">
        <link:definition>022 - Disclosure - Share Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/NonControllingInterest" id="apm_r_NonControllingInterest">
        <link:definition>023 - Disclosure - Non-Controlling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/NetLossPerShare" id="apm_r_NetLossPerShare">
        <link:definition>024 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/CommitmentsandContingencies" id="apm_r_CommitmentsandContingencies">
        <link:definition>025 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/SegmentReporting" id="apm_r_SegmentReporting">
        <link:definition>026 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/SubsequentEvents" id="apm_r_SubsequentEvents">
        <link:definition>027 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/AccountingPoliciesByPolicy" id="apm_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/OrganizationTables" id="apm_r_OrganizationTables">
        <link:definition>996001 - Disclosure - Organization (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables" id="apm_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables" id="apm_r_InvestmentandFairValueMeasurementTables">
        <link:definition>996003 - Disclosure - Investment and Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables" id="apm_r_OtherReceivablesandPrepaymentsTables">
        <link:definition>996004 - Disclosure - Other Receivables and Prepayments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/PropertyandEquipmentNetTables" id="apm_r_PropertyandEquipmentNetTables">
        <link:definition>996005 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/IntangibleAssetsNetTables" id="apm_r_IntangibleAssetsNetTables">
        <link:definition>996006 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/LongTermDepositsTables" id="apm_r_LongTermDepositsTables">
        <link:definition>996007 - Disclosure - Long-Term Deposits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables" id="apm_r_AccountsPayableandAccruedExpensesTables">
        <link:definition>996008 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/IncomeTaxesTables" id="apm_r_IncomeTaxesTables">
        <link:definition>996009 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables" id="apm_r_RelatedPartyBalancesandTransactionsTables">
        <link:definition>996010 - Disclosure - Related Party Balances and Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/VariableInterestEntityTables" id="apm_r_VariableInterestEntityTables">
        <link:definition>996011 - Disclosure - Variable Interest Entity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/LeaseTables" id="apm_r_LeaseTables">
        <link:definition>996012 - Disclosure - Lease (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ShareBasedCompensationTables" id="apm_r_ShareBasedCompensationTables">
        <link:definition>996013 - Disclosure - Share Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/NetLossPerShareTables" id="apm_r_NetLossPerShareTables">
        <link:definition>996014 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/CommitmentsandContingenciesTables" id="apm_r_CommitmentsandContingenciesTables">
        <link:definition>996015 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable" id="apm_r_ScheduleofMajorSubsidiariesConsolidatedTable">
        <link:definition>996016 - Disclosure - Organization (Details) - Schedule of Major Subsidiaries Consolidated</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/LiquidityDetails" id="apm_r_LiquidityDetails">
        <link:definition>996017 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" id="apm_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996018 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable" id="apm_r_ScheduleofEstimatedUsefulLivesTable">
        <link:definition>996019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails" id="apm_r_InvestmentandFairValueMeasurementDetails">
        <link:definition>996020 - Disclosure - Investment and Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" id="apm_r_ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable">
        <link:definition>996021 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable" id="apm_r_ScheduleofFairValueReconciliationofLevel3AssetsTable">
        <link:definition>996022 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Fair Value Reconciliation of Level 3 Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable" id="apm_r_ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable">
        <link:definition>996023 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Quantitative Information about the Group&#8217;s Level 3 Fair Value Measurements of Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable" id="apm_r_ScheduleofUnrealizedGainsandLossesTable">
        <link:definition>996024 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Unrealized Gains and Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable" id="apm_r_ScheduleofCarryingValueofOurNonMarketableInvestmentsTable">
        <link:definition>996025 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Carrying Value of Our Non-Marketable Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsDetails" id="apm_r_OtherReceivablesandPrepaymentsDetails">
        <link:definition>996026 - Disclosure - Other Receivables and Prepayments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable" id="apm_r_ScheduleofOtherReceivablesandPrepaymentsTable">
        <link:definition>996027 - Disclosure - Other Receivables and Prepayments (Details) - Schedule of Other Receivables and Prepayments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/PropertyandEquipmentNetDetails" id="apm_r_PropertyandEquipmentNetDetails">
        <link:definition>996028 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable" id="apm_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996029 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/IntangibleAssetsNetDetails" id="apm_r_IntangibleAssetsNetDetails">
        <link:definition>996030 - Disclosure - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable" id="apm_r_ScheduleofIntangibleAssetsTable">
        <link:definition>996031 - Disclosure - Intangible Assets, Net (Details) - Schedule of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" id="apm_r_ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable">
        <link:definition>996032 - Disclosure - Intangible Assets, Net (Details) - Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable" id="apm_r_ScheduleofLongTermDepositsTable">
        <link:definition>996033 - Disclosure - Long-Term Deposits (Details) - Schedule of Long-Term Deposits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails" id="apm_r_AccountsPayableandAccruedExpensesDetails">
        <link:definition>996034 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" id="apm_r_ScheduleofAccountsPayableandAccruedExpensesTable">
        <link:definition>996035 - Disclosure - Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/IncomeTaxesDetails" id="apm_r_IncomeTaxesDetails">
        <link:definition>996036 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable" id="apm_r_ScheduleofProvisionforIncomeTaxesExpensesTable">
        <link:definition>996037 - Disclosure - Income Taxes (Details) - Schedule of Provision for Income Taxes Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" id="apm_r_ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable">
        <link:definition>996038 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals" id="apm_r_ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals">
        <link:definition>996039 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable" id="apm_r_ScheduleofDeferredTaxAssetandLiabilitiesTable">
        <link:definition>996040 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Asset and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable" id="apm_r_ScheduleofChangesinValuationAllowanceTable">
        <link:definition>996041 - Disclosure - Income Taxes (Details) - Schedule of Changes in Valuation Allowance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails" id="apm_r_RelatedPartyBalancesandTransactionsDetails">
        <link:definition>996042 - Disclosure - Related Party Balances and Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable" id="apm_r_ScheduleofAmountsDuefromRelatedPartiesTable">
        <link:definition>996043 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZk9BQMOWQfrm8jHnK3iPqh/RGOZRChD6nBq3dVwAwj4+/8SLuZTW/liOfKmyEBpRrTV6V//wh8natqXLVrpArUZiEOpCUQ4sWmUCqPSbJB1eeE0YXZR+qpcGF8VKslPcXkQ+inlG1l8YPuGFp3JEZ5VoAJF844sVddHhNq3xJYgqGGsxym9XDdtpNA6QbHCM8/tTkhsY9NGQ==] CSR-->
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable" id="apm_r_ScheduleofAmountsDuetoRelatedPartiesTable">
        <link:definition>996044 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable" id="apm_r_ScheduleofRelatedPartyTransactionsTable">
        <link:definition>996045 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/VariableInterestEntityDetails" id="apm_r_VariableInterestEntityDetails">
        <link:definition>996046 - Disclosure - Variable Interest Entity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable" id="apm_r_ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable">
        <link:definition>996047 - Disclosure - Variable Interest Entity (Details) - Schedule of Aggregate Carrying Value of Vies&#8217; Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/LeaseDetails" id="apm_r_LeaseDetails">
        <link:definition>996048 - Disclosure - Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable" id="apm_r_ScheduleofOperatingLeasesObligationTable">
        <link:definition>996049 - Disclosure - Lease (Details) - Schedule of Operating Leases Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable" id="apm_r_ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable">
        <link:definition>996050 - Disclosure - Lease (Details) - Schedule of Maturity Analysis of Operating Leases Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ConvertibleNoteDetails" id="apm_r_ConvertibleNoteDetails">
        <link:definition>996051 - Disclosure - Convertible Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/OrdinarySharesDetails" id="apm_r_OrdinarySharesDetails">
        <link:definition>996052 - Disclosure - Ordinary Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ShareBasedCompensationDetails" id="apm_r_ShareBasedCompensationDetails">
        <link:definition>996053 - Disclosure - Share Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable" id="apm_r_ScheduleoftheOptionActivityTable">
        <link:definition>996054 - Disclosure - Share Based Compensation (Details) - Schedule of the Option Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" id="apm_r_ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable">
        <link:definition>996055 - Disclosure - Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/NonControllingInterestDetails" id="apm_r_NonControllingInterestDetails">
        <link:definition>996056 - Disclosure - Non-Controlling Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/NetLossPerShareDetails" id="apm_r_NetLossPerShareDetails">
        <link:definition>996057 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable" id="apm_r_ScheduleofbasicanddilutedlossincomepershareTable">
        <link:definition>996058 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted (loss) income per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/CommitmentsandContingenciesDetails" id="apm_r_CommitmentsandContingenciesDetails">
        <link:definition>996059 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable" id="apm_r_ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable">
        <link:definition>996060 - Disclosure - Commitments and Contingencies (Details) - Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/SegmentReportingDetails" id="apm_r_SegmentReportingDetails">
        <link:definition>996061 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/SubsequentEventsDetails" id="apm_r_SubsequentEventsDetails">
        <link:definition>996062 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aptorumgroup.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ScheduleOfMajorSubsidiariesConsolidatedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfMajorSubsidiariesConsolidatedAbstract"/>
  <xs:element name="LiquidityDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LiquidityDisclosureAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfEstimatedUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract"/>
  <xs:element name="ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract"/>
  <xs:element name="ScheduleOfUnrealizedGainsAndLossesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfUnrealizedGainsAndLossesAbstract"/>
  <xs:element name="ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract"/>
  <xs:element name="ScheduleOfOtherReceivablesAndPrepaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfOtherReceivablesAndPrepaymentsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfLongTermDepositsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfLongTermDepositsAbstract"/>
  <xs:element name="ScheduleOfAccountsPayableAndAccruedExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract"/>
  <xs:element name="ScheduleOfProvisionForIncomeTaxesExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfProvisionForIncomeTaxesExpensesAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfChangesInValuationAllowanceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfChangesInValuationAllowanceAbstract"/>
  <xs:element name="ScheduleOfAmountsDueFromRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfAmountsDueFromRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfAmountsDueToRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfAmountsDueToRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfRelatedPartyTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfRelatedPartyTransactionsAbstract"/>
  <xs:element name="ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfOperatingLeasesObligationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfOperatingLeasesObligationAbstract"/>
  <xs:element name="ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract"/>
  <xs:element name="ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract16"/>
  <xs:element name="NonCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NonCurrentAssetsAbstract"/>
  <xs:element name="NonCurrentAssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NonCurrentAssetsAbstract0"/>
  <xs:element name="LongTermInvestmentsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LongTermInvestmentsAbstract0"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract19"/>
  <xs:element name="GrossCarryingAmountAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_GrossCarryingAmountAbstract"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract20"/>
  <xs:element name="LessAccumulatedAmortizationAndImpairmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LessAccumulatedAmortizationAndImpairmentAbstract"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract21"/>
  <xs:element name="IntangibleAssetsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_IntangibleAssetsNetAbstract"/>
  <xs:element name="DeferredTaxAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_DeferredTaxAssetAbstract"/>
  <xs:element name="DeferredTaxLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_DeferredTaxLiabilityAbstract"/>
  <xs:element name="CurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_CurrentAbstract"/>
  <xs:element name="CurrentAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_CurrentAbstract0"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract22"/>
  <xs:element name="NonCurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NonCurrentAbstract"/>
  <xs:element name="LoanFromRelatedPartiesNoteAAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LoanFromRelatedPartiesNoteAAbstract"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract23"/>
  <xs:element name="LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract24"/>
  <xs:element name="IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract25"/>
  <xs:element name="SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract26"/>
  <xs:element name="InterestExpensesNoteAAndNote15Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_InterestExpensesNoteAAndNote15Abstract"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract27"/>
  <xs:element name="LoanToRelatedPartiesNoteBAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LoanToRelatedPartiesNoteBAbstract"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract28"/>
  <xs:element name="LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract29"/>
  <xs:element name="InterestIncomeNoteBAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_InterestIncomeNoteBAbstract"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract30"/>
  <xs:element name="ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract31"/>
  <xs:element name="AdministrativeManagementServicesNoteDAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_AdministrativeManagementServicesNoteDAbstract"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract32"/>
  <xs:element name="HealthcareServicesIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_HealthcareServicesIncomeAbstract"/>
  <xs:element name="December312022Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_December312022Abstract"/>
  <xs:element name="December312022Abstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_December312022Abstract0"/>
  <xs:element name="FinanceLeaseCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_FinanceLeaseCostAbstract"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract33"/>
  <xs:element name="OtherInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_OtherInformationAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract36"/>
  <xs:element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NumeratorAbstract"/>
  <xs:element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_DenominatorAbstract"/>
  <xs:element name="WeightedAverageSharesOutstanding1Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_WeightedAverageSharesOutstanding1Abstract"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract37"/>
  <xs:element name="NetLossPerShareAttributableToAptorumGroupLimited1Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract"/>
  <xs:element name="DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_UnlabeledAbstract38"/>
  <xs:element name="DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract"/>
  <xs:element name="DueFromBrokers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_DueFromBrokers"/>
  <xs:element name="GainOnUseOfDigitalCurrencies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_GainOnUseOfDigitalCurrencies"/>
  <xs:element name="GainOnDerecognitionOfNonfinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_GainOnDerecognitionOfNonfinancialAssets"/>
  <xs:element name="SundryIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_SundryIncome"/>
  <xs:element name="AdjustmentToIssuanceOfSharesToNoncontrollingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest"/>
  <xs:element name="StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction"/>
  <xs:element name="StockIssuedDuringPeriodValueDisposalOfSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries"/>
  <xs:element name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
  <xs:element name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
  <xs:element name="ExchangeDifferenceOnTranslationOfForeignOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_ExchangeDifferenceOnTranslationOfForeignOperation"/>
  <xs:element name="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_StockIssuedDuringPeriodValueIssuanceOfShares"/>
  <xs:element name="StockIssuedDuringPeridSharesIssuanceOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_StockIssuedDuringPeridSharesIssuanceOfShares"/>
  <xs:element name="LossGainOnInvestmentsInMarketableSecuritiesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_LossGainOnInvestmentsInMarketableSecuritiesNet"/>
  <xs:element name="LossOnDisposalOfLonglivedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_LossOnDisposalOfLonglivedAssets"/>
  <xs:element name="AllowanceForCreditLossOfDueFromARelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_AllowanceForCreditLossOfDueFromARelatedParty"/>
  <xs:element name="WritteoffOfPrepaymentAndOtherReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_WritteoffOfPrepaymentAndOtherReceivables"/>
  <xs:element name="GainOnUseOfDigitalsCurrencies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_GainOnUseOfDigitalsCurrencies"/>
  <xs:element name="SettlementOfServiceFeeByDigitalCurrenciesAndTokens" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens"/>
  <xs:element name="InterestExpenseAndAccretionOfConvertibleDebts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_InterestExpenseAndAccretionOfConvertibleDebts"/>
  <xs:element name="AccretionOfFinanceLeaseObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_AccretionOfFinanceLeaseObligation"/>
  <xs:element name="ReversalDeferredCashBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_ReversalDeferredCashBonus"/>
  <xs:element name="IncreaseDecreaseDueFromBrokers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_IncreaseDecreaseDueFromBrokers"/>
  <xs:element name="DisposalOfSubsidiariesNetOfCashDisposed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_DisposalOfSubsidiariesNetOfCashDisposed"/>
  <xs:element name="RepaymentOfLoanFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_RepaymentOfLoanFromRelatedParty"/>
  <xs:element name="ProceedsInBrokerAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_ProceedsInBrokerAccounts"/>
  <xs:element name="SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens"/>
  <xs:element name="ConvertibleNotesConvertedToClassAOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_ConvertibleNotesConvertedToClassAOrdinaryShares"/>
  <xs:element name="SettlementOfDeferredCashBonusByIssuanceOfShareOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions"/>
  <xs:element name="LiquidityDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LiquidityDisclosureTextBlock"/>
  <xs:element name="LiquidityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_LiquidityTable"/>
  <xs:element name="LiquidityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LiquidityLineItems"/>
  <xs:element name="OtherReceivablesandPrepaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_OtherReceivablesandPrepaymentsTable"/>
  <xs:element name="OtherReceivablesandPrepaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_OtherReceivablesandPrepaymentsLineItems"/>
  <xs:element name="LongTermDepositsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_LongTermDepositsTable"/>
  <xs:element name="LongTermDepositsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LongTermDepositsLineItems"/>
  <xs:element name="NoncontrollingInterestsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NoncontrollingInterestsPolicyTextBlock"/>
  <xs:element name="LongtermInvestmentsPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LongtermInvestmentsPolicyPolicyTextBlock"/>
  <xs:element name="OperatingLeasesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_OperatingLeasesPolicyTextBlock"/>
  <xs:element name="WarrantLiabilitiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_WarrantLiabilitiesPolicyTextBlock"/>
  <xs:element name="PropertyPlantAndEquipmentUsefullLifeTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock"/>
  <xs:element name="ScheduleOfUnrealizedLossOnInvestmentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock"/>
  <xs:element name="ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock"/>
  <xs:element name="OtherReceivablesandPrepaymentsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_OtherReceivablesandPrepaymentsTablesTable"/>
  <xs:element name="OtherReceivablesandPrepaymentsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_OtherReceivablesandPrepaymentsTablesLineItems"/>
  <xs:element name="ScheduleOfLongTermDepositsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfLongTermDepositsTableTextBlock"/>
  <xs:element name="LongTermDepositsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_LongTermDepositsTablesTable"/>
  <xs:element name="LongTermDepositsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LongTermDepositsTablesLineItems"/>
  <xs:element name="AccountsPayableandAccruedExpensesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_AccountsPayableandAccruedExpensesTablesTable"/>
  <xs:element name="AccountsPayableandAccruedExpensesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_AccountsPayableandAccruedExpensesTablesLineItems"/>
  <xs:element name="ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfDueToRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock"/>
  <xs:element name="EntityIncorporationsStateCountryName" type="xbrli:normalizedStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_EntityIncorporationsStateCountryName"/>
  <xs:element name="PrincipleActivities" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_PrincipleActivities"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems"/>
  <xs:element name="LeaseholdImprovementsEstimatedUsefulLives" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LeaseholdImprovementsEstimatedUsefulLives"/>
  <xs:element name="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"/>
  <xs:element name="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems"/>
  <xs:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues"/>
  <xs:element name="FairValueOfChangeInUnrealizedAppreciationDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation"/>
  <xs:element name="NetChangeInUnrealizedDepreciationRelatingToInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments"/>
  <xs:element name="FairValueMeasurementValuationTechniques" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_FairValueMeasurementValuationTechniques"/>
  <xs:element name="FairValueMeasurementsUnobservableInput" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_FairValueMeasurementsUnobservableInput"/>
  <xs:element name="FairValueMeasurementsWeightedAverageRange" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_FairValueMeasurementsWeightedAverageRange"/>
  <xs:element name="UpwardAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_UpwardAdjustments"/>
  <xs:element name="DownwardAdjustmentsAndImpairment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_DownwardAdjustmentsAndImpairment"/>
  <xs:element name="TotalUnrealizedGainForNonmarketableInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_TotalUnrealizedGainForNonmarketableInvestments"/>
  <xs:element name="InitialCostBasis" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_InitialCostBasis"/>
  <xs:element name="UpwardAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_UpwardAdjustment"/>
  <xs:element name="DownwardAdjustmentAndImpairment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_DownwardAdjustmentAndImpairment"/>
  <xs:element name="TotalCarryingValueAtTheEndOfThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_TotalCarryingValueAtTheEndOfThePeriod"/>
  <xs:element name="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable"/>
  <xs:element name="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems"/>
  <xs:element name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_PrepaidResearchAndDevelopmentExpenses"/>
  <xs:element name="PrepaidServiceFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_PrepaidServiceFee"/>
  <xs:element name="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"/>
  <xs:element name="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems"/>
  <xs:element name="LongTermDepositsDetailsScheduleofLongTermDepositsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable"/>
  <xs:element name="LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems"/>
  <xs:element name="RentalDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_RentalDeposits"/>
  <xs:element name="PrepaymentsForEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_PrepaymentsForEquipment"/>
  <xs:element name="ResearchAndDevelopmentExpensesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_ResearchAndDevelopmentExpensesPayable"/>
  <xs:element name="CostOfHealthcareServicesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_CostOfHealthcareServicesPayable"/>
  <xs:element name="InsuranceExpensePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_InsuranceExpensePayable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems"/>
  <xs:element name="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems"/>
  <xs:element name="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems"/>
  <xs:element name="DeferredTaxAssetsDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_DeferredTaxAssetsDepreciationAndAmortization"/>
  <xs:element name="NetDeferredTaxAssetsBeforeValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_NetDeferredTaxAssetsBeforeValuationAllowance"/>
  <xs:element name="ValuationAllowanceDeferredTaxAssetIncrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_ValuationAllowanceDeferredTaxAssetIncrease"/>
  <xs:element name="ValuationAllowanceDeferredTaxAssetDecreaseAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
  <xs:element name="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable"/>
  <xs:element name="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems"/>
  <xs:element name="AmountsDueFromRelatedPartiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_AmountsDueFromRelatedPartiesCurrent"/>
  <xs:element name="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable"/>
  <xs:element name="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems"/>
  <xs:element name="AmountsDueToRelatedPartiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_AmountsDueToRelatedPartiesCurrent"/>
  <xs:element name="AmountsDueToRelatedPartiesNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_AmountsDueToRelatedPartiesNoncurrent"/>
  <xs:element name="LoanRepaymentAndInterestPaidToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_LoanRepaymentAndInterestPaidToRelatedParties"/>
  <xs:element name="ConsultantSecondmentManagementAndAdministrativeServicesFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees"/>
  <xs:element name="AdministrativeManagementServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_AdministrativeManagementServices"/>
  <xs:element name="FinanceLeaseDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_FinanceLeaseDepreciation"/>
  <xs:element name="ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable"/>
  <xs:element name="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"/>
  <xs:element name="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor"/>
  <xs:element name="PreclinicalToIndFiling" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_PreclinicalToIndFiling"/>
  <xs:element name="FromEnteringPhase1ToBeforeFirstCommercialSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_FromEnteringPhase1ToBeforeFirstCommercialSale"/>
  <xs:element name="FirstCommercialSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_FirstCommercialSale"/>
  <xs:element name="NetSalesAmountMoreThanCertainThresholdInYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_NetSalesAmountMoreThanCertainThresholdInYear"/>
  <xs:element name="SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal"/>
  <xs:element name="FdaApprovalObtaine" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_FdaApprovalObtaine"/>
  <xs:element name="MilestonePaymentsTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_MilestonePaymentsTotal"/>
  <xs:element name="LiquidityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_LiquidityDetailsTable"/>
  <xs:element name="UnrestrictedCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_UnrestrictedCashEquivalents"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="InvestmentandFairValueMeasurementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_InvestmentandFairValueMeasurementDetailsTable"/>
  <xs:element name="NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners"/>
  <xs:element name="PropertyandEquipmentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_PropertyandEquipmentNetDetailsTable"/>
  <xs:element name="IntangibleAssetsNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_IntangibleAssetsNetDetailsTable"/>
  <xs:element name="WroteOffOfCostRelatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_WroteOffOfCostRelatedAmortization"/>
  <xs:element name="AccountsPayableandAccruedExpensesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_AccountsPayableandAccruedExpensesDetailsTable"/>
  <xs:element name="VestedAndUnvestedShareOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="apm_VestedAndUnvestedShareOptions"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_IncomeTaxDescription"/>
  <xs:element name="LossCarryforwardCancelled" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_LossCarryforwardCancelled"/>
  <xs:element name="RelatedPartyBalancesandTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_RelatedPartyBalancesandTransactionsDetailsTable"/>
  <xs:element name="DecreasedOwnershipPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_DecreasedOwnershipPercentage"/>
  <xs:element name="LoansInterestbearingRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LoansInterestbearingRate"/>
  <xs:element name="ServicesFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_ServicesFees"/>
  <xs:element name="ServicesFeesAdjusted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_ServicesFeesAdjusted"/>
  <xs:element name="RemunerationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_RemunerationAmount"/>
  <xs:element name="VariableInterestEntityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_VariableInterestEntityDetailsTable"/>
  <xs:element name="ShareOfEconomic" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="apm_ShareOfEconomic"/>
  <xs:element name="OperatingLeaseWeightedAverageDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="apm_OperatingLeaseWeightedAverageDiscountRate"/>
  <xs:element name="ConvertibleNoteDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_ConvertibleNoteDetailsTable"/>
  <xs:element name="OrdinarySharesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_OrdinarySharesDetailsTable"/>
  <xs:element name="GrossProceed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="apm_GrossProceed"/>
  <xs:element name="SharesPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="apm_SharesPrice"/>
  <xs:element name="OrdinarySharesClosingPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_OrdinarySharesClosingPricePercentage"/>
  <xs:element name="ShareIssuedToConvertibleNoteHolders" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ShareIssuedToConvertibleNoteHolders"/>
  <xs:element name="ShareBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_ShareBasedCompensationDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2"/>
  <xs:element name="NonControllingInterestDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_NonControllingInterestDetailsTable"/>
  <xs:element name="AdjustmentIncreaseDecreaseRetainedEarningsDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit"/>
  <xs:element name="NetLossPerShareDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_NetLossPerShareDetailsTable"/>
  <xs:element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="apm_MilestonePayments"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="apm_SubsequentEventsDetailsTable"/>
  <xs:element name="sharesOutstandingPerentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_sharesOutstandingPerentage"/>
  <xs:element name="OutstandingSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_OutstandingSharesPercentage"/>
  <xs:element name="ACCMedicalLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ACCMedicalLimitedMember"/>
  <xs:element name="APTUSMANAGEMENTLIMITEDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_APTUSMANAGEMENTLIMITEDMember"/>
  <xs:element name="ActiculeLifeSciencesLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ActiculeLifeSciencesLimitedMember"/>
  <xs:element name="AencoTechnologiesLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_AencoTechnologiesLtdMember"/>
  <xs:element name="AeneasGroupLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_AeneasGroupLimitedMember"/>
  <xs:element name="AeneasManagementLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_AeneasManagementLimitedMember"/>
  <xs:element name="AptorumMedicalLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_AptorumMedicalLimitedMember"/>
  <xs:element name="AptorumTherapeuticsLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_AptorumTherapeuticsLimitedMember"/>
  <xs:element name="CGYInvestmentsLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_CGYInvestmentsLimitedMember"/>
  <xs:element name="ClarkChengMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ClarkChengMember"/>
  <xs:element name="ClavesLifeSciencesLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ClavesLifeSciencesLimitedMember"/>
  <xs:element name="CommonStock1Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_CommonStock1Member"/>
  <xs:element name="ConvertibleNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ConvertibleNotesMember"/>
  <xs:element name="DSFInvestmentHoldingsLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_DSFInvestmentHoldingsLimitedMember"/>
  <xs:element name="EmployeesAndExternalConsultantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_EmployeesAndExternalConsultantsMember"/>
  <xs:element name="EmployeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_EmployeesMember"/>
  <xs:element name="GroupsSubsidiariesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_GroupsSubsidiariesMember"/>
  <xs:element name="HongKongHealthcareServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_HongKongHealthcareServicesMember"/>
  <xs:element name="IanHuenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_IanHuenMember"/>
  <xs:element name="JurchenInvestmentCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_JurchenInvestmentCorporationMember"/>
  <xs:element name="JurchenInvestmentCorporationOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_JurchenInvestmentCorporationOneMember"/>
  <xs:element name="JurchenInvestmentsCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_JurchenInvestmentsCorporationMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LaboratoryEquipmentMember"/>
  <xs:element name="LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember"/>
  <xs:element name="LibraMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LibraMember"/>
  <xs:element name="LibraSciencesLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LibraSciencesLimitedMember"/>
  <xs:element name="LibraTherapeuticsLimitedOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_LibraTherapeuticsLimitedOneMember"/>
  <xs:element name="MiosMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_MiosMember"/>
  <xs:element name="MiosPharmaceuticalsLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_MiosPharmaceuticalsLimitedMember"/>
  <xs:element name="MrClarkChengMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_MrClarkChengMember"/>
  <xs:element name="MrDarrenLuiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_MrDarrenLuiMember"/>
  <xs:element name="MrIanHuenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_MrIanHuenMember"/>
  <xs:element name="NativusLifeSciencesLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NativusLifeSciencesLimitedMember"/>
  <xs:element name="NonemployeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NonemployeesMember"/>
  <xs:element name="PathsDiagnosticsPteLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_PathsDiagnosticsPteLimitedMember"/>
  <xs:element name="PathsInnovationsLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_PathsInnovationsLimitedMember"/>
  <xs:element name="PrepaidPatentedLicensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_PrepaidPatentedLicensesMember"/>
  <xs:element name="SabrinaKhanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_SabrinaKhanMember"/>
  <xs:element name="ScipioLifeSciencesLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScipioLifeSciencesLimitedMember"/>
  <xs:element name="ScipioMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScipioMember"/>
  <xs:element name="ShareOptionHoldersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ShareOptionHoldersMember"/>
  <xs:element name="SharesWarrantHoldersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_SharesWarrantHoldersMember"/>
  <xs:element name="SignateLifeSciencesLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_SignateLifeSciencesLimitedMember"/>
  <xs:element name="TalemMedicalGroupLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_TalemMedicalGroupLimitedMember"/>
  <xs:element name="TwoThousandSeventeenShareOptionPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_TwoThousandSeventeenShareOptionPlanMember"/>
  <xs:element name="VaribaleInterestEntityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_VaribaleInterestEntityMember"/>
  <xs:element name="VidensIncorporationLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_VidensIncorporationLimitedMember"/>
  <xs:element name="mTORHongKongLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_mTORHongKongLimitedMember"/>
  <xs:element name="AccountsPayableAndAccruedExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_AccountsPayableAndAccruedExpensesLineItems"/>
  <xs:element name="NetLossPerShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NetLossPerShareLineItems"/>
  <xs:element name="NonControllingInterestLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_NonControllingInterestLineItems"/>
  <xs:element name="OrdinarySharesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_OrdinarySharesLineItems"/>
  <xs:element name="ScheduleOfTheOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_ScheduleOfTheOptionActivityAbstract"/>
  <xs:element name="VariableInterestEntityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_VariableInterestEntityAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>apm-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 09:10:53 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedBalanceSheet" roleURI="http://aptorumgroup.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedComprehensiveIncome" roleURI="http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedCashFlow" roleURI="http://aptorumgroup.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofUnrealizedGainsandLossesTable" roleURI="http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofCarryingValueofOurNonMarketableInvestmentsTable" roleURI="http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofOtherReceivablesandPrepaymentsTable" roleURI="http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofPropertyandEquipmentTable" roleURI="http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" roleURI="http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofLongTermDepositsTable" roleURI="http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofProvisionforIncomeTaxesExpensesTable" roleURI="http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" roleURI="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofOperatingLeasesObligationTable" roleURI="http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable" roleURI="http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_DueFromBrokers" xlink:href="apm-20231231.xsd#apm_DueFromBrokers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="apm_DueFromBrokers" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfRevenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ProfessionalFees" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnInvestments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnSaleOfInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_GainOnDerecognitionOfNonfinancialAssets" xlink:href="apm-20231231.xsd#apm_GainOnDerecognitionOfNonfinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="apm_GainOnDerecognitionOfNonfinancialAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_SundryIncome" xlink:href="apm-20231231.xsd#apm_SundryIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="apm_SundryIncome" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_GainOnUseOfDigitalCurrencies" xlink:href="apm-20231231.xsd#apm_GainOnUseOfDigitalCurrencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="apm_GainOnUseOfDigitalCurrencies" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_CostsAndExpenses" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_AllowanceForCreditLossOfDueFromARelatedParty" xlink:href="apm-20231231.xsd#apm_AllowanceForCreditLossOfDueFromARelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_AllowanceForCreditLossOfDueFromARelatedParty" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_WritteoffOfPrepaymentAndOtherReceivables" xlink:href="apm-20231231.xsd#apm_WritteoffOfPrepaymentAndOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_WritteoffOfPrepaymentAndOtherReceivables" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseCost" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_InterestExpenseAndAccretionOfConvertibleDebts" xlink:href="apm-20231231.xsd#apm_InterestExpenseAndAccretionOfConvertibleDebts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_InterestExpenseAndAccretionOfConvertibleDebts" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_AccretionOfFinanceLeaseObligation" xlink:href="apm-20231231.xsd#apm_AccretionOfFinanceLeaseObligation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_AccretionOfFinanceLeaseObligation" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_ReversalDeferredCashBonus" xlink:href="apm-20231231.xsd#apm_ReversalDeferredCashBonus"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_ReversalDeferredCashBonus" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="13" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="14" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_LossGainOnInvestmentsInMarketableSecuritiesNet" xlink:href="apm-20231231.xsd#apm_LossGainOnInvestmentsInMarketableSecuritiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_LossGainOnInvestmentsInMarketableSecuritiesNet" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="apm_LossOnDisposalOfLonglivedAssets" xlink:href="apm-20231231.xsd#apm_LossOnDisposalOfLonglivedAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_LossOnDisposalOfLonglivedAssets" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" order="20" weight="-1"/>
    <loc xlink:type="locator" xlink:label="apm_GainOnUseOfDigitalsCurrencies" xlink:href="apm-20231231.xsd#apm_GainOnUseOfDigitalsCurrencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_GainOnUseOfDigitalsCurrencies" order="21" weight="-1"/>
    <loc xlink:type="locator" xlink:label="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens" xlink:href="apm-20231231.xsd#apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens" order="22" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InterestIncomeOther" order="23" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="24" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="25" weight="-1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZk9BQMOWQfrm8jHnK3iPqh/RGOZRChD6nBq3dVwAwj4+/8SLuZTW/liOfKmyEBpRrTV6V//wh8natqXLVrpArUZiEOpCUQ4sWmUCqPSbJB1eeE0YXZR+qpcGF8VKslPcXkQ+inlG1l8YPuGFp3JEZ5VoAJF844sVddHhNq3xJYgqGGsxym9XDdtJCVaQwKUCiyUCpFJX/Tlw==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="26" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="27" weight="-1"/>
    <loc xlink:type="locator" xlink:label="apm_IncreaseDecreaseDueFromBrokers" xlink:href="apm-20231231.xsd#apm_IncreaseDecreaseDueFromBrokers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apm_IncreaseDecreaseDueFromBrokers" order="28" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="29" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="apm_DisposalOfSubsidiariesNetOfCashDisposed" xlink:href="apm-20231231.xsd#apm_DisposalOfSubsidiariesNetOfCashDisposed"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="apm_DisposalOfSubsidiariesNetOfCashDisposed" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="apm_RepaymentOfLoanFromRelatedParty" xlink:href="apm-20231231.xsd#apm_RepaymentOfLoanFromRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="apm_RepaymentOfLoanFromRelatedParty" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherEquity" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromBankDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromBankDebt" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfBankDebt" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable">
    <loc xlink:type="locator" xlink:label="apm_TotalUnrealizedGainForNonmarketableInvestments" xlink:href="apm-20231231.xsd#apm_TotalUnrealizedGainForNonmarketableInvestments"/>
    <loc xlink:type="locator" xlink:label="apm_UpwardAdjustments" xlink:href="apm-20231231.xsd#apm_UpwardAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_TotalUnrealizedGainForNonmarketableInvestments" xlink:to="apm_UpwardAdjustments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_DownwardAdjustmentsAndImpairment" xlink:href="apm-20231231.xsd#apm_DownwardAdjustmentsAndImpairment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_TotalUnrealizedGainForNonmarketableInvestments" xlink:to="apm_DownwardAdjustmentsAndImpairment" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable">
    <loc xlink:type="locator" xlink:label="apm_TotalCarryingValueAtTheEndOfThePeriod" xlink:href="apm-20231231.xsd#apm_TotalCarryingValueAtTheEndOfThePeriod"/>
    <loc xlink:type="locator" xlink:label="apm_InitialCostBasis" xlink:href="apm-20231231.xsd#apm_InitialCostBasis"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_TotalCarryingValueAtTheEndOfThePeriod" xlink:to="apm_InitialCostBasis" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_UpwardAdjustment" xlink:href="apm-20231231.xsd#apm_UpwardAdjustment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_TotalCarryingValueAtTheEndOfThePeriod" xlink:to="apm_UpwardAdjustment" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_DownwardAdjustmentAndImpairment" xlink:href="apm-20231231.xsd#apm_DownwardAdjustmentAndImpairment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_TotalCarryingValueAtTheEndOfThePeriod" xlink:to="apm_DownwardAdjustmentAndImpairment" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaidResearchAndDevelopmentExpenses" xlink:href="apm-20231231.xsd#apm_PrepaidResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="apm_PrepaidResearchAndDevelopmentExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaidServiceFee" xlink:href="apm-20231231.xsd#apm_PrepaidServiceFee"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="apm_PrepaidServiceFee" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidRent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="7" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="apm_RentalDeposits" xlink:href="apm-20231231.xsd#apm_RentalDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="apm_RentalDeposits" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaymentsForEquipment" xlink:href="apm-20231231.xsd#apm_PrepaymentsForEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="apm_PrepaymentsForEquipment" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_ResearchAndDevelopmentExpensesPayable" xlink:href="apm-20231231.xsd#apm_ResearchAndDevelopmentExpensesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="apm_ResearchAndDevelopmentExpensesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_CostOfHealthcareServicesPayable" xlink:href="apm-20231231.xsd#apm_CostOfHealthcareServicesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="apm_CostOfHealthcareServicesPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_InsuranceExpensePayable" xlink:href="apm-20231231.xsd#apm_InsuranceExpensePayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="apm_InsuranceExpensePayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="apm_FinanceLeaseDepreciation" xlink:href="apm-20231231.xsd#apm_FinanceLeaseDepreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="apm_FinanceLeaseDepreciation" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="6" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable">
    <loc xlink:type="locator" xlink:label="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:href="apm-20231231.xsd#apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal"/>
    <loc xlink:type="locator" xlink:label="apm_PreclinicalToIndFiling" xlink:href="apm-20231231.xsd#apm_PreclinicalToIndFiling"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:to="apm_PreclinicalToIndFiling" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_FromEnteringPhase1ToBeforeFirstCommercialSale" xlink:href="apm-20231231.xsd#apm_FromEnteringPhase1ToBeforeFirstCommercialSale"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:to="apm_FromEnteringPhase1ToBeforeFirstCommercialSale" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_FirstCommercialSale" xlink:href="apm-20231231.xsd#apm_FirstCommercialSale"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:to="apm_FirstCommercialSale" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_NetSalesAmountMoreThanCertainThresholdInYear" xlink:href="apm-20231231.xsd#apm_NetSalesAmountMoreThanCertainThresholdInYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:to="apm_NetSalesAmountMoreThanCertainThresholdInYear" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_MilestonePaymentsTotal" xlink:href="apm-20231231.xsd#apm_MilestonePaymentsTotal"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_MilestonePaymentsTotal" xlink:to="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="apm_FdaApprovalObtaine" xlink:href="apm-20231231.xsd#apm_FdaApprovalObtaine"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="apm_MilestonePaymentsTotal" xlink:to="apm_FdaApprovalObtaine" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>apm-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 09:10:53 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedBalanceSheet" roleURI="http://aptorumgroup.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedComprehensiveIncome" roleURI="http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ShareholdersEquityType2or3" roleURI="http://aptorumgroup.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedCashFlow" roleURI="http://aptorumgroup.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_Organization" roleURI="http://aptorumgroup.com/role/Organization"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_Liquidity" roleURI="http://aptorumgroup.com/role/Liquidity"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SummaryofSignificantAccountingPolicies" roleURI="http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_Revenue" roleURI="http://aptorumgroup.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_InvestmentandFairValueMeasurement" roleURI="http://aptorumgroup.com/role/InvestmentandFairValueMeasurement"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OtherReceivablesandPrepayments" roleURI="http://aptorumgroup.com/role/OtherReceivablesandPrepayments"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_PropertyandEquipmentNet" roleURI="http://aptorumgroup.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IntangibleAssetsNet" roleURI="http://aptorumgroup.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LongTermDeposits" roleURI="http://aptorumgroup.com/role/LongTermDeposits"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_AccountsPayableandAccruedExpenses" roleURI="http://aptorumgroup.com/role/AccountsPayableandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IncomeTaxes" roleURI="http://aptorumgroup.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_RelatedPartyBalancesandTransactions" roleURI="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactions"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_VariableInterestEntity" roleURI="http://aptorumgroup.com/role/VariableInterestEntity"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_Lease" roleURI="http://aptorumgroup.com/role/Lease"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConvertibleNote" roleURI="http://aptorumgroup.com/role/ConvertibleNote"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OrdinaryShares" roleURI="http://aptorumgroup.com/role/OrdinaryShares"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ShareBasedCompensation" roleURI="http://aptorumgroup.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NonControllingInterest" roleURI="http://aptorumgroup.com/role/NonControllingInterest"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NetLossPerShare" roleURI="http://aptorumgroup.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_CommitmentsandContingencies" roleURI="http://aptorumgroup.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SegmentReporting" roleURI="http://aptorumgroup.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SubsequentEvents" roleURI="http://aptorumgroup.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_AccountingPoliciesByPolicy" roleURI="http://aptorumgroup.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OrganizationTables" roleURI="http://aptorumgroup.com/role/OrganizationTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_InvestmentandFairValueMeasurementTables" roleURI="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OtherReceivablesandPrepaymentsTables" roleURI="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_PropertyandEquipmentNetTables" roleURI="http://aptorumgroup.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IntangibleAssetsNetTables" roleURI="http://aptorumgroup.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LongTermDepositsTables" roleURI="http://aptorumgroup.com/role/LongTermDepositsTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_AccountsPayableandAccruedExpensesTables" roleURI="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IncomeTaxesTables" roleURI="http://aptorumgroup.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_RelatedPartyBalancesandTransactionsTables" roleURI="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_VariableInterestEntityTables" roleURI="http://aptorumgroup.com/role/VariableInterestEntityTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LeaseTables" roleURI="http://aptorumgroup.com/role/LeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ShareBasedCompensationTables" roleURI="http://aptorumgroup.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NetLossPerShareTables" roleURI="http://aptorumgroup.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_CommitmentsandContingenciesTables" roleURI="http://aptorumgroup.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofMajorSubsidiariesConsolidatedTable" roleURI="http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofEstimatedUsefulLivesTable" roleURI="http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" roleURI="http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofFairValueReconciliationofLevel3AssetsTable" roleURI="http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable" roleURI="http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofUnrealizedGainsandLossesTable" roleURI="http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofCarryingValueofOurNonMarketableInvestmentsTable" roleURI="http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofOtherReceivablesandPrepaymentsTable" roleURI="http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofPropertyandEquipmentTable" roleURI="http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofIntangibleAssetsTable" roleURI="http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" roleURI="http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofLongTermDepositsTable" roleURI="http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofProvisionforIncomeTaxesExpensesTable" roleURI="http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" roleURI="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals" roleURI="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofDeferredTaxAssetandLiabilitiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofChangesinValuationAllowanceTable" roleURI="http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAmountsDuefromRelatedPartiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAmountsDuetoRelatedPartiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofRelatedPartyTransactionsTable" roleURI="http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofOperatingLeasesObligationTable" roleURI="http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleoftheOptionActivityTable" roleURI="http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" roleURI="http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofbasicanddilutedlossincomepershareTable" roleURI="http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable" roleURI="http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LiquidityDetails" roleURI="http://aptorumgroup.com/role/LiquidityDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_InvestmentandFairValueMeasurementDetails" roleURI="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OtherReceivablesandPrepaymentsDetails" roleURI="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_PropertyandEquipmentNetDetails" roleURI="http://aptorumgroup.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IntangibleAssetsNetDetails" roleURI="http://aptorumgroup.com/role/IntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_AccountsPayableandAccruedExpensesDetails" roleURI="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IncomeTaxesDetails" roleURI="http://aptorumgroup.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_RelatedPartyBalancesandTransactionsDetails" roleURI="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_VariableInterestEntityDetails" roleURI="http://aptorumgroup.com/role/VariableInterestEntityDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LeaseDetails" roleURI="http://aptorumgroup.com/role/LeaseDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConvertibleNoteDetails" roleURI="http://aptorumgroup.com/role/ConvertibleNoteDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OrdinarySharesDetails" roleURI="http://aptorumgroup.com/role/OrdinarySharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ShareBasedCompensationDetails" roleURI="http://aptorumgroup.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NonControllingInterestDetails" roleURI="http://aptorumgroup.com/role/NonControllingInterestDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NetLossPerShareDetails" roleURI="http://aptorumgroup.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_CommitmentsandContingenciesDetails" roleURI="http://aptorumgroup.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SegmentReportingDetails" roleURI="http://aptorumgroup.com/role/SegmentReportingDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SubsequentEventsDetails" roleURI="http://aptorumgroup.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#DocumentAndEntityInformation" roleURI="http://aptorumgroup.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_DueFromBrokers" xlink:href="apm-20231231.xsd#apm_DueFromBrokers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="apm_DueFromBrokers" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_LongTermInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_MinorityInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OciNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciNetOfTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OciNetOfTaxAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_GainLossOnSaleOfInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_GainOnUseOfDigitalCurrencies" xlink:href="apm-20231231.xsd#apm_GainOnUseOfDigitalCurrencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="apm_GainOnUseOfDigitalCurrencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_GainOnDerecognitionOfNonfinancialAssets" xlink:href="apm-20231231.xsd#apm_GainOnDerecognitionOfNonfinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="apm_GainOnDerecognitionOfNonfinancialAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SundryIncome" xlink:href="apm-20231231.xsd#apm_SundryIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="apm_SundryIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest" xlink:href="apm-20231231.xsd#apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:href="apm-20231231.xsd#apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodValueIssuanceOfShares" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodValueIssuanceOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="apm_StockIssuedDuringPeriodValueIssuanceOfShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeridSharesIssuanceOfShares" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeridSharesIssuanceOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="apm_StockIssuedDuringPeridSharesIssuanceOfShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apm_StockIssuedDuringPeriodValueExerciseOfWarrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ExchangeDifferenceOnTranslationOfForeignOperation" xlink:href="apm-20231231.xsd#apm_ExchangeDifferenceOnTranslationOfForeignOperation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apm_ExchangeDifferenceOnTranslationOfForeignOperation" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LossGainOnInvestmentsInMarketableSecuritiesNet" xlink:href="apm-20231231.xsd#apm_LossGainOnInvestmentsInMarketableSecuritiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apm_LossGainOnInvestmentsInMarketableSecuritiesNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LossOnDisposalOfLonglivedAssets" xlink:href="apm-20231231.xsd#apm_LossOnDisposalOfLonglivedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apm_LossOnDisposalOfLonglivedAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AllowanceForCreditLossOfDueFromARelatedParty" xlink:href="apm-20231231.xsd#apm_AllowanceForCreditLossOfDueFromARelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apm_AllowanceForCreditLossOfDueFromARelatedParty" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_WritteoffOfPrepaymentAndOtherReceivables" xlink:href="apm-20231231.xsd#apm_WritteoffOfPrepaymentAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apm_WritteoffOfPrepaymentAndOtherReceivables" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_GainOnUseOfDigitalsCurrencies" xlink:href="apm-20231231.xsd#apm_GainOnUseOfDigitalsCurrencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apm_GainOnUseOfDigitalsCurrencies" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens" xlink:href="apm-20231231.xsd#apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestIncomeOther" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_InterestExpenseAndAccretionOfConvertibleDebts" xlink:href="apm-20231231.xsd#apm_InterestExpenseAndAccretionOfConvertibleDebts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apm_InterestExpenseAndAccretionOfConvertibleDebts" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AccretionOfFinanceLeaseObligation" xlink:href="apm-20231231.xsd#apm_AccretionOfFinanceLeaseObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apm_AccretionOfFinanceLeaseObligation" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ReversalDeferredCashBonus" xlink:href="apm-20231231.xsd#apm_ReversalDeferredCashBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apm_ReversalDeferredCashBonus" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_IncreaseDecreaseDueFromBrokers" xlink:href="apm-20231231.xsd#apm_IncreaseDecreaseDueFromBrokers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="apm_IncreaseDecreaseDueFromBrokers" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_DisposalOfSubsidiariesNetOfCashDisposed" xlink:href="apm-20231231.xsd#apm_DisposalOfSubsidiariesNetOfCashDisposed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="apm_DisposalOfSubsidiariesNetOfCashDisposed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_RepaymentOfLoanFromRelatedParty" xlink:href="apm-20231231.xsd#apm_RepaymentOfLoanFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="apm_RepaymentOfLoanFromRelatedParty" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromBankDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ProceedsInBrokerAccounts" xlink:href="apm-20231231.xsd#apm_ProceedsInBrokerAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="apm_ProceedsInBrokerAccounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" xlink:href="apm-20231231.xsd#apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ConvertibleNotesConvertedToClassAOrdinaryShares" xlink:href="apm-20231231.xsd#apm_ConvertibleNotesConvertedToClassAOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="apm_ConvertibleNotesConvertedToClassAOrdinaryShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions" xlink:href="apm-20231231.xsd#apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/Organization">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/Liquidity">
    <loc xlink:type="locator" xlink:label="apm_LiquidityLineItems" xlink:href="apm-20231231.xsd#apm_LiquidityLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_LiquidityTable" xlink:href="apm-20231231.xsd#apm_LiquidityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_LiquidityLineItems" xlink:to="apm_LiquidityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LiquidityDisclosureTextBlock" xlink:href="apm-20231231.xsd#apm_LiquidityDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LiquidityLineItems" xlink:to="apm_LiquidityDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/Revenue">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/InvestmentandFairValueMeasurement">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OtherReceivablesandPrepayments">
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsLineItems" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsTable" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_OtherReceivablesandPrepaymentsLineItems" xlink:to="apm_OtherReceivablesandPrepaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IntangibleAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LongTermDeposits">
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsLineItems" xlink:href="apm-20231231.xsd#apm_LongTermDepositsLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsTable" xlink:href="apm-20231231.xsd#apm_LongTermDepositsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_LongTermDepositsLineItems" xlink:to="apm_LongTermDepositsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LongTermDepositsLineItems" xlink:to="us-gaap_LongTermDebtTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/AccountsPayableandAccruedExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/VariableInterestEntity">
    <loc xlink:type="locator" xlink:label="apm_VariableInterestEntityAbstract" xlink:href="apm-20231231.xsd#apm_VariableInterestEntityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_VariableInterestEntityAbstract" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/Lease">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConvertibleNote">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OrdinaryShares">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ShareBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NonControllingInterest">
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SegmentReporting">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NoncontrollingInterestsPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_NoncontrollingInterestsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apm_NoncontrollingInterestsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LongtermInvestmentsPolicyPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_LongtermInvestmentsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apm_LongtermInvestmentsPolicyPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_OperatingLeasesPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_OperatingLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apm_OperatingLeasesPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_WarrantLiabilitiesPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_WarrantLiabilitiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apm_WarrantLiabilitiesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxUncertaintiesPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesPolicy" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OrganizationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock" xlink:href="apm-20231231.xsd#apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables">
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsTablesLineItems" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsTablesTable" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_OtherReceivablesandPrepaymentsTablesLineItems" xlink:to="apm_OtherReceivablesandPrepaymentsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsTablesLineItems" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IntangibleAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LongTermDepositsTables">
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsTablesLineItems" xlink:href="apm-20231231.xsd#apm_LongTermDepositsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsTablesTable" xlink:href="apm-20231231.xsd#apm_LongTermDepositsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_LongTermDepositsTablesLineItems" xlink:to="apm_LongTermDepositsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfLongTermDepositsTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfLongTermDepositsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LongTermDepositsTablesLineItems" xlink:to="apm_ScheduleOfLongTermDepositsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables">
    <loc xlink:type="locator" xlink:label="apm_AccountsPayableandAccruedExpensesTablesLineItems" xlink:href="apm-20231231.xsd#apm_AccountsPayableandAccruedExpensesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_AccountsPayableandAccruedExpensesTablesTable" xlink:href="apm-20231231.xsd#apm_AccountsPayableandAccruedExpensesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_AccountsPayableandAccruedExpensesTablesLineItems" xlink:to="apm_AccountsPayableandAccruedExpensesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_AccountsPayableandAccruedExpensesTablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="apm_ScheduleOfDueToRelatedPartiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/VariableInterestEntityTables">
    <loc xlink:type="locator" xlink:label="apm_VariableInterestEntityAbstract" xlink:href="apm-20231231.xsd#apm_VariableInterestEntityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_VariableInterestEntityAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LeaseTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ShareBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AptorumTherapeuticsLimitedMember" xlink:href="apm-20231231.xsd#apm_AptorumTherapeuticsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_AptorumTherapeuticsLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_APTUSMANAGEMENTLIMITEDMember" xlink:href="apm-20231231.xsd#apm_APTUSMANAGEMENTLIMITEDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_APTUSMANAGEMENTLIMITEDMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AptorumMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_AptorumMedicalLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_AptorumMedicalLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_PathsInnovationsLimitedMember" xlink:href="apm-20231231.xsd#apm_PathsInnovationsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_PathsInnovationsLimitedMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_PathsDiagnosticsPteLimitedMember" xlink:href="apm-20231231.xsd#apm_PathsDiagnosticsPteLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_PathsDiagnosticsPteLimitedMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ActiculeLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ActiculeLifeSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_ActiculeLifeSciencesLimitedMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ClavesLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ClavesLifeSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_ClavesLifeSciencesLimitedMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NativusLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_NativusLifeSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_NativusLifeSciencesLimitedMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_VidensIncorporationLimitedMember" xlink:href="apm-20231231.xsd#apm_VidensIncorporationLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_VidensIncorporationLimitedMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_MiosPharmaceuticalsLimitedMember" xlink:href="apm-20231231.xsd#apm_MiosPharmaceuticalsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_MiosPharmaceuticalsLimitedMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_mTORHongKongLimitedMember" xlink:href="apm-20231231.xsd#apm_mTORHongKongLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_mTORHongKongLimitedMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ScipioLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ScipioLifeSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_ScipioLifeSciencesLimitedMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SignateLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_SignateLifeSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_SignateLifeSciencesLimitedMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_EntityIncorporationsStateCountryName" xlink:href="apm-20231231.xsd#apm_EntityIncorporationsStateCountryName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="apm_EntityIncorporationsStateCountryName" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_PrincipleActivities" xlink:href="apm-20231231.xsd#apm_PrincipleActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="apm_PrincipleActivities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable">
    <loc xlink:type="locator" xlink:label="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" xlink:href="apm-20231231.xsd#apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" xlink:href="apm-20231231.xsd#apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" xlink:to="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LaboratoryEquipmentMember" xlink:href="apm-20231231.xsd#apm_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="apm_LaboratoryEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LeaseholdImprovementsEstimatedUsefulLives" xlink:href="apm-20231231.xsd#apm_LeaseholdImprovementsEstimatedUsefulLives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" xlink:to="apm_LeaseholdImprovementsEstimatedUsefulLives" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable">
    <loc xlink:type="locator" xlink:label="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" xlink:href="apm-20231231.xsd#apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" xlink:href="apm-20231231.xsd#apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" xlink:to="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_CommonStock1Member" xlink:href="apm-20231231.xsd#apm_CommonStock1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="apm_CommonStock1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NonCurrentAssetsAbstract" xlink:href="apm-20231231.xsd#apm_NonCurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" xlink:to="apm_NonCurrentAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NonCurrentAssetsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation" xlink:href="apm-20231231.xsd#apm_FairValueOfChangeInUnrealizedAppreciationDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments" xlink:href="apm-20231231.xsd#apm_NetChangeInUnrealizedDepreciationRelatingToInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueMeasurementValuationTechniques" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementValuationTechniques"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="apm_FairValueMeasurementValuationTechniques" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueMeasurementsUnobservableInput" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementsUnobservableInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="apm_FairValueMeasurementsUnobservableInput" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueMeasurementsWeightedAverageRange" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementsWeightedAverageRange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="apm_FairValueMeasurementsWeightedAverageRange" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable">
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfUnrealizedGainsAndLossesAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_UpwardAdjustments" xlink:href="apm-20231231.xsd#apm_UpwardAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:to="apm_UpwardAdjustments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_DownwardAdjustmentsAndImpairment" xlink:href="apm-20231231.xsd#apm_DownwardAdjustmentsAndImpairment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:to="apm_DownwardAdjustmentsAndImpairment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_TotalUnrealizedGainForNonmarketableInvestments" xlink:href="apm-20231231.xsd#apm_TotalUnrealizedGainForNonmarketableInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:to="apm_TotalUnrealizedGainForNonmarketableInvestments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable">
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_InitialCostBasis" xlink:href="apm-20231231.xsd#apm_InitialCostBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:to="apm_InitialCostBasis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_UpwardAdjustment" xlink:href="apm-20231231.xsd#apm_UpwardAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:to="apm_UpwardAdjustment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_DownwardAdjustmentAndImpairment" xlink:href="apm-20231231.xsd#apm_DownwardAdjustmentAndImpairment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:to="apm_DownwardAdjustmentAndImpairment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_TotalCarryingValueAtTheEndOfThePeriod" xlink:href="apm-20231231.xsd#apm_TotalCarryingValueAtTheEndOfThePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:to="apm_TotalCarryingValueAtTheEndOfThePeriod" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable">
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaidResearchAndDevelopmentExpenses" xlink:href="apm-20231231.xsd#apm_PrepaidResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="apm_PrepaidResearchAndDevelopmentExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_PrepaidInsurance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaidServiceFee" xlink:href="apm-20231231.xsd#apm_PrepaidServiceFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="apm_PrepaidServiceFee" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_DepositsAssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_PrepaidRent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_OtherReceivables" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LaboratoryEquipmentMember" xlink:href="apm-20231231.xsd#apm_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="apm_LaboratoryEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AutomobilesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AutomobilesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaidPatentedLicensesMember" xlink:href="apm-20231231.xsd#apm_PrepaidPatentedLicensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="apm_PrepaidPatentedLicensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable">
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:href="apm-20231231.xsd#apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable" xlink:href="apm-20231231.xsd#apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:to="apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_RentalDeposits" xlink:href="apm-20231231.xsd#apm_RentalDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:to="apm_RentalDeposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaymentsForEquipment" xlink:href="apm-20231231.xsd#apm_PrepaymentsForEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:to="apm_PrepaymentsForEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable">
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ResearchAndDevelopmentExpensesPayable" xlink:href="apm-20231231.xsd#apm_ResearchAndDevelopmentExpensesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="apm_ResearchAndDevelopmentExpensesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_CostOfHealthcareServicesPayable" xlink:href="apm-20231231.xsd#apm_CostOfHealthcareServicesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="apm_CostOfHealthcareServicesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_InsuranceExpensePayable" xlink:href="apm-20231231.xsd#apm_InsuranceExpensePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="apm_InsuranceExpensePayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable">
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:to="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable">
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_ProfitLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZk9BQMOWQfrm8jHnK3iPqh/RGOZRChD6nBq3dVwAwj4+/8SLuZTW/liOfKmyEBpRrTV6V//wh8natqXLVrpArUZiEOpCUQ4sWmUCqPSbJB1eeE0YXZR+qpcGF8VKslPcXkQ+inlG1l8YPuGFp3JEZ5VoAJF844sVddHhNq3xJYgqGGsxym9XDd3cgplB05kduBwuQzhQEu0w==] CSR-->
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" xlink:to="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_DeferredTaxAssetAbstract" xlink:href="apm-20231231.xsd#apm_DeferredTaxAssetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="apm_DeferredTaxAssetAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_DeferredTaxAssetsDepreciationAndAmortization" xlink:href="apm-20231231.xsd#apm_DeferredTaxAssetsDepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DeferredTaxAssetAbstract" xlink:to="apm_DeferredTaxAssetsDepreciationAndAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_DeferredTaxLiabilityAbstract" xlink:href="apm-20231231.xsd#apm_DeferredTaxLiabilityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="apm_DeferredTaxLiabilityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DeferredTaxLiabilityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NetDeferredTaxAssetsBeforeValuationAllowance" xlink:href="apm-20231231.xsd#apm_NetDeferredTaxAssetsBeforeValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="apm_NetDeferredTaxAssetsBeforeValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_ValuationAllowanceTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ValuationAllowanceDeferredTaxAssetIncrease" xlink:href="apm-20231231.xsd#apm_ValuationAllowanceDeferredTaxAssetIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="apm_ValuationAllowanceDeferredTaxAssetIncrease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:href="apm-20231231.xsd#apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems" xlink:to="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AeneasManagementLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasManagementLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_AeneasManagementLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LibraSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_LibraSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_LibraSciencesLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LibraTherapeuticsLimitedOneMember" xlink:href="apm-20231231.xsd#apm_LibraTherapeuticsLimitedOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_LibraTherapeuticsLimitedOneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_TalemMedicalGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_TalemMedicalGroupLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_TalemMedicalGroupLimitedMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_CurrentAbstract" xlink:href="apm-20231231.xsd#apm_CurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems" xlink:to="apm_CurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AmountsDueFromRelatedPartiesCurrent" xlink:href="apm-20231231.xsd#apm_AmountsDueFromRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CurrentAbstract" xlink:to="apm_AmountsDueFromRelatedPartiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentInLease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentInLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CurrentAbstract" xlink:to="us-gaap_NetInvestmentInLease" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" xlink:to="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AeneasGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasGroupLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_AeneasGroupLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AencoTechnologiesLtdMember" xlink:href="apm-20231231.xsd#apm_AencoTechnologiesLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_AencoTechnologiesLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SabrinaKhanMember" xlink:href="apm-20231231.xsd#apm_SabrinaKhanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_SabrinaKhanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_JurchenInvestmentsCorporationMember" xlink:href="apm-20231231.xsd#apm_JurchenInvestmentsCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_JurchenInvestmentsCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_CurrentAbstract0" xlink:href="apm-20231231.xsd#apm_CurrentAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" xlink:to="apm_CurrentAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AmountsDueToRelatedPartiesCurrent" xlink:href="apm-20231231.xsd#apm_AmountsDueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CurrentAbstract0" xlink:to="apm_AmountsDueToRelatedPartiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NonCurrentAbstract" xlink:href="apm-20231231.xsd#apm_NonCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" xlink:to="apm_NonCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AmountsDueToRelatedPartiesNoncurrent" xlink:href="apm-20231231.xsd#apm_AmountsDueToRelatedPartiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NonCurrentAbstract" xlink:to="apm_AmountsDueToRelatedPartiesNoncurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AeneasGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasGroupLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_AeneasGroupLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_JurchenInvestmentCorporationMember" xlink:href="apm-20231231.xsd#apm_JurchenInvestmentCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_JurchenInvestmentCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_JurchenInvestmentCorporationOneMember" xlink:href="apm-20231231.xsd#apm_JurchenInvestmentCorporationOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_JurchenInvestmentCorporationOneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AencoTechnologiesLtdMember" xlink:href="apm-20231231.xsd#apm_AencoTechnologiesLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_AencoTechnologiesLtdMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_TalemMedicalGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_TalemMedicalGroupLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_TalemMedicalGroupLimitedMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LibraSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_LibraSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_LibraSciencesLimitedMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_CGYInvestmentsLimitedMember" xlink:href="apm-20231231.xsd#apm_CGYInvestmentsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_CGYInvestmentsLimitedMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ACCMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_ACCMedicalLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_ACCMedicalLimitedMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AeneasManagementLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasManagementLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_AeneasManagementLimitedMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LoanRepaymentAndInterestPaidToRelatedParties" xlink:href="apm-20231231.xsd#apm_LoanRepaymentAndInterestPaidToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_LoanRepaymentAndInterestPaidToRelatedParties" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees" xlink:href="apm-20231231.xsd#apm_ConsultantSecondmentManagementAndAdministrativeServicesFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AdministrativeManagementServices" xlink:href="apm-20231231.xsd#apm_AdministrativeManagementServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_AdministrativeManagementServices" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_Revenues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_RepaymentOfLoanFromRelatedParty" xlink:href="apm-20231231.xsd#apm_RepaymentOfLoanFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_RepaymentOfLoanFromRelatedParty" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestIncomeOther" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_OtherAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_OtherLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_AssetsNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable">
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfOperatingLeasesObligationAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_FinanceLeaseCostAbstract" xlink:href="apm-20231231.xsd#apm_FinanceLeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:to="apm_FinanceLeaseCostAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_FinanceLeaseDepreciation" xlink:href="apm-20231231.xsd#apm_FinanceLeaseDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_FinanceLeaseCostAbstract" xlink:to="apm_FinanceLeaseDepreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_VariableLeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_SubleaseIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_LeaseCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:to="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable">
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:href="apm-20231231.xsd#apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable">
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable">
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_WeightedAverageSharesOutstanding1Abstract" xlink:href="apm-20231231.xsd#apm_WeightedAverageSharesOutstanding1Abstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:to="apm_WeightedAverageSharesOutstanding1Abstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_WeightedAverageSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_WeightedAverageSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract" xlink:href="apm-20231231.xsd#apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:to="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable">
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:href="apm-20231231.xsd#apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract" xlink:to="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_PreclinicalToIndFiling" xlink:href="apm-20231231.xsd#apm_PreclinicalToIndFiling"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_PreclinicalToIndFiling" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_FromEnteringPhase1ToBeforeFirstCommercialSale" xlink:href="apm-20231231.xsd#apm_FromEnteringPhase1ToBeforeFirstCommercialSale"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_FromEnteringPhase1ToBeforeFirstCommercialSale" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_FirstCommercialSale" xlink:href="apm-20231231.xsd#apm_FirstCommercialSale"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_FirstCommercialSale" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NetSalesAmountMoreThanCertainThresholdInYear" xlink:href="apm-20231231.xsd#apm_NetSalesAmountMoreThanCertainThresholdInYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_NetSalesAmountMoreThanCertainThresholdInYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:href="apm-20231231.xsd#apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" xlink:href="apm-20231231.xsd#apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract" xlink:to="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_FdaApprovalObtaine" xlink:href="apm-20231231.xsd#apm_FdaApprovalObtaine"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_FdaApprovalObtaine" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_MilestonePaymentsTotal" xlink:href="apm-20231231.xsd#apm_MilestonePaymentsTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_MilestonePaymentsTotal" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LiquidityDetails">
    <loc xlink:type="locator" xlink:label="apm_LiquidityLineItems" xlink:href="apm-20231231.xsd#apm_LiquidityLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_LiquidityDetailsTable" xlink:href="apm-20231231.xsd#apm_LiquidityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_LiquidityLineItems" xlink:to="apm_LiquidityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_LiquidityDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LineOfCreditMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LiquidityLineItems" xlink:to="us-gaap_ProfitLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LiquidityLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LiquidityLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_UnrestrictedCashEquivalents" xlink:href="apm-20231231.xsd#apm_UnrestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_LiquidityLineItems" xlink:to="apm_UnrestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="apm-20231231.xsd#apm_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="apm_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AllowanceForCreditLossOfDueFromARelatedParty" xlink:href="apm-20231231.xsd#apm_AllowanceForCreditLossOfDueFromARelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="apm_AllowanceForCreditLossOfDueFromARelatedParty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_InventoryWriteDown" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_InvestmentandFairValueMeasurementDetailsTable" xlink:href="apm-20231231.xsd#apm_InvestmentandFairValueMeasurementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="apm_InvestmentandFairValueMeasurementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_InvestmentandFairValueMeasurementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_InvestmentandFairValueMeasurementDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_InvestmentandFairValueMeasurementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_InvestmentandFairValueMeasurementDetailsTable" xlink:to="srt_OwnershipAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LibraMember" xlink:href="apm-20231231.xsd#apm_LibraMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_LibraMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_LibraMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_OtherInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="apm-20231231.xsd#apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_WritteoffOfPrepaymentAndOtherReceivables" xlink:href="apm-20231231.xsd#apm_WritteoffOfPrepaymentAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="apm_WritteoffOfPrepaymentAndOtherReceivables" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_PropertyandEquipmentNetDetailsTable" xlink:href="apm-20231231.xsd#apm_PropertyandEquipmentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="apm_PropertyandEquipmentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_PropertyandEquipmentNetDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember" xlink:href="apm-20231231.xsd#apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IntangibleAssetsNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_IntangibleAssetsNetDetailsTable" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="apm_IntangibleAssetsNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_IntangibleAssetsNetDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_HongKongHealthcareServicesMember" xlink:href="apm-20231231.xsd#apm_HongKongHealthcareServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="apm_HongKongHealthcareServicesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_WroteOffOfCostRelatedAmortization" xlink:href="apm-20231231.xsd#apm_WroteOffOfCostRelatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="apm_WroteOffOfCostRelatedAmortization" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails">
    <loc xlink:type="locator" xlink:label="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:href="apm-20231231.xsd#apm_AccountsPayableAndAccruedExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_AccountsPayableandAccruedExpensesDetailsTable" xlink:href="apm-20231231.xsd#apm_AccountsPayableandAccruedExpensesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:to="apm_AccountsPayableandAccruedExpensesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_AccountsPayableandAccruedExpensesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_AccountsPayableandAccruedExpensesDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_AccountsPayableandAccruedExpensesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_NonrelatedPartyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_VestedAndUnvestedShareOptions" xlink:href="apm-20231231.xsd#apm_VestedAndUnvestedShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:to="apm_VestedAndUnvestedShareOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="apm_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_IncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_SG" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_SG"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SG" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CA" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxDescription" xlink:href="apm-20231231.xsd#apm_IncomeTaxDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="apm_IncomeTaxDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LossCarryforwardCancelled" xlink:href="apm-20231231.xsd#apm_LossCarryforwardCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="apm_LossCarryforwardCancelled" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsTable" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_RelatedPartyBalancesandTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="dei_LegalEntityAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_CGYInvestmentsLimitedMember" xlink:href="apm-20231231.xsd#apm_CGYInvestmentsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="apm_CGYInvestmentsLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AeneasManagementLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasManagementLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_AeneasManagementLimitedMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_CGYInvestmentsLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ACCMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_ACCMedicalLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_ACCMedicalLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_MrClarkChengMember" xlink:href="apm-20231231.xsd#apm_MrClarkChengMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_MrClarkChengMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_MrIanHuenMember" xlink:href="apm-20231231.xsd#apm_MrIanHuenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_MrIanHuenMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_MrDarrenLuiMember" xlink:href="apm-20231231.xsd#apm_MrDarrenLuiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_MrDarrenLuiMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_IanHuenMember" xlink:href="apm-20231231.xsd#apm_IanHuenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="apm_IanHuenMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_DecreasedOwnershipPercentage" xlink:href="apm-20231231.xsd#apm_DecreasedOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_DecreasedOwnershipPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermLineOfCredit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LoansInterestbearingRate" xlink:href="apm-20231231.xsd#apm_LoansInterestbearingRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_LoansInterestbearingRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCredit" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ServicesFees" xlink:href="apm-20231231.xsd#apm_ServicesFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_ServicesFees" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ServicesFeesAdjusted" xlink:href="apm-20231231.xsd#apm_ServicesFeesAdjusted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_ServicesFeesAdjusted" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndBenefitsTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndBenefitsTrust"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CompensationAndBenefitsTrust" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_RemunerationAmount" xlink:href="apm-20231231.xsd#apm_RemunerationAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="apm_RemunerationAmount" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/VariableInterestEntityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_VariableInterestEntityDetailsTable" xlink:href="apm-20231231.xsd#apm_VariableInterestEntityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="apm_VariableInterestEntityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_VariableInterestEntityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_VariableInterestEntityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_VariableInterestEntityDetailsTable" xlink:to="us-gaap_TradingActivityByTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_VariableInterestEntityDetailsTable" xlink:to="srt_OwnershipAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_GroupsSubsidiariesMember" xlink:href="apm-20231231.xsd#apm_GroupsSubsidiariesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="apm_GroupsSubsidiariesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_VaribaleInterestEntityMember" xlink:href="apm-20231231.xsd#apm_VaribaleInterestEntityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TradingActivityByTypeDomain" xlink:to="apm_VaribaleInterestEntityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LibraMember" xlink:href="apm-20231231.xsd#apm_LibraMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_LibraMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_MiosMember" xlink:href="apm-20231231.xsd#apm_MiosMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_MiosMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ScipioMember" xlink:href="apm-20231231.xsd#apm_ScipioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_ScipioMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_LibraSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_LibraSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_LibraSciencesLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_MiosPharmaceuticalsLimitedMember" xlink:href="apm-20231231.xsd#apm_MiosPharmaceuticalsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_MiosPharmaceuticalsLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ScipioLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ScipioLifeSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_ScipioLifeSciencesLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ShareOfEconomic" xlink:href="apm-20231231.xsd#apm_ShareOfEconomic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="apm_ShareOfEconomic" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LeaseDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_OperatingLeaseWeightedAverageDiscountRate" xlink:href="apm-20231231.xsd#apm_OperatingLeaseWeightedAverageDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="apm_OperatingLeaseWeightedAverageDiscountRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConvertibleNoteDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_ConvertibleNoteDetailsTable" xlink:href="apm-20231231.xsd#apm_ConvertibleNoteDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="apm_ConvertibleNoteDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ConvertibleNoteDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ConvertibleNoteDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ConvertibleNoteDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ConvertibleNotesMember" xlink:href="apm-20231231.xsd#apm_ConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="apm_ConvertibleNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ConvertibleDebt" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OrdinarySharesDetails">
    <loc xlink:type="locator" xlink:label="apm_OrdinarySharesLineItems" xlink:href="apm-20231231.xsd#apm_OrdinarySharesLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_OrdinarySharesDetailsTable" xlink:href="apm-20231231.xsd#apm_OrdinarySharesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_OrdinarySharesLineItems" xlink:to="apm_OrdinarySharesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_OrdinarySharesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_OrdinarySharesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_OrdinarySharesDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_OrdinarySharesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SharesWarrantHoldersMember" xlink:href="apm-20231231.xsd#apm_SharesWarrantHoldersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="apm_SharesWarrantHoldersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ShareOptionHoldersMember" xlink:href="apm-20231231.xsd#apm_ShareOptionHoldersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="apm_ShareOptionHoldersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_EmployeesAndExternalConsultantsMember" xlink:href="apm-20231231.xsd#apm_EmployeesAndExternalConsultantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="apm_EmployeesAndExternalConsultantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_CommonStockOtherValueOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_GrossProceed" xlink:href="apm-20231231.xsd#apm_GrossProceed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="apm_GrossProceed" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_SharesPrice" xlink:href="apm-20231231.xsd#apm_SharesPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="apm_SharesPrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_OrdinarySharesClosingPricePercentage" xlink:href="apm-20231231.xsd#apm_OrdinarySharesClosingPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="apm_OrdinarySharesClosingPricePercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_SharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ShareIssuedToConvertibleNoteHolders" xlink:href="apm-20231231.xsd#apm_ShareIssuedToConvertibleNoteHolders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_OrdinarySharesLineItems" xlink:to="apm_ShareIssuedToConvertibleNoteHolders" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ShareBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsTable" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="apm_ShareBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ShareBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ShareBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_TwoThousandSeventeenShareOptionPlanMember" xlink:href="apm-20231231.xsd#apm_TwoThousandSeventeenShareOptionPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="apm_TwoThousandSeventeenShareOptionPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_EmployeesMember" xlink:href="apm-20231231.xsd#apm_EmployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="apm_EmployeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_NonemployeesMember" xlink:href="apm-20231231.xsd#apm_NonemployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="apm_NonemployeesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_NonrelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonUnitIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NonControllingInterestDetails">
    <loc xlink:type="locator" xlink:label="apm_NonControllingInterestLineItems" xlink:href="apm-20231231.xsd#apm_NonControllingInterestLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_NonControllingInterestDetailsTable" xlink:href="apm-20231231.xsd#apm_NonControllingInterestDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_NonControllingInterestLineItems" xlink:to="apm_NonControllingInterestDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_NonControllingInterestDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_NonControllingInterestDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_NonControllingInterestDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_NonControllingInterestDetailsTable" xlink:to="srt_OwnershipAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_GroupsSubsidiariesMember" xlink:href="apm-20231231.xsd#apm_GroupsSubsidiariesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="apm_GroupsSubsidiariesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AptorumMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_AptorumMedicalLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="apm_AptorumMedicalLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ClarkChengMember" xlink:href="apm-20231231.xsd#apm_ClarkChengMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="apm_ClarkChengMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_MiosPharmaceuticalsLimitedMember" xlink:href="apm-20231231.xsd#apm_MiosPharmaceuticalsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_MiosPharmaceuticalsLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_ScipioLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ScipioLifeSciencesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="apm_ScipioLifeSciencesLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsUnitsIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOwnershipInterestsUnitsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NonControllingInterestLineItems" xlink:to="us-gaap_OtherOwnershipInterestsUnitsIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NonControllingInterestLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NonControllingInterestLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit" xlink:href="apm-20231231.xsd#apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NonControllingInterestLineItems" xlink:to="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NonControllingInterestLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnersCapitalAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NonControllingInterestLineItems" xlink:to="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NetLossPerShareDetails">
    <loc xlink:type="locator" xlink:label="apm_NetLossPerShareLineItems" xlink:href="apm-20231231.xsd#apm_NetLossPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_NetLossPerShareDetailsTable" xlink:href="apm-20231231.xsd#apm_NetLossPerShareDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="apm_NetLossPerShareLineItems" xlink:to="apm_NetLossPerShareDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_NetLossPerShareDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NetLossPerShareLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="apm_NetLossPerShareLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="apm_MilestonePayments" xlink:href="apm-20231231.xsd#apm_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="apm_MilestonePayments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SegmentReportingDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="apm_SubsequentEventsDetailsTable" xlink:href="apm-20231231.xsd#apm_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="apm_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="apm_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_CGYInvestmentsLimitedMember" xlink:href="apm-20231231.xsd#apm_CGYInvestmentsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_CGYInvestmentsLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_DSFInvestmentHoldingsLimitedMember" xlink:href="apm-20231231.xsd#apm_DSFInvestmentHoldingsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="apm_DSFInvestmentHoldingsLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_sharesOutstandingPerentage" xlink:href="apm-20231231.xsd#apm_sharesOutstandingPerentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="apm_sharesOutstandingPerentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFairValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EquityFairValueAdjustment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="apm_OutstandingSharesPercentage" xlink:href="apm-20231231.xsd#apm_OutstandingSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="apm_OutstandingSharesPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityOtherShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ExcessStockSharesOutstanding" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>apm-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 09:10:53 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total equity attributable to the shareholders of Aptorum Group Limited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net loss before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss attributable to Aptorum Group Limited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other comprehensive (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss attributable to the shareholders of Aptorum Group Limited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net operation cash outflow</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash &#8211; Beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents and restricted cash &#8211; End of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAbstract_lbl" xml:lang="en-US">Investment and Fair Value Measurement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" xlink:to="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" xlink:to="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfUnrealizedGainsAndLossesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfUnrealizedGainsAndLossesAbstract_lbl" xml:lang="en-US">Schedule of Unrealized Gains and Losses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:to="apm_ScheduleOfUnrealizedGainsAndLossesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_TotalUnrealizedGainForNonmarketableInvestments" xlink:href="apm-20231231.xsd#apm_TotalUnrealizedGainForNonmarketableInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="apm_TotalUnrealizedGainForNonmarketableInvestments_lbl" xml:lang="en-US">Total unrealized gain from fair value change of non-marketable investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TotalUnrealizedGainForNonmarketableInvestments" xlink:to="apm_TotalUnrealizedGainForNonmarketableInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of Carrying Value of Our Non-Marketable Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:to="apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_TotalCarryingValueAtTheEndOfThePeriod" xlink:href="apm-20231231.xsd#apm_TotalCarryingValueAtTheEndOfThePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="apm_TotalCarryingValueAtTheEndOfThePeriod_lbl" xml:lang="en-US">Total carrying value at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TotalCarryingValueAtTheEndOfThePeriod" xlink:to="apm_TotalCarryingValueAtTheEndOfThePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Other receivables and prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Intangible Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Long-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract_lbl" xml:lang="en-US">Schedule of accounts payable and accrued expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income taxes expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Effective income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Balances and Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_VariableInterestEntityAbstract" xlink:href="apm-20231231.xsd#apm_VariableInterestEntityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_VariableInterestEntityAbstract_lbl" xml:lang="en-US">Variable Interest Entity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_VariableInterestEntityAbstract" xlink:to="apm_VariableInterestEntityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Maturity Analysis of Operating Leases Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:to="apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future undiscounted cash flow</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Convertible Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xml:lang="en-US">Share Based Compensation [Abstarct]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfTheOptionActivityAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfTheOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfTheOptionActivityAbstract_lbl" xml:lang="en-US">Schedule of the Option Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfTheOptionActivityAbstract" xlink:to="apm_ScheduleOfTheOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of share options, Outstanding, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of share options, Outstanding, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, Outstanding, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US">Non-Controlling Interest [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract_lbl" xml:lang="en-US">Schedule of Basic and Diluted Loss Income Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:to="apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstart]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:href="apm-20231231.xsd#apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal_lbl" xml:lang="en-US">Subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:to="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_MilestonePaymentsTotal" xlink:href="apm-20231231.xsd#apm_MilestonePaymentsTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="apm_MilestonePaymentsTotal_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MilestonePaymentsTotal" xlink:to="apm_MilestonePaymentsTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities, at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Amounts due from related parties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DueFromBrokers" xlink:href="apm-20231231.xsd#apm_DueFromBrokers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DueFromBrokers_lbl" xml:lang="en-US">Due from brokers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DueFromBrokers" xlink:to="apm_DueFromBrokers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Loan receivable from related parties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract" xlink:to="apm_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract0" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract0" xlink:to="apm_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Amounts due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Less: Current portion of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Non-current portion of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes to a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Loan payables to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract1" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract1" xlink:to="apm_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract2" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract2" xlink:to="apm_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Ordinary per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Healthcare services income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract3" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract3" xlink:to="apm_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract4" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract4" xlink:to="apm_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OciNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciNetOfTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OciNetOfTaxAbstract_lbl" xml:lang="en-US">Other income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_OciNetOfTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Loss on investments in marketable securities, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xml:lang="en-US">Unrealized gain from fair value change of the long-term investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Loss on investments in derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl0" xml:lang="en-US">Loss on investments in derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_GainOnDerecognitionOfNonfinancialAssets" xlink:href="apm-20231231.xsd#apm_GainOnDerecognitionOfNonfinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_GainOnDerecognitionOfNonfinancialAssets_lbl" xml:lang="en-US">Gain on derecognition of non-financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GainOnDerecognitionOfNonfinancialAssets" xlink:to="apm_GainOnDerecognitionOfNonfinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest (expense) income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl" xml:lang="en-US">Loss on disposal of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl0" xml:lang="en-US">Loss on disposal of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_SundryIncome" xlink:href="apm-20231231.xsd#apm_SundryIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_SundryIncome_lbl" xml:lang="en-US">Sundry income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SundryIncome" xlink:to="apm_SundryIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract5" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract5" xlink:to="apm_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract6" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract6" xlink:to="apm_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract7" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract7" xlink:to="apm_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net loss per share attributable to Aptorum Group Limited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">- Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">- Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted-average shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">- Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">- Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract8" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract8" xlink:to="apm_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract9" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract9" xlink:to="apm_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Exchange differences on translation of foreign operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract10" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract10" xlink:to="apm_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract11" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract11" xlink:to="apm_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Class A Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Class A Ordinary Shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest" xlink:href="apm-20231231.xsd#apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest_lbl" xml:lang="en-US">Issuance of shares to non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest" xlink:to="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction_lbl" xml:lang="en-US">Disposal of subsidiaries under common control transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" xlink:to="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries_lbl" xml:lang="en-US">Disposal of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries" xlink:to="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="apm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of share options, Outstanding, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ExchangeDifferenceOnTranslationOfForeignOperation" xlink:href="apm-20231231.xsd#apm_ExchangeDifferenceOnTranslationOfForeignOperation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ExchangeDifferenceOnTranslationOfForeignOperation_lbl" xml:lang="en-US">Exchange difference on translation of foreign operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ExchangeDifferenceOnTranslationOfForeignOperation" xlink:to="apm_ExchangeDifferenceOnTranslationOfForeignOperation_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract12" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract12" xlink:to="apm_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract13" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract13" xlink:to="apm_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of shares in exchange of share options and settlement of liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of shares in exchange of share options and settlement of liabilities (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Issuance of shares for share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of shares for share-based compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeriodValueIssuanceOfShares" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodValueIssuanceOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_StockIssuedDuringPeriodValueIssuanceOfShares_lbl" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodValueIssuanceOfShares" xlink:to="apm_StockIssuedDuringPeriodValueIssuanceOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_StockIssuedDuringPeridSharesIssuanceOfShares" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeridSharesIssuanceOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_StockIssuedDuringPeridSharesIssuanceOfShares_lbl" xml:lang="en-US">Issuance of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeridSharesIssuanceOfShares" xlink:to="apm_StockIssuedDuringPeridSharesIssuanceOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Rounding up for reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Rounding up for reverse stock split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract14" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract14" xlink:to="apm_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Amortization and depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment loss on long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AllowanceForCreditLossOfDueFromARelatedParty" xlink:href="apm-20231231.xsd#apm_AllowanceForCreditLossOfDueFromARelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AllowanceForCreditLossOfDueFromARelatedParty_lbl" xml:lang="en-US">Allowance for credit loss of due from a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AllowanceForCreditLossOfDueFromARelatedParty" xlink:to="apm_AllowanceForCreditLossOfDueFromARelatedParty_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="apm_AllowanceForCreditLossOfDueFromARelatedParty_lbl0" xml:lang="en-US">Allowance for credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AllowanceForCreditLossOfDueFromARelatedParty" xlink:to="apm_AllowanceForCreditLossOfDueFromARelatedParty_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_WritteoffOfPrepaymentAndOtherReceivables" xlink:href="apm-20231231.xsd#apm_WritteoffOfPrepaymentAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_WritteoffOfPrepaymentAndOtherReceivables_lbl" xml:lang="en-US">Write-off of prepayment and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WritteoffOfPrepaymentAndOtherReceivables" xlink:to="apm_WritteoffOfPrepaymentAndOtherReceivables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="apm_WritteoffOfPrepaymentAndOtherReceivables_lbl0" xml:lang="en-US">Other operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WritteoffOfPrepaymentAndOtherReceivables" xlink:to="apm_WritteoffOfPrepaymentAndOtherReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Write-down of inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl0" xml:lang="en-US">Written-down of inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_InterestExpenseAndAccretionOfConvertibleDebts" xlink:href="apm-20231231.xsd#apm_InterestExpenseAndAccretionOfConvertibleDebts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_InterestExpenseAndAccretionOfConvertibleDebts_lbl" xml:lang="en-US">Interest expense and accretion of convertible debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InterestExpenseAndAccretionOfConvertibleDebts" xlink:to="apm_InterestExpenseAndAccretionOfConvertibleDebts_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AccretionOfFinanceLeaseObligation" xlink:href="apm-20231231.xsd#apm_AccretionOfFinanceLeaseObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AccretionOfFinanceLeaseObligation_lbl" xml:lang="en-US">Accretion of finance lease obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AccretionOfFinanceLeaseObligation" xlink:to="apm_AccretionOfFinanceLeaseObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ReversalDeferredCashBonus" xlink:href="apm-20231231.xsd#apm_ReversalDeferredCashBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ReversalDeferredCashBonus_lbl" xml:lang="en-US">Reversal of deferred cash bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ReversalDeferredCashBonus" xlink:to="apm_ReversalDeferredCashBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Amounts due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from sales of investment securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Loan from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from issuance of subsidiaries shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of Class A Ordinary Shares and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromBankDebt_lbl" xml:lang="en-US">Loan from a bank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Issuance of Convertible Note to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract15" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract15" xlink:to="apm_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract16" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract16" xlink:to="apm_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ProceedsInBrokerAccounts" xlink:href="apm-20231231.xsd#apm_ProceedsInBrokerAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ProceedsInBrokerAccounts_lbl" xml:lang="en-US">Proceeds in broker accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ProceedsInBrokerAccounts" xlink:to="apm_ProceedsInBrokerAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash operating, investing and financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" xlink:href="apm-20231231.xsd#apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens_lbl" xml:lang="en-US">Settlement of service fee by tokens and digital currencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" xlink:to="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ConvertibleNotesConvertedToClassAOrdinaryShares" xlink:href="apm-20231231.xsd#apm_ConvertibleNotesConvertedToClassAOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ConvertibleNotesConvertedToClassAOrdinaryShares_lbl" xml:lang="en-US">Convertible notes converted to Class A Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConvertibleNotesConvertedToClassAOrdinaryShares" xlink:to="apm_ConvertibleNotesConvertedToClassAOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions" xlink:href="apm-20231231.xsd#apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions_lbl" xml:lang="en-US">Settlement of deferred cash bonus by issuance of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions" xlink:to="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Reconciliation of cash and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of healthcare services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Legal and professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Other operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_GainOnUseOfDigitalCurrencies" xlink:href="apm-20231231.xsd#apm_GainOnUseOfDigitalCurrencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apm_GainOnUseOfDigitalCurrencies_lbl" xml:lang="en-US">Gain on use of digital currencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GainOnUseOfDigitalCurrencies" xlink:to="apm_GainOnUseOfDigitalCurrencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:href="apm-20231231.xsd#apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue_lbl" xml:lang="en-US">Adjustment for change of par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LossGainOnInvestmentsInMarketableSecuritiesNet" xlink:href="apm-20231231.xsd#apm_LossGainOnInvestmentsInMarketableSecuritiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apm_LossGainOnInvestmentsInMarketableSecuritiesNet_lbl" xml:lang="en-US">Loss on investments in marketable securities, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LossGainOnInvestmentsInMarketableSecuritiesNet" xlink:to="apm_LossGainOnInvestmentsInMarketableSecuritiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Unrealized gain from fair value change of the long-term investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Gain on derecognition of non-financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LossOnDisposalOfLonglivedAssets" xlink:href="apm-20231231.xsd#apm_LossOnDisposalOfLonglivedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apm_LossOnDisposalOfLonglivedAssets_lbl" xml:lang="en-US">Loss on disposal of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LossOnDisposalOfLonglivedAssets" xlink:to="apm_LossOnDisposalOfLonglivedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_GainOnUseOfDigitalsCurrencies" xlink:href="apm-20231231.xsd#apm_GainOnUseOfDigitalsCurrencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apm_GainOnUseOfDigitalsCurrencies_lbl" xml:lang="en-US">Gain on use of digital currencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GainOnUseOfDigitalsCurrencies" xlink:to="apm_GainOnUseOfDigitalsCurrencies_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens" xlink:href="apm-20231231.xsd#apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens_lbl" xml:lang="en-US">Settlement of service fee by tokens and digital currencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens" xlink:to="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeOther_lbl0" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other receivables and prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US">Long-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IncreaseDecreaseDueFromBrokers" xlink:href="apm-20231231.xsd#apm_IncreaseDecreaseDueFromBrokers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apm_IncreaseDecreaseDueFromBrokers_lbl" xml:lang="en-US">Due from brokers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncreaseDecreaseDueFromBrokers" xlink:to="apm_IncreaseDecreaseDueFromBrokers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xml:lang="en-US">Amounts due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchases of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DisposalOfSubsidiariesNetOfCashDisposed" xlink:href="apm-20231231.xsd#apm_DisposalOfSubsidiariesNetOfCashDisposed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apm_DisposalOfSubsidiariesNetOfCashDisposed_lbl" xml:lang="en-US">Disposal of subsidiaries, net of cash disposed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DisposalOfSubsidiariesNetOfCashDisposed" xlink:to="apm_DisposalOfSubsidiariesNetOfCashDisposed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xml:lang="en-US">Loan to a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl0" xml:lang="en-US">Loan to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_RepaymentOfLoanFromRelatedParty" xlink:href="apm-20231231.xsd#apm_RepaymentOfLoanFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="apm_RepaymentOfLoanFromRelatedParty_lbl" xml:lang="en-US">Repayment of loan and interest from a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RepaymentOfLoanFromRelatedParty" xlink:to="apm_RepaymentOfLoanFromRelatedParty_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_RepaymentOfLoanFromRelatedParty_lbl0" xml:lang="en-US">Loan repayment and interest received from a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RepaymentOfLoanFromRelatedParty" xlink:to="apm_RepaymentOfLoanFromRelatedParty_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of loan due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Repayment of bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment of finance lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Financing cash flows from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Class A Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonClassAMember_lbl0" xml:lang="en-US">Class A</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonClassAMember_lbl1" xml:lang="en-US">Class A Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl2" xml:lang="en-US">Common Class A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Class B Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonClassBMember_lbl0" xml:lang="en-US">Class B</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonClassBMember_lbl1" xml:lang="en-US">Class B Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stocks [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) income Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non- controlling interests Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">Schedule of Major Subsidiaries Consolidated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Incorporation date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Ownership interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_EntityIncorporationsStateCountryName" xlink:href="apm-20231231.xsd#apm_EntityIncorporationsStateCountryName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_EntityIncorporationsStateCountryName_lbl" xml:lang="en-US">Place of incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_EntityIncorporationsStateCountryName" xlink:to="apm_EntityIncorporationsStateCountryName_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PrincipleActivities" xlink:href="apm-20231231.xsd#apm_PrincipleActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_PrincipleActivities_lbl" xml:lang="en-US">Principle activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrincipleActivities" xlink:to="apm_PrincipleActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LiquidityDisclosureTextBlock" xlink:href="apm-20231231.xsd#apm_LiquidityDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LiquidityDisclosureTextBlock_lbl" xml:lang="en-US">LIQUIDITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LiquidityDisclosureTextBlock" xlink:to="apm_LiquidityDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock" xlink:href="apm-20231231.xsd#apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock" xlink:to="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_LeaseholdImprovementsEstimatedUsefulLives" xlink:href="apm-20231231.xsd#apm_LeaseholdImprovementsEstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LeaseholdImprovementsEstimatedUsefulLives_lbl" xml:lang="en-US">Leasehold improvements, estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LeaseholdImprovementsEstimatedUsefulLives" xlink:to="apm_LeaseholdImprovementsEstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">INVESTMENT AND FAIR VALUE MEASUREMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NonCurrentAssetsAbstract" xlink:href="apm-20231231.xsd#apm_NonCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NonCurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonCurrentAssetsAbstract" xlink:to="apm_NonCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestmentsAbstract_lbl" xml:lang="en-US">Long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total assets at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NonCurrentAssetsAbstract0" xlink:href="apm-20231231.xsd#apm_NonCurrentAssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NonCurrentAssetsAbstract0_lbl" xml:lang="en-US">Non-current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonCurrentAssetsAbstract0" xlink:to="apm_NonCurrentAssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermInvestmentsAbstract0" xlink:href="apm-20231231.xsd#apm_LongTermInvestmentsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LongTermInvestmentsAbstract0_lbl" xml:lang="en-US">Long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongTermInvestmentsAbstract0" xlink:to="apm_LongTermInvestmentsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Reconciliation of Level 3 Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments" xlink:href="apm-20231231.xsd#apm_NetChangeInUnrealizedDepreciationRelatingToInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments_lbl" xml:lang="en-US">Net change in unrealized appreciation relating to investments still held</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments" xlink:to="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract17" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract17" xlink:to="apm_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation" xlink:href="apm-20231231.xsd#apm_FairValueOfChangeInUnrealizedAppreciationDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation_lbl" xml:lang="en-US">Change in unrealized appreciation, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation" xlink:to="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Quantitative Information about the Group&#8217;s Level 3 Fair Value Measurements of Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract18" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract18" xlink:to="apm_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueMeasurementValuationTechniques" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementValuationTechniques"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_FairValueMeasurementValuationTechniques_lbl" xml:lang="en-US">Valuation technique</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementValuationTechniques" xlink:to="apm_FairValueMeasurementValuationTechniques_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueMeasurementsUnobservableInput" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementsUnobservableInput"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_FairValueMeasurementsUnobservableInput_lbl" xml:lang="en-US">Unobservable input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementsUnobservableInput" xlink:to="apm_FairValueMeasurementsUnobservableInput_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FairValueMeasurementsWeightedAverageRange" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementsWeightedAverageRange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_FairValueMeasurementsWeightedAverageRange_lbl" xml:lang="en-US">Range (weighted average)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementsWeightedAverageRange" xlink:to="apm_FairValueMeasurementsWeightedAverageRange_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract19" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract19" xlink:to="apm_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrealized Gains and Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock" xlink:to="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UpwardAdjustments" xlink:href="apm-20231231.xsd#apm_UpwardAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UpwardAdjustments_lbl" xml:lang="en-US">Upward adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UpwardAdjustments" xlink:to="apm_UpwardAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DownwardAdjustmentsAndImpairment" xlink:href="apm-20231231.xsd#apm_DownwardAdjustmentsAndImpairment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DownwardAdjustmentsAndImpairment_lbl" xml:lang="en-US">Downward adjustments and impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DownwardAdjustmentsAndImpairment" xlink:to="apm_DownwardAdjustmentsAndImpairment_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Carrying Value of Our Non-Marketable Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock" xlink:to="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_InitialCostBasis" xlink:href="apm-20231231.xsd#apm_InitialCostBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_InitialCostBasis_lbl" xml:lang="en-US">Initial cost basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InitialCostBasis" xlink:to="apm_InitialCostBasis_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UpwardAdjustment" xlink:href="apm-20231231.xsd#apm_UpwardAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UpwardAdjustment_lbl" xml:lang="en-US">Upward adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UpwardAdjustment" xlink:to="apm_UpwardAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DownwardAdjustmentAndImpairment" xlink:href="apm-20231231.xsd#apm_DownwardAdjustmentAndImpairment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DownwardAdjustmentAndImpairment_lbl" xml:lang="en-US">Downward adjustments and impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DownwardAdjustmentAndImpairment" xlink:to="apm_DownwardAdjustmentAndImpairment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER RECEIVABLES AND PREPAYMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Other Receivables and Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaidResearchAndDevelopmentExpenses" xlink:href="apm-20231231.xsd#apm_PrepaidResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaidResearchAndDevelopmentExpenses" xlink:to="apm_PrepaidResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaidServiceFee" xlink:href="apm-20231231.xsd#apm_PrepaidServiceFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_PrepaidServiceFee_lbl" xml:lang="en-US">Prepaid service fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaidServiceFee" xlink:to="apm_PrepaidServiceFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Rental deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US">Prepaid rental expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, plant and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_GrossCarryingAmountAbstract" xlink:href="apm-20231231.xsd#apm_GrossCarryingAmountAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_GrossCarryingAmountAbstract_lbl" xml:lang="en-US">Gross carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GrossCarryingAmountAbstract" xlink:to="apm_GrossCarryingAmountAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract20" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract20" xlink:to="apm_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LessAccumulatedAmortizationAndImpairmentAbstract" xlink:href="apm-20231231.xsd#apm_LessAccumulatedAmortizationAndImpairmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LessAccumulatedAmortizationAndImpairmentAbstract_lbl" xml:lang="en-US">Less: accumulated amortization and impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LessAccumulatedAmortizationAndImpairmentAbstract" xlink:to="apm_LessAccumulatedAmortizationAndImpairmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract21" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract21" xlink:to="apm_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IntangibleAssetsNetAbstract" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_IntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IntangibleAssetsNetAbstract" xlink:to="apm_IntangibleAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">LONG-TERM DEPOSITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfLongTermDepositsTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfLongTermDepositsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ScheduleOfLongTermDepositsTableTextBlock_lbl" xml:lang="en-US">Schedule of Long-Term Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfLongTermDepositsTableTextBlock" xlink:to="apm_ScheduleOfLongTermDepositsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_RentalDeposits" xlink:href="apm-20231231.xsd#apm_RentalDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_RentalDeposits_lbl" xml:lang="en-US">Rental deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RentalDeposits" xlink:to="apm_RentalDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaymentsForEquipment" xlink:href="apm-20231231.xsd#apm_PrepaymentsForEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_PrepaymentsForEquipment_lbl" xml:lang="en-US">Prepayments for equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaymentsForEquipment" xlink:to="apm_PrepaymentsForEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Deferred bonus and salaries payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ResearchAndDevelopmentExpensesPayable" xlink:href="apm-20231231.xsd#apm_ResearchAndDevelopmentExpensesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ResearchAndDevelopmentExpensesPayable_lbl" xml:lang="en-US">Research and development expenses payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ResearchAndDevelopmentExpensesPayable" xlink:to="apm_ResearchAndDevelopmentExpensesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_CostOfHealthcareServicesPayable" xlink:href="apm-20231231.xsd#apm_CostOfHealthcareServicesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_CostOfHealthcareServicesPayable_lbl" xml:lang="en-US">Cost of healthcare services payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CostOfHealthcareServicesPayable" xlink:to="apm_CostOfHealthcareServicesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_InsuranceExpensePayable" xlink:href="apm-20231231.xsd#apm_InsuranceExpensePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_InsuranceExpensePayable_lbl" xml:lang="en-US">Insurance expenses payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InsuranceExpensePayable" xlink:to="apm_InsuranceExpensePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Provision for Income Taxes Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Provision for income taxes at Hong Kong statutory income tax rate (16.5%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Impact of different tax rates in other jurisdictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Asset and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DeferredTaxAssetAbstract" xlink:href="apm-20231231.xsd#apm_DeferredTaxAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DeferredTaxAssetAbstract_lbl" xml:lang="en-US">Deferred tax asset:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DeferredTaxAssetAbstract" xlink:to="apm_DeferredTaxAssetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Tax loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DeferredTaxAssetsDepreciationAndAmortization" xlink:href="apm-20231231.xsd#apm_DeferredTaxAssetsDepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="apm_DeferredTaxAssetsDepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DeferredTaxLiabilityAbstract" xlink:href="apm-20231231.xsd#apm_DeferredTaxLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DeferredTaxLiabilityAbstract_lbl" xml:lang="en-US">Deferred tax liability:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DeferredTaxLiabilityAbstract" xlink:to="apm_DeferredTaxLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NetDeferredTaxAssetsBeforeValuationAllowance" xlink:href="apm-20231231.xsd#apm_NetDeferredTaxAssetsBeforeValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NetDeferredTaxAssetsBeforeValuationAllowance_lbl" xml:lang="en-US">Net deferred tax assets before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetDeferredTaxAssetsBeforeValuationAllowance" xlink:to="apm_NetDeferredTaxAssetsBeforeValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ValuationAllowanceDeferredTaxAssetIncrease" xlink:href="apm-20231231.xsd#apm_ValuationAllowanceDeferredTaxAssetIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ValuationAllowanceDeferredTaxAssetIncrease_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ValuationAllowanceDeferredTaxAssetIncrease" xlink:to="apm_ValuationAllowanceDeferredTaxAssetIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:href="apm-20231231.xsd#apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount_lbl" xml:lang="en-US">Disposal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:to="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Balances and Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Amounts Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock" xlink:to="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_CurrentAbstract" xlink:href="apm-20231231.xsd#apm_CurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_CurrentAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CurrentAbstract" xlink:to="apm_CurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AmountsDueFromRelatedPartiesCurrent" xlink:href="apm-20231231.xsd#apm_AmountsDueFromRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AmountsDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Amounts due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AmountsDueFromRelatedPartiesCurrent" xlink:to="apm_AmountsDueFromRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Amounts Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:to="apm_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_CurrentAbstract0" xlink:href="apm-20231231.xsd#apm_CurrentAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_CurrentAbstract0_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CurrentAbstract0" xlink:to="apm_CurrentAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AmountsDueToRelatedPartiesCurrent" xlink:href="apm-20231231.xsd#apm_AmountsDueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AmountsDueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Amounts due to related parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AmountsDueToRelatedPartiesCurrent" xlink:to="apm_AmountsDueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract22" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract22" xlink:to="apm_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NonCurrentAbstract" xlink:href="apm-20231231.xsd#apm_NonCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NonCurrentAbstract_lbl" xml:lang="en-US">Non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonCurrentAbstract" xlink:to="apm_NonCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AmountsDueToRelatedPartiesNoncurrent" xlink:href="apm-20231231.xsd#apm_AmountsDueToRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AmountsDueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Amounts due to related parties, Non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AmountsDueToRelatedPartiesNoncurrent" xlink:to="apm_AmountsDueToRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LoanFromRelatedPartiesNoteAAbstract" xlink:href="apm-20231231.xsd#apm_LoanFromRelatedPartiesNoteAAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LoanFromRelatedPartiesNoteAAbstract_lbl" xml:lang="en-US">Loan from related parties (Note a)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanFromRelatedPartiesNoteAAbstract" xlink:to="apm_LoanFromRelatedPartiesNoteAAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract23" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract23" xlink:to="apm_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract" xlink:href="apm-20231231.xsd#apm_LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract_lbl" xml:lang="en-US">Loan repayment and interest paid to related parties (Note a)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract" xlink:to="apm_LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LoanRepaymentAndInterestPaidToRelatedParties" xlink:href="apm-20231231.xsd#apm_LoanRepaymentAndInterestPaidToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LoanRepaymentAndInterestPaidToRelatedParties_lbl" xml:lang="en-US">Loan repayment and interest paid to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanRepaymentAndInterestPaidToRelatedParties" xlink:to="apm_LoanRepaymentAndInterestPaidToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract24" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract24" xlink:to="apm_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract" xlink:href="apm-20231231.xsd#apm_IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract_lbl" xml:lang="en-US">Issuance of Convertible Note to related parties (Note 15)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract" xlink:to="apm_IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract25" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract25" xlink:to="apm_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract" xlink:href="apm-20231231.xsd#apm_SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract_lbl" xml:lang="en-US">Settlement of loan from a related party through issuance of Convertible Note (Note 15)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract" xlink:to="apm_SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees" xlink:href="apm-20231231.xsd#apm_ConsultantSecondmentManagementAndAdministrativeServicesFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees_lbl" xml:lang="en-US">Settlement of loan from a related party through issuance of Convertible Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees" xlink:to="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract26" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract26" xlink:to="apm_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_InterestExpensesNoteAAndNote15Abstract" xlink:href="apm-20231231.xsd#apm_InterestExpensesNoteAAndNote15Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_InterestExpensesNoteAAndNote15Abstract_lbl" xml:lang="en-US">Interest expenses (Note a and Note 15)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InterestExpensesNoteAAndNote15Abstract" xlink:to="apm_InterestExpensesNoteAAndNote15Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract27" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract27" xlink:to="apm_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LoanToRelatedPartiesNoteBAbstract" xlink:href="apm-20231231.xsd#apm_LoanToRelatedPartiesNoteBAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LoanToRelatedPartiesNoteBAbstract_lbl" xml:lang="en-US">Loan to related parties (Note b)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanToRelatedPartiesNoteBAbstract" xlink:to="apm_LoanToRelatedPartiesNoteBAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract28" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract28" xlink:to="apm_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract" xlink:href="apm-20231231.xsd#apm_LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract_lbl" xml:lang="en-US">Loan repayment and interest received from a related party (Note b)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract" xlink:to="apm_LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract29" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract29" xlink:to="apm_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_InterestIncomeNoteBAbstract" xlink:href="apm-20231231.xsd#apm_InterestIncomeNoteBAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_InterestIncomeNoteBAbstract_lbl" xml:lang="en-US">Interest income (Note b)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InterestIncomeNoteBAbstract" xlink:to="apm_InterestIncomeNoteBAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract30" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract30" xlink:to="apm_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract" xlink:href="apm-20231231.xsd#apm_ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract_lbl" xml:lang="en-US">Consultant, secondment, management and administrative services fees (Note c)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract" xlink:to="apm_ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract31" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract31" xlink:to="apm_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AdministrativeManagementServicesNoteDAbstract" xlink:href="apm-20231231.xsd#apm_AdministrativeManagementServicesNoteDAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AdministrativeManagementServicesNoteDAbstract_lbl" xml:lang="en-US">Administrative management services (Note d)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdministrativeManagementServicesNoteDAbstract" xlink:to="apm_AdministrativeManagementServicesNoteDAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AdministrativeManagementServices" xlink:href="apm-20231231.xsd#apm_AdministrativeManagementServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AdministrativeManagementServices_lbl" xml:lang="en-US">Administrative management services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdministrativeManagementServices" xlink:to="apm_AdministrativeManagementServices_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract32" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract32" xlink:to="apm_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_HealthcareServicesIncomeAbstract" xlink:href="apm-20231231.xsd#apm_HealthcareServicesIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_HealthcareServicesIncomeAbstract_lbl" xml:lang="en-US">Healthcare services income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_HealthcareServicesIncomeAbstract" xlink:to="apm_HealthcareServicesIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock_lbl" xml:lang="en-US">VARIABLE INTEREST ENTITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xml:lang="en-US">Schedule of Aggregate Carrying Value of Vies&#8217; Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNet_lbl" xml:lang="en-US">Net Assets/ (Liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_AssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_December312022Abstract" xlink:href="apm-20231231.xsd#apm_December312022Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_December312022Abstract_lbl" xml:lang="en-US">December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_December312022Abstract" xlink:to="apm_December312022Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_lbl" xml:lang="en-US">Maximum Exposure to Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:to="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_December312022Abstract0" xlink:href="apm-20231231.xsd#apm_December312022Abstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_December312022Abstract0_lbl" xml:lang="en-US">December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_December312022Abstract0" xlink:to="apm_December312022Abstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Leases Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FinanceLeaseCostAbstract" xlink:href="apm-20231231.xsd#apm_FinanceLeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_FinanceLeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FinanceLeaseCostAbstract" xlink:to="apm_FinanceLeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FinanceLeaseDepreciation" xlink:href="apm-20231231.xsd#apm_FinanceLeaseDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_FinanceLeaseDepreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FinanceLeaseDepreciation" xlink:to="apm_FinanceLeaseDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract33" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract33" xlink:to="apm_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OtherInformationAbstract" xlink:href="apm-20231231.xsd#apm_OtherInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_OtherInformationAbstract_lbl" xml:lang="en-US">Other information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherInformationAbstract" xlink:to="apm_OtherInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term &#8211; finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term &#8211; operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Weighted average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate &#8211; finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate &#8211; operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity Analysis of Operating Leases Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">ORDINARY SHARES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of the Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Remaining contractual term in years, Outstanding, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract34" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract34" xlink:to="apm_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of share options, Outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-average grant date fair value of share option grants (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Remaining contractual term in years, Outstanding, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic value, Outstanding, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of share options, Outstanding,Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:href="apm-20231231.xsd#apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Remaining contractual term in years, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract35" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract35" xlink:to="apm_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Remaining contractual term in years, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract36" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract36" xlink:to="apm_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term from grant date (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor_lbl" xml:lang="en-US">Dilution factor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">NON-CONTROLLING INTEREST</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted (loss) income per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NumeratorAbstract" xlink:href="apm-20231231.xsd#apm_NumeratorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NumeratorAbstract" xlink:to="apm_NumeratorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to Aptorum Group Limited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DenominatorAbstract" xlink:href="apm-20231231.xsd#apm_DenominatorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DenominatorAbstract" xlink:to="apm_DenominatorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_WeightedAverageSharesOutstanding1Abstract" xlink:href="apm-20231231.xsd#apm_WeightedAverageSharesOutstanding1Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_WeightedAverageSharesOutstanding1Abstract_lbl" xml:lang="en-US">Weighted average shares outstanding(1)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WeightedAverageSharesOutstanding1Abstract" xlink:to="apm_WeightedAverageSharesOutstanding1Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract37" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract37" xlink:to="apm_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract" xlink:href="apm-20231231.xsd#apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract_lbl" xml:lang="en-US">Net loss per share attributable to Aptorum Group Limited(1)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract" xlink:to="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" xlink:to="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:href="apm-20231231.xsd#apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract_lbl" xml:lang="en-US">Drug molecules: up to the conditions and milestones of</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PreclinicalToIndFiling" xlink:href="apm-20231231.xsd#apm_PreclinicalToIndFiling"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_PreclinicalToIndFiling_lbl" xml:lang="en-US">Preclinical to IND filing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PreclinicalToIndFiling" xlink:to="apm_PreclinicalToIndFiling_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FromEnteringPhase1ToBeforeFirstCommercialSale" xlink:href="apm-20231231.xsd#apm_FromEnteringPhase1ToBeforeFirstCommercialSale"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_FromEnteringPhase1ToBeforeFirstCommercialSale_lbl" xml:lang="en-US">From entering phase 1 to before first commercial sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FromEnteringPhase1ToBeforeFirstCommercialSale" xlink:to="apm_FromEnteringPhase1ToBeforeFirstCommercialSale_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FirstCommercialSale" xlink:href="apm-20231231.xsd#apm_FirstCommercialSale"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_FirstCommercialSale_lbl" xml:lang="en-US">First commercial sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FirstCommercialSale" xlink:to="apm_FirstCommercialSale_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NetSalesAmountMoreThanCertainThresholdInYear" xlink:href="apm-20231231.xsd#apm_NetSalesAmountMoreThanCertainThresholdInYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NetSalesAmountMoreThanCertainThresholdInYear_lbl" xml:lang="en-US">Net sales amount more than certain threshold in a year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetSalesAmountMoreThanCertainThresholdInYear" xlink:to="apm_NetSalesAmountMoreThanCertainThresholdInYear_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnlabeledAbstract38" xlink:href="apm-20231231.xsd#apm_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract38" xlink:to="apm_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" xlink:href="apm-20231231.xsd#apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract_lbl" xml:lang="en-US">Diagnostics technology: up to the conditions and milestones of</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_FdaApprovalObtaine" xlink:href="apm-20231231.xsd#apm_FdaApprovalObtaine"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_FdaApprovalObtaine_lbl" xml:lang="en-US">Before FDA approval</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FdaApprovalObtaine" xlink:to="apm_FdaApprovalObtaine_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Provision for income taxes at Hong Kong statutory income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Income tax rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xml:lang="en-US">Non-taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentInLease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentInLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetInvestmentInLease_lbl" xml:lang="en-US">Allowance for credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentInLease" xlink:to="us-gaap_NetInvestmentInLease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Discount on operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of share options, Outstanding, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of share options, Outstanding, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AptorumTherapeuticsLimitedMember" xlink:href="apm-20231231.xsd#apm_AptorumTherapeuticsLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AptorumTherapeuticsLimitedMember_lbl" xml:lang="en-US">Aptorum Therapeutics Limited (&#8220;ATL&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AptorumTherapeuticsLimitedMember" xlink:to="apm_AptorumTherapeuticsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_APTUSMANAGEMENTLIMITEDMember" xlink:href="apm-20231231.xsd#apm_APTUSMANAGEMENTLIMITEDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_APTUSMANAGEMENTLIMITEDMember_lbl" xml:lang="en-US">APTUS MANAGEMENT LIMITED [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_APTUSMANAGEMENTLIMITEDMember" xlink:to="apm_APTUSMANAGEMENTLIMITEDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AptorumMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_AptorumMedicalLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AptorumMedicalLimitedMember_lbl" xml:lang="en-US">Aptorum Medical Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AptorumMedicalLimitedMember" xlink:to="apm_AptorumMedicalLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PathsInnovationsLimitedMember" xlink:href="apm-20231231.xsd#apm_PathsInnovationsLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_PathsInnovationsLimitedMember_lbl" xml:lang="en-US">Paths Innovations Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PathsInnovationsLimitedMember" xlink:to="apm_PathsInnovationsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PathsDiagnosticsPteLimitedMember" xlink:href="apm-20231231.xsd#apm_PathsDiagnosticsPteLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_PathsDiagnosticsPteLimitedMember_lbl" xml:lang="en-US">Paths Diagnostics Pte. Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PathsDiagnosticsPteLimitedMember" xlink:to="apm_PathsDiagnosticsPteLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ActiculeLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ActiculeLifeSciencesLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ActiculeLifeSciencesLimitedMember_lbl" xml:lang="en-US">Acticule Life Sciences Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ActiculeLifeSciencesLimitedMember" xlink:to="apm_ActiculeLifeSciencesLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ClavesLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ClavesLifeSciencesLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ClavesLifeSciencesLimitedMember_lbl" xml:lang="en-US">Claves Life Sciences Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ClavesLifeSciencesLimitedMember" xlink:to="apm_ClavesLifeSciencesLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NativusLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_NativusLifeSciencesLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NativusLifeSciencesLimitedMember_lbl" xml:lang="en-US">Nativus Life Sciences Limited	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NativusLifeSciencesLimitedMember" xlink:to="apm_NativusLifeSciencesLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_VidensIncorporationLimitedMember" xlink:href="apm-20231231.xsd#apm_VidensIncorporationLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_VidensIncorporationLimitedMember_lbl" xml:lang="en-US">Videns Incorporation Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_VidensIncorporationLimitedMember" xlink:to="apm_VidensIncorporationLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_MiosPharmaceuticalsLimitedMember" xlink:href="apm-20231231.xsd#apm_MiosPharmaceuticalsLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_MiosPharmaceuticalsLimitedMember_lbl" xml:lang="en-US">Mios Pharmaceuticals Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MiosPharmaceuticalsLimitedMember" xlink:to="apm_MiosPharmaceuticalsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_mTORHongKongLimitedMember" xlink:href="apm-20231231.xsd#apm_mTORHongKongLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_mTORHongKongLimitedMember_lbl" xml:lang="en-US">mTOR (Hong Kong) Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_mTORHongKongLimitedMember" xlink:to="apm_mTORHongKongLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScipioLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ScipioLifeSciencesLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ScipioLifeSciencesLimitedMember_lbl" xml:lang="en-US">Scipio Life Sciences Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScipioLifeSciencesLimitedMember" xlink:to="apm_ScipioLifeSciencesLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SignateLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_SignateLifeSciencesLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_SignateLifeSciencesLimitedMember_lbl" xml:lang="en-US">Signate Life Sciences Limited	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SignateLifeSciencesLimitedMember" xlink:to="apm_SignateLifeSciencesLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture, fixture, and office and medical equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_LaboratoryEquipmentMember" xlink:href="apm-20231231.xsd#apm_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LaboratoryEquipmentMember" xlink:to="apm_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Motor vehicle [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_CommonStock1Member" xlink:href="apm-20231231.xsd#apm_CommonStock1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_CommonStock1Member_lbl" xml:lang="en-US">Common Stocks One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CommonStock1Member" xlink:to="apm_CommonStock1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair value recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AutomobilesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AutomobilesMember_lbl" xml:lang="en-US">Motor vehicle [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PrepaidPatentedLicensesMember" xlink:href="apm-20231231.xsd#apm_PrepaidPatentedLicensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_PrepaidPatentedLicensesMember_lbl" xml:lang="en-US">Prepaid patented licenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaidPatentedLicensesMember" xlink:to="apm_PrepaidPatentedLicensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AeneasManagementLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasManagementLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AeneasManagementLimitedMember_lbl" xml:lang="en-US">Aeneas Management Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AeneasManagementLimitedMember" xlink:to="apm_AeneasManagementLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LibraSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_LibraSciencesLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LibraSciencesLimitedMember_lbl" xml:lang="en-US">Libra Sciences Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LibraSciencesLimitedMember" xlink:to="apm_LibraSciencesLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LibraTherapeuticsLimitedOneMember" xlink:href="apm-20231231.xsd#apm_LibraTherapeuticsLimitedOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LibraTherapeuticsLimitedOneMember_lbl" xml:lang="en-US">Libra Therapeutics Limited one [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LibraTherapeuticsLimitedOneMember" xlink:to="apm_LibraTherapeuticsLimitedOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_TalemMedicalGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_TalemMedicalGroupLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_TalemMedicalGroupLimitedMember_lbl" xml:lang="en-US">Talem Medical Group Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TalemMedicalGroupLimitedMember" xlink:to="apm_TalemMedicalGroupLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AeneasGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasGroupLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AeneasGroupLimitedMember_lbl" xml:lang="en-US">Aeneas Group Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AeneasGroupLimitedMember" xlink:to="apm_AeneasGroupLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AencoTechnologiesLtdMember" xlink:href="apm-20231231.xsd#apm_AencoTechnologiesLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AencoTechnologiesLtdMember_lbl" xml:lang="en-US">Aenco Technologies Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AencoTechnologiesLtdMember" xlink:to="apm_AencoTechnologiesLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SabrinaKhanMember" xlink:href="apm-20231231.xsd#apm_SabrinaKhanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_SabrinaKhanMember_lbl" xml:lang="en-US">Sabrina Khan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SabrinaKhanMember" xlink:to="apm_SabrinaKhanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_JurchenInvestmentsCorporationMember" xlink:href="apm-20231231.xsd#apm_JurchenInvestmentsCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_JurchenInvestmentsCorporationMember_lbl" xml:lang="en-US">Jurchen Investment Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_JurchenInvestmentsCorporationMember" xlink:to="apm_JurchenInvestmentsCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_JurchenInvestmentCorporationMember" xlink:href="apm-20231231.xsd#apm_JurchenInvestmentCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_JurchenInvestmentCorporationMember_lbl" xml:lang="en-US">Jurchen Investment Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_JurchenInvestmentCorporationMember" xlink:to="apm_JurchenInvestmentCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_JurchenInvestmentCorporationOneMember" xlink:href="apm-20231231.xsd#apm_JurchenInvestmentCorporationOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_JurchenInvestmentCorporationOneMember_lbl" xml:lang="en-US">Jurchen Investment Corporation one [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_JurchenInvestmentCorporationOneMember" xlink:to="apm_JurchenInvestmentCorporationOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_CGYInvestmentsLimitedMember" xlink:href="apm-20231231.xsd#apm_CGYInvestmentsLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_CGYInvestmentsLimitedMember_lbl" xml:lang="en-US">CGY Investments Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CGYInvestmentsLimitedMember" xlink:to="apm_CGYInvestmentsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ACCMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_ACCMedicalLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ACCMedicalLimitedMember_lbl" xml:lang="en-US">ACC Medical Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ACCMedicalLimitedMember" xlink:to="apm_ACCMedicalLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityByTypeAxis_lbl" xml:lang="en-US">Trading Activity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_UnrestrictedCashEquivalents" xlink:href="apm-20231231.xsd#apm_UnrestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_UnrestrictedCashEquivalents_lbl" xml:lang="en-US">Unrestricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnrestrictedCashEquivalents" xlink:to="apm_UnrestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting Period Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Measure the tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity method investment amounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Equity investment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherInvestments_lbl" xml:lang="en-US">Non-marketable investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestments" xlink:to="us-gaap_OtherInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription_lbl" xml:lang="en-US">Voting rights description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription" xlink:to="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="apm-20231231.xsd#apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Voting interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0" xml:lang="en-US">Voting right percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" xml:lang="en-US">Voting power</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl" xml:lang="en-US">Temporary impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses_lbl" xml:lang="en-US">Other operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses" xlink:to="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Impairment loss on intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl" xml:lang="en-US">Loss on disposal of patented license</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_WroteOffOfCostRelatedAmortization" xlink:href="apm-20231231.xsd#apm_WroteOffOfCostRelatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_WroteOffOfCostRelatedAmortization_lbl" xml:lang="en-US">Wrote off of cost related amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WroteOffOfCostRelatedAmortization" xlink:to="apm_WroteOffOfCostRelatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_VestedAndUnvestedShareOptions" xlink:href="apm-20231231.xsd#apm_VestedAndUnvestedShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_VestedAndUnvestedShareOptions_lbl" xml:lang="en-US">Vested and unvested share options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_VestedAndUnvestedShareOptions" xlink:to="apm_VestedAndUnvestedShareOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Deferred cash bonus payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Granting share options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl" xml:lang="en-US">Deferred cash bonus payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Issuance of vested ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Ordinary Share issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxDescription" xlink:href="apm-20231231.xsd#apm_IncomeTaxDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_IncomeTaxDescription_lbl" xml:lang="en-US">Income tax, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxDescription" xlink:to="apm_IncomeTaxDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry-forwards (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LossCarryforwardCancelled" xlink:href="apm-20231231.xsd#apm_LossCarryforwardCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LossCarryforwardCancelled_lbl" xml:lang="en-US">Loss carry-forward (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LossCarryforwardCancelled" xlink:to="apm_LossCarryforwardCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xml:lang="en-US">Owned percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DecreasedOwnershipPercentage" xlink:href="apm-20231231.xsd#apm_DecreasedOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DecreasedOwnershipPercentage_lbl" xml:lang="en-US">Decreased ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DecreasedOwnershipPercentage" xlink:to="apm_DecreasedOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xml:lang="en-US">Line of credit debt financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xml:lang="en-US">Line of credit period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl0" xml:lang="en-US">Issuance of expire years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xml:lang="en-US">Undrawn line of credit amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl" xml:lang="en-US">Loan for the borrowers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LoansInterestbearingRate" xlink:href="apm-20231231.xsd#apm_LoansInterestbearingRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LoansInterestbearingRate_lbl" xml:lang="en-US">Loans interest-bearing rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoansInterestbearingRate" xlink:to="apm_LoansInterestbearingRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xml:lang="en-US">Line of credit maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl" xml:lang="en-US">Outstanding amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Allowance for credit loss recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ServicesFees" xlink:href="apm-20231231.xsd#apm_ServicesFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ServicesFees_lbl" xml:lang="en-US">Services fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ServicesFees" xlink:to="apm_ServicesFees_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ServicesFeesAdjusted" xlink:href="apm-20231231.xsd#apm_ServicesFeesAdjusted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ServicesFeesAdjusted_lbl" xml:lang="en-US">Services fees adjusted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ServicesFeesAdjusted" xlink:to="apm_ServicesFeesAdjusted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndBenefitsTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndBenefitsTrust"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndBenefitsTrust_lbl" xml:lang="en-US">Compensation amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndBenefitsTrust" xlink:to="us-gaap_CompensationAndBenefitsTrust_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_RemunerationAmount" xlink:href="apm-20231231.xsd#apm_RemunerationAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_RemunerationAmount_lbl" xml:lang="en-US">Remuneration amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RemunerationAmount" xlink:to="apm_RemunerationAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock voting rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareOfEconomic" xlink:href="apm-20231231.xsd#apm_ShareOfEconomic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ShareOfEconomic_lbl" xml:lang="en-US">Share of economic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareOfEconomic" xlink:to="apm_ShareOfEconomic_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OperatingLeaseWeightedAverageDiscountRate" xlink:href="apm-20231231.xsd#apm_OperatingLeaseWeightedAverageDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_OperatingLeaseWeightedAverageDiscountRate_lbl" xml:lang="en-US">Weighted average discount rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OperatingLeaseWeightedAverageDiscountRate" xlink:to="apm_OperatingLeaseWeightedAverageDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xml:lang="en-US">Impairment loss of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Oher operating expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument original principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt instrument conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Original principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherValueOutstanding_lbl" xml:lang="en-US">Aggregate offering price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherValueOutstanding" xlink:to="us-gaap_CommonStockOtherValueOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_GrossProceed" xlink:href="apm-20231231.xsd#apm_GrossProceed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_GrossProceed_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GrossProceed" xlink:to="apm_GrossProceed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities_lbl" xml:lang="en-US">Less transaction costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities" xlink:to="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SharesPrice" xlink:href="apm-20231231.xsd#apm_SharesPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_SharesPrice_lbl" xml:lang="en-US">Ordinary shares, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SharesPrice" xlink:to="apm_SharesPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OrdinarySharesClosingPricePercentage" xlink:href="apm-20231231.xsd#apm_OrdinarySharesClosingPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_OrdinarySharesClosingPricePercentage_lbl" xml:lang="en-US">Ordinary shares closing price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OrdinarySharesClosingPricePercentage" xlink:to="apm_OrdinarySharesClosingPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Number of shares issue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share issued price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xml:lang="en-US">Authorized share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional ordinary share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareIssuedToConvertibleNoteHolders" xlink:href="apm-20231231.xsd#apm_ShareIssuedToConvertibleNoteHolders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ShareIssuedToConvertibleNoteHolders_lbl" xml:lang="en-US">Share issued to convertible note holders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareIssuedToConvertibleNoteHolders" xlink:to="apm_ShareIssuedToConvertibleNoteHolders_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonUnitIssued_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Outstanding percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Excersie price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expire date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Cancelled existing vested and unvested shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Deferred cash bonus payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US">Incremental modification cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl" xml:lang="en-US">Maximum contractual term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation charges (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsUnitsIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOwnershipInterestsUnitsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOwnershipInterestsUnitsIssued_lbl" xml:lang="en-US">Share issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsUnitsIssued" xlink:to="us-gaap_OtherOwnershipInterestsUnitsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit" xlink:href="apm-20231231.xsd#apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit_lbl" xml:lang="en-US">Total deficit value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit" xlink:to="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnersCapitalAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total deficit value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest" xlink:to="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Share options and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_MilestonePayments" xlink:href="apm-20231231.xsd#apm_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_MilestonePayments_lbl" xml:lang="en-US">Milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MilestonePayments" xlink:to="apm_MilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_sharesOutstandingPerentage" xlink:href="apm-20231231.xsd#apm_sharesOutstandingPerentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_sharesOutstandingPerentage_lbl" xml:lang="en-US">shares outstanding perentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_sharesOutstandingPerentage" xlink:to="apm_sharesOutstandingPerentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFairValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityFairValueAdjustment_lbl" xml:lang="en-US">Equity value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueAdjustment" xlink:to="us-gaap_EquityFairValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OutstandingSharesPercentage" xlink:href="apm-20231231.xsd#apm_OutstandingSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_OutstandingSharesPercentage_lbl" xml:lang="en-US">Outstanding shares, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OutstandingSharesPercentage" xlink:to="apm_OutstandingSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityOtherShares_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOtherShares" xlink:to="us-gaap_StockholdersEquityOtherShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary share outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesOutstanding" xlink:to="us-gaap_ExcessStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of presentation and consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NoncontrollingInterestsPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_NoncontrollingInterestsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NoncontrollingInterestsPolicyTextBlock_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NoncontrollingInterestsPolicyTextBlock" xlink:to="apm_NoncontrollingInterestsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation and transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivable and amounts due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LongtermInvestmentsPolicyPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_LongtermInvestmentsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LongtermInvestmentsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongtermInvestmentsPolicyPolicyTextBlock" xlink:to="apm_LongtermInvestmentsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZk9BQMOWQfrm8jHnK3iPqh/RGOZRChD6nBq3dVwAwj4+/8SLuZTW/liOfKmyEBpRrTV6V//wh8natqXLVrpArUZiEOpCUQ4sWmUCqPSbJB1eeE0YXZR+qpcGF8VKslPcXkQ+inlG1l8YPuGFp3JEZ5VoAJF844sVddHhNq3xJYgqGGsxym9XDdETLyH/fYUjQBrPgE04klEQ==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OperatingLeasesPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_OperatingLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_OperatingLeasesPolicyTextBlock_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OperatingLeasesPolicyTextBlock" xlink:to="apm_OperatingLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_WarrantLiabilitiesPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_WarrantLiabilitiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_WarrantLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WarrantLiabilitiesPolicyTextBlock" xlink:to="apm_WarrantLiabilitiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of healthcare services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxUncertaintiesPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy_lbl" xml:lang="en-US">Uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:to="us-gaap_IncomeTaxUncertaintiesPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive income or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net income or loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recently issued accounting standards which have not yet been adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US">Line of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LibraMember" xlink:href="apm-20231231.xsd#apm_LibraMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LibraMember_lbl" xml:lang="en-US">Libra [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LibraMember" xlink:to="apm_LibraMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember" xlink:href="apm-20231231.xsd#apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember_lbl" xml:lang="en-US">Leasehold Improvements, Furniture and Fixtures and Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember" xlink:to="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_HongKongHealthcareServicesMember" xlink:href="apm-20231231.xsd#apm_HongKongHealthcareServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_HongKongHealthcareServicesMember_lbl" xml:lang="en-US">Hong Kong healthcare services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_HongKongHealthcareServicesMember" xlink:to="apm_HongKongHealthcareServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_HK"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_HK_lbl" xml:lang="en-US">Hong Kong [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl"/>
    <loc xlink:type="locator" xlink:label="country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_GB_lbl" xml:lang="en-US">United Kingdom [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
    <loc xlink:type="locator" xlink:label="country_SG" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_SG"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_SG_lbl" xml:lang="en-US">Singapore [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_SG" xlink:to="country_SG_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States (Nevada) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="country_CA" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CA_lbl" xml:lang="en-US">Canada [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IanHuenMember" xlink:href="apm-20231231.xsd#apm_IanHuenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_IanHuenMember_lbl" xml:lang="en-US">Ian Huen [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IanHuenMember" xlink:to="apm_IanHuenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_MrClarkChengMember" xlink:href="apm-20231231.xsd#apm_MrClarkChengMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_MrClarkChengMember_lbl" xml:lang="en-US">Mr. Clark Cheng [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MrClarkChengMember" xlink:to="apm_MrClarkChengMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_MrIanHuenMember" xlink:href="apm-20231231.xsd#apm_MrIanHuenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_MrIanHuenMember_lbl" xml:lang="en-US">Mr. Ian Huen [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MrIanHuenMember" xlink:to="apm_MrIanHuenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_MrDarrenLuiMember" xlink:href="apm-20231231.xsd#apm_MrDarrenLuiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_MrDarrenLuiMember_lbl" xml:lang="en-US">Mr. Darren Lui [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MrDarrenLuiMember" xlink:to="apm_MrDarrenLuiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_MiosMember" xlink:href="apm-20231231.xsd#apm_MiosMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_MiosMember_lbl" xml:lang="en-US">Mios [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MiosMember" xlink:to="apm_MiosMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScipioMember" xlink:href="apm-20231231.xsd#apm_ScipioMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ScipioMember_lbl" xml:lang="en-US">Scipio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScipioMember" xlink:to="apm_ScipioMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_GroupsSubsidiariesMember" xlink:href="apm-20231231.xsd#apm_GroupsSubsidiariesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_GroupsSubsidiariesMember_lbl" xml:lang="en-US">Group&#8217;s subsidiaries [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GroupsSubsidiariesMember" xlink:to="apm_GroupsSubsidiariesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_VaribaleInterestEntityMember" xlink:href="apm-20231231.xsd#apm_VaribaleInterestEntityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_VaribaleInterestEntityMember_lbl" xml:lang="en-US">Varibale Interest Entity [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_VaribaleInterestEntityMember" xlink:to="apm_VaribaleInterestEntityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ConvertibleNotesMember" xlink:href="apm-20231231.xsd#apm_ConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConvertibleNotesMember" xlink:to="apm_ConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_EmployeesAndExternalConsultantsMember" xlink:href="apm-20231231.xsd#apm_EmployeesAndExternalConsultantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_EmployeesAndExternalConsultantsMember_lbl" xml:lang="en-US">Employees and External Consultants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_EmployeesAndExternalConsultantsMember" xlink:to="apm_EmployeesAndExternalConsultantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SharesWarrantHoldersMember" xlink:href="apm-20231231.xsd#apm_SharesWarrantHoldersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_SharesWarrantHoldersMember_lbl" xml:lang="en-US">Shares Warrant Holders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SharesWarrantHoldersMember" xlink:to="apm_SharesWarrantHoldersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareOptionHoldersMember" xlink:href="apm-20231231.xsd#apm_ShareOptionHoldersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ShareOptionHoldersMember_lbl" xml:lang="en-US">Share Option Holders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareOptionHoldersMember" xlink:to="apm_ShareOptionHoldersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_TwoThousandSeventeenShareOptionPlanMember" xlink:href="apm-20231231.xsd#apm_TwoThousandSeventeenShareOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_TwoThousandSeventeenShareOptionPlanMember_lbl" xml:lang="en-US">2017 Share Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TwoThousandSeventeenShareOptionPlanMember" xlink:to="apm_TwoThousandSeventeenShareOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_EmployeesMember" xlink:href="apm-20231231.xsd#apm_EmployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_EmployeesMember" xlink:to="apm_EmployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NonemployeesMember" xlink:href="apm-20231231.xsd#apm_NonemployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_NonemployeesMember_lbl" xml:lang="en-US">Non-employees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonemployeesMember" xlink:to="apm_NonemployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ClarkChengMember" xlink:href="apm-20231231.xsd#apm_ClarkChengMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_ClarkChengMember_lbl" xml:lang="en-US">Clark Cheng [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ClarkChengMember" xlink:to="apm_ClarkChengMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_DSFInvestmentHoldingsLimitedMember" xlink:href="apm-20231231.xsd#apm_DSFInvestmentHoldingsLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_DSFInvestmentHoldingsLimitedMember_lbl" xml:lang="en-US">DSF Investment Holdings Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DSFInvestmentHoldingsLimitedMember" xlink:to="apm_DSFInvestmentHoldingsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LiquidityTable" xlink:href="apm-20231231.xsd#apm_LiquidityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LiquidityTable_lbl" xml:lang="en-US">Liquidity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LiquidityTable" xlink:to="apm_LiquidityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LiquidityLineItems" xlink:href="apm-20231231.xsd#apm_LiquidityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LiquidityLineItems_lbl" xml:lang="en-US">Liquidity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LiquidityLineItems" xlink:to="apm_LiquidityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsTable" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OtherReceivablesandPrepaymentsTable_lbl" xml:lang="en-US">Other Receivables and Prepayments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherReceivablesandPrepaymentsTable" xlink:to="apm_OtherReceivablesandPrepaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsLineItems" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OtherReceivablesandPrepaymentsLineItems_lbl" xml:lang="en-US">Other Receivables and Prepayments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherReceivablesandPrepaymentsLineItems" xlink:to="apm_OtherReceivablesandPrepaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsTable" xlink:href="apm-20231231.xsd#apm_LongTermDepositsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LongTermDepositsTable_lbl" xml:lang="en-US">Long-Term Deposits [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongTermDepositsTable" xlink:to="apm_LongTermDepositsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsLineItems" xlink:href="apm-20231231.xsd#apm_LongTermDepositsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LongTermDepositsLineItems_lbl" xml:lang="en-US">Long-Term Deposits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongTermDepositsLineItems" xlink:to="apm_LongTermDepositsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsTablesTable" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OtherReceivablesandPrepaymentsTablesTable_lbl" xml:lang="en-US">Other Receivables and Prepayments (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherReceivablesandPrepaymentsTablesTable" xlink:to="apm_OtherReceivablesandPrepaymentsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsTablesLineItems" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_OtherReceivablesandPrepaymentsTablesLineItems_lbl" xml:lang="en-US">Other Receivables and Prepayments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherReceivablesandPrepaymentsTablesLineItems" xlink:to="apm_OtherReceivablesandPrepaymentsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsTablesTable" xlink:href="apm-20231231.xsd#apm_LongTermDepositsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LongTermDepositsTablesTable_lbl" xml:lang="en-US">Long-Term Deposits (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongTermDepositsTablesTable" xlink:to="apm_LongTermDepositsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsTablesLineItems" xlink:href="apm-20231231.xsd#apm_LongTermDepositsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LongTermDepositsTablesLineItems_lbl" xml:lang="en-US">Long-Term Deposits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongTermDepositsTablesLineItems" xlink:to="apm_LongTermDepositsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AccountsPayableandAccruedExpensesTablesTable" xlink:href="apm-20231231.xsd#apm_AccountsPayableandAccruedExpensesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AccountsPayableandAccruedExpensesTablesTable_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AccountsPayableandAccruedExpensesTablesTable" xlink:to="apm_AccountsPayableandAccruedExpensesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AccountsPayableandAccruedExpensesTablesLineItems" xlink:href="apm-20231231.xsd#apm_AccountsPayableandAccruedExpensesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_AccountsPayableandAccruedExpensesTablesLineItems_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AccountsPayableandAccruedExpensesTablesLineItems" xlink:to="apm_AccountsPayableandAccruedExpensesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" xlink:href="apm-20231231.xsd#apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" xlink:to="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" xlink:href="apm-20231231.xsd#apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" xlink:to="apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" xlink:href="apm-20231231.xsd#apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable_lbl" xml:lang="en-US">Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" xlink:to="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" xlink:href="apm-20231231.xsd#apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems_lbl" xml:lang="en-US">Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" xlink:to="apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable_lbl" xml:lang="en-US">Other Receivables and Prepayments (Details) - Schedule of Other Receivables and Prepayments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" xlink:to="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems_lbl" xml:lang="en-US">Other Receivables and Prepayments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Assets, Net (Details) - Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" xlink:to="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Schedule of Amortization Expense Related to its Finite Lived Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable" xlink:href="apm-20231231.xsd#apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable_lbl" xml:lang="en-US">Long-Term Deposits (Details) - Schedule of Long-Term Deposits [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable" xlink:to="apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:href="apm-20231231.xsd#apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems_lbl" xml:lang="en-US">Schedule of long-term deposits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:to="apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of Provision for Income Taxes Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" xlink:to="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems_lbl" xml:lang="en-US">Schedule of Provision for Income Taxes Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:to="apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" xlink:to="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems_lbl" xml:lang="en-US">Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Parentheticals) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" xlink:to="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems_lbl" xml:lang="en-US">Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" xlink:to="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceTable_lbl" xml:lang="en-US">Valuation Allowance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_ValuationAllowanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceLineItems_lbl" xml:lang="en-US">Schedule of Changes in Valuation Allowance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_ValuationAllowanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable_lbl" xml:lang="en-US">Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" xlink:to="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems_lbl" xml:lang="en-US">Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems" xlink:to="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable_lbl" xml:lang="en-US">Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" xlink:to="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems_lbl" xml:lang="en-US">Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" xlink:to="apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable_lbl" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableInterestEntityLineItems_lbl" xml:lang="en-US">Variable Interest Entity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_VariableInterestEntityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable_lbl" xml:lang="en-US">Share Based Compensation (Details) - Schedule of the Option Activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" xlink:to="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems_lbl" xml:lang="en-US">Share Based Compensation (Details) - Schedule of the Option Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable_lbl" xml:lang="en-US">Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" xlink:to="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems_lbl" xml:lang="en-US">Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_LiquidityDetailsTable" xlink:href="apm-20231231.xsd#apm_LiquidityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LiquidityDetailsTable_lbl" xml:lang="en-US">Liquidity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LiquidityDetailsTable" xlink:to="apm_LiquidityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apm_LiquidityLineItems_lbl0" xml:lang="en-US">Liquidity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LiquidityLineItems" xlink:to="apm_LiquidityLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="apm-20231231.xsd#apm_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="apm_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_InvestmentandFairValueMeasurementDetailsTable" xlink:href="apm-20231231.xsd#apm_InvestmentandFairValueMeasurementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_InvestmentandFairValueMeasurementDetailsTable_lbl" xml:lang="en-US">Investment and Fair Value Measurement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InvestmentandFairValueMeasurementDetailsTable" xlink:to="apm_InvestmentandFairValueMeasurementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems_lbl" xml:lang="en-US">Investment and Fair Value Measurement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_PropertyandEquipmentNetDetailsTable" xlink:href="apm-20231231.xsd#apm_PropertyandEquipmentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PropertyandEquipmentNetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PropertyandEquipmentNetDetailsTable" xlink:to="apm_PropertyandEquipmentNetDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0" xml:lang="en-US">Property and Equipment, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IntangibleAssetsNetDetailsTable" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IntangibleAssetsNetDetailsTable_lbl" xml:lang="en-US">Intangible Assets, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IntangibleAssetsNetDetailsTable" xlink:to="apm_IntangibleAssetsNetDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0" xml:lang="en-US">Intangible Assets, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_AccountsPayableandAccruedExpensesDetailsTable" xlink:href="apm-20231231.xsd#apm_AccountsPayableandAccruedExpensesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AccountsPayableandAccruedExpensesDetailsTable_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AccountsPayableandAccruedExpensesDetailsTable" xlink:to="apm_AccountsPayableandAccruedExpensesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:href="apm-20231231.xsd#apm_AccountsPayableAndAccruedExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AccountsPayableAndAccruedExpensesLineItems_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AccountsPayableAndAccruedExpensesLineItems" xlink:to="apm_AccountsPayableAndAccruedExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_IncomeTaxesDetailsTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxesDetailsTable" xlink:to="apm_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsTable" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_RelatedPartyBalancesandTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Balances and Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="apm_RelatedPartyBalancesandTransactionsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl0" xml:lang="en-US">Related Party Balances and Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityByTypeDomain_lbl" xml:lang="en-US">Trading Activity, by Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeDomain" xlink:to="us-gaap_TradingActivityByTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_VariableInterestEntityDetailsTable" xlink:href="apm-20231231.xsd#apm_VariableInterestEntityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_VariableInterestEntityDetailsTable_lbl" xml:lang="en-US">Variable Interest Entity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_VariableInterestEntityDetailsTable" xlink:to="apm_VariableInterestEntityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ConvertibleNoteDetailsTable" xlink:href="apm-20231231.xsd#apm_ConvertibleNoteDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ConvertibleNoteDetailsTable_lbl" xml:lang="en-US">Convertible Note (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConvertibleNoteDetailsTable" xlink:to="apm_ConvertibleNoteDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Convertible Note [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OrdinarySharesDetailsTable" xlink:href="apm-20231231.xsd#apm_OrdinarySharesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OrdinarySharesDetailsTable_lbl" xml:lang="en-US">Ordinary Shares (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OrdinarySharesDetailsTable" xlink:to="apm_OrdinarySharesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_OrdinarySharesLineItems" xlink:href="apm-20231231.xsd#apm_OrdinarySharesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OrdinarySharesLineItems_lbl" xml:lang="en-US">Ordinary Shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OrdinarySharesLineItems" xlink:to="apm_OrdinarySharesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ShareBasedCompensationDetailsTable" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareBasedCompensationDetailsTable_lbl" xml:lang="en-US">Share Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationDetailsTable" xlink:to="apm_ShareBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share Based Compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NonControllingInterestDetailsTable" xlink:href="apm-20231231.xsd#apm_NonControllingInterestDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NonControllingInterestDetailsTable_lbl" xml:lang="en-US">Non-Controlling Interest (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonControllingInterestDetailsTable" xlink:to="apm_NonControllingInterestDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NonControllingInterestLineItems" xlink:href="apm-20231231.xsd#apm_NonControllingInterestLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NonControllingInterestLineItems_lbl" xml:lang="en-US">Non-Controlling Interest [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonControllingInterestLineItems" xlink:to="apm_NonControllingInterestLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NetLossPerShareDetailsTable" xlink:href="apm-20231231.xsd#apm_NetLossPerShareDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NetLossPerShareDetailsTable_lbl" xml:lang="en-US">Net Loss Per Share (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetLossPerShareDetailsTable" xlink:to="apm_NetLossPerShareDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_NetLossPerShareLineItems" xlink:href="apm-20231231.xsd#apm_NetLossPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NetLossPerShareLineItems_lbl" xml:lang="en-US">Net Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetLossPerShareLineItems" xlink:to="apm_NetLossPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_SubsequentEventsDetailsTable" xlink:href="apm-20231231.xsd#apm_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SubsequentEventsDetailsTable" xlink:to="apm_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_AccretionOfFinanceLeaseObligation_lbl0" xml:lang="en-US">Accretion of finance lease obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AccretionOfFinanceLeaseObligation" xlink:to="apm_AccretionOfFinanceLeaseObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit_lbl0" xml:lang="en-US">Amount of fresh-start adjustment to retained earnings or deficit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit" xlink:to="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest_lbl0" xml:lang="en-US">Amount of adjustment to issuance of shares to non-controlling interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest" xlink:to="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_AdministrativeManagementServices_lbl0" xml:lang="en-US">Administrative management services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdministrativeManagementServices" xlink:to="apm_AdministrativeManagementServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_AllowanceForCreditLossOfDueFromARelatedParty_lbl1" xml:lang="en-US">Allowance for credit loss of due from a related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AllowanceForCreditLossOfDueFromARelatedParty" xlink:to="apm_AllowanceForCreditLossOfDueFromARelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_AmountsDueFromRelatedPartiesCurrent_lbl0" xml:lang="en-US">Amounts dure from related parties classified as current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AmountsDueFromRelatedPartiesCurrent" xlink:to="apm_AmountsDueFromRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_AmountsDueToRelatedPartiesCurrent_lbl0" xml:lang="en-US">Amounts due to related parties, classified as current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AmountsDueToRelatedPartiesCurrent" xlink:to="apm_AmountsDueToRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_AmountsDueToRelatedPartiesNoncurrent_lbl0" xml:lang="en-US">Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AmountsDueToRelatedPartiesNoncurrent" xlink:to="apm_AmountsDueToRelatedPartiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees_lbl0" xml:lang="en-US">Consultant, secondment, management and administrative services fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees" xlink:to="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ConvertibleNotesConvertedToClassAOrdinaryShares_lbl0" xml:lang="en-US">Convertible notes converted to Class A Ordinary Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConvertibleNotesConvertedToClassAOrdinaryShares" xlink:to="apm_ConvertibleNotesConvertedToClassAOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_CostOfHealthcareServicesPayable_lbl0" xml:lang="en-US">Cost of healthcare services payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CostOfHealthcareServicesPayable" xlink:to="apm_CostOfHealthcareServicesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_DecreasedOwnershipPercentage_lbl0" xml:lang="en-US">Decreased ownership percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DecreasedOwnershipPercentage" xlink:to="apm_DecreasedOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_DeferredTaxAssetsDepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation and amortization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="apm_DeferredTaxAssetsDepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_DisposalOfSubsidiariesNetOfCashDisposed_lbl0" xml:lang="en-US">Disposal of subsidiaries net of cash disposed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DisposalOfSubsidiariesNetOfCashDisposed" xlink:to="apm_DisposalOfSubsidiariesNetOfCashDisposed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_DownwardAdjustmentAndImpairment_lbl0" xml:lang="en-US">The amount of downward adjustment and impairment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DownwardAdjustmentAndImpairment" xlink:to="apm_DownwardAdjustmentAndImpairment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_DownwardAdjustmentsAndImpairment_lbl0" xml:lang="en-US">The amount of downward adjustments and impairment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DownwardAdjustmentsAndImpairment" xlink:to="apm_DownwardAdjustmentsAndImpairment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_DueFromBrokers_lbl0" xml:lang="en-US">For an unclassified balance sheet, amounts due from brokers including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DueFromBrokers" xlink:to="apm_DueFromBrokers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_EntityIncorporationsStateCountryName_lbl0" xml:lang="en-US">Place of incorporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_EntityIncorporationsStateCountryName" xlink:to="apm_EntityIncorporationsStateCountryName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ExchangeDifferenceOnTranslationOfForeignOperation_lbl0" xml:lang="en-US">Exchange difference on translation of foreign operation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ExchangeDifferenceOnTranslationOfForeignOperation" xlink:to="apm_ExchangeDifferenceOnTranslationOfForeignOperation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_FairValueMeasurementValuationTechniques_lbl0" xml:lang="en-US">Description of the inputs and valuation technique(s) used to measure fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementValuationTechniques" xlink:to="apm_FairValueMeasurementValuationTechniques_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_lbl1" xml:lang="en-US">Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity&apos;s own assumption about the assumptions market participants would use in pricing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" xlink:to="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_FairValueMeasurementsUnobservableInput_lbl0" xml:lang="en-US">Description of the inputs used to measure fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementsUnobservableInput" xlink:to="apm_FairValueMeasurementsUnobservableInput_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_FairValueMeasurementsWeightedAverageRange_lbl0" xml:lang="en-US">Description of the Range (weighted average).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementsWeightedAverageRange" xlink:to="apm_FairValueMeasurementsWeightedAverageRange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation_lbl0" xml:lang="en-US">Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity&apos;s own assumption about the assumptions market participants would use in pricing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation" xlink:to="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_FdaApprovalObtaine_lbl0" xml:lang="en-US">FDA approval obtained.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FdaApprovalObtaine" xlink:to="apm_FdaApprovalObtaine_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_FinanceLeaseDepreciation_lbl0" xml:lang="en-US">Depreciation expense recognized during period on finance leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FinanceLeaseDepreciation" xlink:to="apm_FinanceLeaseDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_FirstCommercialSale_lbl0" xml:lang="en-US">First commercial sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FirstCommercialSale" xlink:to="apm_FirstCommercialSale_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_FromEnteringPhase1ToBeforeFirstCommercialSale_lbl0" xml:lang="en-US">From entering phase 1 to before first commercial sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FromEnteringPhase1ToBeforeFirstCommercialSale" xlink:to="apm_FromEnteringPhase1ToBeforeFirstCommercialSale_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_GainOnDerecognitionOfNonfinancialAssets_lbl0" xml:lang="en-US">Gain on derecognition of non-financial assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GainOnDerecognitionOfNonfinancialAssets" xlink:to="apm_GainOnDerecognitionOfNonfinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_GainOnUseOfDigitalCurrencies_lbl0" xml:lang="en-US">Gain on use of digital currencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GainOnUseOfDigitalCurrencies" xlink:to="apm_GainOnUseOfDigitalCurrencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_GainOnUseOfDigitalsCurrencies_lbl0" xml:lang="en-US">Gain on use of digital currencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GainOnUseOfDigitalsCurrencies" xlink:to="apm_GainOnUseOfDigitalsCurrencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_GrossProceed_lbl0" xml:lang="en-US">Gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GrossProceed" xlink:to="apm_GrossProceed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_IncomeTaxDescription_lbl0" xml:lang="en-US">Income tax, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxDescription" xlink:to="apm_IncomeTaxDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_IncreaseDecreaseDueFromBrokers_lbl0" xml:lang="en-US">The increase (decrease) during the period in amounts due from brokers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncreaseDecreaseDueFromBrokers" xlink:to="apm_IncreaseDecreaseDueFromBrokers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_InitialCostBasis_lbl0" xml:lang="en-US">Initial cost basis.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InitialCostBasis" xlink:to="apm_InitialCostBasis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_InsuranceExpensePayable_lbl0" xml:lang="en-US">Insurance expense payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InsuranceExpensePayable" xlink:to="apm_InsuranceExpensePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_InterestExpenseAndAccretionOfConvertibleDebts_lbl0" xml:lang="en-US">Amount of interest expense and accretion of convertible debts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InterestExpenseAndAccretionOfConvertibleDebts" xlink:to="apm_InterestExpenseAndAccretionOfConvertibleDebts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_LeaseholdImprovementsEstimatedUsefulLives_lbl0" xml:lang="en-US">Leasehold improvements, estimated useful lives.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LeaseholdImprovementsEstimatedUsefulLives" xlink:to="apm_LeaseholdImprovementsEstimatedUsefulLives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_LiquidityDisclosureTextBlock_lbl0" xml:lang="en-US">The entire disclosure for liquidity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LiquidityDisclosureTextBlock" xlink:to="apm_LiquidityDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_LoanRepaymentAndInterestPaidToRelatedParties_lbl0" xml:lang="en-US">Loan repayments, including interest, made to related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanRepaymentAndInterestPaidToRelatedParties" xlink:to="apm_LoanRepaymentAndInterestPaidToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_LoansInterestbearingRate_lbl0" xml:lang="en-US">Percentage of interest bearing rate of loan per annum.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoansInterestbearingRate" xlink:to="apm_LoansInterestbearingRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_LongtermInvestmentsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for long-term investments Policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongtermInvestmentsPolicyPolicyTextBlock" xlink:to="apm_LongtermInvestmentsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_LossCarryforwardCancelled_lbl0" xml:lang="en-US">The amount of loss carryforward cancelled.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LossCarryforwardCancelled" xlink:to="apm_LossCarryforwardCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_LossGainOnInvestmentsInMarketableSecuritiesNet_lbl0" xml:lang="en-US">Gain on investments in marketable securities, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LossGainOnInvestmentsInMarketableSecuritiesNet" xlink:to="apm_LossGainOnInvestmentsInMarketableSecuritiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_LossOnDisposalOfLonglivedAssets_lbl0" xml:lang="en-US">Loss on disposal of long-lived assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LossOnDisposalOfLonglivedAssets" xlink:to="apm_LossOnDisposalOfLonglivedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_MilestonePayments_lbl0" xml:lang="en-US">Milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MilestonePayments" xlink:to="apm_MilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments_lbl0" xml:lang="en-US">Net change in unrealized depreciation relating to investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments" xlink:to="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_NetDeferredTaxAssetsBeforeValuationAllowance_lbl0" xml:lang="en-US">Net deferred tax assets (liabilities) before valuation allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetDeferredTaxAssetsBeforeValuationAllowance" xlink:to="apm_NetDeferredTaxAssetsBeforeValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_NetSalesAmountMoreThanCertainThresholdInYear_lbl0" xml:lang="en-US">Net sales amount more than certain threshold in a year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetSalesAmountMoreThanCertainThresholdInYear" xlink:to="apm_NetSalesAmountMoreThanCertainThresholdInYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_NoncontrollingInterestsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for Non-controlling interests.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NoncontrollingInterestsPolicyTextBlock" xlink:to="apm_NoncontrollingInterestsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_OperatingLeaseWeightedAverageDiscountRate_lbl0" xml:lang="en-US">Weighted average discount rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OperatingLeaseWeightedAverageDiscountRate" xlink:to="apm_OperatingLeaseWeightedAverageDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_OperatingLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for operating leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OperatingLeasesPolicyTextBlock" xlink:to="apm_OperatingLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_OrdinarySharesClosingPricePercentage_lbl0" xml:lang="en-US">Ordinary shares closing price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OrdinarySharesClosingPricePercentage" xlink:to="apm_OrdinarySharesClosingPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_OutstandingSharesPercentage_lbl0" xml:lang="en-US">Percentage of outstanding shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OutstandingSharesPercentage" xlink:to="apm_OutstandingSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_PreclinicalToIndFiling_lbl0" xml:lang="en-US">Preclinical to IND filing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PreclinicalToIndFiling" xlink:to="apm_PreclinicalToIndFiling_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_PrepaidResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">Prepaid research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaidResearchAndDevelopmentExpenses" xlink:to="apm_PrepaidResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_PrepaidServiceFee_lbl0" xml:lang="en-US">Prepaid service fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaidServiceFee" xlink:to="apm_PrepaidServiceFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_PrepaymentsForEquipment_lbl0" xml:lang="en-US">Prepayments of deposits for equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaymentsForEquipment" xlink:to="apm_PrepaymentsForEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_PrincipleActivities_lbl0" xml:lang="en-US">Principle activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrincipleActivities" xlink:to="apm_PrincipleActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ProceedsInBrokerAccounts_lbl0" xml:lang="en-US">Amount of proceeds in broker accounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ProceedsInBrokerAccounts" xlink:to="apm_ProceedsInBrokerAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of estimated useful lives.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock" xlink:to="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_RemunerationAmount_lbl0" xml:lang="en-US">The amount of the remuneration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RemunerationAmount" xlink:to="apm_RemunerationAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_RentalDeposits_lbl0" xml:lang="en-US">Rental deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RentalDeposits" xlink:to="apm_RentalDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_RepaymentOfLoanFromRelatedParty_lbl1" xml:lang="en-US">Repayment of loan from a related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RepaymentOfLoanFromRelatedParty" xlink:to="apm_RepaymentOfLoanFromRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ResearchAndDevelopmentExpensesPayable_lbl0" xml:lang="en-US">Research and development expenses payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ResearchAndDevelopmentExpensesPayable" xlink:to="apm_ResearchAndDevelopmentExpensesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ReversalDeferredCashBonus_lbl0" xml:lang="en-US">Reversal of deferred cash bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ReversalDeferredCashBonus" xlink:to="apm_ReversalDeferredCashBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of due to related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:to="apm_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ScheduleOfLongTermDepositsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of long-term deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfLongTermDepositsTableTextBlock" xlink:to="apm_ScheduleOfLongTermDepositsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of milestone payments are to be made upon achievements of certain conditions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" xlink:to="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ServicesFees_lbl0" xml:lang="en-US">Amount of services fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ServicesFees" xlink:to="apm_ServicesFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ServicesFeesAdjusted_lbl0" xml:lang="en-US">The amount of services fees adjusted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ServicesFeesAdjusted" xlink:to="apm_ServicesFeesAdjusted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions_lbl0" xml:lang="en-US">Settlement of deferred cash bonus by issuance of share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions" xlink:to="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens_lbl0" xml:lang="en-US">Settlement of service fee by digital currencies and tokens.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens" xlink:to="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens_lbl0" xml:lang="en-US">Settlement of service fee by digital currencies and tokens.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" xlink:to="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor_lbl0" xml:lang="en-US">Dilution factor used in estimating the fair value of stock awards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ShareIssuedToConvertibleNoteHolders_lbl0" xml:lang="en-US">Represent the number of share issued to convertible note holders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareIssuedToConvertibleNoteHolders" xlink:to="apm_ShareIssuedToConvertibleNoteHolders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Remaining contractual term in years, Exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_SharesPrice_lbl0" xml:lang="en-US">Shares price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SharesPrice" xlink:to="apm_SharesPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_StockIssuedDuringPeridSharesIssuanceOfShares_lbl0" xml:lang="en-US">Number of stock issued during period issuance of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeridSharesIssuanceOfShares" xlink:to="apm_StockIssuedDuringPeridSharesIssuanceOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction_lbl0" xml:lang="en-US">Value of disposal of subsidiaries under common control transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" xlink:to="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl0" xml:lang="en-US">Number of shares issued during period shares exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries_lbl0" xml:lang="en-US">Value of Stock disposal of subsidies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries" xlink:to="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl0" xml:lang="en-US">Value of Stock issued exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="apm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_StockIssuedDuringPeriodValueIssuanceOfShares_lbl0" xml:lang="en-US">Value of stock issued during period issuance of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodValueIssuanceOfShares" xlink:to="apm_StockIssuedDuringPeriodValueIssuanceOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue_lbl0" xml:lang="en-US">Value of stock issued during period adjustment for change of par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_SundryIncome_lbl0" xml:lang="en-US">Sundry income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SundryIncome" xlink:to="apm_SundryIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal_lbl0" xml:lang="en-US">Surgical robotics and medical devices up to the conditions and milestones of subtotal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:to="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_TotalCarryingValueAtTheEndOfThePeriod_lbl0" xml:lang="en-US">Total carrying value at the end of the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TotalCarryingValueAtTheEndOfThePeriod" xlink:to="apm_TotalCarryingValueAtTheEndOfThePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_TotalUnrealizedGainForNonmarketableInvestments_lbl0" xml:lang="en-US">Total unrealized gain for non-marketable investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TotalUnrealizedGainForNonmarketableInvestments" xlink:to="apm_TotalUnrealizedGainForNonmarketableInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_UnrestrictedCashEquivalents_lbl0" xml:lang="en-US">Amount of cash equivalents unrestricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnrestrictedCashEquivalents" xlink:to="apm_UnrestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_UpwardAdjustment_lbl0" xml:lang="en-US">Upward adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UpwardAdjustment" xlink:to="apm_UpwardAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_UpwardAdjustments_lbl0" xml:lang="en-US">Upward adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UpwardAdjustments" xlink:to="apm_UpwardAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount_lbl0" xml:lang="en-US">Amount of decrease in the valuation allowance for a specified deferred tax asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:to="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_ValuationAllowanceDeferredTaxAssetIncrease_lbl0" xml:lang="en-US">Amount of increase in the valuation allowance for a specified deferred tax asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ValuationAllowanceDeferredTaxAssetIncrease" xlink:to="apm_ValuationAllowanceDeferredTaxAssetIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_VestedAndUnvestedShareOptions_lbl0" xml:lang="en-US">Number of vested and unvested share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_VestedAndUnvestedShareOptions" xlink:to="apm_VestedAndUnvestedShareOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_WarrantLiabilitiesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for warrant liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WarrantLiabilitiesPolicyTextBlock" xlink:to="apm_WarrantLiabilitiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_WritteoffOfPrepaymentAndOtherReceivables_lbl1" xml:lang="en-US">Writte-off of prepayment and other receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WritteoffOfPrepaymentAndOtherReceivables" xlink:to="apm_WritteoffOfPrepaymentAndOtherReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_WroteOffOfCostRelatedAmortization_lbl0" xml:lang="en-US">Wrote off of cost related amortization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WroteOffOfCostRelatedAmortization" xlink:to="apm_WroteOffOfCostRelatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apm_sharesOutstandingPerentage_lbl0" xml:lang="en-US">shares outstanding perentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_sharesOutstandingPerentage" xlink:to="apm_sharesOutstandingPerentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl0" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_MilestonePaymentsTotal_lbl0" xml:lang="en-US">Milestone Payments Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MilestonePaymentsTotal" xlink:to="apm_MilestonePaymentsTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments_lbl1" xml:lang="en-US">Net Change In Unrealized Depreciation Relating To Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments" xlink:to="apm_NetChangeInUnrealizedDepreciationRelatingToInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_VaribaleInterestEntityMember_lbl0" xml:lang="en-US">Varibale Interest Entity Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_VaribaleInterestEntityMember" xlink:to="apm_VaribaleInterestEntityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries_lbl1" xml:lang="en-US">Stock Issued During Period Value Disposal Of Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries" xlink:to="apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LoansInterestbearingRate_lbl1" xml:lang="en-US">Loans Interestbearing Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoansInterestbearingRate" xlink:to="apm_LoansInterestbearingRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LoanToRelatedPartiesNoteBAbstract_lbl0" xml:lang="en-US">Loan To Related Parties Note BAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanToRelatedPartiesNoteBAbstract" xlink:to="apm_LoanToRelatedPartiesNoteBAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AptorumMedicalLimitedMember_lbl0" xml:lang="en-US">Aptorum Medical Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AptorumMedicalLimitedMember" xlink:to="apm_AptorumMedicalLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AutomobilesMember_lbl0" xml:lang="en-US">Automobiles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SharesWarrantHoldersMember_lbl0" xml:lang="en-US">Shares Warrant Holders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SharesWarrantHoldersMember" xlink:to="apm_SharesWarrantHoldersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ValuationAllowanceDeferredTaxAssetIncrease_lbl1" xml:lang="en-US">Valuation Allowance Deferred Tax Asset Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ValuationAllowanceDeferredTaxAssetIncrease" xlink:to="apm_ValuationAllowanceDeferredTaxAssetIncrease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl2" xml:lang="en-US">Common Class B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PrepaidResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Prepaid Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaidResearchAndDevelopmentExpenses" xlink:to="apm_PrepaidResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonUnitIssued_lbl0" xml:lang="en-US">Common Unit, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl0" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_GainOnDerecognitionOfNonfinancialAssets_lbl1" xml:lang="en-US">Gain On Derecognition Of Nonfinancial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GainOnDerecognitionOfNonfinancialAssets" xlink:to="apm_GainOnDerecognitionOfNonfinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestmentsAbstract_lbl0" xml:lang="en-US">Long-Term Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfChangesInValuationAllowanceAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfChangesInValuationAllowanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfChangesInValuationAllowanceAbstract_lbl" xml:lang="en-US">Schedule Of Changes In Valuation Allowance Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfChangesInValuationAllowanceAbstract" xlink:to="apm_ScheduleOfChangesInValuationAllowanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue_lbl1" xml:lang="en-US">Stockissued During Period Value Adjustment For Change Of Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IanHuenMember_lbl0" xml:lang="en-US">Ian Huen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IanHuenMember" xlink:to="apm_IanHuenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnrestrictedCashEquivalents_lbl1" xml:lang="en-US">Unrestricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnrestrictedCashEquivalents" xlink:to="apm_UnrestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DownwardAdjustmentAndImpairment_lbl1" xml:lang="en-US">Downward Adjustment And Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DownwardAdjustmentAndImpairment" xlink:to="apm_DownwardAdjustmentAndImpairment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DenominatorAbstract_lbl0" xml:lang="en-US">Denominator Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DenominatorAbstract" xlink:to="apm_DenominatorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OutstandingSharesPercentage_lbl1" xml:lang="en-US">Outstanding Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OutstandingSharesPercentage" xlink:to="apm_OutstandingSharesPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_CurrentAbstract0_lbl0" xml:lang="en-US">Current Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CurrentAbstract0" xlink:to="apm_CurrentAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees_lbl1" xml:lang="en-US">Consultant Secondment Management And Administrative Services Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees" xlink:to="apm_ConsultantSecondmentManagementAndAdministrativeServicesFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl1" xml:lang="en-US">Payments to Fund Long-Term Loans to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_CGYInvestmentsLimitedMember_lbl0" xml:lang="en-US">CGYInvestments Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CGYInvestmentsLimitedMember" xlink:to="apm_CGYInvestmentsLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PrepaidServiceFee_lbl1" xml:lang="en-US">Prepaid Service Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaidServiceFee" xlink:to="apm_PrepaidServiceFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl0" xml:lang="en-US">Operating Lease, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl0" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl0" xml:lang="en-US">Capital Units, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_InitialCostBasis_lbl1" xml:lang="en-US">Initial Cost Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InitialCostBasis" xlink:to="apm_InitialCostBasis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl1" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems_lbl0" xml:lang="en-US">Income Taxes Details Scheduleof Income Taxes Expenses Computedatthe Hong Kong Statutory Tax Rate Parentheticals Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" xlink:to="apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Unrealized Loss On Investment Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock" xlink:to="apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems_lbl0" xml:lang="en-US">Other Receivablesand Prepayments Details Scheduleof Other Receivablesand Prepayments Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AdministrativeManagementServices_lbl1" xml:lang="en-US">Administrative Management Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdministrativeManagementServices" xlink:to="apm_AdministrativeManagementServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AmountsDueFromRelatedPartiesCurrent_lbl1" xml:lang="en-US">Amounts Due From Related Parties Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AmountsDueFromRelatedPartiesCurrent" xlink:to="apm_AmountsDueFromRelatedPartiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl0" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromBankDebt_lbl0" xml:lang="en-US">Proceeds from Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LoanRepaymentAndInterestPaidToRelatedParties_lbl1" xml:lang="en-US">Loan Repayment And Interest Paid To Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanRepaymentAndInterestPaidToRelatedParties" xlink:to="apm_LoanRepaymentAndInterestPaidToRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ClarkChengMember_lbl0" xml:lang="en-US">Clark Cheng Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ClarkChengMember" xlink:to="apm_ClarkChengMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Amounts Due From Related Parties Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock" xlink:to="apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FairValueMeasurementsWeightedAverageRange_lbl1" xml:lang="en-US">Fair Value Measurements Weighted Average Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementsWeightedAverageRange" xlink:to="apm_FairValueMeasurementsWeightedAverageRange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_JurchenInvestmentCorporationMember_lbl0" xml:lang="en-US">Jurchen Investment Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_JurchenInvestmentCorporationMember" xlink:to="apm_JurchenInvestmentCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl0" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DisposalOfSubsidiariesNetOfCashDisposed_lbl1" xml:lang="en-US">Disposal Of Subsidiaries Net Of Cash Disposed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DisposalOfSubsidiariesNetOfCashDisposed" xlink:to="apm_DisposalOfSubsidiariesNetOfCashDisposed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AencoTechnologiesLtdMember_lbl0" xml:lang="en-US">Aenco Technologies Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AencoTechnologiesLtdMember" xlink:to="apm_AencoTechnologiesLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Terms2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AmountsDueToRelatedPartiesNoncurrent_lbl1" xml:lang="en-US">Amounts Due To Related Parties Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AmountsDueToRelatedPartiesNoncurrent" xlink:to="apm_AmountsDueToRelatedPartiesNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndBenefitsTrust_lbl0" xml:lang="en-US">Compensation and Benefits Trust</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndBenefitsTrust" xlink:to="us-gaap_CompensationAndBenefitsTrust_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FinanceLeaseCostAbstract_lbl0" xml:lang="en-US">Finance Lease Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FinanceLeaseCostAbstract" xlink:to="apm_FinanceLeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock_lbl0" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl0" xml:lang="en-US">Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_GainOnUseOfDigitalCurrencies_lbl1" xml:lang="en-US">Gain On Use Of Digital Currencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GainOnUseOfDigitalCurrencies" xlink:to="apm_GainOnUseOfDigitalCurrencies_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl0" xml:lang="en-US">Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AptorumTherapeuticsLimitedMember_lbl0" xml:lang="en-US">Aptorum Therapeutics Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AptorumTherapeuticsLimitedMember" xlink:to="apm_AptorumTherapeuticsLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOwnershipInterestsUnitsIssued_lbl0" xml:lang="en-US">Other Ownership Interests, Units Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsUnitsIssued" xlink:to="us-gaap_OtherOwnershipInterestsUnitsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_APTUSMANAGEMENTLIMITEDMember_lbl0" xml:lang="en-US">APTUSMANAGEMENTLIMITEDMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_APTUSMANAGEMENTLIMITEDMember" xlink:to="apm_APTUSMANAGEMENTLIMITEDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl0" xml:lang="en-US">Marketable Securities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_December312022Abstract_lbl0" xml:lang="en-US">December312022 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_December312022Abstract" xlink:to="apm_December312022Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LessAccumulatedAmortizationAndImpairmentAbstract_lbl0" xml:lang="en-US">Less Accumulated Amortization And Impairment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LessAccumulatedAmortizationAndImpairmentAbstract" xlink:to="apm_LessAccumulatedAmortizationAndImpairmentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl0" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IntangibleAssetsNetAbstract_lbl0" xml:lang="en-US">Intangible Assets Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IntangibleAssetsNetAbstract" xlink:to="apm_IntangibleAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_EmployeesAndExternalConsultantsMember_lbl0" xml:lang="en-US">Employees And External Consultants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_EmployeesAndExternalConsultantsMember" xlink:to="apm_EmployeesAndExternalConsultantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PrepaidPatentedLicensesMember_lbl0" xml:lang="en-US">Prepaid Patented Licenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaidPatentedLicensesMember" xlink:to="apm_PrepaidPatentedLicensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareOfEconomic_lbl0" xml:lang="en-US">Share Of Economic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareOfEconomic" xlink:to="apm_ShareOfEconomic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LossGainOnInvestmentsInMarketableSecuritiesNet_lbl1" xml:lang="en-US">Loss Gain On Investments In Marketable Securities Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LossGainOnInvestmentsInMarketableSecuritiesNet" xlink:to="apm_LossGainOnInvestmentsInMarketableSecuritiesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LiquidityDisclosureTextBlock_lbl1" xml:lang="en-US">Liquidity Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LiquidityDisclosureTextBlock" xlink:to="apm_LiquidityDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NetSalesAmountMoreThanCertainThresholdInYear_lbl1" xml:lang="en-US">Net Sales Amount More Than Certain Threshold In Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetSalesAmountMoreThanCertainThresholdInYear" xlink:to="apm_NetSalesAmountMoreThanCertainThresholdInYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NumeratorAbstract_lbl0" xml:lang="en-US">Numerator Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NumeratorAbstract" xlink:to="apm_NumeratorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl1" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ServicesFeesAdjusted_lbl1" xml:lang="en-US">Services Fees Adjusted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ServicesFeesAdjusted" xlink:to="apm_ServicesFeesAdjusted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl0" xml:lang="en-US">Marketable Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SundryIncome_lbl1" xml:lang="en-US">Sundry Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SundryIncome" xlink:to="apm_SundryIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfIntangibleAssetsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfIntangibleAssetsAbstract" xlink:to="apm_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl0" xml:lang="en-US">Nonrelated Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UpwardAdjustments_lbl1" xml:lang="en-US">Upward Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UpwardAdjustments" xlink:to="apm_UpwardAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NoncontrollingInterestsPolicyTextBlock_lbl1" xml:lang="en-US">Noncontrolling Interests Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NoncontrollingInterestsPolicyTextBlock" xlink:to="apm_NoncontrollingInterestsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DownwardAdjustmentsAndImpairment_lbl1" xml:lang="en-US">Downward Adjustments And Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DownwardAdjustmentsAndImpairment" xlink:to="apm_DownwardAdjustmentsAndImpairment_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_TotalCarryingValueAtTheEndOfThePeriod_lbl1" xml:lang="en-US">Total Carrying Value At The End Of The Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TotalCarryingValueAtTheEndOfThePeriod" xlink:to="apm_TotalCarryingValueAtTheEndOfThePeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl0" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl0" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfOperatingLeasesObligationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfOperatingLeasesObligationAbstract_lbl" xml:lang="en-US">Schedule Of Operating Leases Obligation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfOperatingLeasesObligationAbstract" xlink:to="apm_ScheduleOfOperatingLeasesObligationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfProvisionForIncomeTaxesExpensesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfProvisionForIncomeTaxesExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfProvisionForIncomeTaxesExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Provision For Income Taxes Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfProvisionForIncomeTaxesExpensesAbstract" xlink:to="apm_ScheduleOfProvisionForIncomeTaxesExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract_lbl" xml:lang="en-US">Schedule Of Quantitative Information About The Group SLevel3 Fair Value Measurements Of Investment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract" xlink:to="apm_ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl2" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_December312022Abstract0_lbl0" xml:lang="en-US">December312022 Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_December312022Abstract0" xlink:to="apm_December312022Abstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract_lbl0" xml:lang="en-US">Issuance Of Convertible Note To Related Parties Note15 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract" xlink:to="apm_IssuanceOfConvertibleNoteToRelatedPartiesNote15Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription_lbl0" xml:lang="en-US">Key Provisions of Operating or Partnership Agreement, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription" xlink:to="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInvestments_lbl0" xml:lang="en-US">Other Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestments" xlink:to="us-gaap_OtherInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract_lbl" xml:lang="en-US">Schedule Of Milestone Payments Are To Be Made Upon Achievements Of Certain Conditions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract" xlink:to="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OtherReceivablesandPrepaymentsTablesLineItems_lbl0" xml:lang="en-US">Other Receivablesand Prepayments Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherReceivablesandPrepaymentsTablesLineItems" xlink:to="apm_OtherReceivablesandPrepaymentsTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_JurchenInvestmentsCorporationMember_lbl0" xml:lang="en-US">Jurchen Investments Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_JurchenInvestmentsCorporationMember" xlink:to="apm_JurchenInvestmentsCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IncreaseDecreaseDueFromBrokers_lbl1" xml:lang="en-US">Increase Decrease Due From Brokers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncreaseDecreaseDueFromBrokers" xlink:to="apm_IncreaseDecreaseDueFromBrokers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens_lbl1" xml:lang="en-US">Settlement Of Service Fee By Digital Currencies And Tokens</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens" xlink:to="apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl1" xml:lang="en-US">Line of Credit Facility, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_WritteoffOfPrepaymentAndOtherReceivables_lbl2" xml:lang="en-US">Writteoff Of Prepayment And Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WritteoffOfPrepaymentAndOtherReceivables" xlink:to="apm_WritteoffOfPrepaymentAndOtherReceivables_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FairValueMeasurementsUnobservableInput_lbl1" xml:lang="en-US">Fair Value Measurements Unobservable Input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementsUnobservableInput" xlink:to="apm_FairValueMeasurementsUnobservableInput_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_CurrentAbstract_lbl0" xml:lang="en-US">Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CurrentAbstract" xlink:to="apm_CurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NonCurrentAbstract_lbl0" xml:lang="en-US">Non Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonCurrentAbstract" xlink:to="apm_NonCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AccountsPayableandAccruedExpensesTablesLineItems_lbl0" xml:lang="en-US">Accounts Payableand Accrued Expenses Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AccountsPayableandAccruedExpensesTablesLineItems" xlink:to="apm_AccountsPayableandAccruedExpensesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DeferredTaxLiabilityAbstract_lbl0" xml:lang="en-US">Deferred Tax Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DeferredTaxLiabilityAbstract" xlink:to="apm_DeferredTaxLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_sharesOutstandingPerentage_lbl1" xml:lang="en-US">shares Outstanding Perentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_sharesOutstandingPerentage" xlink:to="apm_sharesOutstandingPerentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl0" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfRelatedPartyTransactionsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfRelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Schedule Of Related Party Transactions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfRelatedPartyTransactionsAbstract" xlink:to="apm_ScheduleOfRelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract_lbl0" xml:lang="en-US">Diagnostics Technology Up To The Conditions And Milestones Of Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AccretionOfFinanceLeaseObligation_lbl1" xml:lang="en-US">Accretion Of Finance Lease Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AccretionOfFinanceLeaseObligation" xlink:to="apm_AccretionOfFinanceLeaseObligation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NonCurrentAssetsAbstract_lbl0" xml:lang="en-US">Non Current Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonCurrentAssetsAbstract" xlink:to="apm_NonCurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ConvertibleNotesMember_lbl0" xml:lang="en-US">Convertible Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConvertibleNotesMember" xlink:to="apm_ConvertibleNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DeferredTaxAssetAbstract_lbl0" xml:lang="en-US">Deferred Tax Asset Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DeferredTaxAssetAbstract" xlink:to="apm_DeferredTaxAssetAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfMajorSubsidiariesConsolidatedAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfMajorSubsidiariesConsolidatedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfMajorSubsidiariesConsolidatedAbstract_lbl" xml:lang="en-US">Schedule Of Major Subsidiaries Consolidated Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfMajorSubsidiariesConsolidatedAbstract" xlink:to="apm_ScheduleOfMajorSubsidiariesConsolidatedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-Term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashEquivalents_lbl0" xml:lang="en-US">Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PrepaymentsForEquipment_lbl1" xml:lang="en-US">Prepayments For Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrepaymentsForEquipment" xlink:to="apm_PrepaymentsForEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_GainOnUseOfDigitalsCurrencies_lbl1" xml:lang="en-US">Gain On Use Of Digitals Currencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GainOnUseOfDigitalsCurrencies" xlink:to="apm_GainOnUseOfDigitalsCurrencies_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRent_lbl0" xml:lang="en-US">Prepaid Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl1" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock_lbl1" xml:lang="en-US">Property Plant And Equipment Usefull Life Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock" xlink:to="apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NonemployeesMember_lbl0" xml:lang="en-US">Nonemployees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonemployeesMember" xlink:to="apm_NonemployeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost_lbl0" xml:lang="en-US">Research and Development Expense, Software (Excluding Acquired in Process Cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PreclinicalToIndFiling_lbl1" xml:lang="en-US">Preclinical To Ind Filing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PreclinicalToIndFiling" xlink:to="apm_PreclinicalToIndFiling_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_mTORHongKongLimitedMember_lbl0" xml:lang="en-US">m TORHong Kong Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_mTORHongKongLimitedMember" xlink:to="apm_mTORHongKongLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl0" xml:lang="en-US">Other Cost and Expense, Operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfLongTermDepositsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfLongTermDepositsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfLongTermDepositsAbstract_lbl" xml:lang="en-US">Schedule Of Long Term Deposits Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfLongTermDepositsAbstract" xlink:to="apm_ScheduleOfLongTermDepositsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_InterestIncomeNoteBAbstract_lbl0" xml:lang="en-US">Interest Income Note BAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InterestIncomeNoteBAbstract" xlink:to="apm_InterestIncomeNoteBAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ProceedsInBrokerAccounts_lbl1" xml:lang="en-US">Proceeds In Broker Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ProceedsInBrokerAccounts" xlink:to="apm_ProceedsInBrokerAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LeaseholdImprovementsEstimatedUsefulLives_lbl1" xml:lang="en-US">Leasehold Improvements Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LeaseholdImprovementsEstimatedUsefulLives" xlink:to="apm_LeaseholdImprovementsEstimatedUsefulLives_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FromEnteringPhase1ToBeforeFirstCommercialSale_lbl1" xml:lang="en-US">From Entering Phase1 To Before First Commercial Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FromEnteringPhase1ToBeforeFirstCommercialSale" xlink:to="apm_FromEnteringPhase1ToBeforeFirstCommercialSale_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScipioMember_lbl0" xml:lang="en-US">Scipio Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScipioMember" xlink:to="apm_ScipioMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SignateLifeSciencesLimitedMember_lbl0" xml:lang="en-US">Signate Life Sciences Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SignateLifeSciencesLimitedMember" xlink:to="apm_SignateLifeSciencesLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DeferredTaxAssetsDepreciationAndAmortization_lbl1" xml:lang="en-US">Deferred Tax Assets Depreciation And Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="apm_DeferredTaxAssetsDepreciationAndAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl2" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNet_lbl0" xml:lang="en-US">Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_AssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl0" xml:lang="en-US">Repayments of Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl1" xml:lang="en-US">Interest Income, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl1"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Amortization Expense Related To Its Finite Lived Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract" xlink:to="apm_ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_TwoThousandSeventeenShareOptionPlanMember_lbl0" xml:lang="en-US">Two Thousand Seventeen Share Option Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TwoThousandSeventeenShareOptionPlanMember" xlink:to="apm_TwoThousandSeventeenShareOptionPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Dilution Factor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" xlink:to="apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LibraSciencesLimitedMember_lbl0" xml:lang="en-US">Libra Sciences Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LibraSciencesLimitedMember" xlink:to="apm_LibraSciencesLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl0" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FinanceLeaseDepreciation_lbl1" xml:lang="en-US">Finance Lease Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FinanceLeaseDepreciation" xlink:to="apm_FinanceLeaseDepreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_MiosPharmaceuticalsLimitedMember_lbl0" xml:lang="en-US">Mios Pharmaceuticals Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MiosPharmaceuticalsLimitedMember" xlink:to="apm_MiosPharmaceuticalsLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LibraTherapeuticsLimitedOneMember_lbl0" xml:lang="en-US">Libra Therapeutics Limited One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LibraTherapeuticsLimitedOneMember" xlink:to="apm_LibraTherapeuticsLimitedOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherValueOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherValueOutstanding" xlink:to="us-gaap_CommonStockOtherValueOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl1" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_GrossCarryingAmountAbstract_lbl0" xml:lang="en-US">Gross Carrying Amount Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GrossCarryingAmountAbstract" xlink:to="apm_GrossCarryingAmountAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy_lbl0" xml:lang="en-US">Income Tax Uncertainties, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:to="us-gaap_IncomeTaxUncertaintiesPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ExchangeDifferenceOnTranslationOfForeignOperation_lbl1" xml:lang="en-US">Exchange Difference On Translation Of Foreign Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ExchangeDifferenceOnTranslationOfForeignOperation" xlink:to="apm_ExchangeDifferenceOnTranslationOfForeignOperation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl0" xml:lang="en-US">Loans and Leases Receivable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl0" xml:lang="en-US">Sublease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation_lbl1" xml:lang="en-US">Fair Value Of Change In Unrealized Appreciation Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation" xlink:to="apm_FairValueOfChangeInUnrealizedAppreciationDepreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DSFInvestmentHoldingsLimitedMember_lbl0" xml:lang="en-US">DSFInvestment Holdings Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DSFInvestmentHoldingsLimitedMember" xlink:to="apm_DSFInvestmentHoldingsLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NonCurrentAssetsAbstract0_lbl0" xml:lang="en-US">Non Current Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NonCurrentAssetsAbstract0" xlink:to="apm_NonCurrentAssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl0" xml:lang="en-US">Variable Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule Of Each Stock Option Award Is Estimated On The Date Of Grant Using The Black Scholes Option Pricing Model Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="apm_ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction_lbl1" xml:lang="en-US">Stock Issued During Period Disposal Of Subsidiaries Under Common Control Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" xlink:to="apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl0" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ActiculeLifeSciencesLimitedMember_lbl0" xml:lang="en-US">Acticule Life Sciences Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ActiculeLifeSciencesLimitedMember" xlink:to="apm_ActiculeLifeSciencesLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_TotalUnrealizedGainForNonmarketableInvestments_lbl1" xml:lang="en-US">Total Unrealized Gain For Nonmarketable Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TotalUnrealizedGainForNonmarketableInvestments" xlink:to="apm_TotalUnrealizedGainForNonmarketableInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_GroupsSubsidiariesMember_lbl0" xml:lang="en-US">Groups Subsidiaries Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GroupsSubsidiariesMember" xlink:to="apm_GroupsSubsidiariesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DecreasedOwnershipPercentage_lbl1" xml:lang="en-US">Decreased Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DecreasedOwnershipPercentage" xlink:to="apm_DecreasedOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0" xml:lang="en-US">Computer Software, Intangible Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract38" xlink:to="apm_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LongTermInvestmentsAbstract0_lbl0" xml:lang="en-US">Long Term Investments Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongTermInvestmentsAbstract0" xlink:to="apm_LongTermInvestmentsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_TalemMedicalGroupLimitedMember_lbl0" xml:lang="en-US">Talem Medical Group Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_TalemMedicalGroupLimitedMember" xlink:to="apm_TalemMedicalGroupLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityOtherShares_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Other Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOtherShares" xlink:to="us-gaap_StockholdersEquityOtherShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl0" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScipioLifeSciencesLimitedMember_lbl0" xml:lang="en-US">Scipio Life Sciences Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScipioLifeSciencesLimitedMember" xlink:to="apm_ScipioLifeSciencesLimitedMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfEstimatedUsefulLivesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfEstimatedUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfEstimatedUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Lives Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfEstimatedUsefulLivesAbstract" xlink:to="apm_ScheduleOfEstimatedUsefulLivesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_MrDarrenLuiMember_lbl0" xml:lang="en-US">Mr Darren Lui Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MrDarrenLuiMember" xlink:to="apm_MrDarrenLuiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="apm_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_HealthcareServicesIncomeAbstract_lbl0" xml:lang="en-US">Healthcare Services Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_HealthcareServicesIncomeAbstract" xlink:to="apm_HealthcareServicesIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract18" xlink:to="apm_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract19" xlink:to="apm_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract16" xlink:to="apm_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract17" xlink:to="apm_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Value Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="apm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareIssuedToConvertibleNoteHolders_lbl1" xml:lang="en-US">Share Issued To Convertible Note Holders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareIssuedToConvertibleNoteHolders" xlink:to="apm_ShareIssuedToConvertibleNoteHolders_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PathsDiagnosticsPteLimitedMember_lbl0" xml:lang="en-US">Paths Diagnostics Pte Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PathsDiagnosticsPteLimitedMember" xlink:to="apm_PathsDiagnosticsPteLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_SG_lbl0" xml:lang="en-US">SINGAPORE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_SG" xlink:to="country_SG_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl0" xml:lang="en-US">Long-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract21" xlink:to="apm_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract22" xlink:to="apm_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract20" xlink:to="apm_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract25" xlink:to="apm_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract26" xlink:to="apm_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract23" xlink:to="apm_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ACCMedicalLimitedMember_lbl0" xml:lang="en-US">ACCMedical Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ACCMedicalLimitedMember" xlink:to="apm_ACCMedicalLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract24" xlink:to="apm_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract29" xlink:to="apm_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest_lbl1" xml:lang="en-US">Adjustment To Issuance Of Shares To Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest" xlink:to="apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract27" xlink:to="apm_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesOutstanding_lbl0" xml:lang="en-US">Excess Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesOutstanding" xlink:to="us-gaap_ExcessStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract28" xlink:to="apm_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SabrinaKhanMember_lbl0" xml:lang="en-US">Sabrina Khan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SabrinaKhanMember" xlink:to="apm_SabrinaKhanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfOtherReceivablesAndPrepaymentsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfOtherReceivablesAndPrepaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfOtherReceivablesAndPrepaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Other Receivables And Prepayments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfOtherReceivablesAndPrepaymentsAbstract" xlink:to="apm_ScheduleOfOtherReceivablesAndPrepaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract32" xlink:to="apm_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl1" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract33" xlink:to="apm_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract30" xlink:to="apm_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract31" xlink:to="apm_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LossCarryforwardCancelled_lbl1" xml:lang="en-US">Loss Carryforward Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LossCarryforwardCancelled" xlink:to="apm_LossCarryforwardCancelled_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract36" xlink:to="apm_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract37" xlink:to="apm_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract34" xlink:to="apm_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract35" xlink:to="apm_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract_lbl" xml:lang="en-US">Schedule Of Income Taxes Expenses Computed At The Hong Kong Statutory Tax Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract" xlink:to="apm_ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_EntityIncorporationsStateCountryName_lbl1" xml:lang="en-US">Entity Incorporations State Country Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_EntityIncorporationsStateCountryName" xlink:to="apm_EntityIncorporationsStateCountryName_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl0" xml:lang="en-US">Prepaid Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_IncomeTaxDescription_lbl1" xml:lang="en-US">Income Tax Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_IncomeTaxDescription" xlink:to="apm_IncomeTaxDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl0" xml:lang="en-US">Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract10" xlink:to="apm_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FirstCommercialSale_lbl1" xml:lang="en-US">First Commercial Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FirstCommercialSale" xlink:to="apm_FirstCommercialSale_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract11" xlink:to="apm_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract14" xlink:to="apm_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract15" xlink:to="apm_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract12" xlink:to="apm_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_InsuranceExpensePayable_lbl1" xml:lang="en-US">Insurance Expense Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InsuranceExpensePayable" xlink:to="apm_InsuranceExpensePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract13" xlink:to="apm_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract2" xlink:to="apm_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_StockIssuedDuringPeridSharesIssuanceOfShares_lbl1" xml:lang="en-US">Stock Issued During Perid Shares Issuance Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeridSharesIssuanceOfShares" xlink:to="apm_StockIssuedDuringPeridSharesIssuanceOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract1" xlink:to="apm_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract4" xlink:to="apm_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract3" xlink:to="apm_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract0" xlink:to="apm_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl0" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract9" xlink:to="apm_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract6" xlink:to="apm_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract5" xlink:to="apm_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract8" xlink:to="apm_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract7" xlink:to="apm_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_CostOfHealthcareServicesPayable_lbl1" xml:lang="en-US">Cost Of Healthcare Services Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CostOfHealthcareServicesPayable" xlink:to="apm_CostOfHealthcareServicesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_HongKongHealthcareServicesMember_lbl0" xml:lang="en-US">Hong Kong Healthcare Services Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_HongKongHealthcareServicesMember" xlink:to="apm_HongKongHealthcareServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0" xml:lang="en-US">Short-Term Bank Loans and Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PrincipleActivities_lbl1" xml:lang="en-US">Principle Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PrincipleActivities" xlink:to="apm_PrincipleActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens_lbl1" xml:lang="en-US">Settlements Of Service Fee By Digital Currencies And Tokens</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" xlink:to="apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl0" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_lbl2" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" xlink:to="apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UnlabeledAbstract" xlink:to="apm_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl0" xml:lang="en-US">Gain (Loss) on Sale of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LossOnDisposalOfLonglivedAssets_lbl1" xml:lang="en-US">Loss On Disposal Of Longlived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LossOnDisposalOfLonglivedAssets" xlink:to="apm_LossOnDisposalOfLonglivedAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_PathsInnovationsLimitedMember_lbl0" xml:lang="en-US">Paths Innovations Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_PathsInnovationsLimitedMember" xlink:to="apm_PathsInnovationsLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_MrClarkChengMember_lbl0" xml:lang="en-US">Mr Clark Cheng Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MrClarkChengMember" xlink:to="apm_MrClarkChengMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfLongTermDepositsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Long Term Deposits Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfLongTermDepositsTableTextBlock" xlink:to="apm_ScheduleOfLongTermDepositsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OperatingLeasesPolicyTextBlock_lbl1" xml:lang="en-US">Operating Leases Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OperatingLeasesPolicyTextBlock" xlink:to="apm_OperatingLeasesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_InterestExpensesNoteAAndNote15Abstract_lbl0" xml:lang="en-US">Interest Expenses Note AAnd Note15 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InterestExpensesNoteAAndNote15Abstract" xlink:to="apm_InterestExpensesNoteAAndNote15Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount_lbl1" xml:lang="en-US">Valuation Allowance Deferred Tax Asset Decrease Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:to="apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_MrIanHuenMember_lbl0" xml:lang="en-US">Mr Ian Huen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MrIanHuenMember" xlink:to="apm_MrIanHuenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AdministrativeManagementServicesNoteDAbstract_lbl0" xml:lang="en-US">Administrative Management Services Note DAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdministrativeManagementServicesNoteDAbstract" xlink:to="apm_AdministrativeManagementServicesNoteDAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LongTermDepositsTablesLineItems_lbl0" xml:lang="en-US">Long Term Deposits Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongTermDepositsTablesLineItems" xlink:to="apm_LongTermDepositsTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfAmountsDueToRelatedPartiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAmountsDueToRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfAmountsDueToRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Amounts Due To Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfAmountsDueToRelatedPartiesAbstract" xlink:to="apm_ScheduleOfAmountsDueToRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AllowanceForCreditLossOfDueFromARelatedParty_lbl2" xml:lang="en-US">Allowance For Credit Loss Of Due From ARelated Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AllowanceForCreditLossOfDueFromARelatedParty" xlink:to="apm_AllowanceForCreditLossOfDueFromARelatedParty_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_CommonStock1Member_lbl0" xml:lang="en-US">Common Stock1 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CommonStock1Member" xlink:to="apm_CommonStock1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl0" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl0" xml:lang="en-US">Line of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Deposit Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_VestedAndUnvestedShareOptions_lbl1" xml:lang="en-US">Vested And Unvested Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_VestedAndUnvestedShareOptions" xlink:to="apm_VestedAndUnvestedShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LongtermInvestmentsPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Longterm Investments Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LongtermInvestmentsPolicyPolicyTextBlock" xlink:to="apm_LongtermInvestmentsPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ResearchAndDevelopmentExpensesPayable_lbl1" xml:lang="en-US">Research And Development Expenses Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ResearchAndDevelopmentExpensesPayable" xlink:to="apm_ResearchAndDevelopmentExpensesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LibraMember_lbl0" xml:lang="en-US">Libra Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LibraMember" xlink:to="apm_LibraMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueAdjustment_lbl0" xml:lang="en-US">Equity, Fair Value Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueAdjustment" xlink:to="us-gaap_EquityFairValueAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses_lbl0" xml:lang="en-US">Utilities Operating Expense, Maintenance, Operations, and Other Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses" xlink:to="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl1" xml:lang="en-US">Inventory Write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_RepaymentOfLoanFromRelatedParty_lbl2" xml:lang="en-US">Repayment Of Loan From Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RepaymentOfLoanFromRelatedParty" xlink:to="apm_RepaymentOfLoanFromRelatedParty_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AmountsDueToRelatedPartiesCurrent_lbl1" xml:lang="en-US">Amounts Due To Related Parties Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AmountsDueToRelatedPartiesCurrent" xlink:to="apm_AmountsDueToRelatedPartiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_StockIssuedDuringPeriodValueIssuanceOfShares_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodValueIssuanceOfShares" xlink:to="apm_StockIssuedDuringPeriodValueIssuanceOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl0" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl0" xml:lang="en-US">Common Stock, Voting Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_GB_lbl0" xml:lang="en-US">UNITED KINGDOM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember_lbl0" xml:lang="en-US">Leasehold Improvements Furniture And Fixtures And Office Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember" xlink:to="apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_WroteOffOfCostRelatedAmortization_lbl1" xml:lang="en-US">Wrote Off Of Cost Related Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WroteOffOfCostRelatedAmortization" xlink:to="apm_WroteOffOfCostRelatedAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal_lbl1" xml:lang="en-US">Surgical Robotics And Medical Devices Up To Conditions And Milestones Of Subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:to="apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_MiosMember_lbl0" xml:lang="en-US">Mios Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MiosMember" xlink:to="apm_MiosMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Milestone Payments Are To Be Made Upon Achievements Of Certain Conditions Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" xlink:to="apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">Laboratory Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LaboratoryEquipmentMember" xlink:to="apm_LaboratoryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetInvestmentInLease_lbl0" xml:lang="en-US">Net Investment in Lease, before Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentInLease" xlink:to="us-gaap_NetInvestmentInLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ReversalDeferredCashBonus_lbl1" xml:lang="en-US">Reversal Deferred Cash Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ReversalDeferredCashBonus" xlink:to="apm_ReversalDeferredCashBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ClavesLifeSciencesLimitedMember_lbl0" xml:lang="en-US">Claves Life Sciences Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ClavesLifeSciencesLimitedMember" xlink:to="apm_ClavesLifeSciencesLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl0" xml:lang="en-US">Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_RentalDeposits_lbl1" xml:lang="en-US">Rental Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RentalDeposits" xlink:to="apm_RentalDeposits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ConvertibleNotesConvertedToClassAOrdinaryShares_lbl1" xml:lang="en-US">Convertible Notes Converted To Class AOrdinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConvertibleNotesConvertedToClassAOrdinaryShares" xlink:to="apm_ConvertibleNotesConvertedToClassAOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_lbl0" xml:lang="en-US">Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:to="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Carrying Value Of Our Nonmarketable Investments Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock" xlink:to="apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AeneasGroupLimitedMember_lbl0" xml:lang="en-US">Aeneas Group Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AeneasGroupLimitedMember" xlink:to="apm_AeneasGroupLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NativusLifeSciencesLimitedMember_lbl0" xml:lang="en-US">Nativus Life Sciences Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NativusLifeSciencesLimitedMember" xlink:to="apm_NativusLifeSciencesLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract_lbl0" xml:lang="en-US">Loan Repayment And Interest Received From ARelated Party Note BAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract" xlink:to="apm_LoanRepaymentAndInterestReceivedFromARelatedPartyNoteBAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CA_lbl0" xml:lang="en-US">CANADA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Partners&apos; Capital Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest" xlink:to="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NetDeferredTaxAssetsBeforeValuationAllowance_lbl1" xml:lang="en-US">Net Deferred Tax Assets Before Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetDeferredTaxAssetsBeforeValuationAllowance" xlink:to="apm_NetDeferredTaxAssetsBeforeValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AeneasManagementLimitedMember_lbl0" xml:lang="en-US">Aeneas Management Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AeneasManagementLimitedMember" xlink:to="apm_AeneasManagementLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl0" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Due To Related Parties Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:to="apm_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners_lbl1" xml:lang="en-US">Noncontrolling Interest Ownership Percentage By Noncontrolling Owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract_lbl0" xml:lang="en-US">Consultant Secondment Management And Administrative Services Fees Note CAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract" xlink:to="apm_ConsultantSecondmentManagementAndAdministrativeServicesFeesNoteCAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit_lbl1" xml:lang="en-US">Adjustment Increase Decrease Retained Earnings Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit" xlink:to="apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions_lbl1" xml:lang="en-US">Settlement Of Deferred Cash Bonus By Issuance Of Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions" xlink:to="apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract_lbl0" xml:lang="en-US">Drug Molecules Up To The Conditions And Milestones Of Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfAmountsDueFromRelatedPartiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAmountsDueFromRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfAmountsDueFromRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Amounts Due From Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfAmountsDueFromRelatedPartiesAbstract" xlink:to="apm_ScheduleOfAmountsDueFromRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_VidensIncorporationLimitedMember_lbl0" xml:lang="en-US">Videns Incorporation Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_VidensIncorporationLimitedMember" xlink:to="apm_VidensIncorporationLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl0" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="apm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_UpwardAdjustment_lbl1" xml:lang="en-US">Upward Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_UpwardAdjustment" xlink:to="apm_UpwardAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_MilestonePayments_lbl1" xml:lang="en-US">Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_MilestonePayments" xlink:to="apm_MilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Assets And Liabilities Carried At Fair Value Measured On ARecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract" xlink:to="apm_ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SharesPrice_lbl1" xml:lang="en-US">Shares Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SharesPrice" xlink:to="apm_SharesPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OciNetOfTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Alternative [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_OciNetOfTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_LiquidityDisclosureAbstract" xlink:href="apm-20231231.xsd#apm_LiquidityDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LiquidityDisclosureAbstract_lbl" xml:lang="en-US">Liquidity Disclosure Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LiquidityDisclosureAbstract" xlink:to="apm_LiquidityDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl0" xml:lang="en-US">Proceeds from Other Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FairValueMeasurementValuationTechniques_lbl1" xml:lang="en-US">Fair Value Measurement Valuation Techniques</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FairValueMeasurementValuationTechniques" xlink:to="apm_FairValueMeasurementValuationTechniques_lbl1"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Aggregate Carrying Value Of Vies Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract" xlink:to="apm_ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OtherInformationAbstract_lbl0" xml:lang="en-US">Other Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OtherInformationAbstract" xlink:to="apm_OtherInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ServicesFees_lbl1" xml:lang="en-US">Services Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ServicesFees" xlink:to="apm_ServicesFees_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LoanFromRelatedPartiesNoteAAbstract_lbl0" xml:lang="en-US">Loan From Related Parties Note AAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanFromRelatedPartiesNoteAAbstract" xlink:to="apm_LoanFromRelatedPartiesNoteAAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Reconciliation Of Level3 Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract" xlink:to="apm_ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_InterestExpenseAndAccretionOfConvertibleDebts_lbl1" xml:lang="en-US">Interest Expense And Accretion Of Convertible Debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_InterestExpenseAndAccretionOfConvertibleDebts" xlink:to="apm_InterestExpenseAndAccretionOfConvertibleDebts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl0" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_EmployeesMember_lbl0" xml:lang="en-US">Employees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_EmployeesMember" xlink:to="apm_EmployeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_WarrantLiabilitiesPolicyTextBlock_lbl1" xml:lang="en-US">Warrant Liabilities Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WarrantLiabilitiesPolicyTextBlock" xlink:to="apm_WarrantLiabilitiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl1" xml:lang="en-US">Gain (Loss) on Disposition of Stock in Subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_WeightedAverageSharesOutstanding1Abstract_lbl0" xml:lang="en-US">Weighted Average Shares Outstanding1 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_WeightedAverageSharesOutstanding1Abstract" xlink:to="apm_WeightedAverageSharesOutstanding1Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl0" xml:lang="en-US">Long-Term Debt, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_FdaApprovalObtaine_lbl1" xml:lang="en-US">Fda Approval Obtaine</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_FdaApprovalObtaine" xlink:to="apm_FdaApprovalObtaine_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_DueFromBrokers_lbl1" xml:lang="en-US">Due From Brokers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_DueFromBrokers" xlink:to="apm_DueFromBrokers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_GrossProceed_lbl1" xml:lang="en-US">Gross Proceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_GrossProceed" xlink:to="apm_GrossProceed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl0" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_RemunerationAmount_lbl1" xml:lang="en-US">Remuneration Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_RemunerationAmount" xlink:to="apm_RemunerationAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract_lbl0" xml:lang="en-US">Loan Repayment And Interest Paid To Related Parties Note AAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract" xlink:to="apm_LoanRepaymentAndInterestPaidToRelatedPartiesNoteAAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl1" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Tax Asset And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_JurchenInvestmentCorporationOneMember_lbl0" xml:lang="en-US">Jurchen Investment Corporation One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_JurchenInvestmentCorporationOneMember" xlink:to="apm_JurchenInvestmentCorporationOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OrdinarySharesClosingPricePercentage_lbl1" xml:lang="en-US">Ordinary Shares Closing Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OrdinarySharesClosingPricePercentage" xlink:to="apm_OrdinarySharesClosingPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl0" xml:lang="en-US">Long-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl0" xml:lang="en-US">HONG KONG</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities_lbl0" xml:lang="en-US">Sale Leaseback Transaction, Transaction Costs, Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities" xlink:to="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_OperatingLeaseWeightedAverageDiscountRate_lbl1" xml:lang="en-US">Operating Lease Weighted Average Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_OperatingLeaseWeightedAverageDiscountRate" xlink:to="apm_OperatingLeaseWeightedAverageDiscountRate_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract_lbl0" xml:lang="en-US">Settlement Of Loan From ARelated Party Through Issuance Of Convertible Note Note15 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract" xlink:to="apm_SettlementOfLoanFromARelatedPartyThroughIssuanceOfConvertibleNoteNote15Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl1" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract_lbl0" xml:lang="en-US">Net Loss Per Share Attributable To Aptorum Group Limited1 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract" xlink:to="apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl0" xml:lang="en-US">Investment Owned, Net Assets, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apm_ShareOptionHoldersMember_lbl0" xml:lang="en-US">Share Option Holders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apm_ShareOptionHoldersMember" xlink:to="apm_ShareOptionHoldersMember_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>apm-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 09:10:53 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedBalanceSheet" roleURI="http://aptorumgroup.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedComprehensiveIncome" roleURI="http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ShareholdersEquityType2or3" roleURI="http://aptorumgroup.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConsolidatedCashFlow" roleURI="http://aptorumgroup.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_Organization" roleURI="http://aptorumgroup.com/role/Organization"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_Liquidity" roleURI="http://aptorumgroup.com/role/Liquidity"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SummaryofSignificantAccountingPolicies" roleURI="http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_Revenue" roleURI="http://aptorumgroup.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_InvestmentandFairValueMeasurement" roleURI="http://aptorumgroup.com/role/InvestmentandFairValueMeasurement"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OtherReceivablesandPrepayments" roleURI="http://aptorumgroup.com/role/OtherReceivablesandPrepayments"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_PropertyandEquipmentNet" roleURI="http://aptorumgroup.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IntangibleAssetsNet" roleURI="http://aptorumgroup.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LongTermDeposits" roleURI="http://aptorumgroup.com/role/LongTermDeposits"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_AccountsPayableandAccruedExpenses" roleURI="http://aptorumgroup.com/role/AccountsPayableandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IncomeTaxes" roleURI="http://aptorumgroup.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_RelatedPartyBalancesandTransactions" roleURI="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactions"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_VariableInterestEntity" roleURI="http://aptorumgroup.com/role/VariableInterestEntity"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_Lease" roleURI="http://aptorumgroup.com/role/Lease"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConvertibleNote" roleURI="http://aptorumgroup.com/role/ConvertibleNote"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OrdinaryShares" roleURI="http://aptorumgroup.com/role/OrdinaryShares"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ShareBasedCompensation" roleURI="http://aptorumgroup.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NonControllingInterest" roleURI="http://aptorumgroup.com/role/NonControllingInterest"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NetLossPerShare" roleURI="http://aptorumgroup.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_CommitmentsandContingencies" roleURI="http://aptorumgroup.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SegmentReporting" roleURI="http://aptorumgroup.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SubsequentEvents" roleURI="http://aptorumgroup.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_AccountingPoliciesByPolicy" roleURI="http://aptorumgroup.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OrganizationTables" roleURI="http://aptorumgroup.com/role/OrganizationTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_InvestmentandFairValueMeasurementTables" roleURI="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OtherReceivablesandPrepaymentsTables" roleURI="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_PropertyandEquipmentNetTables" roleURI="http://aptorumgroup.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IntangibleAssetsNetTables" roleURI="http://aptorumgroup.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LongTermDepositsTables" roleURI="http://aptorumgroup.com/role/LongTermDepositsTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_AccountsPayableandAccruedExpensesTables" roleURI="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IncomeTaxesTables" roleURI="http://aptorumgroup.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_RelatedPartyBalancesandTransactionsTables" roleURI="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_VariableInterestEntityTables" roleURI="http://aptorumgroup.com/role/VariableInterestEntityTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LeaseTables" roleURI="http://aptorumgroup.com/role/LeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ShareBasedCompensationTables" roleURI="http://aptorumgroup.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NetLossPerShareTables" roleURI="http://aptorumgroup.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_CommitmentsandContingenciesTables" roleURI="http://aptorumgroup.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofMajorSubsidiariesConsolidatedTable" roleURI="http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofEstimatedUsefulLivesTable" roleURI="http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" roleURI="http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofFairValueReconciliationofLevel3AssetsTable" roleURI="http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable" roleURI="http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofUnrealizedGainsandLossesTable" roleURI="http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofCarryingValueofOurNonMarketableInvestmentsTable" roleURI="http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofOtherReceivablesandPrepaymentsTable" roleURI="http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofPropertyandEquipmentTable" roleURI="http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofIntangibleAssetsTable" roleURI="http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" roleURI="http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofLongTermDepositsTable" roleURI="http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofProvisionforIncomeTaxesExpensesTable" roleURI="http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" roleURI="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals" roleURI="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofDeferredTaxAssetandLiabilitiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofChangesinValuationAllowanceTable" roleURI="http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAmountsDuefromRelatedPartiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAmountsDuetoRelatedPartiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofRelatedPartyTransactionsTable" roleURI="http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofOperatingLeasesObligationTable" roleURI="http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable" roleURI="http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleoftheOptionActivityTable" roleURI="http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" roleURI="http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofbasicanddilutedlossincomepershareTable" roleURI="http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable" roleURI="http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LiquidityDetails" roleURI="http://aptorumgroup.com/role/LiquidityDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_InvestmentandFairValueMeasurementDetails" roleURI="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OtherReceivablesandPrepaymentsDetails" roleURI="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_PropertyandEquipmentNetDetails" roleURI="http://aptorumgroup.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IntangibleAssetsNetDetails" roleURI="http://aptorumgroup.com/role/IntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_AccountsPayableandAccruedExpensesDetails" roleURI="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_IncomeTaxesDetails" roleURI="http://aptorumgroup.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_RelatedPartyBalancesandTransactionsDetails" roleURI="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_VariableInterestEntityDetails" roleURI="http://aptorumgroup.com/role/VariableInterestEntityDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_LeaseDetails" roleURI="http://aptorumgroup.com/role/LeaseDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ConvertibleNoteDetails" roleURI="http://aptorumgroup.com/role/ConvertibleNoteDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_OrdinarySharesDetails" roleURI="http://aptorumgroup.com/role/OrdinarySharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_ShareBasedCompensationDetails" roleURI="http://aptorumgroup.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NonControllingInterestDetails" roleURI="http://aptorumgroup.com/role/NonControllingInterestDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_NetLossPerShareDetails" roleURI="http://aptorumgroup.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_CommitmentsandContingenciesDetails" roleURI="http://aptorumgroup.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SegmentReportingDetails" roleURI="http://aptorumgroup.com/role/SegmentReportingDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#apm_r_SubsequentEventsDetails" roleURI="http://aptorumgroup.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="apm-20231231.xsd#DocumentAndEntityInformation" roleURI="http://aptorumgroup.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueFromBrokers" xlink:href="apm-20231231.xsd#apm_DueFromBrokers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="DueFromBrokers" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_LongTermInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_MinorityInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OciNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciNetOfTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OciNetOfTaxAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_GainLossOnSaleOfInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnUseOfDigitalCurrencies" xlink:href="apm-20231231.xsd#apm_GainOnUseOfDigitalCurrencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="GainOnUseOfDigitalCurrencies" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnDerecognitionOfNonfinancialAssets" xlink:href="apm-20231231.xsd#apm_GainOnDerecognitionOfNonfinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="GainOnDerecognitionOfNonfinancialAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SundryIncome" xlink:href="apm-20231231.xsd#apm_SundryIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="SundryIncome" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OciNetOfTaxAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentToIssuanceOfSharesToNoncontrollingInterest" xlink:href="apm-20231231.xsd#apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentToIssuanceOfSharesToNoncontrollingInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:href="apm-20231231.xsd#apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfShares" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodValueIssuanceOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="StockIssuedDuringPeriodValueIssuanceOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeridSharesIssuanceOfShares" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeridSharesIssuanceOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="StockIssuedDuringPeridSharesIssuanceOfShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockissuedDuringPeriodValueAdjustmentForChangeOfParValue" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueDisposalOfSubsidiaries" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueDisposalOfSubsidiaries" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueExerciseOfWarrants" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="apm-20231231.xsd#apm_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesExerciseOfWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeDifferenceOnTranslationOfForeignOperation" xlink:href="apm-20231231.xsd#apm_ExchangeDifferenceOnTranslationOfForeignOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExchangeDifferenceOnTranslationOfForeignOperation" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossGainOnInvestmentsInMarketableSecuritiesNet" xlink:href="apm-20231231.xsd#apm_LossGainOnInvestmentsInMarketableSecuritiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="LossGainOnInvestmentsInMarketableSecuritiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="LossOnDisposalOfLonglivedAssets" xlink:href="apm-20231231.xsd#apm_LossOnDisposalOfLonglivedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="LossOnDisposalOfLonglivedAssets" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowanceForCreditLossOfDueFromARelatedParty" xlink:href="apm-20231231.xsd#apm_AllowanceForCreditLossOfDueFromARelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AllowanceForCreditLossOfDueFromARelatedParty" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WritteoffOfPrepaymentAndOtherReceivables" xlink:href="apm-20231231.xsd#apm_WritteoffOfPrepaymentAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="WritteoffOfPrepaymentAndOtherReceivables" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnUseOfDigitalsCurrencies" xlink:href="apm-20231231.xsd#apm_GainOnUseOfDigitalsCurrencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainOnUseOfDigitalsCurrencies" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SettlementOfServiceFeeByDigitalCurrenciesAndTokens" xlink:href="apm-20231231.xsd#apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="SettlementOfServiceFeeByDigitalCurrenciesAndTokens" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestIncomeOther" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="InterestExpenseAndAccretionOfConvertibleDebts" xlink:href="apm-20231231.xsd#apm_InterestExpenseAndAccretionOfConvertibleDebts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="InterestExpenseAndAccretionOfConvertibleDebts" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccretionOfFinanceLeaseObligation" xlink:href="apm-20231231.xsd#apm_AccretionOfFinanceLeaseObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccretionOfFinanceLeaseObligation" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReversalDeferredCashBonus" xlink:href="apm-20231231.xsd#apm_ReversalDeferredCashBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ReversalDeferredCashBonus" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseDueFromBrokers" xlink:href="apm-20231231.xsd#apm_IncreaseDecreaseDueFromBrokers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseDueFromBrokers" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalOfSubsidiariesNetOfCashDisposed" xlink:href="apm-20231231.xsd#apm_DisposalOfSubsidiariesNetOfCashDisposed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="DisposalOfSubsidiariesNetOfCashDisposed" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RepaymentOfLoanFromRelatedParty" xlink:href="apm-20231231.xsd#apm_RepaymentOfLoanFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="RepaymentOfLoanFromRelatedParty" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromBankDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsInBrokerAccounts" xlink:href="apm-20231231.xsd#apm_ProceedsInBrokerAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ProceedsInBrokerAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" xlink:href="apm-20231231.xsd#apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="SettlementsOfServiceFeeByDigitalCurrenciesAndTokens" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesConvertedToClassAOrdinaryShares" xlink:href="apm-20231231.xsd#apm_ConvertibleNotesConvertedToClassAOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConvertibleNotesConvertedToClassAOrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SettlementOfDeferredCashBonusByIssuanceOfShareOptions" xlink:href="apm-20231231.xsd#apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="SettlementOfDeferredCashBonusByIssuanceOfShareOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/Organization">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/Liquidity">
    <loc xlink:type="locator" xlink:label="LiquidityDisclosureAbstract" xlink:href="apm-20231231.xsd#apm_LiquidityDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityTable" xlink:href="apm-20231231.xsd#apm_LiquidityTable"/>
    <loc xlink:type="locator" xlink:label="LiquidityLineItems" xlink:href="apm-20231231.xsd#apm_LiquidityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDisclosureAbstract" xlink:to="LiquidityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityTable" xlink:to="LiquidityLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LiquidityDisclosureTextBlock" xlink:href="apm-20231231.xsd#apm_LiquidityDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityLineItems" xlink:to="LiquidityDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/Revenue">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/InvestmentandFairValueMeasurement">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OtherReceivablesandPrepayments">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesandPrepaymentsTable" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsTable"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesandPrepaymentsLineItems" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="OtherReceivablesandPrepaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsTable" xlink:to="OtherReceivablesandPrepaymentsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IntangibleAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LongTermDeposits">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermDepositsTable" xlink:href="apm-20231231.xsd#apm_LongTermDepositsTable"/>
    <loc xlink:type="locator" xlink:label="LongTermDepositsLineItems" xlink:href="apm-20231231.xsd#apm_LongTermDepositsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="LongTermDepositsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDepositsTable" xlink:to="LongTermDepositsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDepositsLineItems" xlink:to="us-gaap_LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/AccountsPayableandAccruedExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/VariableInterestEntity">
    <loc xlink:type="locator" xlink:label="VariableInterestEntityAbstract" xlink:href="apm-20231231.xsd#apm_VariableInterestEntityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableInterestEntityAbstract" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/Lease">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConvertibleNote">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OrdinaryShares">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ShareBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NonControllingInterest">
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SegmentReporting">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncontrollingInterestsPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_NoncontrollingInterestsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NoncontrollingInterestsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermInvestmentsPolicyPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_LongtermInvestmentsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LongtermInvestmentsPolicyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_OperatingLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OperatingLeasesPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilitiesPolicyTextBlock" xlink:href="apm-20231231.xsd#apm_WarrantLiabilitiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="WarrantLiabilitiesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxUncertaintiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxUncertaintiesPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesPolicy" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OrganizationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentUsefullLifeTableTextBlock" xlink:href="apm-20231231.xsd#apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentUsefullLifeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfUnrealizedLossOnInvestmentTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="ScheduleOfUnrealizedLossOnInvestmentTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesandPrepaymentsTablesTable" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsTablesTable"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesandPrepaymentsTablesLineItems" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="OtherReceivablesandPrepaymentsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsTablesTable" xlink:to="OtherReceivablesandPrepaymentsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsTablesLineItems" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IntangibleAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LongTermDepositsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermDepositsTablesTable" xlink:href="apm-20231231.xsd#apm_LongTermDepositsTablesTable"/>
    <loc xlink:type="locator" xlink:label="LongTermDepositsTablesLineItems" xlink:href="apm-20231231.xsd#apm_LongTermDepositsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="LongTermDepositsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDepositsTablesTable" xlink:to="LongTermDepositsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermDepositsTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfLongTermDepositsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDepositsTablesLineItems" xlink:to="ScheduleOfLongTermDepositsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableandAccruedExpensesTablesTable" xlink:href="apm-20231231.xsd#apm_AccountsPayableandAccruedExpensesTablesTable"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableandAccruedExpensesTablesLineItems" xlink:href="apm-20231231.xsd#apm_AccountsPayableandAccruedExpensesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="AccountsPayableandAccruedExpensesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableandAccruedExpensesTablesTable" xlink:to="AccountsPayableandAccruedExpensesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableandAccruedExpensesTablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfDueToRelatedPartiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/VariableInterestEntityTables">
    <loc xlink:type="locator" xlink:label="VariableInterestEntityAbstract" xlink:href="apm-20231231.xsd#apm_VariableInterestEntityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableInterestEntityAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LeaseTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ShareBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" xlink:href="apm-20231231.xsd#apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMajorSubsidiariesConsolidatedAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfMajorSubsidiariesConsolidatedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMajorSubsidiariesConsolidatedAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AptorumTherapeuticsLimitedMember" xlink:href="apm-20231231.xsd#apm_AptorumTherapeuticsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AptorumTherapeuticsLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="APTUSMANAGEMENTLIMITEDMember" xlink:href="apm-20231231.xsd#apm_APTUSMANAGEMENTLIMITEDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="APTUSMANAGEMENTLIMITEDMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AptorumMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_AptorumMedicalLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AptorumMedicalLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PathsInnovationsLimitedMember" xlink:href="apm-20231231.xsd#apm_PathsInnovationsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="PathsInnovationsLimitedMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PathsDiagnosticsPteLimitedMember" xlink:href="apm-20231231.xsd#apm_PathsDiagnosticsPteLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="PathsDiagnosticsPteLimitedMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ActiculeLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ActiculeLifeSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ActiculeLifeSciencesLimitedMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClavesLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ClavesLifeSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ClavesLifeSciencesLimitedMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NativusLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_NativusLifeSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="NativusLifeSciencesLimitedMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VidensIncorporationLimitedMember" xlink:href="apm-20231231.xsd#apm_VidensIncorporationLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="VidensIncorporationLimitedMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MiosPharmaceuticalsLimitedMember" xlink:href="apm-20231231.xsd#apm_MiosPharmaceuticalsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="MiosPharmaceuticalsLimitedMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="mTORHongKongLimitedMember" xlink:href="apm-20231231.xsd#apm_mTORHongKongLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="mTORHongKongLimitedMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScipioLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ScipioLifeSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ScipioLifeSciencesLimitedMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SignateLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_SignateLifeSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="SignateLifeSciencesLimitedMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityIncorporationsStateCountryName" xlink:href="apm-20231231.xsd#apm_EntityIncorporationsStateCountryName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="EntityIncorporationsStateCountryName" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipleActivities" xlink:href="apm-20231231.xsd#apm_PrincipleActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="PrincipleActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfEstimatedUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" xlink:href="apm-20231231.xsd#apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" xlink:href="apm-20231231.xsd#apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="apm-20231231.xsd#apm_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseholdImprovementsEstimatedUsefulLives" xlink:href="apm-20231231.xsd#apm_LeaseholdImprovementsEstimatedUsefulLives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems" xlink:to="LeaseholdImprovementsEstimatedUsefulLives" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" xlink:href="apm-20231231.xsd#apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" xlink:href="apm-20231231.xsd#apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract" xlink:to="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CommonStock1Member" xlink:href="apm-20231231.xsd#apm_CommonStock1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStock1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable" xlink:to="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonCurrentAssetsAbstract" xlink:href="apm-20231231.xsd#apm_NonCurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" xlink:to="NonCurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_0" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfChangeInUnrealizedAppreciationDepreciation" xlink:href="apm-20231231.xsd#apm_FairValueOfChangeInUnrealizedAppreciationDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueOfChangeInUnrealizedAppreciationDepreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetChangeInUnrealizedDepreciationRelatingToInvestments" xlink:href="apm-20231231.xsd#apm_NetChangeInUnrealizedDepreciationRelatingToInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="NetChangeInUnrealizedDepreciationRelatingToInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementValuationTechniques" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementValuationTechniques"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueMeasurementValuationTechniques" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsUnobservableInput" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementsUnobservableInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueMeasurementsUnobservableInput" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsWeightedAverageRange" xlink:href="apm-20231231.xsd#apm_FairValueMeasurementsWeightedAverageRange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="FairValueMeasurementsWeightedAverageRange" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfUnrealizedGainsAndLossesAbstract"/>
    <loc xlink:type="locator" xlink:label="UpwardAdjustments" xlink:href="apm-20231231.xsd#apm_UpwardAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:to="UpwardAdjustments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DownwardAdjustmentsAndImpairment" xlink:href="apm-20231231.xsd#apm_DownwardAdjustmentsAndImpairment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:to="DownwardAdjustmentsAndImpairment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalUnrealizedGainForNonmarketableInvestments" xlink:href="apm-20231231.xsd#apm_TotalUnrealizedGainForNonmarketableInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrealizedGainsAndLossesAbstract" xlink:to="TotalUnrealizedGainForNonmarketableInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="InitialCostBasis" xlink:href="apm-20231231.xsd#apm_InitialCostBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:to="InitialCostBasis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpwardAdjustment" xlink:href="apm-20231231.xsd#apm_UpwardAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:to="UpwardAdjustment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DownwardAdjustmentAndImpairment" xlink:href="apm-20231231.xsd#apm_DownwardAdjustmentAndImpairment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:to="DownwardAdjustmentAndImpairment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalCarryingValueAtTheEndOfThePeriod" xlink:href="apm-20231231.xsd#apm_TotalCarryingValueAtTheEndOfThePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract" xlink:to="TotalCarryingValueAtTheEndOfThePeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherReceivablesAndPrepaymentsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfOtherReceivablesAndPrepaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:href="apm-20231231.xsd#apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherReceivablesAndPrepaymentsAbstract" xlink:to="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable" xlink:to="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidResearchAndDevelopmentExpenses" xlink:href="apm-20231231.xsd#apm_PrepaidResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="PrepaidResearchAndDevelopmentExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_PrepaidInsurance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidServiceFee" xlink:href="apm-20231231.xsd#apm_PrepaidServiceFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="PrepaidServiceFee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_DepositsAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_PrepaidRent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_OtherReceivables" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="apm-20231231.xsd#apm_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AutomobilesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AutomobilesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrepaidPatentedLicensesMember" xlink:href="apm-20231231.xsd#apm_PrepaidPatentedLicensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="PrepaidPatentedLicensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract" xlink:to="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable" xlink:to="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermDepositsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfLongTermDepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermDepositsDetailsScheduleofLongTermDepositsTable" xlink:href="apm-20231231.xsd#apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable"/>
    <loc xlink:type="locator" xlink:label="LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:href="apm-20231231.xsd#apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermDepositsAbstract" xlink:to="LongTermDepositsDetailsScheduleofLongTermDepositsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDepositsDetailsScheduleofLongTermDepositsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDepositsDetailsScheduleofLongTermDepositsTable" xlink:to="LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RentalDeposits" xlink:href="apm-20231231.xsd#apm_RentalDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:to="RentalDeposits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsForEquipment" xlink:href="apm-20231231.xsd#apm_PrepaymentsForEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:to="PrepaymentsForEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDepositsDetailsScheduleofLongTermDepositsLineItems" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesPayable" xlink:href="apm-20231231.xsd#apm_ResearchAndDevelopmentExpensesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="ResearchAndDevelopmentExpensesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CostOfHealthcareServicesPayable" xlink:href="apm-20231231.xsd#apm_CostOfHealthcareServicesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="CostOfHealthcareServicesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InsuranceExpensePayable" xlink:href="apm-20231231.xsd#apm_InsuranceExpensePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="InsuranceExpensePayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedExpensesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProvisionForIncomeTaxesExpensesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfProvisionForIncomeTaxesExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionForIncomeTaxesExpensesAbstract" xlink:to="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable" xlink:to="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZk9BQMOWQfrm8jHnK3iPqh/RGOZRChD6nBq3dVwAwj4+/8SLuZTW/liOfKmyEBpRrTV6V//wh8natqXLVrpArUZiEOpCUQ4sWmUCqPSbJB1eeE0YXZR+qpcGF8VKslPcXkQ+inlG1l8YPuGFp3JEZ5VoAJF844sVddHhNq3xJYgqGGsxym9XDdCckVzuBpb8fh8qHhjv8lYQ==] CSR-->
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract" xlink:to="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable" xlink:to="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract" xlink:to="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable" xlink:to="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetAbstract" xlink:href="apm-20231231.xsd#apm_DeferredTaxAssetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsDepreciationAndAmortization" xlink:href="apm-20231231.xsd#apm_DeferredTaxAssetsDepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetAbstract" xlink:to="DeferredTaxAssetsDepreciationAndAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilityAbstract" xlink:href="apm-20231231.xsd#apm_DeferredTaxLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="DeferredTaxLiabilityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NetDeferredTaxAssetsBeforeValuationAllowance" xlink:href="apm-20231231.xsd#apm_NetDeferredTaxAssetsBeforeValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="NetDeferredTaxAssetsBeforeValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInValuationAllowanceAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfChangesInValuationAllowanceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangesInValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_ValuationAllowanceLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationAllowanceDeferredTaxAssetIncrease" xlink:href="apm-20231231.xsd#apm_ValuationAllowanceDeferredTaxAssetIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="ValuationAllowanceDeferredTaxAssetIncrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:href="apm-20231231.xsd#apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="ValuationAllowanceDeferredTaxAssetDecreaseAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountsDueFromRelatedPartiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAmountsDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountsDueFromRelatedPartiesAbstract" xlink:to="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AeneasManagementLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasManagementLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AeneasManagementLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LibraSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_LibraSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LibraSciencesLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LibraTherapeuticsLimitedOneMember" xlink:href="apm-20231231.xsd#apm_LibraTherapeuticsLimitedOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LibraTherapeuticsLimitedOneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TalemMedicalGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_TalemMedicalGroupLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="TalemMedicalGroupLimitedMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable" xlink:to="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CurrentAbstract" xlink:href="apm-20231231.xsd#apm_CurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems" xlink:to="CurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountsDueFromRelatedPartiesCurrent" xlink:href="apm-20231231.xsd#apm_AmountsDueFromRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="AmountsDueFromRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentInLease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentInLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="us-gaap_NetInvestmentInLease" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountsDueToRelatedPartiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAmountsDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountsDueToRelatedPartiesAbstract" xlink:to="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AeneasGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasGroupLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AeneasGroupLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AencoTechnologiesLtdMember" xlink:href="apm-20231231.xsd#apm_AencoTechnologiesLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AencoTechnologiesLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SabrinaKhanMember" xlink:href="apm-20231231.xsd#apm_SabrinaKhanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SabrinaKhanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JurchenInvestmentsCorporationMember" xlink:href="apm-20231231.xsd#apm_JurchenInvestmentsCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JurchenInvestmentsCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable" xlink:to="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CurrentAbstract0" xlink:href="apm-20231231.xsd#apm_CurrentAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" xlink:to="CurrentAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountsDueToRelatedPartiesCurrent" xlink:href="apm-20231231.xsd#apm_AmountsDueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract0" xlink:to="AmountsDueToRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCurrentAbstract" xlink:href="apm-20231231.xsd#apm_NonCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems" xlink:to="NonCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountsDueToRelatedPartiesNoncurrent" xlink:href="apm-20231231.xsd#apm_AmountsDueToRelatedPartiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAbstract" xlink:to="AmountsDueToRelatedPartiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyTransactionsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfRelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AeneasGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasGroupLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AeneasGroupLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JurchenInvestmentCorporationMember" xlink:href="apm-20231231.xsd#apm_JurchenInvestmentCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JurchenInvestmentCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JurchenInvestmentCorporationOneMember" xlink:href="apm-20231231.xsd#apm_JurchenInvestmentCorporationOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JurchenInvestmentCorporationOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AencoTechnologiesLtdMember" xlink:href="apm-20231231.xsd#apm_AencoTechnologiesLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AencoTechnologiesLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TalemMedicalGroupLimitedMember" xlink:href="apm-20231231.xsd#apm_TalemMedicalGroupLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="TalemMedicalGroupLimitedMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LibraSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_LibraSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LibraSciencesLimitedMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CGYInvestmentsLimitedMember" xlink:href="apm-20231231.xsd#apm_CGYInvestmentsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CGYInvestmentsLimitedMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ACCMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_ACCMedicalLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ACCMedicalLimitedMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AeneasManagementLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasManagementLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AeneasManagementLimitedMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanRepaymentAndInterestPaidToRelatedParties" xlink:href="apm-20231231.xsd#apm_LoanRepaymentAndInterestPaidToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="LoanRepaymentAndInterestPaidToRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultantSecondmentManagementAndAdministrativeServicesFees" xlink:href="apm-20231231.xsd#apm_ConsultantSecondmentManagementAndAdministrativeServicesFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ConsultantSecondmentManagementAndAdministrativeServicesFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdministrativeManagementServices" xlink:href="apm-20231231.xsd#apm_AdministrativeManagementServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="AdministrativeManagementServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_Revenues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RepaymentOfLoanFromRelatedParty" xlink:href="apm-20231231.xsd#apm_RepaymentOfLoanFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="RepaymentOfLoanFromRelatedParty" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestIncomeOther" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_VariableInterestEntityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_OtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_OtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_AssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeasesObligationAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfOperatingLeasesObligationAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseCostAbstract" xlink:href="apm-20231231.xsd#apm_FinanceLeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasesObligationAbstract" xlink:to="FinanceLeaseCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseDepreciation" xlink:href="apm-20231231.xsd#apm_FinanceLeaseDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseCostAbstract" xlink:to="FinanceLeaseDepreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_VariableLeaseCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_SubleaseIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasesObligationAbstract" xlink:to="us-gaap_LeaseCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasesObligationAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheOptionActivityAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfTheOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheOptionActivityAbstract" xlink:to="ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityTable" xlink:to="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:href="apm-20231231.xsd#apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable" xlink:to="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageSharesOutstanding1Abstract" xlink:href="apm-20231231.xsd#apm_WeightedAverageSharesOutstanding1Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:to="WeightedAverageSharesOutstanding1Abstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareAttributableToAptorumGroupLimited1Abstract" xlink:href="apm-20231231.xsd#apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossIncomePerShareAbstract" xlink:to="NetLossPerShareAttributableToAptorumGroupLimited1Abstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareAttributableToAptorumGroupLimited1Abstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareAttributableToAptorumGroupLimited1Abstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract" xlink:href="apm-20231231.xsd#apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract"/>
    <loc xlink:type="locator" xlink:label="DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:href="apm-20231231.xsd#apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract" xlink:to="DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreclinicalToIndFiling" xlink:href="apm-20231231.xsd#apm_PreclinicalToIndFiling"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="PreclinicalToIndFiling" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FromEnteringPhase1ToBeforeFirstCommercialSale" xlink:href="apm-20231231.xsd#apm_FromEnteringPhase1ToBeforeFirstCommercialSale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="FromEnteringPhase1ToBeforeFirstCommercialSale" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstCommercialSale" xlink:href="apm-20231231.xsd#apm_FirstCommercialSale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="FirstCommercialSale" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetSalesAmountMoreThanCertainThresholdInYear" xlink:href="apm-20231231.xsd#apm_NetSalesAmountMoreThanCertainThresholdInYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="NetSalesAmountMoreThanCertainThresholdInYear" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" xlink:href="apm-20231231.xsd#apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract" xlink:to="SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" xlink:href="apm-20231231.xsd#apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract" xlink:to="DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FdaApprovalObtaine" xlink:href="apm-20231231.xsd#apm_FdaApprovalObtaine"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" xlink:to="FdaApprovalObtaine" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsTotal" xlink:href="apm-20231231.xsd#apm_MilestonePaymentsTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract" xlink:to="MilestonePaymentsTotal" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LiquidityDetails">
    <loc xlink:type="locator" xlink:label="LiquidityDisclosureAbstract" xlink:href="apm-20231231.xsd#apm_LiquidityDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityDetailsTable" xlink:href="apm-20231231.xsd#apm_LiquidityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LiquidityLineItems" xlink:href="apm-20231231.xsd#apm_LiquidityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDisclosureAbstract" xlink:to="LiquidityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_LineOfCreditMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsTable" xlink:to="LiquidityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityLineItems" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrestrictedCashEquivalents" xlink:href="apm-20231231.xsd#apm_UnrestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityLineItems" xlink:to="UnrestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="apm-20231231.xsd#apm_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AllowanceForCreditLossOfDueFromARelatedParty" xlink:href="apm-20231231.xsd#apm_AllowanceForCreditLossOfDueFromARelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="AllowanceForCreditLossOfDueFromARelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_InventoryWriteDown" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentandFairValueMeasurementDetailsTable" xlink:href="apm-20231231.xsd#apm_InvestmentandFairValueMeasurementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="InvestmentandFairValueMeasurementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LibraMember" xlink:href="apm-20231231.xsd#apm_LibraMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LibraMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsTable" xlink:to="srt_OwnershipAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LibraMember_0" xlink:href="apm-20231231.xsd#apm_LibraMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="LibraMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentandFairValueMeasurementDetailsTable" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_OtherInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="apm-20231231.xsd#apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="WritteoffOfPrepaymentAndOtherReceivables" xlink:href="apm-20231231.xsd#apm_WritteoffOfPrepaymentAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="WritteoffOfPrepaymentAndOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsTable" xlink:href="apm-20231231.xsd#apm_PropertyandEquipmentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyandEquipmentNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember" xlink:href="apm-20231231.xsd#apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IntangibleAssetsNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsNetDetailsTable" xlink:href="apm-20231231.xsd#apm_IntangibleAssetsNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="IntangibleAssetsNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HongKongHealthcareServicesMember" xlink:href="apm-20231231.xsd#apm_HongKongHealthcareServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="HongKongHealthcareServicesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WroteOffOfCostRelatedAmortization" xlink:href="apm-20231231.xsd#apm_WroteOffOfCostRelatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="WroteOffOfCostRelatedAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableandAccruedExpensesDetailsTable" xlink:href="apm-20231231.xsd#apm_AccountsPayableandAccruedExpensesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableAndAccruedExpensesLineItems" xlink:href="apm-20231231.xsd#apm_AccountsPayableAndAccruedExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="AccountsPayableandAccruedExpensesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableandAccruedExpensesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_NonrelatedPartyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableandAccruedExpensesDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableandAccruedExpensesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableandAccruedExpensesDetailsTable" xlink:to="AccountsPayableAndAccruedExpensesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="VestedAndUnvestedShareOptions" xlink:href="apm-20231231.xsd#apm_VestedAndUnvestedShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpensesLineItems" xlink:to="VestedAndUnvestedShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpensesLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="apm-20231231.xsd#apm_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_GB" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_SG" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_SG"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_SG" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CA" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CA" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxDescription" xlink:href="apm-20231231.xsd#apm_IncomeTaxDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="IncomeTaxDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossCarryforwardCancelled" xlink:href="apm-20231231.xsd#apm_LossCarryforwardCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="LossCarryforwardCancelled" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyBalancesandTransactionsDetailsTable" xlink:href="apm-20231231.xsd#apm_RelatedPartyBalancesandTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyBalancesandTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CGYInvestmentsLimitedMember" xlink:href="apm-20231231.xsd#apm_CGYInvestmentsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="CGYInvestmentsLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AeneasManagementLimitedMember" xlink:href="apm-20231231.xsd#apm_AeneasManagementLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AeneasManagementLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CGYInvestmentsLimitedMember_0" xlink:href="apm-20231231.xsd#apm_CGYInvestmentsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CGYInvestmentsLimitedMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ACCMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_ACCMedicalLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ACCMedicalLimitedMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrClarkChengMember" xlink:href="apm-20231231.xsd#apm_MrClarkChengMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrClarkChengMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrIanHuenMember" xlink:href="apm-20231231.xsd#apm_MrIanHuenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrIanHuenMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrDarrenLuiMember" xlink:href="apm-20231231.xsd#apm_MrDarrenLuiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrDarrenLuiMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="dei_LegalEntityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IanHuenMember" xlink:href="apm-20231231.xsd#apm_IanHuenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="IanHuenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreasedOwnershipPercentage" xlink:href="apm-20231231.xsd#apm_DecreasedOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="DecreasedOwnershipPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermLineOfCredit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoansInterestbearingRate" xlink:href="apm-20231231.xsd#apm_LoansInterestbearingRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="LoansInterestbearingRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCredit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServicesFees" xlink:href="apm-20231231.xsd#apm_ServicesFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ServicesFees" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServicesFeesAdjusted" xlink:href="apm-20231231.xsd#apm_ServicesFeesAdjusted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ServicesFeesAdjusted" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndBenefitsTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndBenefitsTrust"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CompensationAndBenefitsTrust" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemunerationAmount" xlink:href="apm-20231231.xsd#apm_RemunerationAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="RemunerationAmount" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/VariableInterestEntityDetails">
    <loc xlink:type="locator" xlink:label="VariableInterestEntityAbstract" xlink:href="apm-20231231.xsd#apm_VariableInterestEntityAbstract"/>
    <loc xlink:type="locator" xlink:label="VariableInterestEntityDetailsTable" xlink:href="apm-20231231.xsd#apm_VariableInterestEntityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableInterestEntityAbstract" xlink:to="VariableInterestEntityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableInterestEntityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupsSubsidiariesMember" xlink:href="apm-20231231.xsd#apm_GroupsSubsidiariesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="GroupsSubsidiariesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableInterestEntityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LibraMember" xlink:href="apm-20231231.xsd#apm_LibraMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LibraMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MiosMember" xlink:href="apm-20231231.xsd#apm_MiosMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MiosMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScipioMember" xlink:href="apm-20231231.xsd#apm_ScipioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ScipioMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableInterestEntityDetailsTable" xlink:to="us-gaap_TradingActivityByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="VaribaleInterestEntityMember" xlink:href="apm-20231231.xsd#apm_VaribaleInterestEntityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="VaribaleInterestEntityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableInterestEntityDetailsTable" xlink:to="srt_OwnershipAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LibraSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_LibraSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="LibraSciencesLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MiosPharmaceuticalsLimitedMember" xlink:href="apm-20231231.xsd#apm_MiosPharmaceuticalsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="MiosPharmaceuticalsLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScipioLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ScipioLifeSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ScipioLifeSciencesLimitedMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableInterestEntityDetailsTable" xlink:to="us-gaap_VariableInterestEntityLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOfEconomic" xlink:href="apm-20231231.xsd#apm_ShareOfEconomic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="ShareOfEconomic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/LeaseDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseWeightedAverageDiscountRate" xlink:href="apm-20231231.xsd#apm_OperatingLeaseWeightedAverageDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="OperatingLeaseWeightedAverageDiscountRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ConvertibleNoteDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNoteDetailsTable" xlink:href="apm-20231231.xsd#apm_ConvertibleNoteDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ConvertibleNoteDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesMember" xlink:href="apm-20231231.xsd#apm_ConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNotesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteDetailsTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ConvertibleDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/OrdinarySharesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesDetailsTable" xlink:href="apm-20231231.xsd#apm_OrdinarySharesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesLineItems" xlink:href="apm-20231231.xsd#apm_OrdinarySharesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="OrdinarySharesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndExternalConsultantsMember" xlink:href="apm-20231231.xsd#apm_EmployeesAndExternalConsultantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesAndExternalConsultantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassBMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SharesWarrantHoldersMember" xlink:href="apm-20231231.xsd#apm_SharesWarrantHoldersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SharesWarrantHoldersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionHoldersMember" xlink:href="apm-20231231.xsd#apm_ShareOptionHoldersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="ShareOptionHoldersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesDetailsTable" xlink:to="OrdinarySharesLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_CommonStockOtherValueOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceed" xlink:href="apm-20231231.xsd#apm_GrossProceed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="GrossProceed" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesPrice" xlink:href="apm-20231231.xsd#apm_SharesPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="SharesPrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesClosingPricePercentage" xlink:href="apm-20231231.xsd#apm_OrdinarySharesClosingPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="OrdinarySharesClosingPricePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_SharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedToConvertibleNoteHolders" xlink:href="apm-20231231.xsd#apm_ShareIssuedToConvertibleNoteHolders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrdinarySharesLineItems" xlink:to="ShareIssuedToConvertibleNoteHolders" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/ShareBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsTable" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_NonrelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeesMember" xlink:href="apm-20231231.xsd#apm_EmployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonemployeesMember" xlink:href="apm-20231231.xsd#apm_NonemployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="NonemployeesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSeventeenShareOptionPlanMember" xlink:href="apm-20231231.xsd#apm_TwoThousandSeventeenShareOptionPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSeventeenShareOptionPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonUnitIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:href="apm-20231231.xsd#apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NonControllingInterestDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="NonControllingInterestDetailsTable" xlink:href="apm-20231231.xsd#apm_NonControllingInterestDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NonControllingInterestLineItems" xlink:href="apm-20231231.xsd#apm_NonControllingInterestLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="NonControllingInterestDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GroupsSubsidiariesMember" xlink:href="apm-20231231.xsd#apm_GroupsSubsidiariesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="GroupsSubsidiariesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AptorumMedicalLimitedMember" xlink:href="apm-20231231.xsd#apm_AptorumMedicalLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="AptorumMedicalLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClarkChengMember" xlink:href="apm-20231231.xsd#apm_ClarkChengMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ClarkChengMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestDetailsTable" xlink:to="srt_OwnershipAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MiosPharmaceuticalsLimitedMember" xlink:href="apm-20231231.xsd#apm_MiosPharmaceuticalsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="MiosPharmaceuticalsLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScipioLifeSciencesLimitedMember" xlink:href="apm-20231231.xsd#apm_ScipioLifeSciencesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ScipioLifeSciencesLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestDetailsTable" xlink:to="NonControllingInterestLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsUnitsIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOwnershipInterestsUnitsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestLineItems" xlink:to="us-gaap_OtherOwnershipInterestsUnitsIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentIncreaseDecreaseRetainedEarningsDeficit" xlink:href="apm-20231231.xsd#apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestLineItems" xlink:to="AdjustmentIncreaseDecreaseRetainedEarningsDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnersCapitalAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonControllingInterestLineItems" xlink:to="us-gaap_PartnersCapitalAttributableToNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/NetLossPerShareDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareDetailsTable" xlink:href="apm-20231231.xsd#apm_NetLossPerShareDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareLineItems" xlink:href="apm-20231231.xsd#apm_NetLossPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="NetLossPerShareDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="NetLossPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="apm-20231231.xsd#apm_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="MilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SegmentReportingDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="apm-20231231.xsd#apm_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CGYInvestmentsLimitedMember" xlink:href="apm-20231231.xsd#apm_CGYInvestmentsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CGYInvestmentsLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DSFInvestmentHoldingsLimitedMember" xlink:href="apm-20231231.xsd#apm_DSFInvestmentHoldingsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DSFInvestmentHoldingsLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassBMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="sharesOutstandingPerentage" xlink:href="apm-20231231.xsd#apm_sharesOutstandingPerentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sharesOutstandingPerentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFairValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EquityFairValueAdjustment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingSharesPercentage" xlink:href="apm-20231231.xsd#apm_OutstandingSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="OutstandingSharesPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityOtherShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ExcessStockSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://aptorumgroup.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="apm-20231231.xsd#apm_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412296496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">APTORUM GROUP LIMITED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001734005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">17 Hanover Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">W1S 1BN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Ordinary shares, par value $0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">5395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum Asia CPAs llp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, NY<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Ian Huen<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">17 Hanover Square<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">W1S 1BN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">20 8092 9299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">2,937,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">2,243,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329404048">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,005,351<span></span>
</td>
<td class="nump">$ 1,882,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,130,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,709<span></span>
</td>
<td class="nump">174,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">102,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DueFromBrokers', window );">Due from brokers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other receivables and prepayments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">422,071<span></span>
</td>
<td class="nump">744,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,476,092<span></span>
</td>
<td class="nump">7,067,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,663,926<span></span>
</td>
<td class="nump">2,825,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182,057<span></span>
</td>
<td class="nump">347,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,098,846<span></span>
</td>
<td class="nump">9,744,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147,347<span></span>
</td>
<td class="nump">752,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Long-term deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,823<span></span>
</td>
<td class="nump">129,847<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,640,091<span></span>
</td>
<td class="nump">20,867,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,894,341<span></span>
</td>
<td class="nump">6,166,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">125,232<span></span>
</td>
<td class="nump">310,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Bank loan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,013,234<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,098,753<span></span>
</td>
<td class="nump">12,503,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,485<span></span>
</td>
<td class="nump">30,784<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,256,738<span></span>
</td>
<td class="nump">13,034,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">93,018,528<span></span>
</td>
<td class="nump">45,308,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,623)<span></span>
</td>
<td class="nump">33,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(68,161,722)<span></span>
</td>
<td class="num">(65,337,075)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total equity attributable to the shareholders of Aptorum Group Limited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,846,236<span></span>
</td>
<td class="nump">15,712,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,462,883)<span></span>
</td>
<td class="num">(7,878,789)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,383,353<span></span>
</td>
<td class="nump">7,833,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,640,091<span></span>
</td>
<td class="nump">20,867,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">31<span></span>
</td>
<td class="nump">13,269,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22,437,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Amounts due from related parties, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">961<span></span>
</td>
<td class="nump">129,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable from related parties, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">875,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Amounts due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79,180<span></span>
</td>
<td class="nump">12,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes to a related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,058,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Loan payables to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DueFromBrokers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from brokers including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DueFromBrokers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700326115376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">9,999,996,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">2,937,921<span></span>
</td>
<td class="nump">1,326,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">2,937,921<span></span>
</td>
<td class="nump">1,326,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">2,243,776<span></span>
</td>
<td class="nump">2,243,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">2,243,776<span></span>
</td>
<td class="nump">2,243,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700443975872">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Healthcare services income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 431,378<span></span>
</td>
<td class="nump">$ 1,295,889<span></span>
</td>
<td class="nump">$ 1,541,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of healthcare services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(420,812)<span></span>
</td>
<td class="num">(1,215,824)<span></span>
</td>
<td class="num">(1,459,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,198,329)<span></span>
</td>
<td class="num">(9,219,595)<span></span>
</td>
<td class="num">(10,869,642)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,930,637)<span></span>
</td>
<td class="num">(5,220,405)<span></span>
</td>
<td class="num">(5,409,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Legal and professional fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,538,161)<span></span>
</td>
<td class="num">(2,888,140)<span></span>
</td>
<td class="num">(2,617,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,067,690)<span></span>
</td>
<td class="num">(261,038)<span></span>
</td>
<td class="num">(392,511)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,155,629)<span></span>
</td>
<td class="num">(18,805,002)<span></span>
</td>
<td class="num">(20,749,213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciNetOfTaxAbstract', window );"><strong>Other income (expenses), net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on investments in marketable securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,266)<span></span>
</td>
<td class="num">(134,134)<span></span>
</td>
<td class="num">(8,031,595)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Unrealized gain from fair value change of the long-term investments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,353,888<span></span>
</td>
<td class="nump">5,588,051<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on investments in derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_GainOnUseOfDigitalCurrencies', window );">Gain on use of digital currencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_GainOnDerecognitionOfNonfinancialAssets', window );">Gain on derecognition of non-financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(121,145)<span></span>
</td>
<td class="nump">146,588<span></span>
</td>
<td class="num">(93,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Loss on disposal of subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SundryIncome', window );">Sundry income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">159,799<span></span>
</td>
<td class="nump">383,506<span></span>
</td>
<td class="nump">146,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,383,276<span></span>
</td>
<td class="nump">5,984,011<span></span>
</td>
<td class="num">(7,906,858)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,340,975)<span></span>
</td>
<td class="num">(11,525,102)<span></span>
</td>
<td class="num">(27,114,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,516,328<span></span>
</td>
<td class="nump">1,725,542<span></span>
</td>
<td class="nump">2,065,904<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Aptorum Group Limited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,824,647)<span></span>
</td>
<td class="num">$ (9,799,560)<span></span>
</td>
<td class="num">$ (25,048,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net loss per share attributable to Aptorum Group Limited</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">- Basic (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (2.75)<span></span>
</td>
<td class="num">$ (7.15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">- Diluted (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (2.75)<span></span>
</td>
<td class="num">$ (7.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- Basic (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,521,133<span></span>
</td>
<td class="nump">3,569,484<span></span>
</td>
<td class="nump">3,503,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- Diluted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,521,133<span></span>
</td>
<td class="nump">3,569,484<span></span>
</td>
<td class="nump">3,503,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,340,975)<span></span>
</td>
<td class="num">$ (11,525,102)<span></span>
</td>
<td class="num">$ (27,114,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Exchange differences on translation of foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(44,430)<span></span>
</td>
<td class="nump">35,826<span></span>
</td>
<td class="num">(55,315)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(44,430)<span></span>
</td>
<td class="nump">35,826<span></span>
</td>
<td class="num">(55,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,385,405)<span></span>
</td>
<td class="num">(11,489,276)<span></span>
</td>
<td class="num">(27,169,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,516,328<span></span>
</td>
<td class="nump">1,725,542<span></span>
</td>
<td class="nump">2,065,904<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to the shareholders of Aptorum Group Limited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,869,077)<span></span>
</td>
<td class="num">$ (9,763,734)<span></span>
</td>
<td class="num">$ (25,103,704)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_GainOnDerecognitionOfNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on derecognition of non-financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_GainOnDerecognitionOfNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_GainOnUseOfDigitalCurrencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on use of digital currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_GainOnUseOfDigitalCurrencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_SundryIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sundry income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_SundryIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700325956256">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Class A </div>
<div>Ordinary Shares</div>
</th>
<th class="th">
<div>Class B </div>
<div>Ordinary Shares</div>
</th>
<th class="th"><div>Additional Paid-in Capital Amount</div></th>
<th class="th"><div>Accumulated deficit Amount</div></th>
<th class="th"><div>Accumulated other comprehensive (loss) income Amount</div></th>
<th class="th"><div>Non- controlling interests Amount</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,584,324<span></span>
</td>
<td class="nump">$ 22,437,754<span></span>
</td>
<td class="nump">$ 38,247,903<span></span>
</td>
<td class="num">$ (30,489,126)<span></span>
</td>
<td class="nump">$ 53,296<span></span>
</td>
<td class="num">$ (3,681,858)<span></span>
</td>
<td class="nump">$ 38,152,293<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,158,432<span></span>
</td>
<td class="nump">2,243,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A Ordinary Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,387,925<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,612,075<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Ordinary Shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">138,793<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest', window );">Issuance of shares to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">66,783<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(61,423)<span></span>
</td>
<td class="nump">5,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction', window );">Disposal of subsidiaries under common control transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">303,419<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,386)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(1,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries', window );">Disposal of subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,962<span></span>
</td>
<td class="nump">7,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,682,460<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,682,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,012<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">130,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 190,159<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">504,065<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">694,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">19,016<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ExchangeDifferenceOnTranslationOfForeignOperation', window );">Exchange difference on translation of foreign operation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(49,929)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(49,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,048,389)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,065,904)<span></span>
</td>
<td class="num">(27,114,293)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,202,408<span></span>
</td>
<td class="nump">$ 22,437,754<span></span>
</td>
<td class="nump">43,506,717<span></span>
</td>
<td class="num">(55,537,515)<span></span>
</td>
<td class="num">(2,019)<span></span>
</td>
<td class="num">(6,101,223)<span></span>
</td>
<td class="nump">17,506,122<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,320,241<span></span>
</td>
<td class="nump">2,243,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest', window );">Issuance of shares to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">52,024<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(52,024)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,646,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,646,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 67,120<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102,340<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">169,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,712<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ExchangeDifferenceOnTranslationOfForeignOperation', window );">Exchange difference on translation of foreign operation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35,826<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,799,560)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,725,542)<span></span>
</td>
<td class="num">(11,525,102)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,269,528<span></span>
</td>
<td class="nump">$ 22,437,754<span></span>
</td>
<td class="nump">45,308,080<span></span>
</td>
<td class="num">(65,337,075)<span></span>
</td>
<td class="nump">33,807<span></span>
</td>
<td class="num">(7,878,789)<span></span>
</td>
<td class="nump">7,833,305<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,326,953<span></span>
</td>
<td class="nump">2,243,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest', window );">Issuance of shares to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">67,766<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(67,766)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue', window );">Adjustment for change of par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,269,514)<span></span>
</td>
<td class="num">(22,437,732)<span></span>
</td>
<td class="nump">35,707,246<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of shares in exchange of share options and settlement of liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,078,195<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,078,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares in exchange of share options and settlement of liabilities (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">70,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares for share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">176,263<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">176,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares for share-based compensation (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">65,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_StockIssuedDuringPeriodValueIssuanceOfShares', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,575,560<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,575,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_StockIssuedDuringPeridSharesIssuanceOfShares', window );">Issuance of shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">215,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,999,987<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Rounding up for reverse stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Rounding up for reverse stock split (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,088,925<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,088,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,506<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ExchangeDifferenceOnTranslationOfForeignOperation', window );">Exchange difference on translation of foreign operation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44,430)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,824,647)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,516,328)<span></span>
</td>
<td class="num">(4,340,975)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 93,018,528<span></span>
</td>
<td class="num">$ (68,161,722)<span></span>
</td>
<td class="num">$ (10,623)<span></span>
</td>
<td class="num">$ (9,462,883)<span></span>
</td>
<td class="nump">$ 15,383,353<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,937,921<span></span>
</td>
<td class="nump">2,243,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of adjustment to issuance of shares to non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ExchangeDifferenceOnTranslationOfForeignOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange difference on translation of foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ExchangeDifferenceOnTranslationOfForeignOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_StockIssuedDuringPeridSharesIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during period issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_StockIssuedDuringPeridSharesIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of disposal of subsidiaries under common control transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period shares exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of Stock disposal of subsidies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of Stock issued exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_StockIssuedDuringPeriodValueIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during period issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_StockIssuedDuringPeriodValueIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during period adjustment for change of par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412483776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (4,340,975)<span></span>
</td>
<td class="num">$ (11,525,102)<span></span>
</td>
<td class="num">$ (27,114,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Amortization and depreciation</a></td>
<td class="nump">1,125,254<span></span>
</td>
<td class="nump">1,207,510<span></span>
</td>
<td class="nump">1,192,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,265,189<span></span>
</td>
<td class="nump">1,646,999<span></span>
</td>
<td class="nump">1,682,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LossGainOnInvestmentsInMarketableSecuritiesNet', window );">Loss on investments in marketable securities, net</a></td>
<td class="nump">9,266<span></span>
</td>
<td class="nump">134,134<span></span>
</td>
<td class="nump">8,031,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain from fair value change of the long-term investments, net</a></td>
<td class="num">(6,353,888)<span></span>
</td>
<td class="num">(5,588,051)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on investments in derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on derecognition of non-financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LossOnDisposalOfLonglivedAssets', window );">Loss on disposal of long-lived assets</a></td>
<td class="nump">110,852<span></span>
</td>
<td class="nump">205,189<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment loss on long-lived assets</a></td>
<td class="nump">750,381<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AllowanceForCreditLossOfDueFromARelatedParty', window );">Allowance for credit loss of due from a related party</a></td>
<td class="nump">521,007<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_WritteoffOfPrepaymentAndOtherReceivables', window );">Write-off of prepayment and other receivables</a></td>
<td class="nump">62,369<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-down of inventories</a></td>
<td class="nump">13,206<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Loss on disposal of subsidiaries</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_GainOnUseOfDigitalsCurrencies', window );">Gain on use of digital currencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens', window );">Settlement of service fee by tokens and digital currencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">252,345<span></span>
</td>
<td class="nump">349,031<span></span>
</td>
<td class="nump">425,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(235,560)<span></span>
</td>
<td class="num">(41,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_InterestExpenseAndAccretionOfConvertibleDebts', window );">Interest expense and accretion of convertible debts</a></td>
<td class="nump">45,266<span></span>
</td>
<td class="nump">87,537<span></span>
</td>
<td class="nump">130,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AccretionOfFinanceLeaseObligation', window );">Accretion of finance lease obligation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">4,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ReversalDeferredCashBonus', window );">Reversal of deferred cash bonus</a></td>
<td class="num">(1,646,228)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">126,717<span></span>
</td>
<td class="num">(95,704)<span></span>
</td>
<td class="num">(16,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">14,516<span></span>
</td>
<td class="nump">8,053<span></span>
</td>
<td class="nump">3,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other receivables and prepayments</a></td>
<td class="nump">226,805<span></span>
</td>
<td class="num">(105,584)<span></span>
</td>
<td class="nump">695,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Long-term deposits</a></td>
<td class="nump">29,106<span></span>
</td>
<td class="nump">19,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_IncreaseDecreaseDueFromBrokers', window );">Due from brokers</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">75,728<span></span>
</td>
<td class="nump">83,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Amounts due from related parties</a></td>
<td class="nump">63,050<span></span>
</td>
<td class="num">(46,349)<span></span>
</td>
<td class="nump">112,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Amounts due to related parties</a></td>
<td class="num">(8,524)<span></span>
</td>
<td class="num">(6,805)<span></span>
</td>
<td class="num">(264,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">398,635<span></span>
</td>
<td class="nump">1,918,751<span></span>
</td>
<td class="nump">855,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(389,365)<span></span>
</td>
<td class="num">(369,505)<span></span>
</td>
<td class="num">(450,807)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,724,364)<span></span>
</td>
<td class="num">(12,318,965)<span></span>
</td>
<td class="num">(14,651,633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,015)<span></span>
</td>
<td class="num">(186,916)<span></span>
</td>
<td class="num">(131,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">15,385<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DisposalOfSubsidiariesNetOfCashDisposed', window );">Disposal of subsidiaries, net of cash disposed</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(113,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales of investment securities</a></td>
<td class="nump">93,215<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,116,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Loan to a related party</a></td>
<td class="num">(92,459)<span></span>
</td>
<td class="num">(330,341)<span></span>
</td>
<td class="num">(3,358,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_RepaymentOfLoanFromRelatedParty', window );">Repayment of loan and interest from a related party</a></td>
<td class="nump">611,641<span></span>
</td>
<td class="nump">2,962,153<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">624,767<span></span>
</td>
<td class="nump">2,444,896<span></span>
</td>
<td class="nump">16,507,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Loan from related parties</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of loan due to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,489,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from issuance of subsidiaries shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,360<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Class A Ordinary Shares and warrants</a></td>
<td class="nump">1,575,562<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">16,506<span></span>
</td>
<td class="nump">169,460<span></span>
</td>
<td class="nump">694,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">130,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Loan from a bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayment of bank loan</a></td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(49,358)<span></span>
</td>
<td class="num">(53,846)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,092,068<span></span>
</td>
<td class="nump">6,625,462<span></span>
</td>
<td class="nump">2,780,725<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents and restricted cash</a></td>
<td class="num">(3,007,529)<span></span>
</td>
<td class="num">(3,248,607)<span></span>
</td>
<td class="nump">4,636,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash &#8211; Beginning of year</a></td>
<td class="nump">5,012,880<span></span>
</td>
<td class="nump">8,261,487<span></span>
</td>
<td class="nump">3,625,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash &#8211; End of year</a></td>
<td class="nump">2,005,351<span></span>
</td>
<td class="nump">5,012,880<span></span>
</td>
<td class="nump">8,261,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">94,108<span></span>
</td>
<td class="nump">64,744<span></span>
</td>
<td class="nump">273,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ProceedsInBrokerAccounts', window );">Proceeds in broker accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,116,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash operating, investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">338,525<span></span>
</td>
<td class="nump">549,596<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens', window );">Settlement of service fee by tokens and digital currencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ConvertibleNotesConvertedToClassAOrdinaryShares', window );">Convertible notes converted to Class A Ordinary Shares</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions', window );">Settlement of deferred cash bonus by issuance of share options</a></td>
<td class="nump">3,078,196<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="nump">2,005,351<span></span>
</td>
<td class="nump">1,882,545<span></span>
</td>
<td class="nump">8,131,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,130,335<span></span>
</td>
<td class="nump">130,270<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">$ 2,005,351<span></span>
</td>
<td class="nump">$ 5,012,880<span></span>
</td>
<td class="nump">$ 8,261,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AccretionOfFinanceLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AccretionOfFinanceLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AllowanceForCreditLossOfDueFromARelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for credit loss of due from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AllowanceForCreditLossOfDueFromARelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ConvertibleNotesConvertedToClassAOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes converted to Class A Ordinary Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ConvertibleNotesConvertedToClassAOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DisposalOfSubsidiariesNetOfCashDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of subsidiaries net of cash disposed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DisposalOfSubsidiariesNetOfCashDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_GainOnUseOfDigitalsCurrencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on use of digital currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_GainOnUseOfDigitalsCurrencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_IncreaseDecreaseDueFromBrokers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in amounts due from brokers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_IncreaseDecreaseDueFromBrokers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_InterestExpenseAndAccretionOfConvertibleDebts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense and accretion of convertible debts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_InterestExpenseAndAccretionOfConvertibleDebts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LossGainOnInvestmentsInMarketableSecuritiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on investments in marketable securities, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LossGainOnInvestmentsInMarketableSecuritiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LossOnDisposalOfLonglivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on disposal of long-lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LossOnDisposalOfLonglivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ProceedsInBrokerAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds in broker accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ProceedsInBrokerAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_RepaymentOfLoanFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of loan from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_RepaymentOfLoanFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ReversalDeferredCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reversal of deferred cash bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ReversalDeferredCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of deferred cash bonus by issuance of share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of service fee by digital currencies and tokens.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of service fee by digital currencies and tokens.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_WritteoffOfPrepaymentAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Writte-off of prepayment and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_WritteoffOfPrepaymentAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700323100224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. ORGANIZATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the financial statements of Aptorum Group Limited (the &#8220;Company&#8221;) and its subsidiaries. The Company and its subsidiaries are
hereinafter collectively referred to as the &#8220;Group&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, formerly known as APTUS Holdings
Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, is a company incorporated on September 13, 2010 under the laws of the Cayman
Islands with limited liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company researches and develops life science
and biopharmaceutical products within its wholly-owned subsidiary, Aptorum Therapeutics Limited, formerly known as APTUS Therapeutics
Limited (&#8220;Aptorum Therapeutics&#8221;) and its indirect subsidiary companies (collectively, &#8220;Aptorum Therapeutics Group&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Below summarizes the list of the major subsidiaries consolidated as
of December 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 22%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Incorporation<br/>
date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Ownership</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Place of<br/>
incorporation</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Principle activities</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Aptorum Therapeutics Limited (&#8220;ATL&#8221;)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">June 30, 2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">APTUS MANAGEMENT LIMITED</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Hong Kong</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Provision of management services to its holding company and fellow subsidiaries</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Aptorum Medical Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">August 28, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">90%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Provision of medical clinic services</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Paths Innovations Limited </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">April 15, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Investment holding company</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Paths Diagnostics Pte. Limited </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">June 5, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">75%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Singapore</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Acticule Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">June 30, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">80%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Claves Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">August 2, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Nativus Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 7, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Videns Incorporation Limited </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 2, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Mios Pharmaceuticals Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 6, 2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">97.93%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">mTOR (Hong Kong) Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">November 4, 2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">90%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Hong Kong</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Scipio Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 19, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">97.93%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Signate Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">August 28, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700323098896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LiquidityLineItems', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LiquidityDisclosureTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. LIQUIDITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group reported a net loss of $4,340,975 and
net operating cash outflow of $7,724,364 for the year ended December 31, 2023. In addition, the Group had an accumulated deficit of $68,161,722
as of December 31, 2023. The Group&#8217;s operating results for future periods are subject to numerous uncertainties and it is uncertain
if the Group will be able to reduce or eliminate its net losses for the foreseeable future. If management is not able to generate significant
revenues from its product candidates currently in development, the Group may not be able to achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s principal sources of liquidity
have been cash, line of credit facility from related parties, bank loan, public offerings and convertible bonds. As of the date of issuance
of the consolidated financial statements, the Group has approximately $1.0 million of unrestricted cash or cash equivalents, and approximately
$12 million of undrawn line of credit facility from a related party. In addition, the Group will need to maintain its operating costs
at a level through strict cost control and budget, such as staff reductions, to ensure operating costs are minimized and will not exceed
such aforementioned sources of funds to continue as a going concern for a period within 12 months after the issuance of its consolidated
financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group believes that available cash, together
with the efforts from aforementioned management plan and actions, should enable the Group to meet current anticipated cash needs for at
least the next 12 months after the date that the consolidated financial statements are issued and the Group has prepared the consolidated
financial statements on a going concern basis. The Group may, however, need additional capital in the future to fund its continued operations.
If the Group determine that its cash requirements exceed the amount of cash and cash equivalents the Group has at the time, the Group
may seek to issue equity or debt securities or obtain credit facilities. The issuance and sale of additional equity or convertible debts
would result in further dilution to its shareholders. The incurrence of indebtedness would result in increased fixed obligations and could
result in operating covenants that might restrict its operations. The Group cannot assure that the financing will be available in amounts
or on terms acceptable to the Group, if at all.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329462176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Principles of presentation and consolidation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of the Group
are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;),
and include the accounts of the Company, its direct and indirect wholly and majority owned subsidiaries. In accordance with the provisions
of Accounting Standards Codification (&#8220;ASC&#8221;) 810, Consolidation, we consolidate any variable interest entity (&#8220;VIE&#8221;)
of which we are the primary beneficiary. The typical condition for a controlling financial interest ownership is holding a majority of
the voting interests of an entity; however, a controlling financial interest may also exist in entities, such as VIEs, through arrangements
that do not involve controlling voting interests. ASC 810 requires a variable interest holder to consolidate a VIE if that party has the
power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and the obligation to absorb
losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially
be significant to the VIE. We do not consolidate a VIE in which we have a majority ownership interest when we are not considered the primary
beneficiary. We have determined that we are not one of the primary beneficiary of the VIE (see Note 13, Variable Interest Entity). We
evaluate our relationships with the VIE on an ongoing basis to determine whether we become the primary beneficiary. All material intercompany
balances and transactions have been eliminated in preparation of the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Non-controlling interests</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-controlling interests are recognized to reflect
the portion of the equity of majority-owned subsidiaries which are not attributable, directly or indirectly, to the controlling shareholder.
Non-controlling interests are classified as a separate line item in the equity section of the Group&#8217;s consolidated balance sheets
and have been separately disclosed in the Group&#8217;s consolidated statements of operations and comprehensive loss and consolidated
statements of equity to distinguish the interests from that of the Group.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as income
and expenses during the reporting period. Significant accounting estimates reflected in the Group&#8217;s consolidated financial statements
include fair value of long-term investments, fair value measurement for share options, impairment of long-lived assets, allowance for
credit losses and valuation allowance for deferred tax assets. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency translation and transaction</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">USD is the reporting currency. The functional
currency of subsidiaries in the Cayman Islands, Seychelles, Samoa and the United States are USD, the functional currency of subsidiaries
in Hong Kong is Hong Kong Dollars (&#8220;HKD&#8221;), the functional currency of a subsidiary in Singapore is Singapore Dollars (&#8220;SGD&#8221;),
the functional currency of a subsidiary in the United Kingdom is Great British Pound (&#8220;GBP&#8221;), and the functional currency
of subsidiaries in Canada is Canadian Dollars (&#8220;CAD&#8221;). An entity&#8217;s functional currency is the currency of the primary
economic environment in which it operates, normally that is the currency of the environment in which it primarily generates and expends
cash. The management considered various indicators, such as cash flows, market expenses, financing and inter-company transactions and
arrangements in determining the Group&#8217;s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the consolidated financial statements, the
financial information of the Company and its subsidiaries, which use HKD, SGD, GBP and CAD as their functional currency, has been translated
into USD. Assets and liabilities are translated from each subsidiary&#8217;s functional currency at the exchange rates on the balance
sheet dates, equity amounts are translated at historical exchange rates, and revenues, expenses, gains, and losses are translated using
the average exchange rates for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a
separate component of other comprehensive income or loss in the consolidated statements of operations and comprehensive income or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cash and cash equivalents</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consists of cash on
hand, bank deposits and time deposits with an original maturity of three months or less at the date of purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Restricted cash</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash represented time deposits pledged
for banking facilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable and amounts due from related
parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group adopted ASC 326 from January 1, 2023.
Accounts receivable and amounts due from related parties are stated at the original amount less an allowance for credit losses, if any,
based on a review of all outstanding amounts at period end. An allowance is estimated in accordance with ASC Topic 326, <i>Credit Losses</i>
and records the allowance for credit losses as an offset to accounts receivable or amounts due from related parties, and the expected
credit losses charged to the allowance is included in other operating expenses in the consolidated statements of operations and comprehensive
loss. In determining expected credit losses, the Group considers the historical level of credit losses, current economic trends, and reasonable
and supportable forecasts that affect the collectability of the future cash flows. As of December 31, 2023 and 2022, $521,007 and <span style="-sec-ix-hidden: hidden-fact-192">$71</span>
allowance for credit losses were made.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inventories</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at lower of cost and net
realizable value. Cost is determined using the weighted average method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where there is evidence that the utility of inventories,
in their disposal in the ordinary course of business, will be less than cost, whether due to physical deterioration, obsolescence, changes
in price levels, or other causes, the inventories are written down to net realizable value. During the years ended December 31, 2023,
2022 and 2021, the write-down of inventories were $13,206, $<span style="-sec-ix-hidden: hidden-fact-193">nil</span> and $<span style="-sec-ix-hidden: hidden-fact-194">nil</span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Marketable securities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable securities are publicly traded stocks
measured at fair value and classified within Level 1 and 2 in the fair value hierarchy because the Group either uses quoted prices for
identical assets in active markets, inputs that are based upon quoted prices for similar instruments in active markets, or quoted prices
for identical assets in markets with insufficient volume or infrequent transaction (less active markets).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Long-term investments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s long-term investments consist
of equity method investment in common stocks and non-marketable investments in non-redeemable preferred shares of privately-held companies
that are not required to be consolidated under the variable interest or voting models. Long-term investments are classified as non-current
assets on the consolidated balance sheets as those investments do not have stated contractual maturity dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Non-marketable investments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The non-marketable equity securities not accounted
for under the equity method are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in
orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach
as of the transaction date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Equity method investment &#8211; Fair value option</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group elects the fair value option for an
investment that would otherwise be accounted for using the equity method of accounting. Such election is irrevocable and is applied on
an investment by investment basis at initial recognition. The fair value of such investments is based on quoted prices in an active market,
if any, or recent orderly transactions for identical or similar investment of the same issuer. Changes in the fair value of these equity
method investments are recognized in other income (expenses), net in the consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair value measurement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the price that would
be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the
Group considers the principal or most advantageous market in which it would transact its business, and it considers assumptions that market
participants would use when pricing the asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a basis for considering such assumptions, a
three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The hierarchy requires the Group to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s categorization
within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Group has
estimated the fair value amounts of its financial instruments using the available market information and valuation methodologies considered
to be appropriate and has determined that the carrying value of the Group&#8217;s cash, restricted cash, accounts receivable, due from
brokers, other receivables and prepayments, loan receivables from related parties, amounts due from/to related parties, accounts payable
and accrued expenses, bank loan, and loan payables to a related party as of December 31, 2023 and 2022 approximate fair value due to the
short-term nature of these assets and liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and equipment, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment, net, is stated at cost
less accumulated depreciation and impairment losses. Cost represents the purchase price of the asset and other costs incurred to bring
the asset into its existing use. Maintenance, repairs and betterments, including replacement of minor items, are charged to expense; major
additions to physical properties are capitalized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets under construction are stated at cost less
impairment losses. Cost comprises of cost of laboratory equipment delivered but not ready to be used, together with interest expense capitalized
during the period of construction or installation and testing. Capitalization of these costs ceases and the asset concerned is transferred
to the appropriate fixed assets category when substantially all the activities necessary to prepare the asset for its intended use are
completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation of property, plant and equipment
is provided using the straight-line method over their estimated useful lives:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 51%"><span style="font-size: 10pt">Computer equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 48%; text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Furniture, fixture, and office and medical equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Shorter of the remaining lease terms or 5 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Motor vehicle</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon sale or disposal, the applicable amounts
of asset cost and accumulated depreciation are removed from the accounts and the net amount less proceeds from disposal is charged or
credited to income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Intangible assets, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finite-lived intangible assets are carried at
cost less accumulated amortization and impairment if any. The finite intangible assets are amortized over their estimated useful life,
which is the period over which the assets are expected to contribute directly or indirectly to the future cash flows of the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s intangible assets mainly consist
of computer software and is amortized over its useful life. The estimated useful life is generally 5 years. The Group will reassess the
remaining useful life on annual basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of long-lived assets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group reviews its long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When these events
occur, the Group compares the carrying value of the long-lived assets to the estimated undiscounted future cash flows expected to result
from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flow is less than the carrying
amount of the assets, the Group would recognize an impairment loss, which is the excess of carrying amount over the fair value of the
assets, using the expected future discounted cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Convertible notes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group evaluates and accounts for conversion
options embedded in convertible notes in accordance with ASC 815 &#8220;Derivatives and Hedging Activities&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applicable GAAP requires companies to bifurcate
conversion options from their host instruments and account for them as derivative financial instruments according to certain criteria.
The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly
and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded
derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings
as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for the convertible notes as
a single unit of account, unless the conversion feature requires bifurcation and recognition as derivatives. Additionally, the Group uses
the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential
share settlement for instruments that may be settled in cash or shares.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Operating leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of a contract, the Group determines
if the arrangement is, or contains, a lease. Operating lease liabilities are recognized at lease commencement based on the present value
of lease payments over the lease term. Operating lease right-of-use assets are initially measured at cost, which comprises the initial
amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs
incurred and less any lease incentives received. As the rate implicit in the lease cannot be readily determined, the Group uses incremental
borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental
borrowing rate is determined based on the rate of interest that the Group would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term in a similar economic environment. The lease term for all of the Group&#8217;s leases includes
the non-cancellable period of the lease plus any additional periods covered by either a Group&#8217;s option to extend (or not to terminate)
the lease that the Group is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.
For operating leases, the Group recognizes a single lease cost on a straight-line basis over the remaining lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has elected not to recognize right-of-use
assets or lease liabilities for leases with an initial term of 12 months or less and the Group recognizes lease expense for these leases
on a straight-line basis over the lease terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Warrants </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection of the issuance of Class A Ordinary
Shares, the Company may issue warrants to purchase Class A Ordinary Shares. Warrants classified as equity are initially recorded at fair
value and subsequent changes in fair value are not recognized.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues are derived from healthcare services
rendered to patients for healthcare consultation and medical treatment. Revenue is reported at the amount that reflects the consideration
to which the Group expects to be entitled in exchange for providing healthcare services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group recognizes revenue as its performance
obligations are completed. Healthcare services are treated as a single performance obligation satisfied at a point in time because the
performance obligations are generally satisfied over a period of less than one day.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cost of healthcare services</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of healthcare services rendered represents
cost in relation to the medical services provided including the compensation of the physicians, cost of pharmaceutical supplies and medicine
and write-down of inventories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Research and development expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed as
incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including
amortization of the patent license, depreciation of laboratory equipment, costs of engaging external consultants, advisors and contracted
research organization to conduct preclinical development activities and trials, payroll expenses to research and development staff, sponsored
research expenses to universities and research institutions, and impairment of patent license and laboratory equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share-based compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group uses the fair value method of accounting
for the share options granted to directors, employees, external consultants and advisors to measure the cost services received in exchange
for the share based awards. The fair value of share option awards with only service condition is estimated on the grant or offering date
using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires inputs such as the risk-free interest rate,
expected term and expected volatility. These inputs are subjective and generally require significant judgment. The resulting cost is recognized
over the period during which a director, employee, external consultant or advisor is required to provide service in exchange for the awards,
usually the vesting period, which is generally from 9.5 months to 21.5 months. Share-based compensation expense is recognized on a graded
vesting basis, net of actual forfeitures in the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based compensation expense is recorded in
cost of healthcare services, research and development expenses, general and administrative fees and legal and professional fees in the
consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 718, modifications to stock-based
awards are accounted for as exchanges of the original awards for new awards. The incremental fair value, which is the difference between
the fair value of the modified award and the original award immediately before modification, is measured at the modification date. This
incremental fair value is recognized immediately as compensation cost for vested awards. For unvested awards, the incremental compensation
cost, along with any remaining unrecognized compensation cost of the original award, is recognized over the remaining requisite vesting
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for income taxes under the
asset and liability method. Under this method, deferred income taxes are determined based on differences between the financial carrying
amounts of existing assets and liabilities and their tax bases. Income taxes are provided for in accordance with the laws of the relevant
taxing authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is provided for deferred
tax assets if it is more likely than not that these items will either expire before the Group is able to realize their benefits, or that
future deductibility is uncertain. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Uncertain tax positions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for uncertainty in income taxes
using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition
by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit,
including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest
amount that is more than 50% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized
and recorded as necessary in the provision for income taxes. The Group recognizes interest on non-payment of income taxes and penalties
associated with tax positions when a tax position does not meet more likely than not thresholds be sustained under examination. The tax
returns of the Group&#8217;s Hong Kong subsidiaries are subject to examination by the relevant tax authorities. According to the Hong
Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed or has
been assessed at less than the proper amount, the statute of limitation is extended to ten years if the underpayment of taxes is due to
fraud or willful evasion. According to United Kingdom, Singapore, the United States, Canada and Ireland tax rule, trading losses are available
to be carried forward indefinitely. The Group did not have any material interest or penalties associated with tax positions for the years
ended December 31, 2023, 2022 and 2021, and did not have any significant unrecognized uncertain tax positions as of December 31, 2023
and 2022. The Group does not believe that its assessment regarding unrecognized tax benefits will materially change over the next twelve
months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Comprehensive income or loss</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain changes in assets and liabilities are
reported as separate components of the equity section of the consolidated balance sheets, such items, along with net income or loss, are
components of comprehensive income or loss. The components of other comprehensive income or loss consist of exchange differences on translation
of foreign operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Net income or loss per share</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net income or loss per share is computed
by dividing net income or loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during
the period. Diluted net income or loss per share reflects the potential dilution that could occur if securities or other contracts to
issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation
of diluted loss per share in loss periods as their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of credit risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial assets which potentially subject the
Group to concentrations of credit risk consist principally of bank deposits and balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group takes on exposure to credit risk on
cash balances majority held with HSBC for the purposes of payments of Group expenses. The risk of default is considered minimal as the
Group considers HSBC is well established with high credit rating.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recently adopted accounting pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)
No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13
is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held
by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets
held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires
enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used
in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#8217;s portfolio. These disclosures
include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements.
In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13
are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December
15, 2022 for the Group. The Group has adopted ASU 2016-13 on January 1, 2023 and the impact of this adoption for the years ended December
31, 2023 and 2022 were assessed to be not material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recently issued accounting standards which have not yet been adopted</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements,
primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. The amendments
in this ASU are effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years
beginning after December 15, 2024, with early adoption permitted. The Group is still evaluating the effect of the adoption of this guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued Accounting Standards
Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness
of income tax disclosures. The amendments address more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. The ASU also includes certain other amendments to improve
the effectiveness of income tax disclosures. The amendments in this ASU are effective for public business entities for annual periods
beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Group is still evaluating the effect of the
adoption of this guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2024, the SEC approved a rule that
will require registrants to provide certain climate-related information in their registration statements and annual reports. The rule
requires information about a registrant&#8217;s climate-related risks that are reasonably likely to have a material impact on its business,
results of operations, or financial condition. The required information about climate-related risks also includes disclosure of a registrant&#8217;s
greenhouse gas emissions. In addition, the rules will require registrants to present certain climate-related financial metrics in their
audited financial statements. The Group is evaluating the potential impact of this rule on the consolidated financial statements and related
disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group does not believe other recently issued
but not yet effective accounting standards, if currently adopted, would have a material impact on the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700321728816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. REVENUE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023, 2022 and
2021, all revenue came from provision of healthcare services in Hong Kong.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2023, the Group made
a decision to streamline its operations by terminating clinic services and suspending non-lead R&amp;D projects.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700324455824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment and Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investment and Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">INVESTMENT AND FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. INVESTMENT AND FAIR VALUE MEASUREMENT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Assets Measured at Fair Value on a Recurring Basis</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides the assets and liabilities
carried at fair value measured on a recurring basis as of December 31, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Non-current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in">Long-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Common stocks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total assets at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in">Marketable securities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.25in">Common stocks</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,279</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">102,481</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Long-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Common stocks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total assets at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,202</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">92,279</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">77,200</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">179,681</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a reconciliation of Level 3 assets
measured and recorded at fair value on a recurring basis during the years ended December 31, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">77,200</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(77,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net change in unrealized appreciation relating to investments still held at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Balance at January 1, 2022</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">77,200</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in unrealized appreciation, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">77,200</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in unrealized appreciation relating to investments still held at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, an impairment
loss relating to an equity method investment amounted to $77,200, was recorded in other expenses, net, as the Group considered that the
carrying amount of the equity method investment may not be recoverable, and this condition is determined to be other-than-temporary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the quantitative
information about the Group&#8217;s Level 3 fair value measurements of investment as of December 31, 2023 and 2022, which utilized significant
unobservable internally-developed inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>December 31, 2023</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation technique</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Unobservable input</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Range<br/>
(weighted average)</b></p></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Common stocks</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Recent transactions</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Recent transaction price</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$0.0001 - $0.01</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>December 31, 2022</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation technique</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Unobservable input</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Range<br/>
(weighted average)</b></p></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Common stocks</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Recent transactions</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Recent transaction price</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$0.0001 - $0.01</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-marketable investments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s non-marketable investments are
investments in privately held companies without readily determinable fair values. The carrying value of the non-marketable investments
are adjusted based on price changes from observable transactions of identical or similar securities of the same issuer (referred to as
the measurement alternative) or for impairment if the carrying amount of the non-marketable investments may not be fully recoverable.
Any changes in carrying value are recorded within other income (expenses), net in the consolidated statements of operations and comprehensive
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of annual upward or
downwards adjustments and impairment recorded in other income (expenses), net, and included as adjustments to the carrying value of non-marketable
investments held as of&#160;December 31, 2023, 2022 and 2021 based on the observable price in an orderly transaction for the same or similar
security of the same issuers:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Upward adjustments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,431,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,108,872</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Downward adjustments and impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(520,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total unrealized gain from fair value change of non-marketable investments,
net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,431,088</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,588,051</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group did not sell any non-marketable investments
or recorded any realized gains or losses for the non-marketable investments measured at fair value on a non-recurring basis during the
years ended December 31, 2023, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the total carrying
value of the non-marketable investments held as of&#160;December 31, 2023 and 2022&#160;including cumulative unrealized upward and downward
adjustments and impairment made to the initial cost basis of the investments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Initial cost basis</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,079,707</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,079,707</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Upward adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,539,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,108,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Downward adjustments and impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(520,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(520,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total carrying value at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,098,846</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,667,758</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group did not transfer any non-marketable
investments into marketable securities for the years ended December 31, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, one of the
non-marketable investments with initial cost of $2.6 million and had a carrying value of $15.1 million was pledged for a convertible note
issued to a related party (Note 15).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity method investment, fair value option</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2021, one of the Group&#8217;s subsidiaries,
Libra Sciences Limited (&#8220;Libra&#8221;, formerly known as Aptorum Pharmaceutical Development Limited), issued Class A and Class B
ordinary shares to various parties in exchange of licenses or cash. Each Class A share of Libra is entitled to 1 vote while each Class
B share of Libra is entitled to 10 votes. Upon the share issuance, the Group was holding 97.27% economic interest and 31.51% voting power
in Libra. The Group lost the controlling interest in Libra because it was transferred to a third party, and therefore deconsolidated Libra.
However, the Group still owns 97.27% economic interest and 31.51% voting power, which is deemed as having significant influence over Libra.
As a result, the Group&#8217;s investment in Libra is subject to the equity method of accounting. The Group assessed that the fair value
option can better reflect the true value of Libra. Pursuant to ASC 825 &#8211; Financial Instruments (&#8220;ASC 825&#8221;), the Group
elected to apply the fair value option for its investments in Libra and will remeasure its investments in Libra at fair value every reporting
period. For the year ended December 31, 2023, the Group has determined that the carrying value of the investment is not recoverable and
this condition is determined to be other-than-temporary. Consequently, an impairment for the investment of $77,200 has been recognized
for the year end December 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329150352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepayments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OtherReceivablesandPrepaymentsLineItems', window );"><strong>Other Receivables and Prepayments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER RECEIVABLES AND PREPAYMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6.&#160;OTHER RECEIVABLES AND PREPAYMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other receivables and prepayments as of December 31, 2023 and 2022
consisted of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">185,633</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">305,178</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,833</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid service fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,346</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Rental deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid rental expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,752</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,253</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,603</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">422,071</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">744,008</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, the Group
considered certain other receivables and prepayments were not recoverable. Hence, the write-off of other receivables and prepayments of
$62,369 was recorded in other operating expenses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_OtherReceivablesandPrepaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_OtherReceivablesandPrepaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700328989024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. PROPERTY AND EQUIPMENT, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment as of December 31, 2023 and 2022 consisted of:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">81,138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">84,636</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture, fixture, and office and medical equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,292</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">298,738</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">543,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">543,975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,336,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,229,072</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Motor vehicle</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">239,093</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">239,093</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,351,262</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,395,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,687,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,570,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,663,926</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,825,059</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses for property, plant and
equipment amounted to $1,041,234, $1,092,957 and $1,086,564 for the years ended December 31, 2023, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, an impairment loss relating to
the office and medical equipment, and computer equipment related to the Hong Kong healthcare services amounted to $28,128, was recorded
in other operating expenses, as the Group considered that, with the termination of the healthcare services, the carrying amount of these
property and equipment are not recoverable and are fully impaired. For the years ended December 31, 2022 and 2021, no impairment loss
was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, the Group
recorded $79,822 of loss on disposal of laboratory equipment, and furniture, fixture, and office and medical equipment in other operating
expense. For the year ended December 31, 2021, the Group recorded $392 of loss on disposal of office equipment in other operating expenses.
For the year ended December 31, 2022, no gain or loss on disposal was recorded.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700439478912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. INTANGIBLE ASSETS, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Gross carrying amount</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid patented licenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">728,205</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,038,205</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Computer software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">223,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">223,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952,063</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,262,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: accumulated amortization and impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid patented licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">728,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">474,131</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Computer software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,511</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">804,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid patented licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">564,074</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Computer software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,347</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">188,631</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">147,347</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">752,705</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Group has capitalized
eight of the exclusive licenses, which includes seven patented technologies in relation to the Group&#8217;s therapeutics segment respectively.
Pursuant to the license agreements, the Group paid upfront payments and became the exclusive licensee to prosecute certain patents developed
or licensed under the applicable agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, the Group terminated two of the
licenses. The Group is also in the process of terminating the other six licenses, and hence the Group considered that the carrying amount
of these intangible assets are not recoverable and are fully impaired. As a result, the Group recorded $519,496 impairment loss on intangible
assets in research and development expenses. Besides, an impairment loss related to the computer software for Hong Kong healthcare services
amounted to $1,841&#160;was recorded in other operating expenses, as the Group considered that the carrying amount of these intangible
assets are not recoverable and are fully impaired. For the year ended December 31, 2022, a loss on disposal of $205,189 related to a patented
license was recognized in research and development expenses. For the year ended December 31, 2021, no impairment loss and gain or loss
on disposal was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid patented licenses and computer software
are finite-lived intangible assets which are amortized over their estimated useful life. Amortization expenses for finite-lived intangible
assets amounted to $84,020, $114,553 and $106,014 for the years ended December 31, 2023, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group wrote off the cost and the related amortization
of $<span style="-sec-ix-hidden: hidden-fact-215">nil</span>, $<span style="-sec-ix-hidden: hidden-fact-216">nil</span> and $1,344 after the expiration of the computer software for the years ended December 31, 2023, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group expects amortization expense related
to its finite-lived intangible assets for the next five years and thereafter to be as follows as of December 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">For the years ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">38,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,439</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,439</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,031</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">147,347</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329730192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Deposits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LongTermDepositsLineItems', window );"><strong>Long-Term Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LONG-TERM DEPOSITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. LONG-TERM DEPOSITS</b></p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Long-term deposits as of December 31, 2023 and 2022 consisted of:&#160;</p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Rental deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">71,823</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">127,303</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepayments for equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71,823</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">129,847</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LongTermDepositsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LongTermDepositsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700322739936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts payable and accrued expenses as of December 31, 2023 and 2022
consisted of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Deferred bonus and salaries payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">451,660</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,084,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development expenses payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,162,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">563,913</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,324</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,407</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost of healthcare services payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138,316</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Insurance expenses payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,367</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,913</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,835</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,894,341</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,166,807</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group entered into exchange
agreements and cancelled 177,667 existing vested and unvested share options held by related parties option holders and cancelled its obligations
for deferred cash bonus payables of $3.1 million by granting 403,820 share options with 6 months vesting period (see Note 17). The settlement
of obligations of $3.1 million deferred cash bonus payables was deemed as capital contribution from related parties and was credited to
additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group entered into exchange
agreements and cancelled 70,428 existing vested and unvested share options held by non-related parties option holders and cancelled its
obligations for deferred cash bonus payables of $1.6 million by issuance of 70,430 fully vested Class A Ordinary Shares (see Note 16).
The reversal of deferred cash bonus payables for $1.0 million and $0.6 million was credited to research and development expenses and general
and administrative fees, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329380000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The&#160;Company and&#160;its subsidiaries file tax returns separately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cayman Islands: under the current laws of the
Cayman Islands, the Company and its subsidiaries in the Cayman Islands are not subject to taxes on their income and capital gains.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hong Kong: in accordance with the relevant tax
laws and regulations of Hong Kong, a company registered in Hong Kong is subject to income taxes within Hong Kong at the applicable tax
rate on taxable income. In March 2018, the Hong Kong Government introduced a two-tiered profit tax rate regime by enacting the Inland
Revenue (Amendment) (No.3) Ordinance 2018 (the &#8220;Ordinance&#8221;). Under the two-tiered profits tax rate regime, the first $2 million
of assessable profits of qualifying corporations is taxed at 8.25% and the remaining assessable profits at 16.5%. The Ordinance is effective
from the year of assessment 2018-2019. According to the policy, if no election has been made, the whole of the taxpaying entity&#8217;s
assessable profits will be chargeable to Profits Tax at the rate of 16.5% or 15%, as applicable. Because the preferential tax treatment
is not elected by the Group, all the subsidiaries registered in Hong Kong are subject to income tax at a rate of 16.5%. The subsidiaries
registered in Hong Kong did not have assessable profits that were derived Hong Kong during the years ended December 31, 2023, 2022 and
2021. Therefore, no Hong Kong profit tax has been provided for in the periods presented. Our returns for 2017 and subsequent tax years
remain subject to examination by Hong Kong Inland Revenue Department.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">United Kingdom: in accordance with the relevant
tax laws and regulations of United Kingdom, a company registered in the United Kingdom is subject to income taxes within United Kingdom
at the applicable tax rate on taxable income. All the United Kingdom subsidiaries that are not entitled to any tax holiday were subject
to income tax at a rate of 19%. The subsidiary in United Kingdom did not have assessable profits that were derived from United Kingdom
during the years ended December 31, 2023, 2022 and 2021. Therefore, no United Kingdom profit tax has been provided for in the periods
presented. Our returns for 2019 and subsequent tax years remain subject to examination by the UK tax authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Singapore: in accordance with the relevant tax
laws and regulations of Singapore, a company registered in the Singapore is subject to income taxes within Singapore at the applicable
tax rate on taxable income. All the Singapore subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate
of 17%. The subsidiary in Singapore did not have assessable profits that were derived from Singapore during the years ended December 31,
2023, 2022 and 2021. Therefore, no Singapore profit tax has been provided for in the periods presented. Our returns for 2019 and subsequent
tax years remain subject to examination by the Singapore tax authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">United States (Nevada): in accordance with the
relevant tax laws and regulations of the United States, a company registered in the United States is subject to income taxes within the
United States at the applicable tax rate on taxable income. All the United States subsidiaries in Nevada that are not entitled to any
tax holiday were subject to income tax at a rate of 21%. The subsidiary in the United States did not have assessable profits that were
derived from the United States during the years ended December 31, 2023, 2022 and 2021. Therefore, no United States profit tax has been
provided for in the periods presented. Our returns for 2020 and subsequent tax years remain subject to examination by Internal Revenue
Service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Canada: in accordance with the relevant tax laws
and regulations of Canada, a company registered in Canada is subject to income taxes within Canada at the applicable tax rate on taxable
income. All the Canada subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 15%. The subsidiary
in Canada did not have assessable profits that were derived from Canada during the years ended December 31, 2023, 2022 and 2021. Therefore,
no Canada profit tax has been provided for in the periods presented. Our returns for 2019 and subsequent tax years remain subject to examination
by the Canada tax authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The components of the provision for income taxes expenses are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/> December&#160;31,<br/> 2023</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/> December&#160;31,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/> December&#160;31,<br/> 2021</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total income taxes expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reconciliation of income taxes expenses computed
at the Hong Kong statutory tax rate applicable to income tax expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 203</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,340,975</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(11,525,102</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(27,114,293</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for income taxes at Hong Kong statutory income tax rate (16.5%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(716,261</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,901,642</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,473,859</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact of different tax rates in other jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,272</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(263,787</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(214,135</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,071,774</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(907,495</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(716,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,992,463</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,705,603</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,072,924</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,412,159</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Effective income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Deferred tax asset, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and deferred tax liabilities
reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purpose
and the tax bases used for income tax purpose. The following represents the tax effect of each major type of temporary difference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax asset:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Tax loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,956,748</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14,865,121</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,126</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">948,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Impairment of long-lived assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92,416</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,407,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,814,014</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax liability:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(108,926</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,407,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,705,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,407,156</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,705,088</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023 and 2022, the Group had
net operating loss carry-forwards of $102,367,435 and $90,060,983, respectively, including its Hong Kong, Singapore, the United States,
the United Kingdom and Canada operations, which are available to reduce future taxable income and have an unlimited carryover period.
For the year ended December 31, 2023, there was no tax loss carried forward expired, while tax loss brought forward of $28,281 was cancelled
due to the disposal of various subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Valuation allowance was provided against deferred
tax assets in entities where it was determined, it was more likely than not that the benefits of the deferred tax assets will not be realized.
The Group had deferred tax assets which consisted of tax loss carry forward, which can be carried forward to offset future taxable income.
The Group maintains a full valuation allowance on its net deferred tax assets. The management determines it is more likely than not that
all of its deferred tax assets will not be utilized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes in valuation allowance are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance as of January 1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,705,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,632,164</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,561,560</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,705,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,072,924</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,412,159</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Disposal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,535</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(341,555</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance as of December 31</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,407,156</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,705,088</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,632,164</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329534576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Balances and Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Balances and Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. RELATED PARTY BALANCES AND TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a list of a director and related parties to which
the Group has transactions with:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Ian Huen, the Chief Executive Officer and Executive Director of the Group since November 2023. He was a Non-executive Director from June 2022 to November 2023. Before June 2022, he was the Chief Executive Officer and Executive Director;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Jurchen Investment Corporation, the holding company and an entity controlled by Ian Huen;</span></td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">CGY Investment Limited, an entity owns more than 10% voting interest of the Group before April 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Aeneas Group Limited, an entity controlled by Ian Huen;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">(e)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Aenco Technologies Ltd, an entity being 34.56% effectively owned by Ian Huen;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">(f)</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt">Aeneas Management Limited, an entity controlled by Ian Huen;</span></td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(g)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Talem Medical Group Limited, an entity which Clark Cheng was a director;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(h)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Libra Sciences Limited, an entity which was originally a wholly owned subsidiary of ATL. Since December 30, 2021, Libra has been turned into a related party to the Group due to the voting power owned by ATL is decreased to below 50% but more than 20%. (Note 13) </span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Libra Therapeutics Limited, a wholly owned subsidiary of Libra Sciences Limited; </span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(j)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Clark Cheng, a former Executive Director of the Group before November 30, 2023. After his resignation on November 30, 2023, he was no longer a related party of the Group.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">(k)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">ACC Medical Limited, an entity controlled by Clark Cheng.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>(l)</td> <td style="text-align: justify">Darren Lui, a former Executive Director of the Group before November
27, 2023. After his resignation on November 27, 2023, he was no longer a related party of the Group.</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Amounts due from related parties, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amounts due from related parties consisted of the following as of December
31, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Aeneas Management Limited</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">961</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Libra Sciences Limited (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">521,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">378,036</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Libra Therapeutics Limited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,459</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Talem Medical Group Limited (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">610,138</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(521,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">961</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,005,633</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Amounts due to related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amounts due to related parties consisted of the following as of December
31, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Aeneas Group Limited (Note a)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">79,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,110</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Aenco Technologies Ltd</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,013,234</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Clark Cheng</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,583</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">79,180</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,025,927</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jurchen Investment Corporation (Note 15)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,058,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Aeneas Group Limited (Note a)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,058,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">500,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Related party transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related party transactions consisted of the following
for the years ended December 31, 2023, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Loan from related parties (Note a)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan repayment and interest paid to related parties (Note a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,673,389</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,085,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of Convertible Note to related parties (Note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aenco Technologies Ltd</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Settlement of loan from a related party through issuance of Convertible Note (Note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expenses (Note a and Note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">71,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">64,753</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">65,644</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aenco Technologies Ltd</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(13,234</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan to related parties (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Talem Medical Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,358,089</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Libra Sciences Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">92,459</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">330,341</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan repayment and interest received from a related party (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Talem Medical Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">611,641</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,962,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest income (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Talem Medical Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">164,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">39,561</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Libra Sciences Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consultant, secondment, management and administrative services fees (Note c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- CGY Investments Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">153,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">268,102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">173,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- ACC Medical Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">138,768</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">209,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">157,511</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Administrative management services (Note d)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Libra Sciences Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">38,462</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Healthcare services income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Management Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">961</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,564</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note a: On August 13, 2019, Aptorum Therapeutics
Limited (&#8220;ATL&#8221;), a wholly owned subsidiary of the Company, entered into financing arrangements with Aeneas Group Limited,
a related party, and Jurchen Investment Corporation, the ultimate parent of the Group, allowing ATL to access up to a total $15 million
in line of credit debt financing. Both line of credits have originally matured on August 12, 2022. ATL and Aeneas Group Limited has mutually
agreed to extend the line of credit arrangement further 3 years to August 12, 2025. The interest on the outstanding principal indebtedness
is at the rate of 8% per annum. ATL may early repay, in whole or in part, the principal indebtedness and all interest accrued at any time
prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty. As of the issuance
date of this consolidated financial statements, the undrawn line of credit facility is $12 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note b: On November 17, 2021, ATL entered into
a loan agreement with Talem Medical Group Limited (the &#8220;Borrower&#8221;). According to the loan agreement, ATL granted a loan of
up to <span style="-sec-ix-hidden: hidden-fact-253">AUD4,700,000</span> for the Borrower for general working capital purposes of the Borrower and its subsidiaries. The loan is interest-bearing
at a rate of 10% per annum and secured by the entire issued shares of Talem Medical Group (Australia) Pty Limited held by the Borrower.
The loan is initially matured 6 months from the date of the first drawdown. The maturity date was extended for 6 months to the first extended
maturity date, and further extended for another 6 months to the second extended maturity date. As of the date of the issuance of this
consolidated financial statements, there is no outstanding balance from the Borrower following a repayment in February 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 13, 2022, ATL entered a line of credit
facility with Libra Sciences Limited to provide up to a total $1 million line of credit for its daily operation. The line of credit is
originally matured on January 12, 2023, and is extended for additional 3 years. The interest on the outstanding principal indebtedness
is at the rate of 10% per annum. ATL and Libra Science Limited mutually agreed to terminate the line of credit agreement effect as of
March 31, 2023. All existing liabilities arising from the line of credit agreement shall remain enforceable and repayable on demand by
ATL. As of the issuance date of this consolidated financial statements, $0.5 million is outstanding from Libra Sciences Limited. For the
year ended December 31, 2023, the Group has assessed that the amounts due from Libra Science Limited and its subsidiary are potentially
unrecoverable. Accordingly, an allowance for credit loss amounting to $0.5 million has been recognized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note c: CGY Investment Limited provided certain
consultancy, advisory and management services to the Group on potential investment projects related to healthcare or R&amp;D platforms.
CGY Investment Limited is initially entitled to receive HK $104,000 (approximately $13,333) per calendar month plus reimbursement; such
monthly service fee is adjusted to HK$171,200 (approximately US$21,949) with effect from March 1, 2022. In August 2023, CGY Investment
Limited has agreed to suspended its monthly services fee from August 1, 2023. In November 2023, CGY Investment Limited and the Group reached
a mutual agreement to terminate their contractual relationship.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ACC Medical Limited provided certain consultancy,
advisory, and management services to the Group on clinic operations and other related projects for clinics&#8217; business development.
ACC Medical Limited is initially entitled to receive HK $101,542 (approximately $13,018) per calendar month plus reimbursement; such monthly
service fee is adjusted to HK$143,200 (approximately US$18,359 per month) effective from March 1, 2022. During the year ended December
31, 2023 and 2022, ACC Medical Limited also received $28,615 and $23,275 one-off compensation respectively. The agreement was terminated
on June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note d:&#160;On January 1, 2022, Aptus
Management Limited (&#8220;AML&#8221;), a wholly owned subsidiary of the Company, entered into an administrative management services
agreement with Libra Sciences Limited. According to the agreement, AML will provide documentation and administrative services,
include but are not limited to human resources and payroll administration, general secretarial and administrative support, and
accounting and financial reporting services. AML is entitled to receive a fixed amount of services fees of HKD 25,000 (approximately
$3,205) per calendar month with the original expiry date on December 31, 2023. AML and Libra Sciences Limited mutually agreed to
terminate the administrative management service agreement effect as of March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note e: In accordance with mutual agreements reached with the board
of directors, Mr. Clark Cheng and Mr. Ian Huen agreed to forgo their monthly remuneration effective July 1, 2023 until further notice.
Moreover, Mr. Darren Lui, a former executive director before his resignation on November 27, 2023, consented to suspend their monthly
remuneration from August 1, 2023. Additionally, all independent non-executive directors have consented to suspend their monthly remuneration
from September 1, 2023 until further notice. Before the suspension of remuneration, Mr. Clark Cheng, Mr. Ian Huen, and Mr. Darren Lui
had a monthly remuneration of $6,410, $27,333 and $6,667, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329697408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_VariableInterestEntityAbstract', window );"><strong>Variable Interest Entity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">VARIABLE INTEREST ENTITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13. VARIABLE INTEREST ENTITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company consolidates VIEs in which the Group
has a variable interest and is determined to be the primary beneficiary. This determination is based on whether the Group has a variable
interest (or combination of variable interests) that provides the Company with (a) the power to direct the activities that most significantly
impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses or right to receive benefits that could be potentially
significant to the VIE. The Group continually reassesses whether it is the primary beneficiary of a VIE throughout the entire period the
Group is involved with the VIE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2021, three of the Group&#8217;s
subsidiaries, Libra Sciences Limited (&#8220;Libra&#8221;, formerly known as Aptorum Pharmaceutical Development Limited),
Mios Pharmaceuticals Limited (&#8220;Mios&#8221;) and Scipio Life Sciences Limited (&#8220;Scipio&#8221;), issued Class A and Class B
ordinary shares to various parties; for each such entity, each Class A ordinary share is entitled to 1 vote and 1 share of economic benefit
of the respective company, while each Class B ordinary share is entitled to 10 votes and 0.001 share of economic benefit of the respective
company. Following such share issuances, the Group lost its majority voting rights in each of these three companies and only holds 48.33%,
48.39% and 48.36% economic interest in Libra, Mios and Scipio, respectively. However, the Group still holds a majority of each of these
three company&#8217;s outstanding Class A ordinary shares and therefore will absorb/receive portions of these subsidiaries&#8217; expected
losses or residual returns. In addition, none of these three companies have sufficient equity to sustain its own activities, and they
have two classes of ordinary shares which have different rights, benefits and obligations. We determined that all these three companies
are variable interest entities (&#8220;VIE&#8221;). On December 31, 2021, Libra, Mios and Scipio further issued Class A ordinary shares
to the Group in exchange of certain projects licenses. Upon these share issuances, the Group was holding 97.27% economic interest and
31.51% voting power in Libra, 97.93% economic interest and 36.17% voting power in Mios, and 97.93% economic interest and 35.06% voting
power in Scipio, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have considered each of these entity&#8217;s
Memorandum and Article of Association and their respective board of directors (the sole director of each of Mios and Scipio is an executive
director of the Group), and determined that we have the power to manage and make decisions that affect Mios and Scipio&#8217;s research
and development activities, which activities most significantly impact Mios and Scipio&#8217;s economic performance. However, we do not
have such power over Libra&#8217;s research and development activities, which activities most significantly impact Libra&#8217;s economic
performance. Accordingly, we determined that we are the primary beneficiary of Mios and Scipio, but not the primary beneficiary of Libra.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables summarize the aggregate carrying
value of VIEs&#8217; assets and liabilities in the consolidated balance sheets that are consolidated</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Assets/<br/>
 (Liabilities)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">Total</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,352</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,558</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,794</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">61,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">86,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(24,676</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables summarize the aggregate carrying
value of assets and liabilities in the Group&#8217;s consolidated balance sheets that relate to the VIE in which the Group holds a variable
interest but is not the primary beneficiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum<br/> Exposure to<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>December 31, 2023</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">     -</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Total</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">472,695</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">472,695</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">472,695</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s maximum exposure to loss from
its involvement with unconsolidated VIE represents the estimated loss that would be incurred if the VIE is liquidated, so that the fair
value of the equity investment in VIE is zero and the amounts due from the VIE have to be fully impaired.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_VariableInterestEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_VariableInterestEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329500288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. LEASE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Group has two long-term
operating leases for laboratories and clinic with remaining terms expiring from 2024 through 2026 and a weighted average remaining lease
term of 1.9 years. Weighted average discount rates used in the calculation of the operating lease liability is 8%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;year<br/> ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;year<br/> ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Lease cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance lease cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Depreciation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,818</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Interest on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,435</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,345</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349,031</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Short-term lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,598</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Sublease income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">317,566</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">483,882</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">389,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">369,505</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Financing cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">338,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549,596</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Weighted-average remaining lease term &#8211; finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average remaining lease term &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">1.9 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">1.1 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Weighted-average discount rate &#8211; finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, an impairment
loss of $200,916 on right-of-use assets was recognized in other operating expenses as the Group considered that the carrying amount of
a right-of-use asset related to a lease of clinic may not be recoverable. Additionally, the Group early terminated a lease agreement for
a right-of-use asset relating to an office, which resulted in a recognized loss on early termination of the right-of-use asset totaling
$31,030 in other operating expenses. For the years ended December 31, 2022 and 2021, the Group did not recognize any impairment losses
and loss on disposal of right-of-use assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The maturity analysis of operating leases liabilities
as of December 31, 2023 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Remaining periods ending December 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120,824</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,541</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,573</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total future undiscounted cash flow</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">242,938</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Discount on operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,221</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Present value of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,717</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(125,232</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Non-current portion of operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">99,485</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700322749504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. CONVERTIBLE NOTE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2022, the Group entered into a
securities purchase agreement with Aenco Technologies Limited (&#8220;Aenco&#8221;). Pursuant to the securities purchase agreement, Aenco
is purchasing a convertible note in the original principal amount of $3,000,000 (the &#8220;Dec 2022 Note&#8221;). The Dec 2022 Note is
unsecured, convertible into the Company&#8217;s restricted Class A Ordinary Shares at Aencco&#8217;s option. The Dec 2022 Notes have a
maturity date of 12 months subject to the Aenco&#8217;s extension, a bullet interest rate of 7% per annum, and a conversion price of $12.00
per Class A Ordinary share. The Company shall have an obligation to repay the principal amount and interest of the Dec 2022 Note on the
maturity date in cash or in unregistered Class A Ordinary Shares or a combination of such at the Company&#8217;s discretion. In April
2023, Aenco transferred the whole Dec 2022 Note to two external investors, and the two external investors fully converted the Dec 2022
Note into 250,000 Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2023, the Group entered into a securities
purchase agreement with 4 investors. Pursuant to the securities purchase agreement, the investors are purchasing a convertible note in
the original principal amount of $3,000,000 (the &#8220;June 2023 Note&#8221;). The whole proceeds from the June 2023 Note was used to
settle a related party loan. The June 2023 Note is unsecured, convertible into the Company&#8217;s restricted Class A Ordinary Shares
at the Note holders&#8217; option. The June 2023 Notes have a maturity date of 12 months subject to the investors extension, a bullet
interest rate of 7% per annum, and a conversion price of $3.00 per Class A Ordinary share. The Company shall have an obligation to repay
the principal amount and interest of the June 2023 Note on the maturity date in cash or in unregistered Class A Ordinary Shares or a combination
of such at the Company&#8217;s discretion. Immediately following the issuance of June 2023 Note, the June 2023 Note was fully converted
into 1,000,000 Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 11, 2023, the Group entered into
a securities purchase agreement with Jurchen Investment Corporation, the largest shareholder of the Company, pursuant to which the Group
sold a secured convertible note in the aggregate principal amount of $3,000,000 (the &#8220;Sep 2023 Notes&#8221;). The Sep 2023 Notes
are convertible into the Company&#8217;s Class A Ordinary Shares and have a maturity date that is 24 months from the issuance date, although
upon such date the investor has the right to extend the term of the Sep 2023 Note for twelve (12) months or more or such term subject
to mutual consent. The Sep 2023 Notes have an interest rate of 6% per annum and a conversion price of $2.42 per share. The Company has
the right to repay the principal amount of the Sep 2023 Notes, but in the case of such prepayment it must be paid in cash, unless otherwise
agreed by both parties. The Sep 2023 Note is secured by a first priority lien and security interest on certain preferred shares that the
Group owns (&#8220;Collateral&#8221;) (Note 5). Upon the Group&#8217;s disposal of all or a portion of the Collateral, the investor has
the right, to request that the Group prepay the then-remaining outstanding balance of the Sep 2023 Note, in part or in full and the Group
can make that payment in cash or in shares.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700324799040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">ORDINARY SHARES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>16. ORDINARY SHARES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 26, 2021, the Company entered into an
at-the-market offering agreement (the &#8220;Sales Agreement&#8221;), with H.C. Wainwright&#160;&amp; Co., LLC, acting as its sales agent
(the &#8220;Sales Agent&#8221;), relating to the sale of its Class A Ordinary Shares (such offering, the &#8220;ATM Offering&#8221;, or
&#8220;At The Market Offering&#8221;). In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of its
Class A Ordinary Shares having an aggregate offering price of up to $15,000,000 from time to time through the Sales Agent under such prospectus
supplement and the accompanying prospectus. As of the date of issuance of the consolidated financial statements, the Company has issued
215,959 Class A Ordinary Shares at average issuance price of $7.53 per share pursuant to the ATM Offering with gross proceeds of $1.6
million, less transaction costs of $50,183.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2021, the Company entered into a private
placement shares purchase agreement with Jurchen Investment Corporation, issuing 138,793 Class A Ordinary Shares at $28.82 per share,
representing a 10% premium to the last closing price of the Company&#8217;s Class A Ordinary Shares on the NASDAQ stock exchange on that
date. The Company received aggregate gross proceeds of $4,000,000 from the purchase of these shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 23, 2023, the Company effectuate a
10 for 1 share consolidation of its authorized share capital, such that every 10 Class A Ordinary Shares, par value of US$1.00 per share,
in the authorized share capital of the Company (including issued and unissued share capital) were consolidated into 1 Class A Ordinary
Share, par value of US$10.00 per share, and that every 10 Class B Ordinary Shares, par value of US$1.00 per share in the authorized share
capital of the Company (including issued and unissued share capital) were consolidated into 1 Class B Ordinary Share, par value of US$10.00
per share. As a consequence of the reverse stock split, fractional shares were rounded up to the next whole share, resulting in the creation
of an additional 8,018 Class A Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2023, the Company was merged with
Aptorum Group Cayman Limited, a newly established wholly owned subsidiary of the Company, whereby the Company is the surviving company
on the terms of the plan of merger. According to the plan of merger, the par value of its Class A and Class B Ordinary Shares are changed
from <span style="-sec-ix-hidden: hidden-fact-265">USD10</span> to <span style="-sec-ix-hidden: hidden-fact-264">USD0.00001</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group issued 70,430 Class
A Ordinary Shares to a majority of the share option holders. This issuance served as an exchange for their share options and facilitated
the reversal of deferred cash bonus payables owed to these holders (See Note 10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group also issued 65,770
fully vested Class A Ordinary Shares to certain employees and external consultants. The grant date fair value of each of the shares was
$2.68 based on grant date quoted market price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, the Group
issued 791 Class A Ordinary Shares to share option holders as a result of exercise of options. For the year ended December 31, 2022, the
Group issued 6,712 Class A Ordinary Shares to share option holders as a result of exercise of share options. For the year ended December
31, 2021, the Group issued 4,000 and 19,016 Class A Ordinary Shares to warrant holders and share option holders respectively as a result
of exercise of warrants or options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, the Group
issued 1,250,000 Class A Ordinary Shares to convertible note holders upon conversion (See Note 15).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Class A Ordinary Shares and Class B
Ordinary Shares have the same rights except for the following: (i) each Class A Ordinary Share is entitled to one vote while each Class
B Ordinary Share is entitled to ten votes; and (ii) each Class B Ordinary Share is convertible into one Class A Ordinary Share at any
time while Class A Ordinary Shares are not convertible under any circumstances.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700321941776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share Based Compensation [Abstarct]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE BASED COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>17. SHARE BASED COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share option plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2017, the Group adopted the 2017
Share Option Plan (the &#8220;Option Plan&#8221;) and on November 5, 2021, the Group amended the Option Plan. A total of 550,000 Class
A Ordinary Shares (subject to subsequent adjustments described more fully below) may be issued pursuant to awards under the Option Plan.
Subsequent adjustments include that on each January 1, starting with January 1, 2020, an additional number of shares equal to the lesser
of (i) 2% of the outstanding number of Class A Ordinary Shares (on a fully diluted basis) on the immediate preceding December 31, and
(ii) such lower number of Class A Ordinary Shares as may be determined by the board of directors, subject in all cases to adjustments
as provided in Section 10 of the Option Plan. Awards will be made pursuant to agreements and may be subject to vesting and other restrictions
as determined by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">75,235 options were granted on March 11, 2021
to directors, employees, external consultants and advisors of the Group with an exercise price of $27.6 per share, which was based on
the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding the grant
date.&#160;36,796 options vest on January 1, 2022 and expire on December 31, 2032; 36,808 options vest on January 1, 2023 and expire on
December 31, 2033; 906 options vest on June 8, 2021 and expire on June 7, 2032; and 725 options vest on July 14, 2021 and expire on July
13, 2032.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">153,146 options were granted on March 8, 2022
to directors, employees, external consultants and advisors of the Group with an exercise price of $13.4 per share, which was based on
the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding the grant
date.<i>&#160;</i>74,881 options vest on January 1, 2023 and expire on December 31, 2033; 74,906 options vest on January 1, 2024 and expire
on December 31, 2034; 1,866 options vest on June 8, 2022 and expire on June 7, 2033; and 1,493 options vest on July 14, 2022 and expire
on July 13, 2033.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group entered into exchange
agreements and cancelled 177,667 existing vested and unvested share options held by related parties option holders and cancelled the Group&#8217;s
obligations for deferred cash bonus payables of $3.1 million by granting of 403,820 share options (&#8220;New Options&#8221;) with 6 months
vesting period. The New Options&#8217; exercise price was $2.68 per share, which was based on the last closing price of the shares traded
on the NASDAQ stock exchange on the grant date. All options fully vested on October 1, 2023 and expires on September 30, 2033. On March
31, 2023, the Group entered into supplemental agreements with the same related parties option holders to provide additional cash compensation
to cover the exercise price of the New Options. On March 31, 2023, the Group entered into exchange agreements and cancelled 70,428 existing
vested and unvested share options held by non-related parties option holders and cancelled the Group&#8217;s obligations for deferred
cash bonus payables of $1.6 million by issuance of 70,430 fully vested Class A Ordinary Shares. The Group accounted for this exchange
for both related parties and non-related parties share option holders as a modification to share based compensation which required the
remeasurement of existing share options value at the time of the modification. The total incremental cost as a result of the modification
was $0.7 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the option activity for the years
ended December 31, 2023, 2022 and 2021 and changes during the period is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number of<br/> share&#160;options<sup>(1)</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise <br/> price<br/> $</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> contractual<br/> term in<br/> years</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">272,126</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">     &#8239;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">403,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(791</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Modified</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(248,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21.74</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">427,060</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.59</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">420,157</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.42</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number of<br/> share&#160;options<sup>(1)</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise <br/> price<br/> $</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> contractual<br/> term in<br/> years</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">127,404</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31.91</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">       </td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,721</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,268</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(435</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116.71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">272,126</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">21.54</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10.83</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">89,300</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">32.71</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.64</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number of<br/> share&#160;options<sup>(1)</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise <br/> price<br/> $</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> contractual<br/> term in<br/> years</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">71,756</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">      </td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,037</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(550</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding, December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">127,404</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">31.91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11.01</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable, December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">31,456</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">42.62</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.63</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted-average grant date fair value of
share option grants during the years ended December 31, 2023, 2022 and 2021 was $2.68, $10.02 and $25.72, respectively. The maximum contractual
term for share option was 12.8 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each stock option award is estimated
on the date of grant using the Black-Scholes option pricing model under the following assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted in<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted in <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted in<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right">170.10</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right">89.55</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right">97.70</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">3.48</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1.86</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1.64</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term from grant date (in years)</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">5.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">5.63-6.41</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">5.62-6.41</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Dividend rate</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277; -sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279; -sec-ix-hidden: hidden-fact-278">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dilution factor</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Fair value</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right">2.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">9.74
- $10.16</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">25.11 - $26.01</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the grant of share options
to employees and non-employees, the Group recorded share-based compensation charges of $697,446 and $391,479, respectively, for the year
ended December 31, 2023, $1,123,122 and $523,877, respectively, for the year ended December 31, 2022, and $1,203,000 and $479,460, respectively,
for the year ended December 31, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700323387280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Controlling Interest<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Non-Controlling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">NON-CONTROLLING INTEREST</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>18. NON-CONTROLLING INTEREST</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2021, two of the Group&#8217;s
subsidiaries, Mios Pharmaceuticals Limited (&#8220;Mios&#8221;) and Scipio Life Sciences Limited (&#8220;Scipio&#8221;), issued Class
A and Class B ordinary shares to various parties; for each such entity, each Class A ordinary share is entitled to 1 vote and 1 share
of economic interest of the respective company, while each Class B ordinary share is entitled to 10 votes and 0.001 share of economic
interest of the respective company. On December 31, 2021, Mios and Scipio further issued Class A ordinary shares to the Group in exchange
of certain projects licenses. Upon these share issuances, the Group was holding 97.93% economic interest and 36.17% voting power in Mios,
and 97.93% economic interest and 35.06% voting power in Scipio, respectively. Since the sole director of Mios and Scipio is
an executive director of the Group, the Group can effectively participate in all significant financial and operating decisions in these
two companies through the power granted to the sole director in Mios and Scipio&#8217;s Articles of Association. The Group is deemed to
have control over Mios and Scipio and hence these two companies are still within the Group. As a result, a total deficit of $27,293 was
reclassified from additional paid-in capital to non-controlling interests within the Group&#8217;s consolidated financial statements for
the year end December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 2, 2021, Aptorum Medical Limited issued
117 shares to Clark Cheng in according to the appointment agreement, decreasing the equity interest of the Company from 93% to 92%. On
February 25, 2022, Aptorum Medical Limited further issued 119 shares to Clark Cheng in according to the appointment agreement, decreasing
the equity interest of the Company from 92% to 91%. On February 1, 2023, Aptorum Medical Limited further issued 122 shares to Clark Cheng
in according to the appointment agreement, decreasing the equity interest of the Company from 91% to 90%. As a result, a total deficit
of $67,766, $52,024, and $34,130 were reclassified from additional paid-in capital to non-controlling interests within the Group&#8217;s
consolidated financial statements for the years ended December 31, 2023, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412426448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>19. NET LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 30pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the computation of basic and diluted
loss per share:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Net loss attributable to Aptorum Group Limited</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(2,824,647</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(9,799,560</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(25,048,389</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Weighted average shares outstanding<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#8211; Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,521,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,569,484</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,503,396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#8211; Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,521,133</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,569,484</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,503,396</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Net loss per share attributable to Aptorum Group Limited<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#8211; Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.62</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.75</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7.15</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#8211; Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.62</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2.75</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7.15</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023, 2022 and
2021, the total number of share options, warrants and convertible notes excluded from the calculation of diluted earnings per share due
to their anti-dilutive nature, are 1,293,723, 54,054 and 54,054, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700328830480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstart]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>20. COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Contingent Payment Obligations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Group does not have
any non-cancellable purchase commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has contingency payment obligations
under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain condition or
milestone is met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Milestone payments are due upon achievements of
specific conditions, such as Investigational New Drugs (&#8220;IND&#8221;) filing or U.S. Food and Drug Administration (&#8220;FDA&#8221;)
approval, first commercial sale of the licensed products, or other achievements. The aggregate amounts of the contingent milestone payments
that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as
of December 31, 2023 are below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Drug molecules: up to the conditions and milestones of</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Preclinical to IND filing</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">132,564</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">From entering phase 1 to before first commercial sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,376,410</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">First commercial sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,882,051</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net sales amount more than certain threshold in a year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,769,231</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,160,256</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Diagnostics technology: up to the conditions and milestones of</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Before FDA approval</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208,656</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">74,368,912</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023, 2022 and
2021, the Group incurred $50,000, $<span style="-sec-ix-hidden: hidden-fact-280">nil</span> and $<span style="-sec-ix-hidden: hidden-fact-281">nil</span> milestone payments under license agreements, respectively. For the years ended December
31, 2023, 2022 and 2021, the Group did not incur any royalties or research and development funding, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329500288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>21. SEGMENT REPORTING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s chief operating decision maker, the Chief Executive
Officer, reviews the consolidated results when making decisions about allocating resources and accessing performance of the Group as a
whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose
of internal reporting. The Group&#8217;s long-lived assets are substantially located in Hong Kong and majority of the Group&#8217;s revenue
and expense is derived from within Hong Kong. Therefore, no geographical segments are presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700321943520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>22. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has evaluated subsequent events through
the date of issuance of the consolidated financial statements. Except for the events disclosed elsewhere in the consolidate financial
statements and the following events with material financial impact on the Group&#8217;s consolidated financial statements, no other subsequent
event is identified that would have required adjustment or disclosure in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2024, the Group entered into an Agreement
and Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among Company, and YOOV Group Holding Limited, a company organized under
the laws of British Virgin Islands (&#8220;YOOV&#8221;). The Merger Agreement was unanimously approved by Company&#8217;s and YOOV&#8217;s
boards of directors (each board of directors, the &#8220;Board&#8221;), respectively. If the Merger Agreement is approved by Company&#8217;s
and YOOV&#8217;s shareholders (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and
upon consummation of the transactions contemplated by the Merger Agreement, the Group will incorporate a wholly-owned subsidiary under
the laws of the British Virgin Islands (&#8220;Merger Sub&#8221;) that will merge with and into YOOV, with YOOV surviving the merger as
a wholly-owned subsidiary of the Group (collectively, the &#8220;Merger&#8221;). The Group upon the closing is referred to herein as the
&#8220;combined company.&#8221; Upon consummation of the transaction, YOOV will become a wholly-owned subsidiary of the Group, and the
existing YOOV shareholders and existing the Group&#8217;s shareholders will own approximately 90% and 10%, respectively, of the outstanding
shares of the combined company. The consummation of this merger remains uncertain as it is contingent upon the fulfillment of specific
closing conditions.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The obligations of the parties (or, in some cases,
some of the parties) to consummate the Merger are subject to the satisfaction or waiver of certain conditions to closing, including, among
other things: (i) obtaining the approval by the shareholders of Aptorum and YOOV of the matters required under the Merger Agreement, (ii)
approval of the Initial Listing Application by Nasdaq, (iii) consummation of the Separation of ATL, (iv) delivery of legal opinions from
British Virgin Islands counsel and Hong Kong counsel of YOOV to Aptorum and Merger Sub, (v) delivery of legal opinions from Cayman Islands
counsel of Aptorum and British Virgin Islands counsel of Merger Sub to YOOV, (vi) delivery of an opinion by Colliers International (Hong
Kong) Limited to the Board of Aptorum to the effect that (subject to various qualifications and assumptions) the merger consideration
(the total Class A ordinary shares and Class B ordinary shares to be issued to YOOV&#8217;s shareholders) is fair, from a financial point
of view (based on the conclusion that the equity value of YOOV is no less than $250 million), to the shareholders of Aptorum. (vii) availability
of audited financial statements for YOOV and its Subsidiaries as of March 31, 2023 and 2022 the related audited consolidated statements
of operations, of changes in shareholders&#8217; equity and of cash flows for the year ended March 31, 2023 and 2022 in conformity with
International Financial Reporting Standards, which shall not be materially different from the unaudited financial statements of YOOV for
the same period as presented to Aptorum, as determined by Aptorum in its sole discretion, (viii) delivery of fully executed lock-up agreement
and support agreement by the major shareholder of Aptorum and the delivery of fully executed lock-up agreement by the directors and officers
of YOOV and by the shareholders of YOOV who will beneficially own 5% or more outstanding shares of the combined company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Merger, on March 1, 2024,
the Company entered into a Split-Off Agreement (the &#8220;Split-Off Agreement&#8221;, the transaction contemplated by the Split-Off Agreement,
the &#8220;Separation&#8221;) by and among the Company, Aptorum Therapeutics Limited (&#8220;ATL&#8221;), and Jurchen Investment Corporation
(&#8220;Jurchen&#8221;), pursuant to which, the Company will assign and transfer the assets and liabilities of its legacy business to
ATL, and Jurchen will acquire 100% issued and outstanding shares of ATL from the Company and surrender certain ordinary shares of the
Company held by Jurchen to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
closing of the Separation must occur simultaneously with the closing of the Merger, or on a later date, as mutually agreed by the Parties.
The Split-Off Agreement contains conditions precedent to closing of the parties thereto, with respect to, among other things, the following
as applicable to each party:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify"><b>Representations, Warranties and Performance.</b> All representations
and warranties made by the parties in the Split-Off Agreement must have been accurate and truthful, to the best of their knowledge, when
initially made and must remain accurate and truthful, to the best of their knowledge, at the time of the Closing. The parties are obligated
to fulfill all commitments, agreements, and conditions outlined in the Split-Off Agreement to the satisfaction of the parties involved,
with significant emphasis on adherence to these obligations before or at the Closing.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify"><b>Additional Documents.</b> Jurchen shall deliver or cause
to be delivered such additional documents as may be necessary in connection with the consummation of the transactions contemplated by
the Split-Off Agreement and the performance of their obligations hereunder.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify"><b>Release by Buyer and Split-Off Subsidiary.</b> At the
Closing, Jurchen and ATL are required to execute and provide Aptorum with a comprehensive release. This release will absolve Aptorum
from all liabilities and obligations owed to Jurchen or ATL in any capacity, as well as from any claims that Jurchen or ATL may assert
against Aptorum or its related managers, members, officers, directors, shareholders, employees, and agents. However, this release does
not cover liabilities arising from the Split-Off Agreement or any document related to it.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(iv)</td><td style="text-align: justify"><b>Shareholder Approval.</b> Aptorum shall have obtained
the affirmative vote of its shareholders representing at least two-thirds of the voting power of the issued and outstanding ordinary
shares of the Seller entitled to vote at a general meeting of the shareholders voting in person or by proxy, to approve the Split-Off
Agreement and the transaction contemplated herein.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2024, CGY Investments Limited and
DSF Investment Holdings Limited voluntarily converted 401,537 Class B Ordinary Shares and 45,305 Class B Ordinary Shares, respectively
into Class A Ordinary Shares on a one-for-one basis. Upon conversion, 1,796,934 Class B Ordinary Shares were issued and outstanding, CGY
Investments Limited owned 533,575 Class A Ordinary Shares and did not own any Class B Ordinary Share; and DSF Investment Holdings Limited
owned 45,305 Class A Ordinary Shares and did not own any Class B Ordinary Share.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700439486752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of presentation and consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Principles of presentation and consolidation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of the Group
are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;),
and include the accounts of the Company, its direct and indirect wholly and majority owned subsidiaries. In accordance with the provisions
of Accounting Standards Codification (&#8220;ASC&#8221;) 810, Consolidation, we consolidate any variable interest entity (&#8220;VIE&#8221;)
of which we are the primary beneficiary. The typical condition for a controlling financial interest ownership is holding a majority of
the voting interests of an entity; however, a controlling financial interest may also exist in entities, such as VIEs, through arrangements
that do not involve controlling voting interests. ASC 810 requires a variable interest holder to consolidate a VIE if that party has the
power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and the obligation to absorb
losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially
be significant to the VIE. We do not consolidate a VIE in which we have a majority ownership interest when we are not considered the primary
beneficiary. We have determined that we are not one of the primary beneficiary of the VIE (see Note 13, Variable Interest Entity). We
evaluate our relationships with the VIE on an ongoing basis to determine whether we become the primary beneficiary. All material intercompany
balances and transactions have been eliminated in preparation of the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NoncontrollingInterestsPolicyTextBlock', window );">Non-controlling interests</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Non-controlling interests</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-controlling interests are recognized to reflect
the portion of the equity of majority-owned subsidiaries which are not attributable, directly or indirectly, to the controlling shareholder.
Non-controlling interests are classified as a separate line item in the equity section of the Group&#8217;s consolidated balance sheets
and have been separately disclosed in the Group&#8217;s consolidated statements of operations and comprehensive loss and consolidated
statements of equity to distinguish the interests from that of the Group.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as income
and expenses during the reporting period. Significant accounting estimates reflected in the Group&#8217;s consolidated financial statements
include fair value of long-term investments, fair value measurement for share options, impairment of long-lived assets, allowance for
credit losses and valuation allowance for deferred tax assets. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation and transaction</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency translation and transaction</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">USD is the reporting currency. The functional
currency of subsidiaries in the Cayman Islands, Seychelles, Samoa and the United States are USD, the functional currency of subsidiaries
in Hong Kong is Hong Kong Dollars (&#8220;HKD&#8221;), the functional currency of a subsidiary in Singapore is Singapore Dollars (&#8220;SGD&#8221;),
the functional currency of a subsidiary in the United Kingdom is Great British Pound (&#8220;GBP&#8221;), and the functional currency
of subsidiaries in Canada is Canadian Dollars (&#8220;CAD&#8221;). An entity&#8217;s functional currency is the currency of the primary
economic environment in which it operates, normally that is the currency of the environment in which it primarily generates and expends
cash. The management considered various indicators, such as cash flows, market expenses, financing and inter-company transactions and
arrangements in determining the Group&#8217;s functional currency.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the consolidated financial statements, the
financial information of the Company and its subsidiaries, which use HKD, SGD, GBP and CAD as their functional currency, has been translated
into USD. Assets and liabilities are translated from each subsidiary&#8217;s functional currency at the exchange rates on the balance
sheet dates, equity amounts are translated at historical exchange rates, and revenues, expenses, gains, and losses are translated using
the average exchange rates for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a
separate component of other comprehensive income or loss in the consolidated statements of operations and comprehensive income or loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cash and cash equivalents</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consists of cash on
hand, bank deposits and time deposits with an original maturity of three months or less at the date of purchase.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Restricted cash</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash represented time deposits pledged
for banking facilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable and amounts due from related parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable and amounts due from related
parties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group adopted ASC 326 from January 1, 2023.
Accounts receivable and amounts due from related parties are stated at the original amount less an allowance for credit losses, if any,
based on a review of all outstanding amounts at period end. An allowance is estimated in accordance with ASC Topic 326, <i>Credit Losses</i>
and records the allowance for credit losses as an offset to accounts receivable or amounts due from related parties, and the expected
credit losses charged to the allowance is included in other operating expenses in the consolidated statements of operations and comprehensive
loss. In determining expected credit losses, the Group considers the historical level of credit losses, current economic trends, and reasonable
and supportable forecasts that affect the collectability of the future cash flows. As of December 31, 2023 and 2022, $521,007 and <span style="-sec-ix-hidden: hidden-fact-192">$71</span>
allowance for credit losses were made.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inventories</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at lower of cost and net
realizable value. Cost is determined using the weighted average method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where there is evidence that the utility of inventories,
in their disposal in the ordinary course of business, will be less than cost, whether due to physical deterioration, obsolescence, changes
in price levels, or other causes, the inventories are written down to net realizable value. During the years ended December 31, 2023,
2022 and 2021, the write-down of inventories were $13,206, $<span style="-sec-ix-hidden: hidden-fact-193">nil</span> and $<span style="-sec-ix-hidden: hidden-fact-194">nil</span> respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Marketable securities</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable securities are publicly traded stocks
measured at fair value and classified within Level 1 and 2 in the fair value hierarchy because the Group either uses quoted prices for
identical assets in active markets, inputs that are based upon quoted prices for similar instruments in active markets, or quoted prices
for identical assets in markets with insufficient volume or infrequent transaction (less active markets).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LongtermInvestmentsPolicyPolicyTextBlock', window );">Long-term investments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Long-term investments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s long-term investments consist
of equity method investment in common stocks and non-marketable investments in non-redeemable preferred shares of privately-held companies
that are not required to be consolidated under the variable interest or voting models. Long-term investments are classified as non-current
assets on the consolidated balance sheets as those investments do not have stated contractual maturity dates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Non-marketable investments</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The non-marketable equity securities not accounted
for under the equity method are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in
orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach
as of the transaction date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Equity method investment &#8211; Fair value option</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group elects the fair value option for an
investment that would otherwise be accounted for using the equity method of accounting. Such election is irrevocable and is applied on
an investment by investment basis at initial recognition. The fair value of such investments is based on quoted prices in an active market,
if any, or recent orderly transactions for identical or similar investment of the same issuer. Changes in the fair value of these equity
method investments are recognized in other income (expenses), net in the consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair value measurement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the price that would
be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the
Group considers the principal or most advantageous market in which it would transact its business, and it considers assumptions that market
participants would use when pricing the asset or liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a basis for considering such assumptions, a
three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The hierarchy requires the Group to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s categorization
within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Group has
estimated the fair value amounts of its financial instruments using the available market information and valuation methodologies considered
to be appropriate and has determined that the carrying value of the Group&#8217;s cash, restricted cash, accounts receivable, due from
brokers, other receivables and prepayments, loan receivables from related parties, amounts due from/to related parties, accounts payable
and accrued expenses, bank loan, and loan payables to a related party as of December 31, 2023 and 2022 approximate fair value due to the
short-term nature of these assets and liabilities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and equipment, net</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment, net, is stated at cost
less accumulated depreciation and impairment losses. Cost represents the purchase price of the asset and other costs incurred to bring
the asset into its existing use. Maintenance, repairs and betterments, including replacement of minor items, are charged to expense; major
additions to physical properties are capitalized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets under construction are stated at cost less
impairment losses. Cost comprises of cost of laboratory equipment delivered but not ready to be used, together with interest expense capitalized
during the period of construction or installation and testing. Capitalization of these costs ceases and the asset concerned is transferred
to the appropriate fixed assets category when substantially all the activities necessary to prepare the asset for its intended use are
completed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation of property, plant and equipment
is provided using the straight-line method over their estimated useful lives:&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 51%"><span style="font-size: 10pt">Computer equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 48%; text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Furniture, fixture, and office and medical equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Shorter of the remaining lease terms or 5 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Motor vehicle</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon sale or disposal, the applicable amounts
of asset cost and accumulated depreciation are removed from the accounts and the net amount less proceeds from disposal is charged or
credited to income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible assets, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Intangible assets, net</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finite-lived intangible assets are carried at
cost less accumulated amortization and impairment if any. The finite intangible assets are amortized over their estimated useful life,
which is the period over which the assets are expected to contribute directly or indirectly to the future cash flows of the Group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s intangible assets mainly consist
of computer software and is amortized over its useful life. The estimated useful life is generally 5 years. The Group will reassess the
remaining useful life on annual basis.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of long-lived assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group reviews its long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When these events
occur, the Group compares the carrying value of the long-lived assets to the estimated undiscounted future cash flows expected to result
from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flow is less than the carrying
amount of the assets, the Group would recognize an impairment loss, which is the excess of carrying amount over the fair value of the
assets, using the expected future discounted cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Convertible notes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group evaluates and accounts for conversion
options embedded in convertible notes in accordance with ASC 815 &#8220;Derivatives and Hedging Activities&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applicable GAAP requires companies to bifurcate
conversion options from their host instruments and account for them as derivative financial instruments according to certain criteria.
The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly
and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded
derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings
as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for the convertible notes as
a single unit of account, unless the conversion feature requires bifurcation and recognition as derivatives. Additionally, the Group uses
the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential
share settlement for instruments that may be settled in cash or shares.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OperatingLeasesPolicyTextBlock', window );">Operating leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Operating leases</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of a contract, the Group determines
if the arrangement is, or contains, a lease. Operating lease liabilities are recognized at lease commencement based on the present value
of lease payments over the lease term. Operating lease right-of-use assets are initially measured at cost, which comprises the initial
amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs
incurred and less any lease incentives received. As the rate implicit in the lease cannot be readily determined, the Group uses incremental
borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental
borrowing rate is determined based on the rate of interest that the Group would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term in a similar economic environment. The lease term for all of the Group&#8217;s leases includes
the non-cancellable period of the lease plus any additional periods covered by either a Group&#8217;s option to extend (or not to terminate)
the lease that the Group is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.
For operating leases, the Group recognizes a single lease cost on a straight-line basis over the remaining lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has elected not to recognize right-of-use
assets or lease liabilities for leases with an initial term of 12 months or less and the Group recognizes lease expense for these leases
on a straight-line basis over the lease terms.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_WarrantLiabilitiesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Warrants </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection of the issuance of Class A Ordinary
Shares, the Company may issue warrants to purchase Class A Ordinary Shares. Warrants classified as equity are initially recorded at fair
value and subsequent changes in fair value are not recognized.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues are derived from healthcare services
rendered to patients for healthcare consultation and medical treatment. Revenue is reported at the amount that reflects the consideration
to which the Group expects to be entitled in exchange for providing healthcare services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group recognizes revenue as its performance
obligations are completed. Healthcare services are treated as a single performance obligation satisfied at a point in time because the
performance obligations are generally satisfied over a period of less than one day.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of healthcare services</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cost of healthcare services</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of healthcare services rendered represents
cost in relation to the medical services provided including the compensation of the physicians, cost of pharmaceutical supplies and medicine
and write-down of inventories.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Research and development expenses</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed as
incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including
amortization of the patent license, depreciation of laboratory equipment, costs of engaging external consultants, advisors and contracted
research organization to conduct preclinical development activities and trials, payroll expenses to research and development staff, sponsored
research expenses to universities and research institutions, and impairment of patent license and laboratory equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share-based compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group uses the fair value method of accounting
for the share options granted to directors, employees, external consultants and advisors to measure the cost services received in exchange
for the share based awards. The fair value of share option awards with only service condition is estimated on the grant or offering date
using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires inputs such as the risk-free interest rate,
expected term and expected volatility. These inputs are subjective and generally require significant judgment. The resulting cost is recognized
over the period during which a director, employee, external consultant or advisor is required to provide service in exchange for the awards,
usually the vesting period, which is generally from 9.5 months to 21.5 months. Share-based compensation expense is recognized on a graded
vesting basis, net of actual forfeitures in the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based compensation expense is recorded in
cost of healthcare services, research and development expenses, general and administrative fees and legal and professional fees in the
consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 718, modifications to stock-based
awards are accounted for as exchanges of the original awards for new awards. The incremental fair value, which is the difference between
the fair value of the modified award and the original award immediately before modification, is measured at the modification date. This
incremental fair value is recognized immediately as compensation cost for vested awards. For unvested awards, the incremental compensation
cost, along with any remaining unrecognized compensation cost of the original award, is recognized over the remaining requisite vesting
period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for income taxes under the
asset and liability method. Under this method, deferred income taxes are determined based on differences between the financial carrying
amounts of existing assets and liabilities and their tax bases. Income taxes are provided for in accordance with the laws of the relevant
taxing authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is provided for deferred
tax assets if it is more likely than not that these items will either expire before the Group is able to realize their benefits, or that
future deductibility is uncertain. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesPolicy', window );">Uncertain tax positions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Uncertain tax positions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for uncertainty in income taxes
using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition
by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit,
including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest
amount that is more than 50% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized
and recorded as necessary in the provision for income taxes. The Group recognizes interest on non-payment of income taxes and penalties
associated with tax positions when a tax position does not meet more likely than not thresholds be sustained under examination. The tax
returns of the Group&#8217;s Hong Kong subsidiaries are subject to examination by the relevant tax authorities. According to the Hong
Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed or has
been assessed at less than the proper amount, the statute of limitation is extended to ten years if the underpayment of taxes is due to
fraud or willful evasion. According to United Kingdom, Singapore, the United States, Canada and Ireland tax rule, trading losses are available
to be carried forward indefinitely. The Group did not have any material interest or penalties associated with tax positions for the years
ended December 31, 2023, 2022 and 2021, and did not have any significant unrecognized uncertain tax positions as of December 31, 2023
and 2022. The Group does not believe that its assessment regarding unrecognized tax benefits will materially change over the next twelve
months.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income or loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Comprehensive income or loss</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain changes in assets and liabilities are
reported as separate components of the equity section of the consolidated balance sheets, such items, along with net income or loss, are
components of comprehensive income or loss. The components of other comprehensive income or loss consist of exchange differences on translation
of foreign operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net income or loss per share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Net income or loss per share</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net income or loss per share is computed
by dividing net income or loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during
the period. Diluted net income or loss per share reflects the potential dilution that could occur if securities or other contracts to
issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation
of diluted loss per share in loss periods as their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of credit risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial assets which potentially subject the
Group to concentrations of credit risk consist principally of bank deposits and balances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group takes on exposure to credit risk on
cash balances majority held with HSBC for the purposes of payments of Group expenses. The risk of default is considered minimal as the
Group considers HSBC is well established with high credit rating.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recently adopted accounting pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)
No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13
is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held
by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets
held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires
enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used
in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#8217;s portfolio. These disclosures
include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements.
In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13
are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December
15, 2022 for the Group. The Group has adopted ASU 2016-13 on January 1, 2023 and the impact of this adoption for the years ended December
31, 2023 and 2022 were assessed to be not material.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently issued accounting standards which have not yet been adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recently issued accounting standards which have not yet been adopted</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements,
primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. The amendments
in this ASU are effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years
beginning after December 15, 2024, with early adoption permitted. The Group is still evaluating the effect of the adoption of this guidance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued Accounting Standards
Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness
of income tax disclosures. The amendments address more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. The ASU also includes certain other amendments to improve
the effectiveness of income tax disclosures. The amendments in this ASU are effective for public business entities for annual periods
beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Group is still evaluating the effect of the
adoption of this guidance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2024, the SEC approved a rule that
will require registrants to provide certain climate-related information in their registration statements and annual reports. The rule
requires information about a registrant&#8217;s climate-related risks that are reasonably likely to have a material impact on its business,
results of operations, or financial condition. The required information about climate-related risks also includes disclosure of a registrant&#8217;s
greenhouse gas emissions. In addition, the rules will require registrants to present certain climate-related financial metrics in their
audited financial statements. The Group is evaluating the potential impact of this rule on the consolidated financial statements and related
disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group does not believe other recently issued
but not yet effective accounting standards, if currently adopted, would have a material impact on the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LongtermInvestmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-term investments Policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LongtermInvestmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NoncontrollingInterestsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NoncontrollingInterestsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_OperatingLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_OperatingLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_WarrantLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_WarrantLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700328685408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">Schedule of Major Subsidiaries Consolidated</a></td>
<td class="text">Below summarizes the list of the major subsidiaries consolidated as
of December 31, 2023:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 22%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Incorporation<br/>
date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Ownership</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Place of<br/>
incorporation</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Principle activities</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Aptorum Therapeutics Limited (&#8220;ATL&#8221;)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">June 30, 2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">APTUS MANAGEMENT LIMITED</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">May 16, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Hong Kong</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Provision of management services to its holding company and fellow subsidiaries</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Aptorum Medical Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">August 28, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">90%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Provision of medical clinic services</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Paths Innovations Limited </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">April 15, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Investment holding company</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Paths Diagnostics Pte. Limited </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">June 5, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">75%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Singapore</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Acticule Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">June 30, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">80%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Claves Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">August 2, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Nativus Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 7, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Videns Incorporation Limited </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 2, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Mios Pharmaceuticals Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 6, 2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">97.93%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">mTOR (Hong Kong) Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">November 4, 2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">90%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Hong Kong</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Scipio Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 19, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">97.93%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Signate Life Sciences Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">August 28, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Cayman Islands</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development of life science and biopharmaceutical products</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700321960736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock', window );">Schedule of Estimated Useful Lives</a></td>
<td class="text">Depreciation of property, plant and equipment
is provided using the straight-line method over their estimated useful lives:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 51%"><span style="font-size: 10pt">Computer equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 48%; text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Furniture, fixture, and office and medical equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Shorter of the remaining lease terms or 5 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Motor vehicle</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700324604880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment and Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investment and Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis</a></td>
<td class="text">The following table provides the assets and liabilities
carried at fair value measured on a recurring basis as of December 31, 2023 and 2022:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Non-current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in">Long-term investments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Common stocks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total assets at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in">Marketable securities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.25in">Common stocks</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,279</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">102,481</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Long-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Common stocks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total assets at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,202</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">92,279</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">77,200</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">179,681</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value Reconciliation of Level 3 Assets</a></td>
<td class="text">The following is a reconciliation of Level 3 assets
measured and recorded at fair value on a recurring basis during the years ended December 31, 2023 and 2022:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">77,200</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(77,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net change in unrealized appreciation relating to investments still held at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Balance at January 1, 2022</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">77,200</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in unrealized appreciation, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">77,200</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in unrealized appreciation relating to investments still held at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Quantitative Information about the Group&#8217;s Level 3 Fair Value Measurements of Investment</a></td>
<td class="text">The following table presents the quantitative
information about the Group&#8217;s Level 3 fair value measurements of investment as of December 31, 2023 and 2022, which utilized significant
unobservable internally-developed inputs:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>December 31, 2023</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation technique</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Unobservable input</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Range<br/>
(weighted average)</b></p></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Common stocks</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Recent transactions</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Recent transaction price</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$0.0001 - $0.01</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>December 31, 2022</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation technique</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Unobservable input</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Range<br/>
(weighted average)</b></p></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Common stocks</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Recent transactions</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Recent transaction price</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$0.0001 - $0.01</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock', window );">Schedule of Unrealized Gains and Losses</a></td>
<td class="text">The following is a summary of annual upward or
downwards adjustments and impairment recorded in other income (expenses), net, and included as adjustments to the carrying value of non-marketable
investments held as of&#160;December 31, 2023, 2022 and 2021 based on the observable price in an orderly transaction for the same or similar
security of the same issuers:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Upward adjustments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,431,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,108,872</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Downward adjustments and impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(520,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total unrealized gain from fair value change of non-marketable investments,
net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,431,088</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,588,051</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock', window );">Schedule of Carrying Value of Our Non-Marketable Investments</a></td>
<td class="text">The following table summarizes the total carrying
value of the non-marketable investments held as of&#160;December 31, 2023 and 2022&#160;including cumulative unrealized upward and downward
adjustments and impairment made to the initial cost basis of the investments:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Initial cost basis</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,079,707</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,079,707</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Upward adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,539,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,108,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Downward adjustments and impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(520,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(520,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total carrying value at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,098,846</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,667,758</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329157552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepayments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OtherReceivablesandPrepaymentsTablesLineItems', window );"><strong>Other Receivables and Prepayments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Other Receivables and Prepayments</a></td>
<td class="text">Other receivables and prepayments as of December 31, 2023 and 2022
consisted of:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">185,633</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">305,178</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,833</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid service fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,346</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Rental deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid rental expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,752</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,253</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,603</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">422,071</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">744,008</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_OtherReceivablesandPrepaymentsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_OtherReceivablesandPrepaymentsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329697408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property and equipment as of December 31, 2023 and 2022 consisted of:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">81,138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">84,636</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture, fixture, and office and medical equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,292</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">298,738</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">543,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">543,975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,336,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,229,072</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Motor vehicle</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">239,093</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">239,093</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,351,262</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,395,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,687,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,570,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,663,926</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,825,059</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700324903904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Gross carrying amount</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid patented licenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">728,205</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,038,205</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Computer software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">223,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">223,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952,063</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,262,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: accumulated amortization and impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid patented licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">728,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">474,131</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Computer software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,511</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">804,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid patented licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">564,074</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Computer software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,347</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">188,631</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">147,347</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">752,705</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets</a></td>
<td class="text">The Group expects amortization expense related
to its finite-lived intangible assets for the next five years and thereafter to be as follows as of December 31, 2023:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">For the years ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">38,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,439</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,439</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,031</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">147,347</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329697408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Deposits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LongTermDepositsTablesLineItems', window );"><strong>Long-Term Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfLongTermDepositsTableTextBlock', window );">Schedule of Long-Term Deposits</a></td>
<td class="text">Long-term deposits as of December 31, 2023 and 2022 consisted of:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Rental deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">71,823</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">127,303</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepayments for equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71,823</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">129,847</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LongTermDepositsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LongTermDepositsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfLongTermDepositsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfLongTermDepositsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329065424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AccountsPayableandAccruedExpensesTablesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts payable and accrued expenses as of December 31, 2023 and 2022
consisted of:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Deferred bonus and salaries payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">451,660</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,084,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development expenses payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,162,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">563,913</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,324</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,407</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost of healthcare services payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138,316</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Insurance expenses payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,367</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,913</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,835</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,894,341</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,166,807</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AccountsPayableandAccruedExpensesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AccountsPayableandAccruedExpensesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700321663120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes Expenses</a></td>
<td class="text">The components of the provision for income taxes expenses are:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/> December&#160;31,<br/> 2023</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/> December&#160;31,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/> December&#160;31,<br/> 2021</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total income taxes expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate</a></td>
<td class="text">The reconciliation of income taxes expenses computed
at the Hong Kong statutory tax rate applicable to income tax expense is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 203</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,340,975</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(11,525,102</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(27,114,293</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for income taxes at Hong Kong statutory income tax rate (16.5%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(716,261</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,901,642</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,473,859</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact of different tax rates in other jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,272</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(263,787</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(214,135</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,071,774</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(907,495</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(716,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,992,463</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,705,603</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,072,924</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,412,159</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Effective income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Asset and Liabilities</a></td>
<td class="text">Deferred tax assets and deferred tax liabilities
reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purpose
and the tax bases used for income tax purpose. The following represents the tax effect of each major type of temporary difference.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax asset:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Tax loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,956,748</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14,865,121</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,126</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">948,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Impairment of long-lived assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92,416</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,407,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,814,014</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax liability:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(108,926</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,407,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,705,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,407,156</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,705,088</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Changes in Valuation Allowance</a></td>
<td class="text">Changes in valuation allowance are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance as of January 1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,705,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,632,164</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,561,560</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,705,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,072,924</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,412,159</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Disposal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,535</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(341,555</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance as of December 31</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,407,156</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,705,088</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,632,164</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329387424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Balances and Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock', window );">Schedule of Amounts Due from Related Parties</a></td>
<td class="text">Amounts due from related parties consisted of the following as of December
31, 2023 and 2022:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Aeneas Management Limited</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">961</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Libra Sciences Limited (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">521,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">378,036</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Libra Therapeutics Limited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,459</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Talem Medical Group Limited (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">610,138</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(521,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">961</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,005,633</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfDueToRelatedPartiesTableTextBlock', window );">Schedule of Amounts Due to Related Parties</a></td>
<td class="text">Amounts due to related parties consisted of the following as of December
31, 2023 and 2022:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Aeneas Group Limited (Note a)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">79,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,110</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Aenco Technologies Ltd</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,013,234</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Clark Cheng</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,583</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">79,180</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,025,927</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jurchen Investment Corporation (Note 15)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,058,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Aeneas Group Limited (Note a)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,058,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">500,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text">Related party transactions consisted of the following
for the years ended December 31, 2023, 2022 and 2021:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Loan from related parties (Note a)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan repayment and interest paid to related parties (Note a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,673,389</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,085,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of Convertible Note to related parties (Note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aenco Technologies Ltd</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Settlement of loan from a related party through issuance of Convertible Note (Note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expenses (Note a and Note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">71,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">64,753</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Jurchen Investment Corporation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">65,644</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aenco Technologies Ltd</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(13,234</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan to related parties (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Talem Medical Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,358,089</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Libra Sciences Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">92,459</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">330,341</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan repayment and interest received from a related party (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Talem Medical Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">611,641</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,962,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest income (Note b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Talem Medical Group Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">164,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">39,561</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Libra Sciences Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consultant, secondment, management and administrative services fees (Note c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- CGY Investments Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">153,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">268,102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">173,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- ACC Medical Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">138,768</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">209,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">157,511</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Administrative management services (Note d)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Libra Sciences Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">38,462</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Healthcare services income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">- Aeneas Management Limited</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">961</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,564</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfDueToRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfDueToRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329730192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_VariableInterestEntityAbstract', window );"><strong>Variable Interest Entity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Aggregate Carrying Value of Vies&#8217; Assets and Liabilities</a></td>
<td class="text">The following tables summarize the aggregate carrying
value of VIEs&#8217; assets and liabilities in the consolidated balance sheets that are consolidated<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Assets/<br/>
 (Liabilities)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">Total</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,352</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,558</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,794</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">61,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">86,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(24,676</td><td style="text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum<br/> Exposure to<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>December 31, 2023</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">     -</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Total</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">472,695</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">472,695</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">472,695</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_VariableInterestEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_VariableInterestEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-9<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700328709840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Leases Obligation</a></td>
<td class="text">Weighted average discount rates used in the calculation of the operating lease liability is 8%.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;year<br/> ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;year<br/> ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Lease cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance lease cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Depreciation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,818</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Interest on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,435</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,345</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349,031</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Short-term lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,598</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Sublease income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">317,566</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">483,882</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">389,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">369,505</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Financing cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">338,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549,596</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Weighted-average remaining lease term &#8211; finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average remaining lease term &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">1.9 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">1.1 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Weighted-average discount rate &#8211; finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity Analysis of Operating Leases Liabilities</a></td>
<td class="text">The maturity analysis of operating leases liabilities
as of December 31, 2023 is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Remaining periods ending December 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120,824</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,541</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,573</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total future undiscounted cash flow</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">242,938</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Discount on operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,221</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Present value of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,717</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(125,232</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Non-current portion of operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">99,485</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700321955904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share Based Compensation [Abstarct]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of the Option Activity</a></td>
<td class="text">A summary of the option activity for the years
ended December 31, 2023, 2022 and 2021 and changes during the period is presented below:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number of<br/> share&#160;options<sup>(1)</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise <br/> price<br/> $</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> contractual<br/> term in<br/> years</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">272,126</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">     &#8239;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">403,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(791</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Modified</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(248,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21.74</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">427,060</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.59</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">420,157</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.42</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number of<br/> share&#160;options<sup>(1)</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise <br/> price<br/> $</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> contractual<br/> term in<br/> years</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">127,404</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31.91</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">       </td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,721</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,268</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(435</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116.71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">272,126</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">21.54</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10.83</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">89,300</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">32.71</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.64</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number of<br/> share&#160;options<sup>(1)</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise <br/> price<br/> $</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> contractual<br/> term in<br/> years</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding, January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">71,756</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">      </td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,037</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(550</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding, December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">127,404</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">31.91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11.01</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable, December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">31,456</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">42.62</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.63</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model</a></td>
<td class="text">The fair value of each stock option award is estimated
on the date of grant using the Black-Scholes option pricing model under the following assumptions.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted in<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted in <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted in<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right">170.10</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right">89.55</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right">97.70</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">3.48</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1.86</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1.64</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term from grant date (in years)</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">5.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">5.63-6.41</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">5.62-6.41</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Dividend rate</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277; -sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279; -sec-ix-hidden: hidden-fact-278">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dilution factor</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Fair value</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right">2.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">9.74
- $10.16</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">25.11 - $26.01</span></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700321939056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted (loss) income per share</a></td>
<td class="text">The following table sets forth the computation of basic and diluted
loss per share:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Net loss attributable to Aptorum Group Limited</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(2,824,647</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(9,799,560</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(25,048,389</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Weighted average shares outstanding<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#8211; Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,521,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,569,484</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,503,396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#8211; Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,521,133</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,569,484</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,503,396</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Net loss per share attributable to Aptorum Group Limited<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#8211; Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.62</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.75</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7.15</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#8211; Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.62</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2.75</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7.15</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700443962960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstart]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock', window );">Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions</a></td>
<td class="text">The aggregate amounts of the contingent milestone payments
that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as
of December 31, 2023 are below:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Drug molecules: up to the conditions and milestones of</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Preclinical to IND filing</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">132,564</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">From entering phase 1 to before first commercial sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,376,410</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">First commercial sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,882,051</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net sales amount more than certain threshold in a year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,769,231</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,160,256</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Diagnostics technology: up to the conditions and milestones of</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Before FDA approval</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208,656</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">74,368,912</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of milestone payments are to be made upon achievements of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412358336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details) - Schedule of Major Subsidiaries Consolidated<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_AptorumTherapeuticsLimitedMember', window );">Aptorum Therapeutics Limited (&#8220;ATL&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Jun. 30,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_APTUSMANAGEMENTLIMITEDMember', window );">APTUS MANAGEMENT LIMITED [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">May 16,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Hong Kong<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Provision of management services to its holding company and fellow subsidiaries<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_AptorumMedicalLimitedMember', window );">Aptorum Medical Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Aug. 28,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Provision of medical clinic services<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_PathsInnovationsLimitedMember', window );">Paths Innovations Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Apr. 15,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Investment holding company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_PathsDiagnosticsPteLimitedMember', window );">Paths Diagnostics Pte. Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Jun.  05,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_ActiculeLifeSciencesLimitedMember', window );">Acticule Life Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Jun. 30,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_ClavesLifeSciencesLimitedMember', window );">Claves Life Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Aug.  02,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_NativusLifeSciencesLimitedMember', window );">Nativus Life Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Jul.  07,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_VidensIncorporationLimitedMember', window );">Videns Incorporation Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Mar.  02,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_MiosPharmaceuticalsLimitedMember', window );">Mios Pharmaceuticals Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Mar.  06,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">97.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_mTORHongKongLimitedMember', window );">mTOR (Hong Kong) Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Nov.  04,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Hong Kong<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_ScipioLifeSciencesLimitedMember', window );">Scipio Life Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Jul. 19,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">97.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_SignateLifeSciencesLimitedMember', window );">Signate Life Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Aug. 28,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_EntityIncorporationsStateCountryName', window );">Place of incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrincipleActivities', window );">Principle activities</a></td>
<td class="text">Research and development of life science and biopharmaceutical products<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_EntityIncorporationsStateCountryName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Place of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_EntityIncorporationsStateCountryName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_PrincipleActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principle activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_PrincipleActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_AptorumTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_AptorumTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_APTUSMANAGEMENTLIMITEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_APTUSMANAGEMENTLIMITEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_AptorumMedicalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_AptorumMedicalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_PathsInnovationsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_PathsInnovationsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_PathsDiagnosticsPteLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_PathsDiagnosticsPteLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_ActiculeLifeSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_ActiculeLifeSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_ClavesLifeSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_ClavesLifeSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_NativusLifeSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_NativusLifeSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_VidensIncorporationLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_VidensIncorporationLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_MiosPharmaceuticalsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_MiosPharmaceuticalsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_mTORHongKongLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_mTORHongKongLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_ScipioLifeSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_ScipioLifeSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_SignateLifeSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_SignateLifeSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329563120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (4,340,975)<span></span>
</td>
<td class="num">$ (11,525,102)<span></span>
</td>
<td class="num">$ (27,114,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net operation cash outflow</a></td>
<td class="num">(7,724,364)<span></span>
</td>
<td class="num">(12,318,965)<span></span>
</td>
<td class="num">$ (14,651,633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(68,161,722)<span></span>
</td>
<td class="num">$ (65,337,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_UnrestrictedCashEquivalents', window );">Unrestricted cash</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_UnrestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents unrestricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_UnrestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700436789056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AllowanceForCreditLossOfDueFromARelatedParty', window );">Allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521,007<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Written-down of inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,206<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period Term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Measure the tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AllowanceForCreditLossOfDueFromARelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for credit loss of due from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AllowanceForCreditLossOfDueFromARelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329351488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixture, and office and medical equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LeaseholdImprovementsEstimatedUsefulLives', window );">Leasehold improvements, estimated useful lives</a></td>
<td class="text">Shorter of the remaining lease terms or 5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apm_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LeaseholdImprovementsEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold improvements, estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LeaseholdImprovementsEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apm_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apm_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329306096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment and Fair Value Measurement (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems', window );"><strong>Investment and Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment amounted</a></td>
<td class="nump">$ 77,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Non-marketable investments</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription', window );">Voting rights description</a></td>
<td class="text">Each Class A share of Libra is entitled to 1 vote while each Class
B share of Libra is entitled to 10 votes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest</a></td>
<td class="nump">97.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Temporary impairment</a></td>
<td class="nump">$ 77,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems', window );"><strong>Investment and Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Non-marketable investments</a></td>
<td class="nump">$ 15,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems', window );"><strong>Investment and Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interest</a></td>
<td class="nump">31.51%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member] | Libra [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems', window );"><strong>Investment and Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interest</a></td>
<td class="nump">31.51%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraMember', window );">Libra [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems', window );"><strong>Investment and Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest</a></td>
<td class="nump">97.27%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraMember', window );">Libra [Member] | Series of Individually Immaterial Business Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems', window );"><strong>Investment and Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interest</a></td>
<td class="nump">48.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of key provisions in the operating or partnership agreement of the limited liability company or limited partnership, including liability, voting matters, distributions, and other provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_LibraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_LibraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700328706304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 77,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=apm_CommonStock1Member', window );">Common Stocks One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">179,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Common Stocks One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Common Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Common Stocks One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">92,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Common Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">77,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Common Stocks One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">77,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Common Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAssetsAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NonCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NonCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=apm_CommonStock1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=apm_CommonStock1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700325942768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment and Fair Value Measurement (Details) - Schedule of Fair Value Reconciliation of Level 3 Assets - Level 3 [Member] - Fair value recurring [Member] - Warrants [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues', window );">Beginning balance</a></td>
<td class="nump">$ 77,200<span></span>
</td>
<td class="nump">$ 77,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">77,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="num">(77,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FairValueOfChangeInUnrealizedAppreciationDepreciation', window );">Change in unrealized appreciation, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NetChangeInUnrealizedDepreciationRelatingToInvestments', window );">Net change in unrealized appreciation relating to investments still held</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FairValueOfChangeInUnrealizedAppreciationDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FairValueOfChangeInUnrealizedAppreciationDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NetChangeInUnrealizedDepreciationRelatingToInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net change in unrealized depreciation relating to investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NetChangeInUnrealizedDepreciationRelatingToInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700325150992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment and Fair Value Measurement (Details) - Schedule of Quantitative Information about the Group&#8217;s Level 3 Fair Value Measurements of Investment<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember', window );">Common Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FairValueMeasurementValuationTechniques', window );">Valuation technique</a></td>
<td class="text">Recent transactions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FairValueMeasurementsUnobservableInput', window );">Unobservable input</a></td>
<td class="text">Recent transaction price<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FairValueMeasurementsWeightedAverageRange', window );">Range (weighted average)</a></td>
<td class="text">$0.0001 - $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FairValueMeasurementValuationTechniques', window );">Valuation technique</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Recent transactions<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FairValueMeasurementsUnobservableInput', window );">Unobservable input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Recent transaction price<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FairValueMeasurementsWeightedAverageRange', window );">Range (weighted average)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$0.0001 - $0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FairValueMeasurementValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the inputs and valuation technique(s) used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FairValueMeasurementValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FairValueMeasurementsUnobservableInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the inputs used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FairValueMeasurementsUnobservableInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FairValueMeasurementsWeightedAverageRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the Range (weighted average).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FairValueMeasurementsWeightedAverageRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700436781776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment and Fair Value Measurement (Details) - Schedule of Unrealized Gains and Losses - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfUnrealizedGainsAndLossesAbstract', window );"><strong>Schedule of Unrealized Gains and Losses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_UpwardAdjustments', window );">Upward adjustments</a></td>
<td class="nump">$ 6,431,088<span></span>
</td>
<td class="nump">$ 6,108,872<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DownwardAdjustmentsAndImpairment', window );">Downward adjustments and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(520,821)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_TotalUnrealizedGainForNonmarketableInvestments', window );">Total unrealized gain from fair value change of non-marketable investments, net</a></td>
<td class="nump">$ 6,431,088<span></span>
</td>
<td class="nump">$ 5,588,051<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DownwardAdjustmentsAndImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of downward adjustments and impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DownwardAdjustmentsAndImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfUnrealizedGainsAndLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfUnrealizedGainsAndLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_TotalUnrealizedGainForNonmarketableInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total unrealized gain for non-marketable investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_TotalUnrealizedGainForNonmarketableInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_UpwardAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upward adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_UpwardAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700323221040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment and Fair Value Measurement (Details) - Schedule of Carrying Value of Our Non-Marketable Investments - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract', window );"><strong>Schedule of Carrying Value of Our Non-Marketable Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_InitialCostBasis', window );">Initial cost basis</a></td>
<td class="nump">$ 4,079,707<span></span>
</td>
<td class="nump">$ 4,079,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_UpwardAdjustment', window );">Upward adjustments</a></td>
<td class="nump">12,539,960<span></span>
</td>
<td class="nump">6,108,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DownwardAdjustmentAndImpairment', window );">Downward adjustments and impairment</a></td>
<td class="num">(520,821)<span></span>
</td>
<td class="num">(520,821)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_TotalCarryingValueAtTheEndOfThePeriod', window );">Total carrying value at the end of the year</a></td>
<td class="nump">$ 16,098,846<span></span>
</td>
<td class="nump">$ 9,667,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DownwardAdjustmentAndImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of downward adjustment and impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DownwardAdjustmentAndImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_InitialCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_InitialCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_TotalCarryingValueAtTheEndOfThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total carrying value at the end of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_TotalCarryingValueAtTheEndOfThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_UpwardAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upward adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_UpwardAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700324157808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepayments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_WritteoffOfPrepaymentAndOtherReceivables', window );">Other operating expenses</a></td>
<td class="nump">$ 62,369<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_WritteoffOfPrepaymentAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Writte-off of prepayment and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_WritteoffOfPrepaymentAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329624944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables and Prepayments (Details) - Schedule of Other Receivables and Prepayments - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems', window );"><strong>Other Receivables and Prepayments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 185,633<span></span>
</td>
<td class="nump">$ 305,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">33,815<span></span>
</td>
<td class="nump">47,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrepaidServiceFee', window );">Prepaid service fee</a></td>
<td class="nump">46,303<span></span>
</td>
<td class="nump">148,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Rental deposits</a></td>
<td class="nump">102,109<span></span>
</td>
<td class="nump">16,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rental expenses</a></td>
<td class="nump">15,683<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">22,275<span></span>
</td>
<td class="nump">204,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Others</a></td>
<td class="nump">16,253<span></span>
</td>
<td class="nump">21,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 422,071<span></span>
</td>
<td class="nump">$ 744,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_PrepaidServiceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid service fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_PrepaidServiceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700443964928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 1,041,234<span></span>
</td>
<td class="nump">$ 1,092,957<span></span>
</td>
<td class="nump">$ 1,086,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses', window );">Other operating expenses</a></td>
<td class="nump">28,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember', window );">Leasehold Improvements, Furniture and Fixtures and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property, plant and equipment</a></td>
<td class="nump">$ 79,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating expenses for the period that are associated with the utility's normal revenue producing operation; including selling, general, and administrative expenses, costs incurred for routine plant repairs and maintenance, and operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700326102528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of Property and Equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 5,351,262<span></span>
</td>
<td class="nump">$ 7,395,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="nump">3,687,336<span></span>
</td>
<td class="nump">4,570,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,663,926<span></span>
</td>
<td class="nump">2,825,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">81,138<span></span>
</td>
<td class="nump">84,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixture, and office and medical equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">150,292<span></span>
</td>
<td class="nump">298,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">543,975<span></span>
</td>
<td class="nump">543,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apm_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">4,336,764<span></span>
</td>
<td class="nump">6,229,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Motor vehicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 239,093<span></span>
</td>
<td class="nump">$ 239,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apm_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apm_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329153232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Impairment loss on intangible asset</a></td>
<td class="nump">$ 519,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on disposal of patented license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (205,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">84,020<span></span>
</td>
<td class="nump">114,553<span></span>
</td>
<td class="nump">$ 106,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_WroteOffOfCostRelatedAmortization', window );">Wrote off of cost related amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=apm_HongKongHealthcareServicesMember', window );">Hong Kong healthcare services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Impairment loss on intangible asset</a></td>
<td class="nump">$ 1,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_WroteOffOfCostRelatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Wrote off of cost related amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_WroteOffOfCostRelatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=apm_HongKongHealthcareServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=apm_HongKongHealthcareServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700328908720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - Schedule of Intangible Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 952,063<span></span>
</td>
<td class="nump">$ 1,262,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="nump">804,716<span></span>
</td>
<td class="nump">509,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">147,347<span></span>
</td>
<td class="nump">752,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=apm_PrepaidPatentedLicensesMember', window );">Prepaid patented licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">728,205<span></span>
</td>
<td class="nump">1,038,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="nump">728,205<span></span>
</td>
<td class="nump">474,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">564,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">223,858<span></span>
</td>
<td class="nump">223,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="nump">76,511<span></span>
</td>
<td class="nump">35,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 147,347<span></span>
</td>
<td class="nump">$ 188,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=apm_PrepaidPatentedLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=apm_PrepaidPatentedLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700323585792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Amortization Expense Related to its Finite Lived Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">$ 38,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">38,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">38,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">32,031<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 147,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700328649136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Deposits (Details) - Schedule of Long-Term Deposits - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems', window );"><strong>Schedule of long-term deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_RentalDeposits', window );">Rental deposits</a></td>
<td class="nump">$ 71,823<span></span>
</td>
<td class="nump">$ 127,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PrepaymentsForEquipment', window );">Prepayments for equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,544<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Total</a></td>
<td class="nump">$ 71,823<span></span>
</td>
<td class="nump">$ 129,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_PrepaymentsForEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments of deposits for equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_PrepaymentsForEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_RentalDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rental deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_RentalDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412644928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses', window );">Deferred cash bonus payables</a></td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Issuance of vested ordinary shares (in Shares) | shares</a></td>
<td class="nump">70,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Granting share options (in Shares) | shares</a></td>
<td class="nump">403,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_VestedAndUnvestedShareOptions', window );">Vested and unvested share options (in Shares) | shares</a></td>
<td class="nump">177,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Deferred cash bonus payables</a></td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_VestedAndUnvestedShareOptions', window );">Vested and unvested share options (in Shares) | shares</a></td>
<td class="nump">70,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Deferred cash bonus payables</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative fees</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AccountsPayableAndAccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AccountsPayableAndAccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_VestedAndUnvestedShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vested and unvested share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_VestedAndUnvestedShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412760176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract', window );"><strong>Schedule of accounts payable and accrued expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Deferred bonus and salaries payable</a></td>
<td class="nump">$ 451,660<span></span>
</td>
<td class="nump">$ 5,084,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ResearchAndDevelopmentExpensesPayable', window );">Research and development expenses payable</a></td>
<td class="nump">1,162,155<span></span>
</td>
<td class="nump">563,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees payable</a></td>
<td class="nump">175,324<span></span>
</td>
<td class="nump">226,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CostOfHealthcareServicesPayable', window );">Cost of healthcare services payable</a></td>
<td class="nump">61,826<span></span>
</td>
<td class="nump">138,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_InsuranceExpensePayable', window );">Insurance expenses payable</a></td>
<td class="nump">27,463<span></span>
</td>
<td class="nump">33,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Others</a></td>
<td class="nump">15,913<span></span>
</td>
<td class="nump">119,835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 1,894,341<span></span>
</td>
<td class="nump">$ 6,166,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_CostOfHealthcareServicesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of healthcare services payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_CostOfHealthcareServicesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_InsuranceExpensePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance expense payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_InsuranceExpensePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ResearchAndDevelopmentExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ResearchAndDevelopmentExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412315200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate percentage</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards (in Dollars)</a></td>
<td class="nump">$ 102,367,435<span></span>
</td>
<td class="nump">$ 90,060,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LossCarryforwardCancelled', window );">Loss carry-forward (in Dollars)</a></td>
<td class="nump">$ 28,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_IncomeTaxDescription', window );">Income tax, description</a></td>
<td class="text">Under the two-tiered profits tax rate regime, the first $2 million
of assessable profits of qualifying corporations is taxed at 8.25% and the remaining assessable profits at 16.5%. The Ordinance is effective
from the year of assessment 2018-2019. According to the policy, if no election has been made, the whole of the taxpaying entity&#8217;s
assessable profits will be chargeable to Profits Tax at the rate of 16.5% or 15%, as applicable. Because the preferential tax treatment
is not elected by the Group, all the subsidiaries registered in Hong Kong are subject to income tax at a rate of 16.5%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">Singapore [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States (Nevada) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_IncomeTaxDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_IncomeTaxDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LossCarryforwardCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss carryforward cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LossCarryforwardCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700323221040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Provision for Income Taxes Expenses - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems', window );"><strong>Schedule of Provision for Income Taxes Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income taxes expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412303312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems', window );"><strong>Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss before tax</a></td>
<td class="num">$ (4,340,975)<span></span>
</td>
<td class="num">$ (11,525,102)<span></span>
</td>
<td class="num">$ (27,114,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Provision for income taxes at Hong Kong statutory income tax rate (16.5%)</a></td>
<td class="num">(716,261)<span></span>
</td>
<td class="num">(1,901,642)<span></span>
</td>
<td class="num">(4,473,859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Impact of different tax rates in other jurisdictions</a></td>
<td class="num">(16,272)<span></span>
</td>
<td class="num">(263,787)<span></span>
</td>
<td class="num">(214,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome', window );">Non-taxable income</a></td>
<td class="num">(1,071,774)<span></span>
</td>
<td class="num">(907,495)<span></span>
</td>
<td class="num">(716,628)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">98,704<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,992,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,705,603<span></span>
</td>
<td class="nump">3,072,924<span></span>
</td>
<td class="nump">3,412,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700326026992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems', window );"><strong>Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Provision for income taxes at Hong Kong statutory income tax rate</a></td>
<td class="num">(16.50%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700328647408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Deferred Tax Asset and Liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DeferredTaxAssetAbstract', window );"><strong>Deferred tax asset:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Tax loss carry forward</a></td>
<td class="nump">$ 16,956,748<span></span>
</td>
<td class="nump">$ 14,865,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based payment expenses</a></td>
<td class="nump">229,126<span></span>
</td>
<td class="nump">948,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">128,866<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Impairment of long-lived assets</a></td>
<td class="nump">92,416<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset, net</a></td>
<td class="nump">17,407,156<span></span>
</td>
<td class="nump">15,814,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DeferredTaxLiabilityAbstract', window );"><strong>Deferred tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(108,926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NetDeferredTaxAssetsBeforeValuationAllowance', window );">Net deferred tax assets before valuation allowance</a></td>
<td class="nump">17,407,156<span></span>
</td>
<td class="nump">15,705,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(17,407,156)<span></span>
</td>
<td class="num">(15,705,088)<span></span>
</td>
<td class="num">$ (12,632,164)<span></span>
</td>
<td class="num">$ (9,561,560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax asset, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DeferredTaxAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DeferredTaxAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DeferredTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DeferredTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NetDeferredTaxAssetsBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net deferred tax assets (liabilities) before valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NetDeferredTaxAssetsBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700323611600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Changes in Valuation Allowance - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Schedule of Changes in Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning balance</a></td>
<td class="nump">$ 15,705,088<span></span>
</td>
<td class="nump">$ 12,632,164<span></span>
</td>
<td class="nump">$ 9,561,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ValuationAllowanceDeferredTaxAssetIncrease', window );">Additions</a></td>
<td class="nump">1,705,603<span></span>
</td>
<td class="nump">3,072,924<span></span>
</td>
<td class="nump">3,412,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount', window );">Disposal</a></td>
<td class="num">(3,535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(341,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Ending balance</a></td>
<td class="nump">$ 17,407,156<span></span>
</td>
<td class="nump">$ 15,705,088<span></span>
</td>
<td class="nump">$ 12,632,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ValuationAllowanceDeferredTaxAssetIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ValuationAllowanceDeferredTaxAssetIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700324479584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 13, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>HKD ($)</div>
</th>
<th class="th">
<div>Nov. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 13, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>HKD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Line of credit debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of credit period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Undrawn line of credit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedParties', window );">Loan for the borrowers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LoansInterestbearingRate', window );">Loans interest-bearing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit amount</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Line of credit maturity date</a></td>
<td class="text">Jan. 12,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Allowance for credit loss recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ServicesFees', window );">Services fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,205<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndBenefitsTrust', window );">Compensation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DecreasedOwnershipPercentage', window );">Decreased ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DecreasedOwnershipPercentage', window );">Decreased ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=apm_IanHuenMember', window );">Ian Huen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Owned percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasManagementLimitedMember', window );">Aeneas Management Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of credit period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember', window );">CGY Investments Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ServicesFees', window );">Services fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,333<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ServicesFeesAdjusted', window );">Services fees adjusted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,949<span></span>
</td>
<td class="nump">171,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_ACCMedicalLimitedMember', window );">ACC Medical Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ServicesFees', window );">Services fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,018<span></span>
</td>
<td class="nump">101,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ServicesFeesAdjusted', window );">Services fees adjusted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,359<span></span>
</td>
<td class="nump">$ 143,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MrClarkChengMember', window );">Mr. Clark Cheng [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_RemunerationAmount', window );">Remuneration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MrIanHuenMember', window );">Mr. Ian Huen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_RemunerationAmount', window );">Remuneration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MrDarrenLuiMember', window );">Mr. Darren Lui [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_RemunerationAmount', window );">Remuneration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=apm_CGYInvestmentsLimitedMember', window );">CGY Investments Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DecreasedOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decreased ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DecreasedOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LoansInterestbearingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest bearing rate of loan per annum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LoansInterestbearingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_RemunerationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the remuneration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_RemunerationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ServicesFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of services fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ServicesFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ServicesFeesAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of services fees adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ServicesFeesAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndBenefitsTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of a trust established to hold the stock of an employee compensation and benefits plan as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndBenefitsTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of investment owned to net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=apm_IanHuenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=apm_IanHuenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasManagementLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasManagementLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_ACCMedicalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_ACCMedicalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MrClarkChengMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MrClarkChengMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MrIanHuenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MrIanHuenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MrDarrenLuiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MrDarrenLuiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=apm_CGYInvestmentsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=apm_CGYInvestmentsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329600160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 1,005,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentInLease', window );">Allowance for credit loss</a></td>
<td class="num">(521,007)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasManagementLimitedMember', window );">Aeneas Management Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">961<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraSciencesLimitedMember', window );">Libra Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">521,007<span></span>
</td>
<td class="nump">378,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraTherapeuticsLimitedOneMember', window );">Libra Therapeutics Limited one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_TalemMedicalGroupLimitedMember', window );">Talem Medical Group Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 610,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AmountsDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts dure from related parties classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AmountsDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_CurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_CurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-7A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479016/842-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasManagementLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasManagementLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraTherapeuticsLimitedOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraTherapeuticsLimitedOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_TalemMedicalGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_TalemMedicalGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329519680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CurrentAbstract0', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueToRelatedPartiesCurrent', window );">Amounts due to related parties, Current</a></td>
<td class="nump">$ 79,180<span></span>
</td>
<td class="nump">$ 3,025,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueToRelatedPartiesNoncurrent', window );">Amounts due to related parties, Non-current</a></td>
<td class="nump">3,058,500<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasGroupLimitedMember', window );">Aeneas Group Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CurrentAbstract0', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueToRelatedPartiesCurrent', window );">Amounts due to related parties, Current</a></td>
<td class="nump">79,180<span></span>
</td>
<td class="nump">8,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueToRelatedPartiesNoncurrent', window );">Amounts due to related parties, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AencoTechnologiesLtdMember', window );">Aenco Technologies Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CurrentAbstract0', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueToRelatedPartiesCurrent', window );">Amounts due to related parties, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,013,234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_SabrinaKhanMember', window );">Sabrina Khan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CurrentAbstract0', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueToRelatedPartiesCurrent', window );">Amounts due to related parties, Current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_JurchenInvestmentsCorporationMember', window );">Jurchen Investment Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonCurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AmountsDueToRelatedPartiesNoncurrent', window );">Amounts due to related parties, Non-current</a></td>
<td class="nump">$ 3,058,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AmountsDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due to related parties, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AmountsDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AmountsDueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AmountsDueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_CurrentAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_CurrentAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NonCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NonCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AencoTechnologiesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AencoTechnologiesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_SabrinaKhanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_SabrinaKhanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_JurchenInvestmentsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_JurchenInvestmentsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412790880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Related Party Transactions - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasGroupLimitedMember', window );">Aeneas Group Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Loan from related parties</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LoanRepaymentAndInterestPaidToRelatedParties', window );">Loan repayment and interest paid to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,673,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ConsultantSecondmentManagementAndAdministrativeServicesFees', window );">Settlement of loan from a related party through issuance of Convertible Note</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="nump">71,123<span></span>
</td>
<td class="nump">8,110<span></span>
</td>
<td class="nump">64,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_JurchenInvestmentCorporationMember', window );">Jurchen Investment Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Loan from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LoanRepaymentAndInterestPaidToRelatedParties', window );">Loan repayment and interest paid to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,085,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="nump">58,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_JurchenInvestmentCorporationOneMember', window );">Jurchen Investment Corporation one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_LoanRepaymentAndInterestPaidToRelatedParties', window );">Loan repayment and interest paid to related parties</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AencoTechnologiesLtdMember', window );">Aenco Technologies Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issuance of Convertible Note to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="num">(13,234)<span></span>
</td>
<td class="nump">13,234<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_TalemMedicalGroupLimitedMember', window );">Talem Medical Group Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Loan to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,358,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_RepaymentOfLoanFromRelatedParty', window );">Loan repayment and interest received from a related party</a></td>
<td class="nump">611,641<span></span>
</td>
<td class="nump">2,962,153<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">4,637<span></span>
</td>
<td class="nump">164,600<span></span>
</td>
<td class="nump">39,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraSciencesLimitedMember', window );">Libra Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AdministrativeManagementServices', window );">Administrative management services</a></td>
<td class="nump">9,615<span></span>
</td>
<td class="nump">38,462<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Loan to related parties</a></td>
<td class="nump">92,459<span></span>
</td>
<td class="nump">330,341<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">8,963<span></span>
</td>
<td class="nump">14,232<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember', window );">CGY Investments Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ConsultantSecondmentManagementAndAdministrativeServicesFees', window );">Settlement of loan from a related party through issuance of Convertible Note</a></td>
<td class="nump">153,640<span></span>
</td>
<td class="nump">268,102<span></span>
</td>
<td class="nump">173,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_ACCMedicalLimitedMember', window );">ACC Medical Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ConsultantSecondmentManagementAndAdministrativeServicesFees', window );">Settlement of loan from a related party through issuance of Convertible Note</a></td>
<td class="nump">138,768<span></span>
</td>
<td class="nump">209,626<span></span>
</td>
<td class="nump">157,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasManagementLimitedMember', window );">Aeneas Management Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Healthcare services income</a></td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 1,282<span></span>
</td>
<td class="nump">$ 7,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AdministrativeManagementServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Administrative management services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AdministrativeManagementServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ConsultantSecondmentManagementAndAdministrativeServicesFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consultant, secondment, management and administrative services fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ConsultantSecondmentManagementAndAdministrativeServicesFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_LoanRepaymentAndInterestPaidToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan repayments, including interest, made to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_LoanRepaymentAndInterestPaidToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_RepaymentOfLoanFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of loan from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_RepaymentOfLoanFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_JurchenInvestmentCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_JurchenInvestmentCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_JurchenInvestmentCorporationOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_JurchenInvestmentCorporationOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AencoTechnologiesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AencoTechnologiesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_TalemMedicalGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_TalemMedicalGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_ACCMedicalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_ACCMedicalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasManagementLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_AeneasManagementLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412235440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">each Class A ordinary share is entitled to 1 vote and 1 share of economic benefit
of the respective company, while each Class B ordinary share is entitled to 10 votes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareOfEconomic', window );">Share of economic (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment (in Dollars)</a></td>
<td class="nump">$ 77,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_LibraSciencesLimitedMember', window );">Libra Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="nump">97.27%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_MiosPharmaceuticalsLimitedMember', window );">Mios Pharmaceuticals Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="nump">97.93%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_ScipioLifeSciencesLimitedMember', window );">Scipio Life Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="nump">97.93%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingActivityByTypeAxis=apm_VaribaleInterestEntityMember', window );">Varibale Interest Entity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting right percentage</a></td>
<td class="nump">31.51%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member] | Libra [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting right percentage</a></td>
<td class="nump">48.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member] | Mios [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting right percentage</a></td>
<td class="nump">48.39%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member] | Scipio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting right percentage</a></td>
<td class="nump">48.36%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=apm_GroupsSubsidiariesMember', window );">Group&#8217;s subsidiaries [Member] | Libra Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting right percentage</a></td>
<td class="nump">31.51%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=apm_GroupsSubsidiariesMember', window );">Group&#8217;s subsidiaries [Member] | Mios Pharmaceuticals Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting right percentage</a></td>
<td class="nump">36.17%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=apm_GroupsSubsidiariesMember', window );">Group&#8217;s subsidiaries [Member] | Scipio Life Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting right percentage</a></td>
<td class="nump">35.06%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ShareOfEconomic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ShareOfEconomic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_LibraSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_LibraSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_MiosPharmaceuticalsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_MiosPharmaceuticalsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_ScipioLifeSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_ScipioLifeSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingActivityByTypeAxis=apm_VaribaleInterestEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingActivityByTypeAxis=apm_VaribaleInterestEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_LibraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MiosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_MiosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_ScipioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_ScipioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=apm_GroupsSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=apm_GroupsSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700325001456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entity (Details) - Schedule of Aggregate Carrying Value of Vies&#8217; Assets and Liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Assets</a></td>
<td class="nump">$ 24,352<span></span>
</td>
<td class="nump">$ 61,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Liabilities</a></td>
<td class="nump">3,558<span></span>
</td>
<td class="nump">86,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net Assets/ (Liabilities)</a></td>
<td class="nump">20,794<span></span>
</td>
<td class="num">(24,676)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">472,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net Assets/ (Liabilities)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">472,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount', window );">Maximum Exposure to Losses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 472,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net assets (liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479910/205-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph b<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700328857888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OperatingLeaseWeightedAverageDiscountRate', window );">Weighted average discount rates</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss of right-of-use assets</a></td>
<td class="nump">$ 200,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Oher operating expenses.</a></td>
<td class="nump">$ 31,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_OperatingLeaseWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_OperatingLeaseWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700320597312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Details) - Schedule of Operating Leases Obligation - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FinanceLeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FinanceLeaseDepreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 252,345<span></span>
</td>
<td class="nump">349,031<span></span>
</td>
<td class="nump">$ 425,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">65,221<span></span>
</td>
<td class="nump">85,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">317,566<span></span>
</td>
<td class="nump">483,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">389,365<span></span>
</td>
<td class="nump">369,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">49,358<span></span>
</td>
<td class="nump">53,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 338,525<span></span>
</td>
<td class="nump">$ 549,596<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8211; finance leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8211; operating leases</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FinanceLeaseDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation expense recognized during period on finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FinanceLeaseDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700412451552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease (Details) - Schedule of Maturity Analysis of Operating Leases Liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract', window );"><strong>Schedule of Maturity Analysis of Operating Leases Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 120,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">97,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">24,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future undiscounted cash flow</a></td>
<td class="nump">242,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Discount on operating lease liabilities</a></td>
<td class="num">(18,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">224,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liabilities</a></td>
<td class="num">(125,232)<span></span>
</td>
<td class="num">$ (310,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liabilities</a></td>
<td class="nump">$ 99,485<span></span>
</td>
<td class="nump">$ 30,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329218848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Note (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 11, 2023</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Dec. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Original principal amount</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apm_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument conversion price</a></td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes Payable [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=apm_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=apm_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700316171792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 23, 2023</div></th>
<th class="th"><div>Jan. 13, 2022</div></th>
<th class="th"><div>May 26, 2021</div></th>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OrdinarySharesLineItems', window );"><strong>Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherValueOutstanding', window );">Aggregate offering price (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Issuance of expire years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_GrossProceed', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OrdinarySharesClosingPricePercentage', window );">Ordinary shares closing price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price (in Dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=apm_SharesWarrantHoldersMember', window );">Shares Warrant Holders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OrdinarySharesLineItems', window );"><strong>Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,712<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=apm_ShareOptionHoldersMember', window );">Share Option Holders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OrdinarySharesLineItems', window );"><strong>Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OrdinarySharesLineItems', window );"><strong>Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issue</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OrdinarySharesLineItems', window );"><strong>Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issue</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OrdinarySharesLineItems', window );"><strong>Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Issuance of expire years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_GrossProceed', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities', window );">Less transaction costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SharesPrice', window );">Ordinary shares, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issue</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price (in Dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Authorized share capital</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary per share (in Dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional ordinary share</a></td>
<td class="nump">8,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareIssuedToConvertibleNoteHolders', window );">Share issued to convertible note holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OrdinarySharesLineItems', window );"><strong>Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issue</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price (in Dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Authorized share capital</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=apm_EmployeesAndExternalConsultantsMember', window );">Employees and External Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OrdinarySharesLineItems', window );"><strong>Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_GrossProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_GrossProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_OrdinarySharesClosingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares closing price percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_OrdinarySharesClosingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_OrdinarySharesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_OrdinarySharesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ShareIssuedToConvertibleNoteHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the number of share issued to convertible note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ShareIssuedToConvertibleNoteHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_SharesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_SharesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for transaction costs in a sale-leaseback recognized in investing activities. Includes, but is not limited to, closing and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-50<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-52<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-51<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=apm_SharesWarrantHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=apm_SharesWarrantHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=apm_ShareOptionHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=apm_ShareOptionHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=apm_EmployeesAndExternalConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=apm_EmployeesAndExternalConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700326250736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 23, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jul. 14, 2022</div></th>
<th class="th"><div>Jun. 08, 2022</div></th>
<th class="th"><div>Mar. 08, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jul. 14, 2021</div></th>
<th class="th"><div>Jul. 14, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Mar. 11, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Excersie price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,808<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,796<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2033<span></span>
</td>
<td class="text">Jul. 13,  2033<span></span>
</td>
<td class="text">Jun.  07,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 13,  2032<span></span>
</td>
<td class="text">Jun.  07,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Cancelled existing vested and unvested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Deferred cash bonus payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental modification cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apm_TwoThousandSeventeenShareOptionPlanMember', window );">2017 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average grant date fair value of share option grants (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 10.02<span></span>
</td>
<td class="nump">$ 25.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2', window );">Maximum contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | 2017 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares</a></td>
<td class="nump">74,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expire date</a></td>
<td class="text">Dec. 31,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=apm_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation charges (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,446<span></span>
</td>
<td class="nump">$ 1,123,122<span></span>
</td>
<td class="nump">$ 1,203,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=apm_NonemployeesMember', window );">Non-employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation charges (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,479<span></span>
</td>
<td class="nump">$ 523,877<span></span>
</td>
<td class="nump">$ 479,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Deferred cash bonus payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apm_TwoThousandSeventeenShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apm_TwoThousandSeventeenShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=apm_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=apm_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=apm_NonemployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=apm_NonemployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329704416">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Details) - Schedule of the Option Activity - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems', window );"><strong>Share Based Compensation (Details) - Schedule of the Option Activity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share options, Outstanding, Beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">272,126<span></span>
</td>
<td class="nump">127,404<span></span>
</td>
<td class="nump">71,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, Beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21.54<span></span>
</td>
<td class="nump">$ 31.91<span></span>
</td>
<td class="nump">$ 37.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual term in years, Outstanding, Beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10 years 9 months 29 days<span></span>
</td>
<td class="text">11 years 3 days<span></span>
</td>
<td class="text">11 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share options, Outstanding, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">403,820<span></span>
</td>
<td class="nump">153,146<span></span>
</td>
<td class="nump">75,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Remaining contractual term in years, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 3 months 18 days<span></span>
</td>
<td class="text">12 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of share options, Outstanding, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(791)<span></span>
</td>
<td class="num">(6,721)<span></span>
</td>
<td class="num">(19,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="nump">$ 25.25<span></span>
</td>
<td class="nump">$ 36.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic value, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of share options, Outstanding, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(248,095)<span></span>
</td>
<td class="num">(1,268)<span></span>
</td>
<td class="num">(550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21.74<span></span>
</td>
<td class="nump">$ 28.11<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of share options, Outstanding, Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share options, Outstanding, Ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">427,060<span></span>
</td>
<td class="nump">272,126<span></span>
</td>
<td class="nump">127,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, Ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 21.54<span></span>
</td>
<td class="nump">$ 31.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining contractual term in years, Outstanding, Ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years 3 months 10 days<span></span>
</td>
<td class="text">10 years 9 months 29 days<span></span>
</td>
<td class="text">11 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic value, Outstanding, Ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share options, Outstanding,Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">420,157<span></span>
</td>
<td class="nump">89,300<span></span>
</td>
<td class="nump">31,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.43<span></span>
</td>
<td class="nump">$ 32.71<span></span>
</td>
<td class="nump">$ 42.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Remaining contractual term in years, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years 5 months 1 day<span></span>
</td>
<td class="text">9 years 7 months 20 days<span></span>
</td>
<td class="text">9 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic value, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining contractual term in years, Exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700326190704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems', window );"><strong>Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.55%<span></span>
</td>
<td class="nump">97.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.86%<span></span>
</td>
<td class="nump">1.64%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor', window );">Dilution factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems', window );"><strong>Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">170.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term from grant date (in years)</a></td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor', window );">Dilution factor</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value (in Dollars per share)</a></td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 9.74<span></span>
</td>
<td class="nump">$ 25.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems', window );"><strong>Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term from grant date (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 28 days<span></span>
</td>
<td class="text">6 years 4 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.16<span></span>
</td>
<td class="nump">$ 26.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilution factor used in estimating the fair value of stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700323932192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-Controlling Interest (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 30, 2021</div></th>
<th class="th"><div>Jan. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonControllingInterestLineItems', window );"><strong>Non-Controlling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsUnitsIssued', window );">Share issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAttributableToNoncontrollingInterest', window );">Total deficit value (in Dollars)</a></td>
<td class="nump">$ 67,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_MiosPharmaceuticalsLimitedMember', window );">Mios Pharmaceuticals Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonControllingInterestLineItems', window );"><strong>Non-Controlling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="nump">97.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit', window );">Total deficit value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apm_ScipioLifeSciencesLimitedMember', window );">Scipio Life Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonControllingInterestLineItems', window );"><strong>Non-Controlling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="nump">97.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=apm_AptorumMedicalLimitedMember', window );">Aptorum Medical Limited [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonControllingInterestLineItems', window );"><strong>Non-Controlling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=apm_AptorumMedicalLimitedMember', window );">Aptorum Medical Limited [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonControllingInterestLineItems', window );"><strong>Non-Controlling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=apm_ClarkChengMember', window );">Clark Cheng [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonControllingInterestLineItems', window );"><strong>Non-Controlling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=apm_ClarkChengMember', window );">Clark Cheng [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonControllingInterestLineItems', window );"><strong>Non-Controlling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=apm_GroupsSubsidiariesMember', window );">Group&#8217;s subsidiaries [Member] | Mios Pharmaceuticals Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonControllingInterestLineItems', window );"><strong>Non-Controlling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting power</a></td>
<td class="nump">36.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=apm_GroupsSubsidiariesMember', window );">Group&#8217;s subsidiaries [Member] | Scipio Life Sciences Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NonControllingInterestLineItems', window );"><strong>Non-Controlling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting power</a></td>
<td class="nump">35.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fresh-start adjustment to retained earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NonControllingInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NonControllingInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units of other ownership interests issued in a limited partnership or master limited partnership. Does not include limited or general partners' ownership interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all Partners' Capital (deficit) items which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_MiosPharmaceuticalsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_MiosPharmaceuticalsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apm_ScipioLifeSciencesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apm_ScipioLifeSciencesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=apm_AptorumMedicalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=apm_AptorumMedicalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=apm_ClarkChengMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=apm_ClarkChengMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=apm_GroupsSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=apm_GroupsSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329396576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 23, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NetLossPerShareLineItems', window );"><strong>Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Share options and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293,723<span></span>
</td>
<td class="nump">54,054<span></span>
</td>
<td class="nump">54,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NetLossPerShareLineItems', window );"><strong>Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NetLossPerShareLineItems', window );"><strong>Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NetLossPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NetLossPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700436849072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of basic and diluted (loss) income per share - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract', window );"><strong>Schedule of Basic and Diluted Loss Income Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to Aptorum Group Limited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,824,647)<span></span>
</td>
<td class="num">$ (9,799,560)<span></span>
</td>
<td class="num">$ (25,048,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_WeightedAverageSharesOutstanding1Abstract', window );"><strong>Weighted average shares outstanding(1)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,521,133<span></span>
</td>
<td class="nump">3,569,484<span></span>
</td>
<td class="nump">3,503,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,521,133<span></span>
</td>
<td class="nump">3,569,484<span></span>
</td>
<td class="nump">3,503,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract', window );"><strong>Net loss per share attributable to Aptorum Group Limited(1)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (2.75)<span></span>
</td>
<td class="num">$ (7.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (2.75)<span></span>
</td>
<td class="num">$ (7.15)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#8217;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_WeightedAverageSharesOutstanding1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_WeightedAverageSharesOutstanding1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329210752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstart]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700443943168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract', window );"><strong>Drug molecules: up to the conditions and milestones of</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_PreclinicalToIndFiling', window );">Preclinical to IND filing</a></td>
<td class="nump">$ 132,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FromEnteringPhase1ToBeforeFirstCommercialSale', window );">From entering phase 1 to before first commercial sale</a></td>
<td class="nump">17,376,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FirstCommercialSale', window );">First commercial sale</a></td>
<td class="nump">11,882,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_NetSalesAmountMoreThanCertainThresholdInYear', window );">Net sales amount more than certain threshold in a year</a></td>
<td class="nump">44,769,231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal', window );">Subtotal</a></td>
<td class="nump">74,160,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract', window );"><strong>Diagnostics technology: up to the conditions and milestones of</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_FdaApprovalObtaine', window );">Before FDA approval</a></td>
<td class="nump">208,656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_MilestonePaymentsTotal', window );">Total</a></td>
<td class="nump">$ 74,368,912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FdaApprovalObtaine">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>FDA approval obtained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FdaApprovalObtaine</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_FromEnteringPhase1ToBeforeFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>From entering phase 1 to before first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_FromEnteringPhase1ToBeforeFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_MilestonePaymentsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_MilestonePaymentsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_NetSalesAmountMoreThanCertainThresholdInYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales amount more than certain threshold in a year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_NetSalesAmountMoreThanCertainThresholdInYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_PreclinicalToIndFiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preclinical to IND filing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_PreclinicalToIndFiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surgical robotics and medical devices up to the conditions and milestones of subtotal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700321864880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139700329570736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_OutstandingSharesPercentage', window );">Outstanding shares, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_sharesOutstandingPerentage', window );">shares outstanding perentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apm_sharesOutstandingPerentage', window );">shares outstanding perentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Ordinary Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Ordinary Share issued</a></td>
<td class="nump">1,796,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesOutstanding', window );">Ordinary share outstanding</a></td>
<td class="nump">1,796,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember', window );">CGY Investments Limited [Member] | Forecast [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Ordinary shares</a></td>
<td class="nump">401,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember', window );">CGY Investments Limited [Member] | Forecast [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Ordinary shares</a></td>
<td class="nump">533,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_DSFInvestmentHoldingsLimitedMember', window );">DSF Investment Holdings Limited [Member] | Forecast [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Ordinary shares</a></td>
<td class="nump">45,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_DSFInvestmentHoldingsLimitedMember', window );">DSF Investment Holdings Limited [Member] | Forecast [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Ordinary shares</a></td>
<td class="nump">45,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_OutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_OutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apm_sharesOutstandingPerentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>shares outstanding perentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apm_sharesOutstandingPerentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of excess stock held by shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_CGYInvestmentsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_DSFInvestmentHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apm_DSFInvestmentHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>120
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%Q3]%__/ZBRS#Z=&])HR4+9'Z9! Q_!Z)J=^)N^B]^Q5T;O7=GU?VL:X^W*
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M"5YV7^5$LL(T,'=,JG;(#%/5L0+7 '5]R9A\FNB>J.Z!HW]02P,$%     @
MS4N>6.%N!NK/"   72D  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6RM
M6FUOVS@2_BN$][!H@2862;UF$P-IK.OVT%Z#I+G]<+@/C$7;0F712]).N[]^
M25FQ;&G$.#U]26QYYA&?T7#X#,7+)R&_J27G&GU?%:6Z&BVU7E^,QVJVY"NF
MSL6:E^:7N9 KILU7N1BKM>0LJYQ6Q9AX7CA>L;P<32ZK:[=R<BDVNLA+?BN1
MVJQ63/YXSPOQ=#7"H^<+=_EBJ>V%\>1RS1;\GNN']:TTW\9[E"Q?\5+EHD22
MSZ]&U_@BI8EUJ"S^D_,G=? 962J/0GRS7SYF5R//CH@7?*8M!#/_MOR&%X5%
M,N/XLP8=[>]I'0\_/Z/_LR)OR#PRQ6]$\4>>Z>75*!ZAC,_9IM!WXNEW7A,*
M+-Y,%*KZBYYJ6V^$9ANEQ:IV-B-8Y>7N/_M>!^+  =,>!U([D+9#V.- :P?:
M=O!['/S:P3_5(:@=*NKC'?<J<%.FV>12BB<DK;5!LQ^JZ%?>)EYY:1/E7DOS
M:V[\].1&E$H4><8TS]"]-O],%FB%Q!Q]67/)[--4B)49NA$KDXI+FR-;CCX)
MI= 9>KB?HC?_>'LYUF8L%G$\J^][L[LOZ;DO)NBS*/52H;3,>'8,,#8D]DS(
M,Y,;XD2<\MDYHO@=(AZAP("FI[L3P#T]W1T[V-#]<Z$5'NW!N^-;7FXX%-B=
MHP\[VL)RH=9LQJ]&YG$I+K=\-/GU%QQZOT%!&1(L'0CL*&#^/F"^"WWR.V>%
M7LZ8Y,A"YS.N4%[.Q J,X0XKK+!L+=U.?(II%%^.MX?1Z9IAD@1QG!S;I8!=
MX./H .^(4[#G%#B3H)Z!Y0+Q[V9E4%Q!7((A\V%(L'0@L*/8A?O8A<Y\N!%*
MVRJV[.8%%,0=6'#P!,]\XL68M#("L,,$!S'Q6RD!&?I!DAP8'O&*]KPB)Z\[
M$RDF9\NJ)F>F2A1B;4NV,T6B[F "G,24M!)Y"A@F!"=!$K3H 8;8B\,D] G,
M+][SBYW\/O#2)'U1T6.96?%RI>TD,&O.G,/L8F L"?5"&K78 88!(9[OM=E!
MAKYG,'O()7MRB9/<)[ZHJ:VEF'-EY9:YT$<LZ0Z#!#3&(6X1@PSC.,:^UR(&
M&88XBFE/5F*OT1&>D]H7O>02B9,J5@W5RIXP"I/6>*>0I1FP1UN5.H4,:4("
MC'N('0@D["3V56CSB$XDA@%B& =!V)EIH&D<>X'GD38WP)1XD6]F)NUA1QIV
MQ+W$5(]MMU"B-\_<WKY#)=<@0S+D:C,H6CH4VG$H&\6&G?IF4DEBT_ODY98K
MO9/1>6G$NOS&-7LL[ (TV\A<YUSUQY="%3@,V]D#F&'J8]I>AB##V*/XL*(?
M\VT$%W8KKH?2=*9%_I=I'!:F(T5S*59HSG*)MJS8<#1;LG+![1IL<@P5HER<
M:2Y7A_'I#X/?&79(3>F+VPH-, P".XUP.Q!.,G!R(%=>-"(..W5.7UYD7.;;
M:F&#2\E/B"<$SK&!@-(:J*61#K3P<7P:H8;=2NV#31X3GXVJDB7+%[FMN&:J
M2%[.\I[P.#%?$YZ!@%+<57Q^@GLZ -S(/>S6>\_1,>G"9V)1YM7^BHE3*<JS
M>5XR$R*K*93B&HZ4$_\UD1H(*,5=\1B99<_K"56C'+%;.GXL37TQ4VR_CKVM
M%[;^,@-)1X*-4&^7F:XA]L.@78Y2"#"AH=>G0AKAB%]0CG41R7*U%LH*DCE2
MFT>59SF3?7/$"?F:)S\04(H!_4E#VC-)2",^B5M\WF_*3/YP]/ND*P_-$A@E
M;54&V-&8!EYK_4TA/#^D?M3#I%&;Y"2U^4I51KH*T425DJBM&P##((E]#[>7
M2\#P+$J\, [Z'E8C.8E3ATW^S;51 PI,V=KU>(VAIO6*VC,2LC1*VRC^CGZ&
M3$ED9CE)>O0S:40?<8N^9S*(:2WSQ\U.Z&E1E>>9*+4416';AKPN3C#MKDK#
M 0XI:<L=R# B0>!W.'<-B1<&B=?3Z)%&]A&W[.ME?+W60FY6Z(,4FS7ZE*]R
MW=[8K=EVM\M,NTK\T&\W[)"EG;5!V&YL0<S \V/:)U!((^"(>QMNS]CT@$@M
M[5;2SW,?=+=N4+1T*+3C,#<ZD+AUX!EZSU0^0V^,X)F:6</D0<2A5PSO7P#\
M+_X?^ AV7O%AJGCG87NG#S(CY^TZE$)FT3GNZ:Y(H_N(6_>=H6E>;.Q;F5?$
MPPW9%X_HM'@ 9E \ #-'/!IQ1V+G)/RC>N7'LS.VY9*9OK(*@]%$&ZTT*S-3
M8T%R3LGXZODV)%HZ%-IQ1!M)2=R2\G"^W5?!A)/*C=*75%VEYP=&65/:3JNN
M(0W"Q(_;.QF@H4=I$L*I11OU2-WJ\7BJ.4+Q DY/*&A7*\*A  SA4("&KE T
M\I.ZY:=+F]6N1TLLK,T@RQYM!IFZM1EMA"8]96]S=O3>^HUE]];1*=!!-S@'
M14N'0CN.Y\$K:;?63;_76WI9/I]SNSG#JYY42U:J@CUO3,R%-+6Z?-XR%R6<
M3<#&I._[M/T& +"C04S:#1D$%P2T;]VAC=RE;KG[<TG4W96$R77M0'( G(M<
MHVRI>VOR^$Q'[\2'-OYH''3>FTTA2S.7XZ33B::0J9GX81)Z/1TF;90D?>G=
M;YO6_]>>T>[6'MR>089@>P88.MLSVNA&ZA9Y)W"WV_&5>EJ*(N.R.NQS<@-3
MW[[5O(6)%[6;-\@RB4(:=5Y2@)AFL:!1;SRL;CR^TN@>^J)B0==%<=C-K<3&
M[LK;%[-=66D+&F([AUQD"BV-!$6/G-N3<B:!=F?=BA_(YD]UCLK$6/*Y/0N'
MKF^_?KE[^(P^W'UYN$6?/G[^^#6=_OI+3'#TFT*XPL:>,3>J5IG'HL7L&U+K
M(M?OT-,RGRW1$U.(FWI;W<66VW^Q<L/D#T3H[JS3.53<QP='PE9<+JJS>,K4
M,4-T=ZAF?W5_WN]]=<JM=?T&7Z08N'Y-XXNI>0S0+XGYI3HZ.&YNO3MX^)G)
M15XJ5/"Y&89GVH<1DKNS?+LO6JRKPVJ/0FNQJCXN.3-9:@W,[W,A]/,7>X/]
MB<K)WU!+ P04    " #-2YY8G<"3RE$,  !J90  &    'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;+6=:W.C.!:&_XK*LS75735NHPNWGB15N=C U/9TJB^[
M'[;V [&5F!T,'L!)][]?@=W&2$*8S)E.52>VI>=@Z442+P>X>,F+/\HUYQ7Z
MMDFS\G*RKJKM^]FL7*[Y)B[?Y5N>B4\>\V(35^)E\30KMP6/5TVE33HCEN7,
M-G&23:XNFO?NBZN+?%>E2<;O"U3N-INX^'[#T_SE<H(G/][XE#RMJ_J-V=7%
M-G[BGWGU=7M?B%>S(V65;'A6)GF&"OYX.;G&[R/FU!6:$O]*^$MY\C>JO\I#
MGO]1OXA6EQ.KWB*>\F55(V+QZYG?\C2M26([_CQ )\>8=<73OW_0%\V7%U_F
M(2[Y;9[^.UE5Z\N)-T$K_ACOTNI3_A+RPQ>R:]XR3\OF?_1R*&M-T')75OGF
M4%ELP2;)]K_C;X>&.*F :4\%<JA I J$]52@APKTW KL4(%)%6A?!?M0P98C
MN#T5G$,%1ZI@]WUI]U#!/7>3O$,%[]QF]0\5_$8.^_YK.O\NKN*KBR)_045=
M6M#J/QH%-;5%GR=9+?;/52$^342]ZNHVS\H\359QQ5?H<R5^"257)<H?T>=U
M7/!UGJYX4?[\DT>P^RN:_[E+JN]HBKY^OD-O_O'V8E:)C:A1L^4AX.T^(.D+
MF,9EB:[1QV*59&+WVH<I-:"[<T W9X#F9M#U:I74.UZ<HOLX64V3#-W&VZ02
MKZ\W^2ZK-,C% '*YW&UV:=.H8L]+EDG5SPK.9^75FA=HF6_$P+:N1YQGCMZD
M>5F^14DFWN;]44)SE-_S;"K 657DJ?CL2? J+II32*$7&9F17W+1A-UJ,Z'.
MHT3)4:*DX; >SDV<QMF2H[A"=WSY#E'\"R(6L73:VY.<AE2/\\]7&-L>HX1=
MS)Y/M:46)(11U[6E@G.U(/4(<WV+=@LNU()3:C'/Q\3IE@S4DC8EOE0JU/$<
M#WNVURT8Z;80VX3X[19VVIT>VYV>U>YOQ ZQW[?>GM,'-V;J?_!_=1VWKV2K
M'2?UFUINWV]2Z\V-&U&O(-Z7VWC)+R=B3RIY\<PG5S__A!WK5]W.#@D+(&$A
M)"P"@G7$QHYB8T991&6Y:]0F)I[SIXA;IN[OU'-]8DNR,0;7?S6DFTF8*C\'
M$\N5XBV X@5 G!"($ZG?GUG-/_U08Q][W_ZKO7\Z#.E&'7. GE''5D>=6C[2
MT'YG9(]0SRLX_8,2)"R A(60L @(UI&E<Y2E<[8LR[T*JQQE8JFD6RGI!&;D
MGZ^<.R#.W%$$[SBN)R]E@*(%0)Q0W>JI@QF1-CM2B]G4Z1F9W*,$7*,$[I)R
MFY?B4*"6P.ZA3%9)7"1""+MLM5^*;\0A^T$.J"KBK(R;PWB=&HRA1J@!B#-W
ME0:C%F78E^0 %"Y0PTUMZLGK7DTIVIUB]KVM*8=]Q]5WMW?L;N]5W:WK32-I
M1&\"<>9 G 40)P#BA)[2T:[O2,<%T4"ACAC\HQA\HQB:U<:TMM)6S3&W..".
M^W9M(VF$&( X<U]=V3CBN-61]J(%4+P B!,"<:+A[]^1!+9:O\PRBF+^C1?+
MI&S6!"]Q(0;\2CLZ'#"GAR9,'<7NS-%&=/@!=/J-?<O"TGZR@(H70(%"*%"D
M:0%,.TW0[?(3BQ2/[O*APY$!9,_QR*&6?'PE:\;('J.95X#Z#TA :0$H+02E
M15"TKAY;/Q2;#=%3/>;;>D;2CT :,]2WL.W+<C)&&R,GHB[ +68YLCD"%3"
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M\^2T.ZB( 10HA )%FC9P3/=+H*W33<V6]$#O#XY/KS*\J<;P)K;FJC8S?O0
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M0'S^F.?5CQ=U@./C5:[^#U!+ P04    " #-2YY8P$ZZK,$-   23P  &
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MEK9-QK+J'/-8E$IW\93,":(J7Z.[M=4EN7U4DYC8Z\FP/RH-X7#QV"F6XOO
M1V+=<C\PU#>I(?U Q_KL?OUXC&"SDPE60-GPD5KL)^]XLG%O1]S!5A@W4A_'
MTD#RGHMP/&SC@Y 1-[779XPX*@<U/)]4J W[#7+HX%3@5,"#0.O9H4/??'0"
MQT%C$[\SF),(D [CP]/A4^8RG>#OEZ?OH _2;120TE3!=#$[?3D1+GU;I)M@
MVWB>SVW UT&\K/$Y1HX7X'UE;=C?<(#A V_]#U!+ P04    " #-2YY8YI[2
M=W\D  ")<   &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*5=6W/;QI)^
MGU^!\CE[RJZB:$NV8R=.7"7+EVA/[+@B.ZFMK7T8 D-R8A!@,  EYM=OW^8&
M@K)R\A!'(H&9GIZ^?MTS^OZZ[;ZXM3%]<;.I&_?#O77?;[][^-"5:[/1;MYN
M30/?+-MNHWOXM5L]=-O.Z(I>VM0/SQX]^N;A1MOFWLOOZ;./W<OOVZ&O;6,^
M=H4;-AO=[5^9NKW^X=[I/?_!+W:U[O&#AR^_W^J5N3+]Y^W'#GY[&$:I[,8T
MSK9-T9GE#_?.3[][]02?IP=^M>;:)3\7N))%VW[!7RZK'^X]0H),;<H>1]#P
MOYVY,'6- P$9?\B8]\*4^&+ZLQ_]+:T=UK+0SERT]6^VZM<_W'M^KZC,4@]U
M_TM[_:.1]3S%\<JV=O1O<<W//GURKR@'U[<;>1DHV-B&_Z]OA _)"\\?'7GA
M3%XX([IY(J+RM>[UR^^[]KKH\&D8#7^@I=+;0)QM<%.N^@Z^M?!>__**-Z-H
ME\65735V:4O=],5Y6;9#T]MF57QL:UM:X[Y_V,-\^-;#4L9^Q6.?'1G[]*QX
MWS;]VA5OFLI4^0 /@=! [9FG]M79K2.^-N6\>'PZ*\X>G3V^9;S'8?6/:;S'
M?WOUQ?^>+US?@1#]WQ0C>)HGT].@8GWGMKHT/]P#S7&FVYE[+__UC]-O'KVX
M91%/PB*>W#;ZRZO/[]^?__(_Q<]OBZO+=Q\NWUY>G'_X5)Q?7/S\^<.GRP_O
MBH\__W1Y<?GF:HKRV\=^/"_N/GSQL;--:;<UL LX2DMM>LW:UU1%V38.V%GQ
M)Y_6)OG$5,72-AI>UW7AX"4#FM_3.#T\^*YKAZW2G?&CPO,P!GZER[(;X"70
M34O/Z[A[MJ'?N@H&-J!9_3K]=AO)79G&=+JN]_B]V>+PEH?_W%C\[0I)HN'/
M-Z8#,5'W__6/YV=GCUY\GE_-BW?GYQ_I]],7#VBMVZ%S \I2W](PW8#3X#>=
M60TUL2"LCH:X,N70V=[*8V]NRK5N5J:X:#<;Z\@(WL>'9=JK-Q=^PIG"%V M
M]5 9SQ-<9)@ QMCJ9C\K+'Q6V0Y,8L'OR"_7ZY86#Y]M].\MT %*<=W PMVP
M<+:RN@/"YL7E(4-Q_&W7[BR2Z!1R*+(8V-94NJL<D%"1>M'>>]Z=7X5%%,]/
M'\W@J41$9L5U)B) WK[8 25Z41N@O3<@"WT!TH#D^C%_O7SCQT1BKM>V7.-
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MU& 0;!UC(=F2H:,EHO0 ;W!F?J<X>(=G(1-Y5Z5#>;N&Y!#_#Z$4& @BQ=Q
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M0QH3XBY0";;]*!L-AIP8+)+1.S+NL6%X/@MO<T;JC2F9H<JI4KLU2W)B?Y,
M#@/S=G#DD2'7:KLD*<!WBR4H*7P&DWPQ?;!N,V]T,'6AO!",RHE$/7F@ U^K
M-*% \GV4Y0UD;MPFV$V)Y)W,,LFY2M,@!B(3CR;)+1,.!*4",Q/6#F!60'M
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MH93G,&01A&?O^Y'T:%8I_!.(A?A%<1]H1(%"#M$V "\>J$1?<Z9;1YD,S+K
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M76K -U@5Y1./6/]L&<0-1Q"//L'@O@<$&T>['(*DNPSM90@COLJ7/)+R$#9
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M&K(2? "^7[:P<_(+3A#^^N#+_P=02P,$%     @ S4N>6'$Y!O:> @  F 4
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M%IH6X/E4@?#J&U+0OK([_S=02P,$%     @ S4N>6# #+'A& P  1 <  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULG55M;]LV$/[N7W'0@GU2K1?*
MLI+:!NS$6PHLK>%T'8JB'VCI9 N51(VDK>3?[TC9FKNF#K O$E^>>^ZY._(X
M:87\IG:(&IZJLE939Z=U<^-Y*MUAQ=50-%C33BYDQ35-Y=93C42>6:.J]$+?
MC[V*%[4SF]BUE9Q-Q%Z718TK"6I?55P^+[ 4[=0)G-/"NMCNM%GP9I.&;_$1
M]9_-2M+,ZUFRHL):%:(&B?G4F0<WB\C@+>!3@:TZ&X.)9"/$-S-YETT=WPC"
M$E-M&#C]#GB+96F(2,;?1TZG=VD,S\<G]M]L[!3+ABN\%>5?1:9W4R=Q(,.<
M[TN]%NT]'N,9&;Y4E,I^H>VPT<B!=*^TJ([&I* JZN[/GXYY.#-(_)\8A$>#
MT.KN'%F5=USSV42*%J1!$YL9V%"M-8DK:E.41RUIMR [/?N@=RAAC2D6![XI
M40&O,UA);/@SY5ZKB:?)C0%[Z9%RT5&&/Z$,0G@0M=XI6-899M\3>*2O%QF>
M1"["BXQWF Z!!2Z$?L@N\+$^:&;YV/\-&K[,-TI+.C)?7XJ_8X]>9C?7Z$8U
M/,6I0_=$H3R@,_OUER#VWU[0'O7:HTOLLP\?[Y=K6"]OE^\^S1=_+!]A_OX.
M5NOE:O[Y8?G^X^-+@B]3QD-XE16ZG,G_Y*PYRQE7('*@6F&U(>BI7A9'@W"0
M"KK+2F-&N)O!=\#SR< 6HLC )(_+=&<9,CQ0!VF,*\ GZDF*)%Q!D(S<F#$:
M,7_D!N.DMRYJM9>\3A$8<Y-@!-'831CK]TUA"MK-$2&*7>8S"*+$95$\6),3
M7I++1JB"(@O\T W\:PAB-[R.S_196*\F("D)@S>#'W,5AFXX'E$:(G<\"CN
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M/.QPXU^S^PNG%_1J^T8[IS/Z.)<"GGIP 'P_T]I5%[A _;<.I_\'4$L#!!0
M   ( ,U+GEC:=]5QA T  /@G   9    >&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;+U::V_;1A;]SE\Q<)TB!FA9I)YV'H!LITU:.PUL=Q?%8C^,R)$T#<GA
M#LG8WE^_Y\[P*5.RLUTLT,84.7/?CW.'?'NO]-=L(T3.'N(HR=X=;/(\/3LY
MR8*-B'DV4*E(\&2E=,QS_-3KDRS5@H=F4QR=^,/A]"3F,CEX_];<^Z+?OU5%
M'LE$?-$L*^*8Z\=S$:G[=P?>077C1JXW.=TX>?\VY6MQ*_+?TR\:OTYJ*J&,
M19))E3 M5N\.%M[9^9C6FP5_D^(^:UTSTF2IU%?Z\2E\=S D@40D@IPH</SY
M)BY$%!$AB/&ODN9!S9(VMJ\KZC\9W:'+DF?B0D5_EV&^>7<P/V"A6/$BRF_4
M_4=1ZC,A>H&*,O,ON[=K)^ 8%%FNXG(S?L<RL7_Y0VF'UH;Y<,<&O]S@&[DM
M(R/E)<_Y^[=:W3--JT&-+HRJ9C>$DPDYY3;7>"JQ+W]_(R*>BY!]X3I_9.<\
MXDD@,L:3D-UIGF3<&"][>Y*#&6TY"4K"YY:POX.PY[-KE>2;C'U(0A%V"9Q
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M2NO;/U0Z^@1SSPL8+>/07,Q-NHR"O<W6VFW2T'>=(6MWOF+U?/6:G7US5H=
MX5FF03 NJFD$]H*'&N]9.RIL86;_$N9M[0W2: OI-$U]AR[4<T"[FQKJM@,S
MV<Y>,L-<!H\/R7AD83"<MUNG(VJR]5E=_A6,\L7""# >FH ;\TQ-L^*J\D5-
M)X6&]8E;:XY4X#BI0G"D)XWN 0-3*U=^&O8GV*::S/:B:!KTO>_H^B <"X\'
MT4M:3*)'[;#!_(>-3^+D=(R+)#X]/:<'P_CLXF1'8MQ*3$;Q)!GBXGP2)\,)
M+HZ@9'(V8<?_;X0.1V5KQOW[&!FAR,IFLM]S2FLGA-W3$I4%2.) 9?0/1YT]
M\">95_F!X'_7_3L0\I.S<3RY.*U7;NZ:J\>=Z.3!-DT7VE;&AX$&##8W.H^D
M:\\:OF']<:,JMD)* 3/"']@+%TXY" N"0"^]JM!PS<E*%FEEB/+E?!-PVA(Q
M?WB-,<@YR-#K.9=FDWBO/0PJP 4['A;R56OY2QC=; 2,Y[HB2!EDR9W67"!E
M?YJ>5ZHF%O!ZUM_WG6'0^22$(\_"?_BBNH+R\'6H?=I^6YN&3TJ;Y>'#W ,W
M"PFF5V(.T6'_[+07YJ'FQNG2?V"::>=T[B^7@F.+I 5X/]<8Z^L;,M!^<;SY
M'U!+ P04    " #-2YY8<%8O07,%  !7#0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6R55UMOVS84?M>O.'#38@/DBVZVG"8&<FFW NT:-%W[,.R!
MEFB+J$1Z)!7'^_4[AY(=.7:,]<$R2?%\YSM74A=KI7^8@G,+CU4IS66OL'9U
M/AR:K. 5,P.UXA+?+)2NF,6I7@[-2G.6.Z&J'(:CT7A8,2%[LPNW=J=G%ZJV
MI9#\3H.IJXKIS34OU?JR%_2V"U_$LK"T,)Q=K-B2WW/[Y^I.XVRX0\E%Q:41
M2H+FB\O>57!^'=-^M^&;X&O3&0-9,E?J!TT^Y)>]$1'B)<\L(3#\>^ WO"P)
M"&G\TV+V=BI)L#O>HK]WMJ,M<V;XC2J_B]P6E[VT!SE?L+JT7]3Z=][:DQ!>
MIDKCGK!N]@:3'F2UL:IJA9%!)63SSQY;/W0$TM$+ F$K$#K>C2+'\I99-KO0
M:@V:=B,:#9RI3AK)"4E!N;<:WPJ4L[./'$VZ&%J$HH5AUHI=-V+A"V)!")^4
MM(6!=S+G^3[ $#GLB(1;(M?A2<1;G@T@"GP(1V%T B_:&18YO.B48?#7U=Q8
MC:'_^YB-#4)\'('*X=RL6,8O>YCOANL'WIN]>16,1V]/\(MW_.)3Z+./[Z[N
MWQTC=5+L.*D@'H##@RL#:@'H2U[-N=[YTP=;</A-JWH%!3-@UPI*)9=]RW7E
M885K9H5<0DE.,X"U#B6;*UQ56N "DSED2$5DF)ZVP&JD>B<) C# 'U="TW2A
M544:8U2(VI8%3<9.GL':E0C'X0,J7/(.C%/L$1CQ#P93V'"FS0"^/Y?)A<E4
M+2T@.616&WPGI+,O8V56E\Q5.Z+0TC/3H!1L+DIA-R ,I*\''I:VVTCJH#OQ
MF@3*E+'>>R&9S'B+04OGWBU'_V>BT78&??S%$S\-4N^#1#NXL8 O]K62*_L0
M^'&4>)^?,2-4")/0C^($HGCJCZ+ NR^4MBY(W5WCQ _# -+$3Z:I]XUIA"^[
M[%!)W[NOY\V*D)FJN%O[JBPKNQO/,$4F?C(>$_TT\M,T]#ZC"S1*-1T?S?-N
MF"E@Q43N,H-5Y']#N&6=/[F_0M@:0\HQ..C^ ],[)F<$N, #P309<Y"!R"N=
M^M$XH=%XZB>CI(W",?%%-S[D8G1?E*2>.V+Z:M''+ %F#$?6:FXQYQK6_#$K
MF,2D(K,DGB OI0L%+HI2/PD32! \F8Z];6;V7\AF5QKPYE4:!L';0XK]GP0X
M<-&N2' 4-*-#R+UJ>9G,:P@'";S^O_('7-+!"#&:YUY%<3H=CO4C)D%4F%*:
MTL4KE7&-ZPSO$OXT&%/IZ"/!6V/OPJI32RG^;4*H7+(^$<).A#<&:EFFT_,R
MA;>('*LRQT5FVVZA]89$FGQ&]1X[HA3U84LA084MK D,,FV[8<4V()6%.7>\
MR&M8=0.XRG-!I</*<M-MONB3<N,"BR%P;:V%9$O-F]+!7#Q!Q/5<1>Y3BX7(
MN _K0F34D0W>0QJ?L*Z/&M?*9YH[+?*()DMM C5Y9QBP430ZY>C!7L#-"Q$/
MW1& @Z#KC1P["GEO1Q=W;3IYX<ACXR#9K1V8D2MEL(LA_2,I,H"OU(J8K35U
M>881V!CADNL@:[N]B1T_..F88'0@EM1MJ.L_;?"^[.H5D87*G?$TW=OE3L,S
M",*1GX8Q31.88L^- \^=C6'L)Y.H;<V+&HESJ.6V\-"7NVZ'6T-_&J5X-!ES
M#K?;VJ18GFA<OP2I.R]^]>[HQH "#ZRL^1&7[(F%2&P23%IE-[76)+K" ZE-
MGM,Z0SRDHA"5_J%D/_LYZ3.83OTX3>#8/6O8N>Q67"_=E=Z <T5S[]VM[KX:
MKIK+\M/VYI/C$]-+(3$1^ )%1X-)TFMR:CNQ:N6NSG-E\2+NA@5^^7!-&_#]
M0BF[G9""W;?4[#]02P,$%     @ S4N>6!NQ[$].!@  ]A$  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&ULK5C;<MLV%'SG5V"4-./,J+K0=N+&EQG;
M<=MDDM@3.^E#IP\0"8EH0( !0"OZ^^X!2%JR)=7)Y$$V"0('>_;L65Z.YL9^
M<840GGTKE7;'O<+[ZM5PZ+)"E-P-3"4TKDR-+;G'J9T-764%S\.B4@W3T>C%
ML.12]TZ.PMB5/3DRM5=2BRO+7%V6W"[.A#+SX]ZXUPY\E+/"T\#PY*CB,W$M
M_*?JRN)LV$7)92FTDT8S*Z;'O=/QJ[,]FA\F?)9B[I:.&64R,>8+G;S)CWLC
M B24R#Q%X/AW*\Z%4A0(,+XV,7O=EK1P^;B-_GO(';E,N!/G1OTE<U\<]PYZ
M+!=37BO_T<S_%$T^^Q0O,\J%OVP>YZ:8G-7.F[)9# 2EU/$__];PL+3@8+1A
M0=HL2 /NN%% ^9I[?G)DS9Q9FHUH=!!2#:L!3FHJRK6WN"JQSI^<&WTKK)<3
M)=@'X\71T",J71MF382S&"'=$&&<LO=&^\*Q"YV+?#7 $' Z3&F+Z2S=&O&U
MR 9L=]QGZ2C=W1)OM\MQ-\3;?62.[._3B?,6@OAG7;HQV-[Z8-0DKUS%,W'<
M0Q<X86]%[^39D_&+T>$6J'L=U+UMT4_.+S]\OOAX\^;LW07[<'ESL0[?]@CC
M_0&['X5=:@9213D1EOT6>$W[S!>"_6%-73&AO; B9U)[PWCB1%9;Z:5PK*IM
M5D#TC,^L$&A&#WWZ@IT*G1EV([)"&V5F-/6=+*5'D)UG3P[2='08IH3C\>'S
M ;NJK:LYUF,+VGGK)OVX02*[BU+/&&?94B4U55+J$,Q8.9.:*U99J3-9X8B7
MIL9N9LJ>[O9'HQ']V Y-;O"!D$!$D,0=SAO,6+G$I$MJ'>"*O+\"(?!%(<]-
M67&]H"CCEX<.;@5]R8SH.%?<.7;*+FT.A';!K@N.RXS[D&.D*"PR%?G4&@2.
M%?P6["0P(>)LP7(.7$@-O5?&WG/UY%\87<MN1WZ(++[Y:*-]<#BIE8+9RU!S
MYYEM8KW\A560!]>Z+C%/YQW?P8#!;!;F/1VG@]$HH;D/<G.46\R@H82&E&H2
MT,Q,E)SQX,= :D7%%P'O@[K1_AU$[.H?E,6$TM_C!'K(N"L@"#JLM14SZ:*X
M-Q4"4RG1<H+1  R[N3HKJ$+K:IM+EUD12_5&LU- 5PDY52-:!F?1;BHL;4H!
MYH51]\%3F>8F%,:2;B5XAM=;%YFG9>NOLRG*MVA5V.S0QDZB7DF5Z7Y4_(:L
M!V0);VLM6'H0?7:S'RRU:K+)#_;N$'YWJ].4N_R [G][/OG1GH\9(]LU31_+
M5%F3"9&#9VO* &UU#9MSQVI'Q!L8I?=8PR%DQ:D8%;=0HC*\:>-[:V%G/]])
MDD:G80?DD*-AF^4KEK**I?44]GA/N:O1&C])?MQ/=F$G[*?92?)H.[E7G.@G
M[*?[2?(]?E*6(I?8&"T^-0I/S-0#@7Q'+1496P7>WZ32>TZ1!(V-N[[8Y@S7
MHO+Q:6$\WFX/"=_>WM$>WM*XT/!+DE 8/S>V,C8P%&,K;F=4G5#TJ..V4@UE
M?8K?.<N\D""U0Y4X+&G-"N V/2KP&:#-J+;?X1O@8ZEU5GUC]5I"_O6HSM[X
M8 "IKNU-7T!!L)!TKVW0SJ,Z==!$-)ORA:EG15)74'407Q/AKHNQAPL#EMY;
MB-#0U<V]1]BR)7\E/ZC2XLXD%/#MC-/G+1*,EL:2*<?M0H#&/Q+$+FM?@V@0
MXU#\=<1U/?W 2%XL&<DV'TD'>VF8N<8VD&RRDNR61X]U>>.^/*E]JZ&,)-ZV
M=15"!4U+CT2!?(*H7.:M>_1A'$J@V :+[5PZD83^R-EDP288#/<-2;WW@!<J
M>"MIS.9L*BUV &@3E*$DVHI(:;IPL61SV!TJQ(LY86P>2%P46= 2/3[%CC9S
M[;H'=[S@TMW,<M4*G>T$*/M0_*>J\<FP<-G$*N/ (5@A@PXFB/YN'ZAB [1Q
M^P^4>%><?JS.UYI2:&$VQE/=50T__:L5]-F!+-+4WGG00,<3KEJG?%#'/M6$
MV&X<G3RR>^**/I)!@R7_TO1;5]J5&T%D<;#NA6^X]"Y>"E@:?7%P4"RD%5_+
MN]'NH\9I?)>_FQZ_B+R'(TH41HDIEHX&+_=[D:/VQ)LJO-E#0]Z4X; 0',9)
M$W!]:I!R<T(;=)]Z3OX#4$L#!!0    ( ,U+GEB:SU=6O@<  $D4   9
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MN@J#:4WY0MT.TH-=!0]-P#B<1 445:Z7 -X7K!8PE/I4B%@FV/RM[RPS0X,
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MLFBBG=,%?\U (E9:@/>G&AEM?M !Z[>']_\%4$L#!!0    ( ,U+GEB UCQ
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M:5J ^6595NT+,>@^'IW^"U!+ P04    " #-2YY8HR:)/D\%  "4#0  &0
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MRM\!_(.1M3MWSZ2A4[Q;%G1M0F4%Z/M<TK:^>K &VHO8^!]02P,$%     @
MS4N>6*Z<WR/T P  @@@  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
MC599;^,V$'[WKQAHB\4&4&U=OA+;@+-)=U/D,.*DBZ+H RV-+2*4J"6I./GW
M'5*.ZB)>=U]L'C/??#.<0Y.M5$\Z1S3P4HA23[W<F.JTU]-IC@7375EA23=K
MJ0IF:*LV/5TI9)E3*D0O"H)!KV"\]&83=[90LXFLC> E+A3HNBB8>CU'(;=3
M+_3>#N[Y)C?VH#>;5&R#2S2/U4+1KM>B9+S 4G-9@L+UU)N'I^>)E7<"?W#<
MZKTU6$]64C[9S54V]0)+" 6FQB(P^GO&SRB$!2(:WW>87FO2*NZOW]!_<[Z3
M+RNF\;,4WWAF\JDW\B##-:N%N9?;K[CSIV_Q4BFT^X5M(QL''J2U-K+8*1.#
M@I?-/WO9Q6%/8?0CA6BG$#G>C2''\H(9-ILHN05EI0G-+IRK3IO(\=(^RM(H
MNN6D9V:W].[74FM8H()ESA1.>H9P[6TOW6&<-QC1#S#""&YD:7(-EV6&V7\!
M>D2H916]L3J/CB)>8-J%./0A"J+X"%[<>AD[O/BGO82_YBMM%"7%WX<<;N"2
MPW"V4$YUQ5*<>E0)&M4S>K./'\)!<':$;-*238ZASVXO'^#Z;KF$Q>4]++_.
M[R\/,3R.$8Z[\!X''G*$M114B;S<@&$K@:#1:#I4)@=#UZDLJMHP5S)R;3.>
MI\#*##(N:H-91]@X5A1';>-XVOD3F0*T#P\'EYW;ND#%C%2G'?L.3I\9H_BJ
M;A@8"?.*[NL"OBA95W#-"TZFX!?X%/FC*/$'R1!.[';L#\=COS\(FFW4]X-D
MY,>C,9QT+K"45"&-I6^N' F#/9/Q#39L-5!?TH;<L?Y_"D\Z'S^,HC \@W/G
M9^+WH] /XQAB,C+VDU%B5T'LQ^-!*WO11.)_I%M?VUC]I-?O:9&G07<0[7SN
M#OO-:M@-:?6.UE%IBPYS(?99%;(N*0?L(Q^($J4&L$:!RTQ#3A&%%:+MR4;)
MIJV*5]J1BK5/CE%GM6T7YHN'N_O'&_AR?_>X@.NKFZN'RPO'=WBF(73884#B
M]$B:WLC(] ET);CQ89OS-(<MTX#K-3HK0#GY.RMKFAX0Q4UWZ )U9Y>YKY1R
M>I=^U$"P6)&+;TW$_4;6QPXMZ-!J&&F8@+)VDI3L33QD99-?$P.F%'N+3"I+
M(FFX?;I2&@H2OJ2BML;62A9-[3"1UJ*MG5W% /$J*9+[F9#5V*$XD1*GZ):&
M_^J$K8^4P+5"'ZQ8Z$?CV!]:^OW$#_J)H](L?1OQ"G?A[QYJ/+V]N4 UN''3
M3Y,K]-[-B&A/VP$[;^;*O^+-=+YA:L-+#0+7I!I05GF@FHG7;(RLW)1924,S
MRRUS^DA 907H?BTI:+N--=!^=LS^ 5!+ P04    " #-2YY8.K1M+7\$  #A
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R=5DMOXS80ONM7#+3!
MH@546Y(=QYN' <=.MCG8"3;9]E#T0%,CB5A)U)*4L_[W'5*V['0=H^C!,A\S
MWWSSX)#7KU)]TSFB@1]E4>D;/S>FONSW-<^Q9+HG:ZQH)Y6J9(:F*NOK6B%+
MG%)9].,P'/5+)BI_<NW6GM3D6C:F$!4^*=!-63*UN<5"OM[XD;];^"*RW-B%
M_N2Z9AD^H_E:/RF:]3N41)18:2$K4)C>^-/H\G9HY9W 'P)?]<$8K"<K*;_9
MR4-RXX>6$!;(C45@]+?&&1:%!2(:W[>8?F?2*AZ.=^CWSG?R9<4TSF3QITA,
M?N./?4@P94UAOLC7WW'KS[G%X[+0[@NOK>PP]($WVLARJTP,2E&U_^S'-@X'
M"N/W%.*M0NQXMX8<RSDS;'*MY"LH*TUH=N!<==I$3E0V*<]&T:X@/3.9R;(4
MAJ)L-+ J@9FLC*@RK+A ?=TW9,(*]OD6[K:%B]^!BV)8$$*NX:Y*,'D+T"=N
M'<%X1_ V/HDX1]Z#011 ',:#$WB#SN&!PQO\'X?AK^E*&Z;,W\=<;X&'QX'M
MZ;G4->-XX]/QT*C6Z$\^?HA&X=4)VL..]O 4^F3VN%@\O"SNEB_/,%W.8?:X
M?'E8?KY;SA[NGH^1/0T7ASTX";F/BX$GMK'Q@L=5(3)F#Y.&J0:9 B4'RQ6J
M+D$!F!SALY)-#8FD@%;20,[6Z+%J0Y/J-\XJ3F>0K0J$NE$\IR,%?)^4'KQT
M"+1'6[O\;*#>$I%[(EY#=:8 &<\M(6N]$)R:!@++%*+##*CGT#ZAE:) .E,5
M[K!H3\D-*PQEGX:4-Z:L*%5&@FOJ6;6SF)(98A& 2(&C,M3M++-$N-8BE;<'
M%F0%30\6/YD"IA"2!J&I73_*!5EH=V3JZ1JY2 7?XQ[P?JC6!+9UFA6PI'8W
M5TVFX9>/'\9Q'%X]+.=N%%W]"JF@?&=$"[[VGGMP+V7B/+(:,$VHC0AME,/J
M]._GTYV^Q^I:R34K D)2VKCTH.*"#&M&>7L;Z 1(.FFXC269E+2EWGC7II1E
ME ]R@$:E;%JG'0S?5]K/Z?%,SLQ!45%T%7YOA"*S1EHQBJ8=)2)-45F0?P7V
M()XN")T-#6WML*(X4C- &4:"Y 2HO6.U[M*YLM?:I3=U+GDNP*6D*Z<A(Y=;
M:ELGWR%!J7]2R"EC@E. 29Y2N4OA&42#.#@?#;U[)4L@8JCL>NV.362E5TA7
M,[Z3J>@B&%R,@F$4>O?'!:)@/(Z#\#SREO0$L&MZFR!RA' I_E57\B:G$Y++
M(K'18;"APP+#87 Q^A3$@\A[;E9&&H(^@XMA0)TOB,]'WERPK))4O5R#09Y7
MLI#9YC\'Y[;UC^H3=G5)^'$X#D8$[BP-1N/@$UT]=$\[/,M+4[#H!CK6HN@;
M6T,>#:+#CB4JWBA;66?G81"&84"&*E'8W[$6WC^X=BFHF7M<V(Y%P6MOX&ZU
M>[],VVM[+]X^?A9,98+<+S EU;!W<>Z#:A\4[<3(VEWB*VGH2>"&.;W!4%D!
MVD^E-+N)-="]ZB;_ %!+ P04    " #-2YY82]N;"#<#  #C!@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6R-55%OVS@,?N^O(%Q@3[TX<;JMZY(
M;9?KAD.W(NVVA\,]*#)MZRJ+/DFNVW]_E)RX&98%>[$E\>/'C[1(SSJR#ZY"
M]/!4:^/F2>5]<YZF3E98"S>B!@U;"K*U\+RU9>H:BR*/3K5.L_'X35H+99+%
M+)[=VL6,6J^5P5L+KJUK89\O45,W3R;)]F"ERLJ'@W0Q:T2)=^B_-K>6=^G
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MZTC[X>!U'&KG\_#1ZWTQ7K*196YAW&L+\Q7+/@_]^?'CM[CM.VLR,OY[G6L
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ME$,_??[*%08P:+9V5>Q,2^8)DBI2-C[8+"M[Q40(4^NE:]JEJAKG1J8$*JZ
MDYL.-YB$P]*D*'C>Q@% *<3FJ.SQ>UB2 ;-"J R.>]TVVUO JZ/@Y\5OQA_:
MR/[6D<HW^MIDU!>ITQ_5S<;4GB$\0 N'9\J4/U3&'[\)Y-( $# WZ%E80P*F
MJ8W?P1$62S?WH3.F^ G679R>S8I?/2U]\ B^(YYXA+,J<ZVK'I?:]"ULJ@A.
M6(^+TH?V'U4,_'O5(/6R+D#:\OCBJN'9%C%> H5L)X3!>57!!L+ P'<KEI]J
MJ2ND)I;0H/9KIU<LR6EWE@9VUE06)M2B0D!= =DSP<D6W*KTYL6$^G\:U/_3
M2?7_4U.?I'P=&'I,UT^"&M?U1^$7QW]!4@'&:(#$_T *0C99HQU.$G+7M.DV
MH;0A\1F(^>10(PGA>QK47=?:9=\A/<U$L #; G-Z35>!$A2^2G%T&P#!,FRN
MIA>PJC1HX[4%3#3*0L<'; K<-E"P9NM-!UF!$T<C-66"L,J(0<BK(+/=D5:/
M=.7G@?64UJU 9D4C90)F;DN!U]:*[<$6V19.=(/.%$R#8G!@J)E2Y0!D322V
M'6J*WCKFPKA+(NI /*1+GJ3J9X&JGTU2]2='0@:FL<BAH\3\YR"0ZK\SEZ:[
M 7L/#Z&&P1TA:11LP:@L0?UHUKVX:5O]V21SXV8#-?7;'9\);9I>K[T^!+2
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MLLYL\!D&(3$"KC!51[D#C=(2TX-H"8$_T_2=PV@UZ4XO@#MQ74#1EV2"Q#G
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M;M3N ITOE;+;C5-0C_##?P!02P,$%     @ S4N>6-,CQU7/ @  )@8  !D
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M)#49*L=E\SD"EXN'XQ.#0X$^-RF8#5K62@O8<:T:KHJYCD\N35%6GLRZ #"
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MW$3Z5D7[D!Z9B5Q]0G/IIZ"B-K(55^MLA_Z-K,\*]X*Q],BH-H1AGFT- W^
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M+A@<F<8%,#]3RJY?4$%US37^%U!+ P04    " #-2YY86H7V^]0"  !=!@
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M%GT-1)7D= 6G%)_E/*WX"3D<R(DP+C/V IH-Z+$?'H4&([G"ZVHL%(A;3)X
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MP%KQ86-[0_+V'7MA0U2">@,>>^:;?PR_)QNE[TT%8,F3X-),@\K:>AR&IJA
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M6!H-AF<!T:V[V\"JVCMJJ2SZTR\K?!!!NP0\7REE=X%KT#VQ^5]02P,$%
M  @ S4N>6'>)HQGM @  C 8  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&ULI57?;YLP$'[/7V&Q:MHD5#"_0K($*6TWK0_5HG8_'J8].' $5,#,-DW[
MW^]L$DJU-)JT%[BS[_ONNS,^%CLN[F4!H,AC735R:15*M7/'D6D!-9/GO(4&
M=W(N:J;0%5M'M@)89D!UY7BN&SDU*QLK69BUM4@6O%-5V<!:$-G5-1-/%U#Q
MW=*BUF'AMMP62B\XR:)E6[@#]:U="_2<@24K:VADR1LB(%]:*SJ_"'2\"?A>
MPDZ.;*(KV7!^KYWK;&FY6A!4D"K-P/#U )=059H(9?S><UI#2@T<VP?V3Z9V
MK&7#)%SRZD>9J6)IQ1;)(&==I6[Y[C/LZPDU7\HK:9YDU\>&KD723BI>[\&H
MH"Z;_LT>]WT8 >+7 -X>X!G=?2*C\HHIEBP$WQ&AHY%-&Z94@T9Q9:,/Y4X)
MW"T1IY)5FO*N49*LV1/;5$!8DQ%<%!UDY.,CGKT$2=Y]U7OR_<)1F%,CG73/
M?]'S>Z_P4X_<\$85DGQL,LA>$C@H=E#L'11?>"<9KR ])SZUB>=Z_@D^?^B
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MZK _QG13S1S5;(Q<N]EE(0U.0FZYPM&3*2N ]X649K>Q!MIA=OX_4$L#!!0
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MGX\1K+="";9;)?!8G*)*%*)*Q%'EYT2$ T,Z41"A,1_]8\P/V#82+ X]%B7
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M-U)KV*""^X(IA(L'MA6H^_/ 4 +K%F1'L'4+%O\$+(KA5E:FT/"^RC'_/T!
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MDXG*.M#Z3DKS,K )ND=X^1]02P,$%     @ S4N>6'-)&]IM P  ;0<  !D
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M^#0@WYA\V-S> 9%S=K#YG!]]OMY1_PDR ,5RVO+Z-$#&FN^ )CGMV'T:F%_
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MV=L?T='75;]13:PJ_).]4)8: #_,J$5#[3;0^E(INYVX $W3%_\"4$L#!!0
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M5,BK4'^F\G4#3 7(\812L6FH";KW4O 74$L#!!0    ( ,U+GEA,JN-\R@(
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MEJ.!((58:0\4?VN80)IJ1XCQN_%IM4MJX79[X_W2Q(ZQS*F$"4^_LT2MQM;
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M_94K-DVMM)4 :;9E!*DIJ[:':E&S;@_3'ARX"5:-S6R3I'\_VQ"65B2*M+Z
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M2NTJFFIV'U;[X,!-@@8P8YND_?=K ^4CH;3IDI?$P+TGYUX?FQ//]HQ_%UL
MB1Z3.!5S8RME=F6:(MA"0L4ERR!53]:,)U2J2[XQ1<:!AD52$IO$LEPSH5%J
M+&;%O25?S%@NXRB%)4<B3Q+*GSY!S/9S QO/-[Y&FZW4-\S%+*,;> #Y+5MR
M=676*&&40"HBEB(.Z[GQ.[ZZ)I9.*"+^BF O6F.D2UDQ]EU?W(9SP]*,((9
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M8-]QPS7^&4#9!%Q?2FGV@6T^S;\F^0-02P,$%     @ S4N>6,YS:>"* P
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MWMC24.5(5"Z,S(HQ9"F-'6J*VXT=(U&Y#^S[E93F<>$FFWHPC?X#4$L#!!0
M   ( ,U+GEAD8XUG&P,  '<)   9    >&PO=V]R:W-H965T<R]S:&5E=#8T
M+GAM;*V676^;,!2&_XK%IJF5UO)A<*!+(K7IIO5B6M2HV\6T"P<.!14PLTW2
M_OO90!@-%.5B-\$VYQP_[QM_,-\S_B02 (F>\ZP0"R.1LKPR31$FD%-QR4HH
MU)N8\9Q*U>6/IB@YT*A.RC/3L2QBYC0MC.6\'EOSY9Q5,DL+6',DJCRG_.4&
M,K9?&+9Q&+A/'Q.I!\SEO*2/L 'Y4*ZYZIE=E2C-H1 I*Q"'>&%<VU>K0,?7
M 3]2V(M>&VDE6\:>=.<N6AB6!H(,0JDK4/78P0JR3!=2&'_:FD8WI4[LMP_5
MO]3:E98M%;!BV<\TDLG"\ T404RK3-ZS_5=H]7BZ7L@R4?^B?1MK&2BLA&1Y
MFZP(\K1HGO2Y]:&78+MO)#AM@G-J FX3<"VT(:MEW5))EW/.]HCK:%5--VIO
MZFRE)BWTO[B17+U-59Y<7H<AJPHIT)J^T&T&B!814H.\@@A]?E:+18! 9[<@
M:9J)<W2!-FHA196*9#$Z+?L"/6QNT=G[\[DI%;*>V Q;O)L&SWD#[Q;"2X3M
MC\BQ'#R2OCH]W7F=;BJC.K><SBVGKH??J-?73@_:RYYVVFJ'@_9?UULAN5JL
MO\?$-[.YX[/I#7PE2AK"PE [5 #?@;'\\,XFUJ<Q*_Y3L5?&X,X8/%5=&1T#
MYTKXEA65J*T0-*,\A<Z?,?U-45(7U>?-;NEZ-B'6W-SUE0W#/,MW Q)T<:^@
MW0[:G82^5S90'B8U;@0[=:25ZH"2__Z]"?2FM-=CLFWBV)YWQ#Z,\P@.;#R.
M[G7HWB3ZFK,8A#Y*:89BF$;UAJ@S#SON$>DPS'&(:\W&24E'2B9)5TQ(O5T2
MH)E,0LH!Z<67AM/,9 !#;-\A1\C#*!O[V";CR+,.>3:)?%>(BM,BA),6PFQH
MV\PE^(AT&(4Q)F]XZW>@_B3H=YD %V-0_M 8K[_H&JB1*#OPL3=.%714P235
M]2D'XQAT,-CFMA^XV+6/L(=Q1!T:_F"EFKUK47^2?*/\,2T$RB!6F=;E3"GG
MS37?="0KZYMRRZ2Z=^NF6K81<!V@WL>,R4-'7[[=M];R+U!+ P04    " #-
M2YY8<;HXOR0%  !?%P  &0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6RU
M6%U3VS@4?>=7:-*/*3,06\YW&S)3H+ME6KI,*;L/G7U0[&NBK6VYDD+(O]\K
MV=A),"HP[DMBV;KGWB-=71UINA+RAUH :'*;)IDZZBRTSM]ZG@H7D#+5%3ED
M^"46,F4:F_+:4[D$%EFC-/$"WQ]Z*>-99S:U[R[D;"J6.N$97$BBEFG*Y/H8
M$K$ZZM#.W8NO_'JAS0MO-LW9-5R"OLHO)+:\"B7B*62*BXQ(B(\Z[^G;D\ :
MV!Y_<UBIC6=BJ,R%^&$:9]%1QS<100*A-A ,_V[@!)+$(&$</TO03N73&&X^
MWZ'_8<DCF3E3<"*2?WBD%T>=<8=$$+-EHK^*U4<H"0T,7B@297_)JNC;'W5(
MN%1:I*4Q1I#RK/AGM^5 ;!B,_0<,@M(@V#&@_0<,>J5!SQ(M(K.T3IEFLZD4
M*R)-;T0S#W9LK#6RX9F9QDLM\2M'.ST[RT*1 OG&;D&1-Z>@&4_4/CDD5Y>G
MY,W+_:FGT8OIZX4EXG&!&#R 2 -R+C*]4.1#%D&T#>!A>%6,P5V,QX$3\13"
M+NG1 Q+X0:\AH)/'FP>.<'K5D/4L7N\Q0_;],WXE9QI2]6_36!50_68HLT;?
MJIR%<-3!1:A WD!G]OH%'?KOFGBV!+;%NE^Q[KO0[UAK=DLDTT!RD"%D&I=Z
M$^T"B_H6S)22FYG?I</!U+O9).1T^4Q"@XK0P$GH"]9(K(9(AF?7)!%*D9!)
MN3[$VKAB,L+EP#-R*I*$2=6X#@K\X09'B@DZ'/5[NSSO]YQ@F?4GXU[5<8O#
ML.(P='+X?"_J7P8]O!=*, [&="=@I]MG3LRH(C5RDOHH<#X^F9_OYY#.038N
M+"?&4Q=62V!;=,<5W7%[Y63<)NN6P+983RK6DT>6DP/<=54H>6ZV]2;.;J K
MW&0DT0O$6HE#S4%"1'(I8JY57:TD7*/X.+#]8BZ5)B\#W$Z3!'WNB9@PI4 I
M-D^@LL6W/Y<LX?':U(=0R%R86B$R1;A%1C],DW$W&+PB+(LLM@0CG8Q! R+V
MIL/NX%67?,.N?\F(9RP+P<!!'(,5-'NQ%*F%6@.3I H-E9/&#8R.#_%GTB7O
M0XPH,HZTL-USD?!P?4!X3#)!*IFT8(K, 3+4#%')?[40&!0BVT%CMSFS#-$!
MU^O7+\8!';U3>PWQKW"\$(R$"R:OP7Y"YQ?E5TQ@P]".@AER=&#9$B$)';PZ
M0"*$Y3E&:2R[Y!A"ME10!(_:#2<.(V")G32-DE0;SGLX.)G0!2$<\?G:&OPI
MQ3)'2 S(--5RKGC$F>2XALQ<*VWS &MA74V8M!W_0R 3-Z\W- R;;0?=;5HO
MSD1\YGJA?BW4_%\D.C<#\ GG*L(4<=5&-])3RT1;:-N\-P0J;:\^EEAM,6\)
M;9MY4#,/6I1<)=AD6W)-=C9VM\OG4JJE,W5JU-DE9B_#0@KN_&U5-;>%MDVY
MULVTWV+^MJ2(2^:_0U_36F!3M\)^8OX.FO)WM)N_3I?/I53K;>H6W&41OM3(
M!P\(7^"&16S?G<PM:>F2_^]0YK26YG348C*WJM';0MMF7JMTZI3#3TWF<4,R
M![NG++?+YU*J)3AU2^<3EF'VNI.W)<U3\OT="BJH%53@MY>\0:L:JBVT;>:U
MA@J<2N6)R5N"[53BW3L-M\NG4O(VKC!3P..%N=E5>.Q:9KJXS:S>5K?'[^V=
MJ5=W+ZZ>S_%TPO&4ED",IGYWA%N&+&YSBX86N;T0G0NM16H?%X#'(VDZX/=8
M"'W7, ZJ._79_U!+ P04    " #-2YY8YX[OIIX"  !R"0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V-BYX;6RMEEUOVC 4AO^*E4U3*ZWDB[*I@TB%;%HO
M*J'2;A?3+DQR0JPZ=F8[P/[];"=D4(6HJ-R [?A]?,[K.,?C#1?/,@=0:%M0
M)B=.KE1YX[HRR:' <L!+8/I)QD6!E>Z*E2M+ 3BUHH*Z@>>-W (3YD1C.S87
MT9A7BA(&<X%D5118_)T"Y9N)XSN[@0>RRI49<*-QB5>P /54SH7NN2TE)04P
M23A# K*)<^O?Q",SWT[X06 C]]K(9++D_-ET[M*)XYF @$*B# 'KOS7,@%(#
MTF'\:9A.NZ01[K=W]&\V=YW+$DN8<?J3I"J?.)\=E$*&*ZH>^.8[-/E<&U["
MJ;2_:-/,]1R45%+QHA'K" K"ZG^\;7S8$_BC(X*@$00O!<,C@K 1A*\5#!O!
MT#I3IV)]B+'"T5CP#1)FMJ:9AC73JG7ZA)EM7RBAGQ*M4]$=2W@!Z!%O0:*+
M&!0F5%ZB*[30+UA:44 \0W/!U\1NM'[/T('DZU:_@%(WKM#3(D87[R_'KM)Q
M&;J;-#%,ZQB"(S'X ;KG3.6:QE)(#P&N3JC-*MAE-0UZB3$D Q3Z'U'@!6%'
M0+/7RX,.>?QZN=^33=CN46AYX1'>J5OQZW8IE= GZG?77M1K#;O7,E^9&UGB
M!":._HQ($&MPH@_O_)'WI<O'<\+B,\$./!ZV'@_[Z-&L$@*8ZC*L5]@=%NKR
MZDR<^.V< X>N6X>N>QV*(0/M4=IE4:_R!(O.Q(G?SCFP:-1:-.JUZ)$K3!&I
M#Z6RAQ+J0]EE6B_K!-/.Q(G?SJE-<_>J40%B9:NZ1 FOF*H_X>UH>W&XM?7R
MQ?A47RCJ^O\?4]]&[K%8$281A4PCO<$GO>&BKO!U1_'2UKPE5[J"VF:N+T4@
MS 3]/.-<[3IF@?::%?T#4$L#!!0    ( ,U+GEBEUFW5V ,  - ,   9
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MPE\.)C0 WJ\Y5\\+?4#_)V;^'U!+ P04    " #-2YY8DE?IE5<"  !I!0
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MIP'WJD6SP2!]]R8>1Y]/"!WU0D>GT-.YT1OIVY*G LA6*GFI+.Q9E.U%/<>
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M :M+2".9;],@_T:6KSR(GN'VK]C;/Y+JA>"V!TXST#G#2(U"-0;5.%3SH9I
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M!_U^Q;G:-LQ1MOKK(O@'4$L#!!0    ( ,U+GEBB<=J[M ,  )(3   9
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MI\5]]GAWN^ENJAQ5B;*K1-DYGG,$;Y9Q#E2V\2@<!^V.^CV\$BD)8&JH%TT
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M.#-8$R11/.1L#;B>K:+IALF-42L:4NAMG$FNGA*ED_$%5CD 1Q,L$:'B&/3
M3)V4M*(8L Q<(EEQ(N_ 68'HG2!"#WXO,4>2% M@Q )<$#0GE$BBVCUP/9N
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MYP%RI4(F\7=(-NG.,Y"N/%'Z2[Y<SRYZIIP1B<B42P@L?IZ)3Z)((HEY_%.
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M)<$SPJ2 ^#ZGE&]?I('R G[\+U!+ P04    " #-2YY8 (W[&YP$  "W&0
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MD9K^>?&5H#B1;&W>FS\Q*5EF#E<8I9CK!NKW!6-R?Z)O4'VK&?\'4$L#!!0
M   ( ,U+GECM4-HOG 8  ,])   9    >&PO=V]R:W-H965T<R]S:&5E=#@U
M+GAM;+6<76_;-AB%_PKA#D4+K+$^_-DF!EI+%#LT6]"LW46Q"\5F8J+Z<"4Z
M;H']^%&R8IF.PDK%<2YBR=;[O+)YS)?F$76^3;.O^8IS2;['49)?]%92KE_W
M^_EBQ>,P/TO7/%&OW*99'$JUF]WU\W7&PV49%$=]Q[)&_3@426]V7CYWE<W.
MTXV,1,*O,I)OXCC,?KSC4;J]Z-F]AR<^BKN5+)[HS\[7X1V_YO+3^BI3>_T]
M92EBGN0B34C&;R]Z;^W7S)D6 >41GP7?Y@?;I'@K-VGZM=AYO[SH6<49\8@O
M9($(U<,]G_,H*DCJ/+Y5T-X^9Q%XN/U I^6;5V_F)LSY/(W^$4NYNNA->F3)
M;\--)#^F6\:K-S0L>(LTRLO_9+L[=FSUR&*3RS2N@M49Q"+9/8;?JP_B(, >
M/!'@5 %.VP"W"G#;!@RJ@$';@&$5,&P;,*H"1FT#QE7 N&W I J8E*V[:XZR
M+;U0AK/S+-V2K#A:T8J-4A!EM&I"D13:O9:9>E6H.#G[,TU>S=-$9FFD7KHC
M[Q/),YY+\L+C,A11_I*\(I^N/?+BMY?G?:DR%G']145_MZ,[3] ]OC@CKOT[
M<2S';0B?F\,IOSDCUM/A7OOL3D.XWR*[,WPRG+;/;C>$!VW"K2?#F3G\CS!1
M'YW3%-Y7$MGKQ-GKQ"EY;E>=?/F@CB3O)8_S?YL$LL,.FK%%S_PZ7X<+?M%3
M76_.LWO>FSU_9H^L-TUR0<(\),Q'PB@2%B!A# 33).CN)>B:Z+/K59AQ(O)\
MPY?DA4A(^43>V"T925U5MX,-2U@Q%KB?V46'<'\H)F1"OR&A/=434F3"8 >S
MW8.,UIEEV7I.UG1>X_TQ6J,.]HTZ,#;JWZD,HV*P(19"DOLPVO"R;3W5SX19
M<^/NB*.#TQB-QZ.1?K)S8]ZN?<7CE$/5L0[TE#XR)7V<TAW8KJ6G#) I&0BF
M"6&X%\+0*(1+D>;D2GVC8Y5A(\4BC'+R0<1"JF_[ETL>W_"LL< 8L5V_ZDB8
MAX3Y2!A%P@(DC(%@F@1'>PF.3C/&&2$EB(1Y2)B/A%$D+$#"& BF27"\E^#8
MV O^M4UXEJ_$FH@'\:UYMN")#.]XD_1V.-O2*O=T/'6F!W]'E=%X"ET5AH3Y
M2!A%P@(DC(%@FL(F>X5-X ,N([%K_X:$>4B8CX31R:/AFS-VIN[1\ V9DH%@
MFJRF>UE-S3_.%F(M4C5@N^5$;?-DP=L-WXS8KMI"PCPDS$?"*!(6(&$,!-,D
M:%OU7*9UF@%<Q06I$$KSH#0?2J-06@"E,11-U^+!O+J-'<E5O&Y#.?-)=)8:
MDN9#:11*"Z TAJ+I4JNGYFWCM.OL[5JFV28FEWQ93)L\*KOD/W(9?A>Q.L14
MB<U9.G>"T+EZ*,V'TBB4%D!I#$73E5G/V-ONB0HR= (?2O.@-!]*HU!: *4Q
M%$W78FTTV&:GP?^V$?)'ZVJ,G%B?0VD>E.9#:11*"Z T5M&F^@#+;3:P[-JX
ML,W.19OR*Y*?EU^HD0&E>5":#Z51*"V TAB*IBNS]C/L$QD:-M31@-(\*,V'
MTBB4%D!I#$73M5@;&[;9V>A8?I'S[7,HS8/2?"B-0FD!E,8JVE'Y=9XHO[6?
M89L-C7D49E_)?,55!]?U%R_4V(#2/"C-A](HE!9 :0Q%T]58VR#V]$0E%VJ$
M0&D>E.9#:11*"Z TAJ+I5^S6=HACG.+N6'+-L,Y7ZEI-G?W1!84>-*??G//H
M2DT*S1E :0Q%TP53>Q:.V;-XJI2V^/5J)G=6#]36@-)\*(U":0&4QE T78VU
MK>&<:LD!=LT!=M$!=M4!=MD!=MT!=N'!*8P,IS8R'//:@XZE%.I>5+2CLG9<
M2:&F1'-*^[B20LT&*(VA:+I>:K/!,9L-099NUL^?31Q[_"8G^>8F%TL19H+G
M>F']Q6O>S=D["PSJ3D!I/I1&H;0 2F,HFJ[8VL5PAB>JME#? DKSH#0?2J-0
M6@"E,11-UV+M6SC&N>C9YU06$ERG6YXU2F[4=*F4.SI8C%:I">H\0&D^E$:A
MM !*8RB:KJ;:>7#,SD.[6OS+%S";LW?N_Z!6!93F0VD42@N@-(:BZ8JM+0UG
M<J):##4TH#0/2O.A- JE!5 :0]%T+=:&AF->V/'36CQMK,5#ZW@]MCE/9S5!
M+0DHC4)I 93&4+2=FOH'-YXI;G5T&69W(LE)Q&\5WCH;JW%DMKM[T&Y'INOR
M7C0WJ91I7&ZN>+CD67& >OTV3>7#3G%[F_T]G&;_ U!+ P04    " #-2YY8
MZT1.IRH#  "+$   &0   'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6RMF&UO
MVC 0Q[^*E4G3)FWDB8?20:1",JU3F5"K;2^JO3#)0:(F<68;Z+[];"=-21M2
MD/P&;.?^/]MW]H5CLB?T@<4 '#UF:<ZF1LQY<6F:+(PAPZQ'"LC%DS6A&>:B
M2S<F*RC@2(FRU'0L:VAF.,D-;Z+&EM2;D"U/DQR6%+%MEF'Z;P8IV4\-VW@:
MN$TV,9<#IC<I\ ;N@/\LEE3TS)H2)1GD+"$YHK">&E?V96!;4J L?B6P9P=M
M)+>R(N1!=JZCJ6')%4$*(9<(++YV,(<TE22QCK\5U*CGE,+#]A/]J]J\V,P*
M,YB3]'<2\7AJ7!@H@C7>IOR6[+]!M:&!Y(4D9>H3[4M;5QB'6\9)5HG%"K(D
M+[_Q8^6( X'=/R)P*H'S4C \(G K@7OJ#/U*T#]5,*@$:NMFN7?E.!]S[$TH
MV2,JK05--I3WE5KX*\GE0;GC5#Q-A(Y[/\19O"&,H250=!=C"NB##QPG*?N(
M/B,F1]C$Y&(J*3##"CLOL<X1K.V@!<EYS%"01Q U :988[U0YVFA,Z>3^!WG
M/>2XGY!C.6[;@KKE/H0]Y-I'Y?[I<J=%'IPNMSN<X=91<Q7//3UJ]S?"!EUS
MR-B?E@7.2F"_'2C3T24K< A30^0;!G0'AO?^G3VTOK3Y6B?,UPD+-,$:4>G7
M4>EWT;TR$*20&9 AG$=HCRG%.6^[0+-.UKD!*6$#!9/OAIVX@6-W)(_Z[M#7
MK^T&?6O0;UH%;UDUO#.HO3/H],XBR9-LFZ'[!60KH*V'M)-PKD]TPGR=L$ 3
MK!&&81V&H>[4,=09%9TP7R<LT 1K1&541V74>3EN80>4 1+O^_ !L2)->%LD
M1J^O>?/JSCNG.=>].F&!)EC#O1>U>R^Z<P]^?#/W=!+./>4Z8;Y.6* )U@C#
MN [#6'?N&>N,BDZ8KQ,6:((UHF);SS6 I2/[5)1&^K%>Y)_NF<[UL59:H(M6
M>MD\*+HRH!M5[3(4DFW.R[*F'JTKZBM51[X8G\M*6Q5SSYBR3%]@NDG$3\D4
MU@)I]4;"];2L?,L.)X4J[5:$BT)1-6/ $5!I()ZO">%/'3E!_?^#]Q]02P,$
M%     @ S4N>6.#[,Z(K!   "@\  !D   !X;"]W;W)K<VAE971S+W-H965T
M.#<N>&ULK5=M;]HZ%/XK1]DTM=)*W@-T@$0+=[=7[8;:]>[#=#^8Q!"K29S9
M3MG^_;6=- 5JTFKB"\3V>1[[.3[']AEM*'O@*<8"?N59P<=6*D1Y;ML\3G&.
M>(^6N) C*\IR)&23K6U>,HP2#<HSVW.<R,X1*:S)2/<MV&1$*Y&1 B\8\"K/
M$?M]@3.Z&5NN]=1Q2]:I4!WV9%2B-;[#XKY<,-FR6Y:$Y+C@A!; \&IL3=WS
MN>LI@+;XE^ -W_H&)65)Z8-J7"5CRU$KPAF.A:) \N\17^(L4TQR'3\;4JN=
M4P&WOY_8_]+BI9@EXOB29M])(M*Q-; @P2M49>*6;O[&C:!0\<4TX_H7-HVM
M8T%<<4'S!BQ7D).B_D>_&D=L 5S_ ,!K -X^(#H \!N OP\(#@""!A"\%1 V
M "W=KK5KQ\V00),1HQM@REJRJ0_M?8V6_B*%"I0[P>0HD3@Q^2)C\9IR#@O,
MX"Y%#,/)# M$,GX*9W G S.I,@QTI?:#Q("*!!*250(G<)))Y"F0(J8YAE(R
M<,UP!O=W,SAY?SJRA5RCFLF.F_5<UNOQ#JS']>"&%B+E,"\2G.P2V%)<J]![
M4GCI=3+.<-P#W_T(GN/YA@7-W@[W#/#YV^%NAQJ_W2]?\_D'^+8WY*+=D%FS
M(7HGK^KM>-[0'],E%TRFY'^F_:CG"\SSJ7/JG)<HQF-+'D0<LT=L33Z\<R/G
MD\F7QR2;'XELQ\]!Z^>@BUWGA8IN0$(PLJP$6DJG"PK34E!6Y?"9T:J$:Y(3
ML1^FM5]K_DCSJ^/Z<7+F#;P@"OHC^W';9P;#87\X#"-GUW!N8@R=8. /AJWE
MCMBP%1MV!M5W?9S*^$&/F,GKH4YC#O)BX4+&%RG6)ZXQF<-C!L\QR>9'(MOQ
M9]3Z,^H,'IV8AD5==,-^N,8$K4'AUK8'H>>ZOK\71R_M_# :!H-@+XQ,=H[O
M#R-S$/5;T?W.U3=GD$EV-_" [/X;9;^T,\LVV77('K2R!YVYTQX4S]??FXZ,
M PDU.&9"'9-L?B2R'2</6R</_RRANF$'(JL&#;;/4:<7>7MQ9;#R>OUP+ZH,
M5OV>&YICRG6>7V7.GR;3*\@#FAO4:Z)-9@;5)K,.V>HQNMOC/3O">TT.3+-L
M.[MR6A6"ZW?/RWL*9.T$J 80FG!(Y9T&2XQ562,8K0N3[+=L28BZ\V2"RMI$
M%2XP77S[>GM_ Y]OO]XOX/KJYNK;?/;AW<!S^Y\XN)K;=:2YO":YO"4%C1^
MEQD1'V&3DCB%#>* 5RNL9P%9"/V#BDH68.#Y]0.T9\H&>^O]GF.VUH43AU@)
MK9\L;6];G%WHDF2O_U(5;8;^J>N>SUSSB"='-)?]/'5=)=X@MB8%APROY#(<
M&086L+KPJAN"EKJR6%(AZQ3]F<IB%3-E(,=7E(JGAIJ@+7\G_P-02P,$%
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M:R4MDP7(C($A+S=@*>/F%7E#=E@0><V!J /YP#@@F@2RI0^=L09B%=D#TN5
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MFB&U;N^\=F)5U=PS>V7QUFJ&)7XG@'8;\/E!*?LX<5=7_^61_@102P,$%
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M77 M 0P 8' T0/%J)@GD%$!._R#DW$/X-UA1+\3M6AD"&0+(\&B0\Y6DD!&
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M"J8"  "8-0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I-;N)
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M<' N>&UL4$L! A0#%     @ S4N>6,;AZRKN    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ S4N>6)E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #-2YY8^\<@=? &  #/(0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ S4N>6)F2'^:T
M"   ""D  !@              ("!,P\  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( ,U+GEBJB!L/X@(   \+   8              "
M@1T8  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #-2YY8
MX6X&ZL\(  !=*0  &               @($U&P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ S4N>6)W D\I1#   :F4  !@
M     ("!.B0  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M ,U+GEC 3KJLP0T  !)/   8              " @<$P  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #-2YY8H]G1(AH%  #&#@  &
M            @(&X/@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ S4N>6.SA>L<,!@  [ T  !@              ("!"$0  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,U+GECFGM)W?R0  (EP
M   8              " @4I*  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #-2YY8<3D&]IX"  "8!0  &0              @('_;@
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,U+GEB[N '-
MQ@D  +X;   9              " @=1Q  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ S4N>6# #+'A& P  1 <  !D
M ("!T7L  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #-
M2YY8A_22TUD$  "Y"@  &0              @(%.?P  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,U+GEA=&O**H 4  ! .   9
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M970Q."YX;6Q02P$"% ,4    " #-2YY886JON>$'  !]%   &0
M    @(&@J0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M ,U+GEAP5B]!<P4  %<-   9              " @;BQ  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ S4N>6!NQ[$].!@  ]A$  !D
M             ("!8K<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #-2YY8FL]75KX'  !)%   &0              @('GO0  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,U+GEB UCQ \ D
M $@:   9              " @=S%  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ S4N>6*,FB3Y/!0  E T  !D              ("!
M ]   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #-2YY8
MKIS?(_0#  """   &0              @(&)U0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,U+GE@ZM&TM?P0  .$)   9
M      " @;39  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ S4N>6$O;FP@W P  XP8  !D              ("!:MX  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #-2YY84CM5B $*   9&@
M&0              @('8X0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( ,U+GE@A]U!<428  &:    9              " @1#L  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ S4N>6*]_/D<,
M!   S@L  !D              ("!F!(! 'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " #-2YY8TR/'5<\"   F!@  &0
M@(';%@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,U+
MGEB2O;:#%@8  /(2   9              " @>$9 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ S4N>6%J%]OO4 @  708  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( ,U+GECQ0FF)@@4  $P.   9
M  " @> O 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
MS4N>6.SY<_-K!0  M@\  !D              ("!F34! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " #-2YY8!#1+@MD"  "<!@  &0
M            @($[.P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( ,U+GEB%KK*1800  -@*   9              " @4L^ 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ S4N>6)H%$MXQ!0
M( P  !D              ("!XT(! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " #-2YY8V#:+!6\#  "0!P  &0              @(%+
M2 $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,U+GEAS
M21O:;0,  &T'   9              " @?%+ 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ S4N>6)*CZ':)!P  %3@  !D
M     ("!E4\! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,U+GEA6SQ3@J00  $$D   9              "
M@:YF 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ S4N>
M6* Z^$(] P    H  !D              ("!CFL! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " #-2YY8+IRV@EL#   5#@  &0
M        @($";P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( ,U+GEAL[([( P,  #L)   9              " @91R 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ S4N>6$RJXWS* @  B0<
M !D              ("!SG4! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " #-2YY8,%B<['P"  #=!@  &0              @('/> $
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,U+GE@A<M.S
M#P,  - )   9              " @8)[ 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ S4N>6,=X^Z=I P  ? \  !D
M ("!R'X! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #-
M2YY8O;.O^@($  !Y%   &0              @(%H@@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,U+GE@*]]A&7@,  ,<-   9
M          " @:&& 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#
M%     @ S4N>6)-X4&%[ P  LPX  !D              ("!-HH! 'AL+W=O
M<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #-2YY8E3+4&FD"  !"
M!@  &0              @('HC0$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM
M;%!+ 0(4 Q0    ( ,U+GEA/6T0/:0(  '<&   9              " @8B0
M 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ S4N>6,YS
M:>"* P  I X  !D              ("!*),! 'AL+W=O<FMS:&5E=',O<VAE
M970V,RYX;6Q02P$"% ,4    " #-2YY89&.-9QL#  !W"0  &0
M    @('IE@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M ,U+GEAQNCB_) 4  %\7   9              " @3N: 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ S4N>6.>.[Z:> @  <@D  !D
M             ("!EI\! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " #-2YY8I=9MU=@#  #0#   &0              @(%KH@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ,U+GEB25^F55P(
M &D%   9              " @7JF 0!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ S4N>6-!F7#KQ P  >A,  !D              ("!
M"*D! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " #-2YY8
MK]_P$O<"   R"0  &0              @($PK0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( ,U+GE@10./^#PH  /*    9
M      " @5ZP 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%
M  @ S4N>6-Q4@&6# P  QA   !D              ("!I+H! 'AL+W=O<FMS
M:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " #-2YY8HG':N[0#  "2$P
M&0              @(%>O@$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+
M 0(4 Q0    ( ,U+GEC-"N!YU08  .,O   9              " @4G" 0!X
M;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ S4N>6-)7D^DI
M!0  .AT  !D              ("!5<D! 'AL+W=O<FMS:&5E=',O<VAE970W
M-2YX;6Q02P$"% ,4    " #-2YY8WE-2KC0#  #E#   &0
M@(&US@$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( ,U+
MGE@4'+TLQP(  #@(   9              " @2#2 0!X;"]W;W)K<VAE971S
M+W-H965T-S<N>&UL4$L! A0#%     @ S4N>6!U..!S+!   T18  !D
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M=#@R+GAM;%!+ 0(4 Q0    ( ,U+GEBM;._6: 8  (P?   9
M  " @1;[ 0!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @
MS4N>6 "-^QN<!   MQD  !D              ("!M0$" 'AL+W=O<FMS:&5E
M=',O<VAE970X-"YX;6Q02P$"% ,4    " #-2YY8[5#:+YP&  #/20  &0
M            @(&(!@( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4
M Q0    ( ,U+GECK1$ZG*@,  (L0   9              " @5L- @!X;"]W
M;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ S4N>6.#[,Z(K!
M"@\  !D              ("!O! " 'AL+W=O<FMS:&5E=',O<VAE970X-RYX
M;6Q02P$"% ,4    " #-2YY8/F%77%\"  #/!@  &0              @($>
M%0( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( ,U+GEAF
M_0 M+0,  (4(   9              " @;07 @!X;"]W;W)K<VAE971S+W-H
M965T.#DN>&UL4$L! A0#%     @ S4N>6'G+["86 @  DP0  !D
M     ("!&!L" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4
M" #-2YY8FIG$5QH%  ".)P  &0              @(%E'0( >&PO=V]R:W-H
M965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( ,U+GECE4,%24@,  # 5   -
M              "  ;8B @!X;"]S='EL97,N>&UL4$L! A0#%     @ S4N>
M6)>*NQS     $P(   L              ( !,R8" %]R96QS+RYR96QS4$L!
M A0#%     @ S4N>6-4U2.8Z!@  CSL   \              ( !'"<" 'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,U+GEA?3NH*I@(  )@U   :
M          "  8,M @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( ,U+GEA[-A;M/0(  /$S   3              "  6$P @!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !C &, +!L  ,\R @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>289</ContextCount>
  <ElementCount>475</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>92</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Investment and Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/InvestmentandFairValueMeasurement</Role>
      <ShortName>Investment and Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Other Receivables and Prepayments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/OtherReceivablesandPrepayments</Role>
      <ShortName>Other Receivables and Prepayments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Long-Term Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/LongTermDeposits</Role>
      <ShortName>Long-Term Deposits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Related Party Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/RelatedPartyBalancesandTransactions</Role>
      <ShortName>Related Party Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Variable Interest Entity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/VariableInterestEntity</Role>
      <ShortName>Variable Interest Entity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/Lease</Role>
      <ShortName>Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Convertible Note</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ConvertibleNote</Role>
      <ShortName>Convertible Note</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Ordinary Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/OrdinaryShares</Role>
      <ShortName>Ordinary Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Share Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ShareBasedCompensation</Role>
      <ShortName>Share Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Non-Controlling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/NonControllingInterest</Role>
      <ShortName>Non-Controlling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Organization (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/OrganizationTables</Role>
      <ShortName>Organization (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/Organization</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Investment and Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables</Role>
      <ShortName>Investment and Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/InvestmentandFairValueMeasurement</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Other Receivables and Prepayments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables</Role>
      <ShortName>Other Receivables and Prepayments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/OtherReceivablesandPrepayments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IntangibleAssetsNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Long-Term Deposits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/LongTermDepositsTables</Role>
      <ShortName>Long-Term Deposits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/LongTermDeposits</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Related Party Balances and Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables</Role>
      <ShortName>Related Party Balances and Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/RelatedPartyBalancesandTransactions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Variable Interest Entity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/VariableInterestEntityTables</Role>
      <ShortName>Variable Interest Entity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/VariableInterestEntity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/LeaseTables</Role>
      <ShortName>Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/Lease</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Share Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/ShareBasedCompensation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/NetLossPerShare</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/CommitmentsandContingencies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Organization (Details) - Schedule of Major Subsidiaries Consolidated</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable</Role>
      <ShortName>Organization (Details) - Schedule of Major Subsidiaries Consolidated</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/OrganizationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/LiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/Liquidity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Investment and Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails</Role>
      <ShortName>Investment and Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable</Role>
      <ShortName>Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Fair Value Reconciliation of Level 3 Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable</Role>
      <ShortName>Investment and Fair Value Measurement (Details) - Schedule of Fair Value Reconciliation of Level 3 Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Quantitative Information about the Group???s Level 3 Fair Value Measurements of Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable</Role>
      <ShortName>Investment and Fair Value Measurement (Details) - Schedule of Quantitative Information about the Group???s Level 3 Fair Value Measurements of Investment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Unrealized Gains and Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable</Role>
      <ShortName>Investment and Fair Value Measurement (Details) - Schedule of Unrealized Gains and Losses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Carrying Value of Our Non-Marketable Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable</Role>
      <ShortName>Investment and Fair Value Measurement (Details) - Schedule of Carrying Value of Our Non-Marketable Investments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Other Receivables and Prepayments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsDetails</Role>
      <ShortName>Other Receivables and Prepayments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Other Receivables and Prepayments (Details) - Schedule of Other Receivables and Prepayments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable</Role>
      <ShortName>Other Receivables and Prepayments (Details) - Schedule of Other Receivables and Prepayments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Intangible Assets, Net (Details) - Schedule of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets, Net (Details) - Schedule of Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Intangible Assets, Net (Details) - Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets, Net (Details) - Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Long-Term Deposits (Details) - Schedule of Long-Term Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable</Role>
      <ShortName>Long-Term Deposits (Details) - Schedule of Long-Term Deposits</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/LongTermDepositsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IncomeTaxesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Income Taxes (Details) - Schedule of Provision for Income Taxes Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Provision for Income Taxes Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IncomeTaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IncomeTaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IncomeTaxesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Asset and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Deferred Tax Asset and Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IncomeTaxesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Income Taxes (Details) - Schedule of Changes in Valuation Allowance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Changes in Valuation Allowance</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/IncomeTaxesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Related Party Balances and Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails</Role>
      <ShortName>Related Party Balances and Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Related Party Transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Variable Interest Entity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/VariableInterestEntityDetails</Role>
      <ShortName>Variable Interest Entity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/VariableInterestEntityTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Variable Interest Entity (Details) - Schedule of Aggregate Carrying Value of Vies??? Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable</Role>
      <ShortName>Variable Interest Entity (Details) - Schedule of Aggregate Carrying Value of Vies??? Assets and Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/VariableInterestEntityTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/LeaseDetails</Role>
      <ShortName>Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/LeaseTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Lease (Details) - Schedule of Operating Leases Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable</Role>
      <ShortName>Lease (Details) - Schedule of Operating Leases Obligation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/LeaseTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Lease (Details) - Schedule of Maturity Analysis of Operating Leases Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable</Role>
      <ShortName>Lease (Details) - Schedule of Maturity Analysis of Operating Leases Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/LeaseTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Convertible Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ConvertibleNoteDetails</Role>
      <ShortName>Convertible Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/ConvertibleNote</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Ordinary Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/OrdinarySharesDetails</Role>
      <ShortName>Ordinary Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/OrdinaryShares</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Share Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ShareBasedCompensationDetails</Role>
      <ShortName>Share Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Share Based Compensation (Details) - Schedule of the Option Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable</Role>
      <ShortName>Share Based Compensation (Details) - Schedule of the Option Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable</Role>
      <ShortName>Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Non-Controlling Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/NonControllingInterestDetails</Role>
      <ShortName>Non-Controlling Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/NonControllingInterest</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/NetLossPerShareTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted (loss) income per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of basic and diluted (loss) income per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/NetLossPerShareTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996060 - Disclosure - Commitments and Contingencies (Details) - Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996061 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/SegmentReporting</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="ea0203681-20f_aptorum.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996062 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aptorumgroup.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aptorumgroup.com/role/SubsequentEvents</ParentRole>
      <Position>91</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:LoansAndLeasesReceivableRelatedParties -  ea0203681-20f_aptorum.htm 20865, 20876, 20877</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate -  ea0203681-20f_aptorum.htm 20889, 20891</Log>
  </Logs>
  <InputFiles>
    <File>apm-20231231.xsd</File>
    <File>apm-20231231_cal.xml</File>
    <File>apm-20231231_def.xml</File>
    <File>apm-20231231_lab.xml</File>
    <File>apm-20231231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="ea0203681-20f_aptorum.htm">ea0203681-20f_aptorum.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1005">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="56">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>127
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0203681-20f_aptorum.htm": {
   "nsprefix": "apm",
   "nsuri": "http://aptorumgroup.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "apm-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "apm-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apm-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "apm-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apm-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0203681-20f_aptorum.htm"
     ]
    }
   },
   "keyStandard": 368,
   "keyCustom": 107,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 38,
   "memberCustom": 48,
   "hidden": {
    "total": 285,
    "http://aptorumgroup.com/20231231": 101,
    "http://fasb.org/us-gaap/2023": 181,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 289,
   "entityCount": 1,
   "segmentCount": 92,
   "elementCount": 772,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1005,
    "http://xbrl.sec.gov/dei/2023": 56
   },
   "report": {
    "R1": {
     "role": "http://aptorumgroup.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://aptorumgroup.com/role/ShareholdersEquityType2or3",
     "longName": "004 - Statement - Consolidated Statements of Shareholders\u2019 Equity",
     "shortName": "Consolidated Statements of Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://aptorumgroup.com/role/ConsolidatedCashFlow",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://aptorumgroup.com/role/Organization",
     "longName": "006 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://aptorumgroup.com/role/Liquidity",
     "longName": "007 - Disclosure - Liquidity",
     "shortName": "Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "apm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "apm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://aptorumgroup.com/role/Revenue",
     "longName": "009 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://aptorumgroup.com/role/InvestmentandFairValueMeasurement",
     "longName": "010 - Disclosure - Investment and Fair Value Measurement",
     "shortName": "Investment and Fair Value Measurement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://aptorumgroup.com/role/OtherReceivablesandPrepayments",
     "longName": "011 - Disclosure - Other Receivables and Prepayments",
     "shortName": "Other Receivables and Prepayments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://aptorumgroup.com/role/PropertyandEquipmentNet",
     "longName": "012 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://aptorumgroup.com/role/IntangibleAssetsNet",
     "longName": "013 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://aptorumgroup.com/role/LongTermDeposits",
     "longName": "014 - Disclosure - Long-Term Deposits",
     "shortName": "Long-Term Deposits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://aptorumgroup.com/role/AccountsPayableandAccruedExpenses",
     "longName": "015 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://aptorumgroup.com/role/IncomeTaxes",
     "longName": "016 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactions",
     "longName": "017 - Disclosure - Related Party Balances and Transactions",
     "shortName": "Related Party Balances and Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://aptorumgroup.com/role/VariableInterestEntity",
     "longName": "018 - Disclosure - Variable Interest Entity",
     "shortName": "Variable Interest Entity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://aptorumgroup.com/role/Lease",
     "longName": "019 - Disclosure - Lease",
     "shortName": "Lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://aptorumgroup.com/role/ConvertibleNote",
     "longName": "020 - Disclosure - Convertible Note",
     "shortName": "Convertible Note",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://aptorumgroup.com/role/OrdinaryShares",
     "longName": "021 - Disclosure - Ordinary Shares",
     "shortName": "Ordinary Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://aptorumgroup.com/role/ShareBasedCompensation",
     "longName": "022 - Disclosure - Share Based Compensation",
     "shortName": "Share Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aptorumgroup.com/role/NonControllingInterest",
     "longName": "023 - Disclosure - Non-Controlling Interest",
     "shortName": "Non-Controlling Interest",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://aptorumgroup.com/role/NetLossPerShare",
     "longName": "024 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aptorumgroup.com/role/CommitmentsandContingencies",
     "longName": "025 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://aptorumgroup.com/role/SegmentReporting",
     "longName": "026 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://aptorumgroup.com/role/SubsequentEvents",
     "longName": "027 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://aptorumgroup.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://aptorumgroup.com/role/OrganizationTables",
     "longName": "996001 - Disclosure - Organization (Tables)",
     "shortName": "Organization (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996002 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "apm:PropertyPlantAndEquipmentUsefullLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "apm:PropertyPlantAndEquipmentUsefullLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables",
     "longName": "996003 - Disclosure - Investment and Fair Value Measurement (Tables)",
     "shortName": "Investment and Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables",
     "longName": "996004 - Disclosure - Other Receivables and Prepayments (Tables)",
     "shortName": "Other Receivables and Prepayments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://aptorumgroup.com/role/PropertyandEquipmentNetTables",
     "longName": "996005 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://aptorumgroup.com/role/IntangibleAssetsNetTables",
     "longName": "996006 - Disclosure - Intangible Assets, Net (Tables)",
     "shortName": "Intangible Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://aptorumgroup.com/role/LongTermDepositsTables",
     "longName": "996007 - Disclosure - Long-Term Deposits (Tables)",
     "shortName": "Long-Term Deposits (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "apm:ScheduleOfLongTermDepositsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "apm:ScheduleOfLongTermDepositsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables",
     "longName": "996008 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://aptorumgroup.com/role/IncomeTaxesTables",
     "longName": "996009 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables",
     "longName": "996010 - Disclosure - Related Party Balances and Transactions (Tables)",
     "shortName": "Related Party Balances and Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "apm:ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "apm:ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://aptorumgroup.com/role/VariableInterestEntityTables",
     "longName": "996011 - Disclosure - Variable Interest Entity (Tables)",
     "shortName": "Variable Interest Entity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://aptorumgroup.com/role/LeaseTables",
     "longName": "996012 - Disclosure - Lease (Tables)",
     "shortName": "Lease (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://aptorumgroup.com/role/ShareBasedCompensationTables",
     "longName": "996013 - Disclosure - Share Based Compensation (Tables)",
     "shortName": "Share Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://aptorumgroup.com/role/NetLossPerShareTables",
     "longName": "996014 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://aptorumgroup.com/role/CommitmentsandContingenciesTables",
     "longName": "996015 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "apm:ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "apm:ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable",
     "longName": "996016 - Disclosure - Organization (Details) - Schedule of Major Subsidiaries Consolidated",
     "shortName": "Organization (Details) - Schedule of Major Subsidiaries Consolidated",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c56",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c56",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://aptorumgroup.com/role/LiquidityDetails",
     "longName": "996017 - Disclosure - Liquidity (Details)",
     "shortName": "Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "apm:UnrestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "apm:LiquidityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996018 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "apm:AllowanceForCreditLossOfDueFromARelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable",
     "longName": "996019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c85",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c85",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
     "longName": "996020 - Disclosure - Investment and Fair Value Measurement (Details)",
     "shortName": "Investment and Fair Value Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable",
     "longName": "996021 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis",
     "shortName": "Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable",
     "longName": "996022 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Fair Value Reconciliation of Level 3 Assets",
     "shortName": "Investment and Fair Value Measurement (Details) - Schedule of Fair Value Reconciliation of Level 3 Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c112",
      "name": "apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c115",
      "name": "apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable",
     "longName": "996023 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Quantitative Information about the Group\u2019s Level 3 Fair Value Measurements of Investment",
     "shortName": "Investment and Fair Value Measurement (Details) - Schedule of Quantitative Information about the Group\u2019s Level 3 Fair Value Measurements of Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c117",
      "name": "apm:FairValueMeasurementValuationTechniques",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c117",
      "name": "apm:FairValueMeasurementValuationTechniques",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable",
     "longName": "996024 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Unrealized Gains and Losses",
     "shortName": "Investment and Fair Value Measurement (Details) - Schedule of Unrealized Gains and Losses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "apm:UpwardAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "apm:UpwardAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable",
     "longName": "996025 - Disclosure - Investment and Fair Value Measurement (Details) - Schedule of Carrying Value of Our Non-Marketable Investments",
     "shortName": "Investment and Fair Value Measurement (Details) - Schedule of Carrying Value of Our Non-Marketable Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "apm:InitialCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "apm:InitialCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsDetails",
     "longName": "996026 - Disclosure - Other Receivables and Prepayments (Details)",
     "shortName": "Other Receivables and Prepayments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "apm:WritteoffOfPrepaymentAndOtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable",
     "longName": "996027 - Disclosure - Other Receivables and Prepayments (Details) - Schedule of Other Receivables and Prepayments",
     "shortName": "Other Receivables and Prepayments (Details) - Schedule of Other Receivables and Prepayments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "apm:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "apm:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails",
     "longName": "996028 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996029 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment, Net (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://aptorumgroup.com/role/IntangibleAssetsNetDetails",
     "longName": "996030 - Disclosure - Intangible Assets, Net (Details)",
     "shortName": "Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable",
     "longName": "996031 - Disclosure - Intangible Assets, Net (Details) - Schedule of Intangible Assets",
     "shortName": "Intangible Assets, Net (Details) - Schedule of Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable",
     "longName": "996032 - Disclosure - Intangible Assets, Net (Details) - Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets",
     "shortName": "Intangible Assets, Net (Details) - Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable",
     "longName": "996033 - Disclosure - Long-Term Deposits (Details) - Schedule of Long-Term Deposits",
     "shortName": "Long-Term Deposits (Details) - Schedule of Long-Term Deposits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "apm:RentalDeposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "apm:RentalDeposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
     "longName": "996034 - Disclosure - Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c135",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c135",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable",
     "longName": "996035 - Disclosure - Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://aptorumgroup.com/role/IncomeTaxesDetails",
     "longName": "996036 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable",
     "longName": "996037 - Disclosure - Income Taxes (Details) - Schedule of Provision for Income Taxes Expenses",
     "shortName": "Income Taxes (Details) - Schedule of Provision for Income Taxes Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable",
     "longName": "996038 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate",
     "shortName": "Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals",
     "longName": "996039 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Parentheticals)",
     "shortName": "Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Parentheticals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable",
     "longName": "996040 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Asset and Liabilities",
     "shortName": "Income Taxes (Details) - Schedule of Deferred Tax Asset and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable",
     "longName": "996041 - Disclosure - Income Taxes (Details) - Schedule of Changes in Valuation Allowance",
     "shortName": "Income Taxes (Details) - Schedule of Changes in Valuation Allowance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "apm:ValuationAllowanceDeferredTaxAssetIncrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
     "longName": "996042 - Disclosure - Related Party Balances and Transactions (Details)",
     "shortName": "Related Party Balances and Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c146",
      "name": "us-gaap:LongTermLineOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c146",
      "name": "us-gaap:LongTermLineOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable",
     "longName": "996043 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "apm:AmountsDueFromRelatedPartiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "apm:AmountsDueFromRelatedPartiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable",
     "longName": "996044 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "apm:AmountsDueToRelatedPartiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "apm:AmountsDueToRelatedPartiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable",
     "longName": "996045 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Related Party Transactions",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c174",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c174",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://aptorumgroup.com/role/VariableInterestEntityDetails",
     "longName": "996046 - Disclosure - Variable Interest Entity (Details)",
     "shortName": "Variable Interest Entity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable",
     "longName": "996047 - Disclosure - Variable Interest Entity (Details) - Schedule of Aggregate Carrying Value of Vies\u2019 Assets and Liabilities",
     "shortName": "Variable Interest Entity (Details) - Schedule of Aggregate Carrying Value of Vies\u2019 Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c204",
      "name": "us-gaap:OtherAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c204",
      "name": "us-gaap:OtherAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://aptorumgroup.com/role/LeaseDetails",
     "longName": "996048 - Disclosure - Lease (Details)",
     "shortName": "Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "apm:OperatingLeaseWeightedAverageDiscountRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:LeaseCostTableTextBlock",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable",
     "longName": "996049 - Disclosure - Lease (Details) - Schedule of Operating Leases Obligation",
     "shortName": "Lease (Details) - Schedule of Operating Leases Obligation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c10",
      "name": "apm:FinanceLeaseDepreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c10",
      "name": "apm:FinanceLeaseDepreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable",
     "longName": "996050 - Disclosure - Lease (Details) - Schedule of Maturity Analysis of Operating Leases Liabilities",
     "shortName": "Lease (Details) - Schedule of Maturity Analysis of Operating Leases Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://aptorumgroup.com/role/ConvertibleNoteDetails",
     "longName": "996051 - Disclosure - Convertible Note (Details)",
     "shortName": "Convertible Note (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c213",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c213",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://aptorumgroup.com/role/OrdinarySharesDetails",
     "longName": "996052 - Disclosure - Ordinary Shares (Details)",
     "shortName": "Ordinary Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c215",
      "name": "us-gaap:CommonStockOtherValueOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c215",
      "name": "us-gaap:CommonStockOtherValueOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
     "longName": "996053 - Disclosure - Share Based Compensation (Details)",
     "shortName": "Share Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable",
     "longName": "996054 - Disclosure - Share Based Compensation (Details) - Schedule of the Option Activity",
     "shortName": "Share Based Compensation (Details) - Schedule of the Option Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c262",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c267",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable",
     "longName": "996055 - Disclosure - Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model",
     "shortName": "Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c10",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c10",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://aptorumgroup.com/role/NonControllingInterestDetails",
     "longName": "996056 - Disclosure - Non-Controlling Interest (Details)",
     "shortName": "Non-Controlling Interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c281",
      "name": "us-gaap:OtherOwnershipInterestsUnitsIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c281",
      "name": "us-gaap:OtherOwnershipInterestsUnitsIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://aptorumgroup.com/role/NetLossPerShareDetails",
     "longName": "996057 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable",
     "longName": "996058 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted (loss) income per share",
     "shortName": "Net Loss Per Share (Details) - Schedule of basic and diluted (loss) income per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://aptorumgroup.com/role/CommitmentsandContingenciesDetails",
     "longName": "996059 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "apm:MilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "apm:MilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable",
     "longName": "996060 - Disclosure - Commitments and Contingencies (Details) - Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "apm:PreclinicalToIndFiling",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "apm:PreclinicalToIndFiling",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://aptorumgroup.com/role/SegmentReportingDetails",
     "longName": "996061 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://aptorumgroup.com/role/SubsequentEventsDetails",
     "longName": "996062 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EquityFairValueAdjustment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EquityFairValueAdjustment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203681-20f_aptorum.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "apm_ACCMedicalLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ACCMedicalLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACC Medical Limited [Member]",
        "label": "ACCMedical Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_APTUSMANAGEMENTLIMITEDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "APTUSMANAGEMENTLIMITEDMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APTUS MANAGEMENT LIMITED [Member]",
        "label": "APTUSMANAGEMENTLIMITEDMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AccountsPayableAndAccruedExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AccountsPayableAndAccruedExpensesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts payable and accrued expenses",
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "apm_AccountsPayableandAccruedExpensesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AccountsPayableandAccruedExpensesDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AccountsPayableandAccruedExpensesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AccountsPayableandAccruedExpensesTablesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses [Abstract]",
        "label": "Accounts Payableand Accrued Expenses Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AccountsPayableandAccruedExpensesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AccountsPayableandAccruedExpensesTablesTable",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "apm_AccretionOfFinanceLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AccretionOfFinanceLeaseObligation",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of finance lease obligation",
        "documentation": "Accretion of finance lease obligation.",
        "label": "Accretion Of Finance Lease Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees payable",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r201",
      "r615"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income Amount",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r213",
      "r220",
      "r844",
      "r845"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r120",
      "r209",
      "r610",
      "r631",
      "r634"
     ]
    },
    "apm_ActiculeLifeSciencesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ActiculeLifeSciencesLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acticule Life Sciences Limited [Member]",
        "label": "Acticule Life Sciences Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r806",
      "r943"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital Amount",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r650",
      "r859",
      "r860",
      "r861",
      "r916",
      "r947"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "apm_AdjustmentIncreaseDecreaseRetainedEarningsDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AdjustmentIncreaseDecreaseRetainedEarningsDeficit",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deficit value (in Dollars)",
        "documentation": "Amount of fresh-start adjustment to retained earnings or deficit.",
        "label": "Adjustment Increase Decrease Retained Earnings Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AdjustmentToIssuanceOfSharesToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AdjustmentToIssuanceOfSharesToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares to non-controlling interest",
        "documentation": "Amount of adjustment to issuance of shares to non-controlling interest.",
        "label": "Adjustment To Issuance Of Shares To Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r418"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rounding up for reverse stock split",
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r146"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AdministrativeManagementServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AdministrativeManagementServices",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative management services",
        "documentation": "Administrative management services.",
        "label": "Administrative Management Services"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AencoTechnologiesLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AencoTechnologiesLtdMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aenco Technologies Ltd [Member]",
        "label": "Aenco Technologies Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AeneasGroupLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AeneasGroupLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aeneas Group Limited [Member]",
        "label": "Aeneas Group Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AeneasManagementLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AeneasManagementLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aeneas Management Limited [Member]",
        "label": "Aeneas Management Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation charges (in Dollars)",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r462"
     ]
    },
    "apm_AllowanceForCreditLossOfDueFromARelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AllowanceForCreditLossOfDueFromARelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss of due from a related party",
        "verboseLabel": "Allowance for credit losses",
        "documentation": "Allowance for credit loss of due from a related party.",
        "label": "Allowance For Credit Loss Of Due From ARelated Party"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of Intangible Assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r54",
      "r58"
     ]
    },
    "apm_AmountsDueFromRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AmountsDueFromRelatedPartiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts due from related parties",
        "documentation": "Amounts dure from related parties classified as current.",
        "label": "Amounts Due From Related Parties Current"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AmountsDueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AmountsDueToRelatedPartiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts due to related parties, Current",
        "documentation": "Amounts due to related parties, classified as current.",
        "label": "Amounts Due To Related Parties Current"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AmountsDueToRelatedPartiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AmountsDueToRelatedPartiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts due to related parties, Non-current",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Amounts Due To Related Parties Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AptorumMedicalLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AptorumMedicalLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aptorum Medical Limited [Member]",
        "label": "Aptorum Medical Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_AptorumTherapeuticsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "AptorumTherapeuticsLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aptorum Therapeutics Limited (\u201cATL\u201d) [Member]",
        "label": "Aptorum Therapeutics Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r204",
      "r239",
      "r288",
      "r298",
      "r303",
      "r321",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r494",
      "r498",
      "r522",
      "r606",
      "r694",
      "r806",
      "r818",
      "r879",
      "r880",
      "r925"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r212",
      "r239",
      "r321",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r494",
      "r498",
      "r522",
      "r806",
      "r879",
      "r880",
      "r925"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "verboseLabel": "Current Assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_AssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Assets/ (Liabilities)",
        "label": "Net Assets",
        "documentation": "Amount of net assets (liabilities)."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825"
     ]
    },
    "us-gaap_AutomobilesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AutomobilesMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor vehicle [Member]",
        "label": "Automobiles [Member]",
        "documentation": "Vehicles that are used primarily for transporting people."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r799",
      "r800"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r75",
      "r492",
      "r799",
      "r800"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting interest",
        "verboseLabel": "Voting right percentage",
        "netLabel": "Voting power",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada [Member]",
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "apm_CGYInvestmentsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "CGYInvestmentsLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable",
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CGY Investments Limited [Member]",
        "label": "CGYInvestments Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalUnitsAuthorized",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized share capital",
        "label": "Capital Units, Authorized",
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r608",
      "r661",
      "r688",
      "r806",
      "r818",
      "r836"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r157"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents and restricted cash \u2013 Beginning of year",
        "periodEndLabel": "Cash and cash equivalents and restricted cash \u2013 End of year",
        "totalLabel": "Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r130",
      "r235"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r130"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating, investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ClarkChengMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ClarkChengMember",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clark Cheng [Member]",
        "label": "Clark Cheng Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ConvertibleNoteDetails",
      "http://aptorumgroup.com/role/DocumentAndEntityInformation",
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3",
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r205",
      "r206",
      "r207",
      "r239",
      "r267",
      "r271",
      "r274",
      "r276",
      "r282",
      "r283",
      "r321",
      "r345",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r381",
      "r382",
      "r384",
      "r387",
      "r394",
      "r522",
      "r639",
      "r640",
      "r641",
      "r642",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r680",
      "r703",
      "r726",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r831",
      "r853",
      "r863"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "apm_ClavesLifeSciencesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ClavesLifeSciencesLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Claves Life Sciences Limited [Member]",
        "label": "Claves Life Sciences Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r104",
      "r607",
      "r679"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstart]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r339",
      "r340",
      "r759",
      "r877"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://aptorumgroup.com/role/ConvertibleNoteDetails",
      "http://aptorumgroup.com/role/DocumentAndEntityInformation",
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3",
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Ordinary Shares",
        "verboseLabel": "Class A",
        "netLabel": "Class A Ordinary Shares [Member]",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://aptorumgroup.com/role/DocumentAndEntityInformation",
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3",
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Ordinary Shares",
        "verboseLabel": "Class B",
        "netLabel": "Class B Ordinary Shares [Member]",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "apm_CommonStock1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "CommonStock1Member",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stocks One [Member]",
        "label": "Common Stock1 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable",
      "http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "verboseLabel": "Common Stocks [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809",
      "r810",
      "r812",
      "r813",
      "r814",
      "r815",
      "r859",
      "r860",
      "r916",
      "r940",
      "r947"
     ]
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued",
        "label": "Common Stock, Other Shares, Outstanding",
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockOtherValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockOtherValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price (in Dollars)",
        "label": "Common Stock, Other Value, Outstanding",
        "documentation": "Value of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Ordinary per share (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r680"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r114",
      "r680",
      "r700",
      "r947",
      "r948"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r609",
      "r806"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonUnitIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonUnitIssued",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued",
        "label": "Common Unit, Issued",
        "documentation": "Number of common units issued of limited liability company (LLC)."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_CompensationAndBenefitsTrust": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndBenefitsTrust",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation amount",
        "label": "Compensation and Benefits Trust",
        "documentation": "The value of a trust established to hold the stock of an employee compensation and benefits plan as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to the shareholders of Aptorum Group Limited",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r216",
      "r218",
      "r227",
      "r600",
      "r622"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Comprehensive loss attributable to non-controlling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r78",
      "r89",
      "r216",
      "r218",
      "r226",
      "r599",
      "r621"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r155",
      "r216",
      "r218",
      "r225",
      "r598",
      "r620"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income or loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment [Member]",
        "verboseLabel": "Computer Equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software [Member]",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r872",
      "r873"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of credit risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r177"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r494",
      "r495",
      "r498",
      "r499",
      "r566",
      "r769",
      "r878",
      "r881",
      "r882"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of presentation and consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r779"
     ]
    },
    "apm_ConsultantSecondmentManagementAndAdministrativeServicesFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ConsultantSecondmentManagementAndAdministrativeServicesFees",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of loan from a related party through issuance of Convertible Note",
        "documentation": "Consultant, secondment, management and administrative services fees.",
        "label": "Consultant Secondment Management And Administrative Services Fees"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original principal amount",
        "label": "Convertible Debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r161",
      "r937"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Payable [Member]",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r355",
      "r356",
      "r366",
      "r367",
      "r368",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793"
     ]
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes to a related party",
        "label": "Convertible Debt, Noncurrent",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "apm_ConvertibleNoteDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ConvertibleNoteDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ConvertibleNotesConvertedToClassAOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ConvertibleNotesConvertedToClassAOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes converted to Class A Ordinary Shares",
        "documentation": "Convertible notes converted to Class A Ordinary Shares.",
        "label": "Convertible Notes Converted To Class AOrdinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes [Member]",
        "label": "Convertible Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes",
        "label": "Convertible Notes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Payable [Member]",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r160"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible shares",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r63",
      "r113",
      "r145",
      "r390"
     ]
    },
    "apm_CostOfHealthcareServicesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "CostOfHealthcareServicesPayable",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of healthcare services payable",
        "documentation": "Cost of healthcare services payable.",
        "label": "Cost Of Healthcare Services Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of healthcare services",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r239",
      "r321",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r522",
      "r879"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of healthcare services",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "apm_CurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "CurrentAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_CurrentAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "CurrentAbstract0",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r478",
      "r487",
      "r856"
     ]
    },
    "apm_DSFInvestmentHoldingsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DSFInvestmentHoldingsLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DSF Investment Holdings Limited [Member]",
        "label": "DSFInvestment Holdings Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNote"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE NOTE",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r237",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r370",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r111",
      "r112",
      "r160",
      "r161",
      "r243",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r535",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r854"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument conversion price",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r357"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument original principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99",
      "r355",
      "r535",
      "r790",
      "r791"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r356"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r243",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r535",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r854"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "apm_DecreasedOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DecreasedOwnershipPercentage",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decreased ownership percentage",
        "documentation": "Decreased ownership percentage.",
        "label": "Decreased Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Receivables and Prepayments",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r153",
      "r185",
      "r486",
      "r487",
      "r856"
     ]
    },
    "apm_DeferredTaxAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DeferredTaxAssetAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset:",
        "label": "Deferred Tax Asset Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_DeferredTaxAssetsDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DeferredTaxAssetsDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "documentation": "Depreciation and amortization.",
        "label": "Deferred Tax Assets Depreciation And Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset, net",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax loss carry forward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r914"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred cash bonus payables",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r914"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred cash bonus payables",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r914"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r914"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r914"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable",
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax asset, net",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r913"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r914"
     ]
    },
    "apm_DeferredTaxLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DeferredTaxLiabilityAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability:",
        "label": "Deferred Tax Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Long-term deposits",
        "label": "Deposits Assets, Noncurrent",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expenses",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r59"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization and depreciation",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r292"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r670",
      "r685",
      "r686",
      "r687",
      "r690",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r721",
      "r722",
      "r723",
      "r743",
      "r744",
      "r745",
      "r746",
      "r808",
      "r810"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on investments in derivatives",
        "negatedLabel": "Loss on investments in derivatives",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r93",
      "r668",
      "r670",
      "r685",
      "r686",
      "r687",
      "r690",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r721",
      "r722",
      "r723",
      "r743",
      "r744",
      "r745",
      "r746",
      "r778",
      "r808",
      "r810"
     ]
    },
    "apm_DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DiagnosticsTechnologyUpToTheConditionsAndMilestonesOfAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diagnostics technology: up to the conditions and milestones of",
        "label": "Diagnostics Technology Up To The Conditions And Milestones Of Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r420",
      "r451",
      "r452",
      "r454",
      "r802"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block Supplement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_DisposalOfSubsidiariesNetOfCashDisposed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DisposalOfSubsidiariesNetOfCashDisposed",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposal of subsidiaries, net of cash disposed",
        "documentation": "Disposal of subsidiaries net of cash disposed.",
        "label": "Disposal Of Subsidiaries Net Of Cash Disposed"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "apm_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825",
      "r827"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "apm_DownwardAdjustmentAndImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DownwardAdjustmentAndImpairment",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable": {
       "parentTag": "apm_TotalCarryingValueAtTheEndOfThePeriod",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Downward adjustments and impairment",
        "documentation": "The amount of downward adjustment and impairment.",
        "label": "Downward Adjustment And Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "apm_DownwardAdjustmentsAndImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DownwardAdjustmentsAndImpairment",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable": {
       "parentTag": "apm_TotalUnrealizedGainForNonmarketableInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Downward adjustments and impairment",
        "documentation": "The amount of downward adjustments and impairment.",
        "label": "Downward Adjustments And Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "apm_DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DrugMoleculesUpToTheConditionsAndMilestonesOfAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug molecules: up to the conditions and milestones of",
        "label": "Drug Molecules Up To The Conditions And Milestones Of Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_DueFromBrokers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "DueFromBrokers",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from brokers",
        "documentation": "For an unclassified balance sheet, amounts due from brokers including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due From Brokers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome",
      "http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- Basic (in Dollars per share)",
        "verboseLabel": "Basic",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r264",
      "r267",
      "r274",
      "r275",
      "r276",
      "r280",
      "r510",
      "r511",
      "r601",
      "r623",
      "r782"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome",
      "http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- Diluted (in Dollars per share)",
        "verboseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r267",
      "r274",
      "r275",
      "r276",
      "r280",
      "r510",
      "r511",
      "r601",
      "r623",
      "r782"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income or loss per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r277",
      "r278",
      "r279"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure the tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails",
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for income taxes at Hong Kong statutory income tax rate",
        "terseLabel": "Income tax rate percentage",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r469",
      "r488"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred cash bonus payable (in Dollars)",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred bonus and salaries payable",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "apm_EmployeesAndExternalConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "EmployeesAndExternalConsultantsMember",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and External Consultants [Member]",
        "label": "Employees And External Consultants Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees [Member]",
        "label": "Employees Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incorporation date",
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "apm_EntityIncorporationsStateCountryName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "EntityIncorporationsStateCountryName",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Place of incorporation",
        "documentation": "Place of incorporation.",
        "label": "Entity Incorporations State Country Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r192",
      "r220",
      "r221",
      "r222",
      "r244",
      "r245",
      "r246",
      "r250",
      "r258",
      "r260",
      "r281",
      "r322",
      "r325",
      "r396",
      "r455",
      "r456",
      "r457",
      "r479",
      "r480",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r509",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r556",
      "r627",
      "r628",
      "r629",
      "r650",
      "r726"
     ]
    },
    "us-gaap_EquityFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity value (in Dollars)",
        "label": "Equity, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary impairment",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment amounted",
        "verboseLabel": "Equity investment (in Dollars)",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r317",
      "r837",
      "r868"
     ]
    },
    "us-gaap_ExcessStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExcessStockSharesIssued",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of vested ordinary shares (in Shares)",
        "verboseLabel": "Ordinary Share issued",
        "label": "Excess Stock, Shares Issued",
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExcessStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExcessStockSharesOutstanding",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share outstanding",
        "label": "Excess Stock, Shares Outstanding",
        "documentation": "Number of shares of excess stock held by shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "apm_ExchangeDifferenceOnTranslationOfForeignOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ExchangeDifferenceOnTranslationOfForeignOperation",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange difference on translation of foreign operation",
        "documentation": "Exchange difference on translation of foreign operation.",
        "label": "Exchange Difference On Translation Of Foreign Operation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Quantitative Information about the Group\u2019s Level 3 Fair Value Measurements of Investment",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r96"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Reconciliation of Level 3 Assets",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r96"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable",
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r517",
      "r570",
      "r571",
      "r572",
      "r790",
      "r791",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT AND FAIR VALUE MEASUREMENT",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r407",
      "r412",
      "r517",
      "r570",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r407",
      "r412",
      "r517",
      "r571",
      "r790",
      "r791",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable",
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r517",
      "r572",
      "r790",
      "r791",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "apm_FairValueMeasurementValuationTechniques": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FairValueMeasurementValuationTechniques",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation technique",
        "documentation": "Description of the inputs and valuation technique(s) used to measure fair value.",
        "label": "Fair Value Measurement Valuation Techniques"
       }
      }
     },
     "auth_ref": []
    },
    "apm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Values"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r570",
      "r571",
      "r572",
      "r790",
      "r791",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r520"
     ]
    },
    "apm_FairValueMeasurementsUnobservableInput": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FairValueMeasurementsUnobservableInput",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable input",
        "documentation": "Description of the inputs used to measure fair value.",
        "label": "Fair Value Measurements Unobservable Input"
       }
      }
     },
     "auth_ref": []
    },
    "apm_FairValueMeasurementsWeightedAverageRange": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FairValueMeasurementsWeightedAverageRange",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range (weighted average)",
        "documentation": "Description of the Range (weighted average).",
        "label": "Fair Value Measurements Weighted Average Range"
       }
      }
     },
     "auth_ref": []
    },
    "apm_FairValueOfChangeInUnrealizedAppreciationDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FairValueOfChangeInUnrealizedAppreciationDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unrealized appreciation, net",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Of Change In Unrealized Appreciation Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "apm_FdaApprovalObtaine": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FdaApprovalObtaine",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable": {
       "parentTag": "apm_MilestonePaymentsTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Before FDA approval",
        "documentation": "FDA approval obtained.",
        "label": "Fda Approval Obtaine"
       }
      }
     },
     "auth_ref": []
    },
    "apm_FinanceLeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FinanceLeaseCostAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost:",
        "label": "Finance Lease Cost Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_FinanceLeaseDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FinanceLeaseDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "documentation": "Depreciation expense recognized during period on finance leases.",
        "label": "Finance Lease Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r545",
      "r805"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of finance lease obligations",
        "terseLabel": "Financing cash flows from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r550"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate \u2013 finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r805"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term \u2013 finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r805"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r337"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r580",
      "r584"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r584"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNetDetails",
      "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r580"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_FirstCommercialSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FirstCommercialSale",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable": {
       "parentTag": "apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First commercial sale",
        "documentation": "First commercial sale.",
        "label": "First Commercial Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation and transaction",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "apm_FromEnteringPhase1ToBeforeFirstCommercialSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "FromEnteringPhase1ToBeforeFirstCommercialSale",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable": {
       "parentTag": "apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From entering phase 1 to before first commercial sale",
        "documentation": "From entering phase 1 to before first commercial sale.",
        "label": "From Entering Phase1 To Before First Commercial Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, fixture, and office and medical equipment [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom [Member]",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of property, plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r874",
      "r875"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on derecognition of non-financial assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of patented license",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on investments in marketable securities, net",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r830"
     ]
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain from fair value change of the long-term investments, net",
        "label": "Gain (Loss) on Sale of Investments",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "apm_GainOnDerecognitionOfNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "GainOnDerecognitionOfNonfinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derecognition of non-financial assets",
        "documentation": "Gain on derecognition of non-financial assets.",
        "label": "Gain On Derecognition Of Nonfinancial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "apm_GainOnUseOfDigitalCurrencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "GainOnUseOfDigitalCurrencies",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on use of digital currencies",
        "documentation": "Gain on use of digital currencies.",
        "label": "Gain On Use Of Digital Currencies"
       }
      }
     },
     "auth_ref": []
    },
    "apm_GainOnUseOfDigitalsCurrencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "GainOnUseOfDigitalsCurrencies",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on use of digital currencies",
        "documentation": "Gain on use of digital currencies.",
        "label": "Gain On Use Of Digitals Currencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainOrLossOnSaleOfStockInSubsidiary",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of subsidiaries",
        "negatedLabel": "Loss on disposal of subsidiaries",
        "label": "Gain (Loss) on Disposition of Stock in Subsidiary",
        "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r847",
      "r851",
      "r935"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative fees",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r705"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r331",
      "r332",
      "r333",
      "r788"
     ]
    },
    "apm_GrossProceed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "GrossProceed",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds (in Dollars)",
        "documentation": "Gross proceeds.",
        "label": "Gross Proceed"
       }
      }
     },
     "auth_ref": []
    },
    "apm_GroupsSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "GroupsSubsidiariesMember",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group\u2019s subsidiaries [Member]",
        "label": "Groups Subsidiaries Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_HK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "HK",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hong Kong [Member]",
        "label": "HONG KONG"
       }
      }
     },
     "auth_ref": []
    },
    "apm_HongKongHealthcareServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "HongKongHealthcareServicesMember",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hong Kong healthcare services [Member]",
        "label": "Hong Kong Healthcare Services Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_IanHuenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IanHuenMember",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ian Huen [Member]",
        "label": "Ian Huen Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss on long-lived assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r139"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "apm_IncomeTaxDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IncomeTaxDescription",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax, description",
        "documentation": "Income tax, description.",
        "label": "Income Tax Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r465",
      "r470",
      "r471",
      "r476",
      "r484",
      "r489",
      "r490",
      "r491",
      "r644"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable",
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income taxes expense",
        "terseLabel": "Effective income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r188",
      "r259",
      "r260",
      "r293",
      "r468",
      "r485",
      "r625"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r466",
      "r467",
      "r471",
      "r472",
      "r475",
      "r477",
      "r638"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of different tax rates in other jurisdictions",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes at Hong Kong statutory income tax rate (16.5%)",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxExemptIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxExemptIncome",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-taxable income",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_IncomeTaxUncertaintiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxUncertaintiesPolicy",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions",
        "label": "Income Tax Uncertainties, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Abstract]",
        "label": "Income Taxes Details Scheduleof Income Taxes Expenses Computedatthe Hong Kong Statutory Tax Rate Parentheticals Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateParentheticalsTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Parentheticals) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IncomeTaxesDetailsScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Provision for Income Taxes Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IncomeTaxesDetailsScheduleofProvisionforIncomeTaxesExpensesTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of Provision for Income Taxes Expenses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46"
     ]
    },
    "apm_IncreaseDecreaseDueFromBrokers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IncreaseDecreaseDueFromBrokers",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due from brokers",
        "documentation": "The increase (decrease) during the period in amounts due from brokers.",
        "label": "Increase Decrease Due From Brokers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Long-term deposits",
        "label": "Increase (Decrease) in Deposit Assets",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts due from related parties",
        "label": "Increase (Decrease) in Due from Related Parties",
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts due to related parties",
        "label": "Increase (Decrease) in Due to Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r850"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables and prepayments",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options and warrants",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r276"
     ]
    },
    "apm_InitialCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "InitialCostBasis",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable": {
       "parentTag": "apm_TotalCarryingValueAtTheEndOfThePeriod",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial cost basis",
        "documentation": "Initial cost basis.",
        "label": "Initial Cost Basis"
       }
      }
     },
     "auth_ref": []
    },
    "apm_InsuranceExpensePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "InsuranceExpensePayable",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance expenses payable",
        "documentation": "Insurance expense payable.",
        "label": "Insurance Expense Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS, NET",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amortization Expense Related to its Finite Lived Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IntangibleAssetsNetDetailsScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Details) - Schedule of Amortization Expense Related to its Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_IntangibleAssetsNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "IntangibleAssetsNetDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r56"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expenses",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r165",
      "r223",
      "r291",
      "r534",
      "r711",
      "r816",
      "r944"
     ]
    },
    "apm_InterestExpenseAndAccretionOfConvertibleDebts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "InterestExpenseAndAccretionOfConvertibleDebts",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense and accretion of convertible debts",
        "documentation": "Amount of interest expense and accretion of convertible debts.",
        "label": "Interest Expense And Accretion Of Convertible Debts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest (expense) income, net",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income",
        "terseLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r233",
      "r234"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r775",
      "r806"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r198",
      "r210",
      "r327",
      "r328",
      "r330",
      "r578",
      "r780"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write-down of inventories",
        "verboseLabel": "Written-down of inventories",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_InvestmentOwnedPercentOfNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedPercentOfNetAssets",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Owned percentage",
        "label": "Investment Owned, Net Assets, Percentage",
        "documentation": "Percentage of investment owned to net assets."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r666",
      "r667",
      "r735",
      "r740",
      "r741",
      "r742",
      "r748",
      "r810",
      "r941"
     ]
    },
    "apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "InvestmentandFairValueMeasurementDetailsScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment and Fair Value Measurement (Details) - Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_InvestmentandFairValueMeasurementDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "InvestmentandFairValueMeasurementDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment and Fair Value Measurement (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment and Fair Value Measurement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_JurchenInvestmentCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "JurchenInvestmentCorporationMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jurchen Investment Corporation [Member]",
        "label": "Jurchen Investment Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_JurchenInvestmentCorporationOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "JurchenInvestmentCorporationOneMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jurchen Investment Corporation one [Member]",
        "label": "Jurchen Investment Corporation One Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_JurchenInvestmentsCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "JurchenInvestmentsCorporationMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jurchen Investment Corporation [Member]",
        "label": "Jurchen Investments Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_KeyProvisionsOfOperatingOrPartnershipAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "KeyProvisionsOfOperatingOrPartnershipAgreementDescription",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting rights description",
        "label": "Key Provisions of Operating or Partnership Agreement, Description",
        "documentation": "Description of key provisions in the operating or partnership agreement of the limited liability company or limited partnership, including liability, voting matters, distributions, and other provisions."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "apm_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment [Member]",
        "label": "Laboratory Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r805"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/LeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leases Obligation",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "apm_LeaseholdImprovementsEstimatedUsefulLives": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LeaseholdImprovementsEstimatedUsefulLives",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements, estimated useful lives",
        "documentation": "Leasehold improvements, estimated useful lives.",
        "label": "Leasehold Improvements Estimated Useful Lives"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements, Furniture and Fixtures and Office Equipment [Member]",
        "label": "Leasehold Improvements Furniture And Fixtures And Office Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "verboseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/LeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity Analysis of Operating Leases Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future undiscounted cash flow",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Discount on operating lease liabilities",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/Lease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASE",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r239",
      "r321",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r495",
      "r498",
      "r499",
      "r522",
      "r678",
      "r783",
      "r818",
      "r879",
      "r925",
      "r926"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r163",
      "r613",
      "r806",
      "r855",
      "r869",
      "r918"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r197",
      "r239",
      "r321",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r495",
      "r498",
      "r499",
      "r522",
      "r806",
      "r879",
      "r925",
      "r926"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LibraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LibraMember",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Libra [Member]",
        "label": "Libra Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LibraSciencesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LibraSciencesLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Libra Sciences Limited [Member]",
        "label": "Libra Sciences Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LibraTherapeuticsLimitedOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LibraTherapeuticsLimitedOneMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Libra Therapeutics Limited one [Member]",
        "label": "Libra Therapeutics Limited One Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit amount",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r161",
      "r937"
     ]
    },
    "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAverageOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding amount",
        "label": "Line of Credit Facility, Average Outstanding Amount",
        "documentation": "Average amount borrowed under the credit facility during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit period",
        "verboseLabel": "Issuance of expire years",
        "label": "Line of Credit Facility, Expiration Period",
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undrawn line of credit amount",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "documentation": "Fair value of the amount outstanding under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://aptorumgroup.com/role/LiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit [Member]",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "apm_LiquidityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LiquidityDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/LiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LiquidityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LiquidityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity Disclosure Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LiquidityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LiquidityDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/Liquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIQUIDITY",
        "documentation": "The entire disclosure for liquidity.",
        "label": "Liquidity Disclosure Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LiquidityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LiquidityLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/Liquidity",
      "http://aptorumgroup.com/role/LiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity [Abstract]",
        "terseLabel": "Liquidity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LiquidityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LiquidityTable",
     "presentation": [
      "http://aptorumgroup.com/role/Liquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LoanRepaymentAndInterestPaidToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LoanRepaymentAndInterestPaidToRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan repayment and interest paid to related parties",
        "documentation": "Loan repayments, including interest, made to related parties.",
        "label": "Loan Repayment And Interest Paid To Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansAndLeasesReceivableRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan for the borrowers",
        "label": "Loans and Leases Receivable, Related Parties",
        "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r105"
     ]
    },
    "apm_LoansInterestbearingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LoansInterestbearingRate",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans interest-bearing rate",
        "documentation": "Percentage of interest bearing rate of loan per annum.",
        "label": "Loans Interestbearing Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturityDate",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit maturity date",
        "label": "Long-Term Debt, Maturity Date",
        "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/LongTermDeposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONG-TERM DEPOSITS",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "apm_LongTermDepositsDetailsScheduleofLongTermDepositsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LongTermDepositsDetailsScheduleofLongTermDepositsLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of long-term deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LongTermDepositsDetailsScheduleofLongTermDepositsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LongTermDepositsDetailsScheduleofLongTermDepositsTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Deposits (Details) - Schedule of Long-Term Deposits [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LongTermDepositsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LongTermDepositsLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/LongTermDeposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LongTermDepositsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LongTermDepositsTable",
     "presentation": [
      "http://aptorumgroup.com/role/LongTermDeposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Deposits [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LongTermDepositsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LongTermDepositsTablesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/LongTermDepositsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Deposits [Abstract]",
        "label": "Long Term Deposits Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LongTermDepositsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LongTermDepositsTablesTable",
     "presentation": [
      "http://aptorumgroup.com/role/LongTermDepositsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Deposits (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_LongTermLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit debt financing",
        "label": "Long-Term Line of Credit, Noncurrent",
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r61",
      "r62"
     ]
    },
    "apm_LongtermInvestmentsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LongtermInvestmentsPolicyPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "documentation": "Disclosure of accounting policy for long-term investments Policy.",
        "label": "Longterm Investments Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LossCarryforwardCancelled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LossCarryforwardCancelled",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss carry-forward (in Dollars)",
        "documentation": "The amount of loss carryforward cancelled.",
        "label": "Loss Carryforward Cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LossGainOnInvestmentsInMarketableSecuritiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LossGainOnInvestmentsInMarketableSecuritiesNet",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on investments in marketable securities, net",
        "documentation": "Gain on investments in marketable securities, net.",
        "label": "Loss Gain On Investments In Marketable Securities Net"
       }
      }
     },
     "auth_ref": []
    },
    "apm_LossOnDisposalOfLonglivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "LossOnDisposalOfLonglivedAssets",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of long-lived assets",
        "documentation": "Loss on disposal of long-lived assets.",
        "label": "Loss On Disposal Of Longlived Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, at fair value",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShareDetails",
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
      "http://aptorumgroup.com/role/SubsequentEventsDetails",
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r414",
      "r577",
      "r626",
      "r669",
      "r670",
      "r734",
      "r736",
      "r738",
      "r739",
      "r747",
      "r770",
      "r771",
      "r785",
      "r794",
      "r801",
      "r807",
      "r883",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "apm_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "documentation": "Milestone payments.",
        "label": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "apm_MilestonePaymentsTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "MilestonePaymentsTotal",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Milestone Payments Total"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShareDetails",
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
      "http://aptorumgroup.com/role/SubsequentEventsDetails",
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r414",
      "r577",
      "r626",
      "r669",
      "r670",
      "r734",
      "r736",
      "r738",
      "r739",
      "r747",
      "r770",
      "r771",
      "r785",
      "r794",
      "r801",
      "r807",
      "r883",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r162",
      "r239",
      "r321",
      "r345",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r522",
      "r612",
      "r682"
     ]
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CONTROLLING INTEREST",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership",
        "verboseLabel": "Ownership interest percentage",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "apm_MiosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "MiosMember",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mios [Member]",
        "label": "Mios Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_MiosPharmaceuticalsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "MiosPharmaceuticalsLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mios Pharmaceuticals Limited [Member]",
        "label": "Mios Pharmaceuticals Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_MrClarkChengMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "MrClarkChengMember",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Clark Cheng [Member]",
        "label": "Mr Clark Cheng Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_MrDarrenLuiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "MrDarrenLuiMember",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Darren Lui [Member]",
        "label": "Mr Darren Lui Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_MrIanHuenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "MrIanHuenMember",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Ian Huen [Member]",
        "label": "Mr Ian Huen Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NativusLifeSciencesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NativusLifeSciencesLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nativus Life Sciences Limited\t[Member]",
        "label": "Nativus Life Sciences Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/LiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net operation cash outflow",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NetChangeInUnrealizedDepreciationRelatingToInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NetChangeInUnrealizedDepreciationRelatingToInvestments",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in unrealized appreciation relating to investments still held",
        "documentation": "Net change in unrealized depreciation relating to investments.",
        "label": "Net Change In Unrealized Depreciation Relating To Investments"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NetDeferredTaxAssetsBeforeValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NetDeferredTaxAssetsBeforeValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofDeferredTaxAssetandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net deferred tax assets before valuation allowance",
        "documentation": "Net deferred tax assets (liabilities) before valuation allowance.",
        "label": "Net Deferred Tax Assets Before Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Aptorum Group Limited",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r132",
      "r164",
      "r195",
      "r214",
      "r217",
      "r222",
      "r239",
      "r249",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r272",
      "r288",
      "r297",
      "r302",
      "r305",
      "r321",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r511",
      "r522",
      "r619",
      "r702",
      "r724",
      "r725",
      "r784",
      "r816",
      "r879"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to Aptorum Group Limited",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss attributable to non-controlling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r156",
      "r214",
      "r217",
      "r259",
      "r260",
      "r618",
      "r845"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to Aptorum Group Limited",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r253",
      "r254",
      "r255",
      "r256",
      "r264",
      "r265",
      "r273",
      "r276",
      "r288",
      "r297",
      "r302",
      "r305",
      "r784"
     ]
    },
    "us-gaap_NetInvestmentInLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetInvestmentInLease",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for credit loss",
        "label": "Net Investment in Lease, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r326",
      "r555",
      "r870"
     ]
    },
    "apm_NetLossPerShareAttributableToAptorumGroupLimited1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NetLossPerShareAttributableToAptorumGroupLimited1Abstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to Aptorum Group Limited(1)",
        "label": "Net Loss Per Share Attributable To Aptorum Group Limited1 Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NetLossPerShareDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NetLossPerShareDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NetLossPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NetLossPerShareLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NetSalesAmountMoreThanCertainThresholdInYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NetSalesAmountMoreThanCertainThresholdInYear",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable": {
       "parentTag": "apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales amount more than certain threshold in a year",
        "documentation": "Net sales amount more than certain threshold in a year.",
        "label": "Net Sales Amount More Than Certain Threshold In Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently issued accounting standards which have not yet been adopted",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r189",
      "r194",
      "r247",
      "r248",
      "r251",
      "r252",
      "r261",
      "r262",
      "r323",
      "r324",
      "r481",
      "r482",
      "r483",
      "r505",
      "r508",
      "r512",
      "r513",
      "r514",
      "r523",
      "r524",
      "r525",
      "r536",
      "r537",
      "r557",
      "r581",
      "r582",
      "r583",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently adopted accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "apm_NonControllingInterestDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NonControllingInterestDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Controlling Interest (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NonControllingInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NonControllingInterestLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Controlling Interest [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NonCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NonCurrentAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current",
        "label": "Non Current Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NonCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NonCurrentAssetsAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current Assets",
        "label": "Non Current Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Controlling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling interests Amount",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r396",
      "r859",
      "r860",
      "r861",
      "r947"
     ]
    },
    "apm_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest Ownership Percentage By Noncontrolling Owners"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NoncontrollingInterestsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NoncontrollingInterestsPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "documentation": "Disclosure of accounting policy for Non-controlling interests.",
        "label": "Noncontrolling Interests Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "apm_NonemployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "NonemployeesMember",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-employees [Member]",
        "label": "Nonemployees Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expenses), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party [Member]",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan receivable from related parties, net",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r597"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://aptorumgroup.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_OciNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OciNetOfTaxAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expenses), net",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Alternative [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/LeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oher operating expenses.",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r805"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/LeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss of right-of-use assets",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "negatedLabel": "Less: Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ScheduleofMaturityAnalysisofOperatingLeasesLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Non-current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r550"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "apm_OperatingLeaseWeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OperatingLeaseWeightedAverageDiscountRate",
     "presentation": [
      "http://aptorumgroup.com/role/LeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rates",
        "documentation": "Weighted average discount rates.",
        "label": "Operating Lease Weighted Average Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate \u2013 operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r805"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://aptorumgroup.com/role/LeaseDetails",
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term \u2013 operating leases",
        "verboseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r805"
     ]
    },
    "apm_OperatingLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OperatingLeasesPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "documentation": "Disclosure of accounting policy for operating leases.",
        "label": "Operating Leases Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry-forwards (in Dollars)",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "apm_OrdinarySharesClosingPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OrdinarySharesClosingPricePercentage",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares closing price percentage",
        "documentation": "Ordinary shares closing price percentage",
        "label": "Ordinary Shares Closing Price Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "apm_OrdinarySharesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OrdinarySharesDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_OrdinarySharesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OrdinarySharesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/Organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r154",
      "r635",
      "r636"
     ]
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r203",
      "r605",
      "r818"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences on translation of foreign operations",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r11",
      "r155",
      "r215",
      "r218"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating expenses",
        "label": "Other Cost and Expense, Operating",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r624"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/OtherReceivablesandPrepayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER RECEIVABLES AND PREPAYMENTS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative fees",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r946"
     ]
    },
    "us-gaap_OtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInvestments",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-marketable investments",
        "label": "Other Investments",
        "documentation": "Amount of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r604",
      "r673",
      "r674",
      "r818",
      "r942"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts due to related parties",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r806"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan payables to related parties",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_OtherOwnershipInterestsUnitsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOwnershipInterestsUnitsIssued",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued (in Shares)",
        "label": "Other Ownership Interests, Units Issued",
        "documentation": "The number of units of other ownership interests issued in a limited partnership or master limited partnership. Does not include limited or general partners' ownership interests."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r871"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r689"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts due from related parties, net",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Receivables and Prepayments [Abstract]",
        "label": "Other Receivablesand Prepayments Details Scheduleof Other Receivablesand Prepayments Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "apm_OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OtherReceivablesandPrepaymentsDetailsScheduleofOtherReceivablesandPrepaymentsTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables and Prepayments (Details) - Schedule of Other Receivables and Prepayments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_OtherReceivablesandPrepaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OtherReceivablesandPrepaymentsLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/OtherReceivablesandPrepayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables and Prepayments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_OtherReceivablesandPrepaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OtherReceivablesandPrepaymentsTable",
     "presentation": [
      "http://aptorumgroup.com/role/OtherReceivablesandPrepayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables and Prepayments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_OtherReceivablesandPrepaymentsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OtherReceivablesandPrepaymentsTablesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Receivables and Prepayments [Abstract]",
        "label": "Other Receivablesand Prepayments Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "apm_OtherReceivablesandPrepaymentsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OtherReceivablesandPrepaymentsTablesTable",
     "presentation": [
      "http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables and Prepayments (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss on intangible asset",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "apm_OutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "OutstandingSharesPercentage",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding shares, percentage",
        "documentation": "Percentage of outstanding shares.",
        "label": "Outstanding Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PartnersCapitalAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PartnersCapitalAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deficit value (in Dollars)",
        "label": "Partners' Capital Attributable to Noncontrolling Interest",
        "documentation": "Total of all Partners' Capital (deficit) items which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest)."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r146",
      "r147",
      "r162"
     ]
    },
    "apm_PathsDiagnosticsPteLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PathsDiagnosticsPteLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paths Diagnostics Pte. Limited [Member]",
        "label": "Paths Diagnostics Pte Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_PathsInnovationsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PathsInnovationsLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paths Innovations Limited [Member]",
        "label": "Paths Innovations Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of offering costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loan to a related party",
        "terseLabel": "Loan to related parties",
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r922"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "apm_PreclinicalToIndFiling": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PreclinicalToIndFiling",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable": {
       "parentTag": "apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preclinical to IND filing",
        "documentation": "Preclinical to IND filing.",
        "label": "Preclinical To Ind Filing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 9.0
      },
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other receivables and prepayments",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r786",
      "r871"
     ]
    },
    "apm_PrepaidPatentedLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PrepaidPatentedLicensesMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid patented licenses [Member]",
        "label": "Prepaid Patented Licenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidRent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid rental expenses",
        "label": "Prepaid Rent",
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r871"
     ]
    },
    "apm_PrepaidResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development expenses",
        "documentation": "Prepaid research and development expenses.",
        "label": "Prepaid Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "apm_PrepaidServiceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PrepaidServiceFee",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid service fee",
        "documentation": "Prepaid service fee.",
        "label": "Prepaid Service Fee"
       }
      }
     },
     "auth_ref": []
    },
    "apm_PrepaymentsForEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PrepaymentsForEquipment",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable": {
       "parentTag": "us-gaap_DepositsAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments for equipment",
        "documentation": "Prepayments of deposits for equipment.",
        "label": "Prepayments For Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "apm_PrincipleActivities": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PrincipleActivities",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principle activities",
        "documentation": "Principle activities.",
        "label": "Principle Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromBankDebt",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan from a bank",
        "label": "Proceeds from Bank Debt",
        "documentation": "The cash inflow from bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of convertible notes",
        "verboseLabel": "Issuance of Convertible Note to related parties",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Class A Ordinary Shares and warrants",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of subsidiaries shares",
        "label": "Proceeds from Other Equity",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan from related parties",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of investment securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposal of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r17"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "apm_ProceedsInBrokerAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ProceedsInBrokerAccounts",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds in broker accounts",
        "documentation": "Amount of proceeds in broker accounts.",
        "label": "Proceeds In Broker Accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Legal and professional fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r945",
      "r946"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome",
      "http://aptorumgroup.com/role/LiquidityDetails",
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss before tax",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r214",
      "r217",
      "r231",
      "r239",
      "r249",
      "r259",
      "r260",
      "r288",
      "r297",
      "r302",
      "r305",
      "r321",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r493",
      "r496",
      "r497",
      "r511",
      "r522",
      "r602",
      "r617",
      "r649",
      "r702",
      "r724",
      "r725",
      "r784",
      "r803",
      "r804",
      "r817",
      "r845",
      "r879"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails",
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r178",
      "r182",
      "r183"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r200",
      "r616"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails",
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r603",
      "r616",
      "r806"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r178",
      "r182",
      "r614"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails",
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "verboseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "apm_PropertyPlantAndEquipmentUsefullLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PropertyPlantAndEquipmentUsefullLifeTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives",
        "documentation": "Tabular disclosure of estimated useful lives.",
        "label": "Property Plant And Equipment Usefull Life Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "apm_PropertyandEquipmentNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "PropertyandEquipmentNetDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShareDetails",
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
      "http://aptorumgroup.com/role/SubsequentEventsDetails",
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r406",
      "r414",
      "r446",
      "r447",
      "r448",
      "r573",
      "r577",
      "r626",
      "r669",
      "r670",
      "r734",
      "r736",
      "r738",
      "r739",
      "r747",
      "r770",
      "r771",
      "r785",
      "r794",
      "r801",
      "r807",
      "r810",
      "r876",
      "r883",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShareDetails",
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
      "http://aptorumgroup.com/role/SubsequentEventsDetails",
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r406",
      "r414",
      "r446",
      "r447",
      "r448",
      "r573",
      "r577",
      "r626",
      "r669",
      "r670",
      "r734",
      "r736",
      "r738",
      "r739",
      "r747",
      "r770",
      "r771",
      "r785",
      "r794",
      "r801",
      "r807",
      "r810",
      "r876",
      "r883",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuefromRelatedPartiesTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances and Transactions (Details) - Schedule of Amounts Due from Related Parties [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "RelatedPartyBalancesandTransactionsDetailsScheduleofAmountsDuetoRelatedPartiesTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances and Transactions (Details) - Schedule of Amounts Due to Related Parties [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_RelatedPartyBalancesandTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "RelatedPartyBalancesandTransactionsDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances and Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable",
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable",
      "http://aptorumgroup.com/role/SubsequentEventsDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r561",
      "r562",
      "r672",
      "r673",
      "r674",
      "r676",
      "r677",
      "r699",
      "r701",
      "r733"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r561",
      "r562",
      "r563",
      "r564",
      "r672",
      "r673",
      "r674",
      "r676",
      "r677",
      "r699",
      "r701",
      "r733"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss recognized",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r561"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/IntangibleAssetsNetDetails",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r924"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/IntangibleAssetsNetDetails",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Balances and Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r707",
      "r710"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances and Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable",
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable",
      "http://aptorumgroup.com/role/SubsequentEventsDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r561",
      "r562",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r672",
      "r673",
      "r674",
      "r676",
      "r677",
      "r699",
      "r701",
      "r733",
      "r924"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Balances and Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r560",
      "r562",
      "r565",
      "r645",
      "r646",
      "r647",
      "r708",
      "r709",
      "r710",
      "r730",
      "r732"
     ]
    },
    "apm_RemunerationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "RemunerationAmount",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remuneration amount",
        "documentation": "The amount of the remuneration.",
        "label": "Remuneration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "apm_RentalDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "RentalDeposits",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable": {
       "parentTag": "us-gaap_DepositsAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental deposits",
        "documentation": "Rental deposits.",
        "label": "Rental Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "apm_RepaymentOfLoanFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "RepaymentOfLoanFromRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of loan and interest from a related party",
        "terseLabel": "Loan repayment and interest received from a related party",
        "documentation": "Repayment of loan from a related party.",
        "label": "Repayment Of Loan From Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfBankDebt",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of bank loan",
        "label": "Repayments of Bank Debt",
        "documentation": "The cash outflow to settle a bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of loan due to related parties",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r464",
      "r933"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense, Software (Excluding Acquired in Process Cost)",
        "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r911"
     ]
    },
    "apm_ResearchAndDevelopmentExpensesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ResearchAndDevelopmentExpensesPayable",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses payable",
        "documentation": "Research and development expenses payable.",
        "label": "Research And Development Expenses Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r852"
     ]
    },
    "us-gaap_RestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/LiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash Equivalents",
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758",
      "r852",
      "r934",
      "r938"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/LiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r146",
      "r611",
      "r630",
      "r634",
      "r643",
      "r681",
      "r806"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit Amount",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r244",
      "r245",
      "r246",
      "r250",
      "r258",
      "r260",
      "r322",
      "r325",
      "r455",
      "r456",
      "r457",
      "r479",
      "r480",
      "r500",
      "r502",
      "r503",
      "r506",
      "r509",
      "r627",
      "r629",
      "r650",
      "r947"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r772",
      "r781"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Healthcare services income",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r239",
      "r289",
      "r290",
      "r296",
      "r300",
      "r301",
      "r307",
      "r309",
      "r311",
      "r321",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r522",
      "r602",
      "r879"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ReversalDeferredCashBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ReversalDeferredCashBonus",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of deferred cash bonus",
        "documentation": "Reversal of deferred cash bonus.",
        "label": "Reversal Deferred Cash Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r805"
     ]
    },
    "country_SG": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "SG",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Singapore [Member]",
        "label": "SINGAPORE"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SabrinaKhanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SabrinaKhanMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sabrina Khan [Member]",
        "label": "Sabrina Khan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleLeasebackTransactionTransactionCostsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleLeasebackTransactionTransactionCostsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less transaction costs (in Dollars)",
        "label": "Sale Leaseback Transaction, Transaction Costs, Investing Activities",
        "documentation": "Amount of cash outflow for transaction costs in a sale-leaseback recognized in investing activities. Includes, but is not limited to, closing and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r415",
      "r862"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable",
      "http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable",
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable",
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals",
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable",
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable",
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable",
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r415",
      "r832",
      "r862"
     ]
    },
    "apm_ScheduleOfAccountsPayableAndAccruedExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfAccountsPayableAndAccruedExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accounts payable and accrued expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfAggregateCarryingValueOfViesAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Aggregate Carrying Value Of Vies Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfAmortizationExpenseRelatedToItsFiniteLivedIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Amortization Expense Related To Its Finite Lived Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfAmountsDueFromRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfAmountsDueFromRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Amounts Due From Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amounts Due from Related Parties",
        "label": "Schedule Of Amounts Due From Related Parties Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfAmountsDueToRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfAmountsDueToRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Amounts Due To Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnARecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assets And Liabilities Carried At Fair Value Measured On ARecurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfBasicAndDilutedLossIncomePerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfBasicAndDilutedLossIncomePerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Diluted Loss Income Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfCarryingValueOfOurNonMarketableInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Carrying Value of Our Non-Marketable Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Value of Our Non-Marketable Investments",
        "label": "Schedule Of Carrying Value Of Our Nonmarketable Investments Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfChangesInValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfChangesInValuationAllowanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In Valuation Allowance Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision for Income Taxes Expenses",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "apm_ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfDeferredTaxAssetAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Asset And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Asset and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "apm_ScheduleOfDueToRelatedPartiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfDueToRelatedPartiesTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amounts Due to Related Parties",
        "documentation": "Tabular disclosure of due to related parties.",
        "label": "Schedule Of Due To Related Parties Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfEachStockOptionAwardIsEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Each Stock Option Award Is Estimated On The Date Of Grant Using The Black Scholes Option Pricing Model Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of basic and diluted (loss) income per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320"
     ]
    },
    "apm_ScheduleOfEstimatedUsefulLivesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfEstimatedUsefulLivesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517"
     ]
    },
    "apm_ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfFairValueReconciliationOfLevel3AssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Reconciliation Of Level3 Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r580"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57"
     ]
    },
    "apm_ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfIncomeTaxesExpensesComputedAtTheHongKongStatutoryTaxRateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Income Taxes Expenses Computed At The Hong Kong Statutory Tax Rate Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfLongTermDepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfLongTermDepositsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Long Term Deposits Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfLongTermDepositsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfLongTermDepositsTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/LongTermDepositsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Deposits",
        "documentation": "Tabular disclosure of long-term deposits.",
        "label": "Schedule Of Long Term Deposits Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfMajorSubsidiariesConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfMajorSubsidiariesConsolidatedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Major Subsidiaries Consolidated Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfMaturityAnalysisOfOperatingLeasesLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturity Analysis of Operating Leases Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Milestone Payments Are To Be Made Upon Achievements Of Certain Conditions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions",
        "documentation": "Tabular disclosure of milestone payments are to be made upon achievements of certain conditions.",
        "label": "Schedule Of Milestone Payments Are To Be Made Upon Achievements Of Certain Conditions Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfOperatingLeasesObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfOperatingLeasesObligationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Leases Obligation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfOtherReceivablesAndPrepaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfOtherReceivablesAndPrepaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Receivables And Prepayments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "apm_ScheduleOfProvisionForIncomeTaxesExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfProvisionForIncomeTaxesExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Provision For Income Taxes Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfQuantitativeInformationAboutTheGroupSLevel3FairValueMeasurementsOfInvestmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Quantitative Information About The Group SLevel3 Fair Value Measurements Of Investment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfRelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfRelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Related Party Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r102",
      "r706",
      "r707",
      "r710"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/OrganizationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Major Subsidiaries Consolidated",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]",
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table]",
        "documentation": "This table describes the key aspects of a subsidiary (partnership, corporation, or other entity) of the Limited Liability Company (LLC) or Limited Partnership (LP)."
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfTheOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfTheOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Option Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfUnrealizedGainsAndLossesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfUnrealizedGainsAndLossesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrealized Gains and Losses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScheduleOfUnrealizedLossOnInvestmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScheduleOfUnrealizedLossOnInvestmentTableTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrealized Gains and Losses",
        "label": "Schedule Of Unrealized Loss On Investment Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Variable Interest Entities [Table]",
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r83",
      "r84",
      "r86",
      "r494",
      "r495",
      "r498",
      "r499",
      "r574",
      "r575",
      "r576"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Aggregate Carrying Value of Vies\u2019 Assets and Liabilities",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r83",
      "r84",
      "r86"
     ]
    },
    "apm_ScipioLifeSciencesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScipioLifeSciencesLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/NonControllingInterestDetails",
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scipio Life Sciences Limited [Member]",
        "label": "Scipio Life Sciences Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ScipioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ScipioMember",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scipio [Member]",
        "label": "Scipio Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityOwnedAndSoldNotYetPurchasedAtFairValueLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment and Fair Value Measurement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r663",
      "r665",
      "r667",
      "r735",
      "r737",
      "r741",
      "r748",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r795",
      "r810",
      "r884",
      "r939"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r295",
      "r299",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311"
     ]
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series of Individually Immaterial Business Acquisitions [Member]",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "apm_ServicesFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ServicesFees",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services fees",
        "documentation": "Amount of services fees.",
        "label": "Services Fees"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ServicesFeesAdjusted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ServicesFeesAdjusted",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services fees adjusted",
        "documentation": "The amount of services fees adjusted.",
        "label": "Services Fees Adjusted"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SettlementOfDeferredCashBonusByIssuanceOfShareOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SettlementOfDeferredCashBonusByIssuanceOfShareOptions",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of deferred cash bonus by issuance of share options",
        "documentation": "Settlement of deferred cash bonus by issuance of share options.",
        "label": "Settlement Of Deferred Cash Bonus By Issuance Of Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SettlementOfServiceFeeByDigitalCurrenciesAndTokens": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SettlementOfServiceFeeByDigitalCurrenciesAndTokens",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement of service fee by tokens and digital currencies",
        "documentation": "Settlement of service fee by digital currencies and tokens.",
        "label": "Settlement Of Service Fee By Digital Currencies And Tokens"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SettlementsOfServiceFeeByDigitalCurrenciesAndTokens": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SettlementsOfServiceFeeByDigitalCurrenciesAndTokens",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of service fee by tokens and digital currencies",
        "documentation": "Settlement of service fee by digital currencies and tokens.",
        "label": "Settlements Of Service Fee By Digital Currencies And Tokens"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation [Abstarct]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Period Term",
        "verboseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expire date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilution factor",
        "documentation": "Dilution factor used in estimating the fair value of stock awards.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Dilution Factor"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r419",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional ordinary share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granting share options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options, Outstanding,Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic value, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of share options, Outstanding, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of share options, Outstanding, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options, Outstanding, Granted",
        "verboseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual term in years, Granted",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic value, Outstanding, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of share options, Outstanding, Beginning",
        "periodEndLabel": "Number of share options, Outstanding, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding, Beginning",
        "periodEndLabel": "Weighted average exercise price, Outstanding, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426"
     ]
    },
    "apm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contractual term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Terms2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental modification cost (in Dollars)",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Granted",
        "verboseLabel": "Weighted-average grant date fair value of share option grants (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareBasedCompensationDetailsScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) - Schedule of Each Stock Option Award is Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareBasedCompensationDetailsScheduleoftheOptionActivityLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) - Schedule of the Option Activity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ShareBasedCompensationDetailsScheduleoftheOptionActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareBasedCompensationDetailsScheduleoftheOptionActivityTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) - Schedule of the Option Activity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ShareBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareBasedCompensationDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r424",
      "r443",
      "r444",
      "r445",
      "r446",
      "r449",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "apm_ShareIssuedToConvertibleNoteHolders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareIssuedToConvertibleNoteHolders",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued to convertible note holders",
        "documentation": "Represent the number of share issued to convertible note holders.",
        "label": "Share Issued To Convertible Note Holders"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ShareOfEconomic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareOfEconomic",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of economic (in Dollars per share)",
        "label": "Share Of Economic"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ShareOptionHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ShareOptionHoldersMember",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Option Holders [Member]",
        "label": "Share Option Holders Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excersie price per share (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEachStockOptionAwardisEstimatedontheDateofGrantUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term from grant date (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "apm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual term in years, Exercisable",
        "documentation": "Remaining contractual term in years, Exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual term in years, Outstanding, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled existing vested and unvested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual term in years, Outstanding, Beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issue",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued price (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "apm_SharesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SharesPrice",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, per share (in Dollars per share)",
        "documentation": "Shares price.",
        "label": "Shares Price"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SharesWarrantHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SharesWarrantHoldersMember",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Warrant Holders [Member]",
        "label": "Shares Warrant Holders Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBankLoansAndNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank loan",
        "label": "Short-Term Bank Loans and Notes Payable",
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r675",
      "r936"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails",
      "http://aptorumgroup.com/role/LiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://aptorumgroup.com/role/ConvertibleNoteDetails",
      "http://aptorumgroup.com/role/LiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r805"
     ]
    },
    "apm_SignateLifeSciencesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SignateLifeSciencesLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Signate Life Sciences Limited\t[Member]",
        "label": "Signate Life Sciences Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r236"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://aptorumgroup.com/role/ConvertibleNoteDetails",
      "http://aptorumgroup.com/role/DocumentAndEntityInformation",
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3",
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r205",
      "r206",
      "r207",
      "r239",
      "r267",
      "r271",
      "r274",
      "r276",
      "r282",
      "r283",
      "r321",
      "r345",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r381",
      "r382",
      "r384",
      "r387",
      "r394",
      "r522",
      "r639",
      "r640",
      "r641",
      "r642",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r680",
      "r703",
      "r726",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r831",
      "r853",
      "r863"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/ScheduleofAssetsandLiabilitiesCarriedatFairValueMeasuredonaRecurringBasisTable",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r35",
      "r192",
      "r220",
      "r221",
      "r222",
      "r244",
      "r245",
      "r246",
      "r250",
      "r258",
      "r260",
      "r281",
      "r322",
      "r325",
      "r396",
      "r455",
      "r456",
      "r457",
      "r479",
      "r480",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r509",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r556",
      "r627",
      "r628",
      "r629",
      "r650",
      "r726"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r663",
      "r665",
      "r667",
      "r735",
      "r737",
      "r741",
      "r748",
      "r756",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r795",
      "r810",
      "r884",
      "r939"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r281",
      "r579",
      "r637",
      "r662",
      "r671",
      "r672",
      "r673",
      "r674",
      "r676",
      "r677",
      "r680",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r690",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r704",
      "r705",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r726",
      "r811"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmortizationExpenseRelatedtoitsFiniteLivedIntangibleAssetsTable",
      "http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable",
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable",
      "http://aptorumgroup.com/role/ScheduleofIncomeTaxesExpensesComputedattheHongKongStatutoryTaxRateTable_Parentheticals",
      "http://aptorumgroup.com/role/ScheduleofLongTermDepositsTable",
      "http://aptorumgroup.com/role/ScheduleofOtherReceivablesandPrepaymentsTable",
      "http://aptorumgroup.com/role/ScheduleofProvisionforIncomeTaxesExpensesTable",
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r415",
      "r832",
      "r833",
      "r862"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r281",
      "r579",
      "r637",
      "r662",
      "r671",
      "r672",
      "r673",
      "r674",
      "r676",
      "r677",
      "r680",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r690",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r704",
      "r705",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r726",
      "r811"
     ]
    },
    "apm_StockIssuedDuringPeridSharesIssuanceOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "StockIssuedDuringPeridSharesIssuanceOfShares",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares (in Shares)",
        "documentation": "Number of stock issued during period issuance of shares.",
        "label": "Stock Issued During Perid Shares Issuance Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "apm_StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal of subsidiaries under common control transaction",
        "documentation": "Value of disposal of subsidiaries under common control transaction.",
        "label": "Stock Issued During Period Disposal Of Subsidiaries Under Common Control Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r34",
      "r63",
      "r146",
      "r371"
     ]
    },
    "apm_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants (in Shares)",
        "documentation": "Number of shares issued during period shares exercise of warrants.",
        "label": "Stock Issued During Period Shares Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A Ordinary Shares (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r113",
      "r114",
      "r146",
      "r639",
      "r726",
      "r750"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares in exchange of share options and settlement of liabilities (in Shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://aptorumgroup.com/role/NetLossPerShareDetails",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rounding up for reverse stock split (in Shares)",
        "verboseLabel": "Reverse stock split",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for share-based compensation (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r113",
      "r114",
      "r146"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options (in Shares)",
        "negatedLabel": "Number of share options, Outstanding, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r113",
      "r114",
      "r146",
      "r430"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r35",
      "r146"
     ]
    },
    "apm_StockIssuedDuringPeriodValueDisposalOfSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "StockIssuedDuringPeriodValueDisposalOfSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal of subsidiaries",
        "documentation": "Value of Stock disposal of subsidies.",
        "label": "Stock Issued During Period Value Disposal Of Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for share-based compensation",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r113",
      "r114",
      "r146"
     ]
    },
    "apm_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "documentation": "Value of Stock issued exercise of warrants.",
        "label": "Stock Issued During Period Value Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "apm_StockIssuedDuringPeriodValueIssuanceOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfShares",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares",
        "documentation": "Value of stock issued during period issuance of shares.",
        "label": "Stock Issued During Period Value Issuance Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A Ordinary Shares",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r113",
      "r114",
      "r146",
      "r650",
      "r726",
      "r750",
      "r817"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares in exchange of share options and settlement of liabilities",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r35",
      "r146"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://aptorumgroup.com/role/ScheduleoftheOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "verboseLabel": "Equity Option [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity attributable to the shareholders of Aptorum Group Limited",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r117",
      "r118",
      "r134",
      "r682",
      "r700",
      "r727",
      "r728",
      "r806",
      "r818",
      "r855",
      "r869",
      "r918",
      "r947"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet",
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r87",
      "r192",
      "r193",
      "r221",
      "r244",
      "r245",
      "r246",
      "r250",
      "r258",
      "r322",
      "r325",
      "r396",
      "r455",
      "r456",
      "r457",
      "r479",
      "r480",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r509",
      "r527",
      "r528",
      "r532",
      "r556",
      "r628",
      "r629",
      "r648",
      "r682",
      "r700",
      "r727",
      "r728",
      "r754",
      "r817",
      "r855",
      "r869",
      "r918",
      "r947"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinaryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORDINARY SHARES",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r238",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r396",
      "r507",
      "r729",
      "r731",
      "r755"
     ]
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityOtherShares",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Stockholders' Equity, Other Shares",
        "documentation": "Number of increase (decrease) in shares of stock classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "apm_StockissuedDuringPeriodValueAdjustmentForChangeOfParValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "StockissuedDuringPeriodValueAdjustmentForChangeOfParValue",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustment for change of par value",
        "documentation": "Value of stock issued during period adjustment for change of par value.",
        "label": "Stockissued During Period Value Adjustment For Change Of Par Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r805"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r569"
     ]
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://aptorumgroup.com/role/InvestmentandFairValueMeasurementDetails",
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable",
      "http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SundryIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SundryIncome",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sundry income",
        "documentation": "Sundry income.",
        "label": "Sundry Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable": {
       "parentTag": "apm_MilestonePaymentsTotal",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMilestonePaymentsaretobemadeuponAchievementsofCertainConditionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Subtotal",
        "documentation": "Surgical robotics and medical devices up to the conditions and milestones of subtotal.",
        "label": "Surgical Robotics And Medical Devices Up To Conditions And Milestones Of Subtotal"
       }
      }
     },
     "auth_ref": []
    },
    "apm_TalemMedicalGroupLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "TalemMedicalGroupLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAmountsDuefromRelatedPartiesTable",
      "http://aptorumgroup.com/role/ScheduleofRelatedPartyTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Talem Medical Group Limited [Member]",
        "label": "Talem Medical Group Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r923"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://aptorumgroup.com/role/OrdinarySharesDetails",
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_TotalCarryingValueAtTheEndOfThePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "TotalCarryingValueAtTheEndOfThePeriod",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total carrying value at the end of the year",
        "documentation": "Total carrying value at the end of the period.",
        "label": "Total Carrying Value At The End Of The Period"
       }
      }
     },
     "auth_ref": []
    },
    "apm_TotalUnrealizedGainForNonmarketableInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "TotalUnrealizedGainForNonmarketableInvestments",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total unrealized gain from fair value change of non-marketable investments, net",
        "documentation": "Total unrealized gain for non-marketable investments.",
        "label": "Total Unrealized Gain For Nonmarketable Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable and amounts due from related parties",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r314",
      "r315",
      "r316"
     ]
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradingActivityByTypeAxis",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity [Axis]",
        "documentation": "Information by type of trading activity."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradingActivityByTypeDomain",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity, by Type [Domain]",
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aptorumgroup.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "apm_TwoThousandSeventeenShareOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "TwoThousandSeventeenShareOptionPlanMember",
     "presentation": [
      "http://aptorumgroup.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Share Option Plan [Member]",
        "label": "Two Thousand Seventeen Share Option Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://aptorumgroup.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States (Nevada) [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gain from fair value change of the long-term investments, net",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "apm_UnrestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "UnrestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/LiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrestricted cash",
        "documentation": "Amount of cash equivalents unrestricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Unrestricted Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "apm_UpwardAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "UpwardAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable": {
       "parentTag": "apm_TotalCarryingValueAtTheEndOfThePeriod",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofCarryingValueofOurNonMarketableInvestmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upward adjustments",
        "documentation": "Upward adjustments.",
        "label": "Upward Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "apm_UpwardAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "UpwardAdjustments",
     "crdr": "credit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable": {
       "parentTag": "apm_TotalUnrealizedGainForNonmarketableInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofUnrealizedGainsandLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upward adjustments",
        "documentation": "Upward adjustments.",
        "label": "Upward Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r175",
      "r176",
      "r179",
      "r180"
     ]
    },
    "us-gaap_UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating expenses",
        "label": "Utilities Operating Expense, Maintenance, Operations, and Other Costs and Expenses",
        "documentation": "The amount of operating expenses for the period that are associated with the utility's normal revenue producing operation; including selling, general, and administrative expenses, costs incurred for routine plant repairs and maintenance, and operations."
       }
      }
     },
     "auth_ref": []
    },
    "apm_ValuationAllowanceDeferredTaxAssetDecreaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetDecreaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal",
        "documentation": "Amount of decrease in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Decrease Amount"
       }
      }
     },
     "auth_ref": []
    },
    "apm_ValuationAllowanceDeferredTaxAssetIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncrease",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "documentation": "Amount of increase in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Valuation Allowance [Abstract]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceTable",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofChangesinValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Table]",
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "apm_VariableInterestEntityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "VariableInterestEntityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "apm_VariableInterestEntityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "VariableInterestEntityDetailsTable",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VARIABLE INTEREST ENTITY",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityEntityMaximumLossExposureAmount",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum Exposure to Losses",
        "label": "Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount",
        "documentation": "The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r85"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable",
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495",
      "r498",
      "r499",
      "r574",
      "r575",
      "r576"
     ]
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofAggregateCarryingValueofViesAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Primary Beneficiary [Member]",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r494",
      "r495",
      "r498",
      "r499"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofOperatingLeasesObligationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r805"
     ]
    },
    "apm_VaribaleInterestEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "VaribaleInterestEntityMember",
     "presentation": [
      "http://aptorumgroup.com/role/VariableInterestEntityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Varibale Interest Entity [Member]",
        "label": "Varibale Interest Entity Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VehiclesMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor vehicle [Member]",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "apm_VestedAndUnvestedShareOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "VestedAndUnvestedShareOptions",
     "presentation": [
      "http://aptorumgroup.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and unvested share options (in Shares)",
        "documentation": "Number of vested and unvested share options.",
        "label": "Vested And Unvested Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "apm_VidensIncorporationLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "VidensIncorporationLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Videns Incorporation Limited [Member]",
        "label": "Videns Incorporation Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_WarrantLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "WarrantLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://aptorumgroup.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "documentation": "Disclosure of accounting policy for warrant liabilities.",
        "label": "Warrant Liabilities Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofFairValueReconciliationofLevel3AssetsTable",
      "http://aptorumgroup.com/role/ScheduleofQuantitativeInformationabouttheGroupsLevel3FairValueMeasurementsofInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome",
      "http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- Diluted (in Shares)",
        "verboseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r276"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedComprehensiveIncome",
      "http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- Basic (in Shares)",
        "verboseLabel": "Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r276"
     ]
    },
    "apm_WeightedAverageSharesOutstanding1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "WeightedAverageSharesOutstanding1Abstract",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofbasicanddilutedlossincomepershareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding(1)",
        "label": "Weighted Average Shares Outstanding1 Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "apm_WritteoffOfPrepaymentAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "WritteoffOfPrepaymentAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://aptorumgroup.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aptorumgroup.com/role/ConsolidatedCashFlow",
      "http://aptorumgroup.com/role/OtherReceivablesandPrepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write-off of prepayment and other receivables",
        "verboseLabel": "Other operating expenses",
        "documentation": "Writte-off of prepayment and other receivables.",
        "label": "Writteoff Of Prepayment And Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "apm_WroteOffOfCostRelatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "WroteOffOfCostRelatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://aptorumgroup.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wrote off of cost related amortization",
        "documentation": "Wrote off of cost related amortization.",
        "label": "Wrote Off Of Cost Related Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "apm_mTORHongKongLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "mTORHongKongLimitedMember",
     "presentation": [
      "http://aptorumgroup.com/role/ScheduleofMajorSubsidiariesConsolidatedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "mTOR (Hong Kong) Limited [Member]",
        "label": "m TORHong Kong Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "apm_sharesOutstandingPerentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aptorumgroup.com/20231231",
     "localname": "sharesOutstandingPerentage",
     "presentation": [
      "http://aptorumgroup.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "shares outstanding perentage",
        "documentation": "shares outstanding perentage.",
        "label": "shares Outstanding Perentage"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479910/205-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "272",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-13"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-14"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "b",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4F"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.7(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-50"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-51"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-52"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "30",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>128
<FILENAME>0001213900-24-037520-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-037520-xbrl.zip
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M QQ1'** *_I]$/+9?#F%D*D-% BB_T/^HRVS'"9Y[TO>OV<*BRTXEVQTB>6
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MN)$+RD'3O:LWW14O_SHC)Q,V[6R2 BA<H48+3">:0H7\#.S.16ID<(;YDMM
MKM!1Q:,WQBHE'U]'2X :G;1T'=RB=_5;](+Y[,K044 R#/Q3#"(YPH=GENP[
M0Y$-1OT$D<7IH!>EJ_>B<.HO\H![;@AD.:7. 0JJ,4KNR6TUY V,4@==2EV]
M2^F$TH2'#@[&E9RP*GYT]IP1Y:JXFTQ+!YUK7;US[1+&<?J!Q\VG"JI?BJ:;
MLHXF4RWG')/PINFQWN=W'71*=O5.R<5#&EEH>*JXHL Q<5K";+2%=- AUM4[
MQ/@@5FFG?6=D5(^PD7@<]/=U]?X^G7&07C6$@:1_W)/=&O ;&#@.ND&[>C=H
MSH<T:M$MF9FPV0ND]_A;;!4FG4!X%I DC$$47_+D  '_Z0Q$8 *SD=L/9BA"
MO!U^&_X2DFOD0WH,4UUTX(ST-D9( U$[Z#3MZ9VF908L>9.S0KP]X8P\FZ%M
ML)'H.>A"ZNE=2!\A"..I#\ABR*;ZR1E!U0(T.+U].!M!TNOPO%?.$*2!U9",
MQU\&=+@,5N,QBOCF35QA.<#4':^E%ICU/K+GH%NOIW?KB;P:I=PSCDA""TQK
M80 ZY2Z]8TRRVY-,/X1)P#,F#*?%O#D\(1&3KXLWOS9"1*.0>@<=E[T&L7 ]
M!]UUO0:Q<#T'W4X]0RQ<,N/7#]GH=&7&R(@,"VB$F;'G%'P5)AWSOT(TF?*0
MC&M&\02FKWL-DICG6 T8\(XS5-DC;70JVW/0]=?3N_XJKX3T8P9WE(B\74/<
M3U,FBZY.T8SU$K@CO]61ZR<?229G.(1^$D)Z-1]BMIP5[D-&P>)&)1V,G6'$
M:J@;+< .^DM[>G_I(0*3B!G&R*=#Z$\C'.+)W=,1YUKH3;HJRU"R3_!W2&B9
MT!EK)P;D3D7J&(1426N:.CO.?QJES]DS'L 1BE=G0!FFB2*><'$075&>=@=-
M4 S"-)Z#/U*Q ?J6LMPH@4;4AGF9UCN$!/IXDB9O'XP_XV@L-H0(A&F0W7T2
M[A,8K$UY/07Z[!!)%#!:A%/%83I+,/7^N'[P>Y(&W@_Q\K XM42&F/'%EY]<
M<YCJE<@Q)(3B.3%X.S X3+@:/A<T'"(ZQQ2$K.5"!N^K*("$/UJS>*=NN$S1
MXS#/-DBD?M*H^Q!Y>]0=/3V&F8@QI4 QM'9T"XF/N);^"@C/O/)4V:(@1!NJ
MHVXFG<-U#!&/O]$5V;%9NK6 ]>KFZ-87^>L.T7@,^6H,!Y&87F&6(?P8$[9E
MC++D1DYKE>:TF)4'4@^LI<)G[:79_P;C<Y F 7>8/:O3U'BU$M6JBZ'KK+$E
MH]F*DTU*,S.<T2$ZM/I703"EJ7U;N$]Y4LB#?LG?6Q!>\,_093.N(2'ZJ"5*
MF:V_6)+Y;=.0Q_LXOTNI0ZX-*LBSG7+-(2"(EL;9AK84X^3N[K01%5HW,!L?
M_-GQ,4^<7(C]JJ;(=Y<-UA3HEP1YGT\?QCVQD5VZ#K=>Z1?"HK/PAV,(]^\D
M'P?CXA!_AY'+/%B!&,,VHQ)BG*5/AZDM5@@./X2C^]6,Z\V)9F08_![+6L5@
MAF7^5'=94 _=, PN(.,06U+RJY?\)'T?1XG#(M=#UHOW)&(\8DPYA-G_;]KO
M?%^3O@:X0;)JSP,SC_CK.'2:_@P#AVFWI4"K_A<AWLM+,0]E\*Q)>AURG9%S
M3K /8<!LXW2$Y(]D.$RJ%K+%JD[_5,NZ/36&</'BI2Z:_9N_AG,0 DK[ Q*P
M)8+<W?^F?ST=WY00*PM06C#V[RI[Z31I]=,8+4WH,1U8*I[G',+;>#_$_O><
M$4%,WL3YQX?UA!CA:3?Z>:4A[_'!S\^#^,V4U21^,H(G:FI28+7X3U$D6JBZ
MI![Q%=<E)(/Q4=V2@M*[<ZY)Q0:MWK8TUW9'@K8X]=ZS\OMBKDE1C<^H^BHU
MW)&5'IE^'*I/L^DY#I%_YY)*MP1J&H=Q.4=@6M4]2JVAFD9IY>D2]ZBL 6BB
M+3L$+83CNT=>/4;#;FS.GR(]9[9?7'R/-'TC/#Q%8RBTE$ODK@#:[C63Y:/$
MZ6G&<E(XQX,50-OQ0/DN\4SU+K'#/%F9".TNS<( <\[<L,=L5.X6K;ACEC1#
M:_.PHM)H<W/8UT!M8FBZ.:)-* TQ!JI*[@S9.GPFL56>& ;2$\-NRK$1;&WD
M@%TC[@BZ,6"K9^A,+ZDZK*L:P+9B@^)%58>IKT>K#3;=U$MU#G-GLY09AL]1
MQ'")*P=DCE/XE#^[#0_XX"1WGT'UQD3$KZT+:_M2JT#NCT56>/5[/13Y:!["
MOA^C:[%-M%6)][F7DT$9+K+,F!%_A\>7:!*A,?+Y_B]5JCP D>]Y6?U#9N2C
MD.;#"8\7KX*F^\-3=.W>BKAQT@RF[>:Z<F=MO1>B]*G_ 853'/*D^01GBDC5
MU.//+WNH^HQK^6:9&2S' *5!W86$%1)3TXA/4'K0FN_($0Q 7&TAP!&XX+&Q
MG#?\>5KGIN8C,< 8&?? B-R9YX](NG994L'XBN+I581'%)+KU.4T3V)ZP3/+
M^0R$8$*Y(X%3-./N+>/-4VK*)95WQDP\<:7D)%KZ.OOS.8%^VCK;."_^=C=@
M9#5R#/SY#&.YH6)EL;]@3!_B@L/3X<B1%0EJ-"_YOT5;(DT ^B'-ML=8I&V!
M-J*42I/234(5.$T>+V43E;0T%WP0.4JM$JHVJ]3\!I!@>;O.Y=DK8]5O00[Q
M350I77J"RF$R:Z'KJ1[B&(1+S<9OC!QC[<F4PSQH2(A^9\&,,1#R=(S"+KA'
MLV?M&/<*4F-VJ\I$<)<L":DQ$8XT\#<]9>^)RCK@)J+%2"^=)O?CX10>1<%@
MS/X_O>?K+NEV\%<\])9V6G^FD,J5B'L81KJS&;\GLDP34E1 P06D$!!_RF;R
M(;R&(1;Q/_DYFK/[9SOT>@>^J+V\@>$ZG06D#1[BE#TXA9=*,R9E1V<Q1C$]
M1FQUAMR)&51;<TWG/ 2UC\-I=Y320]%I?/2P'-$A]?_4 M4M";"-RZ]MSIW1
MM 9TXYUF-JS"O(JS:KP"LW9=3A=RMA5<1.0Z2YH.KW[W;EZTLY@>=[<"=O"U
M%BS?^@[&\E,=SM-=!]PTJ$\BRO0'0Y&QR7EB=8"-9XD\W^80W"I.Q\\)OD:4
M=3G&I%"N%*[FT*JU-BEZTVGEAMU9R39"Q(H#2='F 9[-DYB?P;)=X4>VB'YB
M__%8IB3&Y(X5O6#FV%,:8>O1N,K06[7'IS$FUZ?N@0?K.>"/HD]AC'RF]O\;
MAJZ*XD=E^I][9.MH-;R+DJ9?8/73W6OQ,)TGHBIL@YVUU!L18;+FA".@TM8^
M9"L>7)RU+]+X.<N-1D28N"$7K[:;)W9R^""R 1'ZC5U](WEJJ_3.@KLA1HTI
M,;HHELF<]E-XW&%?R)TN*[;EG8ZQ^DZ'0^OA_=!G<A]LMC]WEKK[HTQ[\\MP
M=RA-1N6NX\D&NR%=W#JLCE4WCOXT4U)-W;UIN&IW?Y;YJ*=+.RJ7E:MWVNY_
M,J[[^DHM=,, TE?F^6.>+ND%].8KXR!:9('D(359FAS^S&FU27=MID94&+(:
MKOIVO+N<68>H59^0=Y<;M<CUP=F%E,=/Y*J"#K'V4C)/Y;C/2@?<D0'9.I->
M9*BL,O$TR_>87?9T+OGA>G08$^RLV+([9L7Z%!BNI"K;[O.L5NDLV[];%LDN
MA?=Y3&>6/O2#>*?H)$H#&JLA]G &V-2-)N+Y+\:D!(3\Q+[,T9P_#WM%X'$(
MKQVHHWI$(PVB[/DHSHNG)H>'I=J4U<)NJAT!?RJ>X<DF',>#EI=[,?<5'P+^
M'H<8)E>4H6"?]D/@?V>MX!#2M.8Y03[[[0P','RB*OD>>;'FHG<OR)[<LG#/
M7&@\F2Q4[.+Z5I_29);.\T,4"H8<,Z9B4M%<S$R:@?")+" 6U&DMVG-F$89,
MJ?E,E>&3*#A&/$VJNUM=#5Z]Q4[P[(CO WGJB"GC7(=GG^&'+,>(T)@_)LK5
M/0@O@<O10,W(T%MG3XMH-6FZ$T'^.TU=(6>,,<,IB+)\0L,I@51DSHB^04#<
MI;@1%=K%+"$3/C\N\ CS5]3Y4^D,E<_#/\7^EC^FKGU)_3(9Q?RJD;M,VA!]
MADD2 'Z)'U^#<##BG'=YCLA8#0NHE(UKZ+:H-7CU^2$7[S>D1HMK%K :G_$&
M:L0]F,Q0BM.G-WAX,Y/UAFX5W\^YF FS7FDU2/KDFEA7 &]Z/<PN+8YK3&B&
MN^G+ H.;"!(Z1?-SUC?O8P+W[\I%TR+%[(?SM.QJ4V*C[PW8P]<S)L^5#@II
MTI<WHEP;#C9H39- =_/+-3KKD!H?)" XA@/^Q"J_VI =4&TXDN^^XK7JL:^5
M[-A1:3?#;0A48SJ!L2L*KH36A('^1; 57@1?5X>9T=G'M[LF/1U"FT#G0TA]
M@N;RK'R,=$1*5,9;K%0DRKL;8\(]1@=<!83A1A[DO"?37P]Y$X%YKHW,IL@-
M<>)I5&B@L#C6-8W6'K9&<,;AR]B0FU(C"+B@>!3]HQ.D!:;=YCR)<)%J_$<]
M+6E"'J<?^%7"-<84SI((IECN/UI\[2O!$ECSC0&"TM1>V8/F(AFYH[K1 JSQ
M7&\P/F+;+#Q#?D5?B%\?U+"JXC&\\S@O/G-6.8CFKY-R&6]"!ZY+DCU0PURK
MO,#KZ$ TH=3GBRJ]'>PH90:0)C7"VJ8T>U+;W=6LA%*_F@G2^9%T=4H]DIK(
ML!C?\RJ)[2#$_*A=5'/(Z+,"61O&Q-^:%@]RE^?@1QP&!:??RCOFS1S>UX!<
M-4S(-6UA ;99H(U]D-P@B?G48B-J8AF<1;O.!*4]--U&'_N![*1V=+A9@-7'
MJ.=Y0O/+H_D6] **P]+@"!#./+;FC9&/7+[CT9@40Z@$=ZZ<9RN;JU(WH-0N
MXM)YL<-;-AFKZ9V?$84_$O;AZ!HN\W&Z)C,C3,/JER[8!1W'I.Z(]6* 9K3,
MEA4R8\XA@\R 37\Q\. @"[(Y13/67G &9R-(BL0$F*]$#QJQJD.E)^-\>'5Y
MUO_<_W!T=O1Y>'IR=C(\.G2#%A,T/4%^C/PDA/RA[$L?0>XX=DI"M?CTI+'"
M6#R9@4,\X?=78T=HT@/3JW!6B2W6HE6GY*.#9;HL*^HL[\VY1X\.FXFH>8Q)
M,G-1R1F0&<_8TWK#*=LGS&'"0R4=)$L/ST3;P8=OA6<I7"++A,Q(40C(]X,I
MC"9ND%&%H]=LK*AX:M'-!:@.G8$N/&,;!G'3I>,&*3(@0Y+7D@N*.D* $I3Q
MJ9++X^5TXHXTOL-U:7Q9 #2]6CR;A_B.GTA&P=%M#$G$GZ;)+^N[(34[C"8A
M+EIPBYXE<MWI1C*G?$^+ @0(<@2^%I9AF.5I".7<R4Z05 O/F-D91!\3&#E!
M2!F+5CG_G!"?+:U+O7&P? 3<"3HL !I&FZGV((+.4[C$:!IW4@O4>2DJ$&K?
M>0 C7A"3NT7TMA,TZ7$U>N'[."$1ZXS /K]">LO_XLO;8#QF6L<QBM?&K^4,
M&A'@!HT%)'J#7)1R<8]A %9#C6+WZXJ&K,=G.(;!;A@6!2"Z2<"+G$\!F0%?
MD"G2,;LSM&KAF9:H,^*85T$!2#^(R"'@F>M.$^0(]BH>,^M=LDNK:+1'PSPC
M6N*L+Z<6GC%G.(Z@4_M0!2!]F@X03^DA I,(4ZZ+S_GC".X(IA:>\;TI7ODD
MBO"U .'4B#-C,^R!LF<367WV#0:GS"SCU\/<(,J(S12E!D8$1>#3%+BAUF0\
MQCA"'\T1=E6WU:$S!(>(F@X182.+Y87"+#K2#?PZ6'6AF_0KX+%\L7/$J($9
M!A.:1.+E'4=G21T\TZ ; O;/[!C5N8/X&G ZBVUX@X=3G/#+@I>0!UU!&!5&
M\7GHB*JVQVEZW8.@$:A>!'*"/",TK57W!060WQ_TEVXYEX9D+3S39)L-!Q>Y
M7]\EHO2XM$'$Y3O_?>G.OSL9'!M U0[*2N"M.\1I@6EWL\K <8<(JL%G?_7'
M'9ITN$P&5)99=# >5A-.]S/ CTZ6#4;SPB7?8'6&N!IX>KH.L9^(FRI1D-8Y
MX:^.SM*[+:Y09P4RGVIO=QB1E E[!@35_P]02P,$%     @ S4N>6(5UYUL%
M%P  ?24! !0   !A<&TM,C R,S$R,S%?8V%L+GAM;.U=6W/;.+)^WU^A]7DY
MIZ8\LN-D$J>2V9)ERW%B1QY+=BY;6U,P"5D84X "D+*57W\ 7BR*)$@0!$71
M.P]3DRA2-_ UT&CT#>_^]3AS.@M(&2+X_<[^KWL['8@M8B-\]W[G>K3;&_7/
MSG;^]7NG\X]W_]S=[9Q"#"EPH=VY77;Z9#8?6:@SI@"S":&SSO^ZL__K[':F
MKCM_V^T^/#S\:O'O, M1R(A'+<C$!YW=74XP(MFG4!!\VQE[L-.;T\[!7F?O
M\.W^WMM7!YWK<;_S8N_%R^ G_WCG('Q_"QCL\'%C]GXGQNGQECJ_$GK7?;&W
M=]"-OK@3?//MH_A@[?L/!_ZW]P\/#[O^OSY]E:&L+W*R^]VO%^<C:PIG8!=A
MY@)L"08,O67^A^?$ JZ/9.&X.M)OB+_M1E_;%1_M[K_8/=C_]9'9.P%NG<X[
M2AQX!2<=?^1OW>4<OM]A:#9WQ(#\SZ843M[O@/F,TWAQL/\BH/ __(,_Z9]]
M@AEQD"V0/P*.F,AH"J&[TQ&$KZ_.GJ8 YBZAWNR.$F\NA-<57^A*?]_]W?P
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MI!D,JIQCPA2L?<PR+HU;$_*9IR[O65^5&7E5W+AA!+KW%(&N73IE.+=$8J7
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ME8748"3D"HJL86B? (JY$<1B8SF&$V0A\UF9A0R;]0:KR4P%MYH/2;XR@J#
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M^+<]0Q@Q5[C'%[ >N11Q:]1(41%,(5S28+1F3N\$,N;[> ;0N!I-D=]Z^-.
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MX'VE,7B$+&E8:_;C#\B%Q(X@AA-D^E"4<:E@+H=RWLSX"Y@U?:@7@+!6O5<
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M\(]VI:#?$^@GNOVX3LO2&T/?P .I@:J8J?+_WWHOX3I?\Q:NER^;),VIL%\
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MA3Y;/S!]+OK'=ITJ)M6WNCV !!IHUVE!KI1MDQA8RXO^L1TVOU"JWDX0_<@
M/R-(J8&TQU!(PEFCC.'"T'I<,Q%&80W0[:\__B3!/27^GY;)\]OJCTOHJ__8
M(]\8RD&HN];JYO@V9PQ:RZD>^-T9&)1LJ&. DL\812L?WH%!R88Z!BCYC)7^
M5QLH/SR 0<F&.@8H^8QU"F 80WD^ X.2#74,4/(9*]UMUC>2WGX$\NO(0?L
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M[ZN$+D@X]8U-E^M7:_V,(7%UI1JKXNZ5Y^:,Q$P>&2_7*L8)6.7TZ;ZV3<P
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MOA]V*WJ 13R?*GJ<*GI,N:(''W_^.2:4IWH!;0/M\1R7'#/?#0[@ &XEV:(
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MZ'-'?ZW+8:/3=[974,3G*LF#R(C91L\#QQ'Y]P7FK,4S?,IAO(;KBFM"1@!
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MX\'"^9??&%L(@HL)"E\B]<$G%&RS/B31&J;9_+<]/@I9/YKT!O"A#?IL"($
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M&5$*Q.="O2Q6A,NF[#*;FI0;&02:G4#=RS<HA"+KHH0_;UVSI4EU%L=[O-7
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M@BG6& >GQ2EYX9L^GR9K&W@0T_< #R%#8K2TNKXJG%2 %(<I" !"P=-=AZ9
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M#G3 WP@E/S4G]>3:?QDB7)=!;TN+TO6%U1RO@W1M!5P,LIY> O0YD;XWK7N
MJLL47A'Q)=5[?<J>LO'IN?FXP((YTR+GX\S39$!LOK0>A7AWRK+DT#96>C,S
M/,F4&]HY2K>+80JA3<FMM%MC<P1=&1ZD$5B<>90Q<\TK\?:G,DRR@^_HFG0<
M:_;&T!*A=F[B/$F4=0/7G8.!;BY)D& ,8@W8D&9-R^EE:V=PB4RK9M[,.,ZZ
M=R3;FHW9M>H,[^5K:OX--?G;E!PKX>;8/-E6;=IG/O>B9:UX+=C>1 8^SB[>
M>Q=Y &P_VV]2]9+@I<>&XLO],I5#[^V^UZ?[#!FQ'^]WYSLHG@)338-H$:_A
MTU^@#<.[2]'+W66'"<G]5-$8T-8 -_?K3^:(I',;Q9B@88+569;!?*PBCQWB
MSK0$>WS>SG![.U_=^LXISI9#,X\I8S(#*B85U,H;J5'%WQW#U:6"D M) JB
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M ^,@IWY\97>Q32[91/8*FP]S^(N(NO)FFK&GB66?AR)S@4I0*5L>\VC*PT:
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M$=E%['+M;*T$^PHTXI=?@9J,[X.)3T$;IG.JXKC.ZC"N9=R(0%INREBE917
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MW5D%G7%=QP8I<Z;H+&%; -, K5C4BML_8U7,S51.H"IQ\F4^PY]%#$PG_%G
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MOB F;QF:)(-HN;G WRBM3%P05MQP111\[+ "?B1;:C/'Z23*-&L(J;EKRE;
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M&&MJ>H"]#1_@>A_!QBNTY^7F FT1"2)#P1V*4/Y,=I @?EZFY1^(VRK&V'E
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MF 3]ML<F=/XL]:.PJY*(NCN[RI1QPLO[L?CKY\798O6+Q[I="LM?UQN1S7"
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M@X</,?IM#\>] '/#L^O$*TYFI6#9_G4?D+<:-,D'6,2;)-T6&WUPE^QSD#]
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M,J0R,BCI>:HQY "!-I,C\1;?VY?'*&@RL2^/Q>'+_/(8,QGTY3$J^[S +T^
M0+OEC-F+;Q2_7#[N6SW@/78']R1BHWSC=PF;-=4%(112$JXCV64,\<S]\GEG
MLU_URA-\_5^_^_#FS>O?SU87]*?CWW\#_E:0^Q^?X6.J\JOB,I36Q@Q)UZO/
MMY>SJ]FG.0DRN%A<+E;S,W44B;H[#<D1<<*##ND"#GU V8D!$=?X4)!*C0W9
MQ U?QI28N\3GYS"(#-4+L[<GS<+B1:)4RBZU/IF0[A#)I:,VN!,WTAC70?Z
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M,ZZ FI!@S] @D.$ZA;L K:^#G%2;65^@$,89&QKL9R/"_JZ?%HF8X1=H(GW
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M-->&$(A*%**Z%A0(B(0\*TIU^?:N*N0+,@!W'%!W*FDYTG:]4:>B][J,Z6C
M3F$_WR<438$K*$#FX@R Y&R;I#GZ9^ $B9+!/)B18HYXZ64;G8J7A[7V*_KY
MW6O51-JJ,"I?!9. ZY_3)(?+S6:Y(99BF4VC.9;"M96<AM.+*2D[O K/I!_&
MRH;@)<1=05JF2@D:G;U=1RE+JKIP4EL'PRI=)#(14XO7GXLG0VL:Q5AFA%3
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MRG*^>JKRY:>3K S%!)Y71A\#O;)1T@1T^NDD%H5>/"U?EIK"T8N"AIK#2;0
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MM9/W#"KYW1X)IUF2E<E+EJS(J0NEO9+R$X5#M1V:^LU.IF>\C'CO/>EO=27
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M?5JGRFQ2QX9F.!+CT:^J8FQA*CDYT:G:0$,XY"]5C[G!>>E%_I^[),-GEF
M_NE,_(!@$)IGH1)@C+2H??]:HCT'ESU"#N=\];'$-$QG_EQ%"22\9>*RO,F+
M.M6<EC\2J51[G9 HR#?YZ@T!R@.2!5BH<E)K/5 6N\G?I[#K7+1]X#BU ]BB
MVGX'<]E3>5>V-J&17+'-I5B(2S@QBOUE'FMSU/C6;(V=L6 0Z._#(2  $3Y6
MQTBA>L,Z,,73U@6<R*..MB 2Z\>4[2R^;79>-^_9LPQ4R'>9KB?0\P')NBHN
MHB^/\(Y>DCU)5P#9L)C<J<U?R8*X2LBC DPIB;X>(7MW@,6!#:59&_3]UX8_
M0WR&WG?R+.0&I'T_@N85C.20ZIP\B-G>O $\$I_;3&ZPU@<@DA'XEV!;"J?>
M][#N*O4:LD(D$PP+$57%AL[4P:'!\@SL<:'N'/ CD;*H_ODAR9(-I *;GK/\
MHWZ2DT=F]Y"5.:NAQ&-(4%NW:SS$=WFIK]S05HUGDG\<P;B0P4$F>E1KVDZ_
M[U,F T\F4^8>D_+398'CI(*?#$DUS1 $7\X0&\7_P?KAH%_Y?Y5&@S 9-SI2
MU:>/A3.^,@:$ GCV]GF15*E6NZ5_A*+Z9V^_>?X6B6$A=H<*;9U>VR;+9\JY
MI@RGI;9"NUKIFZ9:J:K40IAB"R:Z5$O=@1$>KPAR0>4%?6>R HX*W[<V5(XP
M!VINY6D*UT5=]5<*$9B.#=.!3I6PG-GCV6])EPPDB);GNVI-4/RW(0&6[QCZ
M.7FZU0-"._U41*B=<WIR?<4+W$**891"DZR+J$RT3C+^'8(/$?TRE%>_BW'W
MW:6FR.>54*MG(HW<%D#8Z*9BQ(3"C;34&#53->F!7,/GR]]V28$?BIR@5^VA
M2PK$;("K>VO*R),]PQP&$D!FM,],Q:(7:DAACQYWBLU>83=^^5)=H0 F64$/
MN"CS+,.IR3C+OT7UQZ&-LRKDNTJLGD#/QEE:] \JQ15X379O\HJ9C1#>E=QH
MR*+;EOM%$64E01J2[;*8_BMEJ7=U\/8]KN:K1?3%7$NQ-9VPSGX#,W[;&&W%
MK$B:EFX\:6(I_GV&(-V!/&+([($]7Z=AJ?+H/:'P/*_#*UPDKS20#JHA  &T
M(@+_'4%-FPM1?S1#M$X$6T@HI^4BZC\1""'-/5;R5.)UY(E?PT_M0G!L[=PX
M7]P,/$']+X86SF[T>XJBKI' Y16NHB0M16ITOI+^)C0R."(@GS"JR('Q0YZ]
M_$C^!Q[87947>^X.>HC %[3&%=2LI/$4MQ7>:(VKC5R)ZLJ10 T6J/7W6L=M
M88( %02XH!J9QDO7QH<%J%",PKU"O#&]_\#Q+&^/>?-U3G_30HH==4U\'.WH
MZ=X?=+Z2^W !,"@>U(!#W0ZA01/E!]/?71QC.>A;TVQY,#JE[\$8!6YXNC!9
MDI2S5Z?7O4  H^?(3"2-3>91[4B_W0ODRD-_FYDJI(]XB8F.0A9<2?1UZA-G
MK\S>T67^W'H%L==$>SR2 *BN)>L8Q3WC/\7P)&SLGANG%)8O6V8[!Z=)SQ'9
M.+I70R=W2<IL$B/#2=]&4U>.;CSP^TH@#\P8F@>T>@HTBX?ISEI7F>BUT R8
MG%/8B4#5$3Z ,SX-V'>X+#'61- *,^'5#O^"HV*Q+K#6',< S;IQR;,F,'D&
MMM5G3-V@,P0 $848]@TXF $JX8[DHD<G*0N(,I>9%?%?G0JS0?(U)'15#.^3
MX\M$+:K>/:UQFL*#*\KVCWB;%_9B?W0(XF,0&Q2\U%^?CJ[-VD:QS^/J$;/X
M?U$XB1RDN\V.9K%=X56RU#>1%2-1737J&VDPXJ._#9T]8:5/M1M<N>+)2L4B
MJ^&\NR'$M9,,+YLZQ$K]C U%9"R"P;T.AY?=8LR^E30[;3T]S94=GA_F] Q]
MMO>T>^[VM+N)$E9J[YR<OQO6X Y,4)!7#+FTVB0TN1N3MI7A,V]EV.W:!#//
M$,PM"B$VL[,^3C2EO-.L,-SM=1+.:N_"$\K1JR=?TQB9W?>/^!47)6[Z7H_H
M*MV$N7-H<L_P4$VE1U*O7 UC&.CUQ=$TE+/6%&\^54;)A'@N]+%7/@AT1/J,
MBXR*3T0Q((]+'CI+D#$_P)L1J!GBY+X+$0ZI)4\E$!LS/-^]#T6^Q#@N02.X
MB+)/T*5!&YK$OT5 /X*O:6^*P$>5B@)EJ)&64J]MMA^%Q1+J#/)(6#!$N%8.
MH1VW:R"LZJ*(%@8XBF[<0=O>N]+;55:'\\J;&"]3LH<OUSA[L10)@>\0_;!;
M&<1W79 .QEUFJRGR>1DW/L2;)$LJ?)>\0G)]1?@)S6-8 Y*!;MA\A1BP-Q0:
M:L#Q5BWHUZXC-G1UD.%<4*I>8YGIZ?)I.XU-S]+ACG?KPWV:OG=W)NB][T,9
MZ;D)K$-CYP$9,Z[]L!U2:,+D.HUCAVJ['\19O[W05ZMDB>N8;O/UR3YNXMRG
MT8)128(R5$)/:T =7SH5]NZZOGR&[MM*?V"-OTN/3?-7T^^YUIFR0WK?3G;1
MM9/-:]-8PK)[R]N,655.:.B<2Y9-,2T4@6(3AUP')^"CUJQY"G'Y"XNJ#:P?
M< 1W '4#=Z*W'H$<W:M3LG;+(/JA;Q1*((O ($J[:M1 %OF*+_HK 43>94T@
MY653PLI\??*1<MBI-#9XJ4H[85T)N;+";_IPN\&IQ2#0Z>HZ#8U&28+J(#30
MZO'A2#39;5Y&Z7SUM'LNDSB)"J+?TMPAJ"7,_JSOU22&PUM1!D#3MZ!_'52"
M%D""==1PH[&[0P:QQINY[!QGRWR!E^LL3_,7@M!=9:FN2T<@>0@B8WI'EF^/
MNY:.GJ/=0K&OR^-0S44J6]6]"?$F2B#$ _)(P:FTBU+PU)9OM8Y0F A9--$+
MKHDBA28J%%&Y*IA"_Q"((0DSQ% +J):$D$3/4!1L-80Q)%_A%2X*'"^B+\SB
M>9[)%I'AQF0!D*:(<0LR6)U:WF&#13FH07D0-\Q&Y1&,]7?9U#;0KI.HW7O>
M%O/5]Z*A!D# @\2%/GW<EXTG/C=JM\?#;=:*2#<9,PTIH=UF'6"I8"DWK@;C
MP.[L ]BBVK4'<]ECG$BO;*9#/2953WEE5:9)U VUU&:RT>]S>[9TA"R^P!E>
M)56Y*':EOON.K-?!]A*C$!T6VN5B(DDC#PL+/%KPD@QZB].$#B@S98M8X]_S
MFORT@E:_];IWXYR&B)XMSDBL5_O.3^0)#2>D"#]AE>0'^"D%@"9*AY?9GZA?
MTIE@U8X9R"W/?K"FB(G4^48GMTXI%VE$V! 1)1$J61BH]6BM RSFV<<2G@W)
M"Y0>Y 6!#"%NE/7S#$'SD3EY=K%QJ!D8[@0SD=,]Q>RD>]2M(. Z8X$AXI'^
M<U*M+\E5EF]P83W&^'CF#A80T&<" @D8VF,L2/J2&[FJC3.,57[C)ZCN3M_<
MYIH$[)LIU"%CF"@#)+K$>#R6SK=57NPV"X)!M,6[*EFZ]7WCXY \4-_]S;MQ
MP$)5SS#@Q 7/P1'P_%GG:8R+$H)G]$VJV%]GZ+RJBN1YQ](%JIS7;9I" DV+
M#*5-34.L7Y;3C3C_G!$DULE6Z&XEK1%L3M1FATT]M-9QRQFKD-S+X YW#AGI
MTQY/#ESQ>(D;HGG/-WE1)?^F;U5>A<O-P&V)D);ABBIJ)B-W /$>PA65X _G
MLM]$1:5;A_EL:-X$U&$BQ$!%74O:E3(*3'+/3:YNX@C:E<?P6!;ZU%@>%A^?
M/IS?G[^__G!]O[B[_7"[N+ZR:"N&,0'+"QFPZFDH5JH#YS%*>?,#$AE[Q0.F
MDK>HJ!S@3+VOJ(8KO*3R?W?V]ONW;VV&T/;7"B.H[] >)?:]2!X#C?Z,SE!-
M2"KA(=]^<"S6/:"LZ=/0X%<N<M+2*F@*8],8*[R9>BC97>&-8YO'@^PNR?!\
MQ=I"W41+6AR*AW)(01[,;:Q/B<]H4 1OH"7 S.I('#E,I]/B,DBZO#O)JM-O
M.,L\RK,7D$%^$+_C:JK&EZ4_-7NA+C/Z<_T'#G>&M$Z_H($OXUFBDOZA#/9W
M9'=?+/?8>CKW'WT0"JLXAOW7N];2TCURK63[KE'_2L[WO-CS&OEJMO-OVKT!
MPL2<-.BJ@TBZY'B-Z,,O<%NR2F_DD!W@?.5#43W6[G4-\8JU$ZA\M;KRQ5OP
MW?5FF^9[C"$@\/I+A8L,>F)EY2XEN[,JS8_5>C!5",5P)(U7&-A]'TE.%'8/
MIP%L"6!K[Y=HHFE0U/RIW5>&JE9T](P%W4W!"&^B3VN3MS/%WY7.FWH_D+=$
M5D&$WI+V6##O)M&W7(Q"8ECPQ"\C.=VMXT"[E]--+C^Z()"M)5;AH^ E50$)
MF:-J*CRVV@ [ZWQU3=#/-\G2:(:&R _Q8>C$C0;E[OI44N3)*BQ+\X;<_5'*
M3JH;\CO]PTXL4#:"G]J(C@EUL1H)T:U?#<6>0\J(0MQT/#M_C9*4NH-R*927
MNW>A+ZAVQ<.#J]6&#M6PP*,M1SES<#/:$'49.EIP(/VJ^W84"WW9F@$G%L<E
M!='=9BI;N*%%'.T )*+:)$#D9Z3T$(3J%C><Y)[M<P3#?%5,9]&HU),/C0A?
M\554118'#@_6E08A&-7SX'@^+DVD=$],.]E><SSJ'/+[O,(B <4];YZ.JG-X
M5)WKPZ;0]ZE2'7H.;/!4(_TN^6V7Q/HH;>5Y)L;(YA1%137?)Y>!E-XY927;
M$_]'%\VNJ\O@8IF4L'H<LW*-&=K/;@G:SX;\; FC(?G9X5ZD_D6@?$8$6 3>
M+(/DKG^*4EPR!]F'G.RV=91=DB.08 >-:$K0\6XSZ$NC6Y^@)%,@W)V(  P"
M.(@#0C4DT*P 5KA%-83B[G(8SBVO$6>-!WM>-"5'[O+LA0;-,0^,:W?>QO&?
M%Z@NSI*O$,#C88G" >G4OC>( V4$1Y2.EM&<]>J0.?"T&EY(XJV/^G826HJ>
MGE.[N (*0VDU#[4FO)Y\SNFWO.4<S;M5-8P(LU:,B;<6&KT?,+UXW)%1RS-:
MN .J>O%(C>F5K-1N* T/PLO"O6K0^R*B%B!FJ>WL;?K'JZC"=?5%'P<]0ZFI
M8:HX[>DG8.G!4J.GT-Y,OY)P7Y0G7@P>@^SO=QOHG)D7MO.]_C!\0'$/Y]YK
M0DU4@% #M@H:(Y?JE<?2X/AF5=KW@D42R.AK(P?Z-'JMVD+N.?@?</&5/"%I
M:U\B]01:J<$?SK.X_0OI2T#WK<K\2CZ;L<*8TM?0MTP 0NP3B/[L_%(>$=I(
M>PAOE$;<PYD=HM.BZ?PN#SG N14*/Q""M96D72[R\H@WN4 *4:RF?H4?C_^C
MKN]CB]];H5/>:?X&@NSB?^W*2E\ 6'R+;FBL(?\Z9(B) OF>@5A+H.<31.7(
MM2E+:A>WXED\D20XT^O83K]?O8K<+YB0"U?-%7[%:4Z;C?"7KCG;5PREU[8T
MN$GMF&:_10>259)SYI17BU)3I8G9>Q.:>;PRUWCIU*:21H+A_*'(MQCZM$"Z
M<M7TSX$.'LMT1Q.RYDE*Q?X^*IOOX1>+!!37^G<AY6QDC4K"#KSTY=3=97&Q
M9V%-VGN(?L/#OH*]'F5,>Y=.CPJ_9ULOZPJ, DQE2=/\,Y0(U#U9E/EK]7!4
MCP^YOAW(4ZUR9ZYX/<>@(<1M1N[!'>O,48>WL!]+@A[5"[4MV6D_C 8"V,YK
M&.(? *6GQP>1G".Q:OD-XI1G_:Y?+UB4"G[$2TP>KP31@>67Z\++#830[EH'
M(I7N66?F>)::7#"UKKW)-!NG K$SJ3IIQTD21D(&@E2"L=(O/43S-@7DWV ;
M55WB=<'[7AF@S@-A7> 5'?/F[?=OWYV1__ON2QG_AR,0C_D75F2 6RI=16JP
MJJ@1%;QB@[NH^EU3C:SP:;N]S[-"ZDYH#HEM/N9-&2?12DI)@FK#&FCU?'3.
MM^ <(6\B>GAPFY>^NJ;X6IR;8D!8A41-A(KQ)G)]+G:HD8)Q&QO1>V#_,8N3
MDEZL4%YA">54S+5(*#"P"W>D4T.$>H0-3,2 3J$LR1@VJ*,V1O/3W_WS<0NV
M9&:_K->=ZFW,/D32E\$>R#V<NS>)AB@_7&UGQ&5/U::Z+HJ\N,S)$W$)C\*;
M-'IQ2 8$_2F)4O14D4.960$!#FH H5\!5*""?VYTRJ(9PAFO+V6C'7*LK3;H
MK6^D:+ IUJNA#D+#(*PP3\E?7NHBKXH06V5$>FMT4_T6]0SFX:)#G CLA8P,
M8(LG25WEG[/.0=LJIJ:3D1@G7R:=DG,!?7\VJKJ"<>-"Z^YQ>N\V(2S\^)^O
M^K6IU<]>8$%)>$#I7T7E,V4"!_@[>!#_#J=5*7Y#G\CT>3QL3K\U=5U0TKV5
MZQLT7[52MO\SVN;E?R$>X#0-]^<@>;=CG5PYU)P/ U=B%RHD2IYL"1HG"UT!
M7T9&N^IT"PT&3V:UN<C47""_QPM?,2:+'#JX1$6Q)U<B#4\]KQ9K?)W%\Q7Y
M+PN)T=U"=# 2HUDX,3JOH(\$(A# K@8_,B ![R,G(KN7T@#.3*>^U3W^3/^B
M-?4XU+@B,-@'@<T_3G1JMY<;@WP:AY@AM@X#;U*TM87.N8>WB=67,M-#QPYK
MJ5%)Q$*Z5RT(*K DM9()Z5=DA33]JW3]./D0^E1M#0KZ2#40HY*#E7:?^V%8
M1PK("KXAWX[J^#&C%H5EMTCWC&93(P ;]J@;QPJ-SW T4_TVQ=T6>$UP(+.S
M6!SV#'=,L&Z-Y]%&$\ZD=B57LV<'L,I;W4!1?V>9%]N\H(L*LIS \RC]REJ
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M7GE0R!E ( $#7DW? !CR&OH6-?:0!E1@SXX[S4J+QT".^6JY ?%4F%6/DY/
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M^I)L=AN+WXM]%+PH4PM9F;,:2CSH[B*4Y.F]UIQX>__^_&'^>!WD"&GP4P7
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M3SZ%II2C_#$'3^;/G'8\I!V\.+Q8%IU#^ %*)&9!YQ4B\R"8",%,J)Z*)I;
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M'=%WX&^G]+8.-Q[X6US!CH"^^O,I"788^^K/<04[(H3^ZRD)=CB&_FM<P8Y
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M)O+IR-EFWO6;LA]@$DO.$CCB*JV62?9WFI3O\M4E.]2\'X5XGH@!!$80-H3
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M+)]"::#XW]OD:[K9;2#DS!;*.Q0*9)CQ%8*BFH C&8H@X'7^6F2OT@DE)Q*
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M.*),^XV-HV\>8O/7)-?XYB*;EGLXF%U$TU>Z@E2LN8EV#J[(\R$H0 [YWH#
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M[>#RB(BHVP\:IU2BRYWKQ.X1 V8*EE&FYR]M, H=(U8J-"OMJ)T.%RV3)^@
MU>8O?8:363>=<!^-P$W%V.&LK)/JB?,C:?P(A^:/-*LK]2_\&.5'Z. TJ$E%
MGD7X3CWQN-&0P_75Q;@2#>Q9ZWK3QS/R344#RT.CUWS)CD*NG#UX\_/ZBJ[
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MX-H)/Y(X\R,*]IDN2!>!!456N,?IKTL%J W3*[OC&2ZA'90-PNNW/D.BY6#
MM_5B*\)\6: HOT7E%X*8\0OA!0UH3,0IZP&M:RA"Z'-->@767Y8<#+RXE&[
M!E)1@PO-?+XSGZA(^.-'7NG./' Q2E#!12/!)*Y;22R\-FY$?^0:\A/_WST_
MYA.^ 'Y;?;[C>F]L'X:@F];J#3/I+&$'Y\T969$P%->KY]2253U[0_FK +5Q
MO)UNN%$F$0V$HY-:\87OLT\B;&3J.?5!M. J\5-(F+NSA*Q"MBV%P,P%T@\2
MVGH>,<8,> ER@. [HQQ[; 0<]>GO!@=_J5BLUR%9<Y0UY_\#YYCL$F\J%B,T
MT-JVW(ET>XX]C7)&RT>?KH^!1(.+13<\&[;KFEO_D,;[1>#X^XA&#2*&RTH?
M!;Q:\J-LN4OM*%?_IR(NKK^6%C@6S/&YXV[N8^9^S/%]<D*/1H=8'Q.G\QG_
MB:W>\6T=O^>'Q9K_ZL1WW(\<"B<CRKZ\#:G+_^V:><0WC3#:H\6&3C\ZD7@P
M]SSJ"W?'9Q$G2'A#7.VB0SA=GPV*<,%CWI3S+V8!N<TC#!Q3S![)UO%(LA.J
MN*'DJ8AZG?)KO4-%!I)'AQP<(%B!GIV*-/@S[M-1=6>X\1U8WHY*<H8FL7I
MX;9-;Y:&YCJ4X0%F-G;&XS3I5P,&9O!;\C8TB>Z! JDMC?P-;?UHA3!6$KHF
MQ<KP(-E\N+QKL[?Q)53Y36].A":I&A#!MIL\24*3\&X@8+4=PC?6/?'*WX Q
MK9:3KDE3R]=@U%4SU'6MO?1CJXDJNGY!)Q H99/GK&N2V@T$C-1J:HPNC?*O
M ?=*:TJ,]K[IA01V3ZXEN.NJ:,OG4.G5U6QW;;]:_OE0XLZ8FXA5+[C+E=K_
M4I*"*FV=,$K>Q([O(^%0B]]?<9HJU)+GF 0>\0IZ!633_@ 'E!RIS]P*'E^T
M3V!A@<9W'HG_CR^2Z,NUX^Q^%<\(J7N_7%UPB\K5U/%OQ;.?B!<\1G'(3_0J
M1P6%$2<Q[:^P<J+'M,E"#N^MX/5;XL=1\9N4^RGGM5!F8C9?3GY[MD-X)81L
M3B-7"7+)?XQLT7E$\+:L(66U7(15TIW0+:CA/U9TLME4(_^+M[OTU>E+=T/]
M@SJ+EP,S-8M9NSQ9Z)$P;ZG"EY&]&UUE_&TE,Z4Q%<+QO-"66EM _F1?_I?%
M,X66I@;BXEQ!EG%E[Y6EJ<-#&$D/%O49VSHTL"C2' 'V!M57[S;!%AS+!?@5
M%Z"A,2]#O2;;1Q):E$..X.7(H>"8^4;B]X"(7 VTFP>K<.H[4;1<I>\1%LQD
M.YXR[9,TBQTLRH7WS2 K:"*V,BE6;* $ ?;>ZU75LM!D#*J:/%/.\_LCOY +
M\ LK5D^"8%Z<ES (S,@-E-B);8F=S%QB)S6)&5@VJ<2F;=A+-[U\W=\.L.@F
M.IH]VIPFH5B5I8N]',>!8$P1-:[:93&U\*9DS0<Z3D9&Q8DVT&9$@$3=,IU:
M6+$8Z>KA)&!X_^ $4C=O;YA3#7X%D>' W#/*,FIA#]11;&3E\B??8Q[ #8GM
M"*X3%?;IK"S#;H:!G=%&PA09*8'(<$^;]H$*KP(:-VJF+*HJ.\S=" "']U@+
M>"_*=;.J7BN[K O33.36R:Q<C']&$6,]9<J:K>Q -(N3KHM1N03_,N9Q=Y:0
M"[Z2DY!]Y# 47F-K'TS^>*HO,&?R7S%\"I'\$BU$4;<3C.%8]..;O/@T6)=+
M]CL<%R/-$*5%0B"G--WIE?4!2U<%(W+ 6EF\2MS+!?P]P!UN>.##9L #?5L:
M!#L&W=98[/B#Q5-D0-_Z3I9/4VDA#KSU.E!A"T^JIM7-UL4HP$B)F2M9J0R[
MH^M-O%R]C[)<<6AOLA/7=.);4D^RFT^8L9.B[4.IO0NPX&08IBTN*4^@HB)F
M,9%&%<;YL^LG8K34.\:\3]3WP6,E"B@G<XV31TY4F 8643$2;-%L):>0!:X5
MCZ45S;3W83MWH (HYJZE%9]R-J]F@\QAS8,T.K5*?06M/FYV()J^K+JXA&OW
MTBMCDSP; 4@)%FROOU][&V%(&:]P7ZIK=9:+0YVE=;'J8)Z7J+5X"I?A.?SJ
M5]"WM[21NY$A1\XTMW,/X^!>7PTS=S<LC,7MY\0)/J8A7*Z&:4@WUTKH#-Y>
M?//:PPK\PSU[:Q6^!5EV=FX/LEGMW#[&@;WJ@CG%UIUA]+UIZ@@/DA9("+SE
M'+ 6 ^C'ARW+=OU5.#\ET0&TL'C)4)R1Q]B:2-OQ3,ZN]MC3.IM0$_OK%RY[
M6[(=$69P07$?=G )-X.P1)2] W!>X9]!"4L \;I2=XQ%8^8DL$ULQS210NE.
MH75R"BHARO1J**I]-LSG1$3B(5ITP,@?5&Y%+Q'.RC@.Z6.2YCT^,&$2FAUF
MK/67 "4.VQE2TQ9HB<#E90VIJ4M7E38BM& <*N!QC;B-W=0LP"MS$SED[&7M
M1AW_UJ'>97#J["@_6Z##PRU8\'>T;7FW\A>P&8#I6T&R3=(F!:G;*'JCA61#
M@B@=%R5Z((HV7S<D7JX>G&?X]P(M[-AN@G4UT94&8$C:K"!/-"LFWKD3!GR)
M48G^,[*B+H6OSNM%B%R";%M%5%@.%<6&\42M>Y,3.#_,/,)!R=@@H<YK&K P
MU=),\X!EU0 _+:].)J4F1W ],QB+,LD;'78L=,R+W$&-?AB\U0<&WA:!9]U&
M]Z+#=N0T@W0M/"N<=Q/3(#/??W];;U#ZW^/V+:V/*WMM8UJ'_=K&E+RV,85L
M8_K:C@^@'=\PN;TVA;/;8JS>%&ZX)_W:%,ZNQ.I-X:!>^Z=M7JX:3>&&M/D<
M^,C"/;%EF)+FI2\$Q: %>^\NK1BG<D!T>NM*K)N  4HIS*:D+))XPT+ZQ]%U
MAQ=J ],<;EZ=G$)NG]R@[3**$OL2S+%,YD#1DU_!(^P,^@9ARR2.Q'P]&JQM
M2[",:J9BK' ++E4>+_8A>5_[PM"Z9U\?&&LIQM&&9=!PA2<2)-S&VJ&X 1[S
M":!'2-5WMCI;<-\!"GHLB0?=)+6IH4PFV+(X)+H7@RLM[9UV/,@NN<8^ZN 5
M<H_X*%ZN<HT"/_O+L+%W5J^V5L_\"EL,]MD/F8@"LA8G[/ ,DXCPI6X6@7?&
MB?)9VF(I7PFX+>S"A1K%T))A#\\,MEV[3(V$^HX$?#F^**+VMC2@8BDQ]\#L
MB+4/&Z9#HB777K897*_:)&O8.FY%HBA-<[P@X*Y* _QL!-=DC,'E"5)2>7)A
ME/:MRQ9P6!"T#].%:E9'8S?3#(I684]*05ET) V^>J<&?C:[K\D8@XJKJJP>
MAF?D+%U:I/':NCU(,* Z,3JW!AEW,/O\O7-H(%*OEX&]=HQR'*C[K%U)*XZ)
MG#G(TV*.5-T[/EFNQA!<$Q/N>XNV "6LPBY1.2,A?4H=W2.9Q]_!MR7NQX?N
MMJA)58%Q&"95$+,,WG/O:75&UZ(,*JME;Y8<2T<G='X^Z=W6O7# *X'F1LOH
MXII!7+8.TMRYY>J&!:LBHT[65[-#-OV0)KZ!E!D"V%?(L/EPFER>.5:Y?\OI
M9(5[;&-0DP+*&;@L:JR#FB4SP(-9AN6#.7V,O0SND\>(>M0)H1/W53 BOSUH
MN#2]O(/KVJ CWOLD\,)]_MS<;U0K?S[AK55=%EB_ K,10<>-7-GAP-NE'<\\
M-DD'G^ J$TU#R306N]="$#D'/)\WU#(W!J3=# ]:<9TZ5J$CU!WJXT<->#6U
MN++Y])D)^AP[7 -L2A?]CJ"Q/VM,P>Y?654L.\%E.8Z9Y':U, C.VS>16M'0
MH<A6/W$BZ@)+38X#4VJ=NEJ660M[H&+,$!([HWX2@Z>"MV'!MH_&DCNP";=-
M_L]$#/LBWN*).\!K<I.(BB=^2ZQG.ELRH-KHL>6M85_U60O8/M&J,M@PRGJX
MD6\MIKO&1#V 33RD8N0VS'81B2YVW.</B[K1SF_D<K#C%>_7KZR&*N9@]ZO,
M .Q8.B#'3=I SV+2C2+6V23BJ'(1:JPTM*@O6,A-2I"_M.X?0B>(.,&"V8&7
M_I>?L=[[+<E2'BSUNK1$).J#@-X64]6K(2)#SCE2Z=HI[1J6-5X:4>54J,&^
M<EC2+R5!0,UA-RQ3KM-=T#R!YG_0U,WE* 27RH".@(./S([%3$NE-!I)XFF1
MI0VKJ'WCOQT!:]QXVH1\0X:Q-C-N/)E>X"M=-!\XJ&]8^*UIWX52!\!FBT[[
MG28[< YH^?O:;'+BS2;[5<U^M\G7=I.6^\&]MIN<AJ3&;S?Y1,)'!M4K[+7E
MY$@M)Z&D5B+\C&T=&D!+K8E@7E*3,*A42 30"SD[4H4+S )1A&;S@)+BFDO+
M4CFC +J7#FVO9]'<E>%/I)MEE[ZV=-0#[XELN.=:)I-9D5\WKFGL.551]O -
MM;=5?4:4%6&V()G9CFQC%7:G4L5)<,=RWG\ECD]7>Y%>$?U(O#4Y?Q:!QZS'
M9<H#DTBD'3,PJ;7ACJ32M3J38AUD#UC#,J^Q=+9/A:;AO:NJD9)4!U<U&^54
M5U=@Y?XEQS$K.]#"IE(%PR268S)SP<"8^$,T[G7 WLL:L&=PD]KQXY)YG-HP
M'OC(:3LA>&HIOXH2ADS;E0MKP'#-;#C!61(*A4N!IU-#;LBG]%_@ T\J.&<A
M5C7N(<^H;J$RT\F1A5Q'.AG'T43.#0X"3X10EO0Q#_2!"5K$.,NB[$#MO);V
MW3 ".PFW2RI-,RYAW 52?:-RNW)<Q04+3S=.L.:+N'7"]!\5A&H.>[J2'<"O
MP9U0A_I+'4=(&N 8\?#-\&&9Y,%*KWHRYVS%+)SN/%!&%'L9(<KKPQA"KW 5
M]5FB2RO/MSN?[0G)!O@EH;MQ(G+K.]"Q'S,:7KQ1Z& _9M?E3I4NVD!DL6P2
M1*E$QK0<+11@> KC69(VMB.]!71I==W-5?4/5<'-VBSH,0ZITZF42.\X5!)"
MNFW@7IYT6QF'W.>T2Q5/6?#$<:0M>+.?8_KHDWOB\K^,&RVCK3H(_;2\5-.O
M*@K /B[@_L)$-$F5&)P(\'A^A+HV0720,,R-*Q8</;"6A*]L/.[.I]!/@)K(
M9V]Y=)D-U7#"AJD1\Q,YCB.YH]H6"?:7;DQD#(<JKP:ZD9S1:,<BQ^=>5]&!
MG!NY]X&79G&),H@L_EYJ=V%^7S%!-NW'*$BN(K5][W"MY,L8>%]M 3J-/&L=
M(7>R"+G-E-*Q)6S48SUD<D=^3VA$8^[RA$_4)=E:[XXS1R1O6N-X%4/(G>XS
MV7@2@W--H.S+^3,)72HF#_WLA-P4*DWST00XZ60S7>9,S'G(O!Q(*;9"G.X&
MUN;-D#89=I^[TG];[@1K#Y1#-X[6QS]ASV  4PLMF-2C9_Z6@J<&701,VI(/
M86RA"@"YB#JZ</[LIA?<,[KB&(D(O0>E/H;+5=[Q,!]KK'3QTX<Y[?N= 8\*
M:6*5'WT&0XK4MJ)D/M'7 "^%>-4<X+V<X>HY)JX*</PO%,G@43(K$3@/O*$[
MO%&X *\8\H*.R6]Y*6<*D1D$UIHB&[,MW2EW$YA//9'1>NI$FPN???K"-&7I
MT"2L@&1K!E,GJF'SHP0\;M6?*.?CR?X]=YXNBY,W6"_<F#ZE3W3VADOI$C"5
M<[)#ZK4)5-HL1IV#\1GX.N9JW^,+834CKP0Z190R<*E/*G.;'ACN3K="XC3"
M&(J6P(Z0H/*\3=3NC'",+DV9SG_V2=ZY?[$5#N ?-K)TE5!B.L\VMV)9F]1X
MCVR7QDG<;LW-1C0.8ZE!3XXVQ+ D+<F+A:4#V8/+X(GD'+@,KIWP(TDO@L>L
M+\X,A>B7)D!DS\*VV'79:U#2 5KU]SX(B>/3/X@GJ!;45R@'M@1]V#Z'<Z&7
MXP;5&RTJ8>8R%/VJCN0=?]<P"0#^0A\^["C,> Y#+^<-2C] K46)L#0%B&;O
M 8LH(G'T-;!F]"![X0>)*LLAR\;U/8F"*I$+=L6"M<\UU<MH4W0=NB"\<!'W
M,M @.1)TNU]N=PX-LQOT)>=]L!9E 1EU6?-"OL9WC'F?J.\#[WX]W"]<4PP%
M I>/J=4#QO?9)U'4)K+).<(L!+=<G27D@G-M<4?2IIFW3ACO%8R$%KB7[BOH
M\1:I+N-G?K^)"5NMEJO;D.R<?3I@*<C:I'*F$.[2<+55.2&40:$&&FU+79VA
M6+F2!P/%+S(!_^>]()F<L4_0L20)@I>^Y[MXBYM6F08ZPLR-N7=\D@^BN P.
M90%["W>"/HR?B2^@Q'R3A$N 8$(6 7LO4H#/Z%ID\4?Y"&&U4IKN[U_ZAN_A
MGDGF9-NU0"L?GL2Q7PQ=RZHN+@@YV><T'DD4HZ'91Q(HI<3K WW11[T)DTV2
M+T'OB8>U71$G(J<,O >S!,%+-P)=O(5+[#3S\;+,P&RA-GK$R3"\Z%W?R5J3
M[$N@$%]!S_FS>+DDXO7:=4,2USM%G)%'I8"?'KP7+7)-U@[(YS1/(RE1=$$#
M$79(C=#RT:=KU>*(?A@O.P] @8>%;,>NF\XZ-3C^68Y1K/*$!8G*3F[_]D7O
MV@Z6%5(<'&TS.Y.YEG&U.B/9_R\M*"^CMI0UJ(%X(GWT%9,!=3B*W%:_22HW
M.BSA>^ 8&[0N=@E*S&P._0W1+7P91PUR]]K],AC!%S%"^!9JW;A0C3ZTK"M,
M-,C3@PBV=*Q-W I$K58:"HAEC^TVK+H4ZXL2>PMC 3/T8!3@C*1I("FY(TE?
M@O(E&7<91^&R\+3OW%7R\J?=DY!]Y,Z"TB6[$\ ,]VP?2R#3XL!V:49CZ4%^
MC#-9CG6&(M=F+& >')@"B"OHV.)OX,2]=EF0?I.K.$T$>SR)XL9PZ^S%=2$/
M\"6<,.H\4M]&F^,AE+PH&Z$A .S&QAU+3P.%!;'0F13J>%^2I]?*6[!4.;M5
M_L!*H(%X7M$['8X.F);"N (.#>*TD)J5!"&V>.@BX&6T>.AD,=B4%:,6#UF*
MIVB*ZOZ>T)#4D[V!5: ?'W:ZA?DNJ72$Z.<K>E"W02-?,S=;\5[, !-9OZ*7
MTT[\B6TE:$>,>QA8TH4./@,&@4U;OKB$>)&X^&:YGJ,IA0;F%V(C='@-]O*G
MHQ7R]NM\]=EQF/USO7FI-%2H"FG>DE7F%V#,%V*7<U6[=F+1+6"_7,DZ"%C>
MZ_WX48,&=K:[ M/A!O -\P\NDL 3-:,<ZO:*.4%D.=ZH@WG>%L.(UZ"5V'IY
M7'E)F"@A=H):=%REQK(/PC3;P2D*LY<]D&76ED, :%?_EQ'_D7)TP,1-B_&?
M+%D4,?[31<#+B/]TLACL36FH)UBV52(9W*+3UT UT5-<86^TN7A-;J+V<CV<
M3=%R95G0G:A>AJ"[N0D9Q!F\J],7RJPKN\4-7<;R,D3<RD.42(R,JN-([VSJ
M85J5;5'&<GPO3]HM?!WP>@?W3E/4WN<DBBI-6Y=O*:H7(NU.;H(F^0T.SXTP
M+:H?WPL1>S]?!US18(U[/M"N(,UF!+:!ZN5)N\G-R=RZ3IS@H^7;U@'%-*-K
M ^1Z9![R1.#RA<"21*4H7H1$Y<PS2)0#[$Y<UK):D;S%G5K'-,GTAP'[M<%)
MJ#9R)B(N5\G?AI0O:2<F0N]M]"/OQC7%UTU-*?<PTZ1]'.!N5E\C6LC[9;Q[
M2#DZX&R&>/<0=(K_B0#.D^.3M+B:KXRZ^>2W1>!5?U'ZRVS ;#V_^] "MYA@
M>L>Y=[Y:$? WDY&)G]E[R]BB'9"\7]7DT?5X2FHYC9&F8ZC8$ <GFX[)R0UC
M5 L(/OYTL.Y\+@:J/%[5X-50.A'7;'A7LMMEO2(=OUCV9;!BX3;CO:51IXI8
M9S7Z3YF5)@UUX5LOWCK4@Q_%4X>.[77HJ;>LC^*!3W!C]@QK/-F6/#C/)!(4
M@8NM"GW.8JOQ"6Y(GH[8BM#(99!UF"@*B142*5L_Q0[>&TBEG0W(_<X*^D6O
M'O[C,:DO\"07W3,:N3Z+DI!8.A 'DS.KDW(X\TWZEP-F7-'UAJ_U?915_"T?
M8X<&(D927"PO6#A.!?X02E!5!FK_51X;AH@%)87OV*D]LM(/7QTJ\H$/J0Y&
M3,68L%UZ,KEA,8GR_R:<J%/?B:+%,O3XXL-].O]71?*Z$#&C-9 BU^8D2J9?
M>2Y#H_GOR?Z8G)92F6>P:.UW';BXT18[&UZ+KV!9?^,'[BQZH<-IFITK"B &
MD_$I</ZH(,N"*N![B& ;I"YR])*-,MV90P*?5"3#@7WB6Y%H"SOA(C\(3S/0
MD[#G_#1CU10,$M$ /[+R:LQ9^_>W9<Y><5(SX_+W^J\K'"?/,0F\8]YXA>?.
MCFMGLEV'+-G]R67;#/,R7#L!_2,;'&(\KJL$A'O;$?.IEZE$X-V6""XFEE#'
M/QS-MMP7&)I,;?H@[$<']X%+],2'+_<!)P\Y8@"J@)5A:>!R!'TX&LU,7%%N
MZCP1&]-_73Y\VQ<XE]YGN[[6#+$<0#TT!YATXWXHQH\8KYT+@5QRO5"YPDL^
MPCER%20G-DN=K^:NEM_PLC!66U&/R@)+4H19Y-"-U') J.ZDF@''8WEC>U38
M;MF0CFI)[Y/MU@GW;'5/UP%=45>T@,L>0FFPON4'3#J4U_BBT81ER<'J0&28
MO=W)$5NND")2[.?V?K%6LH\4.3E/9T3,S L28GQ=R;^WM3$:X VW0PXGKZ=)
M0?U,X\UI$L5L2T);&T(9+;+/WR;%:BQ(E86 I\FH>R%[*TG3< +OPJ'A!\=/
MR#5QQ&F9MA0=, RN &UKI\@PF-ZX#VL_.@O6SHQN7,B#+UJ%5BGCZN869#Q\
MO%"6Z-YR'*<8.>D5O2@Y_<+,"$M<SV/FFZ5MH893^[&QFS^J=V(5*+I[N!NF
MSM59%1*V.Z>E5F+C*@D/Y$XZ.D\T]+*?$\ W=*/8KR#PM#SST5H8MP/3%&4I
MO>4KL6V6!U+1YMTI=7@7Q0-#&@;)^\9SJ);.(B64YKT7Y+#M/X!HH49UZ'1D
M7FO'H,'<F0;3ZM-6#KO+M%$$C<D5?1)IP@W EC:8(M)! ^&J8.WO+A6,R-$#
M/5G72L'ZV3G+\TJTHW\@X3:?7IP&H8WN3.0QMEXDTX)$^U947[3RVZ#T._T$
MH3H<G=M.^[>H1U:W_-.7'3G3Y_IPV*5"LN4"7U+,=NF1J,?8UD$@QX&1=MB[
MS<HFOH4ULS3JM:&USF%H[?GSC@31D*?&'&14#,)U?%N!XBY,QDGW*N-\[?M*
MIE0@^T\*LB_O*&->0^VY<6\EAZIS4Q?J ,*Z']6%:7A_@C'N&AVHL,.\"F*4
MMBMX27?T\MR$$\<7Q5<B+/@0.D'$^9"67YD^D!\AE\%9>]?O06>\7=H@V]\]
M.IBQ-Y.JN*L) !J<G>D&^^"$5!RJ18^:\R N$G5UE%$.1B-3MP> Z7.*'*S]
MK:&.%^,^HR:M\E;0X.,L+SII#P>X5_[QWO:'GQ]7)(H(J7:SL/;HV(,,^5ZB
M(,G*3;^'<W.\?M3Z'YANB3D%<>7P;.V -BS8#E)_W+673S-U@6H=/09TP!3C
M8C;,YUR(LD%@8@O9:GS9C<P\M"L';']CJ./%[0RL(N-*.KTZ/^>:1YSNG!-^
M^GFG;"L"P\,J@H_@%F(BSYKD4Z^S-ESO&/-$Y##OQV3KPFY(A.E%Y:@/Z42Y
M Q/S.V@Z=>Q(TF$2N*U#:B UV(?9, VJ''9#Y3)')_ FK5>.^<_\BW5QYS/>
MSZ(S4Q.<K?G1W<C,S\5K&K"06^\"I/T3404C]FPG)=&6-Y02&V?J2=Z0^(I%
M8F9$:A(,+T_G3AAP9A[ 6-HHK6A,C[ Z0%O;HAT/\F;H$UQY&W0P:YYUE6(,
M+LUJAYS $\<'7U[6'-/XX"C!7-1@VN^CK(5[0&\G%3RVMI(F<M267R:Z4.G0
MI,GHV5[&R%HL\H[L6"B6:)I%4(=CZY[5AL;T&*H#'"%RH8 1>PQ"CS K 0L5
M!L[SD+I/'B/R>\)!GC_E=9UF.E:#8VVX30L:X[U1 VAM1[3BP=X'/8*K3N%I
M9=8\M;_9S>-DG_ZT-]T',^X74VG(EG'!GI?5@0H[5*;7&Z:;:SASC>0QB*A3
MIM(<%$5 N!U,U>2ERA/ QK9&N_!]1):K\RBF6R<&GZM; XY:UJ*WS>IL01YQ
M=,%"0M=!/NZBFC^7)V/Z*3.[-]WP<D=C.N:P9P&X#3:(P.A$S;H<UP?HVCU:
ME7#.2?J*7,PE_><)2;K1[UJZAE$40)$4Y,L(A&*H,CW7E[]@'?3<;'FB<B=M
MU%$4]!Q[?5C1#36<<S(.BES,A?U7I*FPXK;,PKU=R]^*9D9N7CNK<@E^A^3P
M73OA1Q(+E;HG;A*F%796MF@'(LS'!CTQ=G$K%^3W8TZ#$Q7(_.MMJ9U?1H[^
ME5@9U QVG3I;<J']@&(_97TX%<0'UY>R%^]\=J8&+XM(",X8I]:&2W9EKHQV
M5IZR.C,+H8\ZK+,@4Z0A?J*^SRFLMP6J_[>5LU<?_PR,_ #FPDV"-O2Z+K<[
M;J_2D8/A&8UV+'+\Y4H<6VFKJ3*UUKQJ$Q+F=(,RXS'<4$;CRB2[<I=AF-%N
MES*H$-KP&)FFV&H5@?I>=P^ &0BFCP6%; #B43J2^=D1Y0!QJ6^,OG#Z8<S!
M'BIPHI#1X#"265>+=/C"'7'9.J#VW^C[\<WKH5Z!?X5\L8),HG9FN;IW_)Y=
M")!_T8IH/E?9+FX5DAP<93+<JA'AJQ:/#V=<ZWR6WK7R#G%6;BXJ&&=U8U5B
M82'EP6&I8369Y2JXY2X?9WD9N)Q@[D&+.[>=ZZH)!?/9WD;\+=)"<&)6AX9C
MMA]Z6M#,P WN9U4A0K0,K -I[[F*A:(\UMIC3R>J>;E7W5PKA(J5KR5,2$@V
MW(IPBY&1.L8+@C+:69W-ZLPLQ#XX2@11?6E7U'W8YG/P]O*MD"I2JA5+3_XP
M:SI HX^G'#F-Q4_P6>JMF.80T5#B6"',D>-.!6TWY%-I,2$+^(\N47VA']X;
M01?]O YE?>X6ZC \4PI<'T0JWT:T+HDN@_+?T,"E.]]>ASX0DEZ,WFA(H= E
MH'#:B.W/UDY _TCAI<,G!C3U+\.JE HMTE%N![J7JPL:.)R'CG_/?T-LSHF%
MH<FXXM+=$"_QR7(ER@FI1YUPOUQ=T2V-C_WK]\+'=(+],LS_0;0<#KA2;.CN
MC$1N2-,X@+5J32LT(COYH*I8B=38D>@\2TKOD^V6KY^MNH?&E\S*YU)GVIJ$
M]#XBJ\3WK^B*I'S1>7LT #J#*)D)JV;99;IWWOK@C3*OL>M'4WI@1I: PY6@
M]#*=,\A;!G<BOYH[7^L3)Z)1U_8!/!0A:,.]0"O.=0<6!W #'?-$ZFP1;62_
M#]AC1,*GK+W]+HG%FSGW!WSJV'2ZH*E#M?.*"@8N$;#R=0#]ZMTD_ ]N6!!6
MEBJ^SQ?E;@+Z>T+L6K5Q:,:,_IJIHBWA(17N'RWY>TZSX],_.%861<O@R!YM
MY], Z)2-D@F/P.KKC>5YZH3AGBM@JKO+U3()N5IN#P5HI34/D*\Q$N0[O[+$
MS;D(57<_:H1/5 L?JX1%?\[;D.R*7M6'.P?0\)O[9+?ST^O,>&-P)#BU'VE4
MV*0ZX%D=EKYQ5X%]I3$(6@\>[G!H'6U+\]#593K3^=':6JO*EBN(.=,@KV1G
M.<:TV?ZILZ-Q=EJG)%/OT \A]>3&F. SD!R4+61D-:HU-D.E,->.ND5\TBF%
M)F_(\&!=:]R3 [<U"UL%I6$&4BOLT:N7)W(!T9&O4OWR_"<DU&MOR]O(* 9#
M QJ3M'13 MK2)E)$.B!T68K$MN,:*_RM3 %FV$=/$5JBWNJ\QNETJK#8Q58T
M[<Z>O?/Z$;L!Q2&D((<+S'5FF  @H];C3<AEP?J!A-LSLF,1+8<-C$O:9S,A
M5+YVU5A U]<&G9V:H'0N^WT0L"?P]DXA[90%S!U^_.4K*%C[VBU<U,UBTU+R
MS"+0/:!0W'K%S5>--/?Q9*9^?-%[\M;9BP7QFS'_39@0+S_RAJ=\Y9#%RUP*
MVO%M9;1T8=(^*A09HWIV:($SN' HPM<Y8;1!XN;&*.B9V-%Z<H4XAT;GB(GJ
M:K#&3CQYX/6Z1OOB0'LI&V"D>[8!*4C.FJG1D-^Z340PTU/S4#5,AEZ?#I"L
MWZ&Z,!D',$HO\6R[8X%X@EBN#JAR/3HA 5G1SD05P/VG3PER=DNO!LCWFP''
ML3,YC\2?KU;$C0^%V)SR.R<FM?S <?3%@!3T]!A#E3'A.L95M$EY\6C)298E
M^HVD*GI4S%5+-'D-E1III"!9V=)R=4CA7/@^^^0$KCUM4$&)FSBK)W<E%D(.
M)!K-3;LCOI.7[.U/'%\L2:1+E <Q#4N:*R.HC'>RX\+UHM/VXTK>^S9UWL\2
M<L&UJ82IQ[KVQ/\TP&+N&55!5F.".CS#<KU*9CTA#PQ,L/W0<,-!9A)5X-$T
M_*&VY8WD""FBQVX?H:,$YCR&K0T9[73\X(0T2Y+/AHJ>!S'E"S7L'"&')C\(
MI::E!\#PTE0I FJO 8L.9JR-HB8U^?90X.=,PWMIKW/P<HKQBBB&Q_52#H@$
M8:OG21L6[&-#07CE+='*+%CU-Q BO[V3:@?_0U^3:R<6$\[VE@6L3P'F-4!;
M\ 8,GF72F+RK\= N4T>H"S'$8)WU['E@RT?1B%5,_A&AIWL2/E'76J<80R(
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M[<,=E0Z$3G!3-AAZ? &<RV?#3H@^1N$3/_7R*GSN'EYN=PX-Q6U/&#[PCA=
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MMKH<N X7W!A!3;AR0#\;Z>-'?K5 T92,\:A/OJKT(ND'=HVU\3XRT8E!A\N
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M?0W_LHG?Z!8-A5/?USH+D_4U%X#+Z8C>[Q[8PX:4  ?>@32.6&-M9G"Q[\[
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M,]NSS9J?[,O_,EZ)OPPQSGD'8!EUF M3)#E8!ZQ7_D_$).KK?9M@AP_06)"
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M$Y$SDOW_.W%J!<0[=T*1TA2=D15U::S@D^C#G,%N-V 47#&_46F?-&(J,4[
MNUL=[W0\M,[]K,%(N.IXHQ9W3A@+HO+AL8LX#NEC$@NW\X')<V. 96]"P4RT
MP(BY4%7K(R?V\>.$15$QFK:<T6=DB'*[6,"SE,G7BD;75Y(O7SEUK^-K38^]
M!JJAGNI47-4R]/"25?J4(;T7=PE@[&%W+^S)KE^WV]_JQLND>WVI>VW _=J
M>]:/I& O==.SCNWG,L140M/1.*]5O)KB[73W36MR#4*ZDD)%$PVH5IB+#J8I
MK=6+RJGC^WD9VR+P?G;"M!836!N&4((3Y--0C$%LALT"'.U"*!9*TZB'Z&XN
M;LY\0Y# I20:7NY5 KZH Z>1Z[,HL79GU,.MOS>OJ4^BF 4D+QI4N;HUO\'L
M"&,DG>S%O;%TJ%>O<97_GJP%_7=DQT*Q^(K&&QW5-8"6=+L5C>G;4=&Y+H,H
M#%V. OK\Z$"$VARI1VZ5Z>(=O(+;!N/N@^I$R&CX/J@!M+4/VM!H)^O(&: :
M&.S\'&JH;$N,$)J)U7@BWH[LT: TV:A3:F@UHNG8<]%,((SW#]P[C#C9PET\
MV9?_Q4+1KP9BI"%3"MNL;&IU. D@[J'"ME(!+$& '>C75_ VH0Y/>3U]]\OQ
MX58[Q;+K:TQ_Q(S#G;S &G-R=G]Q).I'YHO>.MIR4@ RSTVAPAVPJ*MV&7<Q
M8/?>)8$34@95GRV%BR5 U4.I@R,(U=0% >^#:$=<NJ+$ RN<:(>-6$/=I8O'
MFOA6I@R:LEV&?<%"XCI1#/8*U (8Q?O6YG2=&TBUT,?0?L](<+!'D38\6*,;
M-3WK#D;!5.\:A8M+M%CQI24(L-T&O2'V$@8-,FSE4# +4O GZH9-,QI?0S O
MSDL89&#KY$G=0T6VL"VRQ<Q%MAC@2@.([&7EF>GXR\U$LY&KBE\SS5Y[0JBS
M[[4G!![K[?:$F*!]['_F&;U&.$KS74I-L&^)6&6CD$@:H^OX&+O'>,]#6JJ#
M'4O'+.G-*I0N'!I^</R$'$O5@+V]=CPS$)X"LW!L>4F?LERRMM(\Z8[J^AHU
M6T)!))TK1XEH5](_-\SG)$29PJ1E_78&=7;BFM(#>^>^ZF$96#&LD8%\=DD4
M9?FZ*3U6FEBT84&_$>M8QS9.F5_-8,:N-0@K&0_;<BRCFK4P*SP#'*D\6A+:
M&7.3=/I&X)T'<=IT8\7";38N5?ORWP5-GHTF?WA6 :,?FO (/8 N093DFU4T
M/B+NG];LZ2W_/%-V_L-1QSN!&H2M6N UU!**T*MJ)>OHVU!'9<16[!9BR>%\
M?<_2EH7*!M%[SQHXZ^/U/6NF[UFOCR.:CR/CMDE\?8$<_@(Y[CU:F.;L?%QX
M'F=:1*+\AP?^5<_AU.\8](!&N3.KGD8JK(&I(]:66(F.WJ.H7TA-:!CQ*'5-
M+(0CX4+CO-%F;=$43E30<1>QUWKULU<.$=$5T^-R"T. SY>)[O_N&U,I5&:H
M;9DH[LB:BAM)$(N9&  &MP9P2FR6QD':60%;@Z<EFX?020/>^^TC\P<)I0H)
MYSZL*X[:ZE'<R3+-PCR!Q"A20%@'G(X$JBN';;6MSO_3)!0+NJ"1Z_B_$"<\
M#[PS[ND.DD4K4"PG7E<V[5S!Z25Z-*!YKPO=\+OJR=()?B[24^$43H?0U*WE
MR_#$4BY\9YC(JI#F<>[45@_6F--P-Q$Q']Z_##SR_!/90VR@&L1IA63[MDR=
M';EX_CIV'6*)I,P2'YH]B#!, A&T: $\CUW4S9M<:M\A;:H/S$\XV\+]!?4Y
M/ !9U2'.:E,UV)&+YWN\3952<LK]F34+(8Q>%=Z\W(0:+W+A_(#EW_U,?/^G
M@'T*[HD3L8!X:=['L A5-^1YB:N5/\4-%B.44"PCZTT(<8.20YR)W6MA1R&A
MP4$&4_$<KW,7_#<P*1%UF//P'UHY4LAHY/F.39HRW8&64QGJ+**F'4PI1 40
MBC ]K,ZW)%QSQ_-=R#[%&W[AWCD!A#\AASN'H%XG7PJ)#0\ZF(GK?L,/3S@I
M5<#-P^[)^%!(!68XB)98+MU5N$@\RO]U$<<DRG@V."[4 78F'D078PIY#0Y*
MF!Y0Q1N6(.F0%0)R2,DAS\5![^%/(;?A80ESWV(1!(GC9P$3$(E5 ,[*HZBR
MHA .2E#B\!(F.G&E<_H )=0 .K?MU.1*(2R ((6QK,IG**"T)&!G<F1U,:9X
MW!VU*+4:XLH:(0/%^G)@,Y%,DPF%/$:/1)SGI0HN"[EF'$_(4Y8$<;@_91Y$
M>E W_%F<4DJ,*L0($*S0-X1YOAR_DD<L"(@_.+5+"G 6PI*SHI .8GPB3WW,
M_Y^@_VN [26#.@LY=3"E$!9 /L1 89V*@N7P@7T:EO3<!G-.<0H)1PHY(00K
M*C3=,GXG]_]#=T!'EA3LK/P+.6,*>8T>K*AJ4'9J FZH'.#\S-Z!%85D(,(1
M^LZ#("@DSN#=4P$TAP!Y=>6%$(:''70E<,7$>\J&!1 WHP:PF5BN)A,*@0P.
M+>C*XYZX2<AUX^MO'A]H/+"PO@%L)O)H,J%(-QX]<E"0<O[L;D0;N,'7&RG
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ME!W!-\5DO]FCY>R>G!T/OQR*C\/C+R?B\^ 0X\@\T=7)OV/!>]K_YGJ9P+=
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MUK?PZ!?;W_LN:^X)6OSWSJGH?#CZX96IGC;JD,$QU1TT>I[YJO*H=JY]M/W
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M-66=:"Z,PN_Q7"P<*DS7N%:034RDM,-B(NS 0%NV_E=6;26"&>%+!-)GQ&H
M)I3,7"K-A&.ND>)[+<7[>0$T1R9RJT- K4W;$DO>F.5L:W ;M^XDC+];U(2Q
M-+F%N^1&+-0<R\,VP*KF30NA!N7A<%1<J3M)) E]JU2Q68<W#1);K>IA/.!N
M!]?(X2+E$1Z'!3.>!:ESFK3MHXFHZT"WZTV)/EWYP8AVGV>(>VTV"^V+P4FS
M%;ZG[8ZYZ>7[8_VO[].FX:J)/'(O,$R-)8!XCJ7*/**3E))++I6TJCI5/LWN
M>CLU@G6?!:LH_%&% ]S>A(L<*/LY.%%VM?82XIQM]8LX"?U&NAKI6D.@XUZ
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ME.(JJC-DXBVW:ZL]59NBJ :=H^YJA(C$ GZ2Y4I+*$+R4>PF?G% #88?4G-
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M%>!=Y4J007$,>H0.D)[1(P_WI-=F%W/Q+?M6RM63&B;P$POU,9^C:"=;=<=
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MMQ->S!(&@K!P18$$F[HX[^O.V548(:X(HVL<[G.[,&T3%+YPDKMH:\F"8*O
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M)\N*6 "5)DSR@*,&1/V #!.Q!P>4*82D^A)NP2E<E("J>VA"6DQ)I8O25 '
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M8\MCY*OY8G'+E9?8(1DP1!<_TN-/R8,2*ILEL\9/HHAXDL^S%@N00Z(6UJ
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MSP -U>O#2+EG8PE?-$&0(";G:@!;1(GTC=KP46(.OY)NXG'_, OIV*K2=\&
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MH+45!SOH^M'U_8L>0P,/;0-@4Y7'4"@C5][_QA_@J  EBG2$XNZGN RJU[3
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M%6YBV%YQ?0W/!6?$5YAIR=VE(Y>?>[4@?JQ)]W'&>([W>&8:2]\%RMMLHT&
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MV@]!!LM!E\AU2.I[_(HXD7=[A6?LR*_8;66WT!AOB#0WY,1"-=4?CXX</AY
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MZN-VI7NH%)4M2/FWO5DW?$ESQW3'0&H@W#V7F1]4_GMHV<;CNT\L_HR$M5D
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M,[9P7F@5]I#?Z5.[0C)OD!3D"=PCH(!&Y8 =J"*X+B16^GU\"ZP])8K\4>O
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ME%R=Q<#]+!I+5I3J.>'$O@#A36H9Y"PD 2^.]N226EQZ,!4<C(_$"X5'4NB
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MLML5IKW56<$X'C>R!Y//02N9^IEG]DO@EZ+[P(3D2D'7/=7;6^;(5[F9B15
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M-KV.Q@</UTCZ9-SD@8TF""!6U]VUVLM/=IPJ>U3$UYAS'RA7 Q4.A<[H]B1
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M>C)SDAO;!BGBS8=;Z4$RP!V6/^D 27L^'[/7U0TH/TN&'(3[C30_9E Q-+0
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MYDE**@17DAF5E(_!:1R@S"78PQ0H03='G[SFU3DIG6CJ3<SZJ'@-88#15G5
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M1O$=06 ^?_'\A<%<@GP#$=U9WU6>>+MRB:]]8N%F_>&U<&J,9XKJ02D8;PQ
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MU(E"^W/$%6GU,H8.7P-YQ-0]\ULHGB5U&\] D+%*Y92:87:]XZ&<Z9%DW$D
M6#@A00Y8CZF&H$.MCI-MA'V^Q,%GT&>NR0V:C#O@H97!E1S2;U4DD9B&&ZD
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M^RK1$?&&AR^&Q4*Y,&YG0W[MA@X";N@DF%[\^8%V&(X_[ODDT?V*?M0 OY;
M'37X;5F@"8<_V:*%TJ=IMJ-GSE7^UP3W 6RAD/CG71Q3B B??;JNXI:(2_><
M:8CA*:0JY-( !,/LL3-:TN15WV<D)DOGY/7K-VG!\$*1P8IG_)8$>Y^Q+,UR
M?LAD6]%E1(QB"9@  _ /7 )B.7P!/^1"Y[</A\9<7>YT+L_N$SWXCT]X@&;\
MD*/B&PYXN7N#J<,5LI"G809V+J/K09(=ZMR +)MZ'U%>I^#$#ZFB(3C<1^6%
M*+:C$\.W*&<;!9P]I)4', W(MQVMJS%P3KA'1IF_K?5QSIC!D<6(&ZZYW(GX
MT(4@L;L6:$J27P:GI:TAA><% &#C]UO41C;1S6G ^!U'^]_Q_\4PNJ@L6Z2\
M7O+-,S=9!1<14Z0%;MVCXA@@&B#2T+8I+#UMBTPGX#1E7((-;S3RP/M)^QZ/
M,L41$&3$HH6CSJD5^G<F].J .#OK._(7#.@8H$7 R&(P,Q[\-E)JA"P!76-U
MX/7-;K@%5)F!./SRX4XO/Z5;W:>N"T >Z'^8R%=:A\=*,4,:K5E$1:!].,%J
MC#L].B*0KY-V%78PE8C8QW[P#MG]0!)_>@1)?$*0Q,M'D,3O?3LINOK%\TQ.
M_B"Z^E9D]3B(^8;\Z=.98&,4N)P2 ( 5LD3Y$L5L^GG(P&NYNA_<=3Y#I4"6
M?'<^,E9)1LJ2$)NZ4KZ+9LL)->6OYPX["0.H[0(X20.Y7331 8B^H0IE2X%(
MZ\MXYIG?%K?_5O\R\.\K+=<!HTR)(0E1%C7Y/T:BP-QWR#/X+D@+HI;5ID*;
MY=8S4\XXZ%: M_Y]\Y.)SW#;;" F9M7+D/K\*:P98:29:^M_-<JQ0[HBS,$J
M?BL.#95.^/'H/U3DK=196N^MAPEGK?UU-R2MQS2,P?&>?+PTPM\SRE\VZZTZ
M$,QN09/,2V?4[-&2" P7>H!VM@A6X,YQ<=*!G.A'MGD5(TBM*5_VHP3!-WVU
MVHZCD/P7OC""KVM\@I8?. E;G3#EXA>$*8LGA_\RY/(M5RZSG+NRY>NUI7]+
MAC+U72$45BY'ZD @YX7_RVK $FT'[^\27\"LR^Q7$&]H)G+D_7@@?LGOCVW-
M3/GF:QOO&Z]%#N^<3&"\ XLE)!X9F4*M5S 4 00)1#R3WI&HR-T#L,ABWFMQ
M^//0UZN:Y>Q=2E1!3PRP@B&3CM4M-UN7M/I+=\F2 =RF2@D[QO\I6PI):Y:>
MJ'4*Z+F.BA/M+J=2JS28\]Z9#9 2E[-CX*4O'L!#*/9B'LZ<:()(($&_%^9A
MSQF]A[L+SX+'>Q%3R':&;IHR^[5C)]'$ON;H_O[Z6^O*LIS!5'K3#HW& MI,
M&7@25&IXI^2QX#P82W#M11+AIG@F:#!W T+<J%+3(0A"'V229I-?TJ[M-LQB
MW6CF)7]UJ",$5D>8>]!F&(>==WE24=Z6"BE9%:'_G,W)[^6!@W@!@@FA+4V:
MJ8)A.Q!"*H6PVK0C@@ZRX,ILXWTB7Z #ESV5Q!I O0EW& ,(=,4AO:IO@_:/
M&YTO*VF*F7V9E-\):"J'L5>\P^UJPH2%>.BA9)81RG+G7Y8AGO6?25[O-$[V
MV*U]W\\T@MJNCY/S1@]45UU_HX<IK3254(I+?@IM4.<@\'U2TAL04[K7L+N$
M?D>\POFN(5FA-G'GI11[<K!)KOZB^(R]Z\^F:KSC.QD -!6@L-&&NOZ0]3YC
MR?DBOM6G8K!VX;I_R'"VB5:*3:,)V<;="UQ$4B0W6EZ> 7E>[:%S%L",4?X.
MIM<-QBC*P:+.7.W)R2=$(XX/IFM4J -<V5D/:-!WQ02FZAED^"J'PF!RCL&H
M.>JMPR]-WY+!1XN:/>=]HAZ!/#)UM(NWK!__4^!*7-['"_!5@U9?D:F*D^V?
M:4J./&*:<MDN]4+,JM"4Q6T4EU<%&>N4$>/3<#!("CU&+F<CH$O#K/22+N?C
M*"T/0A1<0)<F5<CLPS57Y5/;W[X00N+#;Q1FWDB?7_916X\3P]X,O&27WYD!
M\KY]S>)'OAU.I>\8MYQQ-&BT'*850JYHG)+>9AR^MRD:K"!K)L'9,86+Q!AX
MH,18XC@8DM[X5?)A3ZUPS?6[#&O*$*L#5Z>#\L[V*Y4.!06@F=I3/P(S+X 1
M"#]W!!(B2X7-;1 X&M<!<H/3V+-:>V>(SN"ZON\H%C>-XD\\!(([!/)RZ2%;
M/EJ44T-(D:PM3#8@&)7&J7-/AREP)"WU7V#"'68 UNVJ3M2 *83L_!LFR3V,
MNS%E;@\_[/RLJ<L'=^]FS;7B2?448)3L!-M+#9C(L]"R('4!,S(YSZ'B\E"P
MU5=C"$;@V*%, KR:O2@X"N:*LVMY]L$M$,U;A<#H6[@#=)$6@/NKU@KE\H*2
MM"<S2)?HD=A9(/$K'RJ2-5/F4DZ&#+(%XX/I(6E_6F7%.4%&ZMF]:OIA&T9X
M7*Z"S%9 \J06-^G##J_KM!IPZ\5^?#REHG AA9&!-@:UM:\E,CE[^NFFO+CC
ME(?9*<]8 W[.G!<WSKD<FCKS83KS:/R(0>L'9- $F;RLMWTC@=9LZ1[H@2PW
MJ"N A-TP=*O=>L6]5O+ZR<,)5ECE^"[Q_]F=7-0E%<V[Q%460V:52\2V%.22
MM8@3)I##($=_:<WI.#$Z. ^-9Y&"MSDG\S B;CH083E"O:V#NP^^Z3[X%I;*
M;+#1U=Q%5R.'<6;>L"(-R$LW+*UST-6C#<G3RB%T$^IP3GAXG@M!MX^(>6><
M<(VZ1[JCHU'3O*F*B8J<!WG2#L-L;K0:F_*PBXU\8+UEUR\;'O"6$\<:<G^<
MV.M!4;A>H[%$KDFC;.WK(WHLHY0@<KY>EI_CF6 I2"(/V&?D?W@: HX>FKL9
M0JKP"Q-2C=2K. F7*5 W0[^[U&/>=SR%$4%IDKCF1#Z^'+?H;BMP1]]@>PL#
M !,ZWH<C5>C&Z-JW4FH]4F7=.2VRTHV=\]J<U6&TTU$^X.8**BL(B9$YO>+<
M#O=LD!%K7B"YJB$5]HV$N;=LYM+MYDR4V*7B<._6=3.;U+S*A_*JHD=8HS'O
MHCEKMKE70,]B3426%1 \R_"SLXMW/ 7EE<(]LXMF45,G0.; V4EXS^RB42T]
M]&UT/Z#*5X] E4\(5/GL$:CR>]].IPWS[=;@"NV8\@S:'&5P?4O.RF;=360!
M25R$'5EJ*"$@@7KAQ $;MX7XH";?""7;&49^L>%4.$8" LPB0;@FP'S'(@IT
MD'AU5&V"9E!DAOM;$D<%-?3E7OX@6?,,BVLGYB;>>"7TK:Y 488&1;*1IWK8
M*;W)'R4O_"?2HX8;O%$<+X=83>_CD6;,5+=XH^$7]T U1:?.YZ%S<>Q\!G4^
MB;Z+'=9>&=<?/5%/.'/0!PHS%=8;')U1N[BY67F[.,]L/5IA_0UMY,D#O"WL
M^C-WPM(26 L'0Z[V>NC) 44V:F>R2+.>&D/T"9TD'/&IR^A +?V&%_;.WIBA
M^A"5-K)IE%</>=BEC'Q.I6ND.: B!@?\5P*("#Q%@X..N^6FK?2E]J-04M\&
MRE,(Y%3=L_S6)<,QXA8F"['EZ:$JW7JGK43939DU/,T>0A!!2EBZ*\PH;G63
M1@M5'! 5'A;(FJR)T=US?H*I4L&<40NSS'P35K[2)N?G"8O8W68.DWH9YHX3
M@?IL\];?M%_.:LXGK?!5'%1)#<L%^&9C*U86>S2R_A'^1ALQCO$:&C5#<K,>
MW:I#;A53AJ( /7EE/)U1'RE0#OO57]>>>9P6P$,@LQU'XO@R#O=N4WS?=[M+
MZ[!<QE?:SSM HWW*O&HC YQF].Y);6?X%4P=]*IV%")3O%45!>^^B4VCFB'O
M7O2Y<,=>U??T(3_56;V])D#8J"<2C*I)+6MJL(-); R9P,8P@B,ZGHQ+Z>G,
M\(/KYD,->A_TV4/+$VA5U330"I$>>*MYO?.1],&M:@5N9@#I$'$">YJ?H;L9
MLISHR);: 7-.1:Y>J*"+H6+QZ5]8'"'<>DC<((YP5\\Z3^L^6%NOC$NOMXK\
M20S'-,6I+N3 .JH F>J*7.9GVNA1LQLF%BC3HJ;B))T; KAB8:F'R&ETFD:3
M.D":C3^4XLD91H/H!$W @S?+YL;]YW#/^GK$5$V@N)H%FC9$Y->+3>*SB\[I
M!2-5;%J(0R08AXC^68N5J.<YRRVD'58G[,C!6JQYXW%9FD'8"5+<UO52R(Z<
MRS!=/70 \#]#8JE1I1MYUF-5?@0.VO>@MMHN'U>W(\#PMW2\&\6F)CO9#)L,
M:*!&R$V0OPFPQIY(;R^SV9AT #L5.3.(Y_7@-(/'!0D8S3_<S",%[VWE[ZT+
MA/XI*\3Q ]:T.AHY2#!J9X,*LVUV@.(QO8JLC?E1&JS)EHZ_,F3 C6-2^HTG
MQ(LOO_34(0[CA#:O.%3NFUH*)-#_IG8<AHW"F5A,H)VO6=MP!'A>ZQ@_+I/T
MER.WS]89BR2)<4K]%+[CPC"B\<P1>I2]>ZNCXA\7!$])CF3F-$(_K!^7YEDR
MF+%E?K#@UNWKK333>-\2]XOK68Y/EGF[>23\ZX>?^?II+Z7^?Y:S2_8&\G/5
M@E$<5,"+O]/VJ[@P]B1?8SUA#^BH/=!82<[0;DGKR2E[Q'\'Q5A=5I= ].0R
MLEASKWE!4O%RFSK!X7Z[LWD17><]6<SQK!/_@#KX[(Q7L,KN- ^3A7+H,#^T
M,\K99_),I5+/38\)PY?=.!Q8H1X5K/8E27&H?#E#!><> 3!#',+>,$]L[LWV
MUK\MK?GK"G\Q7B=J\!RV3%:\;"[7'1V "SCD;;T>G?P'3B,[NN+LT".%@R?3
M[&,]^&UVKRIK?-C'*NNGJ[*^>JRR_GZVDP:(*AF_8.W::*]!M+<"+C$N.VF/
MC-X-7?$\G/?=M; U5>U>.7Z0EZ/,570;=LEY$"U<+R"K4>&_RG+])JS4/_SX
MGM5W']?.T<^EUJTQE3>7O:(7 76V.CZ0T?GW=3SMZZ7K!<[+NTQ$*13:0\AH
MKK_]_@1?F&=2Q'0SV!:Y^+%:-&4X*6S8M5OI>&J)OHOCI>3^+Q' T*.V7?N,
M;GD4V.56A.\!U*G2^E0MTIQK2><1F+P'T4\5?02T$TT^?5))IS5=6'655DU2
MN"*7(JQB&-LG&+12(CY-GA4(F0Y6[4"L/VA(P,)F*-AUV"'6@6[I-^K199AU
M&K>P:HAV2OQ!'37.^Z[D2B+5E^FNIH(/WQGL2WBW4W&Q7CU_18AY)5BK^K,J
M7O;9FX_K6C3UB##)%0>"MH9WLLLK8[OG-$'IGMNK1#F4L5@#$%9LQ>61.DZE
M+Y]!]Z6P%D<S+@W/NAYWYU+\(O"Q)IKY0XLNNHO_J%/K&+_#_!,AM]E4Z@7/
M]ANFMP\'-I=O4KGKJ*O#ZUS_:[<%["]"6H5-E^^ P&N<$BSSR__!^XQ&'Y82
MSXA\X]?"J-Z]!JO!%M(1#8\XTM.R]_I:5HEL4#((YQW-M]E4WO)WWW2B? <&
M-:OA)PL]%B)P!JLX8+"\T(43HV0F GY!?CDE[A867E*P&0T'9XY43GX4JDB>
M&?62*["<<15!$O(/:-G!MWK7#!\(%FVM&-);R,@U9KK'@)Y29Q-'P^^3%N/P
M+TR=_P:&[" [%><&V?5YA3,)H5,-_B'BZ2N.3:F&1O/MNL))( .<J0'PG^S[
MQO=Q)G P>#G<?KEGW,-_OWGS=ZZ^%G\1/>8?&+$0/R^^_OOK8&58/;:$;<8W
METIU>E5\35MEN"C^WM!X%*\'JG$.QD%"=].'XMS&^)'19[N+!VO#@CN" 8FC
M<;;7)T_I)GD!^\-95_5+/ CG5R"74%>4E:5/L@\XO2,/]C5]G"B,I2\JVHSU
M_JCXKTOTR;3#;K.QI"BR1FXU<\?ZYM+:P+8S;T=C>GW117_R67=-WIBG<#$B
M\UM'F?Y;1CH<&&FY\^GNS!8!_%GRQFO5$EURVRT-8<E_PW*(Y_Q5<Z4D1QO9
MR,.-SQ[TN9]HDHO&+AMC?J0T_:\QJ&V]R$L$_+4R=0';UE"P@.P/?OBJ.(V>
MS/;9F]4JC7/PNV+F\\0UE<_B["3._#Y[KV3>1OLM\'Z3QT[/']=]7UW6NVVS
M&'2WV<0=O_\AI]+^*S'UUBH @CUR(E1!C9.ND*^EWWHZ">&+UP? 2J#DWCG7
M;S ""EJ-?Z\E;B)2 DK72ZF(ND;)#UXX; 952][_D#\I7W[!S<POGC__-VE&
M9R3A;CLHY?8@T(L578/]"'U$M%X!2H&\IF!/.JV-NU_*#Z(+CQG3AZ 'XX^.
M[#MQW:*V$I3.?_0\VB.8/9?6=:CHR70UB0UJ?JB4QCZZ]!^YJ^;8'*+I6CH*
M9 ?3(C+@BIZ@<+KC[-"2IZ",%OW@%Z"=N?YT5:WFAW["OK>J;U6T.^09J-O*
MM:KV\&/Z WZ,'].Q!AC]$BPF=,[4\>K*HEZON^N'Y@Z*/.GLP(VZ:+D&$%?[
ML!*[2\@EV>-)(5-WGBNY\(\:WEW6%G=6#<T J"UWQ?VKD1F_@2DXK$!UT$D)
M!YP4,T SQFK<#IWPQWNSLAYPDWS,$6=.^EW@CFBUD ZN-S7RBI$:GP.B%,Y6
MO9GW*P[L:/C%\C0T(OG3*%72J+<[NL)GR*:93]Q:8W=2=K><4))\Y:AS>Z%9
MD+FQ#P>=#MD.JI^0]D(?W68T:'M*IH,OK1*![L$PK:.'"[,+8UD/BQA?)YCY
M( ,-^@<"$"A#?KHZJ>&N.R)SU+0O?@MQ5LK='67'/I9+UDT;K)N6*!FF\KR*
M:YT9$85LCE^6+C[S]?+PJ.$N@7[7+2BQ1K\Q?HEUM5<D^>15$'^0#0.9!D0!
M*7F;WH02G-!>.ZO;>M4DMJ^YYWA Q\J!Y):T>QU:ZEF.880JE8PZIH70.S)5
ME]6>$[2<A&0W;%6;= 3O8Z)GV6-_WWD/O$_7"RED'X<AD]WPMMICOSFC2OG8
MR>/=C76 ^=,D5QWRGB]_Q6E0*S=@3M0$R)4[.+HFQ(F<5$/V[ XV&\% 6Y]7
M'"EF#RN-*P=$:!_Z!K@?(N#%(R+@$R("/G]$!/Q^MI.&*=,3^G]VA#I2GU7B
MC1 G91U74C1]<C"[SLI9#X&YR:/'0@V'YGA2MJP?+IK+8AE/+F[QO:CW[#U0
MR;%OL&CF_=8P[\(]1CC202MS.87EA>AV"15*C9;P @#E^EPT!5+YUMPN3ZLO
M3L.-,^Z$>E!MUPLA%"5 *1V9Z[T^R;*T5@5V&)US.HHG0+Z=^&)X'=[]15(+
M(?4*+IK_G[UO;8X:R=+^KE^AZ&@V[ VY\!5#,],1;@,SS$##B^GIV$\;<I5L
M:U"5:B253<VO?\]S+GE1J0ST#C2-*V*W!]NZI#)/GCS7YYE+WO16Z<T^P8$+
MFKB\ $_"[D0OZV)6E(W?!P&Q@MA/91-$W$.D.$,[EZ9805Q<QMM,OUFPSF;5
M,K@6!EO@L:W<8T"[3&O:K5V(_C+P6\)G_[;E<*(UN,/OO)7S=KU)F:P+ [C2
M!VN1"LJR;O.IC!/%QP=1W!4'_'[X*A>D8^$<%U4U1[G&[/+/W^U^QS^#N--^
M_HW#O-5&>PS2NN[J!P[PT\G:-?8:%-2@\<(^C)ZRYCA._M1-["Y]FGSO_1^'
M_K)/?XJ?5!479.QLE=M_NM]-PGL&7U=>! 41M,(@'_0.B"J#>5.S)FK[L9YD
MW,L^&LWA&-D#J?**.1,C!V8(=8,$L=O1R,AC_@1:UZZA0YW7=2-N7ZFX?:2\
M^8JVVY6/.M#]L\>U0T=RY.53*\>& (?%D/%=P5[X! ]VP9C>^2ROEG0*/Z;?
M;J3OCR-]GR!^*_;,I"ZTX#"PCCW IYDLR:T""V3>?%Y.!%\XMJ)""^=\^0')
M&_T1Q.Z+^*)KK.O<ZIL3[T5""US72@VD7#_E+/,EZNCK'Y?@A872<% !4C<K
MH;I9?FD<LMFPX>L))/C/<DBA:(\O:%RFE&QW@SSXT!"URG35T-]XLQZ9=.VN
M2[2+FB/>FJBPF8^D)XB]LCC0LI <M2AC+Q3,=];EE\7:9!8SE_5\-N>I)4,+
M"!/=:X(U2:>HJ)_S'BT*5!3^=&VNCT$R^-\_K<20M7C)F631/%AGW=IDCNZM
M'KR""*G"N*@0S^L;\0LXE\-O&?)';AFJJT\)_,%HN"-0+[0<0&3RF&%G'/[,
M)5?K>1T1[_)D:)>SX6#$N^N6/;_HBN:6*6.Q^(B%OCN;.*Q[6)E.CDAI3VJ3
M0QT'!?56:02!H%W0P\KGFN+S3@@_!(^%U@Z\S((')/FH(.P0(,R$11-2RNVC
MCO7M=F:L13@FP^CWM]X5X<\T!@<$*0>()2CIL F$57.CYX/@QJ# G!=)V&K3
MEYOT8H$B3R!.\5:E#>EC2R"!F&E041.=@(@!156@5FM-?V*=176,<^!*R"JC
MH$851**.J3L...85 Y2)G['&@KAM _A2N^!3+/Q*1X7?*6I <M6^#_&&/0*#
M+[]!#6#9\0"8&Y;Q] 8>@%1J?ETW\C2T2XW2M[VX8-XE@R_AKVJ'/BO8UYI<
M\-O;R)IF_@#TFS7&!!W>N"N1B'#CZB][QEAWI1]G?(CH(UH9&8^#SY0Y5QPJ
MP)0=*&L5QT><?P+5REK-K^C@I'*:L)7B7HRGG%W7%1L;UP7=V"FFC%-.7"_A
ML\.)U+;8G\OH3GF>@!PRSE/N//!@$<_KIA'3E^,YBFGI'QGX[-HJ<^OL2)5H
M5!AD<.OV*.8>\L!2Z"WM,,("(<AY#BX6QA"8,+SBI  +,&C=NGK\3B3[71&"
MG_4XOX2=./D(^17]LG+H9+SW9P*@]<$#J'203+,")*Z0 N$*8LZ2]BI1DF5F
M^IU^< 9)<L=7L[JJ+WV+3O]HX?C_9<.(/CQJ@703F7<@1-C];K<G:W3''3)@
MUIY.ZW:08FIRNYX@,%D?WY +B00'9(RWTJJ2%)0X4=6"J20](6OEX,*5_B1R
MH*Q_DO(;J!-M8=Z@9"6JBNDA(?>VHV)0?5R,3C?%TJG=->=\D-]S&*-BWG-[
M'3,F-ILTT*<5N^QOBET^8['+@TVQRQ]G.YEO^F31>+IZC&>\O#4;D24KY3$#
MD$<LWM: %78(GELUH;:8!:6386]Q9$NMJ87.DI!;::6L<:5NP(:QB2>Z(9PZ
MRW?-'"?DKQ<3.=OLQ N<12<";(N_*Z2KJ[7VC* 1P+HWBO< Y.5EE2":(.I=
ME)/%F%L%)XO.T3_["MY$H3=Z\29OM>GXG5=!0M&(*#GI@WB7RCBOY&:WU5&#
MAL^* YR)O+Y[15)M4?35_&$]T#%:P)"0I.828/41<B:++#GQ/)$-R3X@2F?J
M2<]:OP$X2#+8'5"VGDLIDV"D;*TR!-$T[\)J3%J._ EHA0)1\K])%] LYI=J
MU/.>UI"]6]"$I*K)W;1W4<&0D0[GVB2:*;#N16H^C_,5!G6$86%^:&49-TPB
MTV4SL4+LWRY]XHP*0$I<OZ<0[D%$H-:5PCL'(V5?IXG&_\G3<O+G[_+_W=U]
M@%,R__&S'SC/.W)-#TF@?W[VZLW+D[?/7_V<TO^]_>O3]/35R]<G/__/MPN8
M^]V/)Z,TLN7XHDDQUE[='[B3&X5)W_WXU[(5;!?2L$] \5K/-1\7=H&'=M77
M)F&_0Y$G<W"3TI+NY[6M\:?YDE[N6N+!<4U:@3&FDKT#=)/O[88LK"X,=QL1
M'6-_"T AFO(E!V3^)UW^_=[N;K8K_S_:W=6(C3:I/\H>/<+_/[ KDG5HWV(V
MT6F#M@Q.FI/F\4#AW^/9N[M[HOLA/(?V2!=Y^X1')OU'!LKL3DN:H3(Q;BRB
M(1IAG%U:\-7WK#'Z:$_FKA1+PX6CL09!IL0#YENLC8%H(DY#C1]<TX]\%+E,
M>J%$R\G6/YX_;;<9]6D=D!C_GMY1%"DNSM)9/F5@AA?E>9-GZ<NREE>=C<MY
M66<Q@S7>S\@[?SDY>2UF"O_9 T>=G)TF#_=VA0%3^6-B&#,IJBNGD$@I+QD[
MO(N;6D>U,HS.X,<RZ=WVH1+VNW-I^BH#'+"0S8,W'>R(4?_)_+1/UR'"PRH(
MQ,$RAM0*H_05PVWI@VDX#5V]$'C:<V/*Y+R"Q-WC"+V!F]F:"</".J$(YF'"
M4]A[>^K>GD!I<K=CT:6+N;;*+A2JSWB]?5TDKVKQ?BYH7ROD1L;@P'C*.^<*
M@6AE #?<;&][!BCM9HNVB0"OK'D<6X"VQ8+"$&"Y]R\?T[HPJ<^D"&%T55Q%
MGJZ,?FDI"'(N,BZ@.LZ_:?0Y[O;;]W&F6&U+P\>2MV%5T*(J&2]>N!NAM=*E
MCD9'&CCQR%<>1>7K-"1_!^7[=@ ?)4M6=&RD6Y5FR>%P++,8)@:J1F*JN$K;
M&W-SK#QNSJF[YD2N<<Y7ZZ!5$G[C:SHOB_0-<Y,$D$F!:^ Z*F_JU0V;Q="7
MNPQRLW?G9>"UHM;8Z8.Y<VN2K*Q)-K0,41OVD##)PD^$0*C3QBN\@N^\++4L
MLF4<__=S.G1;C29PJ[:48PFW,%"E6!RV]K:M\ X*0PN'--&5=X,Y6M"W VOT
M<;JUOYTJ*Y1P?X+'#[ZGO\ME08*[#K83,>M$;?I"] @!2[!TA+*!?J;[#MW;
M7%,ON2E,Z.#Y[%=$-MUJ<3+9WV-^*^[GE9(C>=Y"0DD @U< 3/FKPU5:A>0R
ML-;Q D\,*I5Z ]FF3SB*IIN+MGBNDQ[ER]J',,M0SYH1DR(71H-6 QD,G&FI
M(5':35$5"/*$&@1%._5X$=$\)<-OCA[$O]90$GW7@VU$A0 [:]]5GU>.5>2W
M?5SB"L/_<Y^VYKVW?!J@+;:.HV73*V63</96=N7'?:-8;D(ZN)9L#8J6WS(3
M_A:8R?8M66+VU+IY6?=N253><EBP:2'T72+Q$1^;( <,+9#9H(%9*2G1>5"Z
M=]M[;V"!73"31XZ.1K&^TL/1X;'XBZ/#AZ9<R;B:TK&S\TQN2)B0K2FK=/\1
M'T?[G_Z9MWR#GK#Y6.N"3>DZB&WWU(1YP8:^M(T^E1D.(D9$I[9))<)^5119
MB&O1=AZP 4'&KF^_8Y">*4TN$7:^ NP_8^1LN6**)2:>@\5,K\D-F-IV 1K)
MMMIM%RQ=O3F"GT;]1"6D1%S8,>%T][1LJR*?N$N$64U\JT6#D#5+[G5=3JRB
M5IZQ@H7-&<R<E.\L1UPT@%G0![$[J62D1CMK#!W)K>MQ 4R3@%0CB,:*0\@
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MJ5(7#9*AT,E,X>V^QVGMO6.M.F$,!%>R$9!UK.$VD:V&Y"EM40>-D RN'"]
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MQN10998$U6Y:5\D(= C /<FQQNF+19G^LRZY;$)S'CRJ^V*2:\19LE8A24R
M33W3@'D[KP5?Q/7.."QI@XWCG(WA\+9:AA$>HJ4/5;OY5/+GR"<Y.)!<S/'^
M/6OHNVV*=6J3%3,HHHO?B+1O:X/V$*F6XG$1,@0&%M.IR!BMY_/7KS#]QP^R
MO</]]6;26P[E7&J3![KZK>&7?2-POC NN<"C,"+0TG<PG[G !-MY3]^+2H-9
M/RVUORMLR).!1S;^4_?@)_1B3V0?Y'39MV@!K1K[PM_O'3T,+6/Q,5BH+YNZ
MY7*H,4.56A^J$<NN^-%[^]GNP6YVN+^[$35)9NP_D.;)*#Z5]!+_&FQ(?;!!
MEVP._8#N@CPN&7$9"P-RW3MXF!T_.O@85XM<H6"U$Y*%[_<?CA[NQ\X1&@N1
M.6;JT;W=>X@83TLZ(U4&Z#TNJ^]%:2@2ODYKJ5;]^>3LR<G_2P0NM##)YS_2
MT-#59(T^B@M:*!V$=V)Z4@J1]L@3CEC,S:6,L[5]$?@X27B=SS]YK$\N%W#>
MCL34=:9H1$='HZ-]E^^6B]5+C2$YXIG:;)59^K=\)@D6UFWX;[1=6+DM)*]%
MCYCMD/V]@V(.G5?7 F>ML%V[%A!%H:%8O)"P7M*W?5R((OGE[/N]7AC!4HOK
MT%=Z 9HM7U%J<<G9Q <SHGLU-A_U]T%A)'MKAMN+>6"T_:B'RUKWOOQ#\9.5
M+Z>1)%_ZP].]-:/-D@]\>'142M'.:2@S+G3;^!R6\ @SU_E ^NJN;M0@%1KL
MU*0? 5H-2O+6%2BV_@52!1GY8-HI$W@!84U=NKZF+F&8#S6NW NTM;%=--="
MO^@P,_04BF+B*$'"OW6TO%\4F5N>HX=4.0LVR8HBL)1L[V/Y/,(93/)L\$8]
MD+V@XQ(. [FOV6H1FIM5>@X-KN$F1%P5=_>3UN*WK_&\>#0T&+H)YH;;+]AL
MNRN_5OW1>Z$OGUOKH/A)&0*<"G-M9J1$P$\P ("H[#HE71$V](2WJ7.>[141
M_4+;]JO8HB1(?UO0P2A;D]SAT-1,@@SHJFDIH [( 7U_X)9F,>-[N$E-XLXH
M'YBQ7-#EAP$Z3ZAC90P'Z<^XT'LC)RC6)'41_5D=DZ",RMX55%%',?6]'J[8
M[?:NB9(3X]_3X'J<?@5B@D$\GR5!:\20M'#OPRWRXL0E_SB!<?4(]%Y;?!.-
MQ)=AK2FX$Y0[\J(O418>J$)Q#X)G<J=,\&X#W%HO+-!J*$!(<F".X(N7J<)X
MY5RTNW^8DDY&^:MS)R)@/G3W@@WX\BI=S.E(80O3@,!\!OA*SR'6S0Q5#!8/
MSX!A[";\%=Q#?U. 7F)K#Q L,@#KZ49[.=NQN"^ &YTNNH6 QL,K69V<*\:C
M]X!MC>ZI!_=X@P!94+!U\V3L\H9!L&!_=!BXBH.3;P( 9 DMOV9J)DPK>".4
MBG0L$^U&0J^QFFVKG0"[R0V7\04@2"@@01+4JY5?Y@S8VFB(3JQ/+A0$<RXP
M$@.\#/^ [);5R:0HBQ12V[EQD*L'P@M>+I+4'7*):;2<AUUT"!RR?7N>5X9S
MT,63DZG)T GAH!!F<_"2JV@,?X!DCEYC\&-,@2/7MYN*/%%>OS'K! LVL2(3
M*+W# :470(A(AXA:@PIX')YR?0QD5U2EF"IBR/D2"T.L9ALWZ76.P,C]Z1_/
M(S1B";,UE_F,/:Q5.,"X)M5UEMMF,0(Z'PM< =F&;;R8T0NF]:*M FN=OJ$?
MRK$/B*L<>XA.6PS_N5K_*+M-!_83_NP[=:(@M6QG%X@-MFX/$)F6;3JOC,VS
M&_@Z[SBL=.OW[7(WR\DPZ.('9EK??+8X]Y5U#"F"WQO@O(H8IE [)(2]WKDE
M>)%X'0E7&-TR=N=8C^D2WW>Q(IWQ\CM9Y&.*?1F-X>EGOE2P[%*A 1JQV3TZ
M0/""%7(:<Z,_9@$S^7:>I/-B#*J=V[XWB791QP@N6L G<QCY1@S5I7^VB5IE
M,>6NKBB _6A7DBY[N_>R7D.+'LVAHH\=O)794'"D_BS0S*JPR/&![6?G7LYT
M8&*_8/#006ZEZ+2XH&'SKD6:R;B?; 4=3PQ.B#XV\]TU=#^M"N-H4X7Q&:LP
M'FVJ,+Z%+?46BC! _K.XF7).;-4-6[K,GT;F*],*!EQJ>MVV@29+OC4\P+7]
MU'P:Z7*EX_="P5')'+[)23$W4(2F/+W^XP>+5LP\AL-08$WJ(.OS3NUX#N&Q
M!21$B2MAMR$"$HVQT4=TTM:A))G>D%BU2[C@T+U))^8Y$V!49!'*T74RGU?6
M*D^#^3EO)_F_,E\'V#]?X='GC?O-R=L7N/AZ.YT45<D!?X>]5L_I@QE1$P[M
M&N-F7,.;KV),'_=;>I;QKX13(M^:D"5$+_^(=Z\@Y[JGAT_]P B]?4[O39V-
MM75=;B?A &#*R]O%OJW('VW0_]VA.EHYX+;<MVZ'=4-L!9I9:V,S@GGC_2'?
M;2N07 "DDUV=_HM\<@=[(%G^O*7E$PBZ[<#PD]:$B<)XB[LAJ40+7_2K/6]C
M=I8>0TVR]!BIHZ#]-JR.B[RDG2LM1P$!W1S5,_CHZY)TR5:$%RZXZAPC," ^
M Y9V^1B6$D:M3Q6BD);A^_VCW50[H %[4=^VUT9826P8H49U7$ Y;6RFDG%C
M#8#6+XQ.UFCSSB*T<GZ^.(,'&BCF=0&VI,0!%&S/7A+EHX+WH#K'P:ZSH2CY
M@=:Y[#UH79T?AB.]$/_^HJIO'+IMLBQR4-X K3X>8.H&*/J.H5@[S:#$0NQ;
M;]\P2P1W[<!RA<?F.@6N$"51_BR#VZU Z7G![6%=XN)=Y"/>-MFVS(;\R* $
MVM;!F&*6)/?:@GL. EH VI".MD X$&FZN>QJW#!E4I9 "LI8I2"&LE1@7J"F
MU>-W.XMY$*54A&',0?!;U>W3_)]UT\?%#O4.%W[U7Y?<\CI]<-SV5U_0WE>1
M=B*YYG@1M^BJ-M=(60DT^94>W;,0X*?X(IN(]_\A:/1\AE#H3%%J' B*N<KU
M+.W%E,*X0A_C _GDG5<7%T&4*4I.K_Y=O6J!!@H\Z,$(R,#]45# 6PC#P:JH
M)P@5%EI-$7KF280IN',[G+GK\W_[PK?YXWT?Z*_?<IDDOLS?.U<4=AP9K,7B
M^>9=0X<AB!ER!0II+]0.$^HOP9I5>$7%=L(WPCH9+WT #JH*)E0X6GG\F"T\
MI$CO)4$YP_"&I&?XM(%+BK-60H$J WFI"=L_OGLQJE[7=Z\>;\#KO[-['1Y*
M+[(5V,;3!=(-XS$05\OIHJ(U*R3ZZ3;WFK 8:H;1'L@9!$O]M)IT0?14P/MU
M,[X61X=YOP=W/G8PAX "WV6."K>)YM=ZPS /"QY,T=4:1-1 58I?K*L=<(VY
M'%@4O\+X,AU5WP]?J>AT/%2T#L]1)3&[_/-WN]_QSR3P8_OY-P[TUM#*8YKA
M27?U V]U.D*ZQE[#Z<5Q7MFGT5/65 4D?^HF=I<^37(I]W\<^LL^3T;XI*JX
MZ+[[D1S5/]WO)N$]ZYCNWEA1HMFDOS()>F<00:\%Q!]9JA$X[S@OW\0WL2U\
MX^]CM&^5:Q-#K7D9DFS>8A[A/,=FX\H-5LF+[HH,J<P4V#FG_UC$RX;AMJIB
M<EED3)J=""TD=A>/@;D<\'0)G_[61ZNO A1<IV9ELTG@UKZ1P8\DUB&A< W#
M<GX10'UE9P#/ ?.'<3+IGJ:#H6)[[)89&XQS7/3F^YH!(Y3E!6<<.Y5T-]D!
M5WE;<EEM/KE2; =Y9AOS-$C<C'.C7?3=+%ZTY[J&SA#><QME\-4J@X_7!AXF
M(7UB[!*R[<V.$#=0W1P(!G,A)Q(\T%]S0@8L ?YIGG<C=T2S9"63Z0031CS4
M%:OY4_-ZR;K]8M[9W"LSO]%#><=FX%#<1L#_4 +^*>>=<##0\?338LE5+)-
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M%[T"$-\(:V_N5[Q=EM?%S&)Q9&YW> /3"3D!BK2D;6_S;?PD.&T0:OB:0<U
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M]]ADZ&C)"^7A[F=K98CX@":<D]OROJ/A@@TERS64@ #O7"]WV=";JYI.S!V
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M,^!INM^0<8>+K[<9-QW .OBM4'.A#YRGBJLYURA@P#BWBHK@:P/MM_0L_OP
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ML)H7K;+(3HH.A>CGM* W=]ZQ$())U@SS@LNJLEX*,@EEWSC6I;*GB"M-[ ?
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ME[05C!&8^?D<6H8KMZ+A.@07;0UJD(($\3ZPM]NFJ.[O[^X>WV]VC_=V]QY
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MT2%LA?M97KP71@7]R1*!Q&Y^>GRD]V[".NKU7!,@X +Q)6B$8@CF;OYJU>J
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MY4Q$TJT<HSI@&#79MA3)'Q[)^@:YO&28>%THPY 0]\'A[L$W!BT1:(R\G&Y
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MP9XHQO?)[0-$4<L>^=,(4'*R+'?=I!)R"/,E?<_5W"UA2F_Y\B;F?5P*MCJ
MP+WP7.GV3R#.QV6S7Y:J%+.^HHO6"] #IU\X-[_T SYRMG>L,/%QA;N.PL6O
M34"/DAWY%KYUL/?=T?\^?7/TFO_8_PY\?]C].QH^91MV.Z*/07A._J_#<W9S
M%^"O%E/J>DQ+$!!D;7/M7,5K.0-@5,",5($(\9JUG:!T8.)"?K91$#*(QY4
M,F+B.W<%]RRS:K*S+$N1SN$_KC#NDBT\< 81K#?3K..QQ1NTB 979=[K4_$5
MCCQ\EAP)$&2[[C''796&N->1J+,@WT/D>'X.A.TR46W,9B"&6C9SH0B0YO)?
M3__]X &YZ7?SWRY8.R_'F/A$[]%_$Y/70N<=:U>GA20:\=QT[J5U+L0S_81)
MY?87UW+C'NV\4'A# .*Z.6A7E4?L=LMB.AT%!D#[O33!N.]>5 O9#,&]&J\
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M_1'WXZX1H0_- WZHV$*I241, N6<:F&VWJ]UJ%:*BLPOD0H>%GYIC7,&&:K
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M)M*MDTQW=X&\=\RFP@X_D*Q4U'<01('P4RAJRZU\7C>&#<L!CI=[WC972SK
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MY4J7I0>@1) HH-$KLF?,F@G0<$ W-%?EIG%URL=PZROQLA4";)6%NT#)D47
M*L8=*O+<!65E3BYRDB1"BMD>-Q6I-;>*+FTW-+?+="DT@Q L()'0>YAV]AIB
M31*!+F8X,GM_55KSMSN")D8V"86<Z,9Q$<XK]5A%O["TG<=[& 0'L!/-N[)
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MT])[WBKOV@<GBX1S$06HY!-5(SCFAX@%_)0Q'KJ;<>]B?@H?2C^8%6VLRCA
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M0Q\%.<+(M1QHW5 L)YY=)S&<PD>^<AN:<D?=2F_D)@N2A927]KFM[>QNL/^
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MD$,>8"..F7"4=.=&V";FZ.O<&W_3\K4=V*^]B),A0? 6CP*V5Z+?KW$J-M+
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M^T>9ZF$7<\_%+T29(NOC_(N=63-O%HT[GE0UO.?:=V7\6OJT7_;R6G9 6UY
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MEWZ28K@^7W]6ULW5G7MZJ[8HVY$T>5F(3+"[G#/AB^[NO+]E:R$RP(QY[Q;
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M@_>O<'AA>.6?XHUD=<Z2QAC_\E2\J(>H\<,4PQ\,\<D,F:FNDYC@/Q7:J?*
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M2: 2AXDK]7VH=GJC,:-Z"W!B<76XIS/2F JM8LIVV5*[C,\MV&GY\D7:TT1
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MFKQ!4WA,MQ$=3!P2WA_F4Y%;7OOV2O\NB8U"A>(?+= K4F6]Q10_8]4;?ZV
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M 'ZLU61^QK:<G_.7N[?W.M-15^XQN'YY@ >=AM.<AOM^$5Z[AK,/LR^)]Z[
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M4K&ZB5*J\,3QW_TD23$.JWY'-0@]=O2IK+%=,H$?1/$R^1*^-(9S_^&/X.]
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MNM+>G;U+EI^421;SQM&R4!S=6IJ2)TD<OIC_X]\PX$$43X91X$<@+X-^RG%
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M>+-6ETQOCERHYVJ=5YI.-+,-&E7E)'#O@D* 1S%B+A0H)@Q[74S<,/#N[(_
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M2;V6PQ-I1GW)*_91*DU(I0%BN60-W#3L$WN%L(%%(D6"Z<<IMPYW\NQH4J4
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M*'GM!!H<_UU?#QM/<?>,F=:V,=-5QDQ;VYCI2V>H$A&.5J"^8"T#_5#N6-2
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M\&#'_O(>/KLP")3N+\-)AM#Q^-,SA#:"]5R!@4IM&#(5AP)%B5BH-I$GJ&%
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M'U8[BS7H",-Y%L7<<PTNF#9YZA;.!?L_5K.G3K%7##4$:])/SD!O#N?4@-@
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MMC?8:1@ (7VW>02O/@+^MB4,8MVO5A_4Z?YVN[+!=^M%8&)<]WVU^EO,F7_
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M$^<;D'T):0@18=T3#C4-TVD$?M13/4;G.;;#'LJP7COQ ^T-YUD44P.?)>+
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M2L"3JG0X\A$;,)8^AQ'50-#J]*JF:1RG5\9W9$;R8-;FU8@@KN)(8??8L+A
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M/J3)\Q]%>.U^@_#J"/Q^"/Q]E'U._=,QAFYN139?NV$=:3\T:7_%+OSX=&U
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M34PHT)OIS\!(-] LO Z< \'VN2V-QNR'[S*=+50H.?M70'%X:O(Y=)9H]C)
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M(7]*ID/*B"/))Y);N*A$NDS:'G-F$P_B&Y->);DQT@XPZ;? ! ZK#?PY%YE
MS[L,>Y[F5-2M$]="'X-=#OJ)'2Y8(CO/G$3 1_'O$N=;F]W<'A'\+WF>*4R,
MHJ;;#0'?ID,+=**E2"^4!T:I9@4/X6!FX6>Y7.8<*T)O[9POVFUQZ)ZS$Q1\
M<&_S8_2BD+=4YX0U%CCH2&[@0!U(,8-?*V;@M&H9HY+V96L<0JE.(G^VS;8F
M[1OIFI-%R<PPB4ZG[S^=O;7S0->MNHRX_G*%F31EN 6MF9!R>W62#^M^/_?7
M[>(<P/K+F/S10X05X8JS)QR>^C9?;15DP"""=E$9G,)?JJYLCPUU>34=NWDC
MK7S__6^;B6K*2=R\FDUB9IMUMP6R+>NCP*^P"2I909[6,61F((TQ%61R&6'Q
M%=N],UMXF:OL,L*J'M&*11-);)*)J JZT DUR-S%Z+A0J-Z"@,XH#__DO\+9
M_.6A-X<',)7N9=M&5#(U79@HB=/X;__ 8-,V*__A'+[])9JQ*?IS?RO8VMKB
M8I$Q,&#,GF?=UY_')<XOFHU@VVB1+SU2#.EG>%F6[$\5:7/A!(^</_WVCY_[
M>_U@L/S%/T]_!KFRO[TOQ6=2QD :_WM*R&/#;( %,KH(A0VUZOH]D\@:YEKM
M1)E1YG-.)\*$G]I4<YHK?4N7M[ 52!\S*=%-GZOD$MD#SC"$IR9>J"V!T!5@
M:"V@LX TO2AC@)-P7' :54P\@^IQUYT?X%ZWH.%XWXR&4P?#$:P;BWH3Z"(3
MPL=ISK2E<L*&!%9137YGF,Q[A\_Q[AX^YRW.)Z"]E^]97ERYX[JH;8($/L%Z
M%]D_8T!5("_6G:9OF0LWZ'+A[C,7;K?+A?OA+]2*FO?PX,#4P'1J]]>JW0V[
M:!,?#@Z:=6Z3@M%?1>?&3U1T;K<,YUMT[C$00C2V^?CL?-8EDQ+)TRHX)733
M"P8459?=>A-;&/*R<4=65+[[P<[VH$GYWNR_N!?E>WNK1?GNOPBV=O;IDS24
M>X!-2OBA+<NTJ?K>4JH^JV*4=-.T353_:?+&?AZ\"';[._3.SZ!J#_9V")T:
MRT!=%:("S< ^9(=(T=^J]6LNI,!(V=:FUNAQ'K S%7<0:$%+%5"H(>(.XA1)
M:\(H\<31[V"@H,%;[.J+GEZP:(M^L[:X=L[6X03.A^#3:!\<H*)3?7<[_U&S
M%*M6SW2"K+40[*9D/P1\J%!ADP2I";_FS6\H.ZYEN?PN .6.&VF2CDM\(#0V
M7FTZ>@ZZR8(BHPYM5JQ<CX6#HH.HA)DC3TS+;"P!U7FX ),OKHR)@6==LYPK
M3$$(P2R.O:9OEW,NYJ+?8'%2RD05MESE9BJ^''-0 GJ\6JQ4:Q!\&-'[@JS?
M!!_URQ[(++)MW_YQ".9[HU\*Q==.HV2D\Z$BZ"_S*-/9+<ER]9@[1P9):CI3
MC_TVB$IA?$@5M\W-U.,0CP;EH.6Q)#7369\[2ZR?4>AH5RR&P[HQ^[K"/83K
M!O_"_DO%$/WL!D6 '<%$66[XRZ2,9&E\0LY(OAYIJGL_M ZDLSC(#23,SN-7
M4#D.,/U?S0O=8N$<H51,DM@$6\^4'$=?<O<$)K="V8/':S<I*8,&_Q75.?SV
M"(MQ">>,\V-P]IY!3A^GF+> >,[FJAM8EVF9,+*,> /PVN9Y.HY(!S3/G\.:
MT?/.CC5R[KJ@/YC5)]6[\H)=G%=10"D! =1NGFGH['DL>XY.-XUI8A.[D(TA
MS^4S^\?Z7/W6:X"H#Y:O6AKQR/P*R9GI0#U9B"6!2T-A2 DQ!'I3)DI+.GI?
M0C7AV#I-EX@_D&0][J$5,0@#O#R/58C4=UY&,4(TH%D\!:L/$7,8.&><(?A4
ME%RF\26=;HJBM2BS>52 O [\1)W#+A#L4X8NW0NP9O*"IR/HZQ-5X"BH*&!.
M490CTD0Y+CC)9!I&<9DI3/\"D8>6A19'?'T(90*WD*T4LX^@#RRMT^;$VXNH
M-Y,VFK.G"++L.<M4O<<"8N7Q7M.]8<^R+MJ1#^/.@2E5,DB6J^[ W<(::AQ,
MDDZ,=;XT43P*$.+8-R%>4+9,I+.!#(Z21V!#?*+_ E,TG\C!71%00O.XH)%0
M:QIFF\N_XT8B*L5Y4D$7$_9QX[:L^VT^0GFQO*N8 &5U*$QT##@)3)"=2,4T
MK:]<4D*QA<J<R:J](+ $']TURW*.LI\X9QIO\A3!1<:,EH4*<Y%ZQ$Q$DH6Y
MI2QATW+#='J5\S&151ST3910FE$X[7U"MN$XMBR](CA6(-!E'MY[/4,=_L$/
MZT6#2DDW!E7TG-]:^7$MX\>8*,<87W %M;M$_QF9C2<A'3LN/SO/(K0,%M7/
M3/D^(&#C<TYV-VX;NO%L&B!,'0EKN/Z4WU@=WR1OKY/#HWD*CNHA#=S,S?&<
MF^-8'R,P +&G+>YWDB;/,5@SCAS[$?](6DJA3/4 Z40-$&H.<=?TLF(Q1X]5
MO" )C+"TY-^K)J=3C:FN'[ #]/Q3(+1HR@/4U^4WK(MO)L$>RGKHUB<DT\.K
M$&:ARS%,4C02(O?^"C [=!:8)C\XX>P\3*+_2*&59!"GF5M&0-@;=08/=]O6
M05@\2<N-/+-2A4;L& XWG2'7X2L%W(?('+&?JC=.'O13?2EK6=Z2=8E_N0A'
M4<'@A$!#L->&Q\BS+SW&>*1Y!"U;YM>WS-DQ[=5LV!$=>993)<3)EGWQ*ERZ
MIMK;7:JN4\ <<?Z@FY<S55=$A/^(NF!<^$$5?5(EYQCS(G0L.'?EL4N#W1.X
MY9R9SS#!#!7)_!8O1L2%9K1?. QZ>16Y_PG+4!*CJ1R[2"P )M&5G4/0-K"G
M]2FVLDB%,3G@Z\[Q;AGWWNKBWO<9]][KXMX_^H4Z36<&,[[![<, Q9JA:@3+
M96F,MB668R#KX[(A''"&GA5@:@9$%@9&5'(GN3N/@++#C"WC.=<'TC-KS^J.
MW-BW31_<TZ5E5ZB@/1>W$>@+I@4A2*%:GIEW?>20[5W4IS"MC2293GEWQ2N[
M"'$(!\B2"TS\,F%DCXD+C6T&<7Q;7BQVUI64^]AIUZ+)A[!4[$AIHLD2I%WR
MD^GVQ*!A@FJ4^4[@%K1<%?&"R-Q@5>@J91M<A^0]C:_=V>"5XFX)=P\8K5P3
MFH<G=AJ5%(AP0"_?4$@'C>-*HG0)A]DW<;2*89OX'VT2A8G94FHR0E0!D54]
M_'#(Q15JF<-Y4>:>$_!U\V??_^X?V R/I?22][_;]@JZR0!S([TNX54YYS2:
MH!2,"S2.Y99<<$>)&3IE L-.9-_6B7@OV-W<U/Q.T&E!0\3KQA;9TAO]0;"W
MN=D&66W"0?64!;*'//8PD;&%;^D/DQ<M+$%RA@7;57!Q$Z";&OHC)DJ8EX&0
MI 1OU9N%K].&=#>J)F65<CLM^95.2]X-G99\:;7D'_3\URE&*CYAGC=?%OFI
M,2 FA-[S'\$./'",\&#U)DW'!E8W19$)'*F0%MXIPBW$:]@D[$-:.&['[X\"
M3/^P#??Z#]EP[T7/?W/\8?CAX'CXSC_^\.;CR?LA=M5[NM'F6S75.S!-04 H
MG"*JN?3.@ OTD>3#&YWJX1U;7_ :7JJ_Q)L-%XMKB,;.UGDV(2:WFSB-,.\%
MO4I4C]T$E?S]+^<]MHU3Y[#.3XRI \K0VF5XO"$?+'J7T8W,D6O%+0(8)0)C
MNC'MTMSN4B#%@#I,PB9;'$8SC#Z-R0S'$'.JZW$X5#RM- 6BH+#.$QN7B+Y?
M8$*$[C7 +73JW_;(#>U\G/7/P* NS4%O9G>O^ =$XT&42S^./J,.C $^ ^7!
MF0[A!)$KE$Z!2I/*7 ,GG<R8IAX%\]$,X'"6L32>\HTYC,C+ AHB.O47ZW9?
M-(M-,$] =TBB;D/H:O (GF(B6V22)QSH'(&/@SLVX:Y<:/ F$_9N+?S:^R8Q
M![%4%05HIR4B[]/=L:]FBJ\$W1@PI1".(\=.2E( H./7ZLM<\#FJ%W$(K_'
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M$Z:]MZX^)7X\K5 ]<R8Q4V%B8,C8DMY@!!X'59;KLG6EM)BV1*#E".L5L!;
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MZ13N(/W& %J$$T&9I]24-8R]2B?-QO54. W5Y#[/KZAPD=)7*=?S$@%VR55
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M>'$C+B#;N2"'P.AB QB"4<<+W31:WCV2]A_#6J1@5U[8%NW3I3./D.UTIF=
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M.*B?1YN%-O) :PE?VYRT.6ESTN:DS4ES.FFQS1A; JY!*8;4^66GX;&BZ_9
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MTRX4&ZSW$E#+>=EP<#HRB=X4]K?14@H_2UME1X0UVRJG\94-_91IWNR%Z'9
M0@2-AZ$V531Q2I1.>1"EW+I0B;DH\74>/7JS&)PUP70(P^D(GBMV(8KJ3 B&
MBAZ=$RK<BU&>S#D8F."AZIR4*?A8"C#;IV1>7(7MP2/7^8[=NC$URV^NTF#0
M#OR972@E]1'/7GUCTT%RA1\==,!UJLN]!:78<P0A\; UB=-++ 0N9#<"#<$N
MI@]$9P^<4B EP'1D]$!J/U:#YFB)XP].N9Z$S[(7H-OA*+0N9)63Y"Q-YB?D
MLN1!DE#@(XB<>G )1;6MGZB8HGN%RA12A4T$CB6)!^<@@I @8*F(58P&E"R=
M#@0D! ,RQJ=.*7-T."#!Z59E3L\T$KX"38N+-/7,>*5+%<)RZ#F10$&)].G8
M22P>$%SYCMTXJ$0E][U9%H(D4_70$*1K.>BG^KAJI<&6[CG1!8WK9)IF7@'H
MYA\!S@^ZQ$'6%(43.^4-?RS?LMJZ<'F]_3.F FS]! E6-@>?V+=_.4X*QU-<
MNB>5;\^M-@6&-)ART(:F$R&JZ9RD[A>B6[9/[[!13A2-.4ON//"H\P2/JLXI
M"8S*!H_%Z(A<\ CQ"X4GSL'^R%]:/%:J,'BK=KA-L\'W1 GS /E"P =%_W>N
M\\.<X,GGUV\$C!'B["Y@F)(PQ=9%A^N(,E$5^YVM1L3DH"H*0R74=8B<1*Q[
MO5'[Y:B+PG ITU),51&('[R_DK XE5&\?Y&LVP0TQ]1R7CR6<F+KGIKU[[4]
MS#&C<W=S=_Q$;#F/39D-EP!4;(.14M\1F4KE1F06IP'N@E+=!Z<[_O?<=/'Z
M5HE$H2-=@=0!+Y[L@) 5GINY8/S[KS0LC@G49@#"NJ;D-BC@+KC>G670L>J]
M\(;)2 'BWQPOU#"+5"$@0J!;4SD]4R]+?9-Q>8,1FKDD@>MDJE^I0"*.7'^,
M\22P&J-3L8\B@PH30<$UH3:$#6H^$._0":9PDE;=%%Q26T2M[XQC]317&EUM
MF4W/(1O3(;\T3,AX%4\J@XSZ3O%5*S?%MYA9V<O]?<,(6=UB?S"%^,%50%%)
M)&"'YZ%*3N(TZ20T'X%*Z.Z&>[(1(9FY6T;DI"RM1]3<5\.'.[T.IE\-]SOV
M(:$_7-PS&>:)U-4E3LQD@%>,\>6J,7YQAF\QM  ]ISPG""K7R52+5A^M?.,8
M-M3)EKM*L 2G_)J $1H<H;\1+NGMJDW<3@E$A^HB)RM5+$ OPRW/"8Q$(DDP
M75(^8#Q(C<R2PN"H!/,1.#[3JN:C&RA;ZP3N%]L6Z99S(I3 03?#^<*[UIW6
M-C]9S,C  (ZPS=JPU[I&TI6O='BU=:$*,#IP/]LFSD7& _"TD)>U;S-?['6(
M%</IJL@)":;2O#G\);:FMX_IS02S*MF#N51VS8(J"-C,M"M!7U]2*;>XJQ_"
M,+Z*9#N_:["15^8Z:H[%AJ?"[257=67&H0XR6Y9E3M/WI[ :+!9;SY45BP(?
M#$/L<+RTWTXO6(T<I5*+#=]O*K5J>Y@JF2E;PE8G-(4B&L>,6ORPP".9R!%
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M5!-63=17&:PPF$[6.27!L/4JZ_VLLQ..Z=<,L>^S !L=W(/='^:82 >,H8_
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MG!.%L'%P/#9T&)AMBX/"HQ[P(S'6=]P/4"1>!*@'5R+@>2UZ7I6QH!^:G*Q
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M]7Y:D6J2.J,T@=%KQ^I>L6[T9[C<L!(WLP7#N1.9,W[$^R?GS<6#QFM\<SI
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MJJL6M<O#TG(!S9;LX8[:0TD%]JSDNMNB([X/&+N?L8?(\[IA_'?M0+&CW*H
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M=TJG$2_Z2B";[I;9).+IKED\9U0H.^%C0:*5P:1L4:$D#5Z,WVC_M!2<>4Y
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MV4!.)99\IETX\W#1L"<+Q$12A7%OW)8P]FTYL%],_R!CX!\I"(Y#+'6#CWK
MXVR5WM(8 <1=]]@8QL#H(Z84_& A:M!2%:SH;V'6#:;NWSE1%D.^D#/JOOE'
MC<>.6XGU>/YL,L'<5]A*TP%):NNSZ9OIP1GRM*'[YN"_?7&^Q-&';588>3F/
M(IF7>)X#_,V>44%??% X0T'BX8^?A)C,X<E)R(6<"5*ZR^,_ZI%PP$\ITH#+
M"I@_6 BD6L*I4BV?D<BFH>,?"0A-"(AY@G@H+8*=Y1@D78Q;\^6!50\F&9Q+
MU#J4RL)_16E<Y.T*TR_X1(#?^:^3JE_>+X!U#JK\0#CF.:A2$)S]3JI4.ZV?
M5HB^;_R^4FZ3E=6/U< OW0!C ^]_OLZ+:)G9\B#;)^<=HP7;7NOUW@D*;CK4
MS$ZIVT'JUFL]H]=]+UC.65.OZPO=4W;YWVVQC8NJ4Q1":*7POQ(:=(H"??#E
M/Z>%U/(<, '6E(!O*) DZR@BZ<(91K7@JGS"%%LXK6F"JGMRWF[4C%XC/VS/
MNHKP ]ZZ[,(N>P^PBJ$%KA11"F"@4AST8H(=3.XR)1U<E!$MF>.J8\K0,M0R
M'B3:UH8'F$@;&=J_ F$_N]ZMZT3TRUW4TLNCS!UQTC:5O65L71\$L-'N]8Q:
MNQ3DM /<NLS"]^#Z"N[161V&<?2A-:1(@<]L&Y3.>5H0Q?44K#4'@PK*?>"C
MTQ-]^1A)$;[0M A%B."V#-J&KZT&;M-2@=L6W+D_=&#A4CC**=1Y-[J;K91.
MVP0:-OU*3/*AG9A4M,8C#\!DO&PM($U$!@"TC-&_]4& L#"-_YT'(' 6@]ED
M9E-\3M5_1/0#7Y+A#RTE^C$QATP&+RR0_1:NP?4#P=IB_LJ$JQT7*("MCG&"
M_?E^CV&!)"+H18<!=N+P[G96.;QOEN1,!;R&!4, X#TDUGD)RZ0*CDQZ-AKJ
M+:/6[1O=6O>=>&0+[J>P.6T;I="V8&=L6D2H++B2$KA_,2"1;8>P*T'#:#?[
M1K^S'MAFW9+W0:X-&7HS<K7RA&\J[]'[@8(.Z3[W#8_<LLM]"X][O7WTN.?>
MN T/?[$;UREOXTJ/.RI._<7<3P[]PD ."*L4G2T'ZSLLX?@3V6(6\$7P-&;7
MSO!N!/][#^:E.\QVKW3A&NX8M3Y<+*W.T=M;UJ5?X([U3L[[1J?3-;KM4B(K
M[QMO;MGI3/FS(^8E.)X7"@<"5U=\>TK2_4@!L5O?S>,=N(.SH?:YCO2+:BE^
M4<SNCWLDX9T<2'VG[5Q0?7>8^9T4$^ND';K^R7GC;%D^ZA/+M@FQ#/9V;((B
MFY 8GKZ6?FW7BVE@:_#VV;+.$*X&40>G-AN^P+XB;YLX9;K_<?/@T,#)P.1Q
M7E'"H1CAAZGI!7/]PRW\7:^W/W(^/P@VIPJIZQ5PB$8L-C1%4A58,K7'4WSC
M1*<6XU3JB5THL/)GS[XUM$P/Q)VA?;&>/5-_'%A8 .KK7ZR)A?O_ 1]OU'ZA
M/]._Z[\8Q,Y4J/"' \HO1D NIH'KS2;Z_=@$3A^P&2]HNN+0>A2M$$-^-'3!
M:)>VZ<.;=-#XOS]I<+=;#I:$^# 0H]*,5YBA._.)%2U>6<2^1TDAMC6@0@\,
M$PY,?WRFKPELQ8_;/]C\WG-?+1^KB.Y&=[RBR'FY\^[A>P[S_+$UO7CQ&%4=
M73%_X%G$+_'S5S\YOS8'XW!--'UJ,$5TM? *":S YN>KKK_B@7H;6W#V6/B>
M]FG=>S5Z$<N:XG$<_=M45);P 9#"B!QM*"BB* '&KDWAIW3Q%>OOULJL$-VZ
M#H[CN2!QG)<;5 #@N-V]"2*"0H1:@?G"/LWCC_)'0D%WVE DW91ZPZFD;H"R
MU#UK+/L ?](1H=F=P)Y;XN/$6^F+;>1?K.2=3S/?<ICO7PQ S/@$GAHM\F[T
MNQLH=.!/>6R8=9W-D_,FF'3+,OTG9 +<Q:G[QCQ0:#BS\ I&OM<VWKFB>$Y2
M.2**?$-_9@-SY@.[!,0=4FV2=84(#.N).T BQ<((6.R--%/K\O@,M-]@1G"I
MJ&S'L9Q!3/CI&]&J--.UBF6Z9E69KIV-Z23.*D$%@V2D*/C8?,4'%,A5(,G(
MYI "6"4JN>2"]^+S9W9@)%Q,"MYKR*D6W5?_88- !KSC2,=803@88!4K3$$]
M"=C8S_<5Y&3EYM?XS0_7A@-'(0"2P:Q&-GT$DP(\4 Y"E4^<L?N9AZ*5IG'Q
M>*D#R72:>?T7_3-<7<X ==X;QX>WN3(LKU#QM+A$/RHKUQA^4QRZZ10+ &/S
M%!H*K^(-?'VA]IE3")D.&S;I6 ),.3 IS\9R8_#$8M+-U/60>MJ4+-<S/9M%
M$)WTL1D'CI8$3RZJ5G?9)ZM-J27&U6B;PE+KER"9",HBL.<+0..A7:=\?JT^
MOT5?VF04<=+QGV#63W+2R?["U?I^9R7 .&W#,V,.T1..XI]LJ(T6MG)Y(\]6
MH+V4B.J0H!COY',Y$60Z1P29% 29[A%!IBH,?H20.3@(F10S-0W\G^Z/RQDH
MZD[ 44F3LA\;+4*4*\21TCGCJ[A[^NWZ07^XOKR^^?WBTQ?8X(O;*_W^X?K^
MXE^QO:P>\DS.;@]7 F$%LU3\2W-J!3Q)\QX4)=,:7CA#V@5._@CO)W.RJ]S+
M;;\3UPNZ)^?T.%[^S"*$"1Y^G^)P<Q&.7]-%0:.&(P1IXX[*ZX8 ;"4W..29
M1%BE K?BP!)$#S__\9@$6@(41-9(?K[.F@DD20BEKAZHM''WD_+*PZA"QJ"[
M FRGP9@GYRMN;0DT5/%4S0W3$L3R'\3J0=0J+OUKL?1L)FOOY+S>:QN=9O.8
M&;L#<O=/SINUME'O%@B\46R'97FT+ =N:XQ6'%BBK-3@Q#INY#(R[0^B(#>;
M1J_>_E$29;<C%V;6=XU>!N%1E4S9.),CWAL"O8W8H;&Y(I<>^2(^LXR;ABG[
M':-9VW;3#H;'MZ 5)L^W>D8S0\K>+H7T P:6;"#$U/6M@ZMEB(QL/GUN(@K/
M2;9]:<&^U!I&O=;_49BX **U*06UT=\=+Q<KK3W.]8NZ_8%Q?:A-9MVV#F:1
M&?"/RK)Z9M2&YI:MF8N1GDN^N /E)%K'0[2,;.S4/3EO-(Q&]X=3<3<C%QC(
M**^Z[6I7@ZUPLM&:E[P@!U<B5.H)$@)9&/*Y;M0^OU';ZT7SCX: 5^HAWGS'
M6F#@-^I&)X/Q4S*(V_HCO%BV\]XJ?+;7H00#Q$--N=@!'1AP&]:Z1P"N7;B7
MMM^PQLEYM]4R:K5W4I*UTSJ$JQ!6*VOZ( \Z QO!<P.09&;8TB$ME/T&SR\F
M#Y[IO[$P]_W-LP)VZHY&U"]D[7CN2"L\%Q"=0O^$:00,IG$WN@\_)YDSKZ;8
M N.FTS":G667!.5Q+W?%<&590VC21OE^2[W<RDZ_6PS[%Y45<^_A,H/YO6T2
M;3'WD@(GZ5D3C39>U<7D,W3/]/N'N_OKAZ=_46+,]?_]=G./>3&&?GO]5'R)
MD>5@[R#XW5G;<O:;+[.2^KDS8M:/%#\-+?3;\%?H/#/Y_-I$%STUT:5@:JY%
M0\M'PF,FRS&3Y9C)LC;CY$?+5[ET)],95K*$4K#BF1*]K73]%0(3-$H_HR[5
M/CGOU8UZ\X?H3]*H[Y?8'2!VR^@TU\>%]I23\GGFP>1!4S3T$="$_F$2:LT(
MH_?XSPD;4FWST@';AY.ZU]GOAB+63+MF-/K;^JSW0[YZH[%?^J'/O]\SNAG$
M3[4BI5^8Z3,L)\?B.@],[[U#'=8;S?WN)8+LMYI&_T#C7?7&5F[2K>G7KA5%
MOV*OA"\FZ,EFX'KSBHC\WGZWB3!NF\V.T>VT#I31]ZMRMAL(_-EH](W: 0%_
MXK=7VJ5?73@?^BL;6P.;+:[@?444ZXW]JESM)J@,3>"=_C$4G'/CNOO=N%;)
M&[?)M5<!<;QGK0.1<HUFNVXT.H=IP^SY,D,D"J/9;QOM^K;J0$4NLR_,]W]&
M.!G>HX5AO=?4 PIR5_T[ [,NZVQ>1/2[4L@'_[89_@/8[6*"B#-_TN]7LF(V
M+NR>G#>-3J^+BNGQ6MR1^-CM%O?0[FAW:T:KO=Y W'E*U7KI0HDXR8%*0W^O
M[2O+N-QO64:.P9Q)H]-I&OW&$0=[/XI$UKWJ8+:DT6NTC5I[?:%-1?.MY!=W
MDF"EJB0RJ8?0S:9B+PQ]BKM!4&I*2L0$0?(X@%IIJ&?JY+)M?QV/:JT%6GAS
M68LTULQTDTZKFT^U05/M-XQ^>QD.DN3ZFMEN$8/+/]LFS;;7,=H)WKIL*.<+
MK2\-Q$*8L@$V+[3G/PSR>1Q&$!N2<I!L2G-T-1P@+4C(PXB#I>A\B+0M8"U_
M<V&\?^!_QLRT@_$ X7Q%\;"_F]/[+;!L L$/P9!%,NU7$R%.$>.2B3^YCB^3
M& F<!T5_'I2"#OI$>D:]L1S^,F*IC%I**J.!>5X1#*621XH0E 9'HR= 3P*/
MY")3H% F$-F(@U9RDHOG?:9-5Z2:+>>ATA/X^]',MN>">]@"L.:J4Z>>-\==
M9#U-I<T/<P2C7.$PPW6=J.UO?@RP\?87H/6=<V7Y5 D+X]^->"9Y-NYNGYQW
M^Z#5+#N6"+D<90A,>4C#@[# WR4$F[CH&&V0F9"0 *R)4Y,)WK6NPKMFI7EC
M"]%3 ,T[)^?-A&R$5007Y$LC690SK66@68/.ZPNEKWO+GUPZN'O)P8[.=!41
M5[M'Q-44Q-7>$7&U*@Q^1%S]41!7;YS =%ZP5TX6(,Y&I]LKJJ2D=Z;?W#Y=
MW/YZ\^G+M7[Q^'C]]%AT-<E*+,X-J17U=/^,7:#8%S 5AXLDC#=QCU&OUSRT
M\H8D-_!B#[3#3_H_5C[LM?*!HK*+EFFYI0SOL41"@OQ,X4XB9XIL(57Y[/TM
MK-D409P]V-_I@D'; *K7UD?@WD&U1',+2[88>O?(>]LLF.+EQCF%P X+D7QW
M%+R9WGM/"VQNX=8OAEFPH66C:?0VZ"'[0V= U)M;%($4LG7=6LE;5\YU6X'D
MMRWR"XK9N?K)>;_=,&J=ZF+FE13S+X9^%$UM=(J@8'7S7]<_N$-^V&0RNZ\N
M6TS!-)5$LA4IF!6B5Z4F4PYJ^TKK:3\E/>681DJ&HYK)F$VT-;,;2U6\&LHR
M?[:B:0MAX%L&:-OO(]?\:"7MGZ<P2M\QVO7\P'Q'LZEJ>XG1_[;12&C4?"RQ
MJM1&=4_.>PAV7-\6(OX]V4U;4;1W<MZN]8UF!A_"^W46')7UV,@1@U$C],"/
M59I4:-F5FLR^ND[LW*3*W$VAM6$WA0.T7!9E\BT+KK\/[!DJ"[^Z[O#-LNUL
M AGQ8#HMH];=75WLT1+9B252&(_T:MCUJ6LT6R4IK.]W^[8P/HK;/BQ;ZO6,
M3@9W1(7B-MEE ]4QIBL1J]9WD"606QA*Q3%58W.9<"Q:W<N.H:>WW3"Z&3R]
M!96N*@4#Q8-3EY23?9&(QMU0:TS&)N:WA0W>-<J>D[5:##?'![LYU(\-_6UL
M#<:ZY>"VP?Q\]LJ<2(\.V&#L@#1\L>!OEB,*]H"%1+$=??3__$^O4>_^0B5D
MGCEE,Y"O.-*+*,]3:AVU^YGGS["H5@P@)J*;+Q[C"(CJ:DBIGTU''I!1#UL,
M8/#JF0V %9-7Q7#PJ>>"0@[Z6-@+@2_*E[VG@3A87L)?@:\X<*QH/',ZA=_R
M^K-P5C]>B5A8[(=L\.8*'M(DYYSI3^&3%NR)[;O((/@ZD'[ ?.+5L&!0M++@
MA4&^]5WA0-S.,55@K"Q!3"HHU&1!(7QVX7K-54L(A\I$)IW9P0;%6EO82:)S
M14JCZFRR$TS+=KUOM!)Z12X5W")0?D@M35"+SO6:YNQG^B>&.^*OKN.-2G '
MBY80E4FG%N9JV0MSZXTM\!N+(CKVYS1ZK66ME9_DK$U$TBMO4^MH$S9RTQ+:
MU85X9F+)7WE@ BO*%Q<5#76/?)!R_WMRFK99'>P+V#;JO81V+PKKFN&])Z5<
M6&SXXN!MFO&D9*L+7:Y)IB'5ND<MM>[QL&^CE2Z[>)F_E" :\3 Y_D]M]/PG
M2'VNRN"#(M<%NY*\\EO=@IV +T]HKV<^@^, 7QPQD/]J7DP,!V3%Y\+3M@LH
M 75VZ>=@-?MW"3.^UJCM%!>DB)EC]G:]9;03FC:6C!-2Q.P1/:G6,6H)L'Z'
M@ANR"TD0Z9%OGAL0"(C0(GS"WJ$?I)A6L]@TNHJPC":;#Q[N;,>R__97?(-8
M/_NK'?75DEB/=SD#"MQADS-$ WE@FT4R^^@4-9JM!+XS1X$P<T#465X,RB-9
M;3L +BWW&[F:>*7%II5M%+IFO((S:WNO;;X1YY.Z>OKP[AOP>VWI0I3G3X.[
MSH)GUMS$DF\<^"P\^RHY2)QFCPDV=,&.1PUXY-JV^^:O:C>VU%BL[*K=Y<YB
M!>WK@1;E)A2%KB\ 70+I02-&W=M%SUYU:UDO8H6B:P(2!96M;E6XV>LEUK#!
M86HMKJ)B-8,E95HMG]%_ 5L^O;G9+M3&R3F0O%5DCZMB\U1@9]OO,$%NQ;:-
M/9;-3]-OBHU;#XE9I3@B[6?GA]G/S^[,R[:=K9UOYQ8)(;"'W?>=1+!;+H%G
MLW$)&'K-AE$[S)R"Q*#RDQN8]KL,/Y?#0EE1D_N=4E,%UF(FEXM=M[95> $?
MR =,USL"TZ4 T_7?)S!=.&0)J'(;;,Z.L.8VF]G>$.@VF^ZN<>G6R+/- =>^
MN,[+$_,F5^PY2'*6-?KU9E& =/TS_<O=[:^G3]</7_6KZ_N[QYMH.U6W5N+!
M*<;OE<.G:4XG_X[PZ")"47C6S^?"1!]WUK'B%W7WY!P?/\6,$FPG1"^L<AA*
M9W2#1]1]9%%WM.1&3";J*JHG^04WI,V!N@'?QNCTQ0DRO$??/'.Z$HEJ^=$$
MS]BV#KZL7]G,ZY<#QB]Q(MMB^[UO&BZA !9(PPV@ 7>!V5?6N/O$ GP 5@!U
M6DKD]^==QBN++U**]6R69>_DO%LW>HWUH#R'#_2W00[YIF3%I(H&&.RU NFZ
M$V\@)3R)#&:,CRZUPCY<%V'F*LCNRBK(8VW6]L=)X;#/KI>K.6"_1NW#V@DI
M(X?J,GW')3M;^$REL!5N4M<9S#PO,Y/4,]]IQ[JJ+>JJMMLDK'YK](U>M5S:
M&[D%-_?G7 P&F++AWYMSG"<V4AT,X+GA%\M\%MVYUK0@Z'<+\_C4:V?ZQ>7E
MW;?;IT?]_N)?%]2)X/8*?_GP[?I*O_Y_]]>WC]>)7J#MLMDL!^Y?>+]VUK:<
MY(2GW;J3%'])EDW:+$5NFV_$3Q/P@!P"*]"BF@H^2I0QOLX5I:6ZH@K;BH2\
MW<2$MH)VX< \62LNG.IFGAU;252TE40^OT[Q7J'DWBB5<0M=L1'SL([MV75F
M//'7-VW3PSIB(48K[M/80LF^GDQM=\Z8R-]7Y.AE'D4.H3K;V'][N7#GZ$(J
MGMSMD_.V4>NUC'YG?7K9GM(\']95'RX>K@/)'>3>P)2J7*F=9-M*S.HQZIV&
M46\?)G3PQ@[5PDC81>RMIM&O[PY4OB@L.'?$?!\F:MKZB!WLD5 L653&U65]
M9CE%&]91=MM&L[$MD-K!G(8BJ4=M83I&J[;>H;++NP K!-'D3&IS?I@LCR(,
M5W4W^BU<TZ-84A[A50<[N(-^RA\&&K<PRB$>&PC;YM:HPKL6^S>./_-,3)=\
M!ZI0N!AQ=>?:0K V&UVC]>/TT]F:8E@DU#2:G7W*]Q6N%L*K6<JJ>%_ASBV4
M(R)/%@=F-D8 B[O>SJ3S'N/5Q>AG!6\@PC+5^T:OF1]'\!C'/J0X=A:6R:/D
MU\EET.NWC&8"J-<QNEVL25;LUG5!VS?JG8[1RV"AE1'R+@V*HB1$DSM'_TI>
MQ"381XHK<%0/%[$UQZ;SPK0("9/C<Z&J9=OPV!J0Z>9FZMSO# .EP!K?G%?Z
MY^,8+)J[*7XB^2KP\0$_SACD]N@:G03%#E9F^03%Q\>G5<W$QW0:3'?YY\#
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M5@MO-+4-.179' 9LJ5OH+R1\(W0@0<(-#1-C4" "2*,)(1=_%OA2'M=8&F3
MW4?WBSQ]2F<&-WHZ--Y/,2IPRNQ%D1V\)>Q&'*,+DG/1[79/S@)B\VA"(NS
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M$URMJL@@WX1,S]DHMKI,1Z>VIE6:#4DJ;$697A3,";G0)9E>TY()WI5DNG_
ME;5D^@9VO9),;^']*(WZAF1ZT=#/TZZ%3FBG4I<,G2;2$4D^"<&.9T4FV[GS
M2\=;XGPHOO-!!US$J"3'%+;LA&-?ER-JC;HY+#-B8-B3K6\/OS*;C4"[/+F
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M\<5PL>QD2O3@Y*0?.1,$4@*!QR>#&TJ0(<&QZ4@&35?'%.Y3O5G_WVP0<$+
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MZJU*I!W/EW[QF(T-+O<I?'T*;_Z3H;P#V4#QE,"ZBUD@();!6O"_\V5"A9N
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MX1)M!US\H#,7S*M!+PBAR;*U S"14P3G+A*1G-+>;^2;7HNN'BJ8SBQ[,:.
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MJP.(ZFO:R5E=JV:HT=H[$BX(!K3VI0M"UW#^KE:M:0?6!4$^]['UX5AB=P#
M_*RM#ZU\-HM6BM:'17>PE(0/5T']8;0^Z%J#W_!2VL+D=6V*(,&P,3;/DV/
MF\PUO1J.G5QD41RD!-ZSIHZ<(E;?1E-'JP+,M']M';L4G06V=6CMDS.]695<
M@;?'Y[HX'LF<;NSN2UO'R5DP GL_A5:]%.T56D7/U7WY$TNU0GL<-&R([52U
M/)KFYY-K)3">%F:LSOUA]VEU&Z7O+BE( !8STBB\&".; &S4C[UE^R%W)93=
MG-S5\9(&K55MIPO>8W/93K!PV,UEQ1:]+VT_2Z2,][$,=K/C]AK%S*LI9MS>
M3U?R_).,Z]/U>M9Q?3\="^P\T;UN_YG>R#CN[R>N?6_7=M. 5EA[V5'3)C7M
M@H%,6VTOZW0K]=JQSWL?%&TAW65ZZ^2LKN?Q_0Z>!=;/_NZNO4QO8WM9JW%4
ML8M5K'9L+UNC%ZRQ^?:R^K&];'\;1([M9;NGP;&][-A>MI^H/;:7'=O+MI V
M6*>]3$LP8"E;EMKY8A'%3#Q=+>K?UBKMYD]TQT[[T(+VW9.S>KO:2A]5LW<D
M7! +Z.Q-=UF]1MUE>NK F?TAS;&Y;!]KT([ E*9BHB3-99U\%DLQ8W)7;2YK
M-P'GI:W$7P7S!]);5M>Q?*2:87;Q;FF2VZ(H1V]9O4Z]97KWV%NV6+R6I;<L
MIX1=,/YTL[UE6K=2JZ>/-RU=&\8N96>!S65UG/O=JC;ULHK/4IEYV9.-^KXT
MERV,$R=ZSO+7,Y>\J2.?N&P6,Z%IU:ZV9G/U:IZ?MZECEU*\T&:Z.C8)=ZLY
M2KN./1W'GHZ=UI$N[=A(9&'VL;)LLZ,!F\6,V2EF-.!/5T7XLXP6K'>SCA;\
MZ5A@Y\FC=3LV&K6,HPE_YG+2^D]W9=!1%R=U\8)Y3%OMZ0#R-#+44?QT<KB$
MJKB0GHZ&CM=&55OI,;R?C@76S[KLKJ>C4:>>CF/;Y!(EW/@9>CHVW7?16+7O
M(OM>(VT8)V?+S)FI,Z$'YNMX],;D1UIS >\9"#H%4M-RB-"1XTQM9\J"N_[^
MY7]RHOX86Y\M [<,C/7],6WYGF6I$["*2!*KQAALL:FG@G_%/_%4)_2W4,RH
M!O^!Z0P]]<5X96J?,5MUV=1U4$Z_,NL=_@4_ 0$!B(&_1Q8;3-7>_=/=P_<;
M];>'N^_WZK?KF^NGRXO__>^.KK6_>.IR)=?4HDJNMIJ26Y;Q>V! 2H_1,X\3
MRYPNK9>(R3/@NZ2W2!A*V8M>OKW@J-5DK!5(1V\$WH%7JAZ^LZ*^O9B#%_7-
M\%0V&C&BN J;],N-]3J_D+,:,'6$7\]"T10*IL*%4%+T23Y!J:L(X4M_^_\H
M"#P"++;0?YV>JE<FLX:?U7O0JE_@;7_-F(T- EJ[^T7] _L(X&_U]%3\DE<0
M^B#[</+53T$FP<,Z*@KQB:\\6OA9AIZHN9W;R*?6"@C@(-0D$-3FU1?OM3@Y
MNSJ-HL%'P!?UZ7T"6^^Y1M\<?%%OX5!P)-TZB(UZ+?JK7_R?$:*(_B%5Y2CK
MN\SX\[3/X"C"BR>$_>@>6I(](&JC2(H0_639LE%(<0LA.0OFN,B!*' YGY*_
M]L^D$I]WQFT-AMN[I\M']>E./;^[?;S[=GW1 QC4J^O;WNWY=>^;^O@$']Q<
MWCX];AFPCX]<0YJV^KWZ6%4OL/G3]3[-@;$KII!:;1>F-[ <;^:"W1:UUAZ8
MA7LY=[RIEW 8O:3)IB>%RZ;V\_3"U#?AGIR*'D+U&0O&U"' J(X,T^4=6:HS
M4KC1PSLX^5.>.B3%JD[A1=0%IS)["'1*W#C-!X.0I831)-*(_Y.B^NL'6++8
M:)V<@;N>G$5;245'D9<=[PP=;9H/5$N&+XA5TE!29#1G9RCIT,CO=A(E%?04
M)DRX#5453^_8^&&.9^-H@ZI"O:EH6L<.+)ZXI9&1Y@J7*1>2D5H4&?'B[2V-
M+I6C=N9C(UP 584CO0UGO2AC=PF5T%%/'?,0Q7HT-H V,:<6.$5C_MF". &X
MD RX=H)^M3MCB=.ST55CY&W6N%Z*Z1Z5&>!&<<]*\+.!ZZ@F:!Q VQ@UJ@*?
MHB(BU06_X8ILYOD*BJSV4P#=L=!3YZ_![GA\8.P,F07'$\Q\>G@$%H;SAM\8
M(=C59#QN:\R6.3*T$>KOZ72.#,U:L=C._G3-B_:=8.8 &E49"WTR3Q?86Y2H
M 4Y29\_]-#@)4)*:NMWLX(2UNO5;C47=^I<_T/*!G;TZX#Z9ECE]7]@.NKPW
M58;_/ VK2]Z3IT>\$W-W&MM)35Z!DJ5(640G^)C^(T#T@S$-C=A3/6+%3L"[
MC6MO'##>KE4E =*%Y)+A_,-A$5>K'01Q=1PB66VF]T#^5+35#H*VF'%N5]N;
M.;<;;Z][,+T_3T<N8Z#90!6"S:^Z.$(H0\]/ZL2VE9EE;T4[8O$*D'@M<+@*
M?S1.SNK51IY+E#[L!Y5*(Z/7H1+F)JN=/!>@[@N5RB)MUZ%2"ZG42J^@WX!\
MW=C\B,  Y^%%UQE',P4?P0FC^%NF5MUMLI$TC-9)CW6N79"]3$4GZZZ;[9.S
MZ$6/1?38;P?MRX>#+JW-ZY:.*AVD2K(.[W3I/MJUTNVC>W+6JC8D1?W2J:N'
MS&1MK6S$:=6(R1+CNE*83"_=/K0-,MG&/8@+\]4<,GM8,K\A<[EK,^=4@;W:
M9/N+NOR!UL^ A6X:%CK[,F$"CYTU(RL>07?<\E CN\.>K>ITK=RX3-#ZF+LB
MQ$F+"!*>14N7U=GNWU')[J?O$W'J/P%Q<M2>EX,XT@KU'=LL5T$-Q :IG^T2
M@/5$YG8[ZY:68M&7%V#S!9RR6CU6J[F@8F\'!S<_Z;+X2XMZ)KN'2MD6-MFU
MDV$XY32M\K!=.U2<\(),319!WE6H8"=<W]8.E<*\OE23M&.EL_T.K\0K%BE=
M0$HK,O5B/;8O2S=I06M<$U_8C+/(FSE]H9))G@YP1K&Z8T^9.BH;3RSGG3'>
M*@GH/0T^J=!/?P-7<Z*Z;( %3J*9\I3"4;!2R"WJ +YXQN+-46IM>"M_XV#/
MLIP!5I3*>18C8+:WD,-BC(67N[:Z[4JCD92HF4K<V^78AG9R5N]JE4:[FU*6
M7J'*<[\?1%G8#I*V[TXY]HW^=$4#@#4]9X]"MQP; =^S"=OHM)/S=Y<1<$$_
MCU[)LO=6#D^]B+VC:U?1:_5*33(C,=-&UNBHWN1&P!6!$UAI2":>SQ%1R4!$
MK;J@WW>7_97+>Q^6]23<F+;CFM-W/R$?]M_)&@V:7>P]6GMWU)VH=:KJ[=WM
MZ?G=[=/#W;=OU[>_J=>W3Y</EX]/?H?B?FO\.SO"/37./:"YWQS4Q($"]^<3
M*-ZL[YE#TW!-7.?&=#SU'KA_# ;[C.(AGOK-'.. 8?4C_DBO?<&'Z$_MRR<Z
MDH\#<V(Z\-R(X=_8HIS\%7_(_UU%-:G;7SVW#,]3>O0>^EO]JH)E8=K8<R\F
M-8!9\@H .C-/G1CN%"#]0I*/=YK,X#]@@ ([5?@G_#6]N==0_PD^9O'Q#9KZ
MBH,F<%V-/Z%@\PJPL3,&=@YJUP36PB-+9HYAO]/$ (M%UYP'/;%FC1;EME6*
M_1X+TM17DF-W +![]V:C_6Q._$/F?0=AY?$A"UD'*& 2IU:M28QMWW(,4::D
MHZRJQKA3\[F3V"["2:.9BUN(\4B"H,07H45JVBK[ 48GN"A(R %SIX:)34/.
MOP$(3[7, 4IOKZI^G_#N(QP (:CDS0QDVJB%BTUX+XY%XT&6DJK=S%_F-"\(
M Z*![X.=!. O?7V_!QCM:<:"I7:;BD.[R=N^/DB8.YT/:VL4<7W%AB[F>;W!
M7S/3,_'MX;[N1G\XH,B> _:DI]P(;Z9LM$,C\;6DD?0!#QF2;>*\(1/9Q%\5
M)76S[6ZI*-G=,"7UDE*R ZJYWJS6DFY7DI)<0,RWUSZ:.!4#SZ[G@$0>PN*8
M3D!!-"]:3 _X ._='<Q(,D6?#0Y_5 X,\'%_((SUSC40O M+Z0 @G!KD@08V
M1Z LP:<>@82R!Z9AT:+.A+D&[0 1ZZ&3C3\BX:.@3N:"T41A]@++/7/WG&_W
M630("3$7WYK@ZLC6@I%#/030XJYWS_,<@ :QR;N0A;#T " VII<K-.R(NI(=
M2W5>8>5YI.&?+TS@&,1F''(4H6!\ "(POL"WQ]>IPOJJ@<2:65/P0V"U*6!F
MR !9YC1#:*#=R)>CZ@W1'L*XU+4]<!E8\J!UZ'\?&*H%-KPT7.Q?]BXX+)F,
M^HZ&EQA5=,F11'6A &E04P$K &*I[!+;M_![V/3$,(>G@!RPBDU$ E 5HRL"
M[Q;RB'^8O00B ]K"X]0^1B,V0EZCJ534"H\84J+>Q )?8N^-W& NDV]$]"9P
M+F9C]88-T6X-#%!N1"@IC-;,[S9NSMSJ8 Q#HM$B!@_80NZ?ZCF<QF<2/X,!
M647/OI0P)A,'^ AY036>749<4<&](?O[_=4,!/3T/6'DGG,SC?-N"L):^>/+
ME[3Z#9N^.,-K^Y7QDRK1F%D5"#;$R-0DX"1E%VM<]KKQ731@%\G(U0<TFI4K
MUG<YNS?]J,XB?I\SGE,0L$;P;H-\C[T06C)>N4F^5S;$]VND6#?.,2TYQZ3S
M?6>-I.C&=X$>2]+!)+Y7 [X/HM$;8?O.&E'"#;)]!\>C2(+54K97=BGN.VND
M$S?.,%TYPV1@^S4J7S:]BRYX/=UD</C#<IM92;69<UC,_A;!/9WB=LZYB=J;
M3EVS/Z/$Z)-SZ]@16]5G^TQV<Q>KS=N5=BOIX:5EE]8PRPK;C8[YF4I-3U:C
M9$FUU-<0/85M"0RH>J.BU24Y%_!$,917M&>C9/)L5IY>-Q<I"+(HT9Z'K4Q%
M[0=^D6P:8_Y4BN_'@ORAK)4\@8+-41M*H'2KZNWED_KM[O%1O;]\4!]_[SU<
M;CYU8@)Y\??U6G1@RT96R#VV:Q[77T'##GKVD(I8V7#=^5PKO3Y^?AMB$%<P
M"8N/A/(8/S:BZ@-#-B M2":!'NGC^^FD#/D*BN5X7C@T^W-!([12IF5M%OMB
M(-T&J+AG<[:V-21I8_.0_AFDO_D\)%^T<SA0ON_1.*U=8*7\ [5V@94MS]2*
M'$ 2FP9XJY^75MA*\"0ID%U<JKMW[]W->#(L_5QPG=8MFZJD^HR(08UFK!]K
MX$D3$6E8,F1GU6M:(C_-<0U/LM@ZG(R4YS*>Y1<PKU$@!OB]!M]DS+X!DGNO
MAFEQC^7<&8_%E2B8:0?'AG1QU&7!U!IXTLM\%VSZJ'3T1J752+^P?CFQ,EVV
M_)/0.T_OWG8(CE'/2KO;K30EQ75'@N<F^!J!B6()CI=F-RNU1J=2[R23!!NC
M>)Z>P+,+AH48=KJ:S]B$DUFE;J*KYV<&IA@K)*61R>^%4?T;'))W4?WJS2;B
M[JS99+ZGI43X.P*SR=[B,XJ#:E]4DH\%;VIS=IY_OVI=>K_J7.<7OR-5S#^/
M7BZ0T F)NU,;E::N5;1Z,LE?$C[9H"GEX[11,$[K8#]U*XU.GMEV)<#I2M:*
MC]-F\3BMU2OU;IZICMMSD1=8L5P B3!H6M1D'ZZ5W:" :ZW". *%"?[9D(C[
MZ:X'WJ14;1=.R.QR]4C(-41Y9QN$S"C,U[C%>$4CL:0F[Q&8W<]QXVLO]S^#
M2'?D9N1,,>^C4[KGP.S**4W$,-=+/*35[/G:H2O5#M+4?VHP,IQ#<E:+S'Y=
MP;3/-&F["-QI>9#7JA6#/+W:3K^.I$S(6VFND(\\K1CDM:O:&LC[*?W)! <4
MG!3-RB%Z)@X1>-NX=)I'O,[+'S+DP0Z#9/E$HCS N0&:91**/SW-<DEB>0!U
M S3+)(M7I=DV!I&M=D]IWH++%0LEL^\E4C=Y<K9,F4V="3TPGQ/6&Y,?:2X2
M]W("_R9U\"MB<>0X4QNGB0C6 \X3GYRH/\;69\O +3/[]/MCVO(]RXHZ9V/0
MQ%/>BYU,%5)%O,%_8#I#3Z5.[CYCMNJRJ>L8?L\ZEMX;HI7<92.+#:9J[_[I
M[N'[C?K;P]WW>_7;]<WUT^5%T&><,BEKC5(!*@;@?5(7=",]GQ+(0S,/#$CI
M,7KF<6*94R]C+U4=Q+ID*#!A*&4O>OGV@C<S2EHQ7/Y&E5^N[.$[:0C-X(6F
ME013"E0GTA[-.R+JU8"I(_QZ%HJ>98)GTW*GH!Z+J]7Z0Q0Q&>F%B18KFX*%
MB:F(@&+#I8F6= P!-21N4,+9-,R'_1A8LZ'?&$.%]H8UF%E!H;THKU>9$*B1
M SZ<,86W\IEPE 'II_0P$M$VIC.756B\0E&5>30= ;MK#$N4ZA WQAN+SD'$
MB,F>(/W_(9"1F9EI+I_>K5?:>C*W45F^M76*T+:Q-QS5UZC4FLE8?_I EG7J
MK;:QM\;"O96EJ6K18+H-- @EWOE?IZ?JE<FLX6?UWG@&(_:1_37#D2CP_@X
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MV<-O#O@L#VS S%?<.J Z,Y%7WG0SH9I>''?ZQ-SQ5\/^DR !B BR>^,=P2D
MB%9R7G]PUU!TZ15X?3D,[20,[24P7+#^]-;A(S VL;R$&3KSRY-!\"V,!:VV
M_NHTZ*YP9\*:9Z\I$30)*;?.\BGKXP5$"0 2HNXWP[2_.9YW9^,TOKM1Q*+.
M0('E$-0D "2$WP4VM5-()P0E_"R+ $Y%A R.>A%PY,!'(RJ.<>4[^[L'=+@P
MGTV\_HD.0S9VR(6'YB;7S['_5G)]P#H;.,\V99SN1B 2@I+ 'M75;  4*2[:
M1<"R.DH20I) <:.GE-],:(>)CZ)0DI"7FX!E.1RZ! X](3B7WLT()C!]Y4E<
MRU7%J!2<A!A=  Y5,\N@R2?)=%T"2T*B;@F6N@26A%3=$BPR*SMA>&X'%CPR
M"5AB4C:L;G]RKL64"SA&Q)]/#EI \#X7^QSL9RJZ!H6\OO27\G&K!'#)>+I=
M KAD_-W9/5Q2_NI&X5K YQ?@O#N>8='HVZ!1X3O62/!+)L\YN$]A+JD 25ZO
ME1-4"1?6M5*"*F. NIX!5!)T<GC7]36DE*[O&":)_U-O[!@F&9LU=PR31-#5
M6[N%2<KCB=A%*(!!WH8%;_>&.;RVSXT).C DCJG]#:O7F>U1@/\!JW\\<\H>
MF8NCPOF&'D)3G_96R*E(6/>EWX6,9Q-^0>EW(>'R1L*K*/TN)(9N(^&,E'X7
MDG/1R*+!N&UU^0/O&<$@17CI=2%N7B.S!EL*TN9\O49F]54$0+(3E%EW%0&0
M[#!D5EQ% "3CH8366LK;]*6XU=V'<)B)O7,!EU!&RS"6!EO>P).4TQ,*9B>0
M25B^F34452QDLB372E&IHB"3F6[-F'"__,$;V"]$%SAXS3:Y1Y;!HZQ7CLO,
M9_O.[WHOP UMUG<*D<0U:39V"I'D##:;.X5(QN&M74(DY>R$>+]WG9$YQ0!Y
M$6R;$-B;6T[&DPDIO+GE)**UE1"M&UNN+N'O5BR^LYMH7EV&!KT$<$FRUZUZ
M">"2%!6T&KN'2Y8\:Y4@ZB_E^T0A2MD=1NDIV;MPD/1,[5TX2'H"]RX<5)?5
M1NU=.$AV+MI9O8"B'4XI<"LEJXMR460'L;U2ZKHPR"2'J[U2(KLPR&0')EE6
MN0O()"JNO5-'0<KY[9U")'&FVIV=0B0[@]V=0B3A\$YMIQ!).+N3$.^;\Y$D
M;-M)".S-+2?AR4Y""F]N.5DY<D*T;FRYAHR;DM%R4RXK0\,#6.J<F.YN=&^X
M&:V&U,+HC@2X9.1\1\!)PBR==DF D[AYG<ZV8$O!F^P\=7?O@C8DDKY;*P%<
MDA/:+4%(2'8XNR4("4E8O[N-B% .[EK)8J86E(+8:24#>5. R/@G$?+9!B 2
M0=[-F@[=*" R'EDI]7DI)MW0,_<X90<<?KPMK""^62G[621P$E[2:BME0->"
M+@>':;65TJ"%@B=M <M<JCDO0]=N291PFE;+7..R<7"DO)6YPF7CX$AY*7-]
MR\;!D?4IUTH8N<]U!DH8N\]U>$H8O<]UZDH8O\]S7)/]M>7?A^Q\)-MTEXF>
M\V!HT=THTLX=SA(HAOF3K;P[!E+&V<D^WQT#*67;E?R5+0 ITSW:%H+]>8[*
M2IY-(6!)#\=*?DXA8$F/PQ8*/O,<@"U4>^9@^637<29U0J/3<%AC,<HAV7R\
M;:@DD70MV8:\;:ADQS#9D+QMJ&2G,-F:O&VH9(=03PCX+4,E'1>2S^-9 :@\
M<J'@7&XNJ5!P-C>73"@XGYM'(M0+SNCF.7GQ1N-R\%-]G<1O'F:IKY/ZS2.%
MZ^LD?_/,7JHG!.QWVV6&9?Z'#<.90T4/8*HG).H6)A_)1S E;.2-0)(')]*1
M.V)]:G 6\W_XS!]MW48"*0S243MKP) 'B&1'[/5X8I@NLB/.!IN"8$)GD\,
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M;49*'?@IW+L(45FI6^PAW+MPT#(R79C&L^UXZ#;<3]E1(0H:[UT(I]PT+O9
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M" 8)\=VLD3%S(LW9A!<IOR<*H:D291<1RXV(A0L&-W]@/<%J:1$L@?A=M2:
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MR)XX('\K_YI[T__O7'N\Q__6]P?.WG]02P,$%     @ S4N>6(^-.0<I!P
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M?/D,T7)?]M:F<92^3AM;BP3_@JJEPCF A[))J%&#4&$LT#+?PS9&&H:KI>2
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MP8T@[T70'+X6*3)36M(!GBFL%PV>K+4%],;Y36+$"MKI)*7D5&!P3=Z#N9[
M$4&=+(HJ_!8#=<0R@.-?I+R-GQN_*W/G/1BOSKHKHQDS8"12JB_<:L6IO'"+
M "=5BS<'W*13("&N!8^%%&Y""F/9M)13'G,>3B$=;G5=4,6^BMU4"RI*4R"<
MK5=$28)4Z!WP^G@ "H6.1%1C"_BS#>J"VC\@UQ^H8"%Y@=A--H_=WHC+TG,4
M!1:RC(Z21A@2>U=GSA3-"FP;+I=+3X]3'(AD:8.ZC77I'IY^E7K 9[V!I'OV
M]$Z+Q=--@4\]"(\!_6F2\9<'M?09:#($\CX@2/Q5LM&WW(?<&LQ(=5LG26DH
MYO?KY"TTP)TC(C]XR.VL\!,I>4Q"ZMG:^UPQZ81)<0VR.E:XTS_ZL64\ L+?
M7@;_T$'EDH29.?"= OC@\<Q8.N.OVTSZ8]!TFFG1G.:(=7-M'8*,7F(L,![Q
MY1JBY;;LG;G&4?HZ;>Q,)/@;U"T7S@$\5$UBC1J$&E.!GGD+6YAIF*Z6B@-^
MDO2>9C%\*P4Z3@O(2N7?>MAW?S:,+VS#V)$H-7& ?_V&4* #B$0 0K72'K.-
MVQCX-8F)(#V]G/"BV1\;3P_8UDJ :IL5#FV6E *>XD +LTJP/%DJG8W]$?08
MZ"C(&8M8L&6.X,/5^I54E6GI.>0+E2K/L*/KH"+)##)8A.$&3[H(&'^Z7R$K
M"F)!J)&6(R#%H/B@>DEA*IZ&O)!Z M@Z'NK S/P6;A%G/RYY=OZPW^KL]U?C
MS4K<=_!F;=[K(C(.'T5F97O_.XQW<!\LV7XC"D;W&GOO_\>)_V@$JLC'VCF=
M'[)8\N2:[>X<((#\@5JM7;?UA1?__P%&.N,Y' 9[;!UN>LKNXB)_>K"_TZ>^
M</()G*]I\3-P+P##+V:@=42KVVJ=M!_Y,4VK?M)^]^S$5Z=?7H6?8M$OMOX%
M4$L#!!0    ( ,U+GEB3-B6BOP,  $L7   =    96$P,C S-C@Q,#%E>#$S
M+3%?87!T;W)U;2YH=&WM6-MNVS@0?0^0?Q@8:& #OLAQ4NS:J@%?FP!N8L3J
M0Q\IB;*XI4B5I.IXOWZ'DIPZS2)U-W'<19.'V#3)F<-S#CD2W0OOPZQ_?.1>
M3 9C_ 3[YWJ7WFS2=UO%)_:VRFYW>#W^! OOTVSRKA))8;K0=E(#'DNHABNZ
M@AN9$%$O?JC#@BH657 B3IUOYB5$+9GH@E/!%//O.G<-VH.[,#C4Z8&AMZ9!
M.%OB3XHM8X/1A_W);<Q\9J#=:;;=UG#/"4^$K]/>GG($5!BJ>N"3X/-2R4R$
MC4!RJ;JPBIFA^7)'5!D6L8 8)H6&>:9T1H0Y/C(2VG_ Q^:B.6IBKL#V(RGG
MSAY)^2'@O=+U5Z:1BO4CZ3?L ))SGYGC(TL-R A,3&%!E$\$U8WK6T[7, B,
M[3EUG%.HZLS7Q1P-55(#(D*H^C4[8)OE.HQBDB(;\+9C^SQF.$5%ZO!1()80
M%H887.A(AK16S[,B7JHT+H6&QT<R0E&Q:><.4B-5EL![7%,*,Y;D :IVS@D/
MOV2R-Y))2L3Z1.4MC!=*B*FB_AHUL099U^V:=1;$4$8^4=J.U?!9R!6GX9):
M%,1T#Z;.@<WA(9T#(3+"X8:F4J'F:(NI5 DJWYA")%4NTYH2!12U"F%, YKX
MJ'&G7<=!IYV-@4H](,HX1PFPQ9G%R000SA$G&H-A(D5UBJ;!GA4S<3Y5T2\9
M4S3!K:2W3&4-:NV&(-KGU;!V9U4:9(H9C Z3VR F8DDW?FW_V3G+[<D$8D_R
M$P*Q"$,86LQBL0&V%DB80K0I@K+)'T&+IPO.C)@@(K =&#1D>7B;#H=EO  O
M4ZK*D^D^,\U?Q67>8#B;P&@RFRWF@]'EU?MW%:>2M^>#\7C3_FF(*Q::V YU
MWB 6J7!G6QR<I)KB.5E^J^3UU_5N-@F^VLT:$+Y9CI%II:S1KC?^SS#>.F^P
M6$ROK[SM$(V()(RONS\*DH_5[&]:Y*STQVB(L(O'DF(<.DZ] (C^/W-;-HE]
MCAC_.^Q=<Y; SYX _)O4WS#AOYOO.?\96+OKLRO&9US<DP@O/>I+8V32!9_C
M_H%V\QP]IB5GX1.0MG0+'D[>-M0E$07XBXR*NR7]SK+M]I3]?%L:%;A/_BOK
M+\#Z*&8TPKJ--=RPKQ2NBT>S5Q%>4H3J7#%\C$GQ.>:!$K7#2+%7"GX-(0Y;
MG?\_!#^HS,-GKLP?"))6EM\%RU[U>+F3IZ#^<*S_KB?^!26A?1^=YB^P])7\
M Y7;Z=T%PN/EMI6_I/</?UG0LI?AQ>VXO43_!U!+ P04    " #-2YY8MA24
M.R@#  ###   '0   &5A,#(P,S8X,3 Q97@Q-2TQ7V%P=&]R=6TN:'1M[5==
M;]HP%'U'XC]<95*U223D UI:TDBT)1L:!01,$T^320SQEMB9[0RZ7S\[%#36
M=MJT;.K#>$BB^WG.X=J)_3?SVV%0K_EO^KT;=0?]\^>#^; ?^,W=77F;]V[_
M:GRS@-E\,>Q?&BM&Y04X=BYA3C(L8(0W,&49HHV=H0$SS,G*4(DJ=?*[>5W(
M$%\3>@$ZU.Z"Q%MIHI2LE8F3=2*-P+\*^MN$+(D$IVTY?O-*P9[\T/#[O A3
MB7D7?A>$*5E> CD8EDQ*EI4V(SBA2Y%W'[;^]3:/@?REUO[@]C7,IM>7!MXZ
M;=/Y8-N.]3%?&] ;SB\-8P\EP5JR"_!:^;8+&Q++Y )<U\ZWQB.:_0/@?Z[9
M3^9CAT0Q"\>C^=$@2(ZH6#&N8!1YCGF$!%9Q[X(!C7&.U87*>FV*UT2H"CB&
M2;%,202]*&(%E82N(20\.^'B<\&Z JX9%2K%;[Y3,NIN?Z3F$:5*-3K6YV,A
M)%G=&<%[#-&. 4@&,L% :,1XSCB2A%%8W@''*R4$C;1+1^S5N8^8221QI@NP
M%?1RR7B1P6O.BAR&)"-22:BB0J4XA*8'+\/!L ^CL06>YYGN::=SYKT"1.-=
MR,SL_!CBN>USYY6NS@JNT"AL$F+5-*[7>CDG*7AV US;;3747,M$A8@<1R4A
MG8&*F$BA\S4]S9:EI,R'%:&(1@2E(/8LQ-,T4.F[P1'.EIB#YY1=/0V^7E-/
M;J/DH88+,(J2?4>9<(SA#B,N[A4$-7>$Q:"G+7Y84-%(2)3LJ1*=%J6%CBWS
ME:%'::%03W<1>WU=VPSKM2?Q:V"ZNX;R5&^KDF&K='*-H"F:<(MXI!CU!$%P
M/>D).%K:NJSY!7&"='F1H30U(Y0+(TC3O,IU63&S9\-*QRP8_]2 T:*BDL=K
MLU+U*WYW5/XR^E_P&19\_ MAU'\/B_'T+8S#<'#=AY,7YZ=GYUTX@PFF%"8I
M^HH.QEFA-M)ZK>/9!]-W"^?^Z>!R;/4M]I?A3Q)&,9RV3JU6R[5:G5;[T#Y$
MV]+AM<ZMMFL?(-=KF\W&RLJ=!ZF-QXI8]GS_M0<%F_H0LCN5Z,/+-U!+ P04
M    " #-2YY84D5*K#($   !%@  '    &5A,#(P,S8X,3 Q97@T+31?87!T
M;W)U;2YH=&WE6&UOXC@0_H[$?QA%NJJ5*&^E>[=MB@0E1[D%BDJJJI].)IF
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MO8#I#>BE,2QA.1C3-%'WG\*L+0L8%TI^W!PK0$M894ZK#A?U<\N:<*'K3AF
MYBG"AL'Q+9[G6KI%*ZT32P!9H9;XL)7JBQ:Z)0M+=)8?L%L3'W_C%8YSE6<%
MZ27OE#0H24RN(C9T[=CM:P([!<4'&J2R1->F MZ .I%C$+F<.SEU"6R@=/)R
MQ1:MO%@6@UD$=@=,,@$)PB(EC7DL,-IY@QT4&5Y:5/!;P>YKMBC[/6]2DCL2
MR-%D*0C;>:T1D;NRW4VYY%L)_2J/&M#WM::>KQO9:<5S!.D-Y-<9?^,;X MY
M5: )8YB</0:_?,Q8]ADS>X6EW4H,])9^;Z9 HT*+LCV0!*Q>.58Z@^\*1+(T
M2TEATLX%VC25@/#Q0VV$%AXIK>5!(SM& Q+">X+ZO41> P38CXIO2.)-U@9>
ML498'_ =M"=Q(PHL$K).0?N\TFR9:&,J4NZ6[6+F^Q1KL=O#D!![6>_T_H9T
M*N(K#7"VD T7."![F>:YSJH$I:VIDI(X9CTM.KW\EECF]7N\F6OTU-HMUG+4
M><V=)HP>JPG"];8GZQ4G8%.#QE^T+?I1\^;[4$T+-^WW0G;JH(6^F)G]GH\7
MOPE,4_;%D_=0K120 5);-SP&\2K#;[#/QYI0RY&3=D\/SHLBF_V8;4LL2-F[
MGH(Y-+?.')BF9&<MF8_NK2UQ,<5W8&T1^Q#*K)0):06%@@&0B@M55D4*B(43
M \6N/V4P!](*3B&69QBPYLJ1&,?M;1C'L_LAJBI1!H9B3*K?3=)Q2[RY(:8C
M;U1L4P6#HY-DK.I3[O=6:M MO(/ 0"$C1@]X*B'-VB''Q?'KSM)AN\+3*KWF
MS60)Q]+)3B [0A9D3P"\KX#%H;])FE9LM%Y(-D&<3_5&/!CBD5MQ!:A7E>PX
MTS,*=I09.UZ]XZ%CRLB&'(C#-*T <N,LK8R-]A!G0AX"L-RD;Y(LO=Q$SBDB
M::9(%GSX9F__XL/9P<[^4_S3,>"-!S8O(\L1L<W#4.3#[3\:D.(*8@%IR2 H
MN@:">!D$H.+ITNQ19+=CT% #=+YBC@B):M(03.!\_38==NT.6/2 ;#I/XRJ7
MZ\J<U6L=E].78O?%OYXT7@Y=!X%GE@9K<<NZG:(CU/X_=(0VUOBE83$Z?/7V
M6+P^?OOV[/#HZ.3][_]^LOV$_GUQ=OC:_?OKI/Q:\.UL;R/\1N=NFBM58"@I
M<>@(H[3B)U88[(^.W&MVN.VM7<#3Y@MHE,$4#2$V.CH(7FX=?M2(=[$>W>+-
MM(Y;D*K"R$06<Y2<Z*)#XY&TGA8EAY6?]54=-" ][5UF$A1Q&_-=F!N5+YO4
M0R$G[UW$7$CT'VRB25_.:S$O\@2=$.0"GBRX<NJDRRT"'5:'C,X1C(A WZB3
M_FY!E]T]<<JB_26.:T.7>^(_,JGPYW\J)L.;3/%LDSOM=3EE_JYNT0 :#@Y[
M8C3/8;N'A1SK:$^\ES/%L'J?(01V&SS)O45L\T?@Z&',L'ZO-5X<ND?8.+LE
M88$"_\M\K6M6TF1@ U)C!0.DR',I+R8"-DX\<PE"7=.#+P>46(-00<]: ),P
M]P:E).8)8'YID+40RBWK!/6YO'7FXJKDH$)=@EBB- .01M=3Q4FO*/DPQ_)*
MQVC>8K:6RV5J/S)<'>504!8LQL;NGN # C5,!1NCY,?<C$'7\&"*>* 3U0@Z
M3"5@@111(OF,ZH@"U4:PL@.*!\$277#U[\K%)P$?VI^ ,3/0AT@P=PS8>A!2
M44TJ_=Y"+LR>Z)XM^M< L0K1IDXE<$6,_5Z,"4XNI:_F,6'T6VSH+;4U%*=1
MF6&YXRZ7._*6NAM_"1-:,4VLQ>-+L)9%HA'N&:=T(+ 18?$W K[/)AV&2:GN
M3&QU()^;+\M8"&;*JIQF!1C3Q'1+^5$1VP=>PRF&>F+'<?\VY/QUG'J(80AR
M[W/*;) Z8:84"9Q**O2S,8 AVWG-'&!Q:PHP4J,'&4VTH4- X.ZK GX!058E
MF.6^D.2>-'8ZSN*YS<\UC;7<)07Y46/M?3,Z7JR7T;&&^/\IC:69[HE#3KZ]
MJ MF0LV["WD>HSI%VNE!D=,#*;MYK*SC)+(*VPU)8C?DO*[,'VLX3Y0[0J0T
M*?!A3AY8:\(@-8 8PEBI])95@,8C=,E/-E9D0_@QE@Y@E@%(F4@F$=(]^H(T
MD'F%' I56AR>"%M^@J,B=?+V*KN%$M8[XW"'Z[-.)@M C&2*<L+#F7'F7IG_
M]4DMH@JS\F3N*[' :B%K*"PL7R%-G(JROK6"^POJ^F"VJ<(I(TH(<BB)#]^X
M/A]/#W2H=LDSH%6F2!7$!V8HK3&+W$&99_/$(FMQ#'0,IS<+-#96Y-R_5@!G
M2XP"Z<A9DC.I4RK,C[.HFG'96%W;T5R**YEI6P>GCE## $O6B;K"K-?&N.1<
M996R8R2U#'F7C-KOM=3G!.3 "6KBND!23*F8)^+R5C@V;^K<O<AE.1U3PCG#
M5H$%3TCI"S*7;:*,._DP:X$;!7@L?]3G>5]%ZN?U%*EW"J0:)7%W41NJQ4JS
M'(X24X@#FBQ!,6 B0#_"-$KG9* QB@)_RQ'WU\!TK SF'$ZN \ B;U__[O0,
M2H-A],9P]=PQPKH.!Z8'*A@[GDA5Z=FD:_Y?.;!F'N>V!G5YE-U&*3'KZ;!U
M\BKJ=5US7(T'PBCUD:%95R$#!O9[6/Z.,C<A:]>JS9@61@E<ZI,J(FT AXW"
MY%BVJ8U,X!LJ/YM@1P1O/P-5Y9DM2;/2@D.;FZQH4$2SBWD[V62" '0"E5D,
MFB56M)*RMY2Y1T"]!O"+[+IA?3@'1*N*VS7PQ@.T("*54+(H\%E026VS!YO>
M"/A9I?:S#;5;3$0-Y6E6= QB:H#>.U=0P*2+=0BQQE1F5-KJ%(7(U9>25"4D
M3.3U;8;QH];7UI_Y+LD-SW[D,33S&)YU,X_A42#T,;<9D-B0HD1=JIP&S03Z
M/=M- &N3L&,2=^M G;<1+XAXD-2[*&TF>K./PF<Y>F!>_&0FTJZ(LK669*$O
M.,C&L&MZU=2Z^I:X8U[91.J$&G:1^4K5).NT>O"2VA:%H6,FKM2P\2W;[115
MH0X%$2\V<(>0-9V#99\7FD(Z/I6,[>?63JHKX.>]2X$G:6G?[-*YZ8FZP5(8
ME_$J>[A!MO\)+VQ!COJ$ZU$FC 2!S83E6;'8J*O>N/701"DS6-2!2'<E$%"2
MR HHK"RR7E&$U-ZU@4I:X+F.R;86$@G4SC#=A#I^)G"8\;Q&@6;K&(<"G^/2
M9?,:WXXKPDB7\DF:"G" @,31+0G_---EM1E7T.C/-40GJ<?CD,#<:JU?TN^H
M$7&)  JVN(6KTCZ+GSG6&#B)5Q>A/VH,O*\W[)<U"\5]0YP$]/Z.><("P6*Q
MB?U.ZPG:91895!=6*4GS9I,=CMYA0XV 4K-)P[KU#7^72=0+IV5YX]I#(H&X
MUD;/MI_[]K.R&,M4F<W33XF:<^?9HEY.HSO2@@U#S:*:@:F6O=?9UV[*.[3+
MW/]P0 E!'PY$J]<ORL!>9<8E"^ @K-EH%7?0\=?TX4X7CLB+'PZ3U2J$BP]+
MQ,XBILQ^<I%(8[2AZG+N^NA<,+9!)*,&AL>MI&J/IF^)5V1Q8!R-/ M$ XT
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MR!HGQCAPG2HC*/:3-_]BIBJ#8LKV@&1E?0:>;3"\,:V*ALH$:Y56_7?>?]>
M>CQO\CDH7(Z]Y$GX!6K.ZU0"?,YK"9HT3 ]XR<- U>TQST]71 <4#S/TJ>Z'
M;)H37N@*ZXG1M( EV<729.9?FDD=@7/*N*FE(G;;(<$JG4XUFBD(KIJJ_-R)
MY6FWG["+UED8+ZJ;$M%\[LHR[K:9EPQZC&^2+0&2I%T=HIEIJU[YKSB)>R"H
M?>]A_]!C^+/;]YH[ZG8G"?(Y?+WUUS75?IWT+OT_@ &>_QI(_E[D_DY%TT'Q
MR#BDRDZ28X]G(G@;_U/?AC VEBH_WJ0_?^&G_UT]_T]O [\YEHI_7QZ'J#>V
MUAPC)\4,9IHFF^,^HQFH9"8$N7N2N<+'N2.\"5_*.L8LIFUX@7RO<O'UZ>!8
M:!Q?W@#NEVX4@1E^LS6*9J;(%3MW()83[]N#+4Z359)S+%%GKJ7@\(* 1C07
M]PO,@XT5%D7=$DO'Z&_!\D01^ZI<*NL&,[[/CR9"2Q(?#T? :1ER;06(2I[L
M+)2Z)BX@3-B;6IK'*2>M=Y/>ZPY+'&HU<4,!ZI(H*&#T%(8!>']N\663*X\'
M'V-8A5FR"P4B80X-#=31>CH#A=5Y2![&=_8-WJ?[^D;'S+[2=L)*K#=^#;/R
M0J2N)PE\BQO<O7+F5!S]R,Y6"#8/A%@AX$T8!AX>';1>S5,>E?D*0P'14EC%
MHNT&JUAV4\JNLGV*%<UX]IFG<<[IJM+S&YXH\$C_B/Y(%HUEZ_0N;4TRYTY^
MHEB$NU5M;.'@0(!P1?#M]YR1R'Q7UC9V;?L%?TYJ?Z&1*QTQ<BB0,04K\5@:
M_E$RMQ\=WEVTP@HA0]A5TL\-AQ\LRCX\FV"K$<V;>_R8JQ-%['5>I4(6O[W$
MFI;''>N7<9+N%K*A4_EW<"VJC6(CF\&+M24+G)#F(:":#U81_YU"REN7+8D+
MI"M'C3S74,)2\W3U+&I/?_@VX=5:(X!+;5TT#UO8IV=U]1?UMZ& 557&*Y*G
M:<'F:,3NC["CXG-G^Q"H3J6KR\BQ[E@I,:' B T4N".8!_]1M/^Z\A3?(O8Y
MJ2!]W0\V:@B:?N/6#(NN5#(NT0 P3:S1HRKCDA$O @7P2K*U0SW]Z)K>#UI
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MSDY&\XI^,;_6U'[7-UF"C% .*@/V0WZNM8CS91 Y<U!/I\T5.VT %I9?D>H
MR:"#EN@^OB++FMV2G<-(A&F*M&XJ^.]]#K;GK5JB08T<V^M$E;I&,Q>1=Q0\
MMZPN@#^FRK"*( /1:F&4\E7E_9>"ZXL;_/*F6APIN\WAUY$=7VI>1/C#PY.]
MJS.+P$NA"! 2__MP("K>*=0\\E[D\=.Z4PY>P<1A=^86$YW<.'NG=W59Q C9
MO)G+BZ'>D37))BG%.88C3\-]DB/'D*4S-,A>TZ+P^\O2%)+WY10'#N[^?3Y6
MEG>5[$,1A_E)1+"!R:2^ >UB'5$*3G7_TCLMC:-L.X.XZ$[3CYZ#>;5C/%W"
M4 1Y1C B$(U$/KH_A/;KAV[.M%.(%3DD\&_3-9AK[6[(6U]C*; >0GRZ4SX3
M>^H_1=MF=M*_?RU4*KC#[!-%VE*]1(EM0Z(@6OIS7S[<KSTT<0"] ]'MV;.,
MIL!M"3KWF"__ :\0PM&Y35,3O$*.DQ^4G;#QS#Y Q$F6,31!O17,(,S=\^R-
M? L#*S^_Q#92\2?NCS'V'^MUZ'36+5^8 WVOTM8PI[,,V6W_SLV9E'9YLK,=
MF%6-T:8HNB1&##]>MS:%$/897UO1+HB^*VGM2!G?;3"=&[*^D%^I2YBQ\FVG
MTH[L)^-#EI$U> 2DRDZ>W;\=.JB:GM%1EPG[\/PXWFF"P 1%!#*AQ1_P]C(4
M"NSQ.]W%A@-QG7HUE7;%VR1:X37P^A,9LK'G!I]#+QSA8Z; VVI[QX=WET>+
M]]>9L$(L;U)\[9.GZ4-S:>M'W@E5$%ME3^OI8@?X<@/\P!R9(0I3T@,IK'CB
M_J-XFAB5(*L9H8"%.S &%%A,AFGO,Y_GY8//E</#W0BL M.,(NDI,KAZ8X/!
MO#C4T.):TT>GQ6,:8D%#"S364WQJ6EJ\&I#1I\28*=Y[G%!F@/*Z,H@>8E?1
MLXX[AGXM:?S*'@L?;O$7_G(LH\";K<%0X' 0%F$UG34X(GC:"[OP;^YB6HI8
MFK[/=K&$]N-1QA([OJQ!<.H6=GZSYR$F&"QXCK98(ZP_I\OR<Z:=6#LBU\(Y
MS1RRLAK8([ O08[\5S)HL\=>/1S,+!A7[1 Z,W<TB%=TSGZ8;Q#;*[HMV[?%
MDO!S*0!;KP@O LW58_,+!AV%!.G(/_,;J^2')6;?)41@)@W[;2%H_X/MUG]P
M32KB T/U'3\4>&L)!5:^Q!_MUX:.^>C[B2OY82G;#(2XU5:>/"\L[S9=B'T\
M77_)1$/<+F+)8YU2"LD.%_XRX*>W0K19RQ\CFJM(O]KT(CKH=A1A?>G\4N0[
M2/,7>[7\:2^2?[-7MW7*9J0][[U8MZX;5E4/>>J\Y(554Q[FF%>+BRFS.^-L
MU3E!WLK+B7'M8\WFEA@_9S<T82<;9GVOZ 28+ P1)P)="$+DOX+@I>V?YIGZ
MAWE*;-2,*9(=-JHGW% FV.ZB)6JB*P+QHBJSZ)P] GS6WG4+33P;Z.*[N5G4
MEP43\9,$#WA^DGXW%V258L1='4KC[M*V9K:V[42NB$7!G& 3A0$@RW.J]#R(
MRH7TJ'=7R+HL)\H 7U@UHF4+A;^$!%RN$$P%1WB'[WC%KN5VH_'PP[U@"X*+
M>9D=!T1SP>TN-'-\<Q_7O1*6KJX+^Y1!2D03RT?$V Y0W6,(PZ7_-;#E,/5_
M19KQ44*I2\G5FRG5)@C1 :TUKG2(,%<LEU,&.(2WVJ"VH_4:EQ4*[%://$3%
M_O-5^HKKD$:W]WK35(*L1/A/0P-)$B6RKF.R4@IYC(CTY-7)QC<;(G"PRK<S
M\P(7YB3&ZJW@&G]%1N'TZN+UX7+K[:DX%" P5+)<M/%V3RW4^6DXSZJMO==G
M1ZSN$<WEA8!0N NI@HO\*Y&^&[XA=.<;,Y@WZ$+G7/5I!!XS((A'JFS(ICD8
MK'H8+53!#=K^Q49S7=$9D=68+:9*X'*D57>!-&\A)/_"G,QO>ZBZR'/D^9B;
M\5YC?8G66?YY).N&8P<02\0^AQZ1MF29II47G&=39.U^$]F4N77:69%MCZ(%
M1-R0X4@0"?^E$C@3>(>W\4WCXA0WZ"46ZD61O;^#./]*\O$P[%B$4A HXR%>
M85=__.N"SGJ#,1_CI';X4\-OA#.8/_JZ/;<EB/Y:]8*QG&D-$604WIJZU8H"
MO$AEL;:&/!B.Y4&T21/^/>]V9,F]LM#9_H];XY\*+0E>N%C8F6$)S;V?*Z0U
M7,J>D?$"(3KZ3.#:Z+GR!T_:Q(?;;1/APF=/MS/CQP0+@+)YX#[\I5S78:>^
MNR?W!]Y^;S+B/\_L\LD<?"\/5:05-&^?@ZBUHA=EH2O]-H<AI-KPC1]8<XPW
M;WRPQE%_,%:7Q?^;%%4[NHH*QWE)0GTD]X.";&CK'N4K*)!MH I2D<97A?MG
M XG:SWS:%1KYF5WI^3"6S*W0/WU"O8=_K)S1H5;?&+[CQ_ \887RW+FQ4L@/
M-8JZ>!M\@C\)VQ/[XF?/-8LDR);&2A$UGO,8(LH*V\?S\Y%M"M(,K&WD\>G%
MO/_F6HS7S^E%QU_#!_:@,%:QCV^6!KQ&PE.- E],+(^;5*G7J+-ULK &S].<
M]![XL]AMX9]VRPB6#/SYGN\*"F0R@L_@Y%? U_CGF3?','U+5W/\>A8X[WG-
M=]83Y3(9^OAG?522]6W#<*)M?7<[>HP(U$J4'3-V'XAYYKEF1FEU]?F./X%
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MXO& VT=M>MCMZ&Z\K@9N8CBS[ECE):&8VP?O\;6RXPC.JEC/+W+/U1(LQH@
MT9',/[^#A (65X,147C_M**:BMW*@$68Y;%])$YRIQ-H3,?!&75&'-S7)N*C
M"M+_UV#T+^K^,PC_@H4O[5XK2MQ=#<JI13ONCR>GC@TX3VSUD*6(U 6Y^%P:
MQ_R%_DO_JV#_!'B-/P<\I0L^T]<J-G\C?D(ZVKK[M?6&K1!!ZR\_H66*4RB3
MI!TF^LSTFD"1#$M"4%Q2 NM3F<H'6W#E?BGNPOZD%<5:=WGD<6<2^B#J*C$9
M>J:$->VQ>UH$V,-YE-!J)5G5-GF*6%IP=\07$TM$%?F>0$IIDJU:K6%"[J5,
MR: VG"+ZOO@^7!_%ZF1=*YJGK/043_(YA@Q:V$'N!(=FYGX<^[.YWL]/R>#\
M@=4Q?U',/[YB-/0T?O"UA )MVU#@JJ&S?E0$S68%-&I6T7RK/LO;1WVP:@&B
M<]GPVX-WVAX"O.D(5EOMC^#*;,J7#['CC1DK4!GFOG#<%(@W=T\R(&2TQ']M
M\'C7,D![LJV71L_2RYH+T?]?[+UE6%S=DBC<. 1W=P^2X-9XL! \N+M#<$\C
M08++"R2X!+?@&MPAN 5W=]?N"T?FO,EW;\Y\,W/F^>[SS8_]HWKW7JM6[:I:
M5;6K:A5T?*G8GT4\$_ (2^_V%60//4LEESR6K,U=L.)N,/M2X[KR28[E>WMQ
M(4>"^*:CD,JV3Q$_HQ")W!=+_E#-73I!Y;W]KU*7G^^[?.;D3S:],[#X(  +
MSQ&$HE$]0R?K8_!D=;47JD2RE*IEN\X\^4OLJ 7PV6;;\BV1=XT0($JNL46;
MZ<:P)@@I)')W)4F49QX1.*1QWD5FX&F*NZG.308?,DM;&E.TRSX_QS(3V6W]
M49/2ON'@KA4 7';AY251M<XY)OV2E.^#K6E1U0:.81]FTUF1'[V;CSN+G+!!
M*%+2T^8$H64FRH5KZ4N[(/-\^]#CPH=,E E*ODK!POTJ*)JKF>=;NO1:??3"
M2_] ADC K*[^$WRK,A*5BJ\; ]D6#M1NE7J\9L=R\H-:CT+M\67#@1=^*DJS
M\Z)F% 4>_?=M9(!["7()?NM4PFWQF(:^S3B]-"N;&Y] "B4QR*/W9OHB@UL0
M+_2TX*F3HWFISK>T#'S)]-YZA:KA^F0'I:\>Z2]I,(2"/OM  (BD\8U#G()6
MJ[SW?I3^'LGF*86C6U?9I<M"55![..IQPO<4Y2 +0F=41Z[QU3-6S;QDS-3"
M.>%I<U<"+_-O-MOO28_M&J;9)'*LU&K5NKSWK!N30]9%.IX[;&*(MK7!GG-"
M;>/\I:1UKQT".%L3!B,H0 !=D_HHE@D-/)% 44,C6EG5RHIHR3.@+P?G<DQ=
MBCG,:0;:T/^QQGP/SP[,,&:W,KX1*]T9<B6-CUG$"' 4W75\QS@U:_KML+)$
MAFD!'I]!V,6-6?SAE6Z\[[W5UB5<XOW%A/"QL</CY&-?2;R)\+(B<MXX)VJ<
M7V>$'F*H\+S)J6@U1X$2J'@G[V,1U]X078L]U\',SCY $PT=#LT9_DIV6#>B
M=VB1;8EK!F2@"1K6%8< X'G([W7)9_#TSZ85'W531 \$@/\&I>A!?/A8K\C2
M<3LI7,NFV9G8->:NLI<L;8UZL=K[J>(S]]\J/NO3<:Y?,Z72*S?6IZU+6-IR
M)HSFK ]VWI@GF-G?.SOLRCDO$D$ ,>H_]WXSN?YD);?2N'T><K6+U6D4' U=
MZ=T8J2 Q=-3>5.K#T25$$#G<X=J^UQ^[Z58#[HDQQ&(,=AW=9)O%$Y'IVW+H
M]E2O5A(Y]'!ICEI]H%=J;,;<54_$4C!UX(T\%&9U>8O,3E5.(."WYU=+,MF"
M-GL]]0+#8LS*_Z9$HJADM<^!,(+8*5H>B74^8Z<5!B&_3#(KM6_'>-!;=-FC
MU 4=1\'PBSCQHD_P?F5[3-&&R0('X[Y#W["^9U'!3@NF84([,7'C5I7_KL/F
M4<2&R5F+\YCIM./^[5WH12@C"_P%,$]O[-Z;\Z.^;*)2G&*R4KU#6!4RRO/O
MZ[Z-OK.BA'V"%>@6AB"27:VT;W0Q#EZ?3+_Y$:U:@(=CHAB-]9M(2.?3V"*M
MIQDRW( )Q*"0!#"IHO%$J5T:TXPJRBA-#$?Q>]ER=N[E8IJV/FK!Y_W73IU3
M#27S"3&+P.$"GT*^PU(L:1'NR Q?^;<?$1$BDSW#I^WI/[)D3C0//+<)7_")
M?C,$?83ID<>WS>9WD2>Z:LNJD>G!BD?-44%AYREMW$=- =WA[SE:5\/[C7^\
M6VE7B,PH:2DZEKR6=F,>A:][TRB/QF6V#DB^DFO-SYU9Y%ZD4EMEF5DG9]2^
M=X"YOX #C=4XP4NQ$G 2,'&B.WL=)6TO8'MNWK?2BL"W4 L3]>GPQGT8^%;]
M/?TX"V>RK>+WYOY54:)^>/ZM\JW\;OY8"?Q=8C+/6X0(YSWSVG(?F2O=Q==Q
MHD#,RC=C 3B5:%#AI?N%4>T17F!LTF<=;R=S)EYTVMA-!B<%\:H,A8OU"@<_
M-UE/0U!^R31&-6US-=?AW#UUZ*)RZ?'^%&\(-V29K6T->)D_W7G+-"?8KM\]
MRJCXN@C+#5H4AM! !!A^+A3D*X5L:9E_G;>BFZ2AMXN]*)1)DF[5\-PDG'DY
M05D&I1 !%CM%Q7"LR=AJ5J(D/G4R7.VDBT#;.J1YJ**X9SC60'Y+_0W[&CW-
M%D+2.8N 1H!R?1J#I!KO:A+/,)84!:T&VGP0>:#%Z-3JCG&W2X&WX4H+^H"'
M3_ZN(2LNGIG7!R'9AXQP:A.;08TMZKVDI6.:"KW=(L>XQ?F 3.WBLT44&9I<
M3>EY=H]NA[[E2.O1[0Q[=:>^$N<6O!=!YXT"<G1G"DWC57-A]IQ]:%J2IY<X
ME%$D/#I>H0EW'<WLLCZ2#/8N3-M?\&M.)%R \B68(03:".1LT3%Q<P%^>@42
M,/7K26E^:[+$/D:"&+O:I5P2J>D'TMW2**#3 =8<:6]XV#* ,55Q:<0:<@OV
MMM.NI8\#:M54)6>:C0PT% QS8#:*PN=-[-[>MCV]' ED,;%'O6?X:SBP(>GG
MWB'.4!.C$C@ I?^B2XVNU@TNH2![V.EY%T:"B&8DX&%.;>$G8^:IVUCR*P@@
M([7EX4+JGF:6_N')P#TJG,QZZGM*-RJ\36\/ ?@\!3>Y/S[B+ "ZVZVVR$ I
MNY:I4KA],JZ7WH+:Y;) (_)+X-L2+088)C"6+3;XR8Z[FB0_CK-(/W^RJYN+
MU$(!_?_:V=CUL7;@Z3&M:HHH$:SYYJ&N" GONVR41,C>1UON&.-0=TZ)J=8D
MC*YK.P6%BB&ULKYK#0B(Y=M1[K#/[*@A/QC@J0C,C5U<E ZP]8!"\*#?4JK_
M^I+_U+WT,!1P-F!Y;H^RVS*+-WVL8$3!R!!1_CP]D5E*4O^/%!0,C35!^):.
ML)#2>[+:E[RQA&5E)A$]DBHNC BG7",+.U-78]U7E.O2MV+:5R:W\> 7/51?
MFP!L*\$P>9<1?XD*B)!*./#HHZW43VY."5>SJJO$GN2=.79SA><E;MQXU3P,
M\;B 5>>47K<ZC-P#QVV!%$FH,9$_PK2;KF3POW.\VOU!+7AY>Y*DO033YU8J
MY\SE%B5?]RT(;"U<66#,*>JZ^N:X7H+&X'R70S<0Y[ZC=_W<'E[H\T/-F142
M<T.6C2%<OC_G2M"#;[3.X4;=$ )T10D83UO[=05='B4#"XJ547]VYVBB 8]+
M7/^;6^-OGJ@X,!-G)\<UB-.#P>KU^$Y2S_4&Z';P?$Z1D!#U,5>ZW^NKJ/!T
M"%B^.-2\$(C)4W!/!)F$L;';JL^&47TUR%QG9MN&TTO6;P[6?!;3!WQ1()@7
M0U1Z$&:G3Q$K');VC;&F^46*)J%9):O18")-G60$D5N$6/[0)C&:I)0\$EW@
M.DIWW;5*XQMK9%W;U2#I]X.KVB".J^>'H[8";6A^O:AQ:>S/)UI0?QQR!>F^
M_F$T47/HE%=0]\;#VZ/Q5/W*X*!'10OK>JXW<".M53+X09;PE,!C48DEL#\\
MVAVU2T#U1/ A+_#\04\ NE)'NO&@LB[P>4\I5 \@C2-\F0C8.ABU$EC%@RU+
MEL.P!#R5) +>*,G@Q(0DIC?DJMM[KRVFFQXO4(ZS%-O9EX1JMS$K)0M V?JO
M J7?];"68-@N#(]5JW26V6]([B:6=X](",[;X3OU0RE_#(B_24PY%SRV^I+&
M_U+CRYGE '%_=!]6<GB!)NZ,':4,PI6) 4P?R47K^0@R_XL "*""M<HZJ(6C
M)CFOS\0);XG'BQI_KV=^9UBK"+2<W#B7:BE9$3.S6]$CT';YIH$?L97RZE38
M;9QT3U]RPN[P@JG.+N[1;9.JK=?X"-NU"0_'X9>"0W]2TN!C_P#20@;MW1Z^
MX]%'82DM6]RI9H2*E:VG"9<X[35E'CTDW!I@[?3<JM86 JCDZ6F!+'EN9<H%
MFM(;+PU2*X<.TH.\ILTE:',[/'??)25VY+:TG,#NY<]V)K7CFO&[6Z[>J(I@
M'?7I9 @X:#>@!V^-'=F[H(HK\=P&SO80]WX-4<*$FBW\S'LW*$.SGK28%9@A
M*/9+*8>Z@D[WYT<U2MVI?XG^%0(8*65X],;_7T0XE/_:=_->.H(^L-I9@OG
M]*4J#$UJ<.AFU0NR:]?QCEG3JBLW)$[N&,E=&_,;#0I8GV&M0XL,-&WPX\XB
MO'6[!@$ [(2O0X57C*Z-P:!2X6/XQY]"2G-# 8^^UD^_9?_RR.Y_ZS!G?JOD
MSV0+^@2_WY=!+R;WQNUCIU2*;WPU,-Z9"'\KI7KL+ADJ:'3+2TM,_]'YQH'*
MHX1"_P+$BOQUK?S>>IPA _WYY(4"RKSE29=YD>Y-_E*7)=!#A??3R@<I!&K
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M^54DT(,V1VE4(\RQ/I!Y^QHF/^]QN^N)2]K-STIVPU)[W+"CV_]%"?Q-"A
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M>(;9L+;:VL)8T]3,-4$C]@UIM@6 C7 8J.*I@Y<G\5"[>G2+G04!M%6 3G!
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M]P6;=R[O76IBK)0SDI3"+(9IRAIOGPCW%C.%'*XDO"G[W#B60XS/<,TUGBI
MS4&G3C6DFEW9L!(<;P+Q'>6];_F$//D.TX3C_!OF[>5,T;6L6*T)ML/&%SI-
M(PQ<Y!$9! D/Z-]KM.Y]>ZA)29-Z2$DS-4.!! P&&$_>9+'%@#FF10+#[RZ&
MM)Z/<-_Q.Y9R0;]D954[<1(Y*1W2'JVVKY G*F'[.)+H.,"J=/[$(6!.[N:"
M9N(>]><M'ET5"U$'K#1.DMF0)P0,7@#%>?^SU/3TS F19H+Y3>;G$#=E&W=;
M"TLDX*J9_$C3?/J\Z07>DAP&U_UIP>$-^P;&/&OA(FNGW&8;=D(L$FGL#\>F
MU!TBUT7\0@I,=Y' H_(8S$BXW>1^)P.&7@#H@>GL9_ZA1Q21Q*.P^EY;PAZN
M[S[E!T*%]Z<YO57%(A<;)S.6BKR?RD_>*"F^'31)&E8?A>:55_DN%ZQ*?E!2
MO:N2FDX^<N!1NCU251Y./%"<S_SC>CQ[AO= =Z/S@1J5G1-SBR>K#)_M40)A
M<2@]7T=LDSHKY=D.T58&FB5$U7,_][R,Q"4N6 $)Z/;TRV?U6\OGL^9F^]3V
M"K9GX#<5">0P./6*=3!1A.^;J7RX^#S0Y4:\?7,]>6)85-!\<;R6)&96Z9BM
MC"WQ*;E!R$?UWB/@+7'%7RV0>;F9,,4I%C]1;,4&'NSN\Q# N)7GN7!VIA5/
M="W^J-$>X2O0?$().IFEL9E$)5V$J*3+MQL)A$^6_'_V/;W^%H<_C7R5.3TZ
MQ:@4S?%V]<?,6U*7N1\_UN&E$^LY^KJTV*N?-U7M\&K-[5P&FS9VD3=][<.7
M.6^R>8GRJ/:'[*XP[:<F!; A]T5T\(L=]Z\9#7I]U$8:'D+B 25>$KV[]3%<
MH"K[?=Y44)ZR@1! ($DN9I.TBWD12@":5D("2$!I]0K2_WXFQG?I3G!XAW&J
M4Z22; "#="@!"S6V/T ]?G;_6OICG:&$I!X)9]>-4XTJAUK&:$5Z.P7XQD&!
MNB21[O+CF-7BM)+^^C:R#WAZ=@L/-UW#+EDL_?/ZT3O*>PDIJ3)O*Z6^?6^Z
M6VI0I=<W8+O',,PFG*-?U>-:$5X"YAB5PLR(NV2IV9VK('*0+M8O]4I"##^#
M0=*W!R6[EKYH0UXY\]%::-KG3.MN"@J_%_@"T19!CYP2T;9L@7?G*=,]A_E\
M9FQX80%@J E"&+Q5T:?P/VW<;4HK2,IQ9>=E&:K38=!X.TQ&@A,+Z>L1^NZ@
M->CG4')"KU0>7  VBW6.9*4ZN=:U_5JI@G9A(5YH*68:#XQ?,=M*W'$=ZX4Y
MM7[0M1M.T7X;&A266+T!HMOS:3D[GI?>6W&V]+KI9UCI9/ 5C.MEN*U8KX*X
M&4Q$ M8IG>T<JK3$BW*LZ^R2;&Y&OWM<SM[J81XMVAEAQ)UBIQ=CVKHM>9 _
MZ[/C^[FA-AZ[DVURA37@<1S#=>'SNZDRM[OHI/RB]R,?@SA8TW8;"$*3U@6F
M2/8H6!6D9RP\S+68Q0OP,C/4;/(R;R*&\(!]TQ;:9<M-X;?/,LPAITC @71'
M'!5^B]N7E2C+ G2?LN&RV#GE9'E7T<"',8F57/=01.L1S1EQI_-AOU7&OH8H
M*F,U/L>_Q%[R$?;\.XA_GH/F4VP;T.%1QAD=RWCQWT.25_^,FJ^7%ICQ4['L
M=S0G<!B[*_NFU<>%+>^5V@VU(]@K*B"5@9VNXL_N%"O6R_="<] DFHY*ZT*
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MK*C8O)Y2\\Z&?9=^^-ZLP>:F\>+SU'!8X.J@#0\26,2=W0XW,>/'%>=]J>-
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M0#:]:8L":(B<TKG[&'H@BFG6%M'@KTQ@WD)] F[R6"OR!?C3J5,G+8H.5:;
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M\LCUA0A%,MKS:Y-(H$TYQPX-OK=?^K6U!?L:0ZKQ:SDQIRZKT:VC.S"=F=P
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M*K9LJ'P(4.R9?>FM"VEJU8TK$/@!^L%1=6CD<;B#/^[MTU65NNRM!IFO/;K
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MV^M8[B@>]! X1OHNRN]XV_\,;,5B:5Y"5W]JYU?S3Y@B?Y[@;\2/X'X#E_\
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MKSN'S_U'<5W9#Q5DRC9$;E$^3%=SB><P)B8+BHAS3*N\5R[@,ID/LRNX%7P
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M*UQ5J>3?B8G9IO3R\WZV)#G5@\D1;+NN<<-Y0/'=/?P8MG.E_9X6VCMAYH\
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MLKC1-'AD'UGA?;7'X/6>:%;67B)L@*E_F=%CM08%#K *+A(OS$&;6-NL?5!
MM4"WK>9 X,\ H$W<*7, GR&/0F2__FYZ:@@*K((,3P5.^BZ3+Y=!:T?TIX33
M+ZY*;*P0@JU\*"!X#FK_I5GRMX(5"U0U7NHT@V^??X8"/]\;WG^W,!1 =U*%
MB>P1M@@%%L2/7AR_ >>,YB_JNH+^452>0CY#]K$.W? O7FZ+7+'KQOZP]@7C
ME"[$^T@@ZFNS[''0M#XDWZ VPF,5?*5K*'ZW-,P7/N7 1.9OW0/OIIZ+G'<)
M#&VH[MVKQOHA;!M\^E)/_0L\[?;VLF;"9%U-OEV=O8;);(/Y,M%PD#P,PN8!
M/N\"?[6-ZG3@S]/KGVEC\+]>\G^?EWP'\7<N OK61D_!+B_.JH,@HL>PU7:2
MBDW%WSB\W-%=YE+:_EOSTMTYJ<C)]KOI$89 !KHPG?F&T3>>]M^Q;_/_+$A(
M9IF\BM*NYTT'&JD8"=]@N,8BV&H1UI/V?5KVRSW95QZV9F!J:#7AB["[,;$B
MP,$:'W4Y,URM6%]SW[>90%3]H>J.]XIH M:Y].9%=G+HJZ6.-+%[=[+\T[+;
M74_!=5QA5Q1<.BEEL!HY01R6"MNN*))=@_BJ?ZW>0%<R"_M+88A'$"S[^K(
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M\V!#"Y(UBM=9-_X.:-5M9-AM K+U7_L*\?9\K#OPGDCK(?6_7[]\;=GZ20)
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M[B0SY7Y*:!^T9.JL,2?PU9'\VHZV<'[=>-U /<_(Y!%["?:^8Y4XL$&?<-]
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MOA]9W6\_;ZT'2F.<UP0,RO!-HS@=T@VZ*(]<5S[1JD[]F3;(.-@@D[(O&7"
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M12ACOPC:-ZD^&>QY:MN.F''TX#:O"F:FBDVD.J?>7V\-  !/[65#;_HZGF\
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M#]_1UQ)//NK?L=[W(N- O->=".S^ (K]YJB8TFQ)KF QRVR#&6U#2._D-&2
M.J!3#[!V43K@0-">&DP%P]@.U1*28\"&;D1?2C(.]/S%ZQ*$VTV_AK.\)FL:
M'1D]/]3>OZ?OFGD 6.?8&9=E?.ZQROD$4> \IIKP.30TDEIW,Y*S.NP<PD4=
MV+Y0+1(8B]Y3>OIS1!AMZY[>@+$A]D OQ"]-/M9ML44&JY)O@$MN3/[L\V:L
M9PW*Z/5/+SS\3Z3\ED]%M_8U6UJB(2_H!%AL)#EYL?_(T3T;,B4TM8;^63$.
MNHRA- 9)P[M<3J)/)SC[=V$RJ3!-X@/1MLPI]7@(<6^RE>*HQ05@:=:)9B0V
M%IT+GUA)OLRBL:4YMIA8F92A(IJ<!G#= 54P0Y;"6%.D3U5TE>L@)7(NJ9N,
MM;(@]\Q&IP< @5!I2]KMM]*)EH1V^Y6/]4W-WX \!5%9)^1RQ??O2V:Q6I]A
MX:#@_"^7Q2P?I2L1S,%,%N=^&MNDIZ757K0%(*R=QL81SVD>0_8 L %>];8D
M*O.E\HX".%W14C5E4H_=?J^L'@FM@#G,PJ;I=*13.VL27G:^F[GK'\$U+P4!
M@%-#H&^(C1#1(GXRMZ"\:YNFHXG'@[GB%"+OO'<F3Q>;7>"!43M;"M@" 7S'
MJ^Q3)K8F/A%1VW4_;VH.US=6<8<;.$^A[\?J]_1A3$5UOCNDGXY=20[?8^0/
M!J[ZN9A=BZ0V#52E& \PUZY9RZF C&TL/9/%F0U<SBBT\/PT ,#:7G+W=+!Q
M4KI0C:! 7I>N+ZZRJ248G!KNB&2QE!4RJ.NSQ?S)M(X#)?AGY_';__@87FM^
M>3K%2</"H+QJ@*LY)9I3N/>TENII.]J)"6-$IY@+S.GWIFW:8^J46&V'F<?6
M-[L@HR]_%ZK";/XHNCO^DR6)?>0DD= X9OD9K8]:V.' 9["FB# I(2?HG?^
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MC#'=^(0!,+LCFN8YP96V6,:KNN@^).0!\ E>DV-E1PE9O[\7=WRC]LS;F\[
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MU'NU 8E)"A6*\#6^P<[0 6O^*36AI>NK0>4KZWFW[(2FK$2.?M)G-D\ <XF
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M(W=XL2M+Y@<9HLV*0\<@,_?DH:*Z$)HP^YJR]4$DDTV2L)@9GCN@X?&(9XL
MF6D7:U" &J-A+ZG1VPZUOH[<OFU0'"Z#'6O#-F!BU?*OC7#BE_1?K)4YX_P%
M!/2$+NJA\S'3]\TI^!\1@-HC$RC5JF&21R'%PY11E1ZN+Q]C X/P79]EF)$N
M7\2)]>=4_@FS5L/%QGNP)PK@[9;RJJK:ZM2>W;<Y]@3>1#78IWYA9DKDF]^:
M!:U41=M0J/-J^(@ 0LGTX%^IM#'.T"#_ [Y[D^6KFX2[G5A;N%L9YD<,E-+Z
MT+&&-\WF@A+]Z'(:M7+<#A4E-)WHQ0M-#J2\*3!2"XH#:(EH$X$G=M.9!3!0
M%66_F:BPB?TH7BC^?9.+Z7KL('V<\!]R!9N*,IFYEE5+A9YZ;/KCEJ;)RQL%
MG9G&?,495[LW:9J..,8D[;5AB!1M31<I\TRP[QBA?HD=L@/O^M X_6XA&KH+
M\BMV\+VIM%S/Y<#B<O=6#6G* '_?!T^^?A@.H<.S-JY@[N%:7+31MRS5UJ@R
M"5W(13\=V$4L46\G? &BJJ37UXLL 9E\FN.L$5G\/CBW57*SI)P(SC=ARWK5
M>NC+["5APT^T0!*>"W79^H"+(UVYLBK9Q27>MRM5]1<24NRS2V-]4W[X_>I8
ME76*WY'@8F<+$7R:.B_6*ZXL5MLE,L8C-ZOIH9TT(3"F;S"EM6K\G 8MZ@.'
M2BAI<97Q'FWY5=CR^,F"F'4-J> E.0 CO-I\N5CPJ8O8EC0[L(;'1',E#-E8
MR4"FFRY)TK/@0/YIUF%]\8].;%=12;4IGGT"41U"Z89*1I\^FF$\3=T2@MH5
M&JCV]=9U+9S\P7^!OSLB0JIBT"YGTG\7BUV0DD5AYU^!/3N8(DV+^C/S%#L]
M2@8>Q\DL*&.DS9JA&/78^YV6-7S(0V7O!L6NVP& W51%$P#*10MN:O=,U>VT
M]@:BE^''\!BNX%?@&%W+IQ-X4ZD5;J%66?94-LD(M["QECQV(F XSTFF@L@.
M\*BU%[+6:M3)G[AEZ,CT*@3J/0%$*WP6I]E7NJ&\SYCN\&/6\A?S>X64Z?J?
MVK$OW<5(_9_O;;EWHXW'EO(L"A>2/G\&ES6EY0ZHAHS5INS5@[U9WF-QM!]:
M1$_FL=-6'DT;E(Q7V65I8M\R95WE5GQ5RSN<!\7%O>LQ\E8^!R^4[Y0H1!];
M_ 5XODZ&AO.J=GDK?;6.]]I_*ZG+?'J L] 7DMC&?+KNZ3D6C-O2,\<6MOC]
ME,B5HFJ&RF]_AU5+4JU$>DJ=T",S[J$6?^!$@X%R1AR#XZ/MS?7BWA3EC(36
M9"8L0VJ[3% 5F""P<%E55&G91- 08PX?[^Y\(7Q]73,OK9%[(U7+G1!\/HH8
M[+$>]#ID['#-V01).8Q=W]1Q4&2-<9U7$RIDET7#?3<T$1U4^\\= E;#71#R
M-.W7-?1E62_C)33P>&7HD(S+IW0%)*-$,L;[+1UU$$VK$*P"T[!,6$R0F)4&
MS5-2E@6:P@/$S7601:>Q;@$5NQOU*X2ZRD8I<>M]HC='\4"5XYB:=#U,:&-*
M4(^W\/<J-'ZT0M<\.9KA('&D#R;ILH ,[KAK(V0O(R4<RP;.,QQ@+2Z7LPZ^
M5IOQL3AOKH9>1!L35BJ@1Y%!C9:%+1X],S)V>_%,<>56R*P K1X$5":Q(N>E
M'47Z!G*]86*[KAOLG.Y#<\J],G:8<D.9$/?SILHA\^Y3]@Q-C2A3P;G[E_Y%
M2%SE<R=GN=W!\AL&$_8SXZM,A@71N ;E UF&2?.4$*/6:#6((<\0@XD940#&
M?*EOJ];+@2$_N:4.[=*,,H$C</('S ,4:FVW 7!EW?396,UF>-C%A^M8/]&-
M74'"Y[N[M$M:)#5X$4)-XP$J7^GXQZC1.TV6*&Y&B-[7J/ CR3<Y=>YZ9A1/
M_8YUV.%8=L86O4!W>YH[FG=8R^]@X$4/;87&"IUA=?3+0A@/1OZ+F)"E>)/8
MCC]8RRV;_RAMG*K-50 TPA3]+## 2@PCX&B%\1U6",-? +O%!B3DPEA5&@_[
MW-UO> I#<'=E_> C$I3FJVZL-\8NMORZ:+ MZ7DZ-\=6R.*;VVK%!TA*&]'[
MCF/+-(WG;"*R"^P>CHNA"=8DK66LI&+E(^36+M#K2M4^O?>TAR8) IS 8S6*
M)C72+6N>AY&OA&,$%?TK:%;0V!"6R8:S5R;_)"EN>Q<G^OO7':]@IN3Y/%Z,
M"03]0AM;W\WQ%(]#*V8D;P=0P_6M:GJL(24/6^QGMDH1HJ5 ^P5!?36JCT:6
M,G.SX;S9=2'W :GA(8F,=2<;!I4EO.4[US5#IZE(EV/J###=\]\%JB]SJ"]?
MONMRRHPNFNYZ(G>E=E$T[!FH_F'QAYQ >6_=X)MD^#F*_=!FNJAJX\LO/S 3
M>]S&R+:8FR"(:ST]^NQ;XA4A,<5VPULY64KJ'+C<SP RQ@\/FLY*X[1L#> -
MD5<T823+_B_;A?1>N[JD2A/T7Z6" ;T..Q^?!67PG#U*;G6[^2&=GTX%2JL7
MD)Y&V^!%AX$1PHV=Z75,TY?3#L13+069X#=#-/,OWM.1%_=+]!?502*PB/'0
MJ0Q6(QW1%9KX?P&NJ7\ZBTE-RM>%"Z A^RCPW9^1/I8TU9Z"V-0M\1UFDAXJ
M2:C<$W>?;6++G]H&UA8J.$-<V2*^DZ$%?S(Q3EU@T*+!'@0IE)QKF"\9RV#!
M(59/N\4U)_& ]2_@O?=MS5_ DQ?B$DFV<VVRJR^L-/HDYG19/U&--FQ9$P;Y
M]RA_(R-N?XQ<!?,$>JR.3N8G,&>[8GU/6=J#CZ+=:UXP#)2N'*9;']8%9/MN
MY,AI!3O1;*;Q:<J%>TH.!E[PBQ2)>_;T5IX]N6A_\UGN<^&ZZS,9TK@>W!?1
M#^'[[3^[,_0T VD/OM$4DY:$WB#+&77_7Q.N3Q_+CCFL8=UR?*SNU=._@#%[
M'82$@+VLIQ2M^(!Q@#MY2O6[K%=5M2V"P^P**E8PEFP)M5VR.S-@*';V21SM
M-3K(O%I7._?:55=\PCPFPIM$LP;AM7)72U-/RUS!.]#%X;#<8:U[YR_A>?K$
MPR6Q=::'",1/%$0XT^MI/CPJ> <P1FI.@U[J5HT::UJ\96'62N  7._GBW70
M@(X-:@IWCN?[,@J"C=3SN (A*@$0PX_ZEA$D/ANEN0Y(5TWZM GU-DC^8TT+
M A]X')Q"RB6>A3)OXG2-TSRVM95(@G?)"MV0!SAJ2[GL]58O^H8L8^25AO<*
M+]>I5F'VW)S9ON*36>NK6A%]JKA=K\[J." >E:.4>\MT@W+K\ZW.0YGL\7"\
M/:$*<%]U><U5'[*0]'@ A&AHQ/&3+)DT'L_(P>\9Y!A8T@],LG9=>>Z"SG32
MTI+3TU-<XV/)-^=UAW5GP$<BK"I9[%2IJ%C&68Z FD^LH*VNQ<#S_%P-PRN2
M]\L]CS;R085BCF4"6KB[631LE8G*ZIQ-S@[8^>9V#XN-&YNO.V\;Z*:\ L40
M(W/YX)L!E%UNUCCP NT8CN+8$?=:4^[G)8C+#U#6%-!U=\A/@RRT6>9]$F+*
MLEUFIU1=WT1<CW/(NUC>-IJL\QP%WY0C!0B;'%D/Q)":9X:*6SM3F@@?FWT.
M\"^I(UZ^]+?KO*+<Y.3Z*O-(#HU"F65?ZS'7VG:BFO'M<HMVYLB0,N]4,HX_
M5)2!ZM+3.X?6;JT_IB0EA@I(\GZB6-/N"H\9O<;E?$";';NO6XYX[][.M4X3
M7!AJ1L6*$_DR>(EE3#Q!^RV\%%&UT^4!'E'N[HAS2A_>+^\*EZ!:VD]S'4TX
M;9J;BRPYTFU%2  WXN1FL^7JE-T,T'WD@U8.V@@A@142&VNZ?.PV4$]=8)-,
M73&A]>1PA"=L -%1VW$F)&T029<MVWLJU%%M1$C?U.? L)^\B0FN)7]&^=-;
MWD#TV$;L;#%.-F!+W3 1*B%C/% WQDX.&':HM(RXB)&U1ZUKC?OUQO%L788L
M-M<JS^QI0=(165(=8R \*MLC=A:2LO1#$^@,[=K07CT/NL*U39+:9H<M>9AN
MU*H9;\Q7= P(]N\ECIY=Z##_T@[;95F$#C&ZRVQ 9GW!<_8UI^ZE>>1D^6NY
M'\,C-YBG8X)*Y.__ GH4"OT$)N\9,ZZ9M28^-YSY3;'M7X[JPPPZH)C931]H
M[PYPV\R*[XUV$'SEL/$W\H+ F]HUK\(M3\>C!3[EQG%J*@:H[\92X& 12;U'
MQ+-7O]P-\JBO#,W<+$B41?W^F![FJT&BBZR-HM& H,KW/9#P\P=5?8+C",9%
ME[[F26]-3Z9?![1WWNY5OUYMG3CHZUI9?IY5KSJZ90I5+<C]W"C^W4KI!X\W
M1)'2W]M*K<\4&_:&!>#/Y5:OLOG#Z,NCZ/PVG"M%]4HD!:EQ-^-@LT-T7?YD
M1"$+$#PZQ.WT?EA>TLT^:.@(F=:<1F-W"01_',J7+KMXG_)G[@V;JL!1E T^
MB=#J: -NKX*7#(![-:4H&1!V^&:SSI<T@6>+6G"#6?O;B9JL1G).U?AA^@+5
M=V8JS_U\HW/7&%J.)S4\GHEZ<RF5C'SS/PN@.\=J&Z$&6-&[\_,8L=K_]8XQ
MN,3'TPWG,?>WQ4KL94J"-R[^@7O"<-'IB\M:Z=E>;_UMI^$WEAZ-HT)KQQDA
MQGKJE%^_"8W7/J<2H*T.6**%N;(F7.:[S4!>6F)WTB-M>VN,)^U"SL%*W P.
M%U2Q0VAX]<*IZALDFG#W _A+5_4/O,LJ:!ZC6V%XC8815(+-V,,H='?A9+9G
M,R7KZ5X3O(W<TTZI/HDVAV;3-#AU_,385U5)9D^(&[-^2[N'BBT.FOBV@(&)
MU[%>-NO4+S^T(1^'>=%4J5B+.>$94U9ML]!WMVT0GO@4OQAM=0V'<?L<YE,G
M._7B.HV=E$4G]?EB\LXS'?[)8+$MY:=+%+P9&4W\&:*P6 T1K:JC(,[<\NS^
M&@.KK69W)+O(?/T U-B)-KGE4%\.[EXE+%EG3);YC1TRF\(S^":?."W4I%FE
M-XBQ&EH"BP'3]>UQ:OHXX'P6C$(,@]Q=R0_(-(3/S++5#*1KR-:;28+_123'
M<:/65,-AV#Y;4 37B3ZTG+54]<# NA"G[>3P%C:DM>AJW]*C<57=&/1W_N0[
MC<_+2W25$DAGOQ=/."X.IJ&1,#?3$N$?1EAB;)0;/!DOQXK6PVHZ-&'G5&H.
M.!5%:S)\B<AL8=M-OS/U>H^7J&AM!Q/$QS95GT\OH!E_-8)(3<EZ[21U:+2=
MN] $$N"Y#9LF%8^@?_G6*<4MSF'6&6Z3'Z-+4& @\8F4Y0$UPA,=OU]J0!G(
M69E,:+<9?0A*2V U"I8+,2G?07(*]V]#K\9J.&:ZGCM/(&3GJ\@%:7P.];*4
MLI*5.XT7TXTF^%%&W:$$,5;X>[O>X6Y'OA!C5NE]6&)HX@FEF>8!IC%HJU$C
M7W 5%SG.*#/O"+>=PA/E(F*G-\K%HIX2Q9.N)/D*GB=CJ]?31 550!V0@J&F
M*V1%_G$Y[')&:OU1TE/\HR(%)+QR3_L3=462-/19KBO&/3((5#E(@E!F2)7D
MZ]<HC4.6PH%JU];9R@-IM,4X X&D$&6H&,-DAE#C[[DI61^'*6'].L%P/I.,
MYTV+-P^?;IBG<V7\*E%,]K_5KRK:L9H8\>8+-7KQYK.[-/Z7WB9U]C1RS%;I
M']&2K0A=_ABOL"OR%_"?W)GFBXND$/  N;9LE#T(GFW7.+I(E9MZF)@WPZS&
M*J%D>N:.#$]Y?_:'0.>#=8()%>N-GXX%]5/NM;&?M>^!)IY*X>;?E YU/HU6
M&CLT9ODR:V0$C=5YF<>6WN^S ,>8HBW&A[-I#%2(-[+3[M=N1L^$Z#BGG1J'
MJF'=>HA^=RO=\-AQO5^.QWKH1*X,GRL0&3SC)G3S%?Z0Y6DM.=F?"N[=V_FE
M*]8 %%:-V7V"B3H"#Y(,)G<\N@TENBIOPK3,V"F+M]-@L6B LL%^S3B8@:[]
MR/4)[#-E+NV;2B8"!?FXM%7K #28%Z*'KSD8JQHU\<#Q$!KAS[:J 'K]"Y0*
MXRHI<_MS0HV)7[<LK_[*LE#;,=1HTXBDYUKLQS/&5#CT2EN7"^Z8UH.1 "16
M\UBZA\&;%8^U2(*0]HE%#@#O82/"0+PS(M-)<K=!-I_HY20, \7'ZY+785=0
MT[^ EH_*E6QEPD(*?MM)%+XT.P32<HO%:2&S9KB9!'92$.W4T;5W-)0^\)*G
M/78?W$K)UBI&0B):<RNP%5RL#S@+*!B<RP'74W*L7HKE(L1]UP[R;>X_3OOM
M#.SLRM@*H^JK@;PZ$+TO[0U:ABFM\P L3%BO;!T-Y;#B19QTL56#9;YK&>5(
M_./;LZY4?M2F\<")$?X71F["K$;(6!G#_=+'%HVO[[?=(B8,[#!@9ZIO36DK
MW]VBB'0*R!"RQFK< #3;KLQ_2YILHBI@[.,9Z8'RNL?)LW\$04#L/US?+^U_
MT7P?6S9[<13&85-DEDL)Z$X3;7O!_0^P)PO^ C"7_50#LKDJ0[:*AC]944N,
MINA1^G.B](/IA*W\U\/UM3P6Q,>Y*\FP[N;+#5'C6!>UE8:J-MFP4"+<;3MZ
MGX'K&C*.H5\K&+I7&:+0G4,C@<$VGQY_L1/(F]=LX?-J'X.6' +Z[*[LOR)V
M8A0(FFGD =*<)? 5J8ES5;^%&KK$"]%,:UMD:^*&G2WG>N_=KK%N5W51?K1%
M8T]V0X=W:/1&*_03/VN9-)'TV'=W>X*'*+%_OT$=J12]49Y:!;C2()12QB56
MY3]7%+XM_W.BX@/9JU)5Z'DS7Y+"VB%7@&C-US9<R7)"6#^5(%FI(5/GMLZ1
MOA5_FO74KB#4>/Y4S@>^FRU28%/O6C5^9#X46S@J;JN=D)60AF?;G]C8_.29
MF-SKV5T[T.+Q NJ\V0F/S/,Q"7DGTO!5$V6Y:JB)O1L@GLPV]89;-IZ]C&"Q
MK<=MMK8\.,K_IF[A5+&_WTAX_&?%9DQP^4SD<BX%;X.O1H76G.KM.(.W[()3
MISG;[MZ,DLF.)F>DB$-V^=?W]J8=Z3,3W68?<,%.#TJ[393$Z=%CE%L0FIT
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MI"K31.&85W! '0=]OG355,/4P'8]0[A;.88B%;I/&@^FQ<+W35SJ^-=\^A1
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M<12O[U>T(COE$,?7-5G1T;IW:"D [QM<7M&17QG]5(%>)4Y2LI:!*H3!<L'
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M0+&KC>3-6Z.^^@GL#8]-2Q*7NDT";.8>6<T8B6D):D_B,$N!Z-"ZO=F64:6
M0<$A=0BZMYV]\S6S4!OPN:4LLTP7I$,=3W.?WCB V'LP1J8U5C26$NUC]#8^
MDJS^>E3R%9O3<4)9^R]X7)LS9<QW>6>(W>*EN,*FTD0'M[C/M6X*&>CR98+J
M4=Y"&1>R+(LI>[T"+<7I0XR66N.W=44 N,P%]K_4+GI3A1+O/]V2R-2OKR?K
M:* PGRCEONJ\ W@&B"37TR:UO/=C'QN_CCPAW]KA_=].=(@M=\YYPM]>K;7T
M-4RGT7-UKP)_7#39=KC^YQ7M?RLQ\)A@&>VB_3?-"ZJ]S-_..$$].4M;'2:_
M]NQPJ%_>5K+M!65<3^)X;R$$BE0&4QG#J2U7,=$=\/6002M4SX/M$Z#WHQ(S
M^DOZJQ6]M,,:[ISQ'<:Q,05\I%Y1@;%L5'?$8SKO$MM2J>?3H#153\9XW3WW
M,DZ=KT<</]LMDL;S8=H%_:5L)H'H)!"Q=_90-)?VS7RGC ^'W"*1U+[!S^$J
ML^E]D_.&H#*UFN=,1#B4\SU[((Y4GMG*(4*%'9MYU9'>U9*^F(4:<$$+I34]
MW/H+92(L:KP[B6WQ>*82I2,M""*_3#?7AK;2GD*8Y<2$YCAXF&SHUX51&NEY
MHLD80ETJ7J3=*LU$G=+L$,=VC-;+CSY4:<^E/FJ<EO6<^H1CAH4_%G>0YMBP
MC:*502HAQT=EJ&:_1-G*5\J=[#HN Q5M'@W!AAG*(?@T:;8TVX13>QR(4_*D
MY)_##E31DS$G<VZ%K1ZMT4BH*GV@JH]-L9S;>#<S^2*2D'=F=L#\N1!M\F,U
M$1AR'5S08![N*E0&TE[1X^)QVC!\_=H4I##O@9'UO1I[D$OZ!/7XX6=\+NC<
M9*S6,X$342!VG: .AM20GWR!>"ZHH96A:F3KC"3.9V6\!RS%VLOOZ3P VEC.
MS\Q_O<$5^FQ!3OIF_MC@NXV!#'N7.(?%(7F)YY'4=I9A9P)O@CMMS<[W7,2:
M/&,L5]0/ [&I=JPX[S_V,'5#P9[^F(^%BX+BH [;MV\LF;".B9)5'U!Y8(<,
MLQ0T/V+^B5$=TFDWFPT70ZJ\+NCC+U=TPN_(!O#IF;OM00V<WBL[Z=! ['0B
MB?(GXXTH.698K=B8:@0LGW>1GY0@>+>D,Z!C$RZ"YB^SV,Z*.DN-6V=9U!>O
MX$,4??'>(7E//V^G?>I;9ZI0ZG-$69:@BS*YGKJZ$&ML&NC)Y #P3XLG=33Z
M0;YYR^GYS_2/OMP!O$L>SM*?@)T^"K66!^/KH>L(B%F*"?KI:;]]2W:]3M'8
ME457ML9WLV:?E3BW68S7?"U\9L>DF^%:O!\+Z4T(8",LPDV97W.G7'$;]/*,
MLDI<C9A4_9AJ<Z,9+'*X4-CJ:-ELTW%<^OM^.;\:]<':FU,0;]1]W*EM6*M5
M1-K902 EW'-2UHL[T6F/O@,@T^(Q6XI+Z^PH, &#WN]Y0(51ZYFO-+\XNY)3
ML^^J@:16#C5R9N:6BCB2Q9:^#D1=WP&2DQMUM%U[LR"5_GV]5"E=JCB\;/AQ
M^? WCV9\O9ZEP69J4JQ-LNO$M]D+CAYC!,^7XB2OO$N=:!I0Y4N=#QI7A7M7
M%RD7,(*$4 ]F)^FI:4^C'6G!\^<1.SZ:O<R;EF&M)[@-*2Q%NEH%9*K:ER["
MX'21Y&YZK=SF^)=T3,2&7.'O"3A^M"\U-$^8:Z:RFPB+BXP4_UD\,[_9M+R4
M%:I*?TJ;=SF9G3G#(T[BO_C//7BZ*65&1.B>3I0;1\4G^4B6//V,'_!%TYD<
M*WXA\ E<&OJW%$G=#I";Z#$1_?V^11(VDJ2.EW'1*'$0WQ][N9;<HY;HNG@U
M:;*T?TFQ>@<HM[]!Q:?1?6D8]CXN;?'ZU&WNS,R!O]Q"GM+C0G%:S#6WJVYO
MGE9:LL71VLDQ<%(B*K=6.E 99>9\6L2\R9I!LL?!,7@9.ZA*:M,@K-0\Z*JI
M,Y>'B.>R8J^,:#TMF[4/=-SK.2F9D>P8">.WS@:_E_5]Q-Y.332>)G(++G"%
M4:[3GJ8),[(V^S&S>N8-)E2+/#A>+3DK/2_U+3@'F_-5^B>;GK\R1$ZC%>G?
ME$91E1\]M-7I+1D+K*<>IUB=%5"3=.CKJJL2?;DQ%E5F1;M4(&@KKF+3ZYKO
M8M_+XJ+BE1&F#+9L(&XOX3\\RFQG1 P8R/WN194(N6U?: M]Z8C44E"RO0CO
M<B#UC7@P#,ZEIID"IPL/=#7OD'\JLG'1U8TO,=.?(;@:2R2EA]T.RA1ES,2B
M5=@&5"6FRY?)>.>E$C?8SS6=G$)&\FJZSIB6X1]/#U\*BW,,=_D^$2EV?AMR
M#@T)&E0[2P#H.!(K#5YKAJ<F0-L*#'2^4AT*$]7Y(.S=I]M)9=7:XV2M4#XZ
MQ;;KV+= WNBTI\HT!1Y0[75L;G&(3>)!:9UU[4UA<T9S'5E*D^).^#N^&&3R
M.TIQT,>L>J^,\1^J#N/";VR-MX@#7YV:(&5HOL%V=3(%%AH8Z<!/'7V11%#C
M^M@/(ZD=+W+TXBJ'@=G5E[8Q-='V/)JN4$25K>8O'_!O.1HU:;G4F8(Y(L^S
M$NPEZ^<?'7A8L4(&5:BWC"@Q2UU42".SDX3PX$R@_A/*M5S>*._KGTV\B;/
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MH"*JW)?R8-MTU.W%KQEOIJYGGE;OTNLR6,0EMR4I?I'<V"X]VB?YU9NWY2&
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M9@09(M*Y=A./O(TA9OKA&)6'[A-T5RL&[M=7#9[GJAWJB+J\]^8Z:1PZINV
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M;W #%#8G[S?MC+XFO,9;7@^A5._\%K=W2J8G9;<P=W'!4=BZ\E$KC\H\*"9
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MH%4L&5YG>E^/!C!=;I(]4$&LFIS(GOZV9&_O7S9!+!707[$:"J;8&ICR[SG
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M356 [?.&$MUO_[5"_MWOG^M AB%_?-XP7&<3(-_\_R1@L$G^*P(&L5=62YV
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M!0:G[.95[S7%#;I_79T0,4VZ5CX8P+B+I'CNGQ@[83>J5AZ:;FI?KDD[.4+
MB2T%;6>F^PNOU',-2'XM(+'RR5P_E#%]1&];J.Y54(36493& ;T,#9LTL+;Z
M)UW"@&^7JRO2?V5A*4;UG<_[]Z8BZ,$[Z"H<H(0/AIML>*(/QT3-2>%).X3O
M<  (CH%<<J9#8Z?,=6DA2@GOYAR+ YQEF!E0SR]<*9(?]&>IVVL]Y\P4>8WS
M:<HA./Z51Z%L+^FKI=FE(V )7^&XXP 6<:0K-L 5!TS+XH!(/P6ME^UU@.^
MK2<RL UQB:N/CY:3TV9$$^N>AP-.V[;A@ .""BR!"!K>>_,Z:4_#9IRO,PY(
M%H1-<^-OY_AYZD>88+:MQ*&( YKN(!NP 7A3" C'2L#^F$&PDCL,K+VD/<ZS
M&Y$N+5M::;%7B=]&IFZ2SMVI%FFE#O/GUGJG61:&O,>I>;^,U%Y!</GK5RM/
M*Q?'!N</=!HUA>,1QHR;8S-C: )*%:E!M:71"5-NA9I'U UU@-<4YGS2.1RP
M3#:%/M4PI_'3S%+9X)\>+/SX8/2@[8V?[KJ)4K"=DRJP<70JU:*X&K0UFHU
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M[_S"I> _YY)<!J$&^![^[*5]?^VTL9@37BIER8AQ"&&,TV7*Y8ZSD0IO9#N
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ME.8E%.)"^1UNNP??Y<>=6*7GC*SA992D9@W/EQA=;B-.R\9'D+ZLZ\#>!"$
MS/A B87U(U_]3*@)F([-9?T20?[6G>KL9VU>HPJ-DL(?%NMFDV@=RE] Q!##
M'@C6%_N:Y NO65EWDZDU,UH?UQ,-B:#TJ9@E!<Z:9E_B?9)!>*ZI'(2!9!N^
M1RI1'5?DF56-G5DW6(#FH5K]]&7OX,BH-#>NQ/VPQE,SSU"2,(/! K<"69_5
MD:=2FYD(UEV&Q20&B:2U'OIEC\M(F8H$S7>]1>#^F!;9$FC%YVJ+A&2O>*DU
M%_?2H\]G%O2' Q1$M(:$W2,O35TOCOE6]D&Z#=VF9M'E91SH;EIC-4,IQNPQ
M8G:[HXM*+O"1 UZO!PME[>'<I=5DP[IDHYBT4Z;,78"WOT-D2)9CCM?BT-=G
M#RXKJHLV9Q>R;*V:;B8@6#(6BX5W/%UYC1_)1N;55%OU)F1Y%:Z&JK^^8Y'.
M*%)T[M8;3L(O.XK8'="*TF)\<=&51',G?5KEF2N27Y]\HG-W\37P;<I*+7(H
M\)E5@#3'.,BR5@1NS3_3_3#83)&J/K9M58G7;*S$5R+::QAN 1O%QINR-FF.
MN=\UO.P64F+6XY@DO[!=:/$&OWU\<&AI<I2@ZL+VA2*/F)>^_>%NH7>[&;P,
MC%9_R#EHU.=.[L7NQ?W,B8@]5Y90B;U8QTP_V*G,%$8/83F;DJV ,7I._Z*'
M.P#ME#Q;X_"K6[?^FO$2/99M/R?W_F*@?G\VPJ0NKLQZ=^QT[7=I^AX]Y<]Y
MQDG(!7S*;#:V;WQN,\T9PW6Z(FLTLZ>BVXXP!PLO9>GH_YI4SH3IJISC,*F7
M1>X;,V0[P#UPP)D'I9$Q'>:7%S\K5XHB>DR6P*7RNM1/UFJ-^>IX7ZU3#>>Q
M[%_+* Z:D@"MRN^F22ZPA$9<&)37\;2ZE.>3/F:B\O2<CJM [/<',9\;F0LH
M&8T&41N4DPKK!9X9D;+W60X[3SGQM*G>"Z4'+>^GR\\;QWQ?]>?^V"MI2:>8
MYN)YKU0CRW2BC>;-*](WW]<0QN[&2(ZG#X507R,]=';LK4R_VE\G(IOPL$KD
M)RR*;TVX2NY5/_.D)/9>D@-';+2RZ>6/T*&8*]9$?H(=3F7G(F4MSUJ,Q&KQ
M#MX%?2"D+(@:ZA>JAC^OU8!90_)T,T<1SYY17#R=H"(>M[N;3%6A/2Q4YOXV
M?^$2E^LY9%^H27^1(OIF/ V")<%<MJZQ_H4<*+)= <:R\T>7\_+?:@^B2S.J
MXF<8U+5XLNIL[;RQ;V=/V<3H5M'EZQ=O7@ZZG42#&NJ3%[AB+.CBT33*2J!G
MFM.XV_58D7FH] -I6_E9$_?F=PKJ0_=BW,X#;S5(\0"T4P<V'RA34-EM&X:)
MS78&=K\Y3!^L.(C-C+4]O["#H#@]] :;N%CI3$"-KK20Z #>Q<YM%FRP+,,V
M7]A[#",GFIW=*58ER*7YU[,"-%R43F=!MU4&U]/*M;(JXO11E@Y/6U@/Z8:K
MW7N<VQ5<+2!^>9;X-&P.1GFU_.4X9]3!T-:S_7T]V2?OC6].BO0-W)(U-=.^
M%,\9S56^TV-F10_*RH/(^@=;[]:IS]Q]^E'WFW?QLJ RDRP)VZF.(GJD?TD6
M.DM[$"7X[KM:09Z0MU\>^-+GD ?W,'G?W492JP8<,T/47DE%:EK+D(8!56H$
M?^X8'X^ET) A7YM);D:1JH+:("H2TGJ(G-$F96+:["$U3?/E\JJ*N]9J!N4/
MW;H\%):Q;J!F<"!*CJ^NO$^RQ#ISLJ-?7O&V%8USW<?#H2[QQET3]>)[?A#Q
MX)(RJ5DQ1>2%\\]1?-6-5Q"HC /W9 I=:64=-LBM08HVU6RQXN?QP:.7=?*7
M:1RV[+.^;:G%]H\'!(7PE#GP]FDNW+AIRZ9T5S.YBZPRXLN3'C4A,1@9T-J/
MN9+P0#;__LS[%?'.R[Q^7<W)N1Z*E%$=4-B1\!N[635F2]2[AEAW$6[U])*+
M!W%7<F4S\R 9]G0KKO6.T^8_K@>]7%-B'4^D'LQW*N)0&O9O=?8^G ^>I:*)
M-C)<U7&9+C][X#MLDKZ:B]@?\1*=?$ Y9*H0C3"_RE@^,-KJ]BDYZBI5_FTW
M^;#8I1!1^<ZTZU.>KJ"D#,!E&\J]>KW?_4J9L,T=YXVFH(O9Y%0#+QB\;V7[
M,GUR,)QR,"[P/-_Z:N1;C4H(84Z!KJ5YJ%;U@/!\1(WE^"E&-A"/3$&4AC<P
M/=98'=N:+ZNP6+YEYW+&]R43-7?0B^ Z01^MS4%9HYIL!X-K7;N-:5]YGI*)
M'C<8+.Q:@?MH3Q5]:L2V2?X:_ZM9K4_-3..N8:/LKWVN\_^2HAR_>M]-IJ#4
M:;;/@2;I#$=^Y?IH;'"&]8JSR9?^6I!CQN1J2<98]<J[0"X+X<\K9VO$2)?,
M@N&1#P[-YTT\(CU]*,,9*F-)2#2NUZ=?)U:=9OZ1[^::L=+EG(UX6:HEU\:D
MF>]%9"3]O);+-0-JV"+]V$%\:G*%W?C-52AG"(<;V<H%Y'MQ^P.S4=V\B9Z<
M=2FD]-> M,5QG_M/9@^U:F7.%E'0:O%^VC_MX+^7<([(G[0A [!%3-(-BJA'
M7RK+DQSZ\$PK.:"%OL0J$ =H5_I2TSRY+QVE.00KU1*<.FS01@P6/[]6:=0H
M!.HP/%)[S,Z-;,N8V;\T@9'T5,BH)!K/.7?[.DE4S<Q;9W<=/UO=VD/V' +Z
MJ8K''5EH3<G$>D*=&C]E%&3?J8Q\NJIJK.++Z.,4TN*\>G:D8D:!>;ZG(GM5
M<87=7O[6RR"$.:]K.P^]EL%;[VR\:5*I<Y YP,6=AR5'+M$R)0BZ726C6FA;
M;#>\@9@DC=:KZ;,U77+^49G(*14]22*S6)V52,\IT9>C$ Y*>)$8%&5'R-*C
M:JI/Y\#2^^%M$8\FIO91BL_PA 0'MDSV;\W#] Y4,J%\@NXX'9RA2R2B-*?V
M'D>H\'B7&U(B"K%GZ/SPH"\?G8XXR$482=%96C+5PC4/U.N>2X!Z.U*A%O)S
MCV,51PKIKFUJ/).0D_HT('_C7MEVXE6C,B,>EQZ3H?"V42NTT]P=Z[=7J1=T
MG:,GA:K:OOG9]6/N7I*\+=&EK_].KZKJQNZL\E:'@OC1A@/P&'TG8_C>4*'S
MI$YL,41+48F05N:AX8/-AX_1[&"*=Q4WU<CX"!>OR!1F7<SU/$.:D]VR62)*
MFW)1K%%TW[\4],4,JK(U8"@;%9IS%#=[VTCP-;0Y/T.=T+5WB%)_!H7-2!\;
MZ9S5J7"O/+RZOG(JMN[R@'.99\Y%[9HT=W>4X<MKIL_,P_+[BO&XX*+$^G&S
M/,L+XF*5O[+J>4_"5/YU -_ ]T"%BQ\WC;+\A^-&A\N=)59E&.:>7@7%.^LN
MEM6JS0;W%O($.T;\N&^?1+J>BI),2U]YZ5!]*S$YJ4;G-55V>Z(=X8>Z35;C
M\%SJBDZ.W> O>BK9W I9 1=U&DY;*.=I92\GI'Q*F"$P%^2TCB$$U46Z"\OS
MS[#<'HI6$P));"HO:'+ND1R_+SF%ML72.,I"K+S.S\=\&Y#O%M62["/IJ7M4
MD:A8PX)-R["OYZAN@##>C-/<!'AM2MTX6$8=^LU')\9T,RWOM"_V.#\6-0)O
M4#L *YXW@EXFS(!G9 =%FLWM$MFJZP>NO["]8/^":ED.KI$,#>QI,8&-"9/S
M&PD(W:"0UY/-H0>5X$,E 9TF*WM2\,U!Y^G^G</PU7)!(O*ZL(CW?H)ORI"]
M/C42=?U.:XY%4U_+/\!#+F3ZB8\&R F/NP['2W8Z^(L=*N8I)F4A*E@BXL*K
M$:FL&MB>PZ&2U%6IZMU8JA2[]B^OV9D>I[N3CE\GUM5O=EGQYQYP-WW^O?TN
M4[MS1(XKQM)$7FLFW/G,]V8J'%"B2X20-U1/N_@%8K\0)JK3\8R468B8*Y'!
MVO B0?-%<BK_UZ#FHB=E/L(^AD,2133GC 99Y8O?N3\ZQ9Y9-(E6F;O==[]\
M"&5_H:XBOKNB-DHT1'R'E64ET2Z5[,'+,^S!;R@&7<W:B6C'.[YP/]<1)UD&
MN@"7]B:6R?0;;*XMPN[W6,-6*1[E[J>S1K:OFA?%G,$!<?8#;'+&"FG0 DF=
M0U.^4KN,Q)%"X]Y+/ZB_N9J?>J60[UE(CVE74"P%]4 23_>5%?!!SI>4/\EH
MW[!Z^L U8:*T+.S+L"#4X ;_X,7<"("T3#-&E9/XO 9IYC!)L:_IK-IFX?.C
MU.$>U[=&YR.I>8L;DRE_3+OT1PY]YGAF;&17(5L14O0C/QR $Q'0*9S>+7#T
M;#L[>C,.?VT[L 3/.@=.CC^(Q6Y["P-NT_,$ LI=+A[L4G'"VI3@%I:;U3?W
M1#Y-?%^/4M_I*?" ] >P_=7G,69)+<(JJ]<VW2=:TS,%=(3\[Z/4K )A%U<O
M%DQDU!VEEU<8"+W0SC _]T(YF8H5[:K5Z^AV9-*V:6J9?W5=C&ZW;>R]:(_\
M@9%Z9(H]EG-3;;(NQQR\^ZXTYEP:%\E0/._% U!_]9%XXZA%/(RM0WS\F?Z!
MO&O]0@4.<+MI#*,NA=3D\!YAC 84]PMX'G/'E@R& 7.EW]!%+=Y$LC7?$)?B
M'L1QS@NELSI)$NV>B:9$3ZF?3Q_X<9YO5/JQ;TD[\TZ1@2Y!D_!]-KTK'CT4
MBE>ATQ>]R7(GS_9/2-I-\KGD/IAPC>@E/>5&+K=!#_71L.*VCTP_S3XIS2GG
M'6-<ZGCV:ZOL<!7[IU>:Y;3"!64U,@9DQ#,A<H=PTTRTH=Z T\/U>]LLIIJ*
M/71R#Y[N9+M'DR ."E8MGCL)7^(U+U$H61.C5E5B/9ODYRJ?<#[]4VWO'4B7
M,U$_:_QU:G]TT7VV50)J,H34;K5?J=0AS\?X[J>V+XXZ#X;1?_J+#R!*%Y;)
M"J%X?!S93']4GL)GLC+'J0&IR9/.\S%V4E=F:&YHVJ"NF^CZ(CGX>+S*Z]KC
MEY6'O<1O,'1$LNKQCK9>0L;>CZPH>V7.O]N(64V$O*732-..MCY=53:P=*B0
M2Q<MB^CIX5(,DEP^ZRTAZQ\B46-O<SN61?)%_1+S1D+.A6")$5\P581T_N4S
M"$[PE4>N-8I5R21H'XNJH?.#0AN.1N?&3AO)J$@MW,6?A:.%#@?0DWQTC1Z'
M&1COF-..J4?=H^L4;EFKMU\ 2V0-#A7HZP49#5P86%>VXS,OV$FFTFGS_C#Y
M;G.1V9'WLGP.A2X_\^4\@-Q(KR+E.]ID0&UHQVL^"JU/[_C\M'38O%-/48$W
M[ZA?07>"VWZ*EN,U?U/U([(YIGQ*Z49OO0\PRI%7L_-CM(XWO*2%"/OL".-[
M=]C$313/5PUFV&>&+ PK]-/L/J2(</U<^&YF/<4]&ZHX;#K"O$B%S*M:&-(#
M[<U^W$D*Q?IA*Q1S;2L8/8.1])5WTMJ]$2+RXO1P$]XXVQ\?$8^=:'*X[KA$
M6#7,*;&QT"1>#O.[[+W;YF.X_*NZU*^?T2BR](X+ Z8+'PJ5;CS#<H1TCUZY
ME5SI029S@<WUVN:!+G5K-*W7-Z57DWS/I/=<QT:K5S_PC<[=+AV<T!\5OO62
MNL0]_\BUR4AVK<7XAI9DV3RD5)_0\7[#A&)J@/Q74Z/XP_NSO3@@->L9IY@H
MAP KX0'<<18>IL\ U98D&_#[V$&VI;*VM%G047LY0S6Y/JP\?/=L]_R%N L?
M6@X6\^P2J09*35,\7NF[/J9/?SRN.,=R()*<?*J>ZQL2>NZ&7;K=V%W0ZRTQ
M2-1PK;AUYJH_<U0_))ORD+[6^LWBM".KI+=-3J:IPX';,*-6-?,CIIN,U92Q
MJ*'@EN5K<:2B9[Q=PH!MP8KXIHKZ2Z5];V?+-7D>1-!>/1_%'.)7E8Z4#MV9
MX%'M=:<4F[U9G;C((:6Y*%,]$>CI:A&<O4R3YI 0&5OJ.C5INJ]+/YX>X"&Y
MU-SD*9N'V-T].-^6Z+ATQS9A]GY?(^.KXB)O8&*8>C>X/0Q%H*IF:R-\5Z'*
MK&'UMB)1@D^7JEYHBU*K_-G[YMP3K/N/.5F+4<X..S4PJN^MZ1/VG\T^NVWP
MUD0+F1:HB02[=3J6+ON6JV:)0NQOSL2P8Q,'09\1WKI)SWWE"E>]WQ<=92U^
M.VO 950^UDL%+:R9J:E!DVJ+:?<WQ"F_C-+Q;8\Q2RQ)-=>'Y6I<",GTR?MT
MU=E1L<.V1\/E>Q1J FJH&:^\V17R5CQ/APAZ/RU JYL8>&0"10H@<4!XPPS'
MJRZKPZLV^O*V%QSO#-=>R&E.@X:;#RY%;1A7EIX)+K^1^Y(J;7RVYI"2MEUO
ML&AC+6U,X3#T0\G@DR<F1(*!3"2D@?R$Y$W&1N)H?5T?4N6'G->31?==X)(]
M4-Y]K"32?"T;!SR'=&<79BUX:4QRESHILBUOC<O';9F;J/'0"9W1OL6A %TS
MIWJ;<6=YEV;DMFGZ&8V]6["W* D0U!8\_$$KS 3(\G-QA-B>;UUMB^L0YWKA
M$GW<"VMU=\RQ5^2.-XA:U0I9OTP91D%@&C"R$;:C\U53Y,="6=5SZ\!;H\L3
M3,:25M-L[%\.F#L3H07OW,MJNTVNZ&=SS"G1U])C+>IF4URX3^MNO%%]Y,'
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MSJAQC6A5*1:DU#6-$&X@$8R%+TR:"I0?P_(U:WNOPK\\W;OEJN'9)H,9KX^
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M:R-(F#=NX&#CD.'BDG'14=)Q_<L7_"M B(EDBHR.@G0'0"9$0B%$@C<#- "
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MGB)O_AN"3G(Q1SG"2%VKI M7<3B@$W.*1<_8/<223\:BE(M^:&5I';VUKHG
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M)D&JUZ**G'5J*_LGJ@:+NP9%S8GAEN&,('?A=X:RT*!W3,V ?IGT0KZ%@=F
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M3R,:]<$1[P\1FDKU5Z-N9'O\/;O[.54&%%@,8")4N[XIB_F86"Q*J67B1L9
MDW-[STQ5EV.RQ%4/>8-0P8?W*FA\<*+AA)$<XZ,S3X\57A,YD5J3>;4*&SY"
M#6M=_WS\8B.9]Y:!X<OR"1.?#_YX2>^"=SH)STSM-.)8)U<O!O1/NSN4%@U,
MEJZVYI1D2L;]'D]]"31C.7-.CWCS<E4>S6]/?JV.?V@G00,^Q$(W$_2,G-%2
MNX>,0>,S"]V@ACL%1F*N?F5'3JT"SD?][CXZ->>7*$(JRD)DF1OL>^9M7&Z[
MEIH1-@F: E>^VVB.4'N\+B.3/7EA3'=@,U!'%@&H6,,4):%ND>/1KE]%B*_9
MC4V_!XGLH:T?%:>>?ZLSO]EL2"(G6?Q(U\#;("M#C6I/YW@U5N\G,3[FH,D<
MH)>OJQ,7M=#7@CI1BIK#%L;&3:N6*MJ,1UIG'K0$U7%0$!/2?EE-FR%<(-#$
M,*HYM_2RS+96X@?T<SC]$C<:GG(<Q8'SLUSE%U^2AD 8FXK6?"2%[!C:L,@U
MS0^];]_K\N')2[68@J/;4ZD3-$ G\NRCC:55UJG6*@6I'??>$;FAU ^EZR2/
M:TG:C>P65^T<+RFXKPO-H'1MJX\*5&U;6Z*7W>W%LR5CRL<!X''\=%)_C0(K
M#:^7YB^>TLK6)4G%W].73Y"2JTTD830B'8P'5!AWW"JT<"V7PB&<>TL@8AL.
MO. 7I+M?6AURV5R]W!^^P^RG3R&EQA93U^I*E:V$S!A.ST.MO?V3T;_ISNBA
M)1IDFS.1KQ!6-TE2C6GK=^\S%YO[>F2S4T0DJ,[K)*-%*=#55K$>T8<1?GSE
MX2"&TCJ@PC(.%QBQK \=EN>R+\YNT&,*7;H/P2L*&90@BWB$B6:9RJ+MV[W)
M7"S9GLIJO,#AHC-DL!3;*1<DO!)!;*% 3/V1:M6EQG)R/*0D?*?X2T,5B4BV
MEOM7W!A[CGP=R[>?,2-=CO$.?V#M@]FINC>8BXW%O+)2)-;6Y/=-DN8V[: ]
M&;.BS[\Q@POD3>3H,$M/"L8EA&//.\HVCJUT0^(:W!^O*>PM:W#[]F$[U01\
M>H7U0[F:KZBC+ZH-O$IW$9RE8.OD:MP,)BN:@S/&XS=;!_H?=PV(RV%BHE'0
M'3X73,K]> BR;B7NK^P;@HIGKJT2JH1MUSC.,]/Z, E],5J3TY)QK!N(A/63
M7&R^<S/-US'0R1Z<;<N(%\YY^8.G)4B00'77@+%VB5+I[A)T"K*WM\\9[D42
M[^056V/8,-D-X$4I4%M]O8R!R#A'+^\^8!2%G#)41IE7US0*?.FN3OPJ5DLI
MC$8"+-S!;N5WO/CVG 3BJ+9NLM4\A69'?GR^,V!8GXH <DAPL_S!JQ^ZZA1M
M),T$KH*81RF?V^96W[3-H ;DE,^<"%TMI2T:$@TLB::8L%0D)S\P]CS[?H02
MAAM%P+2^3N_:*<RGS1F5!&;.YL'=O\2811)';,F3>_H#;0C@DE&"%@&4F"*
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M\B\-"Q.)S%3S_EM_[?,,ES_X$FY2':[+/<-0S_L4K2]9H=.;<(.U.<R7?V$
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MNLRGQ@W:)J'_R"C4L:6PR.:[>39$_T:TA3%*/@T]+H&N!NV.C Z(R I;O((
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M&.IINGX'/Q=*/#B,#JNPRBD?XQ?BX,RMY*'G<>C!R[X=//&PEBL,+G$0'[=
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M?L8#O-_;</]GA2UX3(*",:M@GL=6ZXX5-'+XE:%U.$X,>WCPMU,5^14M+V2
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MY $,# S@,?H?@!H#[@%X5Z[@7L'!P\7%Q<?'(R"B("8B)"2B)K]&2D%/P\A
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M1%+<N1MB(64D4FD61G62V]HS1_ LOY<'*ZL/ZN B2S%R%*&[1G?7RR1\K>"
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MW'2X6<>W8-)&)D*TOAZC0W5POYVMJDX*!1RPG_N*&&'2BBPLGQ:2-#6N;Z*
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M,_2GZ45DKB/I!NJ&W6J;BKS&\7(*SSKB[\/BE_XGLOHWT?\8_P-02P,$%
M  @ S4N>6-GJO.51.@  3D$   T   !I;6%G95\P,#@N:G!GU;EU6)1?VS8Z
M@(!(27>#=)<T2'=W2$IWQ]"A2*>@='=(I](@,'0CTB7=->P!]/<\[[N?=Q_[
M^[YC_[%'F9EUK[6NZSS/*^Y['7,_<_\+\%)&0EH"  4%!3"$_ /<SP-$ <_A
MX.#A8)_#P\,C(#Q_@82)C(2(B(2'CH&*281/0DR$3TA(2LE$34K.0$%(2,--
MR\#"RL'!04+-(_":C9^)G8/MP0C4<P0$)$0D7&1D7#8R0C*V_^77_3< VG-
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M?>M2\\\&)2]ED6UA?$&2>T#,7L5-[Q5^#O/UE=^2T'#%OYIB1/ON^CW YQ[
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M"=2L4K)RW=KI60TPA>/XCZ4AO1NYS<@],*9396,.*"LG0U0[>T>#7T9Z2UB
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M>$J_8J=9?K(W#_=(ZL4>$Z(;6F!NLV[-D C?OEB8%:<WP7-]MI)\0\Q6F#]
M7G7W3>EENXP.5$>OB:.9K36=S)Z+$1L6Q4:DU*;06!,SRN*'WW+TSR/$A/MX
M%M.OSLJ6*G\TU,=QHT6LUN=1>GEW-!O[D^[ZLRIL*2HGJ"V99MR$/MU+MD](
M*T6F%"_H\.MA:WZTTTXZT#%7Z_F!>/7Z&$3%Y1_96MQ0W@,6.*YBM%9]]!WS
M!D:WG7&QCU<)S)*C&:%V4,O,%N\^_IA83IN2%_4Q'GU/E>+Q775;__::0Y.Y
M;66 5LN%*3-6QB6/C3)TC'R+);+&3+)6?N2WPX6&T_8>:92$TTN\@:#C4 &$
M WW!:)?Z5 ^SL &T.'^8&,DRJ[M0T>8+P/[-+)%O#55P;*;4\DQ0)2[F50Q?
M-2^=_2.#K0=T)X/C&V\J=>[.[P$N$YQV/^?4W!C"8.7%'_!OIA3)Z^&39><_
MT0#&^>WCEYMBTPT?2=I3#$LF%,MNCKB62XH"R<'W .4)LKB?]-K&,V02O0-"
M'\*L]N8&WJF488O@DEX4'VTYB!%*&KVPQS4LA!.7M3#'RLV+O >$O<*^< RN
M;XBMY,$%O1%*U!JWIZJ>R-+^96Y#1TJ=H#H2H.^BP^% S\"E+%'J]!T3X%M+
M.S[31\E"Z[HULZ8JCQ A((_%/4L-7LYYO*6/;X@88XR5:=T#>N?NZ(0>60YI
M?0W4VA?E-?2:Z"^!ELACI&)TQH=E!:^J;D=?X/O3FUZG\ES<;F774;(!Y?$$
M\\-I</O-M,@]<QVJ,A<&%0'JM)Q[;$2,G-PMBE5"BY], X'T?-W'BT1,]/2X
M2!<X*L4VPW _KX1D5IDUCN>%,V3;ZKRA8'\[]1A?=4AX1^=)$2<;%<Y;N;5;
MU"3T8SL0//,-3?$KUMD.)*F5K92YP2 :<L0O6X-7&']7-\G$M"JYCH7/SFX^
MGU6FB$>9C#W'3JDPM E''Q$[7L;">Z@ !;(R4/0ZD<4H;O]HFK2I[+$9)7D/
M$)WI]?'XA;)P/4DO(*L.%%6RYFC0R@WXF,70_9S_;!\^#UJ 25]EBJ"(,?<S
M>C:\T33@D&[3( 5FUT#7[J7^DF(^Y^_*&A;D$VB%O86 U+;*G[T<39\:6TZF
M58X[]JE\6KR\E-A'+EP)0GUK\4$$ R.EQ:;*2<(+X2?V"'I^%I?->^Q+W)_Q
MXB]LR<A-TCL+L)R5:[ -Z*?LRMI&SZ]LU;X'2AG=:A&QAQMZH>C&+^TJ+>I+
MFMM<8+3-Q)BFG_58,%NY_B#+T?LY_"*C#N&'H>/!R*00-O=GOR)Q=ZJMSU;
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M+!S'0'E"",!\LCZ%5=#AN!-0GH<WX\*RQO]/=Z+U1Q>F_ )@<[*JS<^R!&X
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M;&:W->D>L,!SMOF8$/^(FLT?J<R!YPR^9A/_2"*+T+\@[A!@E![V<#N8^!!
M<^#6Y<F]9,NXWECL)=M3N3N]W2LL.];087KF O(:F"/SJ<!1F'=GWRBHLE(
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M-[?+@1QU2C+YD$$>I0U#LST2$,ZKVS?!LU*YAP_93Q7**== GFI<W:6E-!Y
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M\TQ=2QU 0$  L+WY /!+@"?_?/O?NO[IY'^W#P)\%X"6C"""B(N(@ = 2$M
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M_YH-SL45#XCZ$KI@<_Z)!@'! RC@A'C F:)-HY0>*1*&5>J]Z,$#BC1#I_$
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M7#R!O**YUL3=,CWJ P;"_\]Q7E*20I)*2=BCW4>7K  +P8*PVX)%0QR:P'@
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M0*3,UW*W^$I,;&]RKPNX9H7<IO>H$6K,%6X_AW[>P]2LV\9[EXJM; *RIIL
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MD_.ERFVMN=,_)K1/S>UB=5HRALF)I^8KW&PH0&OY32J GYU*&,4!G-QLZ,.
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M=*3-Q+@6K):T>4/S\EO9\=@N \(X]C]$ J1[<6O>%N=Z),Q3^N9/=86?%0(
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MUQ61\#5_Q8UDY(@ZK0IA53]FQYX.H[,2*:[7I1J1;GNGXR0%/IOI&F_;^B-
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M6Q?29>RZY&QQX;-G<6AON6.IVN2DU5S?D&GOH,H;8[Y*B5B\>"?4P?G)\QJ
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M_ )ZRG-N</E,D+0']>;186]M/'G=R8C.344.4^KK7D"H#QA;<PY?ZVX&FDJ
M+]Z,A3#44WRA03@V:?O144V)#LL<'5CTIR<6C5:XL0XN-'1(T$HATG[L?U>R
MZW'Z_CQ%TX;V^BMO4$FJ>.QKC*'WG\;$]K9!JXNEYFQ'6%Q&A?N91D%#3*$W
M'[2B4NXRY_UWQ937@,UL@V/#N#O^E.'4CSA\D@>4+TV)7.>9+/UHI0\1(5L5
MOWJ:XK^/>2@<?T*L&,#$BW;%@5\)T_D^LD4;.G/LFS^?(!6M7=1<<M+4[S,<
MJ7I66=VD_6SH:.O]]G^AY;VBFGK"O]\H*-)[KT+HO7<0E2Y$0.E%I(. ]-"E
M]RY%6J2#= B]]R8@'4(/O2>(&""$U]_[7IUU_N>].Q=S,VOOF;7VGO5]/M]G
M9AX%"NOF['7QXRI>A>ESV4_QY"DA\P<AB6UBUGZ)?AZ+;<_R'[,*F8'DNP9X
M5+T;518;?%-O9#_F]J3+Y5LNLX3LYDWI2TTP,/C74CC$E:\?EADV:+UZ XUZ
MVP8U&=5:[^ILF";LS!2.$74 _J6:>T7A(\LN,MP[TLN.;S7S.EKE;.WIZBC+
M^93$&8L$'(P?GQN/E:+9ZK:4NQ/JYW4VLF/ZO355XK+8'2>54T\FPR'OJUKH
M> "]4X70NWV8>C@P26Q8JB+[VH@MY>5ZHS*#^YM44N),AI!8L9]W!&YUNC]W
M0^BX?7B>VF.5$A I_&5)2;?\M9,;$G9(A,L0'_N(0$0T,3=4,8L9HK'-[RI0
M]G$"Z*'4*IXVX'UJ3+KWK10D]&.2@L-PT4C)_B-?O_XKAM@.B=N$C.\S&X;'
MI%-3YO,F)9-MJADXW (_1[$[S Q%7UL K:T)2(@28VO)Z]Z3?39YY(M-'L]
MR?=XB\!S%_*]_O_'W=G*/DXFBAE0:<XGCP? IP? <+O2V [G ="JF]ZGY2/Q
M+V0NW3Z:,@GU&AJ T/[V"<?B9E_]Z%060SG'X3;:]U%-^E"B@N9DWNLP**^^
M0EF37-?U]9K9'4S8Y/X!X./QB1%3RXS4$@0Y"** W1\CWWT$P(33IBU7T8Z!
MX^JT9R=+B@<WMP9L;HRCK?2V+N%4?)189!H5/CQ?4GX)T_[A*.+FZ_'6__J=
M)2M+)I[LV7BJ)%;\%X_$=U8</_#<\SEX1/:^IX5_M9E0=!<)2%ST:X8ZKRNF
M:.M5Z%$^H;J/&BCZ6_ML0I/?*\W8*7B@)E%9MBXXCG'ZK6+F2Q#3G^=>>J$O
MI*85(+L&_+:I ]XLWXJ5K2!YAA<WKZC>=H2QZ(6Q[K,,3-@2MJFL>2C'5T6^
M,(J\KWD!>_I*8DU 6E$8"_A%&Y<GKD+WJQV7EC0'S,U'_RN\UK-E[QY'%39?
M@I=:)M7VKS?5:2/5H-VD?!,]T3=_97F$\5#98S12A2L.E]-:)J,;[2*D$KY%
MTM01>+-]P=6G!08NGA;/@W;%XJL/Q&(BV#Y]V=K^6F[]\BBS-QU+M</==2VQ
MLC@MMC,M]H+=!K7<QDGIRTFYH5X[-0S)"D-%_6;.VOGG4.@^?U@+2\D-4MQ=
M>/9&K43/6T1]2IM(&AB?N"(M?<]M_$GHG0U[Q^.U^K^Z%)^?BBB_MJ-='];)
M%!P:GVMJZ:IU\HT1!ZYY:>HO5@A*0)5OWR3IW,1._R[>O<+O _8PHZY!6X0O
M3\T:]R74[LH98_"3U>A;F)1HL("(1\<.CC5-H'>+BQ?NOML3DY-,YB[F3I4>
MP?S7^Y>;HTN%!2UP"NQ47T6AY]VV?"+$+,E*?;MVV5])!EAVF1\ !GZ2"Y_>
M0G64 13_&N7_=".1]SK[?]S6!UABEAX E]G,*/:E^^3-5:P'@*YBR/L[-YP-
M5Q3U96(/Z0/ Z;]\*3&:[ 0SZGH6\@"H8.[]<=\:=B&)QK]1?4%57A@+X/I_
M-OJ&CAE^PR?B65S 9  ;\(J6Q6.T]Z#FLTP^-^-U!0N9.X"&K0*KHI=FRE<\
M[[Z(HO*O]F*[DSA?,2^(1C!]C,GZE<NK&MTWGU1L66CUPARX.58;U(]7#\-A
MZLVGJ1VNUAEGW]IKH-ERDI)_?S^[.J$!=G1\BVYYUQ@J*CXY*WM&KNKPS/>
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MSFAWP2'FVY#S_DER6/]]BW] PQ KWOEY%$/ ,M".4:KV\7UA$"YX>N=BX":
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MOAJW.Q37P,ZZ,-M_\*;)N3_LX VI/P#LO2S*AU[\?6+E0/OMW6--'A<6(G?
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M:A._85HS8*]!9:HBAO-AI5W^C'E5FL (CJ^J;:3N(L6[C0SHLM3/\KR3&,X
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M_=FE,65.,($6CHA*<-"FGO4"G_*OUL4S<>DS8_OS=U.*[JO&[Z080GF;D0\
M-%GLSCMD:02<&'_-_M;[6Q$JK5^!==;SA)<"&LBF,\L2[V2@*XOOV98(/PI
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MF5A,W4Y\7+%L_6TT*P[D/MJV'&9U#B@8/H+*7P 7'M2C)O$3P>W:4OTVB)]
M5V1'L,U*LVJ)]%[8AKCBK;?/ 3/O<SY7VKA.3=:@/1ZD#S@F/>.^_XWM^9">
MWB,MFZJD'W/6:!-4;N"3X=J5,V>- HK'?R\C_[;0^C#02I8@%,(.X_2/R4ZC
MVU"Y.-_VH_YY:UL^P[3%7L&J$+ %*T;[=%WOMZR[1:GYT$G8.8"@'Z=M2A@.
M@4LM)K!?2(LG1/I$'^+U);S<\<=J6M03[KX,9>Y!F9<9.\!JI8*\<#!",):F
M9.*==BY%Z33N'/"*CP<.))7Q(+<Y<:=O-A^G#7=D3)84J^>"S-4X$W"KWT_4
M$KU4S%M<]'1XK3GR_5%3@5AYI[=T_?(^"W\6COA(/K@&*598T=$WPE$X'2^
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MPY+Y/)5H#^DY6YM< 66%JCYJ[AW&^P^[^P<:'J&_74[UC7>*5]!)NSS*R_&
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M\1[]&1AAY;V^+GRFO2<2R**Z4\0HUFP=$7P)N/<[>2HT_!!8$/A?NM55<K@
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M9#GT#IYH 6L#F0JRRM;6NQ[Y&5K/E67QV<3-^E=;R:'&]L<.58;Q5%LSA'-
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M/\N(4-.>ZQ5%<)7M1]\7!S#;IH9Z>@8 \,9>R%Y[Y&3]QE(G;UJ2QGN4+.\
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M?$D$^>%S(=.DK$7X::;ZV<;;G9D;IF5<G"K0"43LC7\@]PT_=6T:F <"YH:
M[)Y.Y^/9U.AE?;*B5<U5"T$&[W)5Y:1B&FK-]\Z 7T_!3SV$)366+^N:A@VI
MEVXL< N\?'B\J:Z?[GW('0];5LS#G<X5,OL/WO<*'8C?= >U,&)'@?G"ZZR*
MXVQ!P:=GER6'G P<U .[J1A[ZBY6%_2P08NE.5*1^\@ZV]*M^/N-M8'_2NI%
M _?PP3)X%VXI>8+?Q/[TU?/AO$*61ZO,A B0LVX\>II5[-$C_]T!!>\!S=?
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MQ?P58PS^K;-%6;C5I],Y+$L(<4W]V'H[/DNX[SRX:-L[;15^HFT=P$:&/CM
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M^JG,T6%).[@ .G(ABWF.O,D\=GWO:M/:%KILO3HJT21-;Q3;'#E[Q&,$W4A
M!>L5 41GYLF0Y L971GKI.T>J!N=]AG!D,UGJ/H\1I?YCTL^B5..L5IE6_%7
M;H+Z12I,T@X$C#%7H;2'T_TZ,B:ZKG.QVE:'$K#ILYMQHS3_Z9[1V8%V%3Z@
MGW#PU,QT0OT?J_'5#SSY5WE\FR%Q"!0HGQ&3_[.5+F$S/^JX,M % _1'5\B6
M3$VQ2INC2'G5Q:TLUSA?3.R)<+5Z*=]_+Y7I>9C&[P1"&]\2E:*B>M?8ZIKS
M-QO2RQVX?+-\L)Y#"D929MA1,3"B/7TKL/%]=_BPD5LJR6,C#FC$,99REW=*
M,NC1\A9O],:/\,WS^8AV1M;BSY$@TET]2_"\!^;#\,:JFS:'=FG7E#GO QE:
M0PUD"RAB':5R3(Z5S5=)M497YV]!^"'&(+1(-'U?%ED'[J>SN[E6Z0"+--7P
MU$ I]^PO>CZ&)R]LF3-X:;M2=$!MD.L\6VU919?RD:QG=X!\Y[G?AU-'2Y;Y
M[GMR(0=>J$80=?!$1NFK.0E$+-T:(<;2Y5'Z158";#&_+\MP+6P3QOPZ]FEF
M,9HPQD>;N4\ZV"9!Z/CHV/6(T8Q'OQ>K'H+A&8^L'[H#;/).!%/TE6"FD=91
MWH=&^VHW3Y9VURG>)6DP63#E+Q2GFPL45(S:^A )?:,?]GF*_=O<ZA2H!;H#
M? 3O+<W'*GAL)+CTZX/S2>J96=WT,';EB[U4R/'>VZ?H$AC,N76T2D#^%<\_
MVQW1, )C[SGA$%_(E=;)HB"K=_"73\)P!1?>7U(L_X9]@3K_O<:(5HRIA-K.
M6Z"*F"+SX0O@I7BSAC^%2)PP,N2L(]@\67$5TIVGI:5UGTN]2)_QHB'C)P+#
M^_N6NZY^ LN*,G%Q[&F2SH)4B5:^O&5)67M8#==#DFE %,J5E[5\/">#ZG^N
M(U2\+-[E>]P![D_-PK<PUBXNJ,B].\ KE"^L+)LD4.O"FGC GP'1&ON')*F>
MZ'6EVX5O^B'7?5&5U6Y,__SMPVXDIEW?KAHXD-[XHZ$132(4F5LHG&/'=/ F
MJ%"KICGV<'C7'9="T-B0 0C]^S(2_@H3]^]9L6V8\$(3/#3A2Q1A= GJ2S##
M3 /\(=1L6J>EV=Q2=>UH.>B77M64DH2N@I_NL/*X 'Y#J@3>A3T;-RY:0;($
MZO?3S"#D7]S> :+?/5CO^> P&W&6\<-"Z;=P:;F2C[LK\E'\_=K5UA&B&%21
M6'H;>03P[1T@W/<4[/@:([WQ>WX)N6X:>[0%LO,0+%D*TIS3>)?SLO:A*Z3T
MJ?W]/IH(RE@O]$!$R$8B&P5J)RP0],T*NB:DUJ_X=%:P&HG.=OI[G9A)T/'1
MM*,AO&,JVHZ;R2>"T=:?ZU=._*PV^RT1.UNQ=%PII@/]:+Y_*2-&(HG2!#RO
M#_64B4Q3+"A= %]<_E@66GXES'ESG^KYSR19_3'*WT,?\:XYMZ(1#DF46+;.
MF4"K/$ [1B"@?-ER>=UB.'V-JAG-FF6]V!,$]K#S3FG?OX@Y?!+W0&,)"5JI
MU^(L#0TDQE#_^["GJ-*D=E Q5F"ZDVX?2($UK< T6;1->^.LAF_>- ;DFIU8
MOEO7GH)8J4R+//EAI"SX2L?,@1IBRAJIUN>&X8U,VT(LV@(7*U^@*2:J8(J/
MP9W/)H1_U]N'Z\3I-,Y]5!(DDGU$8HW[CA3]8D><MJFC:(S[ MS(7&<,IL64
M!VIM 1F@UB]G ^G140/!\BBWZ$#Y0A4'I#45/+8^B697[O6'HV]<?JV3>O/6
M>4B(;!W^RN[<=)GX\HN'A+LBA_1HMXOW&'875';/.DO]*/T!FS@Z,6(#"%C8
M8V+M[&#)&/IC^9=<\#3A@GWQ8FZ>>ERR*\ ;:L+?QC#T+Q(8@]<0/W!W@"XX
M7: E)@R^J_@8H[M!'G,!))(LA#FUJI8^RMS" ?7HTGU%=_??7[P4:5Q9&"#]
M:Y<,*5VQ?&$OCZB_ QS0(!H<8R7<* /5, 5(2V(1(BAMO1NI*51J8ZG'88OO
M;2P=VN#GRSS(=9LELY.&R11?-+<EA?%@JPB6LE2[;F(355*(5KTTG/S3PB8T
M=U8)>VJZ>WD'H!9R91,2Z9N'L%RR0:[!DPO:?JU/S?9.EG2Y$O !7>S*6%Y<
M98BM&\#I#D!URQD(1.D4H'8T;L<:Y]W.)XO4'(K_!:"F00Q[3U-2V<KCQL0_
M+[\O]-F&]5P]SB"Q+K(B0%>G;8T__&LE,GD[[5:,R="N1TPBVP>3OZ70NB\2
MS&H)"%"V?W[XWEL2<U5\!^A^)AEI'4.7E91TQB"!H-JEP'P8_SGWX24PPNT8
M]NK)<N]29S9I_[+VW&.#%#?QU]%%EP1FQML1P47!X^Q$)1A>%+S'^I$DD'(<
M>0-[,/DDR'9/,O'E/7_P]GT_E1B*ATB5I5=.XN,OR(,:_*!*[MWA>*=V-:S/
M0 R7Y_!LX'NW*ZGU>.L+#@S\#J![J-F9TA"OPIB@)6$39FR7LQW*N2<Z_KPO
M</G&+F2H$6M[!Z@A[ NY3G(V- B)$4&+#/-*<;IE_!UW1H&PL5DBN' (XLS2
MNX)FB&<SQ[-]PW4KJ7R M5ER%,J;3_PW?%Z[\0XPZ3/-P5TD,S3V,NGXW@O>
MA7]:H$"\";^],L:^N0-,\67;F)G8P]]M2;0?ZX7,*_].6J9:NP,8X'*#Q7:7
M%/17]L8WA*#+IB9<M<Z>,@TVQ.;<[6C-<<[/M';K0R.VB(? 'QRHR_]J76 A
M6_FA@<9(ZTBSC*YFK'BAZ>JN7!Z,)PE-IR7+^JIQPEI^MVG[XJ##G94RM.L0
MQXC5PSA T, >)G@$W"<AI*>R0HMD94^198;Y]4PN!R&DU:(_?O]^CO^@:!O@
M[?P0^M_1 0.?/G%";+IAG? 631ZC@V:&;'VQH_8)VT6>-3*GL5?1"/X<=Z#"
MEA7#P(YA^3A!ID[D#\]2(HT KD*&Q:7A)2^GY<O<\1&9TH@:TS6_L'(006I_
M @OM!\.:KQ7-T?/Z&?4>AG::8NTY#K1L*B(^2HT-:AM5P$>=O.#\^\$4Z]88
M?8.I3OI==I9 \PKH0(_<>N3Y\Q#M)-",JW#AA(A/ AN9SLB;F4,.C9Y1Q<MD
MQO9FF^QW?\Y<\C\I/IOKO(\AU)@P[[?B08%B[@ NK.+Z=9/D$:[UZF?Y#T?]
MRD9#W$I-$[2/)7#WE.B/4@Y/\#[+ U[ EYCA&-[U\))8+3],';I6W?4)Q1!-
MGNQ,WL,Y'G)2M%E]";4W]TA;ZR$G,?E(5D+(6W(RSMZ>+?+^ 0J.I=+^# V:
M^)HK<"M9K1H [P_W-WXO7OSJ8)VHJ)99HHI$4R-9IU4+RT"]7D,P]X<*40^0
MCL'WXQ&&?+QPU+'<\ R??K=]<YF7P8YSHV3IN%F#UCY!J9"*0^<E^"^"5U$B
M>-S/++CE#D! A *&*;([>V*!L[=,@=)S@;R;\@$DBV<"A\'S*JB.BQ:?XG?G
M>7O7-+4AAY(-QD)Q-@Q^IR\_)'U4("R CB-!!]];R2,5E.F[5Y4O#-%S"?!=
M4,F>D:_4]5AA";0.U#$M*>#;_(!YZ,C5[&DXH2W<5?DQ/_69T?H%'FJ%VTHD
M+H1QRF1.??,+9NEPZ?[GAYEX3C'-JHWJW_G<B1.^ JH)U"#_T@,&E?;%2J6I
M#Q%_@2X8;6E"?YE@=A_P'B+F4K)-=!0<2]Z@^@72S[9B^\-NG<>YQW@ODI.,
MV\QJG=YI!CR05FVT7!LW*;/7</C7>,-BRE,W4CNYU4>R#%<B/'QQ#)HO!#YI
M)T(Y6J$0W>2+7;ML>//USX./+\KH/S041UW,?FV<ADG*EFJ(//[HZSWUZN4#
M#>$TRLPB8O>2]K7QS?FXZF!!ES5V=$0/U ]978 ^O:5B?70QW46OCTEKEX3X
MXYO!,F(C.VC !=JD.N_,XYR^JOYZ\]KTXRT2CJ6^^>FP&-6WGI#\ 'KR&3.W
MY9@>D328P+;P3G@9^[?+*X5H0Y_\ &_3<E\>^Q8SXQK;.KS3/Z^2:_E5K*J2
M:BPLU2DY_<TO91;O<6;4NGC/1*$6P:=!&VGR=9GYOFJC;6F!F_)U@S,WG0-D
MY>8[,5JP[;-%*^/P-W6P S2TK(=NOD_1I$$ 9%_*4)_:VI&--<#L;-QX 0_!
MF_"8?]I\&=LI#&TU/0^);#W,BZNPO@/TB=A]LY!>]&9$^C4FSE-2*OBI2I .
MD+H3W7Y$.#R7K4]:/-VD3=O^=-&:HT@P@4S5:19\%VM0$^67PTS Q9GYV%:A
M<=B34)'7Y]^97J LMU[, ^ENI8:XV_64R(8Q2RB+;A=%O0")/)4LL-!V0B:K
M0\;G7@!>UPUP<SX4HH"W:2Y"M'N=5UE1G4^>2O8'[CG?&ITDV!/4 [#&Q_-[
M"W@F2WO>CO]S88UUP-;E#\/@O'XE7Y60K$$N,;A^5D['K-7CP\M#>==6=I_N
M'$E]OCY;%]O:^$CW2CW]3]SFM/PQLKSO5F5+CJK6&A'F; G?Q4&V%A6JHX)Q
M#4K$G095S0-ZT*LDWW&9/DA9%_X$WA5QI0/11T 4G##'_C. NZ;?Y., Z[C"
M']C\OO@71UD=T>WXW]L,_S@SM=6:N^"ZM4ZC/TU.M*E--0&7QCV5*U]TQ=&Q
ML,KK4*&D0F,0__1[+$  [;CUWS"7Z0O*.T"="ZX(>-9787PH&2R(#;D#?%D*
M_@F\@(341]U^;= $].#^Y:%M"2!*"W[S&-%(>%L4<J_R8HT-?N:VS1K,%?Q_
M%2R$,HK^A >6L6?%WFH"-XK$\&Y,,1B[ZCBG#]=I=P#*Z_GSHA/_<("=;=_,
M#O=/N,["X'/_"_COU%MBU3L .CU/?NL83#=TMC H[3OFD>.1I&_-UT\T0D@B
M<%.+S<8V $MN8^#9O?%#:M;@[A6EB*3+RBHK.IVLSO%T,3_?Q'S:PY"$3K9R
M(&TP"T_P9>Q[_[/1^-+KV[2;R '/R+\,RM*!85SW*%I8'P)%.9OP\UQ0-YN+
M=X"X.M3\>I\4_LF/5*S )0E#XK. Y:4[P-\7?M?&(_;K1^Z(T^#2X_8 HO&8
M?1FAH#_%Q6G?#Y;<#+*T8:M9=<TUK*&LF?Q*[.V? :KDKW.2[&9.C<R@EB8*
MLK:EC&DHL4=$AROV0>[NJ@)X*RDA&=NW_G\^EP'.V#;L"!7_"250\[+^[\&U
MY.2E\;P:?&3PBDFRQN <9A8/@S=$",R40H**9 NQZN9Y>?DLCSUL'"W+W.FA
MC@_-_R2U\LERG $N./>ML];I3GE[W:BE,^7*VV.H70B?JF^$=E6K65 F5:L"
M-?7AI3I;U82R R6RNT/_L_N1(@?TRR4]BB4L+*^'Z]HK*;A'\IH]/"4>FD17
M,;#<H??G/.@8@SU3C(JJ\19E^%O1KI0SJU-$7U>NFE]7EH/,E5W*G>&MXIEK
M3TU+DOM!3A_3_FA(0$TBCZ?6.)W6T)^.N3ER;IP#V(0Z8OB# %L<F?PV2'Q@
M3R+VXF'L&RH%<0$JH]<1[]ZZ@TI40^C>9_O%*CQH9L'D49"WM"<M<Y9NYYW?
MJ \04>5!^]7<.9-R'/>G=ZT[',]_[(X!#>.YGPZ+@E7WM#54=AOJ&Q'^Z!Q/
MU,0X7W^$Q'2OGD:QBU550-'9AQ0_H!)V*7'G+S!;SU&6P_';@3PUSN/Z=.HS
M2PT6(=0;G';ZA5- &D)C[7:LN#.L=RE*^Z4^,,5HW<K<&^%Q%E6!"RDH+GIN
MO(\C<Y+%4MT!2+ 114!_1=@=X/M:^F?<[^NFV[@/S8'N_\T&F=P9W\C'.-P!
MBNJNI''5@^SU;KW8'/+#3T// ?\LN Q+_C<8?*&*#E<0R)/P*45+V_"M$5 P
MQXSBF)>$-/!MV^\']E9:Q+TX^#_P)*-'JW%RWM@^,Y812O\*(9Q'!&XQ5'-N
MP/O(Q#?F$]R">5Q$[),VX(_V_;(L2WX<0TJ=+VN5[BWNUFK2O?P#5O=@FS(?
M=-S@(3]+E+[5]B6\7<7N7@)33M>O^&KR#)U#=O6!WQV$=6E*YIL:XRT2AHVD
MQ,0J>C>06^[<84DL?&QG)^1Y<WN,Q6^J:#_W]TNQ[_O6<+^AHN:5%93S%#CE
MW;S$TA!?]LHY_O0JP^ I*%=BX&IHVOPX!=E-OJW.V7HW^EWC)?MDDR7S^F?M
M,1 ;X1IFSH>U<ZHO0J 4?DR@0_0FSKC_NCK.9P/W!J,&0FUC6M'"O;'('HNZ
M]H;ES1%4]VOCHX^!O5SNG1J?4VCXL*9(\&2*J\:P\)[<8H<AW,4G2$/QQDBH
M_<MG+ONK:HJ:%X_$.,E:0=G;5Q[CFBYM5>"G'_]6#E(:O/CYSDB&ZB&1L*Y7
MNFP7HRP\U!N(>2K2@Z "?XA8S0C#FNDD>''#8YAFC=G8IF!;+IF20B\W"PRU
M[$W"J*H@?VHH 42K1OJWQ-2HDU.-_#XYZX_8H#*,\]H8)(_#W%#O<7S:QQ/\
M)P(:$('&N2<*8F@$KZ2+A/$M"Y#\E"9M6NMZYN:/[F^YJNH^R\;*GQ_M4O
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M;*U\XEVDZ.'9>/57D\Y!-R5;O>?!3K*UO%E(]\M.9A>SU*8H!5$DT1FK_.N
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M"-9[_L,?]PPH=[/G0L]H.9,RN;>G=/&WHJY"B-=O\392^=^+I)"X\$YXRQY
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MO*X3MZC_!7YKE%J=8=5!UU/UEUZHML-A]G=3U34$0%#'?=) GZ[WU\&<R$9
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MO%]D/>B=ZRXVW]?HD@@S%0]*L.41(%UC<IIK;7KIS.2_*O18**5/</1W7E4
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MI)YY^GPXD!3^N$$"X-A_>S/HS(+J]FAM,EP/).H8]*K!U;DHUQAQ&!<I4!K
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MW)=ZM\*#+QZ-J-JTGJM7D1CW_<+N0=6;?ELA-%L*55)7/-P,WW3C_9SP:8Z
MYOE9< OAQA$.99,V!XG];N=IB>\A>\U O#\M GX[(X5UN.539K+8Z7<[L#?_
M><7BW00?=^&:;F-7*"^0!>BQ'W,%>-CJYU6FLSR [,P:\EI&DVU:<>'9FZ".
M)8F/P4@_H8K@[G88<:+N+9DE/*ZW0ZW_QYWWR>'H^N0(H.,8)1!+]?V"$B=V
M(0JD<#%BIV^=5GI6Y8+R_U+5\\.%GO[]8DV9Q0ZS0T[#"=@CV.N]+OC%CUE&
MRM&MX3^0CSZH)]V3G=X->I2OQ.QUT:9BL2^R2P_,ZR;/E= =5:)#XKXU)JVJ
MY%1T3(,5Y<E#M&;/J@QJO#,N3KEEV5B;K<\A8E&H>+=299[;&K<<*ZC3%&V5
M_+9R,GF]NC@/J*SYQ3[T<01<A+8)G7XF-%P!;G\B5"Y=TES+W65TEQ@+1!\V
M@6V]IU)8'>C8)</P7DG6"AC_LD 5:40T[Z6U"GJ/;?0Z]G6T]UE3Y7BRT7!!
MW]+;D/V>-$JDG15BSO% Z16%N"E!4@='F8#J:6^3"%IYB5BH?EGOQ$4Q]*/5
MWC(\PB9"6!$!XYV.S"^P1UM_05AS8PH[_I9;G>Z1R8 MISZF[W]O1GH,;ARB
M/4=[WK@_W95]*Q< [,JFQBG8W9A+4Q](U#-Z7#K,BWKI1T-#ZV&SJ!>!8+P5
MV:%$BSY-05S[N7;(RQ9$[?BA)3FFOJ5R7O:OAQ2(H7.1N6GR< 0ZF*^*6YMT
MQ210/C-:]',FYU1[^E*G$3R$K[Z@HUUYJ4(UW:JS1"!RNLB@(#FW/R+A^9&.
MI7V8$#W7ETTXJ>8BU,]$TOBO6ND/C9Z86#SS"^2&!^<:7(N]:0E#Z6-WF<UT
MX_:V"P2M.LY/?<LX!J>K=P"6#@E]N-!N%7UTOX*'MYXD/-J[CEN<Q7M."RSL
ME1XNF:*RM5YK/[E;:=(E6NA!&['1\-GGED!8@!MXN"\%(# D\SXBPGJD!XVM
MPWQJ%5K&^F#0B:&/(5)3TCK46^QT^#L?, )2"Y+6N%<G,7=R4%;E&#:R/MUV
MR4VJ.]6V =(+7V;RP<S6CT:#Z+@A\?LH,H%6#QRBB](+WV"(,^X!TKKXUW,\
MY*Z3":7.[4(I<"\&]E+J&+4C2V5>8TP6>S@=85$R+>:YG253>Y(5BHVEA773
M<V<#XI6=3&P,5%5XZ7O:NN[LO4D2SKP\145;>FDZN?9",O"_Q/2Y'C.R=IZ9
M0T4_ZT\_<S)N?(HHR/2\L_^LT3$U/[SFZ I NVG,_!IO'EB@&GY4V*AEWHV
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M.J.&D#H7S6_J?$6Y+C)/^X6(&=:.;\!E2CNFST#9D97?HU^0*$0.5I[FN'Z
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M@]ST0R3AHVI>KULB>B\&0G3=QF_%.E3]Y!#^IX?]?>O:Y:WM2]_5570@15^
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M.0RHRK2#_APQ%.86?;#='R$ICZ<LZ6.OUS,U 4*]GL#8?SE^T5)Y"E'75LE
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M9RQGUNV@@AGE=?4WK:H$BK*SER%>4B?5,<TF#4.(RPNE*\#HQ>Q4@!F&YO[
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M4Q,E5X ML@XLY/36I5F!#U&Z"I5F>"&\[@[]Z'E]*EU[+S_A;[H%Z(&#HZV
M&:(,W\YIKK$OC"SA7N>*7RZN*HAB.7R97>$*$$3>)]A_$80I*,'F#D'^V6 '
MQ^$D-1J6*6Z6HU^0HRP!CA:??0;:^=]!'7%!'P(LW'- >![ O8>X;YSJ[!ZA
M<AL=NCCXI=8KAPKX#TSS3]B?\@ZLP34#Y@C_<_QW(?9D/ 9(T:Q\%P^4^_44
M-(F5!U[CU?98T-00Y?WWHK*WDF-M+_>5R#D"87(L5;TCT@,QP =S J[1NT:W
M?D=5IG[]!G ONK,$&_JEIX>V4WW_!=YX1P*UK]Y%#C39"5!5<V51<Q(SG2E>
M;DT^=59M$?;6.U32CKL"K'F17P'T&:X ]_(/*5[,2;8 3!.\5Q4U-M=WDK?)
M?Y9F;C :KCT1CQ7F;%/S>^?>M,K<=6#6;I[8"=B7D_M[0X[K:TD(XXM^#2YX
M.VC\:"#=^%M1A8&3V7XR*KUDZ&*@"VLM$(W@@\HO;9^:[UWX,@4M>I<9RV?R
M!80F9G]/[G=_JD93PG(BK6S:.A-OQC+2-S&2YCTXP)L[$*K@3J69XW[KHR:Q
M_3N-_C')\7R-^ELL=41.Z[=_Q_O"G)JBEBYI",?]M.W%8+J'-;%\!@AYG6XQ
MY]Q:=\-UD[5 D0NNXAY)]\)G+EM)?K$R1O$FY)\&MW)4]819GKEX?TFP#@'8
M.)K)WHJG5D/E8FSTOY!]2O[E^_=9W<HFDNQ\\TS)>KWY)U^6R-,7@/W8-7;*
M3?9-H,UO?5GU-%T8[)<0?:OYNH%E<C.T7-2@)=" 08#RE7E)^ EP(E/3<,UD
M+1NI->\4G!/QCY&HH\NV.M";_H1'M'+A76_E+Z:WK^25F?N+GPZR@23D!=81
M-'-:&\,]J[F?*[VR?NP>??\GDO3K4K^QT5<T:.2^)L\WW<,P;B7#$4WWIOMJ
M>GLRL4&*),UXR<[L#]">!QK!LH^^VMR*EXC/& O8"\9PT1,FZO;H.\U]HER\
MQO<6F;"'>G=K.Z(>_VR8XO9O\L1[(XW=2KT;HC5MZS)21O->+$$(DLC:/ECJ
MUT-4.-><3<EN5F]A_BQRFO^X?BD7-W (IFV>JF5!32B;?</.RC1LE!<AO9V<
MIB[3OA/O_##WU]Y3.'1T<7G?3"0[F>QAG&1RK5UJ@I8*%=_0&)8P?"0OG* :
MIVGM+V'CG30\\C[SI?T^=AOB*>S_83M_5Y57Q-U2+;)%J]8V))BJLL.!!GVN
MF:M+\'D8=U05II#>UR2>43^_J/8/2S9;4UP*X3BYQJZ[NS(-/_^.%0RYCS^:
MY$%::6'[K$)@>2X0"X(*T9C 2D-1%='*A5?7^TUB7G[@"M3$:B,<3'.$IW-?
M1PO[M@^)IL;"I4J%>?GO45"&V*#9J_["OK4GKZ<"564?.H!/JW6J^$ZR]XKC
M=OY\U9Y3!FX1MR=JVI;.Y\JAL_L+ER&W6VN;.[E;^*;NZO,T>J6M#T:)5C*;
M?5VU2PA/J.R_WZ8&BX(6AZW"=P]$9KF<HH7E;D_$\80IO]6U)?(P^?LR/WS=
M*P)[?V.C@^J2,X"6<(:G5YVLKZ)P6F8,8,3(MSZJ<&;M77J&5T_T+2=4LGQ)
M*\\3FN_A]3YU;11Y>._Y9+_*O5ERA7\!#!=Y^U*N=,Y*U+CQOF"*.B66Z/&>
M-$[A6?-]$BS-*Q)B_C-S1MAQO^ZY?K[CN_I0.=>"5T-\J]]8U\[C62![)L,F
M)#&#3)>9],M;KE,7U1;"7S=JXMZEO>0N1-X:T\CIY]B E-LWQ]_.U+"ECF.P
M5WM7<+\DF2E7BC7VYO98V$5M"U/F7*>%OUQ1*E]SLS#'4(-C0ZCU5[6U-3&/
MPTO.K2O S0Y(P8KL!'H<*QM][&O@/W[#F=6[O-P11W"P2-M@*]\Z/HEFF_-Z
M3C>E67J])3IV'\V7Q"4W-B6%;3HZQ]$>.@0]&\PX=8 88=&Z<IL>]BGHR0YZ
MHQIA-8#5><-T_D]KII7+&E*(ME(I7%1NX'*N];5+976ZER#2@&6[',O';K(T
MS0DX*CG5H=_N,E4N68F=2U:M71X0!/:GNZ43?:OXD7759L M5U>.O<<QFG*F
M]8^1D _CE#4_7\*0>6@/I&"332C6!&W^=(+!)]'D@OD_H.&(Z\=_&;UN?9X)
M^T@1W2.S2 %[".Z?VD7.%< 91!>@.",U'I/#2F@*QAY-2D%T9,['>\7SMFH(
MCR<GEXWCAW7X#[3A^D15Q"R:.W5L=_T[NL@FW;/&T7&YMF3/ 0N.2F]XRS\3
MQ/LG0&8J +*"D#G0^7TLJL4VKT?&9F%AX0O==U&=XO=G]N)0G3&S3KOM'JYA
MY5,^W-DEM:K; H%,9K<H70 C&-9VD]M;MFI:9B[@\Q3O9T&V5B?QR*>:4F"'
MYK#%M5B%A/*VT])!>18>@9S4,Q.B/Q>A"BA"<DE6%MKY?"CET?TEZ+G_#%=W
MQY>.>I.P(*4 /JAA=S#=(X+'=[UR]$[FEUH]C[R!XL6?R1HY+Y,>MF0>PO:R
M*SDJ*16CYBA?_. PV;LHV;G5=\DXS:4^95/36)VTA%X_(@Z^:_3X&"=B'6L0
MXQTIE"RR.0+X^43W/J'IDA7QJHI>*YZ-7J'&,\7HXS'K9)G+87U:SJMA#Q//
MW;-,)__*6>WV@4ZT7V/;Q!?W/FB+49SJVJ"M!L?:W ,O2]F4?>5!->I^:"%M
MYKE)%Q=.;SENB;VQ!K\<<1! @XFS>6D[55%4TSZ=MCD@7+GX$!F^SMN:;!WY
MP+1K_7'XAS5,1!2!HIN3'X^,.0)1$U0TVV>]A+/-?ZLU0^M.!3WLD?=GJ1_[
MOS?91;F$C017>"US3G.;'!5=N]Q/RTP5GE"J?)Q>I&T3_!4JW?,<9DM!]J18
MRNQ!JE57N(U$38)WPIST&LZ%ANM3]WL>PWMOWGQ#Q5KRHDP"9@-*^5,SC6??
M;(6S?BOU\$!83**/@]XZK/*7$LD"WN&O)8@2C].U%@6Z%6^!'P M\%H# W&^
M>=NGIZ _3 )Z,]B?** $W]KIZRCK*2_!]C_IVAXQ'I"Z\K/817LDD3G ;.9Z
M]>5W\#EQA83EGB6>T-7>RT<U4U6BX4A,&_^RV6]/E>"HH<:6&9?]NAZ8:&N]
M=E2EI=#+=T87_L&?P?2],G\#;E0I-\C2+:BNFU7;YD"R(*7@L>31Q"&B0F\[
MI-$TY\73/C,G4'=5I/'0M<K\\K#W)DRUU2^ WBE)CWZ,M1-Y*DOY,*#&L@=B
M)].?H,HQRNDI\2CQ<V!,SO-RH BVKD4_>'WV2,$R\^VVSQ&R<G-U"4%D)7G-
M2'-1$6:()KB3#"R<YB]:-^GR=L-4/5?M]NGY,PI1K;[]F;\+0!-)]#T^_A6Z
M)/:?+NIQZE< ,BQA2PR!W=DS&3@/@KNNBC,&=ZM86W_?\6NK4[HM2Z=V'A&>
M#VY0 .I6?]JPC"KQD!_M?3*P7]%^#Y^:4@3N7N(C/N] &X]:;LE*6C(VY_AG
M[.? OD!/(EH:FV^DIM]-#.T0_*6/FXU$H$8X&6>BAZX 7+3C16]IE%3?;WG(
M8&V=D@5L0U6-NR,HR9]+]&)7*?R%%A;I2A0#3P1RJAQ.J_Z!.%L#B52D@+:L
M5Z@ EE6H@![N(M0\2\-"?VKR\KG+/0PDRBY#[%0K>;Z@^I^L#:_8#>G,7)R>
M>!P>EMR;&;?<&^EZM.?L=$PA+$@RJW3Z:6XQ]+[!;N\[Z@#Z*<&9I2L=EF#]
M[9GM["[J[WE;M=GF1-6D6FRI+&M086V$]67'!QDXU]?RPU+>D CJPB3GQI^M
M*JU;LB:@O_W3M_NRQ_<+Q#<PM^:[N%V?;5@-&MD0TC.[5FMA(P2OP)R&29WE
MXF\MKC_\M6(*Z[V7JX9RV(B*,,,!$)42/<RG,T<*+_JK% NBF5_XL["@6@JV
M$LY?&N<KHX@J]D[H<\8_XHMB1ON](\)/PK]7:(.7;<M("%_YO]_I$TA):A\#
M==4MI46/'SRH1\S9^5I]-DUL*W3?M2R\_V<SKO#C'8^N8NDB;!QV^"!);]S!
M@]U,Q)W)VZ"$,\N]<,^FB[\@;D!/:PI_S^Q0;K)48+RF+:FFUL??"8JVQWOE
MZ1I " F>6T6\\UFUT4[@5#.0OU&+5<'& ;JE-_,$C@LV2=:=/A96:VT)G=S*
M:V]43UM,>-9I:R9[U]95-(?/5714:+0%24] BWN1U[5'"60:0!^98M),#L7$
M)R8MU#*EA,C2#.B]R(:9;*1J>.,GH*H701>5'[RTJSZG;[D6@A=!)U\,&^M"
MG5:1R)>T=4FC/_?<$O1&D(Y\IDQJ]B0_^*]4ZWCT\UD*AO77$HNB:XHZ9;Y\
ME-$<?WJ>\EFE@KQM!@7P2^*]^%MC/XVV!MA_M'I)^QEM#\UU^VD]G9%8;-A/
M1OKG5GUD'?EA]W7.QEH7MEPZE<(C]4UT3W"N#+ZX.>>.WI*9KZF]>$/@(YK"
MBL7OF\%\5 DV> IL,DSH.4<0'RQ+=1I:A\'$/,Z[U-S?+28&CC[94=S"*@>-
M(YW^%FSM@4[F+K+KK 2,IX#:>$ZBEH*P1;:76)U/TJ'1E&V"N5(Z93-$IO(U
MO/;7C/;CBM^#DC*ST^ :UUTJS$$D^"9)$!L#BN1ZT,XQ3]+^?40$Q5S2X]8R
M.2K3L8W0QW1J[S*O "_:IBJ*J6H$Q47$]_99F8>EK@#\;'\A7 0^KLX1^ ,G
MO].H^EP&6.5FU[\M*&Z)0XOCQK5QN^]D;K@@Y6>F[4HS7UDF1C7:OW5<,F7_
M?GA(2 *ZW&;[3=:0)17CC)5X4R![MTFH\F/JF8'SN,4.,MF?9T/B;$S6  $J
MM]XO&_Y%35?GI;FHWN$RLHZS_U_+!K*+&)3.9]-VPK(79EY8L9R#6R]PY:^8
M0 [6;62@I">?[U]?DLRB1C_0ME8&!3>=!*WD<55_:4YIML\BVFYE&A<FH\VZ
M6GJ:[6(%^89JG5RJ*H/&Z/OLBGB6++;C7[FK^)-!ODYI1&R)QX)P&LLA7 P!
M5D6P99VI^H,[.PKVB5#,V;M):( \9[97D46!FKF%<-S-;8'61&UZSYM#23(U
MT,Y?]=<.7O)RD&(E"T2N;8V]A]@C":S2W%UP7H:B\J?K+< L"TM+V^:I%P,G
MFO.E:,NWK9F>:?@>AIM/C&$N@ 10B5[X$F? 5/E4Z7.Q$D$U&=VM$GX4=,L.
M4?\'MQEEF.P.%4O4K,LER40(0(EV06.U?_VN %$;%PT),)^>?_-FSJ?I3D5H
MH%][J5]#&I,?+T!P>H\RO@PYQ#ZT'I:Z$#ZXRW>1WTXQL.H4Q%FUET$'JYQ5
MB>C].?^\/TK("N9!E'<]Y9MZPMW4053D_["'VR:FCPPRXV2O5T43-%[=8YM
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MY+:B.SD/TCV=LQUGNOI."%@=?V=/$=#)B8]$]4>OV<H=F4^J*['&S-)(ZT=
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M9R6T":RMW('J/9HX*8CED3:EQAO;ZTW>;Y<%HF1^KW5.W9[@MV$3C%^JUG[
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M5,[KAR(?K:%T@">3("(,X"\_+_H>" .@>-O],6<Z=QD#&*X]D(2A@VVNE#&
M1.D(PO[@G%)Z:&_=!2/I\IBI^3=JHU$QE[S$=J%-'@",-8&$8@.; 6+90\*!
M],O2'5$[!K"FDUOI'X@TJK3S7O3\4R@UT[G2V4^ZR$SVAGE7TEJ,T>"C1Y+4
MWH%(4=2> D=WG%8W/#G*P^98@MW@M!3:L:@[I5$5+I@V;QB[.JND=]OF=0M[
MFSGH2SBUVZR.[.M;=?PU\1FP6&6YY^C,'.G%]8S%,\W/.^R=G^9!3VI+_2'@
M6 5.RQ\@G<M3:F,>\/5PH&.N>?+]Z--L?!GRS%D]#J_K8#QJ41@%:@$YW=(-
M H(%SC;N9H8BJR1Y-Z'DX-KWD^,M/JP+54TFJC>7$@9,G>WIO[XNKB7$')01
M$X\#:MT1FPYK392QAT+."]!!/I0PXD]Q!=B[?Y5YZB+;[=,>T_MYH5CQ43&K
MTT)%;5']PO6GTW&<\#HZC:0IF$4B#"A'A?REGDJMRBX>9VAPMC)4F,XXN[>B
M5)GT1]]0H-J,0-PE>J^HZ'Q%ML?$H_-*11\=+'A-7;WN94?7'K3=K?5#ZO5!
M*RY=,JS83@^XWC3#=+(:3-R06-%3;/ FL*KW[15?=]TOOO1X/F7&5Y]Q7?^Z
MS^O-*K*-J^LZD:2I\B"<YMJ]]'1]I5LD^X]JK3N*JGJCV,JI-&3) =INA&5;
M<7X!1&+C -:\#VK[!G/II$5N5%&/@"Z*IS$Q27C48HNBN+6@$-57&=J[C:42
M9<W7F@X=58?[UMH?=@H<5(X+S*1\GZ@QK7\^I,+QW\S.Y>5:3TQYV$;OWDCH
M646DU2],8\SKZ@HAZBQZZI.\LC+67,?YZ'WL64C$_= E;K8'=)8/3'40?9OA
M(5VX8%P39.)FMA*!&OZN;IAG#A?UD;.N&*&A,=N H<%1!NOC8:K:E/FW_/$C
M)$1@Y<LL;)X3968";H%31DG*GRA?!G9U+FW <&RO1,1U?\"E1!SN8H]KN#/$
M?C476K"LC'P5P $7F,2,54&I8^&&VA6ZHWQQ):Q2I9J*&W_?3&N$K!U9L9>7
M%+)02[0>U)RW;?PQ^/6)X%+45Z.2F]NRF(7=1/"H)LE.\-AQ-<UFSR8"8I\;
MG$&!NK$N1MCT>%&ZB*=%[9M^=XQLJL=KRO@P3OQH]O3$VS(&X*?VT-\):;.Y
M^>3$.PXE :=^Z<S!5M44K<B2I/%YD"VFXI08/U1558ZDM#^0"CLD??10QLM,
M^E!8G_6L?MVMRI_:ROV6*[V&@@1K'Z<F:N(KYC0KP!.%Y]YU!9 >$8CU<1A:
M="+P)5+D_9PD+62C<J8C;.C=G.>]4F7@\J.C<?B>0L@35\FL<F>N_&Z+&)>O
MJ_R]LS]M,LU=/%P$*J-2?=?T-6^J.0<&]7].1!52OT7_:E/Y(61E[2/(ORR'
M\' 5'15DW]9IS-;1,^9M:,^JT_" ETUEVFL7_Y(&EW+*+:*_(-,'#8%A!\4S
M%RN&:_*37.,_.S71EBW-S5GK'"H[3^Z+R#J_2KMY(!_J[XBE#3H[&;V3FK;2
M_79M.#92+5F1\7X@"&*N9$YHN-]S=HHJXJ4/!OVB1)'?7OZ8[A)"'O$N0#=4
M#@__1)I7V=TXWHUG2B:24"!37X=QZJ/'%HP4Z"-SN+HNE[V#YRYQT7@3M^+[
MD ;G;EYBL%I_NC?9_F+6%<UXL8/4]!QH(<G>OJ$KI_K5,YT0*#[>0FM,,^>O
MGZVW9!D(:5ZF[O4]N, -Q<>N3M70724=2B&#M_7)FJ74N]2VQ11^G&&X46G.
M_:(=M9RENLVX!/B4 TJYW/@-'FV5M_@5[CJ,%2:RQ;2+EWIU-]2?E(?(^%E]
M>5"7;MW"JZTX#.&)0TVV1B>3P;\=,8#?171H@,YC,NM5\## )H>:6*'[8A"2
MZX --?9?8@!!6'YVF]L5"+$0>_O,7GA_IFBU_0+"'5_GQ-VE?+JZ>MK0/K'K
M/2/A4#'=)/N<E4N*/[Y?<V9 M"CG]FI-!TG@W(>89BN(RL-G*PCZOQXH R0&
M@ &P-]Z%0 X6,0 [DCM^^]1;E?_Q+=@@/@P &RI=JY"@2/?1P\Z'P1A .;"[
MXJXEO/*.]EK>+!+8].\=V7 TGB<&8"ERV8T!3,>OZP0NOQDQW_]Q+?^:O#;1
M= '.M6Y)LE*G^:IQAREQ!(8!&$*_@)#<3]=N?5$RB2-<&<\R[4NYT26V<%(7
M91*^$$UFNCAL5GLLC7@="G-MH,N5%67*WU^%?HY'<I/'0%L@_=9TB46[\@"W
M^4@%TT<^DB3N9BJ]*4QW)7LSBB6-+1W'W@ZESIS[O^]P^_!@=[;^)Z6:GS54
M7\VL[A\TSFV>2@/OOK&<2HOY2^K_%/9\%.:R1;_OZ<#&9E2VQ0:@"U(E=KAA
MU/S^.O+E/7/K?'XQ*TUM1T+])]^N_?PV<>)W'JR7M)4@Y>'.81WR8-:D/MDD
MHK<W"LJ-U<S4[(1LI1P30VT&*819KS[$S!TR?+LU][_7.E<ZN8U0+7>PLRO4
M7X75VK._F#IV:G(0G.$2O&79MLSH5WF6*#!TIN)-O?9M/OF\+=5;C5;:5F9\
M32A \ZSMAI5*E4"B_*=<*HM7K0KS+/ITPCY[*SW)1*U,8R+7+M(U07Q85(K8
M^Y*:]3="U9TFM_7K.(F Q\4X!C"7+XF/.#3:7.N-)[+S=42W;5:3"LXT)I89
MJDXL#[A*J(DIO##2>4%J$*PM.__J!35MG7Z+6>/.P:V#X" &  ^,='X(7:)N
M-GZ19!DU/1I+SC.HE_8@S%;=.2$V!H]9CV3VKQ3Y"^^"":=SLVCYL5OM\YL+
MOTY0.$,[1.3;L9'K9XW78HL0L("OB[?[^.,A)Y^B;DF*8:DW=M#*CY6V[279
M<"+.][."E<-"]+S:0:9V+1J13Y1M>L[ +Y2??K[''-AD64=*@:8?<)V+;=OS
MV5==.S\"AE\3)"FC/U:"CEHKE6_KKYK]I!ABH[>'[GHP@(!_H8U\.O *<//J
MRW5XZ0=?DF&-X+^@%THP=, 4"C3,?3<<"$1%])%;?JB1IZ-,B'O,]'FGM?RQ
M)F#^T>I7'I(_M-=^D_]52S87=5N*A"08W2:@H8<3KP$[N @;IE,N61[YO#O(
M8.:_,G*X>:C09Y"SH]P-]!OG&V^2??0*?5L8OKFJ[\4F[IS+?MST"(V-\2M+
M2V * /P7K&[7]R /F( !X!O?@5Z@R3<]IBX]#G*MT&_M&B=#A-%=HTRDXA=;
M7CA/8=,4TATVU]K1$@]27RA2L>(@YG#=OV\%^=HP9KQFPMU_K2Y.LF/D7GM]
M!6R#).)GMO\)%6ZOY.ZD:?BKX,3"]$AGR*P=NM-YW\?WD58")!1,YR&YCJ9_
M];Z@>$1PLI2@:0&26-I0B@%(8ZDY2.8\=M"\7E5-JI[_^E-QGR^Z$ .(*-4P
MN%W#CFR=UT8-JS]L *M>%Z2,*Q5,%SRN=LOT>Z?6N8=9(V5^[/':\ <2";]0
M=,YU7I!O4&#C!^(@?"$,(-<# R Y!3:4.OB)&J'8WEJ)C<4G3Q]1,^5([[2A
M=C-IF8\# \RDN\J/415*[%BFD=Y% [<8QK%Z#T??C[C,0>5JO@&IM6FR6X[_
M[LC*P<4 GLJ2_T>Y.VQ,_'SK?W<_7YE?[(7[5!X6LP&[ J42W;C-PIO "/HS
M6?Y"/3&Q<?XYU,W,FT4]C]U%6 &VXB6V8TE )#[7X#!YT.OK>"NI]-T;K:O:
M,M#G^+\0I;*R"CY<:ICD#224YY]]C;<RZHO5/"<\+MZ,D&R%HQ\ 3UGMLE69
M%F+NN^6=*M*_/K^?8?,UAOZKV-\\!CD2"37SBZNR$]PW49S<D)UE$,DIR3\%
M]F'3V[='$%G)Y&&MZ9UVC\O",:=0+>D?E*52JGPD]*Y(SZ*25)RLF[C<-TCO
MDMK9;!#6KAJQ;.4C4Z&%JBJ+'/OZE367CK;=#39B.@>/9G;WP)NGX[[P++-/
MGU1GN?AD&.L1K?=%-_-9@1J[[S4ZLC:/TG;_NJ*@J8)WDQ).3'0W#-?GS%H>
M=K,Q,_IRT_ ]F53>.&Z6@,;&[(''<FDB! ^5,LNC2G;D=MV*G9NOG9\=3BC/
MY6^94>DYAYT+MHQQ+(Y96T5?V?$L6":^SW,9>/\59YU<]GW"YPY??T6BD2B6
MM?H;A=Y>/JMWW-N5[E^#O<RI:&4LZ#D7NWC9:)Y%\%\UM?; F++[@MR_=-<^
M_6&G*9&=O_%YG"#8:6_(?7G\L&T^SH2"BDUN]'/;H,-Y#44V:^HOO7R\LH'3
M)JI10PG.%=Y,U2N;<[,0 >70,Y3\C$L3AU;_3-_T9:1@3:GFB1/Q\7*]H[S[
M>>ZEE7X-FASIRQXAR^TJ:,<5(JGYMIX^3OR^)3'RKXQ%\LC-?>#RH+5^?D#?
MKQ])@NJ[K:G4'_#^XK)2+_-W4UQ/G!A=-B%Q3_8WG*,\2&C!,+5)H=HP ;LY
MWW-*M6U[/==]RLC0AB@(\OK+<%NHH8-KNS!A7MBCKOCPRZ:[G-+F1C":^6_)
MOF%+G?#ELQ>E7>WAZK',W_4]MK@9^VCX7KU7'^Y73)+C_-/ 94H#+I^ZY/\<
M[:;2RW%SNN"P$] !&V]XWX<G"2-3!=MK+V:M+#/FK4GHJBE?^'T*8'[8]MK[
M*?6NBTM@H$+$9_[6$Q'O?1BSF*$PA'EPY"7!Z?(G8*X3ZH)BO66M$=H=361(
M3W,&3P_[='S$'3-"L:CV,!<&_.;T_=GMU5&$QO-/Z>Y7BKM]8,CE\EVFI(9P
M6:*_3(#XIFQGP#.X1">)4;1F%*T/#5/%SP>[ H;269+?<QWT$H$NKDRD-*U2
M)937YMB9UZ]M_T%J5\5<<WM*.].[,RUC]V^ "7-$@?^0X$?^I[%GM)SA@_KW
MW9N"1W>H<&O)\QH"BI/$^ET$E7(%S<2SK-(7TE/IZR7P3SI9+Q.1]VKV2(IV
M(4\][&HR8:^*YS)BB1I]E8B$;?N* C]T31>D*;Q/K%2(8V2KP''8R4@_++V5
M-%@R6S$#SPZKE7;/Z;7;+!RM^SF(UM0Z!DZX,\OZ)W]:=)RLW]8UXTI.C+(O
M 1[T\G86TDMYOI,,U"W:/"!KT7DL"I7_=0,T_7ZOF[#KC:2Q8(<S3'C;]U%L
M?4S?E-BN8I RVUG+"RZD[7<RZ1 ;@(=4@,/6$FCIU:7W=-.A15_:JJC^D8<4
MK\(LRPQ/HZ,U3*FU87857+4=6S)IN/)5*'7H>,.&].XB<8XP0+D7 Z /) %O
M#FB!)7H")4_F(CK>II&M&AL9K%R'Z3MFCGK&6'F-4@=]H#"F^USQYM[9;T=>
MJZZY$,BO*T;]@V95_CB*D>:Y'ZK$*YE7\29G'Z4(0WR=-AF^+4VVPB)X"< B
M_>^^J:46F]5=P\8_J$Q<!Q&V:O40S8!%185F"YVT.8/P[^-^P/HZ9KH-U7N#
MX)$_K6L1,?+!*-5YD[7YEO>J$U?%A/6!."Y2XD%$7N;;-!3L,]KEK>Z] JK\
M?ZXRMNN;<HYN_OK.XX861_1-WU2SXLV$T*18L+.RLU!:5Z4>!_@!XV=U3]7P
M?[!4$'P-28]O#9.6:1Z>B$8?O:0;H:+R/QOGW(4MW+=QCI*6:CXK%#"UG9T<
M$>]&-(7,+H9?AFB.=IO_H60.<Q,1M)1S*>BRC7G[(8V=XITC=4SPJ7_<8\F2
MV9'=!/?XN2ZD!"+\-=("H=SOU5Z3"5<C!4</&LK&,)"<I(<U-Y=7*SKZ6+E6
MUMG6L8JK=%60/V-\:95*+LDFO^R*LQ'^\_MW?5_CTV+VD:*,QDW%(5.=BMD;
MN^9*YQG1(9*0_ 1S\N^M8,7?V8J&_(TI&[+_?M=K;TZO=SJX<[.#NU4[U;]_
MB3/D1$L(V#T+3H[#=>-/UO*IL^*KI[O/? _&/?[("Y$</]XETW;7!K+^(<6K
M-,V#,I).91DX6*2'AL9E^OC N46,OD_3]EW-MJ\WZR;]YFD@_\)Z#S+#\WK)
M$$U\][WK'GCM?;36I*3+[(BGJZ1SZ>I?PVG#RI)4H8&T0N]2(^D8J%W#K55J
MG^10!!/1YWPPZD8TPSAZ<2K$T[\YQO.XL_DWRC".EUO;@C+\B[T6M(W N;T!
MQ17PSDI3*?C%5Y(,HN4\NG3NN+>;I>Y3LUGZ3UJY".ALO-U>G^_"X )^>F,Y
MP+LZD$WM4_M5ULDJ:28[Z_W>R]FD/=^BYJF^$H6Y5\JTBTLF]16"6VQ//V\]
M R1^MC^L/72^E=BCK)N?]S<\F>EO(8WVTVI6K/Z8^/C52-FR8?9O >"R/$U]
MY>C;X.2H;[I]BB6%])2G0ZA?&Y&C*\>J,=S.L2P0H:XEWUSYQL1'_$^?>X[K
M9X7M!SV2.-^_GB*,RFLY)OZM*D;=/2[NO6LFM =IJNUFJ[ZPRT.&6GG[Y,W3
M_LSFF)STJ];=/#B"2:UDQS:ZK71&Q D8&GQTJ7B?215#Y?_B]B,:UB4T:60Z
M@8+8$&6)/W"X>K*\F]%N;$A5XN?#57IV'@$W>.[Q:MC20X-*VJ'H0Z+'WD;5
M>=S^P5!+N9G^*#2=" DYY;IQE1^V]'ZA3U^>F #>'Q*%/4?DX%5,*CX!B:91
M R,4_*^K^K8!FUM<J@\8[L$D'YA)_+PU0-T+>*".D,1R6V3CK>+YDF4\:73F
MCVRY)?V,/[.K.#UV@CZ"M]IMBZ^@ZD$*@984Y1O 1;7UVN@JH:5#RJ$;E65I
MRH:6=H30P';53^?"C^N&R\]] 'H,%O?'(#,,E/0<Q;K1,7F[O=K,?Z>2-4PG
M= =FP(9TY;NC1=.E/):;])K)O\?UJ[J2=>SZ2%CIN5),5O?E*;"941\B\(DT
MHX.2^MLZ&?SBJE/F&LDRQF#K52JZ1I=\\YFO=6+6-<F7IFVG(%N2,,9%"O:7
MA:*V>AQ.AGKFS*KK1_R;?YXF-UI$G<93@L^PR=]3E!G<T:%'^OG4Q2^:U0NN
M)?4F>9[DF&.=Q'H#\5#"I=?CHA0_3M*'VG%[81$Y3Y')\/*B+WW2CS-V#*99
M@NZQ-[0D6PX]=[N7JFR)*F^-\X4D^;^N$[B1VRS_21\5*RE".OW30NE5>H,G
M^T?-Y!9Q4UB&HISNC_@%(SI)K9B^N8T]9,:\_EOUNQ5>&U6>$Q>MCMJ?-F,8
M0&=Q>\/-6'-;J :=R#L=VP@,0%N=D;$V[^%W'[&MC"9NE/JCU=N.0LJOPP*/
MTW0B +CY+JJONE$.<#^2I8;+C]."^P%><_#C$-KW;?'O/')HYTWYA,IT3_59
MN-Z5P,<G.8.%IR(6E%L>*^Q]PB;,\0N#W(J-?]&<MF3O+^?$BXN^MG7437_Z
MW#3-[5RV-"#5.3;B0%YZ,!MU1NA3SWC !?J]S2"WV[R<3Z.1Z7257*BJI]:4
M ?HV8^; D=2@G*/$?ORSZ\?^G91:U;-S?G6YWBFEJ.J965'+Y%I9,77?6^^2
MZ-G[W,,55*W67OA!'%O^0W%&,9XC#$W7UQ ,X"'977K:OM'4N1DPV^1<IGAU
M_]1@U[>CLD2VPD&81DPGPU'X\41A$E*@/)NP]2G@D''P=I7HKA,#L(+1_O65
M.L "=H6!VQ<#T(J6G?*\59X_]HQ6>;8Q\.M7%3-A8Y=,&2 1C_%U'IO@J/3N
MK69BXO,':,!('#1 \7 W.<MC7ZFE3JQW*R9!54X !#N]J!T#QH%.M'(78)<^
MR#9L$B0Q]!2<L]^_7P"V,&WOFCSX\'E\<6X@G<QHES^%HX8QS5:IHTH@0CE)
M>&XFD/NNH.LI2JAEU@HA'^>Q;W;@0$"OICYIC9]1L+C2QSVF]^1Q]]G')-'?
MTI.C%6^T6M<! :PLO11;ASVXDB(62S>754O?GNM;NNWUJ*?S]@Z&;_O@5G+4
M/;\X$JO-0%'<&OH_0G0V&-OF/FUTE137GSFJ.LK[H=9@E]\R4B98E:/U9HO3
MZ46$9E$-G_L<F'(SO$\M!KC8#"+NL"I!ME4]VW!.&URS]/K)N(P396-I4I6'
MHS+D$:I\7RGK?86?"#6;:E&*?9>AG9*&<<N?)$<6>HE]9RCANPJMHFW5TY3I
M%',BZS8M)TT]%7FS:).<#&"*6:-0]=6AQ:V7O^1=!F^-=?J&=T\U Y#._\UD
M@1=-8&=5?_/LY=.5(>##ITT.9UO#PO6#%7V<&7=1S<U3*!&+(D.[RUFOV6>7
MPAE.F80<Y81$A$YIY40=%GCDNAK&; <"H.@H5/+=5^8P7B0;[#"7;KVDVD70
M+X#')X)4!M#6X6,>S,PL2:B#A_^8END!%44H%DK$=VW2@H&C9A1H!KLN_)-?
ML5=!1G+U78AG^0'%Q:-KQI"B\BEN(8)6%B._A9GHP>:C^L=Y&>^ZY5D1_JQ/
M/K2:L<)-A0?6;;["78QE]+B'E'E+Z4RMY$DB^M4+@U-<9EC?2H^&V,]XENSW
M3$5E:F2WF?5HPOCTN6K%X#&?2J-[+)$57_UU@014<X.#'O9OB?I(Q"9#"JE5
M3-I_>ZFM3 X=/E#=[;1V #MJ$":^[YE/-6\LX1,X9E>/C:D57=?; J+(-R]_
M-2!9UO$"R<"\&F&;<+,X;KH519L729M]XL83PSR$9X]&5;A\'B^+OXHMC/-5
MA*Z7Y.+S8@#6E?&QPN(I+N YN>^W3Y$VGF[UIBU1// 4H\78M?W#6:#TB=,]
M]:4@L0\D6R('D2?*0Y"6VD.*6G\59*)K "CH_)>3HWN_[Z]EKL3KX"^&8.L%
M#8V'K0*,_-&VBS\4M^9RAY9M(@;675# /M&UPS%GVJF^GV11^2QBVV#?Q)!L
M\?I2=F4242TG 24!5[M2EK9MA!JMY&*869^Q%$5D.(6Y2Y,[Q_E,#L'#R-)?
M8;$B>(I]%#1*RI0J916OZF,-2L>Z_BVYHA\X //S 1T*(;S&'2K]/#NZ3JS3
M*SB-BS  3F-HQ';:UC.?Z'"%A3CYT7M4M8O'0=!&UK[<11+YV0M8N);]*_F-
MW"=[TC0S%M..H94RY7;)34W=VJ96<K;S0^Q4_(</@F$%\W\S1,(EN2G#/!RY
MN01_B<@^4[<]>?M]86$W<:&=0A0_3[PVNRW2Q>CS*[-ON2?*&F1[N8W3::_Z
M;Q21$]4R-C@OWFGXJ'% TQLMS#<EP-B@I$7HPIA3*1=/:[1^C(+$4;.3:H-?
M/VK"=&(NKY#P?3'(5U5Z[MN;YJR"6A9@R(6 Y*OUO]MM+%054UD5D":C[%&A
MEQ5N,V735C"<91I[5>*]8YE+_$4-#EQZ.;&KY;;AW6F2N69.I67_28:MEVK3
MPY!O0KGD&H,A\JD_DP(=^QX&4\%*U%1;]X, G8X]YG-'GU7]?'+0,S>6[+VD
MR:4\]FXI&8XK;4KCWJNSF4E*1Z/#=\0Z^6)-M&OOSG6A7#Y5QY,JYUSQ'6LG
MP&W5DO_\K#;% %BN&7/^G9\71+$_9BN( OS?#L[_:1%"O4.A0"X4EMM3%@-[
M09>.D,9P]-<F)4#?72T&L"T(.E&NO7T!;<9%%T'N5U["2;#M\F[3!S*AYS"
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M>\O!X_QS2V&LI[B[1F<RU_]VV8)T<YQC #L7O%UJ&( C<T'A&1G:3P8#B,<
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M7Y-#B,_N:6!X;^[)\?$7LW-RA B:Z! [#1\E8/L)"B1\XFUOROI!#& _>Q<
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M*3F^SJXB$<I]O7(W8T-KOS*$;MQIWK[I-S;ZH=)2H6MFT3*&JORWF@'.@;3
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M+9H -IZ<V?XN;506.0$2:?5=90E407?;I>SYP[J0OI"^"X^:+1\M==U@I4]
M]9695)$A=!V&(06!#*6#HH5+$/_"-&A;&TR2*[) 0'KYFNWO4^D;4)CV&')
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M1L,!D(W=1NR?JOUBT*=]OFG+:"==7[@6?.03V]R=<B>E\TCKC.X)@72@%N+
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M\NVA59/QOE,!5CM$D%4I*XHR(?L3P-_[_Y@#^"\!"SH-L;I>S.M>WRE-L#=
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M;0 :#+AVAA&R30GK.(\J3W>";VI/2+661ZXT1L'O6A?!L%7BA/3!MDX(I_#
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M;+J,S;K:7A6_#J.CI?1X XFN [S3%Q$;>F+ZS]]4&"/I CQOL0"%>_?-Z@\
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M_7YWISJYN#)R2Q;;L<&Y_"$+Q\?NY %*^1Z=5V'['%<VR7YAQ_#\^JGQ TO
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M&;2B.SV5(>F\6&4N.M]%2O[M)PNL4KQ0W-,$[Q$R7U_@'T')'8,758FM[\S
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MTS?VRN0V!M<4$W?RC 2RX2 NK.D/'FJ6GK@<<T>D-U%3.FP@93Q_7M2+J4B
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MA-Y)J(&T;_.\YSGG*>>?][SOS#__S#=_G#7CWMEFKW6O^[[NZUKK7C)^,,:
M@]>O:E\%F)B8@'O@'X Q#%P&]K&R0EA9]D$@$#:V?>P<O)P<^_=S'.4YQ,4K
MR \3$N07$#@N>D;\N/!I$0$!"<53I\_*RLO+P\25597.J9R1DS^W^R-,^]C8
M./9S'.'D/'+NA,")<__C#Z,&X-X'S+*T,3,) WNXF9BYF1@-  P F%B8?OL
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M6$V$$L,*F<1X#=19?F_0;W;5/%3!I'F7N;*8KYR5DWO9A&U&HD69!YV[0M)
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MIM)5M.1"!I <(O&'UHIMV!$K7-4XG[;GQC&HF_A;+0.=DYO"AF\4(K_D:CX
M@^I.(KKKUNB://KWORG<C5C4&@#'=H&"WWYO9'2^Y(G%L%AC8?9IF2US+Z%^
M!8TLV^Q$\.>/_!W?XK&OY'./PXI_-1]C )UGW>&T5>4\DZUQ5#)/\7F>=GI?
MSD'?R_">PM!3;0^?]C=VI:5.YKD7(J+T2#*F;\,Y#K\-^W&I>0/>DPG'4*\,
M-HZ+P^O9G;=#!N\_<KZA5)^;1T<2]1XF5UCY>(YK*BL2*M]P,P#-;&X?3?P$
M7&ZXC4Y%$D+4LF5/3QS8TEMF "^\-J#3ST9YST1ABFP_M\X_>(KM5.BZ[7.Y
M6V:?:?P=+?A:_]/J=YT+(1U&DF>"=%2:.0TUI;QFW:*,3+;.FM>=+(Y73E$5
M.L\!E[TU(/[TCZ.^]CTC+>Y%QE'1#X D=K,IC@%H'-.CT*LG0.N*?9-Z9IZ<
MB7:PQ:YS%S* Z@6Z_.R&CIKM825<[L<?8Y+?4['U\D^KZC;?+E=MT*W*))+#
M[VORZC/]LUUV<V>)+ABY^^W+):SG<.*2*9H8,PM;YRVAMM]Z[2VB;/Q2,$VT
MZE$_]#4#8'O\''SY#?3WOK<>V"M?/YX(NO5\,OQ%EG^K>)% Q.)UG/9L:M6Z
MO8$F]&3MGU[RAV:!)I70M0^4,X#'#&#'0-"+Q9,!-(UNBUY8H8$WYZZX,JW^
M!@!>UC6=/.C[/I=?]""&';/$!^\>:J)_P>812N@L%M:W-%2*2[COJD\K)S^9
M7>B_+? "S@]0ED.:B7GE?,$54I\69._M+X4.:FGZOJGVWP-G__%O8D(RK"BK
M-FDV=BBWF]:8RB7W9H-=[OFRESZD'5[(%8PNJG \C#DT/7K]M3W@<:[J:+6.
M_SRGIYAIG]-,O]O%W$MS)7?-;ZY=^Y73$+D3G_L;;,$05!"!(I 0&JJ=VN@5
MX(FN@6V+$='XD='OB(Q_6>&N4R.<!XP(:>*6867HYL^;V$<E,UA9<LL6LPNZ
MQCX?%\\ ;*IY: 4-)FJ" 0S [3[LHQ*$;E8Z!DL>8P U[8!'VJZ14 CBH0;T
ML!K [XI['RIIR";XW7'M!(A3L71FI"0BG;J/!-L4;Y#(24,5#Z4^&BSHTMYZ
M2WO*#OY$!O/"'Q%0Q7\S#.RYYWT&<!^$G'6CHE4:2H.BA6Y5^<P /N>@=R3-
MMGW_;8*2OCV/&'KXRRU@J3VU>O2%26CU6?LNE8NDMB:S8\+FYB>S'2XT>WSU
M\5:JMUZ(7S.38%Z$,5/O$%="0\Q2B@(SM*B>(V?;L)O'4GR#ALKGR2R"*6ZN
M#_+2);\]T=B KBO6P=_@O.75!$@Z3=9/>7JV.W?JNT2#\-WEZRJKZJKC_T*X
MYV0,Z<9-(A3W-NGQ1C#B[)!_75C'S.?->;0^4[_]+^$>']E/1?0O*&A:V?H9
M3Y?9+&7+1:D:'TO*I7D$3@P7D!L04*U7U)$T[?2D(HN>/F=A."YSR(XNU0_3
M'Y 1&K>L\Z]K@I=E=[&W).[W"LO,L.=S=,^T&#$?4305?UON:UUDM,M6<E%\
M=64,X!7V<7BJA07'6(4!CQ^E1(,<OPS&IY^:4J5^K^9]RP2\HK((G<RI+F2N
MZ?T06?"H#+$UM/PA=/;5(EQ?\B)FL+S!CFNPZ*.DGM[9ECAJ5!?D=;=%<";U
M(.E7?!K^1A@)8E+X\0X#$!25I68'5/<Z%69'.F:8WC73O=#L?.AJ/5%$GLFD
M1.7B!.R@QZV)]FZW&Z\-/A1JE%QE "LGOF'SY&Z[ZD-ZJO;1$N67#)*_D*YH
MIYO#HLR;(YFQFT%&-*U2G'7([>E@L>"!:R.LB,MO:]:/;^'\%KKH M3;_3Y<
M3V,B"W[-YHQ6%#]J?>5NTSKK/9&TN: .LS PW1'ZFNZ!N>9OU+-L,M[C'.TV
MS_5$Z\%%?[/?@)N)U-P$VY;<V:*YZ=$.%]7CG4E!].M5E0S W!#$U]PGZP!B
MF,Z\ZXD$'(7%C ',IN%>22TQ #"N6E6(>-J+7/3ZK2Z(QM^ 199RC0&TQ*6A
M?ZBC9TMPUK@CM%3TY,V>ZL7C\/4[79#OZR!-]:Y>!"G="9F## !_!/X>WPU=
M^^L=7J8UR!*8?L4@>J#C&Z%WSIN1=C:YAN#TZP>P#.!>!A@=#D43Z[\-9P->
M P,#V<$#6IB)=.N(EHE]X;GZ_C3(LB\ADT,V0K9%QH*"T9_5A._<^49Q=%.@
MB/HE*!Z*@IO7<)&Y<;FS?\FAO[4],;C,VA2;K?B/W0V'WQ9V+O-:P\S(UL9]
MZ0,*WNW7YTKTW.3:3VQ91E(7YF2&^!JJ!ZL.EG2?\-');(L#X*NM9_6FA]$B
MR+-=NW9A>0W;WG<'C3>F/ZC:1):I11-U,-27TM4+60Q %NDM\Q-V'3#[0S"?
MLN=_,6>FV;]@N640D;CUV,_7 [<W0BL&$?ZCX.OIAJV3E2+CCS/SA_ WKFZG
MJKGZT\+KZ%^IV>WV/75UW=/+/I^<D GYGXHQTW4A$GDI3:IRA)CT:=.?MGFC
M\CK33?!!531RQGS# QV@ %_$<0_IZHH\6@49G%LI[0 7P8)@\>BD0$&UR\)J
MUJ^>(*E?%]!OP6SRW2OIGS,-_9AK;U)V^,.6NY9JA&S_<)>A=LG#FS-'-+_I
MMO+,FZ4EA-O@$06G#<(@V3#UB_%KG-[-.X&I9L?V##S[>2Y]*W1#M9JKX[-;
MKMV:>97]^Q)Q2KC_:N+ZGH+L[K0@@P&S@BG9N _S)?Q>6J0'!8<??-=^\%1[
M15M3Q][:Q?MLR #;R;<,@,/N-CVZ_\MDZG#^B>2R;'A0V487I^B389#8)O2X
M;)^Q-Y,)P$.$'F?R>"V^+-F 1N;JN%T\X=?0:0S9%D)K>HGXG%:ZZ.:GEU3<
M3&\W%B??S\@XN7_!5/7#.5"4:",^[42MCMRBP&*W/RA OZ()G.ZZ+&F?W=^@
M!92<=Y["^>M%()!<N]2T F5Q7=>?G^)WX;?LX;B]5-QQM)$*+&,6S;\.Y_*Y
M$D*(&+YM''BYIA19BOXE6%6I%CUM9*0;9?VU"G84<6 %DOXXJ%ORV_S1:U8B
MQ_UK>8LF+7A(;X9.9]MZ+)U,:!;Z)..\M+3MO=-WJUE%^[2ND")3=-3D06]\
MG$GDI\7.W+H'A." B6HCM1")G+"ZA%P&<-Q^96<+),<:"F/BN=Z;?[WC3CAO
MW6Z-%E"%34,+"'K;_(4K.XM2_,4^H-U$3#Z""!#@UDFP#KU,_K*!C%N6-]#T
M2!]E^9<FZ/%3X@J.3X^U=_PDXM,#.Z]!;QGSW74]*63#4/IF]:LS>?Z/5"DB
M#,#U";R9E!.R,5L?P0;C"L,M97\S/V_QZE3W->*WB*9&\R/GPG^$10U)&;[9
M^GF2IJ!Z<F!#-CB%0WW1&U/3/S1&/SKOZQC0$;^T=NG7PWN@;Y;1JSO*OY'F
MM6)T8.X!N4L932@&<#8Y1$HN5>*/0O4?3:J3?AX$JQ-X]-(H [@N@E/'P<G#
M#$ TR)P!E*!I$F%^:NJ_Q7I:_-!MX9((S;K.HQ%R\TEQ+MN9&1G,L]6#S0T)
MOK&9'H^MVX;A0[FU\)H?!R"?'6!D0>\T'U,BO@%+#"%3;O1]W+QS5.7]AP25
M]&UM^,U ,+_@AUS_MA: "/7M%A*E=Q(_?O+?/^YXW7P5I'$J*<?IN27T;87%
M(A*^<84'77>#Q&<0K_C3_I%O,RO7,?VWUW:^6)*[(/LUH4FIMG+SJS]/'U\J
M+HR?-UG,>J4'-WQ.[F)%_>>4A\5[X8?\3[7IG;F&9YO=\OE?Z5"#"/0)),?"
M3@/].(F%CG.A%Z\^BWI#Z]+;O\[,3,2ET>$>L11837;:)<IC-UN?O /[@I]T
MH%6SURV14B"V02NY F32B:KX$"-TTO"OM*1C7E/:TECU9US9WOJLG#JV;@K1
MDWS/EBT3V Y?&W$S,7R+EM7O5H>YD5W,@AHLCO46O9+-7V:)M:'S:'VO?MY"
ME;I58;CI2H(-JRBC"=O8<[=OS%QB8P Q>GU<*7O08VY+_S0MTR2LT)T:V<9%
M86]F@-.(BUV8YQJZ2->>"J(%@!*J^Q:^#4QD13YL1.N@"H15;M773UH> ZM7
MA,\LEFMP8LNT$G%07!(#>(39AI!?T\MJJ0E^JLQT7G &T;-W_>GT5@;0:,
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MP6YL/AG:L-5O:N?4<N[0MZ%+T(^)-D0/=/V.;[@31K)C[TL!2V?FF)W(2/)
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MEV,Z%;Q*88%FV#AKMT_E/MV*[X\P@(<;-/1']_Z)/HSHD-H*VYUA@S<,(#N
MU\#TXXE=!]")4)H.38F&[I89M< #+H0 DT5Z0?&:)%MI]\'KZ!GL*0;@@YW5
M?,H?5%]IUQ53PFV>[B1=7#*)3E)8B#(A->BJZETHOA.4G9M#K<Z&P<WG\,5<
MQ<L]-EQZOT[<[;?;$8LVOUX6:-C'_=9>:*TN'KIY<\B!"4.ZJE+  ,+&RT1>
M(VV%K&[&(%>7T6@J<WT&SK"<;)76%FGO[L(LU!YD0'Z"-JLO)UMG-H*W')76
M'9+H*1NY,<+OYY\8M<F>I2BN*X5(/:#4#?W"1JI]/-_=/W&L>?IKHV6XO_]
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M9'<=B].@2 )9D=U?D=L_D V5(>(J,5?YJ2ZLE+4U)23)2.@,'8"NH /6VNF
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M?G.N:6A+UO)>\:R' IN9F9:3A$.4X<76@>BDD!")43!K=75180108&D(KW'
M\/)[IQQ]Z%DX4[;=G%ANS/URM?[\NZE%]EZ"D+_:%NHW W'AN+\KYBY/GA7>
MF9QP9>327XT+@GL(#Z7Y3M,!6 D:9Z>>QH? A__5N<V#<K!:JV4S\ZJ:ZNNK
M]X^^!L?>"K%C#:U2=VG2SZFT/M>CI\9I)9J-D!F@C!]-D1N??5735D];6"+3
M 4IK$DT(X9\6&#7T>"1"_2_]2+[]M_U(_B<40,.W2R=;=?@.*,&TY>:6N!,E
MW#L<KK&G]CNUQHH<-H)$_WW9A+E]$H10H**FZW.;DNU+C6HFF/?K-S#&K<>$
M=M#\'M28XH2?W-INK Y-B'8;2FA8N:0H=N6UCSS#M#^I(6*O\?D*#5GCMX-*
MJ(\GP99OEB[NV_TD9#BOKC$-=1[]5I]C-#XQ?@5^4?B!A1/E5N,IFGH=,R:/
MMA\>O0O[)*S]<Z'14U04??[#GPN-S#E=LNX]FLI?V,0&JJM=]9E$DD@NS56;
MJ:($J^SWG]&;N:.]NOHZ0=@7?A 6LLMT?#"RR%?PJ_&>U%F=*S?B+5 :E-5;
M3CL(/<L8KVP\>R-TW!S,%Y9;-:Z)Z@:GPBSO(.>U&<D3(XEY3SL$=]P]BIOA
M=LX:3]&C#<Q$N+N&^<B'3^+% 9OM>ZMZA+4QE1@$I#]:V&E0^)3WX7=T *MY
MH[G4S\R:S)B^D1L,\E@+0/3N#>;@;XC?_*^$8"&Z6["T)KH3=R98JUHH).U)
M$F!GC4%II)*167 [[O9K6%@%@W_QMJ>!OSM \*?-64W %X8S"9!0.16KVW3
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MPPS@$<*!%)#*WY.LVI\%&AM[:6F:.WM8]\ NUPRPB6S8H>^B/^CH5GMW^NZ
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MIPPNB'RX;/78.\IK0);!W;1MK5V0'ISOWK"9FMZJMP@Y*]GI Q"$[;VP:_)
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MNY\6^[#]YJD9UK'*Q3MAQ-'4.&[I?%7G6@OJ4Q]V-7@L*LQMZ>!1H;<B09"
MAR"B\M  A+U4GR?I2Y^NV['LG:0?\ <%*"O>%B$HYS!QQBN%<S9C*H8T=PL%
M(8XP(JJJ0A-5,W#UJ?T=<J45+3U[<? J7\TP2]WP]VZ]]RN&9OVN-J$3W\[(
M2PLS7YQ46S+7]9FV]R5Q*F1Q0!KWOZ1ZT4K]5M<5/:RL1,\FS"0-\6AL)3:;
M*(47W((@=P2E@BF6;IAH1[9D[Y,N/^9FD>Z0OLH0L<*19K4'0@>-^_,O>E87
MY2>9)SOEV[$^,+GXY/6T2HR'Z,@]5ZK2TOT:+9,KQ@],BN:9<U5>>7,'*%]V
MQ(U+2Y^MCJ8^K: REUH:YV75?*GA8C%*7,(73,[;VAH_Y=-)/AA;L7/&U+I:
M:(:J;9H>LCY>70UNOZQW2^+)O4'LS'$?.L!\'3E_KN8 $>/[VP>%R^<Z=SK7
MI@,S* U_?5V.A4'W*\B,73]VJ:BPDB))R$%R@?,W5%HJ=8/XLD>4E>Q[BR^,
M>_[=Q6#Y&!"!EKM%![#6'!X-Z?&\05V;HL(I$IV-C4FP-O+7=NR'QFJ'35J=
MAH0:AV$>XE$_G/TVK9<@>7$IH2#PS:3>-M(<R;)U:]I78 ']I">5.,QF!E:E
M QX^@YBB6ZK%UPGLL^BW6P\L09:!VJM$.N 4@]V]V?RE040%*MC8>DPVP>T
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M,C R,S$R,S$N>'-D4$L! A0#%     @ S4N>6(5UYUL%%P  ?24! !0
M         ( !7B4  &%P;2TR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @
MS4N>6-XL[-/_<   \CH' !0              ( !E3P  &%P;2TR,#(S,3(S
M,5]D968N>&UL4$L! A0#%     @ S4N>6(#_I 5Y%@$ )8(- !0
M     ( !QJT  &%P;2TR,#(S,3(S,5]L86(N>&UL4$L! A0#%     @ S4N>
M6//I;$C(<@  J8L' !0              ( !<<0! &%P;2TR,#(S,3(S,5]P
M<F4N>&UL4$L! A0#%     @ S4N>6,2!C3\.D@0 K-HD !D
M ( !:S<" &5A,#(P,S8X,2TR,&9?87!T;W)U;2YH=&U02P$"% ,4    " #-
M2YY8CXTY!RD'  !,*0  '0              @ &PR08 96$P,C S-C@Q,#%E
M>#$R+3%?87!T;W)U;2YH=&U02P$"% ,4    " #-2YY8AUE6!>$&  "X)0
M'0              @ $4T08 96$P,C S-C@Q,#%E>#$R+3)?87!T;W)U;2YH
M=&U02P$"% ,4    " #-2YY8DS8EHK\#  !+%P  '0              @ $P
MV 8 96$P,C S-C@Q,#%E>#$S+3%?87!T;W)U;2YH=&U02P$"% ,4    " #-
M2YY8MA24.R@#  ###   '0              @ $JW 8 96$P,C S-C@Q,#%E
M>#$U+3%?87!T;W)U;2YH=&U02P$"% ,4    " #-2YY84D5*K#($   !%@
M'               @ &-WP8 96$P,C S-C@Q,#%E>#0M-%]A<'1O<G5M+FAT
M;5!+ 0(4 Q0    ( ,U+GEC;,87Y$QD  %Z?   =              "  ?GC
M!@!E83 R,#,V.#$P,65X.3<M,5]A<'1O<G5M+FAT;5!+ 0(4 Q0    ( ,U+
MGEB[2K]S'*D  $';   -              "  4?]!@!I;6%G95\P,#$N:G!G
M4$L! A0#%     @ S4N>6"];H];[@   [L,   T              ( !CJ8'
M &EM86=E7S P,BYJ<&=02P$"% ,4    " #-2YY8A8?^?"S"  #YQ@  #0
M            @ &T)P@ :6UA9V5?,# S+FIP9U!+ 0(4 Q0    ( ,U+GEC8
MMXA('DP  #YC   -              "  0OJ" !I;6%G95\P,#0N:G!G4$L!
M A0#%     @ S4N>6)32"1))*P  ISD   T              ( !5#8) &EM
M86=E7S P-2YJ<&=02P$"% ,4    " #-2YY83(KSBE0Q  "</@  #0
M        @ '(80D :6UA9V5?,# V+FIP9U!+ 0(4 Q0    ( ,U+GEC*ZXWB
MJTT  '56   -              "  4>3"0!I;6%G95\P,#<N:G!G4$L! A0#
M%     @ S4N>6-GJO.51.@  3D$   T              ( !'>$) &EM86=E
M7S P."YJ<&=02P$"% ,4    " #-2YY85 SQW3PR   &0   #0
M    @ &9&PH :6UA9V5?,# Y+FIP9U!+ 0(4 Q0    ( ,U+GE@T?S#BZ24
M   U   -              "  0!."@!I;6%G95\P,3 N:G!G4$L! A0#%
M  @ S4N>6,2R#X_1%P( %38"  T              ( !%'0* &EM86=E7S Q
M,2YJ<&=02P$"% ,4    " #-2YY8EK/!TPY\  #*@P  #0
M@ $0C P :6UA9V5?,#$R+FIP9U!+ 0(4 Q0    ( ,U+GEA'!3F,H74  &R+
M   -              "  4D(#0!I;6%G95\P,3,N:G!G4$L%!@     9 !D
*308  !5^#0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>ea0203681-20f_aptorum_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apm="http://aptorumgroup.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="apm-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:AptorumTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:AptorumTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:APTUSMANAGEMENTLIMITEDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:APTUSMANAGEMENTLIMITEDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:AptorumMedicalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:AptorumMedicalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:PathsInnovationsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:PathsInnovationsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:PathsDiagnosticsPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:PathsDiagnosticsPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ActiculeLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ActiculeLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ClavesLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ClavesLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:NativusLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:NativusLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:VidensIncorporationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:VidensIncorporationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:MiosPharmaceuticalsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:MiosPharmaceuticalsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:mTORHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:mTORHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ScipioLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ScipioLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:SignateLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:SignateLifeSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apm:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:LibraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apm:LeaseholdImprovementsFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apm:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apm:HongKongHealthcareServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">apm:PrepaidPatentedLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">apm:PrepaidPatentedLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">apm:IanHuenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2019-08-13</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-13</startDate>
            <endDate>2019-08-13</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2019-08-13</startDate>
            <endDate>2019-08-13</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2021-11-17</startDate>
            <endDate>2021-11-17</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2022-01-13</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-13</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:ACCMedicalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:MrClarkChengMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:MrIanHuenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:MrDarrenLuiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraTherapeuticsLimitedOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraTherapeuticsLimitedOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AencoTechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:SabrinaKhanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:SabrinaKhanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:JurchenInvestmentCorporationOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AencoTechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AencoTechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AencoTechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:TalemMedicalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:ACCMedicalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:ACCMedicalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:AeneasManagementLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:LibraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:MiosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:ScipioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:LibraSciencesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">apm:GroupsSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:MiosPharmaceuticalsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">apm:GroupsSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:ScipioLifeSciencesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">apm:GroupsSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">apm:VaribaleInterestEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apm:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apm:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-26</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-26</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-23</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-23</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-23</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-23</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2023-01-23</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-23</startDate>
            <endDate>2023-01-23</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesAndExternalConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:SharesWarrantHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:SharesWarrantHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:SharesWarrantHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">apm:ShareOptionHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apm:TwoThousandSeventeenShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-11</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2021-03-11</instant>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-08</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2022-03-08</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2022-07-14</startDate>
            <endDate>2022-07-14</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-23</startDate>
            <endDate>2023-01-23</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-23</startDate>
            <endDate>2023-01-23</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apm:TwoThousandSeventeenShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apm:TwoThousandSeventeenShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apm:TwoThousandSeventeenShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">apm:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apm:MiosPharmaceuticalsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2021-01-02</instant>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:AptorumMedicalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-02</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:AptorumMedicalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-02</instant>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:ClarkChengMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:ClarkChengMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:ClarkChengMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">apm:ClarkChengMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-08</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:DSFInvestmentHoldingsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-08</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:CGYInvestmentsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-08</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001734005</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apm:DSFInvestmentHoldingsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-08</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="hkd">
        <measure>iso4217:HKD</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-26340">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-32">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-44">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-26341">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-26342">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-26343">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-61">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-73">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-26344">001-38764</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-94">APTORUM GROUP LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-111">E9</dei:EntityIncorporationStateCountryCode>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-26345">Ian Huen</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-26346">17 Hanover Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-26347">17 Hanover Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-26348">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-26349">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-26350">W1S 1BN</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-26351">W1S 1BN</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-26352">GB</dei:EntityAddressCountry>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-26353">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-26354">+44</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-26355">20 8092 9299</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-160">Class A Ordinary shares, par value $0.00001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-165">APM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-26356">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-26357"
      unitRef="shares">2937921</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-26358"
      unitRef="shares">2243776</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-26359">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-26360">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-26361">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-26362">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-264">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-276">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-298">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-304">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-26363">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-343">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c0" id="ixv-26364">5395</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0" id="ixv-15933">Marcum Asia CPAs llp</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-15945">New York, NY</dei:AuditorLocation>
    <us-gaap:Cash contextRef="c4" decimals="0" id="ixv-26365" unitRef="usd">2005351</us-gaap:Cash>
    <us-gaap:Cash contextRef="c5" decimals="0" id="ixv-26366" unitRef="usd">1882545</us-gaap:Cash>
    <us-gaap:RestrictedCashCurrent contextRef="c5" decimals="0" id="ixv-26367" unitRef="usd">3130335</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="0" id="ixv-26368" unitRef="usd">47709</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c5" decimals="0" id="ixv-26369" unitRef="usd">174426</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c5" decimals="0" id="ixv-26370" unitRef="usd">27722</us-gaap:InventoryNet>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c5" decimals="0" id="ixv-26371" unitRef="usd">102481</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c6" decimals="0" id="ixv-26372" unitRef="usd">961</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c7" decimals="0" id="ixv-26373" unitRef="usd">129677</us-gaap:OtherReceivablesNetCurrent>
    <apm:DueFromBrokers contextRef="c5" decimals="0" id="ixv-26374" unitRef="usd">652</apm:DueFromBrokers>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c7" decimals="0" id="ixv-26375" unitRef="usd">875956</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" id="ixv-26376" unitRef="usd">422071</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c5" decimals="0" id="ixv-26377" unitRef="usd">744008</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" id="ixv-26378" unitRef="usd">2476092</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="0" id="ixv-26379" unitRef="usd">7067802</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" id="ixv-26380" unitRef="usd">1663926</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="0" id="ixv-26381" unitRef="usd">2825059</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" id="ixv-26382" unitRef="usd">182057</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="0" id="ixv-26383" unitRef="usd">347000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments contextRef="c4" decimals="0" id="ixv-26384" unitRef="usd">16098846</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c5" decimals="0" id="ixv-26385" unitRef="usd">9744958</us-gaap:LongTermInvestments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="0" id="ixv-26386" unitRef="usd">147347</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c5" decimals="0" id="ixv-26387" unitRef="usd">752705</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c4" decimals="0" id="ixv-26388" unitRef="usd">71823</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c5" decimals="0" id="ixv-26389" unitRef="usd">129847</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets contextRef="c4" decimals="0" id="ixv-26390" unitRef="usd">20640091</us-gaap:Assets>
    <us-gaap:Assets contextRef="c5" decimals="0" id="ixv-26391" unitRef="usd">20867371</us-gaap:Assets>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c6" decimals="0" id="ixv-26392" unitRef="usd">79180</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c7" decimals="0" id="ixv-26393" unitRef="usd">12693</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-26394" unitRef="usd">1894341</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-26395" unitRef="usd">6166807</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="0" id="ixv-26396" unitRef="usd">125232</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="0" id="ixv-26397" unitRef="usd">310548</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c5" decimals="0" id="ixv-26398" unitRef="usd">3000000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c5" decimals="0" id="ixv-26399" unitRef="usd">3013234</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-26400" unitRef="usd">2098753</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-26401" unitRef="usd">12503282</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="0" id="ixv-26402" unitRef="usd">99485</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="0" id="ixv-26403" unitRef="usd">30784</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c6" decimals="0" id="ixv-26404" unitRef="usd">3058500</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c7" decimals="0" id="ixv-26405" unitRef="usd">500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c4" decimals="0" id="ixv-26406" unitRef="usd">5256738</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c5" decimals="0" id="ixv-26407" unitRef="usd">13034066</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="5"
      id="ixv-26408"
      unitRef="usdPershares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ixv-26409"
      unitRef="shares">9999996000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-26410"
      unitRef="shares">2937921</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-26411"
      unitRef="shares">2937921</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c8"
      decimals="2"
      id="ixv-26412"
      unitRef="usdPershares">10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c8"
      decimals="0"
      id="ixv-26413"
      unitRef="shares">6000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c8"
      decimals="0"
      id="ixv-26414"
      unitRef="shares">1326953</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c8"
      decimals="0"
      id="ixv-26415"
      unitRef="shares">1326953</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ix_0_fact" unitRef="usd">31</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c8" decimals="0" id="ix_1_fact" unitRef="usd">13269528</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="5"
      id="ixv-26418"
      unitRef="usdPershares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-26419"
      unitRef="shares">4000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-26420"
      unitRef="shares">2243776</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-26421"
      unitRef="shares">2243776</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c9"
      decimals="2"
      id="ixv-26422"
      unitRef="usdPershares">10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c9"
      decimals="0"
      id="ixv-26423"
      unitRef="shares">4000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c9"
      decimals="0"
      id="ixv-26424"
      unitRef="shares">2243776</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c9"
      decimals="0"
      id="ixv-26425"
      unitRef="shares">2243776</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ix_2_fact" unitRef="usd">22</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c9" decimals="0" id="ix_3_fact" unitRef="usd">22437754</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="0" id="ixv-26428" unitRef="usd">93018528</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c5" decimals="0" id="ixv-26429" unitRef="usd">45308080</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="0" id="ixv-26430" unitRef="usd">-10623</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c5" decimals="0" id="ixv-26431" unitRef="usd">33807</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" id="ixv-26432" unitRef="usd">-68161722</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c5" decimals="0" id="ixv-26433" unitRef="usd">-65337075</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-26434" unitRef="usd">24846236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="0" id="ixv-26435" unitRef="usd">15712094</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c4" decimals="0" id="ixv-26436" unitRef="usd">-9462883</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c5" decimals="0" id="ixv-26437" unitRef="usd">-7878789</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c4" decimals="0" id="ixv-26438" unitRef="usd">15383353</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="0" id="ixv-26439" unitRef="usd">7833305</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" id="ixv-26440" unitRef="usd">20640091</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="0" id="ixv-26441" unitRef="usd">20867371</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-26442" unitRef="usd">431378</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c10" decimals="0" id="ixv-26443" unitRef="usd">1295889</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c11" decimals="0" id="ixv-26444" unitRef="usd">1541778</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" id="ixv-26445" unitRef="usd">420812</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c10" decimals="0" id="ixv-26446" unitRef="usd">1215824</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c11" decimals="0" id="ixv-26447" unitRef="usd">1459924</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-26448" unitRef="usd">5198329</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c10" decimals="0" id="ixv-26449" unitRef="usd">9219595</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c11" decimals="0" id="ixv-26450" unitRef="usd">10869642</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-26451" unitRef="usd">1930637</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c10" decimals="0" id="ixv-26452" unitRef="usd">5220405</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c11" decimals="0" id="ixv-26453" unitRef="usd">5409302</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ProfessionalFees contextRef="c0" decimals="0" id="ixv-26454" unitRef="usd">2538161</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c10" decimals="0" id="ixv-26455" unitRef="usd">2888140</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c11" decimals="0" id="ixv-26456" unitRef="usd">2617834</us-gaap:ProfessionalFees>
    <us-gaap:OtherCostAndExpenseOperating contextRef="c0" decimals="0" id="ixv-26457" unitRef="usd">1067690</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="c10" decimals="0" id="ixv-26458" unitRef="usd">261038</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="c11" decimals="0" id="ixv-26459" unitRef="usd">392511</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:CostsAndExpenses contextRef="c0" decimals="0" id="ixv-26460" unitRef="usd">11155629</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c10" decimals="0" id="ixv-26461" unitRef="usd">18805002</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c11" decimals="0" id="ixv-26462" unitRef="usd">20749213</us-gaap:CostsAndExpenses>
    <us-gaap:GainLossOnInvestments contextRef="c0" decimals="0" id="ixv-26463" unitRef="usd">-9266</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c10" decimals="0" id="ixv-26464" unitRef="usd">-134134</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c11" decimals="0" id="ixv-26465" unitRef="usd">-8031595</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c0" decimals="0" id="ixv-26466" unitRef="usd">6353888</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c10" decimals="0" id="ixv-26467" unitRef="usd">5588051</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c11" decimals="0" id="ixv-26468" unitRef="usd">-4289</us-gaap:DerivativeGainLossOnDerivativeNet>
    <apm:GainOnUseOfDigitalCurrencies contextRef="c11" decimals="0" id="ixv-26469" unitRef="usd">-4918</apm:GainOnUseOfDigitalCurrencies>
    <apm:GainOnDerecognitionOfNonfinancialAssets contextRef="c11" decimals="0" id="ixv-26470" unitRef="usd">75000</apm:GainOnDerecognitionOfNonfinancialAssets>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c0" decimals="0" id="ixv-26471" unitRef="usd">-121145</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c10" decimals="0" id="ixv-26472" unitRef="usd">146588</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c11" decimals="0" id="ixv-26473" unitRef="usd">-93601</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary contextRef="c11" decimals="0" id="ixv-26474" unitRef="usd">-3638</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <apm:SundryIncome contextRef="c0" decimals="0" id="ixv-26475" unitRef="usd">159799</apm:SundryIncome>
    <apm:SundryIncome contextRef="c10" decimals="0" id="ixv-26476" unitRef="usd">383506</apm:SundryIncome>
    <apm:SundryIncome contextRef="c11" decimals="0" id="ixv-26477" unitRef="usd">146347</apm:SundryIncome>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-26478" unitRef="usd">6383276</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c10" decimals="0" id="ixv-26479" unitRef="usd">5984011</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c11" decimals="0" id="ixv-26480" unitRef="usd">-7906858</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-26481" unitRef="usd">-4340975</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c10" decimals="0" id="ixv-26482" unitRef="usd">-11525102</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c11" decimals="0" id="ixv-26483" unitRef="usd">-27114293</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-26484" unitRef="usd">-1516328</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c10" decimals="0" id="ixv-26485" unitRef="usd">-1725542</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-26486" unitRef="usd">-2065904</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-26487" unitRef="usd">-2824647</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="0" id="ixv-26488" unitRef="usd">-9799560</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c11" decimals="0" id="ixv-26489" unitRef="usd">-25048389</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ix_4_fact"
      unitRef="usdPershares">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c10"
      decimals="2"
      id="ix_5_fact"
      unitRef="usdPershares">-2.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c11"
      decimals="2"
      id="ix_6_fact"
      unitRef="usdPershares">-7.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ix_7_fact"
      unitRef="usdPershares">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c10"
      decimals="2"
      id="ix_8_fact"
      unitRef="usdPershares">-2.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c11"
      decimals="2"
      id="ix_9_fact"
      unitRef="usdPershares">-7.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ix_10_fact"
      unitRef="shares">4521133</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c10"
      decimals="0"
      id="ix_11_fact"
      unitRef="shares">3569484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c11"
      decimals="0"
      id="ix_12_fact"
      unitRef="shares">3503396</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ix_13_fact"
      unitRef="shares">4521133</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c10"
      decimals="0"
      id="ix_14_fact"
      unitRef="shares">3569484</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c11"
      decimals="0"
      id="ix_15_fact"
      unitRef="shares">3503396</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-26502" unitRef="usd">-4340975</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c10" decimals="0" id="ixv-26503" unitRef="usd">-11525102</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c11" decimals="0" id="ixv-26504" unitRef="usd">-27114293</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" id="ixv-26505" unitRef="usd">-44430</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c10" decimals="0" id="ixv-26506" unitRef="usd">35826</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c11" decimals="0" id="ixv-26507" unitRef="usd">-55315</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c0" decimals="0" id="ixv-26508" unitRef="usd">-44430</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c10" decimals="0" id="ixv-26509" unitRef="usd">35826</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c11" decimals="0" id="ixv-26510" unitRef="usd">-55315</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-26511" unitRef="usd">-4385405</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c10" decimals="0" id="ixv-26512" unitRef="usd">-11489276</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-26513" unitRef="usd">-27169608</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-26514" unitRef="usd">-1516328</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c10" decimals="0" id="ixv-26515" unitRef="usd">-1725542</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-26516" unitRef="usd">-2065904</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" id="ixv-26517" unitRef="usd">-2869077</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c10" decimals="0" id="ixv-26518" unitRef="usd">-9763734</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c11" decimals="0" id="ixv-26519" unitRef="usd">-25103704</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c12"
      decimals="0"
      id="ix_16_fact"
      unitRef="shares">1158432</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="0" id="ixv-26521" unitRef="usd">11584324</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c13"
      decimals="0"
      id="ix_17_fact"
      unitRef="shares">2243776</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="0" id="ixv-26523" unitRef="usd">22437754</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="0" id="ixv-26524" unitRef="usd">38247903</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="0" id="ixv-26525" unitRef="usd">-30489126</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c16" decimals="0" id="ixv-26526" unitRef="usd">53296</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c17" decimals="0" id="ixv-26527" unitRef="usd">-3681858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c18" decimals="0" id="ixv-26528" unitRef="usd">38152293</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c19"
      decimals="0"
      id="ix_18_fact"
      unitRef="shares">138793</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c19" decimals="0" id="ixv-26530" unitRef="usd">1387925</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c21" decimals="0" id="ixv-26531" unitRef="usd">2612075</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c11" decimals="0" id="ixv-26532" unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest contextRef="c21" decimals="0" id="ixv-26533" unitRef="usd">66783</apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest contextRef="c24" decimals="0" id="ixv-26534" unitRef="usd">-61423</apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-26535" unitRef="usd">5360</apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest>
    <apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction contextRef="c21" decimals="0" id="ixv-26536" unitRef="usd">303419</apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction>
    <apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction contextRef="c23" decimals="0" id="ixv-26537" unitRef="usd">-5386</apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction>
    <apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction contextRef="c24" decimals="0" id="ixv-26538" unitRef="usd">-300000</apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction>
    <apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction contextRef="c11" decimals="0" id="ixv-26539" unitRef="usd">-1967</apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction>
    <apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries contextRef="c24" decimals="0" id="ixv-26540" unitRef="usd">7962</apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries>
    <apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries contextRef="c11" decimals="0" id="ixv-26541" unitRef="usd">7962</apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c21" decimals="0" id="ixv-26542" unitRef="usd">1682460</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c11" decimals="0" id="ixv-26543" unitRef="usd">1682460</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apm:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="c19"
      decimals="0"
      id="ix_19_fact"
      unitRef="shares">4000</apm:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <apm:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="c19" decimals="0" id="ixv-26545" unitRef="usd">40000</apm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <apm:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="c21" decimals="0" id="ixv-26546" unitRef="usd">90012</apm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <apm:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="c11" decimals="0" id="ixv-26547" unitRef="usd">130012</apm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c19"
      decimals="0"
      id="ix_20_fact"
      unitRef="shares">19016</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c19" decimals="0" id="ixv-26549" unitRef="usd">190159</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c21" decimals="0" id="ixv-26550" unitRef="usd">504065</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c11" decimals="0" id="ixv-26551" unitRef="usd">694224</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation contextRef="c23" decimals="0" id="ixv-26552" unitRef="usd">-49929</apm:ExchangeDifferenceOnTranslationOfForeignOperation>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation contextRef="c11" decimals="0" id="ixv-26553" unitRef="usd">-49929</apm:ExchangeDifferenceOnTranslationOfForeignOperation>
    <us-gaap:ProfitLoss contextRef="c22" decimals="0" id="ixv-26554" unitRef="usd">-25048389</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c24" decimals="0" id="ixv-26555" unitRef="usd">-2065904</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c11" decimals="0" id="ixv-26556" unitRef="usd">-27114293</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c25"
      decimals="0"
      id="ix_21_fact"
      unitRef="shares">1320241</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c25" decimals="0" id="ixv-26558" unitRef="usd">13202408</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ix_22_fact"
      unitRef="shares">2243776</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c26" decimals="0" id="ixv-26560" unitRef="usd">22437754</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c27" decimals="0" id="ixv-26561" unitRef="usd">43506717</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c28" decimals="0" id="ixv-26562" unitRef="usd">-55537515</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c29" decimals="0" id="ixv-26563" unitRef="usd">-2019</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c30" decimals="0" id="ixv-26564" unitRef="usd">-6101223</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c31" decimals="0" id="ixv-26565" unitRef="usd">17506122</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest contextRef="c34" decimals="0" id="ixv-26566" unitRef="usd">52024</apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest contextRef="c37" decimals="0" id="ixv-26567" unitRef="usd">-52024</apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c34" decimals="0" id="ixv-26568" unitRef="usd">1646999</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c10" decimals="0" id="ixv-26569" unitRef="usd">1646999</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c32"
      decimals="0"
      id="ix_23_fact"
      unitRef="shares">6712</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c32" decimals="0" id="ixv-26571" unitRef="usd">67120</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c34" decimals="0" id="ixv-26572" unitRef="usd">102340</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c10" decimals="0" id="ixv-26573" unitRef="usd">169460</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation contextRef="c36" decimals="0" id="ixv-26574" unitRef="usd">35826</apm:ExchangeDifferenceOnTranslationOfForeignOperation>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation contextRef="c10" decimals="0" id="ixv-26575" unitRef="usd">35826</apm:ExchangeDifferenceOnTranslationOfForeignOperation>
    <us-gaap:ProfitLoss contextRef="c35" decimals="0" id="ixv-26576" unitRef="usd">-9799560</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c37" decimals="0" id="ixv-26577" unitRef="usd">-1725542</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c10" decimals="0" id="ixv-26578" unitRef="usd">-11525102</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c38"
      decimals="0"
      id="ix_24_fact"
      unitRef="shares">1326953</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c38" decimals="0" id="ixv-26580" unitRef="usd">13269528</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c39"
      decimals="0"
      id="ix_25_fact"
      unitRef="shares">2243776</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c39" decimals="0" id="ixv-26582" unitRef="usd">22437754</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c40" decimals="0" id="ixv-26583" unitRef="usd">45308080</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c41" decimals="0" id="ixv-26584" unitRef="usd">-65337075</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c42" decimals="0" id="ixv-26585" unitRef="usd">33807</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c43" decimals="0" id="ixv-26586" unitRef="usd">-7878789</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="0" id="ixv-26587" unitRef="usd">7833305</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue contextRef="c44" decimals="0" id="ixv-26588" unitRef="usd">13269514</apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue>
    <apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue contextRef="c45" decimals="0" id="ixv-26589" unitRef="usd">22437732</apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue>
    <apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue contextRef="c46" decimals="0" id="ixv-26590" unitRef="usd">-35707246</apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest contextRef="c46" decimals="0" id="ixv-26591" unitRef="usd">67766</apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest contextRef="c49" decimals="0" id="ixv-26592" unitRef="usd">-67766</apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c44"
      decimals="0"
      id="ix_26_fact"
      unitRef="shares">70430</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c44" decimals="0" id="ixv-26594" unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c46" decimals="0" id="ixv-26595" unitRef="usd">3078195</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="0" id="ixv-26596" unitRef="usd">3078196</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c44"
      decimals="0"
      id="ix_27_fact"
      unitRef="shares">65770</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c44" decimals="0" id="ixv-26598" unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c46" decimals="0" id="ixv-26599" unitRef="usd">176263</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c0" decimals="0" id="ixv-26600" unitRef="usd">176264</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <apm:StockIssuedDuringPeridSharesIssuanceOfShares
      contextRef="c44"
      decimals="0"
      id="ix_28_fact"
      unitRef="shares">215959</apm:StockIssuedDuringPeridSharesIssuanceOfShares>
    <apm:StockIssuedDuringPeriodValueIssuanceOfShares contextRef="c44" decimals="0" id="ixv-26602" unitRef="usd">2</apm:StockIssuedDuringPeriodValueIssuanceOfShares>
    <apm:StockIssuedDuringPeriodValueIssuanceOfShares contextRef="c46" decimals="0" id="ixv-26603" unitRef="usd">1575560</apm:StockIssuedDuringPeriodValueIssuanceOfShares>
    <apm:StockIssuedDuringPeriodValueIssuanceOfShares contextRef="c0" decimals="0" id="ixv-26604" unitRef="usd">1575562</apm:StockIssuedDuringPeriodValueIssuanceOfShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c46" decimals="0" id="ixv-26605" unitRef="usd">1088925</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="0" id="ixv-26606" unitRef="usd">1088925</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c44"
      decimals="0"
      id="ix_29_fact"
      unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c44" decimals="0" id="ixv-26608" unitRef="usd">13</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c46" decimals="0" id="ixv-26609" unitRef="usd">5999987</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c0" decimals="0" id="ixv-26610" unitRef="usd">6000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c44"
      decimals="0"
      id="ix_30_fact"
      unitRef="shares">791</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c46" decimals="0" id="ixv-26612" unitRef="usd">16506</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="0" id="ixv-26613" unitRef="usd">16506</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c44"
      decimals="0"
      id="ix_31_fact"
      unitRef="shares">8018</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation contextRef="c48" decimals="0" id="ixv-26615" unitRef="usd">-44430</apm:ExchangeDifferenceOnTranslationOfForeignOperation>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation contextRef="c0" decimals="0" id="ixv-26616" unitRef="usd">-44430</apm:ExchangeDifferenceOnTranslationOfForeignOperation>
    <us-gaap:ProfitLoss contextRef="c47" decimals="0" id="ixv-26617" unitRef="usd">-2824647</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c49" decimals="0" id="ixv-26618" unitRef="usd">-1516328</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-26619" unitRef="usd">-4340975</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c50"
      decimals="0"
      id="ix_32_fact"
      unitRef="shares">2937921</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c50" decimals="0" id="ixv-26621" unitRef="usd">31</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c51"
      decimals="0"
      id="ix_33_fact"
      unitRef="shares">2243776</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c51" decimals="0" id="ixv-26623" unitRef="usd">22</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c52" decimals="0" id="ixv-26624" unitRef="usd">93018528</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c53" decimals="0" id="ixv-26625" unitRef="usd">-68161722</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c54" decimals="0" id="ixv-26626" unitRef="usd">-10623</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c55" decimals="0" id="ixv-26627" unitRef="usd">-9462883</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c4" decimals="0" id="ixv-26628" unitRef="usd">15383353</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-26629" unitRef="usd">-4340975</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c10" decimals="0" id="ixv-26630" unitRef="usd">-11525102</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c11" decimals="0" id="ixv-26631" unitRef="usd">-27114293</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" id="ixv-26632" unitRef="usd">1125254</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c10" decimals="0" id="ixv-26633" unitRef="usd">1207510</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c11" decimals="0" id="ixv-26634" unitRef="usd">1192578</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-26635" unitRef="usd">1265189</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c10" decimals="0" id="ixv-26636" unitRef="usd">1646999</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c11" decimals="0" id="ixv-26637" unitRef="usd">1682460</us-gaap:ShareBasedCompensation>
    <apm:LossGainOnInvestmentsInMarketableSecuritiesNet contextRef="c0" decimals="0" id="ixv-26638" unitRef="usd">-9266</apm:LossGainOnInvestmentsInMarketableSecuritiesNet>
    <apm:LossGainOnInvestmentsInMarketableSecuritiesNet contextRef="c10" decimals="0" id="ixv-26639" unitRef="usd">-134134</apm:LossGainOnInvestmentsInMarketableSecuritiesNet>
    <apm:LossGainOnInvestmentsInMarketableSecuritiesNet contextRef="c11" decimals="0" id="ixv-26640" unitRef="usd">-8031595</apm:LossGainOnInvestmentsInMarketableSecuritiesNet>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c0" decimals="0" id="ixv-26641" unitRef="usd">6353888</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c10" decimals="0" id="ixv-26642" unitRef="usd">5588051</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c11" decimals="0" id="ixv-26643" unitRef="usd">-4289</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c11" decimals="0" id="ixv-26644" unitRef="usd">75000</us-gaap:GainLossOnDispositionOfAssets1>
    <apm:LossOnDisposalOfLonglivedAssets contextRef="c0" decimals="0" id="ixv-26645" unitRef="usd">-110852</apm:LossOnDisposalOfLonglivedAssets>
    <apm:LossOnDisposalOfLonglivedAssets contextRef="c10" decimals="0" id="ixv-26646" unitRef="usd">-205189</apm:LossOnDisposalOfLonglivedAssets>
    <apm:LossOnDisposalOfLonglivedAssets contextRef="c11" decimals="0" id="ixv-26647" unitRef="usd">-392</apm:LossOnDisposalOfLonglivedAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c0" decimals="0" id="ixv-26648" unitRef="usd">750381</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <apm:AllowanceForCreditLossOfDueFromARelatedParty contextRef="c0" decimals="0" id="ixv-26649" unitRef="usd">521007</apm:AllowanceForCreditLossOfDueFromARelatedParty>
    <apm:WritteoffOfPrepaymentAndOtherReceivables contextRef="c0" decimals="0" id="ixv-26650" unitRef="usd">62369</apm:WritteoffOfPrepaymentAndOtherReceivables>
    <us-gaap:InventoryWriteDown contextRef="c0" decimals="0" id="ixv-26651" unitRef="usd">13206</us-gaap:InventoryWriteDown>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary contextRef="c11" decimals="0" id="ixv-26652" unitRef="usd">-3638</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <apm:GainOnUseOfDigitalsCurrencies contextRef="c11" decimals="0" id="ixv-26653" unitRef="usd">4918</apm:GainOnUseOfDigitalsCurrencies>
    <apm:SettlementOfServiceFeeByDigitalCurrenciesAndTokens contextRef="c11" decimals="0" id="ixv-26654" unitRef="usd">-90457</apm:SettlementOfServiceFeeByDigitalCurrenciesAndTokens>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="0" id="ixv-26655" unitRef="usd">252345</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c10" decimals="0" id="ixv-26656" unitRef="usd">349031</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c11" decimals="0" id="ixv-26657" unitRef="usd">425280</us-gaap:OperatingLeaseCost>
    <us-gaap:InterestIncomeOther contextRef="c10" decimals="0" id="ixv-26658" unitRef="usd">235560</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c11" decimals="0" id="ixv-26659" unitRef="usd">41246</us-gaap:InterestIncomeOther>
    <apm:InterestExpenseAndAccretionOfConvertibleDebts contextRef="c0" decimals="0" id="ixv-26660" unitRef="usd">45266</apm:InterestExpenseAndAccretionOfConvertibleDebts>
    <apm:InterestExpenseAndAccretionOfConvertibleDebts contextRef="c10" decimals="0" id="ixv-26661" unitRef="usd">87537</apm:InterestExpenseAndAccretionOfConvertibleDebts>
    <apm:InterestExpenseAndAccretionOfConvertibleDebts contextRef="c11" decimals="0" id="ixv-26662" unitRef="usd">130397</apm:InterestExpenseAndAccretionOfConvertibleDebts>
    <apm:AccretionOfFinanceLeaseObligation contextRef="c10" decimals="0" id="ixv-26663" unitRef="usd">1435</apm:AccretionOfFinanceLeaseObligation>
    <apm:AccretionOfFinanceLeaseObligation contextRef="c11" decimals="0" id="ixv-26664" unitRef="usd">4450</apm:AccretionOfFinanceLeaseObligation>
    <apm:ReversalDeferredCashBonus contextRef="c0" decimals="0" id="ixv-26665" unitRef="usd">-1646228</apm:ReversalDeferredCashBonus>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-26666" unitRef="usd">-126717</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c10" decimals="0" id="ixv-26667" unitRef="usd">95704</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c11" decimals="0" id="ixv-26668" unitRef="usd">16501</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-26669" unitRef="usd">-14516</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c10" decimals="0" id="ixv-26670" unitRef="usd">-8053</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c11" decimals="0" id="ixv-26671" unitRef="usd">-3358</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c0" decimals="0" id="ixv-26672" unitRef="usd">-226805</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c10" decimals="0" id="ixv-26673" unitRef="usd">105584</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c11" decimals="0" id="ixv-26674" unitRef="usd">-695308</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="c0" decimals="0" id="ixv-26675" unitRef="usd">-29106</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="c10" decimals="0" id="ixv-26676" unitRef="usd">-19328</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <apm:IncreaseDecreaseDueFromBrokers contextRef="c0" decimals="0" id="ixv-26677" unitRef="usd">-652</apm:IncreaseDecreaseDueFromBrokers>
    <apm:IncreaseDecreaseDueFromBrokers contextRef="c10" decimals="0" id="ixv-26678" unitRef="usd">-75728</apm:IncreaseDecreaseDueFromBrokers>
    <apm:IncreaseDecreaseDueFromBrokers contextRef="c11" decimals="0" id="ixv-26679" unitRef="usd">-83957</apm:IncreaseDecreaseDueFromBrokers>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c0" decimals="0" id="ixv-26680" unitRef="usd">-63050</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c10" decimals="0" id="ixv-26681" unitRef="usd">46349</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c11" decimals="0" id="ixv-26682" unitRef="usd">-112635</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c0" decimals="0" id="ixv-26683" unitRef="usd">-8524</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c10" decimals="0" id="ixv-26684" unitRef="usd">-6805</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c11" decimals="0" id="ixv-26685" unitRef="usd">-264934</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-26686" unitRef="usd">398635</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c10" decimals="0" id="ixv-26687" unitRef="usd">1918751</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c11" decimals="0" id="ixv-26688" unitRef="usd">855272</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-26689" unitRef="usd">-389365</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c10" decimals="0" id="ixv-26690" unitRef="usd">-369505</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c11" decimals="0" id="ixv-26691" unitRef="usd">-450807</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-26692" unitRef="usd">-7724364</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c10" decimals="0" id="ixv-26693" unitRef="usd">-12318965</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c11" decimals="0" id="ixv-26694" unitRef="usd">-14651633</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c11" decimals="0" id="ixv-26695" unitRef="usd">6026</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-26696" unitRef="usd">3015</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c10" decimals="0" id="ixv-26697" unitRef="usd">186916</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c11" decimals="0" id="ixv-26698" unitRef="usd">131750</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-26699" unitRef="usd">15385</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <apm:DisposalOfSubsidiariesNetOfCashDisposed contextRef="c11" decimals="0" id="ixv-26700" unitRef="usd">113830</apm:DisposalOfSubsidiariesNetOfCashDisposed>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c0" decimals="0" id="ixv-26701" unitRef="usd">93215</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c11" decimals="0" id="ixv-26702" unitRef="usd">20116734</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="c0" decimals="0" id="ixv-26703" unitRef="usd">92459</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="c10" decimals="0" id="ixv-26704" unitRef="usd">330341</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="c11" decimals="0" id="ixv-26705" unitRef="usd">3358089</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <apm:RepaymentOfLoanFromRelatedParty contextRef="c0" decimals="0" id="ixv-26706" unitRef="usd">-611641</apm:RepaymentOfLoanFromRelatedParty>
    <apm:RepaymentOfLoanFromRelatedParty contextRef="c10" decimals="0" id="ixv-26707" unitRef="usd">-2962153</apm:RepaymentOfLoanFromRelatedParty>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-26708" unitRef="usd">624767</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c10" decimals="0" id="ixv-26709" unitRef="usd">2444896</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c11" decimals="0" id="ixv-26710" unitRef="usd">16507039</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c0" decimals="0" id="ixv-26711" unitRef="usd">2500000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c10" decimals="0" id="ixv-26712" unitRef="usd">500000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c11" decimals="0" id="ixv-26713" unitRef="usd">3500000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c11" decimals="0" id="ixv-26714" unitRef="usd">5489665</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromOtherEquity contextRef="c10" decimals="0" id="ixv-26715" unitRef="usd">5360</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="0" id="ixv-26716" unitRef="usd">1575562</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c11" decimals="0" id="ixv-26717" unitRef="usd">4000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="0" id="ixv-26718" unitRef="usd">16506</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c10" decimals="0" id="ixv-26719" unitRef="usd">169460</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c11" decimals="0" id="ixv-26720" unitRef="usd">694224</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c11" decimals="0" id="ixv-26721" unitRef="usd">130012</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromBankDebt contextRef="c10" decimals="0" id="ixv-26722" unitRef="usd">3000000</us-gaap:ProceedsFromBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c0" decimals="0" id="ixv-26723" unitRef="usd">3000000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c0" decimals="0" id="ixv-26724" unitRef="usd">3000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c10" decimals="0" id="ixv-26725" unitRef="usd">3000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c10" decimals="0" id="ixv-26726" unitRef="usd">49358</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c11" decimals="0" id="ixv-26727" unitRef="usd">53846</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-26728" unitRef="usd">4092068</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c10" decimals="0" id="ixv-26729" unitRef="usd">6625462</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c11" decimals="0" id="ixv-26730" unitRef="usd">2780725</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-26731" unitRef="usd">-3007529</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c10" decimals="0" id="ixv-26732" unitRef="usd">-3248607</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c11" decimals="0" id="ixv-26733" unitRef="usd">4636131</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="0" id="ixv-26734" unitRef="usd">5012880</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c31" decimals="0" id="ixv-26735" unitRef="usd">8261487</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c18" decimals="0" id="ixv-26736" unitRef="usd">3625356</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-26737" unitRef="usd">2005351</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="0" id="ixv-26738" unitRef="usd">5012880</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c31" decimals="0" id="ixv-26739" unitRef="usd">8261487</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-26740" unitRef="usd">94108</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c10" decimals="0" id="ixv-26741" unitRef="usd">64744</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c11" decimals="0" id="ixv-26742" unitRef="usd">273155</us-gaap:InterestPaidNet>
    <apm:ProceedsInBrokerAccounts contextRef="c11" decimals="0" id="ixv-26743" unitRef="usd">20116734</apm:ProceedsInBrokerAccounts>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-26744" unitRef="usd">338525</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c10" decimals="0" id="ixv-26745" unitRef="usd">549596</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <apm:SettlementsOfServiceFeeByDigitalCurrenciesAndTokens contextRef="c11" decimals="0" id="ixv-26746" unitRef="usd">90457</apm:SettlementsOfServiceFeeByDigitalCurrenciesAndTokens>
    <apm:ConvertibleNotesConvertedToClassAOrdinaryShares contextRef="c0" decimals="0" id="ixv-26747" unitRef="usd">6000000</apm:ConvertibleNotesConvertedToClassAOrdinaryShares>
    <apm:SettlementOfDeferredCashBonusByIssuanceOfShareOptions contextRef="c0" decimals="0" id="ixv-26748" unitRef="usd">3078196</apm:SettlementOfDeferredCashBonusByIssuanceOfShareOptions>
    <us-gaap:Cash contextRef="c4" decimals="0" id="ixv-26749" unitRef="usd">2005351</us-gaap:Cash>
    <us-gaap:Cash contextRef="c5" decimals="0" id="ixv-26750" unitRef="usd">1882545</us-gaap:Cash>
    <us-gaap:Cash contextRef="c31" decimals="0" id="ixv-26751" unitRef="usd">8131217</us-gaap:Cash>
    <us-gaap:RestrictedCashCurrent contextRef="c5" decimals="0" id="ixv-26752" unitRef="usd">3130335</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c31" decimals="0" id="ixv-26753" unitRef="usd">130270</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-26754" unitRef="usd">2005351</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="0" id="ixv-26755" unitRef="usd">5012880</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c31" decimals="0" id="ixv-26756" unitRef="usd">8261487</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-20968">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;1. ORGANIZATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements include
the financial statements of Aptorum Group Limited (the &#x201c;Company&#x201d;) and its subsidiaries. The Company and its subsidiaries are
hereinafter collectively referred to as the &#x201c;Group&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company, formerly known as APTUS Holdings
Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, is a company incorporated on September 13, 2010 under the laws of the Cayman
Islands with limited liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company researches and develops life science
and biopharmaceutical products within its wholly-owned subsidiary, Aptorum Therapeutics Limited, formerly known as APTUS Therapeutics
Limited (&#x201c;Aptorum Therapeutics&#x201d;) and its indirect subsidiary companies (collectively, &#x201c;Aptorum Therapeutics Group&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Below summarizes the list of the major subsidiaries consolidated as
of December 31, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 22%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Incorporation&lt;br/&gt;
date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Ownership&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Place of&lt;br/&gt;
incorporation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Principle activities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Aptorum Therapeutics Limited (&#x201c;ATL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;June 30, 2016&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;APTUS MANAGEMENT LIMITED&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;May 16, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Provision of management services to its holding company and fellow subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Aptorum Medical Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;August 28, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;90%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Provision of medical clinic services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Paths Innovations Limited &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;April 15, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Investment holding company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Paths Diagnostics Pte. Limited &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;June 5, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;75%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Singapore&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Acticule Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;June 30, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;80%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Claves Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;August 2, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Nativus Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;July 7, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Videns Incorporation Limited &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;March 2, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Mios Pharmaceuticals Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;97.93%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;mTOR (Hong Kong) Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;November 4, 2016&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;90%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Scipio Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;July 19, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;97.93%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Signate Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;August 28, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c0" id="ixv-26757">Below summarizes the list of the major subsidiaries consolidated as
of December 31, 2023:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 22%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Incorporation&lt;br/&gt;
date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Ownership&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Place of&lt;br/&gt;
incorporation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Principle activities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Aptorum Therapeutics Limited (&#x201c;ATL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;June 30, 2016&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;APTUS MANAGEMENT LIMITED&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;May 16, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Provision of management services to its holding company and fellow subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Aptorum Medical Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;August 28, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;90%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Provision of medical clinic services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Paths Innovations Limited &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;April 15, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Investment holding company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Paths Diagnostics Pte. Limited &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;June 5, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;75%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Singapore&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Acticule Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;June 30, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;80%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Claves Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;August 2, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Nativus Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;July 7, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Videns Incorporation Limited &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;March 2, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Mios Pharmaceuticals Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;97.93%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;mTOR (Hong Kong) Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;November 4, 2016&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;90%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Scipio Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;July 19, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;97.93%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Signate Life Sciences Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;August 28, 2017&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development of life science and biopharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c56" id="ixv-21009">2016-06-30</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c57" decimals="2" id="ixv-26758" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c56" id="ixv-21016">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c56" id="ixv-21020">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c58" id="ixv-21027">2017-05-16</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c59" decimals="2" id="ixv-26759" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c58" id="ixv-21034">Hong Kong</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c58" id="ixv-21038">Provision of management services to its holding company and fellow subsidiaries</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c60" id="ixv-21045">2017-08-28</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c61" decimals="2" id="ixv-26760" unitRef="pure">0.90</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c60" id="ixv-21052">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c60" id="ixv-21056">Provision of medical clinic services</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c62" id="ixv-21063">2019-04-15</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c63" decimals="2" id="ixv-26761" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c62" id="ixv-21070">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c62" id="ixv-21074">Investment holding company</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c64" id="ixv-21081">2019-06-05</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c65" decimals="2" id="ixv-26762" unitRef="pure">0.75</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c64" id="ixv-21088">Singapore</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c64" id="ixv-21092">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c66" id="ixv-21099">2017-06-30</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c67" decimals="2" id="ixv-26763" unitRef="pure">0.80</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c66" id="ixv-21106">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c66" id="ixv-21110">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c68" id="ixv-21117">2017-08-02</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c69" decimals="2" id="ixv-26764" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c68" id="ixv-21124">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c68" id="ixv-21128">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c70" id="ixv-21135">2017-07-07</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c71" decimals="2" id="ixv-26765" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c70" id="ixv-21142">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c70" id="ixv-21146">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c72" id="ixv-21153">2017-03-02</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c73" decimals="2" id="ixv-26766" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c72" id="ixv-21160">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c72" id="ixv-21164">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c74" id="ixv-21171">2018-03-06</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c75" decimals="4" id="ixv-26767" unitRef="pure">0.9793</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c74" id="ixv-21178">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c74" id="ixv-21182">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c76" id="ixv-21189">2016-11-04</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c77" decimals="2" id="ixv-26768" unitRef="pure">0.90</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c76" id="ixv-21196">Hong Kong</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c76" id="ixv-21200">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c78" id="ixv-21207">2017-07-19</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c79" decimals="4" id="ixv-26769" unitRef="pure">0.9793</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c78" id="ixv-21214">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c78" id="ixv-21218">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c80" id="ixv-21225">2017-08-28</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c81" decimals="2" id="ixv-26770" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <apm:EntityIncorporationsStateCountryName contextRef="c80" id="ixv-21232">Cayman Islands</apm:EntityIncorporationsStateCountryName>
    <apm:PrincipleActivities contextRef="c80" id="ixv-21236">Research and development of life science and biopharmaceutical products</apm:PrincipleActivities>
    <apm:LiquidityDisclosureTextBlock contextRef="c0" id="ixv-21264">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;2. LIQUIDITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group reported a net loss of $4,340,975 and
net operating cash outflow of $7,724,364 for the year ended December 31, 2023. In addition, the Group had an accumulated deficit of $68,161,722
as of December 31, 2023. The Group&#x2019;s operating results for future periods are subject to numerous uncertainties and it is uncertain
if the Group will be able to reduce or eliminate its net losses for the foreseeable future. If management is not able to generate significant
revenues from its product candidates currently in development, the Group may not be able to achieve profitability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s principal sources of liquidity
have been cash, line of credit facility from related parties, bank loan, public offerings and convertible bonds. As of the date of issuance
of the consolidated financial statements, the Group has approximately $1.0 million of unrestricted cash or cash equivalents, and approximately
$12 million of undrawn line of credit facility from a related party. In addition, the Group will need to maintain its operating costs
at a level through strict cost control and budget, such as staff reductions, to ensure operating costs are minimized and will not exceed
such aforementioned sources of funds to continue as a going concern for a period within 12 months after the issuance of its consolidated
financial statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group believes that available cash, together
with the efforts from aforementioned management plan and actions, should enable the Group to meet current anticipated cash needs for at
least the next 12 months after the date that the consolidated financial statements are issued and the Group has prepared the consolidated
financial statements on a going concern basis. The Group may, however, need additional capital in the future to fund its continued operations.
If the Group determine that its cash requirements exceed the amount of cash and cash equivalents the Group has at the time, the Group
may seek to issue equity or debt securities or obtain credit facilities. The issuance and sale of additional equity or convertible debts
would result in further dilution to its shareholders. The incurrence of indebtedness would result in increased fixed obligations and could
result in operating covenants that might restrict its operations. The Group cannot assure that the financing will be available in amounts
or on terms acceptable to the Group, if at all.&lt;/p&gt;</apm:LiquidityDisclosureTextBlock>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-26771" unitRef="usd">-4340975</us-gaap:ProfitLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-26772" unitRef="usd">-7724364</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" id="ixv-26773" unitRef="usd">-68161722</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RestrictedCashEquivalents contextRef="c82" decimals="-5" id="ixv-26774" unitRef="usd">1000000</us-gaap:RestrictedCashEquivalents>
    <apm:UnrestrictedCashEquivalents contextRef="c4" decimals="-6" id="ixv-26775" unitRef="usd">12000000</apm:UnrestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-21277">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Principles of presentation and consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements of the Group
are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America
(&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;),
and include the accounts of the Company, its direct and indirect wholly and majority owned subsidiaries. In accordance with the provisions
of Accounting Standards Codification (&#x201c;ASC&#x201d;) 810, Consolidation, we consolidate any variable interest entity (&#x201c;VIE&#x201d;)
of which we are the primary beneficiary. The typical condition for a controlling financial interest ownership is holding a majority of
the voting interests of an entity; however, a controlling financial interest may also exist in entities, such as VIEs, through arrangements
that do not involve controlling voting interests. ASC 810 requires a variable interest holder to consolidate a VIE if that party has the
power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and the obligation to absorb
losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially
be significant to the VIE. We do not consolidate a VIE in which we have a majority ownership interest when we are not considered the primary
beneficiary. We have determined that we are not one of the primary beneficiary of the VIE (see Note 13, Variable Interest Entity). We
evaluate our relationships with the VIE on an ongoing basis to determine whether we become the primary beneficiary. All material intercompany
balances and transactions have been eliminated in preparation of the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling interests&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Non-controlling interests are recognized to reflect
the portion of the equity of majority-owned subsidiaries which are not attributable, directly or indirectly, to the controlling shareholder.
Non-controlling interests are classified as a separate line item in the equity section of the Group&#x2019;s consolidated balance sheets
and have been separately disclosed in the Group&#x2019;s consolidated statements of operations and comprehensive loss and consolidated
statements of equity to distinguish the interests from that of the Group.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as income
and expenses during the reporting period. Significant accounting estimates reflected in the Group&#x2019;s consolidated financial statements
include fair value of long-term investments, fair value measurement for share options, impairment of long-lived assets, allowance for
credit losses and valuation allowance for deferred tax assets. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency translation and transaction&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;USD is the reporting currency. The functional
currency of subsidiaries in the Cayman Islands, Seychelles, Samoa and the United States are USD, the functional currency of subsidiaries
in Hong Kong is Hong Kong Dollars (&#x201c;HKD&#x201d;), the functional currency of a subsidiary in Singapore is Singapore Dollars (&#x201c;SGD&#x201d;),
the functional currency of a subsidiary in the United Kingdom is Great British Pound (&#x201c;GBP&#x201d;), and the functional currency
of subsidiaries in Canada is Canadian Dollars (&#x201c;CAD&#x201d;). An entity&#x2019;s functional currency is the currency of the primary
economic environment in which it operates, normally that is the currency of the environment in which it primarily generates and expends
cash. The management considered various indicators, such as cash flows, market expenses, financing and inter-company transactions and
arrangements in determining the Group&#x2019;s functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the consolidated financial statements, the
financial information of the Company and its subsidiaries, which use HKD, SGD, GBP and CAD as their functional currency, has been translated
into USD. Assets and liabilities are translated from each subsidiary&#x2019;s functional currency at the exchange rates on the balance
sheet dates, equity amounts are translated at historical exchange rates, and revenues, expenses, gains, and losses are translated using
the average exchange rates for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a
separate component of other comprehensive income or loss in the consolidated statements of operations and comprehensive income or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents consists of cash on
hand, bank deposits and time deposits with an original maturity of three months or less at the date of purchase.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Restricted cash represented time deposits pledged
for banking facilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable and amounts due from related
parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group adopted ASC 326 from January 1, 2023.
Accounts receivable and amounts due from related parties are stated at the original amount less an allowance for credit losses, if any,
based on a review of all outstanding amounts at period end. An allowance is estimated in accordance with ASC Topic 326, &lt;i&gt;Credit Losses&lt;/i&gt;
and records the allowance for credit losses as an offset to accounts receivable or amounts due from related parties, and the expected
credit losses charged to the allowance is included in other operating expenses in the consolidated statements of operations and comprehensive
loss. In determining expected credit losses, the Group considers the historical level of credit losses, current economic trends, and reasonable
and supportable forecasts that affect the collectability of the future cash flows. As of December 31, 2023 and 2022, $521,007 and &lt;span style="-sec-ix-hidden: hidden-fact-192"&gt;$71&lt;/span&gt;
allowance for credit losses were made.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at lower of cost and net
realizable value. Cost is determined using the weighted average method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Where there is evidence that the utility of inventories,
in their disposal in the ordinary course of business, will be less than cost, whether due to physical deterioration, obsolescence, changes
in price levels, or other causes, the inventories are written down to net realizable value. During the years ended December 31, 2023,
2022 and 2021, the write-down of inventories were $13,206, $&lt;span style="-sec-ix-hidden: hidden-fact-193"&gt;nil&lt;/span&gt; and $&lt;span style="-sec-ix-hidden: hidden-fact-194"&gt;nil&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Marketable securities are publicly traded stocks
measured at fair value and classified within Level 1 and 2 in the fair value hierarchy because the Group either uses quoted prices for
identical assets in active markets, inputs that are based upon quoted prices for similar instruments in active markets, or quoted prices
for identical assets in markets with insufficient volume or infrequent transaction (less active markets).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s long-term investments consist
of equity method investment in common stocks and non-marketable investments in non-redeemable preferred shares of privately-held companies
that are not required to be consolidated under the variable interest or voting models. Long-term investments are classified as non-current
assets on the consolidated balance sheets as those investments do not have stated contractual maturity dates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Non-marketable investments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The non-marketable equity securities not accounted
for under the equity method are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in
orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach
as of the transaction date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Equity method investment &#x2013; Fair value option&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group elects the fair value option for an
investment that would otherwise be accounted for using the equity method of accounting. Such election is irrevocable and is applied on
an investment by investment basis at initial recognition. The fair value of such investments is based on quoted prices in an active market,
if any, or recent orderly transactions for identical or similar investment of the same issuer. Changes in the fair value of these equity
method investments are recognized in other income (expenses), net in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Fair value measurement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fair value is defined as the price that would
be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the
Group considers the principal or most advantageous market in which it would transact its business, and it considers assumptions that market
participants would use when pricing the asset or liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a basis for considering such assumptions, a
three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The hierarchy requires the Group to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s categorization
within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Group has
estimated the fair value amounts of its financial instruments using the available market information and valuation methodologies considered
to be appropriate and has determined that the carrying value of the Group&#x2019;s cash, restricted cash, accounts receivable, due from
brokers, other receivables and prepayments, loan receivables from related parties, amounts due from/to related parties, accounts payable
and accrued expenses, bank loan, and loan payables to a related party as of December 31, 2023 and 2022 approximate fair value due to the
short-term nature of these assets and liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment, net, is stated at cost
less accumulated depreciation and impairment losses. Cost represents the purchase price of the asset and other costs incurred to bring
the asset into its existing use. Maintenance, repairs and betterments, including replacement of minor items, are charged to expense; major
additions to physical properties are capitalized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assets under construction are stated at cost less
impairment losses. Cost comprises of cost of laboratory equipment delivered but not ready to be used, together with interest expense capitalized
during the period of construction or installation and testing. Capitalization of these costs ceases and the asset concerned is transferred
to the appropriate fixed assets category when substantially all the activities necessary to prepare the asset for its intended use are
completed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation of property, plant and equipment
is provided using the straight-line method over their estimated useful lives:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 51%"&gt;&lt;span style="font-size: 10pt"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture, fixture, and office and medical equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Shorter of the remaining lease terms or 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon sale or disposal, the applicable amounts
of asset cost and accumulated depreciation are removed from the accounts and the net amount less proceeds from disposal is charged or
credited to income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Finite-lived intangible assets are carried at
cost less accumulated amortization and impairment if any. The finite intangible assets are amortized over their estimated useful life,
which is the period over which the assets are expected to contribute directly or indirectly to the future cash flows of the Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s intangible assets mainly consist
of computer software and is amortized over its useful life. The estimated useful life is generally 5 years. The Group will reassess the
remaining useful life on annual basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group reviews its long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When these events
occur, the Group compares the carrying value of the long-lived assets to the estimated undiscounted future cash flows expected to result
from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flow is less than the carrying
amount of the assets, the Group would recognize an impairment loss, which is the excess of carrying amount over the fair value of the
assets, using the expected future discounted cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Convertible notes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group evaluates and accounts for conversion
options embedded in convertible notes in accordance with ASC 815 &#x201c;Derivatives and Hedging Activities&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Applicable GAAP requires companies to bifurcate
conversion options from their host instruments and account for them as derivative financial instruments according to certain criteria.
The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly
and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded
derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings
as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group accounts for the convertible notes as
a single unit of account, unless the conversion feature requires bifurcation and recognition as derivatives. Additionally, the Group uses
the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential
share settlement for instruments that may be settled in cash or shares.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the inception of a contract, the Group determines
if the arrangement is, or contains, a lease. Operating lease liabilities are recognized at lease commencement based on the present value
of lease payments over the lease term. Operating lease right-of-use assets are initially measured at cost, which comprises the initial
amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs
incurred and less any lease incentives received. As the rate implicit in the lease cannot be readily determined, the Group uses incremental
borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental
borrowing rate is determined based on the rate of interest that the Group would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term in a similar economic environment. The lease term for all of the Group&#x2019;s leases includes
the non-cancellable period of the lease plus any additional periods covered by either a Group&#x2019;s option to extend (or not to terminate)
the lease that the Group is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.
For operating leases, the Group recognizes a single lease cost on a straight-line basis over the remaining lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group has elected not to recognize right-of-use
assets or lease liabilities for leases with an initial term of 12 months or less and the Group recognizes lease expense for these leases
on a straight-line basis over the lease terms.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Warrants &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection of the issuance of Class A Ordinary
Shares, the Company may issue warrants to purchase Class A Ordinary Shares. Warrants classified as equity are initially recorded at fair
value and subsequent changes in fair value are not recognized.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues are derived from healthcare services
rendered to patients for healthcare consultation and medical treatment. Revenue is reported at the amount that reflects the consideration
to which the Group expects to be entitled in exchange for providing healthcare services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group recognizes revenue as its performance
obligations are completed. Healthcare services are treated as a single performance obligation satisfied at a point in time because the
performance obligations are generally satisfied over a period of less than one day.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Cost of healthcare services&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of healthcare services rendered represents
cost in relation to the medical services provided including the compensation of the physicians, cost of pharmaceutical supplies and medicine
and write-down of inventories.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development costs are expensed as
incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including
amortization of the patent license, depreciation of laboratory equipment, costs of engaging external consultants, advisors and contracted
research organization to conduct preclinical development activities and trials, payroll expenses to research and development staff, sponsored
research expenses to universities and research institutions, and impairment of patent license and laboratory equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group uses the fair value method of accounting
for the share options granted to directors, employees, external consultants and advisors to measure the cost services received in exchange
for the share based awards. The fair value of share option awards with only service condition is estimated on the grant or offering date
using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires inputs such as the risk-free interest rate,
expected term and expected volatility. These inputs are subjective and generally require significant judgment. The resulting cost is recognized
over the period during which a director, employee, external consultant or advisor is required to provide service in exchange for the awards,
usually the vesting period, which is generally from 9.5 months to 21.5 months. Share-based compensation expense is recognized on a graded
vesting basis, net of actual forfeitures in the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Share-based compensation expense is recorded in
cost of healthcare services, research and development expenses, general and administrative fees and legal and professional fees in the
consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 718, modifications to stock-based
awards are accounted for as exchanges of the original awards for new awards. The incremental fair value, which is the difference between
the fair value of the modified award and the original award immediately before modification, is measured at the modification date. This
incremental fair value is recognized immediately as compensation cost for vested awards. For unvested awards, the incremental compensation
cost, along with any remaining unrecognized compensation cost of the original award, is recognized over the remaining requisite vesting
period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group accounts for income taxes under the
asset and liability method. Under this method, deferred income taxes are determined based on differences between the financial carrying
amounts of existing assets and liabilities and their tax bases. Income taxes are provided for in accordance with the laws of the relevant
taxing authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A valuation allowance is provided for deferred
tax assets if it is more likely than not that these items will either expire before the Group is able to realize their benefits, or that
future deductibility is uncertain. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group accounts for uncertainty in income taxes
using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition
by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit,
including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest
amount that is more than 50% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized
and recorded as necessary in the provision for income taxes. The Group recognizes interest on non-payment of income taxes and penalties
associated with tax positions when a tax position does not meet more likely than not thresholds be sustained under examination. The tax
returns of the Group&#x2019;s Hong Kong subsidiaries are subject to examination by the relevant tax authorities. According to the Hong
Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed or has
been assessed at less than the proper amount, the statute of limitation is extended to ten years if the underpayment of taxes is due to
fraud or willful evasion. According to United Kingdom, Singapore, the United States, Canada and Ireland tax rule, trading losses are available
to be carried forward indefinitely. The Group did not have any material interest or penalties associated with tax positions for the years
ended December 31, 2023, 2022 and 2021, and did not have any significant unrecognized uncertain tax positions as of December 31, 2023
and 2022. The Group does not believe that its assessment regarding unrecognized tax benefits will materially change over the next twelve
months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Comprehensive income or loss&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain changes in assets and liabilities are
reported as separate components of the equity section of the consolidated balance sheets, such items, along with net income or loss, are
components of comprehensive income or loss. The components of other comprehensive income or loss consist of exchange differences on translation
of foreign operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Net income or loss per share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net income or loss per share is computed
by dividing net income or loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during
the period. Diluted net income or loss per share reflects the potential dilution that could occur if securities or other contracts to
issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation
of diluted loss per share in loss periods as their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of credit risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial assets which potentially subject the
Group to concentrations of credit risk consist principally of bank deposits and balances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group takes on exposure to credit risk on
cash balances majority held with HSBC for the purposes of payments of Group expenses. The risk of default is considered minimal as the
Group considers HSBC is well established with high credit rating.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;)
No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13
is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held
by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets
held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires
enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used
in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#x2019;s portfolio. These disclosures
include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements.
In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13
are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December
15, 2022 for the Group. The Group has adopted ASU 2016-13 on January 1, 2023 and the impact of this adoption for the years ended December
31, 2023 and 2022 were assessed to be not material.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recently issued accounting standards which have not yet been adopted&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements,
primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. The amendments
in this ASU are effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years
beginning after December 15, 2024, with early adoption permitted. The Group is still evaluating the effect of the adoption of this guidance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued Accounting Standards
Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness
of income tax disclosures. The amendments address more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. The ASU also includes certain other amendments to improve
the effectiveness of income tax disclosures. The amendments in this ASU are effective for public business entities for annual periods
beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Group is still evaluating the effect of the
adoption of this guidance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 6, 2024, the SEC approved a rule that
will require registrants to provide certain climate-related information in their registration statements and annual reports. The rule
requires information about a registrant&#x2019;s climate-related risks that are reasonably likely to have a material impact on its business,
results of operations, or financial condition. The required information about climate-related risks also includes disclosure of a registrant&#x2019;s
greenhouse gas emissions. In addition, the rules will require registrants to present certain climate-related financial metrics in their
audited financial statements. The Group is evaluating the potential impact of this rule on the consolidated financial statements and related
disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group does not believe other recently issued
but not yet effective accounting standards, if currently adopted, would have a material impact on the consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-21281">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Principles of presentation and consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements of the Group
are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America
(&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;),
and include the accounts of the Company, its direct and indirect wholly and majority owned subsidiaries. In accordance with the provisions
of Accounting Standards Codification (&#x201c;ASC&#x201d;) 810, Consolidation, we consolidate any variable interest entity (&#x201c;VIE&#x201d;)
of which we are the primary beneficiary. The typical condition for a controlling financial interest ownership is holding a majority of
the voting interests of an entity; however, a controlling financial interest may also exist in entities, such as VIEs, through arrangements
that do not involve controlling voting interests. ASC 810 requires a variable interest holder to consolidate a VIE if that party has the
power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and the obligation to absorb
losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially
be significant to the VIE. We do not consolidate a VIE in which we have a majority ownership interest when we are not considered the primary
beneficiary. We have determined that we are not one of the primary beneficiary of the VIE (see Note 13, Variable Interest Entity). We
evaluate our relationships with the VIE on an ongoing basis to determine whether we become the primary beneficiary. All material intercompany
balances and transactions have been eliminated in preparation of the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <apm:NoncontrollingInterestsPolicyTextBlock contextRef="c0" id="ixv-21314">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling interests&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Non-controlling interests are recognized to reflect
the portion of the equity of majority-owned subsidiaries which are not attributable, directly or indirectly, to the controlling shareholder.
Non-controlling interests are classified as a separate line item in the equity section of the Group&#x2019;s consolidated balance sheets
and have been separately disclosed in the Group&#x2019;s consolidated statements of operations and comprehensive loss and consolidated
statements of equity to distinguish the interests from that of the Group.&#160;&lt;/p&gt;</apm:NoncontrollingInterestsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-21321">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as income
and expenses during the reporting period. Significant accounting estimates reflected in the Group&#x2019;s consolidated financial statements
include fair value of long-term investments, fair value measurement for share options, impairment of long-lived assets, allowance for
credit losses and valuation allowance for deferred tax assets. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-21328">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency translation and transaction&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;USD is the reporting currency. The functional
currency of subsidiaries in the Cayman Islands, Seychelles, Samoa and the United States are USD, the functional currency of subsidiaries
in Hong Kong is Hong Kong Dollars (&#x201c;HKD&#x201d;), the functional currency of a subsidiary in Singapore is Singapore Dollars (&#x201c;SGD&#x201d;),
the functional currency of a subsidiary in the United Kingdom is Great British Pound (&#x201c;GBP&#x201d;), and the functional currency
of subsidiaries in Canada is Canadian Dollars (&#x201c;CAD&#x201d;). An entity&#x2019;s functional currency is the currency of the primary
economic environment in which it operates, normally that is the currency of the environment in which it primarily generates and expends
cash. The management considered various indicators, such as cash flows, market expenses, financing and inter-company transactions and
arrangements in determining the Group&#x2019;s functional currency.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the consolidated financial statements, the
financial information of the Company and its subsidiaries, which use HKD, SGD, GBP and CAD as their functional currency, has been translated
into USD. Assets and liabilities are translated from each subsidiary&#x2019;s functional currency at the exchange rates on the balance
sheet dates, equity amounts are translated at historical exchange rates, and revenues, expenses, gains, and losses are translated using
the average exchange rates for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a
separate component of other comprehensive income or loss in the consolidated statements of operations and comprehensive income or loss.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-21338">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents consists of cash on
hand, bank deposits and time deposits with an original maturity of three months or less at the date of purchase.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0" id="ixv-21345">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Restricted cash represented time deposits pledged
for banking facilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0" id="ixv-21378">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable and amounts due from related
parties&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group adopted ASC 326 from January 1, 2023.
Accounts receivable and amounts due from related parties are stated at the original amount less an allowance for credit losses, if any,
based on a review of all outstanding amounts at period end. An allowance is estimated in accordance with ASC Topic 326, &lt;i&gt;Credit Losses&lt;/i&gt;
and records the allowance for credit losses as an offset to accounts receivable or amounts due from related parties, and the expected
credit losses charged to the allowance is included in other operating expenses in the consolidated statements of operations and comprehensive
loss. In determining expected credit losses, the Group considers the historical level of credit losses, current economic trends, and reasonable
and supportable forecasts that affect the collectability of the future cash flows. As of December 31, 2023 and 2022, $521,007 and &lt;span style="-sec-ix-hidden: hidden-fact-192"&gt;$71&lt;/span&gt;
allowance for credit losses were made.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <apm:AllowanceForCreditLossOfDueFromARelatedParty contextRef="c0" decimals="0" id="ixv-26776" unitRef="usd">521007</apm:AllowanceForCreditLossOfDueFromARelatedParty>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-21387">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at lower of cost and net
realizable value. Cost is determined using the weighted average method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Where there is evidence that the utility of inventories,
in their disposal in the ordinary course of business, will be less than cost, whether due to physical deterioration, obsolescence, changes
in price levels, or other causes, the inventories are written down to net realizable value. During the years ended December 31, 2023,
2022 and 2021, the write-down of inventories were $13,206, $&lt;span style="-sec-ix-hidden: hidden-fact-193"&gt;nil&lt;/span&gt; and $&lt;span style="-sec-ix-hidden: hidden-fact-194"&gt;nil&lt;/span&gt; respectively.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown contextRef="c0" decimals="0" id="ixv-26777" unitRef="usd">13206</us-gaap:InventoryWriteDown>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c0" id="ixv-21399">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Marketable securities are publicly traded stocks
measured at fair value and classified within Level 1 and 2 in the fair value hierarchy because the Group either uses quoted prices for
identical assets in active markets, inputs that are based upon quoted prices for similar instruments in active markets, or quoted prices
for identical assets in markets with insufficient volume or infrequent transaction (less active markets).&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <apm:LongtermInvestmentsPolicyPolicyTextBlock contextRef="c0" id="ixv-21406">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s long-term investments consist
of equity method investment in common stocks and non-marketable investments in non-redeemable preferred shares of privately-held companies
that are not required to be consolidated under the variable interest or voting models. Long-term investments are classified as non-current
assets on the consolidated balance sheets as those investments do not have stated contractual maturity dates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Non-marketable investments&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The non-marketable equity securities not accounted
for under the equity method are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in
orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach
as of the transaction date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Equity method investment &#x2013; Fair value option&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group elects the fair value option for an
investment that would otherwise be accounted for using the equity method of accounting. Such election is irrevocable and is applied on
an investment by investment basis at initial recognition. The fair value of such investments is based on quoted prices in an active market,
if any, or recent orderly transactions for identical or similar investment of the same issuer. Changes in the fair value of these equity
method investments are recognized in other income (expenses), net in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</apm:LongtermInvestmentsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-21453">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Fair value measurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fair value is defined as the price that would
be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the
Group considers the principal or most advantageous market in which it would transact its business, and it considers assumptions that market
participants would use when pricing the asset or liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a basis for considering such assumptions, a
three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The hierarchy requires the Group to maximize the
use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s categorization
within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Group has
estimated the fair value amounts of its financial instruments using the available market information and valuation methodologies considered
to be appropriate and has determined that the carrying value of the Group&#x2019;s cash, restricted cash, accounts receivable, due from
brokers, other receivables and prepayments, loan receivables from related parties, amounts due from/to related parties, accounts payable
and accrued expenses, bank loan, and loan payables to a related party as of December 31, 2023 and 2022 approximate fair value due to the
short-term nature of these assets and liabilities.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-21495">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment, net, is stated at cost
less accumulated depreciation and impairment losses. Cost represents the purchase price of the asset and other costs incurred to bring
the asset into its existing use. Maintenance, repairs and betterments, including replacement of minor items, are charged to expense; major
additions to physical properties are capitalized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assets under construction are stated at cost less
impairment losses. Cost comprises of cost of laboratory equipment delivered but not ready to be used, together with interest expense capitalized
during the period of construction or installation and testing. Capitalization of these costs ceases and the asset concerned is transferred
to the appropriate fixed assets category when substantially all the activities necessary to prepare the asset for its intended use are
completed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation of property, plant and equipment
is provided using the straight-line method over their estimated useful lives:&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 51%"&gt;&lt;span style="font-size: 10pt"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture, fixture, and office and medical equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Shorter of the remaining lease terms or 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon sale or disposal, the applicable amounts
of asset cost and accumulated depreciation are removed from the accounts and the net amount less proceeds from disposal is charged or
credited to income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <apm:PropertyPlantAndEquipmentUsefullLifeTableTextBlock contextRef="c0" id="ixv-26778">Depreciation of property, plant and equipment
is provided using the straight-line method over their estimated useful lives:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 51%"&gt;&lt;span style="font-size: 10pt"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture, fixture, and office and medical equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Shorter of the remaining lease terms or 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</apm:PropertyPlantAndEquipmentUsefullLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c85" id="ixv-26779">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c86" id="ixv-26780">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <apm:LeaseholdImprovementsEstimatedUsefulLives contextRef="c87" id="ixv-21528">Shorter of the remaining lease terms or 5 years</apm:LeaseholdImprovementsEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c88" id="ixv-26781">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c89" id="ixv-26782">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c0" id="ixv-21572">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Finite-lived intangible assets are carried at
cost less accumulated amortization and impairment if any. The finite intangible assets are amortized over their estimated useful life,
which is the period over which the assets are expected to contribute directly or indirectly to the future cash flows of the Group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s intangible assets mainly consist
of computer software and is amortized over its useful life. The estimated useful life is generally 5 years. The Group will reassess the
remaining useful life on annual basis.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c4" id="ixv-26783">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-21582">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group reviews its long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When these events
occur, the Group compares the carrying value of the long-lived assets to the estimated undiscounted future cash flows expected to result
from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flow is less than the carrying
amount of the assets, the Group would recognize an impairment loss, which is the excess of carrying amount over the fair value of the
assets, using the expected future discounted cash flows.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c0" id="ixv-21589">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Convertible notes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group evaluates and accounts for conversion
options embedded in convertible notes in accordance with ASC 815 &#x201c;Derivatives and Hedging Activities&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Applicable GAAP requires companies to bifurcate
conversion options from their host instruments and account for them as derivative financial instruments according to certain criteria.
The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly
and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded
derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings
as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group accounts for the convertible notes as
a single unit of account, unless the conversion feature requires bifurcation and recognition as derivatives. Additionally, the Group uses
the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential
share settlement for instruments that may be settled in cash or shares.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <apm:OperatingLeasesPolicyTextBlock contextRef="c0" id="ixv-21628">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the inception of a contract, the Group determines
if the arrangement is, or contains, a lease. Operating lease liabilities are recognized at lease commencement based on the present value
of lease payments over the lease term. Operating lease right-of-use assets are initially measured at cost, which comprises the initial
amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs
incurred and less any lease incentives received. As the rate implicit in the lease cannot be readily determined, the Group uses incremental
borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental
borrowing rate is determined based on the rate of interest that the Group would have to pay to borrow an amount equal to the lease payments
on a collateralized basis over a similar term in a similar economic environment. The lease term for all of the Group&#x2019;s leases includes
the non-cancellable period of the lease plus any additional periods covered by either a Group&#x2019;s option to extend (or not to terminate)
the lease that the Group is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.
For operating leases, the Group recognizes a single lease cost on a straight-line basis over the remaining lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group has elected not to recognize right-of-use
assets or lease liabilities for leases with an initial term of 12 months or less and the Group recognizes lease expense for these leases
on a straight-line basis over the lease terms.&lt;/p&gt;</apm:OperatingLeasesPolicyTextBlock>
    <apm:WarrantLiabilitiesPolicyTextBlock contextRef="c0" id="ixv-21638">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Warrants &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection of the issuance of Class A Ordinary
Shares, the Company may issue warrants to purchase Class A Ordinary Shares. Warrants classified as equity are initially recorded at fair
value and subsequent changes in fair value are not recognized.&#160;&lt;/p&gt;</apm:WarrantLiabilitiesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0" id="ixv-21645">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues are derived from healthcare services
rendered to patients for healthcare consultation and medical treatment. Revenue is reported at the amount that reflects the consideration
to which the Group expects to be entitled in exchange for providing healthcare services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group recognizes revenue as its performance
obligations are completed. Healthcare services are treated as a single performance obligation satisfied at a point in time because the
performance obligations are generally satisfied over a period of less than one day.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0" id="ixv-21655">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Cost of healthcare services&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of healthcare services rendered represents
cost in relation to the medical services provided including the compensation of the physicians, cost of pharmaceutical supplies and medicine
and write-down of inventories.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-21662">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development costs are expensed as
incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including
amortization of the patent license, depreciation of laboratory equipment, costs of engaging external consultants, advisors and contracted
research organization to conduct preclinical development activities and trials, payroll expenses to research and development staff, sponsored
research expenses to universities and research institutions, and impairment of patent license and laboratory equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-21695">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group uses the fair value method of accounting
for the share options granted to directors, employees, external consultants and advisors to measure the cost services received in exchange
for the share based awards. The fair value of share option awards with only service condition is estimated on the grant or offering date
using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires inputs such as the risk-free interest rate,
expected term and expected volatility. These inputs are subjective and generally require significant judgment. The resulting cost is recognized
over the period during which a director, employee, external consultant or advisor is required to provide service in exchange for the awards,
usually the vesting period, which is generally from 9.5 months to 21.5 months. Share-based compensation expense is recognized on a graded
vesting basis, net of actual forfeitures in the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Share-based compensation expense is recorded in
cost of healthcare services, research and development expenses, general and administrative fees and legal and professional fees in the
consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 718, modifications to stock-based
awards are accounted for as exchanges of the original awards for new awards. The incremental fair value, which is the difference between
the fair value of the modified award and the original award immediately before modification, is measured at the modification date. This
incremental fair value is recognized immediately as compensation cost for vested awards. For unvested awards, the incremental compensation
cost, along with any remaining unrecognized compensation cost of the original award, is recognized over the remaining requisite vesting
period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c83" id="ixv-26784">P9M15D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c84" id="ixv-26785">P21M15D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-21708">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group accounts for income taxes under the
asset and liability method. Under this method, deferred income taxes are determined based on differences between the financial carrying
amounts of existing assets and liabilities and their tax bases. Income taxes are provided for in accordance with the laws of the relevant
taxing authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A valuation allowance is provided for deferred
tax assets if it is more likely than not that these items will either expire before the Group is able to realize their benefits, or that
future deductibility is uncertain. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxUncertaintiesPolicy contextRef="c0" id="ixv-21718">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group accounts for uncertainty in income taxes
using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition
by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit,
including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest
amount that is more than 50% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized
and recorded as necessary in the provision for income taxes. The Group recognizes interest on non-payment of income taxes and penalties
associated with tax positions when a tax position does not meet more likely than not thresholds be sustained under examination. The tax
returns of the Group&#x2019;s Hong Kong subsidiaries are subject to examination by the relevant tax authorities. According to the Hong
Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed or has
been assessed at less than the proper amount, the statute of limitation is extended to ten years if the underpayment of taxes is due to
fraud or willful evasion. According to United Kingdom, Singapore, the United States, Canada and Ireland tax rule, trading losses are available
to be carried forward indefinitely. The Group did not have any material interest or penalties associated with tax positions for the years
ended December 31, 2023, 2022 and 2021, and did not have any significant unrecognized uncertain tax positions as of December 31, 2023
and 2022. The Group does not believe that its assessment regarding unrecognized tax benefits will materially change over the next twelve
months.&lt;/p&gt;</us-gaap:IncomeTaxUncertaintiesPolicy>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" id="ixv-26786" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0" id="ixv-21725">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Comprehensive income or loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain changes in assets and liabilities are
reported as separate components of the equity section of the consolidated balance sheets, such items, along with net income or loss, are
components of comprehensive income or loss. The components of other comprehensive income or loss consist of exchange differences on translation
of foreign operations.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-21732">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Net income or loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net income or loss per share is computed
by dividing net income or loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during
the period. Diluted net income or loss per share reflects the potential dilution that could occur if securities or other contracts to
issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation
of diluted loss per share in loss periods as their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-21765">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of credit risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial assets which potentially subject the
Group to concentrations of credit risk consist principally of bank deposits and balances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group takes on exposure to credit risk on
cash balances majority held with HSBC for the purposes of payments of Group expenses. The risk of default is considered minimal as the
Group considers HSBC is well established with high credit rating.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-21775">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;)
No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13
is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held
by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets
held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires
enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used
in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#x2019;s portfolio. These disclosures
include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements.
In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13
are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December
15, 2022 for the Group. The Group has adopted ASU 2016-13 on January 1, 2023 and the impact of this adoption for the years ended December
31, 2023 and 2022 were assessed to be not material.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c0" id="ixv-21782">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recently issued accounting standards which have not yet been adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements,
primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. The amendments
in this ASU are effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years
beginning after December 15, 2024, with early adoption permitted. The Group is still evaluating the effect of the adoption of this guidance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued Accounting Standards
Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness
of income tax disclosures. The amendments address more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. The ASU also includes certain other amendments to improve
the effectiveness of income tax disclosures. The amendments in this ASU are effective for public business entities for annual periods
beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Group is still evaluating the effect of the
adoption of this guidance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 6, 2024, the SEC approved a rule that
will require registrants to provide certain climate-related information in their registration statements and annual reports. The rule
requires information about a registrant&#x2019;s climate-related risks that are reasonably likely to have a material impact on its business,
results of operations, or financial condition. The required information about climate-related risks also includes disclosure of a registrant&#x2019;s
greenhouse gas emissions. In addition, the rules will require registrants to present certain climate-related financial metrics in their
audited financial statements. The Group is evaluating the potential impact of this rule on the consolidated financial statements and related
disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group does not believe other recently issued
but not yet effective accounting standards, if currently adopted, would have a material impact on the consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-21800">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;4. REVENUE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2023, 2022 and
2021, all revenue came from provision of healthcare services in Hong Kong.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the second quarter of 2023, the Group made
a decision to streamline its operations by terminating clinic services and suspending non-lead R&amp;amp;D projects.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-21837">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;5. INVESTMENT AND FAIR VALUE MEASUREMENT &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Assets Measured at Fair Value on a Recurring Basis&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides the assets and liabilities
carried at fair value measured on a recurring basis as of December 31, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Non-current Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 0.125in"&gt;Long-term investments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Common stocks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total assets at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 0.25in"&gt;Common stocks&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,202&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102,481&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-current Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Long-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Common stocks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total assets at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,202&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;92,279&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;179,681&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is a reconciliation of Level 3 assets
measured and recorded at fair value on a recurring basis during the years ended December 31, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-weight: bold"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(77,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net change in unrealized appreciation relating to investments still held at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in unrealized appreciation, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net change in unrealized appreciation relating to investments still held at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2023, an impairment
loss relating to an equity method investment amounted to $77,200, was recorded in other expenses, net, as the Group considered that the
carrying amount of the equity method investment may not be recoverable, and this condition is determined to be other-than-temporary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents the quantitative
information about the Group&#x2019;s Level 3 fair value measurements of investment as of December 31, 2023 and 2022, which utilized significant
unobservable internally-developed inputs:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 25%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation technique&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Unobservable input&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Range&lt;br/&gt;
(weighted average)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Common stocks&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Recent transactions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Recent transaction price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$0.0001 - $0.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 25%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation technique&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Unobservable input&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Range&lt;br/&gt;
(weighted average)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Common stocks&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Recent transactions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Recent transaction price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$0.0001 - $0.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Non-marketable investments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s non-marketable investments are
investments in privately held companies without readily determinable fair values. The carrying value of the non-marketable investments
are adjusted based on price changes from observable transactions of identical or similar securities of the same issuer (referred to as
the measurement alternative) or for impairment if the carrying amount of the non-marketable investments may not be fully recoverable.
Any changes in carrying value are recorded within other income (expenses), net in the consolidated statements of operations and comprehensive
loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is a summary of annual upward or
downwards adjustments and impairment recorded in other income (expenses), net, and included as adjustments to the carrying value of non-marketable
investments held as of&#160;December 31, 2023, 2022 and 2021 based on the observable price in an orderly transaction for the same or similar
security of the same issuers:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Upward adjustments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,431,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,108,872&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Downward adjustments and impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(520,821&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total unrealized gain from fair value change of non-marketable investments,
net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,431,088&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,588,051&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group did not sell any non-marketable investments
or recorded any realized gains or losses for the non-marketable investments measured at fair value on a non-recurring basis during the
years ended December 31, 2023, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the total carrying
value of the non-marketable investments held as of&#160;December 31, 2023 and 2022&#160;including cumulative unrealized upward and downward
adjustments and impairment made to the initial cost basis of the investments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Initial cost basis&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,079,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,079,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Upward adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,539,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,108,872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Downward adjustments and impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(520,821&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(520,821&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total carrying value at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,098,846&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,667,758&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group did not transfer any non-marketable
investments into marketable securities for the years ended December 31, 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2023, one of the
non-marketable investments with initial cost of $2.6 million and had a carrying value of $15.1 million was pledged for a convertible note
issued to a related party (Note 15).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Equity method investment, fair value option&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2021, one of the Group&#x2019;s subsidiaries,
Libra Sciences Limited (&#x201c;Libra&#x201d;, formerly known as Aptorum Pharmaceutical Development Limited), issued Class A and Class B
ordinary shares to various parties in exchange of licenses or cash. Each Class A share of Libra is entitled to 1 vote while each Class
B share of Libra is entitled to 10 votes. Upon the share issuance, the Group was holding 97.27% economic interest and 31.51% voting power
in Libra. The Group lost the controlling interest in Libra because it was transferred to a third party, and therefore deconsolidated Libra.
However, the Group still owns 97.27% economic interest and 31.51% voting power, which is deemed as having significant influence over Libra.
As a result, the Group&#x2019;s investment in Libra is subject to the equity method of accounting. The Group assessed that the fair value
option can better reflect the true value of Libra. Pursuant to ASC 825 &#x2013; Financial Instruments (&#x201c;ASC 825&#x201d;), the Group
elected to apply the fair value option for its investments in Libra and will remeasure its investments in Libra at fair value every reporting
period. For the year ended December 31, 2023, the Group has determined that the carrying value of the investment is not recoverable and
this condition is determined to be other-than-temporary. Consequently, an impairment for the investment of $77,200 has been recognized
for the year end December 31, 2023.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0" id="ixv-26787">The following table provides the assets and liabilities
carried at fair value measured on a recurring basis as of December 31, 2023 and 2022:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Non-current Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 0.125in"&gt;Long-term investments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Common stocks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total assets at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 0.25in"&gt;Common stocks&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,202&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102,481&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-current Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Long-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Common stocks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total assets at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,202&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;92,279&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;179,681&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c101" decimals="0" id="ixv-26788" unitRef="usd">10202</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c102" decimals="0" id="ixv-26789" unitRef="usd">92279</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c104" decimals="0" id="ixv-26790" unitRef="usd">102481</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c107" decimals="0" id="ixv-26791" unitRef="usd">77200</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c5" decimals="0" id="ixv-26792" unitRef="usd">77200</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c108" decimals="0" id="ixv-26793" unitRef="usd">10202</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c109" decimals="0" id="ixv-26794" unitRef="usd">92279</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c110" decimals="0" id="ixv-26795" unitRef="usd">77200</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c111" decimals="0" id="ixv-26796" unitRef="usd">179681</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c0" id="ixv-26797">The following is a reconciliation of Level 3 assets
measured and recorded at fair value on a recurring basis during the years ended December 31, 2023 and 2022:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-weight: bold"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(77,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net change in unrealized appreciation relating to investments still held at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in unrealized appreciation, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;77,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net change in unrealized appreciation relating to investments still held at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues contextRef="c112" decimals="0" id="ixv-26798" unitRef="usd">77200</apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues>
    <us-gaap:GoodwillImpairmentLoss contextRef="c113" decimals="0" id="ixv-26799" unitRef="usd">77200</us-gaap:GoodwillImpairmentLoss>
    <apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues contextRef="c115" decimals="0" id="ixv-26800" unitRef="usd">77200</apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues>
    <apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues contextRef="c112" decimals="0" id="ixv-26801" unitRef="usd">77200</apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues>
    <us-gaap:EquityMethodInvestments contextRef="c4" decimals="0" id="ixv-26802" unitRef="usd">77200</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c0" id="ixv-26803">The following table presents the quantitative
information about the Group&#x2019;s Level 3 fair value measurements of investment as of December 31, 2023 and 2022, which utilized significant
unobservable internally-developed inputs:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 25%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation technique&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Unobservable input&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Range&lt;br/&gt;
(weighted average)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Common stocks&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Recent transactions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Recent transaction price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$0.0001 - $0.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 25%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation technique&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Unobservable input&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; border-bottom: black 1.5pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Range&lt;br/&gt;
(weighted average)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Common stocks&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Recent transactions&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Recent transaction price&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$0.0001 - $0.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <apm:FairValueMeasurementValuationTechniques contextRef="c117" id="ixv-22183">Recent transactions</apm:FairValueMeasurementValuationTechniques>
    <apm:FairValueMeasurementsUnobservableInput contextRef="c117" id="ixv-22187">Recent transaction price</apm:FairValueMeasurementsUnobservableInput>
    <apm:FairValueMeasurementsWeightedAverageRange contextRef="c117" id="ixv-22191">$0.0001 - $0.01</apm:FairValueMeasurementsWeightedAverageRange>
    <apm:FairValueMeasurementValuationTechniques contextRef="c118" id="ixv-22226">Recent transactions</apm:FairValueMeasurementValuationTechniques>
    <apm:FairValueMeasurementsUnobservableInput contextRef="c118" id="ixv-22230">Recent transaction price</apm:FairValueMeasurementsUnobservableInput>
    <apm:FairValueMeasurementsWeightedAverageRange contextRef="c118" id="ixv-22234">$0.0001 - $0.01</apm:FairValueMeasurementsWeightedAverageRange>
    <apm:ScheduleOfUnrealizedLossOnInvestmentTableTextBlock contextRef="c0" id="ixv-26804">The following is a summary of annual upward or
downwards adjustments and impairment recorded in other income (expenses), net, and included as adjustments to the carrying value of non-marketable
investments held as of&#160;December 31, 2023, 2022 and 2021 based on the observable price in an orderly transaction for the same or similar
security of the same issuers:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Upward adjustments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,431,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,108,872&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Downward adjustments and impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(520,821&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total unrealized gain from fair value change of non-marketable investments,
net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,431,088&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,588,051&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</apm:ScheduleOfUnrealizedLossOnInvestmentTableTextBlock>
    <apm:UpwardAdjustments contextRef="c0" decimals="0" id="ixv-26805" unitRef="usd">6431088</apm:UpwardAdjustments>
    <apm:UpwardAdjustments contextRef="c10" decimals="0" id="ixv-26806" unitRef="usd">6108872</apm:UpwardAdjustments>
    <apm:DownwardAdjustmentsAndImpairment contextRef="c10" decimals="0" id="ixv-26807" unitRef="usd">-520821</apm:DownwardAdjustmentsAndImpairment>
    <apm:TotalUnrealizedGainForNonmarketableInvestments contextRef="c0" decimals="0" id="ixv-26808" unitRef="usd">6431088</apm:TotalUnrealizedGainForNonmarketableInvestments>
    <apm:TotalUnrealizedGainForNonmarketableInvestments contextRef="c10" decimals="0" id="ixv-26809" unitRef="usd">5588051</apm:TotalUnrealizedGainForNonmarketableInvestments>
    <apm:ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock contextRef="c0" id="ixv-26810">The following table summarizes the total carrying
value of the non-marketable investments held as of&#160;December 31, 2023 and 2022&#160;including cumulative unrealized upward and downward
adjustments and impairment made to the initial cost basis of the investments:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Initial cost basis&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,079,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,079,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Upward adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,539,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,108,872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Downward adjustments and impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(520,821&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(520,821&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total carrying value at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,098,846&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,667,758&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</apm:ScheduleOfCarryingValueOfOurNonmarketableInvestmentsTableTextBlock>
    <apm:InitialCostBasis contextRef="c4" decimals="0" id="ixv-26811" unitRef="usd">4079707</apm:InitialCostBasis>
    <apm:InitialCostBasis contextRef="c5" decimals="0" id="ixv-26812" unitRef="usd">4079707</apm:InitialCostBasis>
    <apm:UpwardAdjustment contextRef="c4" decimals="0" id="ixv-26813" unitRef="usd">12539960</apm:UpwardAdjustment>
    <apm:UpwardAdjustment contextRef="c5" decimals="0" id="ixv-26814" unitRef="usd">6108872</apm:UpwardAdjustment>
    <apm:DownwardAdjustmentAndImpairment contextRef="c4" decimals="0" id="ixv-26815" unitRef="usd">-520821</apm:DownwardAdjustmentAndImpairment>
    <apm:DownwardAdjustmentAndImpairment contextRef="c5" decimals="0" id="ixv-26816" unitRef="usd">-520821</apm:DownwardAdjustmentAndImpairment>
    <apm:TotalCarryingValueAtTheEndOfThePeriod contextRef="c4" decimals="0" id="ixv-26817" unitRef="usd">16098846</apm:TotalCarryingValueAtTheEndOfThePeriod>
    <apm:TotalCarryingValueAtTheEndOfThePeriod contextRef="c5" decimals="0" id="ixv-26818" unitRef="usd">9667758</apm:TotalCarryingValueAtTheEndOfThePeriod>
    <us-gaap:OtherInvestments contextRef="c4" decimals="-5" id="ixv-26819" unitRef="usd">2600000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c90" decimals="-5" id="ixv-26820" unitRef="usd">15100000</us-gaap:OtherInvestments>
    <us-gaap:KeyProvisionsOfOperatingOrPartnershipAgreementDescription contextRef="c0" id="ixv-26821">Each Class A share of Libra is entitled to 1 vote while each Class
B share of Libra is entitled to 10 votes.</us-gaap:KeyProvisionsOfOperatingOrPartnershipAgreementDescription>
    <apm:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners contextRef="c91" decimals="4" id="ixv-26822" unitRef="pure">0.9727</apm:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c92" decimals="4" id="ixv-26823" unitRef="pure">0.3151</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <apm:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners contextRef="c4" decimals="4" id="ixv-26824" unitRef="pure">0.9727</apm:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c93" decimals="4" id="ixv-26825" unitRef="pure">0.3151</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c0" decimals="0" id="ixv-26826" unitRef="usd">77200</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-22426">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;6.&#160;OTHER RECEIVABLES AND PREPAYMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other receivables and prepayments as of December 31, 2023 and 2022
consisted of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;185,633&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;305,178&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid service fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Rental deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid rental expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,253&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,603&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;422,071&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;744,008&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2023, the Group
considered certain other receivables and prepayments were not recoverable. Hence, the write-off of other receivables and prepayments of
$62,369 was recorded in other operating expenses.&lt;/p&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0" id="ixv-26827">Other receivables and prepayments as of December 31, 2023 and 2022
consisted of:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;185,633&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;305,178&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid service fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Rental deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid rental expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,253&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,603&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;422,071&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;744,008&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <apm:PrepaidResearchAndDevelopmentExpenses contextRef="c4" decimals="0" id="ixv-26828" unitRef="usd">185633</apm:PrepaidResearchAndDevelopmentExpenses>
    <apm:PrepaidResearchAndDevelopmentExpenses contextRef="c5" decimals="0" id="ixv-26829" unitRef="usd">305178</apm:PrepaidResearchAndDevelopmentExpenses>
    <us-gaap:PrepaidInsurance contextRef="c4" decimals="0" id="ixv-26830" unitRef="usd">33815</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c5" decimals="0" id="ixv-26831" unitRef="usd">47833</us-gaap:PrepaidInsurance>
    <apm:PrepaidServiceFee contextRef="c4" decimals="0" id="ixv-26832" unitRef="usd">46303</apm:PrepaidServiceFee>
    <apm:PrepaidServiceFee contextRef="c5" decimals="0" id="ixv-26833" unitRef="usd">148346</apm:PrepaidServiceFee>
    <us-gaap:DepositsAssetsCurrent contextRef="c4" decimals="0" id="ixv-26834" unitRef="usd">102109</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c5" decimals="0" id="ixv-26835" unitRef="usd">16296</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidRent contextRef="c4" decimals="0" id="ixv-26836" unitRef="usd">15683</us-gaap:PrepaidRent>
    <us-gaap:OtherReceivables contextRef="c4" decimals="0" id="ixv-26837" unitRef="usd">22275</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c5" decimals="0" id="ixv-26838" unitRef="usd">204752</us-gaap:OtherReceivables>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="0" id="ixv-26839" unitRef="usd">16253</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c5" decimals="0" id="ixv-26840" unitRef="usd">21603</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" id="ixv-26841" unitRef="usd">422071</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c5" decimals="0" id="ixv-26842" unitRef="usd">744008</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <apm:WritteoffOfPrepaymentAndOtherReceivables contextRef="c0" decimals="0" id="ixv-26843" unitRef="usd">62369</apm:WritteoffOfPrepaymentAndOtherReceivables>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-22540">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;7. PROPERTY AND EQUIPMENT, NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Property and equipment as of December 31, 2023 and 2022 consisted of:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;81,138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;84,636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture, fixture, and office and medical equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,292&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;298,738&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;543,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;543,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,336,764&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,229,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Motor vehicle&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;239,093&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;239,093&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,351,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,395,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation and impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,687,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,570,455&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,663,926&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,825,059&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expenses for property, plant and
equipment amounted to $1,041,234, $1,092,957 and $1,086,564 for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2023, an impairment loss relating to
the office and medical equipment, and computer equipment related to the Hong Kong healthcare services amounted to $28,128, was recorded
in other operating expenses, as the Group considered that, with the termination of the healthcare services, the carrying amount of these
property and equipment are not recoverable and are fully impaired. For the years ended December 31, 2022 and 2021, no impairment loss
was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2023, the Group
recorded $79,822 of loss on disposal of laboratory equipment, and furniture, fixture, and office and medical equipment in other operating
expense. For the year ended December 31, 2021, the Group recorded $392 of loss on disposal of office equipment in other operating expenses.
For the year ended December 31, 2022, no gain or loss on disposal was recorded.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-26844">Property and equipment as of December 31, 2023 and 2022 consisted of:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;81,138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;84,636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture, fixture, and office and medical equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,292&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;298,738&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;543,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;543,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,336,764&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,229,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Motor vehicle&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;239,093&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;239,093&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,351,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,395,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation and impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,687,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,570,455&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,663,926&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,825,059&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c85" decimals="0" id="ixv-26845" unitRef="usd">81138</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c121" decimals="0" id="ixv-26846" unitRef="usd">84636</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c86" decimals="0" id="ixv-26847" unitRef="usd">150292</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c122" decimals="0" id="ixv-26848" unitRef="usd">298738</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c123" decimals="0" id="ixv-26849" unitRef="usd">543975</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c124" decimals="0" id="ixv-26850" unitRef="usd">543975</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c88" decimals="0" id="ixv-26851" unitRef="usd">4336764</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c125" decimals="0" id="ixv-26852" unitRef="usd">6229072</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c126" decimals="0" id="ixv-26853" unitRef="usd">239093</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c127" decimals="0" id="ixv-26854" unitRef="usd">239093</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="0" id="ixv-26855" unitRef="usd">5351262</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="0" id="ixv-26856" unitRef="usd">7395514</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="0" id="ixv-26857" unitRef="usd">3687336</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="0" id="ixv-26858" unitRef="usd">4570455</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" id="ixv-26859" unitRef="usd">1663926</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="0" id="ixv-26860" unitRef="usd">2825059</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-26861" unitRef="usd">1041234</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c10" decimals="0" id="ixv-26862" unitRef="usd">1092957</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c11" decimals="0" id="ixv-26863" unitRef="usd">1086564</us-gaap:Depreciation>
    <us-gaap:UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses contextRef="c0" decimals="0" id="ixv-26864" unitRef="usd">28128</us-gaap:UtilitiesOperatingExpenseMaintenanceOperationsAndOtherCostsAndExpenses>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c119" decimals="0" id="ixv-26865" unitRef="usd">79822</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c120" decimals="0" id="ixv-26866" unitRef="usd">392</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-22678">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;8. INTANGIBLE ASSETS, NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Gross carrying amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid patented licenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;728,205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,038,205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computer software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;223,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;223,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,262,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: accumulated amortization and impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid patented licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;728,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;474,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computer software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;804,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;509,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid patented licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;564,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computer software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;188,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;147,347&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;752,705&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the Group has capitalized
eight of the exclusive licenses, which includes seven patented technologies in relation to the Group&#x2019;s therapeutics segment respectively.
Pursuant to the license agreements, the Group paid upfront payments and became the exclusive licensee to prosecute certain patents developed
or licensed under the applicable agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2023, the Group terminated two of the
licenses. The Group is also in the process of terminating the other six licenses, and hence the Group considered that the carrying amount
of these intangible assets are not recoverable and are fully impaired. As a result, the Group recorded $519,496 impairment loss on intangible
assets in research and development expenses. Besides, an impairment loss related to the computer software for Hong Kong healthcare services
amounted to $1,841&#160;was recorded in other operating expenses, as the Group considered that the carrying amount of these intangible
assets are not recoverable and are fully impaired. For the year ended December 31, 2022, a loss on disposal of $205,189 related to a patented
license was recognized in research and development expenses. For the year ended December 31, 2021, no impairment loss and gain or loss
on disposal was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid patented licenses and computer software
are finite-lived intangible assets which are amortized over their estimated useful life. Amortization expenses for finite-lived intangible
assets amounted to $84,020, $114,553 and $106,014 for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group wrote off the cost and the related amortization
of $&lt;span style="-sec-ix-hidden: hidden-fact-215"&gt;nil&lt;/span&gt;, $&lt;span style="-sec-ix-hidden: hidden-fact-216"&gt;nil&lt;/span&gt; and $1,344 after the expiration of the computer software for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group expects amortization expense related
to its finite-lived intangible assets for the next five years and thereafter to be as follows as of December 31, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;For the years ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;38,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,031&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;147,347&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0" id="ixv-22683">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Gross carrying amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid patented licenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;728,205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,038,205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computer software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;223,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;223,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,262,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: accumulated amortization and impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid patented licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;728,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;474,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computer software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;804,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;509,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid patented licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;564,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computer software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;188,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;147,347&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;752,705&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c129" decimals="0" id="ixv-26867" unitRef="usd">728205</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c130" decimals="0" id="ixv-26868" unitRef="usd">1038205</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c131" decimals="0" id="ixv-26869" unitRef="usd">223858</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c132" decimals="0" id="ixv-26870" unitRef="usd">223858</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c4" decimals="0" id="ixv-26871" unitRef="usd">952063</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c5" decimals="0" id="ixv-26872" unitRef="usd">1262063</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c129" decimals="0" id="ixv-26873" unitRef="usd">728205</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c130" decimals="0" id="ixv-26874" unitRef="usd">474131</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c131" decimals="0" id="ixv-26875" unitRef="usd">76511</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c132" decimals="0" id="ixv-26876" unitRef="usd">35227</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c4" decimals="0" id="ixv-26877" unitRef="usd">804716</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c5" decimals="0" id="ixv-26878" unitRef="usd">509358</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c130" decimals="0" id="ixv-26879" unitRef="usd">564074</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c131" decimals="0" id="ixv-26880" unitRef="usd">147347</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c132" decimals="0" id="ixv-26881" unitRef="usd">188631</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="0" id="ixv-26882" unitRef="usd">147347</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c5" decimals="0" id="ixv-26883" unitRef="usd">752705</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-26884" unitRef="usd">519496</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c128" decimals="0" id="ixv-26885" unitRef="usd">1841</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c10" decimals="0" id="ixv-26886" unitRef="usd">-205189</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-26887" unitRef="usd">84020</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c10" decimals="0" id="ixv-26888" unitRef="usd">114553</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c11" decimals="0" id="ixv-26889" unitRef="usd">106014</us-gaap:AmortizationOfIntangibleAssets>
    <apm:WroteOffOfCostRelatedAmortization contextRef="c11" decimals="0" id="ixv-26890" unitRef="usd">1344</apm:WroteOffOfCostRelatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-26891">The Group expects amortization expense related
to its finite-lived intangible assets for the next five years and thereafter to be as follows as of December 31, 2023:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;For the years ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;38,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,031&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;147,347&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c4" decimals="0" id="ixv-26892" unitRef="usd">38438</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c4" decimals="0" id="ixv-26893" unitRef="usd">38439</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c4" decimals="0" id="ixv-26894" unitRef="usd">38439</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c4" decimals="0" id="ixv-26895" unitRef="usd">32031</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="0" id="ixv-26896" unitRef="usd">147347</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LongTermDebtTextBlock contextRef="c0" id="ixv-22913">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;9. LONG-TERM DEPOSITS&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Long-term deposits as of December 31, 2023 and 2022 consisted of:&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Rental deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;71,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;127,303&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepayments for equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;71,823&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;129,847&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LongTermDebtTextBlock>
    <apm:ScheduleOfLongTermDepositsTableTextBlock contextRef="c0" id="ixv-26897">Long-term deposits as of December 31, 2023 and 2022 consisted of:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Rental deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;71,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;127,303&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepayments for equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;71,823&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;129,847&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</apm:ScheduleOfLongTermDepositsTableTextBlock>
    <apm:RentalDeposits contextRef="c4" decimals="0" id="ixv-26898" unitRef="usd">71823</apm:RentalDeposits>
    <apm:RentalDeposits contextRef="c5" decimals="0" id="ixv-26899" unitRef="usd">127303</apm:RentalDeposits>
    <apm:PrepaymentsForEquipment contextRef="c5" decimals="0" id="ixv-26900" unitRef="usd">2544</apm:PrepaymentsForEquipment>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c4" decimals="0" id="ixv-26901" unitRef="usd">71823</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c5" decimals="0" id="ixv-26902" unitRef="usd">129847</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-22973">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Accounts payable and accrued expenses as of December 31, 2023 and 2022
consisted of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Deferred bonus and salaries payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;451,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,084,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,162,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;563,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cost of healthcare services payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119,835&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,894,341&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,166,807&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 31, 2023, the Group entered into exchange
agreements and cancelled 177,667 existing vested and unvested share options held by related parties option holders and cancelled its obligations
for deferred cash bonus payables of $3.1 million by granting 403,820 share options with 6 months vesting period (see Note 17). The settlement
of obligations of $3.1 million deferred cash bonus payables was deemed as capital contribution from related parties and was credited to
additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 31, 2023, the Group entered into exchange
agreements and cancelled 70,428 existing vested and unvested share options held by non-related parties option holders and cancelled its
obligations for deferred cash bonus payables of $1.6 million by issuance of 70,430 fully vested Class A Ordinary Shares (see Note 16).
The reversal of deferred cash bonus payables for $1.0 million and $0.6 million was credited to research and development expenses and general
and administrative fees, respectively.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-26903">Accounts payable and accrued expenses as of December 31, 2023 and 2022
consisted of:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Deferred bonus and salaries payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;451,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,084,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,162,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;563,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;226,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cost of healthcare services payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119,835&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,894,341&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,166,807&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-26904" unitRef="usd">451660</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-26905" unitRef="usd">5084969</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <apm:ResearchAndDevelopmentExpensesPayable contextRef="c4" decimals="0" id="ixv-26906" unitRef="usd">1162155</apm:ResearchAndDevelopmentExpensesPayable>
    <apm:ResearchAndDevelopmentExpensesPayable contextRef="c5" decimals="0" id="ixv-26907" unitRef="usd">563913</apm:ResearchAndDevelopmentExpensesPayable>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c4" decimals="0" id="ixv-26908" unitRef="usd">175324</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c5" decimals="0" id="ixv-26909" unitRef="usd">226407</us-gaap:AccruedProfessionalFeesCurrent>
    <apm:CostOfHealthcareServicesPayable contextRef="c4" decimals="0" id="ixv-26910" unitRef="usd">61826</apm:CostOfHealthcareServicesPayable>
    <apm:CostOfHealthcareServicesPayable contextRef="c5" decimals="0" id="ixv-26911" unitRef="usd">138316</apm:CostOfHealthcareServicesPayable>
    <apm:InsuranceExpensePayable contextRef="c4" decimals="0" id="ixv-26912" unitRef="usd">27463</apm:InsuranceExpensePayable>
    <apm:InsuranceExpensePayable contextRef="c5" decimals="0" id="ixv-26913" unitRef="usd">33367</apm:InsuranceExpensePayable>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="0" id="ixv-26914" unitRef="usd">15913</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="0" id="ixv-26915" unitRef="usd">119835</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-26916" unitRef="usd">1894341</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-26917" unitRef="usd">6166807</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <apm:VestedAndUnvestedShareOptions
      contextRef="c133"
      decimals="0"
      id="ixv-26918"
      unitRef="shares">177667</apm:VestedAndUnvestedShareOptions>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="c133"
      decimals="-5"
      id="ixv-26919"
      unitRef="usd">3100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c134"
      decimals="0"
      id="ixv-26920"
      unitRef="shares">403820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
      contextRef="c135"
      decimals="-5"
      id="ixv-26921"
      unitRef="usd">3100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses>
    <apm:VestedAndUnvestedShareOptions
      contextRef="c136"
      decimals="0"
      id="ixv-26922"
      unitRef="shares">70428</apm:VestedAndUnvestedShareOptions>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="c136"
      decimals="-5"
      id="ixv-26923"
      unitRef="usd">1600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c137"
      decimals="0"
      id="ixv-26924"
      unitRef="shares">70430</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
      contextRef="c138"
      decimals="-5"
      id="ixv-26925"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="c138"
      decimals="-5"
      id="ixv-26926"
      unitRef="usd">600000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-23079">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;11. INCOME TAXES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The&#160;Company and&#160;its subsidiaries file tax returns separately.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cayman Islands: under the current laws of the
Cayman Islands, the Company and its subsidiaries in the Cayman Islands are not subject to taxes on their income and capital gains.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Hong Kong: in accordance with the relevant tax
laws and regulations of Hong Kong, a company registered in Hong Kong is subject to income taxes within Hong Kong at the applicable tax
rate on taxable income. In March 2018, the Hong Kong Government introduced a two-tiered profit tax rate regime by enacting the Inland
Revenue (Amendment) (No.3) Ordinance 2018 (the &#x201c;Ordinance&#x201d;). Under the two-tiered profits tax rate regime, the first $2 million
of assessable profits of qualifying corporations is taxed at 8.25% and the remaining assessable profits at 16.5%. The Ordinance is effective
from the year of assessment 2018-2019. According to the policy, if no election has been made, the whole of the taxpaying entity&#x2019;s
assessable profits will be chargeable to Profits Tax at the rate of 16.5% or 15%, as applicable. Because the preferential tax treatment
is not elected by the Group, all the subsidiaries registered in Hong Kong are subject to income tax at a rate of 16.5%. The subsidiaries
registered in Hong Kong did not have assessable profits that were derived Hong Kong during the years ended December 31, 2023, 2022 and
2021. Therefore, no Hong Kong profit tax has been provided for in the periods presented. Our returns for 2017 and subsequent tax years
remain subject to examination by Hong Kong Inland Revenue Department.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;United Kingdom: in accordance with the relevant
tax laws and regulations of United Kingdom, a company registered in the United Kingdom is subject to income taxes within United Kingdom
at the applicable tax rate on taxable income. All the United Kingdom subsidiaries that are not entitled to any tax holiday were subject
to income tax at a rate of 19%. The subsidiary in United Kingdom did not have assessable profits that were derived from United Kingdom
during the years ended December 31, 2023, 2022 and 2021. Therefore, no United Kingdom profit tax has been provided for in the periods
presented. Our returns for 2019 and subsequent tax years remain subject to examination by the UK tax authority.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Singapore: in accordance with the relevant tax
laws and regulations of Singapore, a company registered in the Singapore is subject to income taxes within Singapore at the applicable
tax rate on taxable income. All the Singapore subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate
of 17%. The subsidiary in Singapore did not have assessable profits that were derived from Singapore during the years ended December 31,
2023, 2022 and 2021. Therefore, no Singapore profit tax has been provided for in the periods presented. Our returns for 2019 and subsequent
tax years remain subject to examination by the Singapore tax authority.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;United States (Nevada): in accordance with the
relevant tax laws and regulations of the United States, a company registered in the United States is subject to income taxes within the
United States at the applicable tax rate on taxable income. All the United States subsidiaries in Nevada that are not entitled to any
tax holiday were subject to income tax at a rate of 21%. The subsidiary in the United States did not have assessable profits that were
derived from the United States during the years ended December 31, 2023, 2022 and 2021. Therefore, no United States profit tax has been
provided for in the periods presented. Our returns for 2020 and subsequent tax years remain subject to examination by Internal Revenue
Service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Canada: in accordance with the relevant tax laws
and regulations of Canada, a company registered in Canada is subject to income taxes within Canada at the applicable tax rate on taxable
income. All the Canada subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 15%. The subsidiary
in Canada did not have assessable profits that were derived from Canada during the years ended December 31, 2023, 2022 and 2021. Therefore,
no Canada profit tax has been provided for in the periods presented. Our returns for 2019 and subsequent tax years remain subject to examination
by the Canada tax authority.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The components of the provision for income taxes expenses are:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total income taxes expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The reconciliation of income taxes expenses computed
at the Hong Kong statutory tax rate applicable to income tax expense is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net loss before tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,340,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,525,102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(27,114,293&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Provision for income taxes at Hong Kong statutory income tax rate (16.5%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(716,261&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,901,642&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,473,859&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impact of different tax rates in other jurisdictions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,272&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(263,787&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(214,135&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-taxable income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,071,774&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(907,495&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(716,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,992,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,705,603&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,072,924&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,412,159&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Deferred tax asset, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred tax assets and deferred tax liabilities
reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purpose
and the tax bases used for income tax purpose. The following represents the tax effect of each major type of temporary difference.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Tax loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,956,748&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14,865,121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;948,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Impairment of long-lived assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;92,416&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,407,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,814,014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(108,926&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,407,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,705,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,407,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15,705,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2023 and 2022, the Group had
net operating loss carry-forwards of $102,367,435 and $90,060,983, respectively, including its Hong Kong, Singapore, the United States,
the United Kingdom and Canada operations, which are available to reduce future taxable income and have an unlimited carryover period.
For the year ended December 31, 2023, there was no tax loss carried forward expired, while tax loss brought forward of $28,281 was cancelled
due to the disposal of various subsidiaries.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Valuation allowance was provided against deferred
tax assets in entities where it was determined, it was more likely than not that the benefits of the deferred tax assets will not be realized.
The Group had deferred tax assets which consisted of tax loss carry forward, which can be carried forward to offset future taxable income.
The Group maintains a full valuation allowance on its net deferred tax assets. The management determines it is more likely than not that
all of its deferred tax assets will not be utilized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Changes in valuation allowance are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance as of January 1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,705,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,632,164&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,561,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,705,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,072,924&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,412,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Disposal&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,535&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(341,555&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as of December 31&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,407,156&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,705,088&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,632,164&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <apm:IncomeTaxDescription contextRef="c139" id="ixv-26927">Under the two-tiered profits tax rate regime, the first $2 million
of assessable profits of qualifying corporations is taxed at 8.25% and the remaining assessable profits at 16.5%. The Ordinance is effective
from the year of assessment 2018-2019. According to the policy, if no election has been made, the whole of the taxpaying entity&#x2019;s
assessable profits will be chargeable to Profits Tax at the rate of 16.5% or 15%, as applicable. Because the preferential tax treatment
is not elected by the Group, all the subsidiaries registered in Hong Kong are subject to income tax at a rate of 16.5%.</apm:IncomeTaxDescription>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c140"
      decimals="2"
      id="ixv-26928"
      unitRef="pure">0.19</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c141"
      decimals="2"
      id="ixv-26929"
      unitRef="pure">0.17</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c142"
      decimals="2"
      id="ixv-26930"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c143"
      decimals="2"
      id="ixv-26931"
      unitRef="pure">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-26932">The components of the provision for income taxes expenses are:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total income taxes expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-26933">The reconciliation of income taxes expenses computed
at the Hong Kong statutory tax rate applicable to income tax expense is as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net loss before tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,340,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,525,102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(27,114,293&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Provision for income taxes at Hong Kong statutory income tax rate (16.5%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(716,261&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,901,642&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,473,859&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impact of different tax rates in other jurisdictions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,272&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(263,787&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(214,135&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-taxable income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,071,774&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(907,495&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(716,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,992,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,705,603&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,072,924&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,412,159&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-26934" unitRef="usd">-4340975</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c10" decimals="0" id="ixv-26935" unitRef="usd">-11525102</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c11" decimals="0" id="ixv-26936" unitRef="usd">-27114293</us-gaap:ProfitLoss>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" id="ixv-26937" unitRef="pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="0" id="ixv-26938" unitRef="usd">-716261</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c10" decimals="0" id="ixv-26939" unitRef="usd">-1901642</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c11" decimals="0" id="ixv-26940" unitRef="usd">-4473859</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="0" id="ixv-26941" unitRef="usd">-16272</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c10" decimals="0" id="ixv-26942" unitRef="usd">-263787</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c11" decimals="0" id="ixv-26943" unitRef="usd">-214135</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="c0" decimals="0" id="ixv-26944" unitRef="usd">1071774</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="c10" decimals="0" id="ixv-26945" unitRef="usd">907495</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="c11" decimals="0" id="ixv-26946" unitRef="usd">716628</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c0" decimals="0" id="ixv-26947" unitRef="usd">98704</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c11" decimals="0" id="ixv-26948" unitRef="usd">1992463</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" id="ixv-26949" unitRef="usd">1705603</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c10" decimals="0" id="ixv-26950" unitRef="usd">3072924</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c11" decimals="0" id="ixv-26951" unitRef="usd">3412159</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-26952">Deferred tax assets and deferred tax liabilities
reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purpose
and the tax bases used for income tax purpose. The following represents the tax effect of each major type of temporary difference.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Tax loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,956,748&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14,865,121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;948,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Impairment of long-lived assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;92,416&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,407,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,814,014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(108,926&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,407,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,705,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,407,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15,705,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="0" id="ixv-26953" unitRef="usd">16956748</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c5" decimals="0" id="ixv-26954" unitRef="usd">14865121</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c4" decimals="0" id="ixv-26955" unitRef="usd">229126</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c5" decimals="0" id="ixv-26956" unitRef="usd">948893</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <apm:DeferredTaxAssetsDepreciationAndAmortization contextRef="c4" decimals="0" id="ixv-26957" unitRef="usd">128866</apm:DeferredTaxAssetsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="c4" decimals="0" id="ixv-26958" unitRef="usd">92416</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="0" id="ixv-26959" unitRef="usd">17407156</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c5" decimals="0" id="ixv-26960" unitRef="usd">15814014</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c5" decimals="0" id="ixv-26961" unitRef="usd">108926</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <apm:NetDeferredTaxAssetsBeforeValuationAllowance contextRef="c4" decimals="0" id="ixv-26962" unitRef="usd">17407156</apm:NetDeferredTaxAssetsBeforeValuationAllowance>
    <apm:NetDeferredTaxAssetsBeforeValuationAllowance contextRef="c5" decimals="0" id="ixv-26963" unitRef="usd">15705088</apm:NetDeferredTaxAssetsBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" id="ixv-26964" unitRef="usd">17407156</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" id="ixv-26965" unitRef="usd">15705088</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c4" decimals="0" id="ixv-26966" unitRef="usd">102367435</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c5" decimals="0" id="ixv-26967" unitRef="usd">90060983</us-gaap:OperatingLossCarryforwards>
    <apm:LossCarryforwardCancelled contextRef="c4" decimals="0" id="ixv-26968" unitRef="usd">28281</apm:LossCarryforwardCancelled>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c0" id="ixv-26969">Changes in valuation allowance are as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance as of January 1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,705,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,632,164&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,561,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,705,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,072,924&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,412,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Disposal&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,535&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(341,555&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as of December 31&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,407,156&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,705,088&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,632,164&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" id="ixv-26970" unitRef="usd">15705088</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c31" decimals="0" id="ixv-26971" unitRef="usd">12632164</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c18" decimals="0" id="ixv-26972" unitRef="usd">9561560</us-gaap:DeferredTaxAssetsValuationAllowance>
    <apm:ValuationAllowanceDeferredTaxAssetIncrease contextRef="c0" decimals="0" id="ixv-26973" unitRef="usd">1705603</apm:ValuationAllowanceDeferredTaxAssetIncrease>
    <apm:ValuationAllowanceDeferredTaxAssetIncrease contextRef="c10" decimals="0" id="ixv-26974" unitRef="usd">3072924</apm:ValuationAllowanceDeferredTaxAssetIncrease>
    <apm:ValuationAllowanceDeferredTaxAssetIncrease contextRef="c11" decimals="0" id="ixv-26975" unitRef="usd">3412159</apm:ValuationAllowanceDeferredTaxAssetIncrease>
    <apm:ValuationAllowanceDeferredTaxAssetDecreaseAmount contextRef="c0" decimals="0" id="ixv-26976" unitRef="usd">-3535</apm:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <apm:ValuationAllowanceDeferredTaxAssetDecreaseAmount contextRef="c11" decimals="0" id="ixv-26977" unitRef="usd">-341555</apm:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" id="ixv-26978" unitRef="usd">17407156</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" id="ixv-26979" unitRef="usd">15705088</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c31" decimals="0" id="ixv-26980" unitRef="usd">12632164</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-23610">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;12. RELATED PARTY BALANCES AND TRANSACTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following is a list of a director and related parties to which
the Group has transactions with:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Ian Huen, the Chief Executive Officer and Executive Director of the Group since November 2023. He was a Non-executive Director from June 2022 to November 2023. Before June 2022, he was the Chief Executive Officer and Executive Director;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Jurchen Investment Corporation, the holding company and an entity controlled by Ian Huen;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;CGY Investment Limited, an entity owns more than 10% voting interest of the Group before April 2024;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Aeneas Group Limited, an entity controlled by Ian Huen;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;(e)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Aenco Technologies Ltd, an entity being 34.56% effectively owned by Ian Huen;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top"&gt;&lt;span style="font-size: 10pt"&gt;(f)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-size: 10pt"&gt;Aeneas Management Limited, an entity controlled by Ian Huen;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;(g)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Talem Medical Group Limited, an entity which Clark Cheng was a director;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;(h)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Libra Sciences Limited, an entity which was originally a wholly owned subsidiary of ATL. Since December 30, 2021, Libra has been turned into a related party to the Group due to the voting power owned by ATL is decreased to below 50% but more than 20%. (Note 13) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Libra Therapeutics Limited, a wholly owned subsidiary of Libra Sciences Limited; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;(j)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Clark Cheng, a former Executive Director of the Group before November 30, 2023. After his resignation on November 30, 2023, he was no longer a related party of the Group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;(k)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;ACC Medical Limited, an entity controlled by Clark Cheng.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;(l)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Darren Lui, a former Executive Director of the Group before November
27, 2023. After his resignation on November 27, 2023, he was no longer a related party of the Group.&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Amounts due from related parties, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Amounts due from related parties consisted of the following as of December
31, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Aeneas Management Limited&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;961&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Libra Sciences Limited (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;521,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;378,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Libra Therapeutics Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Talem Medical Group Limited (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;610,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(521,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;961&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,005,633&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Amounts due to related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Amounts due to related parties consisted of the following as of December
31, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Aeneas Group Limited (Note a)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;79,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Aenco Technologies Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,013,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Clark Cheng&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,583&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;79,180&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,025,927&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Jurchen Investment Corporation (Note 15)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,058,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Aeneas Group Limited (Note a)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,058,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Related party transactions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Related party transactions consisted of the following
for the years ended December 31, 2023, 2022 and 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Loan from related parties (Note a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Group Limited&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Jurchen Investment Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loan repayment and interest paid to related parties (Note a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,673,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Jurchen Investment Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,085,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issuance of Convertible Note to related parties (Note 15)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Jurchen Investment Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aenco Technologies Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Settlement of loan from a related party through issuance of Convertible Note (Note 15)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Interest expenses (Note a and Note 15)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;71,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;64,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Jurchen Investment Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;58,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;65,644&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aenco Technologies Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,234&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loan to related parties (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Talem Medical Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,358,089&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Libra Sciences Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;92,459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;330,341&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loan repayment and interest received from a related party (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Talem Medical Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;611,641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,962,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Interest income (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Talem Medical Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;164,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;39,561&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Libra Sciences Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Consultant, secondment, management and administrative services fees (Note c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- CGY Investments Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;153,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;268,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;173,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- ACC Medical Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;138,768&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;209,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;157,511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Administrative management services (Note d)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Libra Sciences Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Healthcare services income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Management Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;961&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Note a: On August 13, 2019, Aptorum Therapeutics
Limited (&#x201c;ATL&#x201d;), a wholly owned subsidiary of the Company, entered into financing arrangements with Aeneas Group Limited,
a related party, and Jurchen Investment Corporation, the ultimate parent of the Group, allowing ATL to access up to a total $15 million
in line of credit debt financing. Both line of credits have originally matured on August 12, 2022. ATL and Aeneas Group Limited has mutually
agreed to extend the line of credit arrangement further 3 years to August 12, 2025. The interest on the outstanding principal indebtedness
is at the rate of 8% per annum. ATL may early repay, in whole or in part, the principal indebtedness and all interest accrued at any time
prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty. As of the issuance
date of this consolidated financial statements, the undrawn line of credit facility is $12 million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Note b: On November 17, 2021, ATL entered into
a loan agreement with Talem Medical Group Limited (the &#x201c;Borrower&#x201d;). According to the loan agreement, ATL granted a loan of
up to &lt;span style="-sec-ix-hidden: hidden-fact-253"&gt;AUD4,700,000&lt;/span&gt; for the Borrower for general working capital purposes of the Borrower and its subsidiaries. The loan is interest-bearing
at a rate of 10% per annum and secured by the entire issued shares of Talem Medical Group (Australia) Pty Limited held by the Borrower.
The loan is initially matured 6 months from the date of the first drawdown. The maturity date was extended for 6 months to the first extended
maturity date, and further extended for another 6 months to the second extended maturity date. As of the date of the issuance of this
consolidated financial statements, there is no outstanding balance from the Borrower following a repayment in February 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 13, 2022, ATL entered a line of credit
facility with Libra Sciences Limited to provide up to a total $1 million line of credit for its daily operation. The line of credit is
originally matured on January 12, 2023, and is extended for additional 3 years. The interest on the outstanding principal indebtedness
is at the rate of 10% per annum. ATL and Libra Science Limited mutually agreed to terminate the line of credit agreement effect as of
March 31, 2023. All existing liabilities arising from the line of credit agreement shall remain enforceable and repayable on demand by
ATL. As of the issuance date of this consolidated financial statements, $0.5 million is outstanding from Libra Sciences Limited. For the
year ended December 31, 2023, the Group has assessed that the amounts due from Libra Science Limited and its subsidiary are potentially
unrecoverable. Accordingly, an allowance for credit loss amounting to $0.5 million has been recognized.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Note c: CGY Investment Limited provided certain
consultancy, advisory and management services to the Group on potential investment projects related to healthcare or R&amp;amp;D platforms.
CGY Investment Limited is initially entitled to receive HK $104,000 (approximately $13,333) per calendar month plus reimbursement; such
monthly service fee is adjusted to HK$171,200 (approximately US$21,949) with effect from March 1, 2022. In August 2023, CGY Investment
Limited has agreed to suspended its monthly services fee from August 1, 2023. In November 2023, CGY Investment Limited and the Group reached
a mutual agreement to terminate their contractual relationship.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ACC Medical Limited provided certain consultancy,
advisory, and management services to the Group on clinic operations and other related projects for clinics&#x2019; business development.
ACC Medical Limited is initially entitled to receive HK $101,542 (approximately $13,018) per calendar month plus reimbursement; such monthly
service fee is adjusted to HK$143,200 (approximately US$18,359 per month) effective from March 1, 2022. During the year ended December
31, 2023 and 2022, ACC Medical Limited also received $28,615 and $23,275 one-off compensation respectively. The agreement was terminated
on June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Note d:&#160;On January 1, 2022, Aptus
Management Limited (&#x201c;AML&#x201d;), a wholly owned subsidiary of the Company, entered into an administrative management services
agreement with Libra Sciences Limited. According to the agreement, AML will provide documentation and administrative services,
include but are not limited to human resources and payroll administration, general secretarial and administrative support, and
accounting and financial reporting services. AML is entitled to receive a fixed amount of services fees of HKD 25,000 (approximately
$3,205) per calendar month with the original expiry date on December 31, 2023. AML and Libra Sciences Limited mutually agreed to
terminate the administrative management service agreement effect as of March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Note e: In accordance with mutual agreements reached with the board
of directors, Mr. Clark Cheng and Mr. Ian Huen agreed to forgo their monthly remuneration effective July 1, 2023 until further notice.
Moreover, Mr. Darren Lui, a former executive director before his resignation on November 27, 2023, consented to suspend their monthly
remuneration from August 1, 2023. Additionally, all independent non-executive directors have consented to suspend their monthly remuneration
from September 1, 2023 until further notice. Before the suspension of remuneration, Mr. Clark Cheng, Mr. Ian Huen, and Mr. Darren Lui
had a monthly remuneration of $6,410, $27,333 and $6,667, respectively.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c144"
      decimals="2"
      id="ixv-26981"
      unitRef="pure">0.10</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="c145"
      decimals="4"
      id="ixv-26982"
      unitRef="pure">0.3456</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <apm:DecreasedOwnershipPercentage contextRef="c84" decimals="2" id="ixv-26983" unitRef="pure">0.50</apm:DecreasedOwnershipPercentage>
    <apm:DecreasedOwnershipPercentage contextRef="c83" decimals="2" id="ixv-26984" unitRef="pure">0.20</apm:DecreasedOwnershipPercentage>
    <apm:ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock contextRef="c0" id="ixv-26985">Amounts due from related parties consisted of the following as of December
31, 2023 and 2022:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Aeneas Management Limited&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;961&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Libra Sciences Limited (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;521,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;378,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Libra Therapeutics Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Talem Medical Group Limited (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;610,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(521,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;961&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,005,633&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</apm:ScheduleOfAmountsDueFromRelatedPartiesTableTextBlock>
    <apm:AmountsDueFromRelatedPartiesCurrent contextRef="c159" decimals="0" id="ixv-26986" unitRef="usd">961</apm:AmountsDueFromRelatedPartiesCurrent>
    <apm:AmountsDueFromRelatedPartiesCurrent contextRef="c161" decimals="0" id="ixv-26987" unitRef="usd">521007</apm:AmountsDueFromRelatedPartiesCurrent>
    <apm:AmountsDueFromRelatedPartiesCurrent contextRef="c162" decimals="0" id="ixv-26988" unitRef="usd">378036</apm:AmountsDueFromRelatedPartiesCurrent>
    <apm:AmountsDueFromRelatedPartiesCurrent contextRef="c164" decimals="0" id="ixv-26989" unitRef="usd">17459</apm:AmountsDueFromRelatedPartiesCurrent>
    <apm:AmountsDueFromRelatedPartiesCurrent contextRef="c166" decimals="0" id="ixv-26990" unitRef="usd">610138</apm:AmountsDueFromRelatedPartiesCurrent>
    <us-gaap:NetInvestmentInLease contextRef="c4" decimals="0" id="ixv-26991" unitRef="usd">521007</us-gaap:NetInvestmentInLease>
    <apm:AmountsDueFromRelatedPartiesCurrent contextRef="c4" decimals="0" id="ixv-26992" unitRef="usd">961</apm:AmountsDueFromRelatedPartiesCurrent>
    <apm:AmountsDueFromRelatedPartiesCurrent contextRef="c5" decimals="0" id="ixv-26993" unitRef="usd">1005633</apm:AmountsDueFromRelatedPartiesCurrent>
    <apm:ScheduleOfDueToRelatedPartiesTableTextBlock contextRef="c0" id="ixv-26994">Amounts due to related parties consisted of the following as of December
31, 2023 and 2022:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Aeneas Group Limited (Note a)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;79,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Aenco Technologies Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,013,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Clark Cheng&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,583&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;79,180&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,025,927&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Jurchen Investment Corporation (Note 15)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,058,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Aeneas Group Limited (Note a)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,058,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</apm:ScheduleOfDueToRelatedPartiesTableTextBlock>
    <apm:AmountsDueToRelatedPartiesCurrent contextRef="c167" decimals="0" id="ixv-26995" unitRef="usd">79180</apm:AmountsDueToRelatedPartiesCurrent>
    <apm:AmountsDueToRelatedPartiesCurrent contextRef="c168" decimals="0" id="ixv-26996" unitRef="usd">8110</apm:AmountsDueToRelatedPartiesCurrent>
    <apm:AmountsDueToRelatedPartiesCurrent contextRef="c169" decimals="0" id="ixv-26997" unitRef="usd">3013234</apm:AmountsDueToRelatedPartiesCurrent>
    <apm:AmountsDueToRelatedPartiesCurrent contextRef="c171" decimals="0" id="ixv-26998" unitRef="usd">4583</apm:AmountsDueToRelatedPartiesCurrent>
    <apm:AmountsDueToRelatedPartiesCurrent contextRef="c4" decimals="0" id="ixv-26999" unitRef="usd">79180</apm:AmountsDueToRelatedPartiesCurrent>
    <apm:AmountsDueToRelatedPartiesCurrent contextRef="c5" decimals="0" id="ixv-27000" unitRef="usd">3025927</apm:AmountsDueToRelatedPartiesCurrent>
    <apm:AmountsDueToRelatedPartiesNoncurrent contextRef="c172" decimals="0" id="ixv-27001" unitRef="usd">3058500</apm:AmountsDueToRelatedPartiesNoncurrent>
    <apm:AmountsDueToRelatedPartiesNoncurrent contextRef="c168" decimals="0" id="ixv-27002" unitRef="usd">500000</apm:AmountsDueToRelatedPartiesNoncurrent>
    <apm:AmountsDueToRelatedPartiesNoncurrent contextRef="c4" decimals="0" id="ixv-27003" unitRef="usd">3058500</apm:AmountsDueToRelatedPartiesNoncurrent>
    <apm:AmountsDueToRelatedPartiesNoncurrent contextRef="c5" decimals="0" id="ixv-27004" unitRef="usd">500000</apm:AmountsDueToRelatedPartiesNoncurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-27005">Related party transactions consisted of the following
for the years ended December 31, 2023, 2022 and 2021:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Loan from related parties (Note a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Group Limited&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Jurchen Investment Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loan repayment and interest paid to related parties (Note a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,673,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Jurchen Investment Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,085,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issuance of Convertible Note to related parties (Note 15)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Jurchen Investment Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aenco Technologies Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Settlement of loan from a related party through issuance of Convertible Note (Note 15)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Interest expenses (Note a and Note 15)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;71,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;64,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Jurchen Investment Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;58,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;65,644&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aenco Technologies Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,234&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loan to related parties (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Talem Medical Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,358,089&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Libra Sciences Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;92,459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;330,341&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loan repayment and interest received from a related party (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Talem Medical Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;611,641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,962,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Interest income (Note b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Talem Medical Group Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;164,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;39,561&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Libra Sciences Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Consultant, secondment, management and administrative services fees (Note c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- CGY Investments Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;153,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;268,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;173,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- ACC Medical Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;138,768&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;209,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;157,511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Administrative management services (Note d)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Libra Sciences Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Healthcare services income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;- Aeneas Management Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;961&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c174" decimals="0" id="ixv-27006" unitRef="usd">2500000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c175" decimals="0" id="ixv-27007" unitRef="usd">500000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c176" decimals="0" id="ixv-27008" unitRef="usd">1000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c178" decimals="0" id="ixv-27009" unitRef="usd">2500000</us-gaap:ProceedsFromRelatedPartyDebt>
    <apm:LoanRepaymentAndInterestPaidToRelatedParties contextRef="c176" decimals="0" id="ixv-27010" unitRef="usd">2673389</apm:LoanRepaymentAndInterestPaidToRelatedParties>
    <apm:LoanRepaymentAndInterestPaidToRelatedParties contextRef="c178" decimals="0" id="ixv-27011" unitRef="usd">3085097</apm:LoanRepaymentAndInterestPaidToRelatedParties>
    <apm:LoanRepaymentAndInterestPaidToRelatedParties contextRef="c179" decimals="0" id="ixv-27012" unitRef="usd">3000000</apm:LoanRepaymentAndInterestPaidToRelatedParties>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c180" decimals="0" id="ixv-27013" unitRef="usd">3000000</us-gaap:ProceedsFromConvertibleDebt>
    <apm:ConsultantSecondmentManagementAndAdministrativeServicesFees contextRef="c174" decimals="0" id="ixv-27014" unitRef="usd">3000000</apm:ConsultantSecondmentManagementAndAdministrativeServicesFees>
    <us-gaap:InterestExpense contextRef="c174" decimals="0" id="ixv-27015" unitRef="usd">71123</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c175" decimals="0" id="ixv-27016" unitRef="usd">8110</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c176" decimals="0" id="ixv-27017" unitRef="usd">64753</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c177" decimals="0" id="ixv-27018" unitRef="usd">58500</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c178" decimals="0" id="ixv-27019" unitRef="usd">65644</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c182" decimals="0" id="ixv-27020" unitRef="usd">-13234</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c180" decimals="0" id="ixv-27021" unitRef="usd">13234</us-gaap:InterestExpense>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="c184" decimals="0" id="ixv-27022" unitRef="usd">3358089</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="c185" decimals="0" id="ixv-27023" unitRef="usd">92459</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="c186" decimals="0" id="ixv-27024" unitRef="usd">330341</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <apm:RepaymentOfLoanFromRelatedParty contextRef="c183" decimals="0" id="ixv-27025" unitRef="usd">611641</apm:RepaymentOfLoanFromRelatedParty>
    <apm:RepaymentOfLoanFromRelatedParty contextRef="c188" decimals="0" id="ixv-27026" unitRef="usd">2962153</apm:RepaymentOfLoanFromRelatedParty>
    <us-gaap:InterestIncomeOther contextRef="c183" decimals="0" id="ixv-27027" unitRef="usd">4637</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c188" decimals="0" id="ixv-27028" unitRef="usd">164600</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c184" decimals="0" id="ixv-27029" unitRef="usd">39561</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c185" decimals="0" id="ixv-27030" unitRef="usd">8963</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c186" decimals="0" id="ixv-27031" unitRef="usd">14232</us-gaap:InterestIncomeOther>
    <apm:ConsultantSecondmentManagementAndAdministrativeServicesFees contextRef="c153" decimals="0" id="ixv-27032" unitRef="usd">153640</apm:ConsultantSecondmentManagementAndAdministrativeServicesFees>
    <apm:ConsultantSecondmentManagementAndAdministrativeServicesFees contextRef="c189" decimals="0" id="ixv-27033" unitRef="usd">268102</apm:ConsultantSecondmentManagementAndAdministrativeServicesFees>
    <apm:ConsultantSecondmentManagementAndAdministrativeServicesFees contextRef="c190" decimals="0" id="ixv-27034" unitRef="usd">173333</apm:ConsultantSecondmentManagementAndAdministrativeServicesFees>
    <apm:ConsultantSecondmentManagementAndAdministrativeServicesFees contextRef="c154" decimals="0" id="ixv-27035" unitRef="usd">138768</apm:ConsultantSecondmentManagementAndAdministrativeServicesFees>
    <apm:ConsultantSecondmentManagementAndAdministrativeServicesFees contextRef="c191" decimals="0" id="ixv-27036" unitRef="usd">209626</apm:ConsultantSecondmentManagementAndAdministrativeServicesFees>
    <apm:ConsultantSecondmentManagementAndAdministrativeServicesFees contextRef="c192" decimals="0" id="ixv-27037" unitRef="usd">157511</apm:ConsultantSecondmentManagementAndAdministrativeServicesFees>
    <apm:AdministrativeManagementServices contextRef="c185" decimals="0" id="ixv-27038" unitRef="usd">9615</apm:AdministrativeManagementServices>
    <apm:AdministrativeManagementServices contextRef="c186" decimals="0" id="ixv-27039" unitRef="usd">38462</apm:AdministrativeManagementServices>
    <us-gaap:Revenues contextRef="c193" decimals="0" id="ixv-27040" unitRef="usd">961</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c194" decimals="0" id="ixv-27041" unitRef="usd">1282</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c195" decimals="0" id="ixv-27042" unitRef="usd">7564</us-gaap:Revenues>
    <us-gaap:LongTermLineOfCredit
      contextRef="c146"
      decimals="-6"
      id="ixv-27043"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c147" id="ixv-27044">P3Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="c148"
      decimals="2"
      id="ixv-27045"
      unitRef="pure">0.08</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="c146"
      decimals="-6"
      id="ixv-27046"
      unitRef="usd">12000000</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <apm:LoansInterestbearingRate
      contextRef="c150"
      decimals="2"
      id="ixv-27047"
      unitRef="pure">0.10</apm:LoansInterestbearingRate>
    <us-gaap:LineOfCredit
      contextRef="c151"
      decimals="-6"
      id="ixv-27048"
      unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:LongTermDebtMaturityDate contextRef="c151" id="ixv-27049">2023-01-12</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c152" id="ixv-27050">P3Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="c152"
      decimals="2"
      id="ixv-27051"
      unitRef="pure">0.10</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="c0" decimals="-5" id="ixv-27052" unitRef="usd">500000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c0" decimals="-5" id="ixv-27053" unitRef="usd">500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <apm:ServicesFees contextRef="c153" decimals="0" id="ixv-27054" unitRef="hkd">104000</apm:ServicesFees>
    <apm:ServicesFees contextRef="c153" decimals="0" id="ixv-27055" unitRef="usd">13333</apm:ServicesFees>
    <apm:ServicesFeesAdjusted contextRef="c153" decimals="0" id="ixv-27056" unitRef="hkd">171200</apm:ServicesFeesAdjusted>
    <apm:ServicesFeesAdjusted contextRef="c153" decimals="0" id="ixv-27057" unitRef="usd">21949</apm:ServicesFeesAdjusted>
    <apm:ServicesFees contextRef="c154" decimals="0" id="ixv-27058" unitRef="hkd">101542</apm:ServicesFees>
    <apm:ServicesFees contextRef="c154" decimals="0" id="ixv-27059" unitRef="usd">13018</apm:ServicesFees>
    <apm:ServicesFeesAdjusted contextRef="c154" decimals="0" id="ixv-27060" unitRef="hkd">143200</apm:ServicesFeesAdjusted>
    <apm:ServicesFeesAdjusted contextRef="c154" decimals="0" id="ixv-27061" unitRef="usd">18359</apm:ServicesFeesAdjusted>
    <us-gaap:CompensationAndBenefitsTrust contextRef="c4" decimals="0" id="ixv-27062" unitRef="usd">28615</us-gaap:CompensationAndBenefitsTrust>
    <us-gaap:CompensationAndBenefitsTrust contextRef="c5" decimals="0" id="ixv-27063" unitRef="usd">23275</us-gaap:CompensationAndBenefitsTrust>
    <apm:ServicesFees contextRef="c155" decimals="0" id="ixv-27064" unitRef="hkd">25000</apm:ServicesFees>
    <apm:ServicesFees contextRef="c155" decimals="0" id="ixv-27065" unitRef="usd">3205</apm:ServicesFees>
    <apm:RemunerationAmount contextRef="c156" decimals="0" id="ixv-27066" unitRef="usd">6410</apm:RemunerationAmount>
    <apm:RemunerationAmount contextRef="c157" decimals="0" id="ixv-27067" unitRef="usd">27333</apm:RemunerationAmount>
    <apm:RemunerationAmount contextRef="c158" decimals="0" id="ixv-27068" unitRef="usd">6667</apm:RemunerationAmount>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c0" id="ixv-24632">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;13. VARIABLE INTEREST ENTITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company consolidates VIEs in which the Group
has a variable interest and is determined to be the primary beneficiary. This determination is based on whether the Group has a variable
interest (or combination of variable interests) that provides the Company with (a) the power to direct the activities that most significantly
impact the VIE&#x2019;s economic performance and (b) the obligation to absorb losses or right to receive benefits that could be potentially
significant to the VIE. The Group continually reassesses whether it is the primary beneficiary of a VIE throughout the entire period the
Group is involved with the VIE.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 30, 2021, three of the Group&#x2019;s
subsidiaries, Libra Sciences Limited (&#x201c;Libra&#x201d;, formerly known as Aptorum Pharmaceutical Development Limited),
Mios Pharmaceuticals Limited (&#x201c;Mios&#x201d;) and Scipio Life Sciences Limited (&#x201c;Scipio&#x201d;), issued Class A and Class B
ordinary shares to various parties; for each such entity, each Class A ordinary share is entitled to 1 vote and 1 share of economic benefit
of the respective company, while each Class B ordinary share is entitled to 10 votes and 0.001 share of economic benefit of the respective
company. Following such share issuances, the Group lost its majority voting rights in each of these three companies and only holds 48.33%,
48.39% and 48.36% economic interest in Libra, Mios and Scipio, respectively. However, the Group still holds a majority of each of these
three company&#x2019;s outstanding Class A ordinary shares and therefore will absorb/receive portions of these subsidiaries&#x2019; expected
losses or residual returns. In addition, none of these three companies have sufficient equity to sustain its own activities, and they
have two classes of ordinary shares which have different rights, benefits and obligations. We determined that all these three companies
are variable interest entities (&#x201c;VIE&#x201d;). On December 31, 2021, Libra, Mios and Scipio further issued Class A ordinary shares
to the Group in exchange of certain projects licenses. Upon these share issuances, the Group was holding 97.27% economic interest and
31.51% voting power in Libra, 97.93% economic interest and 36.17% voting power in Mios, and 97.93% economic interest and 35.06% voting
power in Scipio, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have considered each of these entity&#x2019;s
Memorandum and Article of Association and their respective board of directors (the sole director of each of Mios and Scipio is an executive
director of the Group), and determined that we have the power to manage and make decisions that affect Mios and Scipio&#x2019;s research
and development activities, which activities most significantly impact Mios and Scipio&#x2019;s economic performance. However, we do not
have such power over Libra&#x2019;s research and development activities, which activities most significantly impact Libra&#x2019;s economic
performance. Accordingly, we determined that we are the primary beneficiary of Mios and Scipio, but not the primary beneficiary of Libra.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following tables summarize the aggregate carrying
value of VIEs&#x2019; assets and liabilities in the consolidated balance sheets that are consolidated&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Net Assets/&lt;br/&gt;
 (Liabilities)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;24,352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;61,630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;86,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(24,676&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following tables summarize the aggregate carrying
value of assets and liabilities in the Group&#x2019;s consolidated balance sheets that relate to the VIE in which the Group holds a variable
interest but is not the primary beneficiary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Net Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Maximum&lt;br/&gt; Exposure to&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;     -&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;472,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;472,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;472,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s maximum exposure to loss from
its involvement with unconsolidated VIE represents the estimated loss that would be incurred if the VIE is liquidated, so that the fair
value of the equity investment in VIE is zero and the amounts due from the VIE have to be fully impaired.&lt;/p&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights contextRef="c0" id="ixv-27069">each Class A ordinary share is entitled to 1 vote and 1 share of economic benefit
of the respective company, while each Class B ordinary share is entitled to 10 votes</us-gaap:CommonStockVotingRights>
    <apm:ShareOfEconomic
      contextRef="c4"
      decimals="3"
      id="ixv-27070"
      unitRef="usdPershares">0.001</apm:ShareOfEconomic>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c196"
      decimals="4"
      id="ixv-27071"
      unitRef="pure">0.4833</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c197"
      decimals="4"
      id="ixv-27072"
      unitRef="pure">0.4839</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c198"
      decimals="4"
      id="ixv-27073"
      unitRef="pure">0.4836</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c199"
      decimals="4"
      id="ixv-27074"
      unitRef="pure">0.9727</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c200"
      decimals="4"
      id="ixv-27075"
      unitRef="pure">0.3151</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c75" decimals="4" id="ixv-27076" unitRef="pure">0.9793</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c201"
      decimals="4"
      id="ixv-27077"
      unitRef="pure">0.3617</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c79" decimals="4" id="ixv-27078" unitRef="pure">0.9793</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c202"
      decimals="4"
      id="ixv-27079"
      unitRef="pure">0.3506</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="c0" id="ixv-27080">The following tables summarize the aggregate carrying
value of VIEs&#x2019; assets and liabilities in the consolidated balance sheets that are consolidated&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Net Assets/&lt;br/&gt;
 (Liabilities)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;24,352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;61,630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;86,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(24,676&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Net Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Maximum&lt;br/&gt; Exposure to&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;     -&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;472,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;472,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;472,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:OtherAssets contextRef="c204" decimals="0" id="ixv-27081" unitRef="usd">24352</us-gaap:OtherAssets>
    <us-gaap:OtherLiabilities contextRef="c204" decimals="0" id="ixv-27082" unitRef="usd">3558</us-gaap:OtherLiabilities>
    <us-gaap:AssetsNet contextRef="c204" decimals="0" id="ixv-27083" unitRef="usd">20794</us-gaap:AssetsNet>
    <us-gaap:OtherAssets contextRef="c205" decimals="0" id="ixv-27084" unitRef="usd">61630</us-gaap:OtherAssets>
    <us-gaap:OtherLiabilities contextRef="c205" decimals="0" id="ixv-27085" unitRef="usd">86306</us-gaap:OtherLiabilities>
    <us-gaap:AssetsNet contextRef="c205" decimals="0" id="ixv-27086" unitRef="usd">-24676</us-gaap:AssetsNet>
    <us-gaap:OtherAssets contextRef="c207" decimals="0" id="ixv-27087" unitRef="usd">472695</us-gaap:OtherAssets>
    <us-gaap:AssetsNet contextRef="c207" decimals="0" id="ixv-27088" unitRef="usd">472695</us-gaap:AssetsNet>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount contextRef="c207" decimals="0" id="ixv-27089" unitRef="usd">472695</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:EquityMethodInvestments contextRef="c203" decimals="0" id="ixv-27090" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-24840">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;14. LEASE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2023, the Group has two long-term
operating leases for laboratories and clinic with remaining terms expiring from 2024 through 2026 and a weighted average remaining lease
term of 1.9 years. Weighted average discount rates used in the calculation of the operating lease liability is 8%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For&#160;the&#160;year&lt;br/&gt; ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For&#160;the&#160;year&lt;br/&gt; ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Finance lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252,345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Short-term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Sublease income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;317,566&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;483,882&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;389,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;369,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Financing cash flows from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,525&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average remaining lease term &#x2013; finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1.9 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1.1 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average discount rate &#x2013; finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2023, an impairment
loss of $200,916 on right-of-use assets was recognized in other operating expenses as the Group considered that the carrying amount of
a right-of-use asset related to a lease of clinic may not be recoverable. Additionally, the Group early terminated a lease agreement for
a right-of-use asset relating to an office, which resulted in a recognized loss on early termination of the right-of-use asset totaling
$31,030 in other operating expenses. For the years ended December 31, 2022 and 2021, the Group did not recognize any impairment losses
and loss on disposal of right-of-use assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The maturity analysis of operating leases liabilities
as of December 31, 2023 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Remaining periods ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;120,824&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,541&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24,573&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total future undiscounted cash flow&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;242,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Discount on operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,221&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Current portion of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(125,232&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Non-current portion of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;99,485&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="ixv-27091">P1Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-27092">Weighted average discount rates used in the calculation of the operating lease liability is 8%.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For&#160;the&#160;year&lt;br/&gt; ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For&#160;the&#160;year&lt;br/&gt; ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Finance lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252,345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Short-term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Sublease income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;317,566&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;483,882&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;389,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;369,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Financing cash flows from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,525&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average remaining lease term &#x2013; finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1.9 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1.1 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average discount rate &#x2013; finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <apm:OperatingLeaseWeightedAverageDiscountRate contextRef="c4" decimals="2" id="ixv-27093" unitRef="pure">0.08</apm:OperatingLeaseWeightedAverageDiscountRate>
    <apm:FinanceLeaseDepreciation contextRef="c10" decimals="0" id="ixv-27094" unitRef="usd">47818</apm:FinanceLeaseDepreciation>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c10" decimals="0" id="ixv-27095" unitRef="usd">1435</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="0" id="ixv-27096" unitRef="usd">252345</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c10" decimals="0" id="ixv-27097" unitRef="usd">349031</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c0" decimals="0" id="ixv-27098" unitRef="usd">65221</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c10" decimals="0" id="ixv-27099" unitRef="usd">85598</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="0" id="ixv-27100" unitRef="usd">317566</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c10" decimals="0" id="ixv-27101" unitRef="usd">483882</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-27102" unitRef="usd">389365</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c10" decimals="0" id="ixv-27103" unitRef="usd">369505</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c10" decimals="0" id="ixv-27104" unitRef="usd">49358</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-27105" unitRef="usd">338525</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c10" decimals="0" id="ixv-27106" unitRef="usd">549596</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="ixv-27107">P1Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-27108">P1Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="3" id="ixv-27109" unitRef="pure">0.025</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="3" id="ixv-27110" unitRef="pure">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="3" id="ixv-27111" unitRef="pure">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c0" decimals="0" id="ixv-27112" unitRef="usd">200916</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-27113" unitRef="usd">31030</us-gaap:OperatingExpenses>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-27114">The maturity analysis of operating leases liabilities
as of December 31, 2023 is as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Remaining periods ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;120,824&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,541&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24,573&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total future undiscounted cash flow&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;242,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Discount on operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,221&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Current portion of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(125,232&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Non-current portion of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;99,485&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c4" decimals="0" id="ixv-27115" unitRef="usd">120824</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c4" decimals="0" id="ixv-27116" unitRef="usd">97541</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c4" decimals="0" id="ixv-27117" unitRef="usd">24573</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c4" decimals="0" id="ixv-27118" unitRef="usd">242938</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c4" decimals="0" id="ixv-27119" unitRef="usd">18221</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="0" id="ixv-27120" unitRef="usd">224717</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="0" id="ixv-27121" unitRef="usd">125232</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="0" id="ixv-27122" unitRef="usd">99485</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-25150">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;15. CONVERTIBLE NOTE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 9, 2022, the Group entered into a
securities purchase agreement with Aenco Technologies Limited (&#x201c;Aenco&#x201d;). Pursuant to the securities purchase agreement, Aenco
is purchasing a convertible note in the original principal amount of $3,000,000 (the &#x201c;Dec 2022 Note&#x201d;). The Dec 2022 Note is
unsecured, convertible into the Company&#x2019;s restricted Class A Ordinary Shares at Aencco&#x2019;s option. The Dec 2022 Notes have a
maturity date of 12 months subject to the Aenco&#x2019;s extension, a bullet interest rate of 7% per annum, and a conversion price of $12.00
per Class A Ordinary share. The Company shall have an obligation to repay the principal amount and interest of the Dec 2022 Note on the
maturity date in cash or in unregistered Class A Ordinary Shares or a combination of such at the Company&#x2019;s discretion. In April
2023, Aenco transferred the whole Dec 2022 Note to two external investors, and the two external investors fully converted the Dec 2022
Note into 250,000 Class A Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 28, 2023, the Group entered into a securities
purchase agreement with 4 investors. Pursuant to the securities purchase agreement, the investors are purchasing a convertible note in
the original principal amount of $3,000,000 (the &#x201c;June 2023 Note&#x201d;). The whole proceeds from the June 2023 Note was used to
settle a related party loan. The June 2023 Note is unsecured, convertible into the Company&#x2019;s restricted Class A Ordinary Shares
at the Note holders&#x2019; option. The June 2023 Notes have a maturity date of 12 months subject to the investors extension, a bullet
interest rate of 7% per annum, and a conversion price of $3.00 per Class A Ordinary share. The Company shall have an obligation to repay
the principal amount and interest of the June 2023 Note on the maturity date in cash or in unregistered Class A Ordinary Shares or a combination
of such at the Company&#x2019;s discretion. Immediately following the issuance of June 2023 Note, the June 2023 Note was fully converted
into 1,000,000 Class A Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 11, 2023, the Group entered into
a securities purchase agreement with Jurchen Investment Corporation, the largest shareholder of the Company, pursuant to which the Group
sold a secured convertible note in the aggregate principal amount of $3,000,000 (the &#x201c;Sep 2023 Notes&#x201d;). The Sep 2023 Notes
are convertible into the Company&#x2019;s Class A Ordinary Shares and have a maturity date that is 24 months from the issuance date, although
upon such date the investor has the right to extend the term of the Sep 2023 Note for twelve (12) months or more or such term subject
to mutual consent. The Sep 2023 Notes have an interest rate of 6% per annum and a conversion price of $2.42 per share. The Company has
the right to repay the principal amount of the Sep 2023 Notes, but in the case of such prepayment it must be paid in cash, unless otherwise
agreed by both parties. The Sep 2023 Note is secured by a first priority lien and security interest on certain preferred shares that the
Group owns (&#x201c;Collateral&#x201d;) (Note 5). Upon the Group&#x2019;s disposal of all or a portion of the Collateral, the investor has
the right, to request that the Group prepay the then-remaining outstanding balance of the Sep 2023 Note, in part or in full and the Group
can make that payment in cash or in shares.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c208" decimals="0" id="ixv-27123" unitRef="usd">3000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c208"
      decimals="2"
      id="ixv-27124"
      unitRef="pure">0.07</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c208"
      decimals="2"
      id="ixv-27125"
      unitRef="usdPershares">12</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c209"
      decimals="0"
      id="ixv-27126"
      unitRef="shares">250000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertibleDebt contextRef="c210" decimals="0" id="ixv-27127" unitRef="usd">3000000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c211"
      decimals="2"
      id="ixv-27128"
      unitRef="pure">0.07</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c211"
      decimals="2"
      id="ixv-27129"
      unitRef="usdPershares">3</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c212"
      decimals="0"
      id="ixv-27130"
      unitRef="shares">1000000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertibleDebt contextRef="c213" decimals="0" id="ixv-27131" unitRef="usd">3000000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c214"
      decimals="2"
      id="ixv-27132"
      unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c214"
      decimals="2"
      id="ixv-27133"
      unitRef="usdPershares">2.42</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-25164">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;16. ORDINARY SHARES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 26, 2021, the Company entered into an
at-the-market offering agreement (the &#x201c;Sales Agreement&#x201d;), with H.C. Wainwright&#160;&amp;amp; Co., LLC, acting as its sales agent
(the &#x201c;Sales Agent&#x201d;), relating to the sale of its Class A Ordinary Shares (such offering, the &#x201c;ATM Offering&#x201d;, or
&#x201c;At The Market Offering&#x201d;). In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of its
Class A Ordinary Shares having an aggregate offering price of up to $15,000,000 from time to time through the Sales Agent under such prospectus
supplement and the accompanying prospectus. As of the date of issuance of the consolidated financial statements, the Company has issued
215,959 Class A Ordinary Shares at average issuance price of $7.53 per share pursuant to the ATM Offering with gross proceeds of $1.6
million, less transaction costs of $50,183.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 26, 2021, the Company entered into a private
placement shares purchase agreement with Jurchen Investment Corporation, issuing 138,793 Class A Ordinary Shares at $28.82 per share,
representing a 10% premium to the last closing price of the Company&#x2019;s Class A Ordinary Shares on the NASDAQ stock exchange on that
date. The Company received aggregate gross proceeds of $4,000,000 from the purchase of these shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 23, 2023, the Company effectuate a
10 for 1 share consolidation of its authorized share capital, such that every 10 Class A Ordinary Shares, par value of US$1.00 per share,
in the authorized share capital of the Company (including issued and unissued share capital) were consolidated into 1 Class A Ordinary
Share, par value of US$10.00 per share, and that every 10 Class B Ordinary Shares, par value of US$1.00 per share in the authorized share
capital of the Company (including issued and unissued share capital) were consolidated into 1 Class B Ordinary Share, par value of US$10.00
per share. As a consequence of the reverse stock split, fractional shares were rounded up to the next whole share, resulting in the creation
of an additional 8,018 Class A Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 21, 2023, the Company was merged with
Aptorum Group Cayman Limited, a newly established wholly owned subsidiary of the Company, whereby the Company is the surviving company
on the terms of the plan of merger. According to the plan of merger, the par value of its Class A and Class B Ordinary Shares are changed
from &lt;span style="-sec-ix-hidden: hidden-fact-265"&gt;USD10&lt;/span&gt; to &lt;span style="-sec-ix-hidden: hidden-fact-264"&gt;USD0.00001&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 31, 2023, the Group issued 70,430 Class
A Ordinary Shares to a majority of the share option holders. This issuance served as an exchange for their share options and facilitated
the reversal of deferred cash bonus payables owed to these holders (See Note 10).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 31, 2023, the Group also issued 65,770
fully vested Class A Ordinary Shares to certain employees and external consultants. The grant date fair value of each of the shares was
$2.68 based on grant date quoted market price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2023, the Group
issued 791 Class A Ordinary Shares to share option holders as a result of exercise of options. For the year ended December 31, 2022, the
Group issued 6,712 Class A Ordinary Shares to share option holders as a result of exercise of share options. For the year ended December
31, 2021, the Group issued 4,000 and 19,016 Class A Ordinary Shares to warrant holders and share option holders respectively as a result
of exercise of warrants or options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2023, the Group
issued 1,250,000 Class A Ordinary Shares to convertible note holders upon conversion (See Note 15).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Holders of Class A Ordinary Shares and Class B
Ordinary Shares have the same rights except for the following: (i) each Class A Ordinary Share is entitled to one vote while each Class
B Ordinary Share is entitled to ten votes; and (ii) each Class B Ordinary Share is convertible into one Class A Ordinary Share at any
time while Class A Ordinary Shares are not convertible under any circumstances.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockOtherValueOutstanding contextRef="c215" decimals="0" id="ixv-27134" unitRef="usd">15000000</us-gaap:CommonStockOtherValueOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c216"
      decimals="0"
      id="ixv-27135"
      unitRef="usdPershares">215959</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c217" id="ixv-27136">P7Y6M10D</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <apm:GrossProceed
      contextRef="c217"
      decimals="-5"
      id="ixv-27137"
      unitRef="usd">1600000</apm:GrossProceed>
    <us-gaap:SaleLeasebackTransactionTransactionCostsInvestingActivities contextRef="c217" decimals="0" id="ixv-27138" unitRef="usd">50183</us-gaap:SaleLeasebackTransactionTransactionCostsInvestingActivities>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c218"
      decimals="0"
      id="ixv-27139"
      unitRef="shares">138793</us-gaap:CommonStockOtherSharesOutstanding>
    <apm:SharesPrice
      contextRef="c218"
      decimals="2"
      id="ixv-27140"
      unitRef="usdPershares">28.82</apm:SharesPrice>
    <apm:OrdinarySharesClosingPricePercentage
      contextRef="c219"
      decimals="2"
      id="ixv-27141"
      unitRef="pure">0.10</apm:OrdinarySharesClosingPricePercentage>
    <apm:GrossProceed contextRef="c219" decimals="0" id="ixv-27142" unitRef="usd">4000000</apm:GrossProceed>
    <us-gaap:SharesIssued
      contextRef="c220"
      decimals="0"
      id="ixv-27143"
      unitRef="shares">10</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="c221"
      decimals="0"
      id="ixv-27144"
      unitRef="shares">1</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="c222"
      decimals="0"
      id="ixv-27145"
      unitRef="shares">10</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c222"
      decimals="2"
      id="ixv-27146"
      unitRef="usdPershares">1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="c222"
      decimals="0"
      id="ixv-27147"
      unitRef="shares">1</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c222"
      decimals="2"
      id="ixv-27148"
      unitRef="usdPershares">10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssued
      contextRef="c223"
      decimals="0"
      id="ixv-27149"
      unitRef="shares">10</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c224"
      decimals="2"
      id="ixv-27150"
      unitRef="usdPershares">1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="c223"
      decimals="0"
      id="ixv-27151"
      unitRef="shares">1</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c223"
      decimals="2"
      id="ixv-27152"
      unitRef="usdPershares">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c225"
      decimals="0"
      id="ixv-27153"
      unitRef="shares">8018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharesIssued
      contextRef="c137"
      decimals="0"
      id="ixv-27154"
      unitRef="shares">70430</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="c228"
      decimals="0"
      id="ixv-27155"
      unitRef="shares">65770</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c228"
      decimals="2"
      id="ixv-27156"
      unitRef="usdPershares">2.68</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c229"
      decimals="0"
      id="ixv-27157"
      unitRef="shares">791</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c230"
      decimals="0"
      id="ixv-27158"
      unitRef="shares">6712</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c231"
      decimals="0"
      id="ixv-27159"
      unitRef="shares">4000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c232"
      decimals="0"
      id="ixv-27160"
      unitRef="shares">19016</us-gaap:CommonStockOtherSharesOutstanding>
    <apm:ShareIssuedToConvertibleNoteHolders
      contextRef="c233"
      decimals="0"
      id="ixv-27161"
      unitRef="shares">1250000</apm:ShareIssuedToConvertibleNoteHolders>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-25215">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;17. SHARE BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Share option plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 13, 2017, the Group adopted the 2017
Share Option Plan (the &#x201c;Option Plan&#x201d;) and on November 5, 2021, the Group amended the Option Plan. A total of 550,000 Class
A Ordinary Shares (subject to subsequent adjustments described more fully below) may be issued pursuant to awards under the Option Plan.
Subsequent adjustments include that on each January 1, starting with January 1, 2020, an additional number of shares equal to the lesser
of (i) 2% of the outstanding number of Class A Ordinary Shares (on a fully diluted basis) on the immediate preceding December 31, and
(ii) such lower number of Class A Ordinary Shares as may be determined by the board of directors, subject in all cases to adjustments
as provided in Section 10 of the Option Plan. Awards will be made pursuant to agreements and may be subject to vesting and other restrictions
as determined by the board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;75,235 options were granted on March 11, 2021
to directors, employees, external consultants and advisors of the Group with an exercise price of $27.6 per share, which was based on
the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding the grant
date.&#160;36,796 options vest on January 1, 2022 and expire on December 31, 2032; 36,808 options vest on January 1, 2023 and expire on
December 31, 2033; 906 options vest on June 8, 2021 and expire on June 7, 2032; and 725 options vest on July 14, 2021 and expire on July
13, 2032.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;153,146 options were granted on March 8, 2022
to directors, employees, external consultants and advisors of the Group with an exercise price of $13.4 per share, which was based on
the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding the grant
date.&lt;i&gt;&#160;&lt;/i&gt;74,881 options vest on January 1, 2023 and expire on December 31, 2033; 74,906 options vest on January 1, 2024 and expire
on December 31, 2034; 1,866 options vest on June 8, 2022 and expire on June 7, 2033; and 1,493 options vest on July 14, 2022 and expire
on July 13, 2033.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 31, 2023, the Group entered into exchange
agreements and cancelled 177,667 existing vested and unvested share options held by related parties option holders and cancelled the Group&#x2019;s
obligations for deferred cash bonus payables of $3.1 million by granting of 403,820 share options (&#x201c;New Options&#x201d;) with 6 months
vesting period. The New Options&#x2019; exercise price was $2.68 per share, which was based on the last closing price of the shares traded
on the NASDAQ stock exchange on the grant date. All options fully vested on October 1, 2023 and expires on September 30, 2033. On March
31, 2023, the Group entered into supplemental agreements with the same related parties option holders to provide additional cash compensation
to cover the exercise price of the New Options. On March 31, 2023, the Group entered into exchange agreements and cancelled 70,428 existing
vested and unvested share options held by non-related parties option holders and cancelled the Group&#x2019;s obligations for deferred
cash bonus payables of $1.6 million by issuance of 70,430 fully vested Class A Ordinary Shares. The Group accounted for this exchange
for both related parties and non-related parties share option holders as a modification to share based compensation which required the
remeasurement of existing share options value at the time of the modification. The total incremental cost as a result of the modification
was $0.7 million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the option activity for the years
ended December 31, 2023, 2022 and 2021 and changes during the period is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; share&#160;options&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; $&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining&lt;br/&gt; contractual&lt;br/&gt; term in&lt;br/&gt; years&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;272,126&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;     &#x202f;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;403,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(791&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Modified&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(248,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21.74&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;427,060&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.59&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;420,157&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.42&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; share&#160;options&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; $&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining&lt;br/&gt; contractual&lt;br/&gt; term in&lt;br/&gt; years&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;127,404&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;31.91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;       &lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;153,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,721&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,268&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;116.71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;272,126&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21.54&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10.83&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;89,300&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32.71&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.64&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; share&#160;options&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; $&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining&lt;br/&gt; contractual&lt;br/&gt; term in&lt;br/&gt; years&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;71,756&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37.63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;      &lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,037&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;127,404&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31.91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.01&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,456&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42.62&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.63&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#x2019;s 1 for 10 reverse stock split, which was effective on January 23, 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The weighted-average grant date fair value of
share option grants during the years ended December 31, 2023, 2022 and 2021 was $2.68, $10.02 and $25.72, respectively. The maximum contractual
term for share option was 12.8 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of each stock option award is estimated
on the date of grant using the Black-Scholes option pricing model under the following assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Granted in&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Granted in &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Granted in&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;170.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;89.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;97.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;3.48&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1.64&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected term from grant date (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.63-6.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.62-6.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277; -sec-ix-hidden: hidden-fact-276"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279; -sec-ix-hidden: hidden-fact-278"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Dilution factor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;2.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.74
- $10.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;25.11 - $26.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the grant of share options
to employees and non-employees, the Group recorded share-based compensation charges of $697,446 and $391,479, respectively, for the year
ended December 31, 2023, $1,123,122 and $523,877, respectively, for the year ended December 31, 2022, and $1,203,000 and $479,460, respectively,
for the year ended December 31, 2021.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonUnitIssued
      contextRef="c234"
      decimals="0"
      id="ixv-27162"
      unitRef="shares">550000</us-gaap:CommonUnitIssued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c0" decimals="2" id="ixv-27163" unitRef="pure">0.02</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c235"
      decimals="0"
      id="ixv-27164"
      unitRef="shares">75235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharePrice
      contextRef="c236"
      decimals="1"
      id="ixv-27165"
      unitRef="usdPershares">27.6</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c155"
      decimals="0"
      id="ixv-27166"
      unitRef="shares">36796</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c155" id="ixv-27167">2032-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c237"
      decimals="0"
      id="ixv-27168"
      unitRef="shares">36808</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c237" id="ixv-27169">2033-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c238"
      decimals="0"
      id="ixv-27170"
      unitRef="shares">906</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c238" id="ixv-27171">2032-06-07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c239"
      decimals="0"
      id="ixv-27172"
      unitRef="shares">725</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c240" id="ixv-27173">2032-07-13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c241"
      decimals="0"
      id="ixv-27174"
      unitRef="shares">153146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharePrice
      contextRef="c242"
      decimals="1"
      id="ixv-27175"
      unitRef="usdPershares">13.4</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c243"
      decimals="0"
      id="ixv-27176"
      unitRef="shares">74881</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c243" id="ixv-27177">2033-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c244"
      decimals="0"
      id="ixv-27178"
      unitRef="shares">74906</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c244" id="ixv-27179">2034-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c245"
      decimals="0"
      id="ixv-27180"
      unitRef="shares">1866</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c245" id="ixv-27181">2033-06-07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c246"
      decimals="0"
      id="ixv-27182"
      unitRef="shares">1493</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c246" id="ixv-27183">2033-07-13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="c247"
      decimals="0"
      id="ixv-27184"
      unitRef="shares">177667</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c247"
      decimals="-5"
      id="ixv-27185"
      unitRef="usd">3100000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c247"
      decimals="0"
      id="ixv-27186"
      unitRef="shares">403820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c247" id="ixv-27187">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharePrice
      contextRef="c135"
      decimals="2"
      id="ixv-27188"
      unitRef="usdPershares">2.68</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c0" id="ixv-27189">2033-09-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="c248"
      decimals="0"
      id="ixv-27190"
      unitRef="shares">70428</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c249"
      decimals="-5"
      id="ixv-27191"
      unitRef="usd">1600000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c250"
      decimals="0"
      id="ixv-27192"
      unitRef="shares">70430</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="c248"
      decimals="-5"
      id="ixv-27193"
      unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-27194">A summary of the option activity for the years
ended December 31, 2023, 2022 and 2021 and changes during the period is presented below:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; share&#160;options&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; $&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining&lt;br/&gt; contractual&lt;br/&gt; term in&lt;br/&gt; years&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;272,126&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;     &#x202f;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;403,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(791&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Modified&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(248,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21.74&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;427,060&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.59&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;420,157&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.42&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; share&#160;options&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; $&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining&lt;br/&gt; contractual&lt;br/&gt; term in&lt;br/&gt; years&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;127,404&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;31.91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;       &lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;153,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,721&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,268&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;116.71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;272,126&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21.54&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10.83&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;89,300&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32.71&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.64&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; share&#160;options&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; $&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining&lt;br/&gt; contractual&lt;br/&gt; term in&lt;br/&gt; years&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;71,756&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37.63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;      &lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,037&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;127,404&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31.91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11.01&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,456&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42.62&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.63&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#x2019;s 1 for 10 reverse stock split, which was effective on January 23, 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c262"
      decimals="INF"
      id="ix_34_fact"
      unitRef="shares">272126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c262"
      decimals="2"
      id="ixv-27196"
      unitRef="usdPershares">21.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c263" id="ixv-27197">P10Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c263"
      decimals="INF"
      id="ix_35_fact"
      unitRef="shares">403820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c263"
      decimals="2"
      id="ixv-27199"
      unitRef="usdPershares">2.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c263"
      decimals="INF"
      id="ix_36_fact"
      unitRef="shares">791</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c263"
      decimals="2"
      id="ixv-27201"
      unitRef="usdPershares">20.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c263"
      decimals="INF"
      id="ix_37_fact"
      unitRef="shares">248095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c263"
      decimals="2"
      id="ixv-27203"
      unitRef="usdPershares">21.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c264"
      decimals="INF"
      id="ix_38_fact"
      unitRef="shares">427060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c264"
      decimals="2"
      id="ixv-27205"
      unitRef="usdPershares">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c263" id="ixv-27206">P9Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c264"
      decimals="INF"
      id="ix_39_fact"
      unitRef="shares">420157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c264"
      decimals="2"
      id="ixv-27208"
      unitRef="usdPershares">3.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <apm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="c263" id="ixv-27209">P9Y5M1D</apm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c265"
      decimals="INF"
      id="ix_40_fact"
      unitRef="shares">127404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c265"
      decimals="2"
      id="ixv-27211"
      unitRef="usdPershares">31.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c266" id="ixv-27212">P11Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c266"
      decimals="INF"
      id="ix_41_fact"
      unitRef="shares">153146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c266"
      decimals="2"
      id="ixv-27214"
      unitRef="usdPershares">13.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="c266" id="ixv-27215">P12Y3M18D</apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c266"
      decimals="INF"
      id="ix_42_fact"
      unitRef="shares">6721</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c266"
      decimals="2"
      id="ixv-27217"
      unitRef="usdPershares">25.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c266"
      decimals="INF"
      id="ix_43_fact"
      unitRef="shares">1268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c266"
      decimals="2"
      id="ixv-27219"
      unitRef="usdPershares">28.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c266"
      decimals="INF"
      id="ix_44_fact"
      unitRef="shares">435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c266"
      decimals="2"
      id="ixv-27221"
      unitRef="usdPershares">116.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c262"
      decimals="INF"
      id="ix_45_fact"
      unitRef="shares">272126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c262"
      decimals="2"
      id="ixv-27223"
      unitRef="usdPershares">21.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c266" id="ixv-27224">P10Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c262"
      decimals="INF"
      id="ix_46_fact"
      unitRef="shares">89300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c262"
      decimals="2"
      id="ixv-27226"
      unitRef="usdPershares">32.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <apm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="c266" id="ixv-27227">P9Y7M20D</apm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c267"
      decimals="INF"
      id="ix_47_fact"
      unitRef="shares">71756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c267"
      decimals="2"
      id="ixv-27229"
      unitRef="usdPershares">37.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c268" id="ixv-27230">P11Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c268"
      decimals="INF"
      id="ix_48_fact"
      unitRef="shares">75235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c268"
      decimals="2"
      id="ixv-27232"
      unitRef="usdPershares">27.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="c268" id="ixv-27233">P12Y3M14D</apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c268"
      decimals="INF"
      id="ix_49_fact"
      unitRef="shares">19037</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c268"
      decimals="2"
      id="ixv-27235"
      unitRef="usdPershares">36.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c268"
      decimals="INF"
      id="ix_50_fact"
      unitRef="shares">550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c268"
      decimals="2"
      id="ixv-27237"
      unitRef="usdPershares">29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c265"
      decimals="INF"
      id="ix_51_fact"
      unitRef="shares">127404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c265"
      decimals="2"
      id="ixv-27239"
      unitRef="usdPershares">31.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c268" id="ixv-27240">P11Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c265"
      decimals="INF"
      id="ix_52_fact"
      unitRef="shares">31456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c265"
      decimals="2"
      id="ixv-27242"
      unitRef="usdPershares">42.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <apm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="c268" id="ixv-27243">P9Y7M17D</apm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c251"
      decimals="0"
      id="ixv-27244"
      unitRef="shares">1</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c252"
      decimals="0"
      id="ixv-27245"
      unitRef="shares">10</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c253"
      decimals="2"
      id="ixv-27246"
      unitRef="usdPershares">2.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c254"
      decimals="2"
      id="ixv-27247"
      unitRef="usdPershares">10.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c255"
      decimals="2"
      id="ixv-27248"
      unitRef="usdPershares">25.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2 contextRef="c253" id="ixv-27249">P12Y9M18D</apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-27250">The fair value of each stock option award is estimated
on the date of grant using the Black-Scholes option pricing model under the following assumptions.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Granted in&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Granted in &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Granted in&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;170.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;89.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;97.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;3.48&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1.64&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected term from grant date (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.63-6.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.62-6.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277; -sec-ix-hidden: hidden-fact-276"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279; -sec-ix-hidden: hidden-fact-278"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Dilution factor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;2.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.74
- $10.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;25.11 - $26.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c83" decimals="4" id="ixv-27251" unitRef="pure">1.701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c10" decimals="4" id="ixv-27252" unitRef="pure">0.8955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c11" decimals="4" id="ixv-27253" unitRef="pure">0.977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c83" decimals="4" id="ixv-27254" unitRef="pure">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c10" decimals="4" id="ixv-27255" unitRef="pure">0.0186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c11" decimals="4" id="ixv-27256" unitRef="pure">0.0164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c83" id="ixv-27257">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c269" id="ixv-27258">P5Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c270" id="ixv-27259">P6Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c271" id="ixv-27260">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c272" id="ixv-27261">P6Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor contextRef="c83" decimals="0" id="ixv-27262" unitRef="pure">1</apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor>
    <apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor contextRef="c10" decimals="0" id="ixv-27263" unitRef="pure">1</apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor>
    <apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor contextRef="c11" decimals="0" id="ixv-27264" unitRef="pure">1</apm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDilutionFactor>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c83"
      decimals="2"
      id="ixv-27265"
      unitRef="usdPershares">2.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c269"
      decimals="2"
      id="ixv-27266"
      unitRef="usdPershares">9.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c270"
      decimals="2"
      id="ixv-27267"
      unitRef="usdPershares">10.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c271"
      decimals="2"
      id="ixv-27268"
      unitRef="usdPershares">25.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c272"
      decimals="2"
      id="ixv-27269"
      unitRef="usdPershares">26.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c256" decimals="0" id="ixv-27270" unitRef="usd">697446</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c257" decimals="0" id="ixv-27271" unitRef="usd">391479</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c258" decimals="0" id="ixv-27272" unitRef="usd">1123122</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c259" decimals="0" id="ixv-27273" unitRef="usd">523877</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c260" decimals="0" id="ixv-27274" unitRef="usd">1203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c261" decimals="0" id="ixv-27275" unitRef="usd">479460</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:MinorityInterestDisclosureTextBlock contextRef="c0" id="ixv-25947">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;18. NON-CONTROLLING INTEREST&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 30, 2021, two of the Group&#x2019;s
subsidiaries, Mios Pharmaceuticals Limited (&#x201c;Mios&#x201d;) and Scipio Life Sciences Limited (&#x201c;Scipio&#x201d;), issued Class
A and Class B ordinary shares to various parties; for each such entity, each Class A ordinary share is entitled to 1 vote and 1 share
of economic interest of the respective company, while each Class B ordinary share is entitled to 10 votes and 0.001 share of economic
interest of the respective company. On December 31, 2021, Mios and Scipio further issued Class A ordinary shares to the Group in exchange
of certain projects licenses. Upon these share issuances, the Group was holding 97.93% economic interest and 36.17% voting power in Mios,
and 97.93% economic interest and 35.06% voting power in Scipio, respectively. Since the sole director of Mios and Scipio is
an executive director of the Group, the Group can effectively participate in all significant financial and operating decisions in these
two companies through the power granted to the sole director in Mios and Scipio&#x2019;s Articles of Association. The Group is deemed to
have control over Mios and Scipio and hence these two companies are still within the Group. As a result, a total deficit of $27,293 was
reclassified from additional paid-in capital to non-controlling interests within the Group&#x2019;s consolidated financial statements for
the year end December 31, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 2, 2021, Aptorum Medical Limited issued
117 shares to Clark Cheng in according to the appointment agreement, decreasing the equity interest of the Company from 93% to 92%. On
February 25, 2022, Aptorum Medical Limited further issued 119 shares to Clark Cheng in according to the appointment agreement, decreasing
the equity interest of the Company from 92% to 91%. On February 1, 2023, Aptorum Medical Limited further issued 122 shares to Clark Cheng
in according to the appointment agreement, decreasing the equity interest of the Company from 91% to 90%. As a result, a total deficit
of $67,766, $52,024, and $34,130 were reclassified from additional paid-in capital to non-controlling interests within the Group&#x2019;s
consolidated financial statements for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:OtherOwnershipInterestsUnitsIssued
      contextRef="c273"
      decimals="3"
      id="ixv-27276"
      unitRef="shares">0.001</us-gaap:OtherOwnershipInterestsUnitsIssued>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c75" decimals="4" id="ixv-27277" unitRef="pure">0.9793</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c201"
      decimals="4"
      id="ixv-27278"
      unitRef="pure">0.3617</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c79" decimals="4" id="ixv-27279" unitRef="pure">0.9793</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c202"
      decimals="4"
      id="ixv-27280"
      unitRef="pure">0.3506</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <apm:AdjustmentIncreaseDecreaseRetainedEarningsDeficit contextRef="c274" decimals="0" id="ixv-27281" unitRef="usd">27293</apm:AdjustmentIncreaseDecreaseRetainedEarningsDeficit>
    <us-gaap:OtherOwnershipInterestsUnitsIssued
      contextRef="c275"
      decimals="0"
      id="ixv-27282"
      unitRef="shares">117</us-gaap:OtherOwnershipInterestsUnitsIssued>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c276"
      decimals="2"
      id="ixv-27283"
      unitRef="pure">0.93</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c277"
      decimals="2"
      id="ixv-27284"
      unitRef="pure">0.92</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OtherOwnershipInterestsUnitsIssued
      contextRef="c278"
      decimals="0"
      id="ixv-27285"
      unitRef="shares">119</us-gaap:OtherOwnershipInterestsUnitsIssued>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c279"
      decimals="2"
      id="ixv-27286"
      unitRef="pure">0.92</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c280"
      decimals="2"
      id="ixv-27287"
      unitRef="pure">0.91</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OtherOwnershipInterestsUnitsIssued
      contextRef="c281"
      decimals="0"
      id="ixv-27288"
      unitRef="shares">122</us-gaap:OtherOwnershipInterestsUnitsIssued>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c282"
      decimals="2"
      id="ixv-27289"
      unitRef="pure">0.91</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c283"
      decimals="2"
      id="ixv-27290"
      unitRef="pure">0.90</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PartnersCapitalAttributableToNoncontrollingInterest contextRef="c4" decimals="0" id="ixv-27291" unitRef="usd">67766</us-gaap:PartnersCapitalAttributableToNoncontrollingInterest>
    <us-gaap:PartnersCapitalAttributableToNoncontrollingInterest contextRef="c5" decimals="0" id="ixv-27292" unitRef="usd">52024</us-gaap:PartnersCapitalAttributableToNoncontrollingInterest>
    <us-gaap:PartnersCapitalAttributableToNoncontrollingInterest contextRef="c31" decimals="0" id="ixv-27293" unitRef="usd">34130</us-gaap:PartnersCapitalAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-25958">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;19. NET LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 30pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table sets forth the computation of basic and diluted
loss per share:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;Net loss attributable to Aptorum Group Limited&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(2,824,647&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(9,799,560&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(25,048,389&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Weighted average shares outstanding&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#x2013; Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,521,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,569,484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,503,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#x2013; Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,521,133&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,569,484&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,503,396&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Net loss per share attributable to Aptorum Group Limited&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#x2013; Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.62&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.75&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#x2013; Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.62&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#x2019;s 1 for 10 reverse stock split, which was effective on January 23, 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2023, 2022 and
2021, the total number of share options, warrants and convertible notes excluded from the calculation of diluted earnings per share due
to their anti-dilutive nature, are 1,293,723, 54,054 and 54,054, respectively.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-27294">The following table sets forth the computation of basic and diluted
loss per share:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;Net loss attributable to Aptorum Group Limited&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(2,824,647&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(9,799,560&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(25,048,389&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Weighted average shares outstanding&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#x2013; Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,521,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,569,484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,503,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#x2013; Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,521,133&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,569,484&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,503,396&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Net loss per share attributable to Aptorum Group Limited&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#x2013; Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.62&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.75&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#x2013; Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.62&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#x2019;s 1 for 10 reverse stock split, which was effective on January 23, 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="0" id="ixv-27295" unitRef="usd">-2824647</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c10" decimals="0" id="ixv-27296" unitRef="usd">-9799560</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c11" decimals="0" id="ixv-27297" unitRef="usd">-25048389</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ix_53_fact"
      unitRef="shares">4521133</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c10"
      decimals="0"
      id="ix_54_fact"
      unitRef="shares">3569484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c11"
      decimals="0"
      id="ix_55_fact"
      unitRef="shares">3503396</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ix_56_fact"
      unitRef="shares">4521133</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c10"
      decimals="0"
      id="ix_57_fact"
      unitRef="shares">3569484</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c11"
      decimals="0"
      id="ix_58_fact"
      unitRef="shares">3503396</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ix_59_fact"
      unitRef="usdPershares">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c10"
      decimals="2"
      id="ix_60_fact"
      unitRef="usdPershares">-2.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c11"
      decimals="2"
      id="ix_61_fact"
      unitRef="usdPershares">-7.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ix_62_fact"
      unitRef="usdPershares">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c10"
      decimals="2"
      id="ix_63_fact"
      unitRef="usdPershares">-2.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c11"
      decimals="2"
      id="ix_64_fact"
      unitRef="usdPershares">-7.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c251"
      decimals="0"
      id="ixv-27310"
      unitRef="shares">1</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c252"
      decimals="0"
      id="ixv-27311"
      unitRef="shares">10</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="c0"
      decimals="0"
      id="ixv-27312"
      unitRef="shares">1293723</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="c10"
      decimals="0"
      id="ixv-27313"
      unitRef="shares">54054</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="c11"
      decimals="0"
      id="ixv-27314"
      unitRef="shares">54054</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-26161">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;20. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Contingent Payment Obligations&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2023, the Group does not have
any non-cancellable purchase commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group has contingency payment obligations
under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain condition or
milestone is met.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Milestone payments are due upon achievements of
specific conditions, such as Investigational New Drugs (&#x201c;IND&#x201d;) filing or U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)
approval, first commercial sale of the licensed products, or other achievements. The aggregate amounts of the contingent milestone payments
that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as
of December 31, 2023 are below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Drug molecules: up to the conditions and milestones of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Preclinical to IND filing&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;132,564&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;From entering phase 1 to before first commercial sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,376,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;First commercial sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,882,051&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net sales amount more than certain threshold in a year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,769,231&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Subtotal&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;74,160,256&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Diagnostics technology: up to the conditions and milestones of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Before FDA approval&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;74,368,912&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2023, 2022 and
2021, the Group incurred $50,000, $&lt;span style="-sec-ix-hidden: hidden-fact-280"&gt;nil&lt;/span&gt; and $&lt;span style="-sec-ix-hidden: hidden-fact-281"&gt;nil&lt;/span&gt; milestone payments under license agreements, respectively. For the years ended December
31, 2023, 2022 and 2021, the Group did not incur any royalties or research and development funding, respectively.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <apm:ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock contextRef="c0" id="ixv-27315">The aggregate amounts of the contingent milestone payments
that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as
of December 31, 2023 are below:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Drug molecules: up to the conditions and milestones of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Preclinical to IND filing&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;132,564&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;From entering phase 1 to before first commercial sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,376,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;First commercial sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,882,051&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net sales amount more than certain threshold in a year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,769,231&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Subtotal&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;74,160,256&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Diagnostics technology: up to the conditions and milestones of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Before FDA approval&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;74,368,912&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</apm:ScheduleOfMilestonePaymentsAreToBeMadeUponAchievementsOfCertainConditionsTableTextBlock>
    <apm:PreclinicalToIndFiling contextRef="c4" decimals="0" id="ixv-27316" unitRef="usd">132564</apm:PreclinicalToIndFiling>
    <apm:FromEnteringPhase1ToBeforeFirstCommercialSale contextRef="c4" decimals="0" id="ixv-27317" unitRef="usd">17376410</apm:FromEnteringPhase1ToBeforeFirstCommercialSale>
    <apm:FirstCommercialSale contextRef="c4" decimals="0" id="ixv-27318" unitRef="usd">11882051</apm:FirstCommercialSale>
    <apm:NetSalesAmountMoreThanCertainThresholdInYear contextRef="c4" decimals="0" id="ixv-27319" unitRef="usd">44769231</apm:NetSalesAmountMoreThanCertainThresholdInYear>
    <apm:SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal contextRef="c4" decimals="0" id="ixv-27320" unitRef="usd">74160256</apm:SurgicalRoboticsAndMedicalDevicesUpToConditionsAndMilestonesOfSubtotal>
    <apm:FdaApprovalObtaine contextRef="c4" decimals="0" id="ixv-27321" unitRef="usd">208656</apm:FdaApprovalObtaine>
    <apm:MilestonePaymentsTotal contextRef="c4" decimals="0" id="ixv-27322" unitRef="usd">74368912</apm:MilestonePaymentsTotal>
    <apm:MilestonePayments contextRef="c0" decimals="0" id="ixv-27323" unitRef="usd">50000</apm:MilestonePayments>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-26247">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;21. SEGMENT REPORTING&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s chief operating decision maker, the Chief Executive
Officer, reviews the consolidated results when making decisions about allocating resources and accessing performance of the Group as a
whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose
of internal reporting. The Group&#x2019;s long-lived assets are substantially located in Hong Kong and majority of the Group&#x2019;s revenue
and expense is derived from within Hong Kong. Therefore, no geographical segments are presented.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" id="ixv-27324" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-26256">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;22. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group has evaluated subsequent events through
the date of issuance of the consolidated financial statements. Except for the events disclosed elsewhere in the consolidate financial
statements and the following events with material financial impact on the Group&#x2019;s consolidated financial statements, no other subsequent
event is identified that would have required adjustment or disclosure in the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 1, 2024, the Group entered into an Agreement
and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) by and among Company, and YOOV Group Holding Limited, a company organized under
the laws of British Virgin Islands (&#x201c;YOOV&#x201d;). The Merger Agreement was unanimously approved by Company&#x2019;s and YOOV&#x2019;s
boards of directors (each board of directors, the &#x201c;Board&#x201d;), respectively. If the Merger Agreement is approved by Company&#x2019;s
and YOOV&#x2019;s shareholders (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and
upon consummation of the transactions contemplated by the Merger Agreement, the Group will incorporate a wholly-owned subsidiary under
the laws of the British Virgin Islands (&#x201c;Merger Sub&#x201d;) that will merge with and into YOOV, with YOOV surviving the merger as
a wholly-owned subsidiary of the Group (collectively, the &#x201c;Merger&#x201d;). The Group upon the closing is referred to herein as the
&#x201c;combined company.&#x201d; Upon consummation of the transaction, YOOV will become a wholly-owned subsidiary of the Group, and the
existing YOOV shareholders and existing the Group&#x2019;s shareholders will own approximately 90% and 10%, respectively, of the outstanding
shares of the combined company. The consummation of this merger remains uncertain as it is contingent upon the fulfillment of specific
closing conditions.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The obligations of the parties (or, in some cases,
some of the parties) to consummate the Merger are subject to the satisfaction or waiver of certain conditions to closing, including, among
other things: (i) obtaining the approval by the shareholders of Aptorum and YOOV of the matters required under the Merger Agreement, (ii)
approval of the Initial Listing Application by Nasdaq, (iii) consummation of the Separation of ATL, (iv) delivery of legal opinions from
British Virgin Islands counsel and Hong Kong counsel of YOOV to Aptorum and Merger Sub, (v) delivery of legal opinions from Cayman Islands
counsel of Aptorum and British Virgin Islands counsel of Merger Sub to YOOV, (vi) delivery of an opinion by Colliers International (Hong
Kong) Limited to the Board of Aptorum to the effect that (subject to various qualifications and assumptions) the merger consideration
(the total Class A ordinary shares and Class B ordinary shares to be issued to YOOV&#x2019;s shareholders) is fair, from a financial point
of view (based on the conclusion that the equity value of YOOV is no less than $250 million), to the shareholders of Aptorum. (vii) availability
of audited financial statements for YOOV and its Subsidiaries as of March 31, 2023 and 2022 the related audited consolidated statements
of operations, of changes in shareholders&#x2019; equity and of cash flows for the year ended March 31, 2023 and 2022 in conformity with
International Financial Reporting Standards, which shall not be materially different from the unaudited financial statements of YOOV for
the same period as presented to Aptorum, as determined by Aptorum in its sole discretion, (viii) delivery of fully executed lock-up agreement
and support agreement by the major shareholder of Aptorum and the delivery of fully executed lock-up agreement by the directors and officers
of YOOV and by the shareholders of YOOV who will beneficially own 5% or more outstanding shares of the combined company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Merger, on March 1, 2024,
the Company entered into a Split-Off Agreement (the &#x201c;Split-Off Agreement&#x201d;, the transaction contemplated by the Split-Off Agreement,
the &#x201c;Separation&#x201d;) by and among the Company, Aptorum Therapeutics Limited (&#x201c;ATL&#x201d;), and Jurchen Investment Corporation
(&#x201c;Jurchen&#x201d;), pursuant to which, the Company will assign and transfer the assets and liabilities of its legacy business to
ATL, and Jurchen will acquire 100% issued and outstanding shares of ATL from the Company and surrender certain ordinary shares of the
Company held by Jurchen to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The
closing of the Separation must occur simultaneously with the closing of the Merger, or on a later date, as mutually agreed by the Parties.
The Split-Off Agreement contains conditions precedent to closing of the parties thereto, with respect to, among other things, the following
as applicable to each party:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(i)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Representations, Warranties and Performance.&lt;/b&gt; All representations
and warranties made by the parties in the Split-Off Agreement must have been accurate and truthful, to the best of their knowledge, when
initially made and must remain accurate and truthful, to the best of their knowledge, at the time of the Closing. The parties are obligated
to fulfill all commitments, agreements, and conditions outlined in the Split-Off Agreement to the satisfaction of the parties involved,
with significant emphasis on adherence to these obligations before or at the Closing.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(ii)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Additional Documents.&lt;/b&gt; Jurchen shall deliver or cause
to be delivered such additional documents as may be necessary in connection with the consummation of the transactions contemplated by
the Split-Off Agreement and the performance of their obligations hereunder.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(iii)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Release by Buyer and Split-Off Subsidiary.&lt;/b&gt; At the
Closing, Jurchen and ATL are required to execute and provide Aptorum with a comprehensive release. This release will absolve Aptorum
from all liabilities and obligations owed to Jurchen or ATL in any capacity, as well as from any claims that Jurchen or ATL may assert
against Aptorum or its related managers, members, officers, directors, shareholders, employees, and agents. However, this release does
not cover liabilities arising from the Split-Off Agreement or any document related to it.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(iv)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Shareholder Approval.&lt;/b&gt; Aptorum shall have obtained
the affirmative vote of its shareholders representing at least two-thirds of the voting power of the issued and outstanding ordinary
shares of the Seller entitled to vote at a general meeting of the shareholders voting in person or by proxy, to approve the Split-Off
Agreement and the transaction contemplated herein.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 8, 2024, CGY Investments Limited and
DSF Investment Holdings Limited voluntarily converted 401,537 Class B Ordinary Shares and 45,305 Class B Ordinary Shares, respectively
into Class A Ordinary Shares on a one-for-one basis. Upon conversion, 1,796,934 Class B Ordinary Shares were issued and outstanding, CGY
Investments Limited owned 533,575 Class A Ordinary Shares and did not own any Class B Ordinary Share; and DSF Investment Holdings Limited
owned 45,305 Class A Ordinary Shares and did not own any Class B Ordinary Share.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <apm:sharesOutstandingPerentage contextRef="c84" decimals="2" id="ixv-27325" unitRef="pure">0.90</apm:sharesOutstandingPerentage>
    <apm:sharesOutstandingPerentage contextRef="c83" decimals="2" id="ixv-27326" unitRef="pure">0.10</apm:sharesOutstandingPerentage>
    <us-gaap:EquityFairValueAdjustment contextRef="c0" decimals="-6" id="ixv-27327" unitRef="usd">250000000</us-gaap:EquityFairValueAdjustment>
    <apm:OutstandingSharesPercentage contextRef="c0" decimals="2" id="ixv-27328" unitRef="pure">0.05</apm:OutstandingSharesPercentage>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="c284"
      decimals="0"
      id="ixv-27329"
      unitRef="shares">401537</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="c285"
      decimals="0"
      id="ixv-27330"
      unitRef="shares">45305</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c286"
      decimals="0"
      id="ixv-27331"
      unitRef="shares">1796934</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExcessStockSharesOutstanding
      contextRef="c286"
      decimals="0"
      id="ixv-27332"
      unitRef="shares">1796934</us-gaap:ExcessStockSharesOutstanding>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="c287"
      decimals="0"
      id="ixv-27333"
      unitRef="shares">533575</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="c288"
      decimals="0"
      id="ixv-27334"
      unitRef="shares">45305</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:RestrictedCashCurrent
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:DueFromBrokers
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="c6"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="c7"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c6"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c5"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="c11"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="c0"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="c10"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:GainOnUseOfDigitalCurrencies
      contextRef="c0"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:GainOnUseOfDigitalCurrencies
      contextRef="c10"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:GainOnDerecognitionOfNonfinancialAssets
      contextRef="c0"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:GainOnDerecognitionOfNonfinancialAssets
      contextRef="c10"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="c0"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="c10"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20"
      id="hidden-fact-20"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c22"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c24"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c19"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c20"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c22"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c23"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction
      contextRef="c19"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction
      contextRef="c20"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodDisposalOfSubsidiariesUnderCommonControlTransaction
      contextRef="c22"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries
      contextRef="c19"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries
      contextRef="c20"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries
      contextRef="c21"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries
      contextRef="c22"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueDisposalOfSubsidiaries
      contextRef="c23"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c19"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c22"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c23"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c24"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="c20"
      id="hidden-fact-42"
      unitRef="shares"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="c20"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="c22"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="c23"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="c24"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20"
      id="hidden-fact-47"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c22"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c23"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c24"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c19"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c20"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c21"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c22"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c24"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c19"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c20"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c21"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c23"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c32"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c33"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c35"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c36"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c10"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c32"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c33"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c35"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c36"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c37"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c33"
      id="hidden-fact-71"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c33"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c35"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c36"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c37"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c32"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c33"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c34"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c35"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c37"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c32"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c33"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c34"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c36"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue
      contextRef="c47"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue
      contextRef="c48"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue
      contextRef="c49"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockissuedDuringPeriodValueAdjustmentForChangeOfParValue
      contextRef="c0"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c44"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c45"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c47"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c48"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdjustmentToIssuanceOfSharesToNoncontrollingInterest
      contextRef="c0"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c45"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c47"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c48"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c49"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c45"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c47"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c48"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c49"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueIssuanceOfShares
      contextRef="c45"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueIssuanceOfShares
      contextRef="c47"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueIssuanceOfShares
      contextRef="c48"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:StockIssuedDuringPeriodValueIssuanceOfShares
      contextRef="c49"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c44"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c45"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c47"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c48"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c49"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c45"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c47"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c48"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c49"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c44"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c45"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c47"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c48"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c49"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c44"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c45"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c46"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c47"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c48"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c49"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c0"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c44"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c45"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c46"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c47"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ExchangeDifferenceOnTranslationOfForeignOperation
      contextRef="c49"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c45"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c46"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c48"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c11"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="c0"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="c10"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c0"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c10"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="c10"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="c11"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AllowanceForCreditLossOfDueFromARelatedParty
      contextRef="c10"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AllowanceForCreditLossOfDueFromARelatedParty
      contextRef="c11"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:WritteoffOfPrepaymentAndOtherReceivables
      contextRef="c10"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:WritteoffOfPrepaymentAndOtherReceivables
      contextRef="c11"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="c10"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="c11"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="c0"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="c10"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:GainOnUseOfDigitalsCurrencies
      contextRef="c0"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:GainOnUseOfDigitalsCurrencies
      contextRef="c10"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:SettlementOfServiceFeeByDigitalCurrenciesAndTokens
      contextRef="c0"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:SettlementOfServiceFeeByDigitalCurrenciesAndTokens
      contextRef="c10"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="c0"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AccretionOfFinanceLeaseObligation
      contextRef="c0"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ReversalDeferredCashBonus
      contextRef="c10"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ReversalDeferredCashBonus
      contextRef="c11"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c0"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c10"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c10"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c11"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:DisposalOfSubsidiariesNetOfCashDisposed
      contextRef="c0"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:DisposalOfSubsidiariesNetOfCashDisposed
      contextRef="c10"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="c10"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:RepaymentOfLoanFromRelatedParty
      contextRef="c11"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c0"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c10"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="c0"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="c11"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c10"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c0"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c10"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c11"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c0"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c10"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromBankDebt
      contextRef="c11"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="c10"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c11"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c0"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c10"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c11"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ProceedsInBrokerAccounts
      contextRef="c0"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ProceedsInBrokerAccounts
      contextRef="c10"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c11"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:SettlementsOfServiceFeeByDigitalCurrenciesAndTokens
      contextRef="c0"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:SettlementsOfServiceFeeByDigitalCurrenciesAndTokens
      contextRef="c10"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ConvertibleNotesConvertedToClassAOrdinaryShares
      contextRef="c10"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ConvertibleNotesConvertedToClassAOrdinaryShares
      contextRef="c11"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:SettlementOfDeferredCashBonusByIssuanceOfShareOptions
      contextRef="c10"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:SettlementOfDeferredCashBonusByIssuanceOfShareOptions
      contextRef="c11"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AllowanceForCreditLossOfDueFromARelatedParty
      contextRef="c10"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="c10"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="c11"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c94"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c95"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c96"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c4"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c97"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c98"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c99"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c100"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c103"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c105"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c106"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValues
      contextRef="c114"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:NetChangeInUnrealizedDepreciationRelatingToInvestments
      contextRef="c113"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:FairValueOfChangeInUnrealizedAppreciationDepreciation
      contextRef="c116"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:NetChangeInUnrealizedDepreciationRelatingToInvestments
      contextRef="c116"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:UpwardAdjustments
      contextRef="c11"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:DownwardAdjustmentsAndImpairment
      contextRef="c11"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:TotalUnrealizedGainForNonmarketableInvestments
      contextRef="c11"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidRent
      contextRef="c5"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c129"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:WroteOffOfCostRelatedAmortization
      contextRef="c0"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:WroteOffOfCostRelatedAmortization
      contextRef="c10"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:PrepaymentsForEquipment
      contextRef="c4"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c10"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c10"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c10"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="c10"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c10"
      id="hidden-fact-229"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-230"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="c5"
      id="hidden-fact-231"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
      contextRef="c5"
      id="hidden-fact-232"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="c4"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="c4"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="c5"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AmountsDueFromRelatedPartiesCurrent
      contextRef="c160"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AmountsDueFromRelatedPartiesCurrent
      contextRef="c163"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AmountsDueFromRelatedPartiesCurrent
      contextRef="c165"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetInvestmentInLease
      contextRef="c5"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AmountsDueToRelatedPartiesCurrent
      contextRef="c170"
      id="hidden-fact-240"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AmountsDueToRelatedPartiesNoncurrent
      contextRef="c173"
      id="hidden-fact-241"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c177"
      id="hidden-fact-242"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:LoanRepaymentAndInterestPaidToRelatedParties
      contextRef="c174"
      id="hidden-fact-243"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:LoanRepaymentAndInterestPaidToRelatedParties
      contextRef="c177"
      id="hidden-fact-244"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c181"
      id="hidden-fact-245"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:ConsultantSecondmentManagementAndAdministrativeServicesFees
      contextRef="c175"
      id="hidden-fact-246"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="c181"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="c183"
      id="hidden-fact-248"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="c187"
      id="hidden-fact-249"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:RepaymentOfLoanFromRelatedParty
      contextRef="c184"
      id="hidden-fact-250"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="c187"
      id="hidden-fact-251"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:AdministrativeManagementServices
      contextRef="c187"
      id="hidden-fact-252"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LoansAndLeasesReceivableRelatedParties
      contextRef="c149"
      decimals="0"
      id="hidden-fact-253"
      unitRef="usd">4700000</us-gaap:LoansAndLeasesReceivableRelatedParties>
    <us-gaap:OtherAssets
      contextRef="c206"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilities
      contextRef="c206"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsNet
      contextRef="c206"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount
      contextRef="c206"
      id="hidden-fact-257"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilities
      contextRef="c207"
      id="hidden-fact-258"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:VariableLeaseCost
      contextRef="c0"
      id="hidden-fact-259"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:VariableLeaseCost
      contextRef="c10"
      id="hidden-fact-260"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SubleaseIncome
      contextRef="c0"
      id="hidden-fact-261"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SubleaseIncome
      contextRef="c10"
      id="hidden-fact-262"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="hidden-fact-263" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c227"
      decimals="5"
      id="hidden-fact-264"
      unitRef="usdPershares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c226"
      decimals="0"
      id="hidden-fact-265"
      unitRef="usdPershares">10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c263"
      id="hidden-fact-266"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c264"
      id="hidden-fact-267"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c264"
      id="hidden-fact-268"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c266"
      id="hidden-fact-269"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c262"
      id="hidden-fact-270"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c262"
      id="hidden-fact-271"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c268"
      id="hidden-fact-272"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c265"
      id="hidden-fact-273"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c265"
      id="hidden-fact-274"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c83"
      id="hidden-fact-275"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c269"
      id="hidden-fact-276"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c10"
      id="hidden-fact-277"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c271"
      id="hidden-fact-278"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c11"
      id="hidden-fact-279"
      unitRef="pure"
      xsi:nil="true"/>
    <apm:MilestonePayments
      contextRef="c10"
      id="hidden-fact-280"
      unitRef="usd"
      xsi:nil="true"/>
    <apm:MilestonePayments
      contextRef="c11"
      id="hidden-fact-281"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-27619">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-27620">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-27621">0001734005</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#x2019;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#x2019;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_33_fact"
          xlink:label="ix_33_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-71"
          xlink:label="hidden-fact-71"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_31_fact"
          xlink:label="ix_31_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_32_fact"
          xlink:label="ix_32_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-42"
          xlink:label="hidden-fact-42"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-47"
          xlink:label="hidden-fact-47"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-20"
          xlink:label="hidden-fact-20"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#x2019;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_33_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-71"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_31_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_32_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-42"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-47"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-20"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_41_fact"
          xlink:label="ix_41_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_38_fact"
          xlink:label="ix_38_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_43_fact"
          xlink:label="ix_43_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_47_fact"
          xlink:label="ix_47_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_51_fact"
          xlink:label="ix_51_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_35_fact"
          xlink:label="ix_35_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_42_fact"
          xlink:label="ix_42_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_50_fact"
          xlink:label="ix_50_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_52_fact"
          xlink:label="ix_52_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_36_fact"
          xlink:label="ix_36_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_45_fact"
          xlink:label="ix_45_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_44_fact"
          xlink:label="ix_44_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_39_fact"
          xlink:label="ix_39_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_49_fact"
          xlink:label="ix_49_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_48_fact"
          xlink:label="ix_48_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_46_fact"
          xlink:label="ix_46_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_34_fact"
          xlink:label="ix_34_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_40_fact"
          xlink:label="ix_40_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_37_fact"
          xlink:label="ix_37_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#x2019;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_41_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_38_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_43_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_47_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_51_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_35_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_42_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_50_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_52_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_36_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_45_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_44_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_39_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_49_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_48_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_46_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_34_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_40_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_37_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_63_fact"
          xlink:label="ix_63_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_53_fact"
          xlink:label="ix_53_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_64_fact"
          xlink:label="ix_64_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_58_fact"
          xlink:label="ix_58_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_54_fact"
          xlink:label="ix_54_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_61_fact"
          xlink:label="ix_61_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_59_fact"
          xlink:label="ix_59_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_60_fact"
          xlink:label="ix_60_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_56_fact"
          xlink:label="ix_56_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_57_fact"
          xlink:label="ix_57_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_55_fact"
          xlink:label="ix_55_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_62_fact"
          xlink:label="ix_62_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED&#x2019;s 1 for 10 reverse stock split, which was effective on January 23, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_63_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_53_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_64_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_58_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_54_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_61_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_59_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_60_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_56_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_57_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_55_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_62_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
